	sents	ner_seq	entities	num_entities	num_tokens	prompts	empty_prompts
0	Naloxone reverses the antihypertensive effect of clonidine .	O O O O O O O O	[]	0	0	"Sentence: Naloxone reverses the antihypertensive effect of clonidine .
Diseases: "	"Sentence: Naloxone reverses the antihypertensive effect of clonidine .
Diseases:"
1	In unanesthetized , spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine , 5 to 20 micrograms / kg , was inhibited or reversed by nalozone , 0 . 2 to 2 mg / kg .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: In unanesthetized , spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine , 5 to 20 micrograms / kg , was inhibited or reversed by nalozone , 0 . 2 to 2 mg / kg .
Diseases: hypertensive"	"Sentence: In unanesthetized , spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine , 5 to 20 micrograms / kg , was inhibited or reversed by nalozone , 0 . 2 to 2 mg / kg .
Diseases:"
2	The hypotensive effect of 100 mg / kg alpha - methyldopa was also partially reversed by naloxone .	O B O O O O O O O O O O O O O O O O	['hypotensive']	1	3	"Sentence: The hypotensive effect of 100 mg / kg alpha - methyldopa was also partially reversed by naloxone .
Diseases: hypotensive"	"Sentence: The hypotensive effect of 100 mg / kg alpha - methyldopa was also partially reversed by naloxone .
Diseases:"
3	Naloxone alone did not affect either blood pressure or heart rate .	O O O O O O O O O O O O	[]	0	0	"Sentence: Naloxone alone did not affect either blood pressure or heart rate .
Diseases: "	"Sentence: Naloxone alone did not affect either blood pressure or heart rate .
Diseases:"
4	In brain membranes from spontaneously hypertensive rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 )	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: In brain membranes from spontaneously hypertensive rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 )
Diseases: hypertensive"	"Sentence: In brain membranes from spontaneously hypertensive rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 )
Diseases:"
5	M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .
Diseases: "	"Sentence: M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .
Diseases:"
6	These findings indicate that in spontaneously hypertensive rats the effects of central alpha - adrenoceptor stimulation involve activation of opiate receptors .	O O O O O O B O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: These findings indicate that in spontaneously hypertensive rats the effects of central alpha - adrenoceptor stimulation involve activation of opiate receptors .
Diseases: hypertensive"	"Sentence: These findings indicate that in spontaneously hypertensive rats the effects of central alpha - adrenoceptor stimulation involve activation of opiate receptors .
Diseases:"
7	As naloxone and clonidine do not appear to interact with the same receptor site , the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha - methyldopa and the possible role of the opiate in the central control of sympathetic tone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As naloxone and clonidine do not appear to interact with the same receptor site , the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha - methyldopa and the possible role of the opiate in the central control of sympathetic tone .
Diseases: "	"Sentence: As naloxone and clonidine do not appear to interact with the same receptor site , the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha - methyldopa and the possible role of the opiate in the central control of sympathetic tone .
Diseases:"
8	Lidocaine - induced cardiac asystole .	O O O B I O	['cardiac asystole']	1	6	"Sentence: Lidocaine - induced cardiac asystole .
Diseases: cardiac asystole"	"Sentence: Lidocaine - induced cardiac asystole .
Diseases:"
9	Intravenous administration of a single 50 - mg bolus of lidocaine in a 67 - year - old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	['depression']	1	2	"Sentence: Intravenous administration of a single 50 - mg bolus of lidocaine in a 67 - year - old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers .
Diseases: depression"	"Sentence: Intravenous administration of a single 50 - mg bolus of lidocaine in a 67 - year - old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers .
Diseases:"
10	The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias ; and , thus , this probably represented a true idiosyncrasy to lidocaine .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['bradyarrhythmias']	1	6	"Sentence: The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias ; and , thus , this probably represented a true idiosyncrasy to lidocaine .
Diseases: bradyarrhythmias"	"Sentence: The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias ; and , thus , this probably represented a true idiosyncrasy to lidocaine .
Diseases:"
11	Suxamethonium infusion rate and observed fasciculations .	O O O O O B O	['fasciculations']	1	4	"Sentence: Suxamethonium infusion rate and observed fasciculations .
Diseases: fasciculations"	"Sentence: Suxamethonium infusion rate and observed fasciculations .
Diseases:"
12	A dose - response study .	O O O O O O	[]	0	0	"Sentence: A dose - response study .
Diseases: "	"Sentence: A dose - response study .
Diseases:"
13	Suxamethonium chloride ( Sch ) was administered i . v .	O O O O O O O O O O O	[]	0	0	"Sentence: Suxamethonium chloride ( Sch ) was administered i . v .
Diseases: "	"Sentence: Suxamethonium chloride ( Sch ) was administered i . v .
Diseases:"
14	to 36 adult males at six rates :	O O O O O O O O	[]	0	0	"Sentence: to 36 adult males at six rates :
Diseases: "	"Sentence: to 36 adult males at six rates :
Diseases:"
15	0 . 25 mg s - 1 to 20 mg s - 1 .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: 0 . 25 mg s - 1 to 20 mg s - 1 .
Diseases: "	"Sentence: 0 . 25 mg s - 1 to 20 mg s - 1 .
Diseases:"
16	The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded .	O O O O O O O O O O O O B O O O O O O O O O O O O O	['tetanic']	1	3	"Sentence: The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded .
Diseases: tetanic"	"Sentence: The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded .
Diseases:"
17	Six additional patients received a 30 - mg i . v .	O O O O O O O O O O O O	[]	0	0	"Sentence: Six additional patients received a 30 - mg i . v .
Diseases: "	"Sentence: Six additional patients received a 30 - mg i . v .
Diseases:"
18	bolus dose .	O O O	[]	0	0	"Sentence: bolus dose .
Diseases: "	"Sentence: bolus dose .
Diseases:"
19	Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score .	B O O O O O O O O O O O O O O O O O B O O	['fasciculation', 'fasciculations']	2	8	"Sentence: Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score .
Diseases: fasciculation, fasciculations"	"Sentence: Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score .
Diseases:"
20	The times to first fasciculation , twitch suppression and tetanus suppression were inversely related to the infusion rates .	O O O O B O B O O B O O O O O O O O O	['tetanus', 'fasciculation', 'twitch']	3	9	"Sentence: The times to first fasciculation , twitch suppression and tetanus suppression were inversely related to the infusion rates .
Diseases: tetanus, fasciculation, twitch"	"Sentence: The times to first fasciculation , twitch suppression and tetanus suppression were inversely related to the infusion rates .
Diseases:"
21	Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion .	B O O O O O O O B O O O O O O O O O O	['fasciculation', 'fasciculations']	2	8	"Sentence: Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion .
Diseases: fasciculation, fasciculations"	"Sentence: Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion .
Diseases:"
22	Total fasciculation scores in the 30 - mg bolus group and the 5 - mg s - 1 and 20 - mg s - 1 infusion groups were not significantly different .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['fasciculation']	1	4	"Sentence: Total fasciculation scores in the 30 - mg bolus group and the 5 - mg s - 1 and 20 - mg s - 1 infusion groups were not significantly different .
Diseases: fasciculation"	"Sentence: Total fasciculation scores in the 30 - mg bolus group and the 5 - mg s - 1 and 20 - mg s - 1 infusion groups were not significantly different .
Diseases:"
23	Galanthamine hydrobromide , a longer acting anticholinesterase drug , in the treatment of the central effects of scopolamine ( Hyoscine ) .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Galanthamine hydrobromide , a longer acting anticholinesterase drug , in the treatment of the central effects of scopolamine ( Hyoscine ) .
Diseases: "	"Sentence: Galanthamine hydrobromide , a longer acting anticholinesterase drug , in the treatment of the central effects of scopolamine ( Hyoscine ) .
Diseases:"
24	Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of scopolamine ( hyoscine ) overdosage .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['overdosage']	1	3	"Sentence: Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of scopolamine ( hyoscine ) overdosage .
Diseases: overdosage"	"Sentence: Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of scopolamine ( hyoscine ) overdosage .
Diseases:"
25	It is longer acting than physostigmine and is used in anaesthesia to reverse the non - depolarizing neuromuscular block .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is longer acting than physostigmine and is used in anaesthesia to reverse the non - depolarizing neuromuscular block .
Diseases: "	"Sentence: It is longer acting than physostigmine and is used in anaesthesia to reverse the non - depolarizing neuromuscular block .
Diseases:"
26	However , studies into the dose necessary to combating scopolamine intoxication are indicated .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , studies into the dose necessary to combating scopolamine intoxication are indicated .
Diseases: "	"Sentence: However , studies into the dose necessary to combating scopolamine intoxication are indicated .
Diseases:"
27	Effects of uninephrectomy and high protein feeding on lithium - induced chronic renal failure in rats .	O O O O O O O O O O O B I I O O O	['chronic renal failure']	1	4	"Sentence: Effects of uninephrectomy and high protein feeding on lithium - induced chronic renal failure in rats .
Diseases: chronic renal failure"	"Sentence: Effects of uninephrectomy and high protein feeding on lithium - induced chronic renal failure in rats .
Diseases:"
28	Rats with lithium - induced nephropathy were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of renal failure .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['nephropathy', 'renal failure']	2	7	"Sentence: Rats with lithium - induced nephropathy were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of renal failure .
Diseases: nephropathy, renal failure"	"Sentence: Rats with lithium - induced nephropathy were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of renal failure .
Diseases:"
29	Newborn female Wistar rats were fed a lithium - containing diet ( 50 mmol / kg ) for 8 weeks and then randomized to normal diet , HP diet ( 40 vs . 19 % ) , NX or HP + NX for another 8 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Newborn female Wistar rats were fed a lithium - containing diet ( 50 mmol / kg ) for 8 weeks and then randomized to normal diet , HP diet ( 40 vs . 19 % ) , NX or HP + NX for another 8 weeks .
Diseases: "	"Sentence: Newborn female Wistar rats were fed a lithium - containing diet ( 50 mmol / kg ) for 8 weeks and then randomized to normal diet , HP diet ( 40 vs . 19 % ) , NX or HP + NX for another 8 weeks .
Diseases:"
30	Corresponding non - lithium pretreated groups were generated .	O O O O O O O O O	[]	0	0	"Sentence: Corresponding non - lithium pretreated groups were generated .
Diseases: "	"Sentence: Corresponding non - lithium pretreated groups were generated .
Diseases:"
31	When comparing all lithium treated versus non - lithium - treated groups , lithium caused a reduction in glomerular filtration rate ( GFR ) without significant changes in effective renal plasma flow ( as determined by a marker secreted into the proximal tubules ) or lithium clearance .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When comparing all lithium treated versus non - lithium - treated groups , lithium caused a reduction in glomerular filtration rate ( GFR ) without significant changes in effective renal plasma flow ( as determined by a marker secreted into the proximal tubules ) or lithium clearance .
Diseases: "	"Sentence: When comparing all lithium treated versus non - lithium - treated groups , lithium caused a reduction in glomerular filtration rate ( GFR ) without significant changes in effective renal plasma flow ( as determined by a marker secreted into the proximal tubules ) or lithium clearance .
Diseases:"
32	Consequently , lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Consequently , lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion .
Diseases: "	"Sentence: Consequently , lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion .
Diseases:"
33	Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis .	O O O B O O B O O O B O	['proteinuria', 'glomerulosclerosis', 'hypertension']	3	10	"Sentence: Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis .
Diseases: proteinuria, glomerulosclerosis, hypertension"	"Sentence: Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis .
Diseases:"
34	HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats .	O O O O O O B I O O O O O O O O O O O O O O O O O	['renal failure']	1	3	"Sentence: HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats .
Diseases: renal failure"	"Sentence: HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats .
Diseases:"
35	NX caused an additive deterioration in GFR which , however , was ameliorated by HP .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NX caused an additive deterioration in GFR which , however , was ameliorated by HP .
Diseases: "	"Sentence: NX caused an additive deterioration in GFR which , however , was ameliorated by HP .
Diseases:"
36	NX + HP caused a further rise in blood pressure in Li - pretreated rats .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NX + HP caused a further rise in blood pressure in Li - pretreated rats .
Diseases: "	"Sentence: NX + HP caused a further rise in blood pressure in Li - pretreated rats .
Diseases:"
37	The results indicate that Li - induced nephropathy , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic hypertension .	O O O O O O O B O O O O O O O O O O O O O B O O O B O	['nephropathy', 'proteinuria', 'hypertension']	3	9	"Sentence: The results indicate that Li - induced nephropathy , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic hypertension .
Diseases: nephropathy, proteinuria, hypertension"	"Sentence: The results indicate that Li - induced nephropathy , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic hypertension .
Diseases:"
38	In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow , which may be the functional expression of the formation of nonfiltrating atubular glomeruli .	O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['chronic renal failure']	1	4	"Sentence: In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow , which may be the functional expression of the formation of nonfiltrating atubular glomeruli .
Diseases: chronic renal failure"	"Sentence: In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow , which may be the functional expression of the formation of nonfiltrating atubular glomeruli .
Diseases:"
39	The fractional reabsorption of tubular fluid by the proximal tubules is reduced , leaving the distal delivery unchanged . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The fractional reabsorption of tubular fluid by the proximal tubules is reduced , leaving the distal delivery unchanged . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: "	"Sentence: The fractional reabsorption of tubular fluid by the proximal tubules is reduced , leaving the distal delivery unchanged . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
40	Treatment of Crohn 's disease with fusidic acid : an antibiotic with immunosuppressive properties similar to cyclosporin .	O O B I I O O O O O O O O O O O O O	"[""crohn 's disease""]"	1	5	"Sentence: Treatment of Crohn 's disease with fusidic acid : an antibiotic with immunosuppressive properties similar to cyclosporin .
Diseases: crohn 's disease"	"Sentence: Treatment of Crohn 's disease with fusidic acid : an antibiotic with immunosuppressive properties similar to cyclosporin .
Diseases:"
41	Fusidic acid is an antibiotic with T - cell specific immunosuppressive effects similar to those of cyclosporin .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fusidic acid is an antibiotic with T - cell specific immunosuppressive effects similar to those of cyclosporin .
Diseases: "	"Sentence: Fusidic acid is an antibiotic with T - cell specific immunosuppressive effects similar to those of cyclosporin .
Diseases:"
42	Because of the need for the development of new treatments for Crohn 's disease , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active , therapy - resistant patients .	O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O	"[""crohn 's disease""]"	1	5	"Sentence: Because of the need for the development of new treatments for Crohn 's disease , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active , therapy - resistant patients .
Diseases: crohn 's disease"	"Sentence: Because of the need for the development of new treatments for Crohn 's disease , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active , therapy - resistant patients .
Diseases:"
43	Eight Crohn 's disease patients were included .	O B I I O O O O	"[""crohn 's disease""]"	1	5	"Sentence: Eight Crohn 's disease patients were included .
Diseases: crohn 's disease"	"Sentence: Eight Crohn 's disease patients were included .
Diseases:"
44	Fusidic acid was administered orally in a dose of 500 mg t . d . s .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fusidic acid was administered orally in a dose of 500 mg t . d . s .
Diseases: "	"Sentence: Fusidic acid was administered orally in a dose of 500 mg t . d . s .
Diseases:"
45	and the treatment was planned to last 8 weeks .	O O O O O O O O O O	[]	0	0	"Sentence: and the treatment was planned to last 8 weeks .
Diseases: "	"Sentence: and the treatment was planned to last 8 weeks .
Diseases:"
46	The disease activity was primarily measured by a modified individual grading score .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The disease activity was primarily measured by a modified individual grading score .
Diseases: "	"Sentence: The disease activity was primarily measured by a modified individual grading score .
Diseases:"
47	Five of 8 patients ( 63 % ) improved during fusidic acid treatment : 3 at two weeks and 2 after four weeks .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Five of 8 patients ( 63 % ) improved during fusidic acid treatment : 3 at two weeks and 2 after four weeks .
Diseases: "	"Sentence: Five of 8 patients ( 63 % ) improved during fusidic acid treatment : 3 at two weeks and 2 after four weeks .
Diseases:"
48	There were no serious clinical side effects , but dose reduction was required in two patients because of nausea .	O O O O O O O O O O O O O O O O O O B O	['nausea']	1	3	"Sentence: There were no serious clinical side effects , but dose reduction was required in two patients because of nausea .
Diseases: nausea"	"Sentence: There were no serious clinical side effects , but dose reduction was required in two patients because of nausea .
Diseases:"
49	Biochemically , an increase in alkaline phosphatases was noted in 5 of 8 cases ( 63 % ) , and the greatest increases were seen in those who had elevated levels prior to treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Biochemically , an increase in alkaline phosphatases was noted in 5 of 8 cases ( 63 % ) , and the greatest increases were seen in those who had elevated levels prior to treatment .
Diseases: "	"Sentence: Biochemically , an increase in alkaline phosphatases was noted in 5 of 8 cases ( 63 % ) , and the greatest increases were seen in those who had elevated levels prior to treatment .
Diseases:"
50	All reversed to pre - treatment levels after cessation of treatment .	O O O O O O O O O O O O	[]	0	0	"Sentence: All reversed to pre - treatment levels after cessation of treatment .
Diseases: "	"Sentence: All reversed to pre - treatment levels after cessation of treatment .
Diseases:"
51	The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn 's disease patients in whom conventional treatment is ineffective .	O O O O O O O O O O O O O O O O O O B I I O O O O O O O O	"[""crohn 's disease""]"	1	5	"Sentence: The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn 's disease patients in whom conventional treatment is ineffective .
Diseases: crohn 's disease"	"Sentence: The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn 's disease patients in whom conventional treatment is ineffective .
Diseases:"
52	Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease , we suggest that the role of this treatment should be further investigated .	O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O	['inflammatory bowel disease']	1	3	"Sentence: Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease , we suggest that the role of this treatment should be further investigated .
Diseases: inflammatory bowel disease"	"Sentence: Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease , we suggest that the role of this treatment should be further investigated .
Diseases:"
53	Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers .	O O O B I O O O O O O	['myocardial injury']	1	4	"Sentence: Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers .
Diseases: myocardial injury"	"Sentence: Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers .
Diseases:"
54	The electrocardiograms ( ECG ) of 99 cocaine - abusing patients were compared with the ECGs of 50 schizophrenic controls .	O O O O O O O O O O O O O O O O O O B O O	['schizophrenic']	1	3	"Sentence: The electrocardiograms ( ECG ) of 99 cocaine - abusing patients were compared with the ECGs of 50 schizophrenic controls .
Diseases: schizophrenic"	"Sentence: The electrocardiograms ( ECG ) of 99 cocaine - abusing patients were compared with the ECGs of 50 schizophrenic controls .
Diseases:"
55	Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , ischemia , and bundle branch block .	O O O O O O O O O O O O O O O B I O O B I O B O O B I I O	['bundle branch block', 'myocardial injury', 'ischemia', 'myocardial infarction']	4	20	"Sentence: Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , ischemia , and bundle branch block .
Diseases: bundle branch block, myocardial injury, ischemia, myocardial infarction"	"Sentence: Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , ischemia , and bundle branch block .
Diseases:"
56	Sulpiride - induced tardive dystonia .	O O O B I O	['tardive dystonia']	1	6	"Sentence: Sulpiride - induced tardive dystonia .
Diseases: tardive dystonia"	"Sentence: Sulpiride - induced tardive dystonia .
Diseases:"
57	Sulpiride is a selective D2 - receptor antagonist with antipsychotic and antidepressant properties .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sulpiride is a selective D2 - receptor antagonist with antipsychotic and antidepressant properties .
Diseases: "	"Sentence: Sulpiride is a selective D2 - receptor antagonist with antipsychotic and antidepressant properties .
Diseases:"
58	Although initially thought to be free of extrapyramidal side effects , sulpiride - induced tardive dyskinesia and parkinsonism have been reported occasionally .	O O O O O O O O O O O O O O B I O B O O O O O	['tardive dyskinesia', 'parkinsonism']	2	11	"Sentence: Although initially thought to be free of extrapyramidal side effects , sulpiride - induced tardive dyskinesia and parkinsonism have been reported occasionally .
Diseases: tardive dyskinesia, parkinsonism"	"Sentence: Although initially thought to be free of extrapyramidal side effects , sulpiride - induced tardive dyskinesia and parkinsonism have been reported occasionally .
Diseases:"
59	We studied a 37 - year - old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy .	O O O O O O O O O O O O O B O O O O O O O O	['dystonia']	1	3	"Sentence: We studied a 37 - year - old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy .
Diseases: dystonia"	"Sentence: We studied a 37 - year - old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy .
Diseases:"
60	We could not find any previous reports of sulpiride - induced tardive dystonia .	O O O O O O O O O O O B I O	['tardive dystonia']	1	6	"Sentence: We could not find any previous reports of sulpiride - induced tardive dystonia .
Diseases: tardive dystonia"	"Sentence: We could not find any previous reports of sulpiride - induced tardive dystonia .
Diseases:"
61	Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine .	B I I I O O O O O O	['ocular and auditory toxicity']	1	4	"Sentence: Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine .
Diseases: ocular and auditory toxicity"	"Sentence: Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine .
Diseases:"
62	During an 18 - month period of study 41 hemodialyzed patients receiving desferrioxamine ( 10 - 40 mg / kg BW / 3 times weekly ) for the first time were monitored for detection of audiovisual toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['audiovisual toxicity']	1	5	"Sentence: During an 18 - month period of study 41 hemodialyzed patients receiving desferrioxamine ( 10 - 40 mg / kg BW / 3 times weekly ) for the first time were monitored for detection of audiovisual toxicity .
Diseases: audiovisual toxicity"	"Sentence: During an 18 - month period of study 41 hemodialyzed patients receiving desferrioxamine ( 10 - 40 mg / kg BW / 3 times weekly ) for the first time were monitored for detection of audiovisual toxicity .
Diseases:"
63	6 patients presented clinical symptoms of visual or auditory toxicity .	O O O O O O B I I I O	['visual or auditory toxicity']	1	4	"Sentence: 6 patients presented clinical symptoms of visual or auditory toxicity .
Diseases: visual or auditory toxicity"	"Sentence: 6 patients presented clinical symptoms of visual or auditory toxicity .
Diseases:"
64	Moreover , detailed ophthalmologic and audiologic studies disclosed abnormalities in 7 more asymptomatic patients .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Moreover , detailed ophthalmologic and audiologic studies disclosed abnormalities in 7 more asymptomatic patients .
Diseases: "	"Sentence: Moreover , detailed ophthalmologic and audiologic studies disclosed abnormalities in 7 more asymptomatic patients .
Diseases:"
65	Visual toxicity was of retinal origin and was characterized by a tritan - type dyschromatopsy , sometimes associated with a loss of visual acuity and pigmentary retinal deposits .	B I O O O O O O O O O O O O B O O O O B I I I I O B I I O	['pigmentary retinal deposits', 'dyschromatopsy', 'visual toxicity', 'a loss of visual acuity']	4	22	"Sentence: Visual toxicity was of retinal origin and was characterized by a tritan - type dyschromatopsy , sometimes associated with a loss of visual acuity and pigmentary retinal deposits .
Diseases: pigmentary retinal deposits, dyschromatopsy, visual toxicity, a loss of visual acuity"	"Sentence: Visual toxicity was of retinal origin and was characterized by a tritan - type dyschromatopsy , sometimes associated with a loss of visual acuity and pigmentary retinal deposits .
Diseases:"
66	Auditory toxicity was characterized by a mid - to high - frequency neurosensorial hearing loss and the lesion was of the cochlear type .	B I O O O O O O O O O O B I I O O O O O O O O O	['neurosensorial hearing loss', 'auditory toxicity']	2	10	"Sentence: Auditory toxicity was characterized by a mid - to high - frequency neurosensorial hearing loss and the lesion was of the cochlear type .
Diseases: neurosensorial hearing loss, auditory toxicity"	"Sentence: Auditory toxicity was characterized by a mid - to high - frequency neurosensorial hearing loss and the lesion was of the cochlear type .
Diseases:"
67	Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3 , and a complete reversal of hearing loss in 3 patients and partial recovery in 3 .	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O	['hearing loss']	1	3	"Sentence: Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3 , and a complete reversal of hearing loss in 3 patients and partial recovery in 3 .
Diseases: hearing loss"	"Sentence: Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3 , and a complete reversal of hearing loss in 3 patients and partial recovery in 3 .
Diseases:"
68	This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels .	O B O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels .
Diseases: toxicity"	"Sentence: This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels .
Diseases:"
69	The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine .	O O O O B I O O O O O O O O O O O	['audiovisual toxicity']	1	5	"Sentence: The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine .
Diseases: audiovisual toxicity"	"Sentence: The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine .
Diseases:"
70	Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible .
Diseases: "	"Sentence: Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible .
Diseases:"
71	Myasthenia gravis presenting as weakness after magnesium administration .	B I O O O O O O O	['myasthenia gravis']	1	6	"Sentence: Myasthenia gravis presenting as weakness after magnesium administration .
Diseases: myasthenia gravis"	"Sentence: Myasthenia gravis presenting as weakness after magnesium administration .
Diseases:"
72	We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia .	O O O O O O O O O B I O O O B O O O O O B O	['neuromuscular disease', 'quadriplegic', 'preeclampsia']	3	17	"Sentence: We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia .
Diseases: neuromuscular disease, quadriplegic, preeclampsia"	"Sentence: We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia .
Diseases:"
73	The serum magnesium concentration was 3 . 0 mEq / L , which is usually well tolerated .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The serum magnesium concentration was 3 . 0 mEq / L , which is usually well tolerated .
Diseases: "	"Sentence: The serum magnesium concentration was 3 . 0 mEq / L , which is usually well tolerated .
Diseases:"
74	The magnesium was stopped and she recovered over a few days .	O O O O O O O O O O O O	[]	0	0	"Sentence: The magnesium was stopped and she recovered over a few days .
Diseases: "	"Sentence: The magnesium was stopped and she recovered over a few days .
Diseases:"
75	While she was weak , 2 - Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise , suggesting postsynaptic neuromuscular blockade .	O O O O O O O O O O O O O O O O O O O O O O O O B I I O	['postsynaptic neuromuscular blockade']	1	8	"Sentence: While she was weak , 2 - Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise , suggesting postsynaptic neuromuscular blockade .
Diseases: postsynaptic neuromuscular blockade"	"Sentence: While she was weak , 2 - Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise , suggesting postsynaptic neuromuscular blockade .
Diseases:"
76	After her strength returned , repetitive stimulation was normal , but single fiber EMG revealed increased jitter and blocking .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After her strength returned , repetitive stimulation was normal , but single fiber EMG revealed increased jitter and blocking .
Diseases: "	"Sentence: After her strength returned , repetitive stimulation was normal , but single fiber EMG revealed increased jitter and blocking .
Diseases:"
77	Her acetylcholine receptor antibody level was markedly elevated .	O O O O O O O O O	[]	0	0	"Sentence: Her acetylcholine receptor antibody level was markedly elevated .
Diseases: "	"Sentence: Her acetylcholine receptor antibody level was markedly elevated .
Diseases:"
78	Although paralysis after magnesium administration has been described in patients with known myasthenia gravis , it has not previously been reported to be the initial or only manifestation of the disease .	O B O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['paralysis', 'myasthenia gravis']	2	9	"Sentence: Although paralysis after magnesium administration has been described in patients with known myasthenia gravis , it has not previously been reported to be the initial or only manifestation of the disease .
Diseases: paralysis, myasthenia gravis"	"Sentence: Although paralysis after magnesium administration has been described in patients with known myasthenia gravis , it has not previously been reported to be the initial or only manifestation of the disease .
Diseases:"
79	Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission .	O O O O O O O O O O O O O O O O O O B I I I O	['disorder of neuromuscular transmission']	1	8	"Sentence: Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission .
Diseases: disorder of neuromuscular transmission"	"Sentence: Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission .
Diseases:"
80	Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide .
Diseases: "	"Sentence: Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide .
Diseases:"
81	An experimental study / short communication .	O O O O O O O	[]	0	0	"Sentence: An experimental study / short communication .
Diseases: "	"Sentence: An experimental study / short communication .
Diseases:"
82	Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['hemorrhagic cystitis']	1	7	"Sentence: Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis .
Diseases: hemorrhagic cystitis"	"Sentence: Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis .
Diseases:"
83	The data demonstrate that CAA after i . v .	O O O O O O O O O O	[]	0	0	"Sentence: The data demonstrate that CAA after i . v .
Diseases: "	"Sentence: The data demonstrate that CAA after i . v .
Diseases:"
84	administration does not contribute to bladder damage .	O O O O O B I O	['bladder damage']	1	3	"Sentence: administration does not contribute to bladder damage .
Diseases: bladder damage"	"Sentence: administration does not contribute to bladder damage .
Diseases:"
85	When instilled directly into the bladder , CAA exerts urotoxic effects , it is , however , susceptible to detoxification with mesna .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When instilled directly into the bladder , CAA exerts urotoxic effects , it is , however , susceptible to detoxification with mesna .
Diseases: "	"Sentence: When instilled directly into the bladder , CAA exerts urotoxic effects , it is , however , susceptible to detoxification with mesna .
Diseases:"
86	Source of pain and primitive dysfunction in migraine : an identical site ?	O O B O O O O B O O O O O	['pain', 'migraine']	2	3	"Sentence: Source of pain and primitive dysfunction in migraine : an identical site ?
Diseases: pain, migraine"	"Sentence: Source of pain and primitive dysfunction in migraine : an identical site ?
Diseases:"
87	Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin ( 10 patients ) or placebo ointment ( 10 patients ) in a double blind study .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['migraine']	1	3	"Sentence: Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin ( 10 patients ) or placebo ointment ( 10 patients ) in a double blind study .
Diseases: migraine"	"Sentence: Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin ( 10 patients ) or placebo ointment ( 10 patients ) in a double blind study .
Diseases:"
88	Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group .	O O B O O O O O O O O O O O O O O O O O O O	['migraine']	1	3	"Sentence: Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group .
Diseases: migraine"	"Sentence: Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group .
Diseases:"
89	Subsequently 20 migraine patients , who developed an early onset attack with frontotemporal nitroglycerin , received the drug in a second induction test at other body areas .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['migraine']	1	3	"Sentence: Subsequently 20 migraine patients , who developed an early onset attack with frontotemporal nitroglycerin , received the drug in a second induction test at other body areas .
Diseases: migraine"	"Sentence: Subsequently 20 migraine patients , who developed an early onset attack with frontotemporal nitroglycerin , received the drug in a second induction test at other body areas .
Diseases:"
90	No early onset migraine was observed .	O O O B O O O	['migraine']	1	3	"Sentence: No early onset migraine was observed .
Diseases: migraine"	"Sentence: No early onset migraine was observed .
Diseases:"
91	Thus the migraine - inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .	O O B O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O O	['migraine', 'pain']	2	5	"Sentence: Thus the migraine - inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .
Diseases: migraine, pain"	"Sentence: Thus the migraine - inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .
Diseases:"
92	This is not consistent with a CNS origin of migraine attack .	O O O O O O O O O B O O	['migraine']	1	3	"Sentence: This is not consistent with a CNS origin of migraine attack .
Diseases: migraine"	"Sentence: This is not consistent with a CNS origin of migraine attack .
Diseases:"
93	Clotiazepam - induced acute hepatitis .	O O O O B O	['hepatitis']	1	3	"Sentence: Clotiazepam - induced acute hepatitis .
Diseases: hepatitis"	"Sentence: Clotiazepam - induced acute hepatitis .
Diseases:"
94	We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis , 7 months after the onset of administration of clotiazepam , a thienodiazepine derivative .	O O O O O O O O O O B O B I I O O O O O O O O O O O O O O O	['extensive hepatocellular necrosis', 'hepatitis']	2	10	"Sentence: We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis , 7 months after the onset of administration of clotiazepam , a thienodiazepine derivative .
Diseases: extensive hepatocellular necrosis, hepatitis"	"Sentence: We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis , 7 months after the onset of administration of clotiazepam , a thienodiazepine derivative .
Diseases:"
95	Clotiazepam withdrawal was followed by prompt recovery .	O O O O O O O O	[]	0	0	"Sentence: Clotiazepam withdrawal was followed by prompt recovery .
Diseases: "	"Sentence: Clotiazepam withdrawal was followed by prompt recovery .
Diseases:"
96	The administration of several benzodiazepines , chemically related to clotiazepam , did not interfere with recovery and did not induce any relapse of hepatitis .	O O O O O O O O O O O O O O O O O O O O O O O B O	['hepatitis']	1	3	"Sentence: The administration of several benzodiazepines , chemically related to clotiazepam , did not interfere with recovery and did not induce any relapse of hepatitis .
Diseases: hepatitis"	"Sentence: The administration of several benzodiazepines , chemically related to clotiazepam , did not interfere with recovery and did not induce any relapse of hepatitis .
Diseases:"
97	This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines .	O O O O O O O O B O O O O O O O B O O O O O O	['hepatotoxicity', 'hepatitis']	2	6	"Sentence: This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines .
Diseases: hepatotoxicity, hepatitis"	"Sentence: This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines .
Diseases:"
98	Arterial hypertension as a complication of prolonged ketoconazole treatment .	O B O O O O O O O O	['hypertension']	1	3	"Sentence: Arterial hypertension as a complication of prolonged ketoconazole treatment .
Diseases: hypertension"	"Sentence: Arterial hypertension as a complication of prolonged ketoconazole treatment .
Diseases:"
99	Two of 14 patients with Cushing 's syndrome treated on a long - term basis with ketoconazole developed sustained hypertension .	O O O O O B I I O O O O O O O O O O O B O	"[""cushing 's syndrome"", 'hypertension']"	2	7	"Sentence: Two of 14 patients with Cushing 's syndrome treated on a long - term basis with ketoconazole developed sustained hypertension .
Diseases: cushing 's syndrome, hypertension"	"Sentence: Two of 14 patients with Cushing 's syndrome treated on a long - term basis with ketoconazole developed sustained hypertension .
Diseases:"
100	In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy , yet continuous blood pressure monitoring demonstrated hypertension 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy , yet continuous blood pressure monitoring demonstrated hypertension 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .
Diseases: hypertension"	"Sentence: In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy , yet continuous blood pressure monitoring demonstrated hypertension 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .
Diseases:"
101	In patient 1 , plasma levels of deoxycorticosterone and 11 - deoxycortisol were elevated .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In patient 1 , plasma levels of deoxycorticosterone and 11 - deoxycortisol were elevated .
Diseases: "	"Sentence: In patient 1 , plasma levels of deoxycorticosterone and 11 - deoxycortisol were elevated .
Diseases:"
102	In patient 2 , in addition to an increase in both deoxycorticosterone and 11 - deoxycortisol levels , plasma aldosterone values were raised , with a concomitant suppression of renin levels .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In patient 2 , in addition to an increase in both deoxycorticosterone and 11 - deoxycortisol levels , plasma aldosterone values were raised , with a concomitant suppression of renin levels .
Diseases: "	"Sentence: In patient 2 , in addition to an increase in both deoxycorticosterone and 11 - deoxycortisol levels , plasma aldosterone values were raised , with a concomitant suppression of renin levels .
Diseases:"
103	Our findings show that long - term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid - related hypertension .	O O O O O O O O O O O O O O O O O O O O O O B O	['hypertension']	1	3	"Sentence: Our findings show that long - term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid - related hypertension .
Diseases: hypertension"	"Sentence: Our findings show that long - term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid - related hypertension .
Diseases:"
104	Effects of an inhibitor of angiotensin converting enzyme ( Captopril ) on pulmonary and renal insufficiency due to intravascular coagulation in the rat .	O O O O O O O O O O O O B I I I O O B I O O O O	['pulmonary and renal insufficiency', 'intravascular coagulation']	2	15	"Sentence: Effects of an inhibitor of angiotensin converting enzyme ( Captopril ) on pulmonary and renal insufficiency due to intravascular coagulation in the rat .
Diseases: pulmonary and renal insufficiency, intravascular coagulation"	"Sentence: Effects of an inhibitor of angiotensin converting enzyme ( Captopril ) on pulmonary and renal insufficiency due to intravascular coagulation in the rat .
Diseases:"
105	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .	O O B I O O O O O O O O O O O O O O O O O O O O B I I I O O O O B O B O O O	['sepsis', 'pulmonary and renal insufficiency', 'trauma', 'intravascular coagulation']	4	19	"Sentence: Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .
Diseases: sepsis, pulmonary and renal insufficiency, trauma, intravascular coagulation"	"Sentence: Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .
Diseases:"
106	Injection of Captopril ( 1 mg / kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both pulmonary and renal insufficiency in this rat model .	O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O	['pulmonary and renal insufficiency']	1	8	"Sentence: Injection of Captopril ( 1 mg / kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both pulmonary and renal insufficiency in this rat model .
Diseases: pulmonary and renal insufficiency"	"Sentence: Injection of Captopril ( 1 mg / kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both pulmonary and renal insufficiency in this rat model .
Diseases:"
107	The lung weights were lower and PaO2 was improved in rats given this enzyme - blocking agent .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The lung weights were lower and PaO2 was improved in rats given this enzyme - blocking agent .
Diseases: "	"Sentence: The lung weights were lower and PaO2 was improved in rats given this enzyme - blocking agent .
Diseases:"
108	The contents of albumin in the lungs were not changed , indicating that Captopril did not influence the extravasation of protein .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The contents of albumin in the lungs were not changed , indicating that Captopril did not influence the extravasation of protein .
Diseases: "	"Sentence: The contents of albumin in the lungs were not changed , indicating that Captopril did not influence the extravasation of protein .
Diseases:"
109	Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril .	B I O O O O O O O O O O O O O O O O O	['renal damage']	1	3	"Sentence: Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril .
Diseases: renal damage"	"Sentence: Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril .
Diseases:"
110	The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone .
Diseases: "	"Sentence: The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone .
Diseases:"
111	It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin ( secondary to an increase in bradykinin ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin ( secondary to an increase in bradykinin ) .
Diseases: "	"Sentence: It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin ( secondary to an increase in bradykinin ) .
Diseases:"
112	Captopril may , by the same mechanism , reduce the increase in glomerular filtration that is known to occur after an injection of thrombin , thereby diminishing the aggregation of fibrin monomers in the glomeruli , with the result that less fibrin will be deposited and thus less kidney damage will be produced .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O	['kidney damage']	1	3	"Sentence: Captopril may , by the same mechanism , reduce the increase in glomerular filtration that is known to occur after an injection of thrombin , thereby diminishing the aggregation of fibrin monomers in the glomeruli , with the result that less fibrin will be deposited and thus less kidney damage will be produced .
Diseases: kidney damage"	"Sentence: Captopril may , by the same mechanism , reduce the increase in glomerular filtration that is known to occur after an injection of thrombin , thereby diminishing the aggregation of fibrin monomers in the glomeruli , with the result that less fibrin will be deposited and thus less kidney damage will be produced .
Diseases:"
113	A randomized comparison of labetalol and nitroprusside for induced hypotension .	O O O O O O O O O B O	['hypotension']	1	3	"Sentence: A randomized comparison of labetalol and nitroprusside for induced hypotension .
Diseases: hypotension"	"Sentence: A randomized comparison of labetalol and nitroprusside for induced hypotension .
Diseases:"
114	In a randomized study , labetalol - induced hypotension and nitroprusside - induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .	O O O O O O O O B O O O O B O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: In a randomized study , labetalol - induced hypotension and nitroprusside - induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
Diseases: hypotension"	"Sentence: In a randomized study , labetalol - induced hypotension and nitroprusside - induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .
Diseases:"
115	Each patient was subjected to an identical anesthetic protocol and similar drug - induced reductions in mean arterial blood pressure ( BP ) ( 50 to 55 mmHg ) .	O O O O O O O O O O O O O O B I I I I I O O O O O O O O O O	['reductions in mean arterial blood pressure']	1	8	"Sentence: Each patient was subjected to an identical anesthetic protocol and similar drug - induced reductions in mean arterial blood pressure ( BP ) ( 50 to 55 mmHg ) .
Diseases: reductions in mean arterial blood pressure"	"Sentence: Each patient was subjected to an identical anesthetic protocol and similar drug - induced reductions in mean arterial blood pressure ( BP ) ( 50 to 55 mmHg ) .
Diseases:"
116	Nitroprusside infusion was associated with a significant ( p less than 0 . 05 ) increase in heart rate and cardiac output ; rebound hypertension was observed in three patients after discontinuation of nitroprusside .	O O O O O O O O O O O O O O O B I I I I I I O O B O O O O O O O O O O	['increase in heart rate and cardiac output', 'hypertension']	2	10	"Sentence: Nitroprusside infusion was associated with a significant ( p less than 0 . 05 ) increase in heart rate and cardiac output ; rebound hypertension was observed in three patients after discontinuation of nitroprusside .
Diseases: increase in heart rate and cardiac output, hypertension"	"Sentence: Nitroprusside infusion was associated with a significant ( p less than 0 . 05 ) increase in heart rate and cardiac output ; rebound hypertension was observed in three patients after discontinuation of nitroprusside .
Diseases:"
117	Labetalol administration was not associated with any of these findings .	O O O O O O O O O O O	[]	0	0	"Sentence: Labetalol administration was not associated with any of these findings .
Diseases: "	"Sentence: Labetalol administration was not associated with any of these findings .
Diseases:"
118	Arterial PO2 decreased in both groups .	O O O O O O O	[]	0	0	"Sentence: Arterial PO2 decreased in both groups .
Diseases: "	"Sentence: Arterial PO2 decreased in both groups .
Diseases:"
119	It was concluded that labetalol offers advantages over nitroprusside .	O O O O O O O O O O	[]	0	0	"Sentence: It was concluded that labetalol offers advantages over nitroprusside .
Diseases: "	"Sentence: It was concluded that labetalol offers advantages over nitroprusside .
Diseases:"
120	Chronic carbamazepine treatment in the rat : efficacy , toxicity , and effect on plasma and tissue folate concentrations .	O O O O O O O O O B O O O O O O O O O O	['toxicity']	1	2	"Sentence: Chronic carbamazepine treatment in the rat : efficacy , toxicity , and effect on plasma and tissue folate concentrations .
Diseases: toxicity"	"Sentence: Chronic carbamazepine treatment in the rat : efficacy , toxicity , and effect on plasma and tissue folate concentrations .
Diseases:"
121	Folate depletion has often been a problem in chronic antiepileptic drug ( AED ) therapy .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Folate depletion has often been a problem in chronic antiepileptic drug ( AED ) therapy .
Diseases: "	"Sentence: Folate depletion has often been a problem in chronic antiepileptic drug ( AED ) therapy .
Diseases:"
122	Carbamazepine ( CBZ ) , a commonly used AED , has been implicated in some clinical studies .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Carbamazepine ( CBZ ) , a commonly used AED , has been implicated in some clinical studies .
Diseases: "	"Sentence: Carbamazepine ( CBZ ) , a commonly used AED , has been implicated in some clinical studies .
Diseases:"
123	A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat .
Diseases: "	"Sentence: A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat .
Diseases:"
124	In the course of developing this model , a common vehicle , propylene glycol , by itself in high doses , was found to exhibit protective properties against induced seizures and inhibited weight gain .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B I O	['weight gain', 'seizures']	2	4	"Sentence: In the course of developing this model , a common vehicle , propylene glycol , by itself in high doses , was found to exhibit protective properties against induced seizures and inhibited weight gain .
Diseases: weight gain, seizures"	"Sentence: In the course of developing this model , a common vehicle , propylene glycol , by itself in high doses , was found to exhibit protective properties against induced seizures and inhibited weight gain .
Diseases:"
125	Seizures induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .	B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['seizures']	1	3	"Sentence: Seizures induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .
Diseases: seizures"	"Sentence: Seizures induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .
Diseases:"
126	Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against HFDE - induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B I O O O O O O	['weight gain', 'seizures']	2	4	"Sentence: Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against HFDE - induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment .
Diseases: weight gain, seizures"	"Sentence: Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against HFDE - induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment .
Diseases:"
127	The CBZ levels measured in plasma and brain of these animals , however , were below those normally considered protective .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The CBZ levels measured in plasma and brain of these animals , however , were below those normally considered protective .
Diseases: "	"Sentence: The CBZ levels measured in plasma and brain of these animals , however , were below those normally considered protective .
Diseases:"
128	This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat , and , indeed , the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat , and , indeed , the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment .
Diseases: "	"Sentence: This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat , and , indeed , the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment .
Diseases:"
129	Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs .	O O O O O O O O O O O	[]	0	0	"Sentence: Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs .
Diseases: "	"Sentence: Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs .
Diseases:"
130	In six conscious , trained dogs , maintained on a normal sodium intake of 2 to 4 mEq / kg / day , sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15 - minute i . v .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In six conscious , trained dogs , maintained on a normal sodium intake of 2 to 4 mEq / kg / day , sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15 - minute i . v .
Diseases: "	"Sentence: In six conscious , trained dogs , maintained on a normal sodium intake of 2 to 4 mEq / kg / day , sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15 - minute i . v .
Diseases:"
131	infusions of human alpha - atrial natriuretic factor .	O O O O O O O O O	[]	0	0	"Sentence: infusions of human alpha - atrial natriuretic factor .
Diseases: "	"Sentence: infusions of human alpha - atrial natriuretic factor .
Diseases:"
132	Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['tachycardia', 'hypotension']	2	7	"Sentence: Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin .
Diseases: tachycardia, hypotension"	"Sentence: Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin .
Diseases:"
133	The release rate of epinephrine ( control , 6 . 7 + / - 0 . 6 ng / kg / min ) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 + / - 5 % of control ( p less than 0 . 001 ) during 0 . 1 microgram / kg / min and to 63 + / - 5 % ( 0 . 1 greater than p greater than 0 . 05 ) or 95 + / - 13 % ( not significant ) during 0 . 3 or 1 . 0 microgram / kg / min .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The release rate of epinephrine ( control , 6 . 7 + / - 0 . 6 ng / kg / min ) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 + / - 5 % of control ( p less than 0 . 001 ) during 0 . 1 microgram / kg / min and to 63 + / - 5 % ( 0 . 1 greater than p greater than 0 . 05 ) or 95 + / - 13 % ( not significant ) during 0 . 3 or 1 . 0 microgram / kg / min .
Diseases: "	"Sentence: The release rate of epinephrine ( control , 6 . 7 + / - 0 . 6 ng / kg / min ) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 + / - 5 % of control ( p less than 0 . 001 ) during 0 . 1 microgram / kg / min and to 63 + / - 5 % ( 0 . 1 greater than p greater than 0 . 05 ) or 95 + / - 13 % ( not significant ) during 0 . 3 or 1 . 0 microgram / kg / min .
Diseases:"
134	Steady state arterial plasma concentrations of atrial natriuretic factor were 39 + / - 10 pg / ml ( n = 6 ) during infusions of saline and 284 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Steady state arterial plasma concentrations of atrial natriuretic factor were 39 + / - 10 pg / ml ( n = 6 ) during infusions of saline and 284 + / -
Diseases: "	"Sentence: Steady state arterial plasma concentrations of atrial natriuretic factor were 39 + / - 10 pg / ml ( n = 6 ) during infusions of saline and 284 + / -
Diseases:"
135	24 pg / ml ( n = 6 ) and 1520 + / -	O O O O O O O O O O O O O O	[]	0	0	"Sentence: 24 pg / ml ( n = 6 ) and 1520 + / -
Diseases: "	"Sentence: 24 pg / ml ( n = 6 ) and 1520 + / -
Diseases:"
136	300 pg / ml ( n = 9 ) during 0 . 03 and 0 . 1 microgram / kg / min infusions of the factor . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 300 pg / ml ( n = 9 ) during 0 . 03 and 0 . 1 microgram / kg / min infusions of the factor . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: "	"Sentence: 300 pg / ml ( n = 9 ) during 0 . 03 and 0 . 1 microgram / kg / min infusions of the factor . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
137	Death from chemotherapy in gestational trophoblastic disease .	B O O O B I I O	['death', 'gestational trophoblastic disease']	2	9	"Sentence: Death from chemotherapy in gestational trophoblastic disease .
Diseases: death, gestational trophoblastic disease"	"Sentence: Death from chemotherapy in gestational trophoblastic disease .
Diseases:"
138	Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high - risk stage of choriocarcinoma .	O O O O O O O O O O O O O O O O O O B O	['choriocarcinoma']	1	6	"Sentence: Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high - risk stage of choriocarcinoma .
Diseases: choriocarcinoma"	"Sentence: Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high - risk stage of choriocarcinoma .
Diseases:"
139	Based on this principle a 27 - year old woman , classified as being in the high - risk group ( Goldstein and Berkowitz score : 11 ) , was treated with multiple cytotoxic drugs .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Based on this principle a 27 - year old woman , classified as being in the high - risk group ( Goldstein and Berkowitz score : 11 ) , was treated with multiple cytotoxic drugs .
Diseases: "	"Sentence: Based on this principle a 27 - year old woman , classified as being in the high - risk group ( Goldstein and Berkowitz score : 11 ) , was treated with multiple cytotoxic drugs .
Diseases:"
140	The multiple drug schema consisted of : Etoposide 16 . 213 , Methotrexate , Cyclophosphamide , Actomycin - D , and Cisplatin .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The multiple drug schema consisted of : Etoposide 16 . 213 , Methotrexate , Cyclophosphamide , Actomycin - D , and Cisplatin .
Diseases: "	"Sentence: The multiple drug schema consisted of : Etoposide 16 . 213 , Methotrexate , Cyclophosphamide , Actomycin - D , and Cisplatin .
Diseases:"
141	On the first day of the schedule , moderate high doses of Methotrexate , Etoposide and Cyclophosphamide were administered .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On the first day of the schedule , moderate high doses of Methotrexate , Etoposide and Cyclophosphamide were administered .
Diseases: "	"Sentence: On the first day of the schedule , moderate high doses of Methotrexate , Etoposide and Cyclophosphamide were administered .
Diseases:"
142	Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs , probably originating from the uterus .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	['pulmonary obstruction']	1	4	"Sentence: Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs , probably originating from the uterus .
Diseases: pulmonary obstruction"	"Sentence: Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs , probably originating from the uterus .
Diseases:"
143	Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins , which resulted in an open exchange of tumor plugs to the vascular spaces ; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli .	O O O O O O O O O B B O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O O B O O	['tumor', 'necrosis']	2	6	"Sentence: Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins , which resulted in an open exchange of tumor plugs to the vascular spaces ; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli .
Diseases: tumor, necrosis"	"Sentence: Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins , which resulted in an open exchange of tumor plugs to the vascular spaces ; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli .
Diseases:"
144	In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations , such as spontaneous necrosis , must be considered less likely .	O O O O O O O O O O O O O O O O O O B O O O O O O B O O O O O O O	['embolism', 'necrosis']	2	6	"Sentence: In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations , such as spontaneous necrosis , must be considered less likely .
Diseases: embolism, necrosis"	"Sentence: In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations , such as spontaneous necrosis , must be considered less likely .
Diseases:"
145	Patients with large pelvic tumor loads are , according to existing classifications , at high risk to die and to develop drug resistance .	O O O B I O O O O O O O O O O O O O O O O O O O	['pelvic tumor']	1	3	"Sentence: Patients with large pelvic tumor loads are , according to existing classifications , at high risk to die and to develop drug resistance .
Diseases: pelvic tumor"	"Sentence: Patients with large pelvic tumor loads are , according to existing classifications , at high risk to die and to develop drug resistance .
Diseases:"
146	Notwithstanding these facts our findings suggest that these patients might benefit from relatively mild initial treatment , especially true for patients not previously exposed to this drug .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Notwithstanding these facts our findings suggest that these patients might benefit from relatively mild initial treatment , especially true for patients not previously exposed to this drug .
Diseases: "	"Sentence: Notwithstanding these facts our findings suggest that these patients might benefit from relatively mild initial treatment , especially true for patients not previously exposed to this drug .
Diseases:"
147	Close observation of the response status both clinically and with beta - hCG values may indicate whether and when more agressive combination chemotherapy should be started . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Close observation of the response status both clinically and with beta - hCG values may indicate whether and when more agressive combination chemotherapy should be started . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: "	"Sentence: Close observation of the response status both clinically and with beta - hCG values may indicate whether and when more agressive combination chemotherapy should be started . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
148	Sexual dysfunction among patients with arthritis .	B I O O O B O	['sexual dysfunction', 'arthritis']	2	4	"Sentence: Sexual dysfunction among patients with arthritis .
Diseases: sexual dysfunction, arthritis"	"Sentence: Sexual dysfunction among patients with arthritis .
Diseases:"
149	The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis , osteoarthritis and spondyloarthropathy , 130 of whom were pair - matched to controls .	O O O B O B I O O O O O O B I O B O B O O O O O O O O O O O	['osteoarthritis', 'arthritis', 'spondyloarthropathy', 'sexual dysfunction', 'rheumatoid arthritis']	5	24	"Sentence: The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis , osteoarthritis and spondyloarthropathy , 130 of whom were pair - matched to controls .
Diseases: osteoarthritis, arthritis, spondyloarthropathy, sexual dysfunction, rheumatoid arthritis"	"Sentence: The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis , osteoarthritis and spondyloarthropathy , 130 of whom were pair - matched to controls .
Diseases:"
150	Assessments of marital happiness and depressed mood were also made using the CES - D and the Azrin Marital Happiness Scale ( AMHS ) .	O O O O O B I O O O O O O O O O O O O O O O O O O	['depressed mood']	1	3	"Sentence: Assessments of marital happiness and depressed mood were also made using the CES - D and the Azrin Marital Happiness Scale ( AMHS ) .
Diseases: depressed mood"	"Sentence: Assessments of marital happiness and depressed mood were also made using the CES - D and the Azrin Marital Happiness Scale ( AMHS ) .
Diseases:"
151	Sexual dysfunctions were found to be common among patients and controls , the majority in both groups reporting one or more dysfunctions .	B I O O O O O O O O O O O O O O O O O O O O O	['sexual dysfunctions']	1	4	"Sentence: Sexual dysfunctions were found to be common among patients and controls , the majority in both groups reporting one or more dysfunctions .
Diseases: sexual dysfunctions"	"Sentence: Sexual dysfunctions were found to be common among patients and controls , the majority in both groups reporting one or more dysfunctions .
Diseases:"
152	Impotence was more common among male patients than controls and was found to be associated with co - morbidity and the taking of methotrexate .	B O O O O O O O O O O O O O O O O O O O O O O O O	['impotence']	1	3	"Sentence: Impotence was more common among male patients than controls and was found to be associated with co - morbidity and the taking of methotrexate .
Diseases: impotence"	"Sentence: Impotence was more common among male patients than controls and was found to be associated with co - morbidity and the taking of methotrexate .
Diseases:"
153	Depressed mood was more common among patients and was associated with certain sexual difficulties , but not with impotence .	B I O O O O O O O O O O O O O O O O B O	['impotence', 'depressed mood']	2	6	"Sentence: Depressed mood was more common among patients and was associated with certain sexual difficulties , but not with impotence .
Diseases: impotence, depressed mood"	"Sentence: Depressed mood was more common among patients and was associated with certain sexual difficulties , but not with impotence .
Diseases:"
154	Marital unhappiness , as indicated by AMHS scores , was not associated with arthritis but was associated with sexual dysfunction , sexual dissatisfaction and being female .	O O O O O O O O O O O O O B O O O O B I O O O O O O O	['arthritis', 'sexual dysfunction']	2	5	"Sentence: Marital unhappiness , as indicated by AMHS scores , was not associated with arthritis but was associated with sexual dysfunction , sexual dissatisfaction and being female .
Diseases: arthritis, sexual dysfunction"	"Sentence: Marital unhappiness , as indicated by AMHS scores , was not associated with arthritis but was associated with sexual dysfunction , sexual dissatisfaction and being female .
Diseases:"
155	Does paracetamol cause urothelial cancer or renal papillary necrosis ?	O O O B I O B I I O	['urothelial cancer', 'renal papillary necrosis']	2	10	"Sentence: Does paracetamol cause urothelial cancer or renal papillary necrosis ?
Diseases: urothelial cancer, renal papillary necrosis"	"Sentence: Does paracetamol cause urothelial cancer or renal papillary necrosis ?
Diseases:"
156	The risk of developing renal papillary necrosis or cancer of the renal pelvis , ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .	O O O O B I I O B I I I I I I I I O O O O O O O O O O O O O O O O O O O O O O	['cancer of the renal pelvis , ureter or bladder', 'renal papillary necrosis']	2	18	"Sentence: The risk of developing renal papillary necrosis or cancer of the renal pelvis , ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .
Diseases: cancer of the renal pelvis , ureter or bladder, renal papillary necrosis"	"Sentence: The risk of developing renal papillary necrosis or cancer of the renal pelvis , ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .
Diseases:"
157	The risk of renal papillary necrosis was increased nearly 20 - fold by consumption of phenacetin , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer .	O O O B I I O O O O O O O O O O O O O O O O O B I I I I I I O O O B I O	['ureteric cancer', 'cancer of the renal pelvis and bladder', 'renal papillary necrosis']	3	19	"Sentence: The risk of renal papillary necrosis was increased nearly 20 - fold by consumption of phenacetin , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer .
Diseases: ureteric cancer, cancer of the renal pelvis and bladder, renal papillary necrosis"	"Sentence: The risk of renal papillary necrosis was increased nearly 20 - fold by consumption of phenacetin , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer .
Diseases:"
158	By contrast , we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter .	O O O O O O O O O O O O O O O B I I O O O O B O O O O O O O O O B I I I O	['cancers', 'cancer of the ureter', 'renal papillary necrosis']	3	15	"Sentence: By contrast , we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter .
Diseases: cancers, cancer of the ureter, renal papillary necrosis"	"Sentence: By contrast , we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter .
Diseases:"
159	Dapsone - associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait .	O O O O O B I O O O O O O O O O	['hemolytic anemia']	1	5	"Sentence: Dapsone - associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait .
Diseases: hemolytic anemia"	"Sentence: Dapsone - associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait .
Diseases:"
160	A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis .	O O O O O O O O O O O B O O O O B I O O O O O O O O O O O O O O O O O B O	['leprosy', 'hemolysis', 'hemolytic anemia']	3	13	"Sentence: A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis .
Diseases: leprosy, hemolysis, hemolytic anemia"	"Sentence: A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis .
Diseases:"
161	Her red blood cells ( RBCs ) had increased incubated Heinz body formation , decreased reduced glutathione ( GSH ) , and decreased GSH stability .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Her red blood cells ( RBCs ) had increased incubated Heinz body formation , decreased reduced glutathione ( GSH ) , and decreased GSH stability .
Diseases: "	"Sentence: Her red blood cells ( RBCs ) had increased incubated Heinz body formation , decreased reduced glutathione ( GSH ) , and decreased GSH stability .
Diseases:"
162	The pentose phosphate shunt activity of the dapsone - exposed AE RBCs was increased compared to normal RBCs .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The pentose phosphate shunt activity of the dapsone - exposed AE RBCs was increased compared to normal RBCs .
Diseases: "	"Sentence: The pentose phosphate shunt activity of the dapsone - exposed AE RBCs was increased compared to normal RBCs .
Diseases:"
163	Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation , the GSH content and GSH stability were normal .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation , the GSH content and GSH stability were normal .
Diseases: "	"Sentence: Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation , the GSH content and GSH stability were normal .
Diseases:"
164	The pentose phosphate shunt activity of the non - dapsone - exposed AE RBCs was decreased compared to normal RBCs .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The pentose phosphate shunt activity of the non - dapsone - exposed AE RBCs was decreased compared to normal RBCs .
Diseases: "	"Sentence: The pentose phosphate shunt activity of the non - dapsone - exposed AE RBCs was decreased compared to normal RBCs .
Diseases:"
165	Thus , AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo , since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O	['hemolytic anemia']	1	5	"Sentence: Thus , AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo , since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals .
Diseases: hemolytic anemia"	"Sentence: Thus , AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo , since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals .
Diseases:"
166	Given the influx of Southeast Asians into the United States , oxidant medications should be used with caution , especially if an infection is present , in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['infection']	1	2	"Sentence: Given the influx of Southeast Asians into the United States , oxidant medications should be used with caution , especially if an infection is present , in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E .
Diseases: infection"	"Sentence: Given the influx of Southeast Asians into the United States , oxidant medications should be used with caution , especially if an infection is present , in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E .
Diseases:"
167	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol , propafenone , diltiazem , and sparteine .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol , propafenone , diltiazem , and sparteine .
Diseases: "	"Sentence: Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol , propafenone , diltiazem , and sparteine .
Diseases:"
168	A 47 - year - old patient suffering from coronary artery disease was admitted to the CCU in shock with III .	O O O O O O O O O B I I O O O O O O B O O O	['shock', 'coronary artery disease']	2	5	"Sentence: A 47 - year - old patient suffering from coronary artery disease was admitted to the CCU in shock with III .
Diseases: shock, coronary artery disease"	"Sentence: A 47 - year - old patient suffering from coronary artery disease was admitted to the CCU in shock with III .
Diseases:"
169	AV block , severe hypotension , and impairment of ventricular function .	B I O O B O O B I I I O	['hypotension', 'av block', 'impairment of ventricular function']	3	12	"Sentence: AV block , severe hypotension , and impairment of ventricular function .
Diseases: hypotension, av block, impairment of ventricular function"	"Sentence: AV block , severe hypotension , and impairment of ventricular function .
Diseases:"
170	One week prior to admission a therapy with standard doses of metoprolol ( 100 mg t . i . d .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: One week prior to admission a therapy with standard doses of metoprolol ( 100 mg t . i . d .
Diseases: "	"Sentence: One week prior to admission a therapy with standard doses of metoprolol ( 100 mg t . i . d .
Diseases:"
171	and then 100 mg b . i . d . ) had been initiated .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: and then 100 mg b . i . d . ) had been initiated .
Diseases: "	"Sentence: and then 100 mg b . i . d . ) had been initiated .
Diseases:"
172	Two days before admission diltiazem ( 60 mg b . i . d . ) was prescribed in addition .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two days before admission diltiazem ( 60 mg b . i . d . ) was prescribed in addition .
Diseases: "	"Sentence: Two days before admission diltiazem ( 60 mg b . i . d . ) was prescribed in addition .
Diseases:"
173	Analyses of a blood sample revealed unusually high plasma concentrations of metoprolol ( greater than 3000 ng / ml ) and diltiazem ( 526 ng / ml ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Analyses of a blood sample revealed unusually high plasma concentrations of metoprolol ( greater than 3000 ng / ml ) and diltiazem ( 526 ng / ml ) .
Diseases: "	"Sentence: Analyses of a blood sample revealed unusually high plasma concentrations of metoprolol ( greater than 3000 ng / ml ) and diltiazem ( 526 ng / ml ) .
Diseases:"
174	The patient recovered within 1 week following discontinuation of antianginal therapy .	O O O O O O O O O O O O	[]	0	0	"Sentence: The patient recovered within 1 week following discontinuation of antianginal therapy .
Diseases: "	"Sentence: The patient recovered within 1 week following discontinuation of antianginal therapy .
Diseases:"
175	Three months later the patient was exposed to a single dose of metoprolol , diltiazem , propafenone ( since he had received this drug in the past ) , and sparteine ( as a probe for the debrisoquine / sparteine type polymorphism of oxidative drug metabolism ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Three months later the patient was exposed to a single dose of metoprolol , diltiazem , propafenone ( since he had received this drug in the past ) , and sparteine ( as a probe for the debrisoquine / sparteine type polymorphism of oxidative drug metabolism ) .
Diseases: "	"Sentence: Three months later the patient was exposed to a single dose of metoprolol , diltiazem , propafenone ( since he had received this drug in the past ) , and sparteine ( as a probe for the debrisoquine / sparteine type polymorphism of oxidative drug metabolism ) .
Diseases:"
176	It was found that he was a poor metabolizer of all four drugs , indicating that their metabolism is under the same genetic control .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It was found that he was a poor metabolizer of all four drugs , indicating that their metabolism is under the same genetic control .
Diseases: "	"Sentence: It was found that he was a poor metabolizer of all four drugs , indicating that their metabolism is under the same genetic control .
Diseases:"
177	Therefore , patients belonging to the poor - metabolizer phenotype of sparteine / debrisoquine polymorphism in drug metabolism , which constitutes 6 . 4 % of the German population , may experience adverse drug reactions when treated with standard doses of one of these drugs alone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O	['adverse drug reactions']	1	4	"Sentence: Therefore , patients belonging to the poor - metabolizer phenotype of sparteine / debrisoquine polymorphism in drug metabolism , which constitutes 6 . 4 % of the German population , may experience adverse drug reactions when treated with standard doses of one of these drugs alone .
Diseases: adverse drug reactions"	"Sentence: Therefore , patients belonging to the poor - metabolizer phenotype of sparteine / debrisoquine polymorphism in drug metabolism , which constitutes 6 . 4 % of the German population , may experience adverse drug reactions when treated with standard doses of one of these drugs alone .
Diseases:"
178	Moreover , the coadministration of these frequently used drugs is expected to be especially harmful in this subgroup of patients .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Moreover , the coadministration of these frequently used drugs is expected to be especially harmful in this subgroup of patients .
Diseases: "	"Sentence: Moreover , the coadministration of these frequently used drugs is expected to be especially harmful in this subgroup of patients .
Diseases:"
179	Triazolam - induced brief episodes of secondary mania in a depressed patient .	O O O O O O O B O O B O O	['mania', 'depressed']	2	3	"Sentence: Triazolam - induced brief episodes of secondary mania in a depressed patient .
Diseases: mania, depressed"	"Sentence: Triazolam - induced brief episodes of secondary mania in a depressed patient .
Diseases:"
180	Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman .	O O O O O O O O O B O O B O O O	['mania', 'depressed']	2	3	"Sentence: Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman .
Diseases: mania, depressed"	"Sentence: Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman .
Diseases:"
181	Features of organic mental disorder ( delirium ) were not present .	O O B I I O B O O O O O	['delirium', 'organic mental disorder']	2	7	"Sentence: Features of organic mental disorder ( delirium ) were not present .
Diseases: delirium, organic mental disorder"	"Sentence: Features of organic mental disorder ( delirium ) were not present .
Diseases:"
182	Manic excitement was coincident with the duration of action of triazolam .	B O O O O O O O O O O O	['manic']	1	2	"Sentence: Manic excitement was coincident with the duration of action of triazolam .
Diseases: manic"	"Sentence: Manic excitement was coincident with the duration of action of triazolam .
Diseases:"
183	The possible contribution of the triazolo group to changes in affective status is discussed .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The possible contribution of the triazolo group to changes in affective status is discussed .
Diseases: "	"Sentence: The possible contribution of the triazolo group to changes in affective status is discussed .
Diseases:"
184	On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats .	O O O O O O O O O O B I O O O O O O	['muscular rigidity']	1	4	"Sentence: On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats .
Diseases: muscular rigidity"	"Sentence: On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats .
Diseases:"
185	The development of tolerance to the muscular rigidity produced by morphine was studied in rats .	O O O O O O B I O O O O O O O O	['muscular rigidity']	1	4	"Sentence: The development of tolerance to the muscular rigidity produced by morphine was studied in rats .
Diseases: muscular rigidity"	"Sentence: The development of tolerance to the muscular rigidity produced by morphine was studied in rats .
Diseases:"
186	Saline - pretreated controls given a test dose of morphine ( 20 mg / kg i . p . ) showed a pronounced rigidity recorded as tonic activity in the electromyogram .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['rigidity']	1	2	"Sentence: Saline - pretreated controls given a test dose of morphine ( 20 mg / kg i . p . ) showed a pronounced rigidity recorded as tonic activity in the electromyogram .
Diseases: rigidity"	"Sentence: Saline - pretreated controls given a test dose of morphine ( 20 mg / kg i . p . ) showed a pronounced rigidity recorded as tonic activity in the electromyogram .
Diseases:"
187	Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic ( A group ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O	['rigidity', 'akinetic']	2	5	"Sentence: Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic ( A group ) .
Diseases: rigidity, akinetic"	"Sentence: Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic ( A group ) .
Diseases:"
188	The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped ( S ) licking and / or gnawing in presence of akinetic or hyperkinetic ( K ) behaviour ( AS / KS group ) , suggesting signs of dopaminergic activation .	O O O O O O O O O B O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O	['rigidity', 'akinetic', 'hyperkinetic']	3	9	"Sentence: The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped ( S ) licking and / or gnawing in presence of akinetic or hyperkinetic ( K ) behaviour ( AS / KS group ) , suggesting signs of dopaminergic activation .
Diseases: rigidity, akinetic, hyperkinetic"	"Sentence: The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped ( S ) licking and / or gnawing in presence of akinetic or hyperkinetic ( K ) behaviour ( AS / KS group ) , suggesting signs of dopaminergic activation .
Diseases:"
189	The rigidity was considerably decreased in both groups after 20 days ' treatment .	O B O O O O O O O O O O O O	['rigidity']	1	2	"Sentence: The rigidity was considerably decreased in both groups after 20 days ' treatment .
Diseases: rigidity"	"Sentence: The rigidity was considerably decreased in both groups after 20 days ' treatment .
Diseases:"
190	In a further series of experiments , haloperidol ( 0 . 2 mg / kg i . p . ) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['rigidity']	1	2	"Sentence: In a further series of experiments , haloperidol ( 0 . 2 mg / kg i . p . ) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference .
Diseases: rigidity"	"Sentence: In a further series of experiments , haloperidol ( 0 . 2 mg / kg i . p . ) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference .
Diseases:"
191	Haloperidol enhanced the rigidity in the A group .	O O O B O O O O O	['rigidity']	1	2	"Sentence: Haloperidol enhanced the rigidity in the A group .
Diseases: rigidity"	"Sentence: Haloperidol enhanced the rigidity in the A group .
Diseases:"
192	However , the level in the AS / KS group remained considerably lower than in the A group .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the level in the AS / KS group remained considerably lower than in the A group .
Diseases: "	"Sentence: However , the level in the AS / KS group remained considerably lower than in the A group .
Diseases:"
193	The results suggest that rigidity , which is assumed to be due to an action of morphine in the striatum , can be antagonized by another process leading to dopaminergic activation in the striatum .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['rigidity']	1	2	"Sentence: The results suggest that rigidity , which is assumed to be due to an action of morphine in the striatum , can be antagonized by another process leading to dopaminergic activation in the striatum .
Diseases: rigidity"	"Sentence: The results suggest that rigidity , which is assumed to be due to an action of morphine in the striatum , can be antagonized by another process leading to dopaminergic activation in the striatum .
Diseases:"
194	Nevertheless , there occurs some real tolerance to this effect .	O O O O O O O O O O O	[]	0	0	"Sentence: Nevertheless , there occurs some real tolerance to this effect .
Diseases: "	"Sentence: Nevertheless , there occurs some real tolerance to this effect .
Diseases:"
195	The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS / KS group might be due to rapid shifts in the predominance of various DA - innervated structures .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['rigidity']	1	2	"Sentence: The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS / KS group might be due to rapid shifts in the predominance of various DA - innervated structures .
Diseases: rigidity"	"Sentence: The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS / KS group might be due to rapid shifts in the predominance of various DA - innervated structures .
Diseases:"
196	Compression neuropathy of the radial nerve due to pentazocine - induced fibrous myopathy .	B I I I I I O O O O O B I O	['compression neuropathy of the radial nerve', 'fibrous myopathy']	2	13	"Sentence: Compression neuropathy of the radial nerve due to pentazocine - induced fibrous myopathy .
Diseases: compression neuropathy of the radial nerve, fibrous myopathy"	"Sentence: Compression neuropathy of the radial nerve due to pentazocine - induced fibrous myopathy .
Diseases:"
197	Fibrous myopathy is a common , well - known side effect of repeated pentazocine injection .	B I O O O O O O O O O O O O O O	['fibrous myopathy']	1	5	"Sentence: Fibrous myopathy is a common , well - known side effect of repeated pentazocine injection .
Diseases: fibrous myopathy"	"Sentence: Fibrous myopathy is a common , well - known side effect of repeated pentazocine injection .
Diseases:"
198	However , compression neuropathy due to fibrotic muscle affected by pentazocine - induced myopathy has not previously been reported .	O O B I O O O O O O O O O B O O O O O O	['myopathy', 'compression neuropathy']	2	6	"Sentence: However , compression neuropathy due to fibrotic muscle affected by pentazocine - induced myopathy has not previously been reported .
Diseases: myopathy, compression neuropathy"	"Sentence: However , compression neuropathy due to fibrotic muscle affected by pentazocine - induced myopathy has not previously been reported .
Diseases:"
199	In a 37 - year - old woman with documented pentazocine - induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three - week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['fibrous myopathy']	1	5	"Sentence: In a 37 - year - old woman with documented pentazocine - induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three - week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .
Diseases: fibrous myopathy"	"Sentence: In a 37 - year - old woman with documented pentazocine - induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three - week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .
Diseases:"
200	Surgery revealed the right radial nerve to be severely compressed by the densely fibrotic lateral head of the triceps .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Surgery revealed the right radial nerve to be severely compressed by the densely fibrotic lateral head of the triceps .
Diseases: "	"Sentence: Surgery revealed the right radial nerve to be severely compressed by the densely fibrotic lateral head of the triceps .
Diseases:"
201	Decompression and neurolysis were performed with good subsequent recovery of function .	O O O O O O O O O O O O	[]	0	0	"Sentence: Decompression and neurolysis were performed with good subsequent recovery of function .
Diseases: "	"Sentence: Decompression and neurolysis were performed with good subsequent recovery of function .
Diseases:"
202	Recurrent reversible acute renal failure from amphotericin .	O O B I I O O O	['acute renal failure']	1	4	"Sentence: Recurrent reversible acute renal failure from amphotericin .
Diseases: acute renal failure"	"Sentence: Recurrent reversible acute renal failure from amphotericin .
Diseases:"
203	A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions .	O O O O B O O B O B I I O O O O O O O O O O O O	['acute renal failure', 'cirrhosis', 'sporotrichosis']	3	13	"Sentence: A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions .
Diseases: acute renal failure, cirrhosis, sporotrichosis"	"Sentence: A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions .
Diseases:"
204	The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction .	O O O O B I O O O O O O O O O O O O O O B I O	['renal failure', 'renal dysfunction']	2	6	"Sentence: The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction .
Diseases: renal failure, renal dysfunction"	"Sentence: The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction .
Diseases:"
205	We propose that amphotericin , in the setting of reduced effective arterial volume , may activate tubuloglomerular feedback , thereby contributing to acute renal failure .	O O O O O O O O O O O O O O O O O O O O O O B I I O	['acute renal failure']	1	4	"Sentence: We propose that amphotericin , in the setting of reduced effective arterial volume , may activate tubuloglomerular feedback , thereby contributing to acute renal failure .
Diseases: acute renal failure"	"Sentence: We propose that amphotericin , in the setting of reduced effective arterial volume , may activate tubuloglomerular feedback , thereby contributing to acute renal failure .
Diseases:"
206	Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .	O O B I I I O B O O O O	['neuropathy', 'pleural and pericardial effusion']	2	13	"Sentence: Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .
Diseases: neuropathy, pleural and pericardial effusion"	"Sentence: Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .
Diseases:"
207	A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of supraventricular tachyarrhythmias .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['supraventricular tachyarrhythmias', 'sinuatrial disease']	2	16	"Sentence: A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of supraventricular tachyarrhythmias .
Diseases: supraventricular tachyarrhythmias, sinuatrial disease"	"Sentence: A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of supraventricular tachyarrhythmias .
Diseases:"
208	He developed pneumonitis , pleural and pericardial effusions , and a predominantly proximal motor neuropathy .	O O B O B I I I O O O O B I I O	['pleural and pericardial effusions', 'proximal motor neuropathy', 'pneumonitis']	3	19	"Sentence: He developed pneumonitis , pleural and pericardial effusions , and a predominantly proximal motor neuropathy .
Diseases: pleural and pericardial effusions, proximal motor neuropathy, pneumonitis"	"Sentence: He developed pneumonitis , pleural and pericardial effusions , and a predominantly proximal motor neuropathy .
Diseases:"
209	Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone .
Diseases: "	"Sentence: Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone .
Diseases:"
210	Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['pneumonitis']	1	4	"Sentence: Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .
Diseases: pneumonitis"	"Sentence: Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .
Diseases:"
211	Indomethacin - induced renal insufficiency : recurrence on rechallenge .	O O O B I O O O O O	['renal insufficiency']	1	5	"Sentence: Indomethacin - induced renal insufficiency : recurrence on rechallenge .
Diseases: renal insufficiency"	"Sentence: Indomethacin - induced renal insufficiency : recurrence on rechallenge .
Diseases:"
212	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , ascites , and cor pulmonale after indomethacin therapy .	O O O O O O O O B I O B O O O O B O B O O B I O O O O	['hyperkalemia', 'cirrhosis', 'renal failure', 'ascites', 'cor pulmonale']	5	19	"Sentence: We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , ascites , and cor pulmonale after indomethacin therapy .
Diseases: hyperkalemia, cirrhosis, renal failure, ascites, cor pulmonale"	"Sentence: We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , ascites , and cor pulmonale after indomethacin therapy .
Diseases:"
213	Prompt restoration of renal function followed drug withdrawal , while re - exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria .	O O O O O O O O O O O O O O O O O O O O O O O O B O	['oliguria']	1	3	"Sentence: Prompt restoration of renal function followed drug withdrawal , while re - exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria .
Diseases: oliguria"	"Sentence: Prompt restoration of renal function followed drug withdrawal , while re - exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria .
Diseases:"
214	Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished .
Diseases: "	"Sentence: Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished .
Diseases:"
215	Since nonsteroidal anti - inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure , they should be used with caution in such patients .	O O O O O O O O O O O O O O B I I O O O O O O O O O O O	['acute renal failure']	1	4	"Sentence: Since nonsteroidal anti - inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure , they should be used with caution in such patients .
Diseases: acute renal failure"	"Sentence: Since nonsteroidal anti - inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure , they should be used with caution in such patients .
Diseases:"
216	Comparison of the subjective effects and plasma concentrations following oral and i . m .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Comparison of the subjective effects and plasma concentrations following oral and i . m .
Diseases: "	"Sentence: Comparison of the subjective effects and plasma concentrations following oral and i . m .
Diseases:"
217	administration of flunitrazepam in volunteers .	O O O O O O	[]	0	0	"Sentence: administration of flunitrazepam in volunteers .
Diseases: "	"Sentence: administration of flunitrazepam in volunteers .
Diseases:"
218	Flunitrazepam 0 . 5 , 1 . 0 or 2 . 0 mg was given by the oral or i . m .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Flunitrazepam 0 . 5 , 1 . 0 or 2 . 0 mg was given by the oral or i . m .
Diseases: "	"Sentence: Flunitrazepam 0 . 5 , 1 . 0 or 2 . 0 mg was given by the oral or i . m .
Diseases:"
219	routes to groups of volunteers and its effects compared .	O O O O O O O O O O	[]	0	0	"Sentence: routes to groups of volunteers and its effects compared .
Diseases: "	"Sentence: routes to groups of volunteers and its effects compared .
Diseases:"
220	Plasma concentrations of the drug were estimated by gas - liquid chromatography , in a smaller number of the subjects .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma concentrations of the drug were estimated by gas - liquid chromatography , in a smaller number of the subjects .
Diseases: "	"Sentence: Plasma concentrations of the drug were estimated by gas - liquid chromatography , in a smaller number of the subjects .
Diseases:"
221	The most striking effect was sedation which increased with the dose , 2 mg producing deep sleep although the subjects could still be aroused .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The most striking effect was sedation which increased with the dose , 2 mg producing deep sleep although the subjects could still be aroused .
Diseases: "	"Sentence: The most striking effect was sedation which increased with the dose , 2 mg producing deep sleep although the subjects could still be aroused .
Diseases:"
222	The effects of i . m .	O O O O O O O	[]	0	0	"Sentence: The effects of i . m .
Diseases: "	"Sentence: The effects of i . m .
Diseases:"
223	administration were apparent earlier and sometimes lasted longer than those following oral administration .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: administration were apparent earlier and sometimes lasted longer than those following oral administration .
Diseases: "	"Sentence: administration were apparent earlier and sometimes lasted longer than those following oral administration .
Diseases:"
224	Dizziness was less marked than sedation , but increased with the dose .	B O O O O O O O O O O O O	['dizziness']	1	3	"Sentence: Dizziness was less marked than sedation , but increased with the dose .
Diseases: dizziness"	"Sentence: Dizziness was less marked than sedation , but increased with the dose .
Diseases:"
225	There was pain on i . m .	O O B O O O O O	['pain']	1	1	"Sentence: There was pain on i . m .
Diseases: pain"	"Sentence: There was pain on i . m .
Diseases:"
226	injection of flunitrazepam significantly more often than with isotonic saline .	O O O O O O O O O O O	[]	0	0	"Sentence: injection of flunitrazepam significantly more often than with isotonic saline .
Diseases: "	"Sentence: injection of flunitrazepam significantly more often than with isotonic saline .
Diseases:"
227	Plasma concentrations varied with dose and route and corresponded qualitatively with the subjective effects .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma concentrations varied with dose and route and corresponded qualitatively with the subjective effects .
Diseases: "	"Sentence: Plasma concentrations varied with dose and route and corresponded qualitatively with the subjective effects .
Diseases:"
228	The drug was still present in measurable quantities after 24 h even with the smallest dose .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The drug was still present in measurable quantities after 24 h even with the smallest dose .
Diseases: "	"Sentence: The drug was still present in measurable quantities after 24 h even with the smallest dose .
Diseases:"
229	Changes in heart size during long - term timolol treatment after myocardial infarction .	O O O O O O O O O O O B I O	['myocardial infarction']	1	6	"Sentence: Changes in heart size during long - term timolol treatment after myocardial infarction .
Diseases: myocardial infarction"	"Sentence: Changes in heart size during long - term timolol treatment after myocardial infarction .
Diseases:"
230	The effect of long - term timolol treatment on heart size after myocardial infarction was evaluated by X - ray in a double - blind study including 241 patients ( placebo 126 , timolol 115 ) .	O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: The effect of long - term timolol treatment on heart size after myocardial infarction was evaluated by X - ray in a double - blind study including 241 patients ( placebo 126 , timolol 115 ) .
Diseases: myocardial infarction"	"Sentence: The effect of long - term timolol treatment on heart size after myocardial infarction was evaluated by X - ray in a double - blind study including 241 patients ( placebo 126 , timolol 115 ) .
Diseases:"
231	The follow - up period was 12 months .	O O O O O O O O O	[]	0	0	"Sentence: The follow - up period was 12 months .
Diseases: "	"Sentence: The follow - up period was 12 months .
Diseases:"
232	The timolol - treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The timolol - treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group .
Diseases: "	"Sentence: The timolol - treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group .
Diseases:"
233	These differences may be caused by timolol - induced bradycardia and a compensatory increase in end - diastolic volume .	O O O O O O O O O B O O O O O O O O O O	['bradycardia']	1	4	"Sentence: These differences may be caused by timolol - induced bradycardia and a compensatory increase in end - diastolic volume .
Diseases: bradycardia"	"Sentence: These differences may be caused by timolol - induced bradycardia and a compensatory increase in end - diastolic volume .
Diseases:"
234	The timolol - related increase in heart size was observed only in patients with normal and borderline heart size .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The timolol - related increase in heart size was observed only in patients with normal and borderline heart size .
Diseases: "	"Sentence: The timolol - related increase in heart size was observed only in patients with normal and borderline heart size .
Diseases:"
235	In patients with cardiomegaly , the increase in heart size was similar in both groups .	O O O B O O O O O O O O O O O O	['cardiomegaly']	1	5	"Sentence: In patients with cardiomegaly , the increase in heart size was similar in both groups .
Diseases: cardiomegaly"	"Sentence: In patients with cardiomegaly , the increase in heart size was similar in both groups .
Diseases:"
236	After re - infarction , heart size increased in the placebo group and remained unchanged in the timolol group .	O O O B O O O O O O O O O O O O O O O O	['infarction']	1	3	"Sentence: After re - infarction , heart size increased in the placebo group and remained unchanged in the timolol group .
Diseases: infarction"	"Sentence: After re - infarction , heart size increased in the placebo group and remained unchanged in the timolol group .
Diseases:"
237	Vitamin D3 toxicity in dairy cows .	O O B O O O O	['toxicity']	1	2	"Sentence: Vitamin D3 toxicity in dairy cows .
Diseases: toxicity"	"Sentence: Vitamin D3 toxicity in dairy cows .
Diseases:"
238	Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .	O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O	['hyperphosphatemia', 'hypercalcemia']	2	10	"Sentence: Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
Diseases: hyperphosphatemia, hypercalcemia"	"Sentence: Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .
Diseases:"
239	Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum ( 8 . 8 mg / 100 ml ) than in control cows ( 5 . 5 mg / 100 ml ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum ( 8 . 8 mg / 100 ml ) than in control cows ( 5 . 5 mg / 100 ml ) .
Diseases: "	"Sentence: Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum ( 8 . 8 mg / 100 ml ) than in control cows ( 5 . 5 mg / 100 ml ) .
Diseases:"
240	None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period ; however , 22 % of the control cows developed clinical signs of milk fever during this period .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O B I O O O O	['milk fever']	1	3	"Sentence: None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period ; however , 22 % of the control cows developed clinical signs of milk fever during this period .
Diseases: milk fever"	"Sentence: None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period ; however , 22 % of the control cows developed clinical signs of milk fever during this period .
Diseases:"
241	Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died .	O O O O B O O O O O O O O O O O O O O O O O O O B O O O O O O O	['toxicity']	1	2	"Sentence: Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died .
Diseases: toxicity"	"Sentence: Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died .
Diseases:"
242	There was widespread metastatic calcification in the cows that died .	O O O O O O O O O O O	[]	0	0	"Sentence: There was widespread metastatic calcification in the cows that died .
Diseases: "	"Sentence: There was widespread metastatic calcification in the cows that died .
Diseases:"
243	Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .	O O O O B O O O O O O O O O O O O O O O O O O O O B I O O O O B I O O O O O O O O O O O O O B I O O O O O O	['milk fever', 'toxicity']	2	5	"Sentence: Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .
Diseases: milk fever, toxicity"	"Sentence: Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .
Diseases:"
244	Diseases of peripheral nerves as seen in the Nigerian African .	B I I I O O O O O O O	['diseases of peripheral nerves']	1	6	"Sentence: Diseases of peripheral nerves as seen in the Nigerian African .
Diseases: diseases of peripheral nerves"	"Sentence: Diseases of peripheral nerves as seen in the Nigerian African .
Diseases:"
245	The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders , as seen in 358 Nigerians are presented .	O O O O O O B I I O O O O O O O O O O O O O O O O	['peripheral nerve disease']	1	5	"Sentence: The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders , as seen in 358 Nigerians are presented .
Diseases: peripheral nerve disease"	"Sentence: The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders , as seen in 358 Nigerians are presented .
Diseases:"
246	There is a male preponderance and the peak incidence is in the fourth decade .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There is a male preponderance and the peak incidence is in the fourth decade .
Diseases: "	"Sentence: There is a male preponderance and the peak incidence is in the fourth decade .
Diseases:"
247	Sensori - motor neuropathy was the commonest presentation ( 50 % ) .	B I I I O O O O O O O O O	['sensori - motor neuropathy']	1	7	"Sentence: Sensori - motor neuropathy was the commonest presentation ( 50 % ) .
Diseases: sensori - motor neuropathy"	"Sentence: Sensori - motor neuropathy was the commonest presentation ( 50 % ) .
Diseases:"
248	Guillain - Barr syndrome was the commonest identifiable cause ( 15 . 6 % ) , accounting for half of the cases with motor neuropathy .	B I I I O O O O O O O O O O O O O O O O O O O B I O	['guillain - barr syndrome', 'motor neuropathy']	2	10	"Sentence: Guillain - Barr syndrome was the commonest identifiable cause ( 15 . 6 % ) , accounting for half of the cases with motor neuropathy .
Diseases: guillain - barr syndrome, motor neuropathy"	"Sentence: Guillain - Barr syndrome was the commonest identifiable cause ( 15 . 6 % ) , accounting for half of the cases with motor neuropathy .
Diseases:"
249	Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .	B I O O B I O O O O O O O O O O O O O O O O O O B I I I O	['peripheral neuropathy', 'nutritional deficiency', 'sensori - motor neuropathy']	3	15	"Sentence: Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .
Diseases: peripheral neuropathy, nutritional deficiency, sensori - motor neuropathy"	"Sentence: Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .
Diseases:"
250	Diabetes mellitus was the major cause of autonomic neuropathy .	B I O O O O O B I O	['autonomic neuropathy', 'diabetes mellitus']	2	8	"Sentence: Diabetes mellitus was the major cause of autonomic neuropathy .
Diseases: autonomic neuropathy, diabetes mellitus"	"Sentence: Diabetes mellitus was the major cause of autonomic neuropathy .
Diseases:"
251	Isoniazid was the most frequent agent in drug - induced neuropathy .	O O O O O O O O O O B O	['neuropathy']	1	3	"Sentence: Isoniazid was the most frequent agent in drug - induced neuropathy .
Diseases: neuropathy"	"Sentence: Isoniazid was the most frequent agent in drug - induced neuropathy .
Diseases:"
252	Migraine ( 20 % ) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent ( 26 % ) .	B O O O O O O O O O O B I O B O O O O O O O O O O O O O O O O O O O O O	['cranial neuropathy', 'migraine', 'malignancies']	3	11	"Sentence: Migraine ( 20 % ) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent ( 26 % ) .
Diseases: cranial neuropathy, migraine, malignancies"	"Sentence: Migraine ( 20 % ) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent ( 26 % ) .
Diseases:"
253	In 26 . 5 % of all the cases , the aetiology of the neuropathy was undetermined .	O O O O O O O O O O O O O O B O O O	['neuropathy']	1	3	"Sentence: In 26 . 5 % of all the cases , the aetiology of the neuropathy was undetermined .
Diseases: neuropathy"	"Sentence: In 26 . 5 % of all the cases , the aetiology of the neuropathy was undetermined .
Diseases:"
254	Heredofamilial and connective tissue disorders were rare .	O O B I I O O O	['connective tissue disorders']	1	4	"Sentence: Heredofamilial and connective tissue disorders were rare .
Diseases: connective tissue disorders"	"Sentence: Heredofamilial and connective tissue disorders were rare .
Diseases:"
255	Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed .	O O O O O O O O O O O O O B O O O O	['neuropathies']	1	4	"Sentence: Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed .
Diseases: neuropathies"	"Sentence: Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed .
Diseases:"
256	A double - blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder .	O O O O O O O O O O O O O O O O O O B I O	['depressive disorder']	1	3	"Sentence: A double - blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder .
Diseases: depressive disorder"	"Sentence: A double - blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder .
Diseases:"
257	In a 6 - week double - blind parallel treatment study , dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients .	O O O O O O O O O O O O O O O O O O O O O O O O B O O	['depressed']	1	2	"Sentence: In a 6 - week double - blind parallel treatment study , dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients .
Diseases: depressed"	"Sentence: In a 6 - week double - blind parallel treatment study , dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients .
Diseases:"
258	Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness , and both were significantly superior to placebo .	O O O O O O O O O O O B I O O O O O O O O O	['depressive illness']	1	3	"Sentence: Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness , and both were significantly superior to placebo .
Diseases: depressive illness"	"Sentence: Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness , and both were significantly superior to placebo .
Diseases:"
259	The overall incidence of side effects and the frequency and severity of blurred vision , dry mouth , and drowsiness were significantly less with dothiepin than with amitriptyline .	O O O O O O O O O O O O B I O B I O O O O O O O O O O O O	['blurred vision', 'dry mouth']	2	6	"Sentence: The overall incidence of side effects and the frequency and severity of blurred vision , dry mouth , and drowsiness were significantly less with dothiepin than with amitriptyline .
Diseases: blurred vision, dry mouth"	"Sentence: The overall incidence of side effects and the frequency and severity of blurred vision , dry mouth , and drowsiness were significantly less with dothiepin than with amitriptyline .
Diseases:"
260	Dothiepin also produced fewer CNS and cardiovascular effects .	O O O O O O O O O	[]	0	0	"Sentence: Dothiepin also produced fewer CNS and cardiovascular effects .
Diseases: "	"Sentence: Dothiepin also produced fewer CNS and cardiovascular effects .
Diseases:"
261	There were no clinically important changes in laboratory parameters .	O O O O O O O O O O	[]	0	0	"Sentence: There were no clinically important changes in laboratory parameters .
Diseases: "	"Sentence: There were no clinically important changes in laboratory parameters .
Diseases:"
262	Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients .	O O O O O O O O O O O O O O O O O O O O O B O O	['depressed']	1	2	"Sentence: Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients .
Diseases: depressed"	"Sentence: Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients .
Diseases:"
263	Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia .	O O O O O O O O O B I O B O	['panic disorder', 'agoraphobia']	2	7	"Sentence: Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia .
Diseases: panic disorder, agoraphobia"	"Sentence: Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia .
Diseases:"
264	The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double - blind , randomized and crossover design .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O B O O O O O O O O O O O O O	['panic disorders', 'agoraphobia']	2	7	"Sentence: The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double - blind , randomized and crossover design .
Diseases: panic disorders, agoraphobia"	"Sentence: The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double - blind , randomized and crossover design .
Diseases:"
265	Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol .	O O B I I I O O O O O O O O O O	['impaired immediate free recall']	1	6	"Sentence: Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol .
Diseases: impaired immediate free recall"	"Sentence: Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol .
Diseases:"
266	Delayed free recall was also impaired but the two drugs did not differ .	B I I I I I O O O O O O O O	['delayed free recall was also impaired']	1	7	"Sentence: Delayed free recall was also impaired but the two drugs did not differ .
Diseases: delayed free recall was also impaired"	"Sentence: Delayed free recall was also impaired but the two drugs did not differ .
Diseases:"
267	Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol .
Diseases: "	"Sentence: Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol .
Diseases:"
268	After 2 weeks of treatment , patients tested 5 - 8 h after the last dose of medication did not show any decrement of performance .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 2 weeks of treatment , patients tested 5 - 8 h after the last dose of medication did not show any decrement of performance .
Diseases: "	"Sentence: After 2 weeks of treatment , patients tested 5 - 8 h after the last dose of medication did not show any decrement of performance .
Diseases:"
269	These results are similar to those previously found in healthy subjects .	O O O O O O O O O O O O	[]	0	0	"Sentence: These results are similar to those previously found in healthy subjects .
Diseases: "	"Sentence: These results are similar to those previously found in healthy subjects .
Diseases:"
270	Accumulation of drugs was not reflected in prolonged behavioral impairment .	O O O O O O O O B I O	['behavioral impairment']	1	3	"Sentence: Accumulation of drugs was not reflected in prolonged behavioral impairment .
Diseases: behavioral impairment"	"Sentence: Accumulation of drugs was not reflected in prolonged behavioral impairment .
Diseases:"
271	Effect of aspirin on N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide - induced epithelial proliferation in the urinary bladder and forestomach of the rat .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Effect of aspirin on N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide - induced epithelial proliferation in the urinary bladder and forestomach of the rat .
Diseases: "	"Sentence: Effect of aspirin on N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide - induced epithelial proliferation in the urinary bladder and forestomach of the rat .
Diseases:"
272	The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of forestomach tumors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O B I O	['bladder carcinomas', 'forestomach tumors']	2	8	"Sentence: The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of forestomach tumors .
Diseases: bladder carcinomas, forestomach tumors"	"Sentence: The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of forestomach tumors .
Diseases:"
273	An autoradiographic study was performed on male F - 344 rats fed diet containing FANFT at a level of 0 . 2 % and / or aspirin at a level of 0 . 5 % to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An autoradiographic study was performed on male F - 344 rats fed diet containing FANFT at a level of 0 . 2 % and / or aspirin at a level of 0 . 5 % to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder .
Diseases: "	"Sentence: An autoradiographic study was performed on male F - 344 rats fed diet containing FANFT at a level of 0 . 2 % and / or aspirin at a level of 0 . 5 % to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder .
Diseases:"
274	FANFT - induced cell proliferation in the bladder was significantly suppressed by aspirin co - administration after 4 weeks but not after 12 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: FANFT - induced cell proliferation in the bladder was significantly suppressed by aspirin co - administration after 4 weeks but not after 12 weeks .
Diseases: "	"Sentence: FANFT - induced cell proliferation in the bladder was significantly suppressed by aspirin co - administration after 4 weeks but not after 12 weeks .
Diseases:"
275	In the forestomach , and also in the liver , aspirin did not affect the FANFT - induced increase in labeling index .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the forestomach , and also in the liver , aspirin did not affect the FANFT - induced increase in labeling index .
Diseases: "	"Sentence: In the forestomach , and also in the liver , aspirin did not affect the FANFT - induced increase in labeling index .
Diseases:"
276	The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach , and that aspirin 's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['carcinogenesis']	1	4	"Sentence: The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach , and that aspirin 's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .
Diseases: carcinogenesis"	"Sentence: The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach , and that aspirin 's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .
Diseases:"
277	Also , there appears to be an adaptation by the rats to the chronic ingestion of aspirin .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Also , there appears to be an adaptation by the rats to the chronic ingestion of aspirin .
Diseases: "	"Sentence: Also , there appears to be an adaptation by the rats to the chronic ingestion of aspirin .
Diseases:"
278	Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy ?	O O O B O O O B I I O	['diabetic autonomic neuropathy', 'hypotension']	2	9	"Sentence: Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy ?
Diseases: diabetic autonomic neuropathy, hypotension"	"Sentence: Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy ?
Diseases:"
279	The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 diabetic subjects with autonomic neuropathy .	O O O O O O O O O O O O O O O O O O O B O O B I O O O B O O B I O	['autonomic neuropathy', 'diabetic']	2	6	"Sentence: The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 diabetic subjects with autonomic neuropathy .
Diseases: autonomic neuropathy, diabetic"	"Sentence: The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 diabetic subjects with autonomic neuropathy .
Diseases:"
280	The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B I O O O O O O O O O O O O O O O O O O O B O O B I O	['autonomic neuropathy', 'diabetic']	2	6	"Sentence: The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .
Diseases: autonomic neuropathy, diabetic"	"Sentence: The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .
Diseases:"
281	It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients , particularly those with autonomic neuropathy .	O O O O O O O O O O O O O O B O O O O O B I O	['autonomic neuropathy', 'diabetic']	2	6	"Sentence: It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients , particularly those with autonomic neuropathy .
Diseases: autonomic neuropathy, diabetic"	"Sentence: It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients , particularly those with autonomic neuropathy .
Diseases:"
282	Characterization of estrogen - induced adenohypophyseal tumors in the Fischer 344 rat .	O O O O O B I O O O O O O	['adenohypophyseal tumors']	1	7	"Sentence: Characterization of estrogen - induced adenohypophyseal tumors in the Fischer 344 rat .
Diseases: adenohypophyseal tumors"	"Sentence: Characterization of estrogen - induced adenohypophyseal tumors in the Fischer 344 rat .
Diseases:"
283	Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol ( DES , 8 - 10 mg ) implanted subcutaneously in silastic capsules .	B I O O O O O O O O O O O O O O O O O O O O O O O O O	['pituitary tumors']	1	4	"Sentence: Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol ( DES , 8 - 10 mg ) implanted subcutaneously in silastic capsules .
Diseases: pituitary tumors"	"Sentence: Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol ( DES , 8 - 10 mg ) implanted subcutaneously in silastic capsules .
Diseases:"
284	Over a range of 1 - 150 days of DES treatment , pairs of control and DES - treated rats were sacrificed , and their pituitaries dissociated enzymatically into single - cell preparations .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Over a range of 1 - 150 days of DES treatment , pairs of control and DES - treated rats were sacrificed , and their pituitaries dissociated enzymatically into single - cell preparations .
Diseases: "	"Sentence: Over a range of 1 - 150 days of DES treatment , pairs of control and DES - treated rats were sacrificed , and their pituitaries dissociated enzymatically into single - cell preparations .
Diseases:"
285	The cell populations were examined regarding total cell recovery correlated with gland weight , intracellular prolactin ( PRL ) content and subsequent release in primary culture , immunocytochemical PRL staining , density and / or size alterations via separation on Ficoll - Hypaque and by unit gravity sedimentation , and cell cycle analysis , after acriflavine DNA staining , by laser flow cytometry .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The cell populations were examined regarding total cell recovery correlated with gland weight , intracellular prolactin ( PRL ) content and subsequent release in primary culture , immunocytochemical PRL staining , density and / or size alterations via separation on Ficoll - Hypaque and by unit gravity sedimentation , and cell cycle analysis , after acriflavine DNA staining , by laser flow cytometry .
Diseases: "	"Sentence: The cell populations were examined regarding total cell recovery correlated with gland weight , intracellular prolactin ( PRL ) content and subsequent release in primary culture , immunocytochemical PRL staining , density and / or size alterations via separation on Ficoll - Hypaque and by unit gravity sedimentation , and cell cycle analysis , after acriflavine DNA staining , by laser flow cytometry .
Diseases:"
286	Total cell yields from DES - treated pituitaries increased from 1 . 3 times control yields at 8 days of treatment to 58 . 9 times control values by day 150 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Total cell yields from DES - treated pituitaries increased from 1 . 3 times control yields at 8 days of treatment to 58 . 9 times control values by day 150 .
Diseases: "	"Sentence: Total cell yields from DES - treated pituitaries increased from 1 . 3 times control yields at 8 days of treatment to 58 . 9 times control values by day 150 .
Diseases:"
287	Intracellular PRL content ranged from 1 . 9 to 9 . 4 times control levels , and PRL release in vitro was significantly and consistently higher than controls , after at least 8 days of DES exposure .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Intracellular PRL content ranged from 1 . 9 to 9 . 4 times control levels , and PRL release in vitro was significantly and consistently higher than controls , after at least 8 days of DES exposure .
Diseases: "	"Sentence: Intracellular PRL content ranged from 1 . 9 to 9 . 4 times control levels , and PRL release in vitro was significantly and consistently higher than controls , after at least 8 days of DES exposure .
Diseases:"
288	Beyond 8 days of DES exposure , the immunochemically PRL - positive proportion of cells increased to over 50 % of the total population .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Beyond 8 days of DES exposure , the immunochemically PRL - positive proportion of cells increased to over 50 % of the total population .
Diseases: "	"Sentence: Beyond 8 days of DES exposure , the immunochemically PRL - positive proportion of cells increased to over 50 % of the total population .
Diseases:"
289	Increased density and / or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Increased density and / or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols .
Diseases: "	"Sentence: Increased density and / or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols .
Diseases:"
290	All these effects of DES were more pronounced among previously ovariectomized animals .	O O O O O O O O O O O O O	[]	0	0	"Sentence: All these effects of DES were more pronounced among previously ovariectomized animals .
Diseases: "	"Sentence: All these effects of DES were more pronounced among previously ovariectomized animals .
Diseases:"
291	The data extend the findings of other investigators , further establishing the DES - induced tumor as a model for study of PRL cellular control mechanisms .	O O O O O O O O O O O O O O O B O O O O O O O O O O O	['tumor']	1	3	"Sentence: The data extend the findings of other investigators , further establishing the DES - induced tumor as a model for study of PRL cellular control mechanisms .
Diseases: tumor"	"Sentence: The data extend the findings of other investigators , further establishing the DES - induced tumor as a model for study of PRL cellular control mechanisms .
Diseases:"
292	Triamterene nephrolithiasis complicating dyazide therapy .	O B O O O O	['nephrolithiasis']	1	5	"Sentence: Triamterene nephrolithiasis complicating dyazide therapy .
Diseases: nephrolithiasis"	"Sentence: Triamterene nephrolithiasis complicating dyazide therapy .
Diseases:"
293	A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide - triamterene therapy for hypertension .	O O O O B O O O O O O O O O O O O O O B O	['nephrolithiasis', 'hypertension']	2	7	"Sentence: A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide - triamterene therapy for hypertension .
Diseases: nephrolithiasis, hypertension"	"Sentence: A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide - triamterene therapy for hypertension .
Diseases:"
294	The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts .
Diseases: "	"Sentence: The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts .
Diseases:"
295	Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed .	O O O B O O O O O O O O O O	['nephrolithiasis']	1	5	"Sentence: Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed .
Diseases: nephrolithiasis"	"Sentence: Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed .
Diseases:"
296	Metabolic involvement in adriamycin cardiotoxicity .	O O O O B O	['cardiotoxicity']	1	3	"Sentence: Metabolic involvement in adriamycin cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: Metabolic involvement in adriamycin cardiotoxicity .
Diseases:"
297	The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system .	O B O O O O O O O O O O O O O O O O	['cardiotoxic']	1	3	"Sentence: The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system .
Diseases: cardiotoxic"	"Sentence: The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system .
Diseases:"
298	Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture .
Diseases: "	"Sentence: Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture .
Diseases:"
299	A possible involvement of energy metabolism was suggested previously , and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin - treated cells .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A possible involvement of energy metabolism was suggested previously , and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin - treated cells .
Diseases: "	"Sentence: A possible involvement of energy metabolism was suggested previously , and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin - treated cells .
Diseases:"
300	The adenylate energy charge was found to be significantly decreased , while the phophorylcreatine mole fraction was unchanged .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The adenylate energy charge was found to be significantly decreased , while the phophorylcreatine mole fraction was unchanged .
Diseases: "	"Sentence: The adenylate energy charge was found to be significantly decreased , while the phophorylcreatine mole fraction was unchanged .
Diseases:"
301	Such disparity suggests an inhibition of creatine phosphokinase .	O O O O O O O O O	[]	0	0	"Sentence: Such disparity suggests an inhibition of creatine phosphokinase .
Diseases: "	"Sentence: Such disparity suggests an inhibition of creatine phosphokinase .
Diseases:"
302	The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool .
Diseases: "	"Sentence: The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool .
Diseases:"
303	In the adriamycin - treated cells , the addition of adenosine increased the adenylate charge and , concomitant with this inrcease , the cells ' functional integrity , in terms of percentage of beating cells and rate of contractions , was maintained .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the adriamycin - treated cells , the addition of adenosine increased the adenylate charge and , concomitant with this inrcease , the cells ' functional integrity , in terms of percentage of beating cells and rate of contractions , was maintained .
Diseases: "	"Sentence: In the adriamycin - treated cells , the addition of adenosine increased the adenylate charge and , concomitant with this inrcease , the cells ' functional integrity , in terms of percentage of beating cells and rate of contractions , was maintained .
Diseases:"
304	Age - dependent sensitivity of the rat to neurotoxic effects of streptomycin .	O O O O O O O O B O O O O	['neurotoxic']	1	4	"Sentence: Age - dependent sensitivity of the rat to neurotoxic effects of streptomycin .
Diseases: neurotoxic"	"Sentence: Age - dependent sensitivity of the rat to neurotoxic effects of streptomycin .
Diseases:"
305	Streptomycin sulfate ( 300 mg / kg s . c . ) was injected for various periods into preweanling rats and for 3 weeks into weanling rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Streptomycin sulfate ( 300 mg / kg s . c . ) was injected for various periods into preweanling rats and for 3 weeks into weanling rats .
Diseases: "	"Sentence: Streptomycin sulfate ( 300 mg / kg s . c . ) was injected for various periods into preweanling rats and for 3 weeks into weanling rats .
Diseases:"
306	Beginning at 8 days of age , body movement and hearing were examined for 6 and up to 17 weeks , respectively .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Beginning at 8 days of age , body movement and hearing were examined for 6 and up to 17 weeks , respectively .
Diseases: "	"Sentence: Beginning at 8 days of age , body movement and hearing were examined for 6 and up to 17 weeks , respectively .
Diseases:"
307	Abnormal movements and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to streptomycin than the site ( vestibular or central ) responsible for the dyskinesias .	B I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['dyskinesias', 'abnormal movements', 'deafness']	3	11	"Sentence: Abnormal movements and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to streptomycin than the site ( vestibular or central ) responsible for the dyskinesias .
Diseases: dyskinesias, abnormal movements, deafness"	"Sentence: Abnormal movements and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to streptomycin than the site ( vestibular or central ) responsible for the dyskinesias .
Diseases:"
308	Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis .	O O B O O O O O O B I O	['pulmonary tuberculosis', 'glomerulonephritis']	2	11	"Sentence: Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis .
Diseases: pulmonary tuberculosis, glomerulonephritis"	"Sentence: Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis .
Diseases:"
309	This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['glomerulonephritis']	1	5	"Sentence: This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease .
Diseases: glomerulonephritis"	"Sentence: This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease .
Diseases:"
310	This patient underwent a 10 - month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .	O O O O O O O O O O O O O B I O O O O O O O O O B I O O O O O O O	['pulmonary tuberculosis', 'renal failure']	2	7	"Sentence: This patient underwent a 10 - month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .
Diseases: pulmonary tuberculosis, renal failure"	"Sentence: This patient underwent a 10 - month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .
Diseases:"
311	Renal biopsy revealed severe glomerulonephritis with crescents , electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate .	O O O O B O O O O O O O O O O O O O	['glomerulonephritis']	1	5	"Sentence: Renal biopsy revealed severe glomerulonephritis with crescents , electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate .
Diseases: glomerulonephritis"	"Sentence: Renal biopsy revealed severe glomerulonephritis with crescents , electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate .
Diseases:"
312	Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out .	O O O O O O B O O O O O O	['glomerulonephritis']	1	5	"Sentence: Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out .
Diseases: glomerulonephritis"	"Sentence: Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out .
Diseases:"
313	This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin .	O O O O O O O O O B O O O O B O O O O O O O	['glomerulonephritis']	1	5	"Sentence: This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin .
Diseases: glomerulonephritis"	"Sentence: This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin .
Diseases:"
314	Time course of lipid peroxidation in puromycin aminonucleoside - induced nephropathy .	O O O O O O O O O O B O	['nephropathy']	1	4	"Sentence: Time course of lipid peroxidation in puromycin aminonucleoside - induced nephropathy .
Diseases: nephropathy"	"Sentence: Time course of lipid peroxidation in puromycin aminonucleoside - induced nephropathy .
Diseases:"
315	Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( PAN ) - induced nephropathy , with antioxidants significantly reducing the proteinuria .	O O O O O O O O O O O O O O O O O O B O O O O O O B O	['nephropathy', 'proteinuria']	2	7	"Sentence: Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( PAN ) - induced nephropathy , with antioxidants significantly reducing the proteinuria .
Diseases: nephropathy, proteinuria"	"Sentence: Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( PAN ) - induced nephropathy , with antioxidants significantly reducing the proteinuria .
Diseases:"
316	The temporal relationship between lipid peroxidation in the kidney and proteinuria was examined in this study .	O O O O O O O O O O B O O O O O O	['proteinuria']	1	2	"Sentence: The temporal relationship between lipid peroxidation in the kidney and proteinuria was examined in this study .
Diseases: proteinuria"	"Sentence: The temporal relationship between lipid peroxidation in the kidney and proteinuria was examined in this study .
Diseases:"
317	Rats were treated with a single IV injection of puromycin aminonucleoside , ( PAN , 7 . 5 mg / kg ) and 24 hour urine samples were obtained prior to sacrifice on days 3 , 5 , 7 , 10 , 17 , 27 , 41 ( N = 5 - 10 per group ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Rats were treated with a single IV injection of puromycin aminonucleoside , ( PAN , 7 . 5 mg / kg ) and 24 hour urine samples were obtained prior to sacrifice on days 3 , 5 , 7 , 10 , 17 , 27 , 41 ( N = 5 - 10 per group ) .
Diseases: "	"Sentence: Rats were treated with a single IV injection of puromycin aminonucleoside , ( PAN , 7 . 5 mg / kg ) and 24 hour urine samples were obtained prior to sacrifice on days 3 , 5 , 7 , 10 , 17 , 27 , 41 ( N = 5 - 10 per group ) .
Diseases:"
318	The kidneys were removed , flushed with ice cold TRIS buffer .	O O O O O O O O O O O O	[]	0	0	"Sentence: The kidneys were removed , flushed with ice cold TRIS buffer .
Diseases: "	"Sentence: The kidneys were removed , flushed with ice cold TRIS buffer .
Diseases:"
319	Kidney cortices from each animal were used to prepare homogenates .	O O O O O O O O O O O	[]	0	0	"Sentence: Kidney cortices from each animal were used to prepare homogenates .
Diseases: "	"Sentence: Kidney cortices from each animal were used to prepare homogenates .
Diseases:"
320	Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances .
Diseases: "	"Sentence: Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances .
Diseases:"
321	Proteinuria was evident at day 5 , peaked at day 7 and persisted to day 27 .	B O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Proteinuria was evident at day 5 , peaked at day 7 and persisted to day 27 .
Diseases: proteinuria"	"Sentence: Proteinuria was evident at day 5 , peaked at day 7 and persisted to day 27 .
Diseases:"
322	Lipid peroxidation in homogenates was maximal at day 3 and declined rapidly to control levels by day 17 .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Lipid peroxidation in homogenates was maximal at day 3 and declined rapidly to control levels by day 17 .
Diseases: "	"Sentence: Lipid peroxidation in homogenates was maximal at day 3 and declined rapidly to control levels by day 17 .
Diseases:"
323	This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy .	O O O O O O O O O O O B I O O B O	['proteinuric injury', 'nephropathy']	2	9	"Sentence: This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy .
Diseases: proteinuric injury, nephropathy"	"Sentence: This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy .
Diseases:"
324	Clomipramine - induced sleep disturbance does not impair its prolactin - releasing action .	O O O B I O O O O O O O O O	['sleep disturbance']	1	2	"Sentence: Clomipramine - induced sleep disturbance does not impair its prolactin - releasing action .
Diseases: sleep disturbance"	"Sentence: Clomipramine - induced sleep disturbance does not impair its prolactin - releasing action .
Diseases:"
325	The present study was undertaken to examine the role of sleep disturbance , induced by clomipramine administration , on the secretory rate of prolactin ( PRL ) in addition to the direct drug effect .	O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O	['sleep disturbance']	1	2	"Sentence: The present study was undertaken to examine the role of sleep disturbance , induced by clomipramine administration , on the secretory rate of prolactin ( PRL ) in addition to the direct drug effect .
Diseases: sleep disturbance"	"Sentence: The present study was undertaken to examine the role of sleep disturbance , induced by clomipramine administration , on the secretory rate of prolactin ( PRL ) in addition to the direct drug effect .
Diseases:"
326	Two groups of supine subjects were studied under placebo - controlled conditions , one during the night , when sleeping ( n = 7 ) and the other at daytime , when awake ( n = 6 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two groups of supine subjects were studied under placebo - controlled conditions , one during the night , when sleeping ( n = 7 ) and the other at daytime , when awake ( n = 6 ) .
Diseases: "	"Sentence: Two groups of supine subjects were studied under placebo - controlled conditions , one during the night , when sleeping ( n = 7 ) and the other at daytime , when awake ( n = 6 ) .
Diseases:"
327	Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection .
Diseases: "	"Sentence: Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection .
Diseases:"
328	Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure .
Diseases: "	"Sentence: Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure .
Diseases:"
329	For both experiments the drug intake led to significant increases in PRL secretion , acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For both experiments the drug intake led to significant increases in PRL secretion , acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values .
Diseases: "	"Sentence: For both experiments the drug intake led to significant increases in PRL secretion , acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values .
Diseases:"
330	During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness .
Diseases: "	"Sentence: During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness .
Diseases:"
331	As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies ( 46 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies ( 46 + / -
Diseases: "	"Sentence: As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies ( 46 + / -
Diseases:"
332	19 % vs 34 + / - 10 % ) , it can be concluded that the observed sleep disturbance did not interfere with the drug action per se .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O	['sleep disturbance']	1	2	"Sentence: 19 % vs 34 + / - 10 % ) , it can be concluded that the observed sleep disturbance did not interfere with the drug action per se .
Diseases: sleep disturbance"	"Sentence: 19 % vs 34 + / - 10 % ) , it can be concluded that the observed sleep disturbance did not interfere with the drug action per se .
Diseases:"
333	The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency , as , for both , mean nocturnal values were similar with and without prior clomipramine ingestion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency , as , for both , mean nocturnal values were similar with and without prior clomipramine ingestion .
Diseases: "	"Sentence: The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency , as , for both , mean nocturnal values were similar with and without prior clomipramine ingestion .
Diseases:"
334	Angioedema following the intravenous administration of metoprolol .	B O O O O O O O	['angioedema']	1	4	"Sentence: Angioedema following the intravenous administration of metoprolol .
Diseases: angioedema"	"Sentence: Angioedema following the intravenous administration of metoprolol .
Diseases:"
335	"A 72 - year - old woman was admitted to the hospital with "" flash "" pulmonary edema , preceded by chest pain , requiring intubation ."	O O O O O O O O O O O O O O O O B I O O O B I O O O O	['pulmonary edema', 'chest pain']	2	8	"Sentence: A 72 - year - old woman was admitted to the hospital with "" flash "" pulmonary edema , preceded by chest pain , requiring intubation .
Diseases: pulmonary edema, chest pain"	"Sentence: A 72 - year - old woman was admitted to the hospital with "" flash "" pulmonary edema , preceded by chest pain , requiring intubation .
Diseases:"
336	Her medical history included coronary artery disease with previous myocardial infarctions , hypertension , and diabetes mellitus .	O O O O B I I O O B I O B O O B I O	['myocardial infarctions', 'coronary artery disease', 'diabetes mellitus', 'hypertension']	4	16	"Sentence: Her medical history included coronary artery disease with previous myocardial infarctions , hypertension , and diabetes mellitus .
Diseases: myocardial infarctions, coronary artery disease, diabetes mellitus, hypertension"	"Sentence: Her medical history included coronary artery disease with previous myocardial infarctions , hypertension , and diabetes mellitus .
Diseases:"
337	A history of angioedema secondary to lisinopril therapy was elicited .	O O O B O O O O O O O	['angioedema']	1	4	"Sentence: A history of angioedema secondary to lisinopril therapy was elicited .
Diseases: angioedema"	"Sentence: A history of angioedema secondary to lisinopril therapy was elicited .
Diseases:"
338	Current medications did not include angiotensin - converting enzyme inhibitors or beta - blockers .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Current medications did not include angiotensin - converting enzyme inhibitors or beta - blockers .
Diseases: "	"Sentence: Current medications did not include angiotensin - converting enzyme inhibitors or beta - blockers .
Diseases:"
339	She had no previous beta - blocking drug exposure .	O O O O O O O O O O	[]	0	0	"Sentence: She had no previous beta - blocking drug exposure .
Diseases: "	"Sentence: She had no previous beta - blocking drug exposure .
Diseases:"
340	During the first day of hospitalization ( while intubated ) , intravenous metoprolol was given , resulting in severe angioedema .	O O O O O O O O O O O O O O O O O O O B O	['angioedema']	1	4	"Sentence: During the first day of hospitalization ( while intubated ) , intravenous metoprolol was given , resulting in severe angioedema .
Diseases: angioedema"	"Sentence: During the first day of hospitalization ( while intubated ) , intravenous metoprolol was given , resulting in severe angioedema .
Diseases:"
341	The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride .	O B O O O O O O O O O O	['angioedema']	1	4	"Sentence: The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride .
Diseases: angioedema"	"Sentence: The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride .
Diseases:"
342	Effect of coniine on the developing chick embryo .	O O O O O O O O O	[]	0	0	"Sentence: Effect of coniine on the developing chick embryo .
Diseases: "	"Sentence: Effect of coniine on the developing chick embryo .
Diseases:"
343	Coniine , an alkaloid from Conium maculatum ( poison hemlock ) , has been shown to be teratogenic in livestock .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Coniine , an alkaloid from Conium maculatum ( poison hemlock ) , has been shown to be teratogenic in livestock .
Diseases: "	"Sentence: Coniine , an alkaloid from Conium maculatum ( poison hemlock ) , has been shown to be teratogenic in livestock .
Diseases:"
344	The major teratogenic outcome is arthrogryposis , presumably due to nicotinic receptor blockade .	O O O O O B O O O O O O O O	['arthrogryposis']	1	5	"Sentence: The major teratogenic outcome is arthrogryposis , presumably due to nicotinic receptor blockade .
Diseases: arthrogryposis"	"Sentence: The major teratogenic outcome is arthrogryposis , presumably due to nicotinic receptor blockade .
Diseases:"
345	However , coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits .	O O O O O O O B O O O O O O O O O O O O	['arthrogryposis']	1	5	"Sentence: However , coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits .
Diseases: arthrogryposis"	"Sentence: However , coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits .
Diseases:"
346	The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick .
Diseases: "	"Sentence: The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick .
Diseases:"
347	Concentrations of coniine and nicotine sulfate were 0 . 015 % , 0 . 03 % , 0 . 075 % , 0 . 15 % , 0 . 75 % , 1 . 5 % , 3 % , and 6 % and 1 % , 5 % , and 10 % , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Concentrations of coniine and nicotine sulfate were 0 . 015 % , 0 . 03 % , 0 . 075 % , 0 . 15 % , 0 . 75 % , 1 . 5 % , 3 % , and 6 % and 1 % , 5 % , and 10 % , respectively .
Diseases: "	"Sentence: Concentrations of coniine and nicotine sulfate were 0 . 015 % , 0 . 03 % , 0 . 075 % , 0 . 15 % , 0 . 75 % , 1 . 5 % , 3 % , and 6 % and 1 % , 5 % , and 10 % , respectively .
Diseases:"
348	Both compounds caused deformations and lethality in a dose - dependent manner .	O O O B O O O O O O O O O	['deformations']	1	3	"Sentence: Both compounds caused deformations and lethality in a dose - dependent manner .
Diseases: deformations"	"Sentence: Both compounds caused deformations and lethality in a dose - dependent manner .
Diseases:"
349	All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0 . 75 % .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0 . 75 % .
Diseases: "	"Sentence: All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0 . 75 % .
Diseases:"
350	The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes .	O B O O O O O O O O B I I I I I I I I O	['deformations', 'excessive flexion or extension of one or more toes']	2	14	"Sentence: The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes .
Diseases: deformations, excessive flexion or extension of one or more toes"	"Sentence: The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes .
Diseases:"
351	No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group ; however , extensive cranial hemorrhage occurred in all nicotine sulfate - treated chicks .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O	['cranial hemorrhage']	1	5	"Sentence: No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group ; however , extensive cranial hemorrhage occurred in all nicotine sulfate - treated chicks .
Diseases: cranial hemorrhage"	"Sentence: No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group ; however , extensive cranial hemorrhage occurred in all nicotine sulfate - treated chicks .
Diseases:"
352	There was a statistically significant ( P < or = 0 . 01 ) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was a statistically significant ( P < or = 0 . 01 ) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound .
Diseases: "	"Sentence: There was a statistically significant ( P < or = 0 . 01 ) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound .
Diseases:"
353	Control chicks were in motion an average of 33 . 67 % of the time , while coniine - treated chicks were only moving 8 . 95 % of a 5 - min interval , and no movement was observed for nicotine sulfate treated chicks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Control chicks were in motion an average of 33 . 67 % of the time , while coniine - treated chicks were only moving 8 . 95 % of a 5 - min interval , and no movement was observed for nicotine sulfate treated chicks .
Diseases: "	"Sentence: Control chicks were in motion an average of 33 . 67 % of the time , while coniine - treated chicks were only moving 8 . 95 % of a 5 - min interval , and no movement was observed for nicotine sulfate treated chicks .
Diseases:"
354	In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .	O O O O O O O O O O O O O O O O O O B O	['arthrogryposis']	1	5	"Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .
Diseases: arthrogryposis"	"Sentence: In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .
Diseases:"
355	Data from this model support a mechanism involving nicotinic receptor blockade with subsequent decreased fetal movement .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Data from this model support a mechanism involving nicotinic receptor blockade with subsequent decreased fetal movement .
Diseases: "	"Sentence: Data from this model support a mechanism involving nicotinic receptor blockade with subsequent decreased fetal movement .
Diseases:"
356	Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension .	O O O O O O O O O B O	['hypotension']	1	3	"Sentence: Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension .
Diseases: hypotension"	"Sentence: Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension .
Diseases:"
357	To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( TMP ) induced hypotension on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( TMP ) induced hypotension on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .
Diseases: hypotension"	"Sentence: To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( TMP ) induced hypotension on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .
Diseases:"
358	An initial dose of 0 . 1 microgram . kg - 1 . min - 1 of PGE1 ( 15 patients ) , or 10 micrograms . kg - 1 . min - 1 of TMP ( 15 patients ) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure ( MAP ) at about 60 mmHg .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An initial dose of 0 . 1 microgram . kg - 1 . min - 1 of PGE1 ( 15 patients ) , or 10 micrograms . kg - 1 . min - 1 of TMP ( 15 patients ) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure ( MAP ) at about 60 mmHg .
Diseases: "	"Sentence: An initial dose of 0 . 1 microgram . kg - 1 . min - 1 of PGE1 ( 15 patients ) , or 10 micrograms . kg - 1 . min - 1 of TMP ( 15 patients ) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure ( MAP ) at about 60 mmHg .
Diseases:"
359	The hypotensive drug was discontinued at the completion of the operative procedure .	O B O O O O O O O O O O O	['hypotensive']	1	3	"Sentence: The hypotensive drug was discontinued at the completion of the operative procedure .
Diseases: hypotensive"	"Sentence: The hypotensive drug was discontinued at the completion of the operative procedure .
Diseases:"
360	After starting PGE1 or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: After starting PGE1 or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation .
Diseases: hypotension"	"Sentence: After starting PGE1 or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation .
Diseases:"
361	Heart rate ( HR ) did not change in either group .	O O O O O O O O O O O O	[]	0	0	"Sentence: Heart rate ( HR ) did not change in either group .
Diseases: "	"Sentence: Heart rate ( HR ) did not change in either group .
Diseases:"
362	EBFF did not change during PGE1 infusion whereas in the TMP group , EBF decreased significantly at 30 and 60 min after the start of TMP ( preinfusion : 45 . 9 + / - 13 . 9 ml / 100g / min .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: EBFF did not change during PGE1 infusion whereas in the TMP group , EBF decreased significantly at 30 and 60 min after the start of TMP ( preinfusion : 45 . 9 + / - 13 . 9 ml / 100g / min .
Diseases: "	"Sentence: EBFF did not change during PGE1 infusion whereas in the TMP group , EBF decreased significantly at 30 and 60 min after the start of TMP ( preinfusion : 45 . 9 + / - 13 . 9 ml / 100g / min .
Diseases:"
363	30 min : 32 . 3 + / - 9 . 9 ml / 100 g / min ( P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 30 min : 32 . 3 + / - 9 . 9 ml / 100 g / min ( P < 0 . 05 ) .
Diseases: "	"Sentence: 30 min : 32 . 3 + / - 9 . 9 ml / 100 g / min ( P < 0 . 05 ) .
Diseases:"
364	60 min : 30 + / - 7 . 5 ml / 100 g / min ( P < 0 . 05 ) ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 60 min : 30 + / - 7 . 5 ml / 100 g / min ( P < 0 . 05 ) ) .
Diseases: "	"Sentence: 60 min : 30 + / - 7 . 5 ml / 100 g / min ( P < 0 . 05 ) ) .
Diseases:"
365	These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF .	O O O O O O O O O O O B O O O O O O O O O	['hypotensive']	1	3	"Sentence: These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF .
Diseases: hypotensive"	"Sentence: These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF .
Diseases:"
366	Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat .	O O O O O O O O B I O O O O O O O	['axonal damage']	1	3	"Sentence: Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat .
Diseases: axonal damage"	"Sentence: Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat .
Diseases:"
367	Immunohistochemistry with monoclonal antibodies against neurofilament ( NF ) proteins of middle and high molecular weight class , NF - M and NF - H , was used to study axonal injury in the borderzone of focal lesions in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O	['axonal injury']	1	3	"Sentence: Immunohistochemistry with monoclonal antibodies against neurofilament ( NF ) proteins of middle and high molecular weight class , NF - M and NF - H , was used to study axonal injury in the borderzone of focal lesions in rats .
Diseases: axonal injury"	"Sentence: Immunohistochemistry with monoclonal antibodies against neurofilament ( NF ) proteins of middle and high molecular weight class , NF - M and NF - H , was used to study axonal injury in the borderzone of focal lesions in rats .
Diseases:"
368	Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion .	O B I I I O O O O O O O O O O O O O O O O O	['injury in the cortex']	1	5	"Sentence: Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion .
Diseases: injury in the cortex"	"Sentence: Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion .
Diseases:"
369	Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine - induced status epilepticus .	B I I I I I O O O O O O O B I O	['status epilepticus', 'infarcts in substantia nigra pars reticulata']	2	19	"Sentence: Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine - induced status epilepticus .
Diseases: status epilepticus, infarcts in substantia nigra pars reticulata"	"Sentence: Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine - induced status epilepticus .
Diseases:"
370	Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions .
Diseases: "	"Sentence: Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions .
Diseases:"
371	Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state .
Diseases: "	"Sentence: Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state .
Diseases:"
372	These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions .	O O O O O O O O O O O B I O O O B O O O O	['traumatic', 'axonal damage']	2	5	"Sentence: These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions .
Diseases: traumatic, axonal damage"	"Sentence: These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions .
Diseases:"
373	Increase of Parkinson disability after fluoxetine medication .	O O B I O O O O	['parkinson disability']	1	3	"Sentence: Increase of Parkinson disability after fluoxetine medication .
Diseases: parkinson disability"	"Sentence: Increase of Parkinson disability after fluoxetine medication .
Diseases:"
374	Depression is a major clinical feature of Parkinson 's disease .	B O O O O O O B I I O	"['depression', ""parkinson 's disease""]"	2	8	"Sentence: Depression is a major clinical feature of Parkinson 's disease .
Diseases: depression, parkinson 's disease"	"Sentence: Depression is a major clinical feature of Parkinson 's disease .
Diseases:"
375	We report the increased amount of motor disability in four patients with idiopathic Parkinson 's disease after exposure to the antidepressant fluoxetine .	O O O O O O B I O O O O B I I I O O O O O O O	"[""idiopathic parkinson 's disease"", 'motor disability']"	2	12	"Sentence: We report the increased amount of motor disability in four patients with idiopathic Parkinson 's disease after exposure to the antidepressant fluoxetine .
Diseases: idiopathic parkinson 's disease, motor disability"	"Sentence: We report the increased amount of motor disability in four patients with idiopathic Parkinson 's disease after exposure to the antidepressant fluoxetine .
Diseases:"
376	The possibility of a clinically relevant dopamine - antagonistic capacity of fluoxetine in Parkinson 's disease patients must be considered .	O O O O O O O O O O O O O B I I O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: The possibility of a clinically relevant dopamine - antagonistic capacity of fluoxetine in Parkinson 's disease patients must be considered .
Diseases: parkinson 's disease"	"Sentence: The possibility of a clinically relevant dopamine - antagonistic capacity of fluoxetine in Parkinson 's disease patients must be considered .
Diseases:"
377	Acetaminophen - induced hypotension .	O O O B O	['hypotension']	1	3	"Sentence: Acetaminophen - induced hypotension .
Diseases: hypotension"	"Sentence: Acetaminophen - induced hypotension .
Diseases:"
378	Through 30 years of widespread use , acetaminophen has been shown to be a remarkably safe medication in therapeutic dosages .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Through 30 years of widespread use , acetaminophen has been shown to be a remarkably safe medication in therapeutic dosages .
Diseases: "	"Sentence: Through 30 years of widespread use , acetaminophen has been shown to be a remarkably safe medication in therapeutic dosages .
Diseases:"
379	The potential for acetaminophen to produce cardiovascular toxicities is very low .	O O O O O O B I O O O O	['cardiovascular toxicities']	1	4	"Sentence: The potential for acetaminophen to produce cardiovascular toxicities is very low .
Diseases: cardiovascular toxicities"	"Sentence: The potential for acetaminophen to produce cardiovascular toxicities is very low .
Diseases:"
380	However , acetaminophen has been demonstrated to produce symptoms of anaphylaxis , including hypotension , in sensitive individuals .	O O O O O O O O O O B O O B O O O O O	['anaphylaxis', 'hypotension']	2	7	"Sentence: However , acetaminophen has been demonstrated to produce symptoms of anaphylaxis , including hypotension , in sensitive individuals .
Diseases: anaphylaxis, hypotension"	"Sentence: However , acetaminophen has been demonstrated to produce symptoms of anaphylaxis , including hypotension , in sensitive individuals .
Diseases:"
381	This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen .	O O O O B I O O O O O O B O O O O O O O	['hypotension', 'critically ill']	2	6	"Sentence: This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen .
Diseases: hypotension, critically ill"	"Sentence: This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen .
Diseases:"
382	Other symptoms of allergic reactions were not clinically detectable .	O O O B I O O O O O	['allergic reactions']	1	3	"Sentence: Other symptoms of allergic reactions were not clinically detectable .
Diseases: allergic reactions"	"Sentence: Other symptoms of allergic reactions were not clinically detectable .
Diseases:"
383	The hypotensive episodes were severe enough to require vasopressor administration .	O B O O O O O O O O O	['hypotensive']	1	3	"Sentence: The hypotensive episodes were severe enough to require vasopressor administration .
Diseases: hypotensive"	"Sentence: The hypotensive episodes were severe enough to require vasopressor administration .
Diseases:"
384	The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin .	O O O O O O O O O O O O O B O O O O	['hypotension']	1	3	"Sentence: The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin .
Diseases: hypotension"	"Sentence: The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin .
Diseases:"
385	Acute hepatitis , autoimmune hemolytic anemia , and erythroblastocytopenia induced by ceftriaxone .	O B O B I I O O B O O O O	['autoimmune hemolytic anemia', 'erythroblastocytopenia', 'hepatitis']	3	18	"Sentence: Acute hepatitis , autoimmune hemolytic anemia , and erythroblastocytopenia induced by ceftriaxone .
Diseases: autoimmune hemolytic anemia, erythroblastocytopenia, hepatitis"	"Sentence: Acute hepatitis , autoimmune hemolytic anemia , and erythroblastocytopenia induced by ceftriaxone .
Diseases:"
386	An 80 - yr - old man developed acute hepatitis shortly after ingesting oral ceftriaxone .	O O O O O O O O O B O O O O O O	['hepatitis']	1	3	"Sentence: An 80 - yr - old man developed acute hepatitis shortly after ingesting oral ceftriaxone .
Diseases: hepatitis"	"Sentence: An 80 - yr - old man developed acute hepatitis shortly after ingesting oral ceftriaxone .
Diseases:"
387	Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O B O	['autoimmune hemolytic anemia', 'erythroblastocytopenia']	2	16	"Sentence: Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia .
Diseases: autoimmune hemolytic anemia, erythroblastocytopenia"	"Sentence: Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia .
Diseases:"
388	These responded to systemic steroids and immunoglobulins .	O O O O O O O O	[]	0	0	"Sentence: These responded to systemic steroids and immunoglobulins .
Diseases: "	"Sentence: These responded to systemic steroids and immunoglobulins .
Diseases:"
389	Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics .
Diseases: "	"Sentence: Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics .
Diseases:"
390	Adverse effects of the atypical antipsychotics .	O O O O O O O	[]	0	0	"Sentence: Adverse effects of the atypical antipsychotics .
Diseases: "	"Sentence: Adverse effects of the atypical antipsychotics .
Diseases:"
391	Collaborative Working Group on Clinical Trial Evaluations .	O O O O O O O O	[]	0	0	"Sentence: Collaborative Working Group on Clinical Trial Evaluations .
Diseases: "	"Sentence: Collaborative Working Group on Clinical Trial Evaluations .
Diseases:"
392	Adverse effects of antipsychotics often lead to noncompliance .	O O O O O O O O O	[]	0	0	"Sentence: Adverse effects of antipsychotics often lead to noncompliance .
Diseases: "	"Sentence: Adverse effects of antipsychotics often lead to noncompliance .
Diseases:"
393	Thus , clinicians should address patients ' concerns about adverse effects and attempt to choose medications that will improve their patients ' quality of life as well as overall health .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thus , clinicians should address patients ' concerns about adverse effects and attempt to choose medications that will improve their patients ' quality of life as well as overall health .
Diseases: "	"Sentence: Thus , clinicians should address patients ' concerns about adverse effects and attempt to choose medications that will improve their patients ' quality of life as well as overall health .
Diseases:"
394	The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics .
Diseases: "	"Sentence: The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics .
Diseases:"
395	Conventional agents are associated with unwanted central nervous system effects , including extrapyramidal symptoms ( EPS ) , tardive dyskinesia , sedation , and possible impairment of some cognitive measures , as well as cardiac effects , orthostatic hypotension , hepatic changes , anticholinergic side effects , sexual dysfunction , and weight gain .	O O O O O O O O O O O O B I O B O O B I O O O O O O O O O O O O O O O O O B I O O O O O O O O B I O O B I O	['orthostatic hypotension', 'weight gain', 'extrapyramidal symptoms', 'tardive dyskinesia', 'sexual dysfunction', 'eps']	6	28	"Sentence: Conventional agents are associated with unwanted central nervous system effects , including extrapyramidal symptoms ( EPS ) , tardive dyskinesia , sedation , and possible impairment of some cognitive measures , as well as cardiac effects , orthostatic hypotension , hepatic changes , anticholinergic side effects , sexual dysfunction , and weight gain .
Diseases: orthostatic hypotension, weight gain, extrapyramidal symptoms, tardive dyskinesia, sexual dysfunction, eps"	"Sentence: Conventional agents are associated with unwanted central nervous system effects , including extrapyramidal symptoms ( EPS ) , tardive dyskinesia , sedation , and possible impairment of some cognitive measures , as well as cardiac effects , orthostatic hypotension , hepatic changes , anticholinergic side effects , sexual dysfunction , and weight gain .
Diseases:"
396	The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( clozapine only ) .	O O O O O O O O O B O O O O O O O O O O O O O O O O B I O B I O O O O O B O O O O O O O B O O O O O	['weight gain', 'seizure', 'agranulocytosis', 'sexual dysfunction', 'eps']	5	17	"Sentence: The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( clozapine only ) .
Diseases: weight gain, seizure, agranulocytosis, sexual dysfunction, eps"	"Sentence: The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( clozapine only ) .
Diseases:"
397	Since the incidence and severity of specific adverse effects differ among the various atypicals , the clinician should carefully consider which side effects are most likely to lead to the individual 's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Since the incidence and severity of specific adverse effects differ among the various atypicals , the clinician should carefully consider which side effects are most likely to lead to the individual 's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient .
Diseases: "	"Sentence: Since the incidence and severity of specific adverse effects differ among the various atypicals , the clinician should carefully consider which side effects are most likely to lead to the individual 's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient .
Diseases:"
398	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation .	O O O O O O O B O O O O B I O	['platelet aggregation', 'thrombosis']	2	8	"Sentence: Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation .
Diseases: platelet aggregation, thrombosis"	"Sentence: Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation .
Diseases:"
399	Tetrandrine ( TET ) and fangchinoline ( FAN ) are two naturally occurring analogues with a bisbenzylisoquinoline structure .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Tetrandrine ( TET ) and fangchinoline ( FAN ) are two naturally occurring analogues with a bisbenzylisoquinoline structure .
Diseases: "	"Sentence: Tetrandrine ( TET ) and fangchinoline ( FAN ) are two naturally occurring analogues with a bisbenzylisoquinoline structure .
Diseases:"
400	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O B I O B I O O O	['blood coagulation', 'platelet aggregation', 'thrombosis']	3	13	"Sentence: The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .
Diseases: blood coagulation, platelet aggregation, thrombosis"	"Sentence: The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .
Diseases:"
401	In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and FAN in mice showed the inhibition of thrombosis by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['thrombosis']	1	4	"Sentence: In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and FAN in mice showed the inhibition of thrombosis by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .
Diseases: thrombosis"	"Sentence: In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and FAN in mice showed the inhibition of thrombosis by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .
Diseases:"
402	In the vitro human platelet aggregations induced by the agonists used in tests , TET and FAN showed the inhibitions dose dependently .	O O O O B I O O O O O O O O O O O O O O O O O	['platelet aggregations']	1	4	"Sentence: In the vitro human platelet aggregations induced by the agonists used in tests , TET and FAN showed the inhibitions dose dependently .
Diseases: platelet aggregations"	"Sentence: In the vitro human platelet aggregations induced by the agonists used in tests , TET and FAN showed the inhibitions dose dependently .
Diseases:"
403	In addition , neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time ( APTT ) , prothrombin time ( PT ) and thrombin time ( TT ) using human - citrated plasma .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time ( APTT ) , prothrombin time ( PT ) and thrombin time ( TT ) using human - citrated plasma .
Diseases: "	"Sentence: In addition , neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time ( APTT ) , prothrombin time ( PT ) and thrombin time ( TT ) using human - citrated plasma .
Diseases:"
404	These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities .
Diseases: "	"Sentence: These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities .
Diseases:"
405	Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who can not receive cisplatin .	O O O O B I I I O O O O O O O O O O O O O O	['nonsmall cell lung carcinoma']	1	8	"Sentence: Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who can not receive cisplatin .
Diseases: nonsmall cell lung carcinoma"	"Sentence: Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who can not receive cisplatin .
Diseases:"
406	Oncopaz Cooperative Group .	O O O O	[]	0	0	"Sentence: Oncopaz Cooperative Group .
Diseases: "	"Sentence: Oncopaz Cooperative Group .
Diseases:"
407	BACKGROUND :	O O	[]	0	0	"Sentence: BACKGROUND :
Diseases: "	"Sentence: BACKGROUND :
Diseases:"
408	Although the prevalence of nonsmall cell lung carcinoma ( NSCLC ) is high among elderly patients , few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients .	O O O O B I I I O B O O O O O O O O O O O O O O O B O O O O O O O O	['nonsmall cell lung carcinoma', 'nsclc', 'toxicity']	3	14	"Sentence: Although the prevalence of nonsmall cell lung carcinoma ( NSCLC ) is high among elderly patients , few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients .
Diseases: nonsmall cell lung carcinoma, nsclc, toxicity"	"Sentence: Although the prevalence of nonsmall cell lung carcinoma ( NSCLC ) is high among elderly patients , few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients .
Diseases:"
409	Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable toxicity and improvement in symptoms and quality of life .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['toxicity']	1	2	"Sentence: Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable toxicity and improvement in symptoms and quality of life .
Diseases: toxicity"	"Sentence: Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable toxicity and improvement in symptoms and quality of life .
Diseases:"
410	In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .	O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O	['nsclc', 'toxicity']	2	5	"Sentence: In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .
Diseases: nsclc, toxicity"	"Sentence: In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .
Diseases:"
411	METHODS : Forty - nine patients with advanced NSCLC were included , 38 of whom were age > / = 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nsclc']	1	3	"Sentence: METHODS : Forty - nine patients with advanced NSCLC were included , 38 of whom were age > / = 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin .
Diseases: nsclc"	"Sentence: METHODS : Forty - nine patients with advanced NSCLC were included , 38 of whom were age > / = 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin .
Diseases:"
412	All patients were evaluable for response and toxicity .	O O O O O O O B O	['toxicity']	1	2	"Sentence: All patients were evaluable for response and toxicity .
Diseases: toxicity"	"Sentence: All patients were evaluable for response and toxicity .
Diseases:"
413	Treatment was comprised of VNB , 25 mg / m ( 2 ) , plus GEM , 1000 mg / m ( 2 ) , both on Days 1 , 8 , and 15 every 28 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Treatment was comprised of VNB , 25 mg / m ( 2 ) , plus GEM , 1000 mg / m ( 2 ) , both on Days 1 , 8 , and 15 every 28 days .
Diseases: "	"Sentence: Treatment was comprised of VNB , 25 mg / m ( 2 ) , plus GEM , 1000 mg / m ( 2 ) , both on Days 1 , 8 , and 15 every 28 days .
Diseases:"
414	Patients received a minimum of three courses unless progressive disease was detected .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients received a minimum of three courses unless progressive disease was detected .
Diseases: "	"Sentence: Patients received a minimum of three courses unless progressive disease was detected .
Diseases:"
415	RESULTS :	O O	[]	0	0	"Sentence: RESULTS :
Diseases: "	"Sentence: RESULTS :
Diseases:"
416	One hundred sixty - five courses were administered , with a median of 3 .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: One hundred sixty - five courses were administered , with a median of 3 .
Diseases: "	"Sentence: One hundred sixty - five courses were administered , with a median of 3 .
Diseases:"
417	6 courses per patient .	O O O O O	[]	0	0	"Sentence: 6 courses per patient .
Diseases: "	"Sentence: 6 courses per patient .
Diseases:"
418	The overall response rate was 26 % ( 95 % confidence interval , 15 - 41 % ) .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The overall response rate was 26 % ( 95 % confidence interval , 15 - 41 % ) .
Diseases: "	"Sentence: The overall response rate was 26 % ( 95 % confidence interval , 15 - 41 % ) .
Diseases:"
419	Two patients attained a complete response ( 4 % ) and 11 patients ( 22 % ) achieved a partial response .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two patients attained a complete response ( 4 % ) and 11 patients ( 22 % ) achieved a partial response .
Diseases: "	"Sentence: Two patients attained a complete response ( 4 % ) and 11 patients ( 22 % ) achieved a partial response .
Diseases:"
420	Eastern Cooperative Oncology Group performance status improved in 35 % of those patients with an initial value > 0 , whereas relief of at least 1 symptom without worsening of other symptoms was noted in 27 patients ( 55 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Eastern Cooperative Oncology Group performance status improved in 35 % of those patients with an initial value > 0 , whereas relief of at least 1 symptom without worsening of other symptoms was noted in 27 patients ( 55 % ) .
Diseases: "	"Sentence: Eastern Cooperative Oncology Group performance status improved in 35 % of those patients with an initial value > 0 , whereas relief of at least 1 symptom without worsening of other symptoms was noted in 27 patients ( 55 % ) .
Diseases:"
421	The median time to progression was 16 weeks and the 1 - year survival rate was 33 % .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The median time to progression was 16 weeks and the 1 - year survival rate was 33 % .
Diseases: "	"Sentence: The median time to progression was 16 weeks and the 1 - year survival rate was 33 % .
Diseases:"
422	Toxicity was mild .	B O O O	['toxicity']	1	2	"Sentence: Toxicity was mild .
Diseases: toxicity"	"Sentence: Toxicity was mild .
Diseases:"
423	Six patients ( 12 % ) had World Health Organization Grade 3 - 4 neutropenia , 2 patients ( 4 % ) had Grade 3 - 4 thrombocytopenia , and 2 patients ( 4 % ) had Grade 3 neurotoxicity .	O O O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O B O	['neutropenia', 'thrombocytopenia', 'neurotoxicity']	3	16	"Sentence: Six patients ( 12 % ) had World Health Organization Grade 3 - 4 neutropenia , 2 patients ( 4 % ) had Grade 3 - 4 thrombocytopenia , and 2 patients ( 4 % ) had Grade 3 neurotoxicity .
Diseases: neutropenia, thrombocytopenia, neurotoxicity"	"Sentence: Six patients ( 12 % ) had World Health Organization Grade 3 - 4 neutropenia , 2 patients ( 4 % ) had Grade 3 - 4 thrombocytopenia , and 2 patients ( 4 % ) had Grade 3 neurotoxicity .
Diseases:"
424	Three patients with severe neutropenia ( 6 % ) died of sepsis .	O O O O B O O O O O O B O	['neutropenia', 'sepsis']	2	9	"Sentence: Three patients with severe neutropenia ( 6 % ) died of sepsis .
Diseases: neutropenia, sepsis"	"Sentence: Three patients with severe neutropenia ( 6 % ) died of sepsis .
Diseases:"
425	The median age of those patients developing Grade 3 - 4 neutropenia was significantly higher than that of the remaining patients ( 75 years vs . 72 years ; P = 0 . 047 ) .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['neutropenia']	1	5	"Sentence: The median age of those patients developing Grade 3 - 4 neutropenia was significantly higher than that of the remaining patients ( 75 years vs . 72 years ; P = 0 . 047 ) .
Diseases: neutropenia"	"Sentence: The median age of those patients developing Grade 3 - 4 neutropenia was significantly higher than that of the remaining patients ( 75 years vs . 72 years ; P = 0 . 047 ) .
Diseases:"
426	CONCLUSIONS :	O O	[]	0	0	"Sentence: CONCLUSIONS :
Diseases: "	"Sentence: CONCLUSIONS :
Diseases:"
427	The combination of GEM and VNB is moderately active and well tolerated except in patients age > / = 75 years .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The combination of GEM and VNB is moderately active and well tolerated except in patients age > / = 75 years .
Diseases: "	"Sentence: The combination of GEM and VNB is moderately active and well tolerated except in patients age > / = 75 years .
Diseases:"
428	This age group had an increased risk of myelosuppression .	O O O O O O O O B O	['myelosuppression']	1	5	"Sentence: This age group had an increased risk of myelosuppression .
Diseases: myelosuppression"	"Sentence: This age group had an increased risk of myelosuppression .
Diseases:"
429	Therefore the prophylactic use of granulocyte - colony stimulating factor should be considered with this treatment .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Therefore the prophylactic use of granulocyte - colony stimulating factor should be considered with this treatment .
Diseases: "	"Sentence: Therefore the prophylactic use of granulocyte - colony stimulating factor should be considered with this treatment .
Diseases:"
430	New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC .	O O O O O O O O B O O O O O O O B O	['nsclc', 'toxicity']	2	5	"Sentence: New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC .
Diseases: nsclc, toxicity"	"Sentence: New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC .
Diseases:"
431	Warfarin - induced artery calcification is accelerated by growth and vitamin	O O O B I O O O O O O	['artery calcification']	1	4	"Sentence: Warfarin - induced artery calcification is accelerated by growth and vitamin
Diseases: artery calcification"	"Sentence: Warfarin - induced artery calcification is accelerated by growth and vitamin
Diseases:"
432	D .	O O	[]	0	0	"Sentence: D .
Diseases: "	"Sentence: D .
Diseases:"
433	The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma - carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['calcification', 'artery calcification']	2	7	"Sentence: The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma - carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
Diseases: calcification, artery calcification"	"Sentence: The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma - carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .
Diseases:"
434	The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin - treated rats .	O O O O O O O O O O O O O O B I O O O O O O	['artery calcification']	1	4	"Sentence: The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin - treated rats .
Diseases: artery calcification"	"Sentence: The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin - treated rats .
Diseases:"
435	Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20 - day - old rats and less extensive focal calcification in 42 - day - old rats .	O O O O O O O O O B I I I O O O O O O O O O O O O B O O O O O O O O	['calcification', 'calcification of the artery']	2	9	"Sentence: Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20 - day - old rats and less extensive focal calcification in 42 - day - old rats .
Diseases: calcification, calcification of the artery"	"Sentence: Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20 - day - old rats and less extensive focal calcification in 42 - day - old rats .
Diseases:"
436	In contrast , no artery calcification could be detected in 10 - month - old adult rats even after 4 weeks of Warfarin treatment .	O O O O B I O O O O O O O O O O O O O O O O O O O	['artery calcification']	1	4	"Sentence: In contrast , no artery calcification could be detected in 10 - month - old adult rats even after 4 weeks of Warfarin treatment .
Diseases: artery calcification"	"Sentence: In contrast , no artery calcification could be detected in 10 - month - old adult rats even after 4 weeks of Warfarin treatment .
Diseases:"
437	To directly examine the importance of growth to Warfarin - induced artery calcification in animals of the same age , 20 - day - old rats were fed for 2 weeks either an ad libitum diet or a 6 - g / d restricted diet that maintains weight but prevents growth .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['artery calcification']	1	4	"Sentence: To directly examine the importance of growth to Warfarin - induced artery calcification in animals of the same age , 20 - day - old rats were fed for 2 weeks either an ad libitum diet or a 6 - g / d restricted diet that maintains weight but prevents growth .
Diseases: artery calcification"	"Sentence: To directly examine the importance of growth to Warfarin - induced artery calcification in animals of the same age , 20 - day - old rats were fed for 2 weeks either an ad libitum diet or a 6 - g / d restricted diet that maintains weight but prevents growth .
Diseases:"
438	Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum - fed rats but no detectable artery calcification in the restricted - diet , growth - inhibited group .	O O O O O O O O O O O B I I I O O O O O O O O O O O B I O O O O O O O O O O O	['artery calcification', 'calcification of the artery']	2	10	"Sentence: Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum - fed rats but no detectable artery calcification in the restricted - diet , growth - inhibited group .
Diseases: artery calcification, calcification of the artery"	"Sentence: Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum - fed rats but no detectable artery calcification in the restricted - diet , growth - inhibited group .
Diseases:"
439	Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	['artery calcification']	1	4	"Sentence: Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
Diseases: artery calcification"	"Sentence: Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .
Diseases:"
440	This observation suggests that increased susceptibility to Warfarin - induced artery calcification could be related to higher serum phosphate levels .	O O O O O O O O O O B I O O O O O O O O O	['artery calcification']	1	4	"Sentence: This observation suggests that increased susceptibility to Warfarin - induced artery calcification could be related to higher serum phosphate levels .
Diseases: artery calcification"	"Sentence: This observation suggests that increased susceptibility to Warfarin - induced artery calcification could be related to higher serum phosphate levels .
Diseases:"
441	The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification .	O O O O O O O O O O O O O O O B I O	['artery calcification']	1	4	"Sentence: The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification .
Diseases: artery calcification"	"Sentence: The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification .
Diseases:"
442	High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days .	O O O O O O O O O B I I I O O O O O O O O O O	['calcification of the artery']	1	6	"Sentence: High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days .
Diseases: calcification of the artery"	"Sentence: High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days .
Diseases:"
443	High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media , but at treatment times of 2 weeks or longer yet not at 1 week .	O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O	['calcification of the artery']	1	6	"Sentence: High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media , but at treatment times of 2 weeks or longer yet not at 1 week .
Diseases: calcification of the artery"	"Sentence: High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media , but at treatment times of 2 weeks or longer yet not at 1 week .
Diseases:"
444	In the current study , we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D - treated rats at 3 and 4 days .	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['calcification']	1	3	"Sentence: In the current study , we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D - treated rats at 3 and 4 days .
Diseases: calcification"	"Sentence: In the current study , we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D - treated rats at 3 and 4 days .
Diseases:"
445	There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O	['artery calcification']	1	4	"Sentence: There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .
Diseases: artery calcification"	"Sentence: There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .
Diseases:"
446	Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['calcification']	1	3	"Sentence: Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor .
Diseases: calcification"	"Sentence: Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor .
Diseases:"
447	High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not gamma - carboxylated .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O	['artery calcification']	1	4	"Sentence: High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not gamma - carboxylated .
Diseases: artery calcification"	"Sentence: High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not gamma - carboxylated .
Diseases:"
448	These observations indicate that although the gamma - carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor , they are not required for its accumulation at calcification sites .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O B O O	['calcification']	1	3	"Sentence: These observations indicate that although the gamma - carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor , they are not required for its accumulation at calcification sites .
Diseases: calcification"	"Sentence: These observations indicate that although the gamma - carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor , they are not required for its accumulation at calcification sites .
Diseases:"
449	Antidepressant - induced mania in bipolar patients : identification of risk factors .	O O O B O B O O O O O O O	['mania', 'bipolar']	2	3	"Sentence: Antidepressant - induced mania in bipolar patients : identification of risk factors .
Diseases: mania, bipolar"	"Sentence: Antidepressant - induced mania in bipolar patients : identification of risk factors .
Diseases:"
450	Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression .	O O O O O O O B O O O O O O O O O O O O O O O B I O	['mania', 'bipolar depression']	2	4	"Sentence: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression .
Diseases: mania, bipolar depression"	"Sentence: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression .
Diseases:"
451	METHOD :	O O	[]	0	0	"Sentence: METHOD :
Diseases: "	"Sentence: METHOD :
Diseases:"
452	The response of 44 patients meeting DSM - IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery - Asberg Depression Rating Scale and the Bech - Rafaelson Mania Rating Scale .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bipolar disorder']	1	3	"Sentence: The response of 44 patients meeting DSM - IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery - Asberg Depression Rating Scale and the Bech - Rafaelson Mania Rating Scale .
Diseases: bipolar disorder"	"Sentence: The response of 44 patients meeting DSM - IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery - Asberg Depression Rating Scale and the Bech - Rafaelson Mania Rating Scale .
Diseases:"
453	Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM - IV bipolar I vs . bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs . antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs . anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi - structured Affective Temperament Interview .	O O O O B O B O O O O O O O O O O O O O O O O O O B I I I I O O B I O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bipolar ii', 'hypomanic', 'manic', 'dsm - iv bipolar i']	4	15	"Sentence: Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM - IV bipolar I vs . bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs . antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs . anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi - structured Affective Temperament Interview .
Diseases: bipolar ii, hypomanic, manic, dsm - iv bipolar i"	"Sentence: Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM - IV bipolar I vs . bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs . antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs . anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi - structured Affective Temperament Interview .
Diseases:"
454	Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with SSRIs [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .	O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O	['mania', 'hypomanic', 'manic', 'hypomania']	4	11	"Sentence: Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with SSRIs [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .
Diseases: mania, hypomanic, manic, hypomania"	"Sentence: Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with SSRIs [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .
Diseases:"
455	Sex , age , diagnosis ( bipolar I vs . bipolar II ) , and additional treatment did not affect the risk of switching .	O O O O O O B I O O B I O O O O O O O O O O O O O	['bipolar i', 'bipolar ii']	2	6	"Sentence: Sex , age , diagnosis ( bipolar I vs . bipolar II ) , and additional treatment did not affect the risk of switching .
Diseases: bipolar i, bipolar ii"	"Sentence: Sex , age , diagnosis ( bipolar I vs . bipolar II ) , and additional treatment did not affect the risk of switching .
Diseases:"
456	The incidence of mood switches seemed not to differ between patients receiving an anticonvulsant and those receiving no mood stabilizer .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The incidence of mood switches seemed not to differ between patients receiving an anticonvulsant and those receiving no mood stabilizer .
Diseases: "	"Sentence: The incidence of mood switches seemed not to differ between patients receiving an anticonvulsant and those receiving no mood stabilizer .
Diseases:"
457	In contrast , mood switches were less frequent in patients receiving lithium ( 15 % , 4 / 26 ) than in patients not treated with lithium ( 44 % , 8 / 18 ; p = . 04 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , mood switches were less frequent in patients receiving lithium ( 15 % , 4 / 26 ) than in patients not treated with lithium ( 44 % , 8 / 18 ; p = . 04 ) .
Diseases: "	"Sentence: In contrast , mood switches were less frequent in patients receiving lithium ( 15 % , 4 / 26 ) than in patients not treated with lithium ( 44 % , 8 / 18 ; p = . 04 ) .
Diseases:"
458	The number of previous manic episodes did not affect the probability of switching , whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching ( p = . 008 ) .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['manic']	1	2	"Sentence: The number of previous manic episodes did not affect the probability of switching , whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching ( p = . 008 ) .
Diseases: manic"	"Sentence: The number of previous manic episodes did not affect the probability of switching , whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching ( p = . 008 ) .
Diseases:"
459	CONCLUSION :	O O	[]	0	0	"Sentence: CONCLUSION :
Diseases: "	"Sentence: CONCLUSION :
Diseases:"
460	The frequency of mood switching associated with acute antidepressant therapy may be reduced by lithium treatment .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The frequency of mood switching associated with acute antidepressant therapy may be reduced by lithium treatment .
Diseases: "	"Sentence: The frequency of mood switching associated with acute antidepressant therapy may be reduced by lithium treatment .
Diseases:"
461	Particular attention should be paid to patients with a hyperthymic temperament , who have a greater risk of mood switches .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Particular attention should be paid to patients with a hyperthymic temperament , who have a greater risk of mood switches .
Diseases: "	"Sentence: Particular attention should be paid to patients with a hyperthymic temperament , who have a greater risk of mood switches .
Diseases:"
462	Caffeine - induced cardiac arrhythmia : an unrecognised danger of healthfood products .	O O O B I O O O O O O O O	['cardiac arrhythmia']	1	6	"Sentence: Caffeine - induced cardiac arrhythmia : an unrecognised danger of healthfood products .
Diseases: cardiac arrhythmia"	"Sentence: Caffeine - induced cardiac arrhythmia : an unrecognised danger of healthfood products .
Diseases:"
463	"We describe a 25 - year - old woman with pre - existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a "" natural energy "" guarana health drink containing a high concentration of caffeine ."	O O O O O O O O O O O O O B I I O O O B I O O O O O O O O O O O O O O O O O	['mitral valve prolapse', 'ventricular fibrillation']	2	11	"Sentence: We describe a 25 - year - old woman with pre - existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a "" natural energy "" guarana health drink containing a high concentration of caffeine .
Diseases: mitral valve prolapse, ventricular fibrillation"	"Sentence: We describe a 25 - year - old woman with pre - existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a "" natural energy "" guarana health drink containing a high concentration of caffeine .
Diseases:"
464	This case highlights the need for adequate labelling and regulation of such products .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: This case highlights the need for adequate labelling and regulation of such products .
Diseases: "	"Sentence: This case highlights the need for adequate labelling and regulation of such products .
Diseases:"
465	Bladder retention of urine as a result of continuous intravenous infusion of fentanyl : 2 case reports .	O B I I O O O O O O O O O O O O O O	['retention of urine']	1	4	"Sentence: Bladder retention of urine as a result of continuous intravenous infusion of fentanyl : 2 case reports .
Diseases: retention of urine"	"Sentence: Bladder retention of urine as a result of continuous intravenous infusion of fentanyl : 2 case reports .
Diseases:"
466	Sedation has been commonly used in the neonate to decrease the stress and pain from the noxious stimuli and invasive procedures in the neonatal intensive care unit , as well as to facilitate synchrony between ventilator and spontaneous breaths .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Sedation has been commonly used in the neonate to decrease the stress and pain from the noxious stimuli and invasive procedures in the neonatal intensive care unit , as well as to facilitate synchrony between ventilator and spontaneous breaths .
Diseases: pain"	"Sentence: Sedation has been commonly used in the neonate to decrease the stress and pain from the noxious stimuli and invasive procedures in the neonatal intensive care unit , as well as to facilitate synchrony between ventilator and spontaneous breaths .
Diseases:"
467	Fentanyl , an opioid analgesic , is frequently used in the neonatal intensive care unit setting for these very purposes .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fentanyl , an opioid analgesic , is frequently used in the neonatal intensive care unit setting for these very purposes .
Diseases: "	"Sentence: Fentanyl , an opioid analgesic , is frequently used in the neonatal intensive care unit setting for these very purposes .
Diseases:"
468	Various reported side effects of fentanyl administration include chest wall rigidity , hypotension , respiratory depression , and bradycardia .	O O O O O O O O B I I O B O B I O O B O	['bradycardia', 'respiratory depression', 'hypotension', 'chest wall rigidity']	4	17	"Sentence: Various reported side effects of fentanyl administration include chest wall rigidity , hypotension , respiratory depression , and bradycardia .
Diseases: bradycardia, respiratory depression, hypotension, chest wall rigidity"	"Sentence: Various reported side effects of fentanyl administration include chest wall rigidity , hypotension , respiratory depression , and bradycardia .
Diseases:"
469	Here , 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported .	O O O O O B I I O O O O O O B O O O O O O O O O O O	['hydronephrosis', 'urinary bladder retention']	2	8	"Sentence: Here , 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported .
Diseases: hydronephrosis, urinary bladder retention"	"Sentence: Here , 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported .
Diseases:"
470	Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice .	O O O O B O O O O O O B O O	['cardiomyopathy', 'aids']	2	6	"Sentence: Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice .
Diseases: cardiomyopathy, aids"	"Sentence: Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice .
Diseases:"
471	Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .	O O O O O O O O O O B O B O O O O O O O O O O B O O O B I O	['mitochondrial dysfunction', 'cardiomyopathy', 'cm', 'aids']	4	13	"Sentence: Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .
Diseases: mitochondrial dysfunction, cardiomyopathy, cm, aids"	"Sentence: Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .
Diseases:"
472	To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic AIDS mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of zidovudine , lamivudine , and indinavir or vehicle control for 10 days or 35 days .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['aids']	1	2	"Sentence: To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic AIDS mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of zidovudine , lamivudine , and indinavir or vehicle control for 10 days or 35 days .
Diseases: aids"	"Sentence: To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic AIDS mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of zidovudine , lamivudine , and indinavir or vehicle control for 10 days or 35 days .
Diseases:"
473	At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of CM ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic calcium ATPase	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['cm']	1	1	"Sentence: At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of CM ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic calcium ATPase
Diseases: cm"	"Sentence: At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of CM ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic calcium ATPase
Diseases:"
474	[ SERCA2 ] ) , and determination of plasma LA .	O O O O O O O O O O O	[]	0	0	"Sentence: [ SERCA2 ] ) , and determination of plasma LA .
Diseases: "	"Sentence: [ SERCA2 ] ) , and determination of plasma LA .
Diseases:"
475	Myocardial histologic features were analyzed semiquantitatively and results were confirmed by transmission electron microscopy .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Myocardial histologic features were analyzed semiquantitatively and results were confirmed by transmission electron microscopy .
Diseases: "	"Sentence: Myocardial histologic features were analyzed semiquantitatively and results were confirmed by transmission electron microscopy .
Diseases:"
476	After 35 days in the TG + HAART cohort , left ventricular mass increased 160 % by echocardiography .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 35 days in the TG + HAART cohort , left ventricular mass increased 160 % by echocardiography .
Diseases: "	"Sentence: After 35 days in the TG + HAART cohort , left ventricular mass increased 160 % by echocardiography .
Diseases:"
477	Molecularly , ANF mRNA increased 250 % and SERCA2 mRNA decreased 57 % .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Molecularly , ANF mRNA increased 250 % and SERCA2 mRNA decreased 57 % .
Diseases: "	"Sentence: Molecularly , ANF mRNA increased 250 % and SERCA2 mRNA decreased 57 % .
Diseases:"
478	Biochemically , LA was elevated ( 8 . 5 + / - 2 . 0 mM ) .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Biochemically , LA was elevated ( 8 . 5 + / - 2 . 0 mM ) .
Diseases: "	"Sentence: Biochemically , LA was elevated ( 8 . 5 + / - 2 . 0 mM ) .
Diseases:"
479	Pathologically , granular cytoplasmic changes were found in cardiac myocytes , indicating enlarged , damaged mitochondria .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pathologically , granular cytoplasmic changes were found in cardiac myocytes , indicating enlarged , damaged mitochondria .
Diseases: "	"Sentence: Pathologically , granular cytoplasmic changes were found in cardiac myocytes , indicating enlarged , damaged mitochondria .
Diseases:"
480	Findings were confirmed ultrastructurally .	O O O O O	[]	0	0	"Sentence: Findings were confirmed ultrastructurally .
Diseases: "	"Sentence: Findings were confirmed ultrastructurally .
Diseases:"
481	No changes were found in other cohorts .	O O O O O O O O	[]	0	0	"Sentence: No changes were found in other cohorts .
Diseases: "	"Sentence: No changes were found in other cohorts .
Diseases:"
482	After 10 days , only ANF was elevated , and only in the TG + HAART cohort .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 10 days , only ANF was elevated , and only in the TG + HAART cohort .
Diseases: "	"Sentence: After 10 days , only ANF was elevated , and only in the TG + HAART cohort .
Diseases:"
483	Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice .	O O O O O O O B O O O O B O O O	['cm', 'aids']	2	3	"Sentence: Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice .
Diseases: cm, aids"	"Sentence: Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice .
Diseases:"
484	Oral contraceptives and the risk of myocardial infarction .	O O O O O O B I O	['myocardial infarction']	1	6	"Sentence: Oral contraceptives and the risk of myocardial infarction .
Diseases: myocardial infarction"	"Sentence: Oral contraceptives and the risk of myocardial infarction .
Diseases:"
485	An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some , but not all , studies .	O O O O O O O O O O O O B I O O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some , but not all , studies .
Diseases: myocardial infarction"	"Sentence: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some , but not all , studies .
Diseases:"
486	We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS :	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS :
Diseases: "	"Sentence: We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS :
Diseases:"
487	In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
Diseases: myocardial infarction"	"Sentence: In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .
Diseases:"
488	Subjects supplied information on oral - contraceptive use and major cardiovascular risk factors .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Subjects supplied information on oral - contraceptive use and major cardiovascular risk factors .
Diseases: "	"Sentence: Subjects supplied information on oral - contraceptive use and major cardiovascular risk factors .
Diseases:"
489	An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS :	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS :
Diseases: "	"Sentence: An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS :
Diseases:"
490	The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive , as compared with nonusers , was 2 . 0 ( 95 percent confidence interval , 1 . 5 to 2 . 8 ) .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive , as compared with nonusers , was 2 . 0 ( 95 percent confidence interval , 1 . 5 to 2 . 8 ) .
Diseases: myocardial infarction"	"Sentence: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive , as compared with nonusers , was 2 . 0 ( 95 percent confidence interval , 1 . 5 to 2 . 8 ) .
Diseases:"
491	The adjusted odds ratio was 2 . 5 ( 95 percent confidence interval , 1 . 5 to 4 . 1 ) among women who used second - generation oral contraceptives and 1 . 3 ( 95 percent confidence interval , 0 . 7 to 2 . 5 ) among those who used third - generation oral contraceptives .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The adjusted odds ratio was 2 . 5 ( 95 percent confidence interval , 1 . 5 to 4 . 1 ) among women who used second - generation oral contraceptives and 1 . 3 ( 95 percent confidence interval , 0 . 7 to 2 . 5 ) among those who used third - generation oral contraceptives .
Diseases: "	"Sentence: The adjusted odds ratio was 2 . 5 ( 95 percent confidence interval , 1 . 5 to 4 . 1 ) among women who used second - generation oral contraceptives and 1 . 3 ( 95 percent confidence interval , 0 . 7 to 2 . 5 ) among those who used third - generation oral contraceptives .
Diseases:"
492	Among women who used oral contraceptives , the odds ratio was 2 . 1 ( 95 percent confidence interval , 1 . 5 to 3 . 0 ) for those without a prothrombotic mutation and 1 . 9 ( 95 percent confidence interval , 0 . 6 to 5 . 5 ) for those with a mutation CONCLUSIONS : The risk of myocardial infarction was increased among women who used second - generation oral contraceptives .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: Among women who used oral contraceptives , the odds ratio was 2 . 1 ( 95 percent confidence interval , 1 . 5 to 3 . 0 ) for those without a prothrombotic mutation and 1 . 9 ( 95 percent confidence interval , 0 . 6 to 5 . 5 ) for those with a mutation CONCLUSIONS : The risk of myocardial infarction was increased among women who used second - generation oral contraceptives .
Diseases: myocardial infarction"	"Sentence: Among women who used oral contraceptives , the odds ratio was 2 . 1 ( 95 percent confidence interval , 1 . 5 to 3 . 0 ) for those without a prothrombotic mutation and 1 . 9 ( 95 percent confidence interval , 0 . 6 to 5 . 5 ) for those with a mutation CONCLUSIONS : The risk of myocardial infarction was increased among women who used second - generation oral contraceptives .
Diseases:"
493	The results with respect to the use of third - generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second - generation oral contraceptives .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results with respect to the use of third - generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second - generation oral contraceptives .
Diseases: "	"Sentence: The results with respect to the use of third - generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second - generation oral contraceptives .
Diseases:"
494	The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation .	O O O B I O O O O O O O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation .
Diseases: myocardial infarction"	"Sentence: The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation .
Diseases:"
495	Effects of 5 - HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine - induced locomotor hyperactivity in rats .	O O O O O O O O O O O O O O O O O O O B I O O O	['locomotor hyperactivity']	1	5	"Sentence: Effects of 5 - HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine - induced locomotor hyperactivity in rats .
Diseases: locomotor hyperactivity"	"Sentence: Effects of 5 - HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine - induced locomotor hyperactivity in rats .
Diseases:"
496	The present study was designed to examine the effect of 5 - HT1B receptor ligands microinjected into the subregions of the nucleus accumbens ( the shell and the core ) on the locomotor hyperactivity induced by cocaine in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	['locomotor hyperactivity']	1	5	"Sentence: The present study was designed to examine the effect of 5 - HT1B receptor ligands microinjected into the subregions of the nucleus accumbens ( the shell and the core ) on the locomotor hyperactivity induced by cocaine in rats .
Diseases: locomotor hyperactivity"	"Sentence: The present study was designed to examine the effect of 5 - HT1B receptor ligands microinjected into the subregions of the nucleus accumbens ( the shell and the core ) on the locomotor hyperactivity induced by cocaine in rats .
Diseases:"
497	Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core , and then were locally injected with GR 55562 ( an antagonist of 5 - HT1B receptors ) or CP 93129 ( an agonist of 5 - HT1B receptors ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core , and then were locally injected with GR 55562 ( an antagonist of 5 - HT1B receptors ) or CP 93129 ( an agonist of 5 - HT1B receptors ) .
Diseases: "	"Sentence: Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core , and then were locally injected with GR 55562 ( an antagonist of 5 - HT1B receptors ) or CP 93129 ( an agonist of 5 - HT1B receptors ) .
Diseases:"
498	Given alone to any accumbal subregion , GR 55562 ( 0 . 1 - 10 microg / side ) or CP 93129 ( 0 . 1 - 10 microg / side ) did not change basal locomotor activity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Given alone to any accumbal subregion , GR 55562 ( 0 . 1 - 10 microg / side ) or CP 93129 ( 0 . 1 - 10 microg / side ) did not change basal locomotor activity .
Diseases: "	"Sentence: Given alone to any accumbal subregion , GR 55562 ( 0 . 1 - 10 microg / side ) or CP 93129 ( 0 . 1 - 10 microg / side ) did not change basal locomotor activity .
Diseases:"
499	Systemic cocaine ( 10 mg / kg ) significantly increased the locomotor activity of rats .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Systemic cocaine ( 10 mg / kg ) significantly increased the locomotor activity of rats .
Diseases: "	"Sentence: Systemic cocaine ( 10 mg / kg ) significantly increased the locomotor activity of rats .
Diseases:"
500	GR 55562 ( 0 . 1 - 10 microg / side ) , administered intra - accumbens shell prior to cocaine , dose - dependently attenuated the psychostimulant - induced locomotor hyperactivity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['locomotor hyperactivity']	1	5	"Sentence: GR 55562 ( 0 . 1 - 10 microg / side ) , administered intra - accumbens shell prior to cocaine , dose - dependently attenuated the psychostimulant - induced locomotor hyperactivity .
Diseases: locomotor hyperactivity"	"Sentence: GR 55562 ( 0 . 1 - 10 microg / side ) , administered intra - accumbens shell prior to cocaine , dose - dependently attenuated the psychostimulant - induced locomotor hyperactivity .
Diseases:"
501	Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core .
Diseases: "	"Sentence: Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core .
Diseases:"
502	When injected into the accumbens shell ( but not the core ) before cocaine , CP 93129 ( 0 . 1 - 10 microg / side ) enhanced the locomotor response to cocaine ; the maximum effect being observed after 10 microg / side of the agonist .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When injected into the accumbens shell ( but not the core ) before cocaine , CP 93129 ( 0 . 1 - 10 microg / side ) enhanced the locomotor response to cocaine ; the maximum effect being observed after 10 microg / side of the agonist .
Diseases: "	"Sentence: When injected into the accumbens shell ( but not the core ) before cocaine , CP 93129 ( 0 . 1 - 10 microg / side ) enhanced the locomotor response to cocaine ; the maximum effect being observed after 10 microg / side of the agonist .
Diseases:"
503	The later enhancement was attenuated after intra - accumbens shell treatment with GR 55562 ( 1 microg / side ) .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The later enhancement was attenuated after intra - accumbens shell treatment with GR 55562 ( 1 microg / side ) .
Diseases: "	"Sentence: The later enhancement was attenuated after intra - accumbens shell treatment with GR 55562 ( 1 microg / side ) .
Diseases:"
504	Our findings indicate that cocaine induced hyperlocomotion is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core ,	O O O O O O B O O O O O O O O O O O O O O O O O O	['hyperlocomotion']	1	4	"Sentence: Our findings indicate that cocaine induced hyperlocomotion is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core ,
Diseases: hyperlocomotion"	"Sentence: Our findings indicate that cocaine induced hyperlocomotion is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core ,
Diseases:"
505	this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( GR 55562 ) and agonist ( CP 93129 ) , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( GR 55562 ) and agonist ( CP 93129 ) , respectively .
Diseases: "	"Sentence: this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( GR 55562 ) and agonist ( CP 93129 ) , respectively .
Diseases:"
506	In other words , the present results suggest that the accumbal shell 5 - HT1B receptors play a permissive role in the behavioural response to the psychostimulant .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In other words , the present results suggest that the accumbal shell 5 - HT1B receptors play a permissive role in the behavioural response to the psychostimulant .
Diseases: "	"Sentence: In other words , the present results suggest that the accumbal shell 5 - HT1B receptors play a permissive role in the behavioural response to the psychostimulant .
Diseases:"
507	Ticlopidine - induced cholestatic hepatitis .	O O O B I O	['cholestatic hepatitis']	1	5	"Sentence: Ticlopidine - induced cholestatic hepatitis .
Diseases: cholestatic hepatitis"	"Sentence: Ticlopidine - induced cholestatic hepatitis .
Diseases:"
508	OBJECTIVE :	O O	[]	0	0	"Sentence: OBJECTIVE :
Diseases: "	"Sentence: OBJECTIVE :
Diseases:"
509	To report 2 cases of ticlopidine - induced cholestatic hepatitis , investigate its mechanism , and compare the observed main characteristics with those of the published cases .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['cholestatic hepatitis']	1	5	"Sentence: To report 2 cases of ticlopidine - induced cholestatic hepatitis , investigate its mechanism , and compare the observed main characteristics with those of the published cases .
Diseases: cholestatic hepatitis"	"Sentence: To report 2 cases of ticlopidine - induced cholestatic hepatitis , investigate its mechanism , and compare the observed main characteristics with those of the published cases .
Diseases:"
510	CASE SUMMARIES :	O O O	[]	0	0	"Sentence: CASE SUMMARIES :
Diseases: "	"Sentence: CASE SUMMARIES :
Diseases:"
511	Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty , with complete remission during the follow - up period .	O O O O B I O O O O O O O O O O O O O O O O O O	['cholestatic hepatitis']	1	5	"Sentence: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty , with complete remission during the follow - up period .
Diseases: cholestatic hepatitis"	"Sentence: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty , with complete remission during the follow - up period .
Diseases:"
512	T - cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients , but not in healthy controls .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: T - cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients , but not in healthy controls .
Diseases: "	"Sentence: T - cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients , but not in healthy controls .
Diseases:"
513	DISCUSSION :	O O	[]	0	0	"Sentence: DISCUSSION :
Diseases: "	"Sentence: DISCUSSION :
Diseases:"
514	Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine ; several cases have been reported but few in the English literature .	B I O O O O O O O O O O O O O O O O O O O O O O	['cholestatic hepatitis']	1	5	"Sentence: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine ; several cases have been reported but few in the English literature .
Diseases: cholestatic hepatitis"	"Sentence: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine ; several cases have been reported but few in the English literature .
Diseases:"
515	Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis , which resolved after discontinuation of the drug .	O O O B O O O O O O O O O O O O B I O O O O O O O O O	['jaundice', 'cholestatic hepatitis']	2	9	"Sentence: Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis , which resolved after discontinuation of the drug .
Diseases: jaundice, cholestatic hepatitis"	"Sentence: Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis , which resolved after discontinuation of the drug .
Diseases:"
516	Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course , but complete remission was observed in all reported cases .	B O O O O O O O O O O O O O O O O O O O O O O O O O	['hepatitis']	1	3	"Sentence: Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course , but complete remission was observed in all reported cases .
Diseases: hepatitis"	"Sentence: Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course , but complete remission was observed in all reported cases .
Diseases:"
517	An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine .
Diseases: "	"Sentence: An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine .
Diseases:"
518	The mechanisms of this ticlopidine - induced cholestasis are unclear .	O O O O O O O B O O O	['cholestasis']	1	4	"Sentence: The mechanisms of this ticlopidine - induced cholestasis are unclear .
Diseases: cholestasis"	"Sentence: The mechanisms of this ticlopidine - induced cholestasis are unclear .
Diseases:"
519	Immune mechanisms may be involved in the drug 's hepatotoxicity , as suggested by the T - cell stimulation study reported here .	O O O O O O O O O B O O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: Immune mechanisms may be involved in the drug 's hepatotoxicity , as suggested by the T - cell stimulation study reported here .
Diseases: hepatotoxicity"	"Sentence: Immune mechanisms may be involved in the drug 's hepatotoxicity , as suggested by the T - cell stimulation study reported here .
Diseases:"
520	CONCLUSIONS : Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated .	O O B I O O O O O O O O O O O O O	['cholestatic hepatitis']	1	5	"Sentence: CONCLUSIONS : Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated .
Diseases: cholestatic hepatitis"	"Sentence: CONCLUSIONS : Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated .
Diseases:"
521	Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts .
Diseases: "	"Sentence: Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts .
Diseases:"
522	This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel .
Diseases: "	"Sentence: This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel .
Diseases:"
523	Epithelial sodium channel ( ENaC ) subunit mRNA and protein expression in rats with puromycin aminonucleoside - induced nephrotic syndrome .	O O O O O O O O O O O O O O O O O O B I O	['nephrotic syndrome']	1	5	"Sentence: Epithelial sodium channel ( ENaC ) subunit mRNA and protein expression in rats with puromycin aminonucleoside - induced nephrotic syndrome .
Diseases: nephrotic syndrome"	"Sentence: Epithelial sodium channel ( ENaC ) subunit mRNA and protein expression in rats with puromycin aminonucleoside - induced nephrotic syndrome .
Diseases:"
524	In experimental nephrotic syndrome , urinary sodium excretion is decreased during the early phase of the disease .	O O B I O O O O O O O O O O O O O O	['nephrotic syndrome']	1	5	"Sentence: In experimental nephrotic syndrome , urinary sodium excretion is decreased during the early phase of the disease .
Diseases: nephrotic syndrome"	"Sentence: In experimental nephrotic syndrome , urinary sodium excretion is decreased during the early phase of the disease .
Diseases:"
525	The molecular mechanism ( s ) leading to salt retention has not been completely elucidated .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The molecular mechanism ( s ) leading to salt retention has not been completely elucidated .
Diseases: "	"Sentence: The molecular mechanism ( s ) leading to salt retention has not been completely elucidated .
Diseases:"
526	The rate - limiting constituent of collecting duct sodium transport is the epithelial sodium channel ( ENaC ) .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The rate - limiting constituent of collecting duct sodium transport is the epithelial sodium channel ( ENaC ) .
Diseases: "	"Sentence: The rate - limiting constituent of collecting duct sodium transport is the epithelial sodium channel ( ENaC ) .
Diseases:"
527	We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside ( PAN ) - induced nephrotic syndrome .	O O O O O O O O O O O O O O O O O O B I O	['nephrotic syndrome']	1	5	"Sentence: We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside ( PAN ) - induced nephrotic syndrome .
Diseases: nephrotic syndrome"	"Sentence: We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside ( PAN ) - induced nephrotic syndrome .
Diseases:"
528	The time courses of urinary sodium excretion , plasma aldosterone concentration and proteinuria were studied in male Sprague - Dawley rats treated with a single dose of either PAN or vehicle .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: The time courses of urinary sodium excretion , plasma aldosterone concentration and proteinuria were studied in male Sprague - Dawley rats treated with a single dose of either PAN or vehicle .
Diseases: proteinuria"	"Sentence: The time courses of urinary sodium excretion , plasma aldosterone concentration and proteinuria were studied in male Sprague - Dawley rats treated with a single dose of either PAN or vehicle .
Diseases:"
529	The relative amounts of alphaENaC , betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real - time quantitative TaqMan PCR , and the amounts of proteins by Western blot .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The relative amounts of alphaENaC , betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real - time quantitative TaqMan PCR , and the amounts of proteins by Western blot .
Diseases: "	"Sentence: The relative amounts of alphaENaC , betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real - time quantitative TaqMan PCR , and the amounts of proteins by Western blot .
Diseases:"
530	The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously .	O O O O O O O O O O B O O O O O O O	['proteinuria']	1	2	"Sentence: The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously .
Diseases: proteinuria"	"Sentence: The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously .
Diseases:"
531	Sodium retention occurred on days 2 , 3 and 6 after PAN injection .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sodium retention occurred on days 2 , 3 and 6 after PAN injection .
Diseases: "	"Sentence: Sodium retention occurred on days 2 , 3 and 6 after PAN injection .
Diseases:"
532	A significant up - regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3 .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A significant up - regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3 .
Diseases: "	"Sentence: A significant up - regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3 .
Diseases:"
533	Conversely , down - regulation of alphaENaC , betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations , and was followed by a return of sodium excretion to control values .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Conversely , down - regulation of alphaENaC , betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations , and was followed by a return of sodium excretion to control values .
Diseases: "	"Sentence: Conversely , down - regulation of alphaENaC , betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations , and was followed by a return of sodium excretion to control values .
Diseases:"
534	The amounts of alphaENaC , betaENaC and gammaENaC proteins were not increased during PAN - induced sodium retention .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The amounts of alphaENaC , betaENaC and gammaENaC proteins were not increased during PAN - induced sodium retention .
Diseases: "	"Sentence: The amounts of alphaENaC , betaENaC and gammaENaC proteins were not increased during PAN - induced sodium retention .
Diseases:"
535	In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of PAN - induced nephrotic syndrome in rats , but appears to escape from the regulation by aldosterone after day 3 .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O	['nephrotic syndrome']	1	5	"Sentence: In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of PAN - induced nephrotic syndrome in rats , but appears to escape from the regulation by aldosterone after day 3 .
Diseases: nephrotic syndrome"	"Sentence: In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of PAN - induced nephrotic syndrome in rats , but appears to escape from the regulation by aldosterone after day 3 .
Diseases:"
536	NO - induced migraine attack : strong increase in plasma calcitonin gene - related peptide ( CGRP ) concentration and negative correlation with platelet serotonin release .	O O O B O O O O O O O O O O O O O O O O O O O O O O O	['migraine']	1	3	"Sentence: NO - induced migraine attack : strong increase in plasma calcitonin gene - related peptide ( CGRP ) concentration and negative correlation with platelet serotonin release .
Diseases: migraine"	"Sentence: NO - induced migraine attack : strong increase in plasma calcitonin gene - related peptide ( CGRP ) concentration and negative correlation with platelet serotonin release .
Diseases:"
537	The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O B O O O O O	['headache', 'migraine']	2	4	"Sentence: The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin .
Diseases: headache, migraine"	"Sentence: The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin .
Diseases:"
538	Fifteen female migraineurs ( without aura ) and eight controls participated in the study .	O O B I I I I O O O O O O O O	['migraineurs ( without aura )']	1	8	"Sentence: Fifteen female migraineurs ( without aura ) and eight controls participated in the study .
Diseases: migraineurs ( without aura )"	"Sentence: Fifteen female migraineurs ( without aura ) and eight controls participated in the study .
Diseases:"
539	Sublingual nitroglycerin ( 0 . 5 mg ) was administered .	O O O O O O O O O O O	[]	0	0	"Sentence: Sublingual nitroglycerin ( 0 . 5 mg ) was administered .
Diseases: "	"Sentence: Sublingual nitroglycerin ( 0 . 5 mg ) was administered .
Diseases:"
540	Blood was collected from the antecubital vein four times : 60 min before and after the nitroglycerin application , and 60 and 120 min after the beginning of the migraine attack ( mean 344 and 404 min ; 12 subjects ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['migraine']	1	3	"Sentence: Blood was collected from the antecubital vein four times : 60 min before and after the nitroglycerin application , and 60 and 120 min after the beginning of the migraine attack ( mean 344 and 404 min ; 12 subjects ) .
Diseases: migraine"	"Sentence: Blood was collected from the antecubital vein four times : 60 min before and after the nitroglycerin application , and 60 and 120 min after the beginning of the migraine attack ( mean 344 and 404 min ; 12 subjects ) .
Diseases:"
541	In those subjects who had no migraine attack ( 11 subjects ) a similar time schedule was used .	O O O O O O B O O O O O O O O O O O O	['migraine']	1	3	"Sentence: In those subjects who had no migraine attack ( 11 subjects ) a similar time schedule was used .
Diseases: migraine"	"Sentence: In those subjects who had no migraine attack ( 11 subjects ) a similar time schedule was used .
Diseases:"
542	Plasma CGRP concentration increased significantly ( P < 0 . 01 ) during the migraine attack and returned to baseline after the cessation of the migraine .	O O O O O O O O O O O O O O B O O O O O O O O O O B O	['migraine']	1	3	"Sentence: Plasma CGRP concentration increased significantly ( P < 0 . 01 ) during the migraine attack and returned to baseline after the cessation of the migraine .
Diseases: migraine"	"Sentence: Plasma CGRP concentration increased significantly ( P < 0 . 01 ) during the migraine attack and returned to baseline after the cessation of the migraine .
Diseases:"
543	In addition , both change and peak , showed significant positive correlations with migraine headache intensity ( P < 0 . 001 ) .	O O O O O O O O O O O O O B B O O O O O O O O O	['migraine', 'headache']	2	5	"Sentence: In addition , both change and peak , showed significant positive correlations with migraine headache intensity ( P < 0 . 001 ) .
Diseases: migraine, headache"	"Sentence: In addition , both change and peak , showed significant positive correlations with migraine headache intensity ( P < 0 . 001 ) .
Diseases:"
544	However , plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack .	O O O O O O O O O O B O O O O O O B O O	['headache', 'migraine']	2	4	"Sentence: However , plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack .
Diseases: headache, migraine"	"Sentence: However , plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack .
Diseases:"
545	Basal CGRP concentration was significantly higher and platelet 5 - HT content tended to be lower in subjects who experienced a migraine attack .	O O O O O O O O O O O O O O O O O O O O O B O O	['migraine']	1	3	"Sentence: Basal CGRP concentration was significantly higher and platelet 5 - HT content tended to be lower in subjects who experienced a migraine attack .
Diseases: migraine"	"Sentence: Basal CGRP concentration was significantly higher and platelet 5 - HT content tended to be lower in subjects who experienced a migraine attack .
Diseases:"
546	Platelet serotonin content decreased significantly ( P < 0 . 01 ) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O B O O	['migraine']	1	3	"Sentence: Platelet serotonin content decreased significantly ( P < 0 . 01 ) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack .
Diseases: migraine"	"Sentence: Platelet serotonin content decreased significantly ( P < 0 . 01 ) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack .
Diseases:"
547	In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine .	O O O O O O O O O O O O O O O O O B B O O O O O O O B O	['migraine', 'headache']	2	5	"Sentence: In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine .
Diseases: migraine, headache"	"Sentence: In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine .
Diseases:"
548	In contrast , serotonin release from platelets does not provoke migraine , it may even counteract the headache and the concomitant CGRP release in this model .	O O O O O O O O O O B O O O O O O B O O O O O O O O O	['migraine', 'headache']	2	5	"Sentence: In contrast , serotonin release from platelets does not provoke migraine , it may even counteract the headache and the concomitant CGRP release in this model .
Diseases: migraine, headache"	"Sentence: In contrast , serotonin release from platelets does not provoke migraine , it may even counteract the headache and the concomitant CGRP release in this model .
Diseases:"
549	Coronary aneurysm after implantation of a paclitaxel - eluting stent .	B I O O O O O O O O O	['coronary aneurysm']	1	7	"Sentence: Coronary aneurysm after implantation of a paclitaxel - eluting stent .
Diseases: coronary aneurysm"	"Sentence: Coronary aneurysm after implantation of a paclitaxel - eluting stent .
Diseases:"
550	Formation of coronary aneurysm is a rare complication of stenting with bare metal stents , but based on experimental studies drug - eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition , aneurysm formation and with the potential of stent thrombosis or vessel rupture .	O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B O B I O	['coronary aneurysm', 'aneurysm', 'vessel rupture', 'thrombosis']	4	20	"Sentence: Formation of coronary aneurysm is a rare complication of stenting with bare metal stents , but based on experimental studies drug - eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition , aneurysm formation and with the potential of stent thrombosis or vessel rupture .
Diseases: coronary aneurysm, aneurysm, vessel rupture, thrombosis"	"Sentence: Formation of coronary aneurysm is a rare complication of stenting with bare metal stents , but based on experimental studies drug - eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition , aneurysm formation and with the potential of stent thrombosis or vessel rupture .
Diseases:"
551	We present a 43 - year - old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel - eluting stent .	O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	['coronary aneurysm']	1	7	"Sentence: We present a 43 - year - old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel - eluting stent .
Diseases: coronary aneurysm"	"Sentence: We present a 43 - year - old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel - eluting stent .
Diseases:"
552	The patient was asymptomatic and the aneurysm was detected in a routine control .	O O O O O O B O O O O O O O	['aneurysm']	1	4	"Sentence: The patient was asymptomatic and the aneurysm was detected in a routine control .
Diseases: aneurysm"	"Sentence: The patient was asymptomatic and the aneurysm was detected in a routine control .
Diseases:"
553	Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15 - mm long segment with maximal aneurysm diameter of 6 . 0 mm .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['aneurysm']	1	4	"Sentence: Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15 - mm long segment with maximal aneurysm diameter of 6 . 0 mm .
Diseases: aneurysm"	"Sentence: Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15 - mm long segment with maximal aneurysm diameter of 6 . 0 mm .
Diseases:"
554	The patient was successfully treated with a graft stent .	O O O O O O O O O O	[]	0	0	"Sentence: The patient was successfully treated with a graft stent .
Diseases: "	"Sentence: The patient was successfully treated with a graft stent .
Diseases:"
555	Behavioral effects of urotensin - II centrally administered in mice .	O O O O O O O O O O O	[]	0	0	"Sentence: Behavioral effects of urotensin - II centrally administered in mice .
Diseases: "	"Sentence: Behavioral effects of urotensin - II centrally administered in mice .
Diseases:"
556	Urotensin - II ( U - II ) receptors are widely distributed in the central nervous system .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Urotensin - II ( U - II ) receptors are widely distributed in the central nervous system .
Diseases: "	"Sentence: Urotensin - II ( U - II ) receptors are widely distributed in the central nervous system .
Diseases:"
557	Intracerebroventricular ( i . c . v . ) injection of U - II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion .	O O O O O O O O O O O O O O O B O B O O O O O O O	['bradycardia', 'hypertension']	2	6	"Sentence: Intracerebroventricular ( i . c . v . ) injection of U - II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion .
Diseases: bradycardia, hypertension"	"Sentence: Intracerebroventricular ( i . c . v . ) injection of U - II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion .
Diseases:"
558	However , the behavioral effects of centrally administered U - II have received little attention .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the behavioral effects of centrally administered U - II have received little attention .
Diseases: "	"Sentence: However , the behavioral effects of centrally administered U - II have received little attention .
Diseases:"
559	In the present study , we tested the effects of i . c . v .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the present study , we tested the effects of i . c . v .
Diseases: "	"Sentence: In the present study , we tested the effects of i . c . v .
Diseases:"
560	injections of U - II on behavioral , metabolic , and endocrine responses in mice .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: injections of U - II on behavioral , metabolic , and endocrine responses in mice .
Diseases: "	"Sentence: injections of U - II on behavioral , metabolic , and endocrine responses in mice .
Diseases:"
561	Administration of graded doses of U - II ( 1 - 10 , 000 ng / mouse ) provoked : ( 1 ) a dose - dependent reduction in the number of head dips in the hole - board test ; ( 2 ) a dose - dependent reduction in the number of entries in the white chamber in the black - and - white compartment test , and in the number of entries in the central platform and open arms in the plus - maze test ; and ( 3 ) a dose - dependent increase in the duration of immobility in the forced - swimming test and tail suspension test .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Administration of graded doses of U - II ( 1 - 10 , 000 ng / mouse ) provoked : ( 1 ) a dose - dependent reduction in the number of head dips in the hole - board test ; ( 2 ) a dose - dependent reduction in the number of entries in the white chamber in the black - and - white compartment test , and in the number of entries in the central platform and open arms in the plus - maze test ; and ( 3 ) a dose - dependent increase in the duration of immobility in the forced - swimming test and tail suspension test .
Diseases: "	"Sentence: Administration of graded doses of U - II ( 1 - 10 , 000 ng / mouse ) provoked : ( 1 ) a dose - dependent reduction in the number of head dips in the hole - board test ; ( 2 ) a dose - dependent reduction in the number of entries in the white chamber in the black - and - white compartment test , and in the number of entries in the central platform and open arms in the plus - maze test ; and ( 3 ) a dose - dependent increase in the duration of immobility in the forced - swimming test and tail suspension test .
Diseases:"
562	Intracerebroventricular injection of U - II also caused an increase in : food intake at doses of 100 and 1 , 000 ng / mouse , water intake at doses of 100 - 10 , 000 ng / mouse , and horizontal locomotion activity at a dose of 10 , 000 ng / mouse .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Intracerebroventricular injection of U - II also caused an increase in : food intake at doses of 100 and 1 , 000 ng / mouse , water intake at doses of 100 - 10 , 000 ng / mouse , and horizontal locomotion activity at a dose of 10 , 000 ng / mouse .
Diseases: "	"Sentence: Intracerebroventricular injection of U - II also caused an increase in : food intake at doses of 100 and 1 , 000 ng / mouse , water intake at doses of 100 - 10 , 000 ng / mouse , and horizontal locomotion activity at a dose of 10 , 000 ng / mouse .
Diseases:"
563	Whatever was the dose , the central administration of U - II had no effect on body temperature , nociception , apomorphine - induced penile erection and climbing behavior , and stress - induced plasma corticosterone level .	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	['penile erection']	1	3	"Sentence: Whatever was the dose , the central administration of U - II had no effect on body temperature , nociception , apomorphine - induced penile erection and climbing behavior , and stress - induced plasma corticosterone level .
Diseases: penile erection"	"Sentence: Whatever was the dose , the central administration of U - II had no effect on body temperature , nociception , apomorphine - induced penile erection and climbing behavior , and stress - induced plasma corticosterone level .
Diseases:"
564	Taken together , the present study demonstrates that the central injection of U - II at doses of 1 - 10 , 000 ng / mouse induces anxiogenic - and depressant - like effects in mouse .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Taken together , the present study demonstrates that the central injection of U - II at doses of 1 - 10 , 000 ng / mouse induces anxiogenic - and depressant - like effects in mouse .
Diseases: "	"Sentence: Taken together , the present study demonstrates that the central injection of U - II at doses of 1 - 10 , 000 ng / mouse induces anxiogenic - and depressant - like effects in mouse .
Diseases:"
565	These data suggest that U - II may be involved in some aspects of psychiatric disorders .	O O O O O O O O O O O O O O B I O	['psychiatric disorders']	1	3	"Sentence: These data suggest that U - II may be involved in some aspects of psychiatric disorders .
Diseases: psychiatric disorders"	"Sentence: These data suggest that U - II may be involved in some aspects of psychiatric disorders .
Diseases:"
566	Recurrent dysphonia and acitretin .	O B O O O	['dysphonia']	1	4	"Sentence: Recurrent dysphonia and acitretin .
Diseases: dysphonia"	"Sentence: Recurrent dysphonia and acitretin .
Diseases:"
567	We report the case of a woman complaining of dysphonia while she was treated by acitretin .	O O O O O O O O O B O O O O O O O	['dysphonia']	1	4	"Sentence: We report the case of a woman complaining of dysphonia while she was treated by acitretin .
Diseases: dysphonia"	"Sentence: We report the case of a woman complaining of dysphonia while she was treated by acitretin .
Diseases:"
568	Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced .
Diseases: "	"Sentence: Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced .
Diseases:"
569	To our knowledge , this is the first case of acitretin - induced dysphonia .	O O O O O O O O O O O O O B O	['dysphonia']	1	4	"Sentence: To our knowledge , this is the first case of acitretin - induced dysphonia .
Diseases: dysphonia"	"Sentence: To our knowledge , this is the first case of acitretin - induced dysphonia .
Diseases:"
570	This effect may be related to the pharmacological effect of this drug on mucous membranes .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This effect may be related to the pharmacological effect of this drug on mucous membranes .
Diseases: "	"Sentence: This effect may be related to the pharmacological effect of this drug on mucous membranes .
Diseases:"
571	Pharmacological modulation of pain - related brain activity during normal and central sensitization states in humans .	O O O B O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Pharmacological modulation of pain - related brain activity during normal and central sensitization states in humans .
Diseases: pain"	"Sentence: Pharmacological modulation of pain - related brain activity during normal and central sensitization states in humans .
Diseases:"
572	Abnormal processing of somatosensory inputs in the central nervous system ( central sensitization ) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury ( secondary hyperalgesia ) .	O O O O O O O O O O O O O O O O O O O O O B O O O O O B I O B I O O	['pain', 'secondary hyperalgesia', 'tissue injury']	3	10	"Sentence: Abnormal processing of somatosensory inputs in the central nervous system ( central sensitization ) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury ( secondary hyperalgesia ) .
Diseases: pain, secondary hyperalgesia, tissue injury"	"Sentence: Abnormal processing of somatosensory inputs in the central nervous system ( central sensitization ) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury ( secondary hyperalgesia ) .
Diseases:"
573	Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain .	B I O O O O B I O O O B I O	['neuropathic pain', 'secondary hyperalgesia', 'neurogenic hyperalgesia']	3	17	"Sentence: Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain .
Diseases: neuropathic pain, secondary hyperalgesia, neurogenic hyperalgesia"	"Sentence: Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain .
Diseases:"
574	Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization .	O O O O O O O O O O O O B O O O O O O O O O O O	['hyperalgesia']	1	4	"Sentence: Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization .
Diseases: hyperalgesia"	"Sentence: Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization .
Diseases:"
575	The aim of this study was to assess the effects of gabapentin , a drug effective in neuropathic pain patients , on brain processing of nociceptive information in normal and central sensitization states .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	['neuropathic pain']	1	4	"Sentence: The aim of this study was to assess the effects of gabapentin , a drug effective in neuropathic pain patients , on brain processing of nociceptive information in normal and central sensitization states .
Diseases: neuropathic pain"	"Sentence: The aim of this study was to assess the effects of gabapentin , a drug effective in neuropathic pain patients , on brain processing of nociceptive information in normal and central sensitization states .
Diseases:"
576	Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the gabapentin - induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin - induced secondary hyperalgesia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['secondary hyperalgesia']	1	5	"Sentence: Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the gabapentin - induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin - induced secondary hyperalgesia .
Diseases: secondary hyperalgesia"	"Sentence: Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the gabapentin - induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin - induced secondary hyperalgesia .
Diseases:"
577	The dose of gabapentin was 1 , 800 mg per os , in a single administration .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The dose of gabapentin was 1 , 800 mg per os , in a single administration .
Diseases: "	"Sentence: The dose of gabapentin was 1 , 800 mg per os , in a single administration .
Diseases:"
578	We found that ( i ) gabapentin reduced the activations in the bilateral operculoinsular cortex , independently of the presence of central sensitization ; ( ii ) gabapentin reduced the activation in the brainstem , only during central sensitization ; ( iii ) gabapentin suppressed stimulus - induced deactivations , only during central sensitization ; this effect was more robust than the effect on brain activation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We found that ( i ) gabapentin reduced the activations in the bilateral operculoinsular cortex , independently of the presence of central sensitization ; ( ii ) gabapentin reduced the activation in the brainstem , only during central sensitization ; ( iii ) gabapentin suppressed stimulus - induced deactivations , only during central sensitization ; this effect was more robust than the effect on brain activation .
Diseases: "	"Sentence: We found that ( i ) gabapentin reduced the activations in the bilateral operculoinsular cortex , independently of the presence of central sensitization ; ( ii ) gabapentin reduced the activation in the brainstem , only during central sensitization ; ( iii ) gabapentin suppressed stimulus - induced deactivations , only during central sensitization ; this effect was more robust than the effect on brain activation .
Diseases:"
579	The observed drug - induced effects were not due to changes in the baseline fMRI signal .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The observed drug - induced effects were not due to changes in the baseline fMRI signal .
Diseases: "	"Sentence: The observed drug - induced effects were not due to changes in the baseline fMRI signal .
Diseases:"
580	These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation , thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation , thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present .
Diseases: "	"Sentence: These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation , thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present .
Diseases:"
581	MDMA polydrug users show process - specific central executive impairments coupled with impaired social and emotional judgement processes .	O O O O O O O O O O O O B I I I I I O	['impaired social and emotional judgement processes']	1	8	"Sentence: MDMA polydrug users show process - specific central executive impairments coupled with impaired social and emotional judgement processes .
Diseases: impaired social and emotional judgement processes"	"Sentence: MDMA polydrug users show process - specific central executive impairments coupled with impaired social and emotional judgement processes .
Diseases:"
582	In recent years working memory deficits have been reported in users of MDMA ( 3 , 4 - methylenedioxymethamphetamine , ecstasy ) .	O O O O B I O O O O O O O O O O O O O O O O O	['memory deficits']	1	2	"Sentence: In recent years working memory deficits have been reported in users of MDMA ( 3 , 4 - methylenedioxymethamphetamine , ecstasy ) .
Diseases: memory deficits"	"Sentence: In recent years working memory deficits have been reported in users of MDMA ( 3 , 4 - methylenedioxymethamphetamine , ecstasy ) .
Diseases:"
583	"The current study aimed to assess the impact of MDMA use on three separate central executive processes ( set shifting , inhibition and memory updating ) and also on "" prefrontal "" mediated social and emotional judgement processes ."	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The current study aimed to assess the impact of MDMA use on three separate central executive processes ( set shifting , inhibition and memory updating ) and also on "" prefrontal "" mediated social and emotional judgement processes .
Diseases: "	"Sentence: The current study aimed to assess the impact of MDMA use on three separate central executive processes ( set shifting , inhibition and memory updating ) and also on "" prefrontal "" mediated social and emotional judgement processes .
Diseases:"
584	Fifteen polydrug ecstasy users and 15 polydrug non - ecstasy user controls completed a general drug use questionnaire , the Brixton Spatial Anticipation task ( set shifting ) , Backward Digit Span procedure ( memory updating ) , Inhibition of Return ( inhibition ) , an emotional intelligence scale , the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire ( DEX ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fifteen polydrug ecstasy users and 15 polydrug non - ecstasy user controls completed a general drug use questionnaire , the Brixton Spatial Anticipation task ( set shifting ) , Backward Digit Span procedure ( memory updating ) , Inhibition of Return ( inhibition ) , an emotional intelligence scale , the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire ( DEX ) .
Diseases: "	"Sentence: Fifteen polydrug ecstasy users and 15 polydrug non - ecstasy user controls completed a general drug use questionnaire , the Brixton Spatial Anticipation task ( set shifting ) , Backward Digit Span procedure ( memory updating ) , Inhibition of Return ( inhibition ) , an emotional intelligence scale , the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire ( DEX ) .
Diseases:"
585	Compared with MDMA - free polydrug controls , MDMA polydrug users showed impairments in set shifting and memory updating , and also in social and emotional judgement processes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Compared with MDMA - free polydrug controls , MDMA polydrug users showed impairments in set shifting and memory updating , and also in social and emotional judgement processes .
Diseases: "	"Sentence: Compared with MDMA - free polydrug controls , MDMA polydrug users showed impairments in set shifting and memory updating , and also in social and emotional judgement processes .
Diseases:"
586	The latter two deficits remained significant after controlling for other drug use .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The latter two deficits remained significant after controlling for other drug use .
Diseases: "	"Sentence: The latter two deficits remained significant after controlling for other drug use .
Diseases:"
587	These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational ecstasy use .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational ecstasy use .
Diseases: "	"Sentence: These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational ecstasy use .
Diseases:"
588	Severe citrate toxicity complicating volunteer apheresis platelet donation .	O O B O O O O O O	['toxicity']	1	2	"Sentence: Severe citrate toxicity complicating volunteer apheresis platelet donation .
Diseases: toxicity"	"Sentence: Severe citrate toxicity complicating volunteer apheresis platelet donation .
Diseases:"
589	We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection .	O O O O O O O B O O O O O O O	['toxicity']	1	2	"Sentence: We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection .
Diseases: toxicity"	"Sentence: We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection .
Diseases:"
590	The donor was a 40 - year - old female , first - time apheresis platelet donor .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The donor was a 40 - year - old female , first - time apheresis platelet donor .
Diseases: "	"Sentence: The donor was a 40 - year - old female , first - time apheresis platelet donor .
Diseases:"
591	Past medical history was remarkable for hypertension , hyperlipidemia , and depression .	O O O O O O B O B O O B O	['depression', 'hyperlipidemia', 'hypertension']	3	9	"Sentence: Past medical history was remarkable for hypertension , hyperlipidemia , and depression .
Diseases: depression, hyperlipidemia, hypertension"	"Sentence: Past medical history was remarkable for hypertension , hyperlipidemia , and depression .
Diseases:"
592	Reported medications included bumetanide , pravastatin , and paroxetine .	O O O O O O O O O O	[]	0	0	"Sentence: Reported medications included bumetanide , pravastatin , and paroxetine .
Diseases: "	"Sentence: Reported medications included bumetanide , pravastatin , and paroxetine .
Diseases:"
593	Thirty minutes from the start of the procedure , the donor noted tingling around the mouth , hands , and feet .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty minutes from the start of the procedure , the donor noted tingling around the mouth , hands , and feet .
Diseases: "	"Sentence: Thirty minutes from the start of the procedure , the donor noted tingling around the mouth , hands , and feet .
Diseases:"
594	She then very rapidly developed acute onset of severe facial and extremity tetany .	O O O O O O O O O O O O B O	['tetany']	1	3	"Sentence: She then very rapidly developed acute onset of severe facial and extremity tetany .
Diseases: tetany"	"Sentence: She then very rapidly developed acute onset of severe facial and extremity tetany .
Diseases:"
595	Empirical treatment with intravenous calcium gluconate was initiated , and muscle contractions slowly subsided over approximately 10 to 15 minutes .	O O O O O O O O O O B I O O O O O O O O O	['muscle contractions']	1	4	"Sentence: Empirical treatment with intravenous calcium gluconate was initiated , and muscle contractions slowly subsided over approximately 10 to 15 minutes .
Diseases: muscle contractions"	"Sentence: Empirical treatment with intravenous calcium gluconate was initiated , and muscle contractions slowly subsided over approximately 10 to 15 minutes .
Diseases:"
596	The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia .	O O O O O O O O O O O O O O O O O O O B O	['hypocalcemia']	1	4	"Sentence: The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia .
Diseases: hypocalcemia"	"Sentence: The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia .
Diseases:"
597	Upon additional retrospective analysis , it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia .	O O O O O O O O O O O O O O O O O O B O	['hypocalcemia']	1	4	"Sentence: Upon additional retrospective analysis , it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia .
Diseases: hypocalcemia"	"Sentence: Upon additional retrospective analysis , it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia .
Diseases:"
598	We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity .	O O O O O O O O O O O O B O O O O O O O O O O B O	['hypocalcemia', 'toxicity']	2	6	"Sentence: We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity .
Diseases: hypocalcemia, toxicity"	"Sentence: We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity .
Diseases:"
599	Laboratory measurement of pre - procedure serum calcium levels in selected donors may identify cases requiring heightened vigilance .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Laboratory measurement of pre - procedure serum calcium levels in selected donors may identify cases requiring heightened vigilance .
Diseases: "	"Sentence: Laboratory measurement of pre - procedure serum calcium levels in selected donors may identify cases requiring heightened vigilance .
Diseases:"
600	The case also illustrates the importance of maintaining preparedness for managing rare but serious reactions in volunteer apheresis blood donors .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The case also illustrates the importance of maintaining preparedness for managing rare but serious reactions in volunteer apheresis blood donors .
Diseases: "	"Sentence: The case also illustrates the importance of maintaining preparedness for managing rare but serious reactions in volunteer apheresis blood donors .
Diseases:"
601	Proteinuria after conversion to sirolimus in renal transplant recipients .	B O O O O O O O O O	['proteinuria']	1	2	"Sentence: Proteinuria after conversion to sirolimus in renal transplant recipients .
Diseases: proteinuria"	"Sentence: Proteinuria after conversion to sirolimus in renal transplant recipients .
Diseases:"
602	Sirolimus ( SRL ) is a new , potent immunosuppressive agent .	O O O O O O O O O O O O	[]	0	0	"Sentence: Sirolimus ( SRL ) is a new , potent immunosuppressive agent .
Diseases: "	"Sentence: Sirolimus ( SRL ) is a new , potent immunosuppressive agent .
Diseases:"
603	More recently , proteinuria has been reported as a consequence of sirolimus therapy , although the mechanism has remained unclear .	O O O B O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: More recently , proteinuria has been reported as a consequence of sirolimus therapy , although the mechanism has remained unclear .
Diseases: proteinuria"	"Sentence: More recently , proteinuria has been reported as a consequence of sirolimus therapy , although the mechanism has remained unclear .
Diseases:"
604	We retrospectively examined the records of 25 renal transplant patients , who developed or displayed increased proteinuria after SRL conversion .	O O O O O O O O O O O O O O O O B O O O O	['proteinuria']	1	2	"Sentence: We retrospectively examined the records of 25 renal transplant patients , who developed or displayed increased proteinuria after SRL conversion .
Diseases: proteinuria"	"Sentence: We retrospectively examined the records of 25 renal transplant patients , who developed or displayed increased proteinuria after SRL conversion .
Diseases:"
605	The patient cohort ( 14 men , 11 women ) was treated with SRL as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .	O O O O O O O O O O O O O O O O O O O O B I I O B O O O O O O B O O O O O O B I I O O B I O O B I O O B I I O O O O B O O O O O O	"['chronic allograft nephropathy', 'nephropathy', 'skin cancers', 'neoplasia', 'can', 'renal cell carsinom', 'intestinal tumors', ""kaposi 's sarcoma""]"	8	40	"Sentence: The patient cohort ( 14 men , 11 women ) was treated with SRL as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
Diseases: chronic allograft nephropathy, nephropathy, skin cancers, neoplasia, can, renal cell carsinom, intestinal tumors, kaposi 's sarcoma"	"Sentence: The patient cohort ( 14 men , 11 women ) was treated with SRL as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .
Diseases:"
606	SRL was started at a mean of 78 + / -	O O O O O O O O O O O	[]	0	0	"Sentence: SRL was started at a mean of 78 + / -
Diseases: "	"Sentence: SRL was started at a mean of 78 + / -
Diseases:"
607	42 ( 15 to 163 ) months after transplantation .	O O O O O O O O O O	[]	0	0	"Sentence: 42 ( 15 to 163 ) months after transplantation .
Diseases: "	"Sentence: 42 ( 15 to 163 ) months after transplantation .
Diseases:"
608	Mean follow - up on SRL therapy was 20 + / - 12 ( 6 to 43 ) months .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mean follow - up on SRL therapy was 20 + / - 12 ( 6 to 43 ) months .
Diseases: "	"Sentence: Mean follow - up on SRL therapy was 20 + / - 12 ( 6 to 43 ) months .
Diseases:"
609	Proteinuria increased from 0 . 445 ( 0 to 1 . 5 ) g / d before conversion to 3 . 2 g / dL ( 0 . 2 to 12 ) after conversion ( P = 0 . 001 ) .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Proteinuria increased from 0 . 445 ( 0 to 1 . 5 ) g / d before conversion to 3 . 2 g / dL ( 0 . 2 to 12 ) after conversion ( P = 0 . 001 ) .
Diseases: proteinuria"	"Sentence: Proteinuria increased from 0 . 445 ( 0 to 1 . 5 ) g / d before conversion to 3 . 2 g / dL ( 0 . 2 to 12 ) after conversion ( P = 0 . 001 ) .
Diseases:"
610	Before conversion 8 ( 32 % ) patients had no proteinuria , whereas afterwards all patients had proteinuria .	O O O O O O O O O O B O O O O O O B O	['proteinuria']	1	2	"Sentence: Before conversion 8 ( 32 % ) patients had no proteinuria , whereas afterwards all patients had proteinuria .
Diseases: proteinuria"	"Sentence: Before conversion 8 ( 32 % ) patients had no proteinuria , whereas afterwards all patients had proteinuria .
Diseases:"
611	In 28 % of patients proteinuria remained unchanged , whereas it increased in 68 % of patients .	O O O O O B O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: In 28 % of patients proteinuria remained unchanged , whereas it increased in 68 % of patients .
Diseases: proteinuria"	"Sentence: In 28 % of patients proteinuria remained unchanged , whereas it increased in 68 % of patients .
Diseases:"
612	In 40 % it increased by more than 100 % .	O O O O O O O O O O O	[]	0	0	"Sentence: In 40 % it increased by more than 100 % .
Diseases: "	"Sentence: In 40 % it increased by more than 100 % .
Diseases:"
613	Twenty - eight percent of patients showed increased proteinuria to the nephrotic range .	O O O O O O O O B O O B O O	['nephrotic', 'proteinuria']	2	7	"Sentence: Twenty - eight percent of patients showed increased proteinuria to the nephrotic range .
Diseases: nephrotic, proteinuria"	"Sentence: Twenty - eight percent of patients showed increased proteinuria to the nephrotic range .
Diseases:"
614	Biopsies performed in five patients revealed new pathological changes : One membranoproliferative glomerulopathy and interstitial nephritis .	O O O O O O O O O O O B I O B I O	['membranoproliferative glomerulopathy', 'interstitial nephritis']	2	17	"Sentence: Biopsies performed in five patients revealed new pathological changes : One membranoproliferative glomerulopathy and interstitial nephritis .
Diseases: membranoproliferative glomerulopathy, interstitial nephritis"	"Sentence: Biopsies performed in five patients revealed new pathological changes : One membranoproliferative glomerulopathy and interstitial nephritis .
Diseases:"
615	These patients showed persistently good graft function .	O O O O O O O O	[]	0	0	"Sentence: These patients showed persistently good graft function .
Diseases: "	"Sentence: These patients showed persistently good graft function .
Diseases:"
616	Serum creatinine values did not change significantly : 1 . 98 + / - 0 . 8 mg / dL before SRL therapy and	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serum creatinine values did not change significantly : 1 . 98 + / - 0 . 8 mg / dL before SRL therapy and
Diseases: "	"Sentence: Serum creatinine values did not change significantly : 1 . 98 + / - 0 . 8 mg / dL before SRL therapy and
Diseases:"
617	2 . 53 + / - 1 . 9 mg / dL at last follow - up ( P = . 14 ) .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 2 . 53 + / - 1 . 9 mg / dL at last follow - up ( P = . 14 ) .
Diseases: "	"Sentence: 2 . 53 + / - 1 . 9 mg / dL at last follow - up ( P = . 14 ) .
Diseases:"
618	Five grafts were lost and the patients returned to dialysis .	O O O O O O O O O O O	[]	0	0	"Sentence: Five grafts were lost and the patients returned to dialysis .
Diseases: "	"Sentence: Five grafts were lost and the patients returned to dialysis .
Diseases:"
619	Five patients displayed CAN and Kaposi 's sarcoma .	O O O B O B I I O	"[""kaposi 's sarcoma"", 'can']"	2	10	"Sentence: Five patients displayed CAN and Kaposi 's sarcoma .
Diseases: kaposi 's sarcoma, can"	"Sentence: Five patients displayed CAN and Kaposi 's sarcoma .
Diseases:"
620	Mean urinary protein of patients who returned to dialysis was 1 . 26 ( 0 . 5 to 3 . 5 )	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mean urinary protein of patients who returned to dialysis was 1 . 26 ( 0 . 5 to 3 . 5 )
Diseases: "	"Sentence: Mean urinary protein of patients who returned to dialysis was 1 . 26 ( 0 . 5 to 3 . 5 )
Diseases:"
621	g / d before and 4 . 7 ( 3 to 12 )	O O O O O O O O O O O O O	[]	0	0	"Sentence: g / d before and 4 . 7 ( 3 to 12 )
Diseases: "	"Sentence: g / d before and 4 . 7 ( 3 to 12 )
Diseases:"
622	g / d after conversion ( P = . 01 ) .	O O O O O O O O O O O O	[]	0	0	"Sentence: g / d after conversion ( P = . 01 ) .
Diseases: "	"Sentence: g / d after conversion ( P = . 01 ) .
Diseases:"
623	Mean serum creatinine level before conversion was 2 . 21 mg / dL and thereafter , 4 . 93 mg / dL ( P = . 02 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mean serum creatinine level before conversion was 2 . 21 mg / dL and thereafter , 4 . 93 mg / dL ( P = . 02 ) .
Diseases: "	"Sentence: Mean serum creatinine level before conversion was 2 . 21 mg / dL and thereafter , 4 . 93 mg / dL ( P = . 02 ) .
Diseases:"
624	Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation .	O B O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation .
Diseases: proteinuria"	"Sentence: Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation .
Diseases:"
625	Therefore , conversion should be considered for patients who have not developed advanced CAN and proteinuria .	O O O O O O O O O O O O O B O B O	['proteinuria', 'can']	2	4	"Sentence: Therefore , conversion should be considered for patients who have not developed advanced CAN and proteinuria .
Diseases: proteinuria, can"	"Sentence: Therefore , conversion should be considered for patients who have not developed advanced CAN and proteinuria .
Diseases:"
626	The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy .
Diseases: "	"Sentence: The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy .
Diseases:"
627	In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide - induced cystitis in the rat .	O O O O O O O O O O O O B O O O O	['cystitis']	1	3	"Sentence: In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide - induced cystitis in the rat .
Diseases: cystitis"	"Sentence: In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide - induced cystitis in the rat .
Diseases:"
628	In cyclophosphamide - induced cystitis in the rat , detrusor function is impaired and the expression and effects of muscarinic receptors altered .	O O O O B O O O O O O O O O O O O O O O O O O	['cystitis']	1	3	"Sentence: In cyclophosphamide - induced cystitis in the rat , detrusor function is impaired and the expression and effects of muscarinic receptors altered .
Diseases: cystitis"	"Sentence: In cyclophosphamide - induced cystitis in the rat , detrusor function is impaired and the expression and effects of muscarinic receptors altered .
Diseases:"
629	Whether or not the neuronal transmission may be affected by cystitis was presently investigated .	O O O O O O O O O O B O O O O	['cystitis']	1	3	"Sentence: Whether or not the neuronal transmission may be affected by cystitis was presently investigated .
Diseases: cystitis"	"Sentence: Whether or not the neuronal transmission may be affected by cystitis was presently investigated .
Diseases:"
630	Responses of urinary strip preparations from control and cyclophosphamide - pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic , adrenergic and purinergic receptor antagonists .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Responses of urinary strip preparations from control and cyclophosphamide - pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic , adrenergic and purinergic receptor antagonists .
Diseases: "	"Sentence: Responses of urinary strip preparations from control and cyclophosphamide - pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic , adrenergic and purinergic receptor antagonists .
Diseases:"
631	Generally , atropine reduced contractions , but in contrast to controls , it also reduced responses to low electrical field stimulation intensity ( 1 - 5 Hz ) in inflamed preparations .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Generally , atropine reduced contractions , but in contrast to controls , it also reduced responses to low electrical field stimulation intensity ( 1 - 5 Hz ) in inflamed preparations .
Diseases: "	"Sentence: Generally , atropine reduced contractions , but in contrast to controls , it also reduced responses to low electrical field stimulation intensity ( 1 - 5 Hz ) in inflamed preparations .
Diseases:"
632	In both types , purinoceptor desensitization with alpha , beta - methylene adenosine - 5' - triphosphate ( alpha , beta - meATP ) caused further reductions at low frequencies ( < 10 Hz ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In both types , purinoceptor desensitization with alpha , beta - methylene adenosine - 5' - triphosphate ( alpha , beta - meATP ) caused further reductions at low frequencies ( < 10 Hz ) .
Diseases: "	"Sentence: In both types , purinoceptor desensitization with alpha , beta - methylene adenosine - 5' - triphosphate ( alpha , beta - meATP ) caused further reductions at low frequencies ( < 10 Hz ) .
Diseases:"
633	The muscarinic receptor antagonists atropine , 4 - diphenylacetoxy - N - methylpiperidine ( 4 - DAMP ) ( ' M ( 1 ) / M ( 3 ) / M ( 5 ) - selective ' ) , methoctramine ( ' M ( 2 ) - selective ' ) and pirenzepine ( ' M ( 1 ) - selective ' ) antagonized the tonic component of the electrical field stimulation - evoked contractile response more potently than the phasic component .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The muscarinic receptor antagonists atropine , 4 - diphenylacetoxy - N - methylpiperidine ( 4 - DAMP ) ( ' M ( 1 ) / M ( 3 ) / M ( 5 ) - selective ' ) , methoctramine ( ' M ( 2 ) - selective ' ) and pirenzepine ( ' M ( 1 ) - selective ' ) antagonized the tonic component of the electrical field stimulation - evoked contractile response more potently than the phasic component .
Diseases: "	"Sentence: The muscarinic receptor antagonists atropine , 4 - diphenylacetoxy - N - methylpiperidine ( 4 - DAMP ) ( ' M ( 1 ) / M ( 3 ) / M ( 5 ) - selective ' ) , methoctramine ( ' M ( 2 ) - selective ' ) and pirenzepine ( ' M ( 1 ) - selective ' ) antagonized the tonic component of the electrical field stimulation - evoked contractile response more potently than the phasic component .
Diseases:"
634	4 - DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 4 - DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine .
Diseases: "	"Sentence: 4 - DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine .
Diseases:"
635	In inflamed preparations , the muscarinic receptor antagonism on the phasic component of the electrical field stimulation - evoked contraction was decreased and the pirenzepine and 4 - DAMP antagonism on the tonic component was much less efficient than in controls .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In inflamed preparations , the muscarinic receptor antagonism on the phasic component of the electrical field stimulation - evoked contraction was decreased and the pirenzepine and 4 - DAMP antagonism on the tonic component was much less efficient than in controls .
Diseases: "	"Sentence: In inflamed preparations , the muscarinic receptor antagonism on the phasic component of the electrical field stimulation - evoked contraction was decreased and the pirenzepine and 4 - DAMP antagonism on the tonic component was much less efficient than in controls .
Diseases:"
636	In contrast to controls , methoctramine increased - - instead of decreased - - the tonic responses at high frequencies .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast to controls , methoctramine increased - - instead of decreased - - the tonic responses at high frequencies .
Diseases: "	"Sentence: In contrast to controls , methoctramine increased - - instead of decreased - - the tonic responses at high frequencies .
Diseases:"
637	While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response , isoprenaline - induced relaxations were smaller in inflamed strips .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response , isoprenaline - induced relaxations were smaller in inflamed strips .
Diseases: "	"Sentence: While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response , isoprenaline - induced relaxations were smaller in inflamed strips .
Diseases:"
638	Thus , in cystitis substantial changes of the efferent functional responses occur .	O O O B O O O O O O O O O	['cystitis']	1	3	"Sentence: Thus , in cystitis substantial changes of the efferent functional responses occur .
Diseases: cystitis"	"Sentence: Thus , in cystitis substantial changes of the efferent functional responses occur .
Diseases:"
639	While postjunctional beta - adrenoceptor - mediated relaxations are reduced , effects by prejunctional inhibitory muscarinic receptors may be increased .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: While postjunctional beta - adrenoceptor - mediated relaxations are reduced , effects by prejunctional inhibitory muscarinic receptors may be increased .
Diseases: "	"Sentence: While postjunctional beta - adrenoceptor - mediated relaxations are reduced , effects by prejunctional inhibitory muscarinic receptors may be increased .
Diseases:"
640	Associations between use of benzodiazepines or related drugs and health , physical abilities and cognitive function : a non - randomised clinical study in the elderly .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Associations between use of benzodiazepines or related drugs and health , physical abilities and cognitive function : a non - randomised clinical study in the elderly .
Diseases: "	"Sentence: Associations between use of benzodiazepines or related drugs and health , physical abilities and cognitive function : a non - randomised clinical study in the elderly .
Diseases:"
641	To describe associations between the use of benzodiazepines or related drugs ( BZDs / RDs ) and health , functional abilities and cognitive function in the elderly .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To describe associations between the use of benzodiazepines or related drugs ( BZDs / RDs ) and health , functional abilities and cognitive function in the elderly .
Diseases: "	"Sentence: To describe associations between the use of benzodiazepines or related drugs ( BZDs / RDs ) and health , functional abilities and cognitive function in the elderly .
Diseases:"
642	METHODS : A non - randomised clinical study of patients aged > or = 65 years admitted to acute hospital wards during 1 month .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : A non - randomised clinical study of patients aged > or = 65 years admitted to acute hospital wards during 1 month .
Diseases: "	"Sentence: METHODS : A non - randomised clinical study of patients aged > or = 65 years admitted to acute hospital wards during 1 month .
Diseases:"
643	164 patients ( mean age + / - standard deviation [ SD ] 81 . 6 + / - 6 . 8 years ) were admitted .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 164 patients ( mean age + / - standard deviation [ SD ] 81 . 6 + / - 6 . 8 years ) were admitted .
Diseases: "	"Sentence: 164 patients ( mean age + / - standard deviation [ SD ] 81 . 6 + / - 6 . 8 years ) were admitted .
Diseases:"
644	Of these , nearly half ( n = 78 ) had used BZDs / RDs before admission , and the remainder ( n = 86 ) were non - users .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of these , nearly half ( n = 78 ) had used BZDs / RDs before admission , and the remainder ( n = 86 ) were non - users .
Diseases: "	"Sentence: Of these , nearly half ( n = 78 ) had used BZDs / RDs before admission , and the remainder ( n = 86 ) were non - users .
Diseases:"
645	Cognitive ability was assessed by the Mini - Mental State Examination ( MMSE ) .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cognitive ability was assessed by the Mini - Mental State Examination ( MMSE ) .
Diseases: "	"Sentence: Cognitive ability was assessed by the Mini - Mental State Examination ( MMSE ) .
Diseases:"
646	Patients scoring > or = 20 MMSE sum points were interviewed ( n = 79 ) and questioned regarding symptoms and functional abilities during the week prior to admission .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients scoring > or = 20 MMSE sum points were interviewed ( n = 79 ) and questioned regarding symptoms and functional abilities during the week prior to admission .
Diseases: "	"Sentence: Patients scoring > or = 20 MMSE sum points were interviewed ( n = 79 ) and questioned regarding symptoms and functional abilities during the week prior to admission .
Diseases:"
647	Data on use of BZDs / RDs before admission , current medications and discharge diagnoses were collected from medical records .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Data on use of BZDs / RDs before admission , current medications and discharge diagnoses were collected from medical records .
Diseases: "	"Sentence: Data on use of BZDs / RDs before admission , current medications and discharge diagnoses were collected from medical records .
Diseases:"
648	Health , physical abilities and cognitive function were compared between BZD / RD users and non - users , and adjustments were made for confounding variables .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Health , physical abilities and cognitive function were compared between BZD / RD users and non - users , and adjustments were made for confounding variables .
Diseases: "	"Sentence: Health , physical abilities and cognitive function were compared between BZD / RD users and non - users , and adjustments were made for confounding variables .
Diseases:"
649	The residual serum concentrations of oxazepam , temazepam and zopiclone were analysed .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The residual serum concentrations of oxazepam , temazepam and zopiclone were analysed .
Diseases: "	"Sentence: The residual serum concentrations of oxazepam , temazepam and zopiclone were analysed .
Diseases:"
650	The mean + / -	O O O O O	[]	0	0	"Sentence: The mean + / -
Diseases: "	"Sentence: The mean + / -
Diseases:"
651	SD duration of BZD / RD use was 7 + / - 7 years ( range 1 - 31 ) .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: SD duration of BZD / RD use was 7 + / - 7 years ( range 1 - 31 ) .
Diseases: "	"Sentence: SD duration of BZD / RD use was 7 + / - 7 years ( range 1 - 31 ) .
Diseases:"
652	Two or three BZDs / RDs were concomitantly taken by 26 % of users ( n = 20 ) .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two or three BZDs / RDs were concomitantly taken by 26 % of users ( n = 20 ) .
Diseases: "	"Sentence: Two or three BZDs / RDs were concomitantly taken by 26 % of users ( n = 20 ) .
Diseases:"
653	Long - term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS , which tended to be related to diagnosed dementia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['dementia']	1	3	"Sentence: Long - term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS , which tended to be related to diagnosed dementia .
Diseases: dementia"	"Sentence: Long - term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS , which tended to be related to diagnosed dementia .
Diseases:"
654	After adjustment for these variables as confounders , use of BZDs / RDs was not associated with cognitive function as measured by the MMSE .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After adjustment for these variables as confounders , use of BZDs / RDs was not associated with cognitive function as measured by the MMSE .
Diseases: "	"Sentence: After adjustment for these variables as confounders , use of BZDs / RDs was not associated with cognitive function as measured by the MMSE .
Diseases:"
655	However , use of BZDs / RDs was associated with dizziness , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .	O O O O O O O O O O B O B I I O O O O O B O O O O O O O O O O O O B I O O O O O O O O O	['inability to sleep', 'depressive symptoms', 'tiredness', 'dizziness']	4	13	"Sentence: However , use of BZDs / RDs was associated with dizziness , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .
Diseases: inability to sleep, depressive symptoms, tiredness, dizziness"	"Sentence: However , use of BZDs / RDs was associated with dizziness , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .
Diseases:"
656	Use of BZDs / RDs tended to be associated with a reduced ability to walk and shorter night - time sleep during the week prior to admission .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Use of BZDs / RDs tended to be associated with a reduced ability to walk and shorter night - time sleep during the week prior to admission .
Diseases: "	"Sentence: Use of BZDs / RDs tended to be associated with a reduced ability to walk and shorter night - time sleep during the week prior to admission .
Diseases:"
657	A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables .
Diseases: "	"Sentence: A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables .
Diseases:"
658	CONCLUSIONS : Long - term use and concomitant use of more than one BZD / RD were common in elderly patients hospitalised because of acute illnesses .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : Long - term use and concomitant use of more than one BZD / RD were common in elderly patients hospitalised because of acute illnesses .
Diseases: "	"Sentence: CONCLUSIONS : Long - term use and concomitant use of more than one BZD / RD were common in elderly patients hospitalised because of acute illnesses .
Diseases:"
659	Long - term use was associated with daytime and night - time symptoms indicative of poorer health and potentially caused by the adverse effects of these drugs .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Long - term use was associated with daytime and night - time symptoms indicative of poorer health and potentially caused by the adverse effects of these drugs .
Diseases: "	"Sentence: Long - term use was associated with daytime and night - time symptoms indicative of poorer health and potentially caused by the adverse effects of these drugs .
Diseases:"
660	Acute vocal fold palsy after acute disulfiram intoxication .	O B I I O O O O O	['vocal fold palsy']	1	5	"Sentence: Acute vocal fold palsy after acute disulfiram intoxication .
Diseases: vocal fold palsy"	"Sentence: Acute vocal fold palsy after acute disulfiram intoxication .
Diseases:"
661	Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy .	O B I O O O O B O O O O O O O O O O O O B I I O	['peripheral neuropathy', 'overdose', 'vocal fold palsy']	3	12	"Sentence: Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy .
Diseases: peripheral neuropathy, overdose, vocal fold palsy"	"Sentence: Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy .
Diseases:"
662	A 49 - year - old woman was transferred to our department because of quadriparesis , lancinating pain , sensory loss , and paresthesia of the distal limbs .	O O O O O O O O O O O O O O B O O B O B I O O B O O O O O	['paresthesia', 'pain', 'sensory loss', 'quadriparesis']	4	14	"Sentence: A 49 - year - old woman was transferred to our department because of quadriparesis , lancinating pain , sensory loss , and paresthesia of the distal limbs .
Diseases: paresthesia, pain, sensory loss, quadriparesis"	"Sentence: A 49 - year - old woman was transferred to our department because of quadriparesis , lancinating pain , sensory loss , and paresthesia of the distal limbs .
Diseases:"
663	One month previously , she had taken a single high dose of disulfiram ( 130 tablets of ALCOHOL STOP TAB , Shin - Poong Pharm .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: One month previously , she had taken a single high dose of disulfiram ( 130 tablets of ALCOHOL STOP TAB , Shin - Poong Pharm .
Diseases: "	"Sentence: One month previously , she had taken a single high dose of disulfiram ( 130 tablets of ALCOHOL STOP TAB , Shin - Poong Pharm .
Diseases:"
664	Co . , Ansan , Korea ) in a suicide attempt .	O O O O O O O O O O O O	[]	0	0	"Sentence: Co . , Ansan , Korea ) in a suicide attempt .
Diseases: "	"Sentence: Co . , Ansan , Korea ) in a suicide attempt .
Diseases:"
665	She was not an alcoholic .	O O O O O O	[]	0	0	"Sentence: She was not an alcoholic .
Diseases: "	"Sentence: She was not an alcoholic .
Diseases:"
666	For the first few days after ingestion , she was in a confused state and had mild to moderate ataxia and giddiness .	O O O O O O O O O O O O O O O O O O O B O B O	['giddiness', 'ataxia']	2	7	"Sentence: For the first few days after ingestion , she was in a confused state and had mild to moderate ataxia and giddiness .
Diseases: giddiness, ataxia"	"Sentence: For the first few days after ingestion , she was in a confused state and had mild to moderate ataxia and giddiness .
Diseases:"
667	She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state .	O O B O O O O O O O O O O O O O O O	['hoarseness']	1	3	"Sentence: She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state .
Diseases: hoarseness"	"Sentence: She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state .
Diseases:"
668	A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy .	O O O O O O O O O O B O	['polyneuropathy']	1	4	"Sentence: A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy .
Diseases: polyneuropathy"	"Sentence: A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy .
Diseases:"
669	Laryngeal electromyography ( thyroarytenoid muscle ) showed ample denervation potentials .	O O O O O O O O O O O	[]	0	0	"Sentence: Laryngeal electromyography ( thyroarytenoid muscle ) showed ample denervation potentials .
Diseases: "	"Sentence: Laryngeal electromyography ( thyroarytenoid muscle ) showed ample denervation potentials .
Diseases:"
670	Laryngoscopy revealed asymmetric vocal fold movements during phonation .	O O O O O O O O O	[]	0	0	"Sentence: Laryngoscopy revealed asymmetric vocal fold movements during phonation .
Diseases: "	"Sentence: Laryngoscopy revealed asymmetric vocal fold movements during phonation .
Diseases:"
671	Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer .
Diseases: "	"Sentence: Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer .
Diseases:"
672	This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high - dose disulfiram intoxication .	O O O O O O B O O O O O O O O O O O B O O O O O O O O	['palsy', 'polyneuropathy']	2	8	"Sentence: This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high - dose disulfiram intoxication .
Diseases: palsy, polyneuropathy"	"Sentence: This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high - dose disulfiram intoxication .
Diseases:"
673	Higher optical density of an antigen assay predicts thrombosis in patients with heparin - induced thrombocytopenia .	O O O O O O O O B O O O O O O B O	['thrombocytopenia', 'thrombosis']	2	12	"Sentence: Higher optical density of an antigen assay predicts thrombosis in patients with heparin - induced thrombocytopenia .
Diseases: thrombocytopenia, thrombosis"	"Sentence: Higher optical density of an antigen assay predicts thrombosis in patients with heparin - induced thrombocytopenia .
Diseases:"
674	OBJECTIVES :	O O	[]	0	0	"Sentence: OBJECTIVES :
Diseases: "	"Sentence: OBJECTIVES :
Diseases:"
675	To correlate optical density and percent inhibition of a two - step heparin - induced thrombocytopenia ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .	O O O O O O O O O O O O O O O B O B O O O O B O O O O O O O O O O O O O	['hit', 'thrombocytopenia', 'thrombosis']	3	14	"Sentence: To correlate optical density and percent inhibition of a two - step heparin - induced thrombocytopenia ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .
Diseases: hit, thrombocytopenia, thrombosis"	"Sentence: To correlate optical density and percent inhibition of a two - step heparin - induced thrombocytopenia ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .
Diseases:"
676	PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or thrombocytopenia ( < 150 x 10 ( 9 ) / L ) after exposure to heparin , who had a positive two - step antigen assay [ optical density ( OD ) > 0 . 4 and > 50 inhibition with high concentration of heparin ] were included in the study .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['thrombocytopenia']	1	7	"Sentence: PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or thrombocytopenia ( < 150 x 10 ( 9 ) / L ) after exposure to heparin , who had a positive two - step antigen assay [ optical density ( OD ) > 0 . 4 and > 50 inhibition with high concentration of heparin ] were included in the study .
Diseases: thrombocytopenia"	"Sentence: PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or thrombocytopenia ( < 150 x 10 ( 9 ) / L ) after exposure to heparin , who had a positive two - step antigen assay [ optical density ( OD ) > 0 . 4 and > 50 inhibition with high concentration of heparin ] were included in the study .
Diseases:"
677	Forty of 94 HIT patients had thrombosis at diagnosis ; 54 / 94 had isolated - HIT without thrombosis .	O O O B O O B O O O O O O O O O B O B O	['hit', 'thrombosis']	2	6	"Sentence: Forty of 94 HIT patients had thrombosis at diagnosis ; 54 / 94 had isolated - HIT without thrombosis .
Diseases: hit, thrombosis"	"Sentence: Forty of 94 HIT patients had thrombosis at diagnosis ; 54 / 94 had isolated - HIT without thrombosis .
Diseases:"
678	Eight of the isolated - HIT patients developed thrombosis within the next 30 d ; thus , a total of 48 patients had thrombosis at day 30 .	O O O O O B O O B O O O O O O O O O O O O O O B O O O O	['hit', 'thrombosis']	2	6	"Sentence: Eight of the isolated - HIT patients developed thrombosis within the next 30 d ; thus , a total of 48 patients had thrombosis at day 30 .
Diseases: hit, thrombosis"	"Sentence: Eight of the isolated - HIT patients developed thrombosis within the next 30 d ; thus , a total of 48 patients had thrombosis at day 30 .
Diseases:"
679	At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated - HIT .	O O O O O O O O O O B O O B O O O O O B O	['hit', 'thrombosis']	2	6	"Sentence: At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated - HIT .
Diseases: hit, thrombosis"	"Sentence: At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated - HIT .
Diseases:"
680	However , OD was significantly higher in all patients with thrombosis ( n = 48 , 1 . 34 + / - 0 . 89 ) , including isolated - HIT patients who later developed thrombosis within 30 d ( n = 8 , 1 . 84 + / - 0 . 64 ) as compared to isolated - HIT patients who did not develop thrombosis ( 0 . 96 + / - 0 . 75 ; P = 0 . 011 and P = 0 . 008 ) .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O B O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['hit', 'thrombosis']	2	6	"Sentence: However , OD was significantly higher in all patients with thrombosis ( n = 48 , 1 . 34 + / - 0 . 89 ) , including isolated - HIT patients who later developed thrombosis within 30 d ( n = 8 , 1 . 84 + / - 0 . 64 ) as compared to isolated - HIT patients who did not develop thrombosis ( 0 . 96 + / - 0 . 75 ; P = 0 . 011 and P = 0 . 008 ) .
Diseases: hit, thrombosis"	"Sentence: However , OD was significantly higher in all patients with thrombosis ( n = 48 , 1 . 34 + / - 0 . 89 ) , including isolated - HIT patients who later developed thrombosis within 30 d ( n = 8 , 1 . 84 + / - 0 . 64 ) as compared to isolated - HIT patients who did not develop thrombosis ( 0 . 96 + / - 0 . 75 ; P = 0 . 011 and P = 0 . 008 ) .
Diseases:"
681	The Receiver Operative Characteristic Curve showed that OD > 1 . 27 in the isolated - HIT group had a significantly higher chance of developing thrombosis by day 30 .	O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O	['hit', 'thrombosis']	2	6	"Sentence: The Receiver Operative Characteristic Curve showed that OD > 1 . 27 in the isolated - HIT group had a significantly higher chance of developing thrombosis by day 30 .
Diseases: hit, thrombosis"	"Sentence: The Receiver Operative Characteristic Curve showed that OD > 1 . 27 in the isolated - HIT group had a significantly higher chance of developing thrombosis by day 30 .
Diseases:"
682	None of these groups showed significant difference in percent inhibition .	O O O O O O O O O O O	[]	0	0	"Sentence: None of these groups showed significant difference in percent inhibition .
Diseases: "	"Sentence: None of these groups showed significant difference in percent inhibition .
Diseases:"
683	Multivariate analysis showed a 2 . 8 - fold increased risk of thrombosis in females .	O O O O O O O O O O O O B O O O	['thrombosis']	1	4	"Sentence: Multivariate analysis showed a 2 . 8 - fold increased risk of thrombosis in females .
Diseases: thrombosis"	"Sentence: Multivariate analysis showed a 2 . 8 - fold increased risk of thrombosis in females .
Diseases:"
684	Similarly , thrombotic risk increased with age and OD values .	O O B O O O O O O O O	['thrombotic']	1	4	"Sentence: Similarly , thrombotic risk increased with age and OD values .
Diseases: thrombotic"	"Sentence: Similarly , thrombotic risk increased with age and OD values .
Diseases:"
685	Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated - HIT ; percent inhibition , however , was not predictive .	O O O O O O O O O B O O O O O B O O O O O O O O O O	['hit', 'thrombosis']	2	6	"Sentence: Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated - HIT ; percent inhibition , however , was not predictive .
Diseases: hit, thrombosis"	"Sentence: Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated - HIT ; percent inhibition , however , was not predictive .
Diseases:"
686	Central retinal vein occlusion associated with clomiphene - induced ovulation .	O B I I O O O O O O O	['retinal vein occlusion']	1	6	"Sentence: Central retinal vein occlusion associated with clomiphene - induced ovulation .
Diseases: retinal vein occlusion"	"Sentence: Central retinal vein occlusion associated with clomiphene - induced ovulation .
Diseases:"
687	To report a case of central retinal vein occlusion associated with clomiphene citrate ( CC ) .	O O O O O O B I I O O O O O O O O	['retinal vein occlusion']	1	6	"Sentence: To report a case of central retinal vein occlusion associated with clomiphene citrate ( CC ) .
Diseases: retinal vein occlusion"	"Sentence: To report a case of central retinal vein occlusion associated with clomiphene citrate ( CC ) .
Diseases:"
688	DESIGN : Case study .	O O O O O	[]	0	0	"Sentence: DESIGN : Case study .
Diseases: "	"Sentence: DESIGN : Case study .
Diseases:"
689	SETTING : Ophthalmology clinic of an academic hospital .	O O O O O O O O O	[]	0	0	"Sentence: SETTING : Ophthalmology clinic of an academic hospital .
Diseases: "	"Sentence: SETTING : Ophthalmology clinic of an academic hospital .
Diseases:"
690	PATIENT ( S ) : A 36 - year - old woman referred from the infertility clinic for blurred vision .	O O O O O O O O O O O O O O O B O O B I O	['infertility', 'blurred vision']	2	5	"Sentence: PATIENT ( S ) : A 36 - year - old woman referred from the infertility clinic for blurred vision .
Diseases: infertility, blurred vision"	"Sentence: PATIENT ( S ) : A 36 - year - old woman referred from the infertility clinic for blurred vision .
Diseases:"
691	INTERVENTION ( S ) : Ophthalmic examination after CC therapy .	O O O O O O O O O O O	[]	0	0	"Sentence: INTERVENTION ( S ) : Ophthalmic examination after CC therapy .
Diseases: "	"Sentence: INTERVENTION ( S ) : Ophthalmic examination after CC therapy .
Diseases:"
692	MAIN OUTCOME MEASURE ( S ) : Central retinal vein occlusion after ovulation induction with CC .	O O O O O O O O B I I O O O O O O	['retinal vein occlusion']	1	6	"Sentence: MAIN OUTCOME MEASURE ( S ) : Central retinal vein occlusion after ovulation induction with CC .
Diseases: retinal vein occlusion"	"Sentence: MAIN OUTCOME MEASURE ( S ) : Central retinal vein occlusion after ovulation induction with CC .
Diseases:"
693	RESULT ( S ) : A 36 - year - old Chinese woman developed central retinal vein occlusion after eight courses of CC .	O O O O O O O O O O O O O O O B I I O O O O O O	['retinal vein occlusion']	1	6	"Sentence: RESULT ( S ) : A 36 - year - old Chinese woman developed central retinal vein occlusion after eight courses of CC .
Diseases: retinal vein occlusion"	"Sentence: RESULT ( S ) : A 36 - year - old Chinese woman developed central retinal vein occlusion after eight courses of CC .
Diseases:"
694	A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication , although mild visual disturbance after CC intake is not uncommon .	O O O O O O O B O O O O O O O O O O O O O B I O O O O O O O	['thromboembolic', 'visual disturbance']	2	8	"Sentence: A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication , although mild visual disturbance after CC intake is not uncommon .
Diseases: thromboembolic, visual disturbance"	"Sentence: A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication , although mild visual disturbance after CC intake is not uncommon .
Diseases:"
695	CONCLUSION ( S ) : This is the first reported case of central retinal vein occlusion after treatment with CC .	O O O O O O O O O O O O O B I I O O O O O	['retinal vein occlusion']	1	6	"Sentence: CONCLUSION ( S ) : This is the first reported case of central retinal vein occlusion after treatment with CC .
Diseases: retinal vein occlusion"	"Sentence: CONCLUSION ( S ) : This is the first reported case of central retinal vein occlusion after treatment with CC .
Diseases:"
696	Extra caution is warranted in treating infertility patients with CC , and patients should be well informed of this side effect before commencement of therapy .	O O O O O O B O O O O O O O O O O O O O O O O O O O	['infertility']	1	2	"Sentence: Extra caution is warranted in treating infertility patients with CC , and patients should be well informed of this side effect before commencement of therapy .
Diseases: infertility"	"Sentence: Extra caution is warranted in treating infertility patients with CC , and patients should be well informed of this side effect before commencement of therapy .
Diseases:"
697	Nicotine - induced nystagmus correlates with midpontine activation .	O O O B O O O O O	['nystagmus']	1	4	"Sentence: Nicotine - induced nystagmus correlates with midpontine activation .
Diseases: nystagmus"	"Sentence: Nicotine - induced nystagmus correlates with midpontine activation .
Diseases:"
698	The pathomechanism of nicotine - induced nystagmus ( NIN ) is unknown .	O O O O O O B O B O O O O	['nin', 'nystagmus']	2	7	"Sentence: The pathomechanism of nicotine - induced nystagmus ( NIN ) is unknown .
Diseases: nin, nystagmus"	"Sentence: The pathomechanism of nicotine - induced nystagmus ( NIN ) is unknown .
Diseases:"
699	The aim of this study was to delineate brain structures that are involved in NIN generation .	O O O O O O O O O O O O O O B O O	['nin']	1	1	"Sentence: The aim of this study was to delineate brain structures that are involved in NIN generation .
Diseases: nin"	"Sentence: The aim of this study was to delineate brain structures that are involved in NIN generation .
Diseases:"
700	Eight healthy volunteers inhaled nicotine in darkness during a functional magnetic resonance imaging ( fMRI ) experiment ; eye movements were registered using video - oculography .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Eight healthy volunteers inhaled nicotine in darkness during a functional magnetic resonance imaging ( fMRI ) experiment ; eye movements were registered using video - oculography .
Diseases: "	"Sentence: Eight healthy volunteers inhaled nicotine in darkness during a functional magnetic resonance imaging ( fMRI ) experiment ; eye movements were registered using video - oculography .
Diseases:"
701	NIN correlated with blood oxygen level - dependent ( BOLD ) activity levels in a midpontine site in the posterior basis pontis .	B O O O O O O O O O O O O O O O O O O O O O O	['nin']	1	1	"Sentence: NIN correlated with blood oxygen level - dependent ( BOLD ) activity levels in a midpontine site in the posterior basis pontis .
Diseases: nin"	"Sentence: NIN correlated with blood oxygen level - dependent ( BOLD ) activity levels in a midpontine site in the posterior basis pontis .
Diseases:"
702	NIN - induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis , structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nin']	1	1	"Sentence: NIN - induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis , structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements .
Diseases: nin"	"Sentence: NIN - induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis , structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements .
Diseases:"
703	Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats .	O O O O O B I B O O B O O	['gastric hemorrhagic', 'atherosclerotic', 'ulcers']	3	13	"Sentence: Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats .
Diseases: gastric hemorrhagic, atherosclerotic, ulcers"	"Sentence: Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats .
Diseases:"
704	Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking .	O O O O O B I O O O O O B O O O O	['atherosclerotic', 'gastric hemorrhage']	2	9	"Sentence: Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking .
Diseases: atherosclerotic, gastric hemorrhage"	"Sentence: Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking .
Diseases:"
705	The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O B O O O B O O O O O O O O O	['ulcer', 'atherosclerosis', 'gastric hemorrhage']	3	12	"Sentence: The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .
Diseases: ulcer, atherosclerosis, gastric hemorrhage"	"Sentence: The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .
Diseases:"
706	Additionally , the protective effect of verapamil on this ulcer model was evaluated .	O O O O O O O O O B O O O O	['ulcer']	1	2	"Sentence: Additionally , the protective effect of verapamil on this ulcer model was evaluated .
Diseases: ulcer"	"Sentence: Additionally , the protective effect of verapamil on this ulcer model was evaluated .
Diseases:"
707	Male Wistar rats were challenged intragastrically once daily for 9 days with 1 . 0 ml / kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['atherosclerosis']	1	3	"Sentence: Male Wistar rats were challenged intragastrically once daily for 9 days with 1 . 0 ml / kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis .
Diseases: atherosclerosis"	"Sentence: Male Wistar rats were challenged intragastrically once daily for 9 days with 1 . 0 ml / kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis .
Diseases:"
708	Control rats received corn oil only .	O O O O O O O	[]	0	0	"Sentence: Control rats received corn oil only .
Diseases: "	"Sentence: Control rats received corn oil only .
Diseases:"
709	After gastric surgery , rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After gastric surgery , rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline .
Diseases: "	"Sentence: After gastric surgery , rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline .
Diseases:"
710	Gastric acid back - diffusion , mucosal LPO generation , histamine concentration , microvascular permeability , luminal hemoglobin content and ulcer areas were determined .	O O O O O O O O O O O O O O O O O O O O B O O O O	['ulcer']	1	2	"Sentence: Gastric acid back - diffusion , mucosal LPO generation , histamine concentration , microvascular permeability , luminal hemoglobin content and ulcer areas were determined .
Diseases: ulcer"	"Sentence: Gastric acid back - diffusion , mucosal LPO generation , histamine concentration , microvascular permeability , luminal hemoglobin content and ulcer areas were determined .
Diseases:"
711	Elevated atherosclerotic parameters , such as serum calcium , total cholesterol and low - density lipoprotein concentration were obtained in atherosclerotic rats .	O B O O O O O O O O O O O O O O O O O O B O O	['atherosclerotic']	1	4	"Sentence: Elevated atherosclerotic parameters , such as serum calcium , total cholesterol and low - density lipoprotein concentration were obtained in atherosclerotic rats .
Diseases: atherosclerotic"	"Sentence: Elevated atherosclerotic parameters , such as serum calcium , total cholesterol and low - density lipoprotein concentration were obtained in atherosclerotic rats .
Diseases:"
712	Severe gastric ulcers accompanied with increased ulcerogenic factors , including gastric acid back - diffusion , histamine release , LPO generation and luminal hemoglobin content were also observed in these rats .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ulcers']	1	2	"Sentence: Severe gastric ulcers accompanied with increased ulcerogenic factors , including gastric acid back - diffusion , histamine release , LPO generation and luminal hemoglobin content were also observed in these rats .
Diseases: ulcers"	"Sentence: Severe gastric ulcers accompanied with increased ulcerogenic factors , including gastric acid back - diffusion , histamine release , LPO generation and luminal hemoglobin content were also observed in these rats .
Diseases:"
713	Moreover , a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats .	O O O O O O O O B I O O B O O O O B O O	['atherosclerotic', 'ulcer', 'gastric hemorrhage']	3	12	"Sentence: Moreover , a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats .
Diseases: atherosclerotic, ulcer, gastric hemorrhage"	"Sentence: Moreover , a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats .
Diseases:"
714	This hemorrhagic ulcer and various ulcerogenic parameters were dose - dependently ameliorated by daily intragastric verapamil .	O B B O O O O O O O O O O O O O O	['ulcer', 'hemorrhagic']	2	5	"Sentence: This hemorrhagic ulcer and various ulcerogenic parameters were dose - dependently ameliorated by daily intragastric verapamil .
Diseases: ulcer, hemorrhagic"	"Sentence: This hemorrhagic ulcer and various ulcerogenic parameters were dose - dependently ameliorated by daily intragastric verapamil .
Diseases:"
715	Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back - diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by verapamil in rats .	B O O B I B O O O O O O O O O O O O O O O O O O O O O O O O O O	['gastric hemorrhagic', 'atherosclerosis', 'ulcer']	3	12	"Sentence: Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back - diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by verapamil in rats .
Diseases: gastric hemorrhagic, atherosclerosis, ulcer"	"Sentence: Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back - diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by verapamil in rats .
Diseases:"
716	Adriamycin - induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure .	O O O O O B O O O O O O O O O B I O	['heart failure', 'death']	2	4	"Sentence: Adriamycin - induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure .
Diseases: heart failure, death"	"Sentence: Adriamycin - induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure .
Diseases:"
717	The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear .	O O O B I O O O O O O O O O O	['heart failure']	1	2	"Sentence: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear .
Diseases: heart failure"	"Sentence: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear .
Diseases:"
718	The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin , so that we can develop a novel treatment strategy for heart failure .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O B I O	['heart failure']	1	2	"Sentence: The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin , so that we can develop a novel treatment strategy for heart failure .
Diseases: heart failure"	"Sentence: The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin , so that we can develop a novel treatment strategy for heart failure .
Diseases:"
719	METHODS : 3 - methyladenine ( 3MA ) , a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin .	O O O O O O O O O O O O O O O O O O B I O O O O O O O	['heart failure']	1	2	"Sentence: METHODS : 3 - methyladenine ( 3MA ) , a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin .
Diseases: heart failure"	"Sentence: METHODS : 3 - methyladenine ( 3MA ) , a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin .
Diseases:"
720	Neonatal cardiomyocytes were isolated from Sprague - Dawley rat hearts and randomly divided into controls , an adriamycin - treated group , and a 3MA plus adriamycin - treated group .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Neonatal cardiomyocytes were isolated from Sprague - Dawley rat hearts and randomly divided into controls , an adriamycin - treated group , and a 3MA plus adriamycin - treated group .
Diseases: "	"Sentence: Neonatal cardiomyocytes were isolated from Sprague - Dawley rat hearts and randomly divided into controls , an adriamycin - treated group , and a 3MA plus adriamycin - treated group .
Diseases:"
721	We then examined the morphology , expression of beclin 1 gene , mitochondrial permeability transition ( MPT ) , and Na + - K + ATPase activity in vivo .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We then examined the morphology , expression of beclin 1 gene , mitochondrial permeability transition ( MPT ) , and Na + - K + ATPase activity in vivo .
Diseases: "	"Sentence: We then examined the morphology , expression of beclin 1 gene , mitochondrial permeability transition ( MPT ) , and Na + - K + ATPase activity in vivo .
Diseases:"
722	We also assessed cell viability , mitochondrial membrane potential changes and counted autophagic vacuoles in cultured cardiomyocytes .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We also assessed cell viability , mitochondrial membrane potential changes and counted autophagic vacuoles in cultured cardiomyocytes .
Diseases: "	"Sentence: We also assessed cell viability , mitochondrial membrane potential changes and counted autophagic vacuoles in cultured cardiomyocytes .
Diseases:"
723	In addition , we analyzed the expression of autophagy associated gene , beclin 1 using RT - PCR and Western blotting in an animal model .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , we analyzed the expression of autophagy associated gene , beclin 1 using RT - PCR and Western blotting in an animal model .
Diseases: "	"Sentence: In addition , we analyzed the expression of autophagy associated gene , beclin 1 using RT - PCR and Western blotting in an animal model .
Diseases:"
724	3MA significantly improved cardiac function and reduced mitochondrial injury .	O O O O O O O O O O	[]	0	0	"Sentence: 3MA significantly improved cardiac function and reduced mitochondrial injury .
Diseases: "	"Sentence: 3MA significantly improved cardiac function and reduced mitochondrial injury .
Diseases:"
725	Furthermore , adriamycin induced the formation of autophagic vacuoles , and 3MA strongly downregulated the expression of beclin 1 in adriamycin - induced failing heart and inhibited the formation of autophagic vacuoles .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Furthermore , adriamycin induced the formation of autophagic vacuoles , and 3MA strongly downregulated the expression of beclin 1 in adriamycin - induced failing heart and inhibited the formation of autophagic vacuoles .
Diseases: "	"Sentence: Furthermore , adriamycin induced the formation of autophagic vacuoles , and 3MA strongly downregulated the expression of beclin 1 in adriamycin - induced failing heart and inhibited the formation of autophagic vacuoles .
Diseases:"
726	Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin .	O O B O O O O O O O O B I O O O O O O	['heart failure', 'death']	2	4	"Sentence: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin .
Diseases: heart failure, death"	"Sentence: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin .
Diseases:"
727	Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway .	O O O O O O O O O B I O O O O O O O O	['heart failure']	1	2	"Sentence: Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway .
Diseases: heart failure"	"Sentence: Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway .
Diseases:"
728	Confusion , a rather serious adverse drug reaction with valproic acid : a review of the French Pharmacovigilance database .	B O O O O O O O O O O O O O O O O O O O	['confusion']	1	2	"Sentence: Confusion , a rather serious adverse drug reaction with valproic acid : a review of the French Pharmacovigilance database .
Diseases: confusion"	"Sentence: Confusion , a rather serious adverse drug reaction with valproic acid : a review of the French Pharmacovigilance database .
Diseases:"
729	INTRODUCTION :	O O	[]	0	0	"Sentence: INTRODUCTION :
Diseases: "	"Sentence: INTRODUCTION :
Diseases:"
730	Confusion is an adverse drug reaction frequently observed with valproic acid .	B O O O O O O O O O O O	['confusion']	1	2	"Sentence: Confusion is an adverse drug reaction frequently observed with valproic acid .
Diseases: confusion"	"Sentence: Confusion is an adverse drug reaction frequently observed with valproic acid .
Diseases:"
731	Some case reports are published in the literature but no systematic study from a sample of patients has been published .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Some case reports are published in the literature but no systematic study from a sample of patients has been published .
Diseases: "	"Sentence: Some case reports are published in the literature but no systematic study from a sample of patients has been published .
Diseases:"
732	We performed this study in order to describe the main characteristics of this adverse drug reaction .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We performed this study in order to describe the main characteristics of this adverse drug reaction .
Diseases: "	"Sentence: We performed this study in order to describe the main characteristics of this adverse drug reaction .
Diseases:"
733	METHODS : Using the French Pharmacovigilance database	O O O O O O O	[]	0	0	"Sentence: METHODS : Using the French Pharmacovigilance database
Diseases: "	"Sentence: METHODS : Using the French Pharmacovigilance database
Diseases:"
734	, we selected the cases of confusion reported since 1985 with valproic acid .	O O O O O O B O O O O O O O	['confusion']	1	2	"Sentence: , we selected the cases of confusion reported since 1985 with valproic acid .
Diseases: confusion"	"Sentence: , we selected the cases of confusion reported since 1985 with valproic acid .
Diseases:"
735	RESULTS : 272 cases of confusion were reported with valproic acid : 153 women and 119 men .	O O O O O B O O O O O O O O O O O O	['confusion']	1	2	"Sentence: RESULTS : 272 cases of confusion were reported with valproic acid : 153 women and 119 men .
Diseases: confusion"	"Sentence: RESULTS : 272 cases of confusion were reported with valproic acid : 153 women and 119 men .
Diseases:"
736	Confusion mostly occurred during the two first weeks following valproic acid exposure ( 39 . 7 % ) .	B O O O O O O O O O O O O O O O O O O	['confusion']	1	2	"Sentence: Confusion mostly occurred during the two first weeks following valproic acid exposure ( 39 . 7 % ) .
Diseases: confusion"	"Sentence: Confusion mostly occurred during the two first weeks following valproic acid exposure ( 39 . 7 % ) .
Diseases:"
737	"It was "" serious "" for almost 2 / 3 of the patients ( 62 . 5 % ) and its outcome favourable in most of the cases ( 82 % ) ."	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It was "" serious "" for almost 2 / 3 of the patients ( 62 . 5 % ) and its outcome favourable in most of the cases ( 82 % ) .
Diseases: "	"Sentence: It was "" serious "" for almost 2 / 3 of the patients ( 62 . 5 % ) and its outcome favourable in most of the cases ( 82 % ) .
Diseases:"
738	The occurrence of this ADR was more frequent in patients aged between 61 and 80 years .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The occurrence of this ADR was more frequent in patients aged between 61 and 80 years .
Diseases: "	"Sentence: The occurrence of this ADR was more frequent in patients aged between 61 and 80 years .
Diseases:"
739	This work shows that confusion with valproic acid is a serious , rather frequent but reversible adverse drug reaction .	O O O O B O O O O O O O O O O O O O O O	['confusion']	1	2	"Sentence: This work shows that confusion with valproic acid is a serious , rather frequent but reversible adverse drug reaction .
Diseases: confusion"	"Sentence: This work shows that confusion with valproic acid is a serious , rather frequent but reversible adverse drug reaction .
Diseases:"
740	It occurs especially in older patients and during the first two weeks of treatment .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It occurs especially in older patients and during the first two weeks of treatment .
Diseases: "	"Sentence: It occurs especially in older patients and during the first two weeks of treatment .
Diseases:"
741	Learning and memory deficits in ecstasy users and their neural correlates during a face - learning task .	B I I I O O O O O O O O O O O O O O	['learning and memory deficits']	1	4	"Sentence: Learning and memory deficits in ecstasy users and their neural correlates during a face - learning task .
Diseases: learning and memory deficits"	"Sentence: Learning and memory deficits in ecstasy users and their neural correlates during a face - learning task .
Diseases:"
742	It has been consistently shown that ecstasy users display impairments in learning and memory performance .	O O O O O O O O O B I I I I O O	['impairments in learning and memory']	1	7	"Sentence: It has been consistently shown that ecstasy users display impairments in learning and memory performance .
Diseases: impairments in learning and memory"	"Sentence: It has been consistently shown that ecstasy users display impairments in learning and memory performance .
Diseases:"
743	In addition , working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and / or cortical regions as measured by functional magnetic resonance imaging ( fMRI ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and / or cortical regions as measured by functional magnetic resonance imaging ( fMRI ) .
Diseases: "	"Sentence: In addition , working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and / or cortical regions as measured by functional magnetic resonance imaging ( fMRI ) .
Diseases:"
744	Using functional imaging and a face - learning task , we investigated neural correlates of encoding and recalling face - name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Using functional imaging and a face - learning task , we investigated neural correlates of encoding and recalling face - name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls .
Diseases: "	"Sentence: Using functional imaging and a face - learning task , we investigated neural correlates of encoding and recalling face - name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls .
Diseases:"
745	To address the potential confounding effects of the cannabis use of the ecstasy using group , a second analysis included 14 previously tested cannabis users ( Nestor , L . , Roberts , G . , Garavan , H . , Hester , R . , 2008 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To address the potential confounding effects of the cannabis use of the ecstasy using group , a second analysis included 14 previously tested cannabis users ( Nestor , L . , Roberts , G . , Garavan , H . , Hester , R . , 2008 .
Diseases: "	"Sentence: To address the potential confounding effects of the cannabis use of the ecstasy using group , a second analysis included 14 previously tested cannabis users ( Nestor , L . , Roberts , G . , Garavan , H . , Hester , R . , 2008 .
Diseases:"
746	Deficits in learning and memory : parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users .	B I I I I O O B O O O O O O O	['deficits in learning and memory', 'hyperactivity']	2	10	"Sentence: Deficits in learning and memory : parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users .
Diseases: deficits in learning and memory, hyperactivity"	"Sentence: Deficits in learning and memory : parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users .
Diseases:"
747	Neuroimage 40 , 1328 - 1339 ) .	O O O O O O O O	[]	0	0	"Sentence: Neuroimage 40 , 1328 - 1339 ) .
Diseases: "	"Sentence: Neuroimage 40 , 1328 - 1339 ) .
Diseases:"
748	Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users .
Diseases: "	"Sentence: Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users .
Diseases:"
749	A conjunction analysis of the encode and recall phases of the task revealed ecstasy - specific hyperactivity in bilateral frontal regions , left temporal , right parietal , bilateral temporal , and bilateral occipital brain regions .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: A conjunction analysis of the encode and recall phases of the task revealed ecstasy - specific hyperactivity in bilateral frontal regions , left temporal , right parietal , bilateral temporal , and bilateral occipital brain regions .
Diseases: hyperactivity"	"Sentence: A conjunction analysis of the encode and recall phases of the task revealed ecstasy - specific hyperactivity in bilateral frontal regions , left temporal , right parietal , bilateral temporal , and bilateral occipital brain regions .
Diseases:"
750	Ecstasy - specific hypoactivity was evident in the right dorsal anterior cingulated cortex ( ACC ) and left posterior cingulated cortex .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ecstasy - specific hypoactivity was evident in the right dorsal anterior cingulated cortex ( ACC ) and left posterior cingulated cortex .
Diseases: "	"Sentence: Ecstasy - specific hypoactivity was evident in the right dorsal anterior cingulated cortex ( ACC ) and left posterior cingulated cortex .
Diseases:"
751	In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus , left parahippocampal gyrus , left dorsal cingulate gyrus , and left caudate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus , left parahippocampal gyrus , left dorsal cingulate gyrus , and left caudate .
Diseases: "	"Sentence: In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus , left parahippocampal gyrus , left dorsal cingulate gyrus , and left caudate .
Diseases:"
752	These results elucidated ecstasy - related deficits , only some of which might be attributed to cannabis use .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These results elucidated ecstasy - related deficits , only some of which might be attributed to cannabis use .
Diseases: "	"Sentence: These results elucidated ecstasy - related deficits , only some of which might be attributed to cannabis use .
Diseases:"
753	These ecstasy - specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy .	O O O O O O O O O O O O O O O O O O B O O O O	['neurotoxic']	1	4	"Sentence: These ecstasy - specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy .
Diseases: neurotoxic"	"Sentence: These ecstasy - specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy .
Diseases:"
754	Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin - induced thrombocytopenia with thrombosis .	O O O O O O O O O O O O O O O O O O B O B O	['thrombocytopenia', 'thrombosis']	2	12	"Sentence: Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin - induced thrombocytopenia with thrombosis .
Diseases: thrombocytopenia, thrombosis"	"Sentence: Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin - induced thrombocytopenia with thrombosis .
Diseases:"
755	Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of heparin - induced thrombocytopenia ( HIT ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .	O O O O O O O O O O O O O O O O O O O O O B O B O O B O B O B O O O O O O O O	['hit', 'hitt', 'thrombocytopenia', 'thrombosis']	4	17	"Sentence: Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of heparin - induced thrombocytopenia ( HIT ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
Diseases: hit, hitt, thrombocytopenia, thrombosis"	"Sentence: Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of heparin - induced thrombocytopenia ( HIT ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .
Diseases:"
756	In the following report , a 65 - year - old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation .	O O O O O O O O O O O B I O O O O O O B O O O O O O O O O O O	['hitt', 'critically ill']	2	5	"Sentence: In the following report , a 65 - year - old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation .
Diseases: hitt, critically ill"	"Sentence: In the following report , a 65 - year - old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation .
Diseases:"
757	The patient required massive transfusion support ( 55 units of red blood cells , 42 units of fresh - frozen plasma , 40 units of cryoprecipitate , 40 units of platelets , and three doses of recombinant Factor VIIa ) for severe intraoperative and postoperative bleeding .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O	['intraoperative and postoperative bleeding']	1	7	"Sentence: The patient required massive transfusion support ( 55 units of red blood cells , 42 units of fresh - frozen plasma , 40 units of cryoprecipitate , 40 units of platelets , and three doses of recombinant Factor VIIa ) for severe intraoperative and postoperative bleeding .
Diseases: intraoperative and postoperative bleeding"	"Sentence: The patient required massive transfusion support ( 55 units of red blood cells , 42 units of fresh - frozen plasma , 40 units of cryoprecipitate , 40 units of platelets , and three doses of recombinant Factor VIIa ) for severe intraoperative and postoperative bleeding .
Diseases:"
758	STUDY DESIGN AND METHODS :	O O O O O	[]	0	0	"Sentence: STUDY DESIGN AND METHODS :
Diseases: "	"Sentence: STUDY DESIGN AND METHODS :
Diseases:"
759	Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time ( ECT ) assay .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time ( ECT ) assay .
Diseases: "	"Sentence: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time ( ECT ) assay .
Diseases:"
760	Unexpectedly high concentrations of argatroban were measured in these samples ( range , 0 - 32 microg / mL ) , and a prolonged plasma argatroban half life ( t ( 1 / 2 ) ) of 514 minutes was observed ( published elimination t ( 1 / 2 ) is 39 - 51 minutes [ < or = 181 minutes with hepatic impairment ] ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O	['hepatic impairment']	1	4	"Sentence: Unexpectedly high concentrations of argatroban were measured in these samples ( range , 0 - 32 microg / mL ) , and a prolonged plasma argatroban half life ( t ( 1 / 2 ) ) of 514 minutes was observed ( published elimination t ( 1 / 2 ) is 39 - 51 minutes [ < or = 181 minutes with hepatic impairment ] ) .
Diseases: hepatic impairment"	"Sentence: Unexpectedly high concentrations of argatroban were measured in these samples ( range , 0 - 32 microg / mL ) , and a prolonged plasma argatroban half life ( t ( 1 / 2 ) ) of 514 minutes was observed ( published elimination t ( 1 / 2 ) is 39 - 51 minutes [ < or = 181 minutes with hepatic impairment ] ) .
Diseases:"
761	Correlation of plasma argatroban concentration versus the patient 's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient 's extended coagulopathy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['coagulopathy']	1	4	"Sentence: Correlation of plasma argatroban concentration versus the patient 's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient 's extended coagulopathy .
Diseases: coagulopathy"	"Sentence: Correlation of plasma argatroban concentration versus the patient 's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient 's extended coagulopathy .
Diseases:"
762	Because DTIs do not have reversal agents , surgical teams and transfusion services should remain aware of the possibility of massive transfusion events during anticoagulation with these agents .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Because DTIs do not have reversal agents , surgical teams and transfusion services should remain aware of the possibility of massive transfusion events during anticoagulation with these agents .
Diseases: "	"Sentence: Because DTIs do not have reversal agents , surgical teams and transfusion services should remain aware of the possibility of massive transfusion events during anticoagulation with these agents .
Diseases:"
763	This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy .	O O O O O O O O O O O O O O O O O B O	['coagulopathy']	1	4	"Sentence: This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy .
Diseases: coagulopathy"	"Sentence: This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy .
Diseases:"
764	Antituberculosis therapy - induced acute liver failure : magnitude , profile , prognosis , and predictors of outcome .	O O O O B I I O O O O O O O O O O O O	['acute liver failure']	1	4	"Sentence: Antituberculosis therapy - induced acute liver failure : magnitude , profile , prognosis , and predictors of outcome .
Diseases: acute liver failure"	"Sentence: Antituberculosis therapy - induced acute liver failure : magnitude , profile , prognosis , and predictors of outcome .
Diseases:"
765	Antituberculosis therapy ( ATT ) - associated acute liver failure ( ATT - ALF ) is the commonest drug - induced ALF in South Asia .	O O O O O O O B I I O O O B O O O O O O O B O O O O	['acute liver failure', 'alf']	2	7	"Sentence: Antituberculosis therapy ( ATT ) - associated acute liver failure ( ATT - ALF ) is the commonest drug - induced ALF in South Asia .
Diseases: acute liver failure, alf"	"Sentence: Antituberculosis therapy ( ATT ) - associated acute liver failure ( ATT - ALF ) is the commonest drug - induced ALF in South Asia .
Diseases:"
766	Prospective studies on ATT - ALF are lacking .	O O O O O B O O O	['alf']	1	1	"Sentence: Prospective studies on ATT - ALF are lacking .
Diseases: alf"	"Sentence: Prospective studies on ATT - ALF are lacking .
Diseases:"
767	The current study prospectively evaluated the magnitude , clinical course , outcome , and prognostic factors in ATT - ALF .	O O O O O O O O O O O O O O O O O O O B O	['alf']	1	1	"Sentence: The current study prospectively evaluated the magnitude , clinical course , outcome , and prognostic factors in ATT - ALF .
Diseases: alf"	"Sentence: The current study prospectively evaluated the magnitude , clinical course , outcome , and prognostic factors in ATT - ALF .
Diseases:"
768	From January 1986 to January 2009 , 1223 consecutive ALF patients were evaluated : ATT alone was the cause in 70 ( 5 . 7 % ) patients .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['alf']	1	1	"Sentence: From January 1986 to January 2009 , 1223 consecutive ALF patients were evaluated : ATT alone was the cause in 70 ( 5 . 7 % ) patients .
Diseases: alf"	"Sentence: From January 1986 to January 2009 , 1223 consecutive ALF patients were evaluated : ATT alone was the cause in 70 ( 5 . 7 % ) patients .
Diseases:"
769	Another 15 ( 1 . 2 % ) had ATT and simultaneous hepatitis virus infection .	O O O O O O O O O O O O B I I O	['hepatitis virus infection']	1	5	"Sentence: Another 15 ( 1 . 2 % ) had ATT and simultaneous hepatitis virus infection .
Diseases: hepatitis virus infection"	"Sentence: Another 15 ( 1 . 2 % ) had ATT and simultaneous hepatitis virus infection .
Diseases:"
770	In 44 ( 62 . 8 % ) patients , ATT was prescribed empirically without definitive evidence of tuberculosis .	O O O O O O O O O O O O O O O O O O B O	['tuberculosis']	1	3	"Sentence: In 44 ( 62 . 8 % ) patients , ATT was prescribed empirically without definitive evidence of tuberculosis .
Diseases: tuberculosis"	"Sentence: In 44 ( 62 . 8 % ) patients , ATT was prescribed empirically without definitive evidence of tuberculosis .
Diseases:"
771	ATT - ALF patients were younger ( 32 . 87 [ + / - 15 . 8 ] years ) , and 49 ( 70 % ) of them were women .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['alf']	1	1	"Sentence: ATT - ALF patients were younger ( 32 . 87 [ + / - 15 . 8 ] years ) , and 49 ( 70 % ) of them were women .
Diseases: alf"	"Sentence: ATT - ALF patients were younger ( 32 . 87 [ + / - 15 . 8 ] years ) , and 49 ( 70 % ) of them were women .
Diseases:"
772	Most had hyperacute presentation ; the median icterus encephalopathy interval was 4 . 5 ( 0 - 30 ) days .	O O O O O O O B B O O O O O O O O O O O O	['encephalopathy', 'icterus']	2	7	"Sentence: Most had hyperacute presentation ; the median icterus encephalopathy interval was 4 . 5 ( 0 - 30 ) days .
Diseases: encephalopathy, icterus"	"Sentence: Most had hyperacute presentation ; the median icterus encephalopathy interval was 4 . 5 ( 0 - 30 ) days .
Diseases:"
773	The median duration of ATT before ALF was 30 ( 7 - 350 ) days .	O O O O O O B O O O O O O O O O	['alf']	1	1	"Sentence: The median duration of ATT before ALF was 30 ( 7 - 350 ) days .
Diseases: alf"	"Sentence: The median duration of ATT before ALF was 30 ( 7 - 350 ) days .
Diseases:"
774	At presentation , advanced encephalopathy and cerebral edema were present in 51 ( 76 % ) and 29 ( 41 . 4 % ) patients , respectively .	O O O O B O B I O O O O O O O O O O O O O O O O O O O O	['encephalopathy', 'cerebral edema']	2	7	"Sentence: At presentation , advanced encephalopathy and cerebral edema were present in 51 ( 76 % ) and 29 ( 41 . 4 % ) patients , respectively .
Diseases: encephalopathy, cerebral edema"	"Sentence: At presentation , advanced encephalopathy and cerebral edema were present in 51 ( 76 % ) and 29 ( 41 . 4 % ) patients , respectively .
Diseases:"
775	Gastrointestinal bleed , seizures , infection , and acute renal failure were documented in seven ( 10 % ) , five ( 7 . 1 % ) , 26 ( 37 . 1 % ) , and seven ( 10 % ) patients , respectively .	B I O B O B O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['acute renal failure', 'gastrointestinal bleed', 'seizures', 'infection']	4	11	"Sentence: Gastrointestinal bleed , seizures , infection , and acute renal failure were documented in seven ( 10 % ) , five ( 7 . 1 % ) , 26 ( 37 . 1 % ) , and seven ( 10 % ) patients , respectively .
Diseases: acute renal failure, gastrointestinal bleed, seizures, infection"	"Sentence: Gastrointestinal bleed , seizures , infection , and acute renal failure were documented in seven ( 10 % ) , five ( 7 . 1 % ) , 26 ( 37 . 1 % ) , and seven ( 10 % ) patients , respectively .
Diseases:"
776	Compared with hepatitis E virus ( HEV ) and non - A non - E - induced ALF , ATT - ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes .	O O B I O O O O O O O O O O O O O B O O O B O O O O O O O O O O O O O O O O	['hepatitis e', 'alf']	2	7	"Sentence: Compared with hepatitis E virus ( HEV ) and non - A non - E - induced ALF , ATT - ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes .
Diseases: hepatitis e, alf"	"Sentence: Compared with hepatitis E virus ( HEV ) and non - A non - E - induced ALF , ATT - ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes .
Diseases:"
777	The mortality rate among patients with ATT - ALF was high ( 67 . 1 % , n = 47 ) , and only 23 ( 32 . 9 % ) patients recovered with medical treatment .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['alf']	1	1	"Sentence: The mortality rate among patients with ATT - ALF was high ( 67 . 1 % , n = 47 ) , and only 23 ( 32 . 9 % ) patients recovered with medical treatment .
Diseases: alf"	"Sentence: The mortality rate among patients with ATT - ALF was high ( 67 . 1 % , n = 47 ) , and only 23 ( 32 . 9 % ) patients recovered with medical treatment .
Diseases:"
778	In multivariate analysis , three factors independently predicted mortality : serum bilirubin ( > or = 10 . 8 mg / dL ) , prothrombin time ( PT ) prolongation ( > or = 26 seconds ) , and grade III / IV encephalopathy at presentation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	['encephalopathy']	1	3	"Sentence: In multivariate analysis , three factors independently predicted mortality : serum bilirubin ( > or = 10 . 8 mg / dL ) , prothrombin time ( PT ) prolongation ( > or = 26 seconds ) , and grade III / IV encephalopathy at presentation .
Diseases: encephalopathy"	"Sentence: In multivariate analysis , three factors independently predicted mortality : serum bilirubin ( > or = 10 . 8 mg / dL ) , prothrombin time ( PT ) prolongation ( > or = 26 seconds ) , and grade III / IV encephalopathy at presentation .
Diseases:"
779	CONCLUSION : ATT - ALF constituted 5 . 7 % of ALF at our center and had a high mortality rate .	O O O O B O O O O O O B O O O O O O O O O O	['alf']	1	1	"Sentence: CONCLUSION : ATT - ALF constituted 5 . 7 % of ALF at our center and had a high mortality rate .
Diseases: alf"	"Sentence: CONCLUSION : ATT - ALF constituted 5 . 7 % of ALF at our center and had a high mortality rate .
Diseases:"
780	Because the mortality rate is so high , determining which factors are predictors is less important .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Because the mortality rate is so high , determining which factors are predictors is less important .
Diseases: "	"Sentence: Because the mortality rate is so high , determining which factors are predictors is less important .
Diseases:"
781	A high proportion of patients had consumed ATT empirically , which could have been prevented .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A high proportion of patients had consumed ATT empirically , which could have been prevented .
Diseases: "	"Sentence: A high proportion of patients had consumed ATT empirically , which could have been prevented .
Diseases:"
782	Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution .	B I I I O O O B I I O O O O O O	['central nervous system complications', 'acute lymphoblastic leukemia']	2	10	"Sentence: Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution .
Diseases: central nervous system complications, acute lymphoblastic leukemia"	"Sentence: Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution .
Diseases:"
783	Central nervous system ( CNS ) complications during treatment of childhood acute lymphoblastic leukemia ( ALL ) remain a challenging clinical problem .	B I I I I I I O O O O B I I O B O O O O O O O	['acute lymphoblastic leukemia', 'central nervous system ( cns ) complications', 'all']	3	17	"Sentence: Central nervous system ( CNS ) complications during treatment of childhood acute lymphoblastic leukemia ( ALL ) remain a challenging clinical problem .
Diseases: acute lymphoblastic leukemia, central nervous system ( cns ) complications, all"	"Sentence: Central nervous system ( CNS ) complications during treatment of childhood acute lymphoblastic leukemia ( ALL ) remain a challenging clinical problem .
Diseases:"
784	Outcome improvement with more intensive chemotherapy has significantly increased the incidence and severity of adverse events .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Outcome improvement with more intensive chemotherapy has significantly increased the incidence and severity of adverse events .
Diseases: "	"Sentence: Outcome improvement with more intensive chemotherapy has significantly increased the incidence and severity of adverse events .
Diseases:"
785	This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution , focusing on clinical , radiological , and electrophysiological findings .	O O O O O O B I O B O O O O O O O O O O O O O O O O O	['neurological complications', 'all']	2	7	"Sentence: This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution , focusing on clinical , radiological , and electrophysiological findings .
Diseases: neurological complications, all"	"Sentence: This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution , focusing on clinical , radiological , and electrophysiological findings .
Diseases:"
786	Exclusion criteria included CNS leukemic infiltration at diagnosis , therapy - related peripheral neuropathy , late - onset encephalopathy , or long - term neurocognitive defects .	O O O O B I O O O O O O B I O O O O B O O O O O B I O	['peripheral neuropathy', 'encephalopathy', 'leukemic infiltration', 'neurocognitive defects']	4	19	"Sentence: Exclusion criteria included CNS leukemic infiltration at diagnosis , therapy - related peripheral neuropathy , late - onset encephalopathy , or long - term neurocognitive defects .
Diseases: peripheral neuropathy, encephalopathy, leukemic infiltration, neurocognitive defects"	"Sentence: Exclusion criteria included CNS leukemic infiltration at diagnosis , therapy - related peripheral neuropathy , late - onset encephalopathy , or long - term neurocognitive defects .
Diseases:"
787	During a 9 - year period , we retrospectively collected 27 neurological events ( 11 % ) in as many patients , from 253 children enrolled in the ALL front - line protocol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['all']	1	1	"Sentence: During a 9 - year period , we retrospectively collected 27 neurological events ( 11 % ) in as many patients , from 253 children enrolled in the ALL front - line protocol .
Diseases: all"	"Sentence: During a 9 - year period , we retrospectively collected 27 neurological events ( 11 % ) in as many patients , from 253 children enrolled in the ALL front - line protocol .
Diseases:"
788	CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose methotrexate toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .	O O O O O B O O O O O O O B O O O O O O B I I O O O O O O O O O O B O O O O O O O O B I I I O O O O O O O O O O O O O O O O	['temporal lobe epilepsy', 'inappropriate antidiuretic hormone secretion', 'stroke', 'leukoencephalopathy', 'toxicity']	5	22	"Sentence: CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose methotrexate toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
Diseases: temporal lobe epilepsy, inappropriate antidiuretic hormone secretion, stroke, leukoencephalopathy, toxicity"	"Sentence: CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose methotrexate toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .
Diseases:"
789	In conclusion , CNS complications are frequent events during ALL therapy , and require rapid detection and prompt treatment to limit permanent damage .	O O O O O O O O O B O O O O O O O O O O O O O O	['all']	1	1	"Sentence: In conclusion , CNS complications are frequent events during ALL therapy , and require rapid detection and prompt treatment to limit permanent damage .
Diseases: all"	"Sentence: In conclusion , CNS complications are frequent events during ALL therapy , and require rapid detection and prompt treatment to limit permanent damage .
Diseases:"
790	Safety of capecitabine : a review .	O O O O O O O	[]	0	0	"Sentence: Safety of capecitabine : a review .
Diseases: "	"Sentence: Safety of capecitabine : a review .
Diseases:"
791	IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5 - fluorouracil ( 5 - FU ) , have been the mainstay of treatment for several solid tumors , including colorectal , breast and head and neck cancers , for > 40 years .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B I I I I I I I O O O O O O	['colorectal , breast and head and neck cancers', 'tumors']	2	15	"Sentence: IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5 - fluorouracil ( 5 - FU ) , have been the mainstay of treatment for several solid tumors , including colorectal , breast and head and neck cancers , for > 40 years .
Diseases: colorectal , breast and head and neck cancers, tumors"	"Sentence: IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5 - fluorouracil ( 5 - FU ) , have been the mainstay of treatment for several solid tumors , including colorectal , breast and head and neck cancers , for > 40 years .
Diseases:"
792	AREAS COVERED IN THIS REVIEW : This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: AREAS COVERED IN THIS REVIEW : This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety .
Diseases: "	"Sentence: AREAS COVERED IN THIS REVIEW : This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety .
Diseases:"
793	WHAT THE READER WILL GAIN :	O O O O O O	[]	0	0	"Sentence: WHAT THE READER WILL GAIN :
Diseases: "	"Sentence: WHAT THE READER WILL GAIN :
Diseases:"
794	The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age , renal and kidney disease .	O O O O O O O O O O O O O O O O O O O O O B I I I O	['renal and kidney disease']	1	5	"Sentence: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age , renal and kidney disease .
Diseases: renal and kidney disease"	"Sentence: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age , renal and kidney disease .
Diseases:"
795	We also explore different dosing and schedules of capecitabine administration .	O O O O O O O O O O O	[]	0	0	"Sentence: We also explore different dosing and schedules of capecitabine administration .
Diseases: "	"Sentence: We also explore different dosing and schedules of capecitabine administration .
Diseases:"
796	TAKE HOME MESSAGE : Capecitabine is an oral prodrug of 5 - FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety / efficacy profile .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: TAKE HOME MESSAGE : Capecitabine is an oral prodrug of 5 - FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety / efficacy profile .
Diseases: "	"Sentence: TAKE HOME MESSAGE : Capecitabine is an oral prodrug of 5 - FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety / efficacy profile .
Diseases:"
797	It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers .	O O O O O O O O O O O O O O B I I I I I I I I I I I I I I O	['colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers']	1	22	"Sentence: It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers .
Diseases: colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers"	"Sentence: It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers .
Diseases:"
798	The most commonly reported toxic effects of capecitabine are diarrhea , nausea , vomiting , stomatitis and hand - foot syndrome .	O O O O O O O O O B O B O B O B O B I I I O	['nausea', 'stomatitis', 'hand - foot syndrome', 'vomiting', 'diarrhea']	5	17	"Sentence: The most commonly reported toxic effects of capecitabine are diarrhea , nausea , vomiting , stomatitis and hand - foot syndrome .
Diseases: nausea, stomatitis, hand - foot syndrome, vomiting, diarrhea"	"Sentence: The most commonly reported toxic effects of capecitabine are diarrhea , nausea , vomiting , stomatitis and hand - foot syndrome .
Diseases:"
799	Capecitabine has a well - established safety profile and can be given safely to patients with advanced age , hepatic and renal dysfunctions .	O O O O O O O O O O O O O O O O O O O B I I I O	['hepatic and renal dysfunctions']	1	8	"Sentence: Capecitabine has a well - established safety profile and can be given safely to patients with advanced age , hepatic and renal dysfunctions .
Diseases: hepatic and renal dysfunctions"	"Sentence: Capecitabine has a well - established safety profile and can be given safely to patients with advanced age , hepatic and renal dysfunctions .
Diseases:"
800	Effects of pallidal neurotensin on haloperidol - induced parkinsonian catalepsy : behavioral and electrophysiological studies .	O O O O O O O O B I O O O O O O	['parkinsonian catalepsy']	1	7	"Sentence: Effects of pallidal neurotensin on haloperidol - induced parkinsonian catalepsy : behavioral and electrophysiological studies .
Diseases: parkinsonian catalepsy"	"Sentence: Effects of pallidal neurotensin on haloperidol - induced parkinsonian catalepsy : behavioral and electrophysiological studies .
Diseases:"
801	The globus pallidus plays a critical role in movement regulation .	O O O O O O O O O O O	[]	0	0	"Sentence: The globus pallidus plays a critical role in movement regulation .
Diseases: "	"Sentence: The globus pallidus plays a critical role in movement regulation .
Diseases:"
802	Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum , and systemic administration of a neurotensin analog could produce antiparkinsonian effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum , and systemic administration of a neurotensin analog could produce antiparkinsonian effects .
Diseases: "	"Sentence: Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum , and systemic administration of a neurotensin analog could produce antiparkinsonian effects .
Diseases:"
803	The present study aimed to investigate the effects of pallidal neurotensin on haloperidol - induced parkinsonian symptoms .	O O O O O O O O O O O O O O O B I O	['parkinsonian symptoms']	1	4	"Sentence: The present study aimed to investigate the effects of pallidal neurotensin on haloperidol - induced parkinsonian symptoms .
Diseases: parkinsonian symptoms"	"Sentence: The present study aimed to investigate the effects of pallidal neurotensin on haloperidol - induced parkinsonian symptoms .
Diseases:"
804	METHODS : Behavioral experiments and electrophysiological recordings were performed in the present study .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Behavioral experiments and electrophysiological recordings were performed in the present study .
Diseases: "	"Sentence: METHODS : Behavioral experiments and electrophysiological recordings were performed in the present study .
Diseases:"
805	RESULTS : Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol - induced parkinsonian catalepsy in rats .	O O O O O O O O O O O O O O B I O O O	['parkinsonian catalepsy']	1	7	"Sentence: RESULTS : Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol - induced parkinsonian catalepsy in rats .
Diseases: parkinsonian catalepsy"	"Sentence: RESULTS : Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol - induced parkinsonian catalepsy in rats .
Diseases:"
806	Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration .
Diseases: "	"Sentence: Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration .
Diseases:"
807	The neurotensin type - 1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The neurotensin type - 1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin .
Diseases: "	"Sentence: The neurotensin type - 1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin .
Diseases:"
808	CONCLUSION : Activation of pallidal neurotensin receptors may be involved in neurotensin - induced antiparkinsonian effects .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSION : Activation of pallidal neurotensin receptors may be involved in neurotensin - induced antiparkinsonian effects .
Diseases: "	"Sentence: CONCLUSION : Activation of pallidal neurotensin receptors may be involved in neurotensin - induced antiparkinsonian effects .
Diseases:"
809	Antihypertensive drugs and depression : a reappraisal .	O O O B O O O O	['depression']	1	2	"Sentence: Antihypertensive drugs and depression : a reappraisal .
Diseases: depression"	"Sentence: Antihypertensive drugs and depression : a reappraisal .
Diseases:"
810	Eighty - nine new referral hypertensive out - patients and 46 new referral non - hypertensive chronically physically ill out - patients completed a mood rating scale at regular intervals for one year .	O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: Eighty - nine new referral hypertensive out - patients and 46 new referral non - hypertensive chronically physically ill out - patients completed a mood rating scale at regular intervals for one year .
Diseases: hypertensive"	"Sentence: Eighty - nine new referral hypertensive out - patients and 46 new referral non - hypertensive chronically physically ill out - patients completed a mood rating scale at regular intervals for one year .
Diseases:"
811	The results showed a high prevalence of depression in both groups of patients , with no preponderance in the hypertensive group .	O O O O O O O B O O O O O O O O O O O B O O	['depression', 'hypertensive']	2	5	"Sentence: The results showed a high prevalence of depression in both groups of patients , with no preponderance in the hypertensive group .
Diseases: depression, hypertensive"	"Sentence: The results showed a high prevalence of depression in both groups of patients , with no preponderance in the hypertensive group .
Diseases:"
812	Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients .	B O O B O O O O O O B O O O O O	['depression', 'hypertensive', 'psychiatric']	3	7	"Sentence: Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients .
Diseases: depression, hypertensive, psychiatric"	"Sentence: Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients .
Diseases:"
813	This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories .	O O O O O O O O O B O O O O O O O B O O	['depressions', 'psychiatric']	2	5	"Sentence: This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories .
Diseases: depressions, psychiatric"	"Sentence: This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories .
Diseases:"
814	Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside - induced hypotension .	O O O O O O O O O O O B O	['hypotension']	1	3	"Sentence: Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside - induced hypotension .
Diseases: hypotension"	"Sentence: Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside - induced hypotension .
Diseases:"
815	The effects of continuous positive airway pressure ( CPAP ) on cardiovascular dynamics and pulmonary shunt ( QS / QT ) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40 - 50 per cent .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effects of continuous positive airway pressure ( CPAP ) on cardiovascular dynamics and pulmonary shunt ( QS / QT ) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40 - 50 per cent .
Diseases: "	"Sentence: The effects of continuous positive airway pressure ( CPAP ) on cardiovascular dynamics and pulmonary shunt ( QS / QT ) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40 - 50 per cent .
Diseases:"
816	Before nitroprusside infusion , 5 cm H2O CPAP significantly , P less than . 05 , decreased arterial blood pressure , but did not significantly alter heart rate , cardiac output , systemic vascular resistance , or QS / QT .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Before nitroprusside infusion , 5 cm H2O CPAP significantly , P less than . 05 , decreased arterial blood pressure , but did not significantly alter heart rate , cardiac output , systemic vascular resistance , or QS / QT .
Diseases: "	"Sentence: Before nitroprusside infusion , 5 cm H2O CPAP significantly , P less than . 05 , decreased arterial blood pressure , but did not significantly alter heart rate , cardiac output , systemic vascular resistance , or QS / QT .
Diseases:"
817	Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS / QT .	O O O O O O O O O O B I I I I O O O O O O B I I O O O O O	['decrease in arterial blood pressure', 'decreased cardiac output']	2	12	"Sentence: Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS / QT .
Diseases: decrease in arterial blood pressure, decreased cardiac output"	"Sentence: Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS / QT .
Diseases:"
818	Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate , but did not change cardiac output or QS / QT .	O O O B I I I I O O O O O O O O O O O O O O O O O O O O O	['decreases in arterial blood pressure']	1	8	"Sentence: Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate , but did not change cardiac output or QS / QT .
Diseases: decreases in arterial blood pressure"	"Sentence: Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate , but did not change cardiac output or QS / QT .
Diseases:"
819	Five cm H2O CPAP during nitroprusside did not further alter any of the above - mentioned variables .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Five cm H2O CPAP during nitroprusside did not further alter any of the above - mentioned variables .
Diseases: "	"Sentence: Five cm H2O CPAP during nitroprusside did not further alter any of the above - mentioned variables .
Diseases:"
820	However , 10 cm H2O CPAP decreased arterial blood pressure , cardiac output , and QS / QT .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , 10 cm H2O CPAP decreased arterial blood pressure , cardiac output , and QS / QT .
Diseases: "	"Sentence: However , 10 cm H2O CPAP decreased arterial blood pressure , cardiac output , and QS / QT .
Diseases:"
821	These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40 - 50 per cent do not change cardiac output or QS / QT .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40 - 50 per cent do not change cardiac output or QS / QT .
Diseases: "	"Sentence: These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40 - 50 per cent do not change cardiac output or QS / QT .
Diseases:"
822	During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm H2O ) , while decreasing QS / QT , produce marked decreases in arterial blood pressure and cardiac output .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I I I O	['decreases in arterial blood pressure and cardiac output']	1	11	"Sentence: During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm H2O ) , while decreasing QS / QT , produce marked decreases in arterial blood pressure and cardiac output .
Diseases: decreases in arterial blood pressure and cardiac output"	"Sentence: During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm H2O ) , while decreasing QS / QT , produce marked decreases in arterial blood pressure and cardiac output .
Diseases:"
823	Mediation of enhanced reflex vagal bradycardia by L - dopa via central dopamine formation in dogs .	O O O O O B O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: Mediation of enhanced reflex vagal bradycardia by L - dopa via central dopamine formation in dogs .
Diseases: bradycardia"	"Sentence: Mediation of enhanced reflex vagal bradycardia by L - dopa via central dopamine formation in dogs .
Diseases:"
824	L - Dopa ( 5 mg / kg i . v . ) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK - 486 ( 25 mg / kg i . v . )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: L - Dopa ( 5 mg / kg i . v . ) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK - 486 ( 25 mg / kg i . v . )
Diseases: "	"Sentence: L - Dopa ( 5 mg / kg i . v . ) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK - 486 ( 25 mg / kg i . v . )
Diseases:"
825	in anesthetize MAO - inhibited dogs .	O O O O O O O	[]	0	0	"Sentence: in anesthetize MAO - inhibited dogs .
Diseases: "	"Sentence: in anesthetize MAO - inhibited dogs .
Diseases:"
826	In addition , reflex bradycardia caused by injected norepinephrine was significantly enhanced by L - dopa , DL - Threo - dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: In addition , reflex bradycardia caused by injected norepinephrine was significantly enhanced by L - dopa , DL - Threo - dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .
Diseases: bradycardia"	"Sentence: In addition , reflex bradycardia caused by injected norepinephrine was significantly enhanced by L - dopa , DL - Threo - dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .
Diseases:"
827	FLA - 63 , a dopamine - beta - oxidase inhibitor , did not have any effect on the hypotension , bradycardia or reflex - enhancing effect of L - dopa .	O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O	['bradycardia', 'hypotension']	2	7	"Sentence: FLA - 63 , a dopamine - beta - oxidase inhibitor , did not have any effect on the hypotension , bradycardia or reflex - enhancing effect of L - dopa .
Diseases: bradycardia, hypotension"	"Sentence: FLA - 63 , a dopamine - beta - oxidase inhibitor , did not have any effect on the hypotension , bradycardia or reflex - enhancing effect of L - dopa .
Diseases:"
828	Pimozide did not affect the actions of L - dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pimozide did not affect the actions of L - dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes .
Diseases: "	"Sentence: Pimozide did not affect the actions of L - dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes .
Diseases:"
829	Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine .
Diseases: "	"Sentence: Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine .
Diseases:"
830	However , L - dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate .	O O O O O O O B O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: However , L - dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate .
Diseases: bradycardia"	"Sentence: However , L - dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate .
Diseases:"
831	5 - HTP ( 5 mg / kg i . v . ) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine .	O O O O O O O O O O O O O O O O O O O O O O O B O O O	['bradycardia']	1	4	"Sentence: 5 - HTP ( 5 mg / kg i . v . ) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine .
Diseases: bradycardia"	"Sentence: 5 - HTP ( 5 mg / kg i . v . ) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine .
Diseases:"
832	It is concluded that L - dopa enhances reflex bradycardia through central alpha - receptor stimulation .	O O O O O O O O O B O O O O O O O	['bradycardia']	1	4	"Sentence: It is concluded that L - dopa enhances reflex bradycardia through central alpha - receptor stimulation .
Diseases: bradycardia"	"Sentence: It is concluded that L - dopa enhances reflex bradycardia through central alpha - receptor stimulation .
Diseases:"
833	Furthermore , the effects are mediated through dopamine rather than norepinephrine and do not require the carotid sinus baroreceptors .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Furthermore , the effects are mediated through dopamine rather than norepinephrine and do not require the carotid sinus baroreceptors .
Diseases: "	"Sentence: Furthermore , the effects are mediated through dopamine rather than norepinephrine and do not require the carotid sinus baroreceptors .
Diseases:"
834	Cocaine - induced myocardial infarction : clinical observations and pathogenetic considerations .	O O O B I O O O O O O O	['myocardial infarction']	1	6	"Sentence: Cocaine - induced myocardial infarction : clinical observations and pathogenetic considerations .
Diseases: myocardial infarction"	"Sentence: Cocaine - induced myocardial infarction : clinical observations and pathogenetic considerations .
Diseases:"
835	Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction .	O O O O O O O O O O O O O O O O O B I I O	['acute myocardial infarction']	1	8	"Sentence: Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction .
Diseases: acute myocardial infarction"	"Sentence: Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction .
Diseases:"
836	In individuals with preexisting , high - grade coronary arterial narrowing , acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine - induced increase in rate - pressure product .	O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O	['acute myocardial infarction']	1	8	"Sentence: In individuals with preexisting , high - grade coronary arterial narrowing , acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine - induced increase in rate - pressure product .
Diseases: acute myocardial infarction"	"Sentence: In individuals with preexisting , high - grade coronary arterial narrowing , acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine - induced increase in rate - pressure product .
Diseases:"
837	In other individuals with no underlying atherosclerotic obstruction , coronary occlusion may be due to spasm , thrombus , or both .	O O O O O O B I O B I O O O O B O B O O O O	['atherosclerotic obstruction', 'coronary occlusion', 'spasm', 'thrombus']	4	17	"Sentence: In other individuals with no underlying atherosclerotic obstruction , coronary occlusion may be due to spasm , thrombus , or both .
Diseases: atherosclerotic obstruction, coronary occlusion, spasm, thrombus"	"Sentence: In other individuals with no underlying atherosclerotic obstruction , coronary occlusion may be due to spasm , thrombus , or both .
Diseases:"
838	With regard to spasm , the clinical findings are largely circumstantial , and the locus of cocaine - induced vasoconstriction remains speculative .	O O O B O O O O O O O O O O O O O O O O O O O	['spasm']	1	2	"Sentence: With regard to spasm , the clinical findings are largely circumstantial , and the locus of cocaine - induced vasoconstriction remains speculative .
Diseases: spasm"	"Sentence: With regard to spasm , the clinical findings are largely circumstantial , and the locus of cocaine - induced vasoconstriction remains speculative .
Diseases:"
839	Although certain clinical and experimental findings support the hypothesis that spasm involves the epicardial , medium - size vessels , other data suggest intramural vasoconstriction .	O O O O O O O O O O B O O O O O O O O O O O O O O O	['spasm']	1	2	"Sentence: Although certain clinical and experimental findings support the hypothesis that spasm involves the epicardial , medium - size vessels , other data suggest intramural vasoconstriction .
Diseases: spasm"	"Sentence: Although certain clinical and experimental findings support the hypothesis that spasm involves the epicardial , medium - size vessels , other data suggest intramural vasoconstriction .
Diseases:"
840	Diffuse intramural vasoconstriction is not consistent with reports of segmental , discrete infarction .	O O O O O O O O O O O O B O	['infarction']	1	3	"Sentence: Diffuse intramural vasoconstriction is not consistent with reports of segmental , discrete infarction .
Diseases: infarction"	"Sentence: Diffuse intramural vasoconstriction is not consistent with reports of segmental , discrete infarction .
Diseases:"
841	Whereas certain in vivo data suggest that these effects are alpha - mediated , other in vitro data suggest the opposite .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Whereas certain in vivo data suggest that these effects are alpha - mediated , other in vitro data suggest the opposite .
Diseases: "	"Sentence: Whereas certain in vivo data suggest that these effects are alpha - mediated , other in vitro data suggest the opposite .
Diseases:"
842	The finding of cocaine - induced vasoconstriction in segments of ( noninnervated ) human umbilical artery suggests that the presence or absence of intact innervation is not sufficient to explain the discrepant data involving the possibility of alpha - mediated effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The finding of cocaine - induced vasoconstriction in segments of ( noninnervated ) human umbilical artery suggests that the presence or absence of intact innervation is not sufficient to explain the discrepant data involving the possibility of alpha - mediated effects .
Diseases: "	"Sentence: The finding of cocaine - induced vasoconstriction in segments of ( noninnervated ) human umbilical artery suggests that the presence or absence of intact innervation is not sufficient to explain the discrepant data involving the possibility of alpha - mediated effects .
Diseases:"
843	Finally , the contribution of a primary , thrombotic effect of cocaine has not been excluded .	O O O O O O O O B O O O O O O O O	['thrombotic']	1	4	"Sentence: Finally , the contribution of a primary , thrombotic effect of cocaine has not been excluded .
Diseases: thrombotic"	"Sentence: Finally , the contribution of a primary , thrombotic effect of cocaine has not been excluded .
Diseases:"
844	Rabbit syndrome , antidepressant use , and cerebral perfusion SPECT scan findings .	B I O O O O O O O O O O O	['rabbit syndrome']	1	3	"Sentence: Rabbit syndrome , antidepressant use , and cerebral perfusion SPECT scan findings .
Diseases: rabbit syndrome"	"Sentence: Rabbit syndrome , antidepressant use , and cerebral perfusion SPECT scan findings .
Diseases:"
845	The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy .	O B I O O O O O O O O O O O	['rabbit syndrome']	1	3	"Sentence: The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy .
Diseases: rabbit syndrome"	"Sentence: The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy .
Diseases:"
846	Its occurrence in a patient being treated with imipramine is described , representing the first reported case of this syndrome in conjunction with antidepressants .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Its occurrence in a patient being treated with imipramine is described , representing the first reported case of this syndrome in conjunction with antidepressants .
Diseases: "	"Sentence: Its occurrence in a patient being treated with imipramine is described , representing the first reported case of this syndrome in conjunction with antidepressants .
Diseases:"
847	Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present , and a return to normal perfusion when the rabbit syndrome resolved .	O O O O O O B I I I O O B I O O O O O O O O O O O B I O O	['movement disorder', 'rabbit syndrome', 'decreased basal ganglia perfusion']	3	13	"Sentence: Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present , and a return to normal perfusion when the rabbit syndrome resolved .
Diseases: movement disorder, rabbit syndrome, decreased basal ganglia perfusion"	"Sentence: Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present , and a return to normal perfusion when the rabbit syndrome resolved .
Diseases:"
848	Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease .	O O O O O O O O O B I I I O	['chronic obstructive pulmonary disease']	1	6	"Sentence: Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease .
Diseases: chronic obstructive pulmonary disease"	"Sentence: Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease .
Diseases:"
849	The bronchodilator effects of a single dose of ipratropium bromide aerosol ( 36 micrograms ) and short - acting theophylline tablets ( dose titrated to produce serum levels of 10 - 20 micrograms / mL ) were compared in a double - blind , placebo - controlled crossover study in 21 patients with stable , chronic obstructive pulmonary disease .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O	['chronic obstructive pulmonary disease']	1	6	"Sentence: The bronchodilator effects of a single dose of ipratropium bromide aerosol ( 36 micrograms ) and short - acting theophylline tablets ( dose titrated to produce serum levels of 10 - 20 micrograms / mL ) were compared in a double - blind , placebo - controlled crossover study in 21 patients with stable , chronic obstructive pulmonary disease .
Diseases: chronic obstructive pulmonary disease"	"Sentence: The bronchodilator effects of a single dose of ipratropium bromide aerosol ( 36 micrograms ) and short - acting theophylline tablets ( dose titrated to produce serum levels of 10 - 20 micrograms / mL ) were compared in a double - blind , placebo - controlled crossover study in 21 patients with stable , chronic obstructive pulmonary disease .
Diseases:"
850	Mean peak forced expiratory volume in 1 second ( FEV1 ) increases over baseline and the proportion of patients attaining at least a 15 % increase in the FEV1 ( responders ) were 31 % and 90 % , respectively , for ipratropium and 17 % and 50 % , respectively , for theophylline .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mean peak forced expiratory volume in 1 second ( FEV1 ) increases over baseline and the proportion of patients attaining at least a 15 % increase in the FEV1 ( responders ) were 31 % and 90 % , respectively , for ipratropium and 17 % and 50 % , respectively , for theophylline .
Diseases: "	"Sentence: Mean peak forced expiratory volume in 1 second ( FEV1 ) increases over baseline and the proportion of patients attaining at least a 15 % increase in the FEV1 ( responders ) were 31 % and 90 % , respectively , for ipratropium and 17 % and 50 % , respectively , for theophylline .
Diseases:"
851	The average FEV1 increases during the 6 - hour observation period were 18 % for ipratropium and 8 % for theophylline .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The average FEV1 increases during the 6 - hour observation period were 18 % for ipratropium and 8 % for theophylline .
Diseases: "	"Sentence: The average FEV1 increases during the 6 - hour observation period were 18 % for ipratropium and 8 % for theophylline .
Diseases:"
852	The mean duration of action was 3 . 8 hours with ipratropium and 2 . 4 hours with theophylline .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean duration of action was 3 . 8 hours with ipratropium and 2 . 4 hours with theophylline .
Diseases: "	"Sentence: The mean duration of action was 3 . 8 hours with ipratropium and 2 . 4 hours with theophylline .
Diseases:"
853	While side effects were rare , those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems .	O O O O O O O O O O O O O O B I I I O	['cardiovascular and gastrointestinal systems']	1	5	"Sentence: While side effects were rare , those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems .
Diseases: cardiovascular and gastrointestinal systems"	"Sentence: While side effects were rare , those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems .
Diseases:"
854	These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction .	O O O O O O O O O O O O O O O O B I I O	['chronic airflow obstruction']	1	4	"Sentence: These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction .
Diseases: chronic airflow obstruction"	"Sentence: These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction .
Diseases:"
855	Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats .	O O O O O O O O O B O O O O	['nephropathy']	1	4	"Sentence: Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats .
Diseases: nephropathy"	"Sentence: Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats .
Diseases:"
856	Renal papillary necrosis ( RPN ) and a decreased urinary concentrating ability developed during continuous long - term treatment with aspirin and paracetamol in female Fischer 344 rats .	B I I O B O O O O O O O O O O O O O O O O O O O O O O O O	['rpn', 'renal papillary necrosis']	2	9	"Sentence: Renal papillary necrosis ( RPN ) and a decreased urinary concentrating ability developed during continuous long - term treatment with aspirin and paracetamol in female Fischer 344 rats .
Diseases: rpn, renal papillary necrosis"	"Sentence: Renal papillary necrosis ( RPN ) and a decreased urinary concentrating ability developed during continuous long - term treatment with aspirin and paracetamol in female Fischer 344 rats .
Diseases:"
857	Renal structure and concentrating ability were examined after a recovery period of up to 18 weeks , when no analgesics were given , to investigate whether the analgesic - induced changes were reversible .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Renal structure and concentrating ability were examined after a recovery period of up to 18 weeks , when no analgesics were given , to investigate whether the analgesic - induced changes were reversible .
Diseases: "	"Sentence: Renal structure and concentrating ability were examined after a recovery period of up to 18 weeks , when no analgesics were given , to investigate whether the analgesic - induced changes were reversible .
Diseases:"
858	There was no evidence of repair to the damaged medullary interstitial matrix , or proliferation of remaining undamaged type 1 medullary interstitial cells after the recovery period following analgesic treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was no evidence of repair to the damaged medullary interstitial matrix , or proliferation of remaining undamaged type 1 medullary interstitial cells after the recovery period following analgesic treatment .
Diseases: "	"Sentence: There was no evidence of repair to the damaged medullary interstitial matrix , or proliferation of remaining undamaged type 1 medullary interstitial cells after the recovery period following analgesic treatment .
Diseases:"
859	The recovery of urinary concentrating ability was related to the length of analgesic treatment and the extent of the resulting inner medullary structural damage .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The recovery of urinary concentrating ability was related to the length of analgesic treatment and the extent of the resulting inner medullary structural damage .
Diseases: "	"Sentence: The recovery of urinary concentrating ability was related to the length of analgesic treatment and the extent of the resulting inner medullary structural damage .
Diseases:"
860	During the early stages of analgesic treatment , the changes in urinary concentrating ability were reversible , but after prolonged analgesic treatment , maximum urinary concentrating ability failed to recover .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During the early stages of analgesic treatment , the changes in urinary concentrating ability were reversible , but after prolonged analgesic treatment , maximum urinary concentrating ability failed to recover .
Diseases: "	"Sentence: During the early stages of analgesic treatment , the changes in urinary concentrating ability were reversible , but after prolonged analgesic treatment , maximum urinary concentrating ability failed to recover .
Diseases:"
861	This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['rpn']	1	2	"Sentence: This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN .
Diseases: rpn"	"Sentence: This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN .
Diseases:"
862	The associated urinary concentrating defect is reversible only during the early stages of structural damage to the inner medulla .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The associated urinary concentrating defect is reversible only during the early stages of structural damage to the inner medulla .
Diseases: "	"Sentence: The associated urinary concentrating defect is reversible only during the early stages of structural damage to the inner medulla .
Diseases:"
863	Less frequent lithium administration and lower urine volume .	O O O O O O O O O	[]	0	0	"Sentence: Less frequent lithium administration and lower urine volume .
Diseases: "	"Sentence: Less frequent lithium administration and lower urine volume .
Diseases:"
864	This study was designed to determine whether patients maintained on a regimen of lithium on a once - per - day schedule have lower urine volumes than do patients receiving multiple doses per day .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This study was designed to determine whether patients maintained on a regimen of lithium on a once - per - day schedule have lower urine volumes than do patients receiving multiple doses per day .
Diseases: "	"Sentence: This study was designed to determine whether patients maintained on a regimen of lithium on a once - per - day schedule have lower urine volumes than do patients receiving multiple doses per day .
Diseases:"
865	This was a cross - sectional study of 85 patients from a lithium clinic who received different dose schedules .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This was a cross - sectional study of 85 patients from a lithium clinic who received different dose schedules .
Diseases: "	"Sentence: This was a cross - sectional study of 85 patients from a lithium clinic who received different dose schedules .
Diseases:"
866	Patients were admitted to the hospital for measurement of lithium level , creatinine clearance , urine volume , and maximum osmolality .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients were admitted to the hospital for measurement of lithium level , creatinine clearance , urine volume , and maximum osmolality .
Diseases: "	"Sentence: Patients were admitted to the hospital for measurement of lithium level , creatinine clearance , urine volume , and maximum osmolality .
Diseases:"
867	Multiple daily doses of lithium were associated with higher urine volumes .	O O O O O O O O O O O O	[]	0	0	"Sentence: Multiple daily doses of lithium were associated with higher urine volumes .
Diseases: "	"Sentence: Multiple daily doses of lithium were associated with higher urine volumes .
Diseases:"
868	The dosing schedule , duration of lithium treatment , and daily dose of lithium did not affect maximum osmolality or creatinine clearance .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The dosing schedule , duration of lithium treatment , and daily dose of lithium did not affect maximum osmolality or creatinine clearance .
Diseases: "	"Sentence: The dosing schedule , duration of lithium treatment , and daily dose of lithium did not affect maximum osmolality or creatinine clearance .
Diseases:"
869	Urine volume can be reduced by giving lithium once daily and / or by lowering the total daily dose .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Urine volume can be reduced by giving lithium once daily and / or by lowering the total daily dose .
Diseases: "	"Sentence: Urine volume can be reduced by giving lithium once daily and / or by lowering the total daily dose .
Diseases:"
870	Lithium - induced polyuria seems to be related to extrarenal as well as to renal effects .	O O O B O O O O O O O O O O O O O	['polyuria']	1	2	"Sentence: Lithium - induced polyuria seems to be related to extrarenal as well as to renal effects .
Diseases: polyuria"	"Sentence: Lithium - induced polyuria seems to be related to extrarenal as well as to renal effects .
Diseases:"
871	Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues .	O O O O O O O B O B O O O O	['hyperthermia', 'tumor']	2	5	"Sentence: Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues .
Diseases: hyperthermia, tumor"	"Sentence: Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues .
Diseases:"
872	Thermal enhancement of Adriamycin - mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model .	O O O O O O O O O O O B O O O B O O O O O O O O	['toxicities', 'hyperthermia']	2	7	"Sentence: Thermal enhancement of Adriamycin - mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model .
Diseases: toxicities, hyperthermia"	"Sentence: Thermal enhancement of Adriamycin - mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model .
Diseases:"
873	Antitumor activity was studied using a tumor growth delay assay .	O O O O O O B O O O O	['tumor']	1	3	"Sentence: Antitumor activity was studied using a tumor growth delay assay .
Diseases: tumor"	"Sentence: Antitumor activity was studied using a tumor growth delay assay .
Diseases:"
874	Acute normal tissue toxicities ( i . e . , leukopenia and thrombocytopenia ) and late normal tissue toxicities ( i . e . , myocardial and kidney injury ) were evaluated by functional / physiological assays and by morphological techniques .	O O O B O O O O O O B O B O O O O O B O O O O O O B I I I O O O O O O O O O O O O O	['toxicities', 'leukopenia', 'thrombocytopenia', 'myocardial and kidney injury']	4	23	"Sentence: Acute normal tissue toxicities ( i . e . , leukopenia and thrombocytopenia ) and late normal tissue toxicities ( i . e . , myocardial and kidney injury ) were evaluated by functional / physiological assays and by morphological techniques .
Diseases: toxicities, leukopenia, thrombocytopenia, myocardial and kidney injury"	"Sentence: Acute normal tissue toxicities ( i . e . , leukopenia and thrombocytopenia ) and late normal tissue toxicities ( i . e . , myocardial and kidney injury ) were evaluated by functional / physiological assays and by morphological techniques .
Diseases:"
875	Whole body hyperthermia ( 120 min at 41 . 5 degrees C ) enhanced both Adriamycin - mediated antitumor activity and toxic side effects .	O O B O O O O O O O O O O O O O O O O O O O O O O	['hyperthermia']	1	3	"Sentence: Whole body hyperthermia ( 120 min at 41 . 5 degrees C ) enhanced both Adriamycin - mediated antitumor activity and toxic side effects .
Diseases: hyperthermia"	"Sentence: Whole body hyperthermia ( 120 min at 41 . 5 degrees C ) enhanced both Adriamycin - mediated antitumor activity and toxic side effects .
Diseases:"
876	The thermal enhancement ratio calculated for antitumor activity was 1 . 6 .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The thermal enhancement ratio calculated for antitumor activity was 1 . 6 .
Diseases: "	"Sentence: The thermal enhancement ratio calculated for antitumor activity was 1 . 6 .
Diseases:"
877	"Thermal enhancement ratios estimated for "" acute "" hematological changes were 1 . 3 , whereas those estimated for "" late "" damage ( based on morphological cardiac and renal lesions ) varied between 2 . 4 and 4 . 3 ."	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O	['cardiac and renal lesions']	1	5	"Sentence: Thermal enhancement ratios estimated for "" acute "" hematological changes were 1 . 3 , whereas those estimated for "" late "" damage ( based on morphological cardiac and renal lesions ) varied between 2 . 4 and 4 . 3 .
Diseases: cardiac and renal lesions"	"Sentence: Thermal enhancement ratios estimated for "" acute "" hematological changes were 1 . 3 , whereas those estimated for "" late "" damage ( based on morphological cardiac and renal lesions ) varied between 2 . 4 and 4 . 3 .
Diseases:"
878	Thus , while whole body hyperthermia enhances Adriamycin - mediated antitumor effect , normal tissue toxicity is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .	O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O	['hyperthermia', 'toxicity']	2	5	"Sentence: Thus , while whole body hyperthermia enhances Adriamycin - mediated antitumor effect , normal tissue toxicity is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .
Diseases: hyperthermia, toxicity"	"Sentence: Thus , while whole body hyperthermia enhances Adriamycin - mediated antitumor effect , normal tissue toxicity is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .
Diseases:"
879	Prazosin - induced stress incontinence .	O O O B I O	['stress incontinence']	1	4	"Sentence: Prazosin - induced stress incontinence .
Diseases: stress incontinence"	"Sentence: Prazosin - induced stress incontinence .
Diseases:"
880	A case of genuine stress incontinence due to prazosin , a common antihypertensive drug , is presented .	O O O O B I O O O O O O O O O O O O	['stress incontinence']	1	4	"Sentence: A case of genuine stress incontinence due to prazosin , a common antihypertensive drug , is presented .
Diseases: stress incontinence"	"Sentence: A case of genuine stress incontinence due to prazosin , a common antihypertensive drug , is presented .
Diseases:"
881	Prazosin exerts its antihypertensive effects through vasodilatation caused by selective blockade of postsynaptic alpha - 1 adrenergic receptors .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Prazosin exerts its antihypertensive effects through vasodilatation caused by selective blockade of postsynaptic alpha - 1 adrenergic receptors .
Diseases: "	"Sentence: Prazosin exerts its antihypertensive effects through vasodilatation caused by selective blockade of postsynaptic alpha - 1 adrenergic receptors .
Diseases:"
882	As an alpha - blocker , it also exerts a significant relaxant effect on the bladder neck and urethra .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As an alpha - blocker , it also exerts a significant relaxant effect on the bladder neck and urethra .
Diseases: "	"Sentence: As an alpha - blocker , it also exerts a significant relaxant effect on the bladder neck and urethra .
Diseases:"
883	The patient 's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking verapamil .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The patient 's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking verapamil .
Diseases: "	"Sentence: The patient 's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking verapamil .
Diseases:"
884	Her incontinence resolved with the change of medication .	O B O O O O O O O	['incontinence']	1	3	"Sentence: Her incontinence resolved with the change of medication .
Diseases: incontinence"	"Sentence: Her incontinence resolved with the change of medication .
Diseases:"
885	The restoration of continence was accompanied by a substantial rise in maximum urethral pressure , maximum urethral closure pressure , and functional urethral length .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The restoration of continence was accompanied by a substantial rise in maximum urethral pressure , maximum urethral closure pressure , and functional urethral length .
Diseases: "	"Sentence: The restoration of continence was accompanied by a substantial rise in maximum urethral pressure , maximum urethral closure pressure , and functional urethral length .
Diseases:"
886	Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery , because their incontinence may resolve spontaneously with a change in drug therapy .	O O O O B I O O O O O O O O O O O O O O B O O O O O O O O O O	['incontinence', 'stress incontinence']	2	8	"Sentence: Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery , because their incontinence may resolve spontaneously with a change in drug therapy .
Diseases: incontinence, stress incontinence"	"Sentence: Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery , because their incontinence may resolve spontaneously with a change in drug therapy .
Diseases:"
887	Myocardial infarction following sublingual administration of isosorbide dinitrate .	B I O O O O O O O	['myocardial infarction']	1	6	"Sentence: Myocardial infarction following sublingual administration of isosorbide dinitrate .
Diseases: myocardial infarction"	"Sentence: Myocardial infarction following sublingual administration of isosorbide dinitrate .
Diseases:"
888	A 78 - year - old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually .	O O O O O O O O O B O O O B I O O O O O O O O O O O O O O	['necrosis', 'myocardial infarction']	2	9	"Sentence: A 78 - year - old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually .
Diseases: necrosis, myocardial infarction"	"Sentence: A 78 - year - old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually .
Diseases:"
889	After detailing the course of events , we discuss the role of paradoxical coronary spasm and hypotension - mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency .	O O O O O O O O O O O O O O B O B O O B I O O O O B I I O O O O B I I O	['hypotension', 'myocardial ischemia', 'acute coronary insufficiency', 'coronary arterial stenosis', 'spasm']	5	25	"Sentence: After detailing the course of events , we discuss the role of paradoxical coronary spasm and hypotension - mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency .
Diseases: hypotension, myocardial ischemia, acute coronary insufficiency, coronary arterial stenosis, spasm"	"Sentence: After detailing the course of events , we discuss the role of paradoxical coronary spasm and hypotension - mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency .
Diseases:"
890	Fluoxetine - induced akathisia : clinical and theoretical implications .	O O O B O O O O O O	['akathisia']	1	4	"Sentence: Fluoxetine - induced akathisia : clinical and theoretical implications .
Diseases: akathisia"	"Sentence: Fluoxetine - induced akathisia : clinical and theoretical implications .
Diseases:"
891	Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia .	O O O O O O O O B I I O B I O B O	['major depression', 'obsessive compulsive disorder', 'akathisia']	3	12	"Sentence: Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia .
Diseases: major depression, obsessive compulsive disorder, akathisia"	"Sentence: Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia .
Diseases:"
892	The typical fluoxetine - induced symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O	['akathisia', 'anxiety']	2	6	"Sentence: The typical fluoxetine - induced symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia .
Diseases: akathisia, anxiety"	"Sentence: The typical fluoxetine - induced symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia .
Diseases:"
893	Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical , although somewhat milder .	O O O O O O O O B O O O O O O O O O O O B O O O O O O O	['akathisia']	1	4	"Sentence: Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical , although somewhat milder .
Diseases: akathisia"	"Sentence: Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical , although somewhat milder .
Diseases:"
894	Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol , dose reduction , or both .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['akathisia']	1	4	"Sentence: Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol , dose reduction , or both .
Diseases: akathisia"	"Sentence: Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol , dose reduction , or both .
Diseases:"
895	"The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced "" jitteriness "" may be identical ."	O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['akathisia']	1	4	"Sentence: The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced "" jitteriness "" may be identical .
Diseases: akathisia"	"Sentence: The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced "" jitteriness "" may be identical .
Diseases:"
896	Chronic active hepatitis associated with diclofenac sodium therapy .	B I I O O O O O O	['chronic active hepatitis']	1	4	"Sentence: Chronic active hepatitis associated with diclofenac sodium therapy .
Diseases: chronic active hepatitis"	"Sentence: Chronic active hepatitis associated with diclofenac sodium therapy .
Diseases:"
897	Diclofenac sodium ( Voltarol , Geigy Pharmaceuticals ) is a non - steroidal anti - inflammatory derivative of phenylacetic acid .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Diclofenac sodium ( Voltarol , Geigy Pharmaceuticals ) is a non - steroidal anti - inflammatory derivative of phenylacetic acid .
Diseases: "	"Sentence: Diclofenac sodium ( Voltarol , Geigy Pharmaceuticals ) is a non - steroidal anti - inflammatory derivative of phenylacetic acid .
Diseases:"
898	Although generally well - tolerated , asymptomatic abnormalities of liver function have been recorded and , less commonly , severe hepatitis induced by diclofenac .	O O O O O O O B I I I O O O O O O O O O B O O O O	['hepatitis', 'abnormalities of liver function']	2	8	"Sentence: Although generally well - tolerated , asymptomatic abnormalities of liver function have been recorded and , less commonly , severe hepatitis induced by diclofenac .
Diseases: hepatitis, abnormalities of liver function"	"Sentence: Although generally well - tolerated , asymptomatic abnormalities of liver function have been recorded and , less commonly , severe hepatitis induced by diclofenac .
Diseases:"
899	The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug , a finding not previously reported .	O O O O B I I O O O O O O O O O O O O O O O O O O O O O O	['chronic active hepatitis']	1	4	"Sentence: The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug , a finding not previously reported .
Diseases: chronic active hepatitis"	"Sentence: The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug , a finding not previously reported .
Diseases:"
900	Stroke associated with cocaine use .	B O O O O O	['stroke']	1	1	"Sentence: Stroke associated with cocaine use .
Diseases: stroke"	"Sentence: Stroke associated with cocaine use .
Diseases:"
901	We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature .	O O O O O O O O O O O B O O O O O O O O	['stroke']	1	1	"Sentence: We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature .
Diseases: stroke"	"Sentence: We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature .
Diseases:"
902	Among these 47 patients the mean ( + / - SD ) age was 32 . 5 + / - 12 . 1 years ; 76 % ( 34 / 45 ) were men .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Among these 47 patients the mean ( + / - SD ) age was 32 . 5 + / - 12 . 1 years ; 76 % ( 34 / 45 ) were men .
Diseases: "	"Sentence: Among these 47 patients the mean ( + / - SD ) age was 32 . 5 + / - 12 . 1 years ; 76 % ( 34 / 45 ) were men .
Diseases:"
903	Stroke followed cocaine use by inhalation , intranasal , intravenous , and intramuscular routes .	B O O O O O O O O O O O O O O	['stroke']	1	1	"Sentence: Stroke followed cocaine use by inhalation , intranasal , intravenous , and intramuscular routes .
Diseases: stroke"	"Sentence: Stroke followed cocaine use by inhalation , intranasal , intravenous , and intramuscular routes .
Diseases:"
904	Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy ; cerebral vasculitis was present in two patients .	B I O B I O O O O O O O O O O O O O B I O O O O O O	['intracranial aneurysms', 'cerebral vasculitis', 'arteriovenous malformations']	3	21	"Sentence: Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy ; cerebral vasculitis was present in two patients .
Diseases: intracranial aneurysms, cerebral vasculitis, arteriovenous malformations"	"Sentence: Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy ; cerebral vasculitis was present in two patients .
Diseases:"
905	Cerebral infarction occurred in 10 patients ( 22 % ) , intracerebral hemorrhage in 22 ( 49 % ) , and subarachnoid hemorrhage in 13 ( 29 % ) .	B I O O O O O O O O O B I O O O O O O O O B I O O O O O O O	['cerebral infarction', 'subarachnoid hemorrhage', 'intracerebral hemorrhage']	3	21	"Sentence: Cerebral infarction occurred in 10 patients ( 22 % ) , intracerebral hemorrhage in 22 ( 49 % ) , and subarachnoid hemorrhage in 13 ( 29 % ) .
Diseases: cerebral infarction, subarachnoid hemorrhage, intracerebral hemorrhage"	"Sentence: Cerebral infarction occurred in 10 patients ( 22 % ) , intracerebral hemorrhage in 22 ( 49 % ) , and subarachnoid hemorrhage in 13 ( 29 % ) .
Diseases:"
906	These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .	O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O B O O O O O O O B I O B I O O O O O O O O O B O O O O B I O O O B I O	['intracranial aneurysms', 'cerebral infarction', 'intracranial hemorrhage', 'stroke', 'arteriovenous malformations']	5	30	"Sentence: These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
Diseases: intracranial aneurysms, cerebral infarction, intracranial hemorrhage, stroke, arteriovenous malformations"	"Sentence: These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .
Diseases:"
907	Glyburide - induced hepatitis .	O O O B O	['hepatitis']	1	3	"Sentence: Glyburide - induced hepatitis .
Diseases: hepatitis"	"Sentence: Glyburide - induced hepatitis .
Diseases:"
908	Drug - induced hepatotoxicity , although common , has been reported only infrequently with sulfonylureas .	O O O B O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: Drug - induced hepatotoxicity , although common , has been reported only infrequently with sulfonylureas .
Diseases: hepatotoxicity"	"Sentence: Drug - induced hepatotoxicity , although common , has been reported only infrequently with sulfonylureas .
Diseases:"
909	For glyburide , a second - generation sulfonylurea , only two brief reports of hepatotoxicity exist .	O O O O O O O O O O O O O O B O O	['hepatotoxicity']	1	4	"Sentence: For glyburide , a second - generation sulfonylurea , only two brief reports of hepatotoxicity exist .
Diseases: hepatotoxicity"	"Sentence: For glyburide , a second - generation sulfonylurea , only two brief reports of hepatotoxicity exist .
Diseases:"
910	Two patients with type II diabetes mellitus developed an acute hepatitis - like syndrome soon after initiation of glyburide therapy .	O O O B I I I O O B I I I I O O O O O O O	['acute hepatitis - like syndrome', 'type ii diabetes mellitus']	2	12	"Sentence: Two patients with type II diabetes mellitus developed an acute hepatitis - like syndrome soon after initiation of glyburide therapy .
Diseases: acute hepatitis - like syndrome, type ii diabetes mellitus"	"Sentence: Two patients with type II diabetes mellitus developed an acute hepatitis - like syndrome soon after initiation of glyburide therapy .
Diseases:"
911	There was no serologic evidence of viral infection , and a liver biopsy sample showed a histologic pattern consistent with drug - induced hepatitis .	O O O O O O B I O O O O O O O O O O O O B I I I O	['drug - induced hepatitis', 'viral infection']	2	7	"Sentence: There was no serologic evidence of viral infection , and a liver biopsy sample showed a histologic pattern consistent with drug - induced hepatitis .
Diseases: drug - induced hepatitis, viral infection"	"Sentence: There was no serologic evidence of viral infection , and a liver biopsy sample showed a histologic pattern consistent with drug - induced hepatitis .
Diseases:"
912	Both patients recovered quickly after stopping glyburide therapy and have remained well for a follow - up period of 1 year .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Both patients recovered quickly after stopping glyburide therapy and have remained well for a follow - up period of 1 year .
Diseases: "	"Sentence: Both patients recovered quickly after stopping glyburide therapy and have remained well for a follow - up period of 1 year .
Diseases:"
913	Glyburide can produce an acute hepatitis - like illness in some persons .	O O O O B I I I I O O O O	['acute hepatitis - like illness']	1	6	"Sentence: Glyburide can produce an acute hepatitis - like illness in some persons .
Diseases: acute hepatitis - like illness"	"Sentence: Glyburide can produce an acute hepatitis - like illness in some persons .
Diseases:"
914	Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside - induced hypotension in ventilated dogs .	O O O O O O B O O O O O O B O O O O	['hemorrhage', 'hypotension']	2	7	"Sentence: Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside - induced hypotension in ventilated dogs .
Diseases: hemorrhage, hypotension"	"Sentence: Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside - induced hypotension in ventilated dogs .
Diseases:"
915	The systolic pressure variation ( SPV ) , which is the difference between the maximal and minimal values of the systolic blood pressure ( SBP ) after one positive - pressure breath , was studied in ventilated dogs subjected to hypotension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['hypotension']	1	3	"Sentence: The systolic pressure variation ( SPV ) , which is the difference between the maximal and minimal values of the systolic blood pressure ( SBP ) after one positive - pressure breath , was studied in ventilated dogs subjected to hypotension .
Diseases: hypotension"	"Sentence: The systolic pressure variation ( SPV ) , which is the difference between the maximal and minimal values of the systolic blood pressure ( SBP ) after one positive - pressure breath , was studied in ventilated dogs subjected to hypotension .
Diseases:"
916	Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( HEM , n = 7 ) or by continuous infusion of sodium nitroprusside ( SNP , n = 7 ) .	O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O	['hemorrhage', 'hem']	2	6	"Sentence: Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( HEM , n = 7 ) or by continuous infusion of sodium nitroprusside ( SNP , n = 7 ) .
Diseases: hemorrhage, hem"	"Sentence: Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( HEM , n = 7 ) or by continuous infusion of sodium nitroprusside ( SNP , n = 7 ) .
Diseases:"
917	During HEM - induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group .	O B O O B O O O O O O O O O O O O O O O O O O O	['hypotension', 'hem']	2	5	"Sentence: During HEM - induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group .
Diseases: hypotension, hem"	"Sentence: During HEM - induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group .
Diseases:"
918	The systemic , central venous , pulmonary capillary wedge pressures , and heart rates , were similar in the two groups .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The systemic , central venous , pulmonary capillary wedge pressures , and heart rates , were similar in the two groups .
Diseases: "	"Sentence: The systemic , central venous , pulmonary capillary wedge pressures , and heart rates , were similar in the two groups .
Diseases:"
919	Analysis of the respiratory changes in the arterial pressure waveform enabled differentiation between the two groups .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Analysis of the respiratory changes in the arterial pressure waveform enabled differentiation between the two groups .
Diseases: "	"Sentence: Analysis of the respiratory changes in the arterial pressure waveform enabled differentiation between the two groups .
Diseases:"
920	The SPV during hypotension was 15 . 7 + / -	O O O B O O O O O O O	['hypotension']	1	3	"Sentence: The SPV during hypotension was 15 . 7 + / -
Diseases: hypotension"	"Sentence: The SPV during hypotension was 15 . 7 + / -
Diseases:"
921	6 . 7 mm	O O O O	[]	0	0	"Sentence: 6 . 7 mm
Diseases: "	"Sentence: 6 . 7 mm
Diseases:"
922	Hg in the HEM group , compared with 9 . 1 + / - 2 . 0 mm	O O O B O O O O O O O O O O O O O O	['hem']	1	1	"Sentence: Hg in the HEM group , compared with 9 . 1 + / - 2 . 0 mm
Diseases: hem"	"Sentence: Hg in the HEM group , compared with 9 . 1 + / - 2 . 0 mm
Diseases:"
923	Hg in the SNP group ( P less than 0 . 02 ) .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hg in the SNP group ( P less than 0 . 02 ) .
Diseases: "	"Sentence: Hg in the SNP group ( P less than 0 . 02 ) .
Diseases:"
924	The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20 . 3 + / - 8 . 4 and 10 . 1 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20 . 3 + / - 8 . 4 and 10 . 1 + / -
Diseases: "	"Sentence: The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20 . 3 + / - 8 . 4 and 10 . 1 + / -
Diseases:"
925	3 . 8 mm	O O O O	[]	0	0	"Sentence: 3 . 8 mm
Diseases: "	"Sentence: 3 . 8 mm
Diseases:"
926	Hg in the HEM and SNP groups , respectively , during hypotension ( P less than 0 . 02 ) .	O O O B O O O O O O O B O O O O O O O O O	['hypotension', 'hem']	2	5	"Sentence: Hg in the HEM and SNP groups , respectively , during hypotension ( P less than 0 . 02 ) .
Diseases: hypotension, hem"	"Sentence: Hg in the HEM and SNP groups , respectively , during hypotension ( P less than 0 . 02 ) .
Diseases:"
927	It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload .	O O O O O O O O O O O O O O O O B O O O O O O O O O	['hypotensive']	1	3	"Sentence: It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload .
Diseases: hypotensive"	"Sentence: It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload .
Diseases:"
928	They are thus more important during absolute hypovolemia than during deliberate hypotension .	O O O O O O O B O O O B O	['hypotension', 'hypovolemia']	2	8	"Sentence: They are thus more important during absolute hypovolemia than during deliberate hypotension .
Diseases: hypotension, hypovolemia"	"Sentence: They are thus more important during absolute hypovolemia than during deliberate hypotension .
Diseases:"
929	Drug - induced arterial spasm relieved by lidocaine .	O O O O B O O O O	['spasm']	1	2	"Sentence: Drug - induced arterial spasm relieved by lidocaine .
Diseases: spasm"	"Sentence: Drug - induced arterial spasm relieved by lidocaine .
Diseases:"
930	Case report .	O O O	[]	0	0	"Sentence: Case report .
Diseases: "	"Sentence: Case report .
Diseases:"
931	Following major intracranial surgery in a 35 - year - old man , sodium pentothal was intravenously infused to minimize cerebral ischaemia .	O O O O O O O O O O O O O O O O O O O O B I O	['cerebral ischaemia']	1	6	"Sentence: Following major intracranial surgery in a 35 - year - old man , sodium pentothal was intravenously infused to minimize cerebral ischaemia .
Diseases: cerebral ischaemia"	"Sentence: Following major intracranial surgery in a 35 - year - old man , sodium pentothal was intravenously infused to minimize cerebral ischaemia .
Diseases:"
932	Intense vasospasm with threatened gangrene arose in the arm used for the infusion .	O B O O B O O O O O O O O O	['gangrene', 'vasospasm']	2	6	"Sentence: Intense vasospasm with threatened gangrene arose in the arm used for the infusion .
Diseases: gangrene, vasospasm"	"Sentence: Intense vasospasm with threatened gangrene arose in the arm used for the infusion .
Diseases:"
933	Since the cranial condition precluded use of more usual methods , lidocaine was given intra - arterially , with careful cardiovascular monitoring , to counteract the vasospasm .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['vasospasm']	1	3	"Sentence: Since the cranial condition precluded use of more usual methods , lidocaine was given intra - arterially , with careful cardiovascular monitoring , to counteract the vasospasm .
Diseases: vasospasm"	"Sentence: Since the cranial condition precluded use of more usual methods , lidocaine was given intra - arterially , with careful cardiovascular monitoring , to counteract the vasospasm .
Diseases:"
934	The treatment was rapidly successful .	O O O O O O	[]	0	0	"Sentence: The treatment was rapidly successful .
Diseases: "	"Sentence: The treatment was rapidly successful .
Diseases:"
935	Cerebral blood flow and metabolism during isoflurane - induced hypotension in patients subjected to surgery for cerebral aneurysms .	O O O O O O O O O B O O O O O O B I O	['cerebral aneurysms', 'hypotension']	2	10	"Sentence: Cerebral blood flow and metabolism during isoflurane - induced hypotension in patients subjected to surgery for cerebral aneurysms .
Diseases: cerebral aneurysms, hypotension"	"Sentence: Cerebral blood flow and metabolism during isoflurane - induced hypotension in patients subjected to surgery for cerebral aneurysms .
Diseases:"
936	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane - induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .	O O O O O O O O O O O O O O O B O O O O O O O O O O B I O	['cerebral aneurysm', 'hypotension']	2	10	"Sentence: Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane - induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .
Diseases: cerebral aneurysm, hypotension"	"Sentence: Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane - induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .
Diseases:"
937	Flow and metabolism were measured 5 - 13 days after the subarachnoid haemorrhage by a modification of the classical Kety - Schmidt technique using xenon - 133 i . v .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['subarachnoid haemorrhage']	1	10	"Sentence: Flow and metabolism were measured 5 - 13 days after the subarachnoid haemorrhage by a modification of the classical Kety - Schmidt technique using xenon - 133 i . v .
Diseases: subarachnoid haemorrhage"	"Sentence: Flow and metabolism were measured 5 - 13 days after the subarachnoid haemorrhage by a modification of the classical Kety - Schmidt technique using xenon - 133 i . v .
Diseases:"
938	Anaesthesia was maintained with an inspired isoflurane concentration of 0 . 75 % ( plus 67 % nitrous oxide in oxygen ) , during which CBF and CMRO2 were 34 . 3 + / - 2 . 1 ml / 100 g min - 1 and 2 . 32 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Anaesthesia was maintained with an inspired isoflurane concentration of 0 . 75 % ( plus 67 % nitrous oxide in oxygen ) , during which CBF and CMRO2 were 34 . 3 + / - 2 . 1 ml / 100 g min - 1 and 2 . 32 + / -
Diseases: "	"Sentence: Anaesthesia was maintained with an inspired isoflurane concentration of 0 . 75 % ( plus 67 % nitrous oxide in oxygen ) , during which CBF and CMRO2 were 34 . 3 + / - 2 . 1 ml / 100 g min - 1 and 2 . 32 + / -
Diseases:"
939	0 . 16 ml / 100 g min - 1 at PaCO2 4 . 1 + / - 0 . 1 kPa ( mean + / - SEM ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 0 . 16 ml / 100 g min - 1 at PaCO2 4 . 1 + / - 0 . 1 kPa ( mean + / - SEM ) .
Diseases: "	"Sentence: 0 . 16 ml / 100 g min - 1 at PaCO2 4 . 1 + / - 0 . 1 kPa ( mean + / - SEM ) .
Diseases:"
940	Controlled hypotension to an average MAP of 50 - 55 mm	O B O O O O O O O O O	['hypotension']	1	3	"Sentence: Controlled hypotension to an average MAP of 50 - 55 mm
Diseases: hypotension"	"Sentence: Controlled hypotension to an average MAP of 50 - 55 mm
Diseases:"
941	Hg was induced by increasing the dose of isoflurane , and maintained at an inspired concentration of 2 . 2 + / - 0 . 2 % .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hg was induced by increasing the dose of isoflurane , and maintained at an inspired concentration of 2 . 2 + / - 0 . 2 % .
Diseases: "	"Sentence: Hg was induced by increasing the dose of isoflurane , and maintained at an inspired concentration of 2 . 2 + / - 0 . 2 % .
Diseases:"
942	This resulted in a significant decrease in CMRO2 ( to 1 . 73 + / -	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This resulted in a significant decrease in CMRO2 ( to 1 . 73 + / -
Diseases: "	"Sentence: This resulted in a significant decrease in CMRO2 ( to 1 . 73 + / -
Diseases:"
943	0 . 16 ml / 100 g min - 1 ) , while CBF was unchanged .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 0 . 16 ml / 100 g min - 1 ) , while CBF was unchanged .
Diseases: "	"Sentence: 0 . 16 ml / 100 g min - 1 ) , while CBF was unchanged .
Diseases:"
944	After the clipping of the aneurysm the isoflurane concentration was reduced to 0 . 75 % .	O O O O O B O O O O O O O O O O O	['aneurysm']	1	4	"Sentence: After the clipping of the aneurysm the isoflurane concentration was reduced to 0 . 75 % .
Diseases: aneurysm"	"Sentence: After the clipping of the aneurysm the isoflurane concentration was reduced to 0 . 75 % .
Diseases:"
945	There was a significant increase in CBF , although CMRO2 was unchanged , compared with pre - hypotensive values .	O O O O O O O O O O O O O O O O O B O O	['hypotensive']	1	3	"Sentence: There was a significant increase in CBF , although CMRO2 was unchanged , compared with pre - hypotensive values .
Diseases: hypotensive"	"Sentence: There was a significant increase in CBF , although CMRO2 was unchanged , compared with pre - hypotensive values .
Diseases:"
946	These changes might offer protection to brain tissue during periods of induced hypotension .	O O O O O O O O O O O O B O	['hypotension']	1	3	"Sentence: These changes might offer protection to brain tissue during periods of induced hypotension .
Diseases: hypotension"	"Sentence: These changes might offer protection to brain tissue during periods of induced hypotension .
Diseases:"
947	Allergic reaction to 5 - fluorouracil infusion .	B I O O O O O O	['allergic reaction']	1	3	"Sentence: Allergic reaction to 5 - fluorouracil infusion .
Diseases: allergic reaction"	"Sentence: Allergic reaction to 5 - fluorouracil infusion .
Diseases:"
948	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin - induced impaired renal function .	O B I O O B I O O O O O O O O O O O O O B I I I I O B O O O O O B I I O	['angioneurotic edema', 'cirrhosis', 'carcinoma of the oral cavity', 'allergic reaction', 'impaired renal function']	5	24	"Sentence: An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin - induced impaired renal function .
Diseases: angioneurotic edema, cirrhosis, carcinoma of the oral cavity, allergic reaction, impaired renal function"	"Sentence: An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin - induced impaired renal function .
Diseases:"
949	This reaction occurred during the sixth and seventh courses of infusional chemotherapy .	O O O O O O O O O O O O O	[]	0	0	"Sentence: This reaction occurred during the sixth and seventh courses of infusional chemotherapy .
Diseases: "	"Sentence: This reaction occurred during the sixth and seventh courses of infusional chemotherapy .
Diseases:"
950	Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction .	O O O O O O O O O O O O B I O	['allergic reaction']	1	3	"Sentence: Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction .
Diseases: allergic reaction"	"Sentence: Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction .
Diseases:"
951	Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression .
Diseases: "	"Sentence: Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression .
Diseases:"
952	Amiodarone - induced sinoatrial block .	O O O B I O	['sinoatrial block']	1	5	"Sentence: Amiodarone - induced sinoatrial block .
Diseases: sinoatrial block"	"Sentence: Amiodarone - induced sinoatrial block .
Diseases:"
953	We observed sinoatrial block due to chronic amiodarone administration in a 5 - year - old boy with primary cardiomyopathy , Wolff - Parkinson - White syndrome and supraventricular tachycardia .	O O B I O O O O O O O O O O O O O O B I O B I I I I I O B I O	['sinoatrial block', 'primary cardiomyopathy', 'wolff - parkinson - white syndrome', 'supraventricular tachycardia']	4	29	"Sentence: We observed sinoatrial block due to chronic amiodarone administration in a 5 - year - old boy with primary cardiomyopathy , Wolff - Parkinson - White syndrome and supraventricular tachycardia .
Diseases: sinoatrial block, primary cardiomyopathy, wolff - parkinson - white syndrome, supraventricular tachycardia"	"Sentence: We observed sinoatrial block due to chronic amiodarone administration in a 5 - year - old boy with primary cardiomyopathy , Wolff - Parkinson - White syndrome and supraventricular tachycardia .
Diseases:"
954	Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia .	O O O O O O O O O O O O B I O O O O O B I O	['sinoatrial block', 'sinus bradycardia']	2	12	"Sentence: Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia .
Diseases: sinoatrial block, sinus bradycardia"	"Sentence: Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia .
Diseases:"
955	Possible teratogenicity of sulphasalazine .	O O O O O	[]	0	0	"Sentence: Possible teratogenicity of sulphasalazine .
Diseases: "	"Sentence: Possible teratogenicity of sulphasalazine .
Diseases:"
956	Three infants , born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy , were found to have major congenital anomalies .	O O O O O O O O B I I O O O O O O O O O O O O O B I O	['congenital anomalies', 'inflammatory bowel disease']	2	8	"Sentence: Three infants , born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy , were found to have major congenital anomalies .
Diseases: congenital anomalies, inflammatory bowel disease"	"Sentence: Three infants , born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy , were found to have major congenital anomalies .
Diseases:"
957	In the singleton pregnancy , the mother had ulcerative colitis , and the infant , a male , had coarctation of the aorta and a ventricular septal defect .	O O O O O O O O B I O O O O O O O O O B I I I O O B I I O	['ulcerative colitis', 'ventricular septal defect', 'coarctation of the aorta']	3	22	"Sentence: In the singleton pregnancy , the mother had ulcerative colitis , and the infant , a male , had coarctation of the aorta and a ventricular septal defect .
Diseases: ulcerative colitis, ventricular septal defect, coarctation of the aorta"	"Sentence: In the singleton pregnancy , the mother had ulcerative colitis , and the infant , a male , had coarctation of the aorta and a ventricular septal defect .
Diseases:"
958	In the twin pregnancy , the mother had Crohn 's disease .	O O O O O O O O B I I O	"[""crohn 's disease""]"	1	5	"Sentence: In the twin pregnancy , the mother had Crohn 's disease .
Diseases: crohn 's disease"	"Sentence: In the twin pregnancy , the mother had Crohn 's disease .
Diseases:"
959	The first twin , a female , had a left Potter - type IIa polycystic kidney and a rudimentary left uterine cornu .	O O O O O O O O O O B I I I I I O O B I I I O	['potter - type iia polycystic kidney', 'rudimentary left uterine cornu']	2	17	"Sentence: The first twin , a female , had a left Potter - type IIa polycystic kidney and a rudimentary left uterine cornu .
Diseases: potter - type iia polycystic kidney, rudimentary left uterine cornu"	"Sentence: The first twin , a female , had a left Potter - type IIa polycystic kidney and a rudimentary left uterine cornu .
Diseases:"
960	The second twin , a male , had some features of Potter 's facies , hypoplastic lungs , absent kidneys and ureters , and talipes equinovarus .	O O O O O O O O O O O B I I O B I O B I I I O O B I O	"[""potter 's facies"", 'hypoplastic lungs', 'talipes equinovarus', 'absent kidneys and ureters']"	4	25	"Sentence: The second twin , a male , had some features of Potter 's facies , hypoplastic lungs , absent kidneys and ureters , and talipes equinovarus .
Diseases: potter 's facies, hypoplastic lungs, talipes equinovarus, absent kidneys and ureters"	"Sentence: The second twin , a male , had some features of Potter 's facies , hypoplastic lungs , absent kidneys and ureters , and talipes equinovarus .
Diseases:"
961	Despite reports to the contrary , it is suggested that sulphasalazine may be teratogenic .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Despite reports to the contrary , it is suggested that sulphasalazine may be teratogenic .
Diseases: "	"Sentence: Despite reports to the contrary , it is suggested that sulphasalazine may be teratogenic .
Diseases:"
962	Veno - occlusive liver disease after dacarbazine therapy ( DTIC ) for melanoma .	B I I I I O O O O O O O B O	['veno - occlusive liver disease', 'melanoma']	2	11	"Sentence: Veno - occlusive liver disease after dacarbazine therapy ( DTIC ) for melanoma .
Diseases: veno - occlusive liver disease, melanoma"	"Sentence: Veno - occlusive liver disease after dacarbazine therapy ( DTIC ) for melanoma .
Diseases:"
963	A case of veno - occlusive disease of the liver with fatal outcome after dacarbazine ( DTIC ) therapy for melanoma is reported .	O O O B I I I I I I O O O O O O O O O O B O O O	['melanoma', 'veno - occlusive disease of the liver']	2	14	"Sentence: A case of veno - occlusive disease of the liver with fatal outcome after dacarbazine ( DTIC ) therapy for melanoma is reported .
Diseases: melanoma, veno - occlusive disease of the liver"	"Sentence: A case of veno - occlusive disease of the liver with fatal outcome after dacarbazine ( DTIC ) therapy for melanoma is reported .
Diseases:"
964	There was a fulminant clinical course from start of symptoms until death .	O O O O O O O O O O O B O	['death']	1	1	"Sentence: There was a fulminant clinical course from start of symptoms until death .
Diseases: death"	"Sentence: There was a fulminant clinical course from start of symptoms until death .
Diseases:"
965	At autopsy the liver was enlarged and firm with signs of venous congestion .	O O O O O O O O O O O B I O	['venous congestion']	1	3	"Sentence: At autopsy the liver was enlarged and firm with signs of venous congestion .
Diseases: venous congestion"	"Sentence: At autopsy the liver was enlarged and firm with signs of venous congestion .
Diseases:"
966	Small - and medium - sized hepatic veins were blocked by thrombosis .	O O O O O O O O O O O B O	['thrombosis']	1	4	"Sentence: Small - and medium - sized hepatic veins were blocked by thrombosis .
Diseases: thrombosis"	"Sentence: Small - and medium - sized hepatic veins were blocked by thrombosis .
Diseases:"
967	Eosinophilic infiltrations were found around the vessels .	O O O O O O O O	[]	0	0	"Sentence: Eosinophilic infiltrations were found around the vessels .
Diseases: "	"Sentence: Eosinophilic infiltrations were found around the vessels .
Diseases:"
968	Published cases from the literature are reviewed and pertinent features discussed .	O O O O O O O O O O O O	[]	0	0	"Sentence: Published cases from the literature are reviewed and pertinent features discussed .
Diseases: "	"Sentence: Published cases from the literature are reviewed and pertinent features discussed .
Diseases:"
969	A case of tardive dyskinesia caused by metoclopramide .	O O O B I O O O O	['tardive dyskinesia']	1	7	"Sentence: A case of tardive dyskinesia caused by metoclopramide .
Diseases: tardive dyskinesia"	"Sentence: A case of tardive dyskinesia caused by metoclopramide .
Diseases:"
970	Abnormal involuntary movements appeared in the mouth , tongue , neck and abdomen of a 64 - year - old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days .	B I I O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O	['gastrointestinal disorder', 'abnormal involuntary movements']	2	7	"Sentence: Abnormal involuntary movements appeared in the mouth , tongue , neck and abdomen of a 64 - year - old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days .
Diseases: gastrointestinal disorder, abnormal involuntary movements"	"Sentence: Abnormal involuntary movements appeared in the mouth , tongue , neck and abdomen of a 64 - year - old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days .
Diseases:"
971	The symptoms exacerbated to a maximum in a month .	O O O O O O O O O O	[]	0	0	"Sentence: The symptoms exacerbated to a maximum in a month .
Diseases: "	"Sentence: The symptoms exacerbated to a maximum in a month .
Diseases:"
972	When the metoclopramide administration was discontinued , the abnormal movements gradually improved to a considerable extent .	O O O O O O O O B I O O O O O O O	['abnormal movements']	1	3	"Sentence: When the metoclopramide administration was discontinued , the abnormal movements gradually improved to a considerable extent .
Diseases: abnormal movements"	"Sentence: When the metoclopramide administration was discontinued , the abnormal movements gradually improved to a considerable extent .
Diseases:"
973	Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug .	O O O O O O O B I O O O O O O O O O O	['tardive dyskinesia']	1	7	"Sentence: Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug .
Diseases: tardive dyskinesia"	"Sentence: Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug .
Diseases:"
974	Further observations on the electrophysiologic effects of oral amiodarone therapy .	O O O O O O O O O O O	[]	0	0	"Sentence: Further observations on the electrophysiologic effects of oral amiodarone therapy .
Diseases: "	"Sentence: Further observations on the electrophysiologic effects of oral amiodarone therapy .
Diseases:"
975	A case is presented of a reversible intra - Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities .	O O O O O O O B I I I O O O O O B I O O O O O B I I O	['intra - hisian block', 'atrial tachycardia', 'intraventricular conduction abnormalities']	3	20	"Sentence: A case is presented of a reversible intra - Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities .
Diseases: intra - hisian block, atrial tachycardia, intraventricular conduction abnormalities"	"Sentence: A case is presented of a reversible intra - Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities .
Diseases:"
976	His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals ( 40 and 100 msec , respectively ) .	O O O O O B I O O O O O O O O O O O O O O O O O O O O	['atrial tachycardia']	1	6	"Sentence: His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals ( 40 and 100 msec , respectively ) .
Diseases: atrial tachycardia"	"Sentence: His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals ( 40 and 100 msec , respectively ) .
Diseases:"
977	Thirty days after amiodarone discontinuation , His bundle electrograms showed atrial flutter without intra - Hisian or infra - Hisian delay .	O O O O O O O O O O B I O O O O O O O O O O	['atrial flutter']	1	4	"Sentence: Thirty days after amiodarone discontinuation , His bundle electrograms showed atrial flutter without intra - Hisian or infra - Hisian delay .
Diseases: atrial flutter"	"Sentence: Thirty days after amiodarone discontinuation , His bundle electrograms showed atrial flutter without intra - Hisian or infra - Hisian delay .
Diseases:"
978	Amiodarone should be used with caution during long - term oral therapy in patients with or without clear intraventricular conduction defects .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Amiodarone should be used with caution during long - term oral therapy in patients with or without clear intraventricular conduction defects .
Diseases: "	"Sentence: Amiodarone should be used with caution during long - term oral therapy in patients with or without clear intraventricular conduction defects .
Diseases:"
979	Busulfan - induced hemorrhagic cystitis .	O O O B I O	['hemorrhagic cystitis']	1	7	"Sentence: Busulfan - induced hemorrhagic cystitis .
Diseases: hemorrhagic cystitis"	"Sentence: Busulfan - induced hemorrhagic cystitis .
Diseases:"
980	A case of a busulfan - induced hemorrhage cystitis is reported .	O O O O O O O B I O O O	['hemorrhage cystitis']	1	7	"Sentence: A case of a busulfan - induced hemorrhage cystitis is reported .
Diseases: hemorrhage cystitis"	"Sentence: A case of a busulfan - induced hemorrhage cystitis is reported .
Diseases:"
981	Spontaneous resolution occurred following cessation of the drug .	O O O O O O O O O	[]	0	0	"Sentence: Spontaneous resolution occurred following cessation of the drug .
Diseases: "	"Sentence: Spontaneous resolution occurred following cessation of the drug .
Diseases:"
982	The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide - induced cystitis is discussed and the world literature reviewed .	O O O O O O O O B O O O O O O O B O O O O O O O O	['cystitis']	1	3	"Sentence: The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide - induced cystitis is discussed and the world literature reviewed .
Diseases: cystitis"	"Sentence: The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide - induced cystitis is discussed and the world literature reviewed .
Diseases:"
983	In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites , periodic urinary cytology is suggested in patients on long - term therapy .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['carcinoma']	1	4	"Sentence: In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites , periodic urinary cytology is suggested in patients on long - term therapy .
Diseases: carcinoma"	"Sentence: In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites , periodic urinary cytology is suggested in patients on long - term therapy .
Diseases:"
984	Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats .	O B O O O O O O O O O	['hypertensive']	1	3	"Sentence: Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats .
Diseases: hypertensive"	"Sentence: Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats .
Diseases:"
985	The role of the renin - - angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ( SNP ) - induced hypotension was evaluated .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	['hypotension']	1	3	"Sentence: The role of the renin - - angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ( SNP ) - induced hypotension was evaluated .
Diseases: hypotension"	"Sentence: The role of the renin - - angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ( SNP ) - induced hypotension was evaluated .
Diseases:"
986	Control rats received halothane anesthesia ( 1 MAC ) for one hour , followed by SNP infusion , 40 microgram / kg / min , for 30 min , followed by a 30 - min recovery period .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Control rats received halothane anesthesia ( 1 MAC ) for one hour , followed by SNP infusion , 40 microgram / kg / min , for 30 min , followed by a 30 - min recovery period .
Diseases: "	"Sentence: Control rats received halothane anesthesia ( 1 MAC ) for one hour , followed by SNP infusion , 40 microgram / kg / min , for 30 min , followed by a 30 - min recovery period .
Diseases:"
987	A second group of rats was treated identically and , in addition , received an infusion of saralasin ( a competitive inhibitor of angiotensin II ) throughout the experimental period .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A second group of rats was treated identically and , in addition , received an infusion of saralasin ( a competitive inhibitor of angiotensin II ) throughout the experimental period .
Diseases: "	"Sentence: A second group of rats was treated identically and , in addition , received an infusion of saralasin ( a competitive inhibitor of angiotensin II ) throughout the experimental period .
Diseases:"
988	In each group , SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr , respectively , to 48 torr .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In each group , SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr , respectively , to 48 torr .
Diseases: "	"Sentence: In each group , SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr , respectively , to 48 torr .
Diseases:"
989	During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr , whereas the saralasin - treated animals showed no change .	O O O O O O O O O O B I I I O O O O O O O O O O O O O O	['increase in blood pressure']	1	5	"Sentence: During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr , whereas the saralasin - treated animals showed no change .
Diseases: increase in blood pressure"	"Sentence: During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr , whereas the saralasin - treated animals showed no change .
Diseases:"
990	Following discontinuation of SNP , blood pressure in the control animals rebounded to 94 torr , as compared with 78 torr in the saralasin - treated rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following discontinuation of SNP , blood pressure in the control animals rebounded to 94 torr , as compared with 78 torr in the saralasin - treated rats .
Diseases: "	"Sentence: Following discontinuation of SNP , blood pressure in the control animals rebounded to 94 torr , as compared with 78 torr in the saralasin - treated rats .
Diseases:"
991	This study indicates that with stable halothane anesthesia , the partial recovery of blood pressure during SNP infusion and the post - SNP rebound of blood pressure can be completely blocked by saralasin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This study indicates that with stable halothane anesthesia , the partial recovery of blood pressure during SNP infusion and the post - SNP rebound of blood pressure can be completely blocked by saralasin .
Diseases: "	"Sentence: This study indicates that with stable halothane anesthesia , the partial recovery of blood pressure during SNP infusion and the post - SNP rebound of blood pressure can be completely blocked by saralasin .
Diseases:"
992	This demonstrates the participation of the renin - - angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP .	O O O O O O O O O O O O O O O B O O O O O O	['hypotensive']	1	3	"Sentence: This demonstrates the participation of the renin - - angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP .
Diseases: hypotensive"	"Sentence: This demonstrates the participation of the renin - - angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP .
Diseases:"
993	Toxic hepatitis induced by antithyroid drugs : four cases including one with cross - reactivity between carbimazole and benzylthiouracil .	B I O O O O O O O O O O O O O O O O O O	['toxic hepatitis']	1	3	"Sentence: Toxic hepatitis induced by antithyroid drugs : four cases including one with cross - reactivity between carbimazole and benzylthiouracil .
Diseases: toxic hepatitis"	"Sentence: Toxic hepatitis induced by antithyroid drugs : four cases including one with cross - reactivity between carbimazole and benzylthiouracil .
Diseases:"
994	This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs .	O O O O O O O O O B I I O O O O O	['hepatic adverse effects']	1	5	"Sentence: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs .
Diseases: hepatic adverse effects"	"Sentence: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs .
Diseases:"
995	METHODS :	O O	[]	0	0	"Sentence: METHODS :
Diseases: "	"Sentence: METHODS :
Diseases:"
996	Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department ( in - or out - patients ) from 1986 to 1992 .	O O O O O O O O O B O O O O O O O O O O O O O O O O O	['hyperthyroidism']	1	4	"Sentence: Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department ( in - or out - patients ) from 1986 to 1992 .
Diseases: hyperthyroidism"	"Sentence: Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department ( in - or out - patients ) from 1986 to 1992 .
Diseases:"
997	Four patients ( 1 . 7 % ) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent .	O O O O O O O O O O O B I O O O O O O O O O O O O	['toxic hepatitis']	1	3	"Sentence: Four patients ( 1 . 7 % ) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent .
Diseases: toxic hepatitis"	"Sentence: Four patients ( 1 . 7 % ) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent .
Diseases:"
998	Two patients had a cholestatic hepatitis induced by carbimazole ( N omercazole ) .	O O O O B I O O O O O O O O	['cholestatic hepatitis']	1	5	"Sentence: Two patients had a cholestatic hepatitis induced by carbimazole ( N omercazole ) .
Diseases: cholestatic hepatitis"	"Sentence: Two patients had a cholestatic hepatitis induced by carbimazole ( N omercazole ) .
Diseases:"
999	Two others had a mixed ( cholestatic and cytolytic ) hepatitis following carbimazole .	O O O O O O B O O O B O O O	['hepatitis', 'cholestatic']	2	8	"Sentence: Two others had a mixed ( cholestatic and cytolytic ) hepatitis following carbimazole .
Diseases: hepatitis, cholestatic"	"Sentence: Two others had a mixed ( cholestatic and cytolytic ) hepatitis following carbimazole .
Diseases:"
1000	One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil ( Basd ne ) had replaced carbimazole .	O O O O O O O O O O B O O O O O O O O O O O O	['hepatitis']	1	3	"Sentence: One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil ( Basd ne ) had replaced carbimazole .
Diseases: hepatitis"	"Sentence: One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil ( Basd ne ) had replaced carbimazole .
Diseases:"
1001	Biological features of hepatitis disappeared in all cases after cessation of the incriminated drug , while biliary , viral and immunological searches were negative .	O O O B O O O O O O O O O O O O O O O O O O O O O	['hepatitis']	1	3	"Sentence: Biological features of hepatitis disappeared in all cases after cessation of the incriminated drug , while biliary , viral and immunological searches were negative .
Diseases: hepatitis"	"Sentence: Biological features of hepatitis disappeared in all cases after cessation of the incriminated drug , while biliary , viral and immunological searches were negative .
Diseases:"
1002	Only 2 patients of our retrospective study experienced a mild or severe neutropenia .	O O O O O O O O O O O O B O	['neutropenia']	1	5	"Sentence: Only 2 patients of our retrospective study experienced a mild or severe neutropenia .
Diseases: neutropenia"	"Sentence: Only 2 patients of our retrospective study experienced a mild or severe neutropenia .
Diseases:"
1003	Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants , as for haematological disturbances , a pre - therapeutic determination and a careful follow - up of relevant biological markers .	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['toxic hepatitis']	1	3	"Sentence: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants , as for haematological disturbances , a pre - therapeutic determination and a careful follow - up of relevant biological markers .
Diseases: toxic hepatitis"	"Sentence: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants , as for haematological disturbances , a pre - therapeutic determination and a careful follow - up of relevant biological markers .
Diseases:"
1004	Moreover , hepatotoxicity may not be restricted to one class of antithyroid agents .	O O B O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: Moreover , hepatotoxicity may not be restricted to one class of antithyroid agents .
Diseases: hepatotoxicity"	"Sentence: Moreover , hepatotoxicity may not be restricted to one class of antithyroid agents .
Diseases:"
1005	Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine .	O O O O O O O O O O O O O O B O O O	['toxicity']	1	2	"Sentence: Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine .
Diseases: toxicity"	"Sentence: Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine .
Diseases:"
1006	A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine ( ZDV ) - induced bone marrow suppression .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	['bone marrow suppression']	1	3	"Sentence: A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine ( ZDV ) - induced bone marrow suppression .
Diseases: bone marrow suppression"	"Sentence: A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine ( ZDV ) - induced bone marrow suppression .
Diseases:"
1007	Seventy - five human immunodeficiency virus ( HIV ) - infected patients with CD4 + cell counts < 500 / mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid (	O O O B I I I I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['human immunodeficiency virus ( hiv ) - infected']	1	12	"Sentence: Seventy - five human immunodeficiency virus ( HIV ) - infected patients with CD4 + cell counts < 500 / mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid (
Diseases: human immunodeficiency virus ( hiv ) - infected"	"Sentence: Seventy - five human immunodeficiency virus ( HIV ) - infected patients with CD4 + cell counts < 500 / mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid (
Diseases:"
1008	15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .
Diseases: "	"Sentence: 15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .
Diseases:"
1009	Finally , 15 patients were excluded from the study ( noncompliance 14 , death 1 ) ; thus , 60 patients ( 31 in group I and 29 in group II ) were eligible for analysis .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['death']	1	1	"Sentence: Finally , 15 patients were excluded from the study ( noncompliance 14 , death 1 ) ; thus , 60 patients ( 31 in group I and 29 in group II ) were eligible for analysis .
Diseases: death"	"Sentence: Finally , 15 patients were excluded from the study ( noncompliance 14 , death 1 ) ; thus , 60 patients ( 31 in group I and 29 in group II ) were eligible for analysis .
Diseases:"
1010	No significant differences between groups were found at enrollment .	O O O O O O O O O O	[]	0	0	"Sentence: No significant differences between groups were found at enrollment .
Diseases: "	"Sentence: No significant differences between groups were found at enrollment .
Diseases:"
1011	During the study , vitamin B12 and folate levels were significantly higher in group II patients ; however , no differences in hemoglobin , hematocrit , mean corpuscular volume , and white - cell , neutrophil and platelet counts were observed between groups at 3 , 6 , 9 and 12 months .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During the study , vitamin B12 and folate levels were significantly higher in group II patients ; however , no differences in hemoglobin , hematocrit , mean corpuscular volume , and white - cell , neutrophil and platelet counts were observed between groups at 3 , 6 , 9 and 12 months .
Diseases: "	"Sentence: During the study , vitamin B12 and folate levels were significantly higher in group II patients ; however , no differences in hemoglobin , hematocrit , mean corpuscular volume , and white - cell , neutrophil and platelet counts were observed between groups at 3 , 6 , 9 and 12 months .
Diseases:"
1012	Severe hematologic toxicity ( neutrophil count < 1000 / mm3 and / or hemoglobin < 8 g / dl ) occurred in 4 patients assigned to group I and 7 assigned to group II .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Severe hematologic toxicity ( neutrophil count < 1000 / mm3 and / or hemoglobin < 8 g / dl ) occurred in 4 patients assigned to group I and 7 assigned to group II .
Diseases: toxicity"	"Sentence: Severe hematologic toxicity ( neutrophil count < 1000 / mm3 and / or hemoglobin < 8 g / dl ) occurred in 4 patients assigned to group I and 7 assigned to group II .
Diseases:"
1013	There was no correlation between vitamin B12 or folate levels and development of myelosuppression .	O O O O O O O O O O O O O B O	['myelosuppression']	1	5	"Sentence: There was no correlation between vitamin B12 or folate levels and development of myelosuppression .
Diseases: myelosuppression"	"Sentence: There was no correlation between vitamin B12 or folate levels and development of myelosuppression .
Diseases:"
1014	Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV - induced myelotoxicity in the overall treated population , although a beneficial effect in certain subgroups of patients can not be excluded .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['myelotoxicity']	1	4	"Sentence: Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV - induced myelotoxicity in the overall treated population , although a beneficial effect in certain subgroups of patients can not be excluded .
Diseases: myelotoxicity"	"Sentence: Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV - induced myelotoxicity in the overall treated population , although a beneficial effect in certain subgroups of patients can not be excluded .
Diseases:"
1015	Acute confusion induced by a high - dose infusion of 5 - fluorouracil and folinic acid .	O B O O O O O O O O O O O O O O O	['confusion']	1	2	"Sentence: Acute confusion induced by a high - dose infusion of 5 - fluorouracil and folinic acid .
Diseases: confusion"	"Sentence: Acute confusion induced by a high - dose infusion of 5 - fluorouracil and folinic acid .
Diseases:"
1016	A 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high - dose 5 - fluorouracil ( 2 , 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['gastric adenocarcinoma']	1	9	"Sentence: A 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high - dose 5 - fluorouracil ( 2 , 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma .
Diseases: gastric adenocarcinoma"	"Sentence: A 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high - dose 5 - fluorouracil ( 2 , 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma .
Diseases:"
1017	He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and folinic acid infusion .	O O O O O O O B O B O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['disorientation', 'confusion', 'irritability', 'coma']	4	10	"Sentence: He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and folinic acid infusion .
Diseases: disorientation, confusion, irritability, coma"	"Sentence: He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and folinic acid infusion .
Diseases:"
1018	This complication reappeared on day 25 during the second dose of 5 - fluorouracil and folinic acid , which were then the only drugs given .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This complication reappeared on day 25 during the second dose of 5 - fluorouracil and folinic acid , which were then the only drugs given .
Diseases: "	"Sentence: This complication reappeared on day 25 during the second dose of 5 - fluorouracil and folinic acid , which were then the only drugs given .
Diseases:"
1019	Because folinic acid was unlikely to be associated with this condition , neurotoxicity due to high - dose 5 - fluorouracil was highly suspected .	O O O O O O O O O O O O B O O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: Because folinic acid was unlikely to be associated with this condition , neurotoxicity due to high - dose 5 - fluorouracil was highly suspected .
Diseases: neurotoxicity"	"Sentence: Because folinic acid was unlikely to be associated with this condition , neurotoxicity due to high - dose 5 - fluorouracil was highly suspected .
Diseases:"
1020	The pathogenesis of 5 - fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: The pathogenesis of 5 - fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .
Diseases: neurotoxicity"	"Sentence: The pathogenesis of 5 - fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .
Diseases:"
1021	High - dose 5 - fluorouracil / folinic acid infusion therapy has recently become a popular regimen for various cancers .	O O O O O O O O O O O O O O O O O O O B O	['cancers']	1	2	"Sentence: High - dose 5 - fluorouracil / folinic acid infusion therapy has recently become a popular regimen for various cancers .
Diseases: cancers"	"Sentence: High - dose 5 - fluorouracil / folinic acid infusion therapy has recently become a popular regimen for various cancers .
Diseases:"
1022	It is necessary that both oncologists and neurologists be fully aware of this unusual complication .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is necessary that both oncologists and neurologists be fully aware of this unusual complication .
Diseases: "	"Sentence: It is necessary that both oncologists and neurologists be fully aware of this unusual complication .
Diseases:"
1023	Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics .
Diseases: "	"Sentence: Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics .
Diseases:"
1024	A case report .	O O O O	[]	0	0	"Sentence: A case report .
Diseases: "	"Sentence: A case report .
Diseases:"
1025	Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .	O O O O O O O O O O O O O O O O O B O B I O O O O O O O O O	['organic psychotic', 'schizophrenic']	2	5	"Sentence: Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .
Diseases: organic psychotic, schizophrenic"	"Sentence: Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .
Diseases:"
1026	This change resulted within 2 - 4 weeks in the 50 - 200 % increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['extrapyramidal symptoms']	1	6	"Sentence: This change resulted within 2 - 4 weeks in the 50 - 200 % increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms .
Diseases: extrapyramidal symptoms"	"Sentence: This change resulted within 2 - 4 weeks in the 50 - 200 % increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms .
Diseases:"
1027	None of the patients showed any clinical deteriotation during the following 3 - 6 months .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: None of the patients showed any clinical deteriotation during the following 3 - 6 months .
Diseases: "	"Sentence: None of the patients showed any clinical deteriotation during the following 3 - 6 months .
Diseases:"
1028	The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs .
Diseases: "	"Sentence: The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs .
Diseases:"
1029	Erythema multiforme and hypersensitivity myocarditis caused by ampicillin .	B I O B I O O O O	['erythema multiforme', 'hypersensitivity myocarditis']	2	12	"Sentence: Erythema multiforme and hypersensitivity myocarditis caused by ampicillin .
Diseases: erythema multiforme, hypersensitivity myocarditis"	"Sentence: Erythema multiforme and hypersensitivity myocarditis caused by ampicillin .
Diseases:"
1030	To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin .	O O O O O B I O B I O O O O	['erythema multiforme', 'hypersensitivity myocarditis']	2	12	"Sentence: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin .
Diseases: erythema multiforme, hypersensitivity myocarditis"	"Sentence: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin .
Diseases:"
1031	CASE SUMMARY :	O O O	[]	0	0	"Sentence: CASE SUMMARY :
Diseases: "	"Sentence: CASE SUMMARY :
Diseases:"
1032	A 13 - year - old boy was treated with ampicillin and gentamicin because of suspected septicemia .	O O O O O O O O O O O O O O O O B O	['septicemia']	1	3	"Sentence: A 13 - year - old boy was treated with ampicillin and gentamicin because of suspected septicemia .
Diseases: septicemia"	"Sentence: A 13 - year - old boy was treated with ampicillin and gentamicin because of suspected septicemia .
Diseases:"
1033	Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred .	O O O O B I O B I I O O B O O	['congestive heart failure', 'erythema multiforme', 'myocarditis']	3	15	"Sentence: Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred .
Diseases: congestive heart failure, erythema multiforme, myocarditis"	"Sentence: Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred .
Diseases:"
1034	The patient was treated with methylprednisolone and gradually improved .	O O O O O O O O O O	[]	0	0	"Sentence: The patient was treated with methylprednisolone and gradually improved .
Diseases: "	"Sentence: The patient was treated with methylprednisolone and gradually improved .
Diseases:"
1035	Macrophage - migration inhibition ( MIF ) test with ampicillin was positive .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Macrophage - migration inhibition ( MIF ) test with ampicillin was positive .
Diseases: "	"Sentence: Macrophage - migration inhibition ( MIF ) test with ampicillin was positive .
Diseases:"
1036	After most infections causing erythema multiforme and myocarditis were ruled out , a drug - induced allergic reaction was suspected .	O O B O B I O B O O O O O B I I I I O O O	['erythema multiforme', 'infections', 'drug - induced allergic reaction', 'myocarditis']	4	18	"Sentence: After most infections causing erythema multiforme and myocarditis were ruled out , a drug - induced allergic reaction was suspected .
Diseases: erythema multiforme, infections, drug - induced allergic reaction, myocarditis"	"Sentence: After most infections causing erythema multiforme and myocarditis were ruled out , a drug - induced allergic reaction was suspected .
Diseases:"
1037	Positive MIF test for ampicillin showed sensitization of the patient 's lymphocytes to ampicillin .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Positive MIF test for ampicillin showed sensitization of the patient 's lymphocytes to ampicillin .
Diseases: "	"Sentence: Positive MIF test for ampicillin showed sensitization of the patient 's lymphocytes to ampicillin .
Diseases:"
1038	Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins .	B I O O O O O O O B O O O	['allergy', 'hypersensitivity myocarditis']	2	8	"Sentence: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins .
Diseases: allergy, hypersensitivity myocarditis"	"Sentence: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins .
Diseases:"
1039	Immediate allergic reactions to amoxicillin .	O B I O O O	['allergic reactions']	1	3	"Sentence: Immediate allergic reactions to amoxicillin .
Diseases: allergic reactions"	"Sentence: Immediate allergic reactions to amoxicillin .
Diseases:"
1040	A large group of patients with suspected allergic reactions to beta - lactam antibiotics was evaluated .	O O O O O O O B I O O O O O O O O	['allergic reactions']	1	3	"Sentence: A large group of patients with suspected allergic reactions to beta - lactam antibiotics was evaluated .
Diseases: allergic reactions"	"Sentence: A large group of patients with suspected allergic reactions to beta - lactam antibiotics was evaluated .
Diseases:"
1041	A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta - lactam antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross - reacting with other penicillin derivatives .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O	['allergic']	1	2	"Sentence: A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta - lactam antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross - reacting with other penicillin derivatives .
Diseases: allergic"	"Sentence: A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta - lactam antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross - reacting with other penicillin derivatives .
Diseases:"
1042	Skin tests were performed with benzylpenicilloyl - poly - L - lysine ( BPO - PLL ) , benzylpenicilloate , benzylpenicillin ( PG ) , ampicillin ( AMP ) , and AX .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Skin tests were performed with benzylpenicilloyl - poly - L - lysine ( BPO - PLL ) , benzylpenicilloate , benzylpenicillin ( PG ) , ampicillin ( AMP ) , and AX .
Diseases: "	"Sentence: Skin tests were performed with benzylpenicilloyl - poly - L - lysine ( BPO - PLL ) , benzylpenicilloate , benzylpenicillin ( PG ) , ampicillin ( AMP ) , and AX .
Diseases:"
1043	RAST for BPO - PLL and AX - PLL was done .	O O O O O O O O O O O O	[]	0	0	"Sentence: RAST for BPO - PLL and AX - PLL was done .
Diseases: "	"Sentence: RAST for BPO - PLL and AX - PLL was done .
Diseases:"
1044	When both skin test and RAST for BPO were negative , single - blind , placebo - controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When both skin test and RAST for BPO were negative , single - blind , placebo - controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX .
Diseases: "	"Sentence: When both skin test and RAST for BPO were negative , single - blind , placebo - controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX .
Diseases:"
1045	A total of 177 patients were diagnosed as allergic to beta - lactam antibiotics .	O O O O O O O O B O O O O O O	['allergic']	1	2	"Sentence: A total of 177 patients were diagnosed as allergic to beta - lactam antibiotics .
Diseases: allergic"	"Sentence: A total of 177 patients were diagnosed as allergic to beta - lactam antibiotics .
Diseases:"
1046	We selected the 54 ( 30 . 5 % ) cases of immediate AX allergy with good tolerance of PG .	O O O O O O O O O O O O O O B O O O O O O	['allergy']	1	2	"Sentence: We selected the 54 ( 30 . 5 % ) cases of immediate AX allergy with good tolerance of PG .
Diseases: allergy"	"Sentence: We selected the 54 ( 30 . 5 % ) cases of immediate AX allergy with good tolerance of PG .
Diseases:"
1047	Anaphylaxis was seen in 37 patients ( 69 % ) , the other 17 ( 31 % ) having urticaria and / or angioedema .	B O O O O O O O O O O O O O O O O O O B O O O B O	['urticaria', 'anaphylaxis', 'angioedema']	3	13	"Sentence: Anaphylaxis was seen in 37 patients ( 69 % ) , the other 17 ( 31 % ) having urticaria and / or angioedema .
Diseases: urticaria, anaphylaxis, angioedema"	"Sentence: Anaphylaxis was seen in 37 patients ( 69 % ) , the other 17 ( 31 % ) having urticaria and / or angioedema .
Diseases:"
1048	All the patients were skin test negative to BPO ; 49 of 51 ( 96 % ) were also negative to MDM , and 44 of 46 ( 96 % ) to PG .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['mdm']	1	2	"Sentence: All the patients were skin test negative to BPO ; 49 of 51 ( 96 % ) were also negative to MDM , and 44 of 46 ( 96 % ) to PG .
Diseases: mdm"	"Sentence: All the patients were skin test negative to BPO ; 49 of 51 ( 96 % ) were also negative to MDM , and 44 of 46 ( 96 % ) to PG .
Diseases:"
1049	Skin tests with AX were positive in 34 ( 63 % ) patients .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Skin tests with AX were positive in 34 ( 63 % ) patients .
Diseases: "	"Sentence: Skin tests with AX were positive in 34 ( 63 % ) patients .
Diseases:"
1050	RAST was positive for AX in 22 patients ( 41 % ) and to BPO in just 5 ( 9 % ) .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RAST was positive for AX in 22 patients ( 41 % ) and to BPO in just 5 ( 9 % ) .
Diseases: "	"Sentence: RAST was positive for AX in 22 patients ( 41 % ) and to BPO in just 5 ( 9 % ) .
Diseases:"
1051	None of the sera with negative RAST for AX were positive to BPO .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: None of the sera with negative RAST for AX were positive to BPO .
Diseases: "	"Sentence: None of the sera with negative RAST for AX were positive to BPO .
Diseases:"
1052	Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate allergic reaction to AX , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .	O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	['allergic reaction']	1	3	"Sentence: Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate allergic reaction to AX , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .
Diseases: allergic reaction"	"Sentence: Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate allergic reaction to AX , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .
Diseases:"
1053	PG was well tolerated by all 54 patients .	O O O O O O O O O	[]	0	0	"Sentence: PG was well tolerated by all 54 patients .
Diseases: "	"Sentence: PG was well tolerated by all 54 patients .
Diseases:"
1054	We describe the largest group of AX - allergic patients who have tolerated PG reported so far .	O O O O O O O O B O O O O O O O O O	['allergic']	1	2	"Sentence: We describe the largest group of AX - allergic patients who have tolerated PG reported so far .
Diseases: allergic"	"Sentence: We describe the largest group of AX - allergic patients who have tolerated PG reported so far .
Diseases:"
1055	Diagnosis of these patients can be achieved only if specific AX - related reagents are employed .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Diagnosis of these patients can be achieved only if specific AX - related reagents are employed .
Diseases: "	"Sentence: Diagnosis of these patients can be achieved only if specific AX - related reagents are employed .
Diseases:"
1056	Further studies are necessary to determine the exact extent of this problem and to improve the efficacy of diagnostic methods .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Further studies are necessary to determine the exact extent of this problem and to improve the efficacy of diagnostic methods .
Diseases: "	"Sentence: Further studies are necessary to determine the exact extent of this problem and to improve the efficacy of diagnostic methods .
Diseases:"
1057	Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids .	O B O O O O O O O O O O O	['paralysis']	1	2	"Sentence: Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids .
Diseases: paralysis"	"Sentence: Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids .
Diseases:"
1058	Neuromuscular blocking agents ( NMBAs ) are often used for patients requiring prolonged mechanical ventilation .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Neuromuscular blocking agents ( NMBAs ) are often used for patients requiring prolonged mechanical ventilation .
Diseases: "	"Sentence: Neuromuscular blocking agents ( NMBAs ) are often used for patients requiring prolonged mechanical ventilation .
Diseases:"
1059	Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid - based NMBAs such as vecuronium bromide , especially when used in conjunction with corticosteroids .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['paralysis']	1	2	"Sentence: Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid - based NMBAs such as vecuronium bromide , especially when used in conjunction with corticosteroids .
Diseases: paralysis"	"Sentence: Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid - based NMBAs such as vecuronium bromide , especially when used in conjunction with corticosteroids .
Diseases:"
1060	Atracurium besylate , a short - acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent paralysis , but only when used with corticosteroids .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['paralysis']	1	2	"Sentence: Atracurium besylate , a short - acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent paralysis , but only when used with corticosteroids .
Diseases: paralysis"	"Sentence: Atracurium besylate , a short - acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent paralysis , but only when used with corticosteroids .
Diseases:"
1061	We report a case of atracurium - related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids .	O O O O O O O O B O O O O O O O O O O O O O O O	['paralysis']	1	2	"Sentence: We report a case of atracurium - related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids .
Diseases: paralysis"	"Sentence: We report a case of atracurium - related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids .
Diseases:"
1062	Habitual use of acetaminophen as a risk factor for chronic renal failure : a comparison with phenacetin .	O O O O O O O O O B I I O O O O O O	['chronic renal failure']	1	4	"Sentence: Habitual use of acetaminophen as a risk factor for chronic renal failure : a comparison with phenacetin .
Diseases: chronic renal failure"	"Sentence: Habitual use of acetaminophen as a risk factor for chronic renal failure : a comparison with phenacetin .
Diseases:"
1063	Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end - stage renal disease ( ESRD ) , with a relative risk in the range of 4 to 19 .	O O O O O O O O O O O O O O O O O O O O O B I I O B I I I I O B O O O O O O O O O O O O O O	['esrd', 'end - stage renal disease', 'chronic renal failure']	3	12	"Sentence: Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end - stage renal disease ( ESRD ) , with a relative risk in the range of 4 to 19 .
Diseases: esrd, end - stage renal disease, chronic renal failure"	"Sentence: Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end - stage renal disease ( ESRD ) , with a relative risk in the range of 4 to 19 .
Diseases:"
1064	As a result of these and other studies , phenacetin has now been withdrawn from the market in most countries .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As a result of these and other studies , phenacetin has now been withdrawn from the market in most countries .
Diseases: "	"Sentence: As a result of these and other studies , phenacetin has now been withdrawn from the market in most countries .
Diseases:"
1065	However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD , with a relative risk in the range of 2 to 4 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O B O O O O O O O O O O O O O	['esrd', 'chronic renal failure']	2	6	"Sentence: However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD , with a relative risk in the range of 2 to 4 .
Diseases: esrd, chronic renal failure"	"Sentence: However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD , with a relative risk in the range of 2 to 4 .
Diseases:"
1066	These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD , with the risk of the latter being somewhat less than that of the former .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['esrd']	1	2	"Sentence: These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD , with the risk of the latter being somewhat less than that of the former .
Diseases: esrd"	"Sentence: These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD , with the risk of the latter being somewhat less than that of the former .
Diseases:"
1067	This apparent difference in risk may not be due to differences in nephrotoxic potential of the drugs themselves .	O O O O O O O O O O O O B O O O O O O	['nephrotoxic']	1	4	"Sentence: This apparent difference in risk may not be due to differences in nephrotoxic potential of the drugs themselves .
Diseases: nephrotoxic"	"Sentence: This apparent difference in risk may not be due to differences in nephrotoxic potential of the drugs themselves .
Diseases:"
1068	A lower relative risk would be expected for acetaminophen if the risk of both drugs in combination with other analgesics was higher than the risk of either agent alone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A lower relative risk would be expected for acetaminophen if the risk of both drugs in combination with other analgesics was higher than the risk of either agent alone .
Diseases: "	"Sentence: A lower relative risk would be expected for acetaminophen if the risk of both drugs in combination with other analgesics was higher than the risk of either agent alone .
Diseases:"
1069	Thus , acetaminophen has been used both as a single agent and in combination with other analgesics , whereas phenacetin was available only in combinations .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thus , acetaminophen has been used both as a single agent and in combination with other analgesics , whereas phenacetin was available only in combinations .
Diseases: "	"Sentence: Thus , acetaminophen has been used both as a single agent and in combination with other analgesics , whereas phenacetin was available only in combinations .
Diseases:"
1070	The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated , but can not be dismissed .	O O O O O O O O O O O O B O O O O O O O O O O O O	['esrd']	1	2	"Sentence: The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated , but can not be dismissed .
Diseases: esrd"	"Sentence: The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated , but can not be dismissed .
Diseases:"
1071	Reduction of heparan sulphate - associated anionic sites in the glomerular basement membrane of rats with streptozotocin - induced diabetic nephropathy .	O O O O O O O O O O O O O O O O O O O B I O	['diabetic nephropathy']	1	6	"Sentence: Reduction of heparan sulphate - associated anionic sites in the glomerular basement membrane of rats with streptozotocin - induced diabetic nephropathy .
Diseases: diabetic nephropathy"	"Sentence: Reduction of heparan sulphate - associated anionic sites in the glomerular basement membrane of rats with streptozotocin - induced diabetic nephropathy .
Diseases:"
1072	Heparan sulphate - associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age - adn sex - matched control rats , employing the cationic dye cuprolinic blue .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['diabetes']	1	2	"Sentence: Heparan sulphate - associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age - adn sex - matched control rats , employing the cationic dye cuprolinic blue .
Diseases: diabetes"	"Sentence: Heparan sulphate - associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age - adn sex - matched control rats , employing the cationic dye cuprolinic blue .
Diseases:"
1073	Morphometric analysis at the ultrastructural level was performed using a computerized image processor .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Morphometric analysis at the ultrastructural level was performed using a computerized image processor .
Diseases: "	"Sentence: Morphometric analysis at the ultrastructural level was performed using a computerized image processor .
Diseases:"
1074	The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan - degrading enzymes , showing that pretreatment of the sections with heparitinase abolished all staining , whereas chondroitinase ABC had no effect .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan - degrading enzymes , showing that pretreatment of the sections with heparitinase abolished all staining , whereas chondroitinase ABC had no effect .
Diseases: "	"Sentence: The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan - degrading enzymes , showing that pretreatment of the sections with heparitinase abolished all staining , whereas chondroitinase ABC had no effect .
Diseases:"
1075	The majority of anionic sites ( 74 % in diabetic and 81 % in control rats ) were found within the lamina rara externa of the glomerular basement membrane .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['diabetic']	1	2	"Sentence: The majority of anionic sites ( 74 % in diabetic and 81 % in control rats ) were found within the lamina rara externa of the glomerular basement membrane .
Diseases: diabetic"	"Sentence: The majority of anionic sites ( 74 % in diabetic and 81 % in control rats ) were found within the lamina rara externa of the glomerular basement membrane .
Diseases:"
1076	A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna , and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane ( p < 0 . 001 and p < 0 . 01 for diabetic and control rats , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['diabetic']	1	2	"Sentence: A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna , and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane ( p < 0 . 001 and p < 0 . 01 for diabetic and control rats , respectively ) .
Diseases: diabetic"	"Sentence: A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna , and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane ( p < 0 . 001 and p < 0 . 01 for diabetic and control rats , respectively ) .
Diseases:"
1077	Diabetic rats progressively developed albuminuria reaching 40 . 3 ( 32 . 2 - 62 . 0 )	B O O O B O O O O O O O O O O O O O	['albuminuria', 'diabetic']	2	5	"Sentence: Diabetic rats progressively developed albuminuria reaching 40 . 3 ( 32 . 2 - 62 . 0 )
Diseases: albuminuria, diabetic"	"Sentence: Diabetic rats progressively developed albuminuria reaching 40 . 3 ( 32 . 2 - 62 . 0 )
Diseases:"
1078	mg / 24 h after 8 months in contrast to the control animals ( 0 . 8 ( 0 . 2 - 0 . 9 )	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: mg / 24 h after 8 months in contrast to the control animals ( 0 . 8 ( 0 . 2 - 0 . 9 )
Diseases: "	"Sentence: mg / 24 h after 8 months in contrast to the control animals ( 0 . 8 ( 0 . 2 - 0 . 9 )
Diseases:"
1079	mg / 24 h , p < 0 . 002 ) .	O O O O O O O O O O O O	[]	0	0	"Sentence: mg / 24 h , p < 0 . 002 ) .
Diseases: "	"Sentence: mg / 24 h , p < 0 . 002 ) .
Diseases:"
1080	At the same time , the number of heparan sulphate anionic sites and the total anionic site surface ( number of anionic sites x mean anionic site surface ) in the lamina rara externa of the glomerular basement membrane was reduced by 19 % ( p < 0 . 021 ) and by 26 % ( p < 0 . 02 ) , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At the same time , the number of heparan sulphate anionic sites and the total anionic site surface ( number of anionic sites x mean anionic site surface ) in the lamina rara externa of the glomerular basement membrane was reduced by 19 % ( p < 0 . 021 ) and by 26 % ( p < 0 . 02 ) , respectively .
Diseases: "	"Sentence: At the same time , the number of heparan sulphate anionic sites and the total anionic site surface ( number of anionic sites x mean anionic site surface ) in the lamina rara externa of the glomerular basement membrane was reduced by 19 % ( p < 0 . 021 ) and by 26 % ( p < 0 . 02 ) , respectively .
Diseases:"
1081	Number and total anionic site surface in the remaining part of the glomerular basement membrane ( lamina densa and lamina rara interna ) were not significantly changed .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Number and total anionic site surface in the remaining part of the glomerular basement membrane ( lamina densa and lamina rara interna ) were not significantly changed .
Diseases: "	"Sentence: Number and total anionic site surface in the remaining part of the glomerular basement membrane ( lamina densa and lamina rara interna ) were not significantly changed .
Diseases:"
1082	We conclude that in streptozotocin - diabetic rats with an increased urinary albumin excretion , a reduced heparan sulphate charge barrier / density is found at the lamina rara externa of the glomerular basement membrane .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetic']	1	2	"Sentence: We conclude that in streptozotocin - diabetic rats with an increased urinary albumin excretion , a reduced heparan sulphate charge barrier / density is found at the lamina rara externa of the glomerular basement membrane .
Diseases: diabetic"	"Sentence: We conclude that in streptozotocin - diabetic rats with an increased urinary albumin excretion , a reduced heparan sulphate charge barrier / density is found at the lamina rara externa of the glomerular basement membrane .
Diseases:"
1083	Effect of some anticancer drugs and combined chemotherapy on renal toxicity .	O O O O O O O O O B I O	['renal toxicity']	1	3	"Sentence: Effect of some anticancer drugs and combined chemotherapy on renal toxicity .
Diseases: renal toxicity"	"Sentence: Effect of some anticancer drugs and combined chemotherapy on renal toxicity .
Diseases:"
1084	The nephrotoxic action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: The nephrotoxic action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
Diseases: nephrotoxic"	"Sentence: The nephrotoxic action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .
Diseases:"
1085	After drug administration , creatinine concentrations in the plasma and in the urine of the rats were determined , as well as creatinine clearance .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After drug administration , creatinine concentrations in the plasma and in the urine of the rats were determined , as well as creatinine clearance .
Diseases: "	"Sentence: After drug administration , creatinine concentrations in the plasma and in the urine of the rats were determined , as well as creatinine clearance .
Diseases:"
1086	Histopathologic evaluation of the kidneys was also performed .	O O O O O O O O O	[]	0	0	"Sentence: Histopathologic evaluation of the kidneys was also performed .
Diseases: "	"Sentence: Histopathologic evaluation of the kidneys was also performed .
Diseases:"
1087	After MTX administration a significant increase ( p = 0 . 0228 ) in the plasma creatinine concentration and a significant ( p = 0 . 0001 ) decrease in creatinine clearance was noted compared to controls .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After MTX administration a significant increase ( p = 0 . 0228 ) in the plasma creatinine concentration and a significant ( p = 0 . 0001 ) decrease in creatinine clearance was noted compared to controls .
Diseases: "	"Sentence: After MTX administration a significant increase ( p = 0 . 0228 ) in the plasma creatinine concentration and a significant ( p = 0 . 0001 ) decrease in creatinine clearance was noted compared to controls .
Diseases:"
1088	After the administration of NG , 5 - FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After the administration of NG , 5 - FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics .
Diseases: "	"Sentence: After the administration of NG , 5 - FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics .
Diseases:"
1089	Following polytherapy according to the CMF regimen , a statistically significant decrease ( p = 0 . 0343 ) in creatinine clearance was found , but creatinine concentration did not increase significantly compared to controls .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following polytherapy according to the CMF regimen , a statistically significant decrease ( p = 0 . 0343 ) in creatinine clearance was found , but creatinine concentration did not increase significantly compared to controls .
Diseases: "	"Sentence: Following polytherapy according to the CMF regimen , a statistically significant decrease ( p = 0 . 0343 ) in creatinine clearance was found , but creatinine concentration did not increase significantly compared to controls .
Diseases:"
1090	CY caused hemorrhagic cystitis in 40 % of rats , but it did not cause this complication when combined with 5 - FU and MTX .	O O B I O O O O O O O O O O O O O O O O O O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: CY caused hemorrhagic cystitis in 40 % of rats , but it did not cause this complication when combined with 5 - FU and MTX .
Diseases: hemorrhagic cystitis"	"Sentence: CY caused hemorrhagic cystitis in 40 % of rats , but it did not cause this complication when combined with 5 - FU and MTX .
Diseases:"
1091	Histologic changes were found in rat kidneys after administration of MTX , CY and NG , while no such change was observed after 5 - FU and joint administration of MTX + 5 - FU + CY compared to controls .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Histologic changes were found in rat kidneys after administration of MTX , CY and NG , while no such change was observed after 5 - FU and joint administration of MTX + 5 - FU + CY compared to controls .
Diseases: "	"Sentence: Histologic changes were found in rat kidneys after administration of MTX , CY and NG , while no such change was observed after 5 - FU and joint administration of MTX + 5 - FU + CY compared to controls .
Diseases:"
1092	Our studies indicate that nephrotoxicity of MTX + 5 - FU + CY administered jointly is lower than in monotherapy .	O O O O B O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Our studies indicate that nephrotoxicity of MTX + 5 - FU + CY administered jointly is lower than in monotherapy .
Diseases: nephrotoxicity"	"Sentence: Our studies indicate that nephrotoxicity of MTX + 5 - FU + CY administered jointly is lower than in monotherapy .
Diseases:"
1093	Lithium - associated cognitive and functional deficits reduced by a switch to divalproex sodium : a case series .	O O O B I I I O O O O O O O O O O O O	['cognitive and functional deficits']	1	5	"Sentence: Lithium - associated cognitive and functional deficits reduced by a switch to divalproex sodium : a case series .
Diseases: cognitive and functional deficits"	"Sentence: Lithium - associated cognitive and functional deficits reduced by a switch to divalproex sodium : a case series .
Diseases:"
1094	Lithium remains a first - line treatment for the acute and maintenance treatment of bipolar disorder .	O O O O O O O O O O O O O O B I O	['bipolar disorder']	1	3	"Sentence: Lithium remains a first - line treatment for the acute and maintenance treatment of bipolar disorder .
Diseases: bipolar disorder"	"Sentence: Lithium remains a first - line treatment for the acute and maintenance treatment of bipolar disorder .
Diseases:"
1095	Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .	O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O B I O B I I O O B I O O O	['tremor', 'functional impairments', 'polyuria', 'cognitive deficits', 'loss of creativity']	5	17	"Sentence: Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
Diseases: tremor, functional impairments, polyuria, cognitive deficits, loss of creativity"	"Sentence: Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .
Diseases:"
1096	This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments .	O O O O O O O B O O O O O O O O O B I I I O	['bipolar', 'cognitive and functional impairments']	2	8	"Sentence: This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments .
Diseases: bipolar, cognitive and functional impairments"	"Sentence: This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments .
Diseases:"
1097	Open , case series design .	O O O O O O	[]	0	0	"Sentence: Open , case series design .
Diseases: "	"Sentence: Open , case series design .
Diseases:"
1098	We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our bipolar patients .	O O O O O O O O O O O O O O O O O O O O O O O B I I I I I I O O O O O B O O	['bipolar', 'cognitive , motivational , or creative deficits']	2	10	"Sentence: We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our bipolar patients .
Diseases: bipolar, cognitive , motivational , or creative deficits"	"Sentence: We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our bipolar patients .
Diseases:"
1099	In this preliminary report , divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , loss of creativity , and functional impairments .	O O O O O O O O O O O O O O B O O B I O B I I O O B I O	['cognitive deficits', 'bipolar', 'functional impairments', 'loss of creativity']	4	13	"Sentence: In this preliminary report , divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , loss of creativity , and functional impairments .
Diseases: cognitive deficits, bipolar, functional impairments, loss of creativity"	"Sentence: In this preliminary report , divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , loss of creativity , and functional impairments .
Diseases:"
1100	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( MFL ) : low palliative benefit and high treatment - related toxicity .	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['breast cancer', 'toxicity']	2	5	"Sentence: Treatment of previously treated metastatic breast cancer by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( MFL ) : low palliative benefit and high treatment - related toxicity .
Diseases: breast cancer, toxicity"	"Sentence: Treatment of previously treated metastatic breast cancer by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( MFL ) : low palliative benefit and high treatment - related toxicity .
Diseases:"
1101	For previously treated advanced breast cancer , there is no standard second - line therapy .	O O O O B I O O O O O O O O O O	['breast cancer']	1	3	"Sentence: For previously treated advanced breast cancer , there is no standard second - line therapy .
Diseases: breast cancer"	"Sentence: For previously treated advanced breast cancer , there is no standard second - line therapy .
Diseases:"
1102	Combination chemotherapy with mitoxantrone , high - dose 5 - fluorouracil ( 5 - FU ) and leucovorin ( MFL regimen ) had been reported as an effective and well tolerated regimen .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Combination chemotherapy with mitoxantrone , high - dose 5 - fluorouracil ( 5 - FU ) and leucovorin ( MFL regimen ) had been reported as an effective and well tolerated regimen .
Diseases: "	"Sentence: Combination chemotherapy with mitoxantrone , high - dose 5 - fluorouracil ( 5 - FU ) and leucovorin ( MFL regimen ) had been reported as an effective and well tolerated regimen .
Diseases:"
1103	From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy - treated metastatic breast cancer by mitoxantrone , 12 mg / m2 , on day 1 and continuous infusion of 5 - FU , 3000 mg / m2 , together with leucovorin , 300 mg / m2 , for 48 h from day 1 to 2 .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy - treated metastatic breast cancer by mitoxantrone , 12 mg / m2 , on day 1 and continuous infusion of 5 - FU , 3000 mg / m2 , together with leucovorin , 300 mg / m2 , for 48 h from day 1 to 2 .
Diseases: breast cancer"	"Sentence: From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy - treated metastatic breast cancer by mitoxantrone , 12 mg / m2 , on day 1 and continuous infusion of 5 - FU , 3000 mg / m2 , together with leucovorin , 300 mg / m2 , for 48 h from day 1 to 2 .
Diseases:"
1104	Each course of chemotherapy was given every 4 weeks .	O O O O O O O O O O	[]	0	0	"Sentence: Each course of chemotherapy was given every 4 weeks .
Diseases: "	"Sentence: Each course of chemotherapy was given every 4 weeks .
Diseases:"
1105	Most of these patients had more than two metastatic sites , with lung metastasis predominant .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Most of these patients had more than two metastatic sites , with lung metastasis predominant .
Diseases: "	"Sentence: Most of these patients had more than two metastatic sites , with lung metastasis predominant .
Diseases:"
1106	Seven patients had been treated with anthracycline .	O O O O O O O O	[]	0	0	"Sentence: Seven patients had been treated with anthracycline .
Diseases: "	"Sentence: Seven patients had been treated with anthracycline .
Diseases:"
1107	Seven patients had previously received radiotherapy and seven had received hormone therapy .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Seven patients had previously received radiotherapy and seven had received hormone therapy .
Diseases: "	"Sentence: Seven patients had previously received radiotherapy and seven had received hormone therapy .
Diseases:"
1108	Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68 . 35 mg / m2 .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68 . 35 mg / m2 .
Diseases: "	"Sentence: Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68 . 35 mg / m2 .
Diseases:"
1109	One patient had complete response , seven had stable disease , none had partial response and five had progressive disease .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: One patient had complete response , seven had stable disease , none had partial response and five had progressive disease .
Diseases: "	"Sentence: One patient had complete response , seven had stable disease , none had partial response and five had progressive disease .
Diseases:"
1110	The overall objective response rate was 7 . 6 % .	O O O O O O O O O O O	[]	0	0	"Sentence: The overall objective response rate was 7 . 6 % .
Diseases: "	"Sentence: The overall objective response rate was 7 . 6 % .
Diseases:"
1111	The median follow - up period was 14 months .	O O O O O O O O O O	[]	0	0	"Sentence: The median follow - up period was 14 months .
Diseases: "	"Sentence: The median follow - up period was 14 months .
Diseases:"
1112	Median survival was 16 months .	O O O O O O	[]	0	0	"Sentence: Median survival was 16 months .
Diseases: "	"Sentence: Median survival was 16 months .
Diseases:"
1113	Median progression - free survival was 5 months .	O O O O O O O O O	[]	0	0	"Sentence: Median progression - free survival was 5 months .
Diseases: "	"Sentence: Median progression - free survival was 5 months .
Diseases:"
1114	A complete responder had relapse - free survival up to 17 months .	O O O O O O O O O O O O O	[]	0	0	"Sentence: A complete responder had relapse - free survival up to 17 months .
Diseases: "	"Sentence: A complete responder had relapse - free survival up to 17 months .
Diseases:"
1115	Major toxicities were cardiotoxicity and leukopenia .	O B O B O B O	['cardiotoxicity', 'toxicities', 'leukopenia']	3	11	"Sentence: Major toxicities were cardiotoxicity and leukopenia .
Diseases: cardiotoxicity, toxicities, leukopenia"	"Sentence: Major toxicities were cardiotoxicity and leukopenia .
Diseases:"
1116	Eight patients were dead in the last follow - up ; two of them died of treatment - related toxicity .	O O O O O O O O O O O O O O O O O O O B O	['toxicity']	1	2	"Sentence: Eight patients were dead in the last follow - up ; two of them died of treatment - related toxicity .
Diseases: toxicity"	"Sentence: Eight patients were dead in the last follow - up ; two of them died of treatment - related toxicity .
Diseases:"
1117	The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate .	O O O O O O O O O O B O O O O O O	['toxicity']	1	2	"Sentence: The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate .
Diseases: toxicity"	"Sentence: The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate .
Diseases:"
1118	Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention .	O O O O O B I O O O O O O O O O O B I I O O O O	['impaired heart function', 'breast cancer']	2	8	"Sentence: Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention .
Diseases: impaired heart function, breast cancer"	"Sentence: Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention .
Diseases:"
1119	Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium - induced diabetes insipidus rat .	O O O O O O O O O O O O O O O O O O B I O O	['diabetes insipidus']	1	6	"Sentence: Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium - induced diabetes insipidus rat .
Diseases: diabetes insipidus"	"Sentence: Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium - induced diabetes insipidus rat .
Diseases:"
1120	The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium ( Li ) - induced polyuria , using in situ hybridization histochemistry and radioimmunoassay .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['polyuria']	1	2	"Sentence: The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium ( Li ) - induced polyuria , using in situ hybridization histochemistry and radioimmunoassay .
Diseases: polyuria"	"Sentence: The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium ( Li ) - induced polyuria , using in situ hybridization histochemistry and radioimmunoassay .
Diseases:"
1121	The male Wistar rats consuming a diet that contained LiCl ( 60 mmol / kg ) for 4 weeks developed marked polyuria .	O O O O O O O O O O O O O O O O O O O O O B O	['polyuria']	1	2	"Sentence: The male Wistar rats consuming a diet that contained LiCl ( 60 mmol / kg ) for 4 weeks developed marked polyuria .
Diseases: polyuria"	"Sentence: The male Wistar rats consuming a diet that contained LiCl ( 60 mmol / kg ) for 4 weeks developed marked polyuria .
Diseases:"
1122	The Li - treated rats produced a large volume of hypotonic urine with low ionic concentrations .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The Li - treated rats produced a large volume of hypotonic urine with low ionic concentrations .
Diseases: "	"Sentence: The Li - treated rats produced a large volume of hypotonic urine with low ionic concentrations .
Diseases:"
1123	Plasma sodium concentrations were found to be slightly increased in the Li - treated rats compared with those in controls .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma sodium concentrations were found to be slightly increased in the Li - treated rats compared with those in controls .
Diseases: "	"Sentence: Plasma sodium concentrations were found to be slightly increased in the Li - treated rats compared with those in controls .
Diseases:"
1124	Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li - treated rats compared with controls .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li - treated rats compared with controls .
Diseases: "	"Sentence: Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li - treated rats compared with controls .
Diseases:"
1125	These results suggest that dehydration and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li - induced diabetes insipidus rat .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O	['diabetes insipidus', 'dehydration']	2	8	"Sentence: These results suggest that dehydration and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li - induced diabetes insipidus rat .
Diseases: diabetes insipidus, dehydration"	"Sentence: These results suggest that dehydration and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li - induced diabetes insipidus rat .
Diseases:"
1126	Suxamethonium - induced cardiac arrest and death following 5 days of immobilization .	O O O B I O B O O O O O O	['cardiac arrest', 'death']	2	5	"Sentence: Suxamethonium - induced cardiac arrest and death following 5 days of immobilization .
Diseases: cardiac arrest, death"	"Sentence: Suxamethonium - induced cardiac arrest and death following 5 days of immobilization .
Diseases:"
1127	The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23 - year - old Malawian woman .	O O O O O O O B I O O B O O O O B O O O O O O O O O O O O O O O	['cardiac arrest', 'hyperkalaemia', 'death']	3	10	"Sentence: The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23 - year - old Malawian woman .
Diseases: cardiac arrest, hyperkalaemia, death"	"Sentence: The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23 - year - old Malawian woman .
Diseases:"
1128	Five days after the onset of the symptoms of meningitis , the patient aspirated stomach contents and needed endotracheal intubation .	O O O O O O O O O B O O O O O O O O O O O	['meningitis']	1	3	"Sentence: Five days after the onset of the symptoms of meningitis , the patient aspirated stomach contents and needed endotracheal intubation .
Diseases: meningitis"	"Sentence: Five days after the onset of the symptoms of meningitis , the patient aspirated stomach contents and needed endotracheal intubation .
Diseases:"
1129	Forty seconds after injection of suxamethonium , bradycardia and cardiac arrest occurred .	O O O O O O O B O B I O O	['bradycardia', 'cardiac arrest']	2	7	"Sentence: Forty seconds after injection of suxamethonium , bradycardia and cardiac arrest occurred .
Diseases: bradycardia, cardiac arrest"	"Sentence: Forty seconds after injection of suxamethonium , bradycardia and cardiac arrest occurred .
Diseases:"
1130	Attempts to resuscitate the patient were not successful .	O O O O O O O O O	[]	0	0	"Sentence: Attempts to resuscitate the patient were not successful .
Diseases: "	"Sentence: Attempts to resuscitate the patient were not successful .
Diseases:"
1131	The serum level of potassium was observed to be 8 . 4 mequiv L - 1 .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The serum level of potassium was observed to be 8 . 4 mequiv L - 1 .
Diseases: "	"Sentence: The serum level of potassium was observed to be 8 . 4 mequiv L - 1 .
Diseases:"
1132	Apart from the reduction in the patient 's level of consciousness , there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['hyperkalaemia']	1	4	"Sentence: Apart from the reduction in the patient 's level of consciousness , there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium .
Diseases: hyperkalaemia"	"Sentence: Apart from the reduction in the patient 's level of consciousness , there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium .
Diseases:"
1133	It is postulated that her death was caused by hypersensitivity to suxamethonium , associated with her 5 - day immobilization .	O O O O O B O O O B O O O O O O O O O O O	['hypersensitivity', 'death']	2	5	"Sentence: It is postulated that her death was caused by hypersensitivity to suxamethonium , associated with her 5 - day immobilization .
Diseases: hypersensitivity, death"	"Sentence: It is postulated that her death was caused by hypersensitivity to suxamethonium , associated with her 5 - day immobilization .
Diseases:"
1134	An unusual toxic reaction to axillary block by mepivacaine with adrenaline .	O O O O O O O O O O O O	[]	0	0	"Sentence: An unusual toxic reaction to axillary block by mepivacaine with adrenaline .
Diseases: "	"Sentence: An unusual toxic reaction to axillary block by mepivacaine with adrenaline .
Diseases:"
1135	An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren 's contracture .	O B I I I O O O B I O B O B I O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	"['incomprehensible shouts', 'increase in blood pressure', 'agitation', 'loss of consciousness', 'atrial fibrillation', ""dupuytren 's contracture""]"	6	32	"Sentence: An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren 's contracture .
Diseases: incomprehensible shouts, increase in blood pressure, agitation, loss of consciousness, atrial fibrillation, dupuytren 's contracture"	"Sentence: An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren 's contracture .
Diseases:"
1136	After intravenous administration of labetalol , metoprolol and midazolam the patient 's condition improved , and 15 min later he woke up .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After intravenous administration of labetalol , metoprolol and midazolam the patient 's condition improved , and 15 min later he woke up .
Diseases: "	"Sentence: After intravenous administration of labetalol , metoprolol and midazolam the patient 's condition improved , and 15 min later he woke up .
Diseases:"
1137	The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation .	O O O O O O O O O O O O B I O	['atrial fibrillation']	1	5	"Sentence: The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation .
Diseases: atrial fibrillation"	"Sentence: The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation .
Diseases:"
1138	Postoperatively , the patient refused DC cardioversion and was treated medically .	O O O O O O O O O O O O	[]	0	0	"Sentence: Postoperatively , the patient refused DC cardioversion and was treated medically .
Diseases: "	"Sentence: Postoperatively , the patient refused DC cardioversion and was treated medically .
Diseases:"
1139	Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and / or interaction of these drugs with the patient 's cardiovascular medications were responsible for the perioperative complications .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and / or interaction of these drugs with the patient 's cardiovascular medications were responsible for the perioperative complications .
Diseases: "	"Sentence: Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and / or interaction of these drugs with the patient 's cardiovascular medications were responsible for the perioperative complications .
Diseases:"
1140	Clinical and histopathologic examination of renal allografts treated with tacrolimus ( FK506 ) for at least one year .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical and histopathologic examination of renal allografts treated with tacrolimus ( FK506 ) for at least one year .
Diseases: "	"Sentence: Clinical and histopathologic examination of renal allografts treated with tacrolimus ( FK506 ) for at least one year .
Diseases:"
1141	We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus ( FK506 ) for more than 1 year .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus ( FK506 ) for more than 1 year .
Diseases: "	"Sentence: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus ( FK506 ) for more than 1 year .
Diseases:"
1142	METHODS : Twenty - six renal allograft biopsy specimens from 1 9 renal transplant patients who underwent transplantations between 1991 and 1993 were evaluated .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Twenty - six renal allograft biopsy specimens from 1 9 renal transplant patients who underwent transplantations between 1991 and 1993 were evaluated .
Diseases: "	"Sentence: METHODS : Twenty - six renal allograft biopsy specimens from 1 9 renal transplant patients who underwent transplantations between 1991 and 1993 were evaluated .
Diseases:"
1143	Thirteen biopsies were performed from stable functioning renal allografts with informed consent ( nonepisode biopsy ) and the other 13 were from dysfunctional renal allografts with a clinical indication for biopsy ( episode biopsy ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirteen biopsies were performed from stable functioning renal allografts with informed consent ( nonepisode biopsy ) and the other 13 were from dysfunctional renal allografts with a clinical indication for biopsy ( episode biopsy ) .
Diseases: "	"Sentence: Thirteen biopsies were performed from stable functioning renal allografts with informed consent ( nonepisode biopsy ) and the other 13 were from dysfunctional renal allografts with a clinical indication for biopsy ( episode biopsy ) .
Diseases:"
1144	The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic FK506 nephropathy ( n = 9 ) , and mild - type FK506 nephropathy ( n = 11 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O	['iga nephropathy', 'nephropathy']	2	10	"Sentence: The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic FK506 nephropathy ( n = 9 ) , and mild - type FK506 nephropathy ( n = 11 ) .
Diseases: iga nephropathy, nephropathy"	"Sentence: The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic FK506 nephropathy ( n = 9 ) , and mild - type FK506 nephropathy ( n = 11 ) .
Diseases:"
1145	Of the nonepisode biopsies , 7 and 4 biopsies showed minimal - type and mild - type chronic FK506 nephropathy , respectively .	O O O O O O O O O O O O O O O O O O O B O O O	['nephropathy']	1	4	"Sentence: Of the nonepisode biopsies , 7 and 4 biopsies showed minimal - type and mild - type chronic FK506 nephropathy , respectively .
Diseases: nephropathy"	"Sentence: Of the nonepisode biopsies , 7 and 4 biopsies showed minimal - type and mild - type chronic FK506 nephropathy , respectively .
Diseases:"
1146	Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .	O O B O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O B I O O O O O	['focal segmental glomerulosclerosis', 'nephropathy', 'interstitial fibrosis']	3	19	"Sentence: Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .
Diseases: focal segmental glomerulosclerosis, nephropathy, interstitial fibrosis"	"Sentence: Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .
Diseases:"
1147	The serum creatinine levels of patients in the mild - type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - nephropathy group ( P < 0 . 001 ) .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['nephropathy']	1	4	"Sentence: The serum creatinine levels of patients in the mild - type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - nephropathy group ( P < 0 . 001 ) .
Diseases: nephropathy"	"Sentence: The serum creatinine levels of patients in the mild - type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - nephropathy group ( P < 0 . 001 ) .
Diseases:"
1148	CONCLUSIONS : This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['nephropathy']	1	4	"Sentence: CONCLUSIONS : This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function .
Diseases: nephropathy"	"Sentence: CONCLUSIONS : This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function .
Diseases:"
1149	Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG - 9 .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG - 9 .
Diseases: "	"Sentence: Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG - 9 .
Diseases:"
1150	The effects of PG - 9 ( 3alpha - tropyl 2 - ( p - bromophenyl ) propionate ) , the acetylcholine releaser , on memory processes and nerve growth factor ( NGF ) synthesis were evaluated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effects of PG - 9 ( 3alpha - tropyl 2 - ( p - bromophenyl ) propionate ) , the acetylcholine releaser , on memory processes and nerve growth factor ( NGF ) synthesis were evaluated .
Diseases: "	"Sentence: The effects of PG - 9 ( 3alpha - tropyl 2 - ( p - bromophenyl ) propionate ) , the acetylcholine releaser , on memory processes and nerve growth factor ( NGF ) synthesis were evaluated .
Diseases:"
1151	In the mouse passive - avoidance test , PG - 9 ( 10 - 30 mg / kg , i . p . ) , administered 20 min before the training session , prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1 - selective antagonist S - ( - ) - ET - 126 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: In the mouse passive - avoidance test , PG - 9 ( 10 - 30 mg / kg , i . p . ) , administered 20 min before the training session , prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1 - selective antagonist S - ( - ) - ET - 126 .
Diseases: amnesia"	"Sentence: In the mouse passive - avoidance test , PG - 9 ( 10 - 30 mg / kg , i . p . ) , administered 20 min before the training session , prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1 - selective antagonist S - ( - ) - ET - 126 .
Diseases:"
1152	In the same experimental conditions , PG - 9 ( 5 - 20 microg per mouse , i . c . v . ) was also able to prevent antimuscarine - induced amnesia , demonstrating a central localization of the activity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['amnesia']	1	2	"Sentence: In the same experimental conditions , PG - 9 ( 5 - 20 microg per mouse , i . c . v . ) was also able to prevent antimuscarine - induced amnesia , demonstrating a central localization of the activity .
Diseases: amnesia"	"Sentence: In the same experimental conditions , PG - 9 ( 5 - 20 microg per mouse , i . c . v . ) was also able to prevent antimuscarine - induced amnesia , demonstrating a central localization of the activity .
Diseases:"
1153	At the highest effective doses , PG - 9 did not produce any collateral symptoms as revealed by the Irwin test , and it did not modify spontaneous motility and inspection activity , as revealed by the hole - board test .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At the highest effective doses , PG - 9 did not produce any collateral symptoms as revealed by the Irwin test , and it did not modify spontaneous motility and inspection activity , as revealed by the hole - board test .
Diseases: "	"Sentence: At the highest effective doses , PG - 9 did not produce any collateral symptoms as revealed by the Irwin test , and it did not modify spontaneous motility and inspection activity , as revealed by the hole - board test .
Diseases:"
1154	PG - 9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose - dependent manner .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PG - 9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose - dependent manner .
Diseases: "	"Sentence: PG - 9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose - dependent manner .
Diseases:"
1155	The maximal NGF contents obtained by PG - 9 were 17 . 6 - fold of the control value .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The maximal NGF contents obtained by PG - 9 were 17 . 6 - fold of the control value .
Diseases: "	"Sentence: The maximal NGF contents obtained by PG - 9 were 17 . 6 - fold of the control value .
Diseases:"
1156	During culture , no morphological changes were found at effective concentrations of PG - 9 .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During culture , no morphological changes were found at effective concentrations of PG - 9 .
Diseases: "	"Sentence: During culture , no morphological changes were found at effective concentrations of PG - 9 .
Diseases:"
1157	The current work indicates the ability of PG - 9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The current work indicates the ability of PG - 9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells .
Diseases: "	"Sentence: The current work indicates the ability of PG - 9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells .
Diseases:"
1158	Therefore , PG - 9 could represent a potential useful drug able to improve the function of impaired cognitive processes .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Therefore , PG - 9 could represent a potential useful drug able to improve the function of impaired cognitive processes .
Diseases: "	"Sentence: Therefore , PG - 9 could represent a potential useful drug able to improve the function of impaired cognitive processes .
Diseases:"
1159	Angioedema due to ACE inhibitors : common and inadequately diagnosed .	B O O O O O O O O O O	['angioedema']	1	4	"Sentence: Angioedema due to ACE inhibitors : common and inadequately diagnosed .
Diseases: angioedema"	"Sentence: Angioedema due to ACE inhibitors : common and inadequately diagnosed .
Diseases:"
1160	The estimated incidence of angioedema during angiotensin - converting enzyme ( ACE ) inhibitor treatment is between 1 and 7 per thousand patients .	O O O O B O O O O O O O O O O O O O O O O O O O	['angioedema']	1	4	"Sentence: The estimated incidence of angioedema during angiotensin - converting enzyme ( ACE ) inhibitor treatment is between 1 and 7 per thousand patients .
Diseases: angioedema"	"Sentence: The estimated incidence of angioedema during angiotensin - converting enzyme ( ACE ) inhibitor treatment is between 1 and 7 per thousand patients .
Diseases:"
1161	This potentially serious adverse effect is often preceded by minor manifestations that may serve as a warning .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This potentially serious adverse effect is often preceded by minor manifestations that may serve as a warning .
Diseases: "	"Sentence: This potentially serious adverse effect is often preceded by minor manifestations that may serve as a warning .
Diseases:"
1162	Recurarization in the recovery room .	O O O O O O	[]	0	0	"Sentence: Recurarization in the recovery room .
Diseases: "	"Sentence: Recurarization in the recovery room .
Diseases:"
1163	A case of recurarization in the recovery room is reported .	O O O O O O O O O O O	[]	0	0	"Sentence: A case of recurarization in the recovery room is reported .
Diseases: "	"Sentence: A case of recurarization in the recovery room is reported .
Diseases:"
1164	Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room .
Diseases: "	"Sentence: Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room .
Diseases:"
1165	A respiratory arrest with severe desaturation and bradycardia occurred .	O B I O O B O B O O	['respiratory arrest', 'bradycardia', 'desaturation']	3	12	"Sentence: A respiratory arrest with severe desaturation and bradycardia occurred .
Diseases: respiratory arrest, bradycardia, desaturation"	"Sentence: A respiratory arrest with severe desaturation and bradycardia occurred .
Diseases:"
1166	Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur , following the administration of a small dose of relaxant , are discussed .	O O O O O O O O O O B I O O O O O O O O O O O O O O O O	['neuromuscular blockade']	1	6	"Sentence: Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur , following the administration of a small dose of relaxant , are discussed .
Diseases: neuromuscular blockade"	"Sentence: Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur , following the administration of a small dose of relaxant , are discussed .
Diseases:"
1167	Recurrent use of newer oral contraceptives and the risk of venous thromboembolism .	O O O O O O O O O O B I O	['venous thromboembolism']	1	8	"Sentence: Recurrent use of newer oral contraceptives and the risk of venous thromboembolism .
Diseases: venous thromboembolism"	"Sentence: Recurrent use of newer oral contraceptives and the risk of venous thromboembolism .
Diseases:"
1168	The epidemiological studies that assessed the risk of venous thromboembolism ( VTE ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .	O O O O O O O O B I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['vte', 'venous thromboembolism']	2	11	"Sentence: The epidemiological studies that assessed the risk of venous thromboembolism ( VTE ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .
Diseases: vte, venous thromboembolism"	"Sentence: The epidemiological studies that assessed the risk of venous thromboembolism ( VTE ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .
Diseases:"
1169	Data from a Transnational case - control study were used to assess the risk of VTE for the latter patterns of use , while accounting for duration of use .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['vte']	1	2	"Sentence: Data from a Transnational case - control study were used to assess the risk of VTE for the latter patterns of use , while accounting for duration of use .
Diseases: vte"	"Sentence: Data from a Transnational case - control study were used to assess the risk of VTE for the latter patterns of use , while accounting for duration of use .
Diseases:"
1170	Over the period 1993 - 1996 , 551 cases of VTE were identified in Germany and the UK along with 2066 controls .	O O O O O O O O O O B O O O O O O O O O O O O	['vte']	1	2	"Sentence: Over the period 1993 - 1996 , 551 cases of VTE were identified in Germany and the UK along with 2066 controls .
Diseases: vte"	"Sentence: Over the period 1993 - 1996 , 551 cases of VTE were identified in Germany and the UK along with 2066 controls .
Diseases:"
1171	Totals of 128 cases and 650 controls were analysed for repeat use and 135 cases and 622 controls for switching patterns .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Totals of 128 cases and 650 controls were analysed for repeat use and 135 cases and 622 controls for switching patterns .
Diseases: "	"Sentence: Totals of 128 cases and 650 controls were analysed for repeat use and 135 cases and 622 controls for switching patterns .
Diseases:"
1172	The adjusted rate ratio of VTE for repeat users of third generation OC was 0 . 6 ( 95 % CI : 0 . 3 - 1 . 2 ) relative to repeat users of second generation pills , whereas it was 1 . 3 ( 95 % CI : 0 . 7 - 2 . 4 ) for switchers from second to third generation pills relative to switchers from third to second generation pills .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['vte']	1	2	"Sentence: The adjusted rate ratio of VTE for repeat users of third generation OC was 0 . 6 ( 95 % CI : 0 . 3 - 1 . 2 ) relative to repeat users of second generation pills , whereas it was 1 . 3 ( 95 % CI : 0 . 7 - 2 . 4 ) for switchers from second to third generation pills relative to switchers from third to second generation pills .
Diseases: vte"	"Sentence: The adjusted rate ratio of VTE for repeat users of third generation OC was 0 . 6 ( 95 % CI : 0 . 3 - 1 . 2 ) relative to repeat users of second generation pills , whereas it was 1 . 3 ( 95 % CI : 0 . 7 - 2 . 4 ) for switchers from second to third generation pills relative to switchers from third to second generation pills .
Diseases:"
1173	We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['vte']	1	2	"Sentence: We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills .
Diseases: vte"	"Sentence: We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills .
Diseases:"
1174	These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use .
Diseases: "	"Sentence: These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use .
Diseases:"
1175	Development of apomorphine - induced aggressive behavior : comparison of adult male and female Wistar rats .	O O O O O B I O O O O O O O O O O	['aggressive behavior']	1	2	"Sentence: Development of apomorphine - induced aggressive behavior : comparison of adult male and female Wistar rats .
Diseases: aggressive behavior"	"Sentence: Development of apomorphine - induced aggressive behavior : comparison of adult male and female Wistar rats .
Diseases:"
1176	The development of apomorphine - induced ( 1 . 0 mg / kg s . c .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The development of apomorphine - induced ( 1 . 0 mg / kg s . c .
Diseases: "	"Sentence: The development of apomorphine - induced ( 1 . 0 mg / kg s . c .
Diseases:"
1177	once daily ) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets .	O O O B I O O O O O O O O O O O O O O O O O O O	['aggressive behavior']	1	2	"Sentence: once daily ) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets .
Diseases: aggressive behavior"	"Sentence: once daily ) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets .
Diseases:"
1178	In male animals , repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent .	O O O O O O O O O O O O B I O O O O O O O B O O O O O O O O O O O	['aggressiveness', 'aggressive behavior']	2	6	"Sentence: In male animals , repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent .
Diseases: aggressiveness, aggressive behavior"	"Sentence: In male animals , repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent .
Diseases:"
1179	In female rats , only a weak tendency toward aggressiveness was found .	O O O O O O O O O B O O O	['aggressiveness']	1	3	"Sentence: In female rats , only a weak tendency toward aggressiveness was found .
Diseases: aggressiveness"	"Sentence: In female rats , only a weak tendency toward aggressiveness was found .
Diseases:"
1180	In conclusion , the present study demonstrates gender differences in the development of the apomorphine - induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['aggressive behavior']	1	2	"Sentence: In conclusion , the present study demonstrates gender differences in the development of the apomorphine - induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method .
Diseases: aggressive behavior"	"Sentence: In conclusion , the present study demonstrates gender differences in the development of the apomorphine - induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method .
Diseases:"
1181	Serotonergic antidepressants and urinary incontinence .	O O O B I O	['urinary incontinence']	1	5	"Sentence: Serotonergic antidepressants and urinary incontinence .
Diseases: urinary incontinence"	"Sentence: Serotonergic antidepressants and urinary incontinence .
Diseases:"
1182	Many new serotonergic antidepressants have been introduced over the past decade .	O O O O O O O O O O O O	[]	0	0	"Sentence: Many new serotonergic antidepressants have been introduced over the past decade .
Diseases: "	"Sentence: Many new serotonergic antidepressants have been introduced over the past decade .
Diseases:"
1183	Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature .	O B I O O O O O O O O O O O O O O O O O O O O O O	['urinary incontinence']	1	5	"Sentence: Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature .
Diseases: urinary incontinence"	"Sentence: Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature .
Diseases:"
1184	This concerns 2 male patients who experienced incontinence while taking venlafaxine .	O O O O O O O B O O O O	['incontinence']	1	3	"Sentence: This concerns 2 male patients who experienced incontinence while taking venlafaxine .
Diseases: incontinence"	"Sentence: This concerns 2 male patients who experienced incontinence while taking venlafaxine .
Diseases:"
1185	In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on venlafaxine .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['incontinence']	1	3	"Sentence: In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on venlafaxine .
Diseases: incontinence"	"Sentence: In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on venlafaxine .
Diseases:"
1186	In 2 of the 3 cases the patients were also taking lithium carbonate and beta - blockers , both of which could have contributed to the incontinence .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['incontinence']	1	3	"Sentence: In 2 of the 3 cases the patients were also taking lithium carbonate and beta - blockers , both of which could have contributed to the incontinence .
Diseases: incontinence"	"Sentence: In 2 of the 3 cases the patients were also taking lithium carbonate and beta - blockers , both of which could have contributed to the incontinence .
Diseases:"
1187	Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder .	O O O O B O O O O O O O O O O O O O O O O	['incontinence']	1	3	"Sentence: Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder .
Diseases: incontinence"	"Sentence: Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder .
Diseases:"
1188	Further research is needed to delineate the frequency of this troubling side effect and how best to treat it .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Further research is needed to delineate the frequency of this troubling side effect and how best to treat it .
Diseases: "	"Sentence: Further research is needed to delineate the frequency of this troubling side effect and how best to treat it .
Diseases:"
1189	Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension .	B O O O O O O O O O O O O O O O O O B O	['hypotension', 'hypertension']	2	5	"Sentence: Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension .
Diseases: hypotension, hypertension"	"Sentence: Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension .
Diseases:"
1190	Centrally acting alpha - 2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system .	O O O O O O O O O O O O O O O O O O B O O B I I I I I O	['disorders of the central nervous system', 'spasticity']	2	11	"Sentence: Centrally acting alpha - 2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system .
Diseases: disorders of the central nervous system, spasticity"	"Sentence: Centrally acting alpha - 2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system .
Diseases:"
1191	In addition to their effects on spasticity , certain adverse cardiorespiratory effects have been reported .	O O O O O O B O O O O O O O O O	['spasticity']	1	3	"Sentence: In addition to their effects on spasticity , certain adverse cardiorespiratory effects have been reported .
Diseases: spasticity"	"Sentence: In addition to their effects on spasticity , certain adverse cardiorespiratory effects have been reported .
Diseases:"
1192	Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked .	O O O O O O O O O O O O O O O O B O O O O O O O O	['hypotension']	1	3	"Sentence: Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked .
Diseases: hypotension"	"Sentence: Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked .
Diseases:"
1193	The authors present a 10 - year - old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .	O O O O O O O O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O B O	['spasticity', 'hypotension', 'hypertension']	3	9	"Sentence: The authors present a 10 - year - old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .
Diseases: spasticity, hypotension, hypertension"	"Sentence: The authors present a 10 - year - old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .
Diseases:"
1194	The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients .	O O O O O O O O O O O O O O O O O O O O B O B O O O O	['spasticity', 'hypertension']	2	7	"Sentence: The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients .
Diseases: spasticity, hypertension"	"Sentence: The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients .
Diseases:"
1195	Peritubular capillary basement membrane reduplication in allografts and native kidney disease : a clinicopathologic study of 278 consecutive renal specimens .	O O O O O O O O O B I O O O O O O O O O O	['kidney disease']	1	3	"Sentence: Peritubular capillary basement membrane reduplication in allografts and native kidney disease : a clinicopathologic study of 278 consecutive renal specimens .
Diseases: kidney disease"	"Sentence: Peritubular capillary basement membrane reduplication in allografts and native kidney disease : a clinicopathologic study of 278 consecutive renal specimens .
Diseases:"
1196	An association has been found between transplant glomerulopathy ( TG ) and reduplication of peritubular capillary basement membranes ( PTCR ) .	O O O O O O B I O B O O O O O O O O O O O O	['transplant glomerulopathy', 'tg']	2	9	"Sentence: An association has been found between transplant glomerulopathy ( TG ) and reduplication of peritubular capillary basement membranes ( PTCR ) .
Diseases: transplant glomerulopathy, tg"	"Sentence: An association has been found between transplant glomerulopathy ( TG ) and reduplication of peritubular capillary basement membranes ( PTCR ) .
Diseases:"
1197	Although such an association is of practical and theoretical importance , only one prospective study has tried to confirm it .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although such an association is of practical and theoretical importance , only one prospective study has tried to confirm it .
Diseases: "	"Sentence: Although such an association is of practical and theoretical importance , only one prospective study has tried to confirm it .
Diseases:"
1198	METHODS : We examined 278 consecutive renal specimens ( from 135 transplants and 143 native kidneys ) for ultrastructural evidence of PTCR .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : We examined 278 consecutive renal specimens ( from 135 transplants and 143 native kidneys ) for ultrastructural evidence of PTCR .
Diseases: "	"Sentence: METHODS : We examined 278 consecutive renal specimens ( from 135 transplants and 143 native kidneys ) for ultrastructural evidence of PTCR .
Diseases:"
1199	"In addition to renal allografts with TG , we also examined grafts with acute rejection , recurrent glomerulonephritis , chronic allograft nephropathy and stable grafts ( "" protocol biopsies "" ) ."	O O O O O O B O O O O O O O O O O B O B I I O O O O O O O O O O	['chronic allograft nephropathy', 'tg', 'glomerulonephritis']	3	17	"Sentence: In addition to renal allografts with TG , we also examined grafts with acute rejection , recurrent glomerulonephritis , chronic allograft nephropathy and stable grafts ( "" protocol biopsies "" ) .
Diseases: chronic allograft nephropathy, tg, glomerulonephritis"	"Sentence: In addition to renal allografts with TG , we also examined grafts with acute rejection , recurrent glomerulonephritis , chronic allograft nephropathy and stable grafts ( "" protocol biopsies "" ) .
Diseases:"
1200	Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy , malignant hypertension , acute interstitial nephritis , and acute tubular necrosis .	O O O O O O O O B O O O O O B I O B I O O B I O O B I I O	['thrombotic microangiopathy', 'interstitial nephritis', 'acute tubular necrosis', 'glomerulopathies', 'malignant hypertension']	5	30	"Sentence: Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy , malignant hypertension , acute interstitial nephritis , and acute tubular necrosis .
Diseases: thrombotic microangiopathy, interstitial nephritis, acute tubular necrosis, glomerulopathies, malignant hypertension"	"Sentence: Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy , malignant hypertension , acute interstitial nephritis , and acute tubular necrosis .
Diseases:"
1201	We found PTCR in 14 of 15 cases of TG , in 7 transplant biopsy specimens without TG , and in 13 of 143 native kidney biopsy specimens .	O O O O O O O O O B O O O O O O O B O O O O O O O O O O O	['tg']	1	1	"Sentence: We found PTCR in 14 of 15 cases of TG , in 7 transplant biopsy specimens without TG , and in 13 of 143 native kidney biopsy specimens .
Diseases: tg"	"Sentence: We found PTCR in 14 of 15 cases of TG , in 7 transplant biopsy specimens without TG , and in 13 of 143 native kidney biopsy specimens .
Diseases:"
1202	These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and cocaine - related acute renal failure .	O O O O O B I O B I O B I O B I I I O O B O O O O O B I I O	['lupus nephritis', 'thrombotic microangiopathy', 'glomerulonephritis', 'henoch - schonlein nephritis', 'acute renal failure', 'malignant hypertension']	6	41	"Sentence: These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and cocaine - related acute renal failure .
Diseases: lupus nephritis, thrombotic microangiopathy, glomerulonephritis, henoch - schonlein nephritis, acute renal failure, malignant hypertension"	"Sentence: These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and cocaine - related acute renal failure .
Diseases:"
1203	Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow - up periods of between 3 months and 1 year .	O O O O O B O O O B I O O B O O O O O O O O O O O O O	['renal failure', 'tg', 'proteinuria']	3	9	"Sentence: Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow - up periods of between 3 months and 1 year .
Diseases: renal failure, tg, proteinuria"	"Sentence: Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow - up periods of between 3 months and 1 year .
Diseases:"
1204	CONCLUSIONS : We conclude that in transplants , there is a strong association between well - developed PTCR and TG , while the significance of mild PTCR and its predictive value in the absence of TG is unclear .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O O O	['tg']	1	1	"Sentence: CONCLUSIONS : We conclude that in transplants , there is a strong association between well - developed PTCR and TG , while the significance of mild PTCR and its predictive value in the absence of TG is unclear .
Diseases: tg"	"Sentence: CONCLUSIONS : We conclude that in transplants , there is a strong association between well - developed PTCR and TG , while the significance of mild PTCR and its predictive value in the absence of TG is unclear .
Diseases:"
1205	PTCR also occurs in certain native kidney diseases , though the association is not as strong as that for TG .	O O O O O O B I O O O O O O O O O O O B O	['tg', 'kidney diseases']	2	6	"Sentence: PTCR also occurs in certain native kidney diseases , though the association is not as strong as that for TG .
Diseases: tg, kidney diseases"	"Sentence: PTCR also occurs in certain native kidney diseases , though the association is not as strong as that for TG .
Diseases:"
1206	We suggest that repeated endothelial injury , including immunologic injury , may be the cause of this lesion both in allografts and native kidneys .	O O O O B I O O B I O O O O O O O O O O O O O O O	['endothelial injury', 'immunologic injury']	2	8	"Sentence: We suggest that repeated endothelial injury , including immunologic injury , may be the cause of this lesion both in allografts and native kidneys .
Diseases: endothelial injury, immunologic injury"	"Sentence: We suggest that repeated endothelial injury , including immunologic injury , may be the cause of this lesion both in allografts and native kidneys .
Diseases:"
1207	Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti - cocaine effects in mice .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti - cocaine effects in mice .
Diseases: "	"Sentence: Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti - cocaine effects in mice .
Diseases:"
1208	Cocaine 's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cocaine 's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects .
Diseases: "	"Sentence: Cocaine 's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects .
Diseases:"
1209	Therefore , three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice : BD1018 ( 3S - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) , BD1063 ( 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 4 - methylpiperazine ) , and LR132 ( 1R , 2S - ( + ) - cis - N - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 2 - ( 1 - pyrrolidinyl ) cyclohexylamine ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Therefore , three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice : BD1018 ( 3S - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) , BD1063 ( 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 4 - methylpiperazine ) , and LR132 ( 1R , 2S - ( + ) - cis - N - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 2 - ( 1 - pyrrolidinyl ) cyclohexylamine ) .
Diseases: "	"Sentence: Therefore , three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice : BD1018 ( 3S - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) , BD1063 ( 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 4 - methylpiperazine ) , and LR132 ( 1R , 2S - ( + ) - cis - N - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 2 - ( 1 - pyrrolidinyl ) cyclohexylamine ) .
Diseases:"
1210	Competition binding assays demonstrated that all three compounds have high affinities for sigma1 receptors .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Competition binding assays demonstrated that all three compounds have high affinities for sigma1 receptors .
Diseases: "	"Sentence: Competition binding assays demonstrated that all three compounds have high affinities for sigma1 receptors .
Diseases:"
1211	The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine , opioid , GABA ( A ) and NMDA receptors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine , opioid , GABA ( A ) and NMDA receptors .
Diseases: "	"Sentence: The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine , opioid , GABA ( A ) and NMDA receptors .
Diseases:"
1212	In behavioral studies , pre - treatment of mice with BD1018 , BD1063 , or LR132 significantly attenuated cocaine - induced convulsions and lethality .	O O O O O O O O O O O O O O O O O O O O O B O O O	['convulsions']	1	3	"Sentence: In behavioral studies , pre - treatment of mice with BD1018 , BD1063 , or LR132 significantly attenuated cocaine - induced convulsions and lethality .
Diseases: convulsions"	"Sentence: In behavioral studies , pre - treatment of mice with BD1018 , BD1063 , or LR132 significantly attenuated cocaine - induced convulsions and lethality .
Diseases:"
1213	Moreover , post - treatment with LR132 prevented cocaine - induced lethality in a significant proportion of animals .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Moreover , post - treatment with LR132 prevented cocaine - induced lethality in a significant proportion of animals .
Diseases: "	"Sentence: Moreover , post - treatment with LR132 prevented cocaine - induced lethality in a significant proportion of animals .
Diseases:"
1214	In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral toxicity of cocaine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	['toxicity']	1	2	"Sentence: In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral toxicity of cocaine .
Diseases: toxicity"	"Sentence: In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral toxicity of cocaine .
Diseases:"
1215	At doses where alone , they produced no significant effects on locomotion , BD1018 , BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At doses where alone , they produced no significant effects on locomotion , BD1018 , BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine .
Diseases: "	"Sentence: At doses where alone , they produced no significant effects on locomotion , BD1018 , BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine .
Diseases:"
1216	To further validate the hypothesis that the anti - cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['convulsive']	1	2	"Sentence: To further validate the hypothesis that the anti - cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine .
Diseases: convulsive"	"Sentence: To further validate the hypothesis that the anti - cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine .
Diseases:"
1217	Together , the data suggests that functional antagonism of sigma receptors is capable of attenuating a number of cocaine - induced behaviors .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Together , the data suggests that functional antagonism of sigma receptors is capable of attenuating a number of cocaine - induced behaviors .
Diseases: "	"Sentence: Together , the data suggests that functional antagonism of sigma receptors is capable of attenuating a number of cocaine - induced behaviors .
Diseases:"
1218	Pharmacokinetic / pharmacodynamic assessment of the effects of E4031 , cisapride , terfenadine and terodiline on monophasic action potential duration in dog .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pharmacokinetic / pharmacodynamic assessment of the effects of E4031 , cisapride , terfenadine and terodiline on monophasic action potential duration in dog .
Diseases: "	"Sentence: Pharmacokinetic / pharmacodynamic assessment of the effects of E4031 , cisapride , terfenadine and terodiline on monophasic action potential duration in dog .
Diseases:"
1219	1 .	O O	[]	0	0	"Sentence: 1 .
Diseases: "	"Sentence: 1 .
Diseases:"
1220	Torsades de pointes ( TDP ) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration ( MAPD ) .	B I I O B O O O O O B I O O O O O O O O O O O O O O O	['ventricular tachycardia', 'tdp', 'torsades de pointes']	3	16	"Sentence: Torsades de pointes ( TDP ) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration ( MAPD ) .
Diseases: ventricular tachycardia, tdp, torsades de pointes"	"Sentence: Torsades de pointes ( TDP ) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration ( MAPD ) .
Diseases:"
1221	TDP is a side - effect that has led to withdrawal of several drugs from the market ( e . g . terfenadine and terodiline ) .	B O O O O O O O O O O O O O O O O O O O O O O O O O O	['tdp']	1	2	"Sentence: TDP is a side - effect that has led to withdrawal of several drugs from the market ( e . g . terfenadine and terodiline ) .
Diseases: tdp"	"Sentence: TDP is a side - effect that has led to withdrawal of several drugs from the market ( e . g . terfenadine and terodiline ) .
Diseases:"
1222	2 .	O O	[]	0	0	"Sentence: 2 .
Diseases: "	"Sentence: 2 .
Diseases:"
1223	The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog .	O O O O O O B O O O O O O O O O O O	['tdp']	1	2	"Sentence: The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog .
Diseases: tdp"	"Sentence: The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog .
Diseases:"
1224	Four compounds known to increase QT interval and cause TDP were investigated : terfenadine , terodiline , cisapride and E4031 .	O O O O O O O O O B O O O O O O O O O O O	['tdp']	1	2	"Sentence: Four compounds known to increase QT interval and cause TDP were investigated : terfenadine , terodiline , cisapride and E4031 .
Diseases: tdp"	"Sentence: Four compounds known to increase QT interval and cause TDP were investigated : terfenadine , terodiline , cisapride and E4031 .
Diseases:"
1225	On the basis that only free drug in the systemic circulation will elicit a pharmacological response target , free concentrations in plasma were selected to mimic the free drug exposures in man .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On the basis that only free drug in the systemic circulation will elicit a pharmacological response target , free concentrations in plasma were selected to mimic the free drug exposures in man .
Diseases: "	"Sentence: On the basis that only free drug in the systemic circulation will elicit a pharmacological response target , free concentrations in plasma were selected to mimic the free drug exposures in man .
Diseases:"
1226	Infusion regimens were designed that rapidly achieved and maintained target - free concentrations of these drugs in plasma and data on the relationship between free concentration and changes in MAPD were obtained for these compounds .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Infusion regimens were designed that rapidly achieved and maintained target - free concentrations of these drugs in plasma and data on the relationship between free concentration and changes in MAPD were obtained for these compounds .
Diseases: "	"Sentence: Infusion regimens were designed that rapidly achieved and maintained target - free concentrations of these drugs in plasma and data on the relationship between free concentration and changes in MAPD were obtained for these compounds .
Diseases:"
1227	3 .	O O	[]	0	0	"Sentence: 3 .
Diseases: "	"Sentence: 3 .
Diseases:"
1228	These data indicate that the free ED50 in plasma for terfenadine ( 1 . 9 nM ) , terodiline ( 76 nM ) , cisapride ( 11 nM ) and E4031 ( 1 . 9 nM ) closely correlate with the free concentration in man causing QT effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These data indicate that the free ED50 in plasma for terfenadine ( 1 . 9 nM ) , terodiline ( 76 nM ) , cisapride ( 11 nM ) and E4031 ( 1 . 9 nM ) closely correlate with the free concentration in man causing QT effects .
Diseases: "	"Sentence: These data indicate that the free ED50 in plasma for terfenadine ( 1 . 9 nM ) , terodiline ( 76 nM ) , cisapride ( 11 nM ) and E4031 ( 1 . 9 nM ) closely correlate with the free concentration in man causing QT effects .
Diseases:"
1229	For compounds that have shown TDP in the clinic ( terfenadine , terodiline , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10 - fold ) reflecting their limited safety margins .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tdp']	1	2	"Sentence: For compounds that have shown TDP in the clinic ( terfenadine , terodiline , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10 - fold ) reflecting their limited safety margins .
Diseases: tdp"	"Sentence: For compounds that have shown TDP in the clinic ( terfenadine , terodiline , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10 - fold ) reflecting their limited safety margins .
Diseases:"
1230	These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic / pharmacodynamic studies .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['tdp']	1	2	"Sentence: These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic / pharmacodynamic studies .
Diseases: tdp"	"Sentence: These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic / pharmacodynamic studies .
Diseases:"
1231	Fatal myeloencephalopathy due to accidental intrathecal vincristin administration : a report of two cases .	O B O O O O O O O O O O O O O	['myeloencephalopathy']	1	5	"Sentence: Fatal myeloencephalopathy due to accidental intrathecal vincristin administration : a report of two cases .
Diseases: myeloencephalopathy"	"Sentence: Fatal myeloencephalopathy due to accidental intrathecal vincristin administration : a report of two cases .
Diseases:"
1232	We report on two fatal cases of accidental intrathecal vincristine instillation in a 5 - year old girl with recurrent acute lymphoblastic leucemia and a 57 - year old man with lymphoblastic lymphoma .	O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O B I O	['acute lymphoblastic leucemia', 'lymphoblastic lymphoma']	2	14	"Sentence: We report on two fatal cases of accidental intrathecal vincristine instillation in a 5 - year old girl with recurrent acute lymphoblastic leucemia and a 57 - year old man with lymphoblastic lymphoma .
Diseases: acute lymphoblastic leucemia, lymphoblastic lymphoma"	"Sentence: We report on two fatal cases of accidental intrathecal vincristine instillation in a 5 - year old girl with recurrent acute lymphoblastic leucemia and a 57 - year old man with lymphoblastic lymphoma .
Diseases:"
1233	The girl died seven days , the man four weeks after intrathecal injection of vincristine .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The girl died seven days , the man four weeks after intrathecal injection of vincristine .
Diseases: "	"Sentence: The girl died seven days , the man four weeks after intrathecal injection of vincristine .
Diseases:"
1234	Clinically , the onset was characterized by the signs of opistothonus , sensory and motor dysfunction and ascending paralysis .	O O O O O O O O O O B I I I I I O O B O	['paralysis', 'opistothonus , sensory and motor dysfunction']	2	13	"Sentence: Clinically , the onset was characterized by the signs of opistothonus , sensory and motor dysfunction and ascending paralysis .
Diseases: paralysis, opistothonus , sensory and motor dysfunction"	"Sentence: Clinically , the onset was characterized by the signs of opistothonus , sensory and motor dysfunction and ascending paralysis .
Diseases:"
1235	Histological and immunohistochemical investigations ( HE - LFB , CD - 68 , Neurofilament ) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine , accompanied by secondary changes with numerous prominent macrophages .	O O O O O O O O O O O O O O O O B I I I I O O O B I O O O O O O O O O O O O O O O	['pseudocystic transformation', 'degeneration of myelin and axons']	2	14	"Sentence: Histological and immunohistochemical investigations ( HE - LFB , CD - 68 , Neurofilament ) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine , accompanied by secondary changes with numerous prominent macrophages .
Diseases: pseudocystic transformation, degeneration of myelin and axons"	"Sentence: Histological and immunohistochemical investigations ( HE - LFB , CD - 68 , Neurofilament ) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine , accompanied by secondary changes with numerous prominent macrophages .
Diseases:"
1236	The clinical course and histopathological results of the two cases are presented .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The clinical course and histopathological results of the two cases are presented .
Diseases: "	"Sentence: The clinical course and histopathological results of the two cases are presented .
Diseases:"
1237	A review of all reported cases in the literature is given .	O O O O O O O O O O O O	[]	0	0	"Sentence: A review of all reported cases in the literature is given .
Diseases: "	"Sentence: A review of all reported cases in the literature is given .
Diseases:"
1238	A better controlled regimen for administering vincristine and intrathecal chemotherapy is recommended .	O O O O O O O O O O O O O	[]	0	0	"Sentence: A better controlled regimen for administering vincristine and intrathecal chemotherapy is recommended .
Diseases: "	"Sentence: A better controlled regimen for administering vincristine and intrathecal chemotherapy is recommended .
Diseases:"
1239	Intravenous administration of prochlorperazine by 15 - minute infusion versus 2 - minute bolus does not affect the incidence of akathisia : a prospective , randomized , controlled trial .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['akathisia']	1	4	"Sentence: Intravenous administration of prochlorperazine by 15 - minute infusion versus 2 - minute bolus does not affect the incidence of akathisia : a prospective , randomized , controlled trial .
Diseases: akathisia"	"Sentence: Intravenous administration of prochlorperazine by 15 - minute infusion versus 2 - minute bolus does not affect the incidence of akathisia : a prospective , randomized , controlled trial .
Diseases:"
1240	STUDY OBJECTIVE :	O O O	[]	0	0	"Sentence: STUDY OBJECTIVE :
Diseases: "	"Sentence: STUDY OBJECTIVE :
Diseases:"
1241	We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2 - minute bolus or 15 - minute infusion .	O O O O O O O B O O O O O O O O O O O O O O O O O	['akathisia']	1	4	"Sentence: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2 - minute bolus or 15 - minute infusion .
Diseases: akathisia"	"Sentence: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2 - minute bolus or 15 - minute infusion .
Diseases:"
1242	METHODS : We conducted a prospective , randomized , double - blind study in the emergency department of a central - city teaching hospital .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : We conducted a prospective , randomized , double - blind study in the emergency department of a central - city teaching hospital .
Diseases: "	"Sentence: METHODS : We conducted a prospective , randomized , double - blind study in the emergency department of a central - city teaching hospital .
Diseases:"
1243	Patients aged 18 years or older treated with prochlorperazine for headache , nausea , or vomiting were eligible for inclusion .	O O O O O O O O O O B O B O O B O O O O O	['nausea', 'vomiting', 'headache']	3	7	"Sentence: Patients aged 18 years or older treated with prochlorperazine for headache , nausea , or vomiting were eligible for inclusion .
Diseases: nausea, vomiting, headache"	"Sentence: Patients aged 18 years or older treated with prochlorperazine for headache , nausea , or vomiting were eligible for inclusion .
Diseases:"
1244	Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2 - minute push ( bolus group ) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15 - minute period ( infusion group ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2 - minute push ( bolus group ) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15 - minute period ( infusion group ) .
Diseases: "	"Sentence: Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2 - minute push ( bolus group ) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15 - minute period ( infusion group ) .
Diseases:"
1245	The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration .	O O O O O O O O O O B O O O O O O	['akathisia']	1	4	"Sentence: The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration .
Diseases: akathisia"	"Sentence: The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration .
Diseases:"
1246	Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient - reported akathisia rating scale and a change of at least 1 in the investigator - observed akathisia rating scale .	O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O	['agitation', 'akathisia']	2	7	"Sentence: Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient - reported akathisia rating scale and a change of at least 1 in the investigator - observed akathisia rating scale .
Diseases: agitation, akathisia"	"Sentence: Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient - reported akathisia rating scale and a change of at least 1 in the investigator - observed akathisia rating scale .
Diseases:"
1247	The intensity of headache and nausea was measured with a 100 - mm visual analog scale .	O O O B O B O O O O O O O O O O O	['nausea', 'headache']	2	5	"Sentence: The intensity of headache and nausea was measured with a 100 - mm visual analog scale .
Diseases: nausea, headache"	"Sentence: The intensity of headache and nausea was measured with a 100 - mm visual analog scale .
Diseases:"
1248	One hundred patients were enrolled .	O O O O O O	[]	0	0	"Sentence: One hundred patients were enrolled .
Diseases: "	"Sentence: One hundred patients were enrolled .
Diseases:"
1249	One study participant was excluded after protocol violation .	O O O O O O O O O	[]	0	0	"Sentence: One study participant was excluded after protocol violation .
Diseases: "	"Sentence: One study participant was excluded after protocol violation .
Diseases:"
1250	Seventy - three percent ( 73 / 99 ) of the study participants were treated for headache and 70 % ( 70 / 99 ) for nausea .	O O O O O O O O O O O O O O O O B O O O O O O O O O B O	['nausea', 'headache']	2	5	"Sentence: Seventy - three percent ( 73 / 99 ) of the study participants were treated for headache and 70 % ( 70 / 99 ) for nausea .
Diseases: nausea, headache"	"Sentence: Seventy - three percent ( 73 / 99 ) of the study participants were treated for headache and 70 % ( 70 / 99 ) for nausea .
Diseases:"
1251	In the bolus group , 26 . 0 % ( 13 / 50 ) had akathisia compared with 32 . 7 % ( 16 / 49 ) in the infusion group ( Delta = - 6 . 7 % ; 95 % confidence interval [ CI ] - 24 . 6 % to 11 . 2 % ) .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['akathisia']	1	4	"Sentence: In the bolus group , 26 . 0 % ( 13 / 50 ) had akathisia compared with 32 . 7 % ( 16 / 49 ) in the infusion group ( Delta = - 6 . 7 % ; 95 % confidence interval [ CI ] - 24 . 6 % to 11 . 2 % ) .
Diseases: akathisia"	"Sentence: In the bolus group , 26 . 0 % ( 13 / 50 ) had akathisia compared with 32 . 7 % ( 16 / 49 ) in the infusion group ( Delta = - 6 . 7 % ; 95 % confidence interval [ CI ] - 24 . 6 % to 11 . 2 % ) .
Diseases:"
1252	The difference between the bolus and infusion groups in the percentage of participants who saw a 50 % reduction in their headache intensity within 30 minutes was 11 . 8 % ( 95 % CI - 9 . 6 % to 33 . 3 % ) .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['headache']	1	2	"Sentence: The difference between the bolus and infusion groups in the percentage of participants who saw a 50 % reduction in their headache intensity within 30 minutes was 11 . 8 % ( 95 % CI - 9 . 6 % to 33 . 3 % ) .
Diseases: headache"	"Sentence: The difference between the bolus and infusion groups in the percentage of participants who saw a 50 % reduction in their headache intensity within 30 minutes was 11 . 8 % ( 95 % CI - 9 . 6 % to 33 . 3 % ) .
Diseases:"
1253	The difference in the percentage of patients with a 50 % reduction in their nausea was 12 . 6 % ( 95 % CI - 4 . 6 % to 29 . 8 % ) .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['nausea']	1	3	"Sentence: The difference in the percentage of patients with a 50 % reduction in their nausea was 12 . 6 % ( 95 % CI - 4 . 6 % to 29 . 8 % ) .
Diseases: nausea"	"Sentence: The difference in the percentage of patients with a 50 % reduction in their nausea was 12 . 6 % ( 95 % CI - 4 . 6 % to 29 . 8 % ) .
Diseases:"
1254	A 50 % reduction in the incidence of akathisia when prochlorperazine was administered by means of 15 - minute intravenous infusion versus a 2 - minute intravenous push was not detected .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['akathisia']	1	4	"Sentence: A 50 % reduction in the incidence of akathisia when prochlorperazine was administered by means of 15 - minute intravenous infusion versus a 2 - minute intravenous push was not detected .
Diseases: akathisia"	"Sentence: A 50 % reduction in the incidence of akathisia when prochlorperazine was administered by means of 15 - minute intravenous infusion versus a 2 - minute intravenous push was not detected .
Diseases:"
1255	The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .	O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O	['nausea', 'headache']	2	5	"Sentence: The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .
Diseases: nausea, headache"	"Sentence: The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .
Diseases:"
1256	Antithymocyte globulin in the treatment of D - penicillamine - induced aplastic anemia .	O O O O O O O O O O O B I O	['aplastic anemia']	1	5	"Sentence: Antithymocyte globulin in the treatment of D - penicillamine - induced aplastic anemia .
Diseases: aplastic anemia"	"Sentence: Antithymocyte globulin in the treatment of D - penicillamine - induced aplastic anemia .
Diseases:"
1257	A patient who received antithymocyte globulin therapy for aplastic anemia due to D - penicillamine therapy is described .	O O O O O O O O B I O O O O O O O O O	['aplastic anemia']	1	5	"Sentence: A patient who received antithymocyte globulin therapy for aplastic anemia due to D - penicillamine therapy is described .
Diseases: aplastic anemia"	"Sentence: A patient who received antithymocyte globulin therapy for aplastic anemia due to D - penicillamine therapy is described .
Diseases:"
1258	Bone marrow recovery and peripheral blood recovery were complete 1 month and 3 months , respectively , after treatment , and blood transfusion or other therapies were not necessary in a follow - up period of more than 2 years .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Bone marrow recovery and peripheral blood recovery were complete 1 month and 3 months , respectively , after treatment , and blood transfusion or other therapies were not necessary in a follow - up period of more than 2 years .
Diseases: "	"Sentence: Bone marrow recovery and peripheral blood recovery were complete 1 month and 3 months , respectively , after treatment , and blood transfusion or other therapies were not necessary in a follow - up period of more than 2 years .
Diseases:"
1259	Use of antithymocyte globulin may be the optimal treatment of D - penicillamine - induced aplastic anemia .	O O O O O O O O O O O O O O O B I O	['aplastic anemia']	1	5	"Sentence: Use of antithymocyte globulin may be the optimal treatment of D - penicillamine - induced aplastic anemia .
Diseases: aplastic anemia"	"Sentence: Use of antithymocyte globulin may be the optimal treatment of D - penicillamine - induced aplastic anemia .
Diseases:"
1260	The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure - prone and withdrawal seizure - resistant selected mouse lines .	O O O O O O O O O O O O B O O O O B O O O O O O	['seizure']	1	3	"Sentence: The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure - prone and withdrawal seizure - resistant selected mouse lines .
Diseases: seizure"	"Sentence: The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure - prone and withdrawal seizure - resistant selected mouse lines .
Diseases:"
1261	The septo - hippocampal cholinergic pathway has been implicated in epileptogenesis , and genetic factors influence the response to cholinergic agents , but limited data are available on cholinergic involvement in alcohol withdrawal severity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The septo - hippocampal cholinergic pathway has been implicated in epileptogenesis , and genetic factors influence the response to cholinergic agents , but limited data are available on cholinergic involvement in alcohol withdrawal severity .
Diseases: "	"Sentence: The septo - hippocampal cholinergic pathway has been implicated in epileptogenesis , and genetic factors influence the response to cholinergic agents , but limited data are available on cholinergic involvement in alcohol withdrawal severity .
Diseases:"
1262	Thus , the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thus , the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity .
Diseases: "	"Sentence: Thus , the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity .
Diseases:"
1263	METHODS : Cholinergic convulsant sensitivity was examined in alcohol - na ve Withdrawal Seizure - Prone ( WSP ) and - Resistant ( WSR ) mice .	O O O O O O O O O O O O O B O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: METHODS : Cholinergic convulsant sensitivity was examined in alcohol - na ve Withdrawal Seizure - Prone ( WSP ) and - Resistant ( WSR ) mice .
Diseases: seizure"	"Sentence: METHODS : Cholinergic convulsant sensitivity was examined in alcohol - na ve Withdrawal Seizure - Prone ( WSP ) and - Resistant ( WSR ) mice .
Diseases:"
1264	Animals were administered nicotine , carbachol , or neostigmine via timed tail vein infusion , and the latencies to onset of tremor and clonus were recorded and converted to threshold dose .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['tremor']	1	3	"Sentence: Animals were administered nicotine , carbachol , or neostigmine via timed tail vein infusion , and the latencies to onset of tremor and clonus were recorded and converted to threshold dose .
Diseases: tremor"	"Sentence: Animals were administered nicotine , carbachol , or neostigmine via timed tail vein infusion , and the latencies to onset of tremor and clonus were recorded and converted to threshold dose .
Diseases:"
1265	We also used microdialysis to measure basal and potassium - stimulated acetylcholine ( ACh ) release in the CA1 region of the hippocampus .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We also used microdialysis to measure basal and potassium - stimulated acetylcholine ( ACh ) release in the CA1 region of the hippocampus .
Diseases: "	"Sentence: We also used microdialysis to measure basal and potassium - stimulated acetylcholine ( ACh ) release in the CA1 region of the hippocampus .
Diseases:"
1266	Potassium was applied by reverse dialysis twice , separated by 75 min .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Potassium was applied by reverse dialysis twice , separated by 75 min .
Diseases: "	"Sentence: Potassium was applied by reverse dialysis twice , separated by 75 min .
Diseases:"
1267	Hippocampal ACh also was measured during testing for handling - induced convulsions .	O O O O O O O O O O O B O	['convulsions']	1	3	"Sentence: Hippocampal ACh also was measured during testing for handling - induced convulsions .
Diseases: convulsions"	"Sentence: Hippocampal ACh also was measured during testing for handling - induced convulsions .
Diseases:"
1268	Sensitivity to several convulsion endpoints induced by nicotine , carbachol , and neostigmine were significantly greater in WSR versus WSP mice .	O O O B O O O O O O O O O O O O O O O O O O	['convulsion']	1	2	"Sentence: Sensitivity to several convulsion endpoints induced by nicotine , carbachol , and neostigmine were significantly greater in WSR versus WSP mice .
Diseases: convulsion"	"Sentence: Sensitivity to several convulsion endpoints induced by nicotine , carbachol , and neostigmine were significantly greater in WSR versus WSP mice .
Diseases:"
1269	In microdialysis experiments , the lines did not differ in basal release of ACh , and 50 mM KCl increased ACh output in both lines of mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In microdialysis experiments , the lines did not differ in basal release of ACh , and 50 mM KCl increased ACh output in both lines of mice .
Diseases: "	"Sentence: In microdialysis experiments , the lines did not differ in basal release of ACh , and 50 mM KCl increased ACh output in both lines of mice .
Diseases:"
1270	However , the increase in release of ACh produced by the first application of KCl was 2 - fold higher in WSP versus WSR mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the increase in release of ACh produced by the first application of KCl was 2 - fold higher in WSP versus WSR mice .
Diseases: "	"Sentence: However , the increase in release of ACh produced by the first application of KCl was 2 - fold higher in WSP versus WSR mice .
Diseases:"
1271	When hippocampal ACh was measured during testing for handling - induced convulsions , extracellular ACh was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: When hippocampal ACh was measured during testing for handling - induced convulsions , extracellular ACh was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .
Diseases: convulsions"	"Sentence: When hippocampal ACh was measured during testing for handling - induced convulsions , extracellular ACh was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .
Diseases:"
1272	CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['convulsants']	1	3	"Sentence: CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal .
Diseases: convulsants"	"Sentence: CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal .
Diseases:"
1273	Specifically , WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['convulsants']	1	3	"Sentence: Specifically , WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons .
Diseases: convulsants"	"Sentence: Specifically , WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons .
Diseases:"
1274	Prenatal dexamethasone programs hypertension and renal injury in the rat .	O O O B O B I O O O O	['renal injury', 'hypertension']	2	5	"Sentence: Prenatal dexamethasone programs hypertension and renal injury in the rat .
Diseases: renal injury, hypertension"	"Sentence: Prenatal dexamethasone programs hypertension and renal injury in the rat .
Diseases:"
1275	Dexamethasone is frequently administered to the developing fetus to accelerate pulmonary development .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Dexamethasone is frequently administered to the developing fetus to accelerate pulmonary development .
Diseases: "	"Sentence: Dexamethasone is frequently administered to the developing fetus to accelerate pulmonary development .
Diseases:"
1276	The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats .	O O O O O O O O O O O O O O O B I I I O B I O O O	['renal injury', 'increase in blood pressure']	2	8	"Sentence: The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats .
Diseases: renal injury, increase in blood pressure"	"Sentence: The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats .
Diseases:"
1277	Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone ( 0 . 2 mg / kg body weight ) on gestational days 11 and 12 , 13 and 14 , 15 and 16 , 17 and 18 , or 19 and 20 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone ( 0 . 2 mg / kg body weight ) on gestational days 11 and 12 , 13 and 14 , 15 and 16 , 17 and 18 , or 19 and 20 .
Diseases: "	"Sentence: Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone ( 0 . 2 mg / kg body weight ) on gestational days 11 and 12 , 13 and 14 , 15 and 16 , 17 and 18 , or 19 and 20 .
Diseases:"
1278	Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20 % reduction in glomerular number compared with control at 6 to 9 months of age ( 22 527 + / - 509 versus 28 050 + / - 561 , P < 0 . 05 ) , which was comparable to the percent reduction in glomeruli measured at 3 weeks of age .	O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['reduction in glomerular number']	1	7	"Sentence: Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20 % reduction in glomerular number compared with control at 6 to 9 months of age ( 22 527 + / - 509 versus 28 050 + / - 561 , P < 0 . 05 ) , which was comparable to the percent reduction in glomeruli measured at 3 weeks of age .
Diseases: reduction in glomerular number"	"Sentence: Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20 % reduction in glomerular number compared with control at 6 to 9 months of age ( 22 527 + / - 509 versus 28 050 + / - 561 , P < 0 . 05 ) , which was comparable to the percent reduction in glomeruli measured at 3 weeks of age .
Diseases:"
1279	Six - to 9 - month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17 % reduction in glomeruli ( 23 380 + / - 587 ) compared with control rats ( P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Six - to 9 - month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17 % reduction in glomeruli ( 23 380 + / - 587 ) compared with control rats ( P < 0 . 05 ) .
Diseases: "	"Sentence: Six - to 9 - month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17 % reduction in glomeruli ( 23 380 + / - 587 ) compared with control rats ( P < 0 . 05 ) .
Diseases:"
1280	Male rats that received prenatal dexamethasone on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had elevated blood pressures at 6 months of age ; the latter group did not have a reduction in glomerular number .	O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O B I I I O	['elevated blood pressures', 'reduction in glomerular number']	2	12	"Sentence: Male rats that received prenatal dexamethasone on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had elevated blood pressures at 6 months of age ; the latter group did not have a reduction in glomerular number .
Diseases: elevated blood pressures, reduction in glomerular number"	"Sentence: Male rats that received prenatal dexamethasone on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had elevated blood pressures at 6 months of age ; the latter group did not have a reduction in glomerular number .
Diseases:"
1281	Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats .	O O O O O O O O O O O O O O O B O O O O	['glomerulosclerosis']	1	4	"Sentence: Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats .
Diseases: glomerulosclerosis"	"Sentence: Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats .
Diseases:"
1282	This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number , glomerulosclerosis , and hypertension when administered at specific points during gestation .	O O O O O O O O O O O B I I I O B O O B O O O O O O O O	['hypertension', 'glomerulosclerosis', 'reduction in glomerular number']	3	15	"Sentence: This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number , glomerulosclerosis , and hypertension when administered at specific points during gestation .
Diseases: hypertension, glomerulosclerosis, reduction in glomerular number"	"Sentence: This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number , glomerulosclerosis , and hypertension when administered at specific points during gestation .
Diseases:"
1283	Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number , suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension .	B O O O O O O O O O O O O O O O O O O O O O B I I I O O O O B I I I O O O O O O O O O B O	['reduction in glomerular number', 'hypertension']	2	10	"Sentence: Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number , suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension .
Diseases: reduction in glomerular number, hypertension"	"Sentence: Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number , suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension .
Diseases:"
1284	The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol : a nested cohort analysis and case - control study .	O O O B I O O O O O O O O O O O O O O O O O O O O O	['venous thromboembolism']	1	8	"Sentence: The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol : a nested cohort analysis and case - control study .
Diseases: venous thromboembolism"	"Sentence: The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol : a nested cohort analysis and case - control study .
Diseases:"
1285	Cyproterone acetate combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .	O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O B I I O B O O	['acne', 'polycystic ovary syndrome', 'hirsutism', 'pcos']	4	17	"Sentence: Cyproterone acetate combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
Diseases: acne, polycystic ovary syndrome, hirsutism, pcos"	"Sentence: Cyproterone acetate combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .
Diseases:"
1286	Previous studies have demonstrated an increased risk of venous thromboembolism ( VTE ) associated with CPA / EE compared with conventional combined oral contraceptives ( COCs ) .	O O O O O O O O B I O B O O O O O O O O O O O O O O O O	['vte', 'venous thromboembolism']	2	11	"Sentence: Previous studies have demonstrated an increased risk of venous thromboembolism ( VTE ) associated with CPA / EE compared with conventional combined oral contraceptives ( COCs ) .
Diseases: vte, venous thromboembolism"	"Sentence: Previous studies have demonstrated an increased risk of venous thromboembolism ( VTE ) associated with CPA / EE compared with conventional combined oral contraceptives ( COCs ) .
Diseases:"
1287	We believe the results of those studies may have been affected by residual confounding .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We believe the results of those studies may have been affected by residual confounding .
Diseases: "	"Sentence: We believe the results of those studies may have been affected by residual confounding .
Diseases:"
1288	METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of VTE associated with CPA / EE .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O B O O O O O B O O O O O O	['vte', 'acne', 'pcos', 'hirsutism']	4	12	"Sentence: METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of VTE associated with CPA / EE .
Diseases: vte, acne, pcos, hirsutism"	"Sentence: METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of VTE associated with CPA / EE .
Diseases:"
1289	The age - adjusted incidence rate ratio for CPA / EE versus conventional COCs was 2 . 20 [ 95 % confidence interval ( CI ) 1 . 35 - 3 . 58 ] .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The age - adjusted incidence rate ratio for CPA / EE versus conventional COCs was 2 . 20 [ 95 % confidence interval ( CI ) 1 . 35 - 3 . 58 ] .
Diseases: "	"Sentence: The age - adjusted incidence rate ratio for CPA / EE versus conventional COCs was 2 . 20 [ 95 % confidence interval ( CI ) 1 . 35 - 3 . 58 ] .
Diseases:"
1290	Using as the reference group women who were not using oral contraception , had no recent pregnancy or menopausal symptoms , the case - control analysis gave an adjusted odds ratio ( OR ( adj ) ) of 7 . 44 ( 95 % CI 3 . 67 - 15 . 08 ) for CPA / EE use compared with an OR ( adj ) of 2 . 58 ( 95 % CI 1 . 60 - 4 . 18 ) for use of conventional COCs .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Using as the reference group women who were not using oral contraception , had no recent pregnancy or menopausal symptoms , the case - control analysis gave an adjusted odds ratio ( OR ( adj ) ) of 7 . 44 ( 95 % CI 3 . 67 - 15 . 08 ) for CPA / EE use compared with an OR ( adj ) of 2 . 58 ( 95 % CI 1 . 60 - 4 . 18 ) for use of conventional COCs .
Diseases: "	"Sentence: Using as the reference group women who were not using oral contraception , had no recent pregnancy or menopausal symptoms , the case - control analysis gave an adjusted odds ratio ( OR ( adj ) ) of 7 . 44 ( 95 % CI 3 . 67 - 15 . 08 ) for CPA / EE use compared with an OR ( adj ) of 2 . 58 ( 95 % CI 1 . 60 - 4 . 18 ) for use of conventional COCs .
Diseases:"
1291	CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of CPA / EE in women with acne , hirsutism or PCOS although residual confounding by indication can not be excluded .	O O O O O O O O O B O O O O O O O O O O O B O B O B O O O O O O O O O O	['vte', 'acne', 'pcos', 'hirsutism']	4	12	"Sentence: CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of CPA / EE in women with acne , hirsutism or PCOS although residual confounding by indication can not be excluded .
Diseases: vte, acne, pcos, hirsutism"	"Sentence: CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of CPA / EE in women with acne , hirsutism or PCOS although residual confounding by indication can not be excluded .
Diseases:"
1292	Pseudoacromegaly induced by the long - term use of minoxidil .	B O O O O O O O O O O	['pseudoacromegaly']	1	6	"Sentence: Pseudoacromegaly induced by the long - term use of minoxidil .
Diseases: pseudoacromegaly"	"Sentence: Pseudoacromegaly induced by the long - term use of minoxidil .
Diseases:"
1293	Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland .	B O O B I O O O O O O O O O O O O O	['endocrine disorder', 'acromegaly']	2	8	"Sentence: Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland .
Diseases: endocrine disorder, acromegaly"	"Sentence: Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland .
Diseases:"
1294	Significant disfiguring changes occur as a result of bone , cartilage , and soft tissue hypertrophy , including the thickening of the skin , coarsening of facial features , and cutis verticis gyrata .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B I I O	['cutis verticis gyrata', 'hypertrophy']	2	12	"Sentence: Significant disfiguring changes occur as a result of bone , cartilage , and soft tissue hypertrophy , including the thickening of the skin , coarsening of facial features , and cutis verticis gyrata .
Diseases: cutis verticis gyrata, hypertrophy"	"Sentence: Significant disfiguring changes occur as a result of bone , cartilage , and soft tissue hypertrophy , including the thickening of the skin , coarsening of facial features , and cutis verticis gyrata .
Diseases:"
1295	Pseudoacromegaly , on the other hand , is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin - like growth factor levels .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pseudoacromegaly']	1	6	"Sentence: Pseudoacromegaly , on the other hand , is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin - like growth factor levels .
Diseases: pseudoacromegaly"	"Sentence: Pseudoacromegaly , on the other hand , is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin - like growth factor levels .
Diseases:"
1296	We present a patient with pseudoacromegaly that resulted from the long - term use of minoxidil at an unusually high dose .	O O O O O B O O O O O O O O O O O O O O O O	['pseudoacromegaly']	1	6	"Sentence: We present a patient with pseudoacromegaly that resulted from the long - term use of minoxidil at an unusually high dose .
Diseases: pseudoacromegaly"	"Sentence: We present a patient with pseudoacromegaly that resulted from the long - term use of minoxidil at an unusually high dose .
Diseases:"
1297	This is the first case report of pseudoacromegaly as a side effect of minoxidil use .	O O O O O O O B O O O O O O O O	['pseudoacromegaly']	1	6	"Sentence: This is the first case report of pseudoacromegaly as a side effect of minoxidil use .
Diseases: pseudoacromegaly"	"Sentence: This is the first case report of pseudoacromegaly as a side effect of minoxidil use .
Diseases:"
1298	Combined androgen blockade - induced anemia in prostate cancer patients without bone involvement .	O O O O O B O B I O O O O O	['prostate cancer', 'anemia']	2	6	"Sentence: Combined androgen blockade - induced anemia in prostate cancer patients without bone involvement .
Diseases: prostate cancer, anemia"	"Sentence: Combined androgen blockade - induced anemia in prostate cancer patients without bone involvement .
Diseases:"
1299	To determine the onset and extent of combined androgen blockade ( CAB ) - induced anemia in prostate cancer patients without bone involvement .	O O O O O O O O O O O O O O O B O B I O O O O O	['prostate cancer', 'anemia']	2	6	"Sentence: To determine the onset and extent of combined androgen blockade ( CAB ) - induced anemia in prostate cancer patients without bone involvement .
Diseases: prostate cancer, anemia"	"Sentence: To determine the onset and extent of combined androgen blockade ( CAB ) - induced anemia in prostate cancer patients without bone involvement .
Diseases:"
1300	PATIENTS AND METHODS : Forty - two patients with biopsy - proven prostatic adenocarcinoma [ 26 with stage C ( T3N0M0 ) and 16 with stage D1 ( T3N1M0 ) ] were included in this study .	O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O	['prostatic adenocarcinoma']	1	8	"Sentence: PATIENTS AND METHODS : Forty - two patients with biopsy - proven prostatic adenocarcinoma [ 26 with stage C ( T3N0M0 ) and 16 with stage D1 ( T3N1M0 ) ] were included in this study .
Diseases: prostatic adenocarcinoma"	"Sentence: PATIENTS AND METHODS : Forty - two patients with biopsy - proven prostatic adenocarcinoma [ 26 with stage C ( T3N0M0 ) and 16 with stage D1 ( T3N1M0 ) ] were included in this study .
Diseases:"
1301	All patients received CAB [ leuprolide acetate ( LHRH - A ) 3 . 75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post - CAB ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: All patients received CAB [ leuprolide acetate ( LHRH - A ) 3 . 75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post - CAB ) .
Diseases: anemia"	"Sentence: All patients received CAB [ leuprolide acetate ( LHRH - A ) 3 . 75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post - CAB ) .
Diseases:"
1302	Hb , PSA and Testosterone measurements were recorded .	O O O O O O O O O	[]	0	0	"Sentence: Hb , PSA and Testosterone measurements were recorded .
Diseases: "	"Sentence: Hb , PSA and Testosterone measurements were recorded .
Diseases:"
1303	Patients with stage D2 - 3 disease , abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients with stage D2 - 3 disease , abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study .
Diseases: "	"Sentence: Patients with stage D2 - 3 disease , abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study .
Diseases:"
1304	The duration of the study was six months .	O O O O O O O O O	[]	0	0	"Sentence: The duration of the study was six months .
Diseases: "	"Sentence: The duration of the study was six months .
Diseases:"
1305	The mean hemoglobin ( Hb ) levels were significantly declined in all patients from baseline of 14 . 2 g / dl to 14 . 0 g / dl , 13 . 5 g / dl , 13 . 2 g / dl and 12 . 7 g / dl at 1 , 2 , 3 and 6 months post - CAB , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean hemoglobin ( Hb ) levels were significantly declined in all patients from baseline of 14 . 2 g / dl to 14 . 0 g / dl , 13 . 5 g / dl , 13 . 2 g / dl and 12 . 7 g / dl at 1 , 2 , 3 and 6 months post - CAB , respectively .
Diseases: "	"Sentence: The mean hemoglobin ( Hb ) levels were significantly declined in all patients from baseline of 14 . 2 g / dl to 14 . 0 g / dl , 13 . 5 g / dl , 13 . 2 g / dl and 12 . 7 g / dl at 1 , 2 , 3 and 6 months post - CAB , respectively .
Diseases:"
1306	Severe and clinically evident anemia of Hb < 11 g / dl with clinical symptoms was detected in 6 patients ( 14 . 3 % ) .	O O O O B O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: Severe and clinically evident anemia of Hb < 11 g / dl with clinical symptoms was detected in 6 patients ( 14 . 3 % ) .
Diseases: anemia"	"Sentence: Severe and clinically evident anemia of Hb < 11 g / dl with clinical symptoms was detected in 6 patients ( 14 . 3 % ) .
Diseases:"
1307	This CAB - induced anemia was normochromic and normocytic .	O O O O B O O O O O	['anemia']	1	2	"Sentence: This CAB - induced anemia was normochromic and normocytic .
Diseases: anemia"	"Sentence: This CAB - induced anemia was normochromic and normocytic .
Diseases:"
1308	At six months post - CAB , patients with severe anemia had a Hb mean value of 10 . 2 + / - 0 . 1 g / dl ( X + / - SE ) , whereas the other patients had mild anemia with Hb mean value of 13 . 2 + / -	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	['anemia']	1	2	"Sentence: At six months post - CAB , patients with severe anemia had a Hb mean value of 10 . 2 + / - 0 . 1 g / dl ( X + / - SE ) , whereas the other patients had mild anemia with Hb mean value of 13 . 2 + / -
Diseases: anemia"	"Sentence: At six months post - CAB , patients with severe anemia had a Hb mean value of 10 . 2 + / - 0 . 1 g / dl ( X + / - SE ) , whereas the other patients had mild anemia with Hb mean value of 13 . 2 + / -
Diseases:"
1309	0 . 17 ( X + / - SE ) .	O O O O O O O O O O O	[]	0	0	"Sentence: 0 . 17 ( X + / - SE ) .
Diseases: "	"Sentence: 0 . 17 ( X + / - SE ) .
Diseases:"
1310	The development of severe anemia at 6 months post - CAB was predictable by the reduction of Hb baseline value of more than 2 . 5 g / dl after 3 months of CAB ( p = 0 . 01 ) .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: The development of severe anemia at 6 months post - CAB was predictable by the reduction of Hb baseline value of more than 2 . 5 g / dl after 3 months of CAB ( p = 0 . 01 ) .
Diseases: anemia"	"Sentence: The development of severe anemia at 6 months post - CAB was predictable by the reduction of Hb baseline value of more than 2 . 5 g / dl after 3 months of CAB ( p = 0 . 01 ) .
Diseases:"
1311	The development of severe CAB - induced anemia in prostate cancer patients did not correlate with T baseline values ( T < 3 ng / ml versus T > or = 3 ng / ml ) , with age ( < 76 yrs versus > or = 76 yrs ) , and clinical stage ( stage C versus stage D1 ) .	O O O O O O O B O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['prostate cancer', 'anemia']	2	6	"Sentence: The development of severe CAB - induced anemia in prostate cancer patients did not correlate with T baseline values ( T < 3 ng / ml versus T > or = 3 ng / ml ) , with age ( < 76 yrs versus > or = 76 yrs ) , and clinical stage ( stage C versus stage D1 ) .
Diseases: prostate cancer, anemia"	"Sentence: The development of severe CAB - induced anemia in prostate cancer patients did not correlate with T baseline values ( T < 3 ng / ml versus T > or = 3 ng / ml ) , with age ( < 76 yrs versus > or = 76 yrs ) , and clinical stage ( stage C versus stage D1 ) .
Diseases:"
1312	Severe and clinically evident anemia was easily corrected by subcutaneous injections ( 3 times / week for 1 month ) of recombinant erythropoietin ( rHuEPO - beta ) .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: Severe and clinically evident anemia was easily corrected by subcutaneous injections ( 3 times / week for 1 month ) of recombinant erythropoietin ( rHuEPO - beta ) .
Diseases: anemia"	"Sentence: Severe and clinically evident anemia was easily corrected by subcutaneous injections ( 3 times / week for 1 month ) of recombinant erythropoietin ( rHuEPO - beta ) .
Diseases:"
1313	Our data suggest that rHuEPO - beta correctable CAB - induced anemia occurs in 14 . 3 % of prostate cancer patients after 6 months of therapy .	O O O O O O O O O O O B O O O O O O O B I O O O O O O O	['prostate cancer', 'anemia']	2	6	"Sentence: Our data suggest that rHuEPO - beta correctable CAB - induced anemia occurs in 14 . 3 % of prostate cancer patients after 6 months of therapy .
Diseases: prostate cancer, anemia"	"Sentence: Our data suggest that rHuEPO - beta correctable CAB - induced anemia occurs in 14 . 3 % of prostate cancer patients after 6 months of therapy .
Diseases:"
1314	Reversible dilated cardiomyopathy related to amphotericin B therapy .	O B I O O O O O O	['dilated cardiomyopathy']	1	6	"Sentence: Reversible dilated cardiomyopathy related to amphotericin B therapy .
Diseases: dilated cardiomyopathy"	"Sentence: Reversible dilated cardiomyopathy related to amphotericin B therapy .
Diseases:"
1315	We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B ( AmB ) for disseminated coccidioidomycosis .	O O O O O O B I O O O B I O O O O O O O O O O O O O B O	['heart failure', 'dilated cardiomyopathy', 'coccidioidomycosis']	3	18	"Sentence: We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B ( AmB ) for disseminated coccidioidomycosis .
Diseases: heart failure, dilated cardiomyopathy, coccidioidomycosis"	"Sentence: We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B ( AmB ) for disseminated coccidioidomycosis .
Diseases:"
1316	His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB .	O O O O B I O O O O O O O O	['heart failure']	1	2	"Sentence: His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB .
Diseases: heart failure"	"Sentence: His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB .
Diseases:"
1317	It is important to recognize the rare and potentially reversible toxicity of AmB .	O O O O O O O O O O B O O O	['toxicity']	1	2	"Sentence: It is important to recognize the rare and potentially reversible toxicity of AmB .
Diseases: toxicity"	"Sentence: It is important to recognize the rare and potentially reversible toxicity of AmB .
Diseases:"
1318	Risks of the consumption of beverages containing quinine .	O O O O O O O O O	[]	0	0	"Sentence: Risks of the consumption of beverages containing quinine .
Diseases: "	"Sentence: Risks of the consumption of beverages containing quinine .
Diseases:"
1319	Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy , quinine is widely available in beverages including tonic water and bitter lemon .	O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O	['nocturnal leg cramps']	1	6	"Sentence: Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy , quinine is widely available in beverages including tonic water and bitter lemon .
Diseases: nocturnal leg cramps"	"Sentence: Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy , quinine is widely available in beverages including tonic water and bitter lemon .
Diseases:"
1320	Numerous anecdotal reports suggest that products containing quinine may produce neurological complications , including confusion , altered mental status , seizures , and coma , particularly in older women .	O O O O O O O O O O B I O O B O O O O O B O O B O O O O O O	['seizures', 'confusion', 'neurological complications', 'coma']	4	9	"Sentence: Numerous anecdotal reports suggest that products containing quinine may produce neurological complications , including confusion , altered mental status , seizures , and coma , particularly in older women .
Diseases: seizures, confusion, neurological complications, coma"	"Sentence: Numerous anecdotal reports suggest that products containing quinine may produce neurological complications , including confusion , altered mental status , seizures , and coma , particularly in older women .
Diseases:"
1321	Psychologists need to inquire about consumption of quinine - containing beverages as part of an evaluation process .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Psychologists need to inquire about consumption of quinine - containing beverages as part of an evaluation process .
Diseases: "	"Sentence: Psychologists need to inquire about consumption of quinine - containing beverages as part of an evaluation process .
Diseases:"
1322	Organophosphate - induced convulsions and prevention of neuropathological damages .	O O O B O O O B I O	['neuropathological damages', 'convulsions']	2	9	"Sentence: Organophosphate - induced convulsions and prevention of neuropathological damages .
Diseases: neuropathological damages, convulsions"	"Sentence: Organophosphate - induced convulsions and prevention of neuropathological damages .
Diseases:"
1323	Such organophosphorus ( OP ) compounds as diisopropylfluorophosphate ( DFP ) , sarin and soman are potent inhibitors of acetylcholinesterases ( AChEs ) and butyrylcholinesterases ( BChEs ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Such organophosphorus ( OP ) compounds as diisopropylfluorophosphate ( DFP ) , sarin and soman are potent inhibitors of acetylcholinesterases ( AChEs ) and butyrylcholinesterases ( BChEs ) .
Diseases: "	"Sentence: Such organophosphorus ( OP ) compounds as diisopropylfluorophosphate ( DFP ) , sarin and soman are potent inhibitors of acetylcholinesterases ( AChEs ) and butyrylcholinesterases ( BChEs ) .
Diseases:"
1324	The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( ACh ) levels .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( ACh ) levels .
Diseases: toxicity"	"Sentence: The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( ACh ) levels .
Diseases:"
1325	The protective action of subcutaneously ( SC ) administered antidotes or their combinations in DFP ( 2 . 0 mg / kg BW ) intoxication was studied in 9 - 10 - weeks - old Han - Wistar male rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The protective action of subcutaneously ( SC ) administered antidotes or their combinations in DFP ( 2 . 0 mg / kg BW ) intoxication was studied in 9 - 10 - weeks - old Han - Wistar male rats .
Diseases: "	"Sentence: The protective action of subcutaneously ( SC ) administered antidotes or their combinations in DFP ( 2 . 0 mg / kg BW ) intoxication was studied in 9 - 10 - weeks - old Han - Wistar male rats .
Diseases:"
1326	The rats received AChE reactivator pralidoxime - 2 - chloride ( 2PAM ) ( 30 . 0 mg / kg BW ) , anticonvulsant diazepam ( 2 . 0 mg / kg BW ) , A ( 1 ) - adenosine receptor agonist N ( 6 ) - cyclopentyl adenosine ( CPA ) ( 2 . 0 mg / kg BW ) , NMDA - receptor antagonist dizocilpine maleate ( + - MK801 hydrogen maleate ) ( 2 . 0 mg / kg BW ) or their combinations with cholinolytic drug atropine sulfate ( 50 . 0 mg / kg BW ) immediately or 30 min after the single SC injection of DFP .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The rats received AChE reactivator pralidoxime - 2 - chloride ( 2PAM ) ( 30 . 0 mg / kg BW ) , anticonvulsant diazepam ( 2 . 0 mg / kg BW ) , A ( 1 ) - adenosine receptor agonist N ( 6 ) - cyclopentyl adenosine ( CPA ) ( 2 . 0 mg / kg BW ) , NMDA - receptor antagonist dizocilpine maleate ( + - MK801 hydrogen maleate ) ( 2 . 0 mg / kg BW ) or their combinations with cholinolytic drug atropine sulfate ( 50 . 0 mg / kg BW ) immediately or 30 min after the single SC injection of DFP .
Diseases: "	"Sentence: The rats received AChE reactivator pralidoxime - 2 - chloride ( 2PAM ) ( 30 . 0 mg / kg BW ) , anticonvulsant diazepam ( 2 . 0 mg / kg BW ) , A ( 1 ) - adenosine receptor agonist N ( 6 ) - cyclopentyl adenosine ( CPA ) ( 2 . 0 mg / kg BW ) , NMDA - receptor antagonist dizocilpine maleate ( + - MK801 hydrogen maleate ) ( 2 . 0 mg / kg BW ) or their combinations with cholinolytic drug atropine sulfate ( 50 . 0 mg / kg BW ) immediately or 30 min after the single SC injection of DFP .
Diseases:"
1327	The control rats received atropine sulfate , but also saline and olive oil instead of other antidotes and DFP , respectively .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The control rats received atropine sulfate , but also saline and olive oil instead of other antidotes and DFP , respectively .
Diseases: "	"Sentence: The control rats received atropine sulfate , but also saline and olive oil instead of other antidotes and DFP , respectively .
Diseases:"
1328	All rats were terminated either 24 h or 3 weeks after the DFP injection .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All rats were terminated either 24 h or 3 weeks after the DFP injection .
Diseases: "	"Sentence: All rats were terminated either 24 h or 3 weeks after the DFP injection .
Diseases:"
1329	The rats treated with DFP - atropine showed severe typical OP - induced toxicity signs .	O O O O O O O O O O O O O B O O	['toxicity']	1	2	"Sentence: The rats treated with DFP - atropine showed severe typical OP - induced toxicity signs .
Diseases: toxicity"	"Sentence: The rats treated with DFP - atropine showed severe typical OP - induced toxicity signs .
Diseases:"
1330	When CPA , diazepam or 2PAM was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of poisoning .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['poisoning']	1	3	"Sentence: When CPA , diazepam or 2PAM was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of poisoning .
Diseases: poisoning"	"Sentence: When CPA , diazepam or 2PAM was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of poisoning .
Diseases:"
1331	Atropine - MK801 did not offer any additional protection against DFP toxicity .	O O O O O O O O O O O B O	['toxicity']	1	2	"Sentence: Atropine - MK801 did not offer any additional protection against DFP toxicity .
Diseases: toxicity"	"Sentence: Atropine - MK801 did not offer any additional protection against DFP toxicity .
Diseases:"
1332	In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat .	O O O O O O O O O O O O O O O O O O O B O O O O B O O O O O	['poisoning', 'toxicity']	2	5	"Sentence: In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat .
Diseases: poisoning, toxicity"	"Sentence: In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat .
Diseases:"
1333	Differential modulation by estrogen of alpha2 - adrenergic and I1 - imidazoline receptor - mediated hypotension in female rats .	O O O O O O O O O O O O O O O B O O O O	['hypotension']	1	3	"Sentence: Differential modulation by estrogen of alpha2 - adrenergic and I1 - imidazoline receptor - mediated hypotension in female rats .
Diseases: hypotension"	"Sentence: Differential modulation by estrogen of alpha2 - adrenergic and I1 - imidazoline receptor - mediated hypotension in female rats .
Diseases:"
1334	We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine ( mixed alpha2 - / I1 - receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotensive']	1	3	"Sentence: We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine ( mixed alpha2 - / I1 - receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .
Diseases: hypotensive"	"Sentence: We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine ( mixed alpha2 - / I1 - receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .
Diseases:"
1335	The present study investigated whether this effect of estrogen involves interaction with alpha2 - and / or I1 - receptors .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The present study investigated whether this effect of estrogen involves interaction with alpha2 - and / or I1 - receptors .
Diseases: "	"Sentence: The present study investigated whether this effect of estrogen involves interaction with alpha2 - and / or I1 - receptors .
Diseases:"
1336	Changes evoked by a single intraperitoneal injection of rilmenidine ( 600 microg / kg ) or alpha - methyldopa ( 100 mg / kg ) , selective I1 - and alpha2 - receptor agonists , respectively , in blood pressure , hemodynamic variability , and locomotor activity were assessed in radiotelemetered sham - operated and ovariectomized ( Ovx ) Sprague - Dawley female rats with or without 12 - wk estrogen replacement .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Changes evoked by a single intraperitoneal injection of rilmenidine ( 600 microg / kg ) or alpha - methyldopa ( 100 mg / kg ) , selective I1 - and alpha2 - receptor agonists , respectively , in blood pressure , hemodynamic variability , and locomotor activity were assessed in radiotelemetered sham - operated and ovariectomized ( Ovx ) Sprague - Dawley female rats with or without 12 - wk estrogen replacement .
Diseases: "	"Sentence: Changes evoked by a single intraperitoneal injection of rilmenidine ( 600 microg / kg ) or alpha - methyldopa ( 100 mg / kg ) , selective I1 - and alpha2 - receptor agonists , respectively , in blood pressure , hemodynamic variability , and locomotor activity were assessed in radiotelemetered sham - operated and ovariectomized ( Ovx ) Sprague - Dawley female rats with or without 12 - wk estrogen replacement .
Diseases:"
1337	Three time domain indexes of hemodynamic variability were employed : the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat - to - beat intervals ( SDRR ) and the root mean square of successive differences in R - wave - to - R - wave intervals as measures of heart rate variability .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Three time domain indexes of hemodynamic variability were employed : the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat - to - beat intervals ( SDRR ) and the root mean square of successive differences in R - wave - to - R - wave intervals as measures of heart rate variability .
Diseases: "	"Sentence: Three time domain indexes of hemodynamic variability were employed : the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat - to - beat intervals ( SDRR ) and the root mean square of successive differences in R - wave - to - R - wave intervals as measures of heart rate variability .
Diseases:"
1338	In sham - operated rats , rilmenidine or alpha - methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: In sham - operated rats , rilmenidine or alpha - methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .
Diseases: hypotension"	"Sentence: In sham - operated rats , rilmenidine or alpha - methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .
Diseases:"
1339	SDRR was reduced only by alpha - methyldopa .	O O O O O O O O O	[]	0	0	"Sentence: SDRR was reduced only by alpha - methyldopa .
Diseases: "	"Sentence: SDRR was reduced only by alpha - methyldopa .
Diseases:"
1340	Ovx significantly enhanced the hypotensive response to alpha - methyldopa , in contrast to no effect on rilmenidine hypotension .	O O O O B O O O O O O O O O O O O O B O	['hypotensive', 'hypotension']	2	6	"Sentence: Ovx significantly enhanced the hypotensive response to alpha - methyldopa , in contrast to no effect on rilmenidine hypotension .
Diseases: hypotensive, hypotension"	"Sentence: Ovx significantly enhanced the hypotensive response to alpha - methyldopa , in contrast to no effect on rilmenidine hypotension .
Diseases:"
1341	The enhanced alpha - methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity .	O O O O O B O O O O O O O O O O O B I I I O	['hypotension', 'a reduced locomotor activity']	2	9	"Sentence: The enhanced alpha - methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity .
Diseases: hypotension, a reduced locomotor activity"	"Sentence: The enhanced alpha - methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity .
Diseases:"
1342	Estrogen replacement ( 17beta - estradiol subcutaneous pellet , 14 . 2 microg / day , 12 wk ) of Ovx rats restored the hemodynamic and locomotor effects of alpha - methyldopa to sham - operated levels .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Estrogen replacement ( 17beta - estradiol subcutaneous pellet , 14 . 2 microg / day , 12 wk ) of Ovx rats restored the hemodynamic and locomotor effects of alpha - methyldopa to sham - operated levels .
Diseases: "	"Sentence: Estrogen replacement ( 17beta - estradiol subcutaneous pellet , 14 . 2 microg / day , 12 wk ) of Ovx rats restored the hemodynamic and locomotor effects of alpha - methyldopa to sham - operated levels .
Diseases:"
1343	These findings suggest that estrogen downregulates alpha2 - but not I1 - receptor - mediated hypotension and highlight a role for the cardiac autonomic control in alpha - methyldopa - estrogen interaction .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: These findings suggest that estrogen downregulates alpha2 - but not I1 - receptor - mediated hypotension and highlight a role for the cardiac autonomic control in alpha - methyldopa - estrogen interaction .
Diseases: hypotension"	"Sentence: These findings suggest that estrogen downregulates alpha2 - but not I1 - receptor - mediated hypotension and highlight a role for the cardiac autonomic control in alpha - methyldopa - estrogen interaction .
Diseases:"
1344	Cardioprotective effect of tincture of Crataegus on isoproterenol - induced myocardial infarction in rats .	O O O O O O O O O O B I O O O	['myocardial infarction']	1	6	"Sentence: Cardioprotective effect of tincture of Crataegus on isoproterenol - induced myocardial infarction in rats .
Diseases: myocardial infarction"	"Sentence: Cardioprotective effect of tincture of Crataegus on isoproterenol - induced myocardial infarction in rats .
Diseases:"
1345	Tincture of Crataegus ( TCR ) , an alcoholic extract of the berries of hawthorn ( Crataegus oxycantha ) , is used in herbal and homeopathic medicine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Tincture of Crataegus ( TCR ) , an alcoholic extract of the berries of hawthorn ( Crataegus oxycantha ) , is used in herbal and homeopathic medicine .
Diseases: "	"Sentence: Tincture of Crataegus ( TCR ) , an alcoholic extract of the berries of hawthorn ( Crataegus oxycantha ) , is used in herbal and homeopathic medicine .
Diseases:"
1346	The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats .	O O O O O O O O O O O O O O O B I O O O	['myocardial infarction']	1	6	"Sentence: The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats .
Diseases: myocardial infarction"	"Sentence: The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats .
Diseases:"
1347	Pretreatment of TCR , at a dose of 0 . 5 mL / 100 g bodyweight per day , orally for 30 days , prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol - induced rats ( 85 mg kg ( - 1 )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pretreatment of TCR , at a dose of 0 . 5 mL / 100 g bodyweight per day , orally for 30 days , prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol - induced rats ( 85 mg kg ( - 1 )
Diseases: "	"Sentence: Pretreatment of TCR , at a dose of 0 . 5 mL / 100 g bodyweight per day , orally for 30 days , prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol - induced rats ( 85 mg kg ( - 1 )
Diseases:"
1348	s . c . for 2 days at an interval of 24 h ) .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: s . c . for 2 days at an interval of 24 h ) .
Diseases: "	"Sentence: s . c . for 2 days at an interval of 24 h ) .
Diseases:"
1349	TCR prevented the isoproterenol - induced decrease in antioxidant enzymes in the heart and increased the rate of ADP - stimulated oxygen uptake and respiratory coupling ratio .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: TCR prevented the isoproterenol - induced decrease in antioxidant enzymes in the heart and increased the rate of ADP - stimulated oxygen uptake and respiratory coupling ratio .
Diseases: "	"Sentence: TCR prevented the isoproterenol - induced decrease in antioxidant enzymes in the heart and increased the rate of ADP - stimulated oxygen uptake and respiratory coupling ratio .
Diseases:"
1350	TCR protected against pathological changes induced by isoproterenol in rat heart .	O O O O O O O O O O O O	[]	0	0	"Sentence: TCR protected against pathological changes induced by isoproterenol in rat heart .
Diseases: "	"Sentence: TCR protected against pathological changes induced by isoproterenol in rat heart .
Diseases:"
1351	The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart .
Diseases: "	"Sentence: The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart .
Diseases:"
1352	Safety and adverse effects associated with raloxifene : multiple outcomes of raloxifene evaluation .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Safety and adverse effects associated with raloxifene : multiple outcomes of raloxifene evaluation .
Diseases: "	"Sentence: Safety and adverse effects associated with raloxifene : multiple outcomes of raloxifene evaluation .
Diseases:"
1353	To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen .
Diseases: "	"Sentence: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen .
Diseases:"
1354	The Multiple Outcomes of Raloxifene Evaluation , a multicenter , randomized , double - blind trial , enrolled 7 , 705 postmenopausal women with osteoporosis .	O O O O O O O O O O O O O O O O O O O O O O O O B O	['osteoporosis']	1	5	"Sentence: The Multiple Outcomes of Raloxifene Evaluation , a multicenter , randomized , double - blind trial , enrolled 7 , 705 postmenopausal women with osteoporosis .
Diseases: osteoporosis"	"Sentence: The Multiple Outcomes of Raloxifene Evaluation , a multicenter , randomized , double - blind trial , enrolled 7 , 705 postmenopausal women with osteoporosis .
Diseases:"
1355	Women were randomly assigned to raloxifene 60 mg / d or 120 mg / d or placebo .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Women were randomly assigned to raloxifene 60 mg / d or 120 mg / d or placebo .
Diseases: "	"Sentence: Women were randomly assigned to raloxifene 60 mg / d or 120 mg / d or placebo .
Diseases:"
1356	Outcomes included venous thromboembolism , cataracts , gallbladder disease , and endometrial hyperplasia or cancer .	O O B I O B O B I O O B I I I O	['endometrial hyperplasia or cancer', 'cataracts', 'gallbladder disease', 'venous thromboembolism']	4	26	"Sentence: Outcomes included venous thromboembolism , cataracts , gallbladder disease , and endometrial hyperplasia or cancer .
Diseases: endometrial hyperplasia or cancer, cataracts, gallbladder disease, venous thromboembolism"	"Sentence: Outcomes included venous thromboembolism , cataracts , gallbladder disease , and endometrial hyperplasia or cancer .
Diseases:"
1357	During a mean follow - up of 3 . 3 years , raloxifene was associated with an increased risk for venous thromboembolism ( relative risk [ RR ] 2 . 1 ; 95 % confidence interval [ CI ] 1 . 2 - 3 . 8 ) .	O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O	['venous thromboembolism']	1	8	"Sentence: During a mean follow - up of 3 . 3 years , raloxifene was associated with an increased risk for venous thromboembolism ( relative risk [ RR ] 2 . 1 ; 95 % confidence interval [ CI ] 1 . 2 - 3 . 8 ) .
Diseases: venous thromboembolism"	"Sentence: During a mean follow - up of 3 . 3 years , raloxifene was associated with an increased risk for venous thromboembolism ( relative risk [ RR ] 2 . 1 ; 95 % confidence interval [ CI ] 1 . 2 - 3 . 8 ) .
Diseases:"
1358	The excess event rate was 1 . 8 per 1 , 000 woman - years ( 95 % CI - 0 . 5 - 4 . 1 ) , and the number needed to treat to cause 1 event was 170 ( 95 % CI 100 - 582 ) over 3 . 3 years .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The excess event rate was 1 . 8 per 1 , 000 woman - years ( 95 % CI - 0 . 5 - 4 . 1 ) , and the number needed to treat to cause 1 event was 170 ( 95 % CI 100 - 582 ) over 3 . 3 years .
Diseases: "	"Sentence: The excess event rate was 1 . 8 per 1 , 000 woman - years ( 95 % CI - 0 . 5 - 4 . 1 ) , and the number needed to treat to cause 1 event was 170 ( 95 % CI 100 - 582 ) over 3 . 3 years .
Diseases:"
1359	Risk in the raloxifene group was higher than in the placebo group for the first 2 years , but decreased to about the same rate as in the placebo group thereafter .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Risk in the raloxifene group was higher than in the placebo group for the first 2 years , but decreased to about the same rate as in the placebo group thereafter .
Diseases: "	"Sentence: Risk in the raloxifene group was higher than in the placebo group for the first 2 years , but decreased to about the same rate as in the placebo group thereafter .
Diseases:"
1360	Raloxifene did not increase risk for cataracts ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , gallbladder disease ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , endometrial hyperplasia ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or endometrial cancer ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .	O O O O O O B O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['endometrial cancer', 'cataracts', 'gallbladder disease', 'endometrial hyperplasia']	4	20	"Sentence: Raloxifene did not increase risk for cataracts ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , gallbladder disease ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , endometrial hyperplasia ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or endometrial cancer ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .
Diseases: endometrial cancer, cataracts, gallbladder disease, endometrial hyperplasia"	"Sentence: Raloxifene did not increase risk for cataracts ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , gallbladder disease ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , endometrial hyperplasia ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or endometrial cancer ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .
Diseases:"
1361	Raloxifene was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or endometrial cancer .	O O O O O O O O B I O O O O O O O O B O B I O B I O O B I O	['cataracts', 'endometrial cancer', 'gallbladder disease', 'endometrial hyperplasia', 'venous thromboembolism']	5	29	"Sentence: Raloxifene was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or endometrial cancer .
Diseases: cataracts, endometrial cancer, gallbladder disease, endometrial hyperplasia, venous thromboembolism"	"Sentence: Raloxifene was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or endometrial cancer .
Diseases:"
1362	LEVEL OF EVIDENCE :	O O O O	[]	0	0	"Sentence: LEVEL OF EVIDENCE :
Diseases: "	"Sentence: LEVEL OF EVIDENCE :
Diseases:"
1363	I	O	[]	0	0	"Sentence: I
Diseases: "	"Sentence: I
Diseases:"
1364	Ceftriaxone - associated biliary pseudolithiasis in paediatric surgical patients .	O O O B I O O O O O	['biliary pseudolithiasis']	1	5	"Sentence: Ceftriaxone - associated biliary pseudolithiasis in paediatric surgical patients .
Diseases: biliary pseudolithiasis"	"Sentence: Ceftriaxone - associated biliary pseudolithiasis in paediatric surgical patients .
Diseases:"
1365	It is well known that ceftriaxone leads to pseudolithiasis in some patients .	O O O O O O O O B O O O O	['pseudolithiasis']	1	4	"Sentence: It is well known that ceftriaxone leads to pseudolithiasis in some patients .
Diseases: pseudolithiasis"	"Sentence: It is well known that ceftriaxone leads to pseudolithiasis in some patients .
Diseases:"
1366	Clinical and experimental studies also suggest that situations causing gallbladder dysfunction , such as fasting , may have a role for the development of pseudolithiasis .	O O O O O O O O O B I O O O O O O O O O O O O O B O	['pseudolithiasis', 'gallbladder dysfunction']	2	9	"Sentence: Clinical and experimental studies also suggest that situations causing gallbladder dysfunction , such as fasting , may have a role for the development of pseudolithiasis .
Diseases: pseudolithiasis, gallbladder dysfunction"	"Sentence: Clinical and experimental studies also suggest that situations causing gallbladder dysfunction , such as fasting , may have a role for the development of pseudolithiasis .
Diseases:"
1367	In this study , we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment , who often had to fast in the post - operative period .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['pseudolithiasis']	1	4	"Sentence: In this study , we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment , who often had to fast in the post - operative period .
Diseases: pseudolithiasis"	"Sentence: In this study , we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment , who often had to fast in the post - operative period .
Diseases:"
1368	Fifty children who were given ceftriaxone were evaluated by serial abdominal sonograms .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Fifty children who were given ceftriaxone were evaluated by serial abdominal sonograms .
Diseases: "	"Sentence: Fifty children who were given ceftriaxone were evaluated by serial abdominal sonograms .
Diseases:"
1369	Of those , 13 ( 26 % ) developed biliary pathology .	O O O O O O O O O O O O	[]	0	0	"Sentence: Of those , 13 ( 26 % ) developed biliary pathology .
Diseases: "	"Sentence: Of those , 13 ( 26 % ) developed biliary pathology .
Diseases:"
1370	Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age , sex , duration of the treatment and starvation variables .	O O O O O O O B O O O O O O O O O O O O O O O O O O O	['pseudolithiasis']	1	4	"Sentence: Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age , sex , duration of the treatment and starvation variables .
Diseases: pseudolithiasis"	"Sentence: Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age , sex , duration of the treatment and starvation variables .
Diseases:"
1371	After cessation of the treatment , pseudolithiasis resolved spontaneously within a short period .	O O O O O O B O O O O O O O	['pseudolithiasis']	1	4	"Sentence: After cessation of the treatment , pseudolithiasis resolved spontaneously within a short period .
Diseases: pseudolithiasis"	"Sentence: After cessation of the treatment , pseudolithiasis resolved spontaneously within a short period .
Diseases:"
1372	The incidence of pseudolithiasis is not affected by fasting .	O O O B O O O O O O	['pseudolithiasis']	1	4	"Sentence: The incidence of pseudolithiasis is not affected by fasting .
Diseases: pseudolithiasis"	"Sentence: The incidence of pseudolithiasis is not affected by fasting .
Diseases:"
1373	Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose .	O O O O O O O O O O O B I O	['cocaine overdose']	1	4	"Sentence: Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose .
Diseases: cocaine overdose"	"Sentence: Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose .
Diseases:"
1374	The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive .	O O O O O O O O O O O O B I O O O	['cocaine overdose']	1	4	"Sentence: The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive .
Diseases: cocaine overdose"	"Sentence: The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive .
Diseases:"
1375	Current protein - based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream , inactivating its toxic effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Current protein - based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream , inactivating its toxic effects .
Diseases: "	"Sentence: Current protein - based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream , inactivating its toxic effects .
Diseases:"
1376	The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose .	O O O O O O O O O O O O O O B I O	['cocaine overdose']	1	4	"Sentence: The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose .
Diseases: cocaine overdose"	"Sentence: The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose .
Diseases:"
1377	Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg / kg	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg / kg
Diseases: "	"Sentence: Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg / kg
Diseases:"
1378	( LD50 ) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg / kg .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ( LD50 ) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg / kg .
Diseases: "	"Sentence: ( LD50 ) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg / kg .
Diseases:"
1379	GNC92H2 was delivered 30 min before , concomitantly or 3 min after cocaine treatment .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: GNC92H2 was delivered 30 min before , concomitantly or 3 min after cocaine treatment .
Diseases: "	"Sentence: GNC92H2 was delivered 30 min before , concomitantly or 3 min after cocaine treatment .
Diseases:"
1380	Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O B O O O O	['death', 'seizures', 'toxicity']	3	5	"Sentence: Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .
Diseases: death, seizures, toxicity"	"Sentence: Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .
Diseases:"
1381	Importantly , GNC92H2 prevented death even post - cocaine injection .	O O O O B O O O O O O	['death']	1	1	"Sentence: Importantly , GNC92H2 prevented death even post - cocaine injection .
Diseases: death"	"Sentence: Importantly , GNC92H2 prevented death even post - cocaine injection .
Diseases:"
1382	The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose .	O O O O O O O O O O O O O B I O	['cocaine overdose']	1	4	"Sentence: The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose .
Diseases: cocaine overdose"	"Sentence: The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose .
Diseases:"
1383	The effects of short - term raloxifene therapy on fibrinolysis markers : TAFI , tPA , and PAI - 1 .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effects of short - term raloxifene therapy on fibrinolysis markers : TAFI , tPA , and PAI - 1 .
Diseases: "	"Sentence: The effects of short - term raloxifene therapy on fibrinolysis markers : TAFI , tPA , and PAI - 1 .
Diseases:"
1384	Markers of fibrinolysis , thrombin - activatable fibrinolysis inhibitor ( TAFI ) , tissue - type plasminogen activator ( tPA ) , and plasminogen activator inhibitor - 1 ( PAI - 1 ) levels were studied for the evaluation of short - term effects of raloxifene administration in postmenopausal women .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Markers of fibrinolysis , thrombin - activatable fibrinolysis inhibitor ( TAFI ) , tissue - type plasminogen activator ( tPA ) , and plasminogen activator inhibitor - 1 ( PAI - 1 ) levels were studied for the evaluation of short - term effects of raloxifene administration in postmenopausal women .
Diseases: "	"Sentence: Markers of fibrinolysis , thrombin - activatable fibrinolysis inhibitor ( TAFI ) , tissue - type plasminogen activator ( tPA ) , and plasminogen activator inhibitor - 1 ( PAI - 1 ) levels were studied for the evaluation of short - term effects of raloxifene administration in postmenopausal women .
Diseases:"
1385	Thirty - nine postmenopausal women with osteopenia or osteoporosis were included in this prospective , controlled clinical study .	O O O O O O B O B O O O O O O O O O O	['osteopenia', 'osteoporosis']	2	9	"Sentence: Thirty - nine postmenopausal women with osteopenia or osteoporosis were included in this prospective , controlled clinical study .
Diseases: osteopenia, osteoporosis"	"Sentence: Thirty - nine postmenopausal women with osteopenia or osteoporosis were included in this prospective , controlled clinical study .
Diseases:"
1386	Twenty - five women were given raloxifene hydrochloride ( 60 mg / day ) plus calcium ( 500 mg / day ) .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Twenty - five women were given raloxifene hydrochloride ( 60 mg / day ) plus calcium ( 500 mg / day ) .
Diseases: "	"Sentence: Twenty - five women were given raloxifene hydrochloride ( 60 mg / day ) plus calcium ( 500 mg / day ) .
Diseases:"
1387	Age - matched controls ( n = 14 ) were given only calcium .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Age - matched controls ( n = 14 ) were given only calcium .
Diseases: "	"Sentence: Age - matched controls ( n = 14 ) were given only calcium .
Diseases:"
1388	Plasma TAFI , tPA , and PAI - 1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma TAFI , tPA , and PAI - 1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits .
Diseases: "	"Sentence: Plasma TAFI , tPA , and PAI - 1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits .
Diseases:"
1389	Variations of individuals were assessed by Wilcoxon 's test .	O O O O O O O O O O	[]	0	0	"Sentence: Variations of individuals were assessed by Wilcoxon 's test .
Diseases: "	"Sentence: Variations of individuals were assessed by Wilcoxon 's test .
Diseases:"
1390	Relationship between those markers and demographic characteristics were investigated .	O O O O O O O O O O	[]	0	0	"Sentence: Relationship between those markers and demographic characteristics were investigated .
Diseases: "	"Sentence: Relationship between those markers and demographic characteristics were investigated .
Diseases:"
1391	Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations ( 16 % change , P < 0 . 01 ) , and a significant increase in tPA antigen concentrations ( 25 % change , P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations ( 16 % change , P < 0 . 01 ) , and a significant increase in tPA antigen concentrations ( 25 % change , P < 0 . 05 ) .
Diseases: "	"Sentence: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations ( 16 % change , P < 0 . 01 ) , and a significant increase in tPA antigen concentrations ( 25 % change , P < 0 . 05 ) .
Diseases:"
1392	A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea ( P < 0 . 05 ; r = 0 . 33 ) .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['amenorrhea']	1	3	"Sentence: A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea ( P < 0 . 05 ; r = 0 . 33 ) .
Diseases: amenorrhea"	"Sentence: A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea ( P < 0 . 05 ; r = 0 . 33 ) .
Diseases:"
1393	We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels , but not TAFI levels .	O O O O O O O B I O O O O O O O O O O O O O O O O O	['venous thromboembolism']	1	8	"Sentence: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels , but not TAFI levels .
Diseases: venous thromboembolism"	"Sentence: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels , but not TAFI levels .
Diseases:"
1394	Ketoconazole induced torsades de pointes without concomitant use of QT interval - prolonging drug .	O O B I I O O O O O O O O O O	['torsades de pointes']	1	6	"Sentence: Ketoconazole induced torsades de pointes without concomitant use of QT interval - prolonging drug .
Diseases: torsades de pointes"	"Sentence: Ketoconazole induced torsades de pointes without concomitant use of QT interval - prolonging drug .
Diseases:"
1395	Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval - prolonging drugs .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval - prolonging drugs .
Diseases: "	"Sentence: Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval - prolonging drugs .
Diseases:"
1396	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking ketoconazole for treatment of fungal infection .	O O O O O B I I O O O O B I I O B I I O B O O O O O O O B I O	['tdp', 'torsades de pointes', 'fungal infection', 'coronary artery disease', 'prolonged qt interval']	5	22	"Sentence: We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking ketoconazole for treatment of fungal infection .
Diseases: tdp, torsades de pointes, fungal infection, coronary artery disease, prolonged qt interval"	"Sentence: We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking ketoconazole for treatment of fungal infection .
Diseases:"
1397	Her QT interval returned to normal upon withdrawal of ketoconazole .	O O O O O O O O O O O	[]	0	0	"Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .
Diseases: "	"Sentence: Her QT interval returned to normal upon withdrawal of ketoconazole .
Diseases:"
1398	Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins .
Diseases: "	"Sentence: Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins .
Diseases:"
1399	We postulate that by virtue of its direct blocking action on IKr , ketoconazole alone may prolong QT interval and induce TdP . This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B I I O	['tdp', 'long qt syndrome']	2	7	"Sentence: We postulate that by virtue of its direct blocking action on IKr , ketoconazole alone may prolong QT interval and induce TdP . This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome .
Diseases: tdp, long qt syndrome"	"Sentence: We postulate that by virtue of its direct blocking action on IKr , ketoconazole alone may prolong QT interval and induce TdP . This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome .
Diseases:"
1400	Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions .	O O O O O O O O O O O O B I O	['cognitive dysfunctions']	1	5	"Sentence: Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions .
Diseases: cognitive dysfunctions"	"Sentence: Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions .
Diseases:"
1401	The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions , total serum cholesterol levels and brain cholinesterase activity in mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions , total serum cholesterol levels and brain cholinesterase activity in mice .
Diseases: "	"Sentence: The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions , total serum cholesterol levels and brain cholinesterase activity in mice .
Diseases:"
1402	The ethanolic extract of Daucus carota seeds ( DCE ) was administered orally in three doses ( 100 , 200 , 400 mg / kg ) for seven successive days to different groups of young and aged mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The ethanolic extract of Daucus carota seeds ( DCE ) was administered orally in three doses ( 100 , 200 , 400 mg / kg ) for seven successive days to different groups of young and aged mice .
Diseases: "	"Sentence: The ethanolic extract of Daucus carota seeds ( DCE ) was administered orally in three doses ( 100 , 200 , 400 mg / kg ) for seven successive days to different groups of young and aged mice .
Diseases:"
1403	Elevated plus maze and passive avoidance apparatus served as the exteroceptive behavioral models for testing memory .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Elevated plus maze and passive avoidance apparatus served as the exteroceptive behavioral models for testing memory .
Diseases: "	"Sentence: Elevated plus maze and passive avoidance apparatus served as the exteroceptive behavioral models for testing memory .
Diseases:"
1404	Diazepam - , scopolamine - and ageing - induced amnesia served as the interoceptive behavioral models .	O O O O O O O O O B O O O O O O O	['amnesia']	1	2	"Sentence: Diazepam - , scopolamine - and ageing - induced amnesia served as the interoceptive behavioral models .
Diseases: amnesia"	"Sentence: Diazepam - , scopolamine - and ageing - induced amnesia served as the interoceptive behavioral models .
Diseases:"
1405	DCE ( 200 , 400 mg / kg , p . o . ) showed significant improvement in memory scores of young and aged mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: DCE ( 200 , 400 mg / kg , p . o . ) showed significant improvement in memory scores of young and aged mice .
Diseases: "	"Sentence: DCE ( 200 , 400 mg / kg , p . o . ) showed significant improvement in memory scores of young and aged mice .
Diseases:"
1406	The extent of memory improvement evoked by DCE was 23 % at the dose of 200 mg / kg and 35 % at the dose of 400 mg / kg in young mice using elevated plus maze .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The extent of memory improvement evoked by DCE was 23 % at the dose of 200 mg / kg and 35 % at the dose of 400 mg / kg in young mice using elevated plus maze .
Diseases: "	"Sentence: The extent of memory improvement evoked by DCE was 23 % at the dose of 200 mg / kg and 35 % at the dose of 400 mg / kg in young mice using elevated plus maze .
Diseases:"
1407	Similarly , significant improvements in memory scores were observed using passive avoidance apparatus and aged mice .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Similarly , significant improvements in memory scores were observed using passive avoidance apparatus and aged mice .
Diseases: "	"Sentence: Similarly , significant improvements in memory scores were observed using passive avoidance apparatus and aged mice .
Diseases:"
1408	Furthermore , DCE reversed the amnesia induced by scopolamine ( 0 . 4 mg / kg , i . p . ) and diazepam ( 1 mg / kg , i . p . ) .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: Furthermore , DCE reversed the amnesia induced by scopolamine ( 0 . 4 mg / kg , i . p . ) and diazepam ( 1 mg / kg , i . p . ) .
Diseases: amnesia"	"Sentence: Furthermore , DCE reversed the amnesia induced by scopolamine ( 0 . 4 mg / kg , i . p . ) and diazepam ( 1 mg / kg , i . p . ) .
Diseases:"
1409	Daucus carota extract ( 200 , 400 mg / kg , p . o . ) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Daucus carota extract ( 200 , 400 mg / kg , p . o . ) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice .
Diseases: "	"Sentence: Daucus carota extract ( 200 , 400 mg / kg , p . o . ) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice .
Diseases:"
1410	The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg / kg was 22 % in young and 19 % in aged mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg / kg was 22 % in young and 19 % in aged mice .
Diseases: "	"Sentence: The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg / kg was 22 % in young and 19 % in aged mice .
Diseases:"
1411	There was a remarkable reduction in total cholesterol level as well , to the extent of 23 % in young and 21 % in aged animals with this dose of DCE .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was a remarkable reduction in total cholesterol level as well , to the extent of 23 % in young and 21 % in aged animals with this dose of DCE .
Diseases: "	"Sentence: There was a remarkable reduction in total cholesterol level as well , to the extent of 23 % in young and 21 % in aged animals with this dose of DCE .
Diseases:"
1412	Therefore , DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as , memory improving property , cholesterol lowering property and anticholinesterase activity .	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	['cognitive dysfunctions']	1	5	"Sentence: Therefore , DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as , memory improving property , cholesterol lowering property and anticholinesterase activity .
Diseases: cognitive dysfunctions"	"Sentence: Therefore , DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as , memory improving property , cholesterol lowering property and anticholinesterase activity .
Diseases:"
1413	Cauda equina syndrome after epidural steroid injection : a case report .	B I I O O O O O O O O O	['cauda equina syndrome']	1	6	"Sentence: Cauda equina syndrome after epidural steroid injection : a case report .
Diseases: cauda equina syndrome"	"Sentence: Cauda equina syndrome after epidural steroid injection : a case report .
Diseases:"
1414	Conventional treatment methods of lumbusacral radiculopathy are physical therapy , epidural steroid injections , oral medications , and spinal manipulative therapy .	O O O O O B O O O O O O O O O O O O O O O O	['radiculopathy']	1	4	"Sentence: Conventional treatment methods of lumbusacral radiculopathy are physical therapy , epidural steroid injections , oral medications , and spinal manipulative therapy .
Diseases: radiculopathy"	"Sentence: Conventional treatment methods of lumbusacral radiculopathy are physical therapy , epidural steroid injections , oral medications , and spinal manipulative therapy .
Diseases:"
1415	Cauda equina syndrome is a rare complication of epidural anesthesia .	B I I O O O O O O O O	['cauda equina syndrome']	1	6	"Sentence: Cauda equina syndrome is a rare complication of epidural anesthesia .
Diseases: cauda equina syndrome"	"Sentence: Cauda equina syndrome is a rare complication of epidural anesthesia .
Diseases:"
1416	The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine .	O O O O O O O B I I O O O O O O O O O O	['cauda equina syndrome']	1	6	"Sentence: The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine .
Diseases: cauda equina syndrome"	"Sentence: The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine .
Diseases:"
1417	CLINICAL FEATURES : A 50 - year - old woman with low back and right leg pain was scheduled for epidural steroid injection .	O O O O O O O O O O O B I I I I I O O O O O O O	['low back and right leg pain']	1	6	"Sentence: CLINICAL FEATURES : A 50 - year - old woman with low back and right leg pain was scheduled for epidural steroid injection .
Diseases: low back and right leg pain"	"Sentence: CLINICAL FEATURES : A 50 - year - old woman with low back and right leg pain was scheduled for epidural steroid injection .
Diseases:"
1418	INTERVENTION AND OUTCOME : An 18 - gauge Touhy needle was inserted until loss of resistance occurred at the L4 - 5 level .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: INTERVENTION AND OUTCOME : An 18 - gauge Touhy needle was inserted until loss of resistance occurred at the L4 - 5 level .
Diseases: "	"Sentence: INTERVENTION AND OUTCOME : An 18 - gauge Touhy needle was inserted until loss of resistance occurred at the L4 - 5 level .
Diseases:"
1419	Spread of the contrast medium within the epidural space was determined by radiographic imaging .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Spread of the contrast medium within the epidural space was determined by radiographic imaging .
Diseases: "	"Sentence: Spread of the contrast medium within the epidural space was determined by radiographic imaging .
Diseases:"
1420	After verifying the epidural space , bupivacaine and triamcinolone diacetate were injected .	O O O O O O O O O O O O O	[]	0	0	"Sentence: After verifying the epidural space , bupivacaine and triamcinolone diacetate were injected .
Diseases: "	"Sentence: After verifying the epidural space , bupivacaine and triamcinolone diacetate were injected .
Diseases:"
1421	After the injection , there was a reduction in radicular symptoms .	O O O O O O O O O O O O	[]	0	0	"Sentence: After the injection , there was a reduction in radicular symptoms .
Diseases: "	"Sentence: After the injection , there was a reduction in radicular symptoms .
Diseases:"
1422	Three hours later , she complained of perineal numbness and lower extremity weakness .	O O O O O O O O B O B I I O	['numbness', 'lower extremity weakness']	2	8	"Sentence: Three hours later , she complained of perineal numbness and lower extremity weakness .
Diseases: numbness, lower extremity weakness"	"Sentence: Three hours later , she complained of perineal numbness and lower extremity weakness .
Diseases:"
1423	The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg .	O O O O B I I O O O O O O O O O O O O	['loss of sensation']	1	3	"Sentence: The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg .
Diseases: loss of sensation"	"Sentence: The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg .
Diseases:"
1424	There was a decrease in the perception of pinprick test .	O O O O O O O O O O O	[]	0	0	"Sentence: There was a decrease in the perception of pinprick test .
Diseases: "	"Sentence: There was a decrease in the perception of pinprick test .
Diseases:"
1425	Deep - tendon reflexes were decreased especially in the right leg .	O O O O O O O O O O O O	[]	0	0	"Sentence: Deep - tendon reflexes were decreased especially in the right leg .
Diseases: "	"Sentence: Deep - tendon reflexes were decreased especially in the right leg .
Diseases:"
1426	She was unable to urinate .	O O O O O O	[]	0	0	"Sentence: She was unable to urinate .
Diseases: "	"Sentence: She was unable to urinate .
Diseases:"
1427	The patient 's symptoms improved slightly over the next few hours .	O O O O O O O O O O O O	[]	0	0	"Sentence: The patient 's symptoms improved slightly over the next few hours .
Diseases: "	"Sentence: The patient 's symptoms improved slightly over the next few hours .
Diseases:"
1428	She had a gradual return of motor function and ability of feeling Foley catheter .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: She had a gradual return of motor function and ability of feeling Foley catheter .
Diseases: "	"Sentence: She had a gradual return of motor function and ability of feeling Foley catheter .
Diseases:"
1429	All of the symptoms were completely resolved over the next 8 hours .	O O O O O O O O O O O O O	[]	0	0	"Sentence: All of the symptoms were completely resolved over the next 8 hours .
Diseases: "	"Sentence: All of the symptoms were completely resolved over the next 8 hours .
Diseases:"
1430	Complications associated with epidural steroid injections are rare .	O O O O O O O O O	[]	0	0	"Sentence: Complications associated with epidural steroid injections are rare .
Diseases: "	"Sentence: Complications associated with epidural steroid injections are rare .
Diseases:"
1431	Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important .	O O O O O O B I O O O O O O O	['neurologic deterioration']	1	5	"Sentence: Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important .
Diseases: neurologic deterioration"	"Sentence: Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important .
Diseases:"
1432	High - dose testosterone is associated with atherosclerosis in postmenopausal women .	O O O O O O O B O O O O	['atherosclerosis']	1	3	"Sentence: High - dose testosterone is associated with atherosclerosis in postmenopausal women .
Diseases: atherosclerosis"	"Sentence: High - dose testosterone is associated with atherosclerosis in postmenopausal women .
Diseases:"
1433	To study the long - term effects of androgen treatment on atherosclerosis in postmenopausal women .	O O O O O O O O O O O B O O O O	['atherosclerosis']	1	3	"Sentence: To study the long - term effects of androgen treatment on atherosclerosis in postmenopausal women .
Diseases: atherosclerosis"	"Sentence: To study the long - term effects of androgen treatment on atherosclerosis in postmenopausal women .
Diseases:"
1434	In a population - based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self - reported intramuscularly administered high - dose estrogen - testosterone therapy ( estradiol - and testosterone esters ) and aortic atherosclerosis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['atherosclerosis']	1	3	"Sentence: In a population - based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self - reported intramuscularly administered high - dose estrogen - testosterone therapy ( estradiol - and testosterone esters ) and aortic atherosclerosis .
Diseases: atherosclerosis"	"Sentence: In a population - based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self - reported intramuscularly administered high - dose estrogen - testosterone therapy ( estradiol - and testosterone esters ) and aortic atherosclerosis .
Diseases:"
1435	Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta , which have been shown to reflect intima atherosclerosis .	O B O O O O O O O O O O O O O O O O O O O O B O	['atherosclerosis']	1	3	"Sentence: Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta , which have been shown to reflect intima atherosclerosis .
Diseases: atherosclerosis"	"Sentence: Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta , which have been shown to reflect intima atherosclerosis .
Diseases:"
1436	Hormone therapy users were compared with never users .	O O O O O O O O O	[]	0	0	"Sentence: Hormone therapy users were compared with never users .
Diseases: "	"Sentence: Hormone therapy users were compared with never users .
Diseases:"
1437	Intramuscular hormone therapy use for 1 year or longer was reported by 25 women .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Intramuscular hormone therapy use for 1 year or longer was reported by 25 women .
Diseases: "	"Sentence: Intramuscular hormone therapy use for 1 year or longer was reported by 25 women .
Diseases:"
1438	In almost half of these women severe atherosclerosis of the aorta was present ( n = 11 ) , while in women without hormone use severe atherosclerosis of the aorta was present in less than 20 % ( OR 3 . 1 ; 95 % CI , 1 . 1 - 8 . 5 , adjusted for age , years since menopause , smoking , and body mass index ) .	O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['atherosclerosis']	1	3	"Sentence: In almost half of these women severe atherosclerosis of the aorta was present ( n = 11 ) , while in women without hormone use severe atherosclerosis of the aorta was present in less than 20 % ( OR 3 . 1 ; 95 % CI , 1 . 1 - 8 . 5 , adjusted for age , years since menopause , smoking , and body mass index ) .
Diseases: atherosclerosis"	"Sentence: In almost half of these women severe atherosclerosis of the aorta was present ( n = 11 ) , while in women without hormone use severe atherosclerosis of the aorta was present in less than 20 % ( OR 3 . 1 ; 95 % CI , 1 . 1 - 8 . 5 , adjusted for age , years since menopause , smoking , and body mass index ) .
Diseases:"
1439	The association remained after additional adjustment for diabetes , cholesterol level , systolic blood pressure , or alcohol use .	O O O O O O O B O O O O O O O O O O O O	['diabetes']	1	2	"Sentence: The association remained after additional adjustment for diabetes , cholesterol level , systolic blood pressure , or alcohol use .
Diseases: diabetes"	"Sentence: The association remained after additional adjustment for diabetes , cholesterol level , systolic blood pressure , or alcohol use .
Diseases:"
1440	No association was found for hormone use less than 1 year .	O O O O O O O O O O O O	[]	0	0	"Sentence: No association was found for hormone use less than 1 year .
Diseases: "	"Sentence: No association was found for hormone use less than 1 year .
Diseases:"
1441	Our results suggest that high - dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['atherosclerosis']	1	3	"Sentence: Our results suggest that high - dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless .
Diseases: atherosclerosis"	"Sentence: Our results suggest that high - dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless .
Diseases:"
1442	Sirolimus - associated proteinuria and renal dysfunction .	O O O B O B I O	['proteinuria', 'renal dysfunction']	2	5	"Sentence: Sirolimus - associated proteinuria and renal dysfunction .
Diseases: proteinuria, renal dysfunction"	"Sentence: Sirolimus - associated proteinuria and renal dysfunction .
Diseases:"
1443	Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor - containing mammalian target of rapamycin protein kinase .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor - containing mammalian target of rapamycin protein kinase .
Diseases: "	"Sentence: Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor - containing mammalian target of rapamycin protein kinase .
Diseases:"
1444	Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy .	O O O O O O O O O O O O O O O O O B O	['nephropathy']	1	4	"Sentence: Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy .
Diseases: nephropathy"	"Sentence: Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy .
Diseases:"
1445	Its role in the therapy of glomerulonephritis , autoimmunity , cystic renal diseases and renal cancer is under investigation .	O O O O O O B O B O B I I O B I O O O O	['cystic renal diseases', 'renal cancer', 'autoimmunity', 'glomerulonephritis']	4	20	"Sentence: Its role in the therapy of glomerulonephritis , autoimmunity , cystic renal diseases and renal cancer is under investigation .
Diseases: cystic renal diseases, renal cancer, autoimmunity, glomerulonephritis"	"Sentence: Its role in the therapy of glomerulonephritis , autoimmunity , cystic renal diseases and renal cancer is under investigation .
Diseases:"
1446	Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors , it has been designated a ' non - nephrotoxic drug ' .	O O O O O O O O O O O O O O O O O O O O O O O B O O O	['nephrotoxic']	1	4	"Sentence: Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors , it has been designated a ' non - nephrotoxic drug ' .
Diseases: nephrotoxic"	"Sentence: Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors , it has been designated a ' non - nephrotoxic drug ' .
Diseases:"
1447	However , clinical reports suggest that , under some circumstances , sirolimus is associated with proteinuria and acute renal dysfunction .	O O O O O O O O O O O O O O O B O B I I O	['acute renal dysfunction', 'proteinuria']	2	7	"Sentence: However , clinical reports suggest that , under some circumstances , sirolimus is associated with proteinuria and acute renal dysfunction .
Diseases: acute renal dysfunction, proteinuria"	"Sentence: However , clinical reports suggest that , under some circumstances , sirolimus is associated with proteinuria and acute renal dysfunction .
Diseases:"
1448	A common risk factor appears to be presence of pre - existing chronic renal damage .	O O O O O O O O O O O O B I I O	['chronic renal damage']	1	4	"Sentence: A common risk factor appears to be presence of pre - existing chronic renal damage .
Diseases: chronic renal damage"	"Sentence: A common risk factor appears to be presence of pre - existing chronic renal damage .
Diseases:"
1449	The mechanisms of sirolimus - associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal .	O O O O O O B O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: The mechanisms of sirolimus - associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal .
Diseases: proteinuria"	"Sentence: The mechanisms of sirolimus - associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal .
Diseases:"
1450	It has also been suggested that sirolimus directly causes increased glomerular permeability / injury , but evidence for this mechanism is currently inconclusive .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It has also been suggested that sirolimus directly causes increased glomerular permeability / injury , but evidence for this mechanism is currently inconclusive .
Diseases: "	"Sentence: It has also been suggested that sirolimus directly causes increased glomerular permeability / injury , but evidence for this mechanism is currently inconclusive .
Diseases:"
1451	The acute renal dysfunction associated with sirolimus ( such as in delayed graft function ) may be due to suppression of compensatory renal cell proliferation and survival / repair processes .	O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['acute renal dysfunction']	1	4	"Sentence: The acute renal dysfunction associated with sirolimus ( such as in delayed graft function ) may be due to suppression of compensatory renal cell proliferation and survival / repair processes .
Diseases: acute renal dysfunction"	"Sentence: The acute renal dysfunction associated with sirolimus ( such as in delayed graft function ) may be due to suppression of compensatory renal cell proliferation and survival / repair processes .
Diseases:"
1452	Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O	['proteinuria']	1	2	"Sentence: Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .
Diseases: proteinuria"	"Sentence: Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .
Diseases:"
1453	Further long - term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Further long - term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future .
Diseases: "	"Sentence: Further long - term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future .
Diseases:"
1454	Progressive myopathy with up - regulation of MHC - I associated with statin therapy .	O B O O O O O O O O O O O O O	['myopathy']	1	2	"Sentence: Progressive myopathy with up - regulation of MHC - I associated with statin therapy .
Diseases: myopathy"	"Sentence: Progressive myopathy with up - regulation of MHC - I associated with statin therapy .
Diseases:"
1455	Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug .	O O O O O B O B O O O O O O O O O	['myopathy', 'hyperckaemia']	2	7	"Sentence: Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug .
Diseases: myopathy, hyperckaemia"	"Sentence: Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug .
Diseases:"
1456	What is less well known is a phenomenon whereby statins may induce a myopathy , which persists or may progress after stopping the drug .	O O O O O O O O O O O O O B O O O O O O O O O O O	['myopathy']	1	2	"Sentence: What is less well known is a phenomenon whereby statins may induce a myopathy , which persists or may progress after stopping the drug .
Diseases: myopathy"	"Sentence: What is less well known is a phenomenon whereby statins may induce a myopathy , which persists or may progress after stopping the drug .
Diseases:"
1457	We investigated the muscle pathology in 8 such cases .	O O O O O O O O O O	[]	0	0	"Sentence: We investigated the muscle pathology in 8 such cases .
Diseases: "	"Sentence: We investigated the muscle pathology in 8 such cases .
Diseases:"
1458	All had myofibre necrosis but only 3 had an inflammatory infiltrate .	O O O B O O O O O O O O	['necrosis']	1	2	"Sentence: All had myofibre necrosis but only 3 had an inflammatory infiltrate .
Diseases: necrosis"	"Sentence: All had myofibre necrosis but only 3 had an inflammatory infiltrate .
Diseases:"
1459	In all cases there was diffuse or multifocal up - regulation of MHC - I expression even in non - necrotic fibres .	O O O O O O O O O O O O O O O O O O O O B O O	['necrotic']	1	3	"Sentence: In all cases there was diffuse or multifocal up - regulation of MHC - I expression even in non - necrotic fibres .
Diseases: necrotic"	"Sentence: In all cases there was diffuse or multifocal up - regulation of MHC - I expression even in non - necrotic fibres .
Diseases:"
1460	Progressive improvement occurred in 7 cases after commencement of prednisolone and methotrexate , and in one case spontaneously .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Progressive improvement occurred in 7 cases after commencement of prednisolone and methotrexate , and in one case spontaneously .
Diseases: "	"Sentence: Progressive improvement occurred in 7 cases after commencement of prednisolone and methotrexate , and in one case spontaneously .
Diseases:"
1461	These observations suggest that statins may initiate an immune - mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy .	O O O O O O O O O O O B O O O O O O O O O O O O O	['myopathy']	1	2	"Sentence: These observations suggest that statins may initiate an immune - mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy .
Diseases: myopathy"	"Sentence: These observations suggest that statins may initiate an immune - mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy .
Diseases:"
1462	The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up - regulation of MHC - I expression and antigen presentation by muscle fibres .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myopathy']	1	2	"Sentence: The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up - regulation of MHC - I expression and antigen presentation by muscle fibres .
Diseases: myopathy"	"Sentence: The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up - regulation of MHC - I expression and antigen presentation by muscle fibres .
Diseases:"
1463	Direct inhibition of cardiac hyperpolarization - activated cyclic nucleotide - gated pacemaker channels by clonidine .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Direct inhibition of cardiac hyperpolarization - activated cyclic nucleotide - gated pacemaker channels by clonidine .
Diseases: "	"Sentence: Direct inhibition of cardiac hyperpolarization - activated cyclic nucleotide - gated pacemaker channels by clonidine .
Diseases:"
1464	Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease , including arrhythmia , coronary heart disease , and chronic heart failure .	O O O O O O O O O O O O B I O O B O B I I O O O B I O	['cardiovascular disease', 'coronary heart disease', 'heart failure', 'arrhythmia']	4	15	"Sentence: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease , including arrhythmia , coronary heart disease , and chronic heart failure .
Diseases: cardiovascular disease, coronary heart disease, heart failure, arrhythmia"	"Sentence: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease , including arrhythmia , coronary heart disease , and chronic heart failure .
Diseases:"
1465	Activation of presynaptic alpha2 - adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine ; however , other target proteins have been postulated to contribute to the in vivo actions of clonidine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Activation of presynaptic alpha2 - adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine ; however , other target proteins have been postulated to contribute to the in vivo actions of clonidine .
Diseases: "	"Sentence: Activation of presynaptic alpha2 - adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine ; however , other target proteins have been postulated to contribute to the in vivo actions of clonidine .
Diseases:"
1466	METHODS AND RESULTS : To test whether clonidine elicits pharmacological effects independent of alpha2 - adrenoceptors , we have generated mice with a targeted deletion of all 3 alpha2 - adrenoceptor subtypes ( alpha2ABC - / - ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS AND RESULTS : To test whether clonidine elicits pharmacological effects independent of alpha2 - adrenoceptors , we have generated mice with a targeted deletion of all 3 alpha2 - adrenoceptor subtypes ( alpha2ABC - / - ) .
Diseases: "	"Sentence: METHODS AND RESULTS : To test whether clonidine elicits pharmacological effects independent of alpha2 - adrenoceptors , we have generated mice with a targeted deletion of all 3 alpha2 - adrenoceptor subtypes ( alpha2ABC - / - ) .
Diseases:"
1467	Alpha2ABC - / - mice were completely unresponsive to the analgesic and hypnotic effects of clonidine ; however , clonidine significantly lowered heart rate in alpha2ABC - / - mice by up to 150 bpm .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Alpha2ABC - / - mice were completely unresponsive to the analgesic and hypnotic effects of clonidine ; however , clonidine significantly lowered heart rate in alpha2ABC - / - mice by up to 150 bpm .
Diseases: "	"Sentence: Alpha2ABC - / - mice were completely unresponsive to the analgesic and hypnotic effects of clonidine ; however , clonidine significantly lowered heart rate in alpha2ABC - / - mice by up to 150 bpm .
Diseases:"
1468	Clonidine - induced bradycardia in conscious alpha2ABC - / - mice was 32 . 3 % ( 10 microg / kg ) and 26 . 6 % ( 100 microg / kg ) of the effect in wild - type mice .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: Clonidine - induced bradycardia in conscious alpha2ABC - / - mice was 32 . 3 % ( 10 microg / kg ) and 26 . 6 % ( 100 microg / kg ) of the effect in wild - type mice .
Diseases: bradycardia"	"Sentence: Clonidine - induced bradycardia in conscious alpha2ABC - / - mice was 32 . 3 % ( 10 microg / kg ) and 26 . 6 % ( 100 microg / kg ) of the effect in wild - type mice .
Diseases:"
1469	A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC - knockout and wild - type mice .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC - knockout and wild - type mice .
Diseases: "	"Sentence: A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC - knockout and wild - type mice .
Diseases:"
1470	Clonidine inhibited the native pacemaker current ( I ( f ) ) in isolated sinoatrial node pacemaker cells and the I ( f ) - generating hyperpolarization - activated cyclic nucleotide - gated ( HCN ) 2 and HCN4 channels in transfected HEK293 cells .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clonidine inhibited the native pacemaker current ( I ( f ) ) in isolated sinoatrial node pacemaker cells and the I ( f ) - generating hyperpolarization - activated cyclic nucleotide - gated ( HCN ) 2 and HCN4 channels in transfected HEK293 cells .
Diseases: "	"Sentence: Clonidine inhibited the native pacemaker current ( I ( f ) ) in isolated sinoatrial node pacemaker cells and the I ( f ) - generating hyperpolarization - activated cyclic nucleotide - gated ( HCN ) 2 and HCN4 channels in transfected HEK293 cells .
Diseases:"
1471	As a consequence of blocking I ( f ) , clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild - type and alpha2ABC - knockout mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As a consequence of blocking I ( f ) , clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild - type and alpha2ABC - knockout mice .
Diseases: "	"Sentence: As a consequence of blocking I ( f ) , clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild - type and alpha2ABC - knockout mice .
Diseases:"
1472	CONCLUSIONS : Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene - targeted mice in vivo , and thus , clonidine - like drugs represent novel structures for future HCN channel inhibitors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene - targeted mice in vivo , and thus , clonidine - like drugs represent novel structures for future HCN channel inhibitors .
Diseases: "	"Sentence: CONCLUSIONS : Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene - targeted mice in vivo , and thus , clonidine - like drugs represent novel structures for future HCN channel inhibitors .
Diseases:"
1473	Influence of smoking on developing cochlea .	O O O O O O O	[]	0	0	"Sentence: Influence of smoking on developing cochlea .
Diseases: "	"Sentence: Influence of smoking on developing cochlea .
Diseases:"
1474	Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns ?	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns ?
Diseases: "	"Sentence: Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns ?
Diseases:"
1475	Maternal tobacco smoking has negative effects on fetal growth .	O O O O O O O O O O	[]	0	0	"Sentence: Maternal tobacco smoking has negative effects on fetal growth .
Diseases: "	"Sentence: Maternal tobacco smoking has negative effects on fetal growth .
Diseases:"
1476	The influence of smoking during pregnancy on the developing cochlea has not been estimated , although smoking has been positively associated with hearing loss in adults .	O O O O O O O O O O O O O O O O O O O O O O B I O O O	['hearing loss']	1	3	"Sentence: The influence of smoking during pregnancy on the developing cochlea has not been estimated , although smoking has been positively associated with hearing loss in adults .
Diseases: hearing loss"	"Sentence: The influence of smoking during pregnancy on the developing cochlea has not been estimated , although smoking has been positively associated with hearing loss in adults .
Diseases:"
1477	The objective of this study was to determine the effects of maternal smoking on transient evoked otoacoustic emissions ( TEOAEs ) of healthy neonates .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The objective of this study was to determine the effects of maternal smoking on transient evoked otoacoustic emissions ( TEOAEs ) of healthy neonates .
Diseases: "	"Sentence: The objective of this study was to determine the effects of maternal smoking on transient evoked otoacoustic emissions ( TEOAEs ) of healthy neonates .
Diseases:"
1478	This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns .	O O O O O O O O O O B I O O O O O O O O	['hearing impairment']	1	3	"Sentence: This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns .
Diseases: hearing impairment"	"Sentence: This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns .
Diseases:"
1479	Newborns whose mothers reported smoking during pregnancy ( n = 200 ears ) were compared to a control group of newborns ( n = 200 ears ) , whose mothers were non - smokers .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Newborns whose mothers reported smoking during pregnancy ( n = 200 ears ) were compared to a control group of newborns ( n = 200 ears ) , whose mothers were non - smokers .
Diseases: "	"Sentence: Newborns whose mothers reported smoking during pregnancy ( n = 200 ears ) were compared to a control group of newborns ( n = 200 ears ) , whose mothers were non - smokers .
Diseases:"
1480	Exposure to tobacco was characterized as low ( < 5 cigarettes per day , n = 88 ears ) , moderate ( 5 < or = cigarettes per day < 10 , n = 76 ) or high ( > or = 10 cigarettes per day , n = 36 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Exposure to tobacco was characterized as low ( < 5 cigarettes per day , n = 88 ears ) , moderate ( 5 < or = cigarettes per day < 10 , n = 76 ) or high ( > or = 10 cigarettes per day , n = 36 ) .
Diseases: "	"Sentence: Exposure to tobacco was characterized as low ( < 5 cigarettes per day , n = 88 ears ) , moderate ( 5 < or = cigarettes per day < 10 , n = 76 ) or high ( > or = 10 cigarettes per day , n = 36 ) .
Diseases:"
1481	In exposed neonates , TEOAEs mean response ( across frequency ) and mean amplitude at 4000Hz was significantly lower than in non - exposed neonates .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In exposed neonates , TEOAEs mean response ( across frequency ) and mean amplitude at 4000Hz was significantly lower than in non - exposed neonates .
Diseases: "	"Sentence: In exposed neonates , TEOAEs mean response ( across frequency ) and mean amplitude at 4000Hz was significantly lower than in non - exposed neonates .
Diseases:"
1482	Comparisons between exposed newborns ' subgroups revealed no significant differences .	O O O O O O O O O O O	[]	0	0	"Sentence: Comparisons between exposed newborns ' subgroups revealed no significant differences .
Diseases: "	"Sentence: Comparisons between exposed newborns ' subgroups revealed no significant differences .
Diseases:"
1483	However , by comparing each subgroup to control group , we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups .	O O O O O O O O O O O O O O B I I I O O O O O O O	['decreases of teoaes amplitudes']	1	9	"Sentence: However , by comparing each subgroup to control group , we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups .
Diseases: decreases of teoaes amplitudes"	"Sentence: However , by comparing each subgroup to control group , we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups .
Diseases:"
1484	Mean TEOAEs responses of highly exposed newborns were also significantly lower in comparison to our control group .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mean TEOAEs responses of highly exposed newborns were also significantly lower in comparison to our control group .
Diseases: "	"Sentence: Mean TEOAEs responses of highly exposed newborns were also significantly lower in comparison to our control group .
Diseases:"
1485	In utero , exposure to tobacco smoking seems to have a small impact on outer hair cells .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In utero , exposure to tobacco smoking seems to have a small impact on outer hair cells .
Diseases: "	"Sentence: In utero , exposure to tobacco smoking seems to have a small impact on outer hair cells .
Diseases:"
1486	These effects seem to be equally true for all exposed newborns , regardless of the degree of exposure .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These effects seem to be equally true for all exposed newborns , regardless of the degree of exposure .
Diseases: "	"Sentence: These effects seem to be equally true for all exposed newborns , regardless of the degree of exposure .
Diseases:"
1487	Further studies are needed in order to establish a potential negative effect of maternal smoking on the neonate 's hearing acuity .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Further studies are needed in order to establish a potential negative effect of maternal smoking on the neonate 's hearing acuity .
Diseases: "	"Sentence: Further studies are needed in order to establish a potential negative effect of maternal smoking on the neonate 's hearing acuity .
Diseases:"
1488	Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats : implications for autism .	B O B I O O O O O O O O O B O	['autism', 'neuroinflammation', 'behavioral abnormalities']	3	9	"Sentence: Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats : implications for autism .
Diseases: autism, neuroinflammation, behavioral abnormalities"	"Sentence: Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats : implications for autism .
Diseases:"
1489	Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors .	B O O B I O O O O O O O B I I I I I O B I O	['neurodevelopmental disorder', 'autism', 'deficits in communication and social skills', 'repetitive behaviors']	4	17	"Sentence: Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors .
Diseases: neurodevelopmental disorder, autism, deficits in communication and social skills, repetitive behaviors"	"Sentence: Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors .
Diseases:"
1490	In addition to genetic influences , recent studies suggest that prenatal drug or chemical exposures are risk factors for autism .	O O O O O O O O O O O O O O O O O O O B O	['autism']	1	2	"Sentence: In addition to genetic influences , recent studies suggest that prenatal drug or chemical exposures are risk factors for autism .
Diseases: autism"	"Sentence: In addition to genetic influences , recent studies suggest that prenatal drug or chemical exposures are risk factors for autism .
Diseases:"
1491	Terbutaline , a beta2 - adrenoceptor agonist used to arrest preterm labor , has been associated with increased concordance for autism in dizygotic twins .	O O O O O O O O O O B I O O O O O O O O B O O O O	['autism', 'preterm labor']	2	6	"Sentence: Terbutaline , a beta2 - adrenoceptor agonist used to arrest preterm labor , has been associated with increased concordance for autism in dizygotic twins .
Diseases: autism, preterm labor"	"Sentence: Terbutaline , a beta2 - adrenoceptor agonist used to arrest preterm labor , has been associated with increased concordance for autism in dizygotic twins .
Diseases:"
1492	We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats .
Diseases: "	"Sentence: We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats .
Diseases:"
1493	Newborn rats were given terbutaline ( 10 mg / kg ) daily on postnatal days ( PN ) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Newborn rats were given terbutaline ( 10 mg / kg ) daily on postnatal days ( PN ) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30 .
Diseases: "	"Sentence: Newborn rats were given terbutaline ( 10 mg / kg ) daily on postnatal days ( PN ) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30 .
Diseases:"
1494	Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex , as well as in cerebellar and cerebrocortical white matter .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex , as well as in cerebellar and cerebrocortical white matter .
Diseases: "	"Sentence: Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex , as well as in cerebellar and cerebrocortical white matter .
Diseases:"
1495	None of these effects occurred in animals given terbutaline on PN 11 to 14 .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: None of these effects occurred in animals given terbutaline on PN 11 to 14 .
Diseases: "	"Sentence: None of these effects occurred in animals given terbutaline on PN 11 to 14 .
Diseases:"
1496	In behavioral tests , animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper - reactivity to novelty and aversive stimuli when assessed in a novel open field , as well as in the acoustic startle response test .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In behavioral tests , animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper - reactivity to novelty and aversive stimuli when assessed in a novel open field , as well as in the acoustic startle response test .
Diseases: "	"Sentence: In behavioral tests , animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper - reactivity to novelty and aversive stimuli when assessed in a novel open field , as well as in the acoustic startle response test .
Diseases:"
1497	Our findings indicate that beta2 - adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities , similar to those described in autism .	O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O B O	['autism', 'behavioral abnormalities']	2	5	"Sentence: Our findings indicate that beta2 - adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities , similar to those described in autism .
Diseases: autism, behavioral abnormalities"	"Sentence: Our findings indicate that beta2 - adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities , similar to those described in autism .
Diseases:"
1498	This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders .	O O O O O O O O O O O O O B I I O	['autism spectrum disorders']	1	4	"Sentence: This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders .
Diseases: autism spectrum disorders"	"Sentence: This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders .
Diseases:"
1499	Acute myocarditis associated with clozapine .	O B O O O O	['myocarditis']	1	3	"Sentence: Acute myocarditis associated with clozapine .
Diseases: myocarditis"	"Sentence: Acute myocarditis associated with clozapine .
Diseases:"
1500	A case of acute myocarditis associated with the commencement of clozapine is described , highlighting the onset , course and possible contributing factors .	O O O O B O O O O O O O O O O O O O O O O O O O	['myocarditis']	1	3	"Sentence: A case of acute myocarditis associated with the commencement of clozapine is described , highlighting the onset , course and possible contributing factors .
Diseases: myocarditis"	"Sentence: A case of acute myocarditis associated with the commencement of clozapine is described , highlighting the onset , course and possible contributing factors .
Diseases:"
1501	There is an urgent need to raise awareness about this potentially fatal complication of clozapine use .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There is an urgent need to raise awareness about this potentially fatal complication of clozapine use .
Diseases: "	"Sentence: There is an urgent need to raise awareness about this potentially fatal complication of clozapine use .
Diseases:"
1502	A 20 - year - old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine .	O O O O O O O O B O O O O O B O O O O O	['schizophrenia', 'myocarditis']	2	7	"Sentence: A 20 - year - old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine .
Diseases: schizophrenia, myocarditis"	"Sentence: A 20 - year - old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine .
Diseases:"
1503	The patient recovered with intensive medical support .	O O O O O O O O	[]	0	0	"Sentence: The patient recovered with intensive medical support .
Diseases: "	"Sentence: The patient recovered with intensive medical support .
Diseases:"
1504	The symptoms occurred around 2 weeks after starting clozapine in an inpatient setting .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The symptoms occurred around 2 weeks after starting clozapine in an inpatient setting .
Diseases: "	"Sentence: The symptoms occurred around 2 weeks after starting clozapine in an inpatient setting .
Diseases:"
1505	Possible contributing factors may have been concomitant antidepressant use and unaccustomed physical activity .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Possible contributing factors may have been concomitant antidepressant use and unaccustomed physical activity .
Diseases: "	"Sentence: Possible contributing factors may have been concomitant antidepressant use and unaccustomed physical activity .
Diseases:"
1506	CONCLUSIONS : Myocarditis is an increasingly recognized complication associated with the use of clozapine .	O O B O O O O O O O O O O O O	['myocarditis']	1	3	"Sentence: CONCLUSIONS : Myocarditis is an increasingly recognized complication associated with the use of clozapine .
Diseases: myocarditis"	"Sentence: CONCLUSIONS : Myocarditis is an increasingly recognized complication associated with the use of clozapine .
Diseases:"
1507	It can be fatal if not recognized and treated early .	O O O O O O O O O O O	[]	0	0	"Sentence: It can be fatal if not recognized and treated early .
Diseases: "	"Sentence: It can be fatal if not recognized and treated early .
Diseases:"
1508	Considering that clozapine remains the gold standard in treatment of resistant psychosis , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['psychosis']	1	2	"Sentence: Considering that clozapine remains the gold standard in treatment of resistant psychosis , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients .
Diseases: psychosis"	"Sentence: Considering that clozapine remains the gold standard in treatment of resistant psychosis , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients .
Diseases:"
1509	There are also implications for recommendations and regulations regarding the use of clozapine .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: There are also implications for recommendations and regulations regarding the use of clozapine .
Diseases: "	"Sentence: There are also implications for recommendations and regulations regarding the use of clozapine .
Diseases:"
1510	Encephalopathy induced by levetiracetam added to valproate .	B O O O O O O O	['encephalopathy']	1	3	"Sentence: Encephalopathy induced by levetiracetam added to valproate .
Diseases: encephalopathy"	"Sentence: Encephalopathy induced by levetiracetam added to valproate .
Diseases:"
1511	We report on the manifestation of a levetiracetam ( LEV ) - induced encephalopathy .	O O O O O O O O O O O O O B O	['encephalopathy']	1	3	"Sentence: We report on the manifestation of a levetiracetam ( LEV ) - induced encephalopathy .
Diseases: encephalopathy"	"Sentence: We report on the manifestation of a levetiracetam ( LEV ) - induced encephalopathy .
Diseases:"
1512	FINDINGS :	O O	[]	0	0	"Sentence: FINDINGS :
Diseases: "	"Sentence: FINDINGS :
Diseases:"
1513	A 28 - year - old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .	O O O O O O O O O B I O O B O O O O O O O O O O O O O O O O O O O	['idiopathic epilepsy', 'seizures']	2	7	"Sentence: A 28 - year - old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .
Diseases: idiopathic epilepsy, seizures"	"Sentence: A 28 - year - old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .
Diseases:"
1514	Frequency of generalized tonic - clonic seizures increased from one per 6 months to two per month .	O O O B I I I O O O O O O O O O O O	['tonic - clonic seizures']	1	6	"Sentence: Frequency of generalized tonic - clonic seizures increased from one per 6 months to two per month .
Diseases: tonic - clonic seizures"	"Sentence: Frequency of generalized tonic - clonic seizures increased from one per 6 months to two per month .
Diseases:"
1515	Neuropsychological testing showed impaired word fluency , psychomotor speed and working memory .	O O O B I I I I I I I I O	['impaired word fluency , psychomotor speed and working memory']	1	14	"Sentence: Neuropsychological testing showed impaired word fluency , psychomotor speed and working memory .
Diseases: impaired word fluency , psychomotor speed and working memory"	"Sentence: Neuropsychological testing showed impaired word fluency , psychomotor speed and working memory .
Diseases:"
1516	The interictal electroencephalogram ( EEG ) showed a generalized slowing to 5 per second theta rhythms with bilateral generalized high - amplitude discharges .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The interictal electroencephalogram ( EEG ) showed a generalized slowing to 5 per second theta rhythms with bilateral generalized high - amplitude discharges .
Diseases: "	"Sentence: The interictal electroencephalogram ( EEG ) showed a generalized slowing to 5 per second theta rhythms with bilateral generalized high - amplitude discharges .
Diseases:"
1517	OUTCOME :	O O	[]	0	0	"Sentence: OUTCOME :
Diseases: "	"Sentence: OUTCOME :
Diseases:"
1518	Following discontinuation of LEV , EEG and neuropsychological findings improved and seizure frequency decreased .	O O O O O O O O O O O B O O O	['seizure']	1	3	"Sentence: Following discontinuation of LEV , EEG and neuropsychological findings improved and seizure frequency decreased .
Diseases: seizure"	"Sentence: Following discontinuation of LEV , EEG and neuropsychological findings improved and seizure frequency decreased .
Diseases:"
1519	Norepinephrine signaling through beta - adrenergic receptors is critical for expression of cocaine - induced anxiety .	O O O O O O O O O O O O O O O B O	['anxiety']	1	2	"Sentence: Norepinephrine signaling through beta - adrenergic receptors is critical for expression of cocaine - induced anxiety .
Diseases: anxiety"	"Sentence: Norepinephrine signaling through beta - adrenergic receptors is critical for expression of cocaine - induced anxiety .
Diseases:"
1520	Cocaine is a widely abused psychostimulant that has both rewarding and aversive properties .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cocaine is a widely abused psychostimulant that has both rewarding and aversive properties .
Diseases: "	"Sentence: Cocaine is a widely abused psychostimulant that has both rewarding and aversive properties .
Diseases:"
1521	While the mechanisms underlying cocaine 's rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by cocaine , such as anxiety .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['anxiety']	1	2	"Sentence: While the mechanisms underlying cocaine 's rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by cocaine , such as anxiety .
Diseases: anxiety"	"Sentence: While the mechanisms underlying cocaine 's rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by cocaine , such as anxiety .
Diseases:"
1522	In this study , we evaluated the performance of dopamine beta - hydroxylase knockout ( Dbh - / - ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine - induced anxiety .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['anxiety']	1	2	"Sentence: In this study , we evaluated the performance of dopamine beta - hydroxylase knockout ( Dbh - / - ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine - induced anxiety .
Diseases: anxiety"	"Sentence: In this study , we evaluated the performance of dopamine beta - hydroxylase knockout ( Dbh - / - ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine - induced anxiety .
Diseases:"
1523	We found that cocaine dose - dependently increased anxiety - like behavior in control ( Dbh + / - )	O O O O O O O O B O O O O O O O O O O O	['anxiety']	1	2	"Sentence: We found that cocaine dose - dependently increased anxiety - like behavior in control ( Dbh + / - )
Diseases: anxiety"	"Sentence: We found that cocaine dose - dependently increased anxiety - like behavior in control ( Dbh + / - )
Diseases:"
1524	mice , as measured by a decrease in open arm exploration .	O O O O O O O O O O O O	[]	0	0	"Sentence: mice , as measured by a decrease in open arm exploration .
Diseases: "	"Sentence: mice , as measured by a decrease in open arm exploration .
Diseases:"
1525	The Dbh - / - mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The Dbh - / - mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine .
Diseases: "	"Sentence: The Dbh - / - mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine .
Diseases:"
1526	Cocaine - induced anxiety was also attenuated in Dbh + / -	O O O B O O O O O O O O	['anxiety']	1	2	"Sentence: Cocaine - induced anxiety was also attenuated in Dbh + / -
Diseases: anxiety"	"Sentence: Cocaine - induced anxiety was also attenuated in Dbh + / -
Diseases:"
1527	mice following administration of disulfiram , a dopamine beta - hydroxylase ( DBH ) inhibitor .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: mice following administration of disulfiram , a dopamine beta - hydroxylase ( DBH ) inhibitor .
Diseases: "	"Sentence: mice following administration of disulfiram , a dopamine beta - hydroxylase ( DBH ) inhibitor .
Diseases:"
1528	In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist propranolol blocked cocaine - induced anxiety - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist prazosin and the alpha ( 2 ) antagonist yohimbine had no effect .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['anxiety']	1	2	"Sentence: In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist propranolol blocked cocaine - induced anxiety - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist prazosin and the alpha ( 2 ) antagonist yohimbine had no effect .
Diseases: anxiety"	"Sentence: In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist propranolol blocked cocaine - induced anxiety - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist prazosin and the alpha ( 2 ) antagonist yohimbine had no effect .
Diseases:"
1529	CONCLUSIONS : These results indicate that noradrenergic signaling via beta - adrenergic receptors is required for cocaine - induced anxiety in mice .	O O O O O O O O O O O O O O O O O O O B O O O	['anxiety']	1	2	"Sentence: CONCLUSIONS : These results indicate that noradrenergic signaling via beta - adrenergic receptors is required for cocaine - induced anxiety in mice .
Diseases: anxiety"	"Sentence: CONCLUSIONS : These results indicate that noradrenergic signaling via beta - adrenergic receptors is required for cocaine - induced anxiety in mice .
Diseases:"
1530	Clonidine for attention - deficit / hyperactivity disorder : II .	O O B I I I I I O O O	['attention - deficit / hyperactivity disorder']	1	8	"Sentence: Clonidine for attention - deficit / hyperactivity disorder : II .
Diseases: attention - deficit / hyperactivity disorder"	"Sentence: Clonidine for attention - deficit / hyperactivity disorder : II .
Diseases:"
1531	ECG changes and adverse events analysis .	O O O O O O O	[]	0	0	"Sentence: ECG changes and adverse events analysis .
Diseases: "	"Sentence: ECG changes and adverse events analysis .
Diseases:"
1532	To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention - deficit / hyperactivity disorder ( ADHD ) .	O O O O O O O O O O O O O O O O B I I I I I O B O O	['adhd', 'attention - deficit / hyperactivity disorder']	2	10	"Sentence: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention - deficit / hyperactivity disorder ( ADHD ) .
Diseases: adhd, attention - deficit / hyperactivity disorder"	"Sentence: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention - deficit / hyperactivity disorder ( ADHD ) .
Diseases:"
1533	In a 16 - week multicenter , double - blind trial , 122 children with ADHD were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['adhd']	1	2	"Sentence: In a 16 - week multicenter , double - blind trial , 122 children with ADHD were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .
Diseases: adhd"	"Sentence: In a 16 - week multicenter , double - blind trial , 122 children with ADHD were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .
Diseases:"
1534	Doses were flexibly titrated up to 0 . 6	O O O O O O O O O	[]	0	0	"Sentence: Doses were flexibly titrated up to 0 . 6
Diseases: "	"Sentence: Doses were flexibly titrated up to 0 . 6
Diseases:"
1535	mg / day for clonidine and 60 mg / day for methylphenidate ( both with divided dosing ) .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: mg / day for clonidine and 60 mg / day for methylphenidate ( both with divided dosing ) .
Diseases: "	"Sentence: mg / day for clonidine and 60 mg / day for methylphenidate ( both with divided dosing ) .
Diseases:"
1536	Groups were compared regarding adverse events and changes from baseline to week 16 in electrocardiograms and vital signs .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Groups were compared regarding adverse events and changes from baseline to week 16 in electrocardiograms and vital signs .
Diseases: "	"Sentence: Groups were compared regarding adverse events and changes from baseline to week 16 in electrocardiograms and vital signs .
Diseases:"
1537	There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine ( 17 . 5 % versus 3 . 4 % ; p = . 02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine ( 17 . 5 % versus 3 . 4 % ; p = . 02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .
Diseases: bradycardia"	"Sentence: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine ( 17 . 5 % versus 3 . 4 % ; p = . 02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .
Diseases:"
1538	There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes .
Diseases: "	"Sentence: There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes .
Diseases:"
1539	Moderate or severe adverse events were more common in subjects on clonidine ( 79 . 4 % versus 49 . 2 % ; p = . 0006 ) but not associated with higher rates of early study withdrawal .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Moderate or severe adverse events were more common in subjects on clonidine ( 79 . 4 % versus 49 . 2 % ; p = . 0006 ) but not associated with higher rates of early study withdrawal .
Diseases: "	"Sentence: Moderate or severe adverse events were more common in subjects on clonidine ( 79 . 4 % versus 49 . 2 % ; p = . 0006 ) but not associated with higher rates of early study withdrawal .
Diseases:"
1540	Drowsiness was common on clonidine , but generally resolved by 6 to 8 weeks .	B O O O O O O O O O O O O O O	['drowsiness']	1	3	"Sentence: Drowsiness was common on clonidine , but generally resolved by 6 to 8 weeks .
Diseases: drowsiness"	"Sentence: Drowsiness was common on clonidine , but generally resolved by 6 to 8 weeks .
Diseases:"
1541	Clonidine , used alone or with methylphenidate , appears safe and well tolerated in childhood ADHD .	O O O O O O O O O O O O O O O B O	['adhd']	1	2	"Sentence: Clonidine , used alone or with methylphenidate , appears safe and well tolerated in childhood ADHD .
Diseases: adhd"	"Sentence: Clonidine , used alone or with methylphenidate , appears safe and well tolerated in childhood ADHD .
Diseases:"
1542	Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness .	O O O O O O B O O O O O O O O O B O	['drowsiness', 'bradycardia']	2	8	"Sentence: Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness .
Diseases: drowsiness, bradycardia"	"Sentence: Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness .
Diseases:"
1543	Thalidomide has limited single - agent activity in relapsed or refractory indolent non - Hodgkin lymphomas : a phase II trial of the Cancer and Leukemia Group B . Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma , mantle cell lymphoma and lymphoplasmacytic lymphoma .	O O O O O O O O O O O O B I I I O O O O O O O B O B O O O O O O O O O O O O B I O B I I O B I O	['multiple myeloma', 'mantle cell lymphoma', 'lymphoplasmacytic lymphoma', 'leukemia', 'cancer', 'non - hodgkin lymphomas']	6	30	"Sentence: Thalidomide has limited single - agent activity in relapsed or refractory indolent non - Hodgkin lymphomas : a phase II trial of the Cancer and Leukemia Group B . Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma , mantle cell lymphoma and lymphoplasmacytic lymphoma .
Diseases: multiple myeloma, mantle cell lymphoma, lymphoplasmacytic lymphoma, leukemia, cancer, non - hodgkin lymphomas"	"Sentence: Thalidomide has limited single - agent activity in relapsed or refractory indolent non - Hodgkin lymphomas : a phase II trial of the Cancer and Leukemia Group B . Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma , mantle cell lymphoma and lymphoplasmacytic lymphoma .
Diseases:"
1544	Its activity is believed to be due modulation of the tumour milieu , including downregulation of angiogenesis and inflammatory cytokines .	O O O O O O O O O O B O O O O O O O O O O	['tumour']	1	3	"Sentence: Its activity is believed to be due modulation of the tumour milieu , including downregulation of angiogenesis and inflammatory cytokines .
Diseases: tumour"	"Sentence: Its activity is believed to be due modulation of the tumour milieu , including downregulation of angiogenesis and inflammatory cytokines .
Diseases:"
1545	Between July 2001 and April 2004 , 24 patients with relapsed / refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1 - 2 weeks as tolerated , up to a maximum of 800 mg daily .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['lymphomas']	1	3	"Sentence: Between July 2001 and April 2004 , 24 patients with relapsed / refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1 - 2 weeks as tolerated , up to a maximum of 800 mg daily .
Diseases: lymphomas"	"Sentence: Between July 2001 and April 2004 , 24 patients with relapsed / refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1 - 2 weeks as tolerated , up to a maximum of 800 mg daily .
Diseases:"
1546	Patients had received a median of 2 ( range , 1 - 4 ) prior regimens .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients had received a median of 2 ( range , 1 - 4 ) prior regimens .
Diseases: "	"Sentence: Patients had received a median of 2 ( range , 1 - 4 ) prior regimens .
Diseases:"
1547	Of 24 evaluable patients , two achieved a complete remission and one achieved a partial remission for an overall response rate of 12 . 5 % ( 95 % confidence interval : 2 . 6 - 32 . 4 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of 24 evaluable patients , two achieved a complete remission and one achieved a partial remission for an overall response rate of 12 . 5 % ( 95 % confidence interval : 2 . 6 - 32 . 4 % ) .
Diseases: "	"Sentence: Of 24 evaluable patients , two achieved a complete remission and one achieved a partial remission for an overall response rate of 12 . 5 % ( 95 % confidence interval : 2 . 6 - 32 . 4 % ) .
Diseases:"
1548	Eleven patients progressed during therapy .	O O O O O O	[]	0	0	"Sentence: Eleven patients progressed during therapy .
Diseases: "	"Sentence: Eleven patients progressed during therapy .
Diseases:"
1549	Grade 3 - 4 adverse effects included myelosuppression , fatigue , somnolence / depressed mood , neuropathy and dyspnea .	O O O O O O O B O B O B O B I O B O B O	['myelosuppression', 'somnolence', 'neuropathy', 'dyspnea', 'depressed mood', 'fatigue']	6	22	"Sentence: Grade 3 - 4 adverse effects included myelosuppression , fatigue , somnolence / depressed mood , neuropathy and dyspnea .
Diseases: myelosuppression, somnolence, neuropathy, dyspnea, depressed mood, fatigue"	"Sentence: Grade 3 - 4 adverse effects included myelosuppression , fatigue , somnolence / depressed mood , neuropathy and dyspnea .
Diseases:"
1550	Of concern was the occurrence of four thromboembolic events .	O O O O O O O B O O	['thromboembolic']	1	5	"Sentence: Of concern was the occurrence of four thromboembolic events .
Diseases: thromboembolic"	"Sentence: Of concern was the occurrence of four thromboembolic events .
Diseases:"
1551	Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent , lenalidomide .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['lymphomas']	1	3	"Sentence: Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent , lenalidomide .
Diseases: lymphomas"	"Sentence: Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent , lenalidomide .
Diseases:"
1552	Intracavernous epinephrine : a minimally invasive treatment for priapism in the emergency department .	O O O O O O O O B O O O O O	['priapism']	1	3	"Sentence: Intracavernous epinephrine : a minimally invasive treatment for priapism in the emergency department .
Diseases: priapism"	"Sentence: Intracavernous epinephrine : a minimally invasive treatment for priapism in the emergency department .
Diseases:"
1553	Priapism is the prolonged erection of the penis in the absence of sexual arousal .	B O O O O O O O O O O O O O O	['priapism']	1	3	"Sentence: Priapism is the prolonged erection of the penis in the absence of sexual arousal .
Diseases: priapism"	"Sentence: Priapism is the prolonged erection of the penis in the absence of sexual arousal .
Diseases:"
1554	A 45 - year - old man , an admitted frequent cocaine user , presented to the Emergency Department ( ED ) on two separate occasions with a history of priapism after cocaine use .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['priapism']	1	3	"Sentence: A 45 - year - old man , an admitted frequent cocaine user , presented to the Emergency Department ( ED ) on two separate occasions with a history of priapism after cocaine use .
Diseases: priapism"	"Sentence: A 45 - year - old man , an admitted frequent cocaine user , presented to the Emergency Department ( ED ) on two separate occasions with a history of priapism after cocaine use .
Diseases:"
1555	The management options in the ED , as exemplified by four individual case reports , in particular the use of a minimally invasive method of intracorporal epinephrine instillation , are discussed .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The management options in the ED , as exemplified by four individual case reports , in particular the use of a minimally invasive method of intracorporal epinephrine instillation , are discussed .
Diseases: "	"Sentence: The management options in the ED , as exemplified by four individual case reports , in particular the use of a minimally invasive method of intracorporal epinephrine instillation , are discussed .
Diseases:"
1556	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats .	O O O O O O O O O O O B I O O O	['myocardial infarction']	1	6	"Sentence: Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats .
Diseases: myocardial infarction"	"Sentence: Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats .
Diseases:"
1557	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol ( ISO ) - induced myocardial infarction in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O	['myocardial infarction']	1	6	"Sentence: The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol ( ISO ) - induced myocardial infarction in rats .
Diseases: myocardial infarction"	"Sentence: The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol ( ISO ) - induced myocardial infarction in rats .
Diseases:"
1558	Adult male albino rats , treated with ISO ( 200 mg / kg , s . c . ) for 2 days at an interval of 24 h caused a significant ( P < 0 . 05 ) elevation of heart weight , serum marker enzymes , lipid peroxidation and Ca + 2 ATPase level whereas there was a significant ( P < 0 . 05 ) decrease in body weight , endogenous antioxidants , Na + / K + ATPase and Mg + 2 ATPase levels .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Adult male albino rats , treated with ISO ( 200 mg / kg , s . c . ) for 2 days at an interval of 24 h caused a significant ( P < 0 . 05 ) elevation of heart weight , serum marker enzymes , lipid peroxidation and Ca + 2 ATPase level whereas there was a significant ( P < 0 . 05 ) decrease in body weight , endogenous antioxidants , Na + / K + ATPase and Mg + 2 ATPase levels .
Diseases: "	"Sentence: Adult male albino rats , treated with ISO ( 200 mg / kg , s . c . ) for 2 days at an interval of 24 h caused a significant ( P < 0 . 05 ) elevation of heart weight , serum marker enzymes , lipid peroxidation and Ca + 2 ATPase level whereas there was a significant ( P < 0 . 05 ) decrease in body weight , endogenous antioxidants , Na + / K + ATPase and Mg + 2 ATPase levels .
Diseases:"
1559	Administration of green tea ( 100 mg / kg / day , p . o . ) and vitamin E ( 100 mg / kg / day , p . o . ) together for 30 consecutive days and challenged with ISO on the day 29th and 30th , showed a significant ( P < 0 . 05 ) decrease in heart weight , serum marker enzymes , lipid peroxidation , Ca + 2 ATPase and a significant increase in the body weight , endogenous antioxidants , Na + / K + ATPase and Mg + 2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Administration of green tea ( 100 mg / kg / day , p . o . ) and vitamin E ( 100 mg / kg / day , p . o . ) together for 30 consecutive days and challenged with ISO on the day 29th and 30th , showed a significant ( P < 0 . 05 ) decrease in heart weight , serum marker enzymes , lipid peroxidation , Ca + 2 ATPase and a significant increase in the body weight , endogenous antioxidants , Na + / K + ATPase and Mg + 2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups .
Diseases: "	"Sentence: Administration of green tea ( 100 mg / kg / day , p . o . ) and vitamin E ( 100 mg / kg / day , p . o . ) together for 30 consecutive days and challenged with ISO on the day 29th and 30th , showed a significant ( P < 0 . 05 ) decrease in heart weight , serum marker enzymes , lipid peroxidation , Ca + 2 ATPase and a significant increase in the body weight , endogenous antioxidants , Na + / K + ATPase and Mg + 2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups .
Diseases:"
1560	These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats .	O O O O O O O O O O O O O O O O B I O O O	['myocardial infarction']	1	6	"Sentence: These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats .
Diseases: myocardial infarction"	"Sentence: These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats .
Diseases:"
1561	Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C .	O O B I O O O O O O O B I I O	['ocular myasthenia', 'chronic hepatitis c']	2	9	"Sentence: Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C .
Diseases: ocular myasthenia, chronic hepatitis c"	"Sentence: Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C .
Diseases:"
1562	A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha - 2b and ribavirin for chronic hepatitis C ( CHC ) .	O O O O O O O O O B O O O O O O O O O O O O O O O O O B I I O B O O	['chc', 'chronic hepatitis c', 'diplopia']	3	10	"Sentence: A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha - 2b and ribavirin for chronic hepatitis C ( CHC ) .
Diseases: chc, chronic hepatitis c, diplopia"	"Sentence: A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha - 2b and ribavirin for chronic hepatitis C ( CHC ) .
Diseases:"
1563	Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs .	O O O B I I I I I O B I I I O O O O O O	['restricted right eye movement', 'ptosis on the right upper lid']	2	12	"Sentence: Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs .
Diseases: restricted right eye movement, ptosis on the right upper lid"	"Sentence: Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs .
Diseases:"
1564	A brain imaging study and repetitive nerve stimulation test indicated no abnormality .	O O O O O O O O O O O O O	[]	0	0	"Sentence: A brain imaging study and repetitive nerve stimulation test indicated no abnormality .
Diseases: "	"Sentence: A brain imaging study and repetitive nerve stimulation test indicated no abnormality .
Diseases:"
1565	The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative , and the results of thyroid function tests were normal .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative , and the results of thyroid function tests were normal .
Diseases: "	"Sentence: The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative , and the results of thyroid function tests were normal .
Diseases:"
1566	The patient 's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha - 2b and ribavirin .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The patient 's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha - 2b and ribavirin .
Diseases: "	"Sentence: The patient 's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha - 2b and ribavirin .
Diseases:"
1567	The ocular myasthenia associated with combination therapy of pegylated IFN alpha - 2b and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .	O B I O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['chc', 'ocular myasthenia']	2	9	"Sentence: The ocular myasthenia associated with combination therapy of pegylated IFN alpha - 2b and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
Diseases: chc, ocular myasthenia"	"Sentence: The ocular myasthenia associated with combination therapy of pegylated IFN alpha - 2b and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .
Diseases:"
1568	The glycine transporter - 1 inhibitor SSR103800 displays a selective and specific antipsychotic - like profile in normal and transgenic mice .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The glycine transporter - 1 inhibitor SSR103800 displays a selective and specific antipsychotic - like profile in normal and transgenic mice .
Diseases: "	"Sentence: The glycine transporter - 1 inhibitor SSR103800 displays a selective and specific antipsychotic - like profile in normal and transgenic mice .
Diseases:"
1569	Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission .	B O O O O O O O O O O	['schizophrenia']	1	3	"Sentence: Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission .
Diseases: schizophrenia"	"Sentence: Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission .
Diseases:"
1570	However , the observation that antagonists of the glutamate N - methyl - D - aspartate ( NMDA ) receptor produce schizophrenic - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['schizophrenic']	1	3	"Sentence: However , the observation that antagonists of the glutamate N - methyl - D - aspartate ( NMDA ) receptor produce schizophrenic - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .
Diseases: schizophrenic"	"Sentence: However , the observation that antagonists of the glutamate N - methyl - D - aspartate ( NMDA ) receptor produce schizophrenic - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .
Diseases:"
1571	As a result , there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As a result , there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor .
Diseases: "	"Sentence: As a result , there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor .
Diseases:"
1572	Among them are glycine transporter - 1 ( GlyT1 ) inhibitors such as SSR103800 , which indirectly enhance NMDA receptor function by increasing the glycine ( a co - agonist for the NMDA receptor ) levels in the synapse .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Among them are glycine transporter - 1 ( GlyT1 ) inhibitors such as SSR103800 , which indirectly enhance NMDA receptor function by increasing the glycine ( a co - agonist for the NMDA receptor ) levels in the synapse .
Diseases: "	"Sentence: Among them are glycine transporter - 1 ( GlyT1 ) inhibitors such as SSR103800 , which indirectly enhance NMDA receptor function by increasing the glycine ( a co - agonist for the NMDA receptor ) levels in the synapse .
Diseases:"
1573	This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of hyperactivity , involving either drug challenge ( ie , amphetamine and MK - 801 ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of hyperactivity , involving either drug challenge ( ie , amphetamine and MK - 801 ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .
Diseases: hyperactivity"	"Sentence: This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of hyperactivity , involving either drug challenge ( ie , amphetamine and MK - 801 ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .
Diseases:"
1574	Results showed that SSR103800 ( 10 - 30 mg / kg	O O O O O O O O O O O	[]	0	0	"Sentence: Results showed that SSR103800 ( 10 - 30 mg / kg
Diseases: "	"Sentence: Results showed that SSR103800 ( 10 - 30 mg / kg
Diseases:"
1575	p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .	O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .
Diseases: hyperactivity"	"Sentence: p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .
Diseases:"
1576	In contrast , SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: In contrast , SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg
Diseases: hyperactivity"	"Sentence: In contrast , SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg
Diseases:"
1577	p . o . ) .	O O O O O O	[]	0	0	"Sentence: p . o . ) .
Diseases: "	"Sentence: p . o . ) .
Diseases:"
1578	Importantly , both classical ( haloperidol ) and atypical ( olanzapine , clozapine and aripiprazole ) antipsychotics were effective in all these models of hyperactivity .	O O O O O O O O O O O O O O O O O O O O O O O O B O	['hyperactivity']	1	2	"Sentence: Importantly , both classical ( haloperidol ) and atypical ( olanzapine , clozapine and aripiprazole ) antipsychotics were effective in all these models of hyperactivity .
Diseases: hyperactivity"	"Sentence: Importantly , both classical ( haloperidol ) and atypical ( olanzapine , clozapine and aripiprazole ) antipsychotics were effective in all these models of hyperactivity .
Diseases:"
1579	However , unlike these latter , SSR103800 did not produce catalepsy ( retention on the bar test ) up to 30 mg / kg p . o .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: However , unlike these latter , SSR103800 did not produce catalepsy ( retention on the bar test ) up to 30 mg / kg p . o .
Diseases: catalepsy"	"Sentence: However , unlike these latter , SSR103800 did not produce catalepsy ( retention on the bar test ) up to 30 mg / kg p . o .
Diseases:"
1580	Together these findings show that the GlyT1 inhibitor , SSR103800 , produces antipsychotic - like effects , which differ from those observed with compounds primarily targeting the dopaminergic system , and has a reduced side - effect potential as compared with these latter drugs .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Together these findings show that the GlyT1 inhibitor , SSR103800 , produces antipsychotic - like effects , which differ from those observed with compounds primarily targeting the dopaminergic system , and has a reduced side - effect potential as compared with these latter drugs .
Diseases: "	"Sentence: Together these findings show that the GlyT1 inhibitor , SSR103800 , produces antipsychotic - like effects , which differ from those observed with compounds primarily targeting the dopaminergic system , and has a reduced side - effect potential as compared with these latter drugs .
Diseases:"
1581	Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia - induced hypotension .	O O O O B I I I O O O O B O	['reduces frontal lobe oxygenation', 'hypotension']	2	9	"Sentence: Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia - induced hypotension .
Diseases: reduces frontal lobe oxygenation, hypotension"	"Sentence: Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia - induced hypotension .
Diseases:"
1582	Vasopressor agents are used to correct anesthesia - induced hypotension .	O O O O O O O O O B O	['hypotension']	1	3	"Sentence: Vasopressor agents are used to correct anesthesia - induced hypotension .
Diseases: hypotension"	"Sentence: Vasopressor agents are used to correct anesthesia - induced hypotension .
Diseases:"
1583	We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced hypotension .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['hypotension']	1	3	"Sentence: We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced hypotension .
Diseases: hypotension"	"Sentence: We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced hypotension .
Diseases:"
1584	Following induction of anesthesia by fentanyl ( 0 . 15 mg kg ( - 1 ) ) and propofol ( 2 . 0 mg kg ( - 1 ) ) , 13 patients received phenylephrine ( 0 . 1 mg iv ) and 12 patients received ephedrine ( 10 mg iv ) to restore mean arterial pressure ( MAP ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following induction of anesthesia by fentanyl ( 0 . 15 mg kg ( - 1 ) ) and propofol ( 2 . 0 mg kg ( - 1 ) ) , 13 patients received phenylephrine ( 0 . 1 mg iv ) and 12 patients received ephedrine ( 10 mg iv ) to restore mean arterial pressure ( MAP ) .
Diseases: "	"Sentence: Following induction of anesthesia by fentanyl ( 0 . 15 mg kg ( - 1 ) ) and propofol ( 2 . 0 mg kg ( - 1 ) ) , 13 patients received phenylephrine ( 0 . 1 mg iv ) and 12 patients received ephedrine ( 10 mg iv ) to restore mean arterial pressure ( MAP ) .
Diseases:"
1585	Heart rate ( HR ) , MAP , stroke volume ( SV ) , cardiac output ( CO ) , and frontal lobe oxygenation ( S ( c ) O ( 2 ) ) were registered .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['stroke']	1	1	"Sentence: Heart rate ( HR ) , MAP , stroke volume ( SV ) , cardiac output ( CO ) , and frontal lobe oxygenation ( S ( c ) O ( 2 ) ) were registered .
Diseases: stroke"	"Sentence: Heart rate ( HR ) , MAP , stroke volume ( SV ) , cardiac output ( CO ) , and frontal lobe oxygenation ( S ( c ) O ( 2 ) ) were registered .
Diseases:"
1586	RESULTS : Induction of anesthesia was followed by a decrease in MAP , HR , SV , and CO concomitant with an elevation in S ( c ) O ( 2 ) .	O O O O O O O O B I I I I I I I I I I O O O O O O O O O O O O O O	['a decrease in map , hr , sv , and co']	1	11	"Sentence: RESULTS : Induction of anesthesia was followed by a decrease in MAP , HR , SV , and CO concomitant with an elevation in S ( c ) O ( 2 ) .
Diseases: a decrease in map , hr , sv , and co"	"Sentence: RESULTS : Induction of anesthesia was followed by a decrease in MAP , HR , SV , and CO concomitant with an elevation in S ( c ) O ( 2 ) .
Diseases:"
1587	After administration of phenylephrine , MAP increased ( 51 + / - 12 to 81 + / - 13 mmHg ; P < 0 . 001 ; mean + / - SD ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After administration of phenylephrine , MAP increased ( 51 + / - 12 to 81 + / - 13 mmHg ; P < 0 . 001 ; mean + / - SD ) .
Diseases: "	"Sentence: After administration of phenylephrine , MAP increased ( 51 + / - 12 to 81 + / - 13 mmHg ; P < 0 . 001 ; mean + / - SD ) .
Diseases:"
1588	However , a 14 % ( from 70 + / - 8 % to 60 + / - 7 % ) reduction in S ( c ) O ( 2 )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , a 14 % ( from 70 + / - 8 % to 60 + / - 7 % ) reduction in S ( c ) O ( 2 )
Diseases: "	"Sentence: However , a 14 % ( from 70 + / - 8 % to 60 + / - 7 % ) reduction in S ( c ) O ( 2 )
Diseases:"
1589	( P < 0 . 05 ) followed with no change in CO ( 3 . 7 + / - 1 . 1 to 3 . 4 + / - 0 . 9 l min ( - 1 ) ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ( P < 0 . 05 ) followed with no change in CO ( 3 . 7 + / - 1 . 1 to 3 . 4 + / - 0 . 9 l min ( - 1 ) ) .
Diseases: "	"Sentence: ( P < 0 . 05 ) followed with no change in CO ( 3 . 7 + / - 1 . 1 to 3 . 4 + / - 0 . 9 l min ( - 1 ) ) .
Diseases:"
1590	The administration of ephedrine led to a similar increase in MAP ( 53 + / - 9 to 79 + / - 8 mmHg ; P < 0 . 001 ) , restored CO ( 3 . 2 + / - 1 . 2 to 5 . 0 + / - 1 . 3 l min ( - 1 ) ) , and preserved S ( c ) O ( 2 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The administration of ephedrine led to a similar increase in MAP ( 53 + / - 9 to 79 + / - 8 mmHg ; P < 0 . 001 ) , restored CO ( 3 . 2 + / - 1 . 2 to 5 . 0 + / - 1 . 3 l min ( - 1 ) ) , and preserved S ( c ) O ( 2 ) .
Diseases: "	"Sentence: The administration of ephedrine led to a similar increase in MAP ( 53 + / - 9 to 79 + / - 8 mmHg ; P < 0 . 001 ) , restored CO ( 3 . 2 + / - 1 . 2 to 5 . 0 + / - 1 . 3 l min ( - 1 ) ) , and preserved S ( c ) O ( 2 ) .
Diseases:"
1591	CONCLUSIONS : The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: CONCLUSIONS : The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO .
Diseases: hypotension"	"Sentence: CONCLUSIONS : The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO .
Diseases:"
1592	A novel , multiple symptom model of obsessive - compulsive - like behaviors in animals .	O O O O O O O B I I I I I O O O	['obsessive - compulsive - like behaviors']	1	9	"Sentence: A novel , multiple symptom model of obsessive - compulsive - like behaviors in animals .
Diseases: obsessive - compulsive - like behaviors"	"Sentence: A novel , multiple symptom model of obsessive - compulsive - like behaviors in animals .
Diseases:"
1593	Current animal models of obsessive - compulsive disorder ( OCD ) typically involve acute , drug - induced symptom provocation or a genetic association with stereotypies or anxiety .	O O O O B I I I O B O O O O O O O O O O O O O O O O O B O	['ocd', 'obsessive - compulsive disorder', 'anxiety']	3	10	"Sentence: Current animal models of obsessive - compulsive disorder ( OCD ) typically involve acute , drug - induced symptom provocation or a genetic association with stereotypies or anxiety .
Diseases: ocd, obsessive - compulsive disorder, anxiety"	"Sentence: Current animal models of obsessive - compulsive disorder ( OCD ) typically involve acute , drug - induced symptom provocation or a genetic association with stereotypies or anxiety .
Diseases:"
1594	None of these current models demonstrate multiple OCD - like behaviors .	O O O O O O O B O O O O	['ocd']	1	2	"Sentence: None of these current models demonstrate multiple OCD - like behaviors .
Diseases: ocd"	"Sentence: None of these current models demonstrate multiple OCD - like behaviors .
Diseases:"
1595	Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood .
Diseases: "	"Sentence: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood .
Diseases:"
1596	Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , hoarding , and corticostriatal dysfunction .	O O O O O O O O O O O O O O B O O O O O O O O O B I O O O O O O O O O O O O O O B I O O O O O O O O O O O O B O O B I O	['memory impairment', 'hoarding', 'anxiety', 'behavioral inflexibility', 'corticostriatal dysfunction']	5	19	"Sentence: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , hoarding , and corticostriatal dysfunction .
Diseases: memory impairment, hoarding, anxiety, behavioral inflexibility, corticostriatal dysfunction"	"Sentence: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , hoarding , and corticostriatal dysfunction .
Diseases:"
1597	Dopamine D2 receptors were elevated in the striatum , whereas serotonin 2C , but not serotonin 1A , receptors were elevated in the orbital frontal cortex .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dopamine D2 receptors were elevated in the striatum , whereas serotonin 2C , but not serotonin 1A , receptors were elevated in the orbital frontal cortex .
Diseases: "	"Sentence: Dopamine D2 receptors were elevated in the striatum , whereas serotonin 2C , but not serotonin 1A , receptors were elevated in the orbital frontal cortex .
Diseases:"
1598	This is the first demonstration of multiple symptoms consistent with an OCD - like profile in animals .	O O O O O O O O O O O B O O O O O O	['ocd']	1	2	"Sentence: This is the first demonstration of multiple symptoms consistent with an OCD - like profile in animals .
Diseases: ocd"	"Sentence: This is the first demonstration of multiple symptoms consistent with an OCD - like profile in animals .
Diseases:"
1599	Moreover , these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD .	O O O O O O O O O O O O O O O O O B O	['ocd']	1	2	"Sentence: Moreover , these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD .
Diseases: ocd"	"Sentence: Moreover , these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD .
Diseases:"
1600	This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease - like systems permanently , which could have implications for current and future therapeutic strategies for this and other psychiatric disorders .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['ocd', 'psychiatric disorders']	2	5	"Sentence: This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease - like systems permanently , which could have implications for current and future therapeutic strategies for this and other psychiatric disorders .
Diseases: ocd, psychiatric disorders"	"Sentence: This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease - like systems permanently , which could have implications for current and future therapeutic strategies for this and other psychiatric disorders .
Diseases:"
1601	Late recovery of renal function in a woman with the hemolytic uremic syndrome .	O O O O O O O O O O B I I O	['hemolytic uremic syndrome']	1	7	"Sentence: Late recovery of renal function in a woman with the hemolytic uremic syndrome .
Diseases: hemolytic uremic syndrome"	"Sentence: Late recovery of renal function in a woman with the hemolytic uremic syndrome .
Diseases:"
1602	A case is reported of the hemolytic uremic syndrome ( HUS ) in a woman taking oral contraceptives .	O O O O O O B I I O B O O O O O O O O	['hemolytic uremic syndrome', 'hus']	2	9	"Sentence: A case is reported of the hemolytic uremic syndrome ( HUS ) in a woman taking oral contraceptives .
Diseases: hemolytic uremic syndrome, hus"	"Sentence: A case is reported of the hemolytic uremic syndrome ( HUS ) in a woman taking oral contraceptives .
Diseases:"
1603	She was treated with heparin , dipyridamole and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of anuria , dialysis treatment was stopped .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['anuria']	1	2	"Sentence: She was treated with heparin , dipyridamole and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of anuria , dialysis treatment was stopped .
Diseases: anuria"	"Sentence: She was treated with heparin , dipyridamole and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of anuria , dialysis treatment was stopped .
Diseases:"
1604	This case emphasizes the possibility that HUS in adults is not invariably irreversible and that , despite prolonged oliguria , recovery of renal function can be obtained .	O O O O O O B O O O O O O O O O O O B O O O O O O O O O	['hus', 'oliguria']	2	4	"Sentence: This case emphasizes the possibility that HUS in adults is not invariably irreversible and that , despite prolonged oliguria , recovery of renal function can be obtained .
Diseases: hus, oliguria"	"Sentence: This case emphasizes the possibility that HUS in adults is not invariably irreversible and that , despite prolonged oliguria , recovery of renal function can be obtained .
Diseases:"
1605	Therefore , in adult patients affected by HUS , dialysis should not be discontinued prematurely ; moreover , bilateral nephrectomy , for treatment of severe hypertension and microangiopathic hemolytic anemia , should be performed with caution .	O O O O O O O B O O O O O O O O O O O O O O O O O B O B I I O O O O O O O	['microangiopathic hemolytic anemia', 'hus', 'hypertension']	3	14	"Sentence: Therefore , in adult patients affected by HUS , dialysis should not be discontinued prematurely ; moreover , bilateral nephrectomy , for treatment of severe hypertension and microangiopathic hemolytic anemia , should be performed with caution .
Diseases: microangiopathic hemolytic anemia, hus, hypertension"	"Sentence: Therefore , in adult patients affected by HUS , dialysis should not be discontinued prematurely ; moreover , bilateral nephrectomy , for treatment of severe hypertension and microangiopathic hemolytic anemia , should be performed with caution .
Diseases:"
1606	Effects of acetylsalicylic acid , dipyridamole , and hydrocortisone on epinephrine - induced myocardial injury in dogs .	O O O O O O O O O O O O O B I O O O	['myocardial injury']	1	4	"Sentence: Effects of acetylsalicylic acid , dipyridamole , and hydrocortisone on epinephrine - induced myocardial injury in dogs .
Diseases: myocardial injury"	"Sentence: Effects of acetylsalicylic acid , dipyridamole , and hydrocortisone on epinephrine - induced myocardial injury in dogs .
Diseases:"
1607	A reproducible model for producing diffuse myocardial injury ( epinephrine infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction .	O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O B I O	['myocardial injury', 'myocardial infarction']	2	11	"Sentence: A reproducible model for producing diffuse myocardial injury ( epinephrine infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction .
Diseases: myocardial injury, myocardial infarction"	"Sentence: A reproducible model for producing diffuse myocardial injury ( epinephrine infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction .
Diseases:"
1608	Infusions of epinephrine ( 4 mug per kilogram per minute for 6 hours ) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline - infused control animals ( 4 , 957 vs . 827 counts per minute per gram of dried tissue or fraction ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Infusions of epinephrine ( 4 mug per kilogram per minute for 6 hours ) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline - infused control animals ( 4 , 957 vs . 827 counts per minute per gram of dried tissue or fraction ) .
Diseases: "	"Sentence: Infusions of epinephrine ( 4 mug per kilogram per minute for 6 hours ) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline - infused control animals ( 4 , 957 vs . 827 counts per minute per gram of dried tissue or fraction ) .
Diseases:"
1609	Myocardial concentrations of calcium also increased significantly ( 12 . 0 vs . 5 . 0 mg . per 100 Gm . of fat - free dry weight ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Myocardial concentrations of calcium also increased significantly ( 12 . 0 vs . 5 . 0 mg . per 100 Gm . of fat - free dry weight ) .
Diseases: "	"Sentence: Myocardial concentrations of calcium also increased significantly ( 12 . 0 vs . 5 . 0 mg . per 100 Gm . of fat - free dry weight ) .
Diseases:"
1610	Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq .
Diseases: "	"Sentence: Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq .
Diseases:"
1611	per liter failed to increase calcium influx into the myocardial cell .	O O O O O O O O O O O O	[]	0	0	"Sentence: per liter failed to increase calcium influx into the myocardial cell .
Diseases: "	"Sentence: per liter failed to increase calcium influx into the myocardial cell .
Diseases:"
1612	Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion ( 2 , 682 , 2 , 803 , and 3 , 424 counts per minute per gram of dried fraction , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion ( 2 , 682 , 2 , 803 , and 3 , 424 counts per minute per gram of dried fraction , respectively ) .
Diseases: "	"Sentence: Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion ( 2 , 682 , 2 , 803 , and 3 , 424 counts per minute per gram of dried fraction , respectively ) .
Diseases:"
1613	Myocardial calcium concentrations also were decreased ( 11 . 2 , 8 . 3 , and 8 . 9 mg . per 100 Gm . of fat - free dry weight , respectively ) in the three treatment groups , being significantly decreased only in the last two .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Myocardial calcium concentrations also were decreased ( 11 . 2 , 8 . 3 , and 8 . 9 mg . per 100 Gm . of fat - free dry weight , respectively ) in the three treatment groups , being significantly decreased only in the last two .
Diseases: "	"Sentence: Myocardial calcium concentrations also were decreased ( 11 . 2 , 8 . 3 , and 8 . 9 mg . per 100 Gm . of fat - free dry weight , respectively ) in the three treatment groups , being significantly decreased only in the last two .
Diseases:"
1614	Evidence of microscopic damage was graded as less severe in the three treatment groups .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Evidence of microscopic damage was graded as less severe in the three treatment groups .
Diseases: "	"Sentence: Evidence of microscopic damage was graded as less severe in the three treatment groups .
Diseases:"
1615	Acetylsalicylic acid , dipyridamole , and hydrocortisone all appear to have cardioprotective effects when tested in this model .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Acetylsalicylic acid , dipyridamole , and hydrocortisone all appear to have cardioprotective effects when tested in this model .
Diseases: "	"Sentence: Acetylsalicylic acid , dipyridamole , and hydrocortisone all appear to have cardioprotective effects when tested in this model .
Diseases:"
1616	Changes in depressive status associated with topical beta - blockers .	O O B O O O O O O O O	['depressive']	1	2	"Sentence: Changes in depressive status associated with topical beta - blockers .
Diseases: depressive"	"Sentence: Changes in depressive status associated with topical beta - blockers .
Diseases:"
1617	Depression and sexual dysfunction have been related to side effects of topical beta - blockers .	B O B I O O O O O O O O O O O O	['depression', 'sexual dysfunction']	2	5	"Sentence: Depression and sexual dysfunction have been related to side effects of topical beta - blockers .
Diseases: depression, sexual dysfunction"	"Sentence: Depression and sexual dysfunction have been related to side effects of topical beta - blockers .
Diseases:"
1618	We performed a preliminary study in order to determine any difference between a non selective beta - blocker ( timolol ) and a selective beta - blocker ( betaxolol ) regarding CNS side effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We performed a preliminary study in order to determine any difference between a non selective beta - blocker ( timolol ) and a selective beta - blocker ( betaxolol ) regarding CNS side effects .
Diseases: "	"Sentence: We performed a preliminary study in order to determine any difference between a non selective beta - blocker ( timolol ) and a selective beta - blocker ( betaxolol ) regarding CNS side effects .
Diseases:"
1619	Eight glaucomatous patients chronically treated with timolol 0 . 5 % / 12h , suffering from depression diagnosed through DMS - III - R criteria , were included in the study .	O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['depression', 'glaucomatous']	2	8	"Sentence: Eight glaucomatous patients chronically treated with timolol 0 . 5 % / 12h , suffering from depression diagnosed through DMS - III - R criteria , were included in the study .
Diseases: depression, glaucomatous"	"Sentence: Eight glaucomatous patients chronically treated with timolol 0 . 5 % / 12h , suffering from depression diagnosed through DMS - III - R criteria , were included in the study .
Diseases:"
1620	During the six - month follow up , depression was quantified through the Beck and Zung - Conde scales every two months .	O O O O O O O O B O O O O O O O O O O O O O O	['depression']	1	2	"Sentence: During the six - month follow up , depression was quantified through the Beck and Zung - Conde scales every two months .
Diseases: depression"	"Sentence: During the six - month follow up , depression was quantified through the Beck and Zung - Conde scales every two months .
Diseases:"
1621	In a double blind cross - over study with control group , the patients under timolol treatment presented higher depression values measured through the Beck and the Zung - Conde scales ( p < 0 . 001 vs control ) .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['depression']	1	2	"Sentence: In a double blind cross - over study with control group , the patients under timolol treatment presented higher depression values measured through the Beck and the Zung - Conde scales ( p < 0 . 001 vs control ) .
Diseases: depression"	"Sentence: In a double blind cross - over study with control group , the patients under timolol treatment presented higher depression values measured through the Beck and the Zung - Conde scales ( p < 0 . 001 vs control ) .
Diseases:"
1622	These results suggest that betaxolol could be less of a depression - inducer than timolol in predisposed patients .	O O O O O O O O O O B O O O O O O O O	['depression']	1	2	"Sentence: These results suggest that betaxolol could be less of a depression - inducer than timolol in predisposed patients .
Diseases: depression"	"Sentence: These results suggest that betaxolol could be less of a depression - inducer than timolol in predisposed patients .
Diseases:"
1623	Long - term follow - up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors : an International Society of Pediatric Oncology report .	O O O O O O O O B I O O O O B I I O O O O O O O O O	['malignant mesenchymal tumors', 'renal toxicity']	2	10	"Sentence: Long - term follow - up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors : an International Society of Pediatric Oncology report .
Diseases: malignant mesenchymal tumors, renal toxicity"	"Sentence: Long - term follow - up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors : an International Society of Pediatric Oncology report .
Diseases:"
1624	The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol ( International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .	O O O O O O O B I I O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O	['malignant mesenchymal tumors', 'malignant mesenchymal tumor']	2	15	"Sentence: The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol ( International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .
Diseases: malignant mesenchymal tumors, malignant mesenchymal tumor"	"Sentence: The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol ( International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .
Diseases:"
1625	Total cumulative doses were 36 or 60 g / m2 of ifosfamide ( six or 10 cycles of ifosfamide , vincristine , and dactinomycin [ IVA ] ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Total cumulative doses were 36 or 60 g / m2 of ifosfamide ( six or 10 cycles of ifosfamide , vincristine , and dactinomycin [ IVA ] ) .
Diseases: "	"Sentence: Total cumulative doses were 36 or 60 g / m2 of ifosfamide ( six or 10 cycles of ifosfamide , vincristine , and dactinomycin [ IVA ] ) .
Diseases:"
1626	None of them had received cisplatin chemotherapy .	O O O O O O O O	[]	0	0	"Sentence: None of them had received cisplatin chemotherapy .
Diseases: "	"Sentence: None of them had received cisplatin chemotherapy .
Diseases:"
1627	Ages ranged from 4 months to 17 years ; 58 patients were males and 42 females .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ages ranged from 4 months to 17 years ; 58 patients were males and 42 females .
Diseases: "	"Sentence: Ages ranged from 4 months to 17 years ; 58 patients were males and 42 females .
Diseases:"
1628	The most common primary tumor site was the head and neck .	O O O O B O O O O O O O	['tumor']	1	3	"Sentence: The most common primary tumor site was the head and neck .
Diseases: tumor"	"Sentence: The most common primary tumor site was the head and neck .
Diseases:"
1629	Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , aminoaciduria , urinary pH , osmolarity , creatinine clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .	O O O O O O O O O O O B O B O B O O O O O O O O O O O O O O O O O O O O	['glucosuria', 'proteinuria', 'aminoaciduria']	3	11	"Sentence: Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , aminoaciduria , urinary pH , osmolarity , creatinine clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
Diseases: glucosuria, proteinuria, aminoaciduria"	"Sentence: Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , aminoaciduria , urinary pH , osmolarity , creatinine clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .
Diseases:"
1630	Fifty - eight patients ( 78 % ) had normal renal tests , whereas 16 patients ( 22 % ) had renal abnormalities .	O O O O O O O O O O O O O O O O O O O O O B I O	['renal abnormalities']	1	3	"Sentence: Fifty - eight patients ( 78 % ) had normal renal tests , whereas 16 patients ( 22 % ) had renal abnormalities .
Diseases: renal abnormalities"	"Sentence: Fifty - eight patients ( 78 % ) had normal renal tests , whereas 16 patients ( 22 % ) had renal abnormalities .
Diseases:"
1631	Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in Fanconi 's syndrome ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B I I O B O O O O O O O O O O O O O O O O O O O	"['tdfs', ""fanconi 's syndrome"", 'toxicity']"	3	11	"Sentence: Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in Fanconi 's syndrome ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption .
Diseases: tdfs, fanconi 's syndrome, toxicity"	"Sentence: Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in Fanconi 's syndrome ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption .
Diseases:"
1632	The remaining seven patients had isolated beta 2 microglobulinuria .	O O O O O O O O O O	[]	0	0	"Sentence: The remaining seven patients had isolated beta 2 microglobulinuria .
Diseases: "	"Sentence: The remaining seven patients had isolated beta 2 microglobulinuria .
Diseases:"
1633	Severe toxicity was correlated with the higher cumulative dose of 60 g / m2 of ifosfamide , a younger age ( less than 2 1 / 2 years old ) , and a predominance of vesicoprostatic tumor involvement .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['tumor', 'toxicity']	2	5	"Sentence: Severe toxicity was correlated with the higher cumulative dose of 60 g / m2 of ifosfamide , a younger age ( less than 2 1 / 2 years old ) , and a predominance of vesicoprostatic tumor involvement .
Diseases: tumor, toxicity"	"Sentence: Severe toxicity was correlated with the higher cumulative dose of 60 g / m2 of ifosfamide , a younger age ( less than 2 1 / 2 years old ) , and a predominance of vesicoprostatic tumor involvement .
Diseases:"
1634	This low percentage ( 5 % ) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children .	O O O O O O O O O O O O O O O O O O O O O O O B I O O O	['mesenchymal tumors']	1	5	"Sentence: This low percentage ( 5 % ) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children .
Diseases: mesenchymal tumors"	"Sentence: This low percentage ( 5 % ) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children .
Diseases:"
1635	Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine - induced hyperactivity in rats .	O O O O O O O O O O O O O O O B O O O	['hyperactivity']	1	2	"Sentence: Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine - induced hyperactivity in rats .
Diseases: hyperactivity"	"Sentence: Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine - induced hyperactivity in rats .
Diseases:"
1636	Previous studies have suggested that repeated exposure of rats to the drug or to the experimental environment is necessary to observe nicotine - induced locomotor stimulation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Previous studies have suggested that repeated exposure of rats to the drug or to the experimental environment is necessary to observe nicotine - induced locomotor stimulation .
Diseases: "	"Sentence: Previous studies have suggested that repeated exposure of rats to the drug or to the experimental environment is necessary to observe nicotine - induced locomotor stimulation .
Diseases:"
1637	In the present study the role of habituation to the experimental environment on the stimulant effect of nicotine in rats was examined .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the present study the role of habituation to the experimental environment on the stimulant effect of nicotine in rats was examined .
Diseases: "	"Sentence: In the present study the role of habituation to the experimental environment on the stimulant effect of nicotine in rats was examined .
Diseases:"
1638	In addition , the role of dopamine receptors in mediating nicotine - induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , the role of dopamine receptors in mediating nicotine - induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine .
Diseases: "	"Sentence: In addition , the role of dopamine receptors in mediating nicotine - induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine .
Diseases:"
1639	Locomotor activity was assessed in male Sprague - Dawley rats tested in photocell cages .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Locomotor activity was assessed in male Sprague - Dawley rats tested in photocell cages .
Diseases: "	"Sentence: Locomotor activity was assessed in male Sprague - Dawley rats tested in photocell cages .
Diseases:"
1640	Nicotine ( 1 . 0 mg / kg ) caused a significant increase in locomotor activity in rats that were habituated to the test environment , but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment .	O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['increase in locomotor activity']	1	6	"Sentence: Nicotine ( 1 . 0 mg / kg ) caused a significant increase in locomotor activity in rats that were habituated to the test environment , but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment .
Diseases: increase in locomotor activity"	"Sentence: Nicotine ( 1 . 0 mg / kg ) caused a significant increase in locomotor activity in rats that were habituated to the test environment , but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment .
Diseases:"
1641	The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium , indicating that the response is probably mediated by central nicotinic receptors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium , indicating that the response is probably mediated by central nicotinic receptors .
Diseases: "	"Sentence: The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium , indicating that the response is probably mediated by central nicotinic receptors .
Diseases:"
1642	Nicotine - induced hyperactivity was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1 / D2 antagonist fluphenazine .	O O O B O O O O O O O O O O O O O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: Nicotine - induced hyperactivity was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1 / D2 antagonist fluphenazine .
Diseases: hyperactivity"	"Sentence: Nicotine - induced hyperactivity was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1 / D2 antagonist fluphenazine .
Diseases:"
1643	Pretreatment with the D2 agonist PHNO enhanced nicotine - induced hyperactivity , whereas the D1 agonist SKF 38393 had no effect .	O O O O O O O O O O B O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: Pretreatment with the D2 agonist PHNO enhanced nicotine - induced hyperactivity , whereas the D1 agonist SKF 38393 had no effect .
Diseases: hyperactivity"	"Sentence: Pretreatment with the D2 agonist PHNO enhanced nicotine - induced hyperactivity , whereas the D1 agonist SKF 38393 had no effect .
Diseases:"
1644	The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment .	O O O O O O O O O O B O O O O O O O O	['hyperactivity']	1	2	"Sentence: The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment .
Diseases: hyperactivity"	"Sentence: The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment .
Diseases:"
1645	The effect appears to be mediated by central nicotine receptors , possibly located on dopaminergic neurons , and also requires the activation of both D1 and D2 dopamine receptors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effect appears to be mediated by central nicotine receptors , possibly located on dopaminergic neurons , and also requires the activation of both D1 and D2 dopamine receptors .
Diseases: "	"Sentence: The effect appears to be mediated by central nicotine receptors , possibly located on dopaminergic neurons , and also requires the activation of both D1 and D2 dopamine receptors .
Diseases:"
1646	Neuropsychiatric side effects after the use of mefloquine .	O O O O O O O O O	[]	0	0	"Sentence: Neuropsychiatric side effects after the use of mefloquine .
Diseases: "	"Sentence: Neuropsychiatric side effects after the use of mefloquine .
Diseases:"
1647	This study describes neuropsychiatric side effects in patients after treatment with mefloquine .	O O O O O O O O O O O O O	[]	0	0	"Sentence: This study describes neuropsychiatric side effects in patients after treatment with mefloquine .
Diseases: "	"Sentence: This study describes neuropsychiatric side effects in patients after treatment with mefloquine .
Diseases:"
1648	Reactions consisted mainly of seizures , acute psychoses , anxiety neurosis , and major disturbances of sleep - wake rhythm .	O O O O B O O B O B I O O O B I I I I I O	['disturbances of sleep - wake rhythm', 'anxiety neurosis', 'seizures', 'psychoses']	4	15	"Sentence: Reactions consisted mainly of seizures , acute psychoses , anxiety neurosis , and major disturbances of sleep - wake rhythm .
Diseases: disturbances of sleep - wake rhythm, anxiety neurosis, seizures, psychoses"	"Sentence: Reactions consisted mainly of seizures , acute psychoses , anxiety neurosis , and major disturbances of sleep - wake rhythm .
Diseases:"
1649	Side effects occurred after both therapeutic and prophylactic intake and were graded from moderate to severe .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Side effects occurred after both therapeutic and prophylactic intake and were graded from moderate to severe .
Diseases: "	"Sentence: Side effects occurred after both therapeutic and prophylactic intake and were graded from moderate to severe .
Diseases:"
1650	In a risk analysis of neuropsychiatric side effects in Germany , it is estimated that one of 8 , 000 mefloquine users suffers from such reactions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In a risk analysis of neuropsychiatric side effects in Germany , it is estimated that one of 8 , 000 mefloquine users suffers from such reactions .
Diseases: "	"Sentence: In a risk analysis of neuropsychiatric side effects in Germany , it is estimated that one of 8 , 000 mefloquine users suffers from such reactions .
Diseases:"
1651	The incidence calculation revealed that one of 215 therapeutic users had reactions , compared with one of 13 , 000 in the prophylaxis group , making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The incidence calculation revealed that one of 215 therapeutic users had reactions , compared with one of 13 , 000 in the prophylaxis group , making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis .
Diseases: "	"Sentence: The incidence calculation revealed that one of 215 therapeutic users had reactions , compared with one of 13 , 000 in the prophylaxis group , making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis .
Diseases:"
1652	Therefore , certain limitations for malaria prophylaxis and treatment with mefloquine are recommended .	O O O O O B O O O O O O O O	['malaria']	1	2	"Sentence: Therefore , certain limitations for malaria prophylaxis and treatment with mefloquine are recommended .
Diseases: malaria"	"Sentence: Therefore , certain limitations for malaria prophylaxis and treatment with mefloquine are recommended .
Diseases:"
1653	Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization .	O O O B O O O O O O O O O O O	['pain']	1	1	"Sentence: Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization .
Diseases: pain"	"Sentence: Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization .
Diseases:"
1654	Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution .	O O O O O B O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution .
Diseases: pain"	"Sentence: Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution .
Diseases:"
1655	To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection , we performed a blinded randomized study in patients undergoing cardiac catheterization .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection , we performed a blinded randomized study in patients undergoing cardiac catheterization .
Diseases: pain"	"Sentence: To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection , we performed a blinded randomized study in patients undergoing cardiac catheterization .
Diseases:"
1656	Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area .	O O O O O O O O O B O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area .
Diseases: pain"	"Sentence: Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area .
Diseases:"
1657	The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine ( 2 . 7 + / - 1 . 9 vs . 3 . 8 + / - 2 . 2 , P = 0 . 03 ) .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine ( 2 . 7 + / - 1 . 9 vs . 3 . 8 + / - 2 . 2 , P = 0 . 03 ) .
Diseases: pain"	"Sentence: The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine ( 2 . 7 + / - 1 . 9 vs . 3 . 8 + / - 2 . 2 , P = 0 . 03 ) .
Diseases:"
1658	The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['pain']	1	1	"Sentence: The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues .
Diseases: pain"	"Sentence: The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues .
Diseases:"
1659	Randomized , double - blind trial of mazindol in Duchenne dystrophy .	O O O O O O O O O B I O	['duchenne dystrophy']	1	6	"Sentence: Randomized , double - blind trial of mazindol in Duchenne dystrophy .
Diseases: duchenne dystrophy"	"Sentence: Randomized , double - blind trial of mazindol in Duchenne dystrophy .
Diseases:"
1660	There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy .	O O O O O O O O O O O O O B O B I O	['duchenne dystrophy', 'weakness']	2	10	"Sentence: There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy .
Diseases: duchenne dystrophy, weakness"	"Sentence: There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy .
Diseases:"
1661	We conducted a 12 - month controlled trial of mazindol , a putative growth hormone secretion inhibitor , in 83 boys with Duchenne dystrophy .	O O O O O O O O O O O O O O O O O O O O O O B I O	['duchenne dystrophy']	1	6	"Sentence: We conducted a 12 - month controlled trial of mazindol , a putative growth hormone secretion inhibitor , in 83 boys with Duchenne dystrophy .
Diseases: duchenne dystrophy"	"Sentence: We conducted a 12 - month controlled trial of mazindol , a putative growth hormone secretion inhibitor , in 83 boys with Duchenne dystrophy .
Diseases:"
1662	Muscle strength , contractures , functional ability and pulmonary function were tested at baseline , and 6 and 12 months after treatment with mazindol ( 3 mg / d ) or placebo .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Muscle strength , contractures , functional ability and pulmonary function were tested at baseline , and 6 and 12 months after treatment with mazindol ( 3 mg / d ) or placebo .
Diseases: "	"Sentence: Muscle strength , contractures , functional ability and pulmonary function were tested at baseline , and 6 and 12 months after treatment with mazindol ( 3 mg / d ) or placebo .
Diseases:"
1663	The study was designed to have a power of greater than 0 . 90 to detect a slowing to 25 % of the expected rate of progression of weakness at P less than 0 . 05 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['weakness']	1	2	"Sentence: The study was designed to have a power of greater than 0 . 90 to detect a slowing to 25 % of the expected rate of progression of weakness at P less than 0 . 05 .
Diseases: weakness"	"Sentence: The study was designed to have a power of greater than 0 . 90 to detect a slowing to 25 % of the expected rate of progression of weakness at P less than 0 . 05 .
Diseases:"
1664	Mazindol did not benefit strength at any point in the study .	O O O O O O O O O O O O	[]	0	0	"Sentence: Mazindol did not benefit strength at any point in the study .
Diseases: "	"Sentence: Mazindol did not benefit strength at any point in the study .
Diseases:"
1665	Side effects attributable to mazindol included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .	O O O O O O B I O O O O O B I O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	['decreased appetite', 'dry mouth', 'gastrointestinal symptoms']	3	10	"Sentence: Side effects attributable to mazindol included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .
Diseases: decreased appetite, dry mouth, gastrointestinal symptoms"	"Sentence: Side effects attributable to mazindol included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .
Diseases:"
1666	The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF - I levels obtained following 3 , 6 , 9 , and 12 months in the mazindol treated to those in the placebo groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF - I levels obtained following 3 , 6 , 9 , and 12 months in the mazindol treated to those in the placebo groups .
Diseases: "	"Sentence: The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF - I levels obtained following 3 , 6 , 9 , and 12 months in the mazindol treated to those in the placebo groups .
Diseases:"
1667	Although mazindol - treated patients gained less weight and height than placebo - treated patients , no significant effect on IGF - I levels was observed .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although mazindol - treated patients gained less weight and height than placebo - treated patients , no significant effect on IGF - I levels was observed .
Diseases: "	"Sentence: Although mazindol - treated patients gained less weight and height than placebo - treated patients , no significant effect on IGF - I levels was observed .
Diseases:"
1668	Mazindol doses not slow the progression of weakness in Duchenne dystrophy .	O O O O O O O B O B I O	['duchenne dystrophy', 'weakness']	2	10	"Sentence: Mazindol doses not slow the progression of weakness in Duchenne dystrophy .
Diseases: duchenne dystrophy, weakness"	"Sentence: Mazindol doses not slow the progression of weakness in Duchenne dystrophy .
Diseases:"
1669	Pentoxifylline ( Trental ) does not inhibit dipyridamole - induced coronary hyperemia : implications for dipyridamole - thallium - 201 myocardial imaging .	O O O O O O O O O O O B O O O O O O O O O O O	['hyperemia']	1	4	"Sentence: Pentoxifylline ( Trental ) does not inhibit dipyridamole - induced coronary hyperemia : implications for dipyridamole - thallium - 201 myocardial imaging .
Diseases: hyperemia"	"Sentence: Pentoxifylline ( Trental ) does not inhibit dipyridamole - induced coronary hyperemia : implications for dipyridamole - thallium - 201 myocardial imaging .
Diseases:"
1670	Dipyridamole - thallium - 201 imaging is often performed in patients unable to exercise because of peripheral vascular disease .	O O O O O O O O O O O O O O O O B I I O	['peripheral vascular disease']	1	5	"Sentence: Dipyridamole - thallium - 201 imaging is often performed in patients unable to exercise because of peripheral vascular disease .
Diseases: peripheral vascular disease"	"Sentence: Dipyridamole - thallium - 201 imaging is often performed in patients unable to exercise because of peripheral vascular disease .
Diseases:"
1671	Many of these patients are taking pentoxifylline ( Trental ) , a methylxanthine derivative which may improve intermittent claudication .	O O O O O O O O O O O O O O O O O B I O	['intermittent claudication']	1	6	"Sentence: Many of these patients are taking pentoxifylline ( Trental ) , a methylxanthine derivative which may improve intermittent claudication .
Diseases: intermittent claudication"	"Sentence: Many of these patients are taking pentoxifylline ( Trental ) , a methylxanthine derivative which may improve intermittent claudication .
Diseases:"
1672	Whether pentoxifylline inhibits dipyridamole - induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['hyperemia']	1	4	"Sentence: Whether pentoxifylline inhibits dipyridamole - induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .
Diseases: hyperemia"	"Sentence: Whether pentoxifylline inhibits dipyridamole - induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .
Diseases:"
1673	Therefore , we studied the hyperemic response to dipyridamole in seven open - chest anesthetized dogs after pretreatment with either pentoxifylline ( 0 , 7 . 5 , or 15 mg / kg i . v . ) or theophylline ( 3 mg / kg i . v . ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Therefore , we studied the hyperemic response to dipyridamole in seven open - chest anesthetized dogs after pretreatment with either pentoxifylline ( 0 , 7 . 5 , or 15 mg / kg i . v . ) or theophylline ( 3 mg / kg i . v . ) .
Diseases: "	"Sentence: Therefore , we studied the hyperemic response to dipyridamole in seven open - chest anesthetized dogs after pretreatment with either pentoxifylline ( 0 , 7 . 5 , or 15 mg / kg i . v . ) or theophylline ( 3 mg / kg i . v . ) .
Diseases:"
1674	Baseline circumflex coronary blood flows did not differ significantly among treatment groups .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Baseline circumflex coronary blood flows did not differ significantly among treatment groups .
Diseases: "	"Sentence: Baseline circumflex coronary blood flows did not differ significantly among treatment groups .
Diseases:"
1675	Dipyridamole significantly increased coronary blood flow before and after 7 . 5 or 15 mm / kg	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dipyridamole significantly increased coronary blood flow before and after 7 . 5 or 15 mm / kg
Diseases: "	"Sentence: Dipyridamole significantly increased coronary blood flow before and after 7 . 5 or 15 mm / kg
Diseases:"
1676	i . v .	O O O O	[]	0	0	"Sentence: i . v .
Diseases: "	"Sentence: i . v .
Diseases:"
1677	pentoxifylline ( p less than 0 . 002 ) .	O O O O O O O O O O	[]	0	0	"Sentence: pentoxifylline ( p less than 0 . 002 ) .
Diseases: "	"Sentence: pentoxifylline ( p less than 0 . 002 ) .
Diseases:"
1678	Neither dose of pentoxifylline significantly decreased the dipyridamole - induced hyperemia , while peak coronary blood flow was significantly lower after theophylline ( p less than 0 . 01 ) .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['hyperemia']	1	4	"Sentence: Neither dose of pentoxifylline significantly decreased the dipyridamole - induced hyperemia , while peak coronary blood flow was significantly lower after theophylline ( p less than 0 . 01 ) .
Diseases: hyperemia"	"Sentence: Neither dose of pentoxifylline significantly decreased the dipyridamole - induced hyperemia , while peak coronary blood flow was significantly lower after theophylline ( p less than 0 . 01 ) .
Diseases:"
1679	We conclude that pentoxyifylline does not inhibit dipyridamole - induced coronary hyperemia even at high doses .	O O O O O O O O O O O B O O O O O	['hyperemia']	1	4	"Sentence: We conclude that pentoxyifylline does not inhibit dipyridamole - induced coronary hyperemia even at high doses .
Diseases: hyperemia"	"Sentence: We conclude that pentoxyifylline does not inhibit dipyridamole - induced coronary hyperemia even at high doses .
Diseases:"
1680	Cause of death among patients with Parkinson 's disease : a rare mortality due to cerebral haemorrhage .	O O B O O O B I I O O O O O O B I O	"['cerebral haemorrhage', 'death', ""parkinson 's disease""]"	3	16	"Sentence: Cause of death among patients with Parkinson 's disease : a rare mortality due to cerebral haemorrhage .
Diseases: cerebral haemorrhage, death, parkinson 's disease"	"Sentence: Cause of death among patients with Parkinson 's disease : a rare mortality due to cerebral haemorrhage .
Diseases:"
1681	Causes of death , with special reference to cerebral haemorrhage , among 240 patients with pathologically verified Parkinson 's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985 .	O O B O O O O O B I O O O O O O O B I I O O O O O O O O O O O O O O O O O	"['cerebral haemorrhage', 'death', ""parkinson 's disease""]"	3	16	"Sentence: Causes of death , with special reference to cerebral haemorrhage , among 240 patients with pathologically verified Parkinson 's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985 .
Diseases: cerebral haemorrhage, death, parkinson 's disease"	"Sentence: Causes of death , with special reference to cerebral haemorrhage , among 240 patients with pathologically verified Parkinson 's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985 .
Diseases:"
1682	The leading causes of death were pneumonia and bronchitis ( 44 . 1 % ) , malignant neoplasms ( 11 . 6 % ) , heart diseases ( 4 . 1 % ) , cerebral infarction ( 3 . 7 % ) and septicaemia ( 3 . 3 % ) .	O O O O B O B O B O O O O O O O O B O O O O O O O B I O O O O O O O B I O O O O O O O B O O O O O O O	['pneumonia', 'neoplasms', 'heart diseases', 'cerebral infarction', 'bronchitis', 'septicaemia', 'death']	7	26	"Sentence: The leading causes of death were pneumonia and bronchitis ( 44 . 1 % ) , malignant neoplasms ( 11 . 6 % ) , heart diseases ( 4 . 1 % ) , cerebral infarction ( 3 . 7 % ) and septicaemia ( 3 . 3 % ) .
Diseases: pneumonia, neoplasms, heart diseases, cerebral infarction, bronchitis, septicaemia, death"	"Sentence: The leading causes of death were pneumonia and bronchitis ( 44 . 1 % ) , malignant neoplasms ( 11 . 6 % ) , heart diseases ( 4 . 1 % ) , cerebral infarction ( 3 . 7 % ) and septicaemia ( 3 . 3 % ) .
Diseases:"
1683	Cerebral haemorrhage was the 11th most frequent cause of death , accounting for only 0 . 8 % of deaths among the patients , whereas it was the 5th most common cause of death among the Japanese general population in 1985 .	B I O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O O	['deaths', 'cerebral haemorrhage', 'death']	3	11	"Sentence: Cerebral haemorrhage was the 11th most frequent cause of death , accounting for only 0 . 8 % of deaths among the patients , whereas it was the 5th most common cause of death among the Japanese general population in 1985 .
Diseases: deaths, cerebral haemorrhage, death"	"Sentence: Cerebral haemorrhage was the 11th most frequent cause of death , accounting for only 0 . 8 % of deaths among the patients , whereas it was the 5th most common cause of death among the Japanese general population in 1985 .
Diseases:"
1684	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .	O O O O B I O O O O B O O O B I I O O O B O O O O O B O O O O O O O O B O O	"['parkinsonian', ""parkinson 's disease"", 'cerebral haemorrhage', 'hypotensive', 'death']"	5	21	"Sentence: The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
Diseases: parkinsonian, parkinson 's disease, cerebral haemorrhage, hypotensive, death"	"Sentence: The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson 's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .
Diseases:"
1685	Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever .	O O O O O O O O O B I I O	['argentine hemorrhagic fever']	1	6	"Sentence: Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever .
Diseases: argentine hemorrhagic fever"	"Sentence: Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever .
Diseases:"
1686	Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever ( AHF ) of more than 8 days of evolution .	O O O O O O O O O O O O B I I O B O O O O O O O O O	['ahf', 'argentine hemorrhagic fever']	2	9	"Sentence: Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever ( AHF ) of more than 8 days of evolution .
Diseases: ahf, argentine hemorrhagic fever"	"Sentence: Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever ( AHF ) of more than 8 days of evolution .
Diseases:"
1687	Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers .	O O O O O O O O B O O O O O O O O	['viremia']	1	3	"Sentence: Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers .
Diseases: viremia"	"Sentence: Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers .
Diseases:"
1688	The average time of death was delayed .	O O O O B O O O	['death']	1	1	"Sentence: The average time of death was delayed .
Diseases: death"	"Sentence: The average time of death was delayed .
Diseases:"
1689	A reversible anemia was the only adverse effect observed .	O O B O O O O O O O	['anemia']	1	2	"Sentence: A reversible anemia was the only adverse effect observed .
Diseases: anemia"	"Sentence: A reversible anemia was the only adverse effect observed .
Diseases:"
1690	From these results , we conclude that ribavirin has an antiviral effect in advanced cases of AHF , and that anemia , the only secondary reaction observed , can be easily managed .	O O O O O O O O O O O O O O O O B O O O B O O O O O O O O O O O O	['ahf', 'anemia']	2	5	"Sentence: From these results , we conclude that ribavirin has an antiviral effect in advanced cases of AHF , and that anemia , the only secondary reaction observed , can be easily managed .
Diseases: ahf, anemia"	"Sentence: From these results , we conclude that ribavirin has an antiviral effect in advanced cases of AHF , and that anemia , the only secondary reaction observed , can be easily managed .
Diseases:"
1691	The possible beneficial effect of ribavirin during the initial days of AHF is discussed .	O O O O O O O O O O O B O O O	['ahf']	1	2	"Sentence: The possible beneficial effect of ribavirin during the initial days of AHF is discussed .
Diseases: ahf"	"Sentence: The possible beneficial effect of ribavirin during the initial days of AHF is discussed .
Diseases:"
1692	Dipyridamole - induced myocardial ischemia .	O O O B I O	['myocardial ischemia']	1	6	"Sentence: Dipyridamole - induced myocardial ischemia .
Diseases: myocardial ischemia"	"Sentence: Dipyridamole - induced myocardial ischemia .
Diseases:"
1693	Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures .	B O O O O O O O O O O O O O O O O O O O	['angina']	1	2	"Sentence: Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures .
Diseases: angina"	"Sentence: Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures .
Diseases:"
1694	To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although dipyridamole - induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease .	O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O B I I O	['coronary artery disease', 'myocardial ischemia']	2	10	"Sentence: To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although dipyridamole - induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease .
Diseases: coronary artery disease, myocardial ischemia"	"Sentence: To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although dipyridamole - induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease .
Diseases:"
1695	"Epicardial coronary collateral vessels were demonstrated in all four patients ; a coronary "" steal "" phenomenon may be the mechanism of the dipyridamole - induced ischemia observed ."	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['ischemia']	1	3	"Sentence: Epicardial coronary collateral vessels were demonstrated in all four patients ; a coronary "" steal "" phenomenon may be the mechanism of the dipyridamole - induced ischemia observed .
Diseases: ischemia"	"Sentence: Epicardial coronary collateral vessels were demonstrated in all four patients ; a coronary "" steal "" phenomenon may be the mechanism of the dipyridamole - induced ischemia observed .
Diseases:"
1696	Inhibition of immunoreactive corticotropin - releasing factor secretion into the hypophysial - portal circulation by delayed glucocorticoid feedback .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Inhibition of immunoreactive corticotropin - releasing factor secretion into the hypophysial - portal circulation by delayed glucocorticoid feedback .
Diseases: "	"Sentence: Inhibition of immunoreactive corticotropin - releasing factor secretion into the hypophysial - portal circulation by delayed glucocorticoid feedback .
Diseases:"
1697	Nitroprusside - induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin - releasing factor ( irCRF ) into the hypophysial - portal circulation .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Nitroprusside - induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin - releasing factor ( irCRF ) into the hypophysial - portal circulation .
Diseases: hypotension"	"Sentence: Nitroprusside - induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin - releasing factor ( irCRF ) into the hypophysial - portal circulation .
Diseases:"
1698	Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm .
Diseases: "	"Sentence: Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm .
Diseases:"
1699	Application of a delayed feedback signal , in the form of a 2 - h systemic corticosterone infusion in urethane - anesthetized rats with pharmacological blockade of glucocorticoid synthesis , is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Application of a delayed feedback signal , in the form of a 2 - h systemic corticosterone infusion in urethane - anesthetized rats with pharmacological blockade of glucocorticoid synthesis , is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested .
Diseases: "	"Sentence: Application of a delayed feedback signal , in the form of a 2 - h systemic corticosterone infusion in urethane - anesthetized rats with pharmacological blockade of glucocorticoid synthesis , is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested .
Diseases:"
1700	Resting irCRF levels are suppressed only at the highest corticosterone infusion rate , which resulted in systemic corticosterone levels of 40 micrograms / dl .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Resting irCRF levels are suppressed only at the highest corticosterone infusion rate , which resulted in systemic corticosterone levels of 40 micrograms / dl .
Diseases: "	"Sentence: Resting irCRF levels are suppressed only at the highest corticosterone infusion rate , which resulted in systemic corticosterone levels of 40 micrograms / dl .
Diseases:"
1701	Suppression of irCRF secretion in response to nitroprusside - induced hypotension is observed and occurs at a plasma corticosterone level between 8 - 12 micrograms / dl .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Suppression of irCRF secretion in response to nitroprusside - induced hypotension is observed and occurs at a plasma corticosterone level between 8 - 12 micrograms / dl .
Diseases: hypotension"	"Sentence: Suppression of irCRF secretion in response to nitroprusside - induced hypotension is observed and occurs at a plasma corticosterone level between 8 - 12 micrograms / dl .
Diseases:"
1702	These studies provide further evidence for a strong central component of the delayed feedback process which is mediated by modulation of irCRF release .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These studies provide further evidence for a strong central component of the delayed feedback process which is mediated by modulation of irCRF release .
Diseases: "	"Sentence: These studies provide further evidence for a strong central component of the delayed feedback process which is mediated by modulation of irCRF release .
Diseases:"
1703	Noradrenergic involvement in catalepsy induced by delta 9 - tetrahydrocannabinol .	O O O B O O O O O O O	['catalepsy']	1	4	"Sentence: Noradrenergic involvement in catalepsy induced by delta 9 - tetrahydrocannabinol .
Diseases: catalepsy"	"Sentence: Noradrenergic involvement in catalepsy induced by delta 9 - tetrahydrocannabinol .
Diseases:"
1704	In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9 - tetrahydrocannabinol ( THC ) , the effect of pretreatment with 6 - hydroxydopamine ( 6 - OHDA ) or with desipramine and 6 - OHDA and lesions of the locus coeruleus were investigated in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9 - tetrahydrocannabinol ( THC ) , the effect of pretreatment with 6 - hydroxydopamine ( 6 - OHDA ) or with desipramine and 6 - OHDA and lesions of the locus coeruleus were investigated in rats .
Diseases: "	"Sentence: In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9 - tetrahydrocannabinol ( THC ) , the effect of pretreatment with 6 - hydroxydopamine ( 6 - OHDA ) or with desipramine and 6 - OHDA and lesions of the locus coeruleus were investigated in rats .
Diseases:"
1705	The cataleptogenic effect of THC was significantly reduced in rats treated with 6 - OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6 - OHDA , as compared with control rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The cataleptogenic effect of THC was significantly reduced in rats treated with 6 - OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6 - OHDA , as compared with control rats .
Diseases: "	"Sentence: The cataleptogenic effect of THC was significantly reduced in rats treated with 6 - OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6 - OHDA , as compared with control rats .
Diseases:"
1706	On the contrary , the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6 - OHDA but not in rats treated with 6 - OHDA or in rats with lesions of the locus coeruleus .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On the contrary , the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6 - OHDA but not in rats treated with 6 - OHDA or in rats with lesions of the locus coeruleus .
Diseases: "	"Sentence: On the contrary , the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6 - OHDA but not in rats treated with 6 - OHDA or in rats with lesions of the locus coeruleus .
Diseases:"
1707	These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC , whereas dopaminergic neurons are important in catalepsy induced by haloperidol .	O O O O O O O O O O O O O O B O O O O O O O O O O B O O O O	['catalepsy']	1	4	"Sentence: These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC , whereas dopaminergic neurons are important in catalepsy induced by haloperidol .
Diseases: catalepsy"	"Sentence: These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC , whereas dopaminergic neurons are important in catalepsy induced by haloperidol .
Diseases:"
1708	Intracranial pressure increases during alfentanil - induced rigidity .	O O O O O O O B O	['rigidity']	1	2	"Sentence: Intracranial pressure increases during alfentanil - induced rigidity .
Diseases: rigidity"	"Sentence: Intracranial pressure increases during alfentanil - induced rigidity .
Diseases:"
1709	Intracranial pressure ( ICP ) was measured during alfentanil - induced rigidity in rats .	O O O O O O O O O O O B O O O	['rigidity']	1	2	"Sentence: Intracranial pressure ( ICP ) was measured during alfentanil - induced rigidity in rats .
Diseases: rigidity"	"Sentence: Intracranial pressure ( ICP ) was measured during alfentanil - induced rigidity in rats .
Diseases:"
1710	Ten rats had arterial , central venous ( CVP ) , and subdural cannulae inserted under halothane anesthesia .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ten rats had arterial , central venous ( CVP ) , and subdural cannulae inserted under halothane anesthesia .
Diseases: "	"Sentence: Ten rats had arterial , central venous ( CVP ) , and subdural cannulae inserted under halothane anesthesia .
Diseases:"
1711	The animals were mechanically ventilated to achieve normocarbia ( PCO2 = 42 + / - 1 mmHg , mean + / - SE ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The animals were mechanically ventilated to achieve normocarbia ( PCO2 = 42 + / - 1 mmHg , mean + / - SE ) .
Diseases: "	"Sentence: The animals were mechanically ventilated to achieve normocarbia ( PCO2 = 42 + / - 1 mmHg , mean + / - SE ) .
Diseases:"
1712	Following instrumentation , halothane was discontinued and alfentanil ( 125 mu / kg ) administered iv during emergence from halothane anesthesia .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following instrumentation , halothane was discontinued and alfentanil ( 125 mu / kg ) administered iv during emergence from halothane anesthesia .
Diseases: "	"Sentence: Following instrumentation , halothane was discontinued and alfentanil ( 125 mu / kg ) administered iv during emergence from halothane anesthesia .
Diseases:"
1713	In the five rats that developed somatic rigidity , ICP and CVP increased significantly above baseline ( delta ICP 7 . 5 + / -	O O O O O O B I O O O O O O O O O O O O O O O O O	['somatic rigidity']	1	4	"Sentence: In the five rats that developed somatic rigidity , ICP and CVP increased significantly above baseline ( delta ICP 7 . 5 + / -
Diseases: somatic rigidity"	"Sentence: In the five rats that developed somatic rigidity , ICP and CVP increased significantly above baseline ( delta ICP 7 . 5 + / -
Diseases:"
1714	1 . 0 mmHg , delta CVP 5 . 9 + / - 1 . 3 mmHg ) .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 1 . 0 mmHg , delta CVP 5 . 9 + / - 1 . 3 mmHg ) .
Diseases: "	"Sentence: 1 . 0 mmHg , delta CVP 5 . 9 + / - 1 . 3 mmHg ) .
Diseases:"
1715	These variables returned to baseline when rigidity was abolished with metocurine .	O O O O O O B O O O O O	['rigidity']	1	2	"Sentence: These variables returned to baseline when rigidity was abolished with metocurine .
Diseases: rigidity"	"Sentence: These variables returned to baseline when rigidity was abolished with metocurine .
Diseases:"
1716	In five rats that did not become rigid , ICP and CVP did not change following alfentanil .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In five rats that did not become rigid , ICP and CVP did not change following alfentanil .
Diseases: "	"Sentence: In five rats that did not become rigid , ICP and CVP did not change following alfentanil .
Diseases:"
1717	These observations suggest that rigidity should be prevented when alfentanil , and , presumably , other opiates , are used in the anesthetic management of patients with ICP problems .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['rigidity']	1	2	"Sentence: These observations suggest that rigidity should be prevented when alfentanil , and , presumably , other opiates , are used in the anesthetic management of patients with ICP problems .
Diseases: rigidity"	"Sentence: These observations suggest that rigidity should be prevented when alfentanil , and , presumably , other opiates , are used in the anesthetic management of patients with ICP problems .
Diseases:"
1718	Adverse cardiac effects during induction chemotherapy treatment with cis - platin and 5 - fluorouracil .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Adverse cardiac effects during induction chemotherapy treatment with cis - platin and 5 - fluorouracil .
Diseases: "	"Sentence: Adverse cardiac effects during induction chemotherapy treatment with cis - platin and 5 - fluorouracil .
Diseases:"
1719	Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and / or surgery .	O O O O O B I I I O B I O O O O O O O O O	['head and neck carcinoma', 'esophageal carcinoma']	2	12	"Sentence: Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and / or surgery .
Diseases: head and neck carcinoma, esophageal carcinoma"	"Sentence: Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and / or surgery .
Diseases:"
1720	Obviously , there is a need for effective chemotherapy .	O O O O O O O O O O	[]	0	0	"Sentence: Obviously , there is a need for effective chemotherapy .
Diseases: "	"Sentence: Obviously , there is a need for effective chemotherapy .
Diseases:"
1721	In the present study , cis - platin ( 80 - 120 mg / m2BSA ) and 5 - FU ( 1000 mg / m2BSA daily as a continuous infusion during 5 days ) were given to 76 patients before radiotherapy and surgery .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the present study , cis - platin ( 80 - 120 mg / m2BSA ) and 5 - FU ( 1000 mg / m2BSA daily as a continuous infusion during 5 days ) were given to 76 patients before radiotherapy and surgery .
Diseases: "	"Sentence: In the present study , cis - platin ( 80 - 120 mg / m2BSA ) and 5 - FU ( 1000 mg / m2BSA daily as a continuous infusion during 5 days ) were given to 76 patients before radiotherapy and surgery .
Diseases:"
1722	The aim of the study was to clarify the incidence and severity of adverse cardiac effects to this treatment .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The aim of the study was to clarify the incidence and severity of adverse cardiac effects to this treatment .
Diseases: "	"Sentence: The aim of the study was to clarify the incidence and severity of adverse cardiac effects to this treatment .
Diseases:"
1723	Before treatment all patients had a cardiac evaluation and during treatment serial ECG recordings were performed .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Before treatment all patients had a cardiac evaluation and during treatment serial ECG recordings were performed .
Diseases: "	"Sentence: Before treatment all patients had a cardiac evaluation and during treatment serial ECG recordings were performed .
Diseases:"
1724	In the pre - treatment evaluation , signs of cardiovascular disease were found in 33 patients ( 43 % ) .	O O O O O O O O O B I O O O O O O O O O O	['cardiovascular disease']	1	3	"Sentence: In the pre - treatment evaluation , signs of cardiovascular disease were found in 33 patients ( 43 % ) .
Diseases: cardiovascular disease"	"Sentence: In the pre - treatment evaluation , signs of cardiovascular disease were found in 33 patients ( 43 % ) .
Diseases:"
1725	During treatment , adverse cardiac effects were observed in 14 patients ( 18 % ) .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During treatment , adverse cardiac effects were observed in 14 patients ( 18 % ) .
Diseases: "	"Sentence: During treatment , adverse cardiac effects were observed in 14 patients ( 18 % ) .
Diseases:"
1726	The mean age of these patients was the same as for the entire group , 64 years .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean age of these patients was the same as for the entire group , 64 years .
Diseases: "	"Sentence: The mean age of these patients was the same as for the entire group , 64 years .
Diseases:"
1727	The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre - treatment evaluation .	O O O B O O O O O O O O B I O O O O O O O O O O O	['cardiotoxicity', 'cardiovascular disease']	2	6	"Sentence: The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre - treatment evaluation .
Diseases: cardiotoxicity, cardiovascular disease"	"Sentence: The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre - treatment evaluation .
Diseases:"
1728	The most common signs of cardiotoxicity were chest pain , ST - T wave changes and atrial fibrillation .	O O O O O B O B I O O O O O O O B I O	['cardiotoxicity', 'atrial fibrillation', 'chest pain']	3	12	"Sentence: The most common signs of cardiotoxicity were chest pain , ST - T wave changes and atrial fibrillation .
Diseases: cardiotoxicity, atrial fibrillation, chest pain"	"Sentence: The most common signs of cardiotoxicity were chest pain , ST - T wave changes and atrial fibrillation .
Diseases:"
1729	This was followed by ventricular fibrillation in one patient and sudden death in another .	O O O O B I O O O O B I O O O	['ventricular fibrillation', 'sudden death']	2	8	"Sentence: This was followed by ventricular fibrillation in one patient and sudden death in another .
Diseases: ventricular fibrillation, sudden death"	"Sentence: This was followed by ventricular fibrillation in one patient and sudden death in another .
Diseases:"
1730	It is concluded that patients on 5 - FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed .	O O O O O O O O O O O O O O O O O O O O O O O B I O B O O O	['tachyarrhythmia', 'chest pain']	2	9	"Sentence: It is concluded that patients on 5 - FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed .
Diseases: tachyarrhythmia, chest pain"	"Sentence: It is concluded that patients on 5 - FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed .
Diseases:"
1731	Verapamil - induced carbamazepine neurotoxicity .	O O O O B O	['neurotoxicity']	1	4	"Sentence: Verapamil - induced carbamazepine neurotoxicity .
Diseases: neurotoxicity"	"Sentence: Verapamil - induced carbamazepine neurotoxicity .
Diseases:"
1732	A report of two cases .	O O O O O O	[]	0	0	"Sentence: A report of two cases .
Diseases: "	"Sentence: A report of two cases .
Diseases:"
1733	Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker .	O O O O O O B O O O O O O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker .
Diseases: neurotoxicity"	"Sentence: Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker .
Diseases:"
1734	Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose ( usually reduction of the carbamazepine dose by one half ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose ( usually reduction of the carbamazepine dose by one half ) .
Diseases: "	"Sentence: Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose ( usually reduction of the carbamazepine dose by one half ) .
Diseases:"
1735	Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy .	O O O B I O O O O O O	['auditory neurotoxicity']	1	4	"Sentence: Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy .
Diseases: auditory neurotoxicity"	"Sentence: Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy .
Diseases:"
1736	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion - dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine .	B I I I O O O O O O O O O O O O B O O O O O O O O O O O	['visual and auditory neurotoxicity', 'anemia']	2	8	"Sentence: Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion - dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine .
Diseases: visual and auditory neurotoxicity, anemia"	"Sentence: Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion - dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine .
Diseases:"
1737	Twenty - two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 Hz and in the hearing threshold levels of 30 to 100 decibels .	O O O O O O O O O B I I I I I I I I I I I I I I I I I I O O O O O O O O O O O O	['abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 hz']	1	22	"Sentence: Twenty - two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 Hz and in the hearing threshold levels of 30 to 100 decibels .
Diseases: abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 hz"	"Sentence: Twenty - two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 Hz and in the hearing threshold levels of 30 to 100 decibels .
Diseases:"
1738	When deferoxamine therapy was discontinued and serial studies were performed , audiograms in seven cases reverted to normal or near normal within two to three weeks , and nine of 13 patients with symptoms became asymptomatic .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When deferoxamine therapy was discontinued and serial studies were performed , audiograms in seven cases reverted to normal or near normal within two to three weeks , and nine of 13 patients with symptoms became asymptomatic .
Diseases: "	"Sentence: When deferoxamine therapy was discontinued and serial studies were performed , audiograms in seven cases reverted to normal or near normal within two to three weeks , and nine of 13 patients with symptoms became asymptomatic .
Diseases:"
1739	Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability .	O O O O O O O O O O O O O O B I O	['permanent disability']	1	3	"Sentence: Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability .
Diseases: permanent disability"	"Sentence: Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability .
Diseases:"
1740	Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg / kg per dose , therapy was restarted with lower doses , usually 50 mg / kg per dose or less depending on the degree of auditory abnormality , and with the exception of two cases no further toxicity was demonstrated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O B O O O	['auditory abnormality', 'toxicity']	2	6	"Sentence: Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg / kg per dose , therapy was restarted with lower doses , usually 50 mg / kg per dose or less depending on the degree of auditory abnormality , and with the exception of two cases no further toxicity was demonstrated .
Diseases: auditory abnormality, toxicity"	"Sentence: Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg / kg per dose , therapy was restarted with lower doses , usually 50 mg / kg per dose or less depending on the degree of auditory abnormality , and with the exception of two cases no further toxicity was demonstrated .
Diseases:"
1741	Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving deferoxamine , respectively , provided convincing evidence for a cause - and - effect relation between deferoxamine administration and ototoxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['ototoxicity']	1	3	"Sentence: Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving deferoxamine , respectively , provided convincing evidence for a cause - and - effect relation between deferoxamine administration and ototoxicity .
Diseases: ototoxicity"	"Sentence: Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving deferoxamine , respectively , provided convincing evidence for a cause - and - effect relation between deferoxamine administration and ototoxicity .
Diseases:"
1742	Based on these data , a plan of management was developed that allows effective yet safe administration of deferoxamine .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Based on these data , a plan of management was developed that allows effective yet safe administration of deferoxamine .
Diseases: "	"Sentence: Based on these data , a plan of management was developed that allows effective yet safe administration of deferoxamine .
Diseases:"
1743	A dose of 50 mg / kg is recommended in those without audiogram abnormalities .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A dose of 50 mg / kg is recommended in those without audiogram abnormalities .
Diseases: "	"Sentence: A dose of 50 mg / kg is recommended in those without audiogram abnormalities .
Diseases:"
1744	With mild toxicity , a reduction to 30 or 40 mg / kg per dose should result in a reversal of the abnormal results to normal within four weeks .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: With mild toxicity , a reduction to 30 or 40 mg / kg per dose should result in a reversal of the abnormal results to normal within four weeks .
Diseases: toxicity"	"Sentence: With mild toxicity , a reduction to 30 or 40 mg / kg per dose should result in a reversal of the abnormal results to normal within four weeks .
Diseases:"
1745	Moderate abnormalities require a reduction of deferoxamine to 25 mg / kg per dose with careful monitoring .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Moderate abnormalities require a reduction of deferoxamine to 25 mg / kg per dose with careful monitoring .
Diseases: "	"Sentence: Moderate abnormalities require a reduction of deferoxamine to 25 mg / kg per dose with careful monitoring .
Diseases:"
1746	In those with symptoms of hearing loss , the drug should be stopped for four weeks , and when the audiogram is stable or improved , therapy should be restarted at 10 to 25 mg / kg per dose .	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hearing loss']	1	3	"Sentence: In those with symptoms of hearing loss , the drug should be stopped for four weeks , and when the audiogram is stable or improved , therapy should be restarted at 10 to 25 mg / kg per dose .
Diseases: hearing loss"	"Sentence: In those with symptoms of hearing loss , the drug should be stopped for four weeks , and when the audiogram is stable or improved , therapy should be restarted at 10 to 25 mg / kg per dose .
Diseases:"
1747	Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['auditory dysfunction']	1	3	"Sentence: Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction .
Diseases: auditory dysfunction"	"Sentence: Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction .
Diseases:"
1748	Flurbiprofen in the treatment of juvenile rheumatoid arthritis .	O O O O O B I I O	['juvenile rheumatoid arthritis']	1	7	"Sentence: Flurbiprofen in the treatment of juvenile rheumatoid arthritis .
Diseases: juvenile rheumatoid arthritis"	"Sentence: Flurbiprofen in the treatment of juvenile rheumatoid arthritis .
Diseases:"
1749	Thirty - four patients with juvenile rheumatoid arthritis , who were treated with flurbiprofen at a maximum dose of 4 mg / kg / day , had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment .	O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['juvenile rheumatoid arthritis', 'arthritis']	2	9	"Sentence: Thirty - four patients with juvenile rheumatoid arthritis , who were treated with flurbiprofen at a maximum dose of 4 mg / kg / day , had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment .
Diseases: juvenile rheumatoid arthritis, arthritis"	"Sentence: Thirty - four patients with juvenile rheumatoid arthritis , who were treated with flurbiprofen at a maximum dose of 4 mg / kg / day , had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment .
Diseases:"
1750	Improvements were seen in the number of tender joints , the severity of swelling and tenderness , the time of walk 50 feet , the duration of morning stiffness and the circumference of the left knee .	O O O O O O O B I O O O O B O B O O O O O O O O O O O B I O O O O O O O O	['tenderness', 'tender joints', 'swelling', 'morning stiffness']	4	11	"Sentence: Improvements were seen in the number of tender joints , the severity of swelling and tenderness , the time of walk 50 feet , the duration of morning stiffness and the circumference of the left knee .
Diseases: tenderness, tender joints, swelling, morning stiffness"	"Sentence: Improvements were seen in the number of tender joints , the severity of swelling and tenderness , the time of walk 50 feet , the duration of morning stiffness and the circumference of the left knee .
Diseases:"
1751	The most frequently observed side effect was fecal occult blood ( 25 % of patients ) ; however , there was no other evidence of gastrointestinal ( GI ) bleeding in these patients .	O O O O O O O B I I O O O O O O O O O O O O O O O B I I I I O O O O	['fecal occult blood', 'gastrointestinal ( gi ) bleeding']	2	12	"Sentence: The most frequently observed side effect was fecal occult blood ( 25 % of patients ) ; however , there was no other evidence of gastrointestinal ( GI ) bleeding in these patients .
Diseases: fecal occult blood, gastrointestinal ( gi ) bleeding"	"Sentence: The most frequently observed side effect was fecal occult blood ( 25 % of patients ) ; however , there was no other evidence of gastrointestinal ( GI ) bleeding in these patients .
Diseases:"
1752	One patient was prematurely discontinued from the study for severe headache and abdominal pain .	O O O O O O O O O O B O B I O	['headache', 'abdominal pain']	2	5	"Sentence: One patient was prematurely discontinued from the study for severe headache and abdominal pain .
Diseases: headache, abdominal pain"	"Sentence: One patient was prematurely discontinued from the study for severe headache and abdominal pain .
Diseases:"
1753	Most side effects were mild and related to the GI tract .	O O O O O O O O O O O O	[]	0	0	"Sentence: Most side effects were mild and related to the GI tract .
Diseases: "	"Sentence: Most side effects were mild and related to the GI tract .
Diseases:"
1754	The correlation between neurotoxic esterase inhibition and mipafox - induced neuropathic damage in rats .	O O O B O O O O O O B I O O O	['neuropathic damage', 'neurotoxic']	2	7	"Sentence: The correlation between neurotoxic esterase inhibition and mipafox - induced neuropathic damage in rats .
Diseases: neuropathic damage, neurotoxic"	"Sentence: The correlation between neurotoxic esterase inhibition and mipafox - induced neuropathic damage in rats .
Diseases:"
1755	The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .	O O O B I O O O B O O B O O O O O O O O O O O O O O O O O O O O O O B O O	['neuropathic damage', 'neuropathy', 'neurotoxic']	3	10	"Sentence: The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .
Diseases: neuropathic damage, neuropathy, neurotoxic"	"Sentence: The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .
Diseases:"
1756	Brain and spinal cord NTE activities were measured in Long - Evans male rats 1 hr post - exposure to various dosages of Mipafox ( ip , 1 - 15 mg / kg ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Brain and spinal cord NTE activities were measured in Long - Evans male rats 1 hr post - exposure to various dosages of Mipafox ( ip , 1 - 15 mg / kg ) .
Diseases: "	"Sentence: Brain and spinal cord NTE activities were measured in Long - Evans male rats 1 hr post - exposure to various dosages of Mipafox ( ip , 1 - 15 mg / kg ) .
Diseases:"
1757	These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14 - 21 days post - exposure .	O O O O O O O O B I O O O O O O O O O O O O O O O O O	['cord damage']	1	3	"Sentence: These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14 - 21 days post - exposure .
Diseases: cord damage"	"Sentence: These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14 - 21 days post - exposure .
Diseases:"
1758	Those dosages ( greater than or equal to 10 mg / kg ) that inhibited mean NTE activity in the spinal cord greater than or equal to 73 % and brain greater than or equal to 67 % of control values produced severe ( greater than or equal to 3 ) cervical cord pathology in 85 % of the rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Those dosages ( greater than or equal to 10 mg / kg ) that inhibited mean NTE activity in the spinal cord greater than or equal to 73 % and brain greater than or equal to 67 % of control values produced severe ( greater than or equal to 3 ) cervical cord pathology in 85 % of the rats .
Diseases: "	"Sentence: Those dosages ( greater than or equal to 10 mg / kg ) that inhibited mean NTE activity in the spinal cord greater than or equal to 73 % and brain greater than or equal to 67 % of control values produced severe ( greater than or equal to 3 ) cervical cord pathology in 85 % of the rats .
Diseases:"
1759	In contrast , dosages of Mipafox ( less than or equal to 5 mg / kg ) which inhibited mean NTE activity in spinal cord less than or equal to 61 % and brain less than or equal to 60 % produced this degree of cord damage in only 9 % of the animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O	['cord damage']	1	3	"Sentence: In contrast , dosages of Mipafox ( less than or equal to 5 mg / kg ) which inhibited mean NTE activity in spinal cord less than or equal to 61 % and brain less than or equal to 60 % produced this degree of cord damage in only 9 % of the animals .
Diseases: cord damage"	"Sentence: In contrast , dosages of Mipafox ( less than or equal to 5 mg / kg ) which inhibited mean NTE activity in spinal cord less than or equal to 61 % and brain less than or equal to 60 % produced this degree of cord damage in only 9 % of the animals .
Diseases:"
1760	These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later .	O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	['neuropathic damage']	1	4	"Sentence: These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later .
Diseases: neuropathic damage"	"Sentence: These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later .
Diseases:"
1761	Cerebral infarction with a single oral dose of phenylpropanolamine .	B I O O O O O O O O	['cerebral infarction']	1	6	"Sentence: Cerebral infarction with a single oral dose of phenylpropanolamine .
Diseases: cerebral infarction"	"Sentence: Cerebral infarction with a single oral dose of phenylpropanolamine .
Diseases:"
1762	Phenylpropanolamine ( PPA ) , a synthetic sympathomimetic that is structurally similar to amphetamine , is available over the counter in anorectics , nasal congestants , and cold preparations .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Phenylpropanolamine ( PPA ) , a synthetic sympathomimetic that is structurally similar to amphetamine , is available over the counter in anorectics , nasal congestants , and cold preparations .
Diseases: "	"Sentence: Phenylpropanolamine ( PPA ) , a synthetic sympathomimetic that is structurally similar to amphetamine , is available over the counter in anorectics , nasal congestants , and cold preparations .
Diseases:"
1763	Its prolonged use or overuse has been associated with seizures , intracerebral hemorrhage , neuropsychiatric symptoms , and nonhemorrhagic cerebral infarction .	O O O O O O O O O B O B I O B I O O O B I O	['neuropsychiatric symptoms', 'cerebral infarction', 'seizures', 'intracerebral hemorrhage']	4	20	"Sentence: Its prolonged use or overuse has been associated with seizures , intracerebral hemorrhage , neuropsychiatric symptoms , and nonhemorrhagic cerebral infarction .
Diseases: neuropsychiatric symptoms, cerebral infarction, seizures, intracerebral hemorrhage"	"Sentence: Its prolonged use or overuse has been associated with seizures , intracerebral hemorrhage , neuropsychiatric symptoms , and nonhemorrhagic cerebral infarction .
Diseases:"
1764	We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA .	O O O O O O O O O O O B I O O O O O O O O O	['cerebral infarction']	1	6	"Sentence: We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA .
Diseases: cerebral infarction"	"Sentence: We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA .
Diseases:"
1765	Treatment of psoriasis with azathioprine .	O O B O O O	['psoriasis']	1	3	"Sentence: Treatment of psoriasis with azathioprine .
Diseases: psoriasis"	"Sentence: Treatment of psoriasis with azathioprine .
Diseases:"
1766	Azathioprine treatment benefited 19 ( 66 % ) out of 29 patients suffering from severe psoriasis .	O O O O O O O O O O O O O O O B O	['psoriasis']	1	3	"Sentence: Azathioprine treatment benefited 19 ( 66 % ) out of 29 patients suffering from severe psoriasis .
Diseases: psoriasis"	"Sentence: Azathioprine treatment benefited 19 ( 66 % ) out of 29 patients suffering from severe psoriasis .
Diseases:"
1767	Haematological complications were not troublesome and results of biochemical liver function tests remained normal .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Haematological complications were not troublesome and results of biochemical liver function tests remained normal .
Diseases: "	"Sentence: Haematological complications were not troublesome and results of biochemical liver function tests remained normal .
Diseases:"
1768	Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight .	O B O O O O O O O B O O O O O O O	['cholestasis', 'fibrosis']	2	7	"Sentence: Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight .
Diseases: cholestasis, fibrosis"	"Sentence: Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight .
Diseases:"
1769	Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O	['liver damage']	1	3	"Sentence: Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage .
Diseases: liver damage"	"Sentence: Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage .
Diseases:"
1770	Maternal lithium and neonatal Ebstein 's anomaly : evaluation with cross - sectional echocardiography .	O O O O B I I O O O O O O O O	"[""ebstein 's anomaly""]"	1	5	"Sentence: Maternal lithium and neonatal Ebstein 's anomaly : evaluation with cross - sectional echocardiography .
Diseases: ebstein 's anomaly"	"Sentence: Maternal lithium and neonatal Ebstein 's anomaly : evaluation with cross - sectional echocardiography .
Diseases:"
1771	Cross - sectional echocardiography was used to evaluate two neonates whose mothers ingested lithium during pregnancy .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cross - sectional echocardiography was used to evaluate two neonates whose mothers ingested lithium during pregnancy .
Diseases: "	"Sentence: Cross - sectional echocardiography was used to evaluate two neonates whose mothers ingested lithium during pregnancy .
Diseases:"
1772	In one infant , Ebstein 's anomaly of the tricuspid valve was identified .	O O O O B I I O O O O O O O	"[""ebstein 's anomaly""]"	1	5	"Sentence: In one infant , Ebstein 's anomaly of the tricuspid valve was identified .
Diseases: ebstein 's anomaly"	"Sentence: In one infant , Ebstein 's anomaly of the tricuspid valve was identified .
Diseases:"
1773	In the other infant cross - sectional echocardiography provided reassurance that the infant did not have Ebstein 's anomaly .	O O O O O O O O O O O O O O O O B I I O	"[""ebstein 's anomaly""]"	1	5	"Sentence: In the other infant cross - sectional echocardiography provided reassurance that the infant did not have Ebstein 's anomaly .
Diseases: ebstein 's anomaly"	"Sentence: In the other infant cross - sectional echocardiography provided reassurance that the infant did not have Ebstein 's anomaly .
Diseases:"
1774	Cross - sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate , noninvasive assessment of the presence or absence of lithium - induced cardiac malformations .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['cardiac malformations']	1	5	"Sentence: Cross - sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate , noninvasive assessment of the presence or absence of lithium - induced cardiac malformations .
Diseases: cardiac malformations"	"Sentence: Cross - sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate , noninvasive assessment of the presence or absence of lithium - induced cardiac malformations .
Diseases:"
1775	Effects of training on the extent of experimental myocardial infarction in aging rats .	O O O O O O O O B I O O O O	['myocardial infarction']	1	6	"Sentence: Effects of training on the extent of experimental myocardial infarction in aging rats .
Diseases: myocardial infarction"	"Sentence: Effects of training on the extent of experimental myocardial infarction in aging rats .
Diseases:"
1776	The effects of exercise on the severity of isoproterenol - induced myocardial infarction were studied in female albino rats of 20 , 40 , 60 and 80 weeks of age .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: The effects of exercise on the severity of isoproterenol - induced myocardial infarction were studied in female albino rats of 20 , 40 , 60 and 80 weeks of age .
Diseases: myocardial infarction"	"Sentence: The effects of exercise on the severity of isoproterenol - induced myocardial infarction were studied in female albino rats of 20 , 40 , 60 and 80 weeks of age .
Diseases:"
1777	The rats were trained to swim for a specific duration and for a particular period .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The rats were trained to swim for a specific duration and for a particular period .
Diseases: "	"Sentence: The rats were trained to swim for a specific duration and for a particular period .
Diseases:"
1778	The occurrence of infarcts were confirmed by histological methods .	O O O B O O O O O O	['infarcts']	1	4	"Sentence: The occurrence of infarcts were confirmed by histological methods .
Diseases: infarcts"	"Sentence: The occurrence of infarcts were confirmed by histological methods .
Diseases:"
1779	Elevations in the serum GOT and GPT were maximum in the sedentary - isoproterenols and minimum in the exercise - controls .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Elevations in the serum GOT and GPT were maximum in the sedentary - isoproterenols and minimum in the exercise - controls .
Diseases: "	"Sentence: Elevations in the serum GOT and GPT were maximum in the sedentary - isoproterenols and minimum in the exercise - controls .
Diseases:"
1780	These changes in the serum transaminases were associated with corresponding depletions in the cardiac GOT and GPT .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These changes in the serum transaminases were associated with corresponding depletions in the cardiac GOT and GPT .
Diseases: "	"Sentence: These changes in the serum transaminases were associated with corresponding depletions in the cardiac GOT and GPT .
Diseases:"
1781	However , age was seen to interfere with the responses exhibited by the young and old rats .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , age was seen to interfere with the responses exhibited by the young and old rats .
Diseases: "	"Sentence: However , age was seen to interfere with the responses exhibited by the young and old rats .
Diseases:"
1782	Studies dealing with myocardial infarction are more informative when dealt with age .	O O O B I O O O O O O O O	['myocardial infarction']	1	6	"Sentence: Studies dealing with myocardial infarction are more informative when dealt with age .
Diseases: myocardial infarction"	"Sentence: Studies dealing with myocardial infarction are more informative when dealt with age .
Diseases:"
1783	Effect of polyethylene glycol 400 on adriamycin toxicity in mice .	O O O O O O O B O O O	['toxicity']	1	2	"Sentence: Effect of polyethylene glycol 400 on adriamycin toxicity in mice .
Diseases: toxicity"	"Sentence: Effect of polyethylene glycol 400 on adriamycin toxicity in mice .
Diseases:"
1784	The effect of a widely used organic solvent , polyethylene glycol 400 ( PEG 400 ) , on the toxic action of an acute or chronic treatment with adriamycin ( ADR ) was evaluated in mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effect of a widely used organic solvent , polyethylene glycol 400 ( PEG 400 ) , on the toxic action of an acute or chronic treatment with adriamycin ( ADR ) was evaluated in mice .
Diseases: "	"Sentence: The effect of a widely used organic solvent , polyethylene glycol 400 ( PEG 400 ) , on the toxic action of an acute or chronic treatment with adriamycin ( ADR ) was evaluated in mice .
Diseases:"
1785	PEG 400 impressively decreased both acute high - dose and chronic low - dose - ADR - associated lethality .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PEG 400 impressively decreased both acute high - dose and chronic low - dose - ADR - associated lethality .
Diseases: "	"Sentence: PEG 400 impressively decreased both acute high - dose and chronic low - dose - ADR - associated lethality .
Diseases:"
1786	Light microscopic analysis showed a significant protection against ADR - induced cardiac morphological alterations .	O O O O O O O O O O O B I I O	['cardiac morphological alterations']	1	5	"Sentence: Light microscopic analysis showed a significant protection against ADR - induced cardiac morphological alterations .
Diseases: cardiac morphological alterations"	"Sentence: Light microscopic analysis showed a significant protection against ADR - induced cardiac morphological alterations .
Diseases:"
1787	Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor .	O O O O O O O O O O B I O O B I I O	['ehrlich ascites tumor', 'l1210 leukemia']	2	11	"Sentence: Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor .
Diseases: ehrlich ascites tumor, l1210 leukemia"	"Sentence: Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor .
Diseases:"
1788	Intra - arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system .	O O O O O O O O B I O O O O O O	['malignant gliomas']	1	5	"Sentence: Intra - arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system .
Diseases: malignant gliomas"	"Sentence: Intra - arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system .
Diseases:"
1789	Because of the rapid systemic clearance of BCNU ( 1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea ) , intra - arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['malignant gliomas']	1	5	"Sentence: Because of the rapid systemic clearance of BCNU ( 1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea ) , intra - arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas .
Diseases: malignant gliomas"	"Sentence: Because of the rapid systemic clearance of BCNU ( 1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea ) , intra - arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas .
Diseases:"
1790	Thirty - six patients were treated with BCNU every 6 to 8 weeks , either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system , beginning with a dose of 200 mg / sq m body surface area .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty - six patients were treated with BCNU every 6 to 8 weeks , either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system , beginning with a dose of 200 mg / sq m body surface area .
Diseases: "	"Sentence: Thirty - six patients were treated with BCNU every 6 to 8 weeks , either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system , beginning with a dose of 200 mg / sq m body surface area .
Diseases:"
1791	Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy .	O O O O O O O B O O O O O O O B O O O O O	['tumor', 'astrocytomas']	2	9	"Sentence: Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy .
Diseases: tumor, astrocytomas"	"Sentence: Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy .
Diseases:"
1792	After two to seven cycles of chemotherapy , nine patients showed a decrease in tumor size and surrounding edema on contrast - enhanced computerized tomography scans .	O O O O O O O O O O O O O O B O O O B O O O O O O O O	['tumor', 'edema']	2	6	"Sentence: After two to seven cycles of chemotherapy , nine patients showed a decrease in tumor size and surrounding edema on contrast - enhanced computerized tomography scans .
Diseases: tumor, edema"	"Sentence: After two to seven cycles of chemotherapy , nine patients showed a decrease in tumor size and surrounding edema on contrast - enhanced computerized tomography scans .
Diseases:"
1793	In the nine responders , median duration of chemotherapy response from the time of operation was 25 weeks ( range 12 to more than 91 weeks ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the nine responders , median duration of chemotherapy response from the time of operation was 25 weeks ( range 12 to more than 91 weeks ) .
Diseases: "	"Sentence: In the nine responders , median duration of chemotherapy response from the time of operation was 25 weeks ( range 12 to more than 91 weeks ) .
Diseases:"
1794	The median duration of survival in the 12 patients was 54 weeks ( range 21 to more than 156 weeks ) , with an 18 - month survival rate of 42 % .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The median duration of survival in the 12 patients was 54 weeks ( range 21 to more than 156 weeks ) , with an 18 - month survival rate of 42 % .
Diseases: "	"Sentence: The median duration of survival in the 12 patients was 54 weeks ( range 21 to more than 156 weeks ) , with an 18 - month survival rate of 42 % .
Diseases:"
1795	Twenty - four patients with recurrent Grade I to IV astrocytomas , whose resection and irradiation therapy had failed , received two to eight courses of intra - arterial BCNU therapy .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['astrocytomas']	1	5	"Sentence: Twenty - four patients with recurrent Grade I to IV astrocytomas , whose resection and irradiation therapy had failed , received two to eight courses of intra - arterial BCNU therapy .
Diseases: astrocytomas"	"Sentence: Twenty - four patients with recurrent Grade I to IV astrocytomas , whose resection and irradiation therapy had failed , received two to eight courses of intra - arterial BCNU therapy .
Diseases:"
1796	Seventeen of these had a response or were stable for a median of 20 weeks ( range 6 to more than 66 weeks ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Seventeen of these had a response or were stable for a median of 20 weeks ( range 6 to more than 66 weeks ) .
Diseases: "	"Sentence: Seventeen of these had a response or were stable for a median of 20 weeks ( range 6 to more than 66 weeks ) .
Diseases:"
1797	The catheterization procedure is safe , with no immediate complication in 111 infusions of BCNU .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The catheterization procedure is safe , with no immediate complication in 111 infusions of BCNU .
Diseases: "	"Sentence: The catheterization procedure is safe , with no immediate complication in 111 infusions of BCNU .
Diseases:"
1798	A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis .	O O O O O O O O O B I I O O O B I O	['loss of vision', 'retinal vasculitis']	2	9	"Sentence: A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis .
Diseases: loss of vision, retinal vasculitis"	"Sentence: A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis .
Diseases:"
1799	The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered .	O O O B I O O O O O O O O O O O	['visual loss']	1	2	"Sentence: The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered .
Diseases: visual loss"	"Sentence: The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered .
Diseases:"
1800	Blood pressure response to chronic low - dose intrarenal noradrenaline infusion in conscious rats .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Blood pressure response to chronic low - dose intrarenal noradrenaline infusion in conscious rats .
Diseases: "	"Sentence: Blood pressure response to chronic low - dose intrarenal noradrenaline infusion in conscious rats .
Diseases:"
1801	Sodium chloride solution ( 0 . 9 % ) or noradrenaline in doses of 4 , 12 and 36 micrograms h - 1 kg - 1 was infused for five consecutive days , either intrarenally ( by a new technique ) or intravenously into rats with one kidney removed .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sodium chloride solution ( 0 . 9 % ) or noradrenaline in doses of 4 , 12 and 36 micrograms h - 1 kg - 1 was infused for five consecutive days , either intrarenally ( by a new technique ) or intravenously into rats with one kidney removed .
Diseases: "	"Sentence: Sodium chloride solution ( 0 . 9 % ) or noradrenaline in doses of 4 , 12 and 36 micrograms h - 1 kg - 1 was infused for five consecutive days , either intrarenally ( by a new technique ) or intravenously into rats with one kidney removed .
Diseases:"
1802	Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously .	O O O O O B O O O O O O O O O O O	['hypertension']	1	3	"Sentence: Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously .
Diseases: hypertension"	"Sentence: Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously .
Diseases:"
1803	Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration - blood pressure effect curve towards lower plasma noradrenaline levels .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration - blood pressure effect curve towards lower plasma noradrenaline levels .
Diseases: "	"Sentence: Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration - blood pressure effect curve towards lower plasma noradrenaline levels .
Diseases:"
1804	These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism .
Diseases: hypertension"	"Sentence: These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism .
Diseases:"
1805	Age and renal clearance of cimetidine .	O O O O O O O	[]	0	0	"Sentence: Age and renal clearance of cimetidine .
Diseases: "	"Sentence: Age and renal clearance of cimetidine .
Diseases:"
1806	In 35 patients ( ages 20 to 86 yr ) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high - pressure liquid chromatography and for creatinine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 35 patients ( ages 20 to 86 yr ) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high - pressure liquid chromatography and for creatinine .
Diseases: "	"Sentence: In 35 patients ( ages 20 to 86 yr ) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high - pressure liquid chromatography and for creatinine .
Diseases:"
1807	Cimetidine clearance decreased with age .	O O O O O O	[]	0	0	"Sentence: Cimetidine clearance decreased with age .
Diseases: "	"Sentence: Cimetidine clearance decreased with age .
Diseases:"
1808	The extrapolated 6 - hr serum concentration of cimetidine per unit dose , after intravenous cimetidine , increased with age of the patients .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The extrapolated 6 - hr serum concentration of cimetidine per unit dose , after intravenous cimetidine , increased with age of the patients .
Diseases: "	"Sentence: The extrapolated 6 - hr serum concentration of cimetidine per unit dose , after intravenous cimetidine , increased with age of the patients .
Diseases:"
1809	The ratio of cimetidine clearance to creatinine clearance ( Rc ) averaged 4 . 8 + / - 2 . 0 , indicating net tubular secretion for cimetidine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The ratio of cimetidine clearance to creatinine clearance ( Rc ) averaged 4 . 8 + / - 2 . 0 , indicating net tubular secretion for cimetidine .
Diseases: "	"Sentence: The ratio of cimetidine clearance to creatinine clearance ( Rc ) averaged 4 . 8 + / - 2 . 0 , indicating net tubular secretion for cimetidine .
Diseases:"
1810	Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine , suggesting that secretion of cimetidine is a saturable process .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine , suggesting that secretion of cimetidine is a saturable process .
Diseases: "	"Sentence: Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine , suggesting that secretion of cimetidine is a saturable process .
Diseases:"
1811	There was only one case of dementia possibly due to cimetidine ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1 . 25 microgram / ml .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O	['liver or kidney disease', 'dementia']	2	7	"Sentence: There was only one case of dementia possibly due to cimetidine ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1 . 25 microgram / ml .
Diseases: liver or kidney disease, dementia"	"Sentence: There was only one case of dementia possibly due to cimetidine ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1 . 25 microgram / ml .
Diseases:"
1812	Thus , high cimetidine levels alone do not always induce dementia .	O O O O O O O O O O B O	['dementia']	1	3	"Sentence: Thus , high cimetidine levels alone do not always induce dementia .
Diseases: dementia"	"Sentence: Thus , high cimetidine levels alone do not always induce dementia .
Diseases:"
1813	Development of clear cell adenocarcinoma in DES - exposed offspring under observation .	O O B I I O O O O O O O O	['clear cell adenocarcinoma']	1	8	"Sentence: Development of clear cell adenocarcinoma in DES - exposed offspring under observation .
Diseases: clear cell adenocarcinoma"	"Sentence: Development of clear cell adenocarcinoma in DES - exposed offspring under observation .
Diseases:"
1814	Two cases of clear cell adenocarcinoma of the vagina detected at follow - up in young women exposed in utero to diethylstilbestrol are reported .	O O O B I I I I I O O O O O O O O O O O O O O O O	['clear cell adenocarcinoma of the vagina']	1	11	"Sentence: Two cases of clear cell adenocarcinoma of the vagina detected at follow - up in young women exposed in utero to diethylstilbestrol are reported .
Diseases: clear cell adenocarcinoma of the vagina"	"Sentence: Two cases of clear cell adenocarcinoma of the vagina detected at follow - up in young women exposed in utero to diethylstilbestrol are reported .
Diseases:"
1815	One patient , aged 23 , had been followed for 2 years before carcinoma was diagnosed ; the second patient , aged 22 , had been seen on a regular basis for 5 years , 8 months .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['carcinoma']	1	4	"Sentence: One patient , aged 23 , had been followed for 2 years before carcinoma was diagnosed ; the second patient , aged 22 , had been seen on a regular basis for 5 years , 8 months .
Diseases: carcinoma"	"Sentence: One patient , aged 23 , had been followed for 2 years before carcinoma was diagnosed ; the second patient , aged 22 , had been seen on a regular basis for 5 years , 8 months .
Diseases:"
1816	In both instances , suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix .	O O O O O O O O O B O O O O O O O O O O O O O O	['carcinoma']	1	4	"Sentence: In both instances , suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix .
Diseases: carcinoma"	"Sentence: In both instances , suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix .
Diseases:"
1817	Hysterosalpingography was performed on both patients and , in 1 instance , an abnormal x - ray film was reflected by the gross appearance of the uterine cavity found in the surgical specimen .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hysterosalpingography was performed on both patients and , in 1 instance , an abnormal x - ray film was reflected by the gross appearance of the uterine cavity found in the surgical specimen .
Diseases: "	"Sentence: Hysterosalpingography was performed on both patients and , in 1 instance , an abnormal x - ray film was reflected by the gross appearance of the uterine cavity found in the surgical specimen .
Diseases:"
1818	Phenobarbitone - induced enlargement of the liver in the rat : its relationship to carbon tetrachloride - induced cirrhosis .	O O O B I I I O O O O O O O O O O O B O	['cirrhosis', 'enlargement of the liver']	2	10	"Sentence: Phenobarbitone - induced enlargement of the liver in the rat : its relationship to carbon tetrachloride - induced cirrhosis .
Diseases: cirrhosis, enlargement of the liver"	"Sentence: Phenobarbitone - induced enlargement of the liver in the rat : its relationship to carbon tetrachloride - induced cirrhosis .
Diseases:"
1819	"The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial "" calibrating "" dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver ."	O O O O B I I I O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O	['cirrhosis of the liver', 'enlargement of the liver', 'splenomegaly', 'ascites', 'atrophy']	5	25	"Sentence: The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial "" calibrating "" dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
Diseases: cirrhosis of the liver, enlargement of the liver, splenomegaly, ascites, atrophy"	"Sentence: The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial "" calibrating "" dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .
Diseases:"
1820	At this point it was assumed that the cytochrome P450 / CCl4 toxic state was both maximal and stable .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At this point it was assumed that the cytochrome P450 / CCl4 toxic state was both maximal and stable .
Diseases: "	"Sentence: At this point it was assumed that the cytochrome P450 / CCl4 toxic state was both maximal and stable .
Diseases:"
1821	The optimal rat size to begin phenobarbitone was determined as 100 g , and this size as a group had a mean maximum relative liver weight increase 47 % greater than normal rats of the same body weight .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The optimal rat size to begin phenobarbitone was determined as 100 g , and this size as a group had a mean maximum relative liver weight increase 47 % greater than normal rats of the same body weight .
Diseases: "	"Sentence: The optimal rat size to begin phenobarbitone was determined as 100 g , and this size as a group had a mean maximum relative liver weight increase 47 % greater than normal rats of the same body weight .
Diseases:"
1822	The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone .
Diseases: "	"Sentence: The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone .
Diseases:"
1823	Attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride in rats .	O O O O O O B I I I I I O O O O O	['diabetes - insipidus - like syndrome']	1	10	"Sentence: Attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride in rats .
Diseases: diabetes - insipidus - like syndrome"	"Sentence: Attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride in rats .
Diseases:"
1824	The effect of amiloride on lithium - induced polydipsia and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .	O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['polyuria', 'polydipsia']	2	7	"Sentence: The effect of amiloride on lithium - induced polydipsia and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
Diseases: polyuria, polydipsia"	"Sentence: The effect of amiloride on lithium - induced polydipsia and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .
Diseases:"
1825	Amiloride reduced the drinking and urine volume of rats in an acute ( 6 or 12 h ) and a subacute ( 3 days ) experiment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Amiloride reduced the drinking and urine volume of rats in an acute ( 6 or 12 h ) and a subacute ( 3 days ) experiment .
Diseases: "	"Sentence: Amiloride reduced the drinking and urine volume of rats in an acute ( 6 or 12 h ) and a subacute ( 3 days ) experiment .
Diseases:"
1826	6 h after the administration of amiloride , a reduction was observed in the lithium content of the renal medulla but not in the other organs studied .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 6 h after the administration of amiloride , a reduction was observed in the lithium content of the renal medulla but not in the other organs studied .
Diseases: "	"Sentence: 6 h after the administration of amiloride , a reduction was observed in the lithium content of the renal medulla but not in the other organs studied .
Diseases:"
1827	At 12 h , all the tissues showed a slight increase in lithium levels .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At 12 h , all the tissues showed a slight increase in lithium levels .
Diseases: "	"Sentence: At 12 h , all the tissues showed a slight increase in lithium levels .
Diseases:"
1828	After 3 days of combined treatment , a marked elevation in plasma and tissue lithium levels accompanied a reduction in water intake .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 3 days of combined treatment , a marked elevation in plasma and tissue lithium levels accompanied a reduction in water intake .
Diseases: "	"Sentence: After 3 days of combined treatment , a marked elevation in plasma and tissue lithium levels accompanied a reduction in water intake .
Diseases:"
1829	In all the experiments , the attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .	O O O O O O O O O O O O B I I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetes - insipidus - like syndrome']	1	10	"Sentence: In all the experiments , the attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .
Diseases: diabetes - insipidus - like syndrome"	"Sentence: In all the experiments , the attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .
Diseases:"
1830	It is concluded that acute amiloride administration to lithium - treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .	O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O	['polyuria', 'polydipsia']	2	7	"Sentence: It is concluded that acute amiloride administration to lithium - treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
Diseases: polyuria, polydipsia"	"Sentence: It is concluded that acute amiloride administration to lithium - treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .
Diseases:"
1831	Safety and side - effects of alprazolam .	O O O O O O O O	[]	0	0	"Sentence: Safety and side - effects of alprazolam .
Diseases: "	"Sentence: Safety and side - effects of alprazolam .
Diseases:"
1832	Controlled study in agoraphobia with panic disorder .	O O O B O B I O	['panic disorder', 'agoraphobia']	2	7	"Sentence: Controlled study in agoraphobia with panic disorder .
Diseases: panic disorder, agoraphobia"	"Sentence: Controlled study in agoraphobia with panic disorder .
Diseases:"
1833	The widespread use of benzodiazepines has led to increasing recognition of their unwanted effects .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The widespread use of benzodiazepines has led to increasing recognition of their unwanted effects .
Diseases: "	"Sentence: The widespread use of benzodiazepines has led to increasing recognition of their unwanted effects .
Diseases:"
1834	The efficacy of alprazolam and placebo in panic disorder with agoraphobia , and the side - effect and adverse effect profiles of both drug groups were measured .	O O O O O O O B I O B O O O O O O O O O O O O O O O O O	['panic disorder', 'agoraphobia']	2	7	"Sentence: The efficacy of alprazolam and placebo in panic disorder with agoraphobia , and the side - effect and adverse effect profiles of both drug groups were measured .
Diseases: panic disorder, agoraphobia"	"Sentence: The efficacy of alprazolam and placebo in panic disorder with agoraphobia , and the side - effect and adverse effect profiles of both drug groups were measured .
Diseases:"
1835	In London and Toronto 154 patients who met DSM - III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo .	O O O O O O O O O O O O O B I O B O O O O O O O	['panic disorder', 'agoraphobia']	2	7	"Sentence: In London and Toronto 154 patients who met DSM - III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo .
Diseases: panic disorder, agoraphobia"	"Sentence: In London and Toronto 154 patients who met DSM - III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo .
Diseases:"
1836	Subjects in each drug group also received either exposure or relaxation .	O O O O O O O O O O O O	[]	0	0	"Sentence: Subjects in each drug group also received either exposure or relaxation .
Diseases: "	"Sentence: Subjects in each drug group also received either exposure or relaxation .
Diseases:"
1837	Treatment was from weeks 0 to 8 and was then tapered from weeks 8 to 16 .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Treatment was from weeks 0 to 8 and was then tapered from weeks 8 to 16 .
Diseases: "	"Sentence: Treatment was from weeks 0 to 8 and was then tapered from weeks 8 to 16 .
Diseases:"
1838	Mean alprazolam dose was 5 mg daily .	O O O O O O O O	[]	0	0	"Sentence: Mean alprazolam dose was 5 mg daily .
Diseases: "	"Sentence: Mean alprazolam dose was 5 mg daily .
Diseases:"
1839	Compared with placebo subjects , alprazolam patients developed more adverse reactions ( 21 % v . 0 % ) of depression , enuresis , disinhibition and aggression ; and more side - effects , particularly sedation , irritability , impaired memory , weight loss and ataxia .	O O O O O O O O O O O O O O O O O O O O B O B O O O B O O O O O O O O O O B O B I O B I O B O	['impaired memory', 'depression', 'enuresis', 'weight loss', 'irritability', 'ataxia', 'aggression']	7	22	"Sentence: Compared with placebo subjects , alprazolam patients developed more adverse reactions ( 21 % v . 0 % ) of depression , enuresis , disinhibition and aggression ; and more side - effects , particularly sedation , irritability , impaired memory , weight loss and ataxia .
Diseases: impaired memory, depression, enuresis, weight loss, irritability, ataxia, aggression"	"Sentence: Compared with placebo subjects , alprazolam patients developed more adverse reactions ( 21 % v . 0 % ) of depression , enuresis , disinhibition and aggression ; and more side - effects , particularly sedation , irritability , impaired memory , weight loss and ataxia .
Diseases:"
1840	Side - effects tended to diminish during treatment but remained significant at week 8 .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Side - effects tended to diminish during treatment but remained significant at week 8 .
Diseases: "	"Sentence: Side - effects tended to diminish during treatment but remained significant at week 8 .
Diseases:"
1841	Despite this , the drop - out rate was low .	O O O O O O O O O O O	[]	0	0	"Sentence: Despite this , the drop - out rate was low .
Diseases: "	"Sentence: Despite this , the drop - out rate was low .
Diseases:"
1842	CONCLUSIONS : Alprazolam caused side - effects and adverse effects during treatment but many patients were willing to accept these .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : Alprazolam caused side - effects and adverse effects during treatment but many patients were willing to accept these .
Diseases: "	"Sentence: CONCLUSIONS : Alprazolam caused side - effects and adverse effects during treatment but many patients were willing to accept these .
Diseases:"
1843	Dup 753 prevents the development of puromycin aminonucleoside - induced nephrosis .	O O O O O O O O O O B O	['nephrosis']	1	3	"Sentence: Dup 753 prevents the development of puromycin aminonucleoside - induced nephrosis .
Diseases: nephrosis"	"Sentence: Dup 753 prevents the development of puromycin aminonucleoside - induced nephrosis .
Diseases:"
1844	The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .	O O O B I O O B O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypercholesterolemia', 'nephrotic syndromes', 'proteinuria', 'hypoalbuminemia']	4	22	"Sentence: The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
Diseases: hypercholesterolemia, nephrotic syndromes, proteinuria, hypoalbuminemia"	"Sentence: The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .
Diseases:"
1845	The results suggest a possible involvement of the renin - angiotensin system in the development of puromycin aminonucleoside - induced nephrosis .	O O O O O O O O O O O O O O O O O O O O B O	['nephrosis']	1	3	"Sentence: The results suggest a possible involvement of the renin - angiotensin system in the development of puromycin aminonucleoside - induced nephrosis .
Diseases: nephrosis"	"Sentence: The results suggest a possible involvement of the renin - angiotensin system in the development of puromycin aminonucleoside - induced nephrosis .
Diseases:"
1846	Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .	O O O B I O O O O O B I O	['erectile dysfunction', 'penile pain']	2	7	"Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .
Diseases: erectile dysfunction, penile pain"	"Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .
Diseases:"
1847	In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications .	O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O	['penile pain']	1	3	"Sentence: In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications .
Diseases: penile pain"	"Sentence: In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications .
Diseases:"
1848	A total of 38 consecutive patients who presented to our clinic with impotence received 0 . 2 ml .	O O O O O O O O O O O O B O O O O O O	['impotence']	1	3	"Sentence: A total of 38 consecutive patients who presented to our clinic with impotence received 0 . 2 ml .
Diseases: impotence"	"Sentence: A total of 38 consecutive patients who presented to our clinic with impotence received 0 . 2 ml .
Diseases:"
1849	of a combination of 3 drugs : 6 mg .	O O O O O O O O O O	[]	0	0	"Sentence: of a combination of 3 drugs : 6 mg .
Diseases: "	"Sentence: of a combination of 3 drugs : 6 mg .
Diseases:"
1850	papaverine , 100 micrograms .	O O O O O	[]	0	0	"Sentence: papaverine , 100 micrograms .
Diseases: "	"Sentence: papaverine , 100 micrograms .
Diseases:"
1851	phentolamine and 10 micrograms .	O O O O O	[]	0	0	"Sentence: phentolamine and 10 micrograms .
Diseases: "	"Sentence: phentolamine and 10 micrograms .
Diseases:"
1852	prostaglandin E1 with ( pH 7 . 05 ) or without ( pH 4 . 17 ) the addition of sodium bicarbonate ( 0 . 03 mEq . ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: prostaglandin E1 with ( pH 7 . 05 ) or without ( pH 4 . 17 ) the addition of sodium bicarbonate ( 0 . 03 mEq . ) .
Diseases: "	"Sentence: prostaglandin E1 with ( pH 7 . 05 ) or without ( pH 4 . 17 ) the addition of sodium bicarbonate ( 0 . 03 mEq . ) .
Diseases:"
1853	Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of penile pain .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O B I O	['penile pain']	1	3	"Sentence: Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of penile pain .
Diseases: penile pain"	"Sentence: Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of penile pain .
Diseases:"
1854	From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication , which can be overcome by elevating the pH to a neutral level .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['penile pain']	1	3	"Sentence: From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication , which can be overcome by elevating the pH to a neutral level .
Diseases: penile pain"	"Sentence: From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication , which can be overcome by elevating the pH to a neutral level .
Diseases:"
1855	Prospective study of the long - term effects of somatostatin analog ( octreotide ) on gallbladder function and gallstone formation in Chinese acromegalic patients .	O O O O O O O O O O O O O O O O O O B O O O B O O	['acromegalic', 'gallstone']	2	7	"Sentence: Prospective study of the long - term effects of somatostatin analog ( octreotide ) on gallbladder function and gallstone formation in Chinese acromegalic patients .
Diseases: acromegalic, gallstone"	"Sentence: Prospective study of the long - term effects of somatostatin analog ( octreotide ) on gallbladder function and gallstone formation in Chinese acromegalic patients .
Diseases:"
1856	This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300 - 1500 micrograms / day for a mean of 24 . 2 + / - 13 . 9 months .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['acromegaly']	1	4	"Sentence: This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300 - 1500 micrograms / day for a mean of 24 . 2 + / - 13 . 9 months .
Diseases: acromegaly"	"Sentence: This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300 - 1500 micrograms / day for a mean of 24 . 2 + / - 13 . 9 months .
Diseases:"
1857	During treatment with octreotide , 17 patients developed sludge , 10 had gallstones , and 1 developed acute cholecystitis requiring surgery .	O O O O O O O O O O O O B O O O O B I O O O	['acute cholecystitis', 'gallstones']	2	10	"Sentence: During treatment with octreotide , 17 patients developed sludge , 10 had gallstones , and 1 developed acute cholecystitis requiring surgery .
Diseases: acute cholecystitis, gallstones"	"Sentence: During treatment with octreotide , 17 patients developed sludge , 10 had gallstones , and 1 developed acute cholecystitis requiring surgery .
Diseases:"
1858	In all of 7 patients examined acutely , gallbladder contractility was inhibited after a single 100 - micrograms injection .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In all of 7 patients examined acutely , gallbladder contractility was inhibited after a single 100 - micrograms injection .
Diseases: "	"Sentence: In all of 7 patients examined acutely , gallbladder contractility was inhibited after a single 100 - micrograms injection .
Diseases:"
1859	In 8 patients followed for 24 weeks , gallbladder contractility remained depressed throughout therapy .	O O O O O O O O O O O B O O O	['depressed']	1	2	"Sentence: In 8 patients followed for 24 weeks , gallbladder contractility remained depressed throughout therapy .
Diseases: depressed"	"Sentence: In 8 patients followed for 24 weeks , gallbladder contractility remained depressed throughout therapy .
Diseases:"
1860	After withdrawal of octreotide in 10 patients without gallstones , 8 patients assessed had return of normal gallbladder contractility within 1 month .	O O O O O O O O B O O O O O O O O O O O O O O	['gallstones']	1	2	"Sentence: After withdrawal of octreotide in 10 patients without gallstones , 8 patients assessed had return of normal gallbladder contractility within 1 month .
Diseases: gallstones"	"Sentence: After withdrawal of octreotide in 10 patients without gallstones , 8 patients assessed had return of normal gallbladder contractility within 1 month .
Diseases:"
1861	In 8 of the remaining 10 patients who developed gallstones during treatment , gallbladder contractility normalized in 5 patients ( 3 of whom has disappearance of their stones within 3 weeks ) , and remained depressed in 3 ( 2 of whom had stones present at 6 months ) .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['depressed', 'gallstones']	2	5	"Sentence: In 8 of the remaining 10 patients who developed gallstones during treatment , gallbladder contractility normalized in 5 patients ( 3 of whom has disappearance of their stones within 3 weeks ) , and remained depressed in 3 ( 2 of whom had stones present at 6 months ) .
Diseases: depressed, gallstones"	"Sentence: In 8 of the remaining 10 patients who developed gallstones during treatment , gallbladder contractility normalized in 5 patients ( 3 of whom has disappearance of their stones within 3 weeks ) , and remained depressed in 3 ( 2 of whom had stones present at 6 months ) .
Diseases:"
1862	Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and cholecystitis during octreotide therapy in Chinese acromegalic patients .	O O O O O O O O O O O O O O O O O O O O B O O B O O O O O B O O	['acromegalic', 'cholecystitis', 'gallstones']	3	13	"Sentence: Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and cholecystitis during octreotide therapy in Chinese acromegalic patients .
Diseases: acromegalic, cholecystitis, gallstones"	"Sentence: Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and cholecystitis during octreotide therapy in Chinese acromegalic patients .
Diseases:"
1863	It is therefore very important to follow the changes of gallbladder function during long - term octreotide therapy of acromegalic patients .	O O O O O O O O O O O O O O O O O O O B O O	['acromegalic']	1	4	"Sentence: It is therefore very important to follow the changes of gallbladder function during long - term octreotide therapy of acromegalic patients .
Diseases: acromegalic"	"Sentence: It is therefore very important to follow the changes of gallbladder function during long - term octreotide therapy of acromegalic patients .
Diseases:"
1864	Improvement of levodopa - induced dyskinesia by propranolol in Parkinson 's disease .	O O O O O B O O O B I I O	"['dyskinesia', ""parkinson 's disease""]"	2	11	"Sentence: Improvement of levodopa - induced dyskinesia by propranolol in Parkinson 's disease .
Diseases: dyskinesia, parkinson 's disease"	"Sentence: Improvement of levodopa - induced dyskinesia by propranolol in Parkinson 's disease .
Diseases:"
1865	Seven patients suffering from Parkinson 's disease ( PD ) with severely disabling dyskinesia received low - dose propranolol as an adjunct to the currently used medical treatment .	O O O O B I I O B O O O O B O O O O O O O O O O O O O O O	"['pd', 'dyskinesia', ""parkinson 's disease""]"	3	12	"Sentence: Seven patients suffering from Parkinson 's disease ( PD ) with severely disabling dyskinesia received low - dose propranolol as an adjunct to the currently used medical treatment .
Diseases: pd, dyskinesia, parkinson 's disease"	"Sentence: Seven patients suffering from Parkinson 's disease ( PD ) with severely disabling dyskinesia received low - dose propranolol as an adjunct to the currently used medical treatment .
Diseases:"
1866	There was a significant 40 % improvement in the dyskinesia score without increase of parkinsonian motor disability .	O O O O O O O O O B O O O O B B I O	['dyskinesia', 'parkinsonian', 'motor disability']	3	12	"Sentence: There was a significant 40 % improvement in the dyskinesia score without increase of parkinsonian motor disability .
Diseases: dyskinesia, parkinsonian, motor disability"	"Sentence: There was a significant 40 % improvement in the dyskinesia score without increase of parkinsonian motor disability .
Diseases:"
1867	Ballistic and choreic dyskinesia were markedly ameliorated , whereas dystonia was not .	O O O B O O O O O B O O O	['dyskinesia', 'dystonia']	2	9	"Sentence: Ballistic and choreic dyskinesia were markedly ameliorated , whereas dystonia was not .
Diseases: dyskinesia, dystonia"	"Sentence: Ballistic and choreic dyskinesia were markedly ameliorated , whereas dystonia was not .
Diseases:"
1868	This study suggests that administration of low doses of beta - blockers may improve levodopa - induced ballistic and choreic dyskinesia in PD .	O O O O O O O O O O O O O O O O O O O O B O B O	['pd', 'dyskinesia']	2	6	"Sentence: This study suggests that administration of low doses of beta - blockers may improve levodopa - induced ballistic and choreic dyskinesia in PD .
Diseases: pd, dyskinesia"	"Sentence: This study suggests that administration of low doses of beta - blockers may improve levodopa - induced ballistic and choreic dyskinesia in PD .
Diseases:"
1869	Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats .	O O O B O O O O O O O O O O O	['encephalopathy']	1	3	"Sentence: Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats .
Diseases: encephalopathy"	"Sentence: Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats .
Diseases:"
1870	A transmission electron microscopic study of capillaries in the cerebellar cortex .	O O O O O O O O O O O O	[]	0	0	"Sentence: A transmission electron microscopic study of capillaries in the cerebellar cortex .
Diseases: "	"Sentence: A transmission electron microscopic study of capillaries in the cerebellar cortex .
Diseases:"
1871	"Long - term intragastric application of the antiepileptic drug sodium valproate ( Vupral "" Polfa "" ) at the effective dose of 200 mg / kg"	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Long - term intragastric application of the antiepileptic drug sodium valproate ( Vupral "" Polfa "" ) at the effective dose of 200 mg / kg
Diseases: "	"Sentence: Long - term intragastric application of the antiepileptic drug sodium valproate ( Vupral "" Polfa "" ) at the effective dose of 200 mg / kg
Diseases:"
1872	"b . w . once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating cerebellum damage ( "" valproate encephalopathy "" ) ."	O O O O O O O O O O O O O O O O O O O O B I O B I O O O B O O O	['cerebellum damage', 'encephalopathy', 'neurological disorders']	3	12	"Sentence: b . w . once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating cerebellum damage ( "" valproate encephalopathy "" ) .
Diseases: cerebellum damage, encephalopathy, neurological disorders"	"Sentence: b . w . once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating cerebellum damage ( "" valproate encephalopathy "" ) .
Diseases:"
1873	The first ultrastructural changes in structural elements of the blood - brain - barrier ( BBB ) in the cerebellar cortex were detectable after 3 months of the experiment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The first ultrastructural changes in structural elements of the blood - brain - barrier ( BBB ) in the cerebellar cortex were detectable after 3 months of the experiment .
Diseases: "	"Sentence: The first ultrastructural changes in structural elements of the blood - brain - barrier ( BBB ) in the cerebellar cortex were detectable after 3 months of the experiment .
Diseases:"
1874	They became more severe in the later months of the experiment , and were most severe after 12 months , located mainly in the molecular layer of the cerebellar cortex .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: They became more severe in the later months of the experiment , and were most severe after 12 months , located mainly in the molecular layer of the cerebellar cortex .
Diseases: "	"Sentence: They became more severe in the later months of the experiment , and were most severe after 12 months , located mainly in the molecular layer of the cerebellar cortex .
Diseases:"
1875	Lesions of the capillary included necrosis of endothelial cells .	O O O O O B O O O O	['necrosis']	1	2	"Sentence: Lesions of the capillary included necrosis of endothelial cells .
Diseases: necrosis"	"Sentence: Lesions of the capillary included necrosis of endothelial cells .
Diseases:"
1876	Organelles of these cells , in particular the mitochondria ( increased number and size , distinct degeneration of their matrix and cristae ) and Golgi apparatus were altered .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Organelles of these cells , in particular the mitochondria ( increased number and size , distinct degeneration of their matrix and cristae ) and Golgi apparatus were altered .
Diseases: "	"Sentence: Organelles of these cells , in particular the mitochondria ( increased number and size , distinct degeneration of their matrix and cristae ) and Golgi apparatus were altered .
Diseases:"
1877	Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had luminal protrusions and swollen microvilli .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had luminal protrusions and swollen microvilli .
Diseases: "	"Sentence: Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had luminal protrusions and swollen microvilli .
Diseases:"
1878	Pressure on the vessel wall was produced by enlarged perivascular astrocytic processes .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Pressure on the vessel wall was produced by enlarged perivascular astrocytic processes .
Diseases: "	"Sentence: Pressure on the vessel wall was produced by enlarged perivascular astrocytic processes .
Diseases:"
1879	Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions .	O O B O O O O O O O O O O O O O O O O O O O O	['necrotic']	1	3	"Sentence: Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions .
Diseases: necrotic"	"Sentence: Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions .
Diseases:"
1880	Damage to the vascular basement lamina was also observed .	O O O O O O O O O O	[]	0	0	"Sentence: Damage to the vascular basement lamina was also observed .
Diseases: "	"Sentence: Damage to the vascular basement lamina was also observed .
Diseases:"
1881	Damage to the capillary was accompanied by marked damage to neuroglial cells , mainly to perivascular processes of astrocytes .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Damage to the capillary was accompanied by marked damage to neuroglial cells , mainly to perivascular processes of astrocytes .
Diseases: "	"Sentence: Damage to the capillary was accompanied by marked damage to neuroglial cells , mainly to perivascular processes of astrocytes .
Diseases:"
1882	The proliferation of astrocytes ( Bergmann 's in particular ) and occasionally of oligodendrocytes was found .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The proliferation of astrocytes ( Bergmann 's in particular ) and occasionally of oligodendrocytes was found .
Diseases: "	"Sentence: The proliferation of astrocytes ( Bergmann 's in particular ) and occasionally of oligodendrocytes was found .
Diseases:"
1883	Alterations in the structural elements of the BBB coexisted with marked lesions of neurons of the cerebellum ( Purkinje cells are earliest ) .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Alterations in the structural elements of the BBB coexisted with marked lesions of neurons of the cerebellum ( Purkinje cells are earliest ) .
Diseases: "	"Sentence: Alterations in the structural elements of the BBB coexisted with marked lesions of neurons of the cerebellum ( Purkinje cells are earliest ) .
Diseases:"
1884	In electron micrographs both luminal and antiluminal sides of the BBB of the cerebellar cortex had similar lesions .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In electron micrographs both luminal and antiluminal sides of the BBB of the cerebellar cortex had similar lesions .
Diseases: "	"Sentence: In electron micrographs both luminal and antiluminal sides of the BBB of the cerebellar cortex had similar lesions .
Diseases:"
1885	The possible influence of the hepatic damage , mainly hyperammonemia , upon the development of valproate encephalopathy is discussed .	O O O O O B I O O B O O O O O O B O O O	['hyperammonemia', 'encephalopathy', 'hepatic damage']	3	12	"Sentence: The possible influence of the hepatic damage , mainly hyperammonemia , upon the development of valproate encephalopathy is discussed .
Diseases: hyperammonemia, encephalopathy, hepatic damage"	"Sentence: The possible influence of the hepatic damage , mainly hyperammonemia , upon the development of valproate encephalopathy is discussed .
Diseases:"
1886	Macula toxicity after intravitreal amikacin .	O B O O O O	['toxicity']	1	2	"Sentence: Macula toxicity after intravitreal amikacin .
Diseases: toxicity"	"Sentence: Macula toxicity after intravitreal amikacin .
Diseases:"
1887	Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis , macular infarction may impair full visual recovery .	O O O O O O O O O B O O B O O O O O O	['infarction', 'endophthalmitis']	2	9	"Sentence: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis , macular infarction may impair full visual recovery .
Diseases: infarction, endophthalmitis"	"Sentence: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis , macular infarction may impair full visual recovery .
Diseases:"
1888	METHODS : We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha - haemolytic streptococcal endophthalmitis .	O O O O O O O O O B I O O O O O O O O O O B I O	['streptococcal endophthalmitis', 'retinal toxicity']	2	13	"Sentence: METHODS : We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha - haemolytic streptococcal endophthalmitis .
Diseases: streptococcal endophthalmitis, retinal toxicity"	"Sentence: METHODS : We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha - haemolytic streptococcal endophthalmitis .
Diseases:"
1889	Endophthalmitis resolved with improvement in visual acuity to 6 / 24 at three months .	B O O O O O O O O O O O O O O	['endophthalmitis']	1	5	"Sentence: Endophthalmitis resolved with improvement in visual acuity to 6 / 24 at three months .
Diseases: endophthalmitis"	"Sentence: Endophthalmitis resolved with improvement in visual acuity to 6 / 24 at three months .
Diseases:"
1890	Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis .	O O O O O O O O B O	['telangiectasis']	1	5	"Sentence: Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis .
Diseases: telangiectasis"	"Sentence: Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis .
Diseases:"
1891	CONCLUSIONS : Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia .	O O O O O O O O O B I O O B O	['ischaemia', 'retinal toxicity']	2	7	"Sentence: CONCLUSIONS : Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia .
Diseases: ischaemia, retinal toxicity"	"Sentence: CONCLUSIONS : Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia .
Diseases:"
1892	Treatment strategies aimed at avoiding retinal toxicity are discussed .	O O O O O B I O O O	['retinal toxicity']	1	3	"Sentence: Treatment strategies aimed at avoiding retinal toxicity are discussed .
Diseases: retinal toxicity"	"Sentence: Treatment strategies aimed at avoiding retinal toxicity are discussed .
Diseases:"
1893	Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff - Parkinson - White syndrome and idiopathic dilated cardiomyopathy .	O O O B I I O O O O O O O O O B I I I I I O B I I O	['atrioventricular reentrant tachycardia', 'wolff - parkinson - white syndrome', 'idiopathic dilated cardiomyopathy']	3	32	"Sentence: Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff - Parkinson - White syndrome and idiopathic dilated cardiomyopathy .
Diseases: atrioventricular reentrant tachycardia, wolff - parkinson - white syndrome, idiopathic dilated cardiomyopathy"	"Sentence: Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff - Parkinson - White syndrome and idiopathic dilated cardiomyopathy .
Diseases:"
1894	In a patient with WPW syndrome and idiopathic dilated cardiomyopathy , intractable atrioventricular reentrant tachycardia ( AVRT ) was iatrogenically induced .	O O O O B I O B I I O O B I I O B O O O O O	['atrioventricular reentrant tachycardia', 'avrt', 'idiopathic dilated cardiomyopathy', 'wpw syndrome']	4	30	"Sentence: In a patient with WPW syndrome and idiopathic dilated cardiomyopathy , intractable atrioventricular reentrant tachycardia ( AVRT ) was iatrogenically induced .
Diseases: atrioventricular reentrant tachycardia, avrt, idiopathic dilated cardiomyopathy, wpw syndrome"	"Sentence: In a patient with WPW syndrome and idiopathic dilated cardiomyopathy , intractable atrioventricular reentrant tachycardia ( AVRT ) was iatrogenically induced .
Diseases:"
1895	QRS without preexcitation , caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation , established frequent AVRT attack .	O O O O O O O O O O O O O O O O O O O O O O O O B O O	['avrt']	1	2	"Sentence: QRS without preexcitation , caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation , established frequent AVRT attack .
Diseases: avrt"	"Sentence: QRS without preexcitation , caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation , established frequent AVRT attack .
Diseases:"
1896	Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone - sparing substitutes of chlorofluorocarbons .	O O B I O O O O O O O O O O O O	['liver disease']	1	3	"Sentence: Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone - sparing substitutes of chlorofluorocarbons .
Diseases: liver disease"	"Sentence: Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone - sparing substitutes of chlorofluorocarbons .
Diseases:"
1897	Hydrochlorofluorocarbons ( HCFCs ) are used increasingly in industry as substitutes for ozone - depleting chlorofluorocarbons ( CFCs ) .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hydrochlorofluorocarbons ( HCFCs ) are used increasingly in industry as substitutes for ozone - depleting chlorofluorocarbons ( CFCs ) .
Diseases: "	"Sentence: Hydrochlorofluorocarbons ( HCFCs ) are used increasingly in industry as substitutes for ozone - depleting chlorofluorocarbons ( CFCs ) .
Diseases:"
1898	Limited studies in animals indicate potential hepatotoxicity of some of these compounds .	O O O O O O B O O O O O O	['hepatotoxicity']	1	4	"Sentence: Limited studies in animals indicate potential hepatotoxicity of some of these compounds .
Diseases: hepatotoxicity"	"Sentence: Limited studies in animals indicate potential hepatotoxicity of some of these compounds .
Diseases:"
1899	We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane ( HCFC 123 ) and 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane ( HCFC 124 ) .	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['liver disease']	1	3	"Sentence: We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane ( HCFC 123 ) and 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane ( HCFC 124 ) .
Diseases: liver disease"	"Sentence: We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane ( HCFC 123 ) and 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane ( HCFC 124 ) .
Diseases:"
1900	All nine exposed workers were affected to various degrees .	O O O O O O O O O O	[]	0	0	"Sentence: All nine exposed workers were affected to various degrees .
Diseases: "	"Sentence: All nine exposed workers were affected to various degrees .
Diseases:"
1901	Both compounds are metabolised in the same way as 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the hepatotoxicity of halothane .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	['hepatotoxicity']	1	4	"Sentence: Both compounds are metabolised in the same way as 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the hepatotoxicity of halothane .
Diseases: hepatotoxicity"	"Sentence: Both compounds are metabolised in the same way as 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the hepatotoxicity of halothane .
Diseases:"
1902	We aimed to test whether HCFCs 123 and 124 can result in serious liver disease .	O O O O O O O O O O O O O B I O	['liver disease']	1	3	"Sentence: We aimed to test whether HCFCs 123 and 124 can result in serious liver disease .
Diseases: liver disease"	"Sentence: We aimed to test whether HCFCs 123 and 124 can result in serious liver disease .
Diseases:"
1903	For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done .
Diseases: "	"Sentence: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done .
Diseases:"
1904	The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome - P450 2E1 ( P450 2E1 ) and P58 protein disulphide isomerase isoform ( P58 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome - P450 2E1 ( P450 2E1 ) and P58 protein disulphide isomerase isoform ( P58 ) .
Diseases: "	"Sentence: The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome - P450 2E1 ( P450 2E1 ) and P58 protein disulphide isomerase isoform ( P58 ) .
Diseases:"
1905	The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas ( bridging necrosis ) .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O	['necrosis']	1	2	"Sentence: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas ( bridging necrosis ) .
Diseases: necrosis"	"Sentence: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas ( bridging necrosis ) .
Diseases:"
1906	Trifluoroacetyl - adducted proteins were detected in surviving hepatocytes .	O O O O O O O O O O	[]	0	0	"Sentence: Trifluoroacetyl - adducted proteins were detected in surviving hepatocytes .
Diseases: "	"Sentence: Trifluoroacetyl - adducted proteins were detected in surviving hepatocytes .
Diseases:"
1907	Autoantibodies against P450 2E1 or P58 , previously associated with halothane hepatitis , were detected in the serum of five affected workers .	O O O O O O O O O O B I O O O O O O O O O O O	['halothane hepatitis']	1	4	"Sentence: Autoantibodies against P450 2E1 or P58 , previously associated with halothane hepatitis , were detected in the serum of five affected workers .
Diseases: halothane hepatitis"	"Sentence: Autoantibodies against P450 2E1 or P58 , previously associated with halothane hepatitis , were detected in the serum of five affected workers .
Diseases:"
1908	INTERPRETATION :	O O	[]	0	0	"Sentence: INTERPRETATION :
Diseases: "	"Sentence: INTERPRETATION :
Diseases:"
1909	Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population .	O O O O O O O O O O O O O O B I O O O O O O O O O	['liver injury']	1	3	"Sentence: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population .
Diseases: liver injury"	"Sentence: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population .
Diseases:"
1910	Although the exact mechanism of hepatotoxicity of these agents is not known , the results suggest that trifluoroacetyl - altered liver proteins are involved .	O O O O O B O O O O O O O O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: Although the exact mechanism of hepatotoxicity of these agents is not known , the results suggest that trifluoroacetyl - altered liver proteins are involved .
Diseases: hepatotoxicity"	"Sentence: Although the exact mechanism of hepatotoxicity of these agents is not known , the results suggest that trifluoroacetyl - altered liver proteins are involved .
Diseases:"
1911	In view of the potentially widespread use of these compounds , there is an urgent need to develop safer alternatives .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In view of the potentially widespread use of these compounds , there is an urgent need to develop safer alternatives .
Diseases: "	"Sentence: In view of the potentially widespread use of these compounds , there is an urgent need to develop safer alternatives .
Diseases:"
1912	The effect of different anaesthetic agents in hearing loss following spinal anaesthesia .	O O O O O O O B I O O O O	['hearing loss']	1	3	"Sentence: The effect of different anaesthetic agents in hearing loss following spinal anaesthesia .
Diseases: hearing loss"	"Sentence: The effect of different anaesthetic agents in hearing loss following spinal anaesthesia .
Diseases:"
1913	The cause of hearing loss after spinal anaesthesia is unknown .	O O O B I O O O O O O	['hearing loss']	1	3	"Sentence: The cause of hearing loss after spinal anaesthesia is unknown .
Diseases: hearing loss"	"Sentence: The cause of hearing loss after spinal anaesthesia is unknown .
Diseases:"
1914	Up until now , the only factor studied has been the effect of the diameter of the spinal needle on post - operative sensorineural hearing loss .	O O O O O O O O O O O O O O O O O O O O O O O B I I O	['sensorineural hearing loss']	1	6	"Sentence: Up until now , the only factor studied has been the effect of the diameter of the spinal needle on post - operative sensorineural hearing loss .
Diseases: sensorineural hearing loss"	"Sentence: Up until now , the only factor studied has been the effect of the diameter of the spinal needle on post - operative sensorineural hearing loss .
Diseases:"
1915	The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss .	O O O O O O O O O B I O O O O O O O O O B I O	['hearing loss']	1	3	"Sentence: The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss .
Diseases: hearing loss"	"Sentence: The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss .
Diseases:"
1916	Two groups of 22 similar patients were studied : one group received 6 mL prilocaine 2 % ; and the other received 3 mL bupivacaine 0 . 5 % .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two groups of 22 similar patients were studied : one group received 6 mL prilocaine 2 % ; and the other received 3 mL bupivacaine 0 . 5 % .
Diseases: "	"Sentence: Two groups of 22 similar patients were studied : one group received 6 mL prilocaine 2 % ; and the other received 3 mL bupivacaine 0 . 5 % .
Diseases:"
1917	Patients given prilocaine were more likely to develop hearing loss ( 10 out of 22 ) than those given bupivacaine ( 4 out of 22 ) ( P < 0 . 05 ) .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	['hearing loss']	1	3	"Sentence: Patients given prilocaine were more likely to develop hearing loss ( 10 out of 22 ) than those given bupivacaine ( 4 out of 22 ) ( P < 0 . 05 ) .
Diseases: hearing loss"	"Sentence: Patients given prilocaine were more likely to develop hearing loss ( 10 out of 22 ) than those given bupivacaine ( 4 out of 22 ) ( P < 0 . 05 ) .
Diseases:"
1918	The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine .	O O B I O O O O O O O O O O O O O O O	['hearing loss']	1	3	"Sentence: The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine .
Diseases: hearing loss"	"Sentence: The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine .
Diseases:"
1919	None of the patients complained of subjective hearing loss .	O O O O O O O B I O	['hearing loss']	1	3	"Sentence: None of the patients complained of subjective hearing loss .
Diseases: hearing loss"	"Sentence: None of the patients complained of subjective hearing loss .
Diseases:"
1920	Long - term follow - up of the patients was not possible .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Long - term follow - up of the patients was not possible .
Diseases: "	"Sentence: Long - term follow - up of the patients was not possible .
Diseases:"
1921	A transient neurological deficit following intrathecal injection of 1 % hyperbaric bupivacaine for unilateral spinal anaesthesia .	O O B I O O O O O O O O O O O O O	['neurological deficit']	1	5	"Sentence: A transient neurological deficit following intrathecal injection of 1 % hyperbaric bupivacaine for unilateral spinal anaesthesia .
Diseases: neurological deficit"	"Sentence: A transient neurological deficit following intrathecal injection of 1 % hyperbaric bupivacaine for unilateral spinal anaesthesia .
Diseases:"
1922	We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1 % hyperbaric bupivacaine slowly injected through a 25 - gauge pencil - point spinal needle .	O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['neurological deficit']	1	5	"Sentence: We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1 % hyperbaric bupivacaine slowly injected through a 25 - gauge pencil - point spinal needle .
Diseases: neurological deficit"	"Sentence: We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1 % hyperbaric bupivacaine slowly injected through a 25 - gauge pencil - point spinal needle .
Diseases:"
1923	The surgery and anaesthesia were uneventful , but 3 days after surgery , the patient reported an area of hypoaesthesia over L3 - L4 dermatomes of the leg which had been operated on ( loss of pinprick sensation ) without reduction in muscular strength .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O	['loss of pinprick sensation']	1	6	"Sentence: The surgery and anaesthesia were uneventful , but 3 days after surgery , the patient reported an area of hypoaesthesia over L3 - L4 dermatomes of the leg which had been operated on ( loss of pinprick sensation ) without reduction in muscular strength .
Diseases: loss of pinprick sensation"	"Sentence: The surgery and anaesthesia were uneventful , but 3 days after surgery , the patient reported an area of hypoaesthesia over L3 - L4 dermatomes of the leg which had been operated on ( loss of pinprick sensation ) without reduction in muscular strength .
Diseases:"
1924	Sensation in this area returned to normal over the following 2 weeks .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Sensation in this area returned to normal over the following 2 weeks .
Diseases: "	"Sentence: Sensation in this area returned to normal over the following 2 weeks .
Diseases:"
1925	Prospective multicentre studies with a large population and a long follow - up should be performed in order to evaluate the incidence of this unusual side effect .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Prospective multicentre studies with a large population and a long follow - up should be performed in order to evaluate the incidence of this unusual side effect .
Diseases: "	"Sentence: Prospective multicentre studies with a large population and a long follow - up should be performed in order to evaluate the incidence of this unusual side effect .
Diseases:"
1926	However , we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution ( if pencil - point needle and slow injection rate are employed ) , in order to minimize the risk of a localized high peak anaesthetic concentration , which might lead to a transient neurological deficit .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['neurological deficit']	1	5	"Sentence: However , we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution ( if pencil - point needle and slow injection rate are employed ) , in order to minimize the risk of a localized high peak anaesthetic concentration , which might lead to a transient neurological deficit .
Diseases: neurological deficit"	"Sentence: However , we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution ( if pencil - point needle and slow injection rate are employed ) , in order to minimize the risk of a localized high peak anaesthetic concentration , which might lead to a transient neurological deficit .
Diseases:"
1927	Pethidine - associated seizure in a healthy adolescent receiving pethidine for postoperative pain control .	O O O B O O O O O O O B I O O	['seizure', 'postoperative pain']	2	7	"Sentence: Pethidine - associated seizure in a healthy adolescent receiving pethidine for postoperative pain control .
Diseases: seizure, postoperative pain"	"Sentence: Pethidine - associated seizure in a healthy adolescent receiving pethidine for postoperative pain control .
Diseases:"
1928	A healthy 17 - year - old male received standard intermittent doses of pethidine via a patient - controlled analgesia ( PCA ) pump for management of postoperative pain control .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O	['postoperative pain']	1	3	"Sentence: A healthy 17 - year - old male received standard intermittent doses of pethidine via a patient - controlled analgesia ( PCA ) pump for management of postoperative pain control .
Diseases: postoperative pain"	"Sentence: A healthy 17 - year - old male received standard intermittent doses of pethidine via a patient - controlled analgesia ( PCA ) pump for management of postoperative pain control .
Diseases:"
1929	Twenty - three h postoperatively he developed a brief self - limited seizure .	O O O O O O O O O O O O B O	['seizure']	1	3	"Sentence: Twenty - three h postoperatively he developed a brief self - limited seizure .
Diseases: seizure"	"Sentence: Twenty - three h postoperatively he developed a brief self - limited seizure .
Diseases:"
1930	Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation .
Diseases: "	"Sentence: Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation .
Diseases:"
1931	No other risk factors for CNS toxicity were identified .	O O O O O O B O O O	['toxicity']	1	2	"Sentence: No other risk factors for CNS toxicity were identified .
Diseases: toxicity"	"Sentence: No other risk factors for CNS toxicity were identified .
Diseases:"
1932	This method allowed frequent self - dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This method allowed frequent self - dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine .
Diseases: "	"Sentence: This method allowed frequent self - dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine .
Diseases:"
1933	The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered .
Diseases: "	"Sentence: The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered .
Diseases:"
1934	Drug - associated acute - onset vanishing bile duct and Stevens - Johnson syndromes in a child .	O O O O O O B I I O B I I I O O O O	['stevens - johnson syndromes', 'vanishing bile duct']	2	15	"Sentence: Drug - associated acute - onset vanishing bile duct and Stevens - Johnson syndromes in a child .
Diseases: stevens - johnson syndromes, vanishing bile duct"	"Sentence: Drug - associated acute - onset vanishing bile duct and Stevens - Johnson syndromes in a child .
Diseases:"
1935	Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults , is most often drug or toxin related , and is of unknown pathogenesis .	O B I I O O O O O O O O O B O O O O O O O O O O O O O O O O O	['cholestasis', 'vanishing bile duct']	2	9	"Sentence: Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults , is most often drug or toxin related , and is of unknown pathogenesis .
Diseases: cholestasis, vanishing bile duct"	"Sentence: Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults , is most often drug or toxin related , and is of unknown pathogenesis .
Diseases:"
1936	It has not been reported previously in children .	O O O O O O O O O	[]	0	0	"Sentence: It has not been reported previously in children .
Diseases: "	"Sentence: It has not been reported previously in children .
Diseases:"
1937	Stevens - Johnson syndrome is a well - recognized immune complex - mediated hypersensitivity reaction that affects all age groups , is drug or infection induced , and has classic systemic , mucosal , and dermatologic manifestations .	B I I I O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O	['hypersensitivity', 'infection', 'stevens - johnson syndrome']	3	13	"Sentence: Stevens - Johnson syndrome is a well - recognized immune complex - mediated hypersensitivity reaction that affects all age groups , is drug or infection induced , and has classic systemic , mucosal , and dermatologic manifestations .
Diseases: hypersensitivity, infection, stevens - johnson syndrome"	"Sentence: Stevens - Johnson syndrome is a well - recognized immune complex - mediated hypersensitivity reaction that affects all age groups , is drug or infection induced , and has classic systemic , mucosal , and dermatologic manifestations .
Diseases:"
1938	A previously healthy child who developed acute , severe , rapidly progressive vanishing bile duct syndrome shortly after Stevens - Johnson syndrome is described ; this was temporally associated with ibuprofen use .	O O O O O O O O O O O O B I I I O O B I I I O O O O O O O O O O O	['vanishing bile duct syndrome', 'stevens - johnson syndrome']	2	14	"Sentence: A previously healthy child who developed acute , severe , rapidly progressive vanishing bile duct syndrome shortly after Stevens - Johnson syndrome is described ; this was temporally associated with ibuprofen use .
Diseases: vanishing bile duct syndrome, stevens - johnson syndrome"	"Sentence: A previously healthy child who developed acute , severe , rapidly progressive vanishing bile duct syndrome shortly after Stevens - Johnson syndrome is described ; this was temporally associated with ibuprofen use .
Diseases:"
1939	Despite therapy with ursodeoxycholic acid , prednisone , and then tacrolimus , her cholestatic disease was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .	O O O O O O O O O O O O O B I O O O O B O O O O O O O O	['cholestatic disease', 'cirrhosis']	2	9	"Sentence: Despite therapy with ursodeoxycholic acid , prednisone , and then tacrolimus , her cholestatic disease was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .
Diseases: cholestatic disease, cirrhosis"	"Sentence: Despite therapy with ursodeoxycholic acid , prednisone , and then tacrolimus , her cholestatic disease was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .
Diseases:"
1940	This case documents acute drug - related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens - Johnson syndrome and vanishing bile duct syndrome .	O O O O O O O B I I I O O O O O O O O O O O O O O O B I I I O B I I I O	['vanishing bile duct syndrome', 'stevens - johnson syndrome']	2	14	"Sentence: This case documents acute drug - related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens - Johnson syndrome and vanishing bile duct syndrome .
Diseases: vanishing bile duct syndrome, stevens - johnson syndrome"	"Sentence: This case documents acute drug - related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens - Johnson syndrome and vanishing bile duct syndrome .
Diseases:"
1941	High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium .	O O O B I I O O O O O O O	['primary pulmonary hypertension']	1	3	"Sentence: High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium .
Diseases: primary pulmonary hypertension"	"Sentence: High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium .
Diseases:"
1942	Primary pulmonary hypertension is a rare , progressive and incurable disease , which has been associated with the intake of appetite suppressant drugs .	B I I O O O O O O O O O O O O O O O O O O O O O	['primary pulmonary hypertension']	1	3	"Sentence: Primary pulmonary hypertension is a rare , progressive and incurable disease , which has been associated with the intake of appetite suppressant drugs .
Diseases: primary pulmonary hypertension"	"Sentence: Primary pulmonary hypertension is a rare , progressive and incurable disease , which has been associated with the intake of appetite suppressant drugs .
Diseases:"
1943	The importance of this association was evaluated in Belgium while this country still had no restriction on the prescription of appetite suppressants .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The importance of this association was evaluated in Belgium while this country still had no restriction on the prescription of appetite suppressants .
Diseases: "	"Sentence: The importance of this association was evaluated in Belgium while this country still had no restriction on the prescription of appetite suppressants .
Diseases:"
1944	Thirty - five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months ( 1992 - 1994 ) in Belgium .	O O O O O B I I O O O O O O O O O O O O O O O O O	['primary pulmonary hypertension']	1	3	"Sentence: Thirty - five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months ( 1992 - 1994 ) in Belgium .
Diseases: primary pulmonary hypertension"	"Sentence: Thirty - five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months ( 1992 - 1994 ) in Belgium .
Diseases:"
1945	Exposure to appetite - suppressants was assessed on the basis of hospital records and standardized interview .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Exposure to appetite - suppressants was assessed on the basis of hospital records and standardized interview .
Diseases: "	"Sentence: Exposure to appetite - suppressants was assessed on the basis of hospital records and standardized interview .
Diseases:"
1946	Twenty - three of the patients had previously taken appetite suppressants , mainly fenfluramines , as compared with only 5 of the controls ( 66 versus 6 % , p < 0 . 0001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Twenty - three of the patients had previously taken appetite suppressants , mainly fenfluramines , as compared with only 5 of the controls ( 66 versus 6 % , p < 0 . 0001 ) .
Diseases: "	"Sentence: Twenty - three of the patients had previously taken appetite suppressants , mainly fenfluramines , as compared with only 5 of the controls ( 66 versus 6 % , p < 0 . 0001 ) .
Diseases:"
1947	Five patients died before the interview , all of them had taken appetite suppressants .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Five patients died before the interview , all of them had taken appetite suppressants .
Diseases: "	"Sentence: Five patients died before the interview , all of them had taken appetite suppressants .
Diseases:"
1948	In 8 patients the diagnosis of primary pulmonary hypertension was uncertain , 5 of them had taken appetite suppressants .	O O O O O O B I I O O O O O O O O O O O	['primary pulmonary hypertension']	1	3	"Sentence: In 8 patients the diagnosis of primary pulmonary hypertension was uncertain , 5 of them had taken appetite suppressants .
Diseases: primary pulmonary hypertension"	"Sentence: In 8 patients the diagnosis of primary pulmonary hypertension was uncertain , 5 of them had taken appetite suppressants .
Diseases:"
1949	The patients who had been exposed to appetite suppressants tended to be on average more severely ill , and to have a shorter median delay between onset of symptoms and diagnosis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The patients who had been exposed to appetite suppressants tended to be on average more severely ill , and to have a shorter median delay between onset of symptoms and diagnosis .
Diseases: "	"Sentence: The patients who had been exposed to appetite suppressants tended to be on average more severely ill , and to have a shorter median delay between onset of symptoms and diagnosis .
Diseases:"
1950	A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension .	O O O O O O O O O O O O O O O O B I I O	['primary pulmonary hypertension']	1	3	"Sentence: A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension .
Diseases: primary pulmonary hypertension"	"Sentence: A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension .
Diseases:"
1951	Intake of appetite suppressants may accelerate the progression of the disease .	O O O O O O O O O O O O	[]	0	0	"Sentence: Intake of appetite suppressants may accelerate the progression of the disease .
Diseases: "	"Sentence: Intake of appetite suppressants may accelerate the progression of the disease .
Diseases:"
1952	Choreoathetoid movements associated with rapid adjustment to methadone .	B I O O O O O O O	['choreoathetoid movements']	1	7	"Sentence: Choreoathetoid movements associated with rapid adjustment to methadone .
Diseases: choreoathetoid movements"	"Sentence: Choreoathetoid movements associated with rapid adjustment to methadone .
Diseases:"
1953	Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates .	B I O O O O O B I O O O O O O O O	['choreatiform hyperkinesias', 'movement abnormalities']	2	11	"Sentence: Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates .
Diseases: choreatiform hyperkinesias, movement abnormalities"	"Sentence: Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates .
Diseases:"
1954	This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu - opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	['choreoathetoid movements']	1	7	"Sentence: This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu - opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine .
Diseases: choreoathetoid movements"	"Sentence: This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu - opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine .
Diseases:"
1955	In addition , minor EEG abnormalities occurred .	O O O O O O O O	[]	0	0	"Sentence: In addition , minor EEG abnormalities occurred .
Diseases: "	"Sentence: In addition , minor EEG abnormalities occurred .
Diseases:"
1956	Possible underlying neurobiological phenomena are discussed .	O O O O O O O	[]	0	0	"Sentence: Possible underlying neurobiological phenomena are discussed .
Diseases: "	"Sentence: Possible underlying neurobiological phenomena are discussed .
Diseases:"
1957	Cocaine - induced mood disorder : prevalence rates and psychiatric symptoms in an outpatient cocaine - dependent sample .	O O O B I O O O O B O O O O O O O O O	['psychiatric', 'mood disorder']	2	5	"Sentence: Cocaine - induced mood disorder : prevalence rates and psychiatric symptoms in an outpatient cocaine - dependent sample .
Diseases: psychiatric, mood disorder"	"Sentence: Cocaine - induced mood disorder : prevalence rates and psychiatric symptoms in an outpatient cocaine - dependent sample .
Diseases:"
1958	This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance - induced and other mood disorders .	O O O O O O O O O O O O O O O O O O O B I O	['mood disorders']	1	3	"Sentence: This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance - induced and other mood disorders .
Diseases: mood disorders"	"Sentence: This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance - induced and other mood disorders .
Diseases:"
1959	243 cocaine - dependent outpatients with cocaine - induced mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .	O O O O O O O O O B I O B O O O B I O O O B I O O O O O B O O	['cimd', 'psychiatric', 'mood disorder', 'mood disorders']	4	11	"Sentence: 243 cocaine - dependent outpatients with cocaine - induced mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
Diseases: cimd, psychiatric, mood disorder, mood disorders"	"Sentence: 243 cocaine - dependent outpatients with cocaine - induced mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .
Diseases:"
1960	The prevalence rate for CIMD was 12 % at baseline .	O O O O B O O O O O O	['cimd']	1	3	"Sentence: The prevalence rate for CIMD was 12 % at baseline .
Diseases: cimd"	"Sentence: The prevalence rate for CIMD was 12 % at baseline .
Diseases:"
1961	Introduction of the DSM - IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders .	O O O O O O O O B O O O O O O O O B I O	['cimd', 'depressive disorders']	2	6	"Sentence: Introduction of the DSM - IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders .
Diseases: cimd, depressive disorders"	"Sentence: Introduction of the DSM - IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders .
Diseases:"
1962	Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder .	O O B O O O O O O O O O O O O B I O	['cimd', 'mood disorder']	2	6	"Sentence: Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder .
Diseases: cimd, mood disorder"	"Sentence: Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder .
Diseases:"
1963	These findings suggest some validity for the new DSM - IV diagnosis of CIMD , but also suggest that it requires further specification and replication .	O O O O O O O O O O O O O B O O O O O O O O O O O O	['cimd']	1	3	"Sentence: These findings suggest some validity for the new DSM - IV diagnosis of CIMD , but also suggest that it requires further specification and replication .
Diseases: cimd"	"Sentence: These findings suggest some validity for the new DSM - IV diagnosis of CIMD , but also suggest that it requires further specification and replication .
Diseases:"
1964	Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure .	B O O O O O O O O O O O O O O	['hemolysis']	1	3	"Sentence: Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure .
Diseases: hemolysis"	"Sentence: Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure .
Diseases:"
1965	Tamoxifen ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .	O O O O O O O O O O O O O O O B I O O O O O O O O O O B I O	['hemolytic anemia', 'breast cancer']	2	8	"Sentence: Tamoxifen ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .
Diseases: hemolytic anemia, breast cancer"	"Sentence: Tamoxifen ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .
Diseases:"
1966	This work evaluates the effects of TAM on isolated human erythrocytes , attempting to identify the underlying mechanisms on TAM - induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms .	O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	['hemolytic anemia']	1	5	"Sentence: This work evaluates the effects of TAM on isolated human erythrocytes , attempting to identify the underlying mechanisms on TAM - induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms .
Diseases: hemolytic anemia"	"Sentence: This work evaluates the effects of TAM on isolated human erythrocytes , attempting to identify the underlying mechanisms on TAM - induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms .
Diseases:"
1967	TAM induces hemolysis of erythrocytes as a function of concentration .	O O B O O O O O O O O	['hemolysis']	1	3	"Sentence: TAM induces hemolysis of erythrocytes as a function of concentration .
Diseases: hemolysis"	"Sentence: TAM induces hemolysis of erythrocytes as a function of concentration .
Diseases:"
1968	The extension of hemolysis is variable with erythrocyte samples , but 12 . 5 microM TAM induces total hemolysis of all tested suspensions .	O O O B O O O O O O O O O O O O O O B O O O O O	['hemolysis']	1	3	"Sentence: The extension of hemolysis is variable with erythrocyte samples , but 12 . 5 microM TAM induces total hemolysis of all tested suspensions .
Diseases: hemolysis"	"Sentence: The extension of hemolysis is variable with erythrocyte samples , but 12 . 5 microM TAM induces total hemolysis of all tested suspensions .
Diseases:"
1969	Despite inducing extensive erythrocyte lysis , TAM does not shift the osmotic fragility curves of erythrocytes .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Despite inducing extensive erythrocyte lysis , TAM does not shift the osmotic fragility curves of erythrocytes .
Diseases: "	"Sentence: Despite inducing extensive erythrocyte lysis , TAM does not shift the osmotic fragility curves of erythrocytes .
Diseases:"
1970	The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['hemolysis', 'hemolytic']	2	7	"Sentence: The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .
Diseases: hemolysis, hemolytic"	"Sentence: The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .
Diseases:"
1971	This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM - induced hemolysis .	O O O O O O O O O O O O O O O O O O O O B O	['hemolysis']	1	3	"Sentence: This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM - induced hemolysis .
Diseases: hemolysis"	"Sentence: This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM - induced hemolysis .
Diseases:"
1972	Furthermore , it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH , thus ruling out TAM - induced cell oxidative stress .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Furthermore , it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH , thus ruling out TAM - induced cell oxidative stress .
Diseases: "	"Sentence: Furthermore , it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH , thus ruling out TAM - induced cell oxidative stress .
Diseases:"
1973	Hemolysis caused by TAM was not preceded by the leakage of K ( + ) from the cells , also excluding a colloid - osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['hemolysis']	1	3	"Sentence: Hemolysis caused by TAM was not preceded by the leakage of K ( + ) from the cells , also excluding a colloid - osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .
Diseases: hemolysis"	"Sentence: Hemolysis caused by TAM was not preceded by the leakage of K ( + ) from the cells , also excluding a colloid - osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .
Diseases:"
1974	However , TAM induces release of peripheral proteins of membrane - cytoskeleton and cytosol proteins essentially bound to band 3 .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , TAM induces release of peripheral proteins of membrane - cytoskeleton and cytosol proteins essentially bound to band 3 .
Diseases: "	"Sentence: However , TAM induces release of peripheral proteins of membrane - cytoskeleton and cytosol proteins essentially bound to band 3 .
Diseases:"
1975	Either alpha - T or alpha - TAc increases membrane packing and prevents TAM partition into model membranes .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Either alpha - T or alpha - TAc increases membrane packing and prevents TAM partition into model membranes .
Diseases: "	"Sentence: Either alpha - T or alpha - TAc increases membrane packing and prevents TAM partition into model membranes .
Diseases:"
1976	These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['hemolysis']	1	3	"Sentence: These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .
Diseases: hemolysis"	"Sentence: These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .
Diseases:"
1977	Therefore , TAM - induced hemolysis results from a structural perturbation of red cell membrane , leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hemolysis']	1	3	"Sentence: Therefore , TAM - induced hemolysis results from a structural perturbation of red cell membrane , leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane .
Diseases: hemolysis"	"Sentence: Therefore , TAM - induced hemolysis results from a structural perturbation of red cell membrane , leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane .
Diseases:"
1978	These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM , resulting in hemolytic anemia .	O O O O O O O O O O O O O O O O O B I O	['hemolytic anemia']	1	5	"Sentence: These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM , resulting in hemolytic anemia .
Diseases: hemolytic anemia"	"Sentence: These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM , resulting in hemolytic anemia .
Diseases:"
1979	Additionally , since membrane leakage is a final stage of cytotoxicity , the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Additionally , since membrane leakage is a final stage of cytotoxicity , the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action .
Diseases: "	"Sentence: Additionally , since membrane leakage is a final stage of cytotoxicity , the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action .
Diseases:"
1980	Changes of sodium and ATP affinities of the cardiac ( Na , K ) - ATPase during and after nitric oxide deficient hypertension .	O O O O O O O O O O O O O O O O O O O O O O B O	['hypertension']	1	3	"Sentence: Changes of sodium and ATP affinities of the cardiac ( Na , K ) - ATPase during and after nitric oxide deficient hypertension .
Diseases: hypertension"	"Sentence: Changes of sodium and ATP affinities of the cardiac ( Na , K ) - ATPase during and after nitric oxide deficient hypertension .
Diseases:"
1981	In the cardiovascular system , NO is involved in the regulation of a variety of functions .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the cardiovascular system , NO is involved in the regulation of a variety of functions .
Diseases: "	"Sentence: In the cardiovascular system , NO is involved in the regulation of a variety of functions .
Diseases:"
1982	Inhibition of NO synthesis induces sustained hypertension .	O O O O O O B O	['hypertension']	1	3	"Sentence: Inhibition of NO synthesis induces sustained hypertension .
Diseases: hypertension"	"Sentence: Inhibition of NO synthesis induces sustained hypertension .
Diseases:"
1983	In several models of hypertension , elevation of intracellular sodium level was documented in cardiac tissue .	O O O O B O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: In several models of hypertension , elevation of intracellular sodium level was documented in cardiac tissue .
Diseases: hypertension"	"Sentence: In several models of hypertension , elevation of intracellular sodium level was documented in cardiac tissue .
Diseases:"
1984	To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient hypertension induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient hypertension induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .
Diseases: hypertension"	"Sentence: To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient hypertension induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .
Diseases:"
1985	After 4 - week administration of L - NAME , the systolic blood pressure ( SBP ) increased by 36 % .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 4 - week administration of L - NAME , the systolic blood pressure ( SBP ) increased by 36 % .
Diseases: "	"Sentence: After 4 - week administration of L - NAME , the systolic blood pressure ( SBP ) increased by 36 % .
Diseases:"
1986	Two weeks after terminating the treatment , the SBP recovered to control value .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two weeks after terminating the treatment , the SBP recovered to control value .
Diseases: "	"Sentence: Two weeks after terminating the treatment , the SBP recovered to control value .
Diseases:"
1987	When activating the ( Na , K ) - ATPase with its substrate ATP , no changes in Km and Vmax values were observed in NO - deficient rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When activating the ( Na , K ) - ATPase with its substrate ATP , no changes in Km and Vmax values were observed in NO - deficient rats .
Diseases: "	"Sentence: When activating the ( Na , K ) - ATPase with its substrate ATP , no changes in Km and Vmax values were observed in NO - deficient rats .
Diseases:"
1988	During activation with Na + , the Vmax remained unchanged , however the K ( Na ) increased by 50 % , indicating a profound decrease in the affinity of the Na + - binding site in NO - deficient rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During activation with Na + , the Vmax remained unchanged , however the K ( Na ) increased by 50 % , indicating a profound decrease in the affinity of the Na + - binding site in NO - deficient rats .
Diseases: "	"Sentence: During activation with Na + , the Vmax remained unchanged , however the K ( Na ) increased by 50 % , indicating a profound decrease in the affinity of the Na + - binding site in NO - deficient rats .
Diseases:"
1989	After recovery from hypertension , the activity of ( Na , K ) - ATPase increased , due to higher affinity of the ATP - binding site , as revealed from the lowered Km value for ATP .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: After recovery from hypertension , the activity of ( Na , K ) - ATPase increased , due to higher affinity of the ATP - binding site , as revealed from the lowered Km value for ATP .
Diseases: hypertension"	"Sentence: After recovery from hypertension , the activity of ( Na , K ) - ATPase increased , due to higher affinity of the ATP - binding site , as revealed from the lowered Km value for ATP .
Diseases:"
1990	The K ( Na ) value for Na + returned to control value .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The K ( Na ) value for Na + returned to control value .
Diseases: "	"Sentence: The K ( Na ) value for Na + returned to control value .
Diseases:"
1991	Inhibition of NO - synthase induced a reversible hypertension accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .	O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['depressed', 'hypertension']	2	4	"Sentence: Inhibition of NO - synthase induced a reversible hypertension accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .
Diseases: depressed, hypertension"	"Sentence: Inhibition of NO - synthase induced a reversible hypertension accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .
Diseases:"
1992	After recovery of blood pressure to control values , the extrusion of Na + from cardiac cells was normalized , as revealed by restoration of the ( Na , K ) - ATPase activity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After recovery of blood pressure to control values , the extrusion of Na + from cardiac cells was normalized , as revealed by restoration of the ( Na , K ) - ATPase activity .
Diseases: "	"Sentence: After recovery of blood pressure to control values , the extrusion of Na + from cardiac cells was normalized , as revealed by restoration of the ( Na , K ) - ATPase activity .
Diseases:"
1993	Effects of long - term pretreatment with isoproterenol on bromocriptine - induced tachycardia in conscious rats .	O O O O O O O O O O O O B O O O O	['tachycardia']	1	4	"Sentence: Effects of long - term pretreatment with isoproterenol on bromocriptine - induced tachycardia in conscious rats .
Diseases: tachycardia"	"Sentence: Effects of long - term pretreatment with isoproterenol on bromocriptine - induced tachycardia in conscious rats .
Diseases:"
1994	It has been shown that bromocriptine - induced tachycardia , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5 - day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tachycardia']	1	4	"Sentence: It has been shown that bromocriptine - induced tachycardia , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5 - day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .
Diseases: tachycardia"	"Sentence: It has been shown that bromocriptine - induced tachycardia , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5 - day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .
Diseases:"
1995	This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine - induced tachycardia in conscious rats .	O O O O O O O O O O O O O O O O B O O O O	['tachycardia']	1	4	"Sentence: This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine - induced tachycardia in conscious rats .
Diseases: tachycardia"	"Sentence: This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine - induced tachycardia in conscious rats .
Diseases:"
1996	Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate .	O O O O O O B I O O O O O O O O O	['cardiac hypertrophy']	1	5	"Sentence: Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate .
Diseases: cardiac hypertrophy"	"Sentence: Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate .
Diseases:"
1997	In control rats , intravenous bromocriptine ( 150 microg / kg ) induced significant hypotension and tachycardia .	O O O O O O O O O O O O O O B O B O	['tachycardia', 'hypotension']	2	7	"Sentence: In control rats , intravenous bromocriptine ( 150 microg / kg ) induced significant hypotension and tachycardia .
Diseases: tachycardia, hypotension"	"Sentence: In control rats , intravenous bromocriptine ( 150 microg / kg ) induced significant hypotension and tachycardia .
Diseases:"
1998	Bromocriptine - induced hypotension was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i . v .	O O O B O O O O O O O B O O O O B O O O O O O O O O O O O	['bradycardia', 'tachycardia', 'hypotension']	3	12	"Sentence: Bromocriptine - induced hypotension was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i . v .
Diseases: bradycardia, tachycardia, hypotension"	"Sentence: Bromocriptine - induced hypotension was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i . v .
Diseases:"
1999	domperidone ( 0 . 5 mg / kg ) .	O O O O O O O O O O	[]	0	0	"Sentence: domperidone ( 0 . 5 mg / kg ) .
Diseases: "	"Sentence: domperidone ( 0 . 5 mg / kg ) .
Diseases:"
2000	Neither cardiac vagal nor sympathetic tone was altered by isoproterenol pretreatment .	O O O O O O O O O O O O	[]	0	0	"Sentence: Neither cardiac vagal nor sympathetic tone was altered by isoproterenol pretreatment .
Diseases: "	"Sentence: Neither cardiac vagal nor sympathetic tone was altered by isoproterenol pretreatment .
Diseases:"
2001	In isolated perfused heart preparations from isoproterenol - pretreated rats , the isoproterenol - induced maximal increase in left ventricular systolic pressure was significantly reduced , compared with saline - pretreated rats ( the EC50 of the isoproterenol - induced increase in left ventricular systolic pressure was enhanced approximately 22 - fold ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In isolated perfused heart preparations from isoproterenol - pretreated rats , the isoproterenol - induced maximal increase in left ventricular systolic pressure was significantly reduced , compared with saline - pretreated rats ( the EC50 of the isoproterenol - induced increase in left ventricular systolic pressure was enhanced approximately 22 - fold ) .
Diseases: "	"Sentence: In isolated perfused heart preparations from isoproterenol - pretreated rats , the isoproterenol - induced maximal increase in left ventricular systolic pressure was significantly reduced , compared with saline - pretreated rats ( the EC50 of the isoproterenol - induced increase in left ventricular systolic pressure was enhanced approximately 22 - fold ) .
Diseases:"
2002	These results show that 15 - day isoproterenol pretreatment not only abolished but reversed bromocriptine - induced tachycardia to bradycardia , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .	O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O	['tachycardia', 'bradycardia']	2	9	"Sentence: These results show that 15 - day isoproterenol pretreatment not only abolished but reversed bromocriptine - induced tachycardia to bradycardia , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
Diseases: tachycardia, bradycardia"	"Sentence: These results show that 15 - day isoproterenol pretreatment not only abolished but reversed bromocriptine - induced tachycardia to bradycardia , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .
Diseases:"
2003	They suggest that , in normal conscious rats , the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors .	O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O	['tachycardia', 'bradycardia']	2	9	"Sentence: They suggest that , in normal conscious rats , the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors .
Diseases: tachycardia, bradycardia"	"Sentence: They suggest that , in normal conscious rats , the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors .
Diseases:"
2004	A developmental analysis of clonidine 's effects on cardiac rate and ultrasound production in infant rats .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A developmental analysis of clonidine 's effects on cardiac rate and ultrasound production in infant rats .
Diseases: "	"Sentence: A developmental analysis of clonidine 's effects on cardiac rate and ultrasound production in infant rats .
Diseases:"
2005	Under controlled conditions , infant rats emit ultrasonic vocalizations during extreme cold exposure and after administration of the alpha ( 2 ) adrenoceptor agonist , clonidine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Under controlled conditions , infant rats emit ultrasonic vocalizations during extreme cold exposure and after administration of the alpha ( 2 ) adrenoceptor agonist , clonidine .
Diseases: "	"Sentence: Under controlled conditions , infant rats emit ultrasonic vocalizations during extreme cold exposure and after administration of the alpha ( 2 ) adrenoceptor agonist , clonidine .
Diseases:"
2006	Previous investigations have determined that , in response to clonidine , ultrasound production increases through the 2nd - week postpartum and decreases thereafter .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Previous investigations have determined that , in response to clonidine , ultrasound production increases through the 2nd - week postpartum and decreases thereafter .
Diseases: "	"Sentence: Previous investigations have determined that , in response to clonidine , ultrasound production increases through the 2nd - week postpartum and decreases thereafter .
Diseases:"
2007	Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that clonidine induces sympathetic withdrawal and bradycardia , we hypothesized that clonidine 's developmental effects on cardiac rate and ultrasound production would mirror each other .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that clonidine induces sympathetic withdrawal and bradycardia , we hypothesized that clonidine 's developmental effects on cardiac rate and ultrasound production would mirror each other .
Diseases: bradycardia"	"Sentence: Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that clonidine induces sympathetic withdrawal and bradycardia , we hypothesized that clonidine 's developmental effects on cardiac rate and ultrasound production would mirror each other .
Diseases:"
2008	Therefore , in the present experiment , the effects of clonidine administration ( 0 . 5 mg / kg ) on cardiac rate and ultrasound production were examined in 2 - , 8 - , 15 - , and 20 - day - old rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Therefore , in the present experiment , the effects of clonidine administration ( 0 . 5 mg / kg ) on cardiac rate and ultrasound production were examined in 2 - , 8 - , 15 - , and 20 - day - old rats .
Diseases: "	"Sentence: Therefore , in the present experiment , the effects of clonidine administration ( 0 . 5 mg / kg ) on cardiac rate and ultrasound production were examined in 2 - , 8 - , 15 - , and 20 - day - old rats .
Diseases:"
2009	Age - related changes in ultrasound production corresponded with changes in cardiovascular variables , including baseline cardiac rate and clonidine - induced bradycardia .	O O O O O O O O O O O O O O O O O O O O O O B O	['bradycardia']	1	4	"Sentence: Age - related changes in ultrasound production corresponded with changes in cardiovascular variables , including baseline cardiac rate and clonidine - induced bradycardia .
Diseases: bradycardia"	"Sentence: Age - related changes in ultrasound production corresponded with changes in cardiovascular variables , including baseline cardiac rate and clonidine - induced bradycardia .
Diseases:"
2010	This experiment is discussed with regard to the hypothesis that ultrasound production is the acoustic by - product of a physiological maneuver that compensates for clonidine 's detrimental effects on cardiovascular function .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This experiment is discussed with regard to the hypothesis that ultrasound production is the acoustic by - product of a physiological maneuver that compensates for clonidine 's detrimental effects on cardiovascular function .
Diseases: "	"Sentence: This experiment is discussed with regard to the hypothesis that ultrasound production is the acoustic by - product of a physiological maneuver that compensates for clonidine 's detrimental effects on cardiovascular function .
Diseases:"
2011	Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans .	O O O O O O O O O O O O B O O O O O O O	['hyperalgesia']	1	4	"Sentence: Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans .
Diseases: hyperalgesia"	"Sentence: Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans .
Diseases:"
2012	We have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin .	O O O O O O O O O O O O O O O O O O O B O O O O O O O B O O O O	['pain', 'hyperalgesia']	2	6	"Sentence: We have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin .
Diseases: pain, hyperalgesia"	"Sentence: We have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin .
Diseases:"
2013	In a randomized , double - blind , placebo - controlled , crossover study , we studied 12 volunteers in three experiments .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In a randomized , double - blind , placebo - controlled , crossover study , we studied 12 volunteers in three experiments .
Diseases: "	"Sentence: In a randomized , double - blind , placebo - controlled , crossover study , we studied 12 volunteers in three experiments .
Diseases:"
2014	Capsaicin 100 micrograms was injected intradermally on the volar forearm followed by an i . v .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Capsaicin 100 micrograms was injected intradermally on the volar forearm followed by an i . v .
Diseases: "	"Sentence: Capsaicin 100 micrograms was injected intradermally on the volar forearm followed by an i . v .
Diseases:"
2015	infusion of ketamine ( bolus 0 . 1 mg kg - 1 over 10 min followed by infusion of 7 micrograms kg - 1 min - 1 ) , lidocaine 5 mg kg - 1 or saline for 50 min .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: infusion of ketamine ( bolus 0 . 1 mg kg - 1 over 10 min followed by infusion of 7 micrograms kg - 1 min - 1 ) , lidocaine 5 mg kg - 1 or saline for 50 min .
Diseases: "	"Sentence: infusion of ketamine ( bolus 0 . 1 mg kg - 1 over 10 min followed by infusion of 7 micrograms kg - 1 min - 1 ) , lidocaine 5 mg kg - 1 or saline for 50 min .
Diseases:"
2016	Infusion started 15 min after injection of capsaicin .	O O O O O O O O O	[]	0	0	"Sentence: Infusion started 15 min after injection of capsaicin .
Diseases: "	"Sentence: Infusion started 15 min after injection of capsaicin .
Diseases:"
2017	The following were measured : spontaneous pain , pain evoked by punctate and brush stimuli ( VAS ) , and areas of brush - evoked and punctate - evoked hyperalgesia .	O O O O O O B O B O O O O O O O O O O O O O O O O O O O O B O	['pain', 'hyperalgesia']	2	6	"Sentence: The following were measured : spontaneous pain , pain evoked by punctate and brush stimuli ( VAS ) , and areas of brush - evoked and punctate - evoked hyperalgesia .
Diseases: pain, hyperalgesia"	"Sentence: The following were measured : spontaneous pain , pain evoked by punctate and brush stimuli ( VAS ) , and areas of brush - evoked and punctate - evoked hyperalgesia .
Diseases:"
2018	Ketamine reduced both the area of brush - evoked and punctate - evoked hyperalgesia significantly and it tended to reduce brush - evoked pain .	O O O O O O O O O O O O O B O O O O O O O O O B O	['pain', 'hyperalgesia']	2	6	"Sentence: Ketamine reduced both the area of brush - evoked and punctate - evoked hyperalgesia significantly and it tended to reduce brush - evoked pain .
Diseases: pain, hyperalgesia"	"Sentence: Ketamine reduced both the area of brush - evoked and punctate - evoked hyperalgesia significantly and it tended to reduce brush - evoked pain .
Diseases:"
2019	Lidocaine reduced the area of punctate - evoked hyperalgesia significantly .	O O O O O O O O B O O	['hyperalgesia']	1	4	"Sentence: Lidocaine reduced the area of punctate - evoked hyperalgesia significantly .
Diseases: hyperalgesia"	"Sentence: Lidocaine reduced the area of punctate - evoked hyperalgesia significantly .
Diseases:"
2020	It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain .	O O O O O O O O B O O O O O O B O	['pain']	1	1	"Sentence: It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain .
Diseases: pain"	"Sentence: It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain .
Diseases:"
2021	The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .	O O O O O O O O O O O B O O O O O O B O O O O O O O O O O O	['hyperalgesia']	1	4	"Sentence: The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .
Diseases: hyperalgesia"	"Sentence: The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .
Diseases:"
2022	Cyclosporine and tacrolimus - associated thrombotic microangiopathy .	O O O O O B I O	['thrombotic microangiopathy']	1	8	"Sentence: Cyclosporine and tacrolimus - associated thrombotic microangiopathy .
Diseases: thrombotic microangiopathy"	"Sentence: Cyclosporine and tacrolimus - associated thrombotic microangiopathy .
Diseases:"
2023	The development of thrombotic microangiopathy ( TMA ) associated with the use of cyclosporine has been well documented .	O O O B I O B O O O O O O O O O O O O	['thrombotic microangiopathy', 'tma']	2	11	"Sentence: The development of thrombotic microangiopathy ( TMA ) associated with the use of cyclosporine has been well documented .
Diseases: thrombotic microangiopathy, tma"	"Sentence: The development of thrombotic microangiopathy ( TMA ) associated with the use of cyclosporine has been well documented .
Diseases:"
2024	Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange , plasma infusion , anticoagulation , and intravenous immunoglobulin G infusion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange , plasma infusion , anticoagulation , and intravenous immunoglobulin G infusion .
Diseases: "	"Sentence: Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange , plasma infusion , anticoagulation , and intravenous immunoglobulin G infusion .
Diseases:"
2025	However , for recipients of organ transplantation , removing the inciting agent is not without the attendant risk of precipitating acute rejection and graft loss .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , for recipients of organ transplantation , removing the inciting agent is not without the attendant risk of precipitating acute rejection and graft loss .
Diseases: "	"Sentence: However , for recipients of organ transplantation , removing the inciting agent is not without the attendant risk of precipitating acute rejection and graft loss .
Diseases:"
2026	The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine .
Diseases: "	"Sentence: The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine .
Diseases:"
2027	As a result , switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine - induced TMA .	O O O O O O O O O O O O O O O O O O O O O O O B O	['tma']	1	2	"Sentence: As a result , switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine - induced TMA .
Diseases: tma"	"Sentence: As a result , switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine - induced TMA .
Diseases:"
2028	With the more widespread application of tacrolimus in organ transplantation , tacrolimus - associated TMA has also been recognized .	O O O O O O O O O O O O O O B O O O O O	['tma']	1	2	"Sentence: With the more widespread application of tacrolimus in organ transplantation , tacrolimus - associated TMA has also been recognized .
Diseases: tma"	"Sentence: With the more widespread application of tacrolimus in organ transplantation , tacrolimus - associated TMA has also been recognized .
Diseases:"
2029	However , literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited .	O O O O O O O O O O B O O O O O O O O O O O	['tma']	1	2	"Sentence: However , literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited .
Diseases: tma"	"Sentence: However , literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited .
Diseases:"
2030	We report a case of a living donor renal transplant recipient who developed cyclosporine - induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['tma']	1	2	"Sentence: We report a case of a living donor renal transplant recipient who developed cyclosporine - induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .
Diseases: tma"	"Sentence: We report a case of a living donor renal transplant recipient who developed cyclosporine - induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .
Diseases:"
2031	Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft .	O O O O O O O O O O O O O B O O O O O O O O O	['tma']	1	2	"Sentence: Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft .
Diseases: tma"	"Sentence: Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft .
Diseases:"
2032	Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA .	O O O O O O O O O O O O O O O O O O O O O O B O	['tma']	1	2	"Sentence: Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA .
Diseases: tma"	"Sentence: Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA .
Diseases:"
2033	Repeated transient anuria following losartan administration in a patient with a solitary kidney .	O O B O O O O O O O O O O O	['anuria']	1	2	"Sentence: Repeated transient anuria following losartan administration in a patient with a solitary kidney .
Diseases: anuria"	"Sentence: Repeated transient anuria following losartan administration in a patient with a solitary kidney .
Diseases:"
2034	We report the case of a 70 - year - old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration .	O O O O O O O O O O O B O O O O O O B I I O O O O O O B O O O O	['chronic renal insufficiency', 'anuria', 'hypertensive']	3	12	"Sentence: We report the case of a 70 - year - old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration .
Diseases: chronic renal insufficiency, anuria, hypertensive"	"Sentence: We report the case of a 70 - year - old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration .
Diseases:"
2035	He was hospitalized for a myocardial infarction with pulmonary edema , treated with high - dose diuretics .	O O O O O B I O B I O O O O O O O O	['pulmonary edema', 'myocardial infarction']	2	12	"Sentence: He was hospitalized for a myocardial infarction with pulmonary edema , treated with high - dose diuretics .
Diseases: pulmonary edema, myocardial infarction"	"Sentence: He was hospitalized for a myocardial infarction with pulmonary edema , treated with high - dose diuretics .
Diseases:"
2036	Due to severe systolic dysfunction losartan was prescribed .	O O O B I O O O O	['systolic dysfunction']	1	4	"Sentence: Due to severe systolic dysfunction losartan was prescribed .
Diseases: systolic dysfunction"	"Sentence: Due to severe systolic dysfunction losartan was prescribed .
Diseases:"
2037	Surprisingly , the first dose of 50 mg of losartan resulted in a sudden anuria , which lasted eight hours despite high - dose furosemide and amine infusion .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['anuria']	1	2	"Sentence: Surprisingly , the first dose of 50 mg of losartan resulted in a sudden anuria , which lasted eight hours despite high - dose furosemide and amine infusion .
Diseases: anuria"	"Sentence: Surprisingly , the first dose of 50 mg of losartan resulted in a sudden anuria , which lasted eight hours despite high - dose furosemide and amine infusion .
Diseases:"
2038	One week later , by mistake , losartan was prescribed again and after the second dose of 50 mg , the patient developed a second episode of transient anuria lasting 10 hours .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['anuria']	1	2	"Sentence: One week later , by mistake , losartan was prescribed again and after the second dose of 50 mg , the patient developed a second episode of transient anuria lasting 10 hours .
Diseases: anuria"	"Sentence: One week later , by mistake , losartan was prescribed again and after the second dose of 50 mg , the patient developed a second episode of transient anuria lasting 10 hours .
Diseases:"
2039	During these two episodes , his blood pressure diminished but no severe hypotension was noted .	O O O O O O O O O O O O B O O O	['hypotension']	1	3	"Sentence: During these two episodes , his blood pressure diminished but no severe hypotension was noted .
Diseases: hypotension"	"Sentence: During these two episodes , his blood pressure diminished but no severe hypotension was noted .
Diseases:"
2040	Ultimately , an arteriography showed a 70 - 80 % renal artery stenosis .	O O O O O O O O O O B I I O	['renal artery stenosis']	1	5	"Sentence: Ultimately , an arteriography showed a 70 - 80 % renal artery stenosis .
Diseases: renal artery stenosis"	"Sentence: Ultimately , an arteriography showed a 70 - 80 % renal artery stenosis .
Diseases:"
2041	In this patient , renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin - angiotensin system ( RAS ) .	O O O O B I I O O B I O O O O O O O O O O O O O O O O O O O	['renal artery stenosis', 'heart failure']	2	8	"Sentence: In this patient , renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin - angiotensin system ( RAS ) .
Diseases: renal artery stenosis, heart failure"	"Sentence: In this patient , renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin - angiotensin system ( RAS ) .
Diseases:"
2042	Under such conditions , angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Under such conditions , angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure .
Diseases: "	"Sentence: Under such conditions , angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure .
Diseases:"
2043	This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting .	O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	['renovascular disease']	1	4	"Sentence: This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting .
Diseases: renovascular disease"	"Sentence: This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting .
Diseases:"
2044	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .	O O O O O O O O O B O O O O O O B O O O O B I O O O O B O O O O O O O O O	['necrotic', 'nephrotoxicity', 'cardiotoxicity', 'lung toxicity']	4	15	"Sentence: In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
Diseases: necrotic, nephrotoxicity, cardiotoxicity, lung toxicity"	"Sentence: In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .
Diseases:"
2045	Grape seed extract , primarily a mixture of proanthocyanidins , has been shown to modulate a wide - range of biological , pharmacological and toxicological effects which are mainly cytoprotective .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Grape seed extract , primarily a mixture of proanthocyanidins , has been shown to modulate a wide - range of biological , pharmacological and toxicological effects which are mainly cytoprotective .
Diseases: "	"Sentence: Grape seed extract , primarily a mixture of proanthocyanidins , has been shown to modulate a wide - range of biological , pharmacological and toxicological effects which are mainly cytoprotective .
Diseases:"
2046	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B I O O O O O O O O B O O O	['cardiotoxicity', 'nephrotoxicity', 'lung toxicity']	3	11	"Sentence: This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
Diseases: cardiotoxicity, nephrotoxicity, lung toxicity"	"Sentence: This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .
Diseases:"
2047	Experimental design consisted of four groups : control ( vehicle alone ) , GSPE alone , drug alone and GSPE + drug .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Experimental design consisted of four groups : control ( vehicle alone ) , GSPE alone , drug alone and GSPE + drug .
Diseases: "	"Sentence: Experimental design consisted of four groups : control ( vehicle alone ) , GSPE alone , drug alone and GSPE + drug .
Diseases:"
2048	For the cytoprotection study , animals were orally gavaged 100 mg / Kg GSPE for 7 - 10 days followed by i . p .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For the cytoprotection study , animals were orally gavaged 100 mg / Kg GSPE for 7 - 10 days followed by i . p .
Diseases: "	"Sentence: For the cytoprotection study , animals were orally gavaged 100 mg / Kg GSPE for 7 - 10 days followed by i . p .
Diseases:"
2049	injections of organ specific three drugs ( AAP : 500 mg / Kg for 24 h ; AMI : 50 mg / Kg / day for four days ; DOX :	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: injections of organ specific three drugs ( AAP : 500 mg / Kg for 24 h ; AMI : 50 mg / Kg / day for four days ; DOX :
Diseases: "	"Sentence: injections of organ specific three drugs ( AAP : 500 mg / Kg for 24 h ; AMI : 50 mg / Kg / day for four days ; DOX :
Diseases:"
2050	20 mg / Kg for 48 h ) .	O O O O O O O O O	[]	0	0	"Sentence: 20 mg / Kg for 48 h ) .
Diseases: "	"Sentence: 20 mg / Kg for 48 h ) .
Diseases:"
2051	Parameters of study included analysis of serum chemistry ( ALT , BUN and CPK ) , and orderly fragmentation of genomic DNA ( both endonuclease - dependent and independent ) in addition to microscopic evaluation of damage and / or protection in corresponding PAS stained tissues .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Parameters of study included analysis of serum chemistry ( ALT , BUN and CPK ) , and orderly fragmentation of genomic DNA ( both endonuclease - dependent and independent ) in addition to microscopic evaluation of damage and / or protection in corresponding PAS stained tissues .
Diseases: "	"Sentence: Parameters of study included analysis of serum chemistry ( ALT , BUN and CPK ) , and orderly fragmentation of genomic DNA ( both endonuclease - dependent and independent ) in addition to microscopic evaluation of damage and / or protection in corresponding PAS stained tissues .
Diseases:"
2052	Results indicate that GSPE preexposure prior to AAP , AMI and DOX , provided near complete protection in terms of serum chemistry changes ( ALT , BUN and CPK ) , and significantly reduced DNA fragmentation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Results indicate that GSPE preexposure prior to AAP , AMI and DOX , provided near complete protection in terms of serum chemistry changes ( ALT , BUN and CPK ) , and significantly reduced DNA fragmentation .
Diseases: "	"Sentence: Results indicate that GSPE preexposure prior to AAP , AMI and DOX , provided near complete protection in terms of serum chemistry changes ( ALT , BUN and CPK ) , and significantly reduced DNA fragmentation .
Diseases:"
2053	Histopathological examination of kidney , heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	['tissue damage']	1	3	"Sentence: Histopathological examination of kidney , heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence .
Diseases: tissue damage"	"Sentence: Histopathological examination of kidney , heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence .
Diseases:"
2054	GSPE + drug exposed tissues exhibited minor residual damage or near total recovery .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: GSPE + drug exposed tissues exhibited minor residual damage or near total recovery .
Diseases: "	"Sentence: GSPE + drug exposed tissues exhibited minor residual damage or near total recovery .
Diseases:"
2055	Additionally , histopathological alterations mirrored both serum chemistry changes and the pattern of DNA fragmentation .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Additionally , histopathological alterations mirrored both serum chemistry changes and the pattern of DNA fragmentation .
Diseases: "	"Sentence: Additionally , histopathological alterations mirrored both serum chemistry changes and the pattern of DNA fragmentation .
Diseases:"
2056	Interestingly , all the drugs , such as , AAP , AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['necrosis']	1	2	"Sentence: Interestingly , all the drugs , such as , AAP , AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE .
Diseases: necrosis"	"Sentence: Interestingly , all the drugs , such as , AAP , AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE .
Diseases:"
2057	Since AAP , AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo , the protection by GSPE may be linked to both inhibition of metabolism and / or detoxification of cytotoxic radicals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Since AAP , AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo , the protection by GSPE may be linked to both inhibition of metabolism and / or detoxification of cytotoxic radicals .
Diseases: "	"Sentence: Since AAP , AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo , the protection by GSPE may be linked to both inhibition of metabolism and / or detoxification of cytotoxic radicals .
Diseases:"
2058	In addition , its ' presumed contribution to DNA repair may be another important attribute , which played a role in the chemoprevention process .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , its ' presumed contribution to DNA repair may be another important attribute , which played a role in the chemoprevention process .
Diseases: "	"Sentence: In addition , its ' presumed contribution to DNA repair may be another important attribute , which played a role in the chemoprevention process .
Diseases:"
2059	Additionally , this may have been the first report on AMI - induced apoptotic death in the lung tissue .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Additionally , this may have been the first report on AMI - induced apoptotic death in the lung tissue .
Diseases: "	"Sentence: Additionally , this may have been the first report on AMI - induced apoptotic death in the lung tissue .
Diseases:"
2060	Taken together , these events undoubtedly establish GSPE 's abundant bioavailability , and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Taken together , these events undoubtedly establish GSPE 's abundant bioavailability , and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo .
Diseases: "	"Sentence: Taken together , these events undoubtedly establish GSPE 's abundant bioavailability , and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo .
Diseases:"
2061	Palpebral twitching in a depressed adolescent on citalopram .	B I O O B O O O O	['depressed', 'palpebral twitching']	2	7	"Sentence: Palpebral twitching in a depressed adolescent on citalopram .
Diseases: depressed, palpebral twitching"	"Sentence: Palpebral twitching in a depressed adolescent on citalopram .
Diseases:"
2062	Current estimates suggest that between 0 . 4 % and 8 . 3 % of children and adolescents are affected by major depression .	O O O O O O O O O O O O O O O O O O O O O B I O	['major depression']	1	2	"Sentence: Current estimates suggest that between 0 . 4 % and 8 . 3 % of children and adolescents are affected by major depression .
Diseases: major depression"	"Sentence: Current estimates suggest that between 0 . 4 % and 8 . 3 % of children and adolescents are affected by major depression .
Diseases:"
2063	We report a favorable response to treatment with citalopram by a 15 - year - old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment .	O O O O O O O O O O O O O O O O O O B I O O B I O O O O O O O O	['palpebral twitching', 'major depression']	2	8	"Sentence: We report a favorable response to treatment with citalopram by a 15 - year - old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment .
Diseases: palpebral twitching, major depression"	"Sentence: We report a favorable response to treatment with citalopram by a 15 - year - old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment .
Diseases:"
2064	This may have been a side effect of citalopram as it remitted with redistribution of doses .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This may have been a side effect of citalopram as it remitted with redistribution of doses .
Diseases: "	"Sentence: This may have been a side effect of citalopram as it remitted with redistribution of doses .
Diseases:"
2065	Metamizol potentiates morphine antinociception but not constipation after chronic treatment .	O O O O O O B O O O O	['constipation']	1	2	"Sentence: Metamizol potentiates morphine antinociception but not constipation after chronic treatment .
Diseases: constipation"	"Sentence: Metamizol potentiates morphine antinociception but not constipation after chronic treatment .
Diseases:"
2066	This work evaluates the antinociceptive and constipating effects of the combination of 3 . 2 mg / kg	O O O O O O B O O O O O O O O O O O	['constipating']	1	3	"Sentence: This work evaluates the antinociceptive and constipating effects of the combination of 3 . 2 mg / kg
Diseases: constipating"	"Sentence: This work evaluates the antinociceptive and constipating effects of the combination of 3 . 2 mg / kg
Diseases:"
2067	s . c . morphine with 177 . 8 mg / kg s . c .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: s . c . morphine with 177 . 8 mg / kg s . c .
Diseases: "	"Sentence: s . c . morphine with 177 . 8 mg / kg s . c .
Diseases:"
2068	metamizol in acutely and chronically treated ( once a day for 12 days )	O O O O O O O O O O O O O O	[]	0	0	"Sentence: metamizol in acutely and chronically treated ( once a day for 12 days )
Diseases: "	"Sentence: metamizol in acutely and chronically treated ( once a day for 12 days )
Diseases:"
2069	rats .	O O	[]	0	0	"Sentence: rats .
Diseases: "	"Sentence: rats .
Diseases:"
2070	On the 13th day , antinociceptive effects were assessed using a model of inflammatory nociception , pain - induced functional impairment model , and the charcoal meal test was used to evaluate the intestinal transit .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: On the 13th day , antinociceptive effects were assessed using a model of inflammatory nociception , pain - induced functional impairment model , and the charcoal meal test was used to evaluate the intestinal transit .
Diseases: pain"	"Sentence: On the 13th day , antinociceptive effects were assessed using a model of inflammatory nociception , pain - induced functional impairment model , and the charcoal meal test was used to evaluate the intestinal transit .
Diseases:"
2071	Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single ( 298 + / - 7 vs . 139 + / - 36 units area ( ua ) ; P < 0 . 001 ) and repeated administration ( 280 + / - 17 vs . 131 + / - 22 ua ; P < 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single ( 298 + / - 7 vs . 139 + / - 36 units area ( ua ) ; P < 0 . 001 ) and repeated administration ( 280 + / - 17 vs . 131 + / - 22 ua ; P < 0 . 001 ) .
Diseases: "	"Sentence: Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single ( 298 + / - 7 vs . 139 + / - 36 units area ( ua ) ; P < 0 . 001 ) and repeated administration ( 280 + / - 17 vs . 131 + / - 22 ua ; P < 0 . 001 ) .
Diseases:"
2072	Antinociceptive effect of morphine was reduced in chronically treated rats ( 39 + / - 10 vs . 18 + / - 5 au ) while the combination - induced antinociception was remained similar as an acute treatment ( 298 + / - 7 vs . 280 + / - 17 au ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Antinociceptive effect of morphine was reduced in chronically treated rats ( 39 + / - 10 vs . 18 + / - 5 au ) while the combination - induced antinociception was remained similar as an acute treatment ( 298 + / - 7 vs . 280 + / - 17 au ) .
Diseases: "	"Sentence: Antinociceptive effect of morphine was reduced in chronically treated rats ( 39 + / - 10 vs . 18 + / - 5 au ) while the combination - induced antinociception was remained similar as an acute treatment ( 298 + / - 7 vs . 280 + / - 17 au ) .
Diseases:"
2073	Acute antinociceptive effects of the combination were partially prevented by 3 . 2 mg / kg naloxone s . c .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Acute antinociceptive effects of the combination were partially prevented by 3 . 2 mg / kg naloxone s . c .
Diseases: "	"Sentence: Acute antinociceptive effects of the combination were partially prevented by 3 . 2 mg / kg naloxone s . c .
Diseases:"
2074	( P < 0 . 05 ) , suggesting the partial involvement of the opioidergic system in the synergism observed .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ( P < 0 . 05 ) , suggesting the partial involvement of the opioidergic system in the synergism observed .
Diseases: "	"Sentence: ( P < 0 . 05 ) , suggesting the partial involvement of the opioidergic system in the synergism observed .
Diseases:"
2075	In independent groups , morphine inhibited the intestinal transit in 48 + / - 4 % and 38 + / - 4 % after acute and chronic treatment , respectively , suggesting that tolerance did not develop to the constipating effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['constipating']	1	3	"Sentence: In independent groups , morphine inhibited the intestinal transit in 48 + / - 4 % and 38 + / - 4 % after acute and chronic treatment , respectively , suggesting that tolerance did not develop to the constipating effects .
Diseases: constipating"	"Sentence: In independent groups , morphine inhibited the intestinal transit in 48 + / - 4 % and 38 + / - 4 % after acute and chronic treatment , respectively , suggesting that tolerance did not develop to the constipating effects .
Diseases:"
2076	The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that metamizol did not potentiate morphine - induced constipation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['constipation']	1	2	"Sentence: The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that metamizol did not potentiate morphine - induced constipation .
Diseases: constipation"	"Sentence: The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that metamizol did not potentiate morphine - induced constipation .
Diseases:"
2077	These findings show a significant interaction between morphine and metamizol in chronically treated rats , suggesting that this combination could be useful for the treatment of chronic pain .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['chronic pain']	1	3	"Sentence: These findings show a significant interaction between morphine and metamizol in chronically treated rats , suggesting that this combination could be useful for the treatment of chronic pain .
Diseases: chronic pain"	"Sentence: These findings show a significant interaction between morphine and metamizol in chronically treated rats , suggesting that this combination could be useful for the treatment of chronic pain .
Diseases:"
2078	Ifosfamide encephalopathy presenting with asterixis .	O B O O B O	['encephalopathy', 'asterixis']	2	7	"Sentence: Ifosfamide encephalopathy presenting with asterixis .
Diseases: encephalopathy, asterixis"	"Sentence: Ifosfamide encephalopathy presenting with asterixis .
Diseases:"
2079	CNS toxic effects of the antineoplastic agent ifosfamide ( IFX ) are frequent and include a variety of neurological symptoms that can limit drug use .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CNS toxic effects of the antineoplastic agent ifosfamide ( IFX ) are frequent and include a variety of neurological symptoms that can limit drug use .
Diseases: "	"Sentence: CNS toxic effects of the antineoplastic agent ifosfamide ( IFX ) are frequent and include a variety of neurological symptoms that can limit drug use .
Diseases:"
2080	We report a case of a 51 - year - old man who developed severe , disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O B O	['plasmacytoma', 'myoclonus']	2	10	"Sentence: We report a case of a 51 - year - old man who developed severe , disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma .
Diseases: plasmacytoma, myoclonus"	"Sentence: We report a case of a 51 - year - old man who developed severe , disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma .
Diseases:"
2081	He was awake , revealed no changes of mental status and at rest there were no further motor symptoms .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: He was awake , revealed no changes of mental status and at rest there were no further motor symptoms .
Diseases: "	"Sentence: He was awake , revealed no changes of mental status and at rest there were no further motor symptoms .
Diseases:"
2082	Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities .	O O O O O O O O O O O B I I I I O B I O	['metabolic abnormalities', 'structural lesions of the brain']	2	9	"Sentence: Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities .
Diseases: metabolic abnormalities, structural lesions of the brain"	"Sentence: Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities .
Diseases:"
2083	An electroencephalogram showed continuous , generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy .	O O O O O O O O O O O O O O O B O	['encephalopathy']	1	3	"Sentence: An electroencephalogram showed continuous , generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy .
Diseases: encephalopathy"	"Sentence: An electroencephalogram showed continuous , generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy .
Diseases:"
2084	The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely .	O O O O O O O O O O O B O O O	['asterixis']	1	3	"Sentence: The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely .
Diseases: asterixis"	"Sentence: The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely .
Diseases:"
2085	In the patient described , the presence of asterixis during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['myoclonus', 'asterixis']	2	8	"Sentence: In the patient described , the presence of asterixis during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX .
Diseases: myoclonus, asterixis"	"Sentence: In the patient described , the presence of asterixis during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX .
Diseases:"
2086	Sub - chronic low dose gamma - vinyl GABA ( vigabatrin ) inhibits cocaine - induced increases in nucleus accumbens dopamine .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sub - chronic low dose gamma - vinyl GABA ( vigabatrin ) inhibits cocaine - induced increases in nucleus accumbens dopamine .
Diseases: "	"Sentence: Sub - chronic low dose gamma - vinyl GABA ( vigabatrin ) inhibits cocaine - induced increases in nucleus accumbens dopamine .
Diseases:"
2087	RATIONALE : gamma - Vinyl GABA ( GVG ) irreversibly inhibits GABA - transaminase .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RATIONALE : gamma - Vinyl GABA ( GVG ) irreversibly inhibits GABA - transaminase .
Diseases: "	"Sentence: RATIONALE : gamma - Vinyl GABA ( GVG ) irreversibly inhibits GABA - transaminase .
Diseases:"
2088	This non - receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This non - receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism .
Diseases: "	"Sentence: This non - receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism .
Diseases:"
2089	Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .	O O O O O O B I O O O O O B I I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['substance abuse', 'vfd', 'visual field defects']	3	11	"Sentence: Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
Diseases: substance abuse, vfd, visual field defects"	"Sentence: Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .
Diseases:"
2090	METHODS : Using in vivo microdialysis , we compared acute exposure ( 450 mg / kg ) to an identical sub - chronic exposure ( 150 mg / kg per day for 3 days ) , followed by 1 - or 3 - day washout .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Using in vivo microdialysis , we compared acute exposure ( 450 mg / kg ) to an identical sub - chronic exposure ( 150 mg / kg per day for 3 days ) , followed by 1 - or 3 - day washout .
Diseases: "	"Sentence: METHODS : Using in vivo microdialysis , we compared acute exposure ( 450 mg / kg ) to an identical sub - chronic exposure ( 150 mg / kg per day for 3 days ) , followed by 1 - or 3 - day washout .
Diseases:"
2091	Finally , we examined the low dose of 150 mg / kg ( 50 mg / kg per day ) using a similar washout period .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Finally , we examined the low dose of 150 mg / kg ( 50 mg / kg per day ) using a similar washout period .
Diseases: "	"Sentence: Finally , we examined the low dose of 150 mg / kg ( 50 mg / kg per day ) using a similar washout period .
Diseases:"
2092	Sub - chronic GVG exposure inhibited the effect of cocaine for 3 days , which exceeded in magnitude and duration the identical acute dose .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sub - chronic GVG exposure inhibited the effect of cocaine for 3 days , which exceeded in magnitude and duration the identical acute dose .
Diseases: "	"Sentence: Sub - chronic GVG exposure inhibited the effect of cocaine for 3 days , which exceeded in magnitude and duration the identical acute dose .
Diseases:"
2093	CONCLUSIONS : Sub - chronic low dose GVG potentiates and extends the inhibition of cocaine - induced increases in dopamine , effectively reducing cumulative exposures and the risk for VFDS .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : Sub - chronic low dose GVG potentiates and extends the inhibition of cocaine - induced increases in dopamine , effectively reducing cumulative exposures and the risk for VFDS .
Diseases: "	"Sentence: CONCLUSIONS : Sub - chronic low dose GVG potentiates and extends the inhibition of cocaine - induced increases in dopamine , effectively reducing cumulative exposures and the risk for VFDS .
Diseases:"
2094	Amount of bleeding and hematoma size in the collagenase - induced intracerebral hemorrhage rat model .	O O B O B O O O O O O B I O O O	['hematoma', 'intracerebral hemorrhage', 'bleeding']	3	11	"Sentence: Amount of bleeding and hematoma size in the collagenase - induced intracerebral hemorrhage rat model .
Diseases: hematoma, intracerebral hemorrhage, bleeding"	"Sentence: Amount of bleeding and hematoma size in the collagenase - induced intracerebral hemorrhage rat model .
Diseases:"
2095	The aggravated risk on intracerebral hemorrhage ( ICH ) with drugs used for stroke patients should be estimated carefully .	O O O O B I O B O O O O O B O O O O O O	['stroke', 'ich', 'intracerebral hemorrhage']	3	11	"Sentence: The aggravated risk on intracerebral hemorrhage ( ICH ) with drugs used for stroke patients should be estimated carefully .
Diseases: stroke, ich, intracerebral hemorrhage"	"Sentence: The aggravated risk on intracerebral hemorrhage ( ICH ) with drugs used for stroke patients should be estimated carefully .
Diseases:"
2096	We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration .	O O O O O O O O O O B O O O O B O O	['ich']	1	1	"Sentence: We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration .
Diseases: ich"	"Sentence: We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration .
Diseases:"
2097	In ICH intrastriatally induced by 0 . 014 - unit , 0 . 070 - unit , and 0 . 350 - unit collagenase , the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O	['hematoma', 'ich', 'bleeding']	3	7	"Sentence: In ICH intrastriatally induced by 0 . 014 - unit , 0 . 070 - unit , and 0 . 350 - unit collagenase , the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume .
Diseases: hematoma, ich, bleeding"	"Sentence: In ICH intrastriatally induced by 0 . 014 - unit , 0 . 070 - unit , and 0 . 350 - unit collagenase , the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume .
Diseases:"
2098	The blood amounts and hematoma volumes were significantly correlated , and the hematoma induced by 0 . 014 - unit collagenase was adequate to detect ICH deterioration .	O O O O B O O O O O O O B O O O O O O O O O O O O B O O	['hematoma', 'ich']	2	5	"Sentence: The blood amounts and hematoma volumes were significantly correlated , and the hematoma induced by 0 . 014 - unit collagenase was adequate to detect ICH deterioration .
Diseases: hematoma, ich"	"Sentence: The blood amounts and hematoma volumes were significantly correlated , and the hematoma induced by 0 . 014 - unit collagenase was adequate to detect ICH deterioration .
Diseases:"
2099	In ICH induction using 0 . 014 - unit collagenase , heparin enhanced the hematoma volume 3 . 4 - fold over that seen in control ICH animals and the bleeding 7 . 6 - fold .	O B O O O O O O O O O O O O B O O O O O O O O O O O B O O O B O O O O O O	['hematoma', 'ich', 'bleeding']	3	7	"Sentence: In ICH induction using 0 . 014 - unit collagenase , heparin enhanced the hematoma volume 3 . 4 - fold over that seen in control ICH animals and the bleeding 7 . 6 - fold .
Diseases: hematoma, ich, bleeding"	"Sentence: In ICH induction using 0 . 014 - unit collagenase , heparin enhanced the hematoma volume 3 . 4 - fold over that seen in control ICH animals and the bleeding 7 . 6 - fold .
Diseases:"
2100	Data suggest that this sensitive hemoglobin assay is useful for ICH detection , and that a model with a small ICH induced with a low - dose collagenase should be used for evaluation of drugs that may affect ICH .	O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O B O	['ich']	1	1	"Sentence: Data suggest that this sensitive hemoglobin assay is useful for ICH detection , and that a model with a small ICH induced with a low - dose collagenase should be used for evaluation of drugs that may affect ICH .
Diseases: ich"	"Sentence: Data suggest that this sensitive hemoglobin assay is useful for ICH detection , and that a model with a small ICH induced with a low - dose collagenase should be used for evaluation of drugs that may affect ICH .
Diseases:"
2101	Estradiol reduces seizure - induced hippocampal injury in ovariectomized female but not in male rats .	O O B O O B I O O O O O O O O O	['hippocampal injury', 'seizure']	2	7	"Sentence: Estradiol reduces seizure - induced hippocampal injury in ovariectomized female but not in male rats .
Diseases: hippocampal injury, seizure"	"Sentence: Estradiol reduces seizure - induced hippocampal injury in ovariectomized female but not in male rats .
Diseases:"
2102	Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid - induced status epilepticus ( SE ) .	O O O O O B I O O O O O O B I O B O O	['se', 'hippocampal injury', 'status epilepticus']	3	10	"Sentence: Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid - induced status epilepticus ( SE ) .
Diseases: se, hippocampal injury, status epilepticus"	"Sentence: Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid - induced status epilepticus ( SE ) .
Diseases:"
2103	We compared the effects of 17beta - estradiol in adult male and ovariectomized female rats subjected to lithium - pilocarpine - induced SE .	O O O O O O O O O O O O O O O O O O O O O O B O	['se']	1	1	"Sentence: We compared the effects of 17beta - estradiol in adult male and ovariectomized female rats subjected to lithium - pilocarpine - induced SE .
Diseases: se"	"Sentence: We compared the effects of 17beta - estradiol in adult male and ovariectomized female rats subjected to lithium - pilocarpine - induced SE .
Diseases:"
2104	Rats received subcutaneous injections of 17beta - estradiol ( 2 microg / rat ) or oil once daily for four consecutive days .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Rats received subcutaneous injections of 17beta - estradiol ( 2 microg / rat ) or oil once daily for four consecutive days .
Diseases: "	"Sentence: Rats received subcutaneous injections of 17beta - estradiol ( 2 microg / rat ) or oil once daily for four consecutive days .
Diseases:"
2105	SE was induced 20 h following the second injection and terminated 3 h later .	B O O O O O O O O O O O O O O	['se']	1	1	"Sentence: SE was induced 20 h following the second injection and terminated 3 h later .
Diseases: se"	"Sentence: SE was induced 20 h following the second injection and terminated 3 h later .
Diseases:"
2106	The extent of silver - stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE .	O O O O O O O O O O O O O O O O B O	['se']	1	1	"Sentence: The extent of silver - stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE .
Diseases: se"	"Sentence: The extent of silver - stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE .
Diseases:"
2107	17beta - Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 17beta - Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males .
Diseases: "	"Sentence: 17beta - Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males .
Diseases:"
2108	17beta - Estradiol reduced the argyrophilic neurons in the CA1 and CA3 - C sectors of ovariectomized rats .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 17beta - Estradiol reduced the argyrophilic neurons in the CA1 and CA3 - C sectors of ovariectomized rats .
Diseases: "	"Sentence: 17beta - Estradiol reduced the argyrophilic neurons in the CA1 and CA3 - C sectors of ovariectomized rats .
Diseases:"
2109	In males , estradiol increased the total damage score .	O O O O O O O O O O	[]	0	0	"Sentence: In males , estradiol increased the total damage score .
Diseases: "	"Sentence: In males , estradiol increased the total damage score .
Diseases:"
2110	These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex - related differences in the hormonal environment .	O O O O O O O O O B O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex - related differences in the hormonal environment .
Diseases: seizure"	"Sentence: These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex - related differences in the hormonal environment .
Diseases:"
2111	Delirium during clozapine treatment : incidence and associated risk factors .	B O O O O O O O O O O	['delirium']	1	3	"Sentence: Delirium during clozapine treatment : incidence and associated risk factors .
Diseases: delirium"	"Sentence: Delirium during clozapine treatment : incidence and associated risk factors .
Diseases:"
2112	Incidence and risk factors for delirium during clozapine treatment require further clarification .	O O O O O B O O O O O O O	['delirium']	1	3	"Sentence: Incidence and risk factors for delirium during clozapine treatment require further clarification .
Diseases: delirium"	"Sentence: Incidence and risk factors for delirium during clozapine treatment require further clarification .
Diseases:"
2113	METHODS : We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of delirium , and tested associations with potential risk factors .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['delirium', 'psychiatric']	2	5	"Sentence: METHODS : We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of delirium , and tested associations with potential risk factors .
Diseases: delirium, psychiatric"	"Sentence: METHODS : We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of delirium , and tested associations with potential risk factors .
Diseases:"
2114	RESULTS : Subjects ( n = 139 ) were 72 women and 67 men , aged 40 . 8 + / - 12 . 1 years , hospitalized for 24 . 9 + / - 23 . 3 days , and given clozapine , gradually increased to an average daily dose of 282 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RESULTS : Subjects ( n = 139 ) were 72 women and 67 men , aged 40 . 8 + / - 12 . 1 years , hospitalized for 24 . 9 + / - 23 . 3 days , and given clozapine , gradually increased to an average daily dose of 282 + / -
Diseases: "	"Sentence: RESULTS : Subjects ( n = 139 ) were 72 women and 67 men , aged 40 . 8 + / - 12 . 1 years , hospitalized for 24 . 9 + / - 23 . 3 days , and given clozapine , gradually increased to an average daily dose of 282 + / -
Diseases:"
2115	203 mg ( 3 . 45 + / - 2 . 45 mg / kg ) for 18 . 9 + / - 16 . 4 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 203 mg ( 3 . 45 + / - 2 . 45 mg / kg ) for 18 . 9 + / - 16 . 4 days .
Diseases: "	"Sentence: 203 mg ( 3 . 45 + / - 2 . 45 mg / kg ) for 18 . 9 + / - 16 . 4 days .
Diseases:"
2116	Delirium was diagnosed in 14 ( 10 . 1 % incidence , or 1 . 48 cases / person - years of exposure ) ; 71 . 4 % of cases were moderate or severe .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['delirium']	1	3	"Sentence: Delirium was diagnosed in 14 ( 10 . 1 % incidence , or 1 . 48 cases / person - years of exposure ) ; 71 . 4 % of cases were moderate or severe .
Diseases: delirium"	"Sentence: Delirium was diagnosed in 14 ( 10 . 1 % incidence , or 1 . 48 cases / person - years of exposure ) ; 71 . 4 % of cases were moderate or severe .
Diseases:"
2117	Associated factors were co - treatment with other centrally antimuscarinic agents , poor clinical outcome , older age , and longer hospitalization ( by 17 . 5 days , increasing cost ) ; sex , diagnosis or medical co - morbidity , and daily clozapine dose , which fell with age , were unrelated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Associated factors were co - treatment with other centrally antimuscarinic agents , poor clinical outcome , older age , and longer hospitalization ( by 17 . 5 days , increasing cost ) ; sex , diagnosis or medical co - morbidity , and daily clozapine dose , which fell with age , were unrelated .
Diseases: "	"Sentence: Associated factors were co - treatment with other centrally antimuscarinic agents , poor clinical outcome , older age , and longer hospitalization ( by 17 . 5 days , increasing cost ) ; sex , diagnosis or medical co - morbidity , and daily clozapine dose , which fell with age , were unrelated .
Diseases:"
2118	CONCLUSIONS : Delirium was found in 10 % of clozapine - treated inpatients , particularly in older patients exposed to other central anticholinergics .	O O B O O O O O O O O O O O O O O O O O O O O O	['delirium']	1	3	"Sentence: CONCLUSIONS : Delirium was found in 10 % of clozapine - treated inpatients , particularly in older patients exposed to other central anticholinergics .
Diseases: delirium"	"Sentence: CONCLUSIONS : Delirium was found in 10 % of clozapine - treated inpatients , particularly in older patients exposed to other central anticholinergics .
Diseases:"
2119	Delirium was inconsistently recognized clinically in milder cases and was associated with increased length - of - stay and higher costs , and inferior clinical outcome .	B O O O O O O O O O O O O O O O O O O O O O O O O O O	['delirium']	1	3	"Sentence: Delirium was inconsistently recognized clinically in milder cases and was associated with increased length - of - stay and higher costs , and inferior clinical outcome .
Diseases: delirium"	"Sentence: Delirium was inconsistently recognized clinically in milder cases and was associated with increased length - of - stay and higher costs , and inferior clinical outcome .
Diseases:"
2120	Ketoconazole - induced neurologic sequelae .	O O O B I O	['neurologic sequelae']	1	6	"Sentence: Ketoconazole - induced neurologic sequelae .
Diseases: neurologic sequelae"	"Sentence: Ketoconazole - induced neurologic sequelae .
Diseases:"
2121	A 77 - y - old patient developed weakness of extremities , legs paralysis , dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life .	O O O O O O O O B I I O B I O B O B O O O O O O O O O O O O O O O O	['weakness of extremities', 'dysarthria', 'legs paralysis', 'tremor']	4	15	"Sentence: A 77 - y - old patient developed weakness of extremities , legs paralysis , dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life .
Diseases: weakness of extremities, dysarthria, legs paralysis, tremor"	"Sentence: A 77 - y - old patient developed weakness of extremities , legs paralysis , dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life .
Diseases:"
2122	All complaints faded away within 24 h . Few days later , the patient used another 200 mg ketoconazole tablet , and within an hour experienced a similar clinical picture , which resolved again spontaneously within hours .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All complaints faded away within 24 h . Few days later , the patient used another 200 mg ketoconazole tablet , and within an hour experienced a similar clinical picture , which resolved again spontaneously within hours .
Diseases: "	"Sentence: All complaints faded away within 24 h . Few days later , the patient used another 200 mg ketoconazole tablet , and within an hour experienced a similar clinical picture , which resolved again spontaneously within hours .
Diseases:"
2123	Laboratory evaluations , including head CT scan , were normal .	O O O O O O O O O O O	[]	0	0	"Sentence: Laboratory evaluations , including head CT scan , were normal .
Diseases: "	"Sentence: Laboratory evaluations , including head CT scan , were normal .
Diseases:"
2124	This case illustrates the need for close vigilance in adverse drug reactions , particularly in the elderly .	O O O O O O O O O B I I O O O O O O	['adverse drug reactions']	1	4	"Sentence: This case illustrates the need for close vigilance in adverse drug reactions , particularly in the elderly .
Diseases: adverse drug reactions"	"Sentence: This case illustrates the need for close vigilance in adverse drug reactions , particularly in the elderly .
Diseases:"
2125	Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino - parasympathetic reflex - - an experimental model for vascular dysfunctions in cluster headache .	O O O O O O O O O O O O O O O O O O O O O O O B I O B I O	['vascular dysfunctions', 'cluster headache']	2	8	"Sentence: Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino - parasympathetic reflex - - an experimental model for vascular dysfunctions in cluster headache .
Diseases: vascular dysfunctions, cluster headache"	"Sentence: Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino - parasympathetic reflex - - an experimental model for vascular dysfunctions in cluster headache .
Diseases:"
2126	Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances .	B I O O O O O O O O O B I I O	['intracranial vascular disturbances', 'cluster headache']	2	9	"Sentence: Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances .
Diseases: intracranial vascular disturbances, cluster headache"	"Sentence: Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances .
Diseases:"
2127	Both the trigeminal and the cranial parasympathetic systems may be involved in mediating these dysfunctions .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Both the trigeminal and the cranial parasympathetic systems may be involved in mediating these dysfunctions .
Diseases: "	"Sentence: Both the trigeminal and the cranial parasympathetic systems may be involved in mediating these dysfunctions .
Diseases:"
2128	An experimental model was developed in the rat to measure changes in lacrimation and intracranial blood flow following noxious chemical stimulation of facial mucosa .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An experimental model was developed in the rat to measure changes in lacrimation and intracranial blood flow following noxious chemical stimulation of facial mucosa .
Diseases: "	"Sentence: An experimental model was developed in the rat to measure changes in lacrimation and intracranial blood flow following noxious chemical stimulation of facial mucosa .
Diseases:"
2129	Blood flow was monitored in arteries of the exposed cranial dura mater and the parietal cortex using laser Doppler flowmetry .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Blood flow was monitored in arteries of the exposed cranial dura mater and the parietal cortex using laser Doppler flowmetry .
Diseases: "	"Sentence: Blood flow was monitored in arteries of the exposed cranial dura mater and the parietal cortex using laser Doppler flowmetry .
Diseases:"
2130	Capsaicin ( 0 . 01 - 1 mm ) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation .	O O O O O O O O O O O O O O O O B I I I I I I O O O O	['increases in dural and cortical blood flow']	1	9	"Sentence: Capsaicin ( 0 . 01 - 1 mm ) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation .
Diseases: increases in dural and cortical blood flow"	"Sentence: Capsaicin ( 0 . 01 - 1 mm ) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation .
Diseases:"
2131	These responses were blocked by systemic pre - administration of hexamethonium chloride ( 20 mg / kg ) .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These responses were blocked by systemic pre - administration of hexamethonium chloride ( 20 mg / kg ) .
Diseases: "	"Sentence: These responses were blocked by systemic pre - administration of hexamethonium chloride ( 20 mg / kg ) .
Diseases:"
2132	The evoked increases in dural blood flow were also abolished by topical pre - administration of atropine ( 1 mm ) and [ Lys1 , Pro2 , 5 , Arg3 , 4 , Tyr6 ] - VIP ( 0 . 1 mm ) , a vasoactive intestinal polypeptide ( VIP ) antagonist , onto the exposed dura mater .	O O B I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['increases in dural blood flow']	1	7	"Sentence: The evoked increases in dural blood flow were also abolished by topical pre - administration of atropine ( 1 mm ) and [ Lys1 , Pro2 , 5 , Arg3 , 4 , Tyr6 ] - VIP ( 0 . 1 mm ) , a vasoactive intestinal polypeptide ( VIP ) antagonist , onto the exposed dura mater .
Diseases: increases in dural blood flow"	"Sentence: The evoked increases in dural blood flow were also abolished by topical pre - administration of atropine ( 1 mm ) and [ Lys1 , Pro2 , 5 , Arg3 , 4 , Tyr6 ] - VIP ( 0 . 1 mm ) , a vasoactive intestinal polypeptide ( VIP ) antagonist , onto the exposed dura mater .
Diseases:"
2133	We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino - parasympathetic reflex .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino - parasympathetic reflex .
Diseases: "	"Sentence: We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino - parasympathetic reflex .
Diseases:"
2134	The blood flow responses seem to be mediated by the release of acetylcholine and VIP within the meninges .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The blood flow responses seem to be mediated by the release of acetylcholine and VIP within the meninges .
Diseases: "	"Sentence: The blood flow responses seem to be mediated by the release of acetylcholine and VIP within the meninges .
Diseases:"
2135	Similar mechanisms may be involved in the pathogenesis of cluster headache .	O O O O O O O O O B I O	['cluster headache']	1	3	"Sentence: Similar mechanisms may be involved in the pathogenesis of cluster headache .
Diseases: cluster headache"	"Sentence: Similar mechanisms may be involved in the pathogenesis of cluster headache .
Diseases:"
2136	Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy .	O O O O O O O O O O O B I I O	['temporal lobe epilepsy']	1	4	"Sentence: Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy .
Diseases: temporal lobe epilepsy"	"Sentence: Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy .
Diseases:"
2137	Similar to rats , systemic pilocarpine injection causes status epilepticus ( SE ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL / 6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .	O O O O O O O O B I O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['se', 'status epilepticus', 'seizures']	3	8	"Sentence: Similar to rats , systemic pilocarpine injection causes status epilepticus ( SE ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL / 6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .
Diseases: se, status epilepticus, seizures"	"Sentence: Similar to rats , systemic pilocarpine injection causes status epilepticus ( SE ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL / 6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .
Diseases:"
2138	Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine - treated and untreated mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine - treated and untreated mice .
Diseases: "	"Sentence: Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine - treated and untreated mice .
Diseases:"
2139	In Mg ( 2 + ) - free bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine - treated mice that did not experience SE .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['se']	1	1	"Sentence: In Mg ( 2 + ) - free bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine - treated mice that did not experience SE .
Diseases: se"	"Sentence: In Mg ( 2 + ) - free bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine - treated mice that did not experience SE .
Diseases:"
2140	In SE survivors , similar stimulation resulted in a population spike followed , at a variable latency , by negative DC shifts and repetitive afterdischarges of 3 - 60 s duration , which were blocked by ionotropic glutamate receptor antagonists .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['se']	1	1	"Sentence: In SE survivors , similar stimulation resulted in a population spike followed , at a variable latency , by negative DC shifts and repetitive afterdischarges of 3 - 60 s duration , which were blocked by ionotropic glutamate receptor antagonists .
Diseases: se"	"Sentence: In SE survivors , similar stimulation resulted in a population spike followed , at a variable latency , by negative DC shifts and repetitive afterdischarges of 3 - 60 s duration , which were blocked by ionotropic glutamate receptor antagonists .
Diseases:"
2141	Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1 - 30 s duration in slices from SE survivors but not other groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['se']	1	1	"Sentence: Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1 - 30 s duration in slices from SE survivors but not other groups .
Diseases: se"	"Sentence: Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1 - 30 s duration in slices from SE survivors but not other groups .
Diseases:"
2142	These data support the hypothesis that SE - induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains , resembling rat models of human temporal lobe epilepsy .	O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O B I I O	['se', 'temporal lobe epilepsy', 'seizure']	3	7	"Sentence: These data support the hypothesis that SE - induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains , resembling rat models of human temporal lobe epilepsy .
Diseases: se, temporal lobe epilepsy, seizure"	"Sentence: These data support the hypothesis that SE - induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains , resembling rat models of human temporal lobe epilepsy .
Diseases:"
2143	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine - induced seizures and hypolocomotion in mice .	O O O O O O O O O O O O O O B O B O O O	['hypolocomotion', 'seizures']	2	6	"Sentence: The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine - induced seizures and hypolocomotion in mice .
Diseases: hypolocomotion, seizures"	"Sentence: The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine - induced seizures and hypolocomotion in mice .
Diseases:"
2144	Binding of nicotine to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and death .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B O B O	['tremors', 'seizures', 'death']	3	7	"Sentence: Binding of nicotine to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and death .
Diseases: tremors, seizures, death"	"Sentence: Binding of nicotine to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and death .
Diseases:"
2145	nAChRs are pentameric ion channels usually composed of alpha and beta subunits .	O O O O O O O O O O O O O	[]	0	0	"Sentence: nAChRs are pentameric ion channels usually composed of alpha and beta subunits .
Diseases: "	"Sentence: nAChRs are pentameric ion channels usually composed of alpha and beta subunits .
Diseases:"
2146	A gene cluster comprises the alpha3 , alpha5 and beta4 subunits , which coassemble to form functional receptors .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A gene cluster comprises the alpha3 , alpha5 and beta4 subunits , which coassemble to form functional receptors .
Diseases: "	"Sentence: A gene cluster comprises the alpha3 , alpha5 and beta4 subunits , which coassemble to form functional receptors .
Diseases:"
2147	We examined the role of the beta4 subunits in nicotine - induced seizures and hypolocomotion in beta4 homozygous	O O O O O O O O O O O O B O B O O O	['hypolocomotion', 'seizures']	2	6	"Sentence: We examined the role of the beta4 subunits in nicotine - induced seizures and hypolocomotion in beta4 homozygous
Diseases: hypolocomotion, seizures"	"Sentence: We examined the role of the beta4 subunits in nicotine - induced seizures and hypolocomotion in beta4 homozygous
Diseases:"
2148	( beta4 - / - ) and alpha3 heterozygous ( + / - ) mice .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ( beta4 - / - ) and alpha3 heterozygous ( + / - ) mice .
Diseases: "	"Sentence: ( beta4 - / - ) and alpha3 heterozygous ( + / - ) mice .
Diseases:"
2149	beta4 - / - mice were less sensitive to the effects of nicotine both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to nicotine - induced seizures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: beta4 - / - mice were less sensitive to the effects of nicotine both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to nicotine - induced seizures .
Diseases: seizures"	"Sentence: beta4 - / - mice were less sensitive to the effects of nicotine both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to nicotine - induced seizures .
Diseases:"
2150	Using in situ hybridization probes for the alpha3 and alpha5 subunits , we showed that alpha5 mRNA levels are unchanged , whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb , and the inferior and the superior colliculus of beta4 - / - brains .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Using in situ hybridization probes for the alpha3 and alpha5 subunits , we showed that alpha5 mRNA levels are unchanged , whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb , and the inferior and the superior colliculus of beta4 - / - brains .
Diseases: "	"Sentence: Using in situ hybridization probes for the alpha3 and alpha5 subunits , we showed that alpha5 mRNA levels are unchanged , whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb , and the inferior and the superior colliculus of beta4 - / - brains .
Diseases:"
2151	alpha3 + / -	O O O O	[]	0	0	"Sentence: alpha3 + / -
Diseases: "	"Sentence: alpha3 + / -
Diseases:"
2152	mice were partially resistant to nicotine - induced seizures when compared to wild - type littermates .	O O O O O O O O B O O O O O O O O	['seizures']	1	3	"Sentence: mice were partially resistant to nicotine - induced seizures when compared to wild - type littermates .
Diseases: seizures"	"Sentence: mice were partially resistant to nicotine - induced seizures when compared to wild - type littermates .
Diseases:"
2153	mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 + / - brains .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 + / - brains .
Diseases: "	"Sentence: mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 + / - brains .
Diseases:"
2154	Together , these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine - induced seizures and hypolocomotion .	O O O O O O O O O O O O O O O O O O B O B O	['hypolocomotion', 'seizures']	2	6	"Sentence: Together , these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine - induced seizures and hypolocomotion .
Diseases: hypolocomotion, seizures"	"Sentence: Together , these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine - induced seizures and hypolocomotion .
Diseases:"
2155	Recurrent acute interstitial nephritis induced by azithromycin .	O O B I O O O O	['interstitial nephritis']	1	4	"Sentence: Recurrent acute interstitial nephritis induced by azithromycin .
Diseases: interstitial nephritis"	"Sentence: Recurrent acute interstitial nephritis induced by azithromycin .
Diseases:"
2156	A 14 - year - old girl is reported with recurrent , azithromycin - induced , acute interstitial nephritis .	O O O O O O O O O O O O O O O O O B I O	['interstitial nephritis']	1	4	"Sentence: A 14 - year - old girl is reported with recurrent , azithromycin - induced , acute interstitial nephritis .
Diseases: interstitial nephritis"	"Sentence: A 14 - year - old girl is reported with recurrent , azithromycin - induced , acute interstitial nephritis .
Diseases:"
2157	The second episode was more severe than the first ; and although both were treated with intensive corticosteroid therapy , renal function remained impaired .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The second episode was more severe than the first ; and although both were treated with intensive corticosteroid therapy , renal function remained impaired .
Diseases: "	"Sentence: The second episode was more severe than the first ; and although both were treated with intensive corticosteroid therapy , renal function remained impaired .
Diseases:"
2158	Although most cases of antibiotic induced acute interstitial nephritis are benign and self - limited , some patients are at risk for permanent renal injury .	O O O O O O O B I O O O O O O O O O O O O O O B I O	['renal injury', 'interstitial nephritis']	2	9	"Sentence: Although most cases of antibiotic induced acute interstitial nephritis are benign and self - limited , some patients are at risk for permanent renal injury .
Diseases: renal injury, interstitial nephritis"	"Sentence: Although most cases of antibiotic induced acute interstitial nephritis are benign and self - limited , some patients are at risk for permanent renal injury .
Diseases:"
2159	Valproate - induced encephalopathy .	O O O B O	['encephalopathy']	1	3	"Sentence: Valproate - induced encephalopathy .
Diseases: encephalopathy"	"Sentence: Valproate - induced encephalopathy .
Diseases:"
2160	Valproate - induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals .	O O O B O O O O O O O O O O B O O	['encephalopathy', 'epileptic']	2	6	"Sentence: Valproate - induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals .
Diseases: encephalopathy, epileptic"	"Sentence: Valproate - induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals .
Diseases:"
2161	It may even present in patients who have tolerated this medicine well in the past .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It may even present in patients who have tolerated this medicine well in the past .
Diseases: "	"Sentence: It may even present in patients who have tolerated this medicine well in the past .
Diseases:"
2162	It is usually but not necessarily associated with hyperammonemia .	O O O O O O O O B O	['hyperammonemia']	1	4	"Sentence: It is usually but not necessarily associated with hyperammonemia .
Diseases: hyperammonemia"	"Sentence: It is usually but not necessarily associated with hyperammonemia .
Diseases:"
2163	The EEG shows characteristic triphasic waves in most patients with this complication .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The EEG shows characteristic triphasic waves in most patients with this complication .
Diseases: "	"Sentence: The EEG shows characteristic triphasic waves in most patients with this complication .
Diseases:"
2164	A case of valproate - induced encephalopathy is presented .	O O O O O O B O O O	['encephalopathy']	1	3	"Sentence: A case of valproate - induced encephalopathy is presented .
Diseases: encephalopathy"	"Sentence: A case of valproate - induced encephalopathy is presented .
Diseases:"
2165	The problems in diagnosing this condition are subsequently discussed .	O O O O O O O O O O	[]	0	0	"Sentence: The problems in diagnosing this condition are subsequently discussed .
Diseases: "	"Sentence: The problems in diagnosing this condition are subsequently discussed .
Diseases:"
2166	Nitro - L - arginine methyl ester : a potential protector against gentamicin ototoxicity .	O O O O O O O O O O O O O B O	['ototoxicity']	1	3	"Sentence: Nitro - L - arginine methyl ester : a potential protector against gentamicin ototoxicity .
Diseases: ototoxicity"	"Sentence: Nitro - L - arginine methyl ester : a potential protector against gentamicin ototoxicity .
Diseases:"
2167	The nitric oxide ( NO ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against high - frequency hearing loss caused by gentamicin , but further studies are needed to confirm this .	O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I O O O O O O O O O O O O O	['high - frequency hearing loss']	1	5	"Sentence: The nitric oxide ( NO ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against high - frequency hearing loss caused by gentamicin , but further studies are needed to confirm this .
Diseases: high - frequency hearing loss"	"Sentence: The nitric oxide ( NO ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against high - frequency hearing loss caused by gentamicin , but further studies are needed to confirm this .
Diseases:"
2168	Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .
Diseases: "	"Sentence: Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .
Diseases:"
2169	Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .	O B O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B I I O	['sensorineural hearing loss', 'ototoxicity', 'ototoxic']	3	14	"Sentence: Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .
Diseases: sensorineural hearing loss, ototoxicity, ototoxic"	"Sentence: Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .
Diseases:"
2170	In this experimental study we used 30 Sprague - Dawley rats , 27 of which had gentamicin instilled into the middle ear .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In this experimental study we used 30 Sprague - Dawley rats , 27 of which had gentamicin instilled into the middle ear .
Diseases: "	"Sentence: In this experimental study we used 30 Sprague - Dawley rats , 27 of which had gentamicin instilled into the middle ear .
Diseases:"
2171	The otoprotectant L - NAME was administered topically to 12 / 27 animals .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The otoprotectant L - NAME was administered topically to 12 / 27 animals .
Diseases: "	"Sentence: The otoprotectant L - NAME was administered topically to 12 / 27 animals .
Diseases:"
2172	Its effect was determined in terms of attenuation of hearing loss , measured by shifts in the auditory brainstem response threshold .	O O O O O O O O O B I O O O O O O O O O O O	['hearing loss']	1	3	"Sentence: Its effect was determined in terms of attenuation of hearing loss , measured by shifts in the auditory brainstem response threshold .
Diseases: hearing loss"	"Sentence: Its effect was determined in terms of attenuation of hearing loss , measured by shifts in the auditory brainstem response threshold .
Diseases:"
2173	L - NAME reduced gentamicin - induced hearing loss in the high - frequency range , but gave no protection in the middle or low frequencies .	O O O O O O O B I O O O O O O O O O O O O O O O O O O	['hearing loss']	1	3	"Sentence: L - NAME reduced gentamicin - induced hearing loss in the high - frequency range , but gave no protection in the middle or low frequencies .
Diseases: hearing loss"	"Sentence: L - NAME reduced gentamicin - induced hearing loss in the high - frequency range , but gave no protection in the middle or low frequencies .
Diseases:"
2174	Cerebral vasculitis following oral methylphenidate intake in an adult : a case report .	B I O O O O O O O O O O O O	['cerebral vasculitis']	1	6	"Sentence: Cerebral vasculitis following oral methylphenidate intake in an adult : a case report .
Diseases: cerebral vasculitis"	"Sentence: Cerebral vasculitis following oral methylphenidate intake in an adult : a case report .
Diseases:"
2175	Methylphenidate is structurally and functionally similar to amphetamine .	O O O O O O O O O	[]	0	0	"Sentence: Methylphenidate is structurally and functionally similar to amphetamine .
Diseases: "	"Sentence: Methylphenidate is structurally and functionally similar to amphetamine .
Diseases:"
2176	Cerebral vasculitis associated with amphetamine abuse is well documented , and in rare cases ischaemic stroke has been reported after methylphenidate intake in children .	B I O O B I O O O O O O O O B I O O O O O O O O O	['amphetamine abuse', 'cerebral vasculitis', 'ischaemic stroke']	3	12	"Sentence: Cerebral vasculitis associated with amphetamine abuse is well documented , and in rare cases ischaemic stroke has been reported after methylphenidate intake in children .
Diseases: amphetamine abuse, cerebral vasculitis, ischaemic stroke"	"Sentence: Cerebral vasculitis associated with amphetamine abuse is well documented , and in rare cases ischaemic stroke has been reported after methylphenidate intake in children .
Diseases:"
2177	We report the case of a 63 - year - old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes .	O O O O O O O O O O O O O O O O O O O B O O O O B I O	['hyperactivity', 'ischaemic strokes']	2	7	"Sentence: We report the case of a 63 - year - old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes .
Diseases: hyperactivity, ischaemic strokes"	"Sentence: We report the case of a 63 - year - old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes .
Diseases:"
2178	We consider drug - induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work - up .	O O O O O B I O O O O O O O B I O O O O O O O O O O O O O O	['ischaemic strokes', 'cerebral vasculitis']	2	9	"Sentence: We consider drug - induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work - up .
Diseases: ischaemic strokes, cerebral vasculitis"	"Sentence: We consider drug - induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work - up .
Diseases:"
2179	We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy .	O O O O O B O O O O O O O O O O O O O O O	['vasculitis']	1	3	"Sentence: We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy .
Diseases: vasculitis"	"Sentence: We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy .
Diseases:"
2180	This potential side - effect , though very rare , represents one more reason to be very restrictive in the use of methylphenidate .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This potential side - effect , though very rare , represents one more reason to be very restrictive in the use of methylphenidate .
Diseases: "	"Sentence: This potential side - effect , though very rare , represents one more reason to be very restrictive in the use of methylphenidate .
Diseases:"
2181	Cerebral haemorrhage induced by warfarin - the influence of drug - drug interactions .	B I O O O O O O O O O O O O	['cerebral haemorrhage']	1	8	"Sentence: Cerebral haemorrhage induced by warfarin - the influence of drug - drug interactions .
Diseases: cerebral haemorrhage"	"Sentence: Cerebral haemorrhage induced by warfarin - the influence of drug - drug interactions .
Diseases:"
2182	PURPOSE :	O O	[]	0	0	"Sentence: PURPOSE :
Diseases: "	"Sentence: PURPOSE :
Diseases:"
2183	To evaluate the frequency , severity and preventability of warfarin - induced cerebral haemorrhages due to warfarin and warfarin - drug interactions in patients living in the county of Osterg tland , Sweden .	O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O	['cerebral haemorrhages']	1	8	"Sentence: To evaluate the frequency , severity and preventability of warfarin - induced cerebral haemorrhages due to warfarin and warfarin - drug interactions in patients living in the county of Osterg tland , Sweden .
Diseases: cerebral haemorrhages"	"Sentence: To evaluate the frequency , severity and preventability of warfarin - induced cerebral haemorrhages due to warfarin and warfarin - drug interactions in patients living in the county of Osterg tland , Sweden .
Diseases:"
2184	METHODS : All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000 - 2002 were identified .	O O O O O O O B I O O O O O O O O O O O O	['cerebral haemorrhage']	1	8	"Sentence: METHODS : All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000 - 2002 were identified .
Diseases: cerebral haemorrhage"	"Sentence: METHODS : All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000 - 2002 were identified .
Diseases:"
2185	Medical records were studied retrospectively to evaluate whether warfarin and warfarin - drug interactions could have caused the cerebral haemorrhage .	O O O O O O O O O O O O O O O O O O B I O	['cerebral haemorrhage']	1	8	"Sentence: Medical records were studied retrospectively to evaluate whether warfarin and warfarin - drug interactions could have caused the cerebral haemorrhage .
Diseases: cerebral haemorrhage"	"Sentence: Medical records were studied retrospectively to evaluate whether warfarin and warfarin - drug interactions could have caused the cerebral haemorrhage .
Diseases:"
2186	The proportion of possibly avoidable cases due to drug interactions was estimated .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The proportion of possibly avoidable cases due to drug interactions was estimated .
Diseases: "	"Sentence: The proportion of possibly avoidable cases due to drug interactions was estimated .
Diseases:"
2187	Among 593 patients with cerebral haemorrhage , 59 ( 10 % ) were assessed as related to warfarin treatment .	O O O O B I O O O O O O O O O O O O O O	['cerebral haemorrhage']	1	8	"Sentence: Among 593 patients with cerebral haemorrhage , 59 ( 10 % ) were assessed as related to warfarin treatment .
Diseases: cerebral haemorrhage"	"Sentence: Among 593 patients with cerebral haemorrhage , 59 ( 10 % ) were assessed as related to warfarin treatment .
Diseases:"
2188	This imply an incidence of 1 . 7 / 100 , 000 treatment years .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This imply an incidence of 1 . 7 / 100 , 000 treatment years .
Diseases: "	"Sentence: This imply an incidence of 1 . 7 / 100 , 000 treatment years .
Diseases:"
2189	Of the 59 cases , 26 ( 44 % ) had a fatal outcome , compared to 136 ( 25 % ) among the non - warfarin patients ( p < 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the 59 cases , 26 ( 44 % ) had a fatal outcome , compared to 136 ( 25 % ) among the non - warfarin patients ( p < 0 . 01 ) .
Diseases: "	"Sentence: Of the 59 cases , 26 ( 44 % ) had a fatal outcome , compared to 136 ( 25 % ) among the non - warfarin patients ( p < 0 . 01 ) .
Diseases:"
2190	A warfarin - drug interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['haemorrhage', 'bleeding']	2	7	"Sentence: A warfarin - drug interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .
Diseases: haemorrhage, bleeding"	"Sentence: A warfarin - drug interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .
Diseases:"
2191	Warfarin - induced cerebral haemorrhages are a major clinical problem with a high fatality rate .	O O O B I O O O O O O O O O O O	['cerebral haemorrhages']	1	8	"Sentence: Warfarin - induced cerebral haemorrhages are a major clinical problem with a high fatality rate .
Diseases: cerebral haemorrhages"	"Sentence: Warfarin - induced cerebral haemorrhages are a major clinical problem with a high fatality rate .
Diseases:"
2192	Almost half of the cases was related to a warfarin - drug interaction .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Almost half of the cases was related to a warfarin - drug interaction .
Diseases: "	"Sentence: Almost half of the cases was related to a warfarin - drug interaction .
Diseases:"
2193	A significant proportion of warfarin - related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O	['cerebral haemorrhages']	1	8	"Sentence: A significant proportion of warfarin - related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin .
Diseases: cerebral haemorrhages"	"Sentence: A significant proportion of warfarin - related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin .
Diseases:"
2194	Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub - Tenon 's space .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub - Tenon 's space .
Diseases: "	"Sentence: Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub - Tenon 's space .
Diseases:"
2195	To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub - Tenon 's space at the end of routine cataract surgery .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['cataract']	1	3	"Sentence: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub - Tenon 's space at the end of routine cataract surgery .
Diseases: cataract"	"Sentence: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub - Tenon 's space at the end of routine cataract surgery .
Diseases:"
2196	SETTING : St . Luke 's Hospital , Gwardamangia , Malta .	O O O O O O O O O O O O	[]	0	0	"Sentence: SETTING : St . Luke 's Hospital , Gwardamangia , Malta .
Diseases: "	"Sentence: SETTING : St . Luke 's Hospital , Gwardamangia , Malta .
Diseases:"
2197	METHODS : A double - blind double - armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub - Tenon 's local infiltration of 3 mL of plain lignocaine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : A double - blind double - armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub - Tenon 's local infiltration of 3 mL of plain lignocaine .
Diseases: "	"Sentence: METHODS : A double - blind double - armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub - Tenon 's local infiltration of 3 mL of plain lignocaine .
Diseases:"
2198	At the end of the procedure , Group A ( n = 20 ) had 20 mg / 0 . 5 mL of methylprednisolone and 10 mg / 0 . 5 mL of gentamicin injected into the posterior sub - Tenon 's space and Group B ( n = 20 ) had the same combination injected into the anterior sub - Tenon 's space .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At the end of the procedure , Group A ( n = 20 ) had 20 mg / 0 . 5 mL of methylprednisolone and 10 mg / 0 . 5 mL of gentamicin injected into the posterior sub - Tenon 's space and Group B ( n = 20 ) had the same combination injected into the anterior sub - Tenon 's space .
Diseases: "	"Sentence: At the end of the procedure , Group A ( n = 20 ) had 20 mg / 0 . 5 mL of methylprednisolone and 10 mg / 0 . 5 mL of gentamicin injected into the posterior sub - Tenon 's space and Group B ( n = 20 ) had the same combination injected into the anterior sub - Tenon 's space .
Diseases:"
2199	Postoperatively , all patients were assessed for symptoms of nausea , vomiting , and headache .	O O O O O O O O O B I I O O B O	['headache', 'nausea , vomiting']	2	6	"Sentence: Postoperatively , all patients were assessed for symptoms of nausea , vomiting , and headache .
Diseases: headache, nausea , vomiting"	"Sentence: Postoperatively , all patients were assessed for symptoms of nausea , vomiting , and headache .
Diseases:"
2200	A chi - square test was used to assess the statistical significance of results .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A chi - square test was used to assess the statistical significance of results .
Diseases: "	"Sentence: A chi - square test was used to assess the statistical significance of results .
Diseases:"
2201	Sixty percent in Group A developed postoperative emetic symptoms , headache , or both ; 1 patient in Group B developed symptoms .	O O O O O O B I I O B O O O O O O O O O O O O	['headache', 'postoperative emetic symptoms']	2	8	"Sentence: Sixty percent in Group A developed postoperative emetic symptoms , headache , or both ; 1 patient in Group B developed symptoms .
Diseases: headache, postoperative emetic symptoms"	"Sentence: Sixty percent in Group A developed postoperative emetic symptoms , headache , or both ; 1 patient in Group B developed symptoms .
Diseases:"
2202	The administration of methylprednisolone and gentamicin in the posterior sub - Tenon 's space was related to a high incidence of side effects including nausea , vomiting , and headache .	O O O O O O O O O O O O O O O O O O O O O O O O B I I O O B O	['headache', 'nausea , vomiting']	2	6	"Sentence: The administration of methylprednisolone and gentamicin in the posterior sub - Tenon 's space was related to a high incidence of side effects including nausea , vomiting , and headache .
Diseases: headache, nausea , vomiting"	"Sentence: The administration of methylprednisolone and gentamicin in the posterior sub - Tenon 's space was related to a high incidence of side effects including nausea , vomiting , and headache .
Diseases:"
2203	All adverse effects were self - limiting .	O O O O O O O O	[]	0	0	"Sentence: All adverse effects were self - limiting .
Diseases: "	"Sentence: All adverse effects were self - limiting .
Diseases:"
2204	Cardiac Angiography in Renally Impaired Patients ( CARE ) study : a randomized double - blind trial of contrast - induced nephropathy in patients with chronic kidney disease .	O O O O O O O O O O O O O O O O O O O O O B O O O B I I O	['chronic kidney disease', 'nephropathy']	2	9	"Sentence: Cardiac Angiography in Renally Impaired Patients ( CARE ) study : a randomized double - blind trial of contrast - induced nephropathy in patients with chronic kidney disease .
Diseases: chronic kidney disease, nephropathy"	"Sentence: Cardiac Angiography in Renally Impaired Patients ( CARE ) study : a randomized double - blind trial of contrast - induced nephropathy in patients with chronic kidney disease .
Diseases:"
2205	No direct comparisons exist of the renal tolerability of the low - osmolality contrast medium iopamidol with that of the iso - osmolality contrast medium iodixanol in high - risk patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: No direct comparisons exist of the renal tolerability of the low - osmolality contrast medium iopamidol with that of the iso - osmolality contrast medium iodixanol in high - risk patients .
Diseases: "	"Sentence: No direct comparisons exist of the renal tolerability of the low - osmolality contrast medium iopamidol with that of the iso - osmolality contrast medium iodixanol in high - risk patients .
Diseases:"
2206	METHODS AND RESULTS :	O O O O	[]	0	0	"Sentence: METHODS AND RESULTS :
Diseases: "	"Sentence: METHODS AND RESULTS :
Diseases:"
2207	The present study is a multicenter , randomized , double - blind comparison of iopamidol and iodixanol in patients with chronic kidney disease ( estimated glomerular filtration rate , 20 to 59 mL / min ) who underwent cardiac angiography or percutaneous coronary interventions .	O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O	['chronic kidney disease']	1	4	"Sentence: The present study is a multicenter , randomized , double - blind comparison of iopamidol and iodixanol in patients with chronic kidney disease ( estimated glomerular filtration rate , 20 to 59 mL / min ) who underwent cardiac angiography or percutaneous coronary interventions .
Diseases: chronic kidney disease"	"Sentence: The present study is a multicenter , randomized , double - blind comparison of iopamidol and iodixanol in patients with chronic kidney disease ( estimated glomerular filtration rate , 20 to 59 mL / min ) who underwent cardiac angiography or percutaneous coronary interventions .
Diseases:"
2208	Serum creatinine ( SCr ) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serum creatinine ( SCr ) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications .
Diseases: "	"Sentence: Serum creatinine ( SCr ) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications .
Diseases:"
2209	The primary outcome was a postdose SCr increase > or = 0 . 5 mg / dL	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The primary outcome was a postdose SCr increase > or = 0 . 5 mg / dL
Diseases: "	"Sentence: The primary outcome was a postdose SCr increase > or = 0 . 5 mg / dL
Diseases:"
2210	( 44 . 2 micromol / L ) over baseline .	O O O O O O O O O O O	[]	0	0	"Sentence: ( 44 . 2 micromol / L ) over baseline .
Diseases: "	"Sentence: ( 44 . 2 micromol / L ) over baseline .
Diseases:"
2211	Secondary outcomes were a postdose SCr increase > or = 25 % , a postdose estimated glomerular filtration rate decrease of > or = 25 % , and the mean peak change in SCr .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Secondary outcomes were a postdose SCr increase > or = 25 % , a postdose estimated glomerular filtration rate decrease of > or = 25 % , and the mean peak change in SCr .
Diseases: "	"Sentence: Secondary outcomes were a postdose SCr increase > or = 25 % , a postdose estimated glomerular filtration rate decrease of > or = 25 % , and the mean peak change in SCr .
Diseases:"
2212	In 414 patients , contrast volume , presence of diabetes mellitus , use of N - acetylcysteine , mean baseline SCr , and estimated glomerular filtration rate were comparable in the 2 groups .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O	['diabetes mellitus']	1	4	"Sentence: In 414 patients , contrast volume , presence of diabetes mellitus , use of N - acetylcysteine , mean baseline SCr , and estimated glomerular filtration rate were comparable in the 2 groups .
Diseases: diabetes mellitus"	"Sentence: In 414 patients , contrast volume , presence of diabetes mellitus , use of N - acetylcysteine , mean baseline SCr , and estimated glomerular filtration rate were comparable in the 2 groups .
Diseases:"
2213	SCr increases > or = 0 . 5 mg / dL occurred in 4 . 4 % ( 9 of 204 patients ) after iopamidol and 6 . 7 % ( 14 of 210 patients ) after iodixanol ( P = 0 . 39 ) , whereas rates of SCr increases > or = 25 % were 9 . 8 % and 12 . 4 % , respectively ( P = 0 . 44 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: SCr increases > or = 0 . 5 mg / dL occurred in 4 . 4 % ( 9 of 204 patients ) after iopamidol and 6 . 7 % ( 14 of 210 patients ) after iodixanol ( P = 0 . 39 ) , whereas rates of SCr increases > or = 25 % were 9 . 8 % and 12 . 4 % , respectively ( P = 0 . 44 ) .
Diseases: "	"Sentence: SCr increases > or = 0 . 5 mg / dL occurred in 4 . 4 % ( 9 of 204 patients ) after iopamidol and 6 . 7 % ( 14 of 210 patients ) after iodixanol ( P = 0 . 39 ) , whereas rates of SCr increases > or = 25 % were 9 . 8 % and 12 . 4 % , respectively ( P = 0 . 44 ) .
Diseases:"
2214	In patients with diabetes , SCr increases > or = 0 . 5 mg / dL were 5 . 1 % ( 4 of 78 patients ) with iopamidol and 13 . 0 % ( 12 of 92 patients ) with iodixanol ( P = 0 . 11 ) , whereas SCr increases > or = 25 % were 10 . 3 % and 15 . 2 % , respectively ( P = 0 . 37 ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetes']	1	2	"Sentence: In patients with diabetes , SCr increases > or = 0 . 5 mg / dL were 5 . 1 % ( 4 of 78 patients ) with iopamidol and 13 . 0 % ( 12 of 92 patients ) with iodixanol ( P = 0 . 11 ) , whereas SCr increases > or = 25 % were 10 . 3 % and 15 . 2 % , respectively ( P = 0 . 37 ) .
Diseases: diabetes"	"Sentence: In patients with diabetes , SCr increases > or = 0 . 5 mg / dL were 5 . 1 % ( 4 of 78 patients ) with iopamidol and 13 . 0 % ( 12 of 92 patients ) with iodixanol ( P = 0 . 11 ) , whereas SCr increases > or = 25 % were 10 . 3 % and 15 . 2 % , respectively ( P = 0 . 37 ) .
Diseases:"
2215	Mean post - SCr increases were significantly less with iopamidol ( all patients : 0 . 07 versus 0 . 12 mg / dL , 6 . 2 versus 10 . 6 micromol / L , P = 0 . 03 ; patients with diabetes : 0 . 07 versus 0 . 16 mg / dL , 6 . 2 versus 14 . 1 micromol / L , P = 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetes']	1	2	"Sentence: Mean post - SCr increases were significantly less with iopamidol ( all patients : 0 . 07 versus 0 . 12 mg / dL , 6 . 2 versus 10 . 6 micromol / L , P = 0 . 03 ; patients with diabetes : 0 . 07 versus 0 . 16 mg / dL , 6 . 2 versus 14 . 1 micromol / L , P = 0 . 01 ) .
Diseases: diabetes"	"Sentence: Mean post - SCr increases were significantly less with iopamidol ( all patients : 0 . 07 versus 0 . 12 mg / dL , 6 . 2 versus 10 . 6 micromol / L , P = 0 . 03 ; patients with diabetes : 0 . 07 versus 0 . 16 mg / dL , 6 . 2 versus 14 . 1 micromol / L , P = 0 . 01 ) .
Diseases:"
2216	The rate of contrast - induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or iodixanol to high - risk patients , with or without diabetes mellitus .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['nephropathy', 'diabetes mellitus']	2	8	"Sentence: The rate of contrast - induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or iodixanol to high - risk patients , with or without diabetes mellitus .
Diseases: nephropathy, diabetes mellitus"	"Sentence: The rate of contrast - induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or iodixanol to high - risk patients , with or without diabetes mellitus .
Diseases:"
2217	Any true difference between the agents is small and not likely to be clinically significant .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Any true difference between the agents is small and not likely to be clinically significant .
Diseases: "	"Sentence: Any true difference between the agents is small and not likely to be clinically significant .
Diseases:"
2218	A novel compound , maltolyl p - coumarate , attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models .	O O O O O O O O O O B I O O O O O O O O O B O O	['cognitive deficits', 'dementia']	2	5	"Sentence: A novel compound , maltolyl p - coumarate , attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models .
Diseases: cognitive deficits, dementia"	"Sentence: A novel compound , maltolyl p - coumarate , attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models .
Diseases:"
2219	To develop a novel and effective drug that could enhance cognitive function and neuroprotection , we newly synthesized maltolyl p - coumarate by the esterification of maltol and p - coumaric acid .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To develop a novel and effective drug that could enhance cognitive function and neuroprotection , we newly synthesized maltolyl p - coumarate by the esterification of maltol and p - coumaric acid .
Diseases: "	"Sentence: To develop a novel and effective drug that could enhance cognitive function and neuroprotection , we newly synthesized maltolyl p - coumarate by the esterification of maltol and p - coumaric acid .
Diseases:"
2220	In the present study , we investigated whether maltolyl p - coumarate could improve cognitive decline in scopolamine - injected rats and in amyloid beta peptide ( 1 - 42 ) - infused rats .	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O	['cognitive decline']	1	3	"Sentence: In the present study , we investigated whether maltolyl p - coumarate could improve cognitive decline in scopolamine - injected rats and in amyloid beta peptide ( 1 - 42 ) - infused rats .
Diseases: cognitive decline"	"Sentence: In the present study , we investigated whether maltolyl p - coumarate could improve cognitive decline in scopolamine - injected rats and in amyloid beta peptide ( 1 - 42 ) - infused rats .
Diseases:"
2221	Maltolyl p - coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide ( 1 - 42 ) - infused rats .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cognitive deficits']	1	3	"Sentence: Maltolyl p - coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide ( 1 - 42 ) - infused rats .
Diseases: cognitive deficits"	"Sentence: Maltolyl p - coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide ( 1 - 42 ) - infused rats .
Diseases:"
2222	We also examined the neuroprotective effects of maltolyl p - coumarate in vitro using SH - SY5Y cells .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We also examined the neuroprotective effects of maltolyl p - coumarate in vitro using SH - SY5Y cells .
Diseases: "	"Sentence: We also examined the neuroprotective effects of maltolyl p - coumarate in vitro using SH - SY5Y cells .
Diseases:"
2223	Cells were pretreated with maltolyl p - coumarate , before exposed to amyloid beta peptide ( 1 - 42 ) , glutamate or H2O2 .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cells were pretreated with maltolyl p - coumarate , before exposed to amyloid beta peptide ( 1 - 42 ) , glutamate or H2O2 .
Diseases: "	"Sentence: Cells were pretreated with maltolyl p - coumarate , before exposed to amyloid beta peptide ( 1 - 42 ) , glutamate or H2O2 .
Diseases:"
2224	We found that maltolyl p - coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species , cytochrome c release , and caspase 3 activation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We found that maltolyl p - coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species , cytochrome c release , and caspase 3 activation .
Diseases: "	"Sentence: We found that maltolyl p - coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species , cytochrome c release , and caspase 3 activation .
Diseases:"
2225	Taking these in vitro and in vivo results together , our study suggests that maltolyl p - coumarate is a potentially effective candidate against Alzheimer 's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function .	O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O B I O O B I I I O	"['decline of cognitive function', ""alzheimer 's disease"", 'neuronal death']"	3	15	"Sentence: Taking these in vitro and in vivo results together , our study suggests that maltolyl p - coumarate is a potentially effective candidate against Alzheimer 's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function .
Diseases: decline of cognitive function, alzheimer 's disease, neuronal death"	"Sentence: Taking these in vitro and in vivo results together , our study suggests that maltolyl p - coumarate is a potentially effective candidate against Alzheimer 's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function .
Diseases:"
2226	Interaction between warfarin and levofloxacin : case series .	O O O O O O O O O	[]	0	0	"Sentence: Interaction between warfarin and levofloxacin : case series .
Diseases: "	"Sentence: Interaction between warfarin and levofloxacin : case series .
Diseases:"
2227	Warfarin is the most widely used oral anticoagulant and is indicated for many clinical conditions .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Warfarin is the most widely used oral anticoagulant and is indicated for many clinical conditions .
Diseases: "	"Sentence: Warfarin is the most widely used oral anticoagulant and is indicated for many clinical conditions .
Diseases:"
2228	Levofloxacin , a fluoroquinolone , is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram - positive , Gram - negative , and atypical bacteria .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Levofloxacin , a fluoroquinolone , is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram - positive , Gram - negative , and atypical bacteria .
Diseases: "	"Sentence: Levofloxacin , a fluoroquinolone , is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram - positive , Gram - negative , and atypical bacteria .
Diseases:"
2229	While small prospective studies have not revealed any significant drug - drug interaction between warfarin and levofloxacin , several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: While small prospective studies have not revealed any significant drug - drug interaction between warfarin and levofloxacin , several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin .
Diseases: "	"Sentence: While small prospective studies have not revealed any significant drug - drug interaction between warfarin and levofloxacin , several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin .
Diseases:"
2230	We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin .	O O O O O O B O O O O O O O O O O O O O O O	['bleeding']	1	2	"Sentence: We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin .
Diseases: bleeding"	"Sentence: We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin .
Diseases:"
2231	Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin .
Diseases: "	"Sentence: Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin .
Diseases:"
2232	Mutations associated with lamivudine - resistance in therapy - na ve hepatitis B virus ( HBV ) infected patients with and without HIV co - infection : implications for antiretroviral therapy in HBV and HIV co - infected South African patients .	O O O O O O O O O O O B I I I I I I O O O O B I I I O O O O O O B I I I I I O O O O	['hbv and hiv co - infected', 'hepatitis b virus ( hbv ) infected', 'hiv co - infection']	3	27	"Sentence: Mutations associated with lamivudine - resistance in therapy - na ve hepatitis B virus ( HBV ) infected patients with and without HIV co - infection : implications for antiretroviral therapy in HBV and HIV co - infected South African patients .
Diseases: hbv and hiv co - infected, hepatitis b virus ( hbv ) infected, hiv co - infection"	"Sentence: Mutations associated with lamivudine - resistance in therapy - na ve hepatitis B virus ( HBV ) infected patients with and without HIV co - infection : implications for antiretroviral therapy in HBV and HIV co - infected South African patients .
Diseases:"
2233	This was an exploratory study to investigate lamivudine - resistant hepatitis B virus ( HBV ) strains in selected lamivudine - na ve HBV carriers with and without human immunodeficiency virus ( HIV ) co - infection in South African patients .	O O O O O O O O O O B I O O O O O O O O O O O O O O O O B I I I I I I I I O O O O O	['human immunodeficiency virus ( hiv ) co - infection', 'hepatitis b']	2	16	"Sentence: This was an exploratory study to investigate lamivudine - resistant hepatitis B virus ( HBV ) strains in selected lamivudine - na ve HBV carriers with and without human immunodeficiency virus ( HIV ) co - infection in South African patients .
Diseases: human immunodeficiency virus ( hiv ) co - infection, hepatitis b"	"Sentence: This was an exploratory study to investigate lamivudine - resistant hepatitis B virus ( HBV ) strains in selected lamivudine - na ve HBV carriers with and without human immunodeficiency virus ( HIV ) co - infection in South African patients .
Diseases:"
2234	Thirty - five lamivudine - na ve HBV infected patients with or without HIV co - infection were studied : 15 chronic HBV mono - infected patients and 20 HBV - HIV co - infected patients .	O O O O O O O B I O O O O B I I I O O O O O B I I I O O O B I I I I I O O	['hbv - hiv co - infected', 'hbv mono - infected', 'hbv infected', 'hiv co - infection']	4	27	"Sentence: Thirty - five lamivudine - na ve HBV infected patients with or without HIV co - infection were studied : 15 chronic HBV mono - infected patients and 20 HBV - HIV co - infected patients .
Diseases: hbv - hiv co - infected, hbv mono - infected, hbv infected, hiv co - infection"	"Sentence: Thirty - five lamivudine - na ve HBV infected patients with or without HIV co - infection were studied : 15 chronic HBV mono - infected patients and 20 HBV - HIV co - infected patients .
Diseases:"
2235	The latter group was further sub - divided into 13 occult HBV ( HBsAg - negative ) and 7 overt HBV ( HBsAg - positive ) patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The latter group was further sub - divided into 13 occult HBV ( HBsAg - negative ) and 7 overt HBV ( HBsAg - positive ) patients .
Diseases: "	"Sentence: The latter group was further sub - divided into 13 occult HBV ( HBsAg - negative ) and 7 overt HBV ( HBsAg - positive ) patients .
Diseases:"
2236	HBsAg , anti - HBs , anti - HBc , and anti - HIV 1 / 2 were determined as part of routine diagnosis using Axsym assays ( Abbott Laboratories , North Chicago , IL ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: HBsAg , anti - HBs , anti - HBc , and anti - HIV 1 / 2 were determined as part of routine diagnosis using Axsym assays ( Abbott Laboratories , North Chicago , IL ) .
Diseases: "	"Sentence: HBsAg , anti - HBs , anti - HBc , and anti - HIV 1 / 2 were determined as part of routine diagnosis using Axsym assays ( Abbott Laboratories , North Chicago , IL ) .
Diseases:"
2237	Serum samples were PCR amplified with HBV reverse transcriptase ( RT ) primers , followed by direct sequencing across the tyrosine - methionine - aspartate - aspartate ( YMDD ) motif of the major catalytic region in the C domain of the HBV RT enzyme .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serum samples were PCR amplified with HBV reverse transcriptase ( RT ) primers , followed by direct sequencing across the tyrosine - methionine - aspartate - aspartate ( YMDD ) motif of the major catalytic region in the C domain of the HBV RT enzyme .
Diseases: "	"Sentence: Serum samples were PCR amplified with HBV reverse transcriptase ( RT ) primers , followed by direct sequencing across the tyrosine - methionine - aspartate - aspartate ( YMDD ) motif of the major catalytic region in the C domain of the HBV RT enzyme .
Diseases:"
2238	HBV viral load was performed with Amplicor HBV Monitor test v2 . 0 ( Roche Diagnostics , Penzberg , Germany ) .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: HBV viral load was performed with Amplicor HBV Monitor test v2 . 0 ( Roche Diagnostics , Penzberg , Germany ) .
Diseases: "	"Sentence: HBV viral load was performed with Amplicor HBV Monitor test v2 . 0 ( Roche Diagnostics , Penzberg , Germany ) .
Diseases:"
2239	HBV lamivudine - resistant strains were detected in 3 of 15 mono - infected chronic hepatitis B patients and 10 of 20 HBV - HIV co - infected patients .	O O O O O O O O O O O O O O O B I O O O O O B I I I I I O O	['hepatitis b', 'hbv - hiv co - infected']	2	14	"Sentence: HBV lamivudine - resistant strains were detected in 3 of 15 mono - infected chronic hepatitis B patients and 10 of 20 HBV - HIV co - infected patients .
Diseases: hepatitis b, hbv - hiv co - infected"	"Sentence: HBV lamivudine - resistant strains were detected in 3 of 15 mono - infected chronic hepatitis B patients and 10 of 20 HBV - HIV co - infected patients .
Diseases:"
2240	To the best of our knowledge , this constitutes the first report of HBV lamivudine - resistant strains in therapy - na ve HBV - HIV co - infected patients .	O O O O O O O O O O O O O O O O O O O O O O O B I I I I I O O	['hbv - hiv co - infected']	1	9	"Sentence: To the best of our knowledge , this constitutes the first report of HBV lamivudine - resistant strains in therapy - na ve HBV - HIV co - infected patients .
Diseases: hbv - hiv co - infected"	"Sentence: To the best of our knowledge , this constitutes the first report of HBV lamivudine - resistant strains in therapy - na ve HBV - HIV co - infected patients .
Diseases:"
2241	The HBV viral loads for mono - infected and co - infected patients ranged from 3 . 32 x 10 ( 2 ) to 3 . 82 x 10 ( 7 ) and < 200 to 4 . 40 x 10 ( 3 ) copies / ml , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The HBV viral loads for mono - infected and co - infected patients ranged from 3 . 32 x 10 ( 2 ) to 3 . 82 x 10 ( 7 ) and < 200 to 4 . 40 x 10 ( 3 ) copies / ml , respectively .
Diseases: "	"Sentence: The HBV viral loads for mono - infected and co - infected patients ranged from 3 . 32 x 10 ( 2 ) to 3 . 82 x 10 ( 7 ) and < 200 to 4 . 40 x 10 ( 3 ) copies / ml , respectively .
Diseases:"
2242	It remains to be seen whether such pre - existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine - containing highly active antiretroviral ( ARV ) treatment (	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It remains to be seen whether such pre - existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine - containing highly active antiretroviral ( ARV ) treatment (
Diseases: "	"Sentence: It remains to be seen whether such pre - existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine - containing highly active antiretroviral ( ARV ) treatment (
Diseases:"
2243	HAART ) regimens become widely applied in South Africa , as this is likely to have potential implications in the management of HBV - HIV co - infected patients .	O O O O O O O O O O O O O O O O O O O O O O B I I I I I O O	['hbv - hiv co - infected']	1	9	"Sentence: HAART ) regimens become widely applied in South Africa , as this is likely to have potential implications in the management of HBV - HIV co - infected patients .
Diseases: hbv - hiv co - infected"	"Sentence: HAART ) regimens become widely applied in South Africa , as this is likely to have potential implications in the management of HBV - HIV co - infected patients .
Diseases:"
2244	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain : comparisons to two models of acute pain .	O O O O O O O O O O O O O O O B O O O O O O B I O	['acute pain', 'pain']	2	5	"Sentence: Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain : comparisons to two models of acute pain .
Diseases: acute pain, pain"	"Sentence: Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain : comparisons to two models of acute pain .
Diseases:"
2245	In acute pain models , N - methyl - D - aspartate ( NMDA ) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females .	O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['acute pain']	1	3	"Sentence: In acute pain models , N - methyl - D - aspartate ( NMDA ) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females .
Diseases: acute pain"	"Sentence: In acute pain models , N - methyl - D - aspartate ( NMDA ) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females .
Diseases:"
2246	The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated , neurochemical substrates , and duration of the nociceptive stimulus .	O O O O O O O O O O O O O B O O O O O O B I O O O O O O O O O O O O O O O O O O O O	['acute pain', 'pain']	2	5	"Sentence: The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated , neurochemical substrates , and duration of the nociceptive stimulus .
Diseases: acute pain, pain"	"Sentence: The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated , neurochemical substrates , and duration of the nociceptive stimulus .
Diseases:"
2247	To this end , persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats , following which the tail was immersed in a mildly noxious thermal stimulus , and tail - withdrawal latencies measured .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperalgesia']	1	4	"Sentence: To this end , persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats , following which the tail was immersed in a mildly noxious thermal stimulus , and tail - withdrawal latencies measured .
Diseases: hyperalgesia"	"Sentence: To this end , persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats , following which the tail was immersed in a mildly noxious thermal stimulus , and tail - withdrawal latencies measured .
Diseases:"
2248	For comparison , tests were conducted in two acute pain models , the hotplate and warm water tail - withdrawal procedures .	O O O O O O O O B I O O O O O O O O O O O O	['acute pain']	1	3	"Sentence: For comparison , tests were conducted in two acute pain models , the hotplate and warm water tail - withdrawal procedures .
Diseases: acute pain"	"Sentence: For comparison , tests were conducted in two acute pain models , the hotplate and warm water tail - withdrawal procedures .
Diseases:"
2249	In males , the non - competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose - and time - dependent manner .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In males , the non - competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose - and time - dependent manner .
Diseases: "	"Sentence: In males , the non - competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose - and time - dependent manner .
Diseases:"
2250	Across the doses and pretreatment times examined , enhancement was not observed in females .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Across the doses and pretreatment times examined , enhancement was not observed in females .
Diseases: "	"Sentence: Across the doses and pretreatment times examined , enhancement was not observed in females .
Diseases:"
2251	Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models , with the magnitude of this effect being greater in males .	O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	['acute pain']	1	3	"Sentence: Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models , with the magnitude of this effect being greater in males .
Diseases: acute pain"	"Sentence: Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models , with the magnitude of this effect being greater in males .
Diseases:"
2252	These findings demonstrate a sexually - dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models .	O O O O O O O O O O O O O O O O B O O O O O O O O O B I O O	['acute pain', 'pain']	2	5	"Sentence: These findings demonstrate a sexually - dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models .
Diseases: acute pain, pain"	"Sentence: These findings demonstrate a sexually - dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models .
Diseases:"
2253	Development of proteinuria after switch to sirolimus - based immunosuppression in long - term cardiac transplant patients .	O O B O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Development of proteinuria after switch to sirolimus - based immunosuppression in long - term cardiac transplant patients .
Diseases: proteinuria"	"Sentence: Development of proteinuria after switch to sirolimus - based immunosuppression in long - term cardiac transplant patients .
Diseases:"
2254	Calcineurin - inhibitor therapy can lead to renal dysfunction in heart transplantation patients .	O O O O O O O B I O O O O O	['renal dysfunction']	1	3	"Sentence: Calcineurin - inhibitor therapy can lead to renal dysfunction in heart transplantation patients .
Diseases: renal dysfunction"	"Sentence: Calcineurin - inhibitor therapy can lead to renal dysfunction in heart transplantation patients .
Diseases:"
2255	The novel immunosuppressive ( IS ) drug sirolmus ( Srl ) lacks nephrotoxic effects ; however , proteinuria associated with Srl has been reported following renal transplantation .	O O O O O O O O O O O O B O O O O B O O O O O O O O O O	['nephrotoxic', 'proteinuria']	2	7	"Sentence: The novel immunosuppressive ( IS ) drug sirolmus ( Srl ) lacks nephrotoxic effects ; however , proteinuria associated with Srl has been reported following renal transplantation .
Diseases: nephrotoxic, proteinuria"	"Sentence: The novel immunosuppressive ( IS ) drug sirolmus ( Srl ) lacks nephrotoxic effects ; however , proteinuria associated with Srl has been reported following renal transplantation .
Diseases:"
2256	In cardiac transplantation , the incidence of proteinuria associated with Srl is unknown .	O O O O O O O B O O O O O O	['proteinuria']	1	2	"Sentence: In cardiac transplantation , the incidence of proteinuria associated with Srl is unknown .
Diseases: proteinuria"	"Sentence: In cardiac transplantation , the incidence of proteinuria associated with Srl is unknown .
Diseases:"
2257	In this study , long - term cardiac transplant patients were switched from cyclosporine to Srl - based IS .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In this study , long - term cardiac transplant patients were switched from cyclosporine to Srl - based IS .
Diseases: "	"Sentence: In this study , long - term cardiac transplant patients were switched from cyclosporine to Srl - based IS .
Diseases:"
2258	Concomitant IS consisted of mycophenolate mofetil + / - steroids .	O O O O O O O O O O O	[]	0	0	"Sentence: Concomitant IS consisted of mycophenolate mofetil + / - steroids .
Diseases: "	"Sentence: Concomitant IS consisted of mycophenolate mofetil + / - steroids .
Diseases:"
2259	Proteinuria increased significantly from a median of 0 . 13 g / day ( range 0 - 5 . 7 ) preswitch to 0 . 23 g / day ( 0 - 9 . 88 ) at 24 months postswitch ( p = 0 . 0024 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Proteinuria increased significantly from a median of 0 . 13 g / day ( range 0 - 5 . 7 ) preswitch to 0 . 23 g / day ( 0 - 9 . 88 ) at 24 months postswitch ( p = 0 . 0024 ) .
Diseases: "	"Sentence: Proteinuria increased significantly from a median of 0 . 13 g / day ( range 0 - 5 . 7 ) preswitch to 0 . 23 g / day ( 0 - 9 . 88 ) at 24 months postswitch ( p = 0 . 0024 ) .
Diseases:"
2260	Before the switch , 11 . 5 % of patients had high - grade proteinuria ( > 1 . 0 g / day ) ; this increased to 22 . 9 % postswitch ( p = 0 . 006 ) .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Before the switch , 11 . 5 % of patients had high - grade proteinuria ( > 1 . 0 g / day ) ; this increased to 22 . 9 % postswitch ( p = 0 . 006 ) .
Diseases: proteinuria"	"Sentence: Before the switch , 11 . 5 % of patients had high - grade proteinuria ( > 1 . 0 g / day ) ; this increased to 22 . 9 % postswitch ( p = 0 . 006 ) .
Diseases:"
2261	ACE inhibitor and angiotensin - releasing blocker ( ARB ) therapy reduced proteinuria development .	O O O O O O O O O O O O B O O	['proteinuria']	1	2	"Sentence: ACE inhibitor and angiotensin - releasing blocker ( ARB ) therapy reduced proteinuria development .
Diseases: proteinuria"	"Sentence: ACE inhibitor and angiotensin - releasing blocker ( ARB ) therapy reduced proteinuria development .
Diseases:"
2262	Patients without proteinuria had increased renal function ( median 42 . 5 vs . 64 . 1 , p = 0 . 25 ) , whereas patients who developed high - grade proteinuria showed decreased renal function at the end of follow - up ( median 39 . 6 vs . 29 . 2 , p = 0 . 125 ) .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Patients without proteinuria had increased renal function ( median 42 . 5 vs . 64 . 1 , p = 0 . 25 ) , whereas patients who developed high - grade proteinuria showed decreased renal function at the end of follow - up ( median 39 . 6 vs . 29 . 2 , p = 0 . 125 ) .
Diseases: proteinuria"	"Sentence: Patients without proteinuria had increased renal function ( median 42 . 5 vs . 64 . 1 , p = 0 . 25 ) , whereas patients who developed high - grade proteinuria showed decreased renal function at the end of follow - up ( median 39 . 6 vs . 29 . 2 , p = 0 . 125 ) .
Diseases:"
2263	Thus , proteinuria may develop in cardiac transplant patients after switch to Srl , which may have an adverse effect on renal function in these patients .	O O B O O O O O O O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Thus , proteinuria may develop in cardiac transplant patients after switch to Srl , which may have an adverse effect on renal function in these patients .
Diseases: proteinuria"	"Sentence: Thus , proteinuria may develop in cardiac transplant patients after switch to Srl , which may have an adverse effect on renal function in these patients .
Diseases:"
2264	Srl should be used with ACEi / ARB therapy and patients monitored for proteinuria and increased renal dysfunction .	O O O O O O O O O O O O O B O O B I O	['proteinuria', 'renal dysfunction']	2	5	"Sentence: Srl should be used with ACEi / ARB therapy and patients monitored for proteinuria and increased renal dysfunction .
Diseases: proteinuria, renal dysfunction"	"Sentence: Srl should be used with ACEi / ARB therapy and patients monitored for proteinuria and increased renal dysfunction .
Diseases:"
2265	Synthesis of N - pyrimidinyl - 2 - phenoxyacetamides as adenosine A2A receptor antagonists .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Synthesis of N - pyrimidinyl - 2 - phenoxyacetamides as adenosine A2A receptor antagonists .
Diseases: "	"Sentence: Synthesis of N - pyrimidinyl - 2 - phenoxyacetamides as adenosine A2A receptor antagonists .
Diseases:"
2266	A series of N - pyrimidinyl - 2 - phenoxyacetamide adenosine A ( 2A ) antagonists is described .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A series of N - pyrimidinyl - 2 - phenoxyacetamide adenosine A ( 2A ) antagonists is described .
Diseases: "	"Sentence: A series of N - pyrimidinyl - 2 - phenoxyacetamide adenosine A ( 2A ) antagonists is described .
Diseases:"
2267	SAR studies led to compound 14 with excellent potency ( K ( i ) =	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: SAR studies led to compound 14 with excellent potency ( K ( i ) =
Diseases: "	"Sentence: SAR studies led to compound 14 with excellent potency ( K ( i ) =
Diseases:"
2268	0 . 4 nM ) , selectivity ( A ( 1 ) / A ( 2A ) > 100 ) , and efficacy ( MED 10 mg / kg	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 0 . 4 nM ) , selectivity ( A ( 1 ) / A ( 2A ) > 100 ) , and efficacy ( MED 10 mg / kg
Diseases: "	"Sentence: 0 . 4 nM ) , selectivity ( A ( 1 ) / A ( 2A ) > 100 ) , and efficacy ( MED 10 mg / kg
Diseases:"
2269	p . o . )	O O O O O	[]	0	0	"Sentence: p . o . )
Diseases: "	"Sentence: p . o . )
Diseases:"
2270	in the rat haloperidol - induced catalepsy model for Parkinson 's disease .	O O O O O O B O O B I I O	"['catalepsy', ""parkinson 's disease""]"	2	10	"Sentence: in the rat haloperidol - induced catalepsy model for Parkinson 's disease .
Diseases: catalepsy, parkinson 's disease"	"Sentence: in the rat haloperidol - induced catalepsy model for Parkinson 's disease .
Diseases:"
2271	Methamphetamine - induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling .	O O O B O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: Methamphetamine - induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling .
Diseases: neurotoxicity"	"Sentence: Methamphetamine - induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling .
Diseases:"
2272	Methamphetamine ( METH ) damages dopamine ( DA ) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Methamphetamine ( METH ) damages dopamine ( DA ) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated .
Diseases: "	"Sentence: Methamphetamine ( METH ) damages dopamine ( DA ) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated .
Diseases:"
2273	Cardona et al .	O O O O	[]	0	0	"Sentence: Cardona et al .
Diseases: "	"Sentence: Cardona et al .
Diseases:"
2274	[ Nat .	O O O	[]	0	0	"Sentence: [ Nat .
Diseases: "	"Sentence: [ Nat .
Diseases:"
2275	Neurosci .	O O	[]	0	0	"Sentence: Neurosci .
Diseases: "	"Sentence: Neurosci .
Diseases:"
2276	9 ( 2006 ) , 917 ] recently identified the microglial - specific fractalkine receptor ( CX3CR1 ) as an important mediator of MPTP - induced neurodegeneration of DA neurons .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['neurodegeneration']	1	5	"Sentence: 9 ( 2006 ) , 917 ] recently identified the microglial - specific fractalkine receptor ( CX3CR1 ) as an important mediator of MPTP - induced neurodegeneration of DA neurons .
Diseases: neurodegeneration"	"Sentence: 9 ( 2006 ) , 917 ] recently identified the microglial - specific fractalkine receptor ( CX3CR1 ) as an important mediator of MPTP - induced neurodegeneration of DA neurons .
Diseases:"
2277	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .	O O B I O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O	['cns damage', 'neurotoxicity']	2	6	"Sentence: Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .
Diseases: cns damage, neurotoxicity"	"Sentence: Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .
Diseases:"
2278	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein ( eGFP ) were treated with METH and examined for striatal neurotoxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['neurotoxicity']	1	4	"Sentence: Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein ( eGFP ) were treated with METH and examined for striatal neurotoxicity .
Diseases: neurotoxicity"	"Sentence: Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein ( eGFP ) were treated with METH and examined for striatal neurotoxicity .
Diseases:"
2279	METH depleted DA , caused microglial activation , and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild - type controls .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METH depleted DA , caused microglial activation , and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild - type controls .
Diseases: "	"Sentence: METH depleted DA , caused microglial activation , and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild - type controls .
Diseases:"
2280	The effects of METH in CX3CR1 knockout mice were not gender - dependent and did not extend beyond the striatum .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effects of METH in CX3CR1 knockout mice were not gender - dependent and did not extend beyond the striatum .
Diseases: "	"Sentence: The effects of METH in CX3CR1 knockout mice were not gender - dependent and did not extend beyond the striatum .
Diseases:"
2281	Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation .
Diseases: "	"Sentence: Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation .
Diseases:"
2282	This response was restricted to the striatum and contrasted sharply with unresponsive eGFP - microglia in surrounding brain areas that are not damaged by METH .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This response was restricted to the striatum and contrasted sharply with unresponsive eGFP - microglia in surrounding brain areas that are not damaged by METH .
Diseases: "	"Sentence: This response was restricted to the striatum and contrasted sharply with unresponsive eGFP - microglia in surrounding brain areas that are not damaged by METH .
Diseases:"
2283	We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation .	O O O O O O O O O O O O B O O O O	['neurotoxicity']	1	4	"Sentence: We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation .
Diseases: neurotoxicity"	"Sentence: We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation .
Diseases:"
2284	Furthermore , it appears that striatal - resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Furthermore , it appears that striatal - resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration .
Diseases: "	"Sentence: Furthermore , it appears that striatal - resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration .
Diseases:"
2285	Recovery of tacrolimus - associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient - - case report and review of the literature .	O O O O O B I O O O O O O O O O O O O O O O O O O O O	['brachial neuritis']	1	5	"Sentence: Recovery of tacrolimus - associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient - - case report and review of the literature .
Diseases: brachial neuritis"	"Sentence: Recovery of tacrolimus - associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient - - case report and review of the literature .
Diseases:"
2286	TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics .
Diseases: "	"Sentence: TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics .
Diseases:"
2287	Neurotoxicity is a potentially serious toxic effect .	B O O O O O O O	['neurotoxicity']	1	4	"Sentence: Neurotoxicity is a potentially serious toxic effect .
Diseases: neurotoxicity"	"Sentence: Neurotoxicity is a potentially serious toxic effect .
Diseases:"
2288	It is characterized by encephalopathy , headaches , seizures , or neurological deficits .	O O O O B O B O B O O B I O	['neurological deficits', 'encephalopathy', 'seizures', 'headaches']	4	13	"Sentence: It is characterized by encephalopathy , headaches , seizures , or neurological deficits .
Diseases: neurological deficits, encephalopathy, seizures, headaches"	"Sentence: It is characterized by encephalopathy , headaches , seizures , or neurological deficits .
Diseases:"
2289	Here , we describe an eight - and - a - half - yr - old male renal transplant recipient with right BN .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Here , we describe an eight - and - a - half - yr - old male renal transplant recipient with right BN .
Diseases: "	"Sentence: Here , we describe an eight - and - a - half - yr - old male renal transplant recipient with right BN .
Diseases:"
2290	MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis .	O O O O O O O O O O O O O O O O O B O O B I O	['myelitis', 'brachial plexitis']	2	10	"Sentence: MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis .
Diseases: myelitis, brachial plexitis"	"Sentence: MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis .
Diseases:"
2291	Symptoms persisted for three months despite TAC dose reduction , administration of IVIG and four doses of methylprednisolone pulse therapy .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Symptoms persisted for three months despite TAC dose reduction , administration of IVIG and four doses of methylprednisolone pulse therapy .
Diseases: "	"Sentence: Symptoms persisted for three months despite TAC dose reduction , administration of IVIG and four doses of methylprednisolone pulse therapy .
Diseases:"
2292	Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus .
Diseases: "	"Sentence: Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus .
Diseases:"
2293	Valvular heart disease in patients with Parkinson 's disease treated with pergolide .	B I I O O O B I I O O O O	"['valvular heart disease', ""parkinson 's disease""]"	2	11	"Sentence: Valvular heart disease in patients with Parkinson 's disease treated with pergolide .
Diseases: valvular heart disease, parkinson 's disease"	"Sentence: Valvular heart disease in patients with Parkinson 's disease treated with pergolide .
Diseases:"
2294	Course following treatment modifications .	O O O O O	[]	0	0	"Sentence: Course following treatment modifications .
Diseases: "	"Sentence: Course following treatment modifications .
Diseases:"
2295	Valvular heart abnormalities have been reported in patients with Parkinson 's disease ( PD ) treated with pergolide .	B I I O O O O O O B I I O B O O O O O	"['pd', ""parkinson 's disease"", 'valvular heart abnormalities']"	3	13	"Sentence: Valvular heart abnormalities have been reported in patients with Parkinson 's disease ( PD ) treated with pergolide .
Diseases: pd, parkinson 's disease, valvular heart abnormalities"	"Sentence: Valvular heart abnormalities have been reported in patients with Parkinson 's disease ( PD ) treated with pergolide .
Diseases:"
2296	However , the incidence and severity of these abnormalities vary from study to study and their course after drug withdrawal has not been systematically assessed .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the incidence and severity of these abnormalities vary from study to study and their course after drug withdrawal has not been systematically assessed .
Diseases: "	"Sentence: However , the incidence and severity of these abnormalities vary from study to study and their course after drug withdrawal has not been systematically assessed .
Diseases:"
2297	To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case - control study .	O O O O O O O B I I O O O O O O O O O O O O O O	['valvular heart abnormality']	1	6	"Sentence: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case - control study .
Diseases: valvular heart abnormality"	"Sentence: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case - control study .
Diseases:"
2298	METHODS : All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography .	O O O B O O O O O O O O O O O O O O O O O O O	['pd']	1	1	"Sentence: METHODS : All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography .
Diseases: pd"	"Sentence: METHODS : All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography .
Diseases:"
2299	Thirty PD patients participated in the study .	O B O O O O O O	['pd']	1	1	"Sentence: Thirty PD patients participated in the study .
Diseases: pd"	"Sentence: Thirty PD patients participated in the study .
Diseases:"
2300	A second echocardiography was performed ( median interval : 13 months ) after pergolide withdrawal ( n = 10 patients ) .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A second echocardiography was performed ( median interval : 13 months ) after pergolide withdrawal ( n = 10 patients ) .
Diseases: "	"Sentence: A second echocardiography was performed ( median interval : 13 months ) after pergolide withdrawal ( n = 10 patients ) .
Diseases:"
2301	Controls were age - and sex - matched non - PD patients referred to the cardiology department .	O O O O O O O O O O B O O O O O O O	['pd']	1	1	"Sentence: Controls were age - and sex - matched non - PD patients referred to the cardiology department .
Diseases: pd"	"Sentence: Controls were age - and sex - matched non - PD patients referred to the cardiology department .
Diseases:"
2302	Compared to controls , aortic regurgitation ( OR : 3 . 1 ; 95 % IC : 1 . 1 - 8 . 8 ) and mitral regurgitation ( OR : 10 . 7 ; 95 % IC : 2 . 1 - 53 ) were more frequent in PD patients ( tricuspid : NS ) .	O O O O B I O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['pd', 'mitral regurgitation', 'aortic regurgitation']	3	14	"Sentence: Compared to controls , aortic regurgitation ( OR : 3 . 1 ; 95 % IC : 1 . 1 - 8 . 8 ) and mitral regurgitation ( OR : 10 . 7 ; 95 % IC : 2 . 1 - 53 ) were more frequent in PD patients ( tricuspid : NS ) .
Diseases: pd, mitral regurgitation, aortic regurgitation"	"Sentence: Compared to controls , aortic regurgitation ( OR : 3 . 1 ; 95 % IC : 1 . 1 - 8 . 8 ) and mitral regurgitation ( OR : 10 . 7 ; 95 % IC : 2 . 1 - 53 ) were more frequent in PD patients ( tricuspid : NS ) .
Diseases:"
2303	The number of affected valves ( n = 2 . 4 + / - 0 . 7 ) and the sum of regurgitation grades ( n = 2 . 8 + / - 1 . 09 ) were higher ( p = 0 . 008 and p = 0 . 006 , respectively ) in the pergolide group .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The number of affected valves ( n = 2 . 4 + / - 0 . 7 ) and the sum of regurgitation grades ( n = 2 . 8 + / - 1 . 09 ) were higher ( p = 0 . 008 and p = 0 . 006 , respectively ) in the pergolide group .
Diseases: "	"Sentence: The number of affected valves ( n = 2 . 4 + / - 0 . 7 ) and the sum of regurgitation grades ( n = 2 . 8 + / - 1 . 09 ) were higher ( p = 0 . 008 and p = 0 . 006 , respectively ) in the pergolide group .
Diseases:"
2304	Severity of regurgitation was not correlated with pergolide cumulative dose .	O O O O O O O O O O O	[]	0	0	"Sentence: Severity of regurgitation was not correlated with pergolide cumulative dose .
Diseases: "	"Sentence: Severity of regurgitation was not correlated with pergolide cumulative dose .
Diseases:"
2305	A restrictive pattern of valvular regurgitation , suggestive of the role of pergolide , was observed in 12 / 30 ( 40 % ) patients including two with heart failure .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O B I O	['heart failure', 'valvular regurgitation']	2	9	"Sentence: A restrictive pattern of valvular regurgitation , suggestive of the role of pergolide , was observed in 12 / 30 ( 40 % ) patients including two with heart failure .
Diseases: heart failure, valvular regurgitation"	"Sentence: A restrictive pattern of valvular regurgitation , suggestive of the role of pergolide , was observed in 12 / 30 ( 40 % ) patients including two with heart failure .
Diseases:"
2306	Pergolide was discontinued in 10 patients with valvular heart disease , resulting in a lower regurgitation grade ( p = 0 . 01 ) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination .	O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O	['valvular heart disease', 'heart failure']	2	8	"Sentence: Pergolide was discontinued in 10 patients with valvular heart disease , resulting in a lower regurgitation grade ( p = 0 . 01 ) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination .
Diseases: valvular heart disease, heart failure"	"Sentence: Pergolide was discontinued in 10 patients with valvular heart disease , resulting in a lower regurgitation grade ( p = 0 . 01 ) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination .
Diseases:"
2307	This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non - ergot dopamine agonists .	O O O O O O O O B I O B O O O O O O O O O O O O O O O O O O O O O O O O	['pd', 'valve regurgitation']	2	6	"Sentence: This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non - ergot dopamine agonists .
Diseases: pd, valve regurgitation"	"Sentence: This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non - ergot dopamine agonists .
Diseases:"
2308	Adverse effects of topical papaverine on auditory nerve function .	O O O O O O O O O O	[]	0	0	"Sentence: Adverse effects of topical papaverine on auditory nerve function .
Diseases: "	"Sentence: Adverse effects of topical papaverine on auditory nerve function .
Diseases:"
2309	Papaverine hydrochloride is a direct - acting vasodilator used to manage vasospasm during various neurosurgical operations .	O O O O O O O O O O O B O O O O O	['vasospasm']	1	3	"Sentence: Papaverine hydrochloride is a direct - acting vasodilator used to manage vasospasm during various neurosurgical operations .
Diseases: vasospasm"	"Sentence: Papaverine hydrochloride is a direct - acting vasodilator used to manage vasospasm during various neurosurgical operations .
Diseases:"
2310	Transient cranial nerve dysfunction has been described in a few cases with topical papaverine .	O B I I O O O O O O O O O O O	['cranial nerve dysfunction']	1	5	"Sentence: Transient cranial nerve dysfunction has been described in a few cases with topical papaverine .
Diseases: cranial nerve dysfunction"	"Sentence: Transient cranial nerve dysfunction has been described in a few cases with topical papaverine .
Diseases:"
2311	This study supports previous reports and provides neurophysiological evidence of an adverse effect on the auditory nerve .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This study supports previous reports and provides neurophysiological evidence of an adverse effect on the auditory nerve .
Diseases: "	"Sentence: This study supports previous reports and provides neurophysiological evidence of an adverse effect on the auditory nerve .
Diseases:"
2312	METHODS : We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm .	O O O O O O O O O O O O O O O O O O O O O O B O	['vasospasm']	1	3	"Sentence: METHODS : We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm .
Diseases: vasospasm"	"Sentence: METHODS : We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm .
Diseases:"
2313	Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .	O O O O O O O O O O O B O O O O O O O	['vasospasm']	1	3	"Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .
Diseases: vasospasm"	"Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .
Diseases:"
2314	The timing of papaverine application and ongoing operative events was reviewed relative to changes in neurophysiological recordings .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The timing of papaverine application and ongoing operative events was reviewed relative to changes in neurophysiological recordings .
Diseases: "	"Sentence: The timing of papaverine application and ongoing operative events was reviewed relative to changes in neurophysiological recordings .
Diseases:"
2315	Brainstem auditory evoked potentials ( BAEPs ) were routinely used to monitor cochlear nerve function during these operations .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Brainstem auditory evoked potentials ( BAEPs ) were routinely used to monitor cochlear nerve function during these operations .
Diseases: "	"Sentence: Brainstem auditory evoked potentials ( BAEPs ) were routinely used to monitor cochlear nerve function during these operations .
Diseases:"
2316	A temporal relationship was found between topical papaverine and BAEP changes leading to complete waveform loss .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A temporal relationship was found between topical papaverine and BAEP changes leading to complete waveform loss .
Diseases: "	"Sentence: A temporal relationship was found between topical papaverine and BAEP changes leading to complete waveform loss .
Diseases:"
2317	The average temporal delay between papaverine and the onset of an adverse BAEP change was 5 min .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The average temporal delay between papaverine and the onset of an adverse BAEP change was 5 min .
Diseases: "	"Sentence: The average temporal delay between papaverine and the onset of an adverse BAEP change was 5 min .
Diseases:"
2318	In 10 of 11 patients , BAEP waves II / III - V completely disappeared within 2 to 25 min after papaverine .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 10 of 11 patients , BAEP waves II / III - V completely disappeared within 2 to 25 min after papaverine .
Diseases: "	"Sentence: In 10 of 11 patients , BAEP waves II / III - V completely disappeared within 2 to 25 min after papaverine .
Diseases:"
2319	Eight of these 10 patients had complete loss of BAEP waveforms within 10 min .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Eight of these 10 patients had complete loss of BAEP waveforms within 10 min .
Diseases: "	"Sentence: Eight of these 10 patients had complete loss of BAEP waveforms within 10 min .
Diseases:"
2320	One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss .	O O O O O O O O O O O O B I I O	['sensorineural hearing loss']	1	6	"Sentence: One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss .
Diseases: sensorineural hearing loss"	"Sentence: One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss .
Diseases:"
2321	The average recovery time of BAEP waveforms to pre - papaverine baseline values was 39 min .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The average recovery time of BAEP waveforms to pre - papaverine baseline values was 39 min .
Diseases: "	"Sentence: The average recovery time of BAEP waveforms to pre - papaverine baseline values was 39 min .
Diseases:"
2322	Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway .	O O O O O O B O O O O O O O O O O O O O O O O O O O	['vasospasm']	1	3	"Sentence: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway .
Diseases: vasospasm"	"Sentence: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway .
Diseases:"
2323	The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve .	O O O O O O O O O O O O O O B I I I I I I O	['adverse effect on the proximal eighth nerve']	1	9	"Sentence: The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve .
Diseases: adverse effect on the proximal eighth nerve"	"Sentence: The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve .
Diseases:"
2324	Recommendations to avoid potential cranial nerve deficits from papaverine are provided .	O O O O B I I O O O O O	['cranial nerve deficits']	1	5	"Sentence: Recommendations to avoid potential cranial nerve deficits from papaverine are provided .
Diseases: cranial nerve deficits"	"Sentence: Recommendations to avoid potential cranial nerve deficits from papaverine are provided .
Diseases:"
2325	Massive proteinuria and acute renal failure after oral bisphosphonate ( alendronate ) administration in a patient with focal segmental glomerulosclerosis .	O B O B I I O O O O O O O O O O O B I I O	['acute renal failure', 'focal segmental glomerulosclerosis', 'proteinuria']	3	16	"Sentence: Massive proteinuria and acute renal failure after oral bisphosphonate ( alendronate ) administration in a patient with focal segmental glomerulosclerosis .
Diseases: acute renal failure, focal segmental glomerulosclerosis, proteinuria"	"Sentence: Massive proteinuria and acute renal failure after oral bisphosphonate ( alendronate ) administration in a patient with focal segmental glomerulosclerosis .
Diseases:"
2326	A 61 - year - old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy .	O O O O O O O O O B I O O B I I O O O O O O O O	['focal segmental glomerulosclerosis', 'nephrotic syndrome']	2	15	"Sentence: A 61 - year - old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy .
Diseases: focal segmental glomerulosclerosis, nephrotic syndrome"	"Sentence: A 61 - year - old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy .
Diseases:"
2327	The amount of daily urinary protein decreased from 15 . 6 to 2 . 8 g . Within 14 days of the oral bisphosphonate ( alendronate sodium ) administration , the amount of daily urinary protein increased rapidly up to 12 . 8 g with acute renal failure .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	['acute renal failure']	1	4	"Sentence: The amount of daily urinary protein decreased from 15 . 6 to 2 . 8 g . Within 14 days of the oral bisphosphonate ( alendronate sodium ) administration , the amount of daily urinary protein increased rapidly up to 12 . 8 g with acute renal failure .
Diseases: acute renal failure"	"Sentence: The amount of daily urinary protein decreased from 15 . 6 to 2 . 8 g . Within 14 days of the oral bisphosphonate ( alendronate sodium ) administration , the amount of daily urinary protein increased rapidly up to 12 . 8 g with acute renal failure .
Diseases:"
2328	After discontinuing the oral alendronate , the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After discontinuing the oral alendronate , the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis .
Diseases: "	"Sentence: After discontinuing the oral alendronate , the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis .
Diseases:"
2329	Urinary volume and serum creatinine levels recovered to the normal range , with urinary protein disappearing completely within 40 days .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Urinary volume and serum creatinine levels recovered to the normal range , with urinary protein disappearing completely within 40 days .
Diseases: "	"Sentence: Urinary volume and serum creatinine levels recovered to the normal range , with urinary protein disappearing completely within 40 days .
Diseases:"
2330	This report demonstrates that not only intravenous , but also oral bisphosphonates can aggravate proteinuria and acute renal failure .	O O O O O O O O O O O O O O B O B I I O	['acute renal failure', 'proteinuria']	2	7	"Sentence: This report demonstrates that not only intravenous , but also oral bisphosphonates can aggravate proteinuria and acute renal failure .
Diseases: acute renal failure, proteinuria"	"Sentence: This report demonstrates that not only intravenous , but also oral bisphosphonates can aggravate proteinuria and acute renal failure .
Diseases:"
2331	Serum - and glucocorticoid - inducible kinase 1 in doxorubicin - induced nephrotic syndrome .	O O O O O O O O O O O O B I O	['nephrotic syndrome']	1	5	"Sentence: Serum - and glucocorticoid - inducible kinase 1 in doxorubicin - induced nephrotic syndrome .
Diseases: nephrotic syndrome"	"Sentence: Serum - and glucocorticoid - inducible kinase 1 in doxorubicin - induced nephrotic syndrome .
Diseases:"
2332	Doxorubicin - induced nephropathy leads to epithelial sodium channel ( ENaC ) - dependent volume retention and renal fibrosis .	O O O B O O O O O O O O O O B I O O B O	['volume retention', 'nephropathy', 'fibrosis']	3	10	"Sentence: Doxorubicin - induced nephropathy leads to epithelial sodium channel ( ENaC ) - dependent volume retention and renal fibrosis .
Diseases: volume retention, nephropathy, fibrosis"	"Sentence: Doxorubicin - induced nephropathy leads to epithelial sodium channel ( ENaC ) - dependent volume retention and renal fibrosis .
Diseases:"
2333	The aldosterone - sensitive serum - and glucocorticoid - inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['fibrosis']	1	3	"Sentence: The aldosterone - sensitive serum - and glucocorticoid - inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess .
Diseases: fibrosis"	"Sentence: The aldosterone - sensitive serum - and glucocorticoid - inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess .
Diseases:"
2334	The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome .	O O O O O O O O O O O O O B I O B O B I O	['volume retention', 'nephrotic syndrome', 'fibrosis']	3	11	"Sentence: The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome .
Diseases: volume retention, nephrotic syndrome, fibrosis"	"Sentence: The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome .
Diseases:"
2335	To this end , doxorubicin ( 15 mug / g body wt ) was injected intravenously into gene - targeted mice lacking SGK1 ( sgk1 ( - / - ) ) and their wild - type littermates ( sgk1 ( + / + ) ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To this end , doxorubicin ( 15 mug / g body wt ) was injected intravenously into gene - targeted mice lacking SGK1 ( sgk1 ( - / - ) ) and their wild - type littermates ( sgk1 ( + / + ) ) .
Diseases: "	"Sentence: To this end , doxorubicin ( 15 mug / g body wt ) was injected intravenously into gene - targeted mice lacking SGK1 ( sgk1 ( - / - ) ) and their wild - type littermates ( sgk1 ( + / + ) ) .
Diseases:"
2336	Doxorubicin treatment resulted in heavy proteinuria ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe nephrotic syndrome with ascites , lipidemia , and hypoalbuminemia in both genotypes .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O B O B O O B O O O O	['lipidemia', 'proteinuria', 'hypoalbuminemia', 'nephrotic syndrome', 'ascites']	5	21	"Sentence: Doxorubicin treatment resulted in heavy proteinuria ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe nephrotic syndrome with ascites , lipidemia , and hypoalbuminemia in both genotypes .
Diseases: lipidemia, proteinuria, hypoalbuminemia, nephrotic syndrome, ascites"	"Sentence: Doxorubicin treatment resulted in heavy proteinuria ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe nephrotic syndrome with ascites , lipidemia , and hypoalbuminemia in both genotypes .
Diseases:"
2337	Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1 ( + / + ) mice .	O O O O O B O O O O O O O O O O O O O O O O O O O O O	['nephrotic']	1	4	"Sentence: Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1 ( + / + ) mice .
Diseases: nephrotic"	"Sentence: Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1 ( + / + ) mice .
Diseases:"
2338	Urinary sodium excretion reached signficantly lower values in sgk1 ( + / + ) mice ( 15 + / - 5 mumol / mg crea ) than in sgk1 ( - / - ) mice ( 35 + / - 5 mumol / mg crea ) and was associated with a significantly higher body weight gain in sgk1 ( + / + ) compared with sgk1 ( - / - ) mice ( + 6 . 6 + / - 0 . 7 vs . + 4 . 1 + / - 0 . 8 g ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['weight gain']	1	2	"Sentence: Urinary sodium excretion reached signficantly lower values in sgk1 ( + / + ) mice ( 15 + / - 5 mumol / mg crea ) than in sgk1 ( - / - ) mice ( 35 + / - 5 mumol / mg crea ) and was associated with a significantly higher body weight gain in sgk1 ( + / + ) compared with sgk1 ( - / - ) mice ( + 6 . 6 + / - 0 . 7 vs . + 4 . 1 + / - 0 . 8 g ) .
Diseases: weight gain"	"Sentence: Urinary sodium excretion reached signficantly lower values in sgk1 ( + / + ) mice ( 15 + / - 5 mumol / mg crea ) than in sgk1 ( - / - ) mice ( 35 + / - 5 mumol / mg crea ) and was associated with a significantly higher body weight gain in sgk1 ( + / + ) compared with sgk1 ( - / - ) mice ( + 6 . 6 + / - 0 . 7 vs . + 4 . 1 + / - 0 . 8 g ) .
Diseases:"
2339	During the course of nephrotic syndrome , serum urea concentrations increased significantly faster in sgk1 ( - / - ) mice than in sgk1 ( + / + )	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O	['nephrotic syndrome']	1	5	"Sentence: During the course of nephrotic syndrome , serum urea concentrations increased significantly faster in sgk1 ( - / - ) mice than in sgk1 ( + / + )
Diseases: nephrotic syndrome"	"Sentence: During the course of nephrotic syndrome , serum urea concentrations increased significantly faster in sgk1 ( - / - ) mice than in sgk1 ( + / + )
Diseases:"
2340	mice leading to uremia and a reduced median survival in sgk1 ( - / - ) mice ( 29 vs . 40 days in sgk1 ( + / + ) mice ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['uremia']	1	2	"Sentence: mice leading to uremia and a reduced median survival in sgk1 ( - / - ) mice ( 29 vs . 40 days in sgk1 ( + / + ) mice ) .
Diseases: uremia"	"Sentence: mice leading to uremia and a reduced median survival in sgk1 ( - / - ) mice ( 29 vs . 40 days in sgk1 ( + / + ) mice ) .
Diseases:"
2341	In conclusion , gene - targeted mice lacking SGK1 showed blunted volume retention , yet were not protected against renal fibrosis during experimental nephrotic syndrome .	O O O O O O O O O O O B I O O O O O O O B O O B I O	['volume retention', 'nephrotic syndrome', 'fibrosis']	3	11	"Sentence: In conclusion , gene - targeted mice lacking SGK1 showed blunted volume retention , yet were not protected against renal fibrosis during experimental nephrotic syndrome .
Diseases: volume retention, nephrotic syndrome, fibrosis"	"Sentence: In conclusion , gene - targeted mice lacking SGK1 showed blunted volume retention , yet were not protected against renal fibrosis during experimental nephrotic syndrome .
Diseases:"
2342	Severe and long lasting cholestasis after high - dose co - trimoxazole treatment for Pneumocystis pneumonia in HIV - infected patients - - a report of two cases .	O O O O B O O O O O O O O O B I O B I I O O O O O O O O O	['cholestasis', 'pneumocystis pneumonia', 'hiv - infected']	3	15	"Sentence: Severe and long lasting cholestasis after high - dose co - trimoxazole treatment for Pneumocystis pneumonia in HIV - infected patients - - a report of two cases .
Diseases: cholestasis, pneumocystis pneumonia, hiv - infected"	"Sentence: Severe and long lasting cholestasis after high - dose co - trimoxazole treatment for Pneumocystis pneumonia in HIV - infected patients - - a report of two cases .
Diseases:"
2343	Pneumocystis pneumonia ( PCP ) , a common opportunistic infection in HIV - infected individuals , is generally treated with high doses of co - trimoxazole .	B I O B O O O O B I O B I I O O O O O O O O O O O O O	['pneumocystis pneumonia', 'pcp', 'hiv - infected', 'opportunistic infection']	4	18	"Sentence: Pneumocystis pneumonia ( PCP ) , a common opportunistic infection in HIV - infected individuals , is generally treated with high doses of co - trimoxazole .
Diseases: pneumocystis pneumonia, pcp, hiv - infected, opportunistic infection"	"Sentence: Pneumocystis pneumonia ( PCP ) , a common opportunistic infection in HIV - infected individuals , is generally treated with high doses of co - trimoxazole .
Diseases:"
2344	However , treatment is often limited by adverse effects .	O O O O O O O O O O	[]	0	0	"Sentence: However , treatment is often limited by adverse effects .
Diseases: "	"Sentence: However , treatment is often limited by adverse effects .
Diseases:"
2345	Here , we report two cases of severely immunocompromised HIV - infected patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking liver abscess formation on radiologic exams , during co - trimoxazole treatment for PCP .	O O O O O O O O O B I I O O O O B I O O O O O O O B I O O O O O O O O O O O B O	['liver abscess', 'pcp', 'hiv - infected', 'intrahepatic cholestasis']	4	21	"Sentence: Here , we report two cases of severely immunocompromised HIV - infected patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking liver abscess formation on radiologic exams , during co - trimoxazole treatment for PCP .
Diseases: liver abscess, pcp, hiv - infected, intrahepatic cholestasis"	"Sentence: Here , we report two cases of severely immunocompromised HIV - infected patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking liver abscess formation on radiologic exams , during co - trimoxazole treatment for PCP .
Diseases:"
2346	Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co - trimoxazole treatment , therapy of patient 2 was switched early .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co - trimoxazole treatment , therapy of patient 2 was switched early .
Diseases: "	"Sentence: Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co - trimoxazole treatment , therapy of patient 2 was switched early .
Diseases:"
2347	Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients .	O O B O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients .
Diseases: proteinuria"	"Sentence: Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients .
Diseases:"
2348	Sirolimus is the latest immunosuppressive agent used to prevent rejection , and may have less nephrotoxicity than calcineurin inhibitor ( CNI ) - based regimens .	O O O O O O O O O O O O O O O B O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Sirolimus is the latest immunosuppressive agent used to prevent rejection , and may have less nephrotoxicity than calcineurin inhibitor ( CNI ) - based regimens .
Diseases: nephrotoxicity"	"Sentence: Sirolimus is the latest immunosuppressive agent used to prevent rejection , and may have less nephrotoxicity than calcineurin inhibitor ( CNI ) - based regimens .
Diseases:"
2349	To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus .	O O O O O O O O O O B O O O O O O O	['proteinuria']	1	2	"Sentence: To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus .
Diseases: proteinuria"	"Sentence: To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus .
Diseases:"
2350	We have encountered several patients who developed substantial proteinuria associated with sirolimus use .	O O O O O O O O B O O O O O	['proteinuria']	1	2	"Sentence: We have encountered several patients who developed substantial proteinuria associated with sirolimus use .
Diseases: proteinuria"	"Sentence: We have encountered several patients who developed substantial proteinuria associated with sirolimus use .
Diseases:"
2351	In each patient , the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria .	O O O O O O O O O O O O O O O B O O O O O O O O O B O	['proteinuria']	1	2	"Sentence: In each patient , the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria .
Diseases: proteinuria"	"Sentence: In each patient , the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria .
Diseases:"
2352	METHODS : We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999 - 2003 for whom sirolimus was a component of their immunosuppressant regimen .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999 - 2003 for whom sirolimus was a component of their immunosuppressant regimen .
Diseases: "	"Sentence: METHODS : We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999 - 2003 for whom sirolimus was a component of their immunosuppressant regimen .
Diseases:"
2353	In these patients , the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein : creatinine ratios , an estimate of grams of proteinuria / day .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O B O O O	['proteinuria']	1	2	"Sentence: In these patients , the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein : creatinine ratios , an estimate of grams of proteinuria / day .
Diseases: proteinuria"	"Sentence: In these patients , the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein : creatinine ratios , an estimate of grams of proteinuria / day .
Diseases:"
2354	Laboratory results were compared between prior , during and following sirolimus use .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Laboratory results were compared between prior , during and following sirolimus use .
Diseases: "	"Sentence: Laboratory results were compared between prior , during and following sirolimus use .
Diseases:"
2355	Twenty - eight patients ( 24 % ) developed increased proteinuria from baseline during their post - transplantation course .	O O O O O O O O O O B O O O O O O O O O	['proteinuria']	1	2	"Sentence: Twenty - eight patients ( 24 % ) developed increased proteinuria from baseline during their post - transplantation course .
Diseases: proteinuria"	"Sentence: Twenty - eight patients ( 24 % ) developed increased proteinuria from baseline during their post - transplantation course .
Diseases:"
2356	In 21 patients an alternative cause of proteinuria was either obvious or insufficient data was available to be conclusive .	O O O O O O O B O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: In 21 patients an alternative cause of proteinuria was either obvious or insufficient data was available to be conclusive .
Diseases: proteinuria"	"Sentence: In 21 patients an alternative cause of proteinuria was either obvious or insufficient data was available to be conclusive .
Diseases:"
2357	In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic - range proteinuria .	O O O O O O O O O O O O O O O O O O O O O B O O B O	['nephrotic', 'proteinuria']	2	7	"Sentence: In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic - range proteinuria .
Diseases: nephrotic, proteinuria"	"Sentence: In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic - range proteinuria .
Diseases:"
2358	Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables .	B O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables .
Diseases: proteinuria"	"Sentence: Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables .
Diseases:"
2359	In most patients , discontinuation of sirolimus resulted in a decrease , but not resolution , of proteinuria .	O O O O O O O O O O O O O O O O O B O	['proteinuria']	1	2	"Sentence: In most patients , discontinuation of sirolimus resulted in a decrease , but not resolution , of proteinuria .
Diseases: proteinuria"	"Sentence: In most patients , discontinuation of sirolimus resulted in a decrease , but not resolution , of proteinuria .
Diseases:"
2360	CONCLUSIONS : Sirolimus induces or aggravates pre - existing proteinuria in an unpredictable subset of renal allograft recipients .	O O O O O O O O O B O O O O O O O O O	['proteinuria']	1	2	"Sentence: CONCLUSIONS : Sirolimus induces or aggravates pre - existing proteinuria in an unpredictable subset of renal allograft recipients .
Diseases: proteinuria"	"Sentence: CONCLUSIONS : Sirolimus induces or aggravates pre - existing proteinuria in an unpredictable subset of renal allograft recipients .
Diseases:"
2361	Proteinuria may improve , but does not resolve , when sirolimus is withdrawn .	B O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Proteinuria may improve , but does not resolve , when sirolimus is withdrawn .
Diseases: proteinuria"	"Sentence: Proteinuria may improve , but does not resolve , when sirolimus is withdrawn .
Diseases:"
2362	Comparative cognitive and subjective side effects of immediate - release oxycodone in healthy middle - aged and older adults .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Comparative cognitive and subjective side effects of immediate - release oxycodone in healthy middle - aged and older adults .
Diseases: "	"Sentence: Comparative cognitive and subjective side effects of immediate - release oxycodone in healthy middle - aged and older adults .
Diseases:"
2363	This study measured the objective and subjective neurocognitive effects of a single 10 - mg dose of immediate - release oxycodone in healthy , older ( > 65 years ) , and middle - aged ( 35 to 55 years ) adults who were not suffering from chronic or significant daily pain .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['pain']	1	1	"Sentence: This study measured the objective and subjective neurocognitive effects of a single 10 - mg dose of immediate - release oxycodone in healthy , older ( > 65 years ) , and middle - aged ( 35 to 55 years ) adults who were not suffering from chronic or significant daily pain .
Diseases: pain"	"Sentence: This study measured the objective and subjective neurocognitive effects of a single 10 - mg dose of immediate - release oxycodone in healthy , older ( > 65 years ) , and middle - aged ( 35 to 55 years ) adults who were not suffering from chronic or significant daily pain .
Diseases:"
2364	Seventy - one participants completed 2 separate study days and were blind to medication condition ( placebo , 10 - mg oxycodone ) .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Seventy - one participants completed 2 separate study days and were blind to medication condition ( placebo , 10 - mg oxycodone ) .
Diseases: "	"Sentence: Seventy - one participants completed 2 separate study days and were blind to medication condition ( placebo , 10 - mg oxycodone ) .
Diseases:"
2365	Plasma oxycodone concentration peaked between 60 and 90 minutes postdose ( P < . 01 ) and pupil size , an indication of physiological effects of the medication , peaked at approximately 90 to 120 minutes postdose ( P < . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma oxycodone concentration peaked between 60 and 90 minutes postdose ( P < . 01 ) and pupil size , an indication of physiological effects of the medication , peaked at approximately 90 to 120 minutes postdose ( P < . 01 ) .
Diseases: "	"Sentence: Plasma oxycodone concentration peaked between 60 and 90 minutes postdose ( P < . 01 ) and pupil size , an indication of physiological effects of the medication , peaked at approximately 90 to 120 minutes postdose ( P < . 01 ) .
Diseases:"
2366	Significant declines in simple and sustained attention , working memory , and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose .	O B I I I I I I I I I I I I O O O O O O O O O O O O O O O O O O O O O O O O O	['declines in simple and sustained attention , working memory , and verbal memory']	1	14	"Sentence: Significant declines in simple and sustained attention , working memory , and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose .
Diseases: declines in simple and sustained attention , working memory , and verbal memory"	"Sentence: Significant declines in simple and sustained attention , working memory , and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose .
Diseases:"
2367	For almost all cognitive measures , there were no medication by age - interaction effects , which indicates that the 2 age groups exhibited similar responses to the medication challenge .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For almost all cognitive measures , there were no medication by age - interaction effects , which indicates that the 2 age groups exhibited similar responses to the medication challenge .
Diseases: "	"Sentence: For almost all cognitive measures , there were no medication by age - interaction effects , which indicates that the 2 age groups exhibited similar responses to the medication challenge .
Diseases:"
2368	This study suggests that for healthy older adults who are not suffering from chronic pain , neurocognitive and pharmacodynamic changes in response to a 10 - mg dose of immediate - release oxycodone are similar to those observed for middle - aged adults .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['chronic pain']	1	3	"Sentence: This study suggests that for healthy older adults who are not suffering from chronic pain , neurocognitive and pharmacodynamic changes in response to a 10 - mg dose of immediate - release oxycodone are similar to those observed for middle - aged adults .
Diseases: chronic pain"	"Sentence: This study suggests that for healthy older adults who are not suffering from chronic pain , neurocognitive and pharmacodynamic changes in response to a 10 - mg dose of immediate - release oxycodone are similar to those observed for middle - aged adults .
Diseases:"
2369	PERSPECTIVE :	O O	[]	0	0	"Sentence: PERSPECTIVE :
Diseases: "	"Sentence: PERSPECTIVE :
Diseases:"
2370	Study findings indicate that the metabolism , neurocognitive effects , and physical side effects of oral oxycodone are similar for healthy middle - aged and older adults .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Study findings indicate that the metabolism , neurocognitive effects , and physical side effects of oral oxycodone are similar for healthy middle - aged and older adults .
Diseases: "	"Sentence: Study findings indicate that the metabolism , neurocognitive effects , and physical side effects of oral oxycodone are similar for healthy middle - aged and older adults .
Diseases:"
2371	Therefore , clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Therefore , clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults .
Diseases: "	"Sentence: Therefore , clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults .
Diseases:"
2372	Normalizing effects of modafinil on sleep in chronic cocaine users .	O O O O O O O O O O O	[]	0	0	"Sentence: Normalizing effects of modafinil on sleep in chronic cocaine users .
Diseases: "	"Sentence: Normalizing effects of modafinil on sleep in chronic cocaine users .
Diseases:"
2373	The purpose of the present study was to determine the effect of morning - dosed modafinil on sleep and daytime sleepiness in chronic cocaine users .	O O O O O O O O O O O O O O O O O O O B I O O O O O	['daytime sleepiness']	1	4	"Sentence: The purpose of the present study was to determine the effect of morning - dosed modafinil on sleep and daytime sleepiness in chronic cocaine users .
Diseases: daytime sleepiness"	"Sentence: The purpose of the present study was to determine the effect of morning - dosed modafinil on sleep and daytime sleepiness in chronic cocaine users .
Diseases:"
2374	METHOD : Twenty cocaine - dependent participants were randomly assigned to receive modafinil , 400 mg ( N = 10 ) , or placebo ( N = 10 ) every morning at 7 : 30 a . m . for 16 days in an inpatient , double - blind randomized trial .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHOD : Twenty cocaine - dependent participants were randomly assigned to receive modafinil , 400 mg ( N = 10 ) , or placebo ( N = 10 ) every morning at 7 : 30 a . m . for 16 days in an inpatient , double - blind randomized trial .
Diseases: "	"Sentence: METHOD : Twenty cocaine - dependent participants were randomly assigned to receive modafinil , 400 mg ( N = 10 ) , or placebo ( N = 10 ) every morning at 7 : 30 a . m . for 16 days in an inpatient , double - blind randomized trial .
Diseases:"
2375	Participants underwent polysomnographic sleep recordings on days 1 to 3 , 7 to 9 , and 14 to 16 ( first , second , and third weeks of abstinence ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Participants underwent polysomnographic sleep recordings on days 1 to 3 , 7 to 9 , and 14 to 16 ( first , second , and third weeks of abstinence ) .
Diseases: "	"Sentence: Participants underwent polysomnographic sleep recordings on days 1 to 3 , 7 to 9 , and 14 to 16 ( first , second , and third weeks of abstinence ) .
Diseases:"
2376	The Multiple Sleep Latency Test was performed at 11 : 30 a . m . , 2 : 00 p . m . , and 4 : 30 p . m . on days 2 , 8 , and 15 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The Multiple Sleep Latency Test was performed at 11 : 30 a . m . , 2 : 00 p . m . , and 4 : 30 p . m . on days 2 , 8 , and 15 .
Diseases: "	"Sentence: The Multiple Sleep Latency Test was performed at 11 : 30 a . m . , 2 : 00 p . m . , and 4 : 30 p . m . on days 2 , 8 , and 15 .
Diseases:"
2377	For comparison of sleep architecture variables , 12 healthy comparison participants underwent a single night of experimental polysomnography that followed 1 night of accommodation polysomnography .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For comparison of sleep architecture variables , 12 healthy comparison participants underwent a single night of experimental polysomnography that followed 1 night of accommodation polysomnography .
Diseases: "	"Sentence: For comparison of sleep architecture variables , 12 healthy comparison participants underwent a single night of experimental polysomnography that followed 1 night of accommodation polysomnography .
Diseases:"
2378	Progressive abstinence from cocaine was associated with worsening of all measured polysomnographic sleep outcomes .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Progressive abstinence from cocaine was associated with worsening of all measured polysomnographic sleep outcomes .
Diseases: "	"Sentence: Progressive abstinence from cocaine was associated with worsening of all measured polysomnographic sleep outcomes .
Diseases:"
2379	Compared with placebo , modafinil decreased nighttime sleep latency and increased slow - wave sleep time in cocaine - dependent participants .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Compared with placebo , modafinil decreased nighttime sleep latency and increased slow - wave sleep time in cocaine - dependent participants .
Diseases: "	"Sentence: Compared with placebo , modafinil decreased nighttime sleep latency and increased slow - wave sleep time in cocaine - dependent participants .
Diseases:"
2380	The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence .
Diseases: "	"Sentence: The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence .
Diseases:"
2381	Comparison of slow - wave sleep time , total sleep time , and sleep latency in cocaine - dependent and healthy participants revealed a normalizing effect of modafinil in cocaine - dependent participants .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Comparison of slow - wave sleep time , total sleep time , and sleep latency in cocaine - dependent and healthy participants revealed a normalizing effect of modafinil in cocaine - dependent participants .
Diseases: "	"Sentence: Comparison of slow - wave sleep time , total sleep time , and sleep latency in cocaine - dependent and healthy participants revealed a normalizing effect of modafinil in cocaine - dependent participants .
Diseases:"
2382	Modafinil was associated with increased daytime sleep latency , as measured by the Multiple Sleep Latency Test , and a nearly significant decrease in subjective daytime sleepiness .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['daytime sleepiness']	1	4	"Sentence: Modafinil was associated with increased daytime sleep latency , as measured by the Multiple Sleep Latency Test , and a nearly significant decrease in subjective daytime sleepiness .
Diseases: daytime sleepiness"	"Sentence: Modafinil was associated with increased daytime sleep latency , as measured by the Multiple Sleep Latency Test , and a nearly significant decrease in subjective daytime sleepiness .
Diseases:"
2383	CONCLUSIONS : Morning - dosed modafinil promotes nocturnal sleep , normalizes sleep architecture , and decreases daytime sleepiness in abstinent cocaine users .	O O O O O O O O O O O O O O O O B I O O O O O	['daytime sleepiness']	1	4	"Sentence: CONCLUSIONS : Morning - dosed modafinil promotes nocturnal sleep , normalizes sleep architecture , and decreases daytime sleepiness in abstinent cocaine users .
Diseases: daytime sleepiness"	"Sentence: CONCLUSIONS : Morning - dosed modafinil promotes nocturnal sleep , normalizes sleep architecture , and decreases daytime sleepiness in abstinent cocaine users .
Diseases:"
2384	These effects may be relevant in the treatment of cocaine dependence .	O O O O O O O O O O O O	[]	0	0	"Sentence: These effects may be relevant in the treatment of cocaine dependence .
Diseases: "	"Sentence: These effects may be relevant in the treatment of cocaine dependence .
Diseases:"
2385	Efficacy and safety of asenapine in a placebo - and haloperidol - controlled trial in patients with acute exacerbation of schizophrenia .	O O O O O O O O O O O O O O O O O O O O B O	['schizophrenia']	1	3	"Sentence: Efficacy and safety of asenapine in a placebo - and haloperidol - controlled trial in patients with acute exacerbation of schizophrenia .
Diseases: schizophrenia"	"Sentence: Efficacy and safety of asenapine in a placebo - and haloperidol - controlled trial in patients with acute exacerbation of schizophrenia .
Diseases:"
2386	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features .	O O O O O O O O O O O O O O O B O O B O O O O O B I I O O O B O O	['schizophrenia', 'manic', 'bipolar i disorder', 'psychotic']	4	11	"Sentence: Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features .
Diseases: schizophrenia, manic, bipolar i disorder, psychotic"	"Sentence: Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features .
Diseases:"
2387	In a double - blind 6 - week trial , 458 patients with acute schizophrenia were randomly assigned to fixed - dose treatment with asenapine at 5 mg twice daily ( BID ) , asenapine at 10 mg BID , placebo , or haloperidol at 4 mg BID ( to verify assay sensitivity ) .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['schizophrenia']	1	3	"Sentence: In a double - blind 6 - week trial , 458 patients with acute schizophrenia were randomly assigned to fixed - dose treatment with asenapine at 5 mg twice daily ( BID ) , asenapine at 10 mg BID , placebo , or haloperidol at 4 mg BID ( to verify assay sensitivity ) .
Diseases: schizophrenia"	"Sentence: In a double - blind 6 - week trial , 458 patients with acute schizophrenia were randomly assigned to fixed - dose treatment with asenapine at 5 mg twice daily ( BID ) , asenapine at 10 mg BID , placebo , or haloperidol at 4 mg BID ( to verify assay sensitivity ) .
Diseases:"
2388	With last observations carried forward ( LOCF ) , mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID ( - 16 . 2 ) and haloperidol ( - 15 . 4 ) than placebo ( - 10 . 7 ; both P < 0 . 05 ) ; using mixed model for repeated measures ( MMRM ) , changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID ( - 21 . 3 and - 19 . 4 , respectively ) and haloperidol ( - 20 . 0 ) than placebo ( - 14 . 6 ; all P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: With last observations carried forward ( LOCF ) , mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID ( - 16 . 2 ) and haloperidol ( - 15 . 4 ) than placebo ( - 10 . 7 ; both P < 0 . 05 ) ; using mixed model for repeated measures ( MMRM ) , changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID ( - 21 . 3 and - 19 . 4 , respectively ) and haloperidol ( - 20 . 0 ) than placebo ( - 14 . 6 ; all P < 0 . 05 ) .
Diseases: "	"Sentence: With last observations carried forward ( LOCF ) , mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID ( - 16 . 2 ) and haloperidol ( - 15 . 4 ) than placebo ( - 10 . 7 ; both P < 0 . 05 ) ; using mixed model for repeated measures ( MMRM ) , changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID ( - 21 . 3 and - 19 . 4 , respectively ) and haloperidol ( - 20 . 0 ) than placebo ( - 14 . 6 ; all P < 0 . 05 ) .
Diseases:"
2389	On the Positive and Negative Syndrome Scale positive subscale , all treatments were superior to placebo with LOCF and MMRM ; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On the Positive and Negative Syndrome Scale positive subscale , all treatments were superior to placebo with LOCF and MMRM ; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM .
Diseases: "	"Sentence: On the Positive and Negative Syndrome Scale positive subscale , all treatments were superior to placebo with LOCF and MMRM ; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM .
Diseases:"
2390	Treatment - related adverse events ( AEs ) occurred in 44 % and 52 % , 57 % , and 41 % of the asenapine at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Treatment - related adverse events ( AEs ) occurred in 44 % and 52 % , 57 % , and 41 % of the asenapine at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .
Diseases: "	"Sentence: Treatment - related adverse events ( AEs ) occurred in 44 % and 52 % , 57 % , and 41 % of the asenapine at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .
Diseases:"
2391	Extrapyramidal symptoms reported as AEs occurred in 15 % and 18 % , 34 % , and 10 % of the asenapine at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['extrapyramidal symptoms']	1	6	"Sentence: Extrapyramidal symptoms reported as AEs occurred in 15 % and 18 % , 34 % , and 10 % of the asenapine at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .
Diseases: extrapyramidal symptoms"	"Sentence: Extrapyramidal symptoms reported as AEs occurred in 15 % and 18 % , 34 % , and 10 % of the asenapine at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .
Diseases:"
2392	Across all groups , no more than 5 % of patients had clinically significant weight change .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Across all groups , no more than 5 % of patients had clinically significant weight change .
Diseases: "	"Sentence: Across all groups , no more than 5 % of patients had clinically significant weight change .
Diseases:"
2393	Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol ; greater contrasts were seen in AEs , especially extrapyramidal symptoms .	O O O O O O O O O O O O O O O O O O O O O B I O	['extrapyramidal symptoms']	1	6	"Sentence: Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol ; greater contrasts were seen in AEs , especially extrapyramidal symptoms .
Diseases: extrapyramidal symptoms"	"Sentence: Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol ; greater contrasts were seen in AEs , especially extrapyramidal symptoms .
Diseases:"
2394	Permeability , ultrastructural changes , and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis .	O O O O O O O O O O O O O O O O O O B O	['nephrosis']	1	3	"Sentence: Permeability , ultrastructural changes , and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis .
Diseases: nephrosis"	"Sentence: Permeability , ultrastructural changes , and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis .
Diseases:"
2395	BACKGROUND / AIMS :	O O O O	[]	0	0	"Sentence: BACKGROUND / AIMS :
Diseases: "	"Sentence: BACKGROUND / AIMS :
Diseases:"
2396	It is still unclear what happens in the glomerulus when proteinuria starts .	O O O O O O O O O O B O O	['proteinuria']	1	2	"Sentence: It is still unclear what happens in the glomerulus when proteinuria starts .
Diseases: proteinuria"	"Sentence: It is still unclear what happens in the glomerulus when proteinuria starts .
Diseases:"
2397	Using puromycin aminonucleoside nephrosis ( PAN ) rats , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules nephrin , a - actinin , dendrin , and plekhh2 , the last two of which were only recently discovered in podocytes .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrosis']	1	3	"Sentence: Using puromycin aminonucleoside nephrosis ( PAN ) rats , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules nephrin , a - actinin , dendrin , and plekhh2 , the last two of which were only recently discovered in podocytes .
Diseases: nephrosis"	"Sentence: Using puromycin aminonucleoside nephrosis ( PAN ) rats , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules nephrin , a - actinin , dendrin , and plekhh2 , the last two of which were only recently discovered in podocytes .
Diseases:"
2398	METHODS : Using immune stainings , semiquantitative measurement was performed under the electron microscope .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Using immune stainings , semiquantitative measurement was performed under the electron microscope .
Diseases: "	"Sentence: METHODS : Using immune stainings , semiquantitative measurement was performed under the electron microscope .
Diseases:"
2399	Permeability was assessed using isolated kidney perfusion with tracers .	O O O O O O O O O O	[]	0	0	"Sentence: Permeability was assessed using isolated kidney perfusion with tracers .
Diseases: "	"Sentence: Permeability was assessed using isolated kidney perfusion with tracers .
Diseases:"
2400	Possible effects of ACE inhibition were tested .	O O O O O O O O	[]	0	0	"Sentence: Possible effects of ACE inhibition were tested .
Diseases: "	"Sentence: Possible effects of ACE inhibition were tested .
Diseases:"
2401	By day 2 , some patchy foot process effacement , but no proteinuria , appeared .	O O O O O O O O O O O O B O O O	['proteinuria']	1	2	"Sentence: By day 2 , some patchy foot process effacement , but no proteinuria , appeared .
Diseases: proteinuria"	"Sentence: By day 2 , some patchy foot process effacement , but no proteinuria , appeared .
Diseases:"
2402	The amount of nephrin was reduced in both diseased and normal areas .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The amount of nephrin was reduced in both diseased and normal areas .
Diseases: "	"Sentence: The amount of nephrin was reduced in both diseased and normal areas .
Diseases:"
2403	The other proteins showed few changes , which were limited to diseased areas .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The other proteins showed few changes , which were limited to diseased areas .
Diseases: "	"Sentence: The other proteins showed few changes , which were limited to diseased areas .
Diseases:"
2404	By day 4 , foot process effacement was complete and proteinuria appeared in parallel with signs of size barrier damage .	O O O O O O O O O O B O O O O O O O O O O	['proteinuria']	1	2	"Sentence: By day 4 , foot process effacement was complete and proteinuria appeared in parallel with signs of size barrier damage .
Diseases: proteinuria"	"Sentence: By day 4 , foot process effacement was complete and proteinuria appeared in parallel with signs of size barrier damage .
Diseases:"
2405	Nephrin decreased further , while dendrin and plekhh2 also decreased but a - actinin remained unchanged .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nephrin decreased further , while dendrin and plekhh2 also decreased but a - actinin remained unchanged .
Diseases: "	"Sentence: Nephrin decreased further , while dendrin and plekhh2 also decreased but a - actinin remained unchanged .
Diseases:"
2406	ACE inhibition had no significant protective effect .	O O O O O O O O	[]	0	0	"Sentence: ACE inhibition had no significant protective effect .
Diseases: "	"Sentence: ACE inhibition had no significant protective effect .
Diseases:"
2407	CONCLUSIONS : PAN glomeruli already showed significant pathology by day 4 , despite relatively mild proteinuria .	O O O O O O O O O O O O O O O B O	['proteinuria']	1	2	"Sentence: CONCLUSIONS : PAN glomeruli already showed significant pathology by day 4 , despite relatively mild proteinuria .
Diseases: proteinuria"	"Sentence: CONCLUSIONS : PAN glomeruli already showed significant pathology by day 4 , despite relatively mild proteinuria .
Diseases:"
2408	This was preceded by altered nephrin expression , supporting its pivotal role in podocyte morphology .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This was preceded by altered nephrin expression , supporting its pivotal role in podocyte morphology .
Diseases: "	"Sentence: This was preceded by altered nephrin expression , supporting its pivotal role in podocyte morphology .
Diseases:"
2409	The novel proteins dendrin and plekhh2 were both reduced , suggesting roles in PAN , whereas a - actinin was unchanged .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The novel proteins dendrin and plekhh2 were both reduced , suggesting roles in PAN , whereas a - actinin was unchanged .
Diseases: "	"Sentence: The novel proteins dendrin and plekhh2 were both reduced , suggesting roles in PAN , whereas a - actinin was unchanged .
Diseases:"
2410	Twin preterm neonates with cardiac toxicity related to lopinavir / ritonavir therapy .	O O O O B I O O O O O O O	['cardiac toxicity']	1	3	"Sentence: Twin preterm neonates with cardiac toxicity related to lopinavir / ritonavir therapy .
Diseases: cardiac toxicity"	"Sentence: Twin preterm neonates with cardiac toxicity related to lopinavir / ritonavir therapy .
Diseases:"
2411	We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection .	O O O O O O O O O O O O O O O O O B I I I O	['human immunodeficiency virus infection']	1	7	"Sentence: We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection .
Diseases: human immunodeficiency virus infection"	"Sentence: We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection .
Diseases:"
2412	One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir / ritonavir therapy , a boosted protease - inhibitor agent , while the other twin developed mild bradycardia .	O O O O O O B I O B I O O O O O O O O O O O O O O O O O O O O B O	['bradycardia', 'heart block', 'dilated cardiomyopathy']	3	14	"Sentence: One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir / ritonavir therapy , a boosted protease - inhibitor agent , while the other twin developed mild bradycardia .
Diseases: bradycardia, heart block, dilated cardiomyopathy"	"Sentence: One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir / ritonavir therapy , a boosted protease - inhibitor agent , while the other twin developed mild bradycardia .
Diseases:"
2413	We recommend caution in the use of lopinavir / ritonavir in the immediate neonatal period .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We recommend caution in the use of lopinavir / ritonavir in the immediate neonatal period .
Diseases: "	"Sentence: We recommend caution in the use of lopinavir / ritonavir in the immediate neonatal period .
Diseases:"
2414	Learning of rats under amnesia caused by pentobarbital .	O O O O B O O O O	['amnesia']	1	2	"Sentence: Learning of rats under amnesia caused by pentobarbital .
Diseases: amnesia"	"Sentence: Learning of rats under amnesia caused by pentobarbital .
Diseases:"
2415	Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital ( 15 mg / kg , ip ) was carried out .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital ( 15 mg / kg , ip ) was carried out .
Diseases: amnesia"	"Sentence: Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital ( 15 mg / kg , ip ) was carried out .
Diseases:"
2416	Rats were trained to approach a shelf where they received food reinforcement .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Rats were trained to approach a shelf where they received food reinforcement .
Diseases: "	"Sentence: Rats were trained to approach a shelf where they received food reinforcement .
Diseases:"
2417	In Group 1 the rats were trained under the influence of pentobarbital to run to the same shelf as in the normal state .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In Group 1 the rats were trained under the influence of pentobarbital to run to the same shelf as in the normal state .
Diseases: "	"Sentence: In Group 1 the rats were trained under the influence of pentobarbital to run to the same shelf as in the normal state .
Diseases:"
2418	In Group 2 the rats were trained to approach different shelves in different drug states .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In Group 2 the rats were trained to approach different shelves in different drug states .
Diseases: "	"Sentence: In Group 2 the rats were trained to approach different shelves in different drug states .
Diseases:"
2419	It was shown that memory dissociation occurred in both groups .	O O O O B I O O O O O	['memory dissociation']	1	3	"Sentence: It was shown that memory dissociation occurred in both groups .
Diseases: memory dissociation"	"Sentence: It was shown that memory dissociation occurred in both groups .
Diseases:"
2420	Differences in the parameters of training under the influence of pentobarbital between Groups 1 and 2 were revealed .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Differences in the parameters of training under the influence of pentobarbital between Groups 1 and 2 were revealed .
Diseases: "	"Sentence: Differences in the parameters of training under the influence of pentobarbital between Groups 1 and 2 were revealed .
Diseases:"
2421	These findings show that the brain - dissociated state induced by pentobarbital is formed with the participation of the mechanisms of information perception .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These findings show that the brain - dissociated state induced by pentobarbital is formed with the participation of the mechanisms of information perception .
Diseases: "	"Sentence: These findings show that the brain - dissociated state induced by pentobarbital is formed with the participation of the mechanisms of information perception .
Diseases:"
2422	Angiosarcoma of the liver associated with diethylstilbestrol .	B I I I O O O O	['angiosarcoma of the liver']	1	8	"Sentence: Angiosarcoma of the liver associated with diethylstilbestrol .
Diseases: angiosarcoma of the liver"	"Sentence: Angiosarcoma of the liver associated with diethylstilbestrol .
Diseases:"
2423	Angiosarcoma of the liver occurred in a 76 - year - old man who had been treated for a well - differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years .	B I I I O O O O O O O O O O O O O O O O O O B I I I O O O O O O	['angiosarcoma of the liver', 'adenocarcinoma of the liver']	2	18	"Sentence: Angiosarcoma of the liver occurred in a 76 - year - old man who had been treated for a well - differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years .
Diseases: angiosarcoma of the liver, adenocarcinoma of the liver"	"Sentence: Angiosarcoma of the liver occurred in a 76 - year - old man who had been treated for a well - differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years .
Diseases:"
2424	Angiosarcoma was also present within pulmonary and renal arteries .	B O O O O O O O O O	['angiosarcoma']	1	5	"Sentence: Angiosarcoma was also present within pulmonary and renal arteries .
Diseases: angiosarcoma"	"Sentence: Angiosarcoma was also present within pulmonary and renal arteries .
Diseases:"
2425	The possibility that the intraarterial lesions might represent independent primary tumors is considered .	O O O O B I O O O O B O O O	['intraarterial lesions', 'tumors']	2	7	"Sentence: The possibility that the intraarterial lesions might represent independent primary tumors is considered .
Diseases: intraarterial lesions, tumors"	"Sentence: The possibility that the intraarterial lesions might represent independent primary tumors is considered .
Diseases:"
2426	Role of xanthine oxidase in dexamethasone - induced hypertension in rats .	O O O O O O O O B O O O	['hypertension']	1	3	"Sentence: Role of xanthine oxidase in dexamethasone - induced hypertension in rats .
Diseases: hypertension"	"Sentence: Role of xanthine oxidase in dexamethasone - induced hypertension in rats .
Diseases:"
2427	Glucocorticoid - induced hypertension ( GC - HT ) in the rat is associated with nitric oxide - redox imbalance .	O O O B O O O B O O O O O O O O O O O O O	['ht', 'hypertension']	2	3	"Sentence: Glucocorticoid - induced hypertension ( GC - HT ) in the rat is associated with nitric oxide - redox imbalance .
Diseases: ht, hypertension"	"Sentence: Glucocorticoid - induced hypertension ( GC - HT ) in the rat is associated with nitric oxide - redox imbalance .
Diseases:"
2428	We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone - induced hypertension ( dex - HT ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O B O O	['ht', 'hypertension']	2	3	"Sentence: We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone - induced hypertension ( dex - HT ) .
Diseases: ht, hypertension"	"Sentence: We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone - induced hypertension ( dex - HT ) .
Diseases:"
2429	Thirty male Sprague - Dawley rats were divided randomly into four treatment groups : saline , dexamethasone ( dex ) , allopurinol plus saline , and allopurinol plus dex .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty male Sprague - Dawley rats were divided randomly into four treatment groups : saline , dexamethasone ( dex ) , allopurinol plus saline , and allopurinol plus dex .
Diseases: "	"Sentence: Thirty male Sprague - Dawley rats were divided randomly into four treatment groups : saline , dexamethasone ( dex ) , allopurinol plus saline , and allopurinol plus dex .
Diseases:"
2430	4 .	O O	[]	0	0	"Sentence: 4 .
Diseases: "	"Sentence: 4 .
Diseases:"
2431	Systolic blood pressures ( SBP ) and bodyweights were recorded each alternate day .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Systolic blood pressures ( SBP ) and bodyweights were recorded each alternate day .
Diseases: "	"Sentence: Systolic blood pressures ( SBP ) and bodyweights were recorded each alternate day .
Diseases:"
2432	Thymus weight was used as a marker of glucocorticoid activity , and serum urate to assess XO inhibition .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thymus weight was used as a marker of glucocorticoid activity , and serum urate to assess XO inhibition .
Diseases: "	"Sentence: Thymus weight was used as a marker of glucocorticoid activity , and serum urate to assess XO inhibition .
Diseases:"
2433	5 .	O O	[]	0	0	"Sentence: 5 .
Diseases: "	"Sentence: 5 .
Diseases:"
2434	Dex increased SBP ( 110 + / - 2 - 126 + / -	O B I O O O O O O O O O O O	['increased sbp']	1	4	"Sentence: Dex increased SBP ( 110 + / - 2 - 126 + / -
Diseases: increased sbp"	"Sentence: Dex increased SBP ( 110 + / - 2 - 126 + / -
Diseases:"
2435	"3 mmHg ; P < 0 . 001 ) and decreased thymus ( P < 0 . 001 ) and bodyweights ( P "" < 0 . 01 ) ."	O O O O O O O O O O B I I I I I I I I I I O O O O O O O O O	['decreased thymus ( p < 0 . 001 ) and bodyweights']	1	17	"Sentence: 3 mmHg ; P < 0 . 001 ) and decreased thymus ( P < 0 . 001 ) and bodyweights ( P "" < 0 . 01 ) .
Diseases: decreased thymus ( p < 0 . 001 ) and bodyweights"	"Sentence: 3 mmHg ; P < 0 . 001 ) and decreased thymus ( P < 0 . 001 ) and bodyweights ( P "" < 0 . 01 ) .
Diseases:"
2436	Allopurinol decreased serum urate from 76 + / - 5 to 30 + / - 3 micromol /	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Allopurinol decreased serum urate from 76 + / - 5 to 30 + / - 3 micromol /
Diseases: "	"Sentence: Allopurinol decreased serum urate from 76 + / - 5 to 30 + / - 3 micromol /
Diseases:"
2437	L ( P < 0 . 001 ) in saline and from 84 + / - 13 to 28 + / - 2 micromol / L in dex - treated ( P < 0 . 01 ) groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: L ( P < 0 . 001 ) in saline and from 84 + / - 13 to 28 + / - 2 micromol / L in dex - treated ( P < 0 . 01 ) groups .
Diseases: "	"Sentence: L ( P < 0 . 001 ) in saline and from 84 + / - 13 to 28 + / - 2 micromol / L in dex - treated ( P < 0 . 01 ) groups .
Diseases:"
2438	6 .	O O	[]	0	0	"Sentence: 6 .
Diseases: "	"Sentence: 6 .
Diseases:"
2439	Allopurinol did not prevent dex - HT .	O O O O O O B O	['ht']	1	1	"Sentence: Allopurinol did not prevent dex - HT .
Diseases: ht"	"Sentence: Allopurinol did not prevent dex - HT .
Diseases:"
2440	This , together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension , suggests that XO activity is not a major determinant of GC - HT in the rat .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O	['ht', 'hypertension']	2	3	"Sentence: This , together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension , suggests that XO activity is not a major determinant of GC - HT in the rat .
Diseases: ht, hypertension"	"Sentence: This , together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension , suggests that XO activity is not a major determinant of GC - HT in the rat .
Diseases:"
2441	Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels .
Diseases: "	"Sentence: Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels .
Diseases:"
2442	Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5 - HT2 receptors .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5 - HT2 receptors .
Diseases: "	"Sentence: Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5 - HT2 receptors .
Diseases:"
2443	Previous clinical studies have proposed that risperidone 's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects ; features shared by so - called ' atypical ' neuroleptics .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O	['psychotic symptoms']	1	3	"Sentence: Previous clinical studies have proposed that risperidone 's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects ; features shared by so - called ' atypical ' neuroleptics .
Diseases: psychotic symptoms"	"Sentence: Previous clinical studies have proposed that risperidone 's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects ; features shared by so - called ' atypical ' neuroleptics .
Diseases:"
2444	To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects , we used [ 123I ] IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone ( n = 12 ) or haloperidol ( n = 7 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects , we used [ 123I ] IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone ( n = 12 ) or haloperidol ( n = 7 ) .
Diseases: "	"Sentence: To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects , we used [ 123I ] IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone ( n = 12 ) or haloperidol ( n = 7 ) .
Diseases:"
2445	Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90 % at standard clinical doses .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90 % at standard clinical doses .
Diseases: "	"Sentence: Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90 % at standard clinical doses .
Diseases:"
2446	There was no significant difference between occupancy levels obtained with haloperidol or risperidone .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was no significant difference between occupancy levels obtained with haloperidol or risperidone .
Diseases: "	"Sentence: There was no significant difference between occupancy levels obtained with haloperidol or risperidone .
Diseases:"
2447	Drug - induced parkinsonism was observed in subjects treated with risperidone ( 42 % ) and haloperidol ( 29 % ) and was observed at occupancy levels above 60 % .	B I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['drug - induced parkinsonism']	1	6	"Sentence: Drug - induced parkinsonism was observed in subjects treated with risperidone ( 42 % ) and haloperidol ( 29 % ) and was observed at occupancy levels above 60 % .
Diseases: drug - induced parkinsonism"	"Sentence: Drug - induced parkinsonism was observed in subjects treated with risperidone ( 42 % ) and haloperidol ( 29 % ) and was observed at occupancy levels above 60 % .
Diseases:"
2448	Based on these observations , it is concluded that 5 - HT2 blockade obtained with risperidone at D2 occupancy rates of 60 % and above does not appear to protect against the risk for extrapyramidal side effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Based on these observations , it is concluded that 5 - HT2 blockade obtained with risperidone at D2 occupancy rates of 60 % and above does not appear to protect against the risk for extrapyramidal side effects .
Diseases: "	"Sentence: Based on these observations , it is concluded that 5 - HT2 blockade obtained with risperidone at D2 occupancy rates of 60 % and above does not appear to protect against the risk for extrapyramidal side effects .
Diseases:"
2449	Simvastatin - ezetimibe - induced hepatic failure necessitating liver transplantation .	O O O O O B I O O O O	['hepatic failure']	1	4	"Sentence: Simvastatin - ezetimibe - induced hepatic failure necessitating liver transplantation .
Diseases: hepatic failure"	"Sentence: Simvastatin - ezetimibe - induced hepatic failure necessitating liver transplantation .
Diseases:"
2450	Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3 - hydroxy - 3 - methylglutaryl coenzyme A reductase inhibitor ( statin ) therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3 - hydroxy - 3 - methylglutaryl coenzyme A reductase inhibitor ( statin ) therapy .
Diseases: "	"Sentence: Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3 - hydroxy - 3 - methylglutaryl coenzyme A reductase inhibitor ( statin ) therapy .
Diseases:"
2451	However , hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin - ezetimibe .	O O B O O O O O O O O O O O O O O O O	['hepatotoxic']	1	4	"Sentence: However , hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin - ezetimibe .
Diseases: hepatotoxic"	"Sentence: However , hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin - ezetimibe .
Diseases:"
2452	We describe a 70 - year - old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg / day to simvastatin 10 mg - ezetimibe 40 mg / day .	O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O	['fulminant hepatic failure']	1	6	"Sentence: We describe a 70 - year - old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg / day to simvastatin 10 mg - ezetimibe 40 mg / day .
Diseases: fulminant hepatic failure"	"Sentence: We describe a 70 - year - old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg / day to simvastatin 10 mg - ezetimibe 40 mg / day .
Diseases:"
2453	The patient 's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity .	O O O O O O O O O O O O O O O O O O O B O	['hepatotoxicity']	1	4	"Sentence: The patient 's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity .
Diseases: hepatotoxicity"	"Sentence: The patient 's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity .
Diseases:"
2454	A routine laboratory work - up 10 weeks after conversion revealed elevated serum aminotransferase levels .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A routine laboratory work - up 10 weeks after conversion revealed elevated serum aminotransferase levels .
Diseases: "	"Sentence: A routine laboratory work - up 10 weeks after conversion revealed elevated serum aminotransferase levels .
Diseases:"
2455	Simvastatinezetimibe and escitalopram ( which she was taking for depression ) were discontinued , and other potential causes of hepatotoxicity were excluded .	O O O O O O O O O B O O O O O O O O O B O O O	['hepatotoxicity', 'depression']	2	6	"Sentence: Simvastatinezetimibe and escitalopram ( which she was taking for depression ) were discontinued , and other potential causes of hepatotoxicity were excluded .
Diseases: hepatotoxicity, depression"	"Sentence: Simvastatinezetimibe and escitalopram ( which she was taking for depression ) were discontinued , and other potential causes of hepatotoxicity were excluded .
Diseases:"
2456	A repeat work - up revealed further elevations in aminotransferase levels , and liver biopsy revealed evidence of moderate - to - severe drug toxicity .	O O O O O O O O O O O O O O O O O O O O O O O B I O	['drug toxicity']	1	2	"Sentence: A repeat work - up revealed further elevations in aminotransferase levels , and liver biopsy revealed evidence of moderate - to - severe drug toxicity .
Diseases: drug toxicity"	"Sentence: A repeat work - up revealed further elevations in aminotransferase levels , and liver biopsy revealed evidence of moderate - to - severe drug toxicity .
Diseases:"
2457	She underwent liver transplantation with an uneventful postoperative course .	O O O O O O O O O O	[]	0	0	"Sentence: She underwent liver transplantation with an uneventful postoperative course .
Diseases: "	"Sentence: She underwent liver transplantation with an uneventful postoperative course .
Diseases:"
2458	Her aminotransferase levels returned to normal by postoperative day 23 , and her 2 - year follow - up showed no adverse events .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Her aminotransferase levels returned to normal by postoperative day 23 , and her 2 - year follow - up showed no adverse events .
Diseases: "	"Sentence: Her aminotransferase levels returned to normal by postoperative day 23 , and her 2 - year follow - up showed no adverse events .
Diseases:"
2459	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased simvastatin exposure and subsequent hepatotoxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['hepatotoxicity']	1	4	"Sentence: Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased simvastatin exposure and subsequent hepatotoxicity .
Diseases: hepatotoxicity"	"Sentence: Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased simvastatin exposure and subsequent hepatotoxicity .
Diseases:"
2460	To our knowledge , this is the first case report of simvastatin - ezetimibe - induced liver failure that resulted in liver transplantation .	O O O O O O O O O O O O O O O O B I O O O O O O	['liver failure']	1	3	"Sentence: To our knowledge , this is the first case report of simvastatin - ezetimibe - induced liver failure that resulted in liver transplantation .
Diseases: liver failure"	"Sentence: To our knowledge , this is the first case report of simvastatin - ezetimibe - induced liver failure that resulted in liver transplantation .
Diseases:"
2461	We postulate that the mechanism of the simvastatinezetimibe - induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes .	O O O O O O O O O O B O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: We postulate that the mechanism of the simvastatinezetimibe - induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes .
Diseases: hepatotoxicity"	"Sentence: We postulate that the mechanism of the simvastatinezetimibe - induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes .
Diseases:"
2462	Clinicians should be aware of potential hepatotoxicity with simvastatin - ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: Clinicians should be aware of potential hepatotoxicity with simvastatin - ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage .
Diseases: hepatotoxicity"	"Sentence: Clinicians should be aware of potential hepatotoxicity with simvastatin - ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage .
Diseases:"
2463	"Oral manifestations of "" meth mouth "" : a case report ."	O O O O B I O O O O O O	['meth mouth']	1	3	"Sentence: Oral manifestations of "" meth mouth "" : a case report .
Diseases: meth mouth"	"Sentence: Oral manifestations of "" meth mouth "" : a case report .
Diseases:"
2464	"AIM : The aim of the documentation of this clinical case is to make clinicians aware of "" meth mouth "" and the medical risks associated with this serious condition ."	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	['meth mouth']	1	3	"Sentence: AIM : The aim of the documentation of this clinical case is to make clinicians aware of "" meth mouth "" and the medical risks associated with this serious condition .
Diseases: meth mouth"	"Sentence: AIM : The aim of the documentation of this clinical case is to make clinicians aware of "" meth mouth "" and the medical risks associated with this serious condition .
Diseases:"
2465	Methamphetamine is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , hypertension , hallucinations , and violent behavior .	O O O O O O O O O O O O O O O O O O O O O B I O B O B O O B I O	['hallucinations', 'violent behavior', 'cardiac dysrhythmias', 'hypertension']	4	14	"Sentence: Methamphetamine is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , hypertension , hallucinations , and violent behavior .
Diseases: hallucinations, violent behavior, cardiac dysrhythmias, hypertension"	"Sentence: Methamphetamine is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , hypertension , hallucinations , and violent behavior .
Diseases:"
2466	"Dental patients abusing methamphetamine can present with poor oral hygiene , xerostomia , rampant caries ( "" meth mouth "" ) , and excessive tooth wear ."	O O O O O O O O O O O B O O B O O B I O O O O O B I O	['meth mouth', 'tooth wear', 'xerostomia', 'caries']	4	15	"Sentence: Dental patients abusing methamphetamine can present with poor oral hygiene , xerostomia , rampant caries ( "" meth mouth "" ) , and excessive tooth wear .
Diseases: meth mouth, tooth wear, xerostomia, caries"	"Sentence: Dental patients abusing methamphetamine can present with poor oral hygiene , xerostomia , rampant caries ( "" meth mouth "" ) , and excessive tooth wear .
Diseases:"
2467	Oral rehabilitation of patients using methamphetamine can be challenging .	O O O O O O O O O O	[]	0	0	"Sentence: Oral rehabilitation of patients using methamphetamine can be challenging .
Diseases: "	"Sentence: Oral rehabilitation of patients using methamphetamine can be challenging .
Diseases:"
2468	CASE DESCRIPTION : A 30 - year - old Caucasian woman presented with dental pain , bad breath , and self - reported poor esthetics .	O O O O O O O O O O O O O O B O B I O O O O O O O O	['bad breath', 'pain']	2	4	"Sentence: CASE DESCRIPTION : A 30 - year - old Caucasian woman presented with dental pain , bad breath , and self - reported poor esthetics .
Diseases: bad breath, pain"	"Sentence: CASE DESCRIPTION : A 30 - year - old Caucasian woman presented with dental pain , bad breath , and self - reported poor esthetics .
Diseases:"
2469	A comprehensive examination including her medical history , panoramic radiograph , and intraoral examination revealed 19 carious lesions , which is not very common for a healthy adult .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	['carious lesions']	1	3	"Sentence: A comprehensive examination including her medical history , panoramic radiograph , and intraoral examination revealed 19 carious lesions , which is not very common for a healthy adult .
Diseases: carious lesions"	"Sentence: A comprehensive examination including her medical history , panoramic radiograph , and intraoral examination revealed 19 carious lesions , which is not very common for a healthy adult .
Diseases:"
2470	She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug .	O O O O O O O O O O O O O O O B I O O O O O O O	['carious episodes']	1	3	"Sentence: She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug .
Diseases: carious episodes"	"Sentence: She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug .
Diseases:"
2471	SUMMARY :	O O	[]	0	0	"Sentence: SUMMARY :
Diseases: "	"Sentence: SUMMARY :
Diseases:"
2472	"The patient 's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of "" meth mouth . """	O O O O O O O O O O O O O O O O O O O B I O O	['meth mouth']	1	3	"Sentence: The patient 's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of "" meth mouth . ""
Diseases: meth mouth"	"Sentence: The patient 's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of "" meth mouth . ""
Diseases:"
2473	Although three different dental treatment modalities ( either conventional or implant - supported ) have been offered to the patient since August 2007 , the patient has yet to initiate any treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although three different dental treatment modalities ( either conventional or implant - supported ) have been offered to the patient since August 2007 , the patient has yet to initiate any treatment .
Diseases: "	"Sentence: Although three different dental treatment modalities ( either conventional or implant - supported ) have been offered to the patient since August 2007 , the patient has yet to initiate any treatment .
Diseases:"
2474	CLINICAL SIGNIFICANCE :	O O O	[]	0	0	"Sentence: CLINICAL SIGNIFICANCE :
Diseases: "	"Sentence: CLINICAL SIGNIFICANCE :
Diseases:"
2475	This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines .	O O O O O O O B I O O O O O O O O O O O O O O O O	['meth mouth']	1	3	"Sentence: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines .
Diseases: meth mouth"	"Sentence: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines .
Diseases:"
2476	Dental practitioners also may be skeptical about the reliability of appointment keeping by these patients , as they frequently miss their appointments without reasonable justification .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dental practitioners also may be skeptical about the reliability of appointment keeping by these patients , as they frequently miss their appointments without reasonable justification .
Diseases: "	"Sentence: Dental practitioners also may be skeptical about the reliability of appointment keeping by these patients , as they frequently miss their appointments without reasonable justification .
Diseases:"
2477	Thyroxine abuse : an unusual case of thyrotoxicosis in pregnancy .	O O O O O O O B O O O	['thyrotoxicosis']	1	4	"Sentence: Thyroxine abuse : an unusual case of thyrotoxicosis in pregnancy .
Diseases: thyrotoxicosis"	"Sentence: Thyroxine abuse : an unusual case of thyrotoxicosis in pregnancy .
Diseases:"
2478	Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy .	B I O O O O O O B I O O O O O	['eating disorders', 'drug abuse']	2	5	"Sentence: Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy .
Diseases: eating disorders, drug abuse"	"Sentence: Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy .
Diseases:"
2479	When they do occur they are often unrecognized because of denial but when significant may pose a risk to both the mother and her fetus .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When they do occur they are often unrecognized because of denial but when significant may pose a risk to both the mother and her fetus .
Diseases: "	"Sentence: When they do occur they are often unrecognized because of denial but when significant may pose a risk to both the mother and her fetus .
Diseases:"
2480	This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy , including prolonged and recurrent metabolic disturbances and diuretic abuse .	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	['eating disorders']	1	2	"Sentence: This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy , including prolonged and recurrent metabolic disturbances and diuretic abuse .
Diseases: eating disorders"	"Sentence: This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy , including prolonged and recurrent metabolic disturbances and diuretic abuse .
Diseases:"
2481	In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure , thyroxine abuse should be considered and explored .	O O O O O O O O O O O O O O B I O O O O O O O O B O O O O O O O O O O O	['eating disorders', 'thyrotoxicosis']	2	7	"Sentence: In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure , thyroxine abuse should be considered and explored .
Diseases: eating disorders, thyrotoxicosis"	"Sentence: In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure , thyroxine abuse should be considered and explored .
Diseases:"
2482	Attenuation of methamphetamine - induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment .	O O O O O O O B O O O O O O	['neurotoxicity']	1	4	"Sentence: Attenuation of methamphetamine - induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment .
Diseases: neurotoxicity"	"Sentence: Attenuation of methamphetamine - induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment .
Diseases:"
2483	Immunological activation has been proposed to play a role in methamphetamine - induced dopaminergic terminal damage .	O O O O O O O O O O O O O B I I O	['dopaminergic terminal damage']	1	6	"Sentence: Immunological activation has been proposed to play a role in methamphetamine - induced dopaminergic terminal damage .
Diseases: dopaminergic terminal damage"	"Sentence: Immunological activation has been proposed to play a role in methamphetamine - induced dopaminergic terminal damage .
Diseases:"
2484	In this study , we examined the roles of lipopolysaccharide , a pro - inflammatory and inflammatory factor , treatment in modulating the methamphetamine - induced nigrostriatal dopamine neurotoxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['neurotoxicity']	1	4	"Sentence: In this study , we examined the roles of lipopolysaccharide , a pro - inflammatory and inflammatory factor , treatment in modulating the methamphetamine - induced nigrostriatal dopamine neurotoxicity .
Diseases: neurotoxicity"	"Sentence: In this study , we examined the roles of lipopolysaccharide , a pro - inflammatory and inflammatory factor , treatment in modulating the methamphetamine - induced nigrostriatal dopamine neurotoxicity .
Diseases:"
2485	Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine - elicited hyperthermia three days later .	O O O O O O O O O O O O O B O O O O	['hyperthermia']	1	3	"Sentence: Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine - elicited hyperthermia three days later .
Diseases: hyperthermia"	"Sentence: Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine - elicited hyperthermia three days later .
Diseases:"
2486	Such systemic lipopolysaccharide treatment mitigated methamphetamine - induced striatal dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions in a dose - dependent manner .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Such systemic lipopolysaccharide treatment mitigated methamphetamine - induced striatal dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions in a dose - dependent manner .
Diseases: "	"Sentence: Such systemic lipopolysaccharide treatment mitigated methamphetamine - induced striatal dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions in a dose - dependent manner .
Diseases:"
2487	As the most potent dose ( 1 mg / kg ) of lipopolysaccharide was administered two weeks , one day before or after the methamphetamine dosing regimen , methamphetamine - induced striatal dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions remained unaltered .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As the most potent dose ( 1 mg / kg ) of lipopolysaccharide was administered two weeks , one day before or after the methamphetamine dosing regimen , methamphetamine - induced striatal dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions remained unaltered .
Diseases: "	"Sentence: As the most potent dose ( 1 mg / kg ) of lipopolysaccharide was administered two weeks , one day before or after the methamphetamine dosing regimen , methamphetamine - induced striatal dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions remained unaltered .
Diseases:"
2488	Moreover , systemic lipopolysaccharide pretreatment ( 1 mg / kg ) attenuated local methamphetamine infusion - produced dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions in the striatum , indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Moreover , systemic lipopolysaccharide pretreatment ( 1 mg / kg ) attenuated local methamphetamine infusion - produced dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions in the striatum , indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine .
Diseases: "	"Sentence: Moreover , systemic lipopolysaccharide pretreatment ( 1 mg / kg ) attenuated local methamphetamine infusion - produced dopamine and 3 , 4 - dihydroxyphenylacetic acid depletions in the striatum , indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine .
Diseases:"
2489	We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine - induced nigrostriatal dopamine neurotoxicity .	O O O O O O O O O O O O O O O O O O O O B O	['neurotoxicity']	1	4	"Sentence: We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine - induced nigrostriatal dopamine neurotoxicity .
Diseases: neurotoxicity"	"Sentence: We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine - induced nigrostriatal dopamine neurotoxicity .
Diseases:"
2490	Effect of converting enzyme inhibition on the course of adriamycin - induced nephropathy .	O O O O O O O O O O O O B O	['nephropathy']	1	4	"Sentence: Effect of converting enzyme inhibition on the course of adriamycin - induced nephropathy .
Diseases: nephropathy"	"Sentence: Effect of converting enzyme inhibition on the course of adriamycin - induced nephropathy .
Diseases:"
2491	The effect of the converting enzyme inhibitor ( CEI ) enalapril was assessed in Munich - Wistar rats with established adriamycin nephrosis .	O O O O O O O O O O O O O O O O O O O O O B O	['nephrosis']	1	3	"Sentence: The effect of the converting enzyme inhibitor ( CEI ) enalapril was assessed in Munich - Wistar rats with established adriamycin nephrosis .
Diseases: nephrosis"	"Sentence: The effect of the converting enzyme inhibitor ( CEI ) enalapril was assessed in Munich - Wistar rats with established adriamycin nephrosis .
Diseases:"
2492	Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria , blood pressure , and plasma albumin concentration .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['albuminuria']	1	3	"Sentence: Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria , blood pressure , and plasma albumin concentration .
Diseases: albuminuria"	"Sentence: Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria , blood pressure , and plasma albumin concentration .
Diseases:"
2493	Groups 1 and 3 remained untreated while groups 2 and 4 received enalapril .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Groups 1 and 3 remained untreated while groups 2 and 4 received enalapril .
Diseases: "	"Sentence: Groups 1 and 3 remained untreated while groups 2 and 4 received enalapril .
Diseases:"
2494	Groups 1 and 2 underwent micropuncture studies after 10 days .	O O O O O O O O O O O	[]	0	0	"Sentence: Groups 1 and 2 underwent micropuncture studies after 10 days .
Diseases: "	"Sentence: Groups 1 and 2 underwent micropuncture studies after 10 days .
Diseases:"
2495	These short - term studies showed that enalapril reduced arterial blood pressure ( 101 + / - 2 vs . 124 + / -	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These short - term studies showed that enalapril reduced arterial blood pressure ( 101 + / - 2 vs . 124 + / -
Diseases: "	"Sentence: These short - term studies showed that enalapril reduced arterial blood pressure ( 101 + / - 2 vs . 124 + / -
Diseases:"
2496	3 mm Hg , group 2 vs . 1 , P less than 0 . 05 ) and glomerular capillary pressure ( 54 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 3 mm Hg , group 2 vs . 1 , P less than 0 . 05 ) and glomerular capillary pressure ( 54 + / -
Diseases: "	"Sentence: 3 mm Hg , group 2 vs . 1 , P less than 0 . 05 ) and glomerular capillary pressure ( 54 + / -
Diseases:"
2497	1 vs . 61 + / -	O O O O O O O	[]	0	0	"Sentence: 1 vs . 61 + / -
Diseases: "	"Sentence: 1 vs . 61 + / -
Diseases:"
2498	2 mm	O O	[]	0	0	"Sentence: 2 mm
Diseases: "	"Sentence: 2 mm
Diseases:"
2499	Hg , P less than 0 . 05 ) without reducing albuminuria ( 617 + / -	O O O O O O O O O O O B O O O O O	['albuminuria']	1	3	"Sentence: Hg , P less than 0 . 05 ) without reducing albuminuria ( 617 + / -
Diseases: albuminuria"	"Sentence: Hg , P less than 0 . 05 ) without reducing albuminuria ( 617 + / -
Diseases:"
2500	50 vs . 570 + / -	O O O O O O O	[]	0	0	"Sentence: 50 vs . 570 + / -
Diseases: "	"Sentence: 50 vs . 570 + / -
Diseases:"
2501	47 mg / day ) or GFR ( 1 . 03 + / -	O O O O O O O O O O O O O O	[]	0	0	"Sentence: 47 mg / day ) or GFR ( 1 . 03 + / -
Diseases: "	"Sentence: 47 mg / day ) or GFR ( 1 . 03 + / -
Diseases:"
2502	0 . 04 vs . 1 . 04 + / - 0 . 11 ml / min ) .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 0 . 04 vs . 1 . 04 + / - 0 . 11 ml / min ) .
Diseases: "	"Sentence: 0 . 04 vs . 1 . 04 + / - 0 . 11 ml / min ) .
Diseases:"
2503	Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis .	O O O O O O O O O O O O O O O O O O O O O B I O O B O	['renal injury', 'nephrosis']	2	7	"Sentence: Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis .
Diseases: renal injury, nephrosis"	"Sentence: Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis .
Diseases:"
2504	Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4 .	O O O O O O O O B O O O O	['albuminuria']	1	3	"Sentence: Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4 .
Diseases: albuminuria"	"Sentence: Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4 .
Diseases:"
2505	Untreated group 3 rats exhibited a progressive reduction in GFR ( 0 . 35 + / - 0 . 08 ml / min at 4 months , 0 . 27 + / - 0 . 07 ml / min at 6 months ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Untreated group 3 rats exhibited a progressive reduction in GFR ( 0 . 35 + / - 0 . 08 ml / min at 4 months , 0 . 27 + / - 0 . 07 ml / min at 6 months ) .
Diseases: "	"Sentence: Untreated group 3 rats exhibited a progressive reduction in GFR ( 0 . 35 + / - 0 . 08 ml / min at 4 months , 0 . 27 + / - 0 . 07 ml / min at 6 months ) .
Diseases:"
2506	Enalapril treatment blunted but did not prevent reduction in GFR in group 4 ( 0 . 86 + / - 0 . 15 ml / min at 4 months , 0 . 69 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Enalapril treatment blunted but did not prevent reduction in GFR in group 4 ( 0 . 86 + / - 0 . 15 ml / min at 4 months , 0 . 69 + / -
Diseases: "	"Sentence: Enalapril treatment blunted but did not prevent reduction in GFR in group 4 ( 0 . 86 + / - 0 . 15 ml / min at 4 months , 0 . 69 + / -
Diseases:"
2507	0 . 13 ml / min at 6 months , both P less than 0 . 05 vs . group 3 ) .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 0 . 13 ml / min at 6 months , both P less than 0 . 05 vs . group 3 ) .
Diseases: "	"Sentence: 0 . 13 ml / min at 6 months , both P less than 0 . 05 vs . group 3 ) .
Diseases:"
2508	Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O B I O O O O O O O O O O O O O O	['glomerular sclerosis']	1	3	"Sentence: Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: glomerular sclerosis"	"Sentence: Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
2509	Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy .	O O O O O O O B O O O O O O	['apnea']	1	2	"Sentence: Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy .
Diseases: apnea"	"Sentence: Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy .
Diseases:"
2510	BACKGROUND : patients undergoing electroconvulsive therapy ( ECT ) often receive succinylcholine as part of the anesthetic procedure .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: BACKGROUND : patients undergoing electroconvulsive therapy ( ECT ) often receive succinylcholine as part of the anesthetic procedure .
Diseases: "	"Sentence: BACKGROUND : patients undergoing electroconvulsive therapy ( ECT ) often receive succinylcholine as part of the anesthetic procedure .
Diseases:"
2511	The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme ( BChE ) , the most common being the K - and the A - variants .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme ( BChE ) , the most common being the K - and the A - variants .
Diseases: "	"Sentence: The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme ( BChE ) , the most common being the K - and the A - variants .
Diseases:"
2512	The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene ( BCHE ) in patients with a suspected prolonged duration of action of succinylcholine after ECT .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene ( BCHE ) in patients with a suspected prolonged duration of action of succinylcholine after ECT .
Diseases: "	"Sentence: The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene ( BCHE ) in patients with a suspected prolonged duration of action of succinylcholine after ECT .
Diseases:"
2513	METHODS : a total of 13 patients were referred to the Danish Cholinesterase Research Unit after ECT during 38 months .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : a total of 13 patients were referred to the Danish Cholinesterase Research Unit after ECT during 38 months .
Diseases: "	"Sentence: METHODS : a total of 13 patients were referred to the Danish Cholinesterase Research Unit after ECT during 38 months .
Diseases:"
2514	We determined the BChE activity and the BCHE genotype using molecular genetic methods , the duration of apnea , time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['apnea']	1	2	"Sentence: We determined the BChE activity and the BCHE genotype using molecular genetic methods , the duration of apnea , time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used .
Diseases: apnea"	"Sentence: We determined the BChE activity and the BCHE genotype using molecular genetic methods , the duration of apnea , time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used .
Diseases:"
2515	The duration of apnea was compared with published data on normal subjects .	O O O B O O O O O O O O O	['apnea']	1	2	"Sentence: The duration of apnea was compared with published data on normal subjects .
Diseases: apnea"	"Sentence: The duration of apnea was compared with published data on normal subjects .
Diseases:"
2516	RESULTS : in 11 patients , mutations were found in the BCHE gene , the K - variant being the most frequent .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RESULTS : in 11 patients , mutations were found in the BCHE gene , the K - variant being the most frequent .
Diseases: "	"Sentence: RESULTS : in 11 patients , mutations were found in the BCHE gene , the K - variant being the most frequent .
Diseases:"
2517	The duration of apnea was 5 - 15 min compared with 3 - 5 . 3 min from the literature .	O O O B O O O O O O O O O O O O O O O O O	['apnea']	1	2	"Sentence: The duration of apnea was 5 - 15 min compared with 3 - 5 . 3 min from the literature .
Diseases: apnea"	"Sentence: The duration of apnea was 5 - 15 min compared with 3 - 5 . 3 min from the literature .
Diseases:"
2518	Severe distress was noted in the recovery phase in two patients .	O O O O O O O O O O O O	[]	0	0	"Sentence: Severe distress was noted in the recovery phase in two patients .
Diseases: "	"Sentence: Severe distress was noted in the recovery phase in two patients .
Diseases:"
2519	Neuromuscular monitoring was used in two patients .	O O O O O O O O	[]	0	0	"Sentence: Neuromuscular monitoring was used in two patients .
Diseases: "	"Sentence: Neuromuscular monitoring was used in two patients .
Diseases:"
2520	CONCLUSION : eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE , indicating that this is the possible reason for a prolonged period of apnea .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['apnea']	1	2	"Sentence: CONCLUSION : eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE , indicating that this is the possible reason for a prolonged period of apnea .
Diseases: apnea"	"Sentence: CONCLUSION : eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE , indicating that this is the possible reason for a prolonged period of apnea .
Diseases:"
2521	We recommend objective neuromuscular monitoring during the first ECT .	O O O O O O O O O O	[]	0	0	"Sentence: We recommend objective neuromuscular monitoring during the first ECT .
Diseases: "	"Sentence: We recommend objective neuromuscular monitoring during the first ECT .
Diseases:"
2522	Ketamine sedation for the reduction of children 's fractures in the emergency department .	O O O O O O O O B O O O O O	['fractures']	1	3	"Sentence: Ketamine sedation for the reduction of children 's fractures in the emergency department .
Diseases: fractures"	"Sentence: Ketamine sedation for the reduction of children 's fractures in the emergency department .
Diseases:"
2523	There recently has been a resurgence in the utilization of ketamine , a unique anesthetic , for emergency - department procedures requiring sedation .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There recently has been a resurgence in the utilization of ketamine , a unique anesthetic , for emergency - department procedures requiring sedation .
Diseases: "	"Sentence: There recently has been a resurgence in the utilization of ketamine , a unique anesthetic , for emergency - department procedures requiring sedation .
Diseases:"
2524	The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children 's fractures in the emergency department .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['fractures']	1	3	"Sentence: The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children 's fractures in the emergency department .
Diseases: fractures"	"Sentence: The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children 's fractures in the emergency department .
Diseases:"
2525	METHODS : One hundred and fourteen children ( average age , 5 . 3 years ; range , twelve months to ten years and ten months ) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level - I trauma center were prospectively evaluated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O B O O O O O	['fracture', 'dislocation', 'trauma']	3	8	"Sentence: METHODS : One hundred and fourteen children ( average age , 5 . 3 years ; range , twelve months to ten years and ten months ) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level - I trauma center were prospectively evaluated .
Diseases: fracture, dislocation, trauma"	"Sentence: METHODS : One hundred and fourteen children ( average age , 5 . 3 years ; range , twelve months to ten years and ten months ) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level - I trauma center were prospectively evaluated .
Diseases:"
2526	Ketamine hydrochloride was administered intravenously ( at a dose of two milligrams per kilogram of body weight ) in ninety - nine of the patients and intramuscularly ( at a dose of four milligrams per kilogram of body weight ) in the other fifteen .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ketamine hydrochloride was administered intravenously ( at a dose of two milligrams per kilogram of body weight ) in ninety - nine of the patients and intramuscularly ( at a dose of four milligrams per kilogram of body weight ) in the other fifteen .
Diseases: "	"Sentence: Ketamine hydrochloride was administered intravenously ( at a dose of two milligrams per kilogram of body weight ) in ninety - nine of the patients and intramuscularly ( at a dose of four milligrams per kilogram of body weight ) in the other fifteen .
Diseases:"
2527	A board - certified emergency physician skilled in airway management supervised administration of the anesthetic , and the patients were monitored by a registered nurse .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A board - certified emergency physician skilled in airway management supervised administration of the anesthetic , and the patients were monitored by a registered nurse .
Diseases: "	"Sentence: A board - certified emergency physician skilled in airway management supervised administration of the anesthetic , and the patients were monitored by a registered nurse .
Diseases:"
2528	Any pain during the reduction was rated by the orthopaedic surgeon treating the patient according to the Children 's Hospital of Eastern Ontario Pain Scale ( CHEOPS ) .	O B O O O O O O O O O O O O O O O O O O O O O B O O O O O	['pain']	1	1	"Sentence: Any pain during the reduction was rated by the orthopaedic surgeon treating the patient according to the Children 's Hospital of Eastern Ontario Pain Scale ( CHEOPS ) .
Diseases: pain"	"Sentence: Any pain during the reduction was rated by the orthopaedic surgeon treating the patient according to the Children 's Hospital of Eastern Ontario Pain Scale ( CHEOPS ) .
Diseases:"
2529	The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty - six seconds ( range , twenty seconds to five minutes ) , and the average time from intramuscular administration to manipulation was four minutes and forty - two seconds ( range , sixty seconds to fifteen minutes ) .	O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['fracture', 'dislocation']	2	6	"Sentence: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty - six seconds ( range , twenty seconds to five minutes ) , and the average time from intramuscular administration to manipulation was four minutes and forty - two seconds ( range , sixty seconds to fifteen minutes ) .
Diseases: fracture, dislocation"	"Sentence: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty - six seconds ( range , twenty seconds to five minutes ) , and the average time from intramuscular administration to manipulation was four minutes and forty - two seconds ( range , sixty seconds to fifteen minutes ) .
Diseases:"
2530	The average score according to the Children 's Hospital of Eastern Ontario Pain Scale was 6 . 4 points ( range , 5 to 10 points ) , reflecting minimal or no pain during fracture reduction .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O B O B O O	['pain', 'fracture']	2	3	"Sentence: The average score according to the Children 's Hospital of Eastern Ontario Pain Scale was 6 . 4 points ( range , 5 to 10 points ) , reflecting minimal or no pain during fracture reduction .
Diseases: pain, fracture"	"Sentence: The average score according to the Children 's Hospital of Eastern Ontario Pain Scale was 6 . 4 points ( range , 5 to 10 points ) , reflecting minimal or no pain during fracture reduction .
Diseases:"
2531	Adequate fracture reduction was obtained in 111 of the children .	O B O O O O O O O O O	['fracture']	1	3	"Sentence: Adequate fracture reduction was obtained in 111 of the children .
Diseases: fracture"	"Sentence: Adequate fracture reduction was obtained in 111 of the children .
Diseases:"
2532	Ninety - nine percent ( sixty - eight ) of the sixty - nine parents present during the reduction were pleased with the sedation and would allow it to be used again in a similar situation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ninety - nine percent ( sixty - eight ) of the sixty - nine parents present during the reduction were pleased with the sedation and would allow it to be used again in a similar situation .
Diseases: "	"Sentence: Ninety - nine percent ( sixty - eight ) of the sixty - nine parents present during the reduction were pleased with the sedation and would allow it to be used again in a similar situation .
Diseases:"
2533	Patency of the airway and independent respiration were maintained in all of the patients .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patency of the airway and independent respiration were maintained in all of the patients .
Diseases: "	"Sentence: Patency of the airway and independent respiration were maintained in all of the patients .
Diseases:"
2534	Blood pressure and heart rate remained stable .	O O O O O O O O	[]	0	0	"Sentence: Blood pressure and heart rate remained stable .
Diseases: "	"Sentence: Blood pressure and heart rate remained stable .
Diseases:"
2535	Minor side effects included nausea ( thirteen patients ) , emesis ( eight of the thirteen patients with nausea ) , clumsiness ( evident as ataxic movements in ten patients ) , and dysphoric reaction ( one patient ) .	O O O O B O O O O O B O O O O O O O B O O B O O O B I O O O O O O B I O O O O O	['nausea', 'emesis', 'dysphoric reaction', 'ataxic movements', 'clumsiness']	5	19	"Sentence: Minor side effects included nausea ( thirteen patients ) , emesis ( eight of the thirteen patients with nausea ) , clumsiness ( evident as ataxic movements in ten patients ) , and dysphoric reaction ( one patient ) .
Diseases: nausea, emesis, dysphoric reaction, ataxic movements, clumsiness"	"Sentence: Minor side effects included nausea ( thirteen patients ) , emesis ( eight of the thirteen patients with nausea ) , clumsiness ( evident as ataxic movements in ten patients ) , and dysphoric reaction ( one patient ) .
Diseases:"
2536	No long - term sequelae were noted , and no patients had hallucinations or nightmares .	O O O O O O O O O O O O B O O O	['hallucinations']	1	3	"Sentence: No long - term sequelae were noted , and no patients had hallucinations or nightmares .
Diseases: hallucinations"	"Sentence: No long - term sequelae were noted , and no patients had hallucinations or nightmares .
Diseases:"
2537	CONCLUSIONS : Ketamine reliably , safely , and quickly provided adequate sedation to effectively facilitate the reduction of children 's fractures in the emergency department at our institution .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['fractures']	1	3	"Sentence: CONCLUSIONS : Ketamine reliably , safely , and quickly provided adequate sedation to effectively facilitate the reduction of children 's fractures in the emergency department at our institution .
Diseases: fractures"	"Sentence: CONCLUSIONS : Ketamine reliably , safely , and quickly provided adequate sedation to effectively facilitate the reduction of children 's fractures in the emergency department at our institution .
Diseases:"
2538	Ketamine should only be used in an environment such as the emergency department , where proper one - on - one monitoring is used and board - certified physicians skilled in airway management are directly involved in the care of the patient .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ketamine should only be used in an environment such as the emergency department , where proper one - on - one monitoring is used and board - certified physicians skilled in airway management are directly involved in the care of the patient .
Diseases: "	"Sentence: Ketamine should only be used in an environment such as the emergency department , where proper one - on - one monitoring is used and board - certified physicians skilled in airway management are directly involved in the care of the patient .
Diseases:"
2539	Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders .	O O O O O O O O O B I O	['rheumatologic disorders']	1	5	"Sentence: Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders .
Diseases: rheumatologic disorders"	"Sentence: Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders .
Diseases:"
2540	The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen ( HBs Ag ) positive patients with rheumatologic disease .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['rheumatologic disease']	1	5	"Sentence: The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen ( HBs Ag ) positive patients with rheumatologic disease .
Diseases: rheumatologic disease"	"Sentence: The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen ( HBs Ag ) positive patients with rheumatologic disease .
Diseases:"
2541	From June 2004 to October 2006 , 11 HBs Ag positive patients with rheumatologic diseases , who were on both immunosuppressive and prophylactic lamivudine therapies , were retrospectively assessed .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	['rheumatologic diseases']	1	5	"Sentence: From June 2004 to October 2006 , 11 HBs Ag positive patients with rheumatologic diseases , who were on both immunosuppressive and prophylactic lamivudine therapies , were retrospectively assessed .
Diseases: rheumatologic diseases"	"Sentence: From June 2004 to October 2006 , 11 HBs Ag positive patients with rheumatologic diseases , who were on both immunosuppressive and prophylactic lamivudine therapies , were retrospectively assessed .
Diseases:"
2542	Liver function tests , hepatitis B virus ( HBV ) serologic markers , and HBV DNA levels of the patients during follow - up were obtained from hospital file records .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O	['hepatitis b']	1	4	"Sentence: Liver function tests , hepatitis B virus ( HBV ) serologic markers , and HBV DNA levels of the patients during follow - up were obtained from hospital file records .
Diseases: hepatitis b"	"Sentence: Liver function tests , hepatitis B virus ( HBV ) serologic markers , and HBV DNA levels of the patients during follow - up were obtained from hospital file records .
Diseases:"
2543	Eleven patients ( six male ) with median age 47 years ( range 27 - 73 ) , median disease duration 50 months ( range 9 - 178 ) and median follow - up period of patients 13 . 8 months ( range 5 - 27 ) were enrolled in this study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Eleven patients ( six male ) with median age 47 years ( range 27 - 73 ) , median disease duration 50 months ( range 9 - 178 ) and median follow - up period of patients 13 . 8 months ( range 5 - 27 ) were enrolled in this study .
Diseases: "	"Sentence: Eleven patients ( six male ) with median age 47 years ( range 27 - 73 ) , median disease duration 50 months ( range 9 - 178 ) and median follow - up period of patients 13 . 8 months ( range 5 - 27 ) were enrolled in this study .
Diseases:"
2544	Lamivudine therapy was started 3 - 7 days prior to immunosuppressive therapy in all patients .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Lamivudine therapy was started 3 - 7 days prior to immunosuppressive therapy in all patients .
Diseases: "	"Sentence: Lamivudine therapy was started 3 - 7 days prior to immunosuppressive therapy in all patients .
Diseases:"
2545	Baseline , liver function tests were elevated in two patients ( fourth patient : ALT : 122 IU / l , AST : 111 IU / l , tenth patient : ALT : 294 IU / l , AST : 274 IU / l , with minimal changes in the liver biopsy in both ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Baseline , liver function tests were elevated in two patients ( fourth patient : ALT : 122 IU / l , AST : 111 IU / l , tenth patient : ALT : 294 IU / l , AST : 274 IU / l , with minimal changes in the liver biopsy in both ) .
Diseases: "	"Sentence: Baseline , liver function tests were elevated in two patients ( fourth patient : ALT : 122 IU / l , AST : 111 IU / l , tenth patient : ALT : 294 IU / l , AST : 274 IU / l , with minimal changes in the liver biopsy in both ) .
Diseases:"
2546	Shortly after treatment their tests normalized and during follow - up period none of the patients had abnormal liver function tests .	O O O O O O O O O O O O O O O O O B I I O O	['abnormal liver function']	1	4	"Sentence: Shortly after treatment their tests normalized and during follow - up period none of the patients had abnormal liver function tests .
Diseases: abnormal liver function"	"Sentence: Shortly after treatment their tests normalized and during follow - up period none of the patients had abnormal liver function tests .
Diseases:"
2547	In four patients HBV DNA levels were higher than normal at baseline .	O O O O O O O O O O O O O	[]	0	0	"Sentence: In four patients HBV DNA levels were higher than normal at baseline .
Diseases: "	"Sentence: In four patients HBV DNA levels were higher than normal at baseline .
Diseases:"
2548	Two of these normalized and the others increased later .	O O O O O O O O O O	[]	0	0	"Sentence: Two of these normalized and the others increased later .
Diseases: "	"Sentence: Two of these normalized and the others increased later .
Diseases:"
2549	In three additional patients , HBV DNA levels were increased during follow - up .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In three additional patients , HBV DNA levels were increased during follow - up .
Diseases: "	"Sentence: In three additional patients , HBV DNA levels were increased during follow - up .
Diseases:"
2550	None of the patients had significant clinical sings of HBV activation .	O O O O O O O O O O O O	[]	0	0	"Sentence: None of the patients had significant clinical sings of HBV activation .
Diseases: "	"Sentence: None of the patients had significant clinical sings of HBV activation .
Diseases:"
2551	Lamivudine was well tolerated and was continued in all patients .	O O O O O O O O O O O	[]	0	0	"Sentence: Lamivudine was well tolerated and was continued in all patients .
Diseases: "	"Sentence: Lamivudine was well tolerated and was continued in all patients .
Diseases:"
2552	Prophylactic administration of lamivudine in patients who required immunosuppressive therapy seems to be safe , well tolerated and effective in preventing HBV reactivation .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Prophylactic administration of lamivudine in patients who required immunosuppressive therapy seems to be safe , well tolerated and effective in preventing HBV reactivation .
Diseases: "	"Sentence: Prophylactic administration of lamivudine in patients who required immunosuppressive therapy seems to be safe , well tolerated and effective in preventing HBV reactivation .
Diseases:"
2553	Safety of transesophageal echocardiography in adults : study in a multidisciplinary hospital .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Safety of transesophageal echocardiography in adults : study in a multidisciplinary hospital .
Diseases: "	"Sentence: Safety of transesophageal echocardiography in adults : study in a multidisciplinary hospital .
Diseases:"
2554	BACKGROUND : TEE is a semi - invasive tool broadly used and its utilization associated to sedatives drugs might to affect the procedure safety .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: BACKGROUND : TEE is a semi - invasive tool broadly used and its utilization associated to sedatives drugs might to affect the procedure safety .
Diseases: "	"Sentence: BACKGROUND : TEE is a semi - invasive tool broadly used and its utilization associated to sedatives drugs might to affect the procedure safety .
Diseases:"
2555	OBJECTIVE : to analyze aspects of TEE safety associated to the use of Midazolan ( MZ ) and Flumazenil ( FL ) and the influence of the clinical variables on the event rate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: OBJECTIVE : to analyze aspects of TEE safety associated to the use of Midazolan ( MZ ) and Flumazenil ( FL ) and the influence of the clinical variables on the event rate .
Diseases: "	"Sentence: OBJECTIVE : to analyze aspects of TEE safety associated to the use of Midazolan ( MZ ) and Flumazenil ( FL ) and the influence of the clinical variables on the event rate .
Diseases:"
2556	METHOD : prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHOD : prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation .
Diseases: "	"Sentence: METHOD : prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation .
Diseases:"
2557	We analyzed the following events : complications related with the topical anesthesia , with MZ use and with the procedure .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We analyzed the following events : complications related with the topical anesthesia , with MZ use and with the procedure .
Diseases: "	"Sentence: We analyzed the following events : complications related with the topical anesthesia , with MZ use and with the procedure .
Diseases:"
2558	Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( MP ) , duration of the test , mitral regurgitation ( MR ) and the MZ dose .	O O O O O O O O O O O O O O O O O O O O B O B O B O O O O O O O B I O B O O O O O O	['mr', 'myocardiopathy', 'mp', 'mitral regurgitation', 'stroke']	5	16	"Sentence: Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( MP ) , duration of the test , mitral regurgitation ( MR ) and the MZ dose .
Diseases: mr, myocardiopathy, mp, mitral regurgitation, stroke"	"Sentence: Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( MP ) , duration of the test , mitral regurgitation ( MR ) and the MZ dose .
Diseases:"
2559	RESULTS : All patients ( 65 + / - 16 yrs ; 58 % males ) finished the examination .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RESULTS : All patients ( 65 + / - 16 yrs ; 58 % males ) finished the examination .
Diseases: "	"Sentence: RESULTS : All patients ( 65 + / - 16 yrs ; 58 % males ) finished the examination .
Diseases:"
2560	The mean doses of MZ and FL were 4 . 3 + / - 1 . 9 mg and 0 . 28 + / - 0 . 2 mg , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean doses of MZ and FL were 4 . 3 + / - 1 . 9 mg and 0 . 28 + / - 0 . 2 mg , respectively .
Diseases: "	"Sentence: The mean doses of MZ and FL were 4 . 3 + / - 1 . 9 mg and 0 . 28 + / - 0 . 2 mg , respectively .
Diseases:"
2561	The duration of the examination and the mean ejection fraction ( EF ) were 16 . 4 + / - 6 . 1 minutes and 60 + / - 9 % , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The duration of the examination and the mean ejection fraction ( EF ) were 16 . 4 + / - 6 . 1 minutes and 60 + / - 9 % , respectively .
Diseases: "	"Sentence: The duration of the examination and the mean ejection fraction ( EF ) were 16 . 4 + / - 6 . 1 minutes and 60 + / - 9 % , respectively .
Diseases:"
2562	Mild hypoxia ( SO2 < 90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 ( 5 . 8 % ) due to hypoxia caused by MZ use .	O B O O O O O O O O O O O O O O O O O O O O O O O O B O O O B I O O O O O O O O O O O O O B O O O O O	['airway obstruction', 'hypoxia']	2	7	"Sentence: Mild hypoxia ( SO2 < 90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 ( 5 . 8 % ) due to hypoxia caused by MZ use .
Diseases: airway obstruction, hypoxia"	"Sentence: Mild hypoxia ( SO2 < 90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 ( 5 . 8 % ) due to hypoxia caused by MZ use .
Diseases:"
2563	Transient hypotension ( SAP < 90mmHg ) occurred in 1 patient ( 0 . 7 % ) .	O B O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Transient hypotension ( SAP < 90mmHg ) occurred in 1 patient ( 0 . 7 % ) .
Diseases: hypotension"	"Sentence: Transient hypotension ( SAP < 90mmHg ) occurred in 1 patient ( 0 . 7 % ) .
Diseases:"
2564	The multivariate analysis showed that severe MR , MP ( EF < 45 % ) and high doses of MZ ( > 5 mg ) were associated with events ( p < 0 . 001 ) .	O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['mr', 'mp']	2	3	"Sentence: The multivariate analysis showed that severe MR , MP ( EF < 45 % ) and high doses of MZ ( > 5 mg ) were associated with events ( p < 0 . 001 ) .
Diseases: mr, mp"	"Sentence: The multivariate analysis showed that severe MR , MP ( EF < 45 % ) and high doses of MZ ( > 5 mg ) were associated with events ( p < 0 . 001 ) .
Diseases:"
2565	The EF was 40 % , in the group with MP and 44 % in the group with severe MR and it can be a factor associated with clinical events in the last group .	O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O O O O	['mr', 'mp']	2	3	"Sentence: The EF was 40 % , in the group with MP and 44 % in the group with severe MR and it can be a factor associated with clinical events in the last group .
Diseases: mr, mp"	"Sentence: The EF was 40 % , in the group with MP and 44 % in the group with severe MR and it can be a factor associated with clinical events in the last group .
Diseases:"
2566	CONCLUSION : TEE with sedation presents a low rate of events .	O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSION : TEE with sedation presents a low rate of events .
Diseases: "	"Sentence: CONCLUSION : TEE with sedation presents a low rate of events .
Diseases:"
2567	There were no severe events and there was no need to interrupt the examinations .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There were no severe events and there was no need to interrupt the examinations .
Diseases: "	"Sentence: There were no severe events and there was no need to interrupt the examinations .
Diseases:"
2568	Effects of calcium channel blockers on bupivacaine - induced toxicity .	O O O O O O O O O B O	['toxicity']	1	2	"Sentence: Effects of calcium channel blockers on bupivacaine - induced toxicity .
Diseases: toxicity"	"Sentence: Effects of calcium channel blockers on bupivacaine - induced toxicity .
Diseases:"
2569	The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine - induced acute toxicity .	O O O O O O O O O O O O O O O O O O O B O	['toxicity']	1	2	"Sentence: The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine - induced acute toxicity .
Diseases: toxicity"	"Sentence: The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine - induced acute toxicity .
Diseases:"
2570	For each of the three tested calcium channel blockers ( diltiazem , verapamil and bepridil ) 6 groups of mice were treated by two different doses , i . e . 2 and 10 mg / kg / i . p . , or an equal volume of saline for the control group ( n = 20 ) ; 15 minutes later , all the animals were injected with a single 50 mg / kg / i . p .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For each of the three tested calcium channel blockers ( diltiazem , verapamil and bepridil ) 6 groups of mice were treated by two different doses , i . e . 2 and 10 mg / kg / i . p . , or an equal volume of saline for the control group ( n = 20 ) ; 15 minutes later , all the animals were injected with a single 50 mg / kg / i . p .
Diseases: "	"Sentence: For each of the three tested calcium channel blockers ( diltiazem , verapamil and bepridil ) 6 groups of mice were treated by two different doses , i . e . 2 and 10 mg / kg / i . p . , or an equal volume of saline for the control group ( n = 20 ) ; 15 minutes later , all the animals were injected with a single 50 mg / kg / i . p .
Diseases:"
2571	dose of bupivacaine .	O O O O	[]	0	0	"Sentence: dose of bupivacaine .
Diseases: "	"Sentence: dose of bupivacaine .
Diseases:"
2572	The convulsant activity , the time of latency to convulse and the mortality rate were assessed in each group .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The convulsant activity , the time of latency to convulse and the mortality rate were assessed in each group .
Diseases: "	"Sentence: The convulsant activity , the time of latency to convulse and the mortality rate were assessed in each group .
Diseases:"
2573	The local anesthetic - induced mortality was significantly increased by the three different calcium channel blockers .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The local anesthetic - induced mortality was significantly increased by the three different calcium channel blockers .
Diseases: "	"Sentence: The local anesthetic - induced mortality was significantly increased by the three different calcium channel blockers .
Diseases:"
2574	The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine - induced convulsions ; this effect was less pronounced with bepridil .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['convulsions']	1	3	"Sentence: The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine - induced convulsions ; this effect was less pronounced with bepridil .
Diseases: convulsions"	"Sentence: The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine - induced convulsions ; this effect was less pronounced with bepridil .
Diseases:"
2575	Selegiline - induced postural hypotension in Parkinson 's disease : a longitudinal study on the effects of drug withdrawal .	O O O B I O B I I O O O O O O O O O O O	"['postural hypotension', ""parkinson 's disease""]"	2	10	"Sentence: Selegiline - induced postural hypotension in Parkinson 's disease : a longitudinal study on the effects of drug withdrawal .
Diseases: postural hypotension, parkinson 's disease"	"Sentence: Selegiline - induced postural hypotension in Parkinson 's disease : a longitudinal study on the effects of drug withdrawal .
Diseases:"
2576	The United Kingdom Parkinson 's Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson 's disease ( PD ) randomized to receive 10 mg selegiline per day and L - dopa compared with those taking L - dopa alone .	O O O B I I O O O O O O O O O O O O O B I I O B O O O O O O O O O O O O O O O O O O O O O O	"['pd', ""parkinson 's disease""]"	2	7	"Sentence: The United Kingdom Parkinson 's Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson 's disease ( PD ) randomized to receive 10 mg selegiline per day and L - dopa compared with those taking L - dopa alone .
Diseases: pd, parkinson 's disease"	"Sentence: The United Kingdom Parkinson 's Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson 's disease ( PD ) randomized to receive 10 mg selegiline per day and L - dopa compared with those taking L - dopa alone .
Diseases:"
2577	Recently , we found that therapy with selegiline and L - dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline .	O O O O O O O O O O O O O O O O B I I O O O O O O O O	['systolic orthostatic hypotension']	1	8	"Sentence: Recently , we found that therapy with selegiline and L - dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline .
Diseases: systolic orthostatic hypotension"	"Sentence: Recently , we found that therapy with selegiline and L - dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline .
Diseases:"
2578	This unwanted effect on postural blood pressure was not the result of underlying autonomic failure .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This unwanted effect on postural blood pressure was not the result of underlying autonomic failure .
Diseases: "	"Sentence: This unwanted effect on postural blood pressure was not the result of underlying autonomic failure .
Diseases:"
2579	The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['orthostatic hypotension']	1	5	"Sentence: The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension .
Diseases: orthostatic hypotension"	"Sentence: The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension .
Diseases:"
2580	The cardiovascular responses to standing and head - up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn .	O O O O O O O O O O O O O O B O O O O O O O O O O	['pd']	1	1	"Sentence: The cardiovascular responses to standing and head - up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn .
Diseases: pd"	"Sentence: The cardiovascular responses to standing and head - up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn .
Diseases:"
2581	RESULTS : Head - up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline , one of whom lost consciousness with unrecordable blood pressures .	O O O O O O O B I I O O O O O O O B O O O O O O O O O O O O O O	['pd', 'systolic orthostatic hypotension']	2	10	"Sentence: RESULTS : Head - up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline , one of whom lost consciousness with unrecordable blood pressures .
Diseases: pd, systolic orthostatic hypotension"	"Sentence: RESULTS : Head - up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline , one of whom lost consciousness with unrecordable blood pressures .
Diseases:"
2582	A lesser degree of orthostatic hypotension occurred with standing .	O O O O B I O O O O	['orthostatic hypotension']	1	5	"Sentence: A lesser degree of orthostatic hypotension occurred with standing .
Diseases: orthostatic hypotension"	"Sentence: A lesser degree of orthostatic hypotension occurred with standing .
Diseases:"
2583	Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug .	B I O O O O O O O O O O O O O O O O O O O	['orthostatic hypotension']	1	5	"Sentence: Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug .
Diseases: orthostatic hypotension"	"Sentence: Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug .
Diseases:"
2584	Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action .	O O O O B I I I I I I I O O O O O O O O O	['reduced the supine systolic and diastolic blood pressures']	1	14	"Sentence: Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action .
Diseases: reduced the supine systolic and diastolic blood pressures"	"Sentence: Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action .
Diseases:"
2585	This study confirms our previous finding that selegiline in combination with L - dopa is associated with selective orthostatic hypotension .	O O O O O O O O O O O O O O O O O O B I O	['orthostatic hypotension']	1	5	"Sentence: This study confirms our previous finding that selegiline in combination with L - dopa is associated with selective orthostatic hypotension .
Diseases: orthostatic hypotension"	"Sentence: This study confirms our previous finding that selegiline in combination with L - dopa is associated with selective orthostatic hypotension .
Diseases:"
2586	The possibilities that these cardiovascular findings might be the result of non - selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The possibilities that these cardiovascular findings might be the result of non - selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed .
Diseases: "	"Sentence: The possibilities that these cardiovascular findings might be the result of non - selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed .
Diseases:"
2587	Explicit episodic memory for sensory - discriminative components of capsaicin - induced pain : immediate and delayed ratings .	O O O O O O O O O O O O B O O O O O O	['pain']	1	1	"Sentence: Explicit episodic memory for sensory - discriminative components of capsaicin - induced pain : immediate and delayed ratings .
Diseases: pain"	"Sentence: Explicit episodic memory for sensory - discriminative components of capsaicin - induced pain : immediate and delayed ratings .
Diseases:"
2588	Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions .	B O O O O O O B O O O O O O B O O	['pain']	1	1	"Sentence: Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions .
Diseases: pain"	"Sentence: Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions .
Diseases:"
2589	Systematic investigations of the human capacity to remember sensory features of experimental pain are sparse .	O O O O O O O O O O O O B O O O	['pain']	1	1	"Sentence: Systematic investigations of the human capacity to remember sensory features of experimental pain are sparse .
Diseases: pain"	"Sentence: Systematic investigations of the human capacity to remember sensory features of experimental pain are sparse .
Diseases:"
2590	In order to address long - term pain memory , nine healthy male volunteers received intradermal injections of three doses of capsaicin ( 0 . 05 , 1 and 20 microg , separated by 15 min breaks ) , each given three times in a balanced design across three sessions at one week intervals .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: In order to address long - term pain memory , nine healthy male volunteers received intradermal injections of three doses of capsaicin ( 0 . 05 , 1 and 20 microg , separated by 15 min breaks ) , each given three times in a balanced design across three sessions at one week intervals .
Diseases: pain"	"Sentence: In order to address long - term pain memory , nine healthy male volunteers received intradermal injections of three doses of capsaicin ( 0 . 05 , 1 and 20 microg , separated by 15 min breaks ) , each given three times in a balanced design across three sessions at one week intervals .
Diseases:"
2591	Pain rating was performed using a computerized visual analogue scale ( 0 - 100 ) digitized at 1 / s , either immediately online or one hour or one day after injection .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Pain rating was performed using a computerized visual analogue scale ( 0 - 100 ) digitized at 1 / s , either immediately online or one hour or one day after injection .
Diseases: pain"	"Sentence: Pain rating was performed using a computerized visual analogue scale ( 0 - 100 ) digitized at 1 / s , either immediately online or one hour or one day after injection .
Diseases:"
2592	Subjects also recalled their pains one week later .	O O O O B O O O O	['pains']	1	2	"Sentence: Subjects also recalled their pains one week later .
Diseases: pains"	"Sentence: Subjects also recalled their pains one week later .
Diseases:"
2593	Capsaicin injection reliably induced a dose - dependent flare ( p < 0 . 001 ) without any difference within or across sessions .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Capsaicin injection reliably induced a dose - dependent flare ( p < 0 . 001 ) without any difference within or across sessions .
Diseases: "	"Sentence: Capsaicin injection reliably induced a dose - dependent flare ( p < 0 . 001 ) without any difference within or across sessions .
Diseases:"
2594	The strong burning pain decayed exponentially within a few minutes .	O O O B O O O O O O O	['pain']	1	1	"Sentence: The strong burning pain decayed exponentially within a few minutes .
Diseases: pain"	"Sentence: The strong burning pain decayed exponentially within a few minutes .
Diseases:"
2595	Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses ( both p < 0 . 001 ) , regardless of whether first - time ratings were requested immediately , after one hour or after one day .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses ( both p < 0 . 001 ) , regardless of whether first - time ratings were requested immediately , after one hour or after one day .
Diseases: pain"	"Sentence: Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses ( both p < 0 . 001 ) , regardless of whether first - time ratings were requested immediately , after one hour or after one day .
Diseases:"
2596	Pain recall after one week was similarly precise ( magnitude : p < 0 . 01 , duration : p < 0 . 05 ) .	B O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Pain recall after one week was similarly precise ( magnitude : p < 0 . 01 , duration : p < 0 . 05 ) .
Diseases: pain"	"Sentence: Pain recall after one week was similarly precise ( magnitude : p < 0 . 01 , duration : p < 0 . 05 ) .
Diseases:"
2597	Correlation with rating recall after one week was best when first - time ratings were requested as late as one day after injection ( R ( 2 ) = 0 . 79 ) indicating that both rating retrievals utilized similar memory traces .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Correlation with rating recall after one week was best when first - time ratings were requested as late as one day after injection ( R ( 2 ) = 0 . 79 ) indicating that both rating retrievals utilized similar memory traces .
Diseases: "	"Sentence: Correlation with rating recall after one week was best when first - time ratings were requested as late as one day after injection ( R ( 2 ) = 0 . 79 ) indicating that both rating retrievals utilized similar memory traces .
Diseases:"
2598	These results indicate a reliable memory for magnitude and duration of experimentally induced pain .	O O O O O O O O O O O O O B O	['pain']	1	1	"Sentence: These results indicate a reliable memory for magnitude and duration of experimentally induced pain .
Diseases: pain"	"Sentence: These results indicate a reliable memory for magnitude and duration of experimentally induced pain .
Diseases:"
2599	The data further suggest that the consolidation of this memory is an important interim stage , and may take up to one day .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The data further suggest that the consolidation of this memory is an important interim stage , and may take up to one day .
Diseases: "	"Sentence: The data further suggest that the consolidation of this memory is an important interim stage , and may take up to one day .
Diseases:"
2600	Reversibility of captopril - induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension .	O O O O O B I O O O O O O O O B I O	['renal insufficiency', 'renovascular hypertension']	2	9	"Sentence: Reversibility of captopril - induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension .
Diseases: renal insufficiency, renovascular hypertension"	"Sentence: Reversibility of captopril - induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension .
Diseases:"
2601	We report a case of severe hypertension with an occluded renal artery to a solitary kidney , who developed sudden deterioration of renal function following treatment with captopril .	O O O O O O B O O O O O O O O O O O O B I I I I O O O O O	['sudden deterioration of renal function', 'hypertension']	2	8	"Sentence: We report a case of severe hypertension with an occluded renal artery to a solitary kidney , who developed sudden deterioration of renal function following treatment with captopril .
Diseases: sudden deterioration of renal function, hypertension"	"Sentence: We report a case of severe hypertension with an occluded renal artery to a solitary kidney , who developed sudden deterioration of renal function following treatment with captopril .
Diseases:"
2602	His renal function remained impaired but stable during 2 years ' treatment with captopril but returned to pre - treatment levels soon after cessation of the drug .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: His renal function remained impaired but stable during 2 years ' treatment with captopril but returned to pre - treatment levels soon after cessation of the drug .
Diseases: "	"Sentence: His renal function remained impaired but stable during 2 years ' treatment with captopril but returned to pre - treatment levels soon after cessation of the drug .
Diseases:"
2603	This indicates reversibility in captopril - induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O	['renal failure']	1	3	"Sentence: This indicates reversibility in captopril - induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition .
Diseases: renal failure"	"Sentence: This indicates reversibility in captopril - induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition .
Diseases:"
2604	Liver disease caused by propylthiouracil .	B I O O O O	['liver disease']	1	3	"Sentence: Liver disease caused by propylthiouracil .
Diseases: liver disease"	"Sentence: Liver disease caused by propylthiouracil .
Diseases:"
2605	This report presents the clinical , laboratory , and light and electron microscopic observations on a patient with chronic active ( aggressive ) hepatitis caused by the administration of propylthiouracil .	O O O O O O O O O O O O O O O O O O B I I I I I O O O O O O O	['chronic active ( aggressive ) hepatitis']	1	7	"Sentence: This report presents the clinical , laboratory , and light and electron microscopic observations on a patient with chronic active ( aggressive ) hepatitis caused by the administration of propylthiouracil .
Diseases: chronic active ( aggressive ) hepatitis"	"Sentence: This report presents the clinical , laboratory , and light and electron microscopic observations on a patient with chronic active ( aggressive ) hepatitis caused by the administration of propylthiouracil .
Diseases:"
2606	This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease .	O O O O O O O O O O O O O O O O O O B I O	['liver disease']	1	3	"Sentence: This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease .
Diseases: liver disease"	"Sentence: This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease .
Diseases:"
2607	Capsaicin - induced muscle pain alters the excitability of the human jaw - stretch reflex .	O O O B I O O O O O O O O O O O	['muscle pain']	1	3	"Sentence: Capsaicin - induced muscle pain alters the excitability of the human jaw - stretch reflex .
Diseases: muscle pain"	"Sentence: Capsaicin - induced muscle pain alters the excitability of the human jaw - stretch reflex .
Diseases:"
2608	The pathophysiology of painful temporomandibular disorders is not fully understood , but evidence suggests that muscle pain modulates motor function in characteristic ways .	O O O O B I O O O O O O O O O B I O O O O O O O	['temporomandibular disorders', 'muscle pain']	2	10	"Sentence: The pathophysiology of painful temporomandibular disorders is not fully understood , but evidence suggests that muscle pain modulates motor function in characteristic ways .
Diseases: temporomandibular disorders, muscle pain"	"Sentence: The pathophysiology of painful temporomandibular disorders is not fully understood , but evidence suggests that muscle pain modulates motor function in characteristic ways .
Diseases:"
2609	This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw - stretch reflex and whether this process would be sensitive to length and velocity of the stretch .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nociceptive muscle']	1	5	"Sentence: This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw - stretch reflex and whether this process would be sensitive to length and velocity of the stretch .
Diseases: nociceptive muscle"	"Sentence: This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw - stretch reflex and whether this process would be sensitive to length and velocity of the stretch .
Diseases:"
2610	Capsaicin ( 10 micro g ) was injected into the masseter muscle to induce pain in 11 healthy volunteers .	O O O O O O O O O O O O O O B O O O O O	['pain']	1	1	"Sentence: Capsaicin ( 10 micro g ) was injected into the masseter muscle to induce pain in 11 healthy volunteers .
Diseases: pain"	"Sentence: Capsaicin ( 10 micro g ) was injected into the masseter muscle to induce pain in 11 healthy volunteers .
Diseases:"
2611	Short - latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before , during , and after the pain .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['pain']	1	1	"Sentence: Short - latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before , during , and after the pain .
Diseases: pain"	"Sentence: Short - latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before , during , and after the pain .
Diseases:"
2612	The normalized reflex amplitude increased with an increase in velocity at a given displacement , but remained constant with different displacements at a given velocity .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The normalized reflex amplitude increased with an increase in velocity at a given displacement , but remained constant with different displacements at a given velocity .
Diseases: "	"Sentence: The normalized reflex amplitude increased with an increase in velocity at a given displacement , but remained constant with different displacements at a given velocity .
Diseases:"
2613	The normalized reflex amplitude was significantly higher during pain , but only at faster stretches in the painful muscle .	O O O O O O O O B O O O O O O O O B I O	['pain', 'painful muscle']	2	4	"Sentence: The normalized reflex amplitude was significantly higher during pain , but only at faster stretches in the painful muscle .
Diseases: pain, painful muscle"	"Sentence: The normalized reflex amplitude was significantly higher during pain , but only at faster stretches in the painful muscle .
Diseases:"
2614	Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings .	O O O O O O O O B I O O O O O O O O O O	['muscle pain']	1	3	"Sentence: Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings .
Diseases: muscle pain"	"Sentence: Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings .
Diseases:"
2615	Repetitive transcranial magnetic stimulation for levodopa - induced dyskinesias in Parkinson 's disease .	O O O O O O O O B O B I I O	"['dyskinesias', ""parkinson 's disease""]"	2	11	"Sentence: Repetitive transcranial magnetic stimulation for levodopa - induced dyskinesias in Parkinson 's disease .
Diseases: dyskinesias, parkinson 's disease"	"Sentence: Repetitive transcranial magnetic stimulation for levodopa - induced dyskinesias in Parkinson 's disease .
Diseases:"
2616	"In a placebo - controlled , single - blinded , crossover study , we assessed the effect of "" real "" repetitive transcranial magnetic stimulation ( rTMS ) versus "" sham "" rTMS ( placebo ) on peak dose dyskinesias in patients with Parkinson 's disease ( PD ) ."	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O B I I O B O O	"['dyskinesias', 'pd', ""parkinson 's disease""]"	3	14	"Sentence: In a placebo - controlled , single - blinded , crossover study , we assessed the effect of "" real "" repetitive transcranial magnetic stimulation ( rTMS ) versus "" sham "" rTMS ( placebo ) on peak dose dyskinesias in patients with Parkinson 's disease ( PD ) .
Diseases: dyskinesias, pd, parkinson 's disease"	"Sentence: In a placebo - controlled , single - blinded , crossover study , we assessed the effect of "" real "" repetitive transcranial magnetic stimulation ( rTMS ) versus "" sham "" rTMS ( placebo ) on peak dose dyskinesias in patients with Parkinson 's disease ( PD ) .
Diseases:"
2617	Ten patients with PD and prominent dyskinesias had rTMS ( 1 , 800 pulses ; 1 Hz rate ) delivered over the motor cortex for 4 consecutive days twice , once real stimuli and once sham stimulation were used ; evaluations were done at the baseline and 1 day after the end of each of the treatment series .	O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pd', 'dyskinesias']	2	6	"Sentence: Ten patients with PD and prominent dyskinesias had rTMS ( 1 , 800 pulses ; 1 Hz rate ) delivered over the motor cortex for 4 consecutive days twice , once real stimuli and once sham stimulation were used ; evaluations were done at the baseline and 1 day after the end of each of the treatment series .
Diseases: pd, dyskinesias"	"Sentence: Ten patients with PD and prominent dyskinesias had rTMS ( 1 , 800 pulses ; 1 Hz rate ) delivered over the motor cortex for 4 consecutive days twice , once real stimuli and once sham stimulation were used ; evaluations were done at the baseline and 1 day after the end of each of the treatment series .
Diseases:"
2618	Direct comparison between sham and real rTMS effects showed no significant difference in clinician - assessed dyskinesia severity .	O O O O O O O O O O O O O O O O B O O	['dyskinesia']	1	5	"Sentence: Direct comparison between sham and real rTMS effects showed no significant difference in clinician - assessed dyskinesia severity .
Diseases: dyskinesia"	"Sentence: Direct comparison between sham and real rTMS effects showed no significant difference in clinician - assessed dyskinesia severity .
Diseases:"
2619	However , comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo .	O O O O O O O O O O O O B O O O O O O O O	['dyskinesia']	1	5	"Sentence: However , comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo .
Diseases: dyskinesia"	"Sentence: However , comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo .
Diseases:"
2620	The major effect was on dystonia subscore .	O O O O O B O O	['dystonia']	1	3	"Sentence: The major effect was on dystonia subscore .
Diseases: dystonia"	"Sentence: The major effect was on dystonia subscore .
Diseases:"
2621	Similarly , in patient diaries , although both treatments caused reduction in subjective dyskinesia scores during the days of intervention , the effect was sustained for 3 days after the intervention for the real rTMS only .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesia']	1	5	"Sentence: Similarly , in patient diaries , although both treatments caused reduction in subjective dyskinesia scores during the days of intervention , the effect was sustained for 3 days after the intervention for the real rTMS only .
Diseases: dyskinesia"	"Sentence: Similarly , in patient diaries , although both treatments caused reduction in subjective dyskinesia scores during the days of intervention , the effect was sustained for 3 days after the intervention for the real rTMS only .
Diseases:"
2622	Following rTMS , no side effects and no adverse effects on motor function and PD symptoms were noted .	O O O O O O O O O O O O O O B O O O O	['pd']	1	1	"Sentence: Following rTMS , no side effects and no adverse effects on motor function and PD symptoms were noted .
Diseases: pd"	"Sentence: Following rTMS , no side effects and no adverse effects on motor function and PD symptoms were noted .
Diseases:"
2623	The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low - frequency rTMS on dyskinesias in PD .	O O O O O O O O O O O O O O O O O O O O B O B O	['dyskinesias', 'pd']	2	8	"Sentence: The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low - frequency rTMS on dyskinesias in PD .
Diseases: dyskinesias, pd"	"Sentence: The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low - frequency rTMS on dyskinesias in PD .
Diseases:"
2624	The effects may be further exploited for potential therapeutic uses .	O O O O O O O O O O O	[]	0	0	"Sentence: The effects may be further exploited for potential therapeutic uses .
Diseases: "	"Sentence: The effects may be further exploited for potential therapeutic uses .
Diseases:"
2625	Disulfiram - like syndrome after hydrogen cyanamide professional skin exposure : two case reports in France .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Disulfiram - like syndrome after hydrogen cyanamide professional skin exposure : two case reports in France .
Diseases: "	"Sentence: Disulfiram - like syndrome after hydrogen cyanamide professional skin exposure : two case reports in France .
Diseases:"
2626	Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees .
Diseases: "	"Sentence: Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees .
Diseases:"
2627	Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use .
Diseases: "	"Sentence: Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use .
Diseases:"
2628	The purpose of this report is to describe two cases of a disulfiram - like syndrome following occupational exposure to hydrogen cyanamide .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The purpose of this report is to describe two cases of a disulfiram - like syndrome following occupational exposure to hydrogen cyanamide .
Diseases: "	"Sentence: The purpose of this report is to describe two cases of a disulfiram - like syndrome following occupational exposure to hydrogen cyanamide .
Diseases:"
2629	The first case involved a 59 - year - old man who used Dormex , which contains hydrogen cyanamide , without protection after consuming a large amount of alcohol during a meal .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The first case involved a 59 - year - old man who used Dormex , which contains hydrogen cyanamide , without protection after consuming a large amount of alcohol during a meal .
Diseases: "	"Sentence: The first case involved a 59 - year - old man who used Dormex , which contains hydrogen cyanamide , without protection after consuming a large amount of alcohol during a meal .
Diseases:"
2630	In less than 1 hour after the ingestion of alcohol , he developed malaise with flushing of the face , tachycardia , and dyspnea .	O O O O O O O O O O O O O O O B I I I O B O O B O	['dyspnea', 'tachycardia', 'flushing of the face']	3	15	"Sentence: In less than 1 hour after the ingestion of alcohol , he developed malaise with flushing of the face , tachycardia , and dyspnea .
Diseases: dyspnea, tachycardia, flushing of the face"	"Sentence: In less than 1 hour after the ingestion of alcohol , he developed malaise with flushing of the face , tachycardia , and dyspnea .
Diseases:"
2631	Manifestations regressed spontaneously under surveillance in the hospital .	O O O O O O O O O	[]	0	0	"Sentence: Manifestations regressed spontaneously under surveillance in the hospital .
Diseases: "	"Sentence: Manifestations regressed spontaneously under surveillance in the hospital .
Diseases:"
2632	The second case occurred in a 55 - year - old farmer following cutaneous contact with Dormex .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The second case occurred in a 55 - year - old farmer following cutaneous contact with Dormex .
Diseases: "	"Sentence: The second case occurred in a 55 - year - old farmer following cutaneous contact with Dormex .
Diseases:"
2633	Five hours after exposure , he developed disulfiram - like syndrome with flushing , tachycardia , and arterial hypotension after consuming three glasses of wine .	O O O O O O O O O O O O B O B O O B I O O O O O O O	['tachycardia', 'arterial hypotension', 'flushing']	3	12	"Sentence: Five hours after exposure , he developed disulfiram - like syndrome with flushing , tachycardia , and arterial hypotension after consuming three glasses of wine .
Diseases: tachycardia, arterial hypotension, flushing"	"Sentence: Five hours after exposure , he developed disulfiram - like syndrome with flushing , tachycardia , and arterial hypotension after consuming three glasses of wine .
Diseases:"
2634	The patient recovered spontaneously in 3 hours under surveillance in the hospital .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The patient recovered spontaneously in 3 hours under surveillance in the hospital .
Diseases: "	"Sentence: The patient recovered spontaneously in 3 hours under surveillance in the hospital .
Diseases:"
2635	These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use .
Diseases: "	"Sentence: These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use .
Diseases:"
2636	Repeated trimipramine induces dopamine D2 / D3 and alpha1 - adrenergic up - regulation .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Repeated trimipramine induces dopamine D2 / D3 and alpha1 - adrenergic up - regulation .
Diseases: "	"Sentence: Repeated trimipramine induces dopamine D2 / D3 and alpha1 - adrenergic up - regulation .
Diseases:"
2637	Trimipramine ( TRI ) , which shows a clinical antidepressant activity , is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5 - hydroxytryptamine , nor does it induce beta - adrenergic down - regulation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Trimipramine ( TRI ) , which shows a clinical antidepressant activity , is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5 - hydroxytryptamine , nor does it induce beta - adrenergic down - regulation .
Diseases: "	"Sentence: Trimipramine ( TRI ) , which shows a clinical antidepressant activity , is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5 - hydroxytryptamine , nor does it induce beta - adrenergic down - regulation .
Diseases:"
2638	The mechanism of its antidepressant activity is still unknown .	O O O O O O O O O O	[]	0	0	"Sentence: The mechanism of its antidepressant activity is still unknown .
Diseases: "	"Sentence: The mechanism of its antidepressant activity is still unknown .
Diseases:"
2639	The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1 - adrenergic systems , demonstrated by us previously for various antidepressants .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1 - adrenergic systems , demonstrated by us previously for various antidepressants .
Diseases: "	"Sentence: The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1 - adrenergic systems , demonstrated by us previously for various antidepressants .
Diseases:"
2640	TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days .
Diseases: "	"Sentence: TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days .
Diseases:"
2641	In the acute experiment TRI ( given i . p . ) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5 - hydroxytryptophan head twitches in rats .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['hypothermia']	1	3	"Sentence: In the acute experiment TRI ( given i . p . ) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5 - hydroxytryptophan head twitches in rats .
Diseases: hypothermia"	"Sentence: In the acute experiment TRI ( given i . p . ) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5 - hydroxytryptophan head twitches in rats .
Diseases:"
2642	TRI given repeatedly to rats increases the locomotor hyperactivity induced by d - amphetamine , quinpirole and ( + ) - 7 - hydroxy - dipropyloaminotetralin ( dopamine D2 and D3 effects ) .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: TRI given repeatedly to rats increases the locomotor hyperactivity induced by d - amphetamine , quinpirole and ( + ) - 7 - hydroxy - dipropyloaminotetralin ( dopamine D2 and D3 effects ) .
Diseases: hyperactivity"	"Sentence: TRI given repeatedly to rats increases the locomotor hyperactivity induced by d - amphetamine , quinpirole and ( + ) - 7 - hydroxy - dipropyloaminotetralin ( dopamine D2 and D3 effects ) .
Diseases:"
2643	The stereotypies induced by d - amphetamine or apomorphine are not potentiated by TRI .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The stereotypies induced by d - amphetamine or apomorphine are not potentiated by TRI .
Diseases: "	"Sentence: The stereotypies induced by d - amphetamine or apomorphine are not potentiated by TRI .
Diseases:"
2644	It increases the behaviour stimulation evoked by phenylephrine ( given intraventricularly ) in rats , evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice , both these effects being mediated by an alpha1 - adrenergic receptor .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['aggressiveness']	1	3	"Sentence: It increases the behaviour stimulation evoked by phenylephrine ( given intraventricularly ) in rats , evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice , both these effects being mediated by an alpha1 - adrenergic receptor .
Diseases: aggressiveness"	"Sentence: It increases the behaviour stimulation evoked by phenylephrine ( given intraventricularly ) in rats , evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice , both these effects being mediated by an alpha1 - adrenergic receptor .
Diseases:"
2645	It may be concluded that , like other tricyclic antidepressants studied previously , TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 ( locomotor activity but not stereotypy ) as well as alpha1 - adrenergic receptors to their agonists .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It may be concluded that , like other tricyclic antidepressants studied previously , TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 ( locomotor activity but not stereotypy ) as well as alpha1 - adrenergic receptors to their agonists .
Diseases: "	"Sentence: It may be concluded that , like other tricyclic antidepressants studied previously , TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 ( locomotor activity but not stereotypy ) as well as alpha1 - adrenergic receptors to their agonists .
Diseases:"
2646	A question arises whether the reuptake inhibition is of any importance to the adaptive changes induced by repeated antidepressants , suggested to be responsible for the antidepressant activity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A question arises whether the reuptake inhibition is of any importance to the adaptive changes induced by repeated antidepressants , suggested to be responsible for the antidepressant activity .
Diseases: "	"Sentence: A question arises whether the reuptake inhibition is of any importance to the adaptive changes induced by repeated antidepressants , suggested to be responsible for the antidepressant activity .
Diseases:"
2647	Ranitidine - induced acute interstitial nephritis in a cadaveric renal allograft .	O O O O B I O O O O O O	['interstitial nephritis']	1	4	"Sentence: Ranitidine - induced acute interstitial nephritis in a cadaveric renal allograft .
Diseases: interstitial nephritis"	"Sentence: Ranitidine - induced acute interstitial nephritis in a cadaveric renal allograft .
Diseases:"
2648	Ranitidine frequently is used for preventing peptic ulceration after renal transplantation .	O O O O O O O O O O O O	[]	0	0	"Sentence: Ranitidine frequently is used for preventing peptic ulceration after renal transplantation .
Diseases: "	"Sentence: Ranitidine frequently is used for preventing peptic ulceration after renal transplantation .
Diseases:"
2649	This drug occasionally has been associated with acute interstitial nephritis in native kidneys .	O O O O O O O O B I O O O O	['interstitial nephritis']	1	4	"Sentence: This drug occasionally has been associated with acute interstitial nephritis in native kidneys .
Diseases: interstitial nephritis"	"Sentence: This drug occasionally has been associated with acute interstitial nephritis in native kidneys .
Diseases:"
2650	There are no similar reports with renal transplantation .	O O O O O O O O O	[]	0	0	"Sentence: There are no similar reports with renal transplantation .
Diseases: "	"Sentence: There are no similar reports with renal transplantation .
Diseases:"
2651	We report a case of ranitidine - induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	['interstitial nephritis']	1	4	"Sentence: We report a case of ranitidine - induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug .
Diseases: interstitial nephritis"	"Sentence: We report a case of ranitidine - induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug .
Diseases:"
2652	The biopsy specimen showed pathognomonic features , including eosinophilic infiltration of the interstitial compartment .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The biopsy specimen showed pathognomonic features , including eosinophilic infiltration of the interstitial compartment .
Diseases: "	"Sentence: The biopsy specimen showed pathognomonic features , including eosinophilic infiltration of the interstitial compartment .
Diseases:"
2653	Allograft function improved rapidly and returned to baseline after stopping the drug .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Allograft function improved rapidly and returned to baseline after stopping the drug .
Diseases: "	"Sentence: Allograft function improved rapidly and returned to baseline after stopping the drug .
Diseases:"
2654	Late , late doxorubicin cardiotoxicity .	O O O O B O	['cardiotoxicity']	1	3	"Sentence: Late , late doxorubicin cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: Late , late doxorubicin cardiotoxicity .
Diseases:"
2655	Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent .	B I O O O O O O O O O O O O O O O	['cardiac toxicity']	1	3	"Sentence: Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent .
Diseases: cardiac toxicity"	"Sentence: Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent .
Diseases:"
2656	Cardiomyopathy is frequent when the total dose exceeds 600 mg / m2 and occurs within one to six months after cessation of therapy .	B O O O O O O O O O O O O O O O O O O O O O O O	['cardiomyopathy']	1	4	"Sentence: Cardiomyopathy is frequent when the total dose exceeds 600 mg / m2 and occurs within one to six months after cessation of therapy .
Diseases: cardiomyopathy"	"Sentence: Cardiomyopathy is frequent when the total dose exceeds 600 mg / m2 and occurs within one to six months after cessation of therapy .
Diseases:"
2657	A patient is reported who developed progressive cardiomyopathy two and one - half years after receiving 580 mg / m2 which apparently represents late , late cardiotoxicity .	O O O O O O O B O O O O O O O O O O O O O O O O O O B O	['cardiotoxicity', 'cardiomyopathy']	2	8	"Sentence: A patient is reported who developed progressive cardiomyopathy two and one - half years after receiving 580 mg / m2 which apparently represents late , late cardiotoxicity .
Diseases: cardiotoxicity, cardiomyopathy"	"Sentence: A patient is reported who developed progressive cardiomyopathy two and one - half years after receiving 580 mg / m2 which apparently represents late , late cardiotoxicity .
Diseases:"
2658	Acetazolamide - induced nephrolithiasis : implications for treatment of neuromuscular disorders .	O O O B O O O O O B I O	['neuromuscular disorders', 'nephrolithiasis']	2	11	"Sentence: Acetazolamide - induced nephrolithiasis : implications for treatment of neuromuscular disorders .
Diseases: neuromuscular disorders, nephrolithiasis"	"Sentence: Acetazolamide - induced nephrolithiasis : implications for treatment of neuromuscular disorders .
Diseases:"
2659	Carbonic anhydrase inhibitors can cause nephrolithiasis .	O O O O O B O	['nephrolithiasis']	1	5	"Sentence: Carbonic anhydrase inhibitors can cause nephrolithiasis .
Diseases: nephrolithiasis"	"Sentence: Carbonic anhydrase inhibitors can cause nephrolithiasis .
Diseases:"
2660	We studied 20 patients receiving long - term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia .	O O O O O O O O O O O O O O B O B O	['paralysis', 'myotonia']	2	6	"Sentence: We studied 20 patients receiving long - term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia .
Diseases: paralysis, myotonia"	"Sentence: We studied 20 patients receiving long - term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia .
Diseases:"
2661	Three patients on acetazolamide ( 15 % ) developed renal calculi .	O O O O O O O O O B I O	['renal calculi']	1	4	"Sentence: Three patients on acetazolamide ( 15 % ) developed renal calculi .
Diseases: renal calculi"	"Sentence: Three patients on acetazolamide ( 15 % ) developed renal calculi .
Diseases:"
2662	Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another , permitting continued treatment .	O O O O O B I O O O O O O O O B O O O O O O O	['renal calculus', 'calculus']	2	5	"Sentence: Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another , permitting continued treatment .
Diseases: renal calculus, calculus"	"Sentence: Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another , permitting continued treatment .
Diseases:"
2663	Renal function remained normal in all patients .	O O O O O O O O	[]	0	0	"Sentence: Renal function remained normal in all patients .
Diseases: "	"Sentence: Renal function remained normal in all patients .
Diseases:"
2664	Nephrolithiasis is a complication of acetazolamide but does not preclude its use .	B O O O O O O O O O O O O	['nephrolithiasis']	1	5	"Sentence: Nephrolithiasis is a complication of acetazolamide but does not preclude its use .
Diseases: nephrolithiasis"	"Sentence: Nephrolithiasis is a complication of acetazolamide but does not preclude its use .
Diseases:"
2665	Is the treatment of scabies hazardous ?	O O O O B O O	['scabies']	1	2	"Sentence: Is the treatment of scabies hazardous ?
Diseases: scabies"	"Sentence: Is the treatment of scabies hazardous ?
Diseases:"
2666	Treatment for scabies is usually initiated by general practitioners ; most consider lindane ( gamma benzene hexachloride ) the treatment of choice .	O O B O O O O O O O O O O O O O O O O O O O O	['scabies']	1	2	"Sentence: Treatment for scabies is usually initiated by general practitioners ; most consider lindane ( gamma benzene hexachloride ) the treatment of choice .
Diseases: scabies"	"Sentence: Treatment for scabies is usually initiated by general practitioners ; most consider lindane ( gamma benzene hexachloride ) the treatment of choice .
Diseases:"
2667	Lindane is also widely used as an agricultural and industrial pesticide , and as a result the toxic profile of this insecticide is well understood .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Lindane is also widely used as an agricultural and industrial pesticide , and as a result the toxic profile of this insecticide is well understood .
Diseases: "	"Sentence: Lindane is also widely used as an agricultural and industrial pesticide , and as a result the toxic profile of this insecticide is well understood .
Diseases:"
2668	Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia .	O O O O O O O B I I I I I O O O O O B I O	['toxic to the central nervous system', 'aplastic anaemia']	2	13	"Sentence: Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia .
Diseases: toxic to the central nervous system, aplastic anaemia"	"Sentence: Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia .
Diseases:"
2669	Preparations containing lindane continue to be sold over the counter and may represent a hazard to poorly informed patients .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Preparations containing lindane continue to be sold over the counter and may represent a hazard to poorly informed patients .
Diseases: "	"Sentence: Preparations containing lindane continue to be sold over the counter and may represent a hazard to poorly informed patients .
Diseases:"
2670	This literature review suggests that general practitioners should prescribe scabicides with increased caution for certain at - risk groups , and give adequate warnings regarding potential toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['toxicity']	1	2	"Sentence: This literature review suggests that general practitioners should prescribe scabicides with increased caution for certain at - risk groups , and give adequate warnings regarding potential toxicity .
Diseases: toxicity"	"Sentence: This literature review suggests that general practitioners should prescribe scabicides with increased caution for certain at - risk groups , and give adequate warnings regarding potential toxicity .
Diseases:"
2671	Anaesthetists ' nightmare : masseter spasm after induction in an undiagnosed case of myotonia congenita .	O O O O B I O O O O O O O B I O	['masseter spasm', 'myotonia congenita']	2	10	"Sentence: Anaesthetists ' nightmare : masseter spasm after induction in an undiagnosed case of myotonia congenita .
Diseases: masseter spasm, myotonia congenita"	"Sentence: Anaesthetists ' nightmare : masseter spasm after induction in an undiagnosed case of myotonia congenita .
Diseases:"
2672	We report an undiagnosed case of myotonia congenita in a 24 - year - old previously healthy primigravida , who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia .	O O O O O O B I O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	['masseter spasm', 'myotonia congenita']	2	10	"Sentence: We report an undiagnosed case of myotonia congenita in a 24 - year - old previously healthy primigravida , who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia .
Diseases: masseter spasm, myotonia congenita"	"Sentence: We report an undiagnosed case of myotonia congenita in a 24 - year - old previously healthy primigravida , who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia .
Diseases:"
2673	Neither the patient nor the anaesthetist was aware of the diagnosis before this potentially lethal complication occurred .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Neither the patient nor the anaesthetist was aware of the diagnosis before this potentially lethal complication occurred .
Diseases: "	"Sentence: Neither the patient nor the anaesthetist was aware of the diagnosis before this potentially lethal complication occurred .
Diseases:"
2674	Toxicity in rhesus monkeys following administration of the 8 - aminoquinoline 8 - [ ( 4 - amino - l - methylbutyl ) amino ] - 5 - ( l - hexyloxy ) - 6 - methoxy - 4 - methylquinoline ( WR242511 ) .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Toxicity in rhesus monkeys following administration of the 8 - aminoquinoline 8 - [ ( 4 - amino - l - methylbutyl ) amino ] - 5 - ( l - hexyloxy ) - 6 - methoxy - 4 - methylquinoline ( WR242511 ) .
Diseases: toxicity"	"Sentence: Toxicity in rhesus monkeys following administration of the 8 - aminoquinoline 8 - [ ( 4 - amino - l - methylbutyl ) amino ] - 5 - ( l - hexyloxy ) - 6 - methoxy - 4 - methylquinoline ( WR242511 ) .
Diseases:"
2675	Many substances that form methemoglobin ( MHb ) effectively counter cyanide ( CN ) toxicity .	O O O O O O O O O O O O O O B O	['toxicity']	1	2	"Sentence: Many substances that form methemoglobin ( MHb ) effectively counter cyanide ( CN ) toxicity .
Diseases: toxicity"	"Sentence: Many substances that form methemoglobin ( MHb ) effectively counter cyanide ( CN ) toxicity .
Diseases:"
2676	Although MHb formers are generally applied as treatments for CN poisoning , it has been proposed that a stable , long - acting MHb former could serve as a CN pretreatment .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['poisoning']	1	3	"Sentence: Although MHb formers are generally applied as treatments for CN poisoning , it has been proposed that a stable , long - acting MHb former could serve as a CN pretreatment .
Diseases: poisoning"	"Sentence: Although MHb formers are generally applied as treatments for CN poisoning , it has been proposed that a stable , long - acting MHb former could serve as a CN pretreatment .
Diseases:"
2677	Using this rationale , the 8 - aminoquinoline WR242511 , a potent long - lasting MHb former in rodents and beagle dogs , was studied in the rhesus monkey for advanced development as a potential CN pretreatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Using this rationale , the 8 - aminoquinoline WR242511 , a potent long - lasting MHb former in rodents and beagle dogs , was studied in the rhesus monkey for advanced development as a potential CN pretreatment .
Diseases: "	"Sentence: Using this rationale , the 8 - aminoquinoline WR242511 , a potent long - lasting MHb former in rodents and beagle dogs , was studied in the rhesus monkey for advanced development as a potential CN pretreatment .
Diseases:"
2678	In this study , WR242511 was administered intravenously ( IV ) in 2 female and 4 male rhesus monkeys in doses of 3 . 5 and / or 7 . 0 mg / kg ; a single male also received WR242511 orally ( PO ) at 7 . 0 mg / kg .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In this study , WR242511 was administered intravenously ( IV ) in 2 female and 4 male rhesus monkeys in doses of 3 . 5 and / or 7 . 0 mg / kg ; a single male also received WR242511 orally ( PO ) at 7 . 0 mg / kg .
Diseases: "	"Sentence: In this study , WR242511 was administered intravenously ( IV ) in 2 female and 4 male rhesus monkeys in doses of 3 . 5 and / or 7 . 0 mg / kg ; a single male also received WR242511 orally ( PO ) at 7 . 0 mg / kg .
Diseases:"
2679	Health status and MHb levels were monitored following exposure .	O O O O O O O O O O	[]	0	0	"Sentence: Health status and MHb levels were monitored following exposure .
Diseases: "	"Sentence: Health status and MHb levels were monitored following exposure .
Diseases:"
2680	The selected doses of WR242511 , which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere , produced very little MHb ( mean < 2 . 0 % ) in the rhesus monkey .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['methemoglobinemia']	1	6	"Sentence: The selected doses of WR242511 , which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere , produced very little MHb ( mean < 2 . 0 % ) in the rhesus monkey .
Diseases: methemoglobinemia"	"Sentence: The selected doses of WR242511 , which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere , produced very little MHb ( mean < 2 . 0 % ) in the rhesus monkey .
Diseases:"
2681	Furthermore , transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 ( 3 . 5 or 7 . 0 mg / kg ) , and 2 lethalities occurred ( one IV and one PO ) following the 7 . 0 mg / kg dose .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hemoglobinuria']	1	3	"Sentence: Furthermore , transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 ( 3 . 5 or 7 . 0 mg / kg ) , and 2 lethalities occurred ( one IV and one PO ) following the 7 . 0 mg / kg dose .
Diseases: hemoglobinuria"	"Sentence: Furthermore , transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 ( 3 . 5 or 7 . 0 mg / kg ) , and 2 lethalities occurred ( one IV and one PO ) following the 7 . 0 mg / kg dose .
Diseases:"
2682	Myoglobinuria was also observed following the 7 . 0 mg / kg dose .	B O O O O O O O O O O O O O	['myoglobinuria']	1	3	"Sentence: Myoglobinuria was also observed following the 7 . 0 mg / kg dose .
Diseases: myoglobinuria"	"Sentence: Myoglobinuria was also observed following the 7 . 0 mg / kg dose .
Diseases:"
2683	Histopathology analyses in the 2 animals that died revealed liver and kidney toxicity , with greater severity in the orally - treated animal .	O O O O O O O O O B I I I O O O O O O O O O O O	['liver and kidney toxicity']	1	5	"Sentence: Histopathology analyses in the 2 animals that died revealed liver and kidney toxicity , with greater severity in the orally - treated animal .
Diseases: liver and kidney toxicity"	"Sentence: Histopathology analyses in the 2 animals that died revealed liver and kidney toxicity , with greater severity in the orally - treated animal .
Diseases:"
2684	CONCLUSIONS : These data demonstrate direct and / or indirect drug - induced toxicity .	O O O O O O O O O O O O O B O	['toxicity']	1	2	"Sentence: CONCLUSIONS : These data demonstrate direct and / or indirect drug - induced toxicity .
Diseases: toxicity"	"Sentence: CONCLUSIONS : These data demonstrate direct and / or indirect drug - induced toxicity .
Diseases:"
2685	It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti - CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O	['poisoning', 'toxicity']	2	5	"Sentence: It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti - CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity .
Diseases: poisoning, toxicity"	"Sentence: It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti - CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity .
Diseases:"
2686	Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss .	O O O O O O O O O B I O	['hearing loss']	1	3	"Sentence: Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss .
Diseases: hearing loss"	"Sentence: Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss .
Diseases:"
2687	Tonotopic organization is an essential feature of the primary auditory area ( A1 ) of primate cortex .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Tonotopic organization is an essential feature of the primary auditory area ( A1 ) of primate cortex .
Diseases: "	"Sentence: Tonotopic organization is an essential feature of the primary auditory area ( A1 ) of primate cortex .
Diseases:"
2688	In A1 of macaque monkeys , low frequencies are represented rostrolaterally and high frequencies are represented caudomedially .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In A1 of macaque monkeys , low frequencies are represented rostrolaterally and high frequencies are represented caudomedially .
Diseases: "	"Sentence: In A1 of macaque monkeys , low frequencies are represented rostrolaterally and high frequencies are represented caudomedially .
Diseases:"
2689	The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss .	O O O O O O O O O O O O O O O O O B I O	['hearing loss']	1	3	"Sentence: The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss .
Diseases: hearing loss"	"Sentence: The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss .
Diseases:"
2690	Under anesthesia , the superior temporal gyrus of adult macaque monkeys was exposed , and the tonotopic organization of A1 was mapped using conventional microelectrode recording techniques .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Under anesthesia , the superior temporal gyrus of adult macaque monkeys was exposed , and the tonotopic organization of A1 was mapped using conventional microelectrode recording techniques .
Diseases: "	"Sentence: Under anesthesia , the superior temporal gyrus of adult macaque monkeys was exposed , and the tonotopic organization of A1 was mapped using conventional microelectrode recording techniques .
Diseases:"
2691	Following recovery , the monkeys were selectively deafened for high frequencies using kanamycin and furosemide .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following recovery , the monkeys were selectively deafened for high frequencies using kanamycin and furosemide .
Diseases: "	"Sentence: Following recovery , the monkeys were selectively deafened for high frequencies using kanamycin and furosemide .
Diseases:"
2692	The actual frequencies deafened were determined by the loss of tone - burst elicited auditory brainstem responses .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The actual frequencies deafened were determined by the loss of tone - burst elicited auditory brainstem responses .
Diseases: "	"Sentence: The actual frequencies deafened were determined by the loss of tone - burst elicited auditory brainstem responses .
Diseases:"
2693	Three months after deafening , A1 was remapped .	O O O O O O O O O	[]	0	0	"Sentence: Three months after deafening , A1 was remapped .
Diseases: "	"Sentence: Three months after deafening , A1 was remapped .
Diseases:"
2694	Postmortem cytoarchitectural features identifying A1 were correlated with the electrophysiologic data .	O O O O O O O O O O O O	[]	0	0	"Sentence: Postmortem cytoarchitectural features identifying A1 were correlated with the electrophysiologic data .
Diseases: "	"Sentence: Postmortem cytoarchitectural features identifying A1 were correlated with the electrophysiologic data .
Diseases:"
2695	The results indicate that the deprived area of A1 undergoes extensive reorganization and becomes responsive to intact cochlear frequencies .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results indicate that the deprived area of A1 undergoes extensive reorganization and becomes responsive to intact cochlear frequencies .
Diseases: "	"Sentence: The results indicate that the deprived area of A1 undergoes extensive reorganization and becomes responsive to intact cochlear frequencies .
Diseases:"
2696	The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss .	O O O O O O O O O O O O O O O O B I O	['hearing loss']	1	3	"Sentence: The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss .
Diseases: hearing loss"	"Sentence: The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss .
Diseases:"
2697	The site of common side effects of sumatriptan .	O O O O O O O O O	[]	0	0	"Sentence: The site of common side effects of sumatriptan .
Diseases: "	"Sentence: The site of common side effects of sumatriptan .
Diseases:"
2698	Atypical sensations following the use of subcutaneous sumatriptan are common , but of uncertain origin .	B I O O O O O O O O O O O O O O	['atypical sensations']	1	4	"Sentence: Atypical sensations following the use of subcutaneous sumatriptan are common , but of uncertain origin .
Diseases: atypical sensations"	"Sentence: Atypical sensations following the use of subcutaneous sumatriptan are common , but of uncertain origin .
Diseases:"
2699	They are almost always benign , but can be mistaken for a serious adverse event by the patient .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: They are almost always benign , but can be mistaken for a serious adverse event by the patient .
Diseases: "	"Sentence: They are almost always benign , but can be mistaken for a serious adverse event by the patient .
Diseases:"
2700	Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn .	O O O O O B I I I O O O O O O O B O	['sunburn', 'tingling or burning sensations']	2	9	"Sentence: Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn .
Diseases: sunburn, tingling or burning sensations"	"Sentence: Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn .
Diseases:"
2701	In these individuals , side effects are most likely generated superficially in the skin .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In these individuals , side effects are most likely generated superficially in the skin .
Diseases: "	"Sentence: In these individuals , side effects are most likely generated superficially in the skin .
Diseases:"
2702	Tremor side effects of salbutamol , quantified by a laser pointer technique .	B O O O O O O O O O O O O	['tremor']	1	3	"Sentence: Tremor side effects of salbutamol , quantified by a laser pointer technique .
Diseases: tremor"	"Sentence: Tremor side effects of salbutamol , quantified by a laser pointer technique .
Diseases:"
2703	To study tremor side effects of salbutamol an easily applicable , quick and low - priced method is needed .	O O B O O O O O O O O O O O O O O O O O	['tremor']	1	3	"Sentence: To study tremor side effects of salbutamol an easily applicable , quick and low - priced method is needed .
Diseases: tremor"	"Sentence: To study tremor side effects of salbutamol an easily applicable , quick and low - priced method is needed .
Diseases:"
2704	A new method using a commercially available , pen - shaped laser pointer was developed .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A new method using a commercially available , pen - shaped laser pointer was developed .
Diseases: "	"Sentence: A new method using a commercially available , pen - shaped laser pointer was developed .
Diseases:"
2705	Aim of the study was to determine sensitivity , reproducibility , reference values and the agreement with a questionnaire .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Aim of the study was to determine sensitivity , reproducibility , reference values and the agreement with a questionnaire .
Diseases: "	"Sentence: Aim of the study was to determine sensitivity , reproducibility , reference values and the agreement with a questionnaire .
Diseases:"
2706	Tremor was measured using a laser pointer technique .	B O O O O O O O O	['tremor']	1	3	"Sentence: Tremor was measured using a laser pointer technique .
Diseases: tremor"	"Sentence: Tremor was measured using a laser pointer technique .
Diseases:"
2707	To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol .	O O O O O B O O O O B I I O O O O O O O O	['obstructive lung disease', 'tremor']	2	8	"Sentence: To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol .
Diseases: obstructive lung disease, tremor"	"Sentence: To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol .
Diseases:"
2708	Subjects were asked to aim at the centre of a target , subdivided in concentric circles , from 5 m distance .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Subjects were asked to aim at the centre of a target , subdivided in concentric circles , from 5 m distance .
Diseases: "	"Sentence: Subjects were asked to aim at the centre of a target , subdivided in concentric circles , from 5 m distance .
Diseases:"
2709	The circle in which the participant succeeded to aim was recorded in millimetres radius .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The circle in which the participant succeeded to aim was recorded in millimetres radius .
Diseases: "	"Sentence: The circle in which the participant succeeded to aim was recorded in millimetres radius .
Diseases:"
2710	In another series of measurements , reproducibility and reference values of the tremor was assessed in 65 healthy subjects in three sessions , at 9 a . m . , 4 p . m . and 9 a . m . , respectively , 1 week later .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tremor']	1	3	"Sentence: In another series of measurements , reproducibility and reference values of the tremor was assessed in 65 healthy subjects in three sessions , at 9 a . m . , 4 p . m . and 9 a . m . , respectively , 1 week later .
Diseases: tremor"	"Sentence: In another series of measurements , reproducibility and reference values of the tremor was assessed in 65 healthy subjects in three sessions , at 9 a . m . , 4 p . m . and 9 a . m . , respectively , 1 week later .
Diseases:"
2711	Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2 - kg weight until exhaustion .	O B O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O	['tremor']	1	3	"Sentence: Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2 - kg weight until exhaustion .
Diseases: tremor"	"Sentence: Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2 - kg weight until exhaustion .
Diseases:"
2712	Inter - observer variability was measured in a series of 10 healthy subjects .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Inter - observer variability was measured in a series of 10 healthy subjects .
Diseases: "	"Sentence: Inter - observer variability was measured in a series of 10 healthy subjects .
Diseases:"
2713	Tremor was measured simultaneously by two independent observers .	B O O O O O O O O	['tremor']	1	3	"Sentence: Tremor was measured simultaneously by two independent observers .
Diseases: tremor"	"Sentence: Tremor was measured simultaneously by two independent observers .
Diseases:"
2714	Salbutamol significantly increased tremor severity in patients in a dose - dependent way .	O O O B O O O O O O O O O O	['tremor']	1	3	"Sentence: Salbutamol significantly increased tremor severity in patients in a dose - dependent way .
Diseases: tremor"	"Sentence: Salbutamol significantly increased tremor severity in patients in a dose - dependent way .
Diseases:"
2715	Within healthy adults no age - dependency could be found ( b = 0 . 262 mm / year ; P = 0 . 72 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Within healthy adults no age - dependency could be found ( b = 0 . 262 mm / year ; P = 0 . 72 ) .
Diseases: "	"Sentence: Within healthy adults no age - dependency could be found ( b = 0 . 262 mm / year ; P = 0 . 72 ) .
Diseases:"
2716	There was no agreement between the questionnaire and tremor severity ( r = 0 . 093 ; P = 0 . 53 ) .	O O O O O O O O B O O O O O O O O O O O O O O O	['tremor']	1	3	"Sentence: There was no agreement between the questionnaire and tremor severity ( r = 0 . 093 ; P = 0 . 53 ) .
Diseases: tremor"	"Sentence: There was no agreement between the questionnaire and tremor severity ( r = 0 . 093 ; P = 0 . 53 ) .
Diseases:"
2717	Postural tremor showed no significant difference between the first and third session ( P = 0 . 07 ) .	O B O O O O O O O O O O O O O O O O O O	['tremor']	1	3	"Sentence: Postural tremor showed no significant difference between the first and third session ( P = 0 . 07 ) .
Diseases: tremor"	"Sentence: Postural tremor showed no significant difference between the first and third session ( P = 0 . 07 ) .
Diseases:"
2718	Support of the arm decreased tremor severity , exhaustion increased tremor severity significantly .	O O O O O B O O O O B O O O	['tremor']	1	3	"Sentence: Support of the arm decreased tremor severity , exhaustion increased tremor severity significantly .
Diseases: tremor"	"Sentence: Support of the arm decreased tremor severity , exhaustion increased tremor severity significantly .
Diseases:"
2719	A good agreement was found between two independent observers ( interclass correlation coefficient 0 . 72 ) .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A good agreement was found between two independent observers ( interclass correlation coefficient 0 . 72 ) .
Diseases: "	"Sentence: A good agreement was found between two independent observers ( interclass correlation coefficient 0 . 72 ) .
Diseases:"
2720	Quantifying tremor by using an inexpensive laser pointer is , with the exception of children ( < 12 years ) a sensitive and reproducible method .	O B O O O O O O O O O O O O O O O O O O O O O O O O	['tremor']	1	3	"Sentence: Quantifying tremor by using an inexpensive laser pointer is , with the exception of children ( < 12 years ) a sensitive and reproducible method .
Diseases: tremor"	"Sentence: Quantifying tremor by using an inexpensive laser pointer is , with the exception of children ( < 12 years ) a sensitive and reproducible method .
Diseases:"
2721	Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen - independent prostate cancer .	O O O B I O O O O O O O O O O O O O O B I O	['prostate cancer', 'venous thromboembolism']	2	12	"Sentence: Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen - independent prostate cancer .
Diseases: prostate cancer, venous thromboembolism"	"Sentence: Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen - independent prostate cancer .
Diseases:"
2722	To evaluate the frequency of venous thromboembolism ( VTE ) in patients with advanced androgen - independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide .	O O O O O B I O B O O O O O O O O B I O O O O O O O O O O O O	['vte', 'prostate cancer', 'venous thromboembolism']	3	14	"Sentence: To evaluate the frequency of venous thromboembolism ( VTE ) in patients with advanced androgen - independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide .
Diseases: vte, prostate cancer, venous thromboembolism"	"Sentence: To evaluate the frequency of venous thromboembolism ( VTE ) in patients with advanced androgen - independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide .
Diseases:"
2723	DESIGN : Retrospective analysis of a randomized phase II trial .	O O O O O O O O O O O	[]	0	0	"Sentence: DESIGN : Retrospective analysis of a randomized phase II trial .
Diseases: "	"Sentence: DESIGN : Retrospective analysis of a randomized phase II trial .
Diseases:"
2724	SETTING : National Institutes of Health clinical research center .	O O O O O O O O O O	[]	0	0	"Sentence: SETTING : National Institutes of Health clinical research center .
Diseases: "	"Sentence: SETTING : National Institutes of Health clinical research center .
Diseases:"
2725	PATIENTS :	O O	[]	0	0	"Sentence: PATIENTS :
Diseases: "	"Sentence: PATIENTS :
Diseases:"
2726	Seventy men , aged 50 - 80 years , with advanced androgen - independent prostate cancer .	O O O O O O O O O O O O O O B I O	['prostate cancer']	1	3	"Sentence: Seventy men , aged 50 - 80 years , with advanced androgen - independent prostate cancer .
Diseases: prostate cancer"	"Sentence: Seventy men , aged 50 - 80 years , with advanced androgen - independent prostate cancer .
Diseases:"
2727	INTERVENTION :	O O	[]	0	0	"Sentence: INTERVENTION :
Diseases: "	"Sentence: INTERVENTION :
Diseases:"
2728	Each patient received either intravenous docetaxel 30 mg / m2 / week for 3 consecutive weeks , followed by 1 week off , or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Each patient received either intravenous docetaxel 30 mg / m2 / week for 3 consecutive weeks , followed by 1 week off , or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen .
Diseases: "	"Sentence: Each patient received either intravenous docetaxel 30 mg / m2 / week for 3 consecutive weeks , followed by 1 week off , or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen .
Diseases:"
2729	This 4 - week cycle was repeated until there was evidence of excessive toxicity or disease progression .	O O O O O O O O O O O O O B O O O O	['toxicity']	1	2	"Sentence: This 4 - week cycle was repeated until there was evidence of excessive toxicity or disease progression .
Diseases: toxicity"	"Sentence: This 4 - week cycle was repeated until there was evidence of excessive toxicity or disease progression .
Diseases:"
2730	MEASUREMENTS AND MAIN RESULTS :	O O O O O	[]	0	0	"Sentence: MEASUREMENTS AND MAIN RESULTS :
Diseases: "	"Sentence: MEASUREMENTS AND MAIN RESULTS :
Diseases:"
2731	None of 23 patients who received docetaxel alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus thalidomide developed VTE ( p = 0 . 025 ) .	O O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O	['vte']	1	2	"Sentence: None of 23 patients who received docetaxel alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus thalidomide developed VTE ( p = 0 . 025 ) .
Diseases: vte"	"Sentence: None of 23 patients who received docetaxel alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus thalidomide developed VTE ( p = 0 . 025 ) .
Diseases:"
2732	The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE .	O O O O O O O O O O B I O O O O O B O	['vte', 'prostate cancer']	2	5	"Sentence: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE .
Diseases: vte, prostate cancer"	"Sentence: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE .
Diseases:"
2733	Clinicians should be aware of this potential complication when adding thalidomide to chemotherapeutic regimens .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinicians should be aware of this potential complication when adding thalidomide to chemotherapeutic regimens .
Diseases: "	"Sentence: Clinicians should be aware of this potential complication when adding thalidomide to chemotherapeutic regimens .
Diseases:"
2734	Sublingual absorption of the quaternary ammonium antiarrhythmic agent , UM - 272 .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Sublingual absorption of the quaternary ammonium antiarrhythmic agent , UM - 272 .
Diseases: "	"Sentence: Sublingual absorption of the quaternary ammonium antiarrhythmic agent , UM - 272 .
Diseases:"
2735	UM - 272 ( N , N - dimethylpropranolol ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with ouabain - induced ventricular tachycardias .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['ventricular tachycardias']	1	6	"Sentence: UM - 272 ( N , N - dimethylpropranolol ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with ouabain - induced ventricular tachycardias .
Diseases: ventricular tachycardias"	"Sentence: UM - 272 ( N , N - dimethylpropranolol ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with ouabain - induced ventricular tachycardias .
Diseases:"
2736	Both anti - arrhythmic efficacy and bioavailability were compared to oral drug .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Both anti - arrhythmic efficacy and bioavailability were compared to oral drug .
Diseases: "	"Sentence: Both anti - arrhythmic efficacy and bioavailability were compared to oral drug .
Diseases:"
2737	Sublingual UM - 272 converted ventricular tachycardia to sinus rhythm in all 5 dogs .	O O O O O B I O O O O O O O O	['ventricular tachycardia']	1	6	"Sentence: Sublingual UM - 272 converted ventricular tachycardia to sinus rhythm in all 5 dogs .
Diseases: ventricular tachycardia"	"Sentence: Sublingual UM - 272 converted ventricular tachycardia to sinus rhythm in all 5 dogs .
Diseases:"
2738	The area under the plasma concentration time curve at 90 min was 4 - 12 times greater than for oral drug , suggesting the existence of an absorption - limiting process in the intestine , and providing an alternate form of administration for quaternary drugs .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The area under the plasma concentration time curve at 90 min was 4 - 12 times greater than for oral drug , suggesting the existence of an absorption - limiting process in the intestine , and providing an alternate form of administration for quaternary drugs .
Diseases: "	"Sentence: The area under the plasma concentration time curve at 90 min was 4 - 12 times greater than for oral drug , suggesting the existence of an absorption - limiting process in the intestine , and providing an alternate form of administration for quaternary drugs .
Diseases:"
2739	Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin : a case report with fatal outcome .	O B O B I O O O O O O O O O O O	['thrombocytopenia', 'haemolytic anaemia']	2	14	"Sentence: Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin : a case report with fatal outcome .
Diseases: thrombocytopenia, haemolytic anaemia"	"Sentence: Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin : a case report with fatal outcome .
Diseases:"
2740	Haematological adverse reactions associated with fatal outcome are rare during treatment with ciprofloxacin .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Haematological adverse reactions associated with fatal outcome are rare during treatment with ciprofloxacin .
Diseases: "	"Sentence: Haematological adverse reactions associated with fatal outcome are rare during treatment with ciprofloxacin .
Diseases:"
2741	A 30 - year old Caucasian man reported with abdominal pain and jaundice after 3 - day administration of oral ciprofloxacin for a suspect of urinary tract infection .	O O O O O O O O O B I O B O O O O O O O O O O O O B I I O	['jaundice', 'abdominal pain', 'urinary tract infection']	3	10	"Sentence: A 30 - year old Caucasian man reported with abdominal pain and jaundice after 3 - day administration of oral ciprofloxacin for a suspect of urinary tract infection .
Diseases: jaundice, abdominal pain, urinary tract infection"	"Sentence: A 30 - year old Caucasian man reported with abdominal pain and jaundice after 3 - day administration of oral ciprofloxacin for a suspect of urinary tract infection .
Diseases:"
2742	Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis .	O O O O O O O O B O B O	['haemolysis', 'thrombocytopenia']	2	12	"Sentence: Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis .
Diseases: haemolysis, thrombocytopenia"	"Sentence: Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis .
Diseases:"
2743	The patient progressively developed petechiae and purpura on thorax and lower limbs .	O O O O B O B O O O O O O	['petechiae', 'purpura']	2	7	"Sentence: The patient progressively developed petechiae and purpura on thorax and lower limbs .
Diseases: petechiae, purpura"	"Sentence: The patient progressively developed petechiae and purpura on thorax and lower limbs .
Diseases:"
2744	Despite pharmacological and supportive interventions , laboratory parameters worsened and the patient died 17 hours after admission .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Despite pharmacological and supportive interventions , laboratory parameters worsened and the patient died 17 hours after admission .
Diseases: "	"Sentence: Despite pharmacological and supportive interventions , laboratory parameters worsened and the patient died 17 hours after admission .
Diseases:"
2745	An accurate autopsy revealed most organs with diffuse petechial haemorrhages .	O O O O O O O O O B O	['haemorrhages']	1	5	"Sentence: An accurate autopsy revealed most organs with diffuse petechial haemorrhages .
Diseases: haemorrhages"	"Sentence: An accurate autopsy revealed most organs with diffuse petechial haemorrhages .
Diseases:"
2746	No signs of bone marrow depression were found .	O O O B I I O O O	['bone marrow depression']	1	3	"Sentence: No signs of bone marrow depression were found .
Diseases: bone marrow depression"	"Sentence: No signs of bone marrow depression were found .
Diseases:"
2747	No thrombi or signs of microangiopathies were observed in arterial vessels .	O B O O O B O O O O O O	['microangiopathies', 'thrombi']	2	9	"Sentence: No thrombi or signs of microangiopathies were observed in arterial vessels .
Diseases: microangiopathies, thrombi"	"Sentence: No thrombi or signs of microangiopathies were observed in arterial vessels .
Diseases:"
2748	Blood and urine cultures did not show any bacterial growth .	O O O O O O O O O O O	[]	0	0	"Sentence: Blood and urine cultures did not show any bacterial growth .
Diseases: "	"Sentence: Blood and urine cultures did not show any bacterial growth .
Diseases:"
2749	This case report shows that ciprofloxacin may precipitate life - threatening thrombocytopenia and haemolytic anaemia , even in the early phases of treatment and without apparent previous exposures .	O O O O O O O O O O O B O B I O O O O O O O O O O O O O O	['thrombocytopenia', 'haemolytic anaemia']	2	14	"Sentence: This case report shows that ciprofloxacin may precipitate life - threatening thrombocytopenia and haemolytic anaemia , even in the early phases of treatment and without apparent previous exposures .
Diseases: thrombocytopenia, haemolytic anaemia"	"Sentence: This case report shows that ciprofloxacin may precipitate life - threatening thrombocytopenia and haemolytic anaemia , even in the early phases of treatment and without apparent previous exposures .
Diseases:"
2750	Simvastatin - induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism .	O O O O O B I O B O O B O	['hypothyroidism', 'compartment syndrome', 'myonecrosis']	3	12	"Sentence: Simvastatin - induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism .
Diseases: hypothyroidism, compartment syndrome, myonecrosis"	"Sentence: Simvastatin - induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism .
Diseases:"
2751	A 54 - year - old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis .	O O O O O O B O O O O O O O O O B I O B O	['hypothyroid', 'compartment syndrome', 'myonecrosis']	3	11	"Sentence: A 54 - year - old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis .
Diseases: hypothyroid, compartment syndrome, myonecrosis"	"Sentence: A 54 - year - old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis .
Diseases:"
2752	Urgent fasciotomies were performed and the patient made an uneventful recovery with the withdrawal of simvastatin .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Urgent fasciotomies were performed and the patient made an uneventful recovery with the withdrawal of simvastatin .
Diseases: "	"Sentence: Urgent fasciotomies were performed and the patient made an uneventful recovery with the withdrawal of simvastatin .
Diseases:"
2753	It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients .	O O O O O O O O O O O O O O O O O O O O O O O O B O O	['arteriopathic']	1	4	"Sentence: It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients .
Diseases: arteriopathic"	"Sentence: It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients .
Diseases:"
2754	Bile duct hamartoma occurring in association with long - term treatment with danazol .	B I I O O O O O O O O O O O	['bile duct hamartoma']	1	6	"Sentence: Bile duct hamartoma occurring in association with long - term treatment with danazol .
Diseases: bile duct hamartoma"	"Sentence: Bile duct hamartoma occurring in association with long - term treatment with danazol .
Diseases:"
2755	We report a case of bile duct hamartoma which developed in a patient who had been on long - term danazol treatment .	O O O O O B I I O O O O O O O O O O O O O O O	['bile duct hamartoma']	1	6	"Sentence: We report a case of bile duct hamartoma which developed in a patient who had been on long - term danazol treatment .
Diseases: bile duct hamartoma"	"Sentence: We report a case of bile duct hamartoma which developed in a patient who had been on long - term danazol treatment .
Diseases:"
2756	Such patients should be under close follow - up , preferably with periodic ultrasound examination of the liver .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Such patients should be under close follow - up , preferably with periodic ultrasound examination of the liver .
Diseases: "	"Sentence: Such patients should be under close follow - up , preferably with periodic ultrasound examination of the liver .
Diseases:"
2757	If the patient develops a liver mass , because of non - specific clinical features and imaging appearances , biopsy may be the only way to achieve a definitive diagnosis .	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	['liver mass']	1	3	"Sentence: If the patient develops a liver mass , because of non - specific clinical features and imaging appearances , biopsy may be the only way to achieve a definitive diagnosis .
Diseases: liver mass"	"Sentence: If the patient develops a liver mass , because of non - specific clinical features and imaging appearances , biopsy may be the only way to achieve a definitive diagnosis .
Diseases:"
2758	Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid .	B I O O O O O O O O O	['granulomatous hepatitis']	1	6	"Sentence: Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid .
Diseases: granulomatous hepatitis"	"Sentence: Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid .
Diseases:"
2759	We report the case of a patient with amoxicillin - clavulanic acid - induced hepatitis with histologic multiple granulomas .	O O O O O O O O O O O O O O B O O O B O	['granulomas', 'hepatitis']	2	5	"Sentence: We report the case of a patient with amoxicillin - clavulanic acid - induced hepatitis with histologic multiple granulomas .
Diseases: granulomas, hepatitis"	"Sentence: We report the case of a patient with amoxicillin - clavulanic acid - induced hepatitis with histologic multiple granulomas .
Diseases:"
2760	This type of lesion broadens the spectrum of liver injury due to this drug combination , mainly represented by a benign cholestatic syndrome .	O O O O O O O O B I O O O O O O O O O O O B I O	['cholestatic syndrome', 'liver injury']	2	8	"Sentence: This type of lesion broadens the spectrum of liver injury due to this drug combination , mainly represented by a benign cholestatic syndrome .
Diseases: cholestatic syndrome, liver injury"	"Sentence: This type of lesion broadens the spectrum of liver injury due to this drug combination , mainly represented by a benign cholestatic syndrome .
Diseases:"
2761	The association of granulomas and eosinophilia favor an immunoallergic mechanism .	O O O B O B O O O O O	['granulomas', 'eosinophilia']	2	9	"Sentence: The association of granulomas and eosinophilia favor an immunoallergic mechanism .
Diseases: granulomas, eosinophilia"	"Sentence: The association of granulomas and eosinophilia favor an immunoallergic mechanism .
Diseases:"
2762	As penicillin derivatives and amoxicillin alone are known to induce such types of lesions , the amoxicillin component , with or without a potentiating effect of clavulanic acid , might have a major role .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As penicillin derivatives and amoxicillin alone are known to induce such types of lesions , the amoxicillin component , with or without a potentiating effect of clavulanic acid , might have a major role .
Diseases: "	"Sentence: As penicillin derivatives and amoxicillin alone are known to induce such types of lesions , the amoxicillin component , with or without a potentiating effect of clavulanic acid , might have a major role .
Diseases:"
2763	Intracranial aneurysms and cocaine abuse : analysis of prognostic indicators .	B I O B I O O O O O O	['intracranial aneurysms', 'cocaine abuse']	2	11	"Sentence: Intracranial aneurysms and cocaine abuse : analysis of prognostic indicators .
Diseases: intracranial aneurysms, cocaine abuse"	"Sentence: Intracranial aneurysms and cocaine abuse : analysis of prognostic indicators .
Diseases:"
2764	The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor .	O O O B I O O B I O O O O	['subarachnoid hemorrhage', 'cocaine abuse']	2	10	"Sentence: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor .
Diseases: subarachnoid hemorrhage, cocaine abuse"	"Sentence: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor .
Diseases:"
2765	However , no study in the literature has reported the use of a statistical model to analyze the variables that influence outcome .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , no study in the literature has reported the use of a statistical model to analyze the variables that influence outcome .
Diseases: "	"Sentence: However , no study in the literature has reported the use of a statistical model to analyze the variables that influence outcome .
Diseases:"
2766	A review of admissions during a 6 - year period revealed 14 patients with cocaine - related aneurysms .	O O O O O O O O O O O O O O O O O B O	['aneurysms']	1	4	"Sentence: A review of admissions during a 6 - year period revealed 14 patients with cocaine - related aneurysms .
Diseases: aneurysms"	"Sentence: A review of admissions during a 6 - year period revealed 14 patients with cocaine - related aneurysms .
Diseases:"
2767	This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse .	O O O O O O O O O O O O B I O O O O B I O	['cocaine abuse', 'ruptured aneurysms']	2	9	"Sentence: This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse .
Diseases: cocaine abuse, ruptured aneurysms"	"Sentence: This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse .
Diseases:"
2768	Age at presentation , time of ictus after intoxication , Hunt and Hess grade of subarachnoid hemorrhage , size of the aneurysm , location of the aneurysm , and the Glasgow Outcome Scale score were assessed and compared .	O O O O O O O O O O O O O O O B I O O O O B O O O O B O O O O O O O O O O O O	['aneurysm', 'subarachnoid hemorrhage']	2	12	"Sentence: Age at presentation , time of ictus after intoxication , Hunt and Hess grade of subarachnoid hemorrhage , size of the aneurysm , location of the aneurysm , and the Glasgow Outcome Scale score were assessed and compared .
Diseases: aneurysm, subarachnoid hemorrhage"	"Sentence: Age at presentation , time of ictus after intoxication , Hunt and Hess grade of subarachnoid hemorrhage , size of the aneurysm , location of the aneurysm , and the Glasgow Outcome Scale score were assessed and compared .
Diseases:"
2769	The patients in the study group were significantly younger than the patients in the control group ( P < 0 . 002 ) .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The patients in the study group were significantly younger than the patients in the control group ( P < 0 . 002 ) .
Diseases: "	"Sentence: The patients in the study group were significantly younger than the patients in the control group ( P < 0 . 002 ) .
Diseases:"
2770	In patients in the study group , all aneurysms were located in the anterior circulation .	O O O O O O O O B O O O O O O O	['aneurysms']	1	4	"Sentence: In patients in the study group , all aneurysms were located in the anterior circulation .
Diseases: aneurysms"	"Sentence: In patients in the study group , all aneurysms were located in the anterior circulation .
Diseases:"
2771	The majority of these aneurysms were smaller than those of the control group ( 8 + / -	O O O O B O O O O O O O O O O O O O	['aneurysms']	1	4	"Sentence: The majority of these aneurysms were smaller than those of the control group ( 8 + / -
Diseases: aneurysms"	"Sentence: The majority of these aneurysms were smaller than those of the control group ( 8 + / -
Diseases:"
2772	6 . 08 mm versus 11 + / - 5 . 4 mm ; P = 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 6 . 08 mm versus 11 + / - 5 . 4 mm ; P = 0 . 05 ) .
Diseases: "	"Sentence: 6 . 08 mm versus 11 + / - 5 . 4 mm ; P = 0 . 05 ) .
Diseases:"
2773	The differences in mortality and morbidity between the two groups were not significant .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The differences in mortality and morbidity between the two groups were not significant .
Diseases: "	"Sentence: The differences in mortality and morbidity between the two groups were not significant .
Diseases:"
2774	Hunt and Hess grade ( P < 0 . 005 ) and age ( P < 0 . 007 ) were significant predictors of outcome for the patients with cocaine - related aneurysms .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['aneurysms']	1	4	"Sentence: Hunt and Hess grade ( P < 0 . 005 ) and age ( P < 0 . 007 ) were significant predictors of outcome for the patients with cocaine - related aneurysms .
Diseases: aneurysms"	"Sentence: Hunt and Hess grade ( P < 0 . 005 ) and age ( P < 0 . 007 ) were significant predictors of outcome for the patients with cocaine - related aneurysms .
Diseases:"
2775	Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms .	O O O B I O O O O O O O O O B O	['aneurysms', 'aneurysmal rupture']	2	10	"Sentence: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms .
Diseases: aneurysms, aneurysmal rupture"	"Sentence: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms .
Diseases:"
2776	Contrary to the published literature , this group did reasonably well with aggressive management .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Contrary to the published literature , this group did reasonably well with aggressive management .
Diseases: "	"Sentence: Contrary to the published literature , this group did reasonably well with aggressive management .
Diseases:"
2777	Anti - epileptic drugs - induced de novo absence seizures .	O O B O O O O O B I O	['epileptic', 'absence seizures']	2	6	"Sentence: Anti - epileptic drugs - induced de novo absence seizures .
Diseases: epileptic, absence seizures"	"Sentence: Anti - epileptic drugs - induced de novo absence seizures .
Diseases:"
2778	The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin .	O O O O O O O O B I O O O O O O O	['absence epilepsy']	1	3	"Sentence: The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin .
Diseases: absence epilepsy"	"Sentence: The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin .
Diseases:"
2779	Despite the underlying diseases , the prognosis for drug - induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	['absence seizure']	1	3	"Sentence: Despite the underlying diseases , the prognosis for drug - induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs .
Diseases: absence seizure"	"Sentence: Despite the underlying diseases , the prognosis for drug - induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs .
Diseases:"
2780	The gamma - aminobutyric acid - transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy .	O O O O O O O O O O O O O O O O O O O O B I O	['absence epilepsy']	1	3	"Sentence: The gamma - aminobutyric acid - transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy .
Diseases: absence epilepsy"	"Sentence: The gamma - aminobutyric acid - transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy .
Diseases:"
2781	Because drug - induced de novo absence seizure is rare , pro - absence drugs can only be considered a promoting factor .	O O O O O O B I O O O O O O O O O O O O O O O	['absence seizure']	1	3	"Sentence: Because drug - induced de novo absence seizure is rare , pro - absence drugs can only be considered a promoting factor .
Diseases: absence seizure"	"Sentence: Because drug - induced de novo absence seizure is rare , pro - absence drugs can only be considered a promoting factor .
Diseases:"
2782	The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure .	O O O O O O O O O O O O O O O O O O O O O B I O	['absence seizure']	1	3	"Sentence: The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure .
Diseases: absence seizure"	"Sentence: The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure .
Diseases:"
2783	The possibility of drug - induced aggravation should be considered whenever an unexpected increase in seizure frequency and / or new seizure types appear following a change in drug treatment .	O O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O	['seizure']	1	3	"Sentence: The possibility of drug - induced aggravation should be considered whenever an unexpected increase in seizure frequency and / or new seizure types appear following a change in drug treatment .
Diseases: seizure"	"Sentence: The possibility of drug - induced aggravation should be considered whenever an unexpected increase in seizure frequency and / or new seizure types appear following a change in drug treatment .
Diseases:"
2784	By understanding the underlying mechanism of absence epilepsy , we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug - induced absence seizures .	O O O O O O B I O O O O O O O O O O O O B O O O O O B I O	['absence epilepsy', 'epilepsy', 'absence seizures']	3	8	"Sentence: By understanding the underlying mechanism of absence epilepsy , we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug - induced absence seizures .
Diseases: absence epilepsy, epilepsy, absence seizures"	"Sentence: By understanding the underlying mechanism of absence epilepsy , we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug - induced absence seizures .
Diseases:"
2785	Procainamide - induced polymorphous ventricular tachycardia .	O O O O B I O	['ventricular tachycardia']	1	6	"Sentence: Procainamide - induced polymorphous ventricular tachycardia .
Diseases: ventricular tachycardia"	"Sentence: Procainamide - induced polymorphous ventricular tachycardia .
Diseases:"
2786	Seven cases of procainamide - induced polymorphous ventricular tachycardia are presented .	O O O O O O O B I O O O	['ventricular tachycardia']	1	6	"Sentence: Seven cases of procainamide - induced polymorphous ventricular tachycardia are presented .
Diseases: ventricular tachycardia"	"Sentence: Seven cases of procainamide - induced polymorphous ventricular tachycardia are presented .
Diseases:"
2787	In four patients , polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia .	O O O O O B I O O O O O O O O O O O O O O O O B I O	['ventricular tachycardia']	1	6	"Sentence: In four patients , polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia .
Diseases: ventricular tachycardia"	"Sentence: In four patients , polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia .
Diseases:"
2788	In the remaining three patients , procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter .	O O O O O O O O O O O O O O B I I O B I O	['atrial flutter', 'premature ventricular contractions']	2	10	"Sentence: In the remaining three patients , procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter .
Diseases: atrial flutter, premature ventricular contractions"	"Sentence: In the remaining three patients , procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter .
Diseases:"
2789	These patients had Q - T prolongation and recurrent syncope due to polymorphous ventricular tachycardia .	O O O B I I I O O B O O O B I O	['q - t prolongation', 'ventricular tachycardia', 'syncope']	3	15	"Sentence: These patients had Q - T prolongation and recurrent syncope due to polymorphous ventricular tachycardia .
Diseases: q - t prolongation, ventricular tachycardia, syncope"	"Sentence: These patients had Q - T prolongation and recurrent syncope due to polymorphous ventricular tachycardia .
Diseases:"
2790	In four patients , the arrhythmia was rapidly diagnosed and treated with disappearance of further episodes of the arrhythmia .	O O O O O B O O O O O O O O O O O O B O	['arrhythmia']	1	4	"Sentence: In four patients , the arrhythmia was rapidly diagnosed and treated with disappearance of further episodes of the arrhythmia .
Diseases: arrhythmia"	"Sentence: In four patients , the arrhythmia was rapidly diagnosed and treated with disappearance of further episodes of the arrhythmia .
Diseases:"
2791	In two patients , the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died .	O O O O O B O O O B I O O O O O	['ventricular fibrillation', 'arrhythmia']	2	10	"Sentence: In two patients , the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died .
Diseases: ventricular fibrillation, arrhythmia"	"Sentence: In two patients , the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died .
Diseases:"
2792	In the seventh patient , a permanent ventricular pacemaker was inserted and , despite continuation of procainamide therapy , polymorphous ventricular tachycardia did not reoccur .	O O O O O O O O O O O O O O O O O O O O B I O O O O	['ventricular tachycardia']	1	6	"Sentence: In the seventh patient , a permanent ventricular pacemaker was inserted and , despite continuation of procainamide therapy , polymorphous ventricular tachycardia did not reoccur .
Diseases: ventricular tachycardia"	"Sentence: In the seventh patient , a permanent ventricular pacemaker was inserted and , despite continuation of procainamide therapy , polymorphous ventricular tachycardia did not reoccur .
Diseases:"
2793	These seven cases demonstrate that procainamide can produce an acquired prolonged Q - T syndrome with polymorphous ventricular tachycardia .	O O O O O O O O O O B I I I I O O B I O	['ventricular tachycardia', 'prolonged q - t syndrome']	2	12	"Sentence: These seven cases demonstrate that procainamide can produce an acquired prolonged Q - T syndrome with polymorphous ventricular tachycardia .
Diseases: ventricular tachycardia, prolonged q - t syndrome"	"Sentence: These seven cases demonstrate that procainamide can produce an acquired prolonged Q - T syndrome with polymorphous ventricular tachycardia .
Diseases:"
2794	Role of activation of bradykinin B2 receptors in disruption of the blood - brain barrier during acute hypertension .	O O O O O O O O O O O O O O O O O B O	['hypertension']	1	3	"Sentence: Role of activation of bradykinin B2 receptors in disruption of the blood - brain barrier during acute hypertension .
Diseases: hypertension"	"Sentence: Role of activation of bradykinin B2 receptors in disruption of the blood - brain barrier during acute hypertension .
Diseases:"
2795	Cellular mechanisms which account for disruption the blood - brain barrier during acute hypertension are not clear .	O O O O O O O O O O O O O B O O O O	['hypertension']	1	3	"Sentence: Cellular mechanisms which account for disruption the blood - brain barrier during acute hypertension are not clear .
Diseases: hypertension"	"Sentence: Cellular mechanisms which account for disruption the blood - brain barrier during acute hypertension are not clear .
Diseases:"
2796	The goal of this study was to determine the role of synthesis / release of bradykinin to activate B2 receptors in disruption of the blood - brain barrier during acute hypertension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['hypertension']	1	3	"Sentence: The goal of this study was to determine the role of synthesis / release of bradykinin to activate B2 receptors in disruption of the blood - brain barrier during acute hypertension .
Diseases: hypertension"	"Sentence: The goal of this study was to determine the role of synthesis / release of bradykinin to activate B2 receptors in disruption of the blood - brain barrier during acute hypertension .
Diseases:"
2797	Permeability of the blood - brain barrier was quantitated by clearance of fluorescent - labeled dextran before and during phenylephrine - induced acute hypertension in rats treated with vehicle and Hoe - 140 ( 0 . 1 microM ) .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: Permeability of the blood - brain barrier was quantitated by clearance of fluorescent - labeled dextran before and during phenylephrine - induced acute hypertension in rats treated with vehicle and Hoe - 140 ( 0 . 1 microM ) .
Diseases: hypertension"	"Sentence: Permeability of the blood - brain barrier was quantitated by clearance of fluorescent - labeled dextran before and during phenylephrine - induced acute hypertension in rats treated with vehicle and Hoe - 140 ( 0 . 1 microM ) .
Diseases:"
2798	Phenylephrine infusion increased arterial pressure , arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Phenylephrine infusion increased arterial pressure , arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups .
Diseases: "	"Sentence: Phenylephrine infusion increased arterial pressure , arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups .
Diseases:"
2799	These findings suggest that disruption of the blood - brain barrier during acute hypertension is not related to the synthesis / release of bradykinin to activate B2 receptors .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: These findings suggest that disruption of the blood - brain barrier during acute hypertension is not related to the synthesis / release of bradykinin to activate B2 receptors .
Diseases: hypertension"	"Sentence: These findings suggest that disruption of the blood - brain barrier during acute hypertension is not related to the synthesis / release of bradykinin to activate B2 receptors .
Diseases:"
2800	5 - azacytidine potentiates initiation induced by carcinogens in rat liver .	O O O O B I I I O O O O	['initiation induced by carcinogens']	1	6	"Sentence: 5 - azacytidine potentiates initiation induced by carcinogens in rat liver .
Diseases: initiation induced by carcinogens"	"Sentence: 5 - azacytidine potentiates initiation induced by carcinogens in rat liver .
Diseases:"
2801	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process , 5 - azacytidine ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( 1 , 2 - DMH ) ( 100 mg / kg ) .	O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['initiation of carcinogenic process']	1	6	"Sentence: To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process , 5 - azacytidine ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( 1 , 2 - DMH ) ( 100 mg / kg ) .
Diseases: initiation of carcinogenic process"	"Sentence: To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process , 5 - azacytidine ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( 1 , 2 - DMH ) ( 100 mg / kg ) .
Diseases:"
2802	The initiated hepatocytes in the liver were assayed as the gamma - glutamyltransferase ( gamma - GT ) positive foci formed following a 2 - week selection regimen consisting of dietary 0 . 02 % 2 - acetylaminofluorene coupled with a necrogenic dose of CCl4 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The initiated hepatocytes in the liver were assayed as the gamma - glutamyltransferase ( gamma - GT ) positive foci formed following a 2 - week selection regimen consisting of dietary 0 . 02 % 2 - acetylaminofluorene coupled with a necrogenic dose of CCl4 .
Diseases: "	"Sentence: The initiated hepatocytes in the liver were assayed as the gamma - glutamyltransferase ( gamma - GT ) positive foci formed following a 2 - week selection regimen consisting of dietary 0 . 02 % 2 - acetylaminofluorene coupled with a necrogenic dose of CCl4 .
Diseases:"
2803	The results obtained indicate that with all three carcinogens , administration of 5 - AzC during repair synthesis increased the incidence of initiated hepatocytes , for example 10 - 20 foci / cm2 in 5 - AzC and carcinogen - treated rats compared with 3 - 5 foci / cm2 in rats treated with carcinogen only .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results obtained indicate that with all three carcinogens , administration of 5 - AzC during repair synthesis increased the incidence of initiated hepatocytes , for example 10 - 20 foci / cm2 in 5 - AzC and carcinogen - treated rats compared with 3 - 5 foci / cm2 in rats treated with carcinogen only .
Diseases: "	"Sentence: The results obtained indicate that with all three carcinogens , administration of 5 - AzC during repair synthesis increased the incidence of initiated hepatocytes , for example 10 - 20 foci / cm2 in 5 - AzC and carcinogen - treated rats compared with 3 - 5 foci / cm2 in rats treated with carcinogen only .
Diseases:"
2804	Administration of [ 3H ] - 5 - azadeoxycytidine during the repair synthesis induced by 1 , 2 - DMH further showed that 0 . 019 mol % of cytosine residues in DNA were substituted by the analogue , indicating that incorporation of 5 - AzC occurs during repair synthesis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Administration of [ 3H ] - 5 - azadeoxycytidine during the repair synthesis induced by 1 , 2 - DMH further showed that 0 . 019 mol % of cytosine residues in DNA were substituted by the analogue , indicating that incorporation of 5 - AzC occurs during repair synthesis .
Diseases: "	"Sentence: Administration of [ 3H ] - 5 - azadeoxycytidine during the repair synthesis induced by 1 , 2 - DMH further showed that 0 . 019 mol % of cytosine residues in DNA were substituted by the analogue , indicating that incorporation of 5 - AzC occurs during repair synthesis .
Diseases:"
2805	In the absence of the carcinogen , 5 - AzC given after a two thirds partial hepatectomy , when its incorporation should be maximum , failed to induce any gamma - GT positive foci .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the absence of the carcinogen , 5 - AzC given after a two thirds partial hepatectomy , when its incorporation should be maximum , failed to induce any gamma - GT positive foci .
Diseases: "	"Sentence: In the absence of the carcinogen , 5 - AzC given after a two thirds partial hepatectomy , when its incorporation should be maximum , failed to induce any gamma - GT positive foci .
Diseases:"
2806	The results suggest that hypomethylation of DNA per se may not be sufficient for initiation .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results suggest that hypomethylation of DNA per se may not be sufficient for initiation .
Diseases: "	"Sentence: The results suggest that hypomethylation of DNA per se may not be sufficient for initiation .
Diseases:"
2807	Perhaps two events might be necessary for initiation , the first caused by the carcinogen and a second involving hypomethylation of DNA .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Perhaps two events might be necessary for initiation , the first caused by the carcinogen and a second involving hypomethylation of DNA .
Diseases: "	"Sentence: Perhaps two events might be necessary for initiation , the first caused by the carcinogen and a second involving hypomethylation of DNA .
Diseases:"
2808	Withdrawal - emergent rabbit syndrome during dose reduction of risperidone .	B I I I I O O O O O O	['withdrawal - emergent rabbit syndrome']	1	8	"Sentence: Withdrawal - emergent rabbit syndrome during dose reduction of risperidone .
Diseases: withdrawal - emergent rabbit syndrome"	"Sentence: Withdrawal - emergent rabbit syndrome during dose reduction of risperidone .
Diseases:"
2809	Rabbit syndrome ( RS ) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication .	B I O B O O O O O O O O O O O O O	['rabbit syndrome', 'rs']	2	5	"Sentence: Rabbit syndrome ( RS ) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication .
Diseases: rabbit syndrome, rs"	"Sentence: Rabbit syndrome ( RS ) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication .
Diseases:"
2810	Here we present a case of withdrawal - emergent RS , which is the first of its kind to be reported .	O O O O O O B I I I O O O O O O O O O O O O	['withdrawal - emergent rs']	1	7	"Sentence: Here we present a case of withdrawal - emergent RS , which is the first of its kind to be reported .
Diseases: withdrawal - emergent rs"	"Sentence: Here we present a case of withdrawal - emergent RS , which is the first of its kind to be reported .
Diseases:"
2811	The patient developed RS during dose reduction of risperidone .	O O O B O O O O O O	['rs']	1	1	"Sentence: The patient developed RS during dose reduction of risperidone .
Diseases: rs"	"Sentence: The patient developed RS during dose reduction of risperidone .
Diseases:"
2812	The symptom was treated successfully with trihexyphenidyl anticholinergic therapy .	O O O O O O O O O O	[]	0	0	"Sentence: The symptom was treated successfully with trihexyphenidyl anticholinergic therapy .
Diseases: "	"Sentence: The symptom was treated successfully with trihexyphenidyl anticholinergic therapy .
Diseases:"
2813	The underlying mechanism of withdrawal - emergent RS in the present case may have been related to the pharmacological profile of risperidone , a serotonin - dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .	O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['withdrawal - emergent rs', 'rs']	2	9	"Sentence: The underlying mechanism of withdrawal - emergent RS in the present case may have been related to the pharmacological profile of risperidone , a serotonin - dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
Diseases: withdrawal - emergent rs, rs"	"Sentence: The underlying mechanism of withdrawal - emergent RS in the present case may have been related to the pharmacological profile of risperidone , a serotonin - dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .
Diseases:"
2814	Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram .	O O O O O O O B I O O B O O O O O O O	['hypertensive', 'myocardial infarction']	2	10	"Sentence: Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram .
Diseases: hypertensive, myocardial infarction"	"Sentence: Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram .
Diseases:"
2815	Verapamil is an effective and relatively - safe antihypertensive drug .	O O O O O O O O O O O	[]	0	0	"Sentence: Verapamil is an effective and relatively - safe antihypertensive drug .
Diseases: "	"Sentence: Verapamil is an effective and relatively - safe antihypertensive drug .
Diseases:"
2816	Serious adverse effects are uncommon and mainly have been related to the depression of cardiac contractility and conduction , especially when the drug is combined with beta - blocking agents .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['depression']	1	2	"Sentence: Serious adverse effects are uncommon and mainly have been related to the depression of cardiac contractility and conduction , especially when the drug is combined with beta - blocking agents .
Diseases: depression"	"Sentence: Serious adverse effects are uncommon and mainly have been related to the depression of cardiac contractility and conduction , especially when the drug is combined with beta - blocking agents .
Diseases:"
2817	We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension .	O O O O O O B I O O O O O O O O O O O O O O O O O O B O	['hypertension', 'myocardial infarction']	2	8	"Sentence: We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension .
Diseases: hypertension, myocardial infarction"	"Sentence: We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension .
Diseases:"
2818	Possible mechanisms that involve a verapamil - related increase in platelet and / or vascular alpha 2 - adrenoreceptor affinity for catecholamines are discussed .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Possible mechanisms that involve a verapamil - related increase in platelet and / or vascular alpha 2 - adrenoreceptor affinity for catecholamines are discussed .
Diseases: "	"Sentence: Possible mechanisms that involve a verapamil - related increase in platelet and / or vascular alpha 2 - adrenoreceptor affinity for catecholamines are discussed .
Diseases:"
2819	Remission induction of meningeal leukemia with high - dose intravenous methotrexate .	O O O B I O O O O O O O	['meningeal leukemia']	1	4	"Sentence: Remission induction of meningeal leukemia with high - dose intravenous methotrexate .
Diseases: meningeal leukemia"	"Sentence: Remission induction of meningeal leukemia with high - dose intravenous methotrexate .
Diseases:"
2820	Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high - dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10 ( - 5 ) mol / L without the need for concomitant intrathecal dosing .	O O O B I I O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['meningeal disease', 'acute lymphoblastic leukemia']	2	10	"Sentence: Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high - dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10 ( - 5 ) mol / L without the need for concomitant intrathecal dosing .
Diseases: meningeal disease, acute lymphoblastic leukemia"	"Sentence: Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high - dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10 ( - 5 ) mol / L without the need for concomitant intrathecal dosing .
Diseases:"
2821	The methotrexate was administered as a loading dose of 6 , 000 mg / m2 for a period of one hour followed by an infusion of 1 , 200 mg / m2 / h for 23 hours .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The methotrexate was administered as a loading dose of 6 , 000 mg / m2 for a period of one hour followed by an infusion of 1 , 200 mg / m2 / h for 23 hours .
Diseases: "	"Sentence: The methotrexate was administered as a loading dose of 6 , 000 mg / m2 for a period of one hour followed by an infusion of 1 , 200 mg / m2 / h for 23 hours .
Diseases:"
2822	Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg / m2 followed by 12 mg / m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10 ( - 7 ) mol /	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg / m2 followed by 12 mg / m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10 ( - 7 ) mol /
Diseases: "	"Sentence: Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg / m2 followed by 12 mg / m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10 ( - 7 ) mol /
Diseases:"
2823	L .	O O	[]	0	0	"Sentence: L .
Diseases: "	"Sentence: L .
Diseases:"
2824	The mean steady - state plasma and CSF methotrexate concentrations achieved were 1 . 1 X 10 ( - 3 ) mol / L and 3 . 6 X 10 ( - 5 ) mol / L , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean steady - state plasma and CSF methotrexate concentrations achieved were 1 . 1 X 10 ( - 3 ) mol / L and 3 . 6 X 10 ( - 5 ) mol / L , respectively .
Diseases: "	"Sentence: The mean steady - state plasma and CSF methotrexate concentrations achieved were 1 . 1 X 10 ( - 3 ) mol / L and 3 . 6 X 10 ( - 5 ) mol / L , respectively .
Diseases:"
2825	All 20 patients responded to this regimen , 16 / 20 ( 80 % ) achieved a complete remission , and 20 % obtained a partial remission .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All 20 patients responded to this regimen , 16 / 20 ( 80 % ) achieved a complete remission , and 20 % obtained a partial remission .
Diseases: "	"Sentence: All 20 patients responded to this regimen , 16 / 20 ( 80 % ) achieved a complete remission , and 20 % obtained a partial remission .
Diseases:"
2826	The most common toxicities encountered were transient serum transaminase and bilirubin elevations , neutropenia , and mucositis .	O O O B O O O O O O O O O B O O B O	['toxicities', 'neutropenia', 'mucositis']	3	12	"Sentence: The most common toxicities encountered were transient serum transaminase and bilirubin elevations , neutropenia , and mucositis .
Diseases: toxicities, neutropenia, mucositis"	"Sentence: The most common toxicities encountered were transient serum transaminase and bilirubin elevations , neutropenia , and mucositis .
Diseases:"
2827	One patient had focal seizures and transient hemiparesis but recovered completely .	O O O O B O B I O O O O	['transient hemiparesis', 'seizures']	2	8	"Sentence: One patient had focal seizures and transient hemiparesis but recovered completely .
Diseases: transient hemiparesis, seizures"	"Sentence: One patient had focal seizures and transient hemiparesis but recovered completely .
Diseases:"
2828	High - dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia .	O O O O O O O O O O O O O O O O O O B I I O	['acute lymphoblastic leukemia']	1	6	"Sentence: High - dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia .
Diseases: acute lymphoblastic leukemia"	"Sentence: High - dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia .
Diseases:"
2829	Hypersensitivity to carbamazepine presenting with a leukemoid reaction , eosinophilia , erythroderma , and renal failure .	B O O O O O B I O B O B O O B I O	['hypersensitivity', 'erythroderma', 'leukemoid reaction', 'renal failure', 'eosinophilia']	5	24	"Sentence: Hypersensitivity to carbamazepine presenting with a leukemoid reaction , eosinophilia , erythroderma , and renal failure .
Diseases: hypersensitivity, erythroderma, leukemoid reaction, renal failure, eosinophilia"	"Sentence: Hypersensitivity to carbamazepine presenting with a leukemoid reaction , eosinophilia , erythroderma , and renal failure .
Diseases:"
2830	We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .	O O O O O O B O O O O O B O O O B I O B O B O O B I O	['hypersensitivity', 'erythroderma', 'leukemoid reaction', 'renal failure', 'hyponatremia', 'eosinophilia']	6	30	"Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .
Diseases: hypersensitivity, erythroderma, leukemoid reaction, renal failure, hyponatremia, eosinophilia"	"Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .
Diseases:"
2831	This is the first report of such an unusual reaction to carbamazepine .	O O O O O O O O O O O O O	[]	0	0	"Sentence: This is the first report of such an unusual reaction to carbamazepine .
Diseases: "	"Sentence: This is the first report of such an unusual reaction to carbamazepine .
Diseases:"
2832	The interpeduncular nucleus regulates nicotine 's effects on free - field activity .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The interpeduncular nucleus regulates nicotine 's effects on free - field activity .
Diseases: "	"Sentence: The interpeduncular nucleus regulates nicotine 's effects on free - field activity .
Diseases:"
2833	Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat .
Diseases: "	"Sentence: Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat .
Diseases:"
2834	Compared with sham - operated controls , lesions significantly ( p < 0 . 25 ) blunted the early ( < 60 min ) free - field locomotor hypoactivity caused by nicotine ( 0 . 5 mg kg ( - 1 ) , i . m . ) , enhanced the later ( 60 - 120 min ) nicotine - induced hyperactivity , and raised spontaneous nocturnal activity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['hyperactivity', 'locomotor hypoactivity']	2	8	"Sentence: Compared with sham - operated controls , lesions significantly ( p < 0 . 25 ) blunted the early ( < 60 min ) free - field locomotor hypoactivity caused by nicotine ( 0 . 5 mg kg ( - 1 ) , i . m . ) , enhanced the later ( 60 - 120 min ) nicotine - induced hyperactivity , and raised spontaneous nocturnal activity .
Diseases: hyperactivity, locomotor hypoactivity"	"Sentence: Compared with sham - operated controls , lesions significantly ( p < 0 . 25 ) blunted the early ( < 60 min ) free - field locomotor hypoactivity caused by nicotine ( 0 . 5 mg kg ( - 1 ) , i . m . ) , enhanced the later ( 60 - 120 min ) nicotine - induced hyperactivity , and raised spontaneous nocturnal activity .
Diseases:"
2835	Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus ( p < 0 . 025 ) , but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus ( p < 0 . 025 ) , but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region .
Diseases: "	"Sentence: Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus ( p < 0 . 025 ) , but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region .
Diseases:"
2836	We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain .	O O O O O O O O B O O O O O O O O O O O O O O	['depression']	1	2	"Sentence: We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain .
Diseases: depression"	"Sentence: We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain .
Diseases:"
2837	Assessment of a new non - invasive index of cardiac performance for detection of dobutamine - induced myocardial ischemia .	O O O O O O O O O O O O O O O O O B I O	['myocardial ischemia']	1	6	"Sentence: Assessment of a new non - invasive index of cardiac performance for detection of dobutamine - induced myocardial ischemia .
Diseases: myocardial ischemia"	"Sentence: Assessment of a new non - invasive index of cardiac performance for detection of dobutamine - induced myocardial ischemia .
Diseases:"
2838	Electrocardiography has a very low sensitivity in detecting dobutamine - induced myocardial ischemia .	O O O O O O O O O O O B I O	['myocardial ischemia']	1	6	"Sentence: Electrocardiography has a very low sensitivity in detecting dobutamine - induced myocardial ischemia .
Diseases: myocardial ischemia"	"Sentence: Electrocardiography has a very low sensitivity in detecting dobutamine - induced myocardial ischemia .
Diseases:"
2839	To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting dobutamine - induced myocardial ischemia , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O B O	['myocardial ischemia', 'ischemia']	2	10	"Sentence: To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting dobutamine - induced myocardial ischemia , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .
Diseases: myocardial ischemia, ischemia"	"Sentence: To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting dobutamine - induced myocardial ischemia , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .
Diseases:"
2840	The study group comprised 40 patients undergoing Sestamibi - SPECT / dobutamine stress test .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The study group comprised 40 patients undergoing Sestamibi - SPECT / dobutamine stress test .
Diseases: "	"Sentence: The study group comprised 40 patients undergoing Sestamibi - SPECT / dobutamine stress test .
Diseases:"
2841	Simultaneous measurements of ECG and brachial artery dP / dtejc were performed at each dobutamine level .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Simultaneous measurements of ECG and brachial artery dP / dtejc were performed at each dobutamine level .
Diseases: "	"Sentence: Simultaneous measurements of ECG and brachial artery dP / dtejc were performed at each dobutamine level .
Diseases:"
2842	In 19 of the 40 patients perfusion defects compatible with ischemia were detected on SPECT .	O O O O O O O O O O B O O O O O	['ischemia']	1	3	"Sentence: In 19 of the 40 patients perfusion defects compatible with ischemia were detected on SPECT .
Diseases: ischemia"	"Sentence: In 19 of the 40 patients perfusion defects compatible with ischemia were detected on SPECT .
Diseases:"
2843	The increase in dP / dtejc during infusion of dobutamine in this group was severely impaired as compared to the non - ischemic group .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The increase in dP / dtejc during infusion of dobutamine in this group was severely impaired as compared to the non - ischemic group .
Diseases: "	"Sentence: The increase in dP / dtejc during infusion of dobutamine in this group was severely impaired as compared to the non - ischemic group .
Diseases:"
2844	dP / dtejc outcome was combined with the ECG results , giving an ECG - enhanced value , and compared to ECG alone .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: dP / dtejc outcome was combined with the ECG results , giving an ECG - enhanced value , and compared to ECG alone .
Diseases: "	"Sentence: dP / dtejc outcome was combined with the ECG results , giving an ECG - enhanced value , and compared to ECG alone .
Diseases:"
2845	The sensitivity improved dramatically from 16 % to 79 % , positive predictive value increased from 60 % to 68 % and negative predictive value from 54 % to 78 % , and specificity decreased from 90 % to 67 % .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The sensitivity improved dramatically from 16 % to 79 % , positive predictive value increased from 60 % to 68 % and negative predictive value from 54 % to 78 % , and specificity decreased from 90 % to 67 % .
Diseases: "	"Sentence: The sensitivity improved dramatically from 16 % to 79 % , positive predictive value increased from 60 % to 68 % and negative predictive value from 54 % to 78 % , and specificity decreased from 90 % to 67 % .
Diseases:"
2846	CONCLUSIONS : If ECG alone is used for specificity , the combination with dP / dtejc improved the sensitivity of the test and could be a cost - savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia , especially in patients unable to exercise .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O	['myocardial ischemia']	1	6	"Sentence: CONCLUSIONS : If ECG alone is used for specificity , the combination with dP / dtejc improved the sensitivity of the test and could be a cost - savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia , especially in patients unable to exercise .
Diseases: myocardial ischemia"	"Sentence: CONCLUSIONS : If ECG alone is used for specificity , the combination with dP / dtejc improved the sensitivity of the test and could be a cost - savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia , especially in patients unable to exercise .
Diseases:"
2847	Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage .	B I I O O O O O O O O O O O O O	['acute liver failure']	1	4	"Sentence: Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage .
Diseases: acute liver failure"	"Sentence: Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage .
Diseases:"
2848	The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol ( acetaminophen ) is currently debated .	O O O O O O O O O B O O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol ( acetaminophen ) is currently debated .
Diseases: hepatotoxicity"	"Sentence: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol ( acetaminophen ) is currently debated .
Diseases:"
2849	CASE REPORT :	O O O	[]	0	0	"Sentence: CASE REPORT :
Diseases: "	"Sentence: CASE REPORT :
Diseases:"
2850	We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3 - 5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol / day .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	['liver failure']	1	3	"Sentence: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3 - 5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol / day .
Diseases: liver failure"	"Sentence: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3 - 5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol / day .
Diseases:"
2851	A paracetamol serum level obtained in one of these patients was not in the toxic range .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A paracetamol serum level obtained in one of these patients was not in the toxic range .
Diseases: "	"Sentence: A paracetamol serum level obtained in one of these patients was not in the toxic range .
Diseases:"
2852	Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed .	O O O O O O O B O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed .
Diseases: hepatotoxicity"	"Sentence: Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed .
Diseases:"
2853	In patients with risk factors , e . g . regular consumption of alcohol , liver failure is possible when therapeutic doses are ingested .	O O O O O O O O O O O O O O O B I O O O O O O O O	['liver failure']	1	3	"Sentence: In patients with risk factors , e . g . regular consumption of alcohol , liver failure is possible when therapeutic doses are ingested .
Diseases: liver failure"	"Sentence: In patients with risk factors , e . g . regular consumption of alcohol , liver failure is possible when therapeutic doses are ingested .
Diseases:"
2854	We propose that the paracetamol dose should not exceed 2 g / day in such patients and that their liver function should be monitored closely while being treated with paracetamol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We propose that the paracetamol dose should not exceed 2 g / day in such patients and that their liver function should be monitored closely while being treated with paracetamol .
Diseases: "	"Sentence: We propose that the paracetamol dose should not exceed 2 g / day in such patients and that their liver function should be monitored closely while being treated with paracetamol .
Diseases:"
2855	Cocaine related chest pain : are we seeing the tip of an iceberg ?	O O B I O O O O O O O O O O	['chest pain']	1	2	"Sentence: Cocaine related chest pain : are we seeing the tip of an iceberg ?
Diseases: chest pain"	"Sentence: Cocaine related chest pain : are we seeing the tip of an iceberg ?
Diseases:"
2856	The recreational use of cocaine is on the increase .	O O O O O O O O O O	[]	0	0	"Sentence: The recreational use of cocaine is on the increase .
Diseases: "	"Sentence: The recreational use of cocaine is on the increase .
Diseases:"
2857	The emergency nurse ought to be familiar with some of the cardiovascular consequences of cocaine use .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The emergency nurse ought to be familiar with some of the cardiovascular consequences of cocaine use .
Diseases: "	"Sentence: The emergency nurse ought to be familiar with some of the cardiovascular consequences of cocaine use .
Diseases:"
2858	In particular , the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O B I O O O O O O O	['chest pain']	1	2	"Sentence: In particular , the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk .
Diseases: chest pain"	"Sentence: In particular , the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk .
Diseases:"
2859	The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed .	O O O B I O O O O O O O O O O O O	['chest pain']	1	2	"Sentence: The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed .
Diseases: chest pain"	"Sentence: The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed .
Diseases:"
2860	Finally , moral issues relating to the testing of potential cocaine users will be addressed .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Finally , moral issues relating to the testing of potential cocaine users will be addressed .
Diseases: "	"Sentence: Finally , moral issues relating to the testing of potential cocaine users will be addressed .
Diseases:"
2861	Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin , amiodarone , and atazanavir .	O B O B I I O O O O O O O O O O O O	['acute renal failure', 'rhabdomyolysis']	2	11	"Sentence: Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin , amiodarone , and atazanavir .
Diseases: acute renal failure, rhabdomyolysis"	"Sentence: Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin , amiodarone , and atazanavir .
Diseases:"
2862	To report a case of a severe interaction between simvastatin , amiodarone , and atazanavir resulting in rhabdomyolysis and acute renal failure .	O O O O O O O O O O O O O O O O O B O B I I O	['acute renal failure', 'rhabdomyolysis']	2	11	"Sentence: To report a case of a severe interaction between simvastatin , amiodarone , and atazanavir resulting in rhabdomyolysis and acute renal failure .
Diseases: acute renal failure, rhabdomyolysis"	"Sentence: To report a case of a severe interaction between simvastatin , amiodarone , and atazanavir resulting in rhabdomyolysis and acute renal failure .
Diseases:"
2863	A 72 - year - old white man with underlying human immunodeficiency virus , atrial fibrillation , coronary artery disease , and hyperlipidemia presented with generalized pain , fatigue , and dark orange urine for 3 days .	O O O O O O O O O O B I I O B I O B I I O O B O O O B O B O O O O O O O O O	['coronary artery disease', 'hyperlipidemia', 'atrial fibrillation', 'human immunodeficiency virus', 'pain', 'fatigue']	6	25	"Sentence: A 72 - year - old white man with underlying human immunodeficiency virus , atrial fibrillation , coronary artery disease , and hyperlipidemia presented with generalized pain , fatigue , and dark orange urine for 3 days .
Diseases: coronary artery disease, hyperlipidemia, atrial fibrillation, human immunodeficiency virus, pain, fatigue"	"Sentence: A 72 - year - old white man with underlying human immunodeficiency virus , atrial fibrillation , coronary artery disease , and hyperlipidemia presented with generalized pain , fatigue , and dark orange urine for 3 days .
Diseases:"
2864	The patient was taking 80 mg simvastatin at bedtime ( initiated 27 days earlier ) ; amiodarone at a dose of 400 mg daily for 7 days , then 200 mg daily ( initiated 19 days earlier ) ; and 400 mg atazanavir daily ( initiated at least 2 years previously ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The patient was taking 80 mg simvastatin at bedtime ( initiated 27 days earlier ) ; amiodarone at a dose of 400 mg daily for 7 days , then 200 mg daily ( initiated 19 days earlier ) ; and 400 mg atazanavir daily ( initiated at least 2 years previously ) .
Diseases: "	"Sentence: The patient was taking 80 mg simvastatin at bedtime ( initiated 27 days earlier ) ; amiodarone at a dose of 400 mg daily for 7 days , then 200 mg daily ( initiated 19 days earlier ) ; and 400 mg atazanavir daily ( initiated at least 2 years previously ) .
Diseases:"
2865	Laboratory evaluation revealed 66 , 680 U / L creatine kinase , 93 mg / dL blood urea nitrogen , 4 . 6 mg / dL creatinine , 1579 U / L aspartate aminotransferase , and 738 U / L alanine aminotransferase .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Laboratory evaluation revealed 66 , 680 U / L creatine kinase , 93 mg / dL blood urea nitrogen , 4 . 6 mg / dL creatinine , 1579 U / L aspartate aminotransferase , and 738 U / L alanine aminotransferase .
Diseases: "	"Sentence: Laboratory evaluation revealed 66 , 680 U / L creatine kinase , 93 mg / dL blood urea nitrogen , 4 . 6 mg / dL creatinine , 1579 U / L aspartate aminotransferase , and 738 U / L alanine aminotransferase .
Diseases:"
2866	Simvastatin , amiodarone , and the patient 's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis .	O O O O O O O O B I I O O O O O O O O O O O O O O O O O O	['human immunodeficiency virus']	1	6	"Sentence: Simvastatin , amiodarone , and the patient 's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis .
Diseases: human immunodeficiency virus"	"Sentence: Simvastatin , amiodarone , and the patient 's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis .
Diseases:"
2867	Nine days later the patient 's creatine kinase had dropped to 1695 U / L and creatinine was 3 . 3 mg / dL . The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nine days later the patient 's creatine kinase had dropped to 1695 U / L and creatinine was 3 . 3 mg / dL . The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered .
Diseases: "	"Sentence: Nine days later the patient 's creatine kinase had dropped to 1695 U / L and creatinine was 3 . 3 mg / dL . The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered .
Diseases:"
2868	The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism .	O O O B O O O O O O O O O O O O O	['rhabdomyolysis']	1	6	"Sentence: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism .
Diseases: rhabdomyolysis"	"Sentence: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism .
Diseases:"
2869	Simvastatin is metabolized by CYP3A4 .	O O O O O O	[]	0	0	"Sentence: Simvastatin is metabolized by CYP3A4 .
Diseases: "	"Sentence: Simvastatin is metabolized by CYP3A4 .
Diseases:"
2870	Amiodarone and atazanavir are recognized CYP3A4 inhibitors .	O O O O O O O O	[]	0	0	"Sentence: Amiodarone and atazanavir are recognized CYP3A4 inhibitors .
Diseases: "	"Sentence: Amiodarone and atazanavir are recognized CYP3A4 inhibitors .
Diseases:"
2871	CONCLUSIONS : Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions .
Diseases: "	"Sentence: CONCLUSIONS : Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions .
Diseases:"
2872	In patients requiring the concurrent use of statins and CYP3A4 inhibitors , pravastatin , fluvastatin , and rosuvastatin carry the lowest risk of drug interactions ; atorvastatin carries moderate risk , whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In patients requiring the concurrent use of statins and CYP3A4 inhibitors , pravastatin , fluvastatin , and rosuvastatin carry the lowest risk of drug interactions ; atorvastatin carries moderate risk , whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors .
Diseases: "	"Sentence: In patients requiring the concurrent use of statins and CYP3A4 inhibitors , pravastatin , fluvastatin , and rosuvastatin carry the lowest risk of drug interactions ; atorvastatin carries moderate risk , whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors .
Diseases:"
2873	Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma .	O O O O O O O B I I I O	['squamous cell esophageal carcinoma']	1	9	"Sentence: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma .
Diseases: squamous cell esophageal carcinoma"	"Sentence: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma .
Diseases:"
2874	European Organization for Research and Treatment of Cancer Gastrointestinal	O O O O O O O B O	['cancer']	1	1	"Sentence: European Organization for Research and Treatment of Cancer Gastrointestinal
Diseases: cancer"	"Sentence: European Organization for Research and Treatment of Cancer Gastrointestinal
Diseases:"
2875	Treat Cancer Cooperative Group .	O B O O O	['cancer']	1	1	"Sentence: Treat Cancer Cooperative Group .
Diseases: cancer"	"Sentence: Treat Cancer Cooperative Group .
Diseases:"
2876	To evaluate the response rate and toxic effects of vinorelbine ( VNB ) administered as a single agent in metastatic squamous cell esophageal carcinoma .	O O O O O O O O O O O O O O O O O O O O B I I I O	['squamous cell esophageal carcinoma']	1	9	"Sentence: To evaluate the response rate and toxic effects of vinorelbine ( VNB ) administered as a single agent in metastatic squamous cell esophageal carcinoma .
Diseases: squamous cell esophageal carcinoma"	"Sentence: To evaluate the response rate and toxic effects of vinorelbine ( VNB ) administered as a single agent in metastatic squamous cell esophageal carcinoma .
Diseases:"
2877	PATIENTS AND METHODS : Forty - six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PATIENTS AND METHODS : Forty - six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy .
Diseases: "	"Sentence: PATIENTS AND METHODS : Forty - six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy .
Diseases:"
2878	Thirty patients without prior chemotherapy and 16 pretreated with cisplatin - based chemotherapy were assessable for toxicity and response .	O O O O O O O O O O O O O O O O B O O O	['toxicity']	1	2	"Sentence: Thirty patients without prior chemotherapy and 16 pretreated with cisplatin - based chemotherapy were assessable for toxicity and response .
Diseases: toxicity"	"Sentence: Thirty patients without prior chemotherapy and 16 pretreated with cisplatin - based chemotherapy were assessable for toxicity and response .
Diseases:"
2879	VNB was administered weekly as a 25 - mg / m2 short intravenous ( i . v . )	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: VNB was administered weekly as a 25 - mg / m2 short intravenous ( i . v . )
Diseases: "	"Sentence: VNB was administered weekly as a 25 - mg / m2 short intravenous ( i . v . )
Diseases:"
2880	infusion .	O O	[]	0	0	"Sentence: infusion .
Diseases: "	"Sentence: infusion .
Diseases:"
2881	Six of 30 patients ( 20 % ) without prior chemotherapy achieved a partial response ( PR ) ( 95 % confidence interval [ CI ] , 8 % to 39 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Six of 30 patients ( 20 % ) without prior chemotherapy achieved a partial response ( PR ) ( 95 % confidence interval [ CI ] , 8 % to 39 % ) .
Diseases: "	"Sentence: Six of 30 patients ( 20 % ) without prior chemotherapy achieved a partial response ( PR ) ( 95 % confidence interval [ CI ] , 8 % to 39 % ) .
Diseases:"
2882	The median duration of response was 21 weeks ( range , 17 to 28 ) .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The median duration of response was 21 weeks ( range , 17 to 28 ) .
Diseases: "	"Sentence: The median duration of response was 21 weeks ( range , 17 to 28 ) .
Diseases:"
2883	One of 16 patients ( 6 % ) with prior chemotherapy had a complete response ( CR ) of 31 weeks ' duration ( 95 % CI , 0 % to 30 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: One of 16 patients ( 6 % ) with prior chemotherapy had a complete response ( CR ) of 31 weeks ' duration ( 95 % CI , 0 % to 30 % ) .
Diseases: "	"Sentence: One of 16 patients ( 6 % ) with prior chemotherapy had a complete response ( CR ) of 31 weeks ' duration ( 95 % CI , 0 % to 30 % ) .
Diseases:"
2884	The overall response rate ( World Health Organization [ WHO ] criteria ) was 15 % ( CR , 2 % ; PR 13 % ; 95 % CI , 6 % to 29 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The overall response rate ( World Health Organization [ WHO ] criteria ) was 15 % ( CR , 2 % ; PR 13 % ; 95 % CI , 6 % to 29 % ) .
Diseases: "	"Sentence: The overall response rate ( World Health Organization [ WHO ] criteria ) was 15 % ( CR , 2 % ; PR 13 % ; 95 % CI , 6 % to 29 % ) .
Diseases:"
2885	The median dose - intensity ( DI ) was 20 mg / m2 / wk .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The median dose - intensity ( DI ) was 20 mg / m2 / wk .
Diseases: "	"Sentence: The median dose - intensity ( DI ) was 20 mg / m2 / wk .
Diseases:"
2886	VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred .	O O O O O O O O O O O O B O O	['toxicity']	1	2	"Sentence: VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred .
Diseases: toxicity"	"Sentence: VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred .
Diseases:"
2887	At least one episode of grade 3 or 4 granulocytopenia was seen in 59 % of patients .	O O O O O O O O O B O O O O O O O O	['granulocytopenia']	1	6	"Sentence: At least one episode of grade 3 or 4 granulocytopenia was seen in 59 % of patients .
Diseases: granulocytopenia"	"Sentence: At least one episode of grade 3 or 4 granulocytopenia was seen in 59 % of patients .
Diseases:"
2888	A grade 2 or 3 infection occurred in 16 % of patients , but no toxic deaths occurred .	O O O O O B O O O O O O O O O O B O O	['deaths', 'infection']	2	4	"Sentence: A grade 2 or 3 infection occurred in 16 % of patients , but no toxic deaths occurred .
Diseases: deaths, infection"	"Sentence: A grade 2 or 3 infection occurred in 16 % of patients , but no toxic deaths occurred .
Diseases:"
2889	Other side effects were rare , and peripheral neurotoxicity has been minor ( 26 % grade 1 ) .	O O O O O O O B I O O O O O O O O O O	['peripheral neurotoxicity']	1	5	"Sentence: Other side effects were rare , and peripheral neurotoxicity has been minor ( 26 % grade 1 ) .
Diseases: peripheral neurotoxicity"	"Sentence: Other side effects were rare , and peripheral neurotoxicity has been minor ( 26 % grade 1 ) .
Diseases:"
2890	These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma .	O O O O O O O O O O O B I I I O	['esophageal squamous cell carcinoma']	1	9	"Sentence: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma .
Diseases: esophageal squamous cell carcinoma"	"Sentence: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma .
Diseases:"
2891	Given its excellent tolerance profile and low toxicity , further evaluation of VNB in combination therapy is warranted .	O O O O O O O B O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Given its excellent tolerance profile and low toxicity , further evaluation of VNB in combination therapy is warranted .
Diseases: toxicity"	"Sentence: Given its excellent tolerance profile and low toxicity , further evaluation of VNB in combination therapy is warranted .
Diseases:"
2892	Paclitaxel , cisplatin , and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma .	O O O O O O O O O O O O O O O B I I I O	['nonsmall cell lung carcinoma']	1	8	"Sentence: Paclitaxel , cisplatin , and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma .
Diseases: nonsmall cell lung carcinoma"	"Sentence: Paclitaxel , cisplatin , and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma .
Diseases:"
2893	Cisplatin - based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma ( NSCLC ) .	O O O O O O O O O O O O O B I I I O B O O	['nonsmall cell lung carcinoma', 'nsclc']	2	12	"Sentence: Cisplatin - based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma ( NSCLC ) .
Diseases: nonsmall cell lung carcinoma, nsclc"	"Sentence: Cisplatin - based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma ( NSCLC ) .
Diseases:"
2894	The emergence of new active drugs might translate into more effective regimens for the treatment of this disease .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The emergence of new active drugs might translate into more effective regimens for the treatment of this disease .
Diseases: "	"Sentence: The emergence of new active drugs might translate into more effective regimens for the treatment of this disease .
Diseases:"
2895	The objective of this study was to determine the feasibility , response rate , and toxicity of a paclitaxel , cisplatin , and gemcitabine combination to treat metastatic NSCLC .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O B O	['nsclc', 'toxicity']	2	5	"Sentence: The objective of this study was to determine the feasibility , response rate , and toxicity of a paclitaxel , cisplatin , and gemcitabine combination to treat metastatic NSCLC .
Diseases: nsclc, toxicity"	"Sentence: The objective of this study was to determine the feasibility , response rate , and toxicity of a paclitaxel , cisplatin , and gemcitabine combination to treat metastatic NSCLC .
Diseases:"
2896	Thirty - five consecutive chemotherapy - naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of paclitaxel ( 135 mg / m ( 2 ) given intravenously in 3 hours ) on Day 1 , cisplatin ( 120 mg / m ( 2 ) given intravenously in 6 hours ) on Day 1 , and gemcitabine ( 800 mg / m ( 2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nsclc']	1	3	"Sentence: Thirty - five consecutive chemotherapy - naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of paclitaxel ( 135 mg / m ( 2 ) given intravenously in 3 hours ) on Day 1 , cisplatin ( 120 mg / m ( 2 ) given intravenously in 6 hours ) on Day 1 , and gemcitabine ( 800 mg / m ( 2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .
Diseases: nsclc"	"Sentence: Thirty - five consecutive chemotherapy - naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of paclitaxel ( 135 mg / m ( 2 ) given intravenously in 3 hours ) on Day 1 , cisplatin ( 120 mg / m ( 2 ) given intravenously in 6 hours ) on Day 1 , and gemcitabine ( 800 mg / m ( 2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .
Diseases:"
2897	Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second - line chemotherapy after disease progression , the response and toxicity rates reported refer only to the chemotherapy regimen given .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['toxicity']	1	2	"Sentence: Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second - line chemotherapy after disease progression , the response and toxicity rates reported refer only to the chemotherapy regimen given .
Diseases: toxicity"	"Sentence: Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second - line chemotherapy after disease progression , the response and toxicity rates reported refer only to the chemotherapy regimen given .
Diseases:"
2898	All the patients were examined for toxicity ; 34 were examinable for response .	O O O O O O B O O O O O O O	['toxicity']	1	2	"Sentence: All the patients were examined for toxicity ; 34 were examinable for response .
Diseases: toxicity"	"Sentence: All the patients were examined for toxicity ; 34 were examinable for response .
Diseases:"
2899	An objective response was observed in 73 . 5 % of the patients ( 95 % confidence interval [ CI ] , 55 . 6 - 87 . 1 % ) , including 4 complete responses ( 11 . 7 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An objective response was observed in 73 . 5 % of the patients ( 95 % confidence interval [ CI ] , 55 . 6 - 87 . 1 % ) , including 4 complete responses ( 11 . 7 % ) .
Diseases: "	"Sentence: An objective response was observed in 73 . 5 % of the patients ( 95 % confidence interval [ CI ] , 55 . 6 - 87 . 1 % ) , including 4 complete responses ( 11 . 7 % ) .
Diseases:"
2900	According to intention - to - treat , the overall response rate was 71 . 4 % ( 95 % CI , 53 . 7 - 85 . 4 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: According to intention - to - treat , the overall response rate was 71 . 4 % ( 95 % CI , 53 . 7 - 85 . 4 % ) .
Diseases: "	"Sentence: According to intention - to - treat , the overall response rate was 71 . 4 % ( 95 % CI , 53 . 7 - 85 . 4 % ) .
Diseases:"
2901	After 154 courses of therapy , the median dose intensity was 131 mg / m ( 2 ) for paclitaxel ( 97 . 3 % ) , 117 mg / m ( 2 ) for cisplatin ( 97 . 3 % ) , and 1378 mg / m ( 2 ) for gemcitabine ( 86 . 2 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 154 courses of therapy , the median dose intensity was 131 mg / m ( 2 ) for paclitaxel ( 97 . 3 % ) , 117 mg / m ( 2 ) for cisplatin ( 97 . 3 % ) , and 1378 mg / m ( 2 ) for gemcitabine ( 86 . 2 % ) .
Diseases: "	"Sentence: After 154 courses of therapy , the median dose intensity was 131 mg / m ( 2 ) for paclitaxel ( 97 . 3 % ) , 117 mg / m ( 2 ) for cisplatin ( 97 . 3 % ) , and 1378 mg / m ( 2 ) for gemcitabine ( 86 . 2 % ) .
Diseases:"
2902	World Health Organization Grade 3 - 4 neutropenia and thrombocytopenia occurred in 39 . 9 % and 11 . 4 % of patients , respectively .	O O O O O O O B O B O O O O O O O O O O O O O O O O	['neutropenia', 'thrombocytopenia']	2	13	"Sentence: World Health Organization Grade 3 - 4 neutropenia and thrombocytopenia occurred in 39 . 9 % and 11 . 4 % of patients , respectively .
Diseases: neutropenia, thrombocytopenia"	"Sentence: World Health Organization Grade 3 - 4 neutropenia and thrombocytopenia occurred in 39 . 9 % and 11 . 4 % of patients , respectively .
Diseases:"
2903	There was one treatment - related death .	O O O O O O B O	['death']	1	1	"Sentence: There was one treatment - related death .
Diseases: death"	"Sentence: There was one treatment - related death .
Diseases:"
2904	Nonhematologic toxicities were mild .	O B O O O	['toxicities']	1	3	"Sentence: Nonhematologic toxicities were mild .
Diseases: toxicities"	"Sentence: Nonhematologic toxicities were mild .
Diseases:"
2905	After a median follow - up of 22 months , the median progression free survival rate was 7 months , and the median survival time was 16 months .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After a median follow - up of 22 months , the median progression free survival rate was 7 months , and the median survival time was 16 months .
Diseases: "	"Sentence: After a median follow - up of 22 months , the median progression free survival rate was 7 months , and the median survival time was 16 months .
Diseases:"
2906	The combination of paclitaxel , cisplatin , and gemcitabine is well tolerated and shows high activity in metastatic NSCLC .	O O O O O O O O O O O O O O O O O O B O	['nsclc']	1	3	"Sentence: The combination of paclitaxel , cisplatin , and gemcitabine is well tolerated and shows high activity in metastatic NSCLC .
Diseases: nsclc"	"Sentence: The combination of paclitaxel , cisplatin , and gemcitabine is well tolerated and shows high activity in metastatic NSCLC .
Diseases:"
2907	This treatment merits further comparison with other cisplatin - based regimens .	O O O O O O O O O O O O	[]	0	0	"Sentence: This treatment merits further comparison with other cisplatin - based regimens .
Diseases: "	"Sentence: This treatment merits further comparison with other cisplatin - based regimens .
Diseases:"
2908	Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution .	O O O O O O O O O O	[]	0	0	"Sentence: Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution .
Diseases: "	"Sentence: Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution .
Diseases:"
2909	We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1 % apraclonidine in their right eyes .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1 % apraclonidine in their right eyes .
Diseases: "	"Sentence: We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1 % apraclonidine in their right eyes .
Diseases:"
2910	Examinations , including blood pressure , pulse rate , conjunctiva and cornea , intraocular pressure ( IOP ) , pupil diameter , basal tear secretion and margin reflex distance of both upper and lower eyelids , were performed prior to entry and at 1 , 3 , 5 and 7 hours after instillation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Examinations , including blood pressure , pulse rate , conjunctiva and cornea , intraocular pressure ( IOP ) , pupil diameter , basal tear secretion and margin reflex distance of both upper and lower eyelids , were performed prior to entry and at 1 , 3 , 5 and 7 hours after instillation .
Diseases: "	"Sentence: Examinations , including blood pressure , pulse rate , conjunctiva and cornea , intraocular pressure ( IOP ) , pupil diameter , basal tear secretion and margin reflex distance of both upper and lower eyelids , were performed prior to entry and at 1 , 3 , 5 and 7 hours after instillation .
Diseases:"
2911	The ocular hypotensive effects were statistically significant for apraclonidine - treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1 % apraclonidine .	O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ocular hypotensive']	1	3	"Sentence: The ocular hypotensive effects were statistically significant for apraclonidine - treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1 % apraclonidine .
Diseases: ocular hypotensive"	"Sentence: The ocular hypotensive effects were statistically significant for apraclonidine - treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1 % apraclonidine .
Diseases:"
2912	Decreases in systolic blood pressure were statistically , but not clinically , significant .	B I I I I O O O O O O O O O	['decreases in systolic blood pressure']	1	9	"Sentence: Decreases in systolic blood pressure were statistically , but not clinically , significant .
Diseases: decreases in systolic blood pressure"	"Sentence: Decreases in systolic blood pressure were statistically , but not clinically , significant .
Diseases:"
2913	No significant changes in diastolic blood pressure , pulse rate and basal tear secretion were noted .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: No significant changes in diastolic blood pressure , pulse rate and basal tear secretion were noted .
Diseases: "	"Sentence: No significant changes in diastolic blood pressure , pulse rate and basal tear secretion were noted .
Diseases:"
2914	Conjunctival blanching and mydriasis were commonly found .	B I O B O O O O	['conjunctival blanching', 'mydriasis']	2	11	"Sentence: Conjunctival blanching and mydriasis were commonly found .
Diseases: conjunctival blanching, mydriasis"	"Sentence: Conjunctival blanching and mydriasis were commonly found .
Diseases:"
2915	Upper lid retraction was frequently noted .	O O O O O O O	[]	0	0	"Sentence: Upper lid retraction was frequently noted .
Diseases: "	"Sentence: Upper lid retraction was frequently noted .
Diseases:"
2916	While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance , one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B I O O O O O O O O	['corneal abrasion', 'entropion']	2	10	"Sentence: While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance , one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication .
Diseases: corneal abrasion, entropion"	"Sentence: While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance , one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication .
Diseases:"
2917	This may well be a particularly notable finding in Asian people .	O O O O O O O O O O O O	[]	0	0	"Sentence: This may well be a particularly notable finding in Asian people .
Diseases: "	"Sentence: This may well be a particularly notable finding in Asian people .
Diseases:"
2918	Carmofur - induced organic mental disorders .	O O O B I I O	['organic mental disorders']	1	3	"Sentence: Carmofur - induced organic mental disorders .
Diseases: organic mental disorders"	"Sentence: Carmofur - induced organic mental disorders .
Diseases:"
2919	Organic mental disorder was observed in a 29 - year - old female in the prognostic period after the onset of carmofur - induced leukoencephalopathy .	B I I O O O O O O O O O O O O O O O O O O O O O B O	['organic mental disorder', 'leukoencephalopathy']	2	9	"Sentence: Organic mental disorder was observed in a 29 - year - old female in the prognostic period after the onset of carmofur - induced leukoencephalopathy .
Diseases: organic mental disorder, leukoencephalopathy"	"Sentence: Organic mental disorder was observed in a 29 - year - old female in the prognostic period after the onset of carmofur - induced leukoencephalopathy .
Diseases:"
2920	Symptoms such as euphoria , emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM - III - R .	O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O	['organic personality syndrome']	1	3	"Sentence: Symptoms such as euphoria , emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM - III - R .
Diseases: organic personality syndrome"	"Sentence: Symptoms such as euphoria , emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM - III - R .
Diseases:"
2921	It is referred to as a frontal lobe syndrome .	O O O O O O B I I O	['frontal lobe syndrome']	1	4	"Sentence: It is referred to as a frontal lobe syndrome .
Diseases: frontal lobe syndrome"	"Sentence: It is referred to as a frontal lobe syndrome .
Diseases:"
2922	Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns .
Diseases: "	"Sentence: Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns .
Diseases:"
2923	Consequently , carmofur - induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state .	O O O O O B O O O O B I I O O O O O	['leukoencephalopathy', 'organic personality syndrome']	2	9	"Sentence: Consequently , carmofur - induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state .
Diseases: leukoencephalopathy, organic personality syndrome"	"Sentence: Consequently , carmofur - induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state .
Diseases:"
2924	It may be attributed to the structural damage to the frontal lobe .	O O O O O O B I I I I I O	['structural damage to the frontal lobe']	1	7	"Sentence: It may be attributed to the structural damage to the frontal lobe .
Diseases: structural damage to the frontal lobe"	"Sentence: It may be attributed to the structural damage to the frontal lobe .
Diseases:"
2925	International mexiletine and placebo antiarrhythmic coronary trial : I . Report on arrhythmia and other findings .	O O O O O O O O O O O O B O O O O	['arrhythmia']	1	4	"Sentence: International mexiletine and placebo antiarrhythmic coronary trial : I . Report on arrhythmia and other findings .
Diseases: arrhythmia"	"Sentence: International mexiletine and placebo antiarrhythmic coronary trial : I . Report on arrhythmia and other findings .
Diseases:"
2926	Impact Research Group .	O O O O	[]	0	0	"Sentence: Impact Research Group .
Diseases: "	"Sentence: Impact Research Group .
Diseases:"
2927	The antiarrhythmic effects of the sustained release form of mexiletine ( Mexitil - Perlongets ) were evaluated in a double - blind placebo trial in 630 patients with recent documented myocardial infarction .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['myocardial infarction']	1	6	"Sentence: The antiarrhythmic effects of the sustained release form of mexiletine ( Mexitil - Perlongets ) were evaluated in a double - blind placebo trial in 630 patients with recent documented myocardial infarction .
Diseases: myocardial infarction"	"Sentence: The antiarrhythmic effects of the sustained release form of mexiletine ( Mexitil - Perlongets ) were evaluated in a double - blind placebo trial in 630 patients with recent documented myocardial infarction .
Diseases:"
2928	The primary response variable was based on central reading of 24 hour ambulatory electrocardiographic recordings and was defined as the occurrence of 30 or more single premature ventricular complexes in any two consecutive 30 minute blocks or one or more runs of two or more premature ventricular complexes in the entire 24 hour electrocardiographic recording .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The primary response variable was based on central reading of 24 hour ambulatory electrocardiographic recordings and was defined as the occurrence of 30 or more single premature ventricular complexes in any two consecutive 30 minute blocks or one or more runs of two or more premature ventricular complexes in the entire 24 hour electrocardiographic recording .
Diseases: "	"Sentence: The primary response variable was based on central reading of 24 hour ambulatory electrocardiographic recordings and was defined as the occurrence of 30 or more single premature ventricular complexes in any two consecutive 30 minute blocks or one or more runs of two or more premature ventricular complexes in the entire 24 hour electrocardiographic recording .
Diseases:"
2929	Large differences , regarded as statistically significant , between the mexiletine and placebo groups were noted in that end point at months 1 and 4 , but only trends were observed at month 12 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Large differences , regarded as statistically significant , between the mexiletine and placebo groups were noted in that end point at months 1 and 4 , but only trends were observed at month 12 .
Diseases: "	"Sentence: Large differences , regarded as statistically significant , between the mexiletine and placebo groups were noted in that end point at months 1 and 4 , but only trends were observed at month 12 .
Diseases:"
2930	These differences were observed even though the serum mexiletine levels obtained in this study were generally lower than those observed in studies that have used the regular form of the drug .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These differences were observed even though the serum mexiletine levels obtained in this study were generally lower than those observed in studies that have used the regular form of the drug .
Diseases: "	"Sentence: These differences were observed even though the serum mexiletine levels obtained in this study were generally lower than those observed in studies that have used the regular form of the drug .
Diseases:"
2931	There were more deaths in the mexiletine group ( 7 . 6 % ) than in the placebo group ( 4 . 8 % ) ; the difference was not statistically significant .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['deaths']	1	2	"Sentence: There were more deaths in the mexiletine group ( 7 . 6 % ) than in the placebo group ( 4 . 8 % ) ; the difference was not statistically significant .
Diseases: deaths"	"Sentence: There were more deaths in the mexiletine group ( 7 . 6 % ) than in the placebo group ( 4 . 8 % ) ; the difference was not statistically significant .
Diseases:"
2932	The incidence of coronary events was similar in both groups .	O O O O O O O O O O O	[]	0	0	"Sentence: The incidence of coronary events was similar in both groups .
Diseases: "	"Sentence: The incidence of coronary events was similar in both groups .
Diseases:"
2933	Previously recognized side effects , particularly tremor and gastrointestinal problems , were more frequent in the mexiletine group than in the placebo group .	O O O O O O B O B I O O O O O O O O O O O O O O	['tremor', 'gastrointestinal problems']	2	6	"Sentence: Previously recognized side effects , particularly tremor and gastrointestinal problems , were more frequent in the mexiletine group than in the placebo group .
Diseases: tremor, gastrointestinal problems"	"Sentence: Previously recognized side effects , particularly tremor and gastrointestinal problems , were more frequent in the mexiletine group than in the placebo group .
Diseases:"
2934	Regional localization of the antagonism of amphetamine - induced hyperactivity by intracerebral calcitonin injections .	O O O O O O O O O B O O O O O	['hyperactivity']	1	2	"Sentence: Regional localization of the antagonism of amphetamine - induced hyperactivity by intracerebral calcitonin injections .
Diseases: hyperactivity"	"Sentence: Regional localization of the antagonism of amphetamine - induced hyperactivity by intracerebral calcitonin injections .
Diseases:"
2935	Calcitonin receptors are found in the brain , and intracerebral infusions of calcitonin can produce behavioral effects .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Calcitonin receptors are found in the brain , and intracerebral infusions of calcitonin can produce behavioral effects .
Diseases: "	"Sentence: Calcitonin receptors are found in the brain , and intracerebral infusions of calcitonin can produce behavioral effects .
Diseases:"
2936	Among these behavioral effects are decreases in food intake and decreases in amphetamine - induced locomotor activity .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Among these behavioral effects are decreases in food intake and decreases in amphetamine - induced locomotor activity .
Diseases: "	"Sentence: Among these behavioral effects are decreases in food intake and decreases in amphetamine - induced locomotor activity .
Diseases:"
2937	In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens .
Diseases: "	"Sentence: In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens .
Diseases:"
2938	In the present experiment calcitonin decreased locomotor activity when locally injected into the same sites where it decreases food intake .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the present experiment calcitonin decreased locomotor activity when locally injected into the same sites where it decreases food intake .
Diseases: "	"Sentence: In the present experiment calcitonin decreased locomotor activity when locally injected into the same sites where it decreases food intake .
Diseases:"
2939	The areas where calcitonin is most effective in decreasing locomotor activity are located in the hypothalamus and nucleus accumbens , suggesting that these areas are the major sites of action of calcitonin in inhibiting amphetamine - induced locomotor activity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The areas where calcitonin is most effective in decreasing locomotor activity are located in the hypothalamus and nucleus accumbens , suggesting that these areas are the major sites of action of calcitonin in inhibiting amphetamine - induced locomotor activity .
Diseases: "	"Sentence: The areas where calcitonin is most effective in decreasing locomotor activity are located in the hypothalamus and nucleus accumbens , suggesting that these areas are the major sites of action of calcitonin in inhibiting amphetamine - induced locomotor activity .
Diseases:"
2940	Fatal intracranial bleeding associated with prehospital use of epinephrine .	O B I O O O O O O O	['intracranial bleeding']	1	5	"Sentence: Fatal intracranial bleeding associated with prehospital use of epinephrine .
Diseases: intracranial bleeding"	"Sentence: Fatal intracranial bleeding associated with prehospital use of epinephrine .
Diseases:"
2941	We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing .	O O O O O O O O O O O O O O O O O B I O O O O B I O B O	['allergic reaction', 'pulmonary edema', 'wheezing']	3	11	"Sentence: We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing .
Diseases: allergic reaction, pulmonary edema, wheezing"	"Sentence: We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing .
Diseases:"
2942	The sudden onset of respiratory distress , rash , and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine .	O O O O B I O B O O O O O O O O O O O O O O O O O O O O	['respiratory distress', 'rash']	2	6	"Sentence: The sudden onset of respiratory distress , rash , and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine .
Diseases: respiratory distress, rash"	"Sentence: The sudden onset of respiratory distress , rash , and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine .
Diseases:"
2943	Subsequently , acute cardiac arrest and fatal subarachnoid hemorrhage occurred .	O O O B I O O B I O O	['subarachnoid hemorrhage', 'cardiac arrest']	2	10	"Sentence: Subsequently , acute cardiac arrest and fatal subarachnoid hemorrhage occurred .
Diseases: subarachnoid hemorrhage, cardiac arrest"	"Sentence: Subsequently , acute cardiac arrest and fatal subarachnoid hemorrhage occurred .
Diseases:"
2944	Epinephrine has a proven role in cardiac arrest in prehospital care ; however , use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution .	O O O O O O B I O O O O O O O O O O O O O B I O O B O O O O O O	['allergic reaction', 'cardiac arrest', 'hypertension']	3	8	"Sentence: Epinephrine has a proven role in cardiac arrest in prehospital care ; however , use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution .
Diseases: allergic reaction, cardiac arrest, hypertension"	"Sentence: Epinephrine has a proven role in cardiac arrest in prehospital care ; however , use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution .
Diseases:"
2945	A case of massive rhabdomyolysis following molindone administration .	O O O O B O O O O	['rhabdomyolysis']	1	6	"Sentence: A case of massive rhabdomyolysis following molindone administration .
Diseases: rhabdomyolysis"	"Sentence: A case of massive rhabdomyolysis following molindone administration .
Diseases:"
2946	Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop .	B O O O O O O B O O O O O O	['rhabdomyolysis', 'psychiatric']	2	8	"Sentence: Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop .
Diseases: rhabdomyolysis, psychiatric"	"Sentence: Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop .
Diseases:"
2947	The clinical signs and symptoms , typical laboratory features , and complications of rhabdomyolysis are presented .	O O O O O O O O O O O O O B O O O	['rhabdomyolysis']	1	6	"Sentence: The clinical signs and symptoms , typical laboratory features , and complications of rhabdomyolysis are presented .
Diseases: rhabdomyolysis"	"Sentence: The clinical signs and symptoms , typical laboratory features , and complications of rhabdomyolysis are presented .
Diseases:"
2948	The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration .	O O O O B O O O O O O B O O B I I O O O O	['acute renal failure', 'schizophrenic', 'rhabdomyolysis']	3	14	"Sentence: The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration .
Diseases: acute renal failure, schizophrenic, rhabdomyolysis"	"Sentence: The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration .
Diseases:"
2949	Physicians who prescribe molindone should be aware of this reaction .	O O O O O O O O O O O	[]	0	0	"Sentence: Physicians who prescribe molindone should be aware of this reaction .
Diseases: "	"Sentence: Physicians who prescribe molindone should be aware of this reaction .
Diseases:"
2950	Cardiovascular alterations in rat fetuses exposed to calcium channel blockers .	B I O O O O O O O O O	['cardiovascular alterations']	1	3	"Sentence: Cardiovascular alterations in rat fetuses exposed to calcium channel blockers .
Diseases: cardiovascular alterations"	"Sentence: Cardiovascular alterations in rat fetuses exposed to calcium channel blockers .
Diseases:"
2951	Preclinical toxicologic investigation suggested that a new calcium channel blocker , Ro 40 - 5967 , induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O	['cardiovascular alterations']	1	3	"Sentence: Preclinical toxicologic investigation suggested that a new calcium channel blocker , Ro 40 - 5967 , induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis .
Diseases: cardiovascular alterations"	"Sentence: Preclinical toxicologic investigation suggested that a new calcium channel blocker , Ro 40 - 5967 , induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis .
Diseases:"
2952	The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect .	O O O O O O O O O O O O O O O O B I O O O O O O	['cardiovascular malformations']	1	5	"Sentence: The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect .
Diseases: cardiovascular malformations"	"Sentence: The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect .
Diseases:"
2953	We studied three calcium channel blockers of different structure , nifedipine , diltiazem , and verapamil , along with the new agent .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We studied three calcium channel blockers of different structure , nifedipine , diltiazem , and verapamil , along with the new agent .
Diseases: "	"Sentence: We studied three calcium channel blockers of different structure , nifedipine , diltiazem , and verapamil , along with the new agent .
Diseases:"
2954	Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['cardiovascular malformations']	1	5	"Sentence: Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations .
Diseases: cardiovascular malformations"	"Sentence: Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations .
Diseases:"
2955	A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers , but this incidence was statistically significant only for verapamil and nifedipine .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiovascular malformations']	1	5	"Sentence: A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers , but this incidence was statistically significant only for verapamil and nifedipine .
Diseases: cardiovascular malformations"	"Sentence: A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers , but this incidence was statistically significant only for verapamil and nifedipine .
Diseases:"
2956	All four agents were associated with aortic arch branching variants , although significantly increased only for Ro 40 - 5967 and verapamil .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All four agents were associated with aortic arch branching variants , although significantly increased only for Ro 40 - 5967 and verapamil .
Diseases: "	"Sentence: All four agents were associated with aortic arch branching variants , although significantly increased only for Ro 40 - 5967 and verapamil .
Diseases:"
2957	Differential impact of immune escape mutations G145R and P120 T on the replication of lamivudine - resistant hepatitis B virus e antigen - positive and - negative strains .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Differential impact of immune escape mutations G145R and P120 T on the replication of lamivudine - resistant hepatitis B virus e antigen - positive and - negative strains .
Diseases: "	"Sentence: Differential impact of immune escape mutations G145R and P120 T on the replication of lamivudine - resistant hepatitis B virus e antigen - positive and - negative strains .
Diseases:"
2958	Immune escape variants of the hepatitis B virus ( HBV ) represent an emerging clinical challenge , because they can be associated with vaccine escape , HBV reactivation , and failure of diagnostic tests .	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hepatitis b']	1	4	"Sentence: Immune escape variants of the hepatitis B virus ( HBV ) represent an emerging clinical challenge , because they can be associated with vaccine escape , HBV reactivation , and failure of diagnostic tests .
Diseases: hepatitis b"	"Sentence: Immune escape variants of the hepatitis B virus ( HBV ) represent an emerging clinical challenge , because they can be associated with vaccine escape , HBV reactivation , and failure of diagnostic tests .
Diseases:"
2959	Recent data suggest a preferential selection of immune escape mutants in distinct peripheral blood leukocyte compartments of infected individuals .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Recent data suggest a preferential selection of immune escape mutants in distinct peripheral blood leukocyte compartments of infected individuals .
Diseases: "	"Sentence: Recent data suggest a preferential selection of immune escape mutants in distinct peripheral blood leukocyte compartments of infected individuals .
Diseases:"
2960	We therefore systematically analyzed the functional impact of the most prevalent immune escape variants , the sG145R and sP120 T mutants , on the viral replication efficacy and antiviral drug susceptibility of common treatment - associated mutants with resistance to lamivudine ( LAM ) and / or HBeAg negativity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We therefore systematically analyzed the functional impact of the most prevalent immune escape variants , the sG145R and sP120 T mutants , on the viral replication efficacy and antiviral drug susceptibility of common treatment - associated mutants with resistance to lamivudine ( LAM ) and / or HBeAg negativity .
Diseases: "	"Sentence: We therefore systematically analyzed the functional impact of the most prevalent immune escape variants , the sG145R and sP120 T mutants , on the viral replication efficacy and antiviral drug susceptibility of common treatment - associated mutants with resistance to lamivudine ( LAM ) and / or HBeAg negativity .
Diseases:"
2961	Replication - competent HBV strains with sG145R or sP120 T and LAM resistance ( rtM204I or rtL180M / rtM204V ) were generated on an HBeAg - positive and an HBeAg - negative background with precore ( PC ) and basal core promoter ( BCP ) mutants .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Replication - competent HBV strains with sG145R or sP120 T and LAM resistance ( rtM204I or rtL180M / rtM204V ) were generated on an HBeAg - positive and an HBeAg - negative background with precore ( PC ) and basal core promoter ( BCP ) mutants .
Diseases: "	"Sentence: Replication - competent HBV strains with sG145R or sP120 T and LAM resistance ( rtM204I or rtL180M / rtM204V ) were generated on an HBeAg - positive and an HBeAg - negative background with precore ( PC ) and basal core promoter ( BCP ) mutants .
Diseases:"
2962	The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM - resistant HBV mutants to the levels of wild - type HBV , and PC or BCP mutations further enhanced viral replication .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM - resistant HBV mutants to the levels of wild - type HBV , and PC or BCP mutations further enhanced viral replication .
Diseases: "	"Sentence: The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM - resistant HBV mutants to the levels of wild - type HBV , and PC or BCP mutations further enhanced viral replication .
Diseases:"
2963	Although the sP120 T substitution also impaired HBsAg secretion , it did not enhance the replication of LAM - resistant clones .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although the sP120 T substitution also impaired HBsAg secretion , it did not enhance the replication of LAM - resistant clones .
Diseases: "	"Sentence: Although the sP120 T substitution also impaired HBsAg secretion , it did not enhance the replication of LAM - resistant clones .
Diseases:"
2964	However , the concomitant occurrence of HBeAg negativity ( PC / BCP ) , sP120 T , and LAM resistance resulted in the restoration of replication to levels of wild - type HBV .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the concomitant occurrence of HBeAg negativity ( PC / BCP ) , sP120 T , and LAM resistance resulted in the restoration of replication to levels of wild - type HBV .
Diseases: "	"Sentence: However , the concomitant occurrence of HBeAg negativity ( PC / BCP ) , sP120 T , and LAM resistance resulted in the restoration of replication to levels of wild - type HBV .
Diseases:"
2965	In all clones with combined immune escape and LAM resistance mutations , the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In all clones with combined immune escape and LAM resistance mutations , the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro .
Diseases: "	"Sentence: In all clones with combined immune escape and LAM resistance mutations , the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro .
Diseases:"
2966	These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants , supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants , supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns .
Diseases: "	"Sentence: These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants , supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns .
Diseases:"
2967	The effects of sevoflurane on lidocaine - induced convulsions .	O O O O O O O O B O	['convulsions']	1	3	"Sentence: The effects of sevoflurane on lidocaine - induced convulsions .
Diseases: convulsions"	"Sentence: The effects of sevoflurane on lidocaine - induced convulsions .
Diseases:"
2968	The influence of sevoflurane on lidocaine - induced convulsions was studied in cats .	O O O O O O O O B O O O O O	['convulsions']	1	3	"Sentence: The influence of sevoflurane on lidocaine - induced convulsions was studied in cats .
Diseases: convulsions"	"Sentence: The influence of sevoflurane on lidocaine - induced convulsions was studied in cats .
Diseases:"
2969	The convulsive threshold ( mean + / - SD ) was 41 . 4 + / -	O B O O O O O O O O O O O O O O O	['convulsive']	1	2	"Sentence: The convulsive threshold ( mean + / - SD ) was 41 . 4 + / -
Diseases: convulsive"	"Sentence: The convulsive threshold ( mean + / - SD ) was 41 . 4 + / -
Diseases:"
2970	6 . 5 mg .	O O O O O	[]	0	0	"Sentence: 6 . 5 mg .
Diseases: "	"Sentence: 6 . 5 mg .
Diseases:"
2971	l ( - 1 ) with lidocaine infusion ( 6 mg . kg ( - 1 ) . min ( - 1 ) ) , increasing significantly to 66 . 6 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: l ( - 1 ) with lidocaine infusion ( 6 mg . kg ( - 1 ) . min ( - 1 ) ) , increasing significantly to 66 . 6 + / -
Diseases: "	"Sentence: l ( - 1 ) with lidocaine infusion ( 6 mg . kg ( - 1 ) . min ( - 1 ) ) , increasing significantly to 66 . 6 + / -
Diseases:"
2972	10 . 9 mg .	O O O O O	[]	0	0	"Sentence: 10 . 9 mg .
Diseases: "	"Sentence: 10 . 9 mg .
Diseases:"
2973	l ( - 1 ) when the end - tidal concentration of sevoflurane was 0 . 8 % .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: l ( - 1 ) when the end - tidal concentration of sevoflurane was 0 . 8 % .
Diseases: "	"Sentence: l ( - 1 ) when the end - tidal concentration of sevoflurane was 0 . 8 % .
Diseases:"
2974	However , the threshold ( 61 . 6 + / - 8 . 7 mg . l ( - 1 ) ) during 1 . 6 % sevoflurane was not significant from that during 0 . 8 % sevoflurane , indicating a celling effect .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the threshold ( 61 . 6 + / - 8 . 7 mg . l ( - 1 ) ) during 1 . 6 % sevoflurane was not significant from that during 0 . 8 % sevoflurane , indicating a celling effect .
Diseases: "	"Sentence: However , the threshold ( 61 . 6 + / - 8 . 7 mg . l ( - 1 ) ) during 1 . 6 % sevoflurane was not significant from that during 0 . 8 % sevoflurane , indicating a celling effect .
Diseases:"
2975	There was no significant difference in the convulsive threshold between sevoflurane and enflurane .	O O O O O O O B O O O O O O	['convulsive']	1	2	"Sentence: There was no significant difference in the convulsive threshold between sevoflurane and enflurane .
Diseases: convulsive"	"Sentence: There was no significant difference in the convulsive threshold between sevoflurane and enflurane .
Diseases:"
2976	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1 . 6 % sevoflurane , and in 0 . 8 % and 1 . 6 % enflurane .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1 . 6 % sevoflurane , and in 0 . 8 % and 1 . 6 % enflurane .
Diseases: convulsions"	"Sentence: The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1 . 6 % sevoflurane , and in 0 . 8 % and 1 . 6 % enflurane .
Diseases:"
2977	However , there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg .
Diseases: "	"Sentence: However , there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg .
Diseases:"
2978	Apamin , a selective blocker of calcium - dependent potassium channels , was administered intracerebroventricularly in rats anesthetized with 0 . 8 % sevoflurane to investigate the mechanism of the anticonvulsive effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Apamin , a selective blocker of calcium - dependent potassium channels , was administered intracerebroventricularly in rats anesthetized with 0 . 8 % sevoflurane to investigate the mechanism of the anticonvulsive effects .
Diseases: "	"Sentence: Apamin , a selective blocker of calcium - dependent potassium channels , was administered intracerebroventricularly in rats anesthetized with 0 . 8 % sevoflurane to investigate the mechanism of the anticonvulsive effects .
Diseases:"
2979	Apamin ( 10 ng ) had a tendency to decrease the convulsive threshold ( 21 . 6 + / - 2 . 2 to 19 . 9 + / - 2 . 5 mg .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['convulsive']	1	2	"Sentence: Apamin ( 10 ng ) had a tendency to decrease the convulsive threshold ( 21 . 6 + / - 2 . 2 to 19 . 9 + / - 2 . 5 mg .
Diseases: convulsive"	"Sentence: Apamin ( 10 ng ) had a tendency to decrease the convulsive threshold ( 21 . 6 + / - 2 . 2 to 19 . 9 + / - 2 . 5 mg .
Diseases:"
2980	l ( - 1 ) )	O O O O O O	[]	0	0	"Sentence: l ( - 1 ) )
Diseases: "	"Sentence: l ( - 1 ) )
Diseases:"
2981	but this was not statistically significant .	O O O O O O O	[]	0	0	"Sentence: but this was not statistically significant .
Diseases: "	"Sentence: but this was not statistically significant .
Diseases:"
2982	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression .	O O O O O O O B O O O B O O O O O O O B O	['convulsive', 'depression', 'toxicity']	3	6	"Sentence: It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression .
Diseases: convulsive, depression, toxicity"	"Sentence: It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression .
Diseases:"
2983	Anti - oxidant effects of atorvastatin in dexamethasone - induced hypertension in the rat .	O O O O O O O O O O B O O O O	['hypertension']	1	3	"Sentence: Anti - oxidant effects of atorvastatin in dexamethasone - induced hypertension in the rat .
Diseases: hypertension"	"Sentence: Anti - oxidant effects of atorvastatin in dexamethasone - induced hypertension in the rat .
Diseases:"
2984	Dexamethasone ( Dex ) - induced hypertension is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( O2 - ) production .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: Dexamethasone ( Dex ) - induced hypertension is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( O2 - ) production .
Diseases: hypertension"	"Sentence: Dexamethasone ( Dex ) - induced hypertension is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( O2 - ) production .
Diseases:"
2985	Atorvastatin ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2 - production in various forms of hypertension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['hypertension']	1	3	"Sentence: Atorvastatin ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2 - production in various forms of hypertension .
Diseases: hypertension"	"Sentence: Atorvastatin ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2 - production in various forms of hypertension .
Diseases:"
2986	In the present study , we investigated whether 50 mg / kg per day , p . o .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the present study , we investigated whether 50 mg / kg per day , p . o .
Diseases: "	"Sentence: In the present study , we investigated whether 50 mg / kg per day , p . o .
Diseases:"
2987	, Ato could prevent endothelial NO synthase ( eNOS ) downregulation and the increase in O2 - in Sprague - Dawley ( SD ) rats , thereby reducing blood pressure .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: , Ato could prevent endothelial NO synthase ( eNOS ) downregulation and the increase in O2 - in Sprague - Dawley ( SD ) rats , thereby reducing blood pressure .
Diseases: "	"Sentence: , Ato could prevent endothelial NO synthase ( eNOS ) downregulation and the increase in O2 - in Sprague - Dawley ( SD ) rats , thereby reducing blood pressure .
Diseases:"
2988	Male SD rats ( n = 30 ) were treated with Ato ( 50 mg / kg per day in drinking water ) or tap water for 15 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Male SD rats ( n = 30 ) were treated with Ato ( 50 mg / kg per day in drinking water ) or tap water for 15 days .
Diseases: "	"Sentence: Male SD rats ( n = 30 ) were treated with Ato ( 50 mg / kg per day in drinking water ) or tap water for 15 days .
Diseases:"
2989	Dexamethasone ( 10 microg / kg per day , s . c . ) or saline was started after 4 days in Ato - treated and non - treated rats and continued for 11 - 13 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dexamethasone ( 10 microg / kg per day , s . c . ) or saline was started after 4 days in Ato - treated and non - treated rats and continued for 11 - 13 days .
Diseases: "	"Sentence: Dexamethasone ( 10 microg / kg per day , s . c . ) or saline was started after 4 days in Ato - treated and non - treated rats and continued for 11 - 13 days .
Diseases:"
2990	Systolic blood pressure ( SBP ) was measured on alternate days using the tail - cuff method .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Systolic blood pressure ( SBP ) was measured on alternate days using the tail - cuff method .
Diseases: "	"Sentence: Systolic blood pressure ( SBP ) was measured on alternate days using the tail - cuff method .
Diseases:"
2991	Endothelial function was assessed by acetylcholine - induced vasorelaxation and phenylephrine - induced vasoconstriction in aortic segments .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Endothelial function was assessed by acetylcholine - induced vasorelaxation and phenylephrine - induced vasoconstriction in aortic segments .
Diseases: "	"Sentence: Endothelial function was assessed by acetylcholine - induced vasorelaxation and phenylephrine - induced vasoconstriction in aortic segments .
Diseases:"
2992	Vascular eNOS	O O	[]	0	0	"Sentence: Vascular eNOS
Diseases: "	"Sentence: Vascular eNOS
Diseases:"
2993	mRNA was assessed by semi - quantitative reverse transcription - polymerase chain reaction .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: mRNA was assessed by semi - quantitative reverse transcription - polymerase chain reaction .
Diseases: "	"Sentence: mRNA was assessed by semi - quantitative reverse transcription - polymerase chain reaction .
Diseases:"
2994	In rats treated with Dex alone , SBP was increased from 109 + / - 2 to 133 + / -	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In rats treated with Dex alone , SBP was increased from 109 + / - 2 to 133 + / -
Diseases: "	"Sentence: In rats treated with Dex alone , SBP was increased from 109 + / - 2 to 133 + / -
Diseases:"
2995	2 mmHg on Days 4 and Day 14 , respectively ( P < 0 . 001 ) .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 2 mmHg on Days 4 and Day 14 , respectively ( P < 0 . 001 ) .
Diseases: "	"Sentence: 2 mmHg on Days 4 and Day 14 , respectively ( P < 0 . 001 ) .
Diseases:"
2996	In the Ato + Dex group , SBP was increased from 113 + / - 2 to 119 + / -	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the Ato + Dex group , SBP was increased from 113 + / - 2 to 119 + / -
Diseases: "	"Sentence: In the Ato + Dex group , SBP was increased from 113 + / - 2 to 119 + / -
Diseases:"
2997	2 mmHg on Days 4 to 14 , respectively ( P < 0 . 001 ) , but was significantly lower than SBP in the group treated with Dex alone ( P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 2 mmHg on Days 4 to 14 , respectively ( P < 0 . 001 ) , but was significantly lower than SBP in the group treated with Dex alone ( P < 0 . 05 ) .
Diseases: "	"Sentence: 2 mmHg on Days 4 to 14 , respectively ( P < 0 . 001 ) , but was significantly lower than SBP in the group treated with Dex alone ( P < 0 . 05 ) .
Diseases:"
2998	Endothelial - dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group ( P < 0 . 05 and P < 0 . 0001 , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Endothelial - dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group ( P < 0 . 05 and P < 0 . 0001 , respectively ) .
Diseases: "	"Sentence: Endothelial - dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group ( P < 0 . 05 and P < 0 . 0001 , respectively ) .
Diseases:"
2999	Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone ( P < 0 . 0001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone ( P < 0 . 0001 ) .
Diseases: "	"Sentence: Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone ( P < 0 . 0001 ) .
Diseases:"
3000	Treatment with Ato improved endothelial function , reduced superoxide production and reduced SBP in Dex - treated SD rats .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Treatment with Ato improved endothelial function , reduced superoxide production and reduced SBP in Dex - treated SD rats .
Diseases: "	"Sentence: Treatment with Ato improved endothelial function , reduced superoxide production and reduced SBP in Dex - treated SD rats .
Diseases:"
3001	99mTc - glucarate for detection of isoproterenol - induced myocardial infarction in rats .	O O O O O O O O O B I O O O	['myocardial infarction']	1	6	"Sentence: 99mTc - glucarate for detection of isoproterenol - induced myocardial infarction in rats .
Diseases: myocardial infarction"	"Sentence: 99mTc - glucarate for detection of isoproterenol - induced myocardial infarction in rats .
Diseases:"
3002	Infarct - avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction .	B O O O O O O O O O O O O B I O	['infarct', 'myocardial infarction']	2	10	"Sentence: Infarct - avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction .
Diseases: infarct, myocardial infarction"	"Sentence: Infarct - avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction .
Diseases:"
3003	The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol .	O O O O O O B O O O O O O O O O O O O O	['infarction']	1	3	"Sentence: The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol .
Diseases: infarction"	"Sentence: The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol .
Diseases:"
3004	A new infarct - avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ .	O O B O O O O O O O O O O O O O O O O O	['infarct']	1	3	"Sentence: A new infarct - avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ .
Diseases: infarct"	"Sentence: A new infarct - avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ .
Diseases:"
3005	99mTc - glucarate was easy to prepare , stable for 96 h and was used to study its biodistribution in rats with isoproterenol - induced acute myocardial infarction .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['myocardial infarction']	1	6	"Sentence: 99mTc - glucarate was easy to prepare , stable for 96 h and was used to study its biodistribution in rats with isoproterenol - induced acute myocardial infarction .
Diseases: myocardial infarction"	"Sentence: 99mTc - glucarate was easy to prepare , stable for 96 h and was used to study its biodistribution in rats with isoproterenol - induced acute myocardial infarction .
Diseases:"
3006	Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration .	O O O O O O O O B O O O O O O	['infarct']	1	3	"Sentence: Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration .
Diseases: infarct"	"Sentence: Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration .
Diseases:"
3007	The rat biodistribution studies showed a rapid blood clearance via the kidneys .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The rat biodistribution studies showed a rapid blood clearance via the kidneys .
Diseases: "	"Sentence: The rat biodistribution studies showed a rapid blood clearance via the kidneys .
Diseases:"
3008	Thirty minutes after 99mTc - glucarate administration the standardised heart uptake value S ( h ) UV was 4 . 7 in infarcted rat heart which is six times more than in normal rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty minutes after 99mTc - glucarate administration the standardised heart uptake value S ( h ) UV was 4 . 7 in infarcted rat heart which is six times more than in normal rats .
Diseases: "	"Sentence: Thirty minutes after 99mTc - glucarate administration the standardised heart uptake value S ( h ) UV was 4 . 7 in infarcted rat heart which is six times more than in normal rats .
Diseases:"
3009	ROIs drawn over the gamma camera images showed a ratio of 4 . 4 .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ROIs drawn over the gamma camera images showed a ratio of 4 . 4 .
Diseases: "	"Sentence: ROIs drawn over the gamma camera images showed a ratio of 4 . 4 .
Diseases:"
3010	The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect , in patients , early cardiac infarction .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['cardiac infarction']	1	5	"Sentence: The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect , in patients , early cardiac infarction .
Diseases: cardiac infarction"	"Sentence: The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect , in patients , early cardiac infarction .
Diseases:"
3011	A randomized , placebo - controlled dose - comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer 's disease .	O O O O O O O O O O O O O B O B I O B I I O	"['psychosis', 'disruptive behaviors', ""alzheimer 's disease""]"	3	12	"Sentence: A randomized , placebo - controlled dose - comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer 's disease .
Diseases: psychosis, disruptive behaviors, alzheimer 's disease"	"Sentence: A randomized , placebo - controlled dose - comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer 's disease .
Diseases:"
3012	The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer 's disease .	O O O O O O O O O O O O O O O O O O O O O O O O B O B I O O O B I I O	"['psychosis', 'disruptive behaviors', ""alzheimer 's disease""]"	3	12	"Sentence: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer 's disease .
Diseases: psychosis, disruptive behaviors, alzheimer 's disease"	"Sentence: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer 's disease .
Diseases:"
3013	In a 6 - week random - assignment , double - blind , placebo - controlled trial ( phase A ) , haloperidol , 2 - 3 mg / day ( standard dose ) , and haloperidol , 0 . 50 - 0 . 75 mg / day ( low dose ) , were compared in 71 outpatients with Alzheimer 's disease .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	"[""alzheimer 's disease""]"	1	6	"Sentence: In a 6 - week random - assignment , double - blind , placebo - controlled trial ( phase A ) , haloperidol , 2 - 3 mg / day ( standard dose ) , and haloperidol , 0 . 50 - 0 . 75 mg / day ( low dose ) , were compared in 71 outpatients with Alzheimer 's disease .
Diseases: alzheimer 's disease"	"Sentence: In a 6 - week random - assignment , double - blind , placebo - controlled trial ( phase A ) , haloperidol , 2 - 3 mg / day ( standard dose ) , and haloperidol , 0 . 50 - 0 . 75 mg / day ( low dose ) , were compared in 71 outpatients with Alzheimer 's disease .
Diseases:"
3014	For the subsequent 6 - week double - blind crossover phase ( phase B ) , patients taking standard - or low - dose haloperidol were switched to placebo , and patients taking placebo were randomly assigned to standard - or low - dose haloperidol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For the subsequent 6 - week double - blind crossover phase ( phase B ) , patients taking standard - or low - dose haloperidol were switched to placebo , and patients taking placebo were randomly assigned to standard - or low - dose haloperidol .
Diseases: "	"Sentence: For the subsequent 6 - week double - blind crossover phase ( phase B ) , patients taking standard - or low - dose haloperidol were switched to placebo , and patients taking placebo were randomly assigned to standard - or low - dose haloperidol .
Diseases:"
3015	For the 60 patients who completed phase A , standard - dose haloperidol was efficacious and superior to both low - dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O B I O	['psychosis', 'psychomotor agitation']	2	7	"Sentence: For the 60 patients who completed phase A , standard - dose haloperidol was efficacious and superior to both low - dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation .
Diseases: psychosis, psychomotor agitation"	"Sentence: For the 60 patients who completed phase A , standard - dose haloperidol was efficacious and superior to both low - dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation .
Diseases:"
3016	Response rates according to three sets of criteria were greater with the standard dose ( 55 % - 60 % ) than the low dose ( 25 % - 35 % ) and placebo ( 25 % - 30 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Response rates according to three sets of criteria were greater with the standard dose ( 55 % - 60 % ) than the low dose ( 25 % - 35 % ) and placebo ( 25 % - 30 % ) .
Diseases: "	"Sentence: Response rates according to three sets of criteria were greater with the standard dose ( 55 % - 60 % ) than the low dose ( 25 % - 35 % ) and placebo ( 25 % - 30 % ) .
Diseases:"
3017	The advantage of standard dose over low dose was replicated in phase B .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The advantage of standard dose over low dose was replicated in phase B .
Diseases: "	"Sentence: The advantage of standard dose over low dose was replicated in phase B .
Diseases:"
3018	In phase A , extrapyramidal signs tended to be greater with the standard dose than in the other two conditions , primarily because of a subgroup ( 20 % ) who developed moderate to severe signs .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['extrapyramidal signs']	1	6	"Sentence: In phase A , extrapyramidal signs tended to be greater with the standard dose than in the other two conditions , primarily because of a subgroup ( 20 % ) who developed moderate to severe signs .
Diseases: extrapyramidal signs"	"Sentence: In phase A , extrapyramidal signs tended to be greater with the standard dose than in the other two conditions , primarily because of a subgroup ( 20 % ) who developed moderate to severe signs .
Diseases:"
3019	Low - dose haloperidol did not differ from placebo on any measure of efficacy or side effects .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Low - dose haloperidol did not differ from placebo on any measure of efficacy or side effects .
Diseases: "	"Sentence: Low - dose haloperidol did not differ from placebo on any measure of efficacy or side effects .
Diseases:"
3020	The results indicated a favorable therapeutic profile for haloperidol in doses of 2 - 3 mg / day , although a subgroup developed moderate to severe extrapyramidal signs .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['extrapyramidal signs']	1	6	"Sentence: The results indicated a favorable therapeutic profile for haloperidol in doses of 2 - 3 mg / day , although a subgroup developed moderate to severe extrapyramidal signs .
Diseases: extrapyramidal signs"	"Sentence: The results indicated a favorable therapeutic profile for haloperidol in doses of 2 - 3 mg / day , although a subgroup developed moderate to severe extrapyramidal signs .
Diseases:"
3021	A starting dose of 1 mg / day with gradual , upward dose titration is recommended .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A starting dose of 1 mg / day with gradual , upward dose titration is recommended .
Diseases: "	"Sentence: A starting dose of 1 mg / day with gradual , upward dose titration is recommended .
Diseases:"
3022	The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer 's disease patients with psychosis and disruptive behaviors .	O O O O O O O O O O O O O O O B I I O O B O B I O	"['psychosis', 'disruptive behaviors', ""alzheimer 's disease""]"	3	12	"Sentence: The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer 's disease patients with psychosis and disruptive behaviors .
Diseases: psychosis, disruptive behaviors, alzheimer 's disease"	"Sentence: The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer 's disease patients with psychosis and disruptive behaviors .
Diseases:"
3023	Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin - induced renal damage .	O O O O O O O O O O O O O O O B I O	['renal damage']	1	3	"Sentence: Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin - induced renal damage .
Diseases: renal damage"	"Sentence: Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin - induced renal damage .
Diseases:"
3024	In man , differences in angiotensin - converting enzyme ( ACE ) levels , related to ACE ( I / D ) genotype , are associated with renal prognosis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In man , differences in angiotensin - converting enzyme ( ACE ) levels , related to ACE ( I / D ) genotype , are associated with renal prognosis .
Diseases: "	"Sentence: In man , differences in angiotensin - converting enzyme ( ACE ) levels , related to ACE ( I / D ) genotype , are associated with renal prognosis .
Diseases:"
3025	This raises the hypothesis that individual differences in renal ACE activity are involved in renal susceptibility to inflicted damage .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This raises the hypothesis that individual differences in renal ACE activity are involved in renal susceptibility to inflicted damage .
Diseases: "	"Sentence: This raises the hypothesis that individual differences in renal ACE activity are involved in renal susceptibility to inflicted damage .
Diseases:"
3026	Therefore , we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats .	O O O O O O O O O O O O O O O B I O O O O O O O O O O	['renal damage']	1	3	"Sentence: Therefore , we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats .
Diseases: renal damage"	"Sentence: Therefore , we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats .
Diseases:"
3027	METHODS : Renal ACE activity ( Hip - His - Leu cleavage by cortical homogenates ) was determined by renal biopsy in 27 adult male Wistar rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Renal ACE activity ( Hip - His - Leu cleavage by cortical homogenates ) was determined by renal biopsy in 27 adult male Wistar rats .
Diseases: "	"Sentence: METHODS : Renal ACE activity ( Hip - His - Leu cleavage by cortical homogenates ) was determined by renal biopsy in 27 adult male Wistar rats .
Diseases:"
3028	After 1 week of recovery , proteinuria was induced by adriamycin [ 1 . 5 mg / kg intravenously ( i . v . )	O O O O O O B O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: After 1 week of recovery , proteinuria was induced by adriamycin [ 1 . 5 mg / kg intravenously ( i . v . )
Diseases: proteinuria"	"Sentence: After 1 week of recovery , proteinuria was induced by adriamycin [ 1 . 5 mg / kg intravenously ( i . v . )
Diseases:"
3029	n = 18 ; controls , saline i . v .	O O O O O O O O O O O	[]	0	0	"Sentence: n = 18 ; controls , saline i . v .
Diseases: "	"Sentence: n = 18 ; controls , saline i . v .
Diseases:"
3030	n = 9 ] .	O O O O O	[]	0	0	"Sentence: n = 9 ] .
Diseases: "	"Sentence: n = 9 ] .
Diseases:"
3031	Proteinuria was measured every 2 weeks .	B O O O O O O	['proteinuria']	1	2	"Sentence: Proteinuria was measured every 2 weeks .
Diseases: proteinuria"	"Sentence: Proteinuria was measured every 2 weeks .
Diseases:"
3032	After 12 weeks , rats were sacrificed and their kidneys harvested .	O O O O O O O O O O O O	[]	0	0	"Sentence: After 12 weeks , rats were sacrificed and their kidneys harvested .
Diseases: "	"Sentence: After 12 weeks , rats were sacrificed and their kidneys harvested .
Diseases:"
3033	As anticipated , adriamycin elicited nephrotic range proteinuria , renal interstitial damage and mild focal glomerulosclerosis .	O O O O O B O B O B I I O O B I O	['renal interstitial damage', 'focal glomerulosclerosis', 'nephrotic', 'proteinuria']	4	20	"Sentence: As anticipated , adriamycin elicited nephrotic range proteinuria , renal interstitial damage and mild focal glomerulosclerosis .
Diseases: renal interstitial damage, focal glomerulosclerosis, nephrotic, proteinuria"	"Sentence: As anticipated , adriamycin elicited nephrotic range proteinuria , renal interstitial damage and mild focal glomerulosclerosis .
Diseases:"
3034	Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin ( r = 0 . 62 , P < 0 . 01 ) , renal interstitial alpha - smooth muscle actin ( r = 0 . 49 , P < 0 . 05 ) , interstitial macrophage influx ( r = 0 . 56 , P < 0 . 05 ) , interstitial collagen III ( r = 0 . 53 , P < 0 . 05 ) , glomerular alpha - smooth muscle actin ( r = 0 . 74 , P < 0 . 01 ) and glomerular desmin ( r = 0 . 48 , P < 0 . 05 ) .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin ( r = 0 . 62 , P < 0 . 01 ) , renal interstitial alpha - smooth muscle actin ( r = 0 . 49 , P < 0 . 05 ) , interstitial macrophage influx ( r = 0 . 56 , P < 0 . 05 ) , interstitial collagen III ( r = 0 . 53 , P < 0 . 05 ) , glomerular alpha - smooth muscle actin ( r = 0 . 74 , P < 0 . 01 ) and glomerular desmin ( r = 0 . 48 , P < 0 . 05 ) .
Diseases: proteinuria"	"Sentence: Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin ( r = 0 . 62 , P < 0 . 01 ) , renal interstitial alpha - smooth muscle actin ( r = 0 . 49 , P < 0 . 05 ) , interstitial macrophage influx ( r = 0 . 56 , P < 0 . 05 ) , interstitial collagen III ( r = 0 . 53 , P < 0 . 05 ) , glomerular alpha - smooth muscle actin ( r = 0 . 74 , P < 0 . 01 ) and glomerular desmin ( r = 0 . 48 , P < 0 . 05 ) .
Diseases:"
3035	Baseline renal ACE did not correlate with focal glomerulosclerosis ( r = 0 . 22 , NS ) .	O O O O O O O B I O O O O O O O O O O	['focal glomerulosclerosis']	1	7	"Sentence: Baseline renal ACE did not correlate with focal glomerulosclerosis ( r = 0 . 22 , NS ) .
Diseases: focal glomerulosclerosis"	"Sentence: Baseline renal ACE did not correlate with focal glomerulosclerosis ( r = 0 . 22 , NS ) .
Diseases:"
3036	In controls , no predictive values for renal parameters were observed .	O O O O O O O O O O O O	[]	0	0	"Sentence: In controls , no predictive values for renal parameters were observed .
Diseases: "	"Sentence: In controls , no predictive values for renal parameters were observed .
Diseases:"
3037	CONCLUSION : Individual differences in renal ACE activity predict the severity of adriamycin - induced renal damage in this outbred rat strain .	O O O O O O O O O O O O O O O B I O O O O O O	['renal damage']	1	3	"Sentence: CONCLUSION : Individual differences in renal ACE activity predict the severity of adriamycin - induced renal damage in this outbred rat strain .
Diseases: renal damage"	"Sentence: CONCLUSION : Individual differences in renal ACE activity predict the severity of adriamycin - induced renal damage in this outbred rat strain .
Diseases:"
3038	This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage .	O O O O O O O O O O O O O O O O O B I O	['renal damage']	1	3	"Sentence: This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage .
Diseases: renal damage"	"Sentence: This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage .
Diseases:"
3039	Clinical nephrotoxicity of tobramycin and gentamicin .	O B O O O O O	['nephrotoxicity']	1	4	"Sentence: Clinical nephrotoxicity of tobramycin and gentamicin .
Diseases: nephrotoxicity"	"Sentence: Clinical nephrotoxicity of tobramycin and gentamicin .
Diseases:"
3040	A prospective study .	O O O O	[]	0	0	"Sentence: A prospective study .
Diseases: "	"Sentence: A prospective study .
Diseases:"
3041	Nearly 3 . 2 million people in this country receive aminoglycoside antibiotics annually .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nearly 3 . 2 million people in this country receive aminoglycoside antibiotics annually .
Diseases: "	"Sentence: Nearly 3 . 2 million people in this country receive aminoglycoside antibiotics annually .
Diseases:"
3042	Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies .	O O O O O O O O B O B O O O O O O O	['nephrotoxicity', 'ototoxicity']	2	8	"Sentence: Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies .
Diseases: nephrotoxicity, ototoxicity"	"Sentence: Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies .
Diseases:"
3043	In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg / kg / day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside - related renal failure , defined as at least a one - third reduction in renal function .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O	['renal failure']	1	3	"Sentence: In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg / kg / day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside - related renal failure , defined as at least a one - third reduction in renal function .
Diseases: renal failure"	"Sentence: In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg / kg / day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside - related renal failure , defined as at least a one - third reduction in renal function .
Diseases:"
3044	In these 62 patients , no other causes for renal failure could be identified .	O O O O O O O O O B I O O O O	['renal failure']	1	3	"Sentence: In these 62 patients , no other causes for renal failure could be identified .
Diseases: renal failure"	"Sentence: In these 62 patients , no other causes for renal failure could be identified .
Diseases:"
3045	Five of 33 ( 15 % ) of the tobramycin - treated patients and 16 of 29 ( 55 . 2 % ) of the gentamicin - treated patients had renal failure .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['renal failure']	1	3	"Sentence: Five of 33 ( 15 % ) of the tobramycin - treated patients and 16 of 29 ( 55 . 2 % ) of the gentamicin - treated patients had renal failure .
Diseases: renal failure"	"Sentence: Five of 33 ( 15 % ) of the tobramycin - treated patients and 16 of 29 ( 55 . 2 % ) of the gentamicin - treated patients had renal failure .
Diseases:"
3046	Thus , gentamicin was associated with renal failure more than three times as often as was tobramycin .	O O O O O O B I O O O O O O O O O O	['renal failure']	1	3	"Sentence: Thus , gentamicin was associated with renal failure more than three times as often as was tobramycin .
Diseases: renal failure"	"Sentence: Thus , gentamicin was associated with renal failure more than three times as often as was tobramycin .
Diseases:"
3047	Neuroprotective action of MPEP , a selective mGluR5 antagonist , in methamphetamine - induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats .	O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O	['hyperthermia', 'neurotoxicity']	2	6	"Sentence: Neuroprotective action of MPEP , a selective mGluR5 antagonist , in methamphetamine - induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats .
Diseases: hyperthermia, neurotoxicity"	"Sentence: Neuroprotective action of MPEP , a selective mGluR5 antagonist , in methamphetamine - induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats .
Diseases:"
3048	The aim of this study was to examine the role of metabotropic glutamate receptor 5 ( mGluR5 ) in the toxic action of methamphetamine on dopaminergic neurones in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The aim of this study was to examine the role of metabotropic glutamate receptor 5 ( mGluR5 ) in the toxic action of methamphetamine on dopaminergic neurones in rats .
Diseases: "	"Sentence: The aim of this study was to examine the role of metabotropic glutamate receptor 5 ( mGluR5 ) in the toxic action of methamphetamine on dopaminergic neurones in rats .
Diseases:"
3049	Methamphetamine ( 10 mg / kg sc ) , administered five times , reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Methamphetamine ( 10 mg / kg sc ) , administered five times , reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection .
Diseases: "	"Sentence: Methamphetamine ( 10 mg / kg sc ) , administered five times , reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection .
Diseases:"
3050	A selective antagonist of mGluR5 , 2 - methyl - 6 - ( phenylethynyl ) pyridine ( MPEP ; 5 mg / kg ip ) , when administered five times immediately before each methamphetamine injection reversed the above - mentioned methamphetamine effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A selective antagonist of mGluR5 , 2 - methyl - 6 - ( phenylethynyl ) pyridine ( MPEP ; 5 mg / kg ip ) , when administered five times immediately before each methamphetamine injection reversed the above - mentioned methamphetamine effects .
Diseases: "	"Sentence: A selective antagonist of mGluR5 , 2 - methyl - 6 - ( phenylethynyl ) pyridine ( MPEP ; 5 mg / kg ip ) , when administered five times immediately before each methamphetamine injection reversed the above - mentioned methamphetamine effects .
Diseases:"
3051	A single MPEP ( 5 mg / kg ip ) injection reduced the basal extracellular dopamine level in the striatum , as well as dopamine release stimulated either by methamphetamine ( 10 mg / kg sc ) or by intrastriatally administered veratridine ( 100 microM ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A single MPEP ( 5 mg / kg ip ) injection reduced the basal extracellular dopamine level in the striatum , as well as dopamine release stimulated either by methamphetamine ( 10 mg / kg sc ) or by intrastriatally administered veratridine ( 100 microM ) .
Diseases: "	"Sentence: A single MPEP ( 5 mg / kg ip ) injection reduced the basal extracellular dopamine level in the striatum , as well as dopamine release stimulated either by methamphetamine ( 10 mg / kg sc ) or by intrastriatally administered veratridine ( 100 microM ) .
Diseases:"
3052	Moreover , it transiently diminished the methamphetamine ( 10 mg / kg sc ) - induced hyperthermia and reduced basal body temperature .	O O O O O O O O O O O O O O O O B O O O O O O	['hyperthermia']	1	3	"Sentence: Moreover , it transiently diminished the methamphetamine ( 10 mg / kg sc ) - induced hyperthermia and reduced basal body temperature .
Diseases: hyperthermia"	"Sentence: Moreover , it transiently diminished the methamphetamine ( 10 mg / kg sc ) - induced hyperthermia and reduced basal body temperature .
Diseases:"
3053	MPEP administered into the striatum at high concentrations ( 500 microM ) increased extracellular dopamine levels , while lower concentrations ( 50 - 100 microM ) were devoid of any effect .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: MPEP administered into the striatum at high concentrations ( 500 microM ) increased extracellular dopamine levels , while lower concentrations ( 50 - 100 microM ) were devoid of any effect .
Diseases: "	"Sentence: MPEP administered into the striatum at high concentrations ( 500 microM ) increased extracellular dopamine levels , while lower concentrations ( 50 - 100 microM ) were devoid of any effect .
Diseases:"
3054	The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine - induced toxicity .	O O O O O O O O O O O O O O O O O O O O O B O	['toxicity']	1	2	"Sentence: The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine - induced toxicity .
Diseases: toxicity"	"Sentence: The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine - induced toxicity .
Diseases:"
3055	Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine - induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in hyperthermia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['hyperthermia']	1	3	"Sentence: Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine - induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in hyperthermia .
Diseases: hyperthermia"	"Sentence: Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine - induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in hyperthermia .
Diseases:"
3056	Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl .	O O O O O O O O O O	[]	0	0	"Sentence: Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl .
Diseases: "	"Sentence: Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl .
Diseases:"
3057	In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme ( CYP ) 2D6 .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme ( CYP ) 2D6 .
Diseases: "	"Sentence: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme ( CYP ) 2D6 .
Diseases:"
3058	The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity , using desipramine as a probe substrate , in healthy subjects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity , using desipramine as a probe substrate , in healthy subjects .
Diseases: "	"Sentence: The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity , using desipramine as a probe substrate , in healthy subjects .
Diseases:"
3059	Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized , open - label , crossover study to receive a single oral dose of desipramine ( 50 mg ) on two separate occasions , once alone and once after multiple doses of cinacalcet ( 90 mg for 7 days ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized , open - label , crossover study to receive a single oral dose of desipramine ( 50 mg ) on two separate occasions , once alone and once after multiple doses of cinacalcet ( 90 mg for 7 days ) .
Diseases: "	"Sentence: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized , open - label , crossover study to receive a single oral dose of desipramine ( 50 mg ) on two separate occasions , once alone and once after multiple doses of cinacalcet ( 90 mg for 7 days ) .
Diseases:"
3060	Blood samples were obtained predose and up to 72 h postdose .	O O O O O O O O O O O O	[]	0	0	"Sentence: Blood samples were obtained predose and up to 72 h postdose .
Diseases: "	"Sentence: Blood samples were obtained predose and up to 72 h postdose .
Diseases:"
3061	Fourteen subjects completed both treatment arms .	O O O O O O O	[]	0	0	"Sentence: Fourteen subjects completed both treatment arms .
Diseases: "	"Sentence: Fourteen subjects completed both treatment arms .
Diseases:"
3062	Relative to desipramine alone , mean AUC and C ( max ) of desipramine increased 3 . 6 - and 1 . 8 - fold when coadministered with cinacalcet .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Relative to desipramine alone , mean AUC and C ( max ) of desipramine increased 3 . 6 - and 1 . 8 - fold when coadministered with cinacalcet .
Diseases: "	"Sentence: Relative to desipramine alone , mean AUC and C ( max ) of desipramine increased 3 . 6 - and 1 . 8 - fold when coadministered with cinacalcet .
Diseases:"
3063	The t ( 1 / 2 , z ) of desipramine was longer when desipramine was coadministered with cinacalcet ( 21 . 0 versus 43 . 3 hs ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The t ( 1 / 2 , z ) of desipramine was longer when desipramine was coadministered with cinacalcet ( 21 . 0 versus 43 . 3 hs ) .
Diseases: "	"Sentence: The t ( 1 / 2 , z ) of desipramine was longer when desipramine was coadministered with cinacalcet ( 21 . 0 versus 43 . 3 hs ) .
Diseases:"
3064	The t ( max ) was similar between the regimens .	O O O O O O O O O O O	[]	0	0	"Sentence: The t ( max ) was similar between the regimens .
Diseases: "	"Sentence: The t ( max ) was similar between the regimens .
Diseases:"
3065	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and headache ) have been reported for patients treated with either desipramine or cinacalcet .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O	['nausea', 'headache']	2	5	"Sentence: Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and headache ) have been reported for patients treated with either desipramine or cinacalcet .
Diseases: nausea, headache"	"Sentence: Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and headache ) have been reported for patients treated with either desipramine or cinacalcet .
Diseases:"
3066	This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6 .	O O O O O O O O O O O O	[]	0	0	"Sentence: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6 .
Diseases: "	"Sentence: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6 .
Diseases:"
3067	These data suggest that during concomitant treatment with cinacalcet , dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These data suggest that during concomitant treatment with cinacalcet , dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6 .
Diseases: "	"Sentence: These data suggest that during concomitant treatment with cinacalcet , dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6 .
Diseases:"
3068	Proteomic analysis of striatal proteins in the rat model of L - DOPA - induced dyskinesia .	O O O O O O O O O O O O O O O B O	['dyskinesia']	1	5	"Sentence: Proteomic analysis of striatal proteins in the rat model of L - DOPA - induced dyskinesia .
Diseases: dyskinesia"	"Sentence: Proteomic analysis of striatal proteins in the rat model of L - DOPA - induced dyskinesia .
Diseases:"
3069	L - DOPA - induced dyskinesia ( LID ) is among the motor complications that arise in Parkinson 's disease ( PD ) patients after a prolonged treatment with L - DOPA .	O O O O O B O B O O O O O O O O O B I I O B O O O O O O O O O O O	"['pd', 'dyskinesia', ""parkinson 's disease"", 'lid']"	4	14	"Sentence: L - DOPA - induced dyskinesia ( LID ) is among the motor complications that arise in Parkinson 's disease ( PD ) patients after a prolonged treatment with L - DOPA .
Diseases: pd, dyskinesia, parkinson 's disease, lid"	"Sentence: L - DOPA - induced dyskinesia ( LID ) is among the motor complications that arise in Parkinson 's disease ( PD ) patients after a prolonged treatment with L - DOPA .
Diseases:"
3070	To this day , transcriptome analysis has been performed in a rat model of LID [ Neurobiol .	O O O O O O O O O O O O O O B O O O	['lid']	1	2	"Sentence: To this day , transcriptome analysis has been performed in a rat model of LID [ Neurobiol .
Diseases: lid"	"Sentence: To this day , transcriptome analysis has been performed in a rat model of LID [ Neurobiol .
Diseases:"
3071	Dis . , 17 ( 2004 ) , 219 ] but information regarding the proteome is still lacking .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dis . , 17 ( 2004 ) , 219 ] but information regarding the proteome is still lacking .
Diseases: "	"Sentence: Dis . , 17 ( 2004 ) , 219 ] but information regarding the proteome is still lacking .
Diseases:"
3072	In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6 - hydroxydopamine - lesion rat model of PD treated with saline , L - DOPA or bromocriptine using two - dimensional difference gel electrophoresis and mass spectrometry ( MS ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['pd']	1	1	"Sentence: In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6 - hydroxydopamine - lesion rat model of PD treated with saline , L - DOPA or bromocriptine using two - dimensional difference gel electrophoresis and mass spectrometry ( MS ) .
Diseases: pd"	"Sentence: In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6 - hydroxydopamine - lesion rat model of PD treated with saline , L - DOPA or bromocriptine using two - dimensional difference gel electrophoresis and mass spectrometry ( MS ) .
Diseases:"
3073	Rats treated with L - DOPA were allocated to two groups based on the presence or absence of LID .	O O O O O O O O O O O O O O O O O O B O	['lid']	1	2	"Sentence: Rats treated with L - DOPA were allocated to two groups based on the presence or absence of LID .
Diseases: lid"	"Sentence: Rats treated with L - DOPA were allocated to two groups based on the presence or absence of LID .
Diseases:"
3074	Among the 2000 spots compared for statistical difference , 67 spots were significantly changed in abundance and identified using matrix - assisted laser desorption / ionization time - of - flight MS , atmospheric pressure matrix - assisted laser desorption / ionization and HPLC coupled tandem MS ( LC / MS / MS ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Among the 2000 spots compared for statistical difference , 67 spots were significantly changed in abundance and identified using matrix - assisted laser desorption / ionization time - of - flight MS , atmospheric pressure matrix - assisted laser desorption / ionization and HPLC coupled tandem MS ( LC / MS / MS ) .
Diseases: "	"Sentence: Among the 2000 spots compared for statistical difference , 67 spots were significantly changed in abundance and identified using matrix - assisted laser desorption / ionization time - of - flight MS , atmospheric pressure matrix - assisted laser desorption / ionization and HPLC coupled tandem MS ( LC / MS / MS ) .
Diseases:"
3075	Out of these 67 proteins , LID significantly changed the expression level of five proteins : alphabeta - crystalin , gamma - enolase , guanidoacetate methyltransferase , vinculin , and proteasome alpha - 2 subunit .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['lid']	1	2	"Sentence: Out of these 67 proteins , LID significantly changed the expression level of five proteins : alphabeta - crystalin , gamma - enolase , guanidoacetate methyltransferase , vinculin , and proteasome alpha - 2 subunit .
Diseases: lid"	"Sentence: Out of these 67 proteins , LID significantly changed the expression level of five proteins : alphabeta - crystalin , gamma - enolase , guanidoacetate methyltransferase , vinculin , and proteasome alpha - 2 subunit .
Diseases:"
3076	Complementary techniques such as western immunoblotting and immunohistochemistry were performed to investigate the validity of the data obtained using the proteomic approach .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Complementary techniques such as western immunoblotting and immunohistochemistry were performed to investigate the validity of the data obtained using the proteomic approach .
Diseases: "	"Sentence: Complementary techniques such as western immunoblotting and immunohistochemistry were performed to investigate the validity of the data obtained using the proteomic approach .
Diseases:"
3077	In conclusion , this study provides new insights into the protein changes occurring in LID .	O O O O O O O O O O O O O O B O	['lid']	1	2	"Sentence: In conclusion , this study provides new insights into the protein changes occurring in LID .
Diseases: lid"	"Sentence: In conclusion , this study provides new insights into the protein changes occurring in LID .
Diseases:"
3078	Pseudo - allergic reactions to corticosteroids : diagnosis and alternatives .	O O B I O O O O O O O	['allergic reactions']	1	3	"Sentence: Pseudo - allergic reactions to corticosteroids : diagnosis and alternatives .
Diseases: allergic reactions"	"Sentence: Pseudo - allergic reactions to corticosteroids : diagnosis and alternatives .
Diseases:"
3079	Two patients treated with parenteral paramethasone ( Triniol ) and dexamethasone ( Sedionbel ) are described .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two patients treated with parenteral paramethasone ( Triniol ) and dexamethasone ( Sedionbel ) are described .
Diseases: "	"Sentence: Two patients treated with parenteral paramethasone ( Triniol ) and dexamethasone ( Sedionbel ) are described .
Diseases:"
3080	A few minutes after administration of the drugs , they presented urticaria ( patients 1 and 2 ) and conjunctivitis ( patient 1 ) .	O O O O O O O O O O O B O O O O O O O B O O O O O	['urticaria', 'conjunctivitis']	2	8	"Sentence: A few minutes after administration of the drugs , they presented urticaria ( patients 1 and 2 ) and conjunctivitis ( patient 1 ) .
Diseases: urticaria, conjunctivitis"	"Sentence: A few minutes after administration of the drugs , they presented urticaria ( patients 1 and 2 ) and conjunctivitis ( patient 1 ) .
Diseases:"
3081	The purpose of our study was to determine the cause of the patients ' reactions , the immunological mechanisms involved and whether these patients would be able to tolerate any kind of corticoid .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The purpose of our study was to determine the cause of the patients ' reactions , the immunological mechanisms involved and whether these patients would be able to tolerate any kind of corticoid .
Diseases: "	"Sentence: The purpose of our study was to determine the cause of the patients ' reactions , the immunological mechanisms involved and whether these patients would be able to tolerate any kind of corticoid .
Diseases:"
3082	Clinical examinations and skin , oral and parenteral challenges with different corticosteroids and ELISA tests were performed .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical examinations and skin , oral and parenteral challenges with different corticosteroids and ELISA tests were performed .
Diseases: "	"Sentence: Clinical examinations and skin , oral and parenteral challenges with different corticosteroids and ELISA tests were performed .
Diseases:"
3083	In the two patients , skin and ELISA tests with paramethasone were negative , as was the prick test with each of its excipients .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the two patients , skin and ELISA tests with paramethasone were negative , as was the prick test with each of its excipients .
Diseases: "	"Sentence: In the two patients , skin and ELISA tests with paramethasone were negative , as was the prick test with each of its excipients .
Diseases:"
3084	A single - blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug , and negative with its excipients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A single - blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug , and negative with its excipients .
Diseases: "	"Sentence: A single - blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug , and negative with its excipients .
Diseases:"
3085	We also carried out oral and parenteral challenges with other corticosteroids and found intolerance to some of them .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We also carried out oral and parenteral challenges with other corticosteroids and found intolerance to some of them .
Diseases: "	"Sentence: We also carried out oral and parenteral challenges with other corticosteroids and found intolerance to some of them .
Diseases:"
3086	These results suggest that paramethasone caused pseudoallergic reactions in our patients .	O O O O O O O O O O O O	[]	0	0	"Sentence: These results suggest that paramethasone caused pseudoallergic reactions in our patients .
Diseases: "	"Sentence: These results suggest that paramethasone caused pseudoallergic reactions in our patients .
Diseases:"
3087	Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients ; however , a few of them were tolerated .	O O O O O O B O O O O O O O O O O O O O O	['hypersensitivity']	1	3	"Sentence: Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients ; however , a few of them were tolerated .
Diseases: hypersensitivity"	"Sentence: Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients ; however , a few of them were tolerated .
Diseases:"
3088	The basic mechanisms of those reactions are not yet fully understood .	O O O O O O O O O O O O	[]	0	0	"Sentence: The basic mechanisms of those reactions are not yet fully understood .
Diseases: "	"Sentence: The basic mechanisms of those reactions are not yet fully understood .
Diseases:"
3089	To our knowledge , this is the first report of a pseudo - allergy caused by paramethasone .	O O O O O O O O O O O O O B O O O O	['allergy']	1	2	"Sentence: To our knowledge , this is the first report of a pseudo - allergy caused by paramethasone .
Diseases: allergy"	"Sentence: To our knowledge , this is the first report of a pseudo - allergy caused by paramethasone .
Diseases:"
3090	Valproic acid induced encephalopathy - - 19 new cases in Germany from 1994 to 2003 - - a side effect associated to VPA - therapy not only in young children .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['encephalopathy']	1	3	"Sentence: Valproic acid induced encephalopathy - - 19 new cases in Germany from 1994 to 2003 - - a side effect associated to VPA - therapy not only in young children .
Diseases: encephalopathy"	"Sentence: Valproic acid induced encephalopathy - - 19 new cases in Germany from 1994 to 2003 - - a side effect associated to VPA - therapy not only in young children .
Diseases:"
3091	Valproic acid ( VPA ) is a broad - spectrum antiepileptic drug and is usually well - tolerated .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Valproic acid ( VPA ) is a broad - spectrum antiepileptic drug and is usually well - tolerated .
Diseases: "	"Sentence: Valproic acid ( VPA ) is a broad - spectrum antiepileptic drug and is usually well - tolerated .
Diseases:"
3092	Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , VPA - induced hepatotoxicity and VPA - induced encephalopathy .	O O O O O O O O O O O B O B I I O O O O B O O O O B O	['hepatotoxicity', 'pancreatitis', 'encephalopathy', 'bone marrow suppression']	4	15	"Sentence: Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , VPA - induced hepatotoxicity and VPA - induced encephalopathy .
Diseases: hepatotoxicity, pancreatitis, encephalopathy, bone marrow suppression"	"Sentence: Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , VPA - induced hepatotoxicity and VPA - induced encephalopathy .
Diseases:"
3093	The typical signs of VPA - induced encephalopathy are impaired consciousness , sometimes marked EEG background slowing , increased seizure frequency , with or without hyperammonemia .	O O O O O O O B O B I O O O O O O O O B O O O O O B O	['hyperammonemia', 'encephalopathy', 'impaired consciousness', 'seizure']	4	13	"Sentence: The typical signs of VPA - induced encephalopathy are impaired consciousness , sometimes marked EEG background slowing , increased seizure frequency , with or without hyperammonemia .
Diseases: hyperammonemia, encephalopathy, impaired consciousness, seizure"	"Sentence: The typical signs of VPA - induced encephalopathy are impaired consciousness , sometimes marked EEG background slowing , increased seizure frequency , with or without hyperammonemia .
Diseases:"
3094	There is still no proof of causative effect of VPA in patients with encephalopathy , but only of an association with an assumed causal relation .	O O O O O O O O O O O O O B O O O O O O O O O O O O	['encephalopathy']	1	3	"Sentence: There is still no proof of causative effect of VPA in patients with encephalopathy , but only of an association with an assumed causal relation .
Diseases: encephalopathy"	"Sentence: There is still no proof of causative effect of VPA in patients with encephalopathy , but only of an association with an assumed causal relation .
Diseases:"
3095	We report 19 patients with VPA - associated encephalopathy in Germany from the years 1994 to 2003 , none of whom had been published previously .	O O O O O O O O B O O O O O O O O O O O O O O O O O	['encephalopathy']	1	3	"Sentence: We report 19 patients with VPA - associated encephalopathy in Germany from the years 1994 to 2003 , none of whom had been published previously .
Diseases: encephalopathy"	"Sentence: We report 19 patients with VPA - associated encephalopathy in Germany from the years 1994 to 2003 , none of whom had been published previously .
Diseases:"
3096	Haemolytic - uraemic syndrome after treatment with metronidazole .	B I I I O O O O O	['haemolytic - uraemic syndrome']	1	9	"Sentence: Haemolytic - uraemic syndrome after treatment with metronidazole .
Diseases: haemolytic - uraemic syndrome"	"Sentence: Haemolytic - uraemic syndrome after treatment with metronidazole .
Diseases:"
3097	This paper describes the clinical features of six children who developed the haemolytic - uraemic syndrome after treatment with metronidazole .	O O O O O O O O O O O O B I I I O O O O O	['haemolytic - uraemic syndrome']	1	9	"Sentence: This paper describes the clinical features of six children who developed the haemolytic - uraemic syndrome after treatment with metronidazole .
Diseases: haemolytic - uraemic syndrome"	"Sentence: This paper describes the clinical features of six children who developed the haemolytic - uraemic syndrome after treatment with metronidazole .
Diseases:"
3098	These children were older and were more likely to have undergone recent bowel surgery than are other children with this condition .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These children were older and were more likely to have undergone recent bowel surgery than are other children with this condition .
Diseases: "	"Sentence: These children were older and were more likely to have undergone recent bowel surgery than are other children with this condition .
Diseases:"
3099	While the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome .	O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O B I I I O	['haemolytic - uraemic syndrome']	1	9	"Sentence: While the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome .
Diseases: haemolytic - uraemic syndrome"	"Sentence: While the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome .
Diseases:"
3100	Risk factors of sensorineural hearing loss in preterm infants .	O O O B I I O O O O	['sensorineural hearing loss']	1	6	"Sentence: Risk factors of sensorineural hearing loss in preterm infants .
Diseases: sensorineural hearing loss"	"Sentence: Risk factors of sensorineural hearing loss in preterm infants .
Diseases:"
3101	Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991 , 8 children ( 1 . 46 % ) developed severe progressive and bilateral sensorineural hearing loss .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	['sensorineural hearing loss']	1	6	"Sentence: Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991 , 8 children ( 1 . 46 % ) developed severe progressive and bilateral sensorineural hearing loss .
Diseases: sensorineural hearing loss"	"Sentence: Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991 , 8 children ( 1 . 46 % ) developed severe progressive and bilateral sensorineural hearing loss .
Diseases:"
3102	Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications .	O O O O O O B I O O O O O O O O O O O O O O O O O O O	['hearing loss']	1	3	"Sentence: Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications .
Diseases: hearing loss"	"Sentence: Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications .
Diseases:"
3103	Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications .	O O O O O O B I O O O O O O O O	['hearing loss']	1	3	"Sentence: Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications .
Diseases: hearing loss"	"Sentence: Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications .
Diseases:"
3104	Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs , particularly aminoglycosides and furosemide .	B O O O O O O O O O O O O B O O O O O O O	['ototoxicity', 'ototoxic']	2	7	"Sentence: Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs , particularly aminoglycosides and furosemide .
Diseases: ototoxicity, ototoxic"	"Sentence: Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs , particularly aminoglycosides and furosemide .
Diseases:"
3105	Finally , we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	['hearing loss']	1	3	"Sentence: Finally , we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe .
Diseases: hearing loss"	"Sentence: Finally , we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe .
Diseases:"
3106	Pharmacokinetic and clinical studies in patients with cimetidine - associated mental confusion .	O O O O O O O O O O O B O	['confusion']	1	2	"Sentence: Pharmacokinetic and clinical studies in patients with cimetidine - associated mental confusion .
Diseases: confusion"	"Sentence: Pharmacokinetic and clinical studies in patients with cimetidine - associated mental confusion .
Diseases:"
3107	15 cases of cimetidine - associated mental confusion have been reported .	O O O O O O O B O O O O	['confusion']	1	2	"Sentence: 15 cases of cimetidine - associated mental confusion have been reported .
Diseases: confusion"	"Sentence: 15 cases of cimetidine - associated mental confusion have been reported .
Diseases:"
3108	In order that this syndrome might be investigated changes in mental status ( M . S . ) were correlated with serum concentrations and renal and hepatic function in 36 patients , 30 patients had no M . S . change on cimetidine and 6 had moderate to severe changes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In order that this syndrome might be investigated changes in mental status ( M . S . ) were correlated with serum concentrations and renal and hepatic function in 36 patients , 30 patients had no M . S . change on cimetidine and 6 had moderate to severe changes .
Diseases: "	"Sentence: In order that this syndrome might be investigated changes in mental status ( M . S . ) were correlated with serum concentrations and renal and hepatic function in 36 patients , 30 patients had no M . S . change on cimetidine and 6 had moderate to severe changes .
Diseases:"
3109	These 6 patients had both renal and liver dysfunction ( P less than 0 . 05 ) , as well as cimetidine trough - concentrations of more than 1 . 25 microgram / ml ( P less than 0 . 05 ) .	O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal and liver dysfunction']	1	5	"Sentence: These 6 patients had both renal and liver dysfunction ( P less than 0 . 05 ) , as well as cimetidine trough - concentrations of more than 1 . 25 microgram / ml ( P less than 0 . 05 ) .
Diseases: renal and liver dysfunction"	"Sentence: These 6 patients had both renal and liver dysfunction ( P less than 0 . 05 ) , as well as cimetidine trough - concentrations of more than 1 . 25 microgram / ml ( P less than 0 . 05 ) .
Diseases:"
3110	The severity of M . S . changes increased as trough - concentrations rose , 5 patients had lumbar puncture .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The severity of M . S . changes increased as trough - concentrations rose , 5 patients had lumbar puncture .
Diseases: "	"Sentence: The severity of M . S . changes increased as trough - concentrations rose , 5 patients had lumbar puncture .
Diseases:"
3111	The cerebrospinal fluid : serum ratio of cimetidine concentrations was 0 . 24 : 1 and indicates that cimetidine passes the blood - brain barrier ; it also raises the possibility that M . S . changes are due to blockade of histamine H2 - receptors in the central nervous system .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The cerebrospinal fluid : serum ratio of cimetidine concentrations was 0 . 24 : 1 and indicates that cimetidine passes the blood - brain barrier ; it also raises the possibility that M . S . changes are due to blockade of histamine H2 - receptors in the central nervous system .
Diseases: "	"Sentence: The cerebrospinal fluid : serum ratio of cimetidine concentrations was 0 . 24 : 1 and indicates that cimetidine passes the blood - brain barrier ; it also raises the possibility that M . S . changes are due to blockade of histamine H2 - receptors in the central nervous system .
Diseases:"
3112	Patients likely to have both raised trough - concentrations and mental confusion are those with both severe renal and hepatic dysfunction .	O O O O O O O O O O O B O O O O O B I I I O	['renal and hepatic dysfunction', 'confusion']	2	8	"Sentence: Patients likely to have both raised trough - concentrations and mental confusion are those with both severe renal and hepatic dysfunction .
Diseases: renal and hepatic dysfunction, confusion"	"Sentence: Patients likely to have both raised trough - concentrations and mental confusion are those with both severe renal and hepatic dysfunction .
Diseases:"
3113	They should be closely observed and should be given reduced doses of cimetidine .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: They should be closely observed and should be given reduced doses of cimetidine .
Diseases: "	"Sentence: They should be closely observed and should be given reduced doses of cimetidine .
Diseases:"
3114	Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis .	O O O O O O O O O O O O B I I I O	['intrahepatic and extrahepatic cholestasis']	1	14	"Sentence: Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis .
Diseases: intrahepatic and extrahepatic cholestasis"	"Sentence: Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis .
Diseases:"
3115	Hepatocyte tight junctions ( TJs ) , the only intercellular barrier between the sinusoidal and the canalicular spaces , play a key role in bile formation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hepatocyte tight junctions ( TJs ) , the only intercellular barrier between the sinusoidal and the canalicular spaces , play a key role in bile formation .
Diseases: "	"Sentence: Hepatocyte tight junctions ( TJs ) , the only intercellular barrier between the sinusoidal and the canalicular spaces , play a key role in bile formation .
Diseases:"
3116	Although hepatocyte TJs are impaired in cholestasis , attempts to localize the precise site of hepatocyte TJ damage by freeze - fracture electron microscopy have produced limited information .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['cholestasis']	1	4	"Sentence: Although hepatocyte TJs are impaired in cholestasis , attempts to localize the precise site of hepatocyte TJ damage by freeze - fracture electron microscopy have produced limited information .
Diseases: cholestasis"	"Sentence: Although hepatocyte TJs are impaired in cholestasis , attempts to localize the precise site of hepatocyte TJ damage by freeze - fracture electron microscopy have produced limited information .
Diseases:"
3117	Recently , several TJ - associated proteins like ZO - 1 and 7H6 have been identified and characterized .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Recently , several TJ - associated proteins like ZO - 1 and 7H6 have been identified and characterized .
Diseases: "	"Sentence: Recently , several TJ - associated proteins like ZO - 1 and 7H6 have been identified and characterized .
Diseases:"
3118	Immunolocalization of 7H6 appears to closely correlate with paracellular permeability .	O O O O O O O O O O O	[]	0	0	"Sentence: Immunolocalization of 7H6 appears to closely correlate with paracellular permeability .
Diseases: "	"Sentence: Immunolocalization of 7H6 appears to closely correlate with paracellular permeability .
Diseases:"
3119	We used rat models of intrahepatic cholestasis by ethinyl estradiol ( EE ) treatment and extrahepatic cholestasis by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .	O O O O O B I O O O O O O O O B I O O O O O O O O O O O O O O O O	['extrahepatic cholestasis', 'intrahepatic cholestasis']	2	17	"Sentence: We used rat models of intrahepatic cholestasis by ethinyl estradiol ( EE ) treatment and extrahepatic cholestasis by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
Diseases: extrahepatic cholestasis, intrahepatic cholestasis"	"Sentence: We used rat models of intrahepatic cholestasis by ethinyl estradiol ( EE ) treatment and extrahepatic cholestasis by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .
Diseases:"
3120	Alterations in hepatocyte TJs were assessed by double - immunolabeling for 7H6 and ZO - 1 using a confocal laser scanning microscope .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Alterations in hepatocyte TJs were assessed by double - immunolabeling for 7H6 and ZO - 1 using a confocal laser scanning microscope .
Diseases: "	"Sentence: Alterations in hepatocyte TJs were assessed by double - immunolabeling for 7H6 and ZO - 1 using a confocal laser scanning microscope .
Diseases:"
3121	In control rats , immunostaining for 7H6 and ZO - 1 colocalized to outline bile canaliculi in a continuous fashion .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In control rats , immunostaining for 7H6 and ZO - 1 colocalized to outline bile canaliculi in a continuous fashion .
Diseases: "	"Sentence: In control rats , immunostaining for 7H6 and ZO - 1 colocalized to outline bile canaliculi in a continuous fashion .
Diseases:"
3122	In contrast , 7H6 and ZO - 1 immunostaining was more discontinuous , outlining the bile canaliculi after BDL .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , 7H6 and ZO - 1 immunostaining was more discontinuous , outlining the bile canaliculi after BDL .
Diseases: "	"Sentence: In contrast , 7H6 and ZO - 1 immunostaining was more discontinuous , outlining the bile canaliculi after BDL .
Diseases:"
3123	Immunostaining for 7H6 , not ZO - 1 , decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunostaining for 7H6 , not ZO - 1 , decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL .
Diseases: "	"Sentence: Immunostaining for 7H6 , not ZO - 1 , decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL .
Diseases:"
3124	After EE treatment , changes in immunostaining for 7H6 and ZO - 1 were similar to those seen in periportal hepatocytes after BDL , but distributed more diffusely throughout the lobule .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After EE treatment , changes in immunostaining for 7H6 and ZO - 1 were similar to those seen in periportal hepatocytes after BDL , but distributed more diffusely throughout the lobule .
Diseases: "	"Sentence: After EE treatment , changes in immunostaining for 7H6 and ZO - 1 were similar to those seen in periportal hepatocytes after BDL , but distributed more diffusely throughout the lobule .
Diseases:"
3125	This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability .
Diseases: "	"Sentence: This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability .
Diseases:"
3126	Long term audiological evaluation of beta - thalassemic patients .	O O O O O B I I O O	['beta - thalassemic']	1	6	"Sentence: Long term audiological evaluation of beta - thalassemic patients .
Diseases: beta - thalassemic"	"Sentence: Long term audiological evaluation of beta - thalassemic patients .
Diseases:"
3127	The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta - thalassemia major .	O O O O O O O O O O O O O O O O B I O O O O O O B I I O O	['hearing loss', 'beta - thalassemia']	2	10	"Sentence: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta - thalassemia major .
Diseases: hearing loss, beta - thalassemia"	"Sentence: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta - thalassemia major .
Diseases:"
3128	METHODS : One hundred and four ( 104 ) patients aged 6 - 35 years ( mean 17 , 2 years ) participated in the study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : One hundred and four ( 104 ) patients aged 6 - 35 years ( mean 17 , 2 years ) participated in the study .
Diseases: "	"Sentence: METHODS : One hundred and four ( 104 ) patients aged 6 - 35 years ( mean 17 , 2 years ) participated in the study .
Diseases:"
3129	All patients were on a regular transfusion - chelation program maintaining a mean hemoglobin level of 9 . 5 gr / dl .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All patients were on a regular transfusion - chelation program maintaining a mean hemoglobin level of 9 . 5 gr / dl .
Diseases: "	"Sentence: All patients were on a regular transfusion - chelation program maintaining a mean hemoglobin level of 9 . 5 gr / dl .
Diseases:"
3130	Subjects were receiving desferrioxamine ( DFO ) chelation treatment with a mean daily dose of 50 - 60 mg / kg , 5 - 6 days a week during the first six years of the study , which was then reduced to 40 - 50 mg / kg for the following eight years .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Subjects were receiving desferrioxamine ( DFO ) chelation treatment with a mean daily dose of 50 - 60 mg / kg , 5 - 6 days a week during the first six years of the study , which was then reduced to 40 - 50 mg / kg for the following eight years .
Diseases: "	"Sentence: Subjects were receiving desferrioxamine ( DFO ) chelation treatment with a mean daily dose of 50 - 60 mg / kg , 5 - 6 days a week during the first six years of the study , which was then reduced to 40 - 50 mg / kg for the following eight years .
Diseases:"
3131	Patients were followed for 8 - 14 years .	O O O O O O O O O	[]	0	0	"Sentence: Patients were followed for 8 - 14 years .
Diseases: "	"Sentence: Patients were followed for 8 - 14 years .
Diseases:"
3132	Overall , 21 out of 104 patients ( 20 . 2 % ) presented with high frequency sensorineural hearing loss ( SNHL ) , either unilateral or bilateral .	O O O O O O O O O O O O O O O O O B I I O B O O O O O O O	['sensorineural hearing loss', 'snhl']	2	9	"Sentence: Overall , 21 out of 104 patients ( 20 . 2 % ) presented with high frequency sensorineural hearing loss ( SNHL ) , either unilateral or bilateral .
Diseases: sensorineural hearing loss, snhl"	"Sentence: Overall , 21 out of 104 patients ( 20 . 2 % ) presented with high frequency sensorineural hearing loss ( SNHL ) , either unilateral or bilateral .
Diseases:"
3133	No ototoxic factor , other than DFO , was present in any of the patients .	O B O O O O O O O O O O O O O O	['ototoxic']	1	3	"Sentence: No ototoxic factor , other than DFO , was present in any of the patients .
Diseases: ototoxic"	"Sentence: No ototoxic factor , other than DFO , was present in any of the patients .
Diseases:"
3134	Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing , however , no statistically significant difference was observed .	O O B O O O O O O O O O O O O O O O O O O O O O O	['snhl']	1	2	"Sentence: Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing , however , no statistically significant difference was observed .
Diseases: snhl"	"Sentence: Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing , however , no statistically significant difference was observed .
Diseases:"
3135	Subjects with SNHL were submitted to DFO reduction or temporary withdrawal .	O O B O O O O O O O O O	['snhl']	1	2	"Sentence: Subjects with SNHL were submitted to DFO reduction or temporary withdrawal .
Diseases: snhl"	"Sentence: Subjects with SNHL were submitted to DFO reduction or temporary withdrawal .
Diseases:"
3136	Following intervention , 7 out of 21 affected patients recovered , 10 remained stable and 4 demonstrated aggravation .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following intervention , 7 out of 21 affected patients recovered , 10 remained stable and 4 demonstrated aggravation .
Diseases: "	"Sentence: Following intervention , 7 out of 21 affected patients recovered , 10 remained stable and 4 demonstrated aggravation .
Diseases:"
3137	The findings are indicative of DFO 's contributing role in the development of hearing impairment .	O O O O O O O O O O O O O B I O	['hearing impairment']	1	3	"Sentence: The findings are indicative of DFO 's contributing role in the development of hearing impairment .
Diseases: hearing impairment"	"Sentence: The findings are indicative of DFO 's contributing role in the development of hearing impairment .
Diseases:"
3138	Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O B I O	['hearing impairment', 'thalassemic']	2	8	"Sentence: Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment .
Diseases: hearing impairment, thalassemic"	"Sentence: Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment .
Diseases:"
3139	Design and analysis of the HYPREN - trial : safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure .	O O O O O O O O O O O O O O O O O O O O O O B I I O	['congestive heart failure']	1	5	"Sentence: Design and analysis of the HYPREN - trial : safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure .
Diseases: congestive heart failure"	"Sentence: Design and analysis of the HYPREN - trial : safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure .
Diseases:"
3140	Since the introduction of angiotensin converting enzyme ( ACE ) inhibitors into the adjunctive treatment of patients with congestive heart failure , cases of severe hypotension , especially on the first day of treatment , have occasionally been reported .	O O O O O O O O O O O O O O O O O O B I I O O O O B O O O O O O O O O O O O O O	['congestive heart failure', 'hypotension']	2	8	"Sentence: Since the introduction of angiotensin converting enzyme ( ACE ) inhibitors into the adjunctive treatment of patients with congestive heart failure , cases of severe hypotension , especially on the first day of treatment , have occasionally been reported .
Diseases: congestive heart failure, hypotension"	"Sentence: Since the introduction of angiotensin converting enzyme ( ACE ) inhibitors into the adjunctive treatment of patients with congestive heart failure , cases of severe hypotension , especially on the first day of treatment , have occasionally been reported .
Diseases:"
3141	To assess the safety of the ACE inhibitor enalapril a multicenter , randomized , prazosin - controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['hypotension']	1	3	"Sentence: To assess the safety of the ACE inhibitor enalapril a multicenter , randomized , prazosin - controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment .
Diseases: hypotension"	"Sentence: To assess the safety of the ACE inhibitor enalapril a multicenter , randomized , prazosin - controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment .
Diseases:"
3142	Trial medication was 2 . 5 mg enalapril or 0 . 5 prazosin .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Trial medication was 2 . 5 mg enalapril or 0 . 5 prazosin .
Diseases: "	"Sentence: Trial medication was 2 . 5 mg enalapril or 0 . 5 prazosin .
Diseases:"
3143	Subjects were 1210 inpatients with New York Heart Association ( NYHA ) functional class II and III .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Subjects were 1210 inpatients with New York Heart Association ( NYHA ) functional class II and III .
Diseases: "	"Sentence: Subjects were 1210 inpatients with New York Heart Association ( NYHA ) functional class II and III .
Diseases:"
3144	Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension ( 5 . 2 % ) than the patients who received prazosin ( 12 . 9 % ) .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension ( 5 . 2 % ) than the patients who received prazosin ( 12 . 9 % ) .
Diseases: hypotension"	"Sentence: Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension ( 5 . 2 % ) than the patients who received prazosin ( 12 . 9 % ) .
Diseases:"
3145	All patients recovered .	O O O O	[]	0	0	"Sentence: All patients recovered .
Diseases: "	"Sentence: All patients recovered .
Diseases:"
3146	It was concluded that treatment with enalapril was well tolerated and it is , therefore , unreasonable to restrict the initiation of treatment with enalapril to inpatients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It was concluded that treatment with enalapril was well tolerated and it is , therefore , unreasonable to restrict the initiation of treatment with enalapril to inpatients .
Diseases: "	"Sentence: It was concluded that treatment with enalapril was well tolerated and it is , therefore , unreasonable to restrict the initiation of treatment with enalapril to inpatients .
Diseases:"
3147	Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine - induced anemia and in bone marrow endothelial cells .	O O O O O O O O O O O O B O O O O O O O	['anemia']	1	2	"Sentence: Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine - induced anemia and in bone marrow endothelial cells .
Diseases: anemia"	"Sentence: Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine - induced anemia and in bone marrow endothelial cells .
Diseases:"
3148	Azidothymidine ( AZT ) - induced anemia in mice can be reversed by the administration of IGF - IL - 3 ( fusion protein of insulin - like growth factor II ( IGF II ) and interleukin 3 ) .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: Azidothymidine ( AZT ) - induced anemia in mice can be reversed by the administration of IGF - IL - 3 ( fusion protein of insulin - like growth factor II ( IGF II ) and interleukin 3 ) .
Diseases: anemia"	"Sentence: Azidothymidine ( AZT ) - induced anemia in mice can be reversed by the administration of IGF - IL - 3 ( fusion protein of insulin - like growth factor II ( IGF II ) and interleukin 3 ) .
Diseases:"
3149	Although interleukin 3 ( IL - 3 ) and erythropoietin ( EPO ) are known to act synergistically on hematopoietic cell proliferation in vitro , injection of IGF - IL - 3 and EPO in AZT - treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF - IL - 3 or EPO alone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although interleukin 3 ( IL - 3 ) and erythropoietin ( EPO ) are known to act synergistically on hematopoietic cell proliferation in vitro , injection of IGF - IL - 3 and EPO in AZT - treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF - IL - 3 or EPO alone .
Diseases: "	"Sentence: Although interleukin 3 ( IL - 3 ) and erythropoietin ( EPO ) are known to act synergistically on hematopoietic cell proliferation in vitro , injection of IGF - IL - 3 and EPO in AZT - treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF - IL - 3 or EPO alone .
Diseases:"
3150	We tested the hypothesis that the antagonistic effect of IL - 3 and EPO on erythroid cells may be mediated by endothelial cells .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We tested the hypothesis that the antagonistic effect of IL - 3 and EPO on erythroid cells may be mediated by endothelial cells .
Diseases: "	"Sentence: We tested the hypothesis that the antagonistic effect of IL - 3 and EPO on erythroid cells may be mediated by endothelial cells .
Diseases:"
3151	Bovine liver erythroid cells were cultured on monolayers of human bone marrow endothelial cells previously treated with EPO and IGF - IL - 3 .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Bovine liver erythroid cells were cultured on monolayers of human bone marrow endothelial cells previously treated with EPO and IGF - IL - 3 .
Diseases: "	"Sentence: Bovine liver erythroid cells were cultured on monolayers of human bone marrow endothelial cells previously treated with EPO and IGF - IL - 3 .
Diseases:"
3152	There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre - treated with IGF - IL - 3 and EPO .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre - treated with IGF - IL - 3 and EPO .
Diseases: "	"Sentence: There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre - treated with IGF - IL - 3 and EPO .
Diseases:"
3153	Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL - 3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL - 3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone .
Diseases: "	"Sentence: Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL - 3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone .
Diseases:"
3154	These results suggest that endothelial cells treated simultaneously with EPO and IL - 3 have a negative effect on erythroid cell production .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These results suggest that endothelial cells treated simultaneously with EPO and IL - 3 have a negative effect on erythroid cell production .
Diseases: "	"Sentence: These results suggest that endothelial cells treated simultaneously with EPO and IL - 3 have a negative effect on erythroid cell production .
Diseases:"
3155	Interactive effects of variations in [ Na ] o and [ Ca ] o on rat atrial spontaneous frequency .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Interactive effects of variations in [ Na ] o and [ Ca ] o on rat atrial spontaneous frequency .
Diseases: "	"Sentence: Interactive effects of variations in [ Na ] o and [ Ca ] o on rat atrial spontaneous frequency .
Diseases:"
3156	The effects of varying the extracellular concentrations of Na and Ca ( [ Na ] o and [ Ca ] o ) on both , the spontaneous beating and the negative chronotropic action of verapamil , were studied in the isolated rat atria .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effects of varying the extracellular concentrations of Na and Ca ( [ Na ] o and [ Ca ] o ) on both , the spontaneous beating and the negative chronotropic action of verapamil , were studied in the isolated rat atria .
Diseases: "	"Sentence: The effects of varying the extracellular concentrations of Na and Ca ( [ Na ] o and [ Ca ] o ) on both , the spontaneous beating and the negative chronotropic action of verapamil , were studied in the isolated rat atria .
Diseases:"
3157	Basal frequency ( BF ) evaluated by surface electrogram was 223 + / - 4 beats / min .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Basal frequency ( BF ) evaluated by surface electrogram was 223 + / - 4 beats / min .
Diseases: "	"Sentence: Basal frequency ( BF ) evaluated by surface electrogram was 223 + / - 4 beats / min .
Diseases:"
3158	in control Krebs - Ringer containing 137 mM Na and 1 . 35 mM Ca ( N ) .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: in control Krebs - Ringer containing 137 mM Na and 1 . 35 mM Ca ( N ) .
Diseases: "	"Sentence: in control Krebs - Ringer containing 137 mM Na and 1 . 35 mM Ca ( N ) .
Diseases:"
3159	It decreased by 16 + / - 3 % by lowering [ Na ] o to 78 mM ( LNa ) , 23 + / - 2 % by lowering simultaneously [ Na ] o to 78 mM and [ Ca ] o to 0 . 675 mM ( LNa + LCa ) and 31 + / - 5 % by lowering [ Na ] o to 78 mM plus increasing [ Ca ] o to 3 . 6 mM ( LNa + HCa ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It decreased by 16 + / - 3 % by lowering [ Na ] o to 78 mM ( LNa ) , 23 + / - 2 % by lowering simultaneously [ Na ] o to 78 mM and [ Ca ] o to 0 . 675 mM ( LNa + LCa ) and 31 + / - 5 % by lowering [ Na ] o to 78 mM plus increasing [ Ca ] o to 3 . 6 mM ( LNa + HCa ) .
Diseases: "	"Sentence: It decreased by 16 + / - 3 % by lowering [ Na ] o to 78 mM ( LNa ) , 23 + / - 2 % by lowering simultaneously [ Na ] o to 78 mM and [ Ca ] o to 0 . 675 mM ( LNa + LCa ) and 31 + / - 5 % by lowering [ Na ] o to 78 mM plus increasing [ Ca ] o to 3 . 6 mM ( LNa + HCa ) .
Diseases:"
3160	At normal [ Na ] o , decrease ( 0 . 675 mM ) or increase ( 3 . 6 mM ) of [ Ca ] o did not modify BF ; a reduction of ten times ( 0 . 135 mM of normal [ Ca ] o was effective to reduce BF by 40 + / - 13 % .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At normal [ Na ] o , decrease ( 0 . 675 mM ) or increase ( 3 . 6 mM ) of [ Ca ] o did not modify BF ; a reduction of ten times ( 0 . 135 mM of normal [ Ca ] o was effective to reduce BF by 40 + / - 13 % .
Diseases: "	"Sentence: At normal [ Na ] o , decrease ( 0 . 675 mM ) or increase ( 3 . 6 mM ) of [ Ca ] o did not modify BF ; a reduction of ten times ( 0 . 135 mM of normal [ Ca ] o was effective to reduce BF by 40 + / - 13 % .
Diseases:"
3161	All negative chronotropic effects were BF - dependent .	O O O O O O O O O	[]	0	0	"Sentence: All negative chronotropic effects were BF - dependent .
Diseases: "	"Sentence: All negative chronotropic effects were BF - dependent .
Diseases:"
3162	Dose - dependent bradycardia induced by verapamil was potentiated by LNa , LCa , and HCa .	O O O B O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: Dose - dependent bradycardia induced by verapamil was potentiated by LNa , LCa , and HCa .
Diseases: bradycardia"	"Sentence: Dose - dependent bradycardia induced by verapamil was potentiated by LNa , LCa , and HCa .
Diseases:"
3163	Independent but not additive effects of Na and Ca are shown by decreases in the values of [ verapamil ] o needed to reduce BF by 30 % ( IC30 ) with the following order of inhibitory potency : LNa > LCa > HCa > N , resulting LNa + HCa similar to LNa .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Independent but not additive effects of Na and Ca are shown by decreases in the values of [ verapamil ] o needed to reduce BF by 30 % ( IC30 ) with the following order of inhibitory potency : LNa > LCa > HCa > N , resulting LNa + HCa similar to LNa .
Diseases: "	"Sentence: Independent but not additive effects of Na and Ca are shown by decreases in the values of [ verapamil ] o needed to reduce BF by 30 % ( IC30 ) with the following order of inhibitory potency : LNa > LCa > HCa > N , resulting LNa + HCa similar to LNa .
Diseases:"
3164	The [ verapamil ] o that arrested atrial beating ( AC ) was also potentiated with the order LNa = LNa + LCa = LNa + HCa = LCa > HCa =	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The [ verapamil ] o that arrested atrial beating ( AC ) was also potentiated with the order LNa = LNa + LCa = LNa + HCa = LCa > HCa =
Diseases: "	"Sentence: The [ verapamil ] o that arrested atrial beating ( AC ) was also potentiated with the order LNa = LNa + LCa = LNa + HCa = LCa > HCa =
Diseases:"
3165	N .	O O	[]	0	0	"Sentence: N .
Diseases: "	"Sentence: N .
Diseases:"
3166	The results indicate that rat atrial spontaneous beating is more dependent on [ Na ] o than on [ Ca ] o in a range of + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results indicate that rat atrial spontaneous beating is more dependent on [ Na ] o than on [ Ca ] o in a range of + / -
Diseases: "	"Sentence: The results indicate that rat atrial spontaneous beating is more dependent on [ Na ] o than on [ Ca ] o in a range of + / -
Diseases:"
3167	50 % of their normal concentration .	O O O O O O O	[]	0	0	"Sentence: 50 % of their normal concentration .
Diseases: "	"Sentence: 50 % of their normal concentration .
Diseases:"
3168	Also the enhancement of verapamil effects on atrial beating was more pronounced at LNa than at LCa . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Also the enhancement of verapamil effects on atrial beating was more pronounced at LNa than at LCa . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: "	"Sentence: Also the enhancement of verapamil effects on atrial beating was more pronounced at LNa than at LCa . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
3169	Sodium status influences chronic amphotericin B nephrotoxicity in rats .	O O O O O O B O O O	['nephrotoxicity']	1	4	"Sentence: Sodium status influences chronic amphotericin B nephrotoxicity in rats .
Diseases: nephrotoxicity"	"Sentence: Sodium status influences chronic amphotericin B nephrotoxicity in rats .
Diseases:"
3170	The nephrotoxic potential of amphotericin B ( 5 mg / kg per day intraperitoneally for 3 weeks ) has been investigated in salt - depleted , normal - salt , and salt - loaded rats .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: The nephrotoxic potential of amphotericin B ( 5 mg / kg per day intraperitoneally for 3 weeks ) has been investigated in salt - depleted , normal - salt , and salt - loaded rats .
Diseases: nephrotoxic"	"Sentence: The nephrotoxic potential of amphotericin B ( 5 mg / kg per day intraperitoneally for 3 weeks ) has been investigated in salt - depleted , normal - salt , and salt - loaded rats .
Diseases:"
3171	In salt - depleted rats , amphotericin B decreased creatinine clearance linearly with time , with an 85 % reduction by week 3 .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In salt - depleted rats , amphotericin B decreased creatinine clearance linearly with time , with an 85 % reduction by week 3 .
Diseases: "	"Sentence: In salt - depleted rats , amphotericin B decreased creatinine clearance linearly with time , with an 85 % reduction by week 3 .
Diseases:"
3172	In contrast , in normal - salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3 , and in salt - loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43 % at week 3 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , in normal - salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3 , and in salt - loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43 % at week 3 .
Diseases: "	"Sentence: In contrast , in normal - salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3 , and in salt - loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43 % at week 3 .
Diseases:"
3173	All rats in the sodium - depleted group had histopathological evidence of patchy tubular cytoplasmic degeneration in tubules that was not observed in any normal - salt or salt - loaded rat .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All rats in the sodium - depleted group had histopathological evidence of patchy tubular cytoplasmic degeneration in tubules that was not observed in any normal - salt or salt - loaded rat .
Diseases: "	"Sentence: All rats in the sodium - depleted group had histopathological evidence of patchy tubular cytoplasmic degeneration in tubules that was not observed in any normal - salt or salt - loaded rat .
Diseases:"
3174	Concentrations of amphotericin B in plasma were not significantly different among the three groups at any time during the study .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Concentrations of amphotericin B in plasma were not significantly different among the three groups at any time during the study .
Diseases: "	"Sentence: Concentrations of amphotericin B in plasma were not significantly different among the three groups at any time during the study .
Diseases:"
3175	However , at the end of 3 weeks , amphotericin B levels in the kidneys and liver were significantly higher in salt - depleted and normal - salt rats than those in salt - loaded rats , with plasma / kidney ratios of 21 , 14 , and 8 in salt - depleted , normal - salt , and salt - loaded rats , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , at the end of 3 weeks , amphotericin B levels in the kidneys and liver were significantly higher in salt - depleted and normal - salt rats than those in salt - loaded rats , with plasma / kidney ratios of 21 , 14 , and 8 in salt - depleted , normal - salt , and salt - loaded rats , respectively .
Diseases: "	"Sentence: However , at the end of 3 weeks , amphotericin B levels in the kidneys and liver were significantly higher in salt - depleted and normal - salt rats than those in salt - loaded rats , with plasma / kidney ratios of 21 , 14 , and 8 in salt - depleted , normal - salt , and salt - loaded rats , respectively .
Diseases:"
3176	In conclusion , reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In conclusion , reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats .
Diseases: "	"Sentence: In conclusion , reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats .
Diseases:"
3177	Reversible inferior colliculus lesion in metronidazole - induced encephalopathy : magnetic resonance findings on diffusion - weighted and fluid attenuated inversion recovery imaging .	O B I I O O O O B O O O O O O O O O O O O O O O	['inferior colliculus lesion', 'encephalopathy']	2	12	"Sentence: Reversible inferior colliculus lesion in metronidazole - induced encephalopathy : magnetic resonance findings on diffusion - weighted and fluid attenuated inversion recovery imaging .
Diseases: inferior colliculus lesion, encephalopathy"	"Sentence: Reversible inferior colliculus lesion in metronidazole - induced encephalopathy : magnetic resonance findings on diffusion - weighted and fluid attenuated inversion recovery imaging .
Diseases:"
3178	This is to present reversible inferior colliculus lesions in metronidazole - induced encephalopathy , to focus on the diffusion - weighted imaging ( DWI ) and fluid attenuated inversion recovery ( FLAIR ) imaging .	O O O O O B I I O O O O B O O O O O O O O O O O O O O O O O O O O O O	['encephalopathy', 'inferior colliculus lesions']	2	9	"Sentence: This is to present reversible inferior colliculus lesions in metronidazole - induced encephalopathy , to focus on the diffusion - weighted imaging ( DWI ) and fluid attenuated inversion recovery ( FLAIR ) imaging .
Diseases: encephalopathy, inferior colliculus lesions"	"Sentence: This is to present reversible inferior colliculus lesions in metronidazole - induced encephalopathy , to focus on the diffusion - weighted imaging ( DWI ) and fluid attenuated inversion recovery ( FLAIR ) imaging .
Diseases:"
3179	MATERIALS AND METHODS : From November 2005 to September 2007 , 8 patients ( 5 men and 3 women ) were diagnosed as having metronidazole - induced encephalopathy ( age range ; 43 - 78 years ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['encephalopathy']	1	3	"Sentence: MATERIALS AND METHODS : From November 2005 to September 2007 , 8 patients ( 5 men and 3 women ) were diagnosed as having metronidazole - induced encephalopathy ( age range ; 43 - 78 years ) .
Diseases: encephalopathy"	"Sentence: MATERIALS AND METHODS : From November 2005 to September 2007 , 8 patients ( 5 men and 3 women ) were diagnosed as having metronidazole - induced encephalopathy ( age range ; 43 - 78 years ) .
Diseases:"
3180	They had been taking metronidazole ( total dosage , 45 - 120 g ; duration , 30 days to 2 months ) to treat the infection in various organs .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['infection']	1	2	"Sentence: They had been taking metronidazole ( total dosage , 45 - 120 g ; duration , 30 days to 2 months ) to treat the infection in various organs .
Diseases: infection"	"Sentence: They had been taking metronidazole ( total dosage , 45 - 120 g ; duration , 30 days to 2 months ) to treat the infection in various organs .
Diseases:"
3181	Initial brain magnetic resonance imaging ( MRI ) were obtained after the hospitalization , including DWI ( 8 / 8 ) , apparent diffusion coefficient ( ADC ) map ( 4 / 8 ) , FLAIR ( 7 / 8 ) , and T2 - weighted image ( 8 / 8 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Initial brain magnetic resonance imaging ( MRI ) were obtained after the hospitalization , including DWI ( 8 / 8 ) , apparent diffusion coefficient ( ADC ) map ( 4 / 8 ) , FLAIR ( 7 / 8 ) , and T2 - weighted image ( 8 / 8 ) .
Diseases: "	"Sentence: Initial brain magnetic resonance imaging ( MRI ) were obtained after the hospitalization , including DWI ( 8 / 8 ) , apparent diffusion coefficient ( ADC ) map ( 4 / 8 ) , FLAIR ( 7 / 8 ) , and T2 - weighted image ( 8 / 8 ) .
Diseases:"
3182	Follow - up MRIs were performed on 5 patients from third to 14th days after discontinuation of metronidazole administration .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Follow - up MRIs were performed on 5 patients from third to 14th days after discontinuation of metronidazole administration .
Diseases: "	"Sentence: Follow - up MRIs were performed on 5 patients from third to 14th days after discontinuation of metronidazole administration .
Diseases:"
3183	Findings of initial and follow - up MRIs were retrospectively evaluated by 2 neuroradiologists by consensus , to analyze the presence of abnormal signal intensities , their locations , and signal changes on follow - up images .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Findings of initial and follow - up MRIs were retrospectively evaluated by 2 neuroradiologists by consensus , to analyze the presence of abnormal signal intensities , their locations , and signal changes on follow - up images .
Diseases: "	"Sentence: Findings of initial and follow - up MRIs were retrospectively evaluated by 2 neuroradiologists by consensus , to analyze the presence of abnormal signal intensities , their locations , and signal changes on follow - up images .
Diseases:"
3184	Initial MRIs showed abnormal high signal intensities on DWI and FLAIR ( or T2 - weighted image ) at the dentate nucleus ( 8 / 8 ) , inferior colliculus ( 6 / 8 ) , corpus callosum ( 2 / 8 ) , pons ( 2 / 8 ) , medulla ( 1 / 8 ) , and bilateral cerebral white matter ( 1 / 8 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Initial MRIs showed abnormal high signal intensities on DWI and FLAIR ( or T2 - weighted image ) at the dentate nucleus ( 8 / 8 ) , inferior colliculus ( 6 / 8 ) , corpus callosum ( 2 / 8 ) , pons ( 2 / 8 ) , medulla ( 1 / 8 ) , and bilateral cerebral white matter ( 1 / 8 ) .
Diseases: "	"Sentence: Initial MRIs showed abnormal high signal intensities on DWI and FLAIR ( or T2 - weighted image ) at the dentate nucleus ( 8 / 8 ) , inferior colliculus ( 6 / 8 ) , corpus callosum ( 2 / 8 ) , pons ( 2 / 8 ) , medulla ( 1 / 8 ) , and bilateral cerebral white matter ( 1 / 8 ) .
Diseases:"
3185	High - signal intensity lesions on DWI tended to show low signal intensity on ADC map ( 3 / 4 ) , but in one patient , high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: High - signal intensity lesions on DWI tended to show low signal intensity on ADC map ( 3 / 4 ) , but in one patient , high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map .
Diseases: "	"Sentence: High - signal intensity lesions on DWI tended to show low signal intensity on ADC map ( 3 / 4 ) , but in one patient , high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map .
Diseases:"
3186	All the lesions in dentate , inferior colliculus , pons , and medullas had been resolved completely on follow - up MRIs in 5 patients , but in 1 patient of them , corpus callosal lesion persisted .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O	['callosal lesion']	1	4	"Sentence: All the lesions in dentate , inferior colliculus , pons , and medullas had been resolved completely on follow - up MRIs in 5 patients , but in 1 patient of them , corpus callosal lesion persisted .
Diseases: callosal lesion"	"Sentence: All the lesions in dentate , inferior colliculus , pons , and medullas had been resolved completely on follow - up MRIs in 5 patients , but in 1 patient of them , corpus callosal lesion persisted .
Diseases:"
3187	CONCLUSIONS : Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole - induced encephalopathy , next to the dentate nucleus involvement .	O O O B I I O O O O O O O O O O B O O O O O O O O	['encephalopathy', 'inferior colliculus lesions']	2	9	"Sentence: CONCLUSIONS : Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole - induced encephalopathy , next to the dentate nucleus involvement .
Diseases: encephalopathy, inferior colliculus lesions"	"Sentence: CONCLUSIONS : Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole - induced encephalopathy , next to the dentate nucleus involvement .
Diseases:"
3188	Comparison of the respiratory effects of i . v .	O O O O O O O O O O	[]	0	0	"Sentence: Comparison of the respiratory effects of i . v .
Diseases: "	"Sentence: Comparison of the respiratory effects of i . v .
Diseases:"
3189	infusions of morphine and regional analgesia by extradural block .	O O O O O O O O O O	[]	0	0	"Sentence: infusions of morphine and regional analgesia by extradural block .
Diseases: "	"Sentence: infusions of morphine and regional analgesia by extradural block .
Diseases:"
3190	The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i . v .	O O O O O B O O O O O O O O O O O O	['apnoea']	1	4	"Sentence: The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i . v .
Diseases: apnoea"	"Sentence: The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i . v .
Diseases:"
3191	infusion of morphine ( mean 73 . 6 mg ) and five patients receiving a continuous extradural infusion of 0 . 25 % bupivacaine ( mean 192 mg ) in the 24 - h period following upper abdominal surgery .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: infusion of morphine ( mean 73 . 6 mg ) and five patients receiving a continuous extradural infusion of 0 . 25 % bupivacaine ( mean 192 mg ) in the 24 - h period following upper abdominal surgery .
Diseases: "	"Sentence: infusion of morphine ( mean 73 . 6 mg ) and five patients receiving a continuous extradural infusion of 0 . 25 % bupivacaine ( mean 192 mg ) in the 24 - h period following upper abdominal surgery .
Diseases:"
3192	Monitoring consisted of airflow detection by a carbon dioxide analyser , chest wall movement detected by pneumatic capsules , and continuous electrocardiograph recorded with a Holter ambulatory monitor .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Monitoring consisted of airflow detection by a carbon dioxide analyser , chest wall movement detected by pneumatic capsules , and continuous electrocardiograph recorded with a Holter ambulatory monitor .
Diseases: "	"Sentence: Monitoring consisted of airflow detection by a carbon dioxide analyser , chest wall movement detected by pneumatic capsules , and continuous electrocardiograph recorded with a Holter ambulatory monitor .
Diseases:"
3193	Both obstructive ( P less than 0 . 05 ) and central apnoea ( P less than 0 . 05 ) occurred more frequently in patients who had a morphine infusion .	O B I I I I I I I I I I I O O O O O O O O O O O O O O O O O O O	['obstructive ( p less than 0 . 05 ) and central apnoea']	1	17	"Sentence: Both obstructive ( P less than 0 . 05 ) and central apnoea ( P less than 0 . 05 ) occurred more frequently in patients who had a morphine infusion .
Diseases: obstructive ( p less than 0 . 05 ) and central apnoea"	"Sentence: Both obstructive ( P less than 0 . 05 ) and central apnoea ( P less than 0 . 05 ) occurred more frequently in patients who had a morphine infusion .
Diseases:"
3194	There was also a higher incidence of tachyarrhythmias ( P less than 0 . 05 ) and ventricular ectopic beats ( P less than 0 . 05 ) in the morphine infusion group .	O O O O O O O B O O O O O O O O O B I I O O O O O O O O O O O O O O	['tachyarrhythmias', 'ventricular ectopic beats']	2	12	"Sentence: There was also a higher incidence of tachyarrhythmias ( P less than 0 . 05 ) and ventricular ectopic beats ( P less than 0 . 05 ) in the morphine infusion group .
Diseases: tachyarrhythmias, ventricular ectopic beats"	"Sentence: There was also a higher incidence of tachyarrhythmias ( P less than 0 . 05 ) and ventricular ectopic beats ( P less than 0 . 05 ) in the morphine infusion group .
Diseases:"
3195	Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages .	O O O O O O O B O O O B O	['epileptic', 'overdosages']	2	7	"Sentence: Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages .
Diseases: epileptic, overdosages"	"Sentence: Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages .
Diseases:"
3196	The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication .	O O O O O O O O O O O O O O B I O O O O O O O O	['cerebellar atrophy']	1	6	"Sentence: The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication .
Diseases: cerebellar atrophy"	"Sentence: The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication .
Diseases:"
3197	Five females and 6 males , 21 - 59 years of age , were examined with a 1 . 5 - T whole - body system using a circular polarized head coil .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Five females and 6 males , 21 - 59 years of age , were examined with a 1 . 5 - T whole - body system using a circular polarized head coil .
Diseases: "	"Sentence: Five females and 6 males , 21 - 59 years of age , were examined with a 1 . 5 - T whole - body system using a circular polarized head coil .
Diseases:"
3198	Conventional spin echo images were acquired in the sagittal and transverse orientation .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Conventional spin echo images were acquired in the sagittal and transverse orientation .
Diseases: "	"Sentence: Conventional spin echo images were acquired in the sagittal and transverse orientation .
Diseases:"
3199	In addition , we performed a high - resolution 3D gradient echo , T1 - weighted sequences at a 1 - mm slice thickness .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , we performed a high - resolution 3D gradient echo , T1 - weighted sequences at a 1 - mm slice thickness .
Diseases: "	"Sentence: In addition , we performed a high - resolution 3D gradient echo , T1 - weighted sequences at a 1 - mm slice thickness .
Diseases:"
3200	The images were subsequently processed to obtain volumetric data for the cerebellum .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The images were subsequently processed to obtain volumetric data for the cerebellum .
Diseases: "	"Sentence: The images were subsequently processed to obtain volumetric data for the cerebellum .
Diseases:"
3201	Cerebellar volume for the patient group ranged between 67 . 66 and 131 . 08 ml ( mean 108 . 9 ml ) .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cerebellar volume for the patient group ranged between 67 . 66 and 131 . 08 ml ( mean 108 . 9 ml ) .
Diseases: "	"Sentence: Cerebellar volume for the patient group ranged between 67 . 66 and 131 . 08 ml ( mean 108 . 9 ml ) .
Diseases:"
3202	In addition 3D gradient echo data sets from 10 healthy male and 10 healthy female age - matched volunteers were used to compare cerebellar volumes .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition 3D gradient echo data sets from 10 healthy male and 10 healthy female age - matched volunteers were used to compare cerebellar volumes .
Diseases: "	"Sentence: In addition 3D gradient echo data sets from 10 healthy male and 10 healthy female age - matched volunteers were used to compare cerebellar volumes .
Diseases:"
3203	Using linear regression we found that no correlation exists between seizure duration , elevation of phenytoin serum levels and cerebellar volume .	O O O O O O O O O O B O O O O O O O O O O O	['seizure']	1	3	"Sentence: Using linear regression we found that no correlation exists between seizure duration , elevation of phenytoin serum levels and cerebellar volume .
Diseases: seizure"	"Sentence: Using linear regression we found that no correlation exists between seizure duration , elevation of phenytoin serum levels and cerebellar volume .
Diseases:"
3204	However , multiple regression for the daily dosage , duration of phenytoin treatment and cerebellar volume revealed a correlation of these parameters .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , multiple regression for the daily dosage , duration of phenytoin treatment and cerebellar volume revealed a correlation of these parameters .
Diseases: "	"Sentence: However , multiple regression for the daily dosage , duration of phenytoin treatment and cerebellar volume revealed a correlation of these parameters .
Diseases:"
3205	We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients .	O O O O B O O O O O B I O O O O O O O O O O O O B I O O O O O	['cerebellar atrophy', 'overdosage']	2	10	"Sentence: We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients .
Diseases: cerebellar atrophy, overdosage"	"Sentence: We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients .
Diseases:"
3206	Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders .	O O O O O O O O O O O O O B I O	['cerebellar disorders']	1	5	"Sentence: Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders .
Diseases: cerebellar disorders"	"Sentence: Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders .
Diseases:"
3207	Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin - induced cardiomyopathy rats , and their relationship with echocardiographic and histological findings .	O O O O O O O O O O O B I O O O O B O O O O O O O O O O O	['myocardial damage', 'cardiomyopathy']	2	9	"Sentence: Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin - induced cardiomyopathy rats , and their relationship with echocardiographic and histological findings .
Diseases: myocardial damage, cardiomyopathy"	"Sentence: Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin - induced cardiomyopathy rats , and their relationship with echocardiographic and histological findings .
Diseases:"
3208	Cardiac troponins I ( cTnI ) and T ( cTnT ) have been shown to be highly sensitive and specific markers of myocardial cell injury .	O O O O O O O O O O O O O O O O O O O O O O B I I O	['myocardial cell injury']	1	5	"Sentence: Cardiac troponins I ( cTnI ) and T ( cTnT ) have been shown to be highly sensitive and specific markers of myocardial cell injury .
Diseases: myocardial cell injury"	"Sentence: Cardiac troponins I ( cTnI ) and T ( cTnT ) have been shown to be highly sensitive and specific markers of myocardial cell injury .
Diseases:"
3209	We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ( DOX ) - induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .	O O O O O O O O O O O O O B I O O O O O O O O O O O B O O O O O O O O O O O O O O O B I O O O O O O O O O O	['myocardial damage', 'cardiomyopathy', 'cardiac disorders']	3	12	"Sentence: We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ( DOX ) - induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
Diseases: myocardial damage, cardiomyopathy, cardiac disorders"	"Sentence: We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ( DOX ) - induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .
Diseases:"
3210	Thirty - five Wistar rats were given 1 . 5 mg / kg DOX , i . v .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty - five Wistar rats were given 1 . 5 mg / kg DOX , i . v .
Diseases: "	"Sentence: Thirty - five Wistar rats were given 1 . 5 mg / kg DOX , i . v .
Diseases:"
3211	, weekly for up to 8 weeks for a total cumulative dose of 12 mg / kg BW .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: , weekly for up to 8 weeks for a total cumulative dose of 12 mg / kg BW .
Diseases: "	"Sentence: , weekly for up to 8 weeks for a total cumulative dose of 12 mg / kg BW .
Diseases:"
3212	Ten rats received saline as a control group .	O O O O O O O O O	[]	0	0	"Sentence: Ten rats received saline as a control group .
Diseases: "	"Sentence: Ten rats received saline as a control group .
Diseases:"
3213	cTnI was measured with Access ( R )	O O O O O O O O	[]	0	0	"Sentence: cTnI was measured with Access ( R )
Diseases: "	"Sentence: cTnI was measured with Access ( R )
Diseases:"
3214	( ng / ml ) and a research immunoassay ( pg / ml ) , and compared with cTnT , CK - MB mass and CK .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ( ng / ml ) and a research immunoassay ( pg / ml ) , and compared with cTnT , CK - MB mass and CK .
Diseases: "	"Sentence: ( ng / ml ) and a research immunoassay ( pg / ml ) , and compared with cTnT , CK - MB mass and CK .
Diseases:"
3215	By using transthoracic echocardiography , anterior and posterior wall thickness , LV diameters and LV fractional shortening ( FS ) were measured in all rats before DOX or saline , and at weeks 6 and 9 after treatment in all surviving rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: By using transthoracic echocardiography , anterior and posterior wall thickness , LV diameters and LV fractional shortening ( FS ) were measured in all rats before DOX or saline , and at weeks 6 and 9 after treatment in all surviving rats .
Diseases: "	"Sentence: By using transthoracic echocardiography , anterior and posterior wall thickness , LV diameters and LV fractional shortening ( FS ) were measured in all rats before DOX or saline , and at weeks 6 and 9 after treatment in all surviving rats .
Diseases:"
3216	Histology was performed in DOX - rats at 6 and 9 weeks after the last DOX dose and in all controls .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Histology was performed in DOX - rats at 6 and 9 weeks after the last DOX dose and in all controls .
Diseases: "	"Sentence: Histology was performed in DOX - rats at 6 and 9 weeks after the last DOX dose and in all controls .
Diseases:"
3217	RESULTS : Eighteen of the DOX rats died prematurely of general toxicity during the 9 - week period .	O O O O O O O O O O O B O O O O O O O	['toxicity']	1	2	"Sentence: RESULTS : Eighteen of the DOX rats died prematurely of general toxicity during the 9 - week period .
Diseases: toxicity"	"Sentence: RESULTS : Eighteen of the DOX rats died prematurely of general toxicity during the 9 - week period .
Diseases:"
3218	End - diastolic ( ED ) and end - systolic ( ES ) LV diameters / BW significantly increased , whereas LV FS was decreased after 9 weeks in the DOX group ( p < 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: End - diastolic ( ED ) and end - systolic ( ES ) LV diameters / BW significantly increased , whereas LV FS was decreased after 9 weeks in the DOX group ( p < 0 . 001 ) .
Diseases: "	"Sentence: End - diastolic ( ED ) and end - systolic ( ES ) LV diameters / BW significantly increased , whereas LV FS was decreased after 9 weeks in the DOX group ( p < 0 . 001 ) .
Diseases:"
3219	These parameters remained unchanged in controls .	O O O O O O O	[]	0	0	"Sentence: These parameters remained unchanged in controls .
Diseases: "	"Sentence: These parameters remained unchanged in controls .
Diseases:"
3220	Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis .	O O O O O O O O O O O O O O O O O B O	['fibrosis']	1	3	"Sentence: Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis .
Diseases: fibrosis"	"Sentence: Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis .
Diseases:"
3221	In 7 of the 18 rats , degeneration and myocyte vacuolisation were found .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 7 of the 18 rats , degeneration and myocyte vacuolisation were found .
Diseases: "	"Sentence: In 7 of the 18 rats , degeneration and myocyte vacuolisation were found .
Diseases:"
3222	Only five of the controls exhibited evidence of very slight perivascular fibrosis .	O O O O O O O O O O O B O	['fibrosis']	1	3	"Sentence: Only five of the controls exhibited evidence of very slight perivascular fibrosis .
Diseases: fibrosis"	"Sentence: Only five of the controls exhibited evidence of very slight perivascular fibrosis .
Diseases:"
3223	A significant rise in cTnT was found in DOX rats after cumulative doses of 7 . 5 and 12 mg / kg in comparison with baseline ( p < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A significant rise in cTnT was found in DOX rats after cumulative doses of 7 . 5 and 12 mg / kg in comparison with baseline ( p < 0 . 05 ) .
Diseases: "	"Sentence: A significant rise in cTnT was found in DOX rats after cumulative doses of 7 . 5 and 12 mg / kg in comparison with baseline ( p < 0 . 05 ) .
Diseases:"
3224	cTnT found in rats after 12 mg / kg were significantly greater than that found after 7 . 5 mg / kg DOX .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: cTnT found in rats after 12 mg / kg were significantly greater than that found after 7 . 5 mg / kg DOX .
Diseases: "	"Sentence: cTnT found in rats after 12 mg / kg were significantly greater than that found after 7 . 5 mg / kg DOX .
Diseases:"
3225	Maximal cTnI ( pg / ml ) and cTnT levels were significantly increased in DOX rats compared with controls ( p = 0 . 006 , 0 . 007 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Maximal cTnI ( pg / ml ) and cTnT levels were significantly increased in DOX rats compared with controls ( p = 0 . 006 , 0 . 007 ) .
Diseases: "	"Sentence: Maximal cTnI ( pg / ml ) and cTnT levels were significantly increased in DOX rats compared with controls ( p = 0 . 006 , 0 . 007 ) .
Diseases:"
3226	cTnI ( ng / ml ) , CK - MB mass and CK remained unchanged in DOX rats compared with controls .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: cTnI ( ng / ml ) , CK - MB mass and CK remained unchanged in DOX rats compared with controls .
Diseases: "	"Sentence: cTnI ( ng / ml ) , CK - MB mass and CK remained unchanged in DOX rats compared with controls .
Diseases:"
3227	All markers remained stable in controls .	O O O O O O O	[]	0	0	"Sentence: All markers remained stable in controls .
Diseases: "	"Sentence: All markers remained stable in controls .
Diseases:"
3228	Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters / BW ( r = 0 . 81 and 0 . 65 ; p < 0 . 0001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters / BW ( r = 0 . 81 and 0 . 65 ; p < 0 . 0001 ) .
Diseases: "	"Sentence: Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters / BW ( r = 0 . 81 and 0 . 65 ; p < 0 . 0001 ) .
Diseases:"
3229	A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes , and between LV diameters / BW and histological findings .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes , and between LV diameters / BW and histological findings .
Diseases: "	"Sentence: A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes , and between LV diameters / BW and histological findings .
Diseases:"
3230	Among markers of ischemic injury after DOX in rats , cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes .	O O O B I O O O O O O O O O O O O B I O O O O O O O O	['myocardial damage', 'ischemic injury']	2	9	"Sentence: Among markers of ischemic injury after DOX in rats , cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes .
Diseases: myocardial damage, ischemic injury"	"Sentence: Among markers of ischemic injury after DOX in rats , cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes .
Diseases:"
3231	Although there was a discrepancy between the amount of cTnI and cTnT after DOX , probably due to heterogeneity in cross - reactivities of mAbs to various cTnI and cTnT forms , it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['cardiotoxicity']	1	3	"Sentence: Although there was a discrepancy between the amount of cTnI and cTnT after DOX , probably due to heterogeneity in cross - reactivities of mAbs to various cTnI and cTnT forms , it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments .
Diseases: cardiotoxicity"	"Sentence: Although there was a discrepancy between the amount of cTnI and cTnT after DOX , probably due to heterogeneity in cross - reactivities of mAbs to various cTnI and cTnT forms , it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments .
Diseases:"
3232	Calcineurin - inhibitor induced pain syndrome ( CIPS ) : a severe disabling complication after organ transplantation .	O O O O B O O B O O O O O O O O O O	['pain', 'cips']	2	4	"Sentence: Calcineurin - inhibitor induced pain syndrome ( CIPS ) : a severe disabling complication after organ transplantation .
Diseases: pain, cips"	"Sentence: Calcineurin - inhibitor induced pain syndrome ( CIPS ) : a severe disabling complication after organ transplantation .
Diseases:"
3233	Bone pain after transplantation is a frequent complication that can be caused by several diseases .	O B O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Bone pain after transplantation is a frequent complication that can be caused by several diseases .
Diseases: pain"	"Sentence: Bone pain after transplantation is a frequent complication that can be caused by several diseases .
Diseases:"
3234	Treatment strategies depend on the correct diagnosis of the pain .	O O O O O O O O O B O	['pain']	1	1	"Sentence: Treatment strategies depend on the correct diagnosis of the pain .
Diseases: pain"	"Sentence: Treatment strategies depend on the correct diagnosis of the pain .
Diseases:"
3235	Nine patients with severe pain in their feet , which was registered after transplantation , were investigated .	O O O O B O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Nine patients with severe pain in their feet , which was registered after transplantation , were investigated .
Diseases: pain"	"Sentence: Nine patients with severe pain in their feet , which was registered after transplantation , were investigated .
Diseases:"
3236	Bone scans showed an increased tracer uptake of the foot bones .	O O O O O O O O O O O O	[]	0	0	"Sentence: Bone scans showed an increased tracer uptake of the foot bones .
Diseases: "	"Sentence: Bone scans showed an increased tracer uptake of the foot bones .
Diseases:"
3237	Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones .	O O O O B I I O O O O O	['bone marrow oedema']	1	5	"Sentence: Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones .
Diseases: bone marrow oedema"	"Sentence: Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones .
Diseases:"
3238	Pain was not explained by other diseases causing foot pain , like reflex sympathetic dystrophy , polyneuropathy , Morton 's neuralgia , gout , osteoporosis , avascular necrosis , intermittent claudication , orthopaedic foot deformities , stress fractures , and hyperparathyroidism .	B O O O O O O O O B O O B I I O B O B I I O B O B O B I O B I O O B I O B I O O B O	"['avascular necrosis', 'intermittent claudication', 'gout', 'polyneuropathy', ""morton 's neuralgia"", 'foot deformities', 'osteoporosis', 'stress fractures', 'pain', 'hyperparathyroidism', 'reflex sympathetic dystrophy']"	11	51	"Sentence: Pain was not explained by other diseases causing foot pain , like reflex sympathetic dystrophy , polyneuropathy , Morton 's neuralgia , gout , osteoporosis , avascular necrosis , intermittent claudication , orthopaedic foot deformities , stress fractures , and hyperparathyroidism .
Diseases: avascular necrosis, intermittent claudication, gout, polyneuropathy, morton 's neuralgia, foot deformities, osteoporosis, stress fractures, pain, hyperparathyroidism, reflex sympathetic dystrophy"	"Sentence: Pain was not explained by other diseases causing foot pain , like reflex sympathetic dystrophy , polyneuropathy , Morton 's neuralgia , gout , osteoporosis , avascular necrosis , intermittent claudication , orthopaedic foot deformities , stress fractures , and hyperparathyroidism .
Diseases:"
3239	The reduction of cyclosporine - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain .	O O O O O O O O O O O O O O O O O O O O B O	['pain']	1	1	"Sentence: The reduction of cyclosporine - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain .
Diseases: pain"	"Sentence: The reduction of cyclosporine - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain .
Diseases:"
3240	The Calcineurin - inhibitor Induced Pain Syndrome ( CIPS ) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .	O O O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain', 'cips']	2	4	"Sentence: The Calcineurin - inhibitor Induced Pain Syndrome ( CIPS ) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
Diseases: pain, cips"	"Sentence: The Calcineurin - inhibitor Induced Pain Syndrome ( CIPS ) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .
Diseases:"
3241	Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS .	O O O O O O O O O O O O O O O O O O B O	['cips']	1	2	"Sentence: Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS .
Diseases: cips"	"Sentence: Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS .
Diseases:"
3242	The haemodynamic effects of propofol in combination with ephedrine in elderly patients ( ASA groups 3 and 4 ) .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The haemodynamic effects of propofol in combination with ephedrine in elderly patients ( ASA groups 3 and 4 ) .
Diseases: "	"Sentence: The haemodynamic effects of propofol in combination with ephedrine in elderly patients ( ASA groups 3 and 4 ) .
Diseases:"
3243	The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients .
Diseases: "	"Sentence: The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients .
Diseases:"
3244	We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response .	O O O O O O O O O O O O O O O O O O O B O O	['hypotensive']	1	3	"Sentence: We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response .
Diseases: hypotensive"	"Sentence: We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response .
Diseases:"
3245	The haemodynamic effects of adding 15 , 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3 / 4 patients over 60 years presenting for genito - urinary surgery .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The haemodynamic effects of adding 15 , 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3 / 4 patients over 60 years presenting for genito - urinary surgery .
Diseases: "	"Sentence: The haemodynamic effects of adding 15 , 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3 / 4 patients over 60 years presenting for genito - urinary surgery .
Diseases:"
3246	The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study .	O O O O O O O O O O O O O O O B O O O O O O O O O O O	['hypotensive']	1	3	"Sentence: The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study .
Diseases: hypotensive"	"Sentence: The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study .
Diseases:"
3247	However , marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients , occasionally reaching high levels in individual patients .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['tachycardia']	1	4	"Sentence: However , marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients , occasionally reaching high levels in individual patients .
Diseases: tachycardia"	"Sentence: However , marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients , occasionally reaching high levels in individual patients .
Diseases:"
3248	Due to the risk of this tachycardia inducing myocardial ischemia , we would not recommend the use in elderly patients of any of the ephedrine / propofol / mixtures studied .	O O O O O O B O B I O O O O O O O O O O O O O O O O O O O O O	['tachycardia', 'myocardial ischemia']	2	11	"Sentence: Due to the risk of this tachycardia inducing myocardial ischemia , we would not recommend the use in elderly patients of any of the ephedrine / propofol / mixtures studied .
Diseases: tachycardia, myocardial ischemia"	"Sentence: Due to the risk of this tachycardia inducing myocardial ischemia , we would not recommend the use in elderly patients of any of the ephedrine / propofol / mixtures studied .
Diseases:"
3249	Neurotoxicity of halogenated hydroxyquinolines : clinical analysis of cases reported outside Japan .	B O O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: Neurotoxicity of halogenated hydroxyquinolines : clinical analysis of cases reported outside Japan .
Diseases: neurotoxicity"	"Sentence: Neurotoxicity of halogenated hydroxyquinolines : clinical analysis of cases reported outside Japan .
Diseases:"
3250	An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan .	O O O O O O O O O B O O O O O O O O O	['neurotoxic']	1	4	"Sentence: An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan .
Diseases: neurotoxic"	"Sentence: An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan .
Diseases:"
3251	In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded .
Diseases: "	"Sentence: In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded .
Diseases:"
3252	Of the remainder , a relationship to clioquinol was considered probable in 42 and possible in 69 cases .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the remainder , a relationship to clioquinol was considered probable in 42 and possible in 69 cases .
Diseases: "	"Sentence: Of the remainder , a relationship to clioquinol was considered probable in 42 and possible in 69 cases .
Diseases:"
3253	In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period .	O O O O O O O B I O O O O O B O O O O O O O O O O O O O O O O	['encephalopathy', 'neurological disturbance']	2	6	"Sentence: In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period .
Diseases: encephalopathy, neurological disturbance"	"Sentence: In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period .
Diseases:"
3254	The most common manifestation , observed in 15 further cases , was isolated optic atrophy .	O O O O O O O O O O O O O B I O	['optic atrophy']	1	4	"Sentence: The most common manifestation , observed in 15 further cases , was isolated optic atrophy .
Diseases: optic atrophy"	"Sentence: The most common manifestation , observed in 15 further cases , was isolated optic atrophy .
Diseases:"
3255	This was most frequently found in children , many of whom had received clioquinol as treatment for acrodermatitis enteropathica .	O O O O O O O O O O O O O O O O O B I O	['acrodermatitis enteropathica']	1	8	"Sentence: This was most frequently found in children , many of whom had received clioquinol as treatment for acrodermatitis enteropathica .
Diseases: acrodermatitis enteropathica"	"Sentence: This was most frequently found in children , many of whom had received clioquinol as treatment for acrodermatitis enteropathica .
Diseases:"
3256	In the remaining cases , a combination of myelopathy , visual disturbance , and peripheral neuropathy was the most common manifestation .	O O O O O O O O B O B I O O B I O O O O O O	['peripheral neuropathy', 'myelopathy', 'visual disturbance']	3	12	"Sentence: In the remaining cases , a combination of myelopathy , visual disturbance , and peripheral neuropathy was the most common manifestation .
Diseases: peripheral neuropathy, myelopathy, visual disturbance"	"Sentence: In the remaining cases , a combination of myelopathy , visual disturbance , and peripheral neuropathy was the most common manifestation .
Diseases:"
3257	Isolated myelopathy or peripheral neuropathy , or these manifestations occurring together , were infrequent .	O B O B I O O O O O O O O O O	['peripheral neuropathy', 'myelopathy']	2	9	"Sentence: Isolated myelopathy or peripheral neuropathy , or these manifestations occurring together , were infrequent .
Diseases: peripheral neuropathy, myelopathy"	"Sentence: Isolated myelopathy or peripheral neuropathy , or these manifestations occurring together , were infrequent .
Diseases:"
3258	The onset of all manifestations ( except toxic encephalopathy ) was usually subacute , with subsequent partial recovery .	O O O O O O O O B O O O O O O O O O O	['encephalopathy']	1	3	"Sentence: The onset of all manifestations ( except toxic encephalopathy ) was usually subacute , with subsequent partial recovery .
Diseases: encephalopathy"	"Sentence: The onset of all manifestations ( except toxic encephalopathy ) was usually subacute , with subsequent partial recovery .
Diseases:"
3259	Older subjects tended to display more side effects .	O O O O O O O O O	[]	0	0	"Sentence: Older subjects tended to display more side effects .
Diseases: "	"Sentence: Older subjects tended to display more side effects .
Diseases:"
3260	The full syndrome of subacute myelo - optic neuropathy was more frequent in women , but they tended to have taken greater quantities of the drug .	O O O O O B I I I O O O O O O O O O O O O O O O O O O	['myelo - optic neuropathy']	1	6	"Sentence: The full syndrome of subacute myelo - optic neuropathy was more frequent in women , but they tended to have taken greater quantities of the drug .
Diseases: myelo - optic neuropathy"	"Sentence: The full syndrome of subacute myelo - optic neuropathy was more frequent in women , but they tended to have taken greater quantities of the drug .
Diseases:"
3261	Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats .	B I O O O O O O O O O O O O	['epileptic seizures']	1	4	"Sentence: Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats .
Diseases: epileptic seizures"	"Sentence: Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats .
Diseases:"
3262	Fibrin sealants ( FS ) derived from human plasma are frequently used in neurosurgery .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fibrin sealants ( FS ) derived from human plasma are frequently used in neurosurgery .
Diseases: "	"Sentence: Fibrin sealants ( FS ) derived from human plasma are frequently used in neurosurgery .
Diseases:"
3263	In order to increase clot stability , FS typically contain aprotinin , a natural fibrinolysis inhibitor .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In order to increase clot stability , FS typically contain aprotinin , a natural fibrinolysis inhibitor .
Diseases: "	"Sentence: In order to increase clot stability , FS typically contain aprotinin , a natural fibrinolysis inhibitor .
Diseases:"
3264	Recently , synthetic fibrinolysis inhibitors such as tranexamic acid ( tAMCA ) have been considered as substitutes for aprotinin .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Recently , synthetic fibrinolysis inhibitors such as tranexamic acid ( tAMCA ) have been considered as substitutes for aprotinin .
Diseases: "	"Sentence: Recently , synthetic fibrinolysis inhibitors such as tranexamic acid ( tAMCA ) have been considered as substitutes for aprotinin .
Diseases:"
3265	However , tAMCA has been shown to cause epileptic seizures .	O O O O O O O O B I O	['epileptic seizures']	1	4	"Sentence: However , tAMCA has been shown to cause epileptic seizures .
Diseases: epileptic seizures"	"Sentence: However , tAMCA has been shown to cause epileptic seizures .
Diseases:"
3266	We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS .	O O O O O O O O B O O O O O O O	['convulsive']	1	2	"Sentence: We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS .
Diseases: convulsive"	"Sentence: We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS .
Diseases:"
3267	FS containing aprotinin or different concentrations of tAMCA ( 0 . 5 - 47 . 5 mg / ml ) were applied to the pial surface of the cortex of anaesthetized rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: FS containing aprotinin or different concentrations of tAMCA ( 0 . 5 - 47 . 5 mg / ml ) were applied to the pial surface of the cortex of anaesthetized rats .
Diseases: "	"Sentence: FS containing aprotinin or different concentrations of tAMCA ( 0 . 5 - 47 . 5 mg / ml ) were applied to the pial surface of the cortex of anaesthetized rats .
Diseases:"
3268	The response of the animals was evaluated using electroencephalography and by monitoring the clinical behaviour during and after recovery from anaesthesia .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The response of the animals was evaluated using electroencephalography and by monitoring the clinical behaviour during and after recovery from anaesthesia .
Diseases: "	"Sentence: The response of the animals was evaluated using electroencephalography and by monitoring the clinical behaviour during and after recovery from anaesthesia .
Diseases:"
3269	FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours .	O O O O O O O O O O O O B O O	['convulsive']	1	2	"Sentence: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours .
Diseases: convulsive"	"Sentence: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours .
Diseases:"
3270	The degree of these seizures increased with increasing concentration of tAMCA .	O O O O B O O O O O O O	['seizures']	1	3	"Sentence: The degree of these seizures increased with increasing concentration of tAMCA .
Diseases: seizures"	"Sentence: The degree of these seizures increased with increasing concentration of tAMCA .
Diseases:"
3271	Thus , FS containing 47 . 5 mg / ml tAMCA evoked generalized seizures in all tested rats ( n = 6 ) while the lowest concentration of tAMCA ( 0 . 5 mg / ml ) only evoked brief episodes of jerk - correlated convulsive potentials in 1 of 6 rats .	O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['convulsive', 'generalized seizures']	2	5	"Sentence: Thus , FS containing 47 . 5 mg / ml tAMCA evoked generalized seizures in all tested rats ( n = 6 ) while the lowest concentration of tAMCA ( 0 . 5 mg / ml ) only evoked brief episodes of jerk - correlated convulsive potentials in 1 of 6 rats .
Diseases: convulsive, generalized seizures"	"Sentence: Thus , FS containing 47 . 5 mg / ml tAMCA evoked generalized seizures in all tested rats ( n = 6 ) while the lowest concentration of tAMCA ( 0 . 5 mg / ml ) only evoked brief episodes of jerk - correlated convulsive potentials in 1 of 6 rats .
Diseases:"
3272	In contrast , FS containing aprotinin did not evoke any paroxysmal activity .	O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , FS containing aprotinin did not evoke any paroxysmal activity .
Diseases: "	"Sentence: In contrast , FS containing aprotinin did not evoke any paroxysmal activity .
Diseases:"
3273	Tranexamic acid retains its convulsive action within FS .	O O O O B O O O O	['convulsive']	1	2	"Sentence: Tranexamic acid retains its convulsive action within FS .
Diseases: convulsive"	"Sentence: Tranexamic acid retains its convulsive action within FS .
Diseases:"
3274	Thus , use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thus , use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient .
Diseases: "	"Sentence: Thus , use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient .
Diseases:"
3275	A diet promoting sugar dependency causes behavioral cross - sensitization to a low dose of amphetamine .	O O O B I O B I I I O O O O O O O	['sugar dependency', 'behavioral cross - sensitization']	2	9	"Sentence: A diet promoting sugar dependency causes behavioral cross - sensitization to a low dose of amphetamine .
Diseases: sugar dependency, behavioral cross - sensitization"	"Sentence: A diet promoting sugar dependency causes behavioral cross - sensitization to a low dose of amphetamine .
Diseases:"
3276	Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency .	O O O O O O O O O O O O O O O O O O O O O O O O B I O	['drug dependency']	1	2	"Sentence: Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency .
Diseases: drug dependency"	"Sentence: Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency .
Diseases:"
3277	The present study examined whether female rats on various regimens of sugar access would show behavioral cross - sensitization to a low dose of amphetamine .	O O O O O O O O O O O O O O O B I I I O O O O O O O	['behavioral cross - sensitization']	1	6	"Sentence: The present study examined whether female rats on various regimens of sugar access would show behavioral cross - sensitization to a low dose of amphetamine .
Diseases: behavioral cross - sensitization"	"Sentence: The present study examined whether female rats on various regimens of sugar access would show behavioral cross - sensitization to a low dose of amphetamine .
Diseases:"
3278	After a 30 - min baseline measure of locomotor activity ( day 0 ) , animals were maintained on a cyclic diet of 12 - h deprivation followed by 12 - h access to 10 % sucrose solution and chow pellets ( 12 h access starting 4 h after onset of the dark period ) for 21 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After a 30 - min baseline measure of locomotor activity ( day 0 ) , animals were maintained on a cyclic diet of 12 - h deprivation followed by 12 - h access to 10 % sucrose solution and chow pellets ( 12 h access starting 4 h after onset of the dark period ) for 21 days .
Diseases: "	"Sentence: After a 30 - min baseline measure of locomotor activity ( day 0 ) , animals were maintained on a cyclic diet of 12 - h deprivation followed by 12 - h access to 10 % sucrose solution and chow pellets ( 12 h access starting 4 h after onset of the dark period ) for 21 days .
Diseases:"
3279	Locomotor activity was measured again for 30 min at the beginning of days 1 and 21 of sugar access .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Locomotor activity was measured again for 30 min at the beginning of days 1 and 21 of sugar access .
Diseases: "	"Sentence: Locomotor activity was measured again for 30 min at the beginning of days 1 and 21 of sugar access .
Diseases:"
3280	Beginning on day 22 , all rats were maintained on ad libitum chow .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Beginning on day 22 , all rats were maintained on ad libitum chow .
Diseases: "	"Sentence: Beginning on day 22 , all rats were maintained on ad libitum chow .
Diseases:"
3281	Nine days later locomotor activity was measured in response to a single low dose of amphetamine ( 0 . 5 mg / kg ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nine days later locomotor activity was measured in response to a single low dose of amphetamine ( 0 . 5 mg / kg ) .
Diseases: "	"Sentence: Nine days later locomotor activity was measured in response to a single low dose of amphetamine ( 0 . 5 mg / kg ) .
Diseases:"
3282	The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperactive']	1	2	"Sentence: The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
Diseases: hyperactive"	"Sentence: The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .
Diseases:"
3283	These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine , possibly due to a lasting alteration in the dopamine system .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine , possibly due to a lasting alteration in the dopamine system .
Diseases: "	"Sentence: These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine , possibly due to a lasting alteration in the dopamine system .
Diseases:"
3284	D - penicillamine - induced angiopathy in rats .	O O O O O B O O O	['angiopathy']	1	3	"Sentence: D - penicillamine - induced angiopathy in rats .
Diseases: angiopathy"	"Sentence: D - penicillamine - induced angiopathy in rats .
Diseases:"
3285	The effect of high dose D - penicillamine treatment on aortic permeability to albumin and on the ultrastructure of the vessel .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effect of high dose D - penicillamine treatment on aortic permeability to albumin and on the ultrastructure of the vessel .
Diseases: "	"Sentence: The effect of high dose D - penicillamine treatment on aortic permeability to albumin and on the ultrastructure of the vessel .
Diseases:"
3286	Male Sprague - Dawley rats were treated with D - penicillamine ( D - pen ) 500 mg / kg / day for 10 or 42 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Male Sprague - Dawley rats were treated with D - penicillamine ( D - pen ) 500 mg / kg / day for 10 or 42 days .
Diseases: "	"Sentence: Male Sprague - Dawley rats were treated with D - penicillamine ( D - pen ) 500 mg / kg / day for 10 or 42 days .
Diseases:"
3287	Pair fed rats served as controls .	O O O O O O O	[]	0	0	"Sentence: Pair fed rats served as controls .
Diseases: "	"Sentence: Pair fed rats served as controls .
Diseases:"
3288	Changes in aortic morphology were examined by light - and transmission - electron microscopy ( TEM ) .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Changes in aortic morphology were examined by light - and transmission - electron microscopy ( TEM ) .
Diseases: "	"Sentence: Changes in aortic morphology were examined by light - and transmission - electron microscopy ( TEM ) .
Diseases:"
3289	In addition , the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes , 24 and 48 hours after i . v . injection of human serum 131I - albumin ( 131I - HSA ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes , 24 and 48 hours after i . v . injection of human serum 131I - albumin ( 131I - HSA ) .
Diseases: "	"Sentence: In addition , the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes , 24 and 48 hours after i . v . injection of human serum 131I - albumin ( 131I - HSA ) .
Diseases:"
3290	TEM revealed extensive elastolysis in the arterial wall of D - pen - treated rats , consistent with an inhibitory effect on crosslink formation .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: TEM revealed extensive elastolysis in the arterial wall of D - pen - treated rats , consistent with an inhibitory effect on crosslink formation .
Diseases: "	"Sentence: TEM revealed extensive elastolysis in the arterial wall of D - pen - treated rats , consistent with an inhibitory effect on crosslink formation .
Diseases:"
3291	In experimental animals excess deposition of collagen and glycoaminoglycans was observed in the subendothelial and medial layer of the aortic wall , together with prominent basal membrane substance around aortic smooth muscle cells .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In experimental animals excess deposition of collagen and glycoaminoglycans was observed in the subendothelial and medial layer of the aortic wall , together with prominent basal membrane substance around aortic smooth muscle cells .
Diseases: "	"Sentence: In experimental animals excess deposition of collagen and glycoaminoglycans was observed in the subendothelial and medial layer of the aortic wall , together with prominent basal membrane substance around aortic smooth muscle cells .
Diseases:"
3292	The aorta / serum - ratio and the radioactive build - up 24 and 48 hours after injection of 131I - HSA was reduced in animals treated with D - pen for 42 days , indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The aorta / serum - ratio and the radioactive build - up 24 and 48 hours after injection of 131I - HSA was reduced in animals treated with D - pen for 42 days , indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate .
Diseases: "	"Sentence: The aorta / serum - ratio and the radioactive build - up 24 and 48 hours after injection of 131I - HSA was reduced in animals treated with D - pen for 42 days , indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate .
Diseases:"
3293	The endothelial ultrastructure was unaffected by D - pen , and no differences in aortic 131I - HSA radioactivity or aorta / serum - ratio were recorded between experimental and control groups 10 minutes after tracer injection , indicating that the permeability of the endothelial barrier to albumin remained unaffected by D - pen treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The endothelial ultrastructure was unaffected by D - pen , and no differences in aortic 131I - HSA radioactivity or aorta / serum - ratio were recorded between experimental and control groups 10 minutes after tracer injection , indicating that the permeability of the endothelial barrier to albumin remained unaffected by D - pen treatment .
Diseases: "	"Sentence: The endothelial ultrastructure was unaffected by D - pen , and no differences in aortic 131I - HSA radioactivity or aorta / serum - ratio were recorded between experimental and control groups 10 minutes after tracer injection , indicating that the permeability of the endothelial barrier to albumin remained unaffected by D - pen treatment .
Diseases:"
3294	These observations support the hypothesis that treatment with high doses of D - pen may induce a fibroproliferative response in rat aorta , possibly by an inhibitory effect on the cross - linking of collagen and elastin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These observations support the hypothesis that treatment with high doses of D - pen may induce a fibroproliferative response in rat aorta , possibly by an inhibitory effect on the cross - linking of collagen and elastin .
Diseases: "	"Sentence: These observations support the hypothesis that treatment with high doses of D - pen may induce a fibroproliferative response in rat aorta , possibly by an inhibitory effect on the cross - linking of collagen and elastin .
Diseases:"
3295	Brain natriuretic peptide is a predictor of anthracycline - induced cardiotoxicity .	O O O O O O O O O O B O	['cardiotoxicity']	1	3	"Sentence: Brain natriuretic peptide is a predictor of anthracycline - induced cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: Brain natriuretic peptide is a predictor of anthracycline - induced cardiotoxicity .
Diseases:"
3296	Anthracyclines are effective antineoplastic drugs , but they frequently cause dose - related cardiotoxicity .	O O O O O O O O O O O O O B O	['cardiotoxicity']	1	3	"Sentence: Anthracyclines are effective antineoplastic drugs , but they frequently cause dose - related cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: Anthracyclines are effective antineoplastic drugs , but they frequently cause dose - related cardiotoxicity .
Diseases:"
3297	The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction .	O B O O O O O O O O O O O O O O O O O O O B I O	['cardiotoxicity', 'cardiac dysfunction']	2	6	"Sentence: The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction .
Diseases: cardiotoxicity, cardiac dysfunction"	"Sentence: The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction .
Diseases:"
3298	We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline - induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin ( DNR ) - containing regimen .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O B I O O O O O O O O O O O	['cardiotoxicity', 'acute leukemia']	2	6	"Sentence: We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline - induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin ( DNR ) - containing regimen .
Diseases: cardiotoxicity, acute leukemia"	"Sentence: We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline - induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin ( DNR ) - containing regimen .
Diseases:"
3299	Thirteen patients with acute leukemia were treated with a DNR - containing regimen .	O O O B I O O O O O O O O O	['acute leukemia']	1	3	"Sentence: Thirteen patients with acute leukemia were treated with a DNR - containing regimen .
Diseases: acute leukemia"	"Sentence: Thirteen patients with acute leukemia were treated with a DNR - containing regimen .
Diseases:"
3300	Cardiac functions were evaluated with radionuclide angiography before chemotherapies .	O O O O O O O O O O	[]	0	0	"Sentence: Cardiac functions were evaluated with radionuclide angiography before chemotherapies .
Diseases: "	"Sentence: Cardiac functions were evaluated with radionuclide angiography before chemotherapies .
Diseases:"
3301	The plasma levels of atrial natriuretic peptide ( ANP ) and BNP were measured at the time of radionuclide angiography .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The plasma levels of atrial natriuretic peptide ( ANP ) and BNP were measured at the time of radionuclide angiography .
Diseases: "	"Sentence: The plasma levels of atrial natriuretic peptide ( ANP ) and BNP were measured at the time of radionuclide angiography .
Diseases:"
3302	Three patients developed congestive heart failure after the completion of chemotherapy .	O O O B I I O O O O O O	['congestive heart failure']	1	5	"Sentence: Three patients developed congestive heart failure after the completion of chemotherapy .
Diseases: congestive heart failure"	"Sentence: Three patients developed congestive heart failure after the completion of chemotherapy .
Diseases:"
3303	Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy .	O O O O O O O B I O O O O O O	['heart failure']	1	2	"Sentence: Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy .
Diseases: heart failure"	"Sentence: Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy .
Diseases:"
3304	The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit ( 40 pg / ml ) before the detection of clinical or subclinical heart failure by radionuclide angiography .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O B I O O O O	['heart failure']	1	2	"Sentence: The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit ( 40 pg / ml ) before the detection of clinical or subclinical heart failure by radionuclide angiography .
Diseases: heart failure"	"Sentence: The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit ( 40 pg / ml ) before the detection of clinical or subclinical heart failure by radionuclide angiography .
Diseases:"
3305	On the other hand , BNP did not increase in the patients without heart failure given DNR , even at more than 700 mg / m ( 2 ) .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	['heart failure']	1	2	"Sentence: On the other hand , BNP did not increase in the patients without heart failure given DNR , even at more than 700 mg / m ( 2 ) .
Diseases: heart failure"	"Sentence: On the other hand , BNP did not increase in the patients without heart failure given DNR , even at more than 700 mg / m ( 2 ) .
Diseases:"
3306	The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure .	O O O O O O O O O O O O O O O O O B I O	['heart failure']	1	2	"Sentence: The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure .
Diseases: heart failure"	"Sentence: The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure .
Diseases:"
3307	These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline - induced cardiotoxicity .	O O O O O O O O O O O O O O O O O O O B O	['cardiotoxicity']	1	3	"Sentence: These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline - induced cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline - induced cardiotoxicity .
Diseases:"
3308	Antibacterial medication use during pregnancy and risk of birth defects : National Birth Defects Prevention Study .	O O O O O O O O B I O O B I O O O	['birth defects']	1	2	"Sentence: Antibacterial medication use during pregnancy and risk of birth defects : National Birth Defects Prevention Study .
Diseases: birth defects"	"Sentence: Antibacterial medication use during pregnancy and risk of birth defects : National Birth Defects Prevention Study .
Diseases:"
3309	To estimate the association between antibacterial medications and selected birth defects .	O O O O O O O O O B I O	['birth defects']	1	2	"Sentence: To estimate the association between antibacterial medications and selected birth defects .
Diseases: birth defects"	"Sentence: To estimate the association between antibacterial medications and selected birth defects .
Diseases:"
3310	DESIGN , SETTING , AND PARTICIPANTS : Population - based , multisite , case - control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states ( n = 13 155 ) and control women randomly selected from the same geographical regions ( n = 4941 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['birth defect', 'birth defects']	2	5	"Sentence: DESIGN , SETTING , AND PARTICIPANTS : Population - based , multisite , case - control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states ( n = 13 155 ) and control women randomly selected from the same geographical regions ( n = 4941 ) .
Diseases: birth defect, birth defects"	"Sentence: DESIGN , SETTING , AND PARTICIPANTS : Population - based , multisite , case - control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states ( n = 13 155 ) and control women randomly selected from the same geographical regions ( n = 4941 ) .
Diseases:"
3311	MAIN EXPOSURE : Reported maternal use of antibacterials ( 1 month before pregnancy through the end of the first trimester ) .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: MAIN EXPOSURE : Reported maternal use of antibacterials ( 1 month before pregnancy through the end of the first trimester ) .
Diseases: "	"Sentence: MAIN EXPOSURE : Reported maternal use of antibacterials ( 1 month before pregnancy through the end of the first trimester ) .
Diseases:"
3312	MAIN OUTCOME MEASURE :	O O O O	[]	0	0	"Sentence: MAIN OUTCOME MEASURE :
Diseases: "	"Sentence: MAIN OUTCOME MEASURE :
Diseases:"
3313	Odds ratios ( ORs ) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders .	O O O O O O O O O O O O O B I O O O O O	['birth defects']	1	2	"Sentence: Odds ratios ( ORs ) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders .
Diseases: birth defects"	"Sentence: Odds ratios ( ORs ) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders .
Diseases:"
3314	The reported use of antibacterials increased during pregnancy , peaking during the third month .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The reported use of antibacterials increased during pregnancy , peaking during the third month .
Diseases: "	"Sentence: The reported use of antibacterials increased during pregnancy , peaking during the third month .
Diseases:"
3315	Sulfonamides were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O	['hypoplastic left heart syndrome', 'diaphragmatic hernia', 'transverse limb deficiency', 'coarctation of the aorta', 'choanal atresia', 'anencephaly']	6	40	"Sentence: Sulfonamides were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .
Diseases: hypoplastic left heart syndrome, diaphragmatic hernia, transverse limb deficiency, coarctation of the aorta, choanal atresia, anencephaly"	"Sentence: Sulfonamides were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .
Diseases:"
3316	Nitrofurantoins were associated with anophthalmia or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .	O O O O B O B O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O B I O B I O O O O O O O O O O O O O O O O O O O O	['hypoplastic left heart syndrome', 'microphthalmos', 'cleft palate', 'cleft lip', 'atrial septal defects', 'anophthalmia']	6	30	"Sentence: Nitrofurantoins were associated with anophthalmia or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .
Diseases: hypoplastic left heart syndrome, microphthalmos, cleft palate, cleft lip, atrial septal defects, anophthalmia"	"Sentence: Nitrofurantoins were associated with anophthalmia or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .
Diseases:"
3317	Other antibacterial agents that showed associations included erythromycins ( 2 defects ) , penicillins ( 1 defect ) , cephalosporins ( 1 defect ) , and quinolones ( 1 defect ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Other antibacterial agents that showed associations included erythromycins ( 2 defects ) , penicillins ( 1 defect ) , cephalosporins ( 1 defect ) , and quinolones ( 1 defect ) .
Diseases: "	"Sentence: Other antibacterial agents that showed associations included erythromycins ( 2 defects ) , penicillins ( 1 defect ) , cephalosporins ( 1 defect ) , and quinolones ( 1 defect ) .
Diseases:"
3318	Reassuringly , penicillins , erythromycins , and cephalosporins , although used commonly by pregnant women , were not associated with many birth defects .	O O O O O O O O O O O O O O O O O O O O O B I O	['birth defects']	1	2	"Sentence: Reassuringly , penicillins , erythromycins , and cephalosporins , although used commonly by pregnant women , were not associated with many birth defects .
Diseases: birth defects"	"Sentence: Reassuringly , penicillins , erythromycins , and cephalosporins , although used commonly by pregnant women , were not associated with many birth defects .
Diseases:"
3319	Sulfonamides and nitrofurantoins were associated with several birth defects , indicating a need for additional scrutiny .	O O O O O O O B I O O O O O O O O	['birth defects']	1	2	"Sentence: Sulfonamides and nitrofurantoins were associated with several birth defects , indicating a need for additional scrutiny .
Diseases: birth defects"	"Sentence: Sulfonamides and nitrofurantoins were associated with several birth defects , indicating a need for additional scrutiny .
Diseases:"
3320	Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens .	O O B O O O B I O O O O O O	['neoplasms', 'rheumatoid arthritis']	2	9	"Sentence: Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens .
Diseases: neoplasms, rheumatoid arthritis"	"Sentence: Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens .
Diseases:"
3321	Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis .	O O O O O O O O O O O O O O O O B I O	['rheumatoid arthritis']	1	5	"Sentence: Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis .
Diseases: rheumatoid arthritis"	"Sentence: Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis .
Diseases:"
3322	The drugs commonly used are cyclophosphamide and chlorambucil ( alkylating agents ) , azathioprine ( purine analogue ) , and methotrexate ( folic acid analogue ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The drugs commonly used are cyclophosphamide and chlorambucil ( alkylating agents ) , azathioprine ( purine analogue ) , and methotrexate ( folic acid analogue ) .
Diseases: "	"Sentence: The drugs commonly used are cyclophosphamide and chlorambucil ( alkylating agents ) , azathioprine ( purine analogue ) , and methotrexate ( folic acid analogue ) .
Diseases:"
3323	There is evidence that all four immunosuppressive drugs can reduce synovitis , but disease activity almost always recurs after therapy is stopped .	O O O O O O O O O O B O O O O O O O O O O O O	['synovitis']	1	3	"Sentence: There is evidence that all four immunosuppressive drugs can reduce synovitis , but disease activity almost always recurs after therapy is stopped .
Diseases: synovitis"	"Sentence: There is evidence that all four immunosuppressive drugs can reduce synovitis , but disease activity almost always recurs after therapy is stopped .
Diseases:"
3324	Since adverse reactions are frequent , less than 50 percent of patients are able to continue a particular drug for more than one year .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Since adverse reactions are frequent , less than 50 percent of patients are able to continue a particular drug for more than one year .
Diseases: "	"Sentence: Since adverse reactions are frequent , less than 50 percent of patients are able to continue a particular drug for more than one year .
Diseases:"
3325	Since it takes three to 12 months to achieve maximal effects , those patients who are unable to continue the drug receive little benefit from it .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Since it takes three to 12 months to achieve maximal effects , those patients who are unable to continue the drug receive little benefit from it .
Diseases: "	"Sentence: Since it takes three to 12 months to achieve maximal effects , those patients who are unable to continue the drug receive little benefit from it .
Diseases:"
3326	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia , and both alkylating agents and azathioprine are associated with the development of non - Hodgkin 's lymphoma .	O O O O O O O O O O O O B I I O O O O O O O O O O O O O B I I I I O	"['acute nonlymphocytic leukemia', ""non - hodgkin 's lymphoma""]"	2	19	"Sentence: Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia , and both alkylating agents and azathioprine are associated with the development of non - Hodgkin 's lymphoma .
Diseases: acute nonlymphocytic leukemia, non - hodgkin 's lymphoma"	"Sentence: Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia , and both alkylating agents and azathioprine are associated with the development of non - Hodgkin 's lymphoma .
Diseases:"
3327	Cyclophosphamide therapy increases the risk of carcinoma of the bladder .	O O O O O O B I I I O	['carcinoma of the bladder']	1	7	"Sentence: Cyclophosphamide therapy increases the risk of carcinoma of the bladder .
Diseases: carcinoma of the bladder"	"Sentence: Cyclophosphamide therapy increases the risk of carcinoma of the bladder .
Diseases:"
3328	There have been several long - term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased .	O O O O O O O O O O O B I O O O O O O O O O O O O O B O O O O	['cancers', 'rheumatoid arthritis']	2	7	"Sentence: There have been several long - term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased .
Diseases: cancers, rheumatoid arthritis"	"Sentence: There have been several long - term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased .
Diseases:"
3329	Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly alkylating agents , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life - threatening complications .	O O O O O O O B O B I O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	['malignancy', 'rheumatoid arthritis']	2	9	"Sentence: Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly alkylating agents , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life - threatening complications .
Diseases: malignancy, rheumatoid arthritis"	"Sentence: Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly alkylating agents , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life - threatening complications .
Diseases:"
3330	Patterns of hepatic injury induced by methyldopa .	O O B I O O O O	['hepatic injury']	1	4	"Sentence: Patterns of hepatic injury induced by methyldopa .
Diseases: hepatic injury"	"Sentence: Patterns of hepatic injury induced by methyldopa .
Diseases:"
3331	Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977 .	O O O B I O O O O O O O O O O	['liver disease']	1	3	"Sentence: Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977 .
Diseases: liver disease"	"Sentence: Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977 .
Diseases:"
3332	Illness occurred within 1 - - 9 weeks of commencement of therapy in 9 patients , the remaining 3 patients having received the drug for 13 months , 15 months and 7 years before experiencing symptoms .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Illness occurred within 1 - - 9 weeks of commencement of therapy in 9 patients , the remaining 3 patients having received the drug for 13 months , 15 months and 7 years before experiencing symptoms .
Diseases: "	"Sentence: Illness occurred within 1 - - 9 weeks of commencement of therapy in 9 patients , the remaining 3 patients having received the drug for 13 months , 15 months and 7 years before experiencing symptoms .
Diseases:"
3333	Jaundice with tender hepatomegaly , usually preceded by symptoms of malaise , anorexia , nausea and vomiting , and associated with upper abdominal pain , was an invariable finding in all patients .	B O O B O O O O O O O O B O B O B O O O O O B I O O O O O O O O O	['abdominal pain', 'nausea', 'anorexia', 'jaundice', 'hepatomegaly', 'vomiting']	6	21	"Sentence: Jaundice with tender hepatomegaly , usually preceded by symptoms of malaise , anorexia , nausea and vomiting , and associated with upper abdominal pain , was an invariable finding in all patients .
Diseases: abdominal pain, nausea, anorexia, jaundice, hepatomegaly, vomiting"	"Sentence: Jaundice with tender hepatomegaly , usually preceded by symptoms of malaise , anorexia , nausea and vomiting , and associated with upper abdominal pain , was an invariable finding in all patients .
Diseases:"
3334	Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury , the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis .	O O O O O O B O O O O O O B I O O O O O O O B I O O O B O B I I O	['fatty change', 'hepatic injury', 'massive hepatic necrosis', 'necrosis']	4	16	"Sentence: Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury , the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis .
Diseases: fatty change, hepatic injury, massive hepatic necrosis, necrosis"	"Sentence: Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury , the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis .
Diseases:"
3335	Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis .	O O O O O O B I O B I I O O B O	['cholestasis', 'acute hepatitis', 'chronic active hepatitis']	3	11	"Sentence: Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis .
Diseases: cholestasis, acute hepatitis, chronic active hepatitis"	"Sentence: Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis .
Diseases:"
3336	The drug was withdrawn on presentation to hospital in 11 patients , with rapid clinical improvement in 9 .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The drug was withdrawn on presentation to hospital in 11 patients , with rapid clinical improvement in 9 .
Diseases: "	"Sentence: The drug was withdrawn on presentation to hospital in 11 patients , with rapid clinical improvement in 9 .
Diseases:"
3337	One patient died , having presented in hepatic failure , and another , who had been taking methyldopa for 7 years , showed slower clinical and biochemical resolution over a period of several months .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O	['hepatic failure']	1	4	"Sentence: One patient died , having presented in hepatic failure , and another , who had been taking methyldopa for 7 years , showed slower clinical and biochemical resolution over a period of several months .
Diseases: hepatic failure"	"Sentence: One patient died , having presented in hepatic failure , and another , who had been taking methyldopa for 7 years , showed slower clinical and biochemical resolution over a period of several months .
Diseases:"
3338	The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa - induced hepatitis .	O O O O O O O B I O O O O O O O O O O O O O O O O B O	['fulminant hepatitis', 'hepatitis']	2	6	"Sentence: The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa - induced hepatitis .
Diseases: fulminant hepatitis, hepatitis"	"Sentence: The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa - induced hepatitis .
Diseases:"
3339	In this latter patient , and in 2 others , the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re - exposure to the drug .	O O O O O O O O O O O O O O O O B I O O O O O O B O O O O O O O O O O O	['hepatic dysfunction', 'hepatitis']	2	6	"Sentence: In this latter patient , and in 2 others , the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re - exposure to the drug .
Diseases: hepatic dysfunction, hepatitis"	"Sentence: In this latter patient , and in 2 others , the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re - exposure to the drug .
Diseases:"
3340	A phase I / II study of paclitaxel plus cisplatin as first - line therapy for head and neck cancers : preliminary results .	O O O O O O O O O O O O O O O O B I I I O O O O	['head and neck cancers']	1	4	"Sentence: A phase I / II study of paclitaxel plus cisplatin as first - line therapy for head and neck cancers : preliminary results .
Diseases: head and neck cancers"	"Sentence: A phase I / II study of paclitaxel plus cisplatin as first - line therapy for head and neck cancers : preliminary results .
Diseases:"
3341	Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy .	O O O O O B I I I O O O O O O O O O	['head and neck carcinomas']	1	5	"Sentence: Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy .
Diseases: head and neck carcinomas"	"Sentence: Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy .
Diseases:"
3342	Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel / cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O B I O O	['ovarian cancer', 'head and neck cancer']	2	8	"Sentence: Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel / cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
Diseases: ovarian cancer, head and neck cancer"	"Sentence: Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel / cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .
Diseases:"
3343	We initiated a phase I / II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed - dose cisplatin with granulocyte colony - stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O B I I I O	['head and neck carcinoma', 'toxicity']	2	7	"Sentence: We initiated a phase I / II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed - dose cisplatin with granulocyte colony - stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma .
Diseases: head and neck carcinoma, toxicity"	"Sentence: We initiated a phase I / II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed - dose cisplatin with granulocyte colony - stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma .
Diseases:"
3344	To date , 23 men with a median age of 50 years and good performance status have entered the trial .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To date , 23 men with a median age of 50 years and good performance status have entered the trial .
Diseases: "	"Sentence: To date , 23 men with a median age of 50 years and good performance status have entered the trial .
Diseases:"
3345	Primary tumor sites were oropharynx , 10 patients ; hypopharynx , four ; larynx , two ; oral cavity , three ; unknown primary , two ; and nasal cavity and parotid gland , one each .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tumor']	1	3	"Sentence: Primary tumor sites were oropharynx , 10 patients ; hypopharynx , four ; larynx , two ; oral cavity , three ; unknown primary , two ; and nasal cavity and parotid gland , one each .
Diseases: tumor"	"Sentence: Primary tumor sites were oropharynx , 10 patients ; hypopharynx , four ; larynx , two ; oral cavity , three ; unknown primary , two ; and nasal cavity and parotid gland , one each .
Diseases:"
3346	Of 20 patients evaluable for toxicity , four had stage III and 16 had stage IV disease .	O O O O O B O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Of 20 patients evaluable for toxicity , four had stage III and 16 had stage IV disease .
Diseases: toxicity"	"Sentence: Of 20 patients evaluable for toxicity , four had stage III and 16 had stage IV disease .
Diseases:"
3347	Treatment , given every 21 days for a maximum of three cycles , consisted of paclitaxel by 3 - hour infusion followed the next day by a fixed dose of cisplatin ( 75 mg / m2 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Treatment , given every 21 days for a maximum of three cycles , consisted of paclitaxel by 3 - hour infusion followed the next day by a fixed dose of cisplatin ( 75 mg / m2 ) .
Diseases: "	"Sentence: Treatment , given every 21 days for a maximum of three cycles , consisted of paclitaxel by 3 - hour infusion followed the next day by a fixed dose of cisplatin ( 75 mg / m2 ) .
Diseases:"
3348	The dose levels incorporate escalating paclitaxel doses , and intrapatient escalations within a given dose level are permitted if toxicity permits .	O O O O O O O O O O O O O O O O O O O B O O	['toxicity']	1	2	"Sentence: The dose levels incorporate escalating paclitaxel doses , and intrapatient escalations within a given dose level are permitted if toxicity permits .
Diseases: toxicity"	"Sentence: The dose levels incorporate escalating paclitaxel doses , and intrapatient escalations within a given dose level are permitted if toxicity permits .
Diseases:"
3349	At the time of this writing , dose level 4 ( 260 , 270 , and 280 mg / m2 ) is being evaluated ; three patients from this level are evaluable .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At the time of this writing , dose level 4 ( 260 , 270 , and 280 mg / m2 ) is being evaluated ; three patients from this level are evaluable .
Diseases: "	"Sentence: At the time of this writing , dose level 4 ( 260 , 270 , and 280 mg / m2 ) is being evaluated ; three patients from this level are evaluable .
Diseases:"
3350	With paclitaxel doses of 200 mg / m2 and higher , granulocyte colony - stimulating factor 5 micrograms / kg / d is given ( days 4 through 12 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: With paclitaxel doses of 200 mg / m2 and higher , granulocyte colony - stimulating factor 5 micrograms / kg / d is given ( days 4 through 12 ) .
Diseases: "	"Sentence: With paclitaxel doses of 200 mg / m2 and higher , granulocyte colony - stimulating factor 5 micrograms / kg / d is given ( days 4 through 12 ) .
Diseases:"
3351	Of 18 patients evaluable for response , seven ( 39 % ) achieved a complete response and six ( 33 % ) achieved a partial response .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of 18 patients evaluable for response , seven ( 39 % ) achieved a complete response and six ( 33 % ) achieved a partial response .
Diseases: "	"Sentence: Of 18 patients evaluable for response , seven ( 39 % ) achieved a complete response and six ( 33 % ) achieved a partial response .
Diseases:"
3352	Three patients had no change and disease progressed in two .	O O O O O O O O O O O	[]	0	0	"Sentence: Three patients had no change and disease progressed in two .
Diseases: "	"Sentence: Three patients had no change and disease progressed in two .
Diseases:"
3353	The overall response rate is 72 % .	O O O O O O O O	[]	0	0	"Sentence: The overall response rate is 72 % .
Diseases: "	"Sentence: The overall response rate is 72 % .
Diseases:"
3354	Eleven responding patients had subsequent surgery / radiotherapy or radical radiotherapy .	O O O O O O O O O O O O	[]	0	0	"Sentence: Eleven responding patients had subsequent surgery / radiotherapy or radical radiotherapy .
Diseases: "	"Sentence: Eleven responding patients had subsequent surgery / radiotherapy or radical radiotherapy .
Diseases:"
3355	Two pathologic complete responses were observed in patients who had achieved clinical complete responses .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two pathologic complete responses were observed in patients who had achieved clinical complete responses .
Diseases: "	"Sentence: Two pathologic complete responses were observed in patients who had achieved clinical complete responses .
Diseases:"
3356	Alopecia , paresthesias , and arthralgias / myalgias have occurred frequently , but with one exception ( a grade 3 myalgia ) they have been grade 1 or 2 .	B O B O O B O B O O O O O O O O O O O O B O O O O O O O O O	['myalgias', 'paresthesias', 'myalgia', 'arthralgias', 'alopecia']	5	22	"Sentence: Alopecia , paresthesias , and arthralgias / myalgias have occurred frequently , but with one exception ( a grade 3 myalgia ) they have been grade 1 or 2 .
Diseases: myalgias, paresthesias, myalgia, arthralgias, alopecia"	"Sentence: Alopecia , paresthesias , and arthralgias / myalgias have occurred frequently , but with one exception ( a grade 3 myalgia ) they have been grade 1 or 2 .
Diseases:"
3357	No dose - limiting hematologic toxicity has been seen .	O O O O O B O O O O	['toxicity']	1	2	"Sentence: No dose - limiting hematologic toxicity has been seen .
Diseases: toxicity"	"Sentence: No dose - limiting hematologic toxicity has been seen .
Diseases:"
3358	Paclitaxel / cisplatin is an effective first - line regimen for locoregionally advanced head and neck cancer and continued study is warranted .	O O O O O O O O O O O O O B I I I O O O O O O	['head and neck cancer']	1	4	"Sentence: Paclitaxel / cisplatin is an effective first - line regimen for locoregionally advanced head and neck cancer and continued study is warranted .
Diseases: head and neck cancer"	"Sentence: Paclitaxel / cisplatin is an effective first - line regimen for locoregionally advanced head and neck cancer and continued study is warranted .
Diseases:"
3359	Results thus far suggest no dose - response effect for paclitaxel doses above 200 mg / m2 .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Results thus far suggest no dose - response effect for paclitaxel doses above 200 mg / m2 .
Diseases: "	"Sentence: Results thus far suggest no dose - response effect for paclitaxel doses above 200 mg / m2 .
Diseases:"
3360	A phase I study of 4' - 0 - tetrahydropyranyladriamycin .	O O O O O O O O O O O	[]	0	0	"Sentence: A phase I study of 4' - 0 - tetrahydropyranyladriamycin .
Diseases: "	"Sentence: A phase I study of 4' - 0 - tetrahydropyranyladriamycin .
Diseases:"
3361	Clinical pharmacology and pharmacokinetics .	O O O O O	[]	0	0	"Sentence: Clinical pharmacology and pharmacokinetics .
Diseases: "	"Sentence: Clinical pharmacology and pharmacokinetics .
Diseases:"
3362	A Phase I study of intravenous ( IV ) bolus 4' - 0 - tetrahydropyranyladriamycin ( Pirarubicin ) was done in 55 patients in good performance status with refractory tumors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['tumors']	1	3	"Sentence: A Phase I study of intravenous ( IV ) bolus 4' - 0 - tetrahydropyranyladriamycin ( Pirarubicin ) was done in 55 patients in good performance status with refractory tumors .
Diseases: tumors"	"Sentence: A Phase I study of intravenous ( IV ) bolus 4' - 0 - tetrahydropyranyladriamycin ( Pirarubicin ) was done in 55 patients in good performance status with refractory tumors .
Diseases:"
3363	Twenty - six had minimal prior therapy ( good risk ) , 23 had extensive prior therapy ( poor risk ) , and six had renal and / or hepatic dysfunction .	O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I O	['renal and / or hepatic dysfunction']	1	8	"Sentence: Twenty - six had minimal prior therapy ( good risk ) , 23 had extensive prior therapy ( poor risk ) , and six had renal and / or hepatic dysfunction .
Diseases: renal and / or hepatic dysfunction"	"Sentence: Twenty - six had minimal prior therapy ( good risk ) , 23 had extensive prior therapy ( poor risk ) , and six had renal and / or hepatic dysfunction .
Diseases:"
3364	A total of 167 courses at doses of 15 to 70 mg / m2 were evaluable .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A total of 167 courses at doses of 15 to 70 mg / m2 were evaluable .
Diseases: "	"Sentence: A total of 167 courses at doses of 15 to 70 mg / m2 were evaluable .
Diseases:"
3365	Maximum tolerated dose in good - risk patients was 70 mg / m2 , and in poor - risk patients , 60 mg / m2 .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Maximum tolerated dose in good - risk patients was 70 mg / m2 , and in poor - risk patients , 60 mg / m2 .
Diseases: "	"Sentence: Maximum tolerated dose in good - risk patients was 70 mg / m2 , and in poor - risk patients , 60 mg / m2 .
Diseases:"
3366	The dose - limiting toxic effect was transient noncumulative granulocytopenia .	O O O O O O O O O B O	['granulocytopenia']	1	6	"Sentence: The dose - limiting toxic effect was transient noncumulative granulocytopenia .
Diseases: granulocytopenia"	"Sentence: The dose - limiting toxic effect was transient noncumulative granulocytopenia .
Diseases:"
3367	Granulocyte nadir was on day 14 ( range , 4 - 22 ) .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Granulocyte nadir was on day 14 ( range , 4 - 22 ) .
Diseases: "	"Sentence: Granulocyte nadir was on day 14 ( range , 4 - 22 ) .
Diseases:"
3368	Less frequent toxic effects included thrombocytopenia , anemia , nausea , mild alopecia , phlebitis , and mucositis .	O O O O O B O B O B O O B O B O O B O	['mucositis', 'nausea', 'anemia', 'thrombocytopenia', 'phlebitis', 'alopecia']	6	27	"Sentence: Less frequent toxic effects included thrombocytopenia , anemia , nausea , mild alopecia , phlebitis , and mucositis .
Diseases: mucositis, nausea, anemia, thrombocytopenia, phlebitis, alopecia"	"Sentence: Less frequent toxic effects included thrombocytopenia , anemia , nausea , mild alopecia , phlebitis , and mucositis .
Diseases:"
3369	Myelosuppression was more in patients with hepatic dysfunction .	B O O O O O B I O	['myelosuppression', 'hepatic dysfunction']	2	9	"Sentence: Myelosuppression was more in patients with hepatic dysfunction .
Diseases: myelosuppression, hepatic dysfunction"	"Sentence: Myelosuppression was more in patients with hepatic dysfunction .
Diseases:"
3370	Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1 / 2 alpha ( + / - SE ) of 2 . 5 + / - 0 . 85 minutes , T beta 1 / 2 of 25 . 6 + / - 6 . 5 minutes , and T 1 / 2 gamma of 23 . 6 + / - 7 . 6 hours .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1 / 2 alpha ( + / - SE ) of 2 . 5 + / - 0 . 85 minutes , T beta 1 / 2 of 25 . 6 + / - 6 . 5 minutes , and T 1 / 2 gamma of 23 . 6 + / - 7 . 6 hours .
Diseases: "	"Sentence: Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1 / 2 alpha ( + / - SE ) of 2 . 5 + / - 0 . 85 minutes , T beta 1 / 2 of 25 . 6 + / - 6 . 5 minutes , and T 1 / 2 gamma of 23 . 6 + / - 7 . 6 hours .
Diseases:"
3371	The area under the curve was 537 + / - 149 ng / ml x hours , volume of distribution ( Vd ) 3504 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The area under the curve was 537 + / - 149 ng / ml x hours , volume of distribution ( Vd ) 3504 + / -
Diseases: "	"Sentence: The area under the curve was 537 + / - 149 ng / ml x hours , volume of distribution ( Vd ) 3504 + / -
Diseases:"
3372	644 l / m2 , and total clearance ( ClT ) was 204 + 39 . 3 l / hour / m2 .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 644 l / m2 , and total clearance ( ClT ) was 204 + 39 . 3 l / hour / m2 .
Diseases: "	"Sentence: 644 l / m2 , and total clearance ( ClT ) was 204 + 39 . 3 l / hour / m2 .
Diseases:"
3373	Adriamycinol , doxorubicin , adriamycinone , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10 % of the total metabolites .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Adriamycinol , doxorubicin , adriamycinone , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10 % of the total metabolites .
Diseases: "	"Sentence: Adriamycinol , doxorubicin , adriamycinone , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10 % of the total metabolites .
Diseases:"
3374	Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10 % .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10 % .
Diseases: "	"Sentence: Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10 % .
Diseases:"
3375	Activity was noted in mesothelioma , leiomyosarcoma , and basal cell carcinoma .	O O O O B O B O O B I I O	['basal cell carcinoma', 'leiomyosarcoma', 'mesothelioma']	3	19	"Sentence: Activity was noted in mesothelioma , leiomyosarcoma , and basal cell carcinoma .
Diseases: basal cell carcinoma, leiomyosarcoma, mesothelioma"	"Sentence: Activity was noted in mesothelioma , leiomyosarcoma , and basal cell carcinoma .
Diseases:"
3376	The recommended starting dose for Phase II trials is 60 mg / m2 IV bolus every 3 weeks .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The recommended starting dose for Phase II trials is 60 mg / m2 IV bolus every 3 weeks .
Diseases: "	"Sentence: The recommended starting dose for Phase II trials is 60 mg / m2 IV bolus every 3 weeks .
Diseases:"
3377	Differential effects of gamma - hexachlorocyclohexane ( lindane ) on pharmacologically - induced seizures .	O O O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: Differential effects of gamma - hexachlorocyclohexane ( lindane ) on pharmacologically - induced seizures .
Diseases: seizures"	"Sentence: Differential effects of gamma - hexachlorocyclohexane ( lindane ) on pharmacologically - induced seizures .
Diseases:"
3378	Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O B O O	['seizures', 'seizure']	2	5	"Sentence: Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h
Diseases: seizures, seizure"	"Sentence: Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h
Diseases:"
3379	after exposure to gamma - HCH ( Vohland et al . 1981 ) .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: after exposure to gamma - HCH ( Vohland et al . 1981 ) .
Diseases: "	"Sentence: after exposure to gamma - HCH ( Vohland et al . 1981 ) .
Diseases:"
3380	In this study , the severity of response to other seizure - inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg / kg gamma - HCH .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: In this study , the severity of response to other seizure - inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg / kg gamma - HCH .
Diseases: seizure"	"Sentence: In this study , the severity of response to other seizure - inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg / kg gamma - HCH .
Diseases:"
3381	One hour after the administration of gamma - HCH , the activity of seizure - inducing agents was increased , regardless of their mechanism , while 24 h after gamma - HCH a differential response was observed .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: One hour after the administration of gamma - HCH , the activity of seizure - inducing agents was increased , regardless of their mechanism , while 24 h after gamma - HCH a differential response was observed .
Diseases: seizure"	"Sentence: One hour after the administration of gamma - HCH , the activity of seizure - inducing agents was increased , regardless of their mechanism , while 24 h after gamma - HCH a differential response was observed .
Diseases:"
3382	Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .	B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
Diseases: seizure"	"Sentence: Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .
Diseases:"
3383	In vitro , gamma - HCH , pentylenetetrazol and picrotoxin were shown to inhibit 3H - TBOB binding in mouse whole brain , with IC50 values of 4 . 6 , 404 and 9 . 4 microM , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In vitro , gamma - HCH , pentylenetetrazol and picrotoxin were shown to inhibit 3H - TBOB binding in mouse whole brain , with IC50 values of 4 . 6 , 404 and 9 . 4 microM , respectively .
Diseases: "	"Sentence: In vitro , gamma - HCH , pentylenetetrazol and picrotoxin were shown to inhibit 3H - TBOB binding in mouse whole brain , with IC50 values of 4 . 6 , 404 and 9 . 4 microM , respectively .
Diseases:"
3384	MPA , BCC , DMCM , and STR showed no inhibition of 3H - TBOB ( t - butyl bicyclo - orthobenzoate ) binding at concentrations of 100 micron .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: MPA , BCC , DMCM , and STR showed no inhibition of 3H - TBOB ( t - butyl bicyclo - orthobenzoate ) binding at concentrations of 100 micron .
Diseases: "	"Sentence: MPA , BCC , DMCM , and STR showed no inhibition of 3H - TBOB ( t - butyl bicyclo - orthobenzoate ) binding at concentrations of 100 micron .
Diseases:"
3385	The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma - HCH , since the response to only these two seizure - inducing agents is decreased .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O	['seizure']	1	3	"Sentence: The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma - HCH , since the response to only these two seizure - inducing agents is decreased .
Diseases: seizure"	"Sentence: The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma - HCH , since the response to only these two seizure - inducing agents is decreased .
Diseases:"
3386	The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma - HCH may be the GABA - A receptor - linked chloride channel .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma - HCH may be the GABA - A receptor - linked chloride channel .
Diseases: seizure"	"Sentence: The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma - HCH may be the GABA - A receptor - linked chloride channel .
Diseases:"
3387	Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas .	O B I I I O O O O O O O B O	['glioblastomas', 'ocular and orbital toxicity']	2	11	"Sentence: Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas .
Diseases: glioblastomas, ocular and orbital toxicity"	"Sentence: Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas .
Diseases:"
3388	Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood .	B O O B I O O O O O O O O	['glioblastoma', 'malignant tumor']	2	9	"Sentence: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood .
Diseases: glioblastoma, malignant tumor"	"Sentence: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood .
Diseases:"
3389	With current treatment regimens including combined surgery , radiation and chemotherapy , the average life expectancy of the patients is limited to approximately 1 year .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: With current treatment regimens including combined surgery , radiation and chemotherapy , the average life expectancy of the patients is limited to approximately 1 year .
Diseases: "	"Sentence: With current treatment regimens including combined surgery , radiation and chemotherapy , the average life expectancy of the patients is limited to approximately 1 year .
Diseases:"
3390	Therefore , patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen .	O O O O B O O O O O O O O O O O O	['glioblastoma']	1	5	"Sentence: Therefore , patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen .
Diseases: glioblastoma"	"Sentence: Therefore , patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen .
Diseases:"
3391	Generally , carboplatin is said to have milder side effects than cisplatin , whose ocular and orbital toxicity are well known .	O O O O O O O O O O O O O O B I I I O O O O	['ocular and orbital toxicity']	1	4	"Sentence: Generally , carboplatin is said to have milder side effects than cisplatin , whose ocular and orbital toxicity are well known .
Diseases: ocular and orbital toxicity"	"Sentence: Generally , carboplatin is said to have milder side effects than cisplatin , whose ocular and orbital toxicity are well known .
Diseases:"
3392	However , we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin , which is infrequently reported .	O O O O O O O O B I I I O O O O O O O O O O O	['ocular and orbital toxicity']	1	4	"Sentence: However , we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin , which is infrequently reported .
Diseases: ocular and orbital toxicity"	"Sentence: However , we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin , which is infrequently reported .
Diseases:"
3393	CASE : A 58 - year - old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe .	O O O O O O O O O O O O O O O O O B O O O O O O	['glioblastomas']	1	5	"Sentence: CASE : A 58 - year - old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe .
Diseases: glioblastomas"	"Sentence: CASE : A 58 - year - old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe .
Diseases:"
3394	He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection .	O O O B I I I I I I I O O O O O O	['pain and visual disturbance in the ipsilateral eye']	1	10	"Sentence: He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection .
Diseases: pain and visual disturbance in the ipsilateral eye"	"Sentence: He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection .
Diseases:"
3395	Various ocular symptoms and findings caused by carboplatin toxicity were seen .	O O O O O O O O B O O O	['toxicity']	1	2	"Sentence: Various ocular symptoms and findings caused by carboplatin toxicity were seen .
Diseases: toxicity"	"Sentence: Various ocular symptoms and findings caused by carboplatin toxicity were seen .
Diseases:"
3396	He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection .
Diseases: "	"Sentence: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection .
Diseases:"
3397	Although the intraocular pressure elevation caused by secondary acute angle - closure glaucoma decreased and ocular pain diminished , inexorable papilledema and exudative retinal detachment continued for 3 weeks .	O O O O O O O O O O O O B O O B I O O O B O O B I O O O O O	['papilledema', 'glaucoma', 'retinal detachment', 'ocular pain']	4	17	"Sentence: Although the intraocular pressure elevation caused by secondary acute angle - closure glaucoma decreased and ocular pain diminished , inexorable papilledema and exudative retinal detachment continued for 3 weeks .
Diseases: papilledema, glaucoma, retinal detachment, ocular pain"	"Sentence: Although the intraocular pressure elevation caused by secondary acute angle - closure glaucoma decreased and ocular pain diminished , inexorable papilledema and exudative retinal detachment continued for 3 weeks .
Diseases:"
3398	Finally , 6 weeks later , diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost .	O O O O O O O B I O B I O O O O O O O O O O O	['chorioretinal atrophy', 'optic atrophy']	2	10	"Sentence: Finally , 6 weeks later , diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost .
Diseases: chorioretinal atrophy, optic atrophy"	"Sentence: Finally , 6 weeks later , diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost .
Diseases:"
3399	CONCLUSION : When performing intracarotid injection of carboplatin , we must be aware of its potentially blinding ocular toxicity .	O O O O O O O O O O O O O O O O O B I O	['ocular toxicity']	1	2	"Sentence: CONCLUSION : When performing intracarotid injection of carboplatin , we must be aware of its potentially blinding ocular toxicity .
Diseases: ocular toxicity"	"Sentence: CONCLUSION : When performing intracarotid injection of carboplatin , we must be aware of its potentially blinding ocular toxicity .
Diseases:"
3400	It is recommended that further studies and investigations are undertaken in the effort to minimize such severe side effects .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is recommended that further studies and investigations are undertaken in the effort to minimize such severe side effects .
Diseases: "	"Sentence: It is recommended that further studies and investigations are undertaken in the effort to minimize such severe side effects .
Diseases:"
3401	Phase II study of the amsacrine analogue CI - 921 ( NSC 343499 ) in non - small cell lung cancer .	O O O O O O O O O O O O O O O B I I I I I O	['non - small cell lung cancer']	1	6	"Sentence: Phase II study of the amsacrine analogue CI - 921 ( NSC 343499 ) in non - small cell lung cancer .
Diseases: non - small cell lung cancer"	"Sentence: Phase II study of the amsacrine analogue CI - 921 ( NSC 343499 ) in non - small cell lung cancer .
Diseases:"
3402	CI - 921 ( NSC 343499 ; 9 - [ [ 2 - methoxy - 4 - [ ( methylsulphonyl ) amino ] phenyl ] amino ] - N , 5 - dimethyl - 4 - acridinecarboxamide ) is a topoisomerase II poison with high experimental antitumour activity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CI - 921 ( NSC 343499 ; 9 - [ [ 2 - methoxy - 4 - [ ( methylsulphonyl ) amino ] phenyl ] amino ] - N , 5 - dimethyl - 4 - acridinecarboxamide ) is a topoisomerase II poison with high experimental antitumour activity .
Diseases: "	"Sentence: CI - 921 ( NSC 343499 ; 9 - [ [ 2 - methoxy - 4 - [ ( methylsulphonyl ) amino ] phenyl ] amino ] - N , 5 - dimethyl - 4 - acridinecarboxamide ) is a topoisomerase II poison with high experimental antitumour activity .
Diseases:"
3403	It was administered by 15 min infusion to 16 evaluable patients with non - small cell lung cancer ( NSCLC ) ( 7 with no prior treatment , 9 patients in relapse following surgery / radiotherapy ) at a dose ( 648 mg / m2 divided over 3 days , repeated every 3 weeks ) determined by phase	O O O O O O O O O O O O B I I I I I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nsclc', 'non - small cell lung cancer']	2	10	"Sentence: It was administered by 15 min infusion to 16 evaluable patients with non - small cell lung cancer ( NSCLC ) ( 7 with no prior treatment , 9 patients in relapse following surgery / radiotherapy ) at a dose ( 648 mg / m2 divided over 3 days , repeated every 3 weeks ) determined by phase
Diseases: nsclc, non - small cell lung cancer"	"Sentence: It was administered by 15 min infusion to 16 evaluable patients with non - small cell lung cancer ( NSCLC ) ( 7 with no prior treatment , 9 patients in relapse following surgery / radiotherapy ) at a dose ( 648 mg / m2 divided over 3 days , repeated every 3 weeks ) determined by phase
Diseases:"
3404	I trial .	O O O	[]	0	0	"Sentence: I trial .
Diseases: "	"Sentence: I trial .
Diseases:"
3405	Patients had a median performance status of 1 ( WHO ) , and median age of 61 years .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients had a median performance status of 1 ( WHO ) , and median age of 61 years .
Diseases: "	"Sentence: Patients had a median performance status of 1 ( WHO ) , and median age of 61 years .
Diseases:"
3406	The histology comprised squamous carcinoma ( 11 ) , adenocarcinoma ( 1 ) , mixed histology ( 2 ) , bronchio - alveolar carcinoma ( 1 ) and large cell undifferentiated carcinoma ( 1 ) .	O O O B I O O O O B O O O O O O O O O O B I I I O O O O O O B I O O O O	['squamous carcinoma', 'bronchio - alveolar carcinoma', 'undifferentiated carcinoma', 'adenocarcinoma']	4	26	"Sentence: The histology comprised squamous carcinoma ( 11 ) , adenocarcinoma ( 1 ) , mixed histology ( 2 ) , bronchio - alveolar carcinoma ( 1 ) and large cell undifferentiated carcinoma ( 1 ) .
Diseases: squamous carcinoma, bronchio - alveolar carcinoma, undifferentiated carcinoma, adenocarcinoma"	"Sentence: The histology comprised squamous carcinoma ( 11 ) , adenocarcinoma ( 1 ) , mixed histology ( 2 ) , bronchio - alveolar carcinoma ( 1 ) and large cell undifferentiated carcinoma ( 1 ) .
Diseases:"
3407	Neutropenia grade greater than or equal to 3 was seen in 15 patients , infections with recovery in 3 , and grand mal seizures in 1 patient .	B O O O O O O O O O O O O O B O O O O O O O O B O O O O	['infections', 'neutropenia', 'seizures']	3	9	"Sentence: Neutropenia grade greater than or equal to 3 was seen in 15 patients , infections with recovery in 3 , and grand mal seizures in 1 patient .
Diseases: infections, neutropenia, seizures"	"Sentence: Neutropenia grade greater than or equal to 3 was seen in 15 patients , infections with recovery in 3 , and grand mal seizures in 1 patient .
Diseases:"
3408	Grade less than or equal to 2 nausea and vomiting occurred in 66 % courses and phlebitis in the infusion arm in 37 % .	O O O O O O O B O B O O O O O O B O O O O O O O O	['nausea', 'vomiting', 'phlebitis']	3	10	"Sentence: Grade less than or equal to 2 nausea and vomiting occurred in 66 % courses and phlebitis in the infusion arm in 37 % .
Diseases: nausea, vomiting, phlebitis"	"Sentence: Grade less than or equal to 2 nausea and vomiting occurred in 66 % courses and phlebitis in the infusion arm in 37 % .
Diseases:"
3409	1 patient with squamous cell carcinoma achieved a partial response lasting 5 months .	O O O B I I O O O O O O O O	['squamous cell carcinoma']	1	5	"Sentence: 1 patient with squamous cell carcinoma achieved a partial response lasting 5 months .
Diseases: squamous cell carcinoma"	"Sentence: 1 patient with squamous cell carcinoma achieved a partial response lasting 5 months .
Diseases:"
3410	Further testing in this and other tumour types using multiple daily schedules is warranted .	O O O O O O B O O O O O O O O	['tumour']	1	3	"Sentence: Further testing in this and other tumour types using multiple daily schedules is warranted .
Diseases: tumour"	"Sentence: Further testing in this and other tumour types using multiple daily schedules is warranted .
Diseases:"
3411	Alpha - lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy .	O O O O O B I O B O O O B O	['neuropathy', 'mitochondrial damage', 'neurotoxicity']	3	9	"Sentence: Alpha - lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy .
Diseases: neuropathy, mitochondrial damage, neurotoxicity"	"Sentence: Alpha - lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy .
Diseases:"
3412	The study investigates if alpha - lipoic acid is neuroprotective against chemotherapy induced neurotoxicity , if mitochondrial damage plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of alpha - lipoic acid depend on mitochondria protection .	O O O O O O O O O O O O O B O O B I O O O O O B I I O O O O O O O O O O O O O O O	['mitochondrial damage', 'toxic neurodegenerative cascade', 'neurotoxicity']	3	13	"Sentence: The study investigates if alpha - lipoic acid is neuroprotective against chemotherapy induced neurotoxicity , if mitochondrial damage plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of alpha - lipoic acid depend on mitochondria protection .
Diseases: mitochondrial damage, toxic neurodegenerative cascade, neurotoxicity"	"Sentence: The study investigates if alpha - lipoic acid is neuroprotective against chemotherapy induced neurotoxicity , if mitochondrial damage plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of alpha - lipoic acid depend on mitochondria protection .
Diseases:"
3413	We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion ( DRG ) sensory neurons to paclitaxel and cisplatin , two widely used and highly effective chemotherapeutic drugs .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['peripheral neuropathy']	1	5	"Sentence: We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion ( DRG ) sensory neurons to paclitaxel and cisplatin , two widely used and highly effective chemotherapeutic drugs .
Diseases: peripheral neuropathy"	"Sentence: We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion ( DRG ) sensory neurons to paclitaxel and cisplatin , two widely used and highly effective chemotherapeutic drugs .
Diseases:"
3414	This approach allowed investigating the efficacy of alpha - lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha - lipoic acid .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	['axonal damage']	1	3	"Sentence: This approach allowed investigating the efficacy of alpha - lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha - lipoic acid .
Diseases: axonal damage"	"Sentence: This approach allowed investigating the efficacy of alpha - lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha - lipoic acid .
Diseases:"
3415	Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons .	O O O O O O O O O O B I O O O O O O O O O O O O O	['mitochondrial impairment']	1	4	"Sentence: Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons .
Diseases: mitochondrial impairment"	"Sentence: Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons .
Diseases:"
3416	Alpha - lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons : it rescues the mitochondrial toxicity and induces the expression of frataxin , an essential mitochondrial protein with anti - oxidant and chaperone properties .	O O O O O O O O O O B O O O O O O O B I O O O O O O O O O O O O O O O O O O O	['mitochondrial toxicity', 'neurotoxicity']	2	7	"Sentence: Alpha - lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons : it rescues the mitochondrial toxicity and induces the expression of frataxin , an essential mitochondrial protein with anti - oxidant and chaperone properties .
Diseases: mitochondrial toxicity, neurotoxicity"	"Sentence: Alpha - lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons : it rescues the mitochondrial toxicity and induces the expression of frataxin , an essential mitochondrial protein with anti - oxidant and chaperone properties .
Diseases:"
3417	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity .	O O B I O O O O O O O O O O O B O	['mitochondrial toxicity', 'neurotoxicity']	2	7	"Sentence: In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity .
Diseases: mitochondrial toxicity, neurotoxicity"	"Sentence: In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity .
Diseases:"
3418	Alpha - lipoic acid protects sensory neurons through its anti - oxidant and mitochondrial regulatory functions , possibly inducing the expression of frataxin .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Alpha - lipoic acid protects sensory neurons through its anti - oxidant and mitochondrial regulatory functions , possibly inducing the expression of frataxin .
Diseases: "	"Sentence: Alpha - lipoic acid protects sensory neurons through its anti - oxidant and mitochondrial regulatory functions , possibly inducing the expression of frataxin .
Diseases:"
3419	These findings suggest that alpha - lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials .	O O O O O O O O O O O O O O B I I O O O O O O O O O O O	['peripheral nerve toxicity']	1	5	"Sentence: These findings suggest that alpha - lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials .
Diseases: peripheral nerve toxicity"	"Sentence: These findings suggest that alpha - lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials .
Diseases:"
3420	Optimising stroke prevention in non - valvular atrial fibrillation .	O B O O O O O B I O	['stroke', 'atrial fibrillation']	2	7	"Sentence: Optimising stroke prevention in non - valvular atrial fibrillation .
Diseases: stroke, atrial fibrillation"	"Sentence: Optimising stroke prevention in non - valvular atrial fibrillation .
Diseases:"
3421	Atrial fibrillation is associated with substantial morbidity and mortality .	B I O O O O O O O O	['atrial fibrillation']	1	5	"Sentence: Atrial fibrillation is associated with substantial morbidity and mortality .
Diseases: atrial fibrillation"	"Sentence: Atrial fibrillation is associated with substantial morbidity and mortality .
Diseases:"
3422	Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62 % , and that aspirin alone reduces the risk by 22 % .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['stroke']	1	1	"Sentence: Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62 % , and that aspirin alone reduces the risk by 22 % .
Diseases: stroke"	"Sentence: Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62 % , and that aspirin alone reduces the risk by 22 % .
Diseases:"
3423	Overall , in high - risk patients , warfarin is superior to aspirin in preventing strokes , with a relative risk reduction of 36 % .	O O O O O O O O O O O O O O O B O O O O O O O O O O	['strokes']	1	2	"Sentence: Overall , in high - risk patients , warfarin is superior to aspirin in preventing strokes , with a relative risk reduction of 36 % .
Diseases: strokes"	"Sentence: Overall , in high - risk patients , warfarin is superior to aspirin in preventing strokes , with a relative risk reduction of 36 % .
Diseases:"
3424	Ximelagatran , an oral direct thrombin inhibitor , was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events , but has been recently withdrawn because of abnormal liver function tests .	O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O B I I O O	['abnormal liver function', 'embolic events']	2	8	"Sentence: Ximelagatran , an oral direct thrombin inhibitor , was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events , but has been recently withdrawn because of abnormal liver function tests .
Diseases: abnormal liver function, embolic events"	"Sentence: Ximelagatran , an oral direct thrombin inhibitor , was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events , but has been recently withdrawn because of abnormal liver function tests .
Diseases:"
3425	The ACTIVE - W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['atrial fibrillation', 'embolic events']	2	9	"Sentence: The ACTIVE - W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .
Diseases: atrial fibrillation, embolic events"	"Sentence: The ACTIVE - W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .
Diseases:"
3426	Idraparinux , a Factor Xa inhibitor , is being evaluated in patients with atrial fibrillation .	O O O O O O O O O O O O O B I O	['atrial fibrillation']	1	5	"Sentence: Idraparinux , a Factor Xa inhibitor , is being evaluated in patients with atrial fibrillation .
Diseases: atrial fibrillation"	"Sentence: Idraparinux , a Factor Xa inhibitor , is being evaluated in patients with atrial fibrillation .
Diseases:"
3427	Angiotensin - converting enzyme inhibitors and angiotensin II receptor - blocking drugs hold promise in atrial fibrillation through cardiac remodelling .	O O O O O O O O O O O O O O O B I O B I O	['atrial fibrillation', 'cardiac remodelling']	2	9	"Sentence: Angiotensin - converting enzyme inhibitors and angiotensin II receptor - blocking drugs hold promise in atrial fibrillation through cardiac remodelling .
Diseases: atrial fibrillation, cardiac remodelling"	"Sentence: Angiotensin - converting enzyme inhibitors and angiotensin II receptor - blocking drugs hold promise in atrial fibrillation through cardiac remodelling .
Diseases:"
3428	Preliminary studies suggest that statins could interfere with the risk of recurrence after electrical cardioversion .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Preliminary studies suggest that statins could interfere with the risk of recurrence after electrical cardioversion .
Diseases: "	"Sentence: Preliminary studies suggest that statins could interfere with the risk of recurrence after electrical cardioversion .
Diseases:"
3429	Finally , percutaneous methods for the exclusion of left atrial appendage are under investigation in high - risk patients .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Finally , percutaneous methods for the exclusion of left atrial appendage are under investigation in high - risk patients .
Diseases: "	"Sentence: Finally , percutaneous methods for the exclusion of left atrial appendage are under investigation in high - risk patients .
Diseases:"
3430	Interaction of cyclosporin A with antineoplastic agents .	O O O O O O O O	[]	0	0	"Sentence: Interaction of cyclosporin A with antineoplastic agents .
Diseases: "	"Sentence: Interaction of cyclosporin A with antineoplastic agents .
Diseases:"
3431	A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T - lymphocytic leukemia in relapse .	O O O O O O O O O O O O O O B I I I I O O O	['acute t - lymphocytic leukemia']	1	8	"Sentence: A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T - lymphocytic leukemia in relapse .
Diseases: acute t - lymphocytic leukemia"	"Sentence: A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T - lymphocytic leukemia in relapse .
Diseases:"
3432	The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow .	O O O O O O O O O O O O O O B I O O O O	['leukemic infiltration']	1	4	"Sentence: The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow .
Diseases: leukemic infiltration"	"Sentence: The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow .
Diseases:"
3433	Severe side effects in terms of mental confusion and progressive hyperbilirubinemia , however , point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues .	O O O O O O O B O O B O O O O O O O O O O O O O O O B O O O O	['toxicity', 'confusion', 'hyperbilirubinemia']	3	10	"Sentence: Severe side effects in terms of mental confusion and progressive hyperbilirubinemia , however , point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues .
Diseases: toxicity, confusion, hyperbilirubinemia"	"Sentence: Severe side effects in terms of mental confusion and progressive hyperbilirubinemia , however , point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues .
Diseases:"
3434	This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T - cell functions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T - cell functions .
Diseases: "	"Sentence: This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T - cell functions .
Diseases:"
3435	The hematologic effects of cefonicid and cefazedone in the dog : a potential model of cephalosporin hematotoxicity in man .	O O O O O O O O O O O O O O O O B O O O	['hematotoxicity']	1	3	"Sentence: The hematologic effects of cefonicid and cefazedone in the dog : a potential model of cephalosporin hematotoxicity in man .
Diseases: hematotoxicity"	"Sentence: The hematologic effects of cefonicid and cefazedone in the dog : a potential model of cephalosporin hematotoxicity in man .
Diseases:"
3436	Cephalosporin antibiotics cause a variety of hematologic disturbances in man , the pathogeneses and hematopathology of which remain poorly characterized .	O O O O O O B I O O O O O O O O O O O O O	['hematologic disturbances']	1	3	"Sentence: Cephalosporin antibiotics cause a variety of hematologic disturbances in man , the pathogeneses and hematopathology of which remain poorly characterized .
Diseases: hematologic disturbances"	"Sentence: Cephalosporin antibiotics cause a variety of hematologic disturbances in man , the pathogeneses and hematopathology of which remain poorly characterized .
Diseases:"
3437	There is a need for a well - defined animal model in which these blood dyscrasias can be studied .	O O O O O O O O O O O O O O B I O O O O	['blood dyscrasias']	1	5	"Sentence: There is a need for a well - defined animal model in which these blood dyscrasias can be studied .
Diseases: blood dyscrasias"	"Sentence: There is a need for a well - defined animal model in which these blood dyscrasias can be studied .
Diseases:"
3438	In four subacute toxicity studies , the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose - dependent incidence of anemia , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .	O O O B O O O O O O O O O O O O O O O O O O O B O B O O B O O O O O O O O	['thrombocytopenia', 'anemia', 'neutropenia', 'toxicity']	4	17	"Sentence: In four subacute toxicity studies , the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose - dependent incidence of anemia , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
Diseases: thrombocytopenia, anemia, neutropenia, toxicity"	"Sentence: In four subacute toxicity studies , the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose - dependent incidence of anemia , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .
Diseases:"
3439	A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50 % of dogs receiving 400 - 500 mg / kg cefonicid or 540 - 840 mg / kg cefazedone .	O O B O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['cytopenias', 'anemia']	2	7	"Sentence: A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50 % of dogs receiving 400 - 500 mg / kg cefonicid or 540 - 840 mg / kg cefazedone .
Diseases: cytopenias, anemia"	"Sentence: A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50 % of dogs receiving 400 - 500 mg / kg cefonicid or 540 - 840 mg / kg cefazedone .
Diseases:"
3440	All three cytopenias were completely reversible following cessation of treatment ; the time required for recovery of the erythron ( approximately 1 month ) was considerably longer than that of the granulocytes and platelets ( hours to a few days ) .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cytopenias']	1	4	"Sentence: All three cytopenias were completely reversible following cessation of treatment ; the time required for recovery of the erythron ( approximately 1 month ) was considerably longer than that of the granulocytes and platelets ( hours to a few days ) .
Diseases: cytopenias"	"Sentence: All three cytopenias were completely reversible following cessation of treatment ; the time required for recovery of the erythron ( approximately 1 month ) was considerably longer than that of the granulocytes and platelets ( hours to a few days ) .
Diseases:"
3441	Upon rechallenge with either cephalosporin , the hematologic syndrome was reproduced in most dogs tested ; cefonicid ( but not cefazedone ) - treated dogs showed a substantially reduced induction period ( 15 + / - 5 days ) compared to that of the first exposure to the drug ( 61 + / - 24 days ) .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hematologic syndrome']	1	3	"Sentence: Upon rechallenge with either cephalosporin , the hematologic syndrome was reproduced in most dogs tested ; cefonicid ( but not cefazedone ) - treated dogs showed a substantially reduced induction period ( 15 + / - 5 days ) compared to that of the first exposure to the drug ( 61 + / - 24 days ) .
Diseases: hematologic syndrome"	"Sentence: Upon rechallenge with either cephalosporin , the hematologic syndrome was reproduced in most dogs tested ; cefonicid ( but not cefazedone ) - treated dogs showed a substantially reduced induction period ( 15 + / - 5 days ) compared to that of the first exposure to the drug ( 61 + / - 24 days ) .
Diseases:"
3442	This observation , along with the rapid rate of decline in red cell mass parameters of affected dogs , suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O	['cytopenia', 'hemolytic']	2	8	"Sentence: This observation , along with the rapid rate of decline in red cell mass parameters of affected dogs , suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia .
Diseases: cytopenia, hemolytic"	"Sentence: This observation , along with the rapid rate of decline in red cell mass parameters of affected dogs , suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia .
Diseases:"
3443	We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin - induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .	O O O O O O O O O O O O O O O O B O O O O O O B I O O O O O O O O O O O O O O O O O	['hematotoxicity', 'blood dyscrasias']	2	9	"Sentence: We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin - induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .
Diseases: hematotoxicity, blood dyscrasias"	"Sentence: We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin - induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .
Diseases:"
3444	A pyridoxine - dependent behavioral disorder unmasked by isoniazid .	O O O O B I O O O O	['behavioral disorder']	1	3	"Sentence: A pyridoxine - dependent behavioral disorder unmasked by isoniazid .
Diseases: behavioral disorder"	"Sentence: A pyridoxine - dependent behavioral disorder unmasked by isoniazid .
Diseases:"
3445	A 3 - year - old girl had behavioral deterioration , with hyperkinesis , irritability , and sleeping difficulties after the therapeutic administration of isoniazid .	O O O O O O O O B I O O B O B O O B I O O O O O O O	['sleeping difficulties', 'behavioral deterioration', 'irritability', 'hyperkinesis']	4	13	"Sentence: A 3 - year - old girl had behavioral deterioration , with hyperkinesis , irritability , and sleeping difficulties after the therapeutic administration of isoniazid .
Diseases: sleeping difficulties, behavioral deterioration, irritability, hyperkinesis"	"Sentence: A 3 - year - old girl had behavioral deterioration , with hyperkinesis , irritability , and sleeping difficulties after the therapeutic administration of isoniazid .
Diseases:"
3446	The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms .
Diseases: "	"Sentence: The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms .
Diseases:"
3447	After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine .
Diseases: "	"Sentence: After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine .
Diseases:"
3448	A placebo had no effect , but niacinamide was as effective as pyridoxine .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: A placebo had no effect , but niacinamide was as effective as pyridoxine .
Diseases: "	"Sentence: A placebo had no effect , but niacinamide was as effective as pyridoxine .
Diseases:"
3449	Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis .	O O O O O O O O O O B O	['hyperkinesis']	1	4	"Sentence: Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis .
Diseases: hyperkinesis"	"Sentence: Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis .
Diseases:"
3450	The level of pyridoxal in the blood was normal during the periods of relapse .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The level of pyridoxal in the blood was normal during the periods of relapse .
Diseases: "	"Sentence: The level of pyridoxal in the blood was normal during the periods of relapse .
Diseases:"
3451	Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism .
Diseases: "	"Sentence: Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism .
Diseases:"
3452	The patient has been followed for six years and has required pharmacologic doses of pyridoxine to control her behavior .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The patient has been followed for six years and has required pharmacologic doses of pyridoxine to control her behavior .
Diseases: "	"Sentence: The patient has been followed for six years and has required pharmacologic doses of pyridoxine to control her behavior .
Diseases:"
3453	A selective dopamine D4 receptor antagonist , NRA0160 : a preclinical neuropharmacological profile .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: A selective dopamine D4 receptor antagonist , NRA0160 : a preclinical neuropharmacological profile .
Diseases: "	"Sentence: A selective dopamine D4 receptor antagonist , NRA0160 : a preclinical neuropharmacological profile .
Diseases:"
3454	NRA0160 , 5 - [ 2 - ( 4 - ( 3 - fluorobenzylidene ) piperidin - 1 - yl ) ethyl ] - 4 - ( 4 - fluorophenyl ) thiazole - 2 - carboxamide , has a high affinity for human cloned dopamine D4 . 2 , D4 . 4 and D4 . 7 receptors , with Ki values of 0 . 5 , 0 . 9 and 2 . 7 nM , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NRA0160 , 5 - [ 2 - ( 4 - ( 3 - fluorobenzylidene ) piperidin - 1 - yl ) ethyl ] - 4 - ( 4 - fluorophenyl ) thiazole - 2 - carboxamide , has a high affinity for human cloned dopamine D4 . 2 , D4 . 4 and D4 . 7 receptors , with Ki values of 0 . 5 , 0 . 9 and 2 . 7 nM , respectively .
Diseases: "	"Sentence: NRA0160 , 5 - [ 2 - ( 4 - ( 3 - fluorobenzylidene ) piperidin - 1 - yl ) ethyl ] - 4 - ( 4 - fluorophenyl ) thiazole - 2 - carboxamide , has a high affinity for human cloned dopamine D4 . 2 , D4 . 4 and D4 . 7 receptors , with Ki values of 0 . 5 , 0 . 9 and 2 . 7 nM , respectively .
Diseases:"
3455	NRA0160 is over 20 , 000fold more potent at the dopamine D4 . 2 receptor compared with the human cloned dopamine D2L receptor .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NRA0160 is over 20 , 000fold more potent at the dopamine D4 . 2 receptor compared with the human cloned dopamine D2L receptor .
Diseases: "	"Sentence: NRA0160 is over 20 , 000fold more potent at the dopamine D4 . 2 receptor compared with the human cloned dopamine D2L receptor .
Diseases:"
3456	NRA0160 has negligible affinity for the human cloned dopamine D3 receptor ( Ki = 39 nM ) , rat serotonin ( 5 - HT ) 2A receptors ( Ki = 180 nM ) and rat alpha1 adrenoceptor ( Ki = 237 nM ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NRA0160 has negligible affinity for the human cloned dopamine D3 receptor ( Ki = 39 nM ) , rat serotonin ( 5 - HT ) 2A receptors ( Ki = 180 nM ) and rat alpha1 adrenoceptor ( Ki = 237 nM ) .
Diseases: "	"Sentence: NRA0160 has negligible affinity for the human cloned dopamine D3 receptor ( Ki = 39 nM ) , rat serotonin ( 5 - HT ) 2A receptors ( Ki = 180 nM ) and rat alpha1 adrenoceptor ( Ki = 237 nM ) .
Diseases:"
3457	NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine ( MAP ) in mice .	O O O O O B O O O O O O O O O	['hyperactivity']	1	2	"Sentence: NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine ( MAP ) in mice .
Diseases: hyperactivity"	"Sentence: NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine ( MAP ) in mice .
Diseases:"
3458	NRA0160 and clozapine antagonized MAP - induced stereotyped behavior in mice , although their effects did not exceed 50 % inhibition , even at the highest dose given .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NRA0160 and clozapine antagonized MAP - induced stereotyped behavior in mice , although their effects did not exceed 50 % inhibition , even at the highest dose given .
Diseases: "	"Sentence: NRA0160 and clozapine antagonized MAP - induced stereotyped behavior in mice , although their effects did not exceed 50 % inhibition , even at the highest dose given .
Diseases:"
3459	NRA0160 and clozapine significantly induced catalepsy in rats , although their effects did not exceed 50 % induction even at the highest dose given .	O O O O O B O O O O O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: NRA0160 and clozapine significantly induced catalepsy in rats , although their effects did not exceed 50 % induction even at the highest dose given .
Diseases: catalepsy"	"Sentence: NRA0160 and clozapine significantly induced catalepsy in rats , although their effects did not exceed 50 % induction even at the highest dose given .
Diseases:"
3460	NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition ( PPI ) in rats produced by apomorphine .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition ( PPI ) in rats produced by apomorphine .
Diseases: "	"Sentence: NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition ( PPI ) in rats produced by apomorphine .
Diseases:"
3461	NRA0160 and clozapine significantly shortened the phencyclidine ( PCP ) - induced prolonged swimming latency in rats in a water maze task .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NRA0160 and clozapine significantly shortened the phencyclidine ( PCP ) - induced prolonged swimming latency in rats in a water maze task .
Diseases: "	"Sentence: NRA0160 and clozapine significantly shortened the phencyclidine ( PCP ) - induced prolonged swimming latency in rats in a water maze task .
Diseases:"
3462	These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics .
Diseases: "	"Sentence: These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics .
Diseases:"
3463	Prolonged cholestasis after troleandomycin - induced acute hepatitis .	O B O O O O O B O	['cholestasis', 'hepatitis']	2	6	"Sentence: Prolonged cholestasis after troleandomycin - induced acute hepatitis .
Diseases: cholestasis, hepatitis"	"Sentence: Prolonged cholestasis after troleandomycin - induced acute hepatitis .
Diseases:"
3464	We report the case of a patient in whom troleandomycin - induced hepatitis was followed by prolonged anicteric cholestasis .	O O O O O O O O O O O O B O O O O O B O	['cholestasis', 'hepatitis']	2	6	"Sentence: We report the case of a patient in whom troleandomycin - induced hepatitis was followed by prolonged anicteric cholestasis .
Diseases: cholestasis, hepatitis"	"Sentence: We report the case of a patient in whom troleandomycin - induced hepatitis was followed by prolonged anicteric cholestasis .
Diseases:"
3465	Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia .	B O O O O O O O O O O O O B O	['hypereosinophilia', 'jaundice']	2	11	"Sentence: Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia .
Diseases: hypereosinophilia, jaundice"	"Sentence: Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia .
Diseases:"
3466	Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities .	B O O O O O O O O O O B O O B O O O O O O O O O O	['cholestasis', 'jaundice', 'pruritus']	3	12	"Sentence: Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities .
Diseases: cholestasis, jaundice, pruritus"	"Sentence: Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities .
Diseases:"
3467	Finally , pruritus disappeared within 19 months , and liver tests returned to normal 27 months after the onset of hepatitis .	O O B O O O O O O O O O O O O O O O O O B O	['pruritus', 'hepatitis']	2	5	"Sentence: Finally , pruritus disappeared within 19 months , and liver tests returned to normal 27 months after the onset of hepatitis .
Diseases: pruritus, hepatitis"	"Sentence: Finally , pruritus disappeared within 19 months , and liver tests returned to normal 27 months after the onset of hepatitis .
Diseases:"
3468	This observation demonstrates that prolonged cholestasis can follow troleandomycin - induced acute hepatitis .	O O O O O B O O O O O O B O	['cholestasis', 'hepatitis']	2	6	"Sentence: This observation demonstrates that prolonged cholestasis can follow troleandomycin - induced acute hepatitis .
Diseases: cholestasis, hepatitis"	"Sentence: This observation demonstrates that prolonged cholestasis can follow troleandomycin - induced acute hepatitis .
Diseases:"
3469	HMG CoA reductase inhibitors .	O O O O O	[]	0	0	"Sentence: HMG CoA reductase inhibitors .
Diseases: "	"Sentence: HMG CoA reductase inhibitors .
Diseases:"
3470	Current clinical experience .	O O O O	[]	0	0	"Sentence: Current clinical experience .
Diseases: "	"Sentence: Current clinical experience .
Diseases:"
3471	Lovastatin and simvastatin are the 2 best - known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Lovastatin and simvastatin are the 2 best - known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors .
Diseases: "	"Sentence: Lovastatin and simvastatin are the 2 best - known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors .
Diseases:"
3472	Clinical experience with lovastatin includes over 5000 patients , 700 of whom have been treated for 2 years or more , and experience with simvastatin includes over 3500 patients , of whom 350 have been treated for 18 months or more .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical experience with lovastatin includes over 5000 patients , 700 of whom have been treated for 2 years or more , and experience with simvastatin includes over 3500 patients , of whom 350 have been treated for 18 months or more .
Diseases: "	"Sentence: Clinical experience with lovastatin includes over 5000 patients , 700 of whom have been treated for 2 years or more , and experience with simvastatin includes over 3500 patients , of whom 350 have been treated for 18 months or more .
Diseases:"
3473	Lovastatin has been marketed in the United States for over 6 months .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Lovastatin has been marketed in the United States for over 6 months .
Diseases: "	"Sentence: Lovastatin has been marketed in the United States for over 6 months .
Diseases:"
3474	Both agents show substantial clinical efficacy , with reductions in total cholesterol of over 30 % and in LDL - cholesterol of 40 % in clinical studies .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Both agents show substantial clinical efficacy , with reductions in total cholesterol of over 30 % and in LDL - cholesterol of 40 % in clinical studies .
Diseases: "	"Sentence: Both agents show substantial clinical efficacy , with reductions in total cholesterol of over 30 % and in LDL - cholesterol of 40 % in clinical studies .
Diseases:"
3475	Modest increases in HDL - cholesterol levels of about 10 % are also reported .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Modest increases in HDL - cholesterol levels of about 10 % are also reported .
Diseases: "	"Sentence: Modest increases in HDL - cholesterol levels of about 10 % are also reported .
Diseases:"
3476	Clinical tolerability of both agents has been good , with fewer than 3 % of patients withdrawn from treatment because of clinical adverse experiences .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical tolerability of both agents has been good , with fewer than 3 % of patients withdrawn from treatment because of clinical adverse experiences .
Diseases: "	"Sentence: Clinical tolerability of both agents has been good , with fewer than 3 % of patients withdrawn from treatment because of clinical adverse experiences .
Diseases:"
3477	Ophthalmological examinations in over 1100 patients treated with one or the other agent have revealed no evidence of significant short term ( up to 2 years ) cataractogenic potential .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ophthalmological examinations in over 1100 patients treated with one or the other agent have revealed no evidence of significant short term ( up to 2 years ) cataractogenic potential .
Diseases: "	"Sentence: Ophthalmological examinations in over 1100 patients treated with one or the other agent have revealed no evidence of significant short term ( up to 2 years ) cataractogenic potential .
Diseases:"
3478	One to 2 % of patients have elevations of serum transaminases to greater than 3 times the upper limit of normal .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: One to 2 % of patients have elevations of serum transaminases to greater than 3 times the upper limit of normal .
Diseases: "	"Sentence: One to 2 % of patients have elevations of serum transaminases to greater than 3 times the upper limit of normal .
Diseases:"
3479	These episodes are asymptomatic and reversible when therapy is discontinued .	O O O O O O O O O O O	[]	0	0	"Sentence: These episodes are asymptomatic and reversible when therapy is discontinued .
Diseases: "	"Sentence: These episodes are asymptomatic and reversible when therapy is discontinued .
Diseases:"
3480	Minor elevations of creatine kinase levels are reported in about 5 % of patients .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Minor elevations of creatine kinase levels are reported in about 5 % of patients .
Diseases: "	"Sentence: Minor elevations of creatine kinase levels are reported in about 5 % of patients .
Diseases:"
3481	Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .	B O O O O O O B O O O O O O O B I O O O O O O O O O O O O O O O O O O O O	['myopathy', 'renal failure', 'myoglobinuria']	3	9	"Sentence: Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .
Diseases: myopathy, renal failure, myoglobinuria"	"Sentence: Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .
Diseases:"
3482	Lovastatin and simvastatin are both effective and well - tolerated agents for lowering elevated levels of serum cholesterol .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Lovastatin and simvastatin are both effective and well - tolerated agents for lowering elevated levels of serum cholesterol .
Diseases: "	"Sentence: Lovastatin and simvastatin are both effective and well - tolerated agents for lowering elevated levels of serum cholesterol .
Diseases:"
3483	As wider use confirms their safety profile , they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences .	O O O O O O O O O O O O O O O O O O B O O O O	['hypercholesterolaemia']	1	5	"Sentence: As wider use confirms their safety profile , they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences .
Diseases: hypercholesterolaemia"	"Sentence: As wider use confirms their safety profile , they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences .
Diseases:"
3484	Sulfasalazine - induced lupus erythematosus .	O O O B I O	['lupus erythematosus']	1	9	"Sentence: Sulfasalazine - induced lupus erythematosus .
Diseases: lupus erythematosus"	"Sentence: Sulfasalazine - induced lupus erythematosus .
Diseases:"
3485	Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis .	B O O B I O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O B I O	['ulcerative colitis', 'cardiac tamponade', 'pneumonitis', 'pleural effusions']	4	19	"Sentence: Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis .
Diseases: ulcerative colitis, cardiac tamponade, pneumonitis, pleural effusions"	"Sentence: Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis .
Diseases:"
3486	After cessation of the sulfasalazine and completion of a six - week course of corticosteroids , these problems resolved over a period of four to six months .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After cessation of the sulfasalazine and completion of a six - week course of corticosteroids , these problems resolved over a period of four to six months .
Diseases: "	"Sentence: After cessation of the sulfasalazine and completion of a six - week course of corticosteroids , these problems resolved over a period of four to six months .
Diseases:"
3487	It is suggested that the patient had sulfasalazine - induced lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .	O O O O O O O O O O B O O O O B O O O O O O O O O O O	['lupus', 'serositis']	2	7	"Sentence: It is suggested that the patient had sulfasalazine - induced lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .
Diseases: lupus, serositis"	"Sentence: It is suggested that the patient had sulfasalazine - induced lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .
Diseases:"
3488	Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine - induced lupus syndrome .	O O O O O O O O B I I O O O O O O O O O O B I O	['lupus syndrome', 'inflammatory bowel disease']	2	8	"Sentence: Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine - induced lupus syndrome .
Diseases: lupus syndrome, inflammatory bowel disease"	"Sentence: Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine - induced lupus syndrome .
Diseases:"
3489	Optimization of levodopa therapy .	O O O O O	[]	0	0	"Sentence: Optimization of levodopa therapy .
Diseases: "	"Sentence: Optimization of levodopa therapy .
Diseases:"
3490	"While there is no single correct starting dose for levodopa therapy , many individuals can be started on either the 25 / 100 or controlled - release formula , following the general rule not to attempt to titrate carbidopa - levodopa to the point of "" normality , "" which can lead to toxicity ."	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['toxicity']	1	2	"Sentence: While there is no single correct starting dose for levodopa therapy , many individuals can be started on either the 25 / 100 or controlled - release formula , following the general rule not to attempt to titrate carbidopa - levodopa to the point of "" normality , "" which can lead to toxicity .
Diseases: toxicity"	"Sentence: While there is no single correct starting dose for levodopa therapy , many individuals can be started on either the 25 / 100 or controlled - release formula , following the general rule not to attempt to titrate carbidopa - levodopa to the point of "" normality , "" which can lead to toxicity .
Diseases:"
3491	The physician should also determine the proper use of any adjunctive medications ; such combined therapy has become the standard approach to treatment .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The physician should also determine the proper use of any adjunctive medications ; such combined therapy has become the standard approach to treatment .
Diseases: "	"Sentence: The physician should also determine the proper use of any adjunctive medications ; such combined therapy has become the standard approach to treatment .
Diseases:"
3492	Following the initial period of therapy , emerging difficulties require a reassessment of therapeutic approaches , such as dosage adjustment or introduction of a dopamine agonist .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following the initial period of therapy , emerging difficulties require a reassessment of therapeutic approaches , such as dosage adjustment or introduction of a dopamine agonist .
Diseases: "	"Sentence: Following the initial period of therapy , emerging difficulties require a reassessment of therapeutic approaches , such as dosage adjustment or introduction of a dopamine agonist .
Diseases:"
3493	Other possible adverse effects - - such as gastrointestinal disorders , orthostatic hypotension , levodopa - induced psychosis , sleep disturbances or parasomnias , or drug interactions - - also require carefully monitored individual treatment .	O O O O O O O O B I O B I O O O O B O B I O B O O O O O O O O O O O O O	['orthostatic hypotension', 'sleep disturbances', 'psychosis', 'parasomnias', 'gastrointestinal disorders']	5	18	"Sentence: Other possible adverse effects - - such as gastrointestinal disorders , orthostatic hypotension , levodopa - induced psychosis , sleep disturbances or parasomnias , or drug interactions - - also require carefully monitored individual treatment .
Diseases: orthostatic hypotension, sleep disturbances, psychosis, parasomnias, gastrointestinal disorders"	"Sentence: Other possible adverse effects - - such as gastrointestinal disorders , orthostatic hypotension , levodopa - induced psychosis , sleep disturbances or parasomnias , or drug interactions - - also require carefully monitored individual treatment .
Diseases:"
3494	Nonpharmacologic concerns can help the Parkinson 's disease patient achieve and maintain optimal functioning , including daily exercise , physical therapy , and involvement with support groups .	O O O O O B I I O O O O O O O O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: Nonpharmacologic concerns can help the Parkinson 's disease patient achieve and maintain optimal functioning , including daily exercise , physical therapy , and involvement with support groups .
Diseases: parkinson 's disease"	"Sentence: Nonpharmacologic concerns can help the Parkinson 's disease patient achieve and maintain optimal functioning , including daily exercise , physical therapy , and involvement with support groups .
Diseases:"
3495	Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia .	O O O B O O O O O B I O	['cerebral hypoxia', 'coma']	2	8	"Sentence: Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia .
Diseases: cerebral hypoxia, coma"	"Sentence: Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia .
Diseases:"
3496	Four patients who were rendered comatose or stuporous by drug intoxication , but who were not hypoxic , are described .	O O O O O B O B O O O O O O O O O O O O O	['stuporous', 'comatose']	2	7	"Sentence: Four patients who were rendered comatose or stuporous by drug intoxication , but who were not hypoxic , are described .
Diseases: stuporous, comatose"	"Sentence: Four patients who were rendered comatose or stuporous by drug intoxication , but who were not hypoxic , are described .
Diseases:"
3497	Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms , and one took a suicidal overdose of nitrazepam .	O O O O O O O O O B I O O O O O O B O O O	['overdose', 'withdrawal symptoms']	2	5	"Sentence: Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms , and one took a suicidal overdose of nitrazepam .
Diseases: overdose, withdrawal symptoms"	"Sentence: Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms , and one took a suicidal overdose of nitrazepam .
Diseases:"
3498	The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of ' alpha coma ' , showing non - reactive generalized or frontally predominant alpha activity in the EEG .	O O O O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['overdose', 'coma']	2	4	"Sentence: The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of ' alpha coma ' , showing non - reactive generalized or frontally predominant alpha activity in the EEG .
Diseases: overdose, coma"	"Sentence: The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of ' alpha coma ' , showing non - reactive generalized or frontally predominant alpha activity in the EEG .
Diseases:"
3499	The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non - reactive activity in the slow beta range .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non - reactive activity in the slow beta range .
Diseases: "	"Sentence: The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non - reactive activity in the slow beta range .
Diseases:"
3500	All four recovered completely without neurological sequelae following the withdrawal of the offending agents .	O O O O O B I O O O O O O O O	['neurological sequelae']	1	6	"Sentence: All four recovered completely without neurological sequelae following the withdrawal of the offending agents .
Diseases: neurological sequelae"	"Sentence: All four recovered completely without neurological sequelae following the withdrawal of the offending agents .
Diseases:"
3501	The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed .	O O O O O O O O O O B O O O O O O O O O	['depression']	1	2	"Sentence: The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed .
Diseases: depression"	"Sentence: The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed .
Diseases:"
3502	It is suggested that in both situations disturbed reticulo - thalamic interactions are important in the pathogenesis of alpha coma .	O O O O O O O O O O O O O O O O O O O B O	['coma']	1	2	"Sentence: It is suggested that in both situations disturbed reticulo - thalamic interactions are important in the pathogenesis of alpha coma .
Diseases: coma"	"Sentence: It is suggested that in both situations disturbed reticulo - thalamic interactions are important in the pathogenesis of alpha coma .
Diseases:"
3503	It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication , in the absence of significant hypoxaemia , a favourable outcome may be anticipated .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['hypoxaemia']	1	4	"Sentence: It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication , in the absence of significant hypoxaemia , a favourable outcome may be anticipated .
Diseases: hypoxaemia"	"Sentence: It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication , in the absence of significant hypoxaemia , a favourable outcome may be anticipated .
Diseases:"
3504	Omitting fentanyl reduces nausea and vomiting , without increasing pain , after sevoflurane for day surgery .	O O O B O B O O O B O O O O O O O	['nausea', 'vomiting', 'pain']	3	7	"Sentence: Omitting fentanyl reduces nausea and vomiting , without increasing pain , after sevoflurane for day surgery .
Diseases: nausea, vomiting, pain"	"Sentence: Omitting fentanyl reduces nausea and vomiting , without increasing pain , after sevoflurane for day surgery .
Diseases:"
3505	BACKGROUND AND OBJECTIVE :	O O O O	[]	0	0	"Sentence: BACKGROUND AND OBJECTIVE :
Diseases: "	"Sentence: BACKGROUND AND OBJECTIVE :
Diseases:"
3506	Despite advantages of induction and maintenance of anaesthesia with sevoflurane , postoperative nausea and vomiting occurs frequently .	O O O O O O O O O O O B I I I O O O	['postoperative nausea and vomiting']	1	5	"Sentence: Despite advantages of induction and maintenance of anaesthesia with sevoflurane , postoperative nausea and vomiting occurs frequently .
Diseases: postoperative nausea and vomiting"	"Sentence: Despite advantages of induction and maintenance of anaesthesia with sevoflurane , postoperative nausea and vomiting occurs frequently .
Diseases:"
3507	Fentanyl is a commonly used supplement that may contribute to this , although it may also improve analgesia .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fentanyl is a commonly used supplement that may contribute to this , although it may also improve analgesia .
Diseases: "	"Sentence: Fentanyl is a commonly used supplement that may contribute to this , although it may also improve analgesia .
Diseases:"
3508	METHODS : This double - blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients .	O O O O O O O O O O O O O B I I I O B O O O O O O O O O O O O O O O	['pain', 'postoperative nausea and vomiting']	2	7	"Sentence: METHODS : This double - blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients .
Diseases: pain, postoperative nausea and vomiting"	"Sentence: METHODS : This double - blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients .
Diseases:"
3509	Patients were randomly allocated to either receive or not receive 1 1 fentanyl , while a third group received dexamethasone in addition to fentanyl .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients were randomly allocated to either receive or not receive 1 1 fentanyl , while a third group received dexamethasone in addition to fentanyl .
Diseases: "	"Sentence: Patients were randomly allocated to either receive or not receive 1 1 fentanyl , while a third group received dexamethasone in addition to fentanyl .
Diseases:"
3510	RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .	O O O O O O O O O O O O B I I I O O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nausea', 'vomiting', 'postoperative nausea and vomiting']	3	11	"Sentence: RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
Diseases: nausea, vomiting, postoperative nausea and vomiting"	"Sentence: RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .
Diseases:"
3511	Antiemetic requirements were reduced from 24 % and 31 % to 7 % ( P = 0 . 0012 ) .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Antiemetic requirements were reduced from 24 % and 31 % to 7 % ( P = 0 . 0012 ) .
Diseases: "	"Sentence: Antiemetic requirements were reduced from 24 % and 31 % to 7 % ( P = 0 . 0012 ) .
Diseases:"
3512	Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting .	O O O O O O O O O O O B I I I O	['postoperative nausea and vomiting']	1	5	"Sentence: Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting .
Diseases: postoperative nausea and vomiting"	"Sentence: Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting .
Diseases:"
3513	Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids , reducing postoperative nausea and vomiting and nausea prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0 . 049 and P = 0 . 035 ) , respectively , while nausea in the first 24 h was decreased from 42 % to 27 %	O O O O O O O O O O O O O O O O B I I I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['nausea', 'postoperative nausea and vomiting']	2	9	"Sentence: Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids , reducing postoperative nausea and vomiting and nausea prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0 . 049 and P = 0 . 035 ) , respectively , while nausea in the first 24 h was decreased from 42 % to 27 %
Diseases: nausea, postoperative nausea and vomiting"	"Sentence: Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids , reducing postoperative nausea and vomiting and nausea prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0 . 049 and P = 0 . 035 ) , respectively , while nausea in the first 24 h was decreased from 42 % to 27 %
Diseases:"
3514	( P = 0 . 034 ) .	O O O O O O O O	[]	0	0	"Sentence: ( P = 0 . 034 ) .
Diseases: "	"Sentence: ( P = 0 . 034 ) .
Diseases:"
3515	Pain severity and analgesic requirements were unaffected by the omission of fentanyl .	B O O O O O O O O O O O O	['pain']	1	1	"Sentence: Pain severity and analgesic requirements were unaffected by the omission of fentanyl .
Diseases: pain"	"Sentence: Pain severity and analgesic requirements were unaffected by the omission of fentanyl .
Diseases:"
3516	Fentanyl did reduce minor intraoperative movement but had no sevoflurane - sparing effect and increased respiratory depression , hypotension and bradycardia .	O O O O O O O O O O O O O O O B I O B O B O	['bradycardia', 'respiratory depression', 'hypotension']	3	12	"Sentence: Fentanyl did reduce minor intraoperative movement but had no sevoflurane - sparing effect and increased respiratory depression , hypotension and bradycardia .
Diseases: bradycardia, respiratory depression, hypotension"	"Sentence: Fentanyl did reduce minor intraoperative movement but had no sevoflurane - sparing effect and increased respiratory depression , hypotension and bradycardia .
Diseases:"
3517	As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery .	O O O B I I I O O O O B I O O O O O O O O O O O O O O O O O O O O O O O	['postoperative nausea and vomiting', 'postoperative pain']	2	9	"Sentence: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery .
Diseases: postoperative nausea and vomiting, postoperative pain"	"Sentence: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery .
Diseases:"
3518	Renal Fanconi syndrome and myopathy after liver transplantation : drug - related mitochondrial cytopathy ?	B I I O B O O O O O O O B I O	['myopathy', 'renal fanconi syndrome', 'mitochondrial cytopathy']	3	12	"Sentence: Renal Fanconi syndrome and myopathy after liver transplantation : drug - related mitochondrial cytopathy ?
Diseases: myopathy, renal fanconi syndrome, mitochondrial cytopathy"	"Sentence: Renal Fanconi syndrome and myopathy after liver transplantation : drug - related mitochondrial cytopathy ?
Diseases:"
3519	Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children .
Diseases: "	"Sentence: Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children .
Diseases:"
3520	However , combinations of different therapeutic regimens require consideration of potential adverse reactions .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , combinations of different therapeutic regimens require consideration of potential adverse reactions .
Diseases: "	"Sentence: However , combinations of different therapeutic regimens require consideration of potential adverse reactions .
Diseases:"
3521	We describe a 15 - yr - old girl who had orthotopic liver transplantation because of Wilson 's disease .	O O O O O O O O O O O O O O O O B I I O	"[""wilson 's disease""]"	1	6	"Sentence: We describe a 15 - yr - old girl who had orthotopic liver transplantation because of Wilson 's disease .
Diseases: wilson 's disease"	"Sentence: We describe a 15 - yr - old girl who had orthotopic liver transplantation because of Wilson 's disease .
Diseases:"
3522	Tacrolimus , MMF , and steroids were given as immunosuppressant .	O O O O O O O O O O O	[]	0	0	"Sentence: Tacrolimus , MMF , and steroids were given as immunosuppressant .
Diseases: "	"Sentence: Tacrolimus , MMF , and steroids were given as immunosuppressant .
Diseases:"
3523	Lamivudine was added because of de nova hepatitis B infection during her follow - up .	O O O O O O O B I I O O O O O O	['hepatitis b infection']	1	5	"Sentence: Lamivudine was added because of de nova hepatitis B infection during her follow - up .
Diseases: hepatitis b infection"	"Sentence: Lamivudine was added because of de nova hepatitis B infection during her follow - up .
Diseases:"
3524	Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis , hypophosphatemia , glycosuria , and aminoaciduria .	O O O O O O B I I O O B I O B O B O O B O	['metabolic acidosis', 'aminoaciduria', 'renal fanconi syndrome', 'glycosuria', 'hypophosphatemia']	5	23	"Sentence: Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis , hypophosphatemia , glycosuria , and aminoaciduria .
Diseases: metabolic acidosis, aminoaciduria, renal fanconi syndrome, glycosuria, hypophosphatemia"	"Sentence: Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis , hypophosphatemia , glycosuria , and aminoaciduria .
Diseases:"
3525	Although tacrolimus was suspected to be the cause of late post - transplant renal acidosis and was replaced by sirolimus , acidosis , and electrolyte imbalance got worse .	O O O O O O O O O O O O O O B O O O O O O B O O O O O O O	['acidosis']	1	2	"Sentence: Although tacrolimus was suspected to be the cause of late post - transplant renal acidosis and was replaced by sirolimus , acidosis , and electrolyte imbalance got worse .
Diseases: acidosis"	"Sentence: Although tacrolimus was suspected to be the cause of late post - transplant renal acidosis and was replaced by sirolimus , acidosis , and electrolyte imbalance got worse .
Diseases:"
3526	Proximal muscle weakness has developed during her follow - up .	O B I O O O O O O O O	['muscle weakness']	1	3	"Sentence: Proximal muscle weakness has developed during her follow - up .
Diseases: muscle weakness"	"Sentence: Proximal muscle weakness has developed during her follow - up .
Diseases:"
3527	Fanconi syndrome , as well as myopathy , is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA .	B I O O O O B O O O O O O O B I O O O O O O O	['myopathy', 'fanconi syndrome', 'mitochondrial disorders']	3	9	"Sentence: Fanconi syndrome , as well as myopathy , is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA .
Diseases: myopathy, fanconi syndrome, mitochondrial disorders"	"Sentence: Fanconi syndrome , as well as myopathy , is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA .
Diseases:"
3528	We suggest that our patient 's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine .	O O O O O O B I O B O O O O B I O O O O O O O O O O	['myopathy', 'mitochondrial dysfunction', 'tubular dysfunction']	3	9	"Sentence: We suggest that our patient 's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine .
Diseases: myopathy, mitochondrial dysfunction, tubular dysfunction"	"Sentence: We suggest that our patient 's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine .
Diseases:"
3529	Antipsychotic - like profile of thioperamide , a selective H3 - receptor antagonist in mice .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Antipsychotic - like profile of thioperamide , a selective H3 - receptor antagonist in mice .
Diseases: "	"Sentence: Antipsychotic - like profile of thioperamide , a selective H3 - receptor antagonist in mice .
Diseases:"
3530	Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia .	O O O O O O O O O O O O O O O O B O	['schizophrenia']	1	3	"Sentence: Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia .
Diseases: schizophrenia"	"Sentence: Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia .
Diseases:"
3531	The present study was designed to study the effect of histamine H ( 3 ) - receptor ligands on neuroleptic - induced catalepsy , apomorphine - induced climbing behavior and amphetamine - induced locomotor activities in mice .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: The present study was designed to study the effect of histamine H ( 3 ) - receptor ligands on neuroleptic - induced catalepsy , apomorphine - induced climbing behavior and amphetamine - induced locomotor activities in mice .
Diseases: catalepsy"	"Sentence: The present study was designed to study the effect of histamine H ( 3 ) - receptor ligands on neuroleptic - induced catalepsy , apomorphine - induced climbing behavior and amphetamine - induced locomotor activities in mice .
Diseases:"
3532	Catalepsy was induced by haloperidol ( 2 mg / kg p . o . ) , while apomorphine ( 1 . 5 mg / kg s . c . ) and amphetamine ( 2 mg / kg s . c . ) were used for studying climbing behavior and locomotor activities , respectively .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: Catalepsy was induced by haloperidol ( 2 mg / kg p . o . ) , while apomorphine ( 1 . 5 mg / kg s . c . ) and amphetamine ( 2 mg / kg s . c . ) were used for studying climbing behavior and locomotor activities , respectively .
Diseases: catalepsy"	"Sentence: Catalepsy was induced by haloperidol ( 2 mg / kg p . o . ) , while apomorphine ( 1 . 5 mg / kg s . c . ) and amphetamine ( 2 mg / kg s . c . ) were used for studying climbing behavior and locomotor activities , respectively .
Diseases:"
3533	( R ) - alpha - methylhistamine ( RAMH ) ( 5 microg i . c . v . ) and thioperamide ( THP ) ( 15 mg / kg i . p . ) , per se did not cause catalepsy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['catalepsy']	1	4	"Sentence: ( R ) - alpha - methylhistamine ( RAMH ) ( 5 microg i . c . v . ) and thioperamide ( THP ) ( 15 mg / kg i . p . ) , per se did not cause catalepsy .
Diseases: catalepsy"	"Sentence: ( R ) - alpha - methylhistamine ( RAMH ) ( 5 microg i . c . v . ) and thioperamide ( THP ) ( 15 mg / kg i . p . ) , per se did not cause catalepsy .
Diseases:"
3534	Administration of THP ( 3 . 75 , 7 . 5 and 15 mg / kg i . p . )	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Administration of THP ( 3 . 75 , 7 . 5 and 15 mg / kg i . p . )
Diseases: "	"Sentence: Administration of THP ( 3 . 75 , 7 . 5 and 15 mg / kg i . p . )
Diseases:"
3535	1 h prior to haloperidol resulted in a dose - dependent increase in the catalepsy times ( P < 0 . 05 ) .	O O O O O O O O O O O O O O B O O O O O O O O O	['catalepsy']	1	4	"Sentence: 1 h prior to haloperidol resulted in a dose - dependent increase in the catalepsy times ( P < 0 . 05 ) .
Diseases: catalepsy"	"Sentence: 1 h prior to haloperidol resulted in a dose - dependent increase in the catalepsy times ( P < 0 . 05 ) .
Diseases:"
3536	However , pretreatment with RAMH significantly reversed such an effect of THP ( 15 mg / kg i . p . ) .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , pretreatment with RAMH significantly reversed such an effect of THP ( 15 mg / kg i . p . ) .
Diseases: "	"Sentence: However , pretreatment with RAMH significantly reversed such an effect of THP ( 15 mg / kg i . p . ) .
Diseases:"
3537	RAMH per se showed significant reduction in locomotor time , distance traveled and average speed but THP ( 15 mg / kg i . p . ) per se had no effect on these parameters .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RAMH per se showed significant reduction in locomotor time , distance traveled and average speed but THP ( 15 mg / kg i . p . ) per se had no effect on these parameters .
Diseases: "	"Sentence: RAMH per se showed significant reduction in locomotor time , distance traveled and average speed but THP ( 15 mg / kg i . p . ) per se had no effect on these parameters .
Diseases:"
3538	On amphetamine - induced hyperactivity , THP ( 3 . 75 and 7 . 5 mg / kg i . p . )	O O O O B O O O O O O O O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: On amphetamine - induced hyperactivity , THP ( 3 . 75 and 7 . 5 mg / kg i . p . )
Diseases: hyperactivity"	"Sentence: On amphetamine - induced hyperactivity , THP ( 3 . 75 and 7 . 5 mg / kg i . p . )
Diseases:"
3539	reduced locomotor time , distance traveled and average speed ( P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: reduced locomotor time , distance traveled and average speed ( P < 0 . 05 ) .
Diseases: "	"Sentence: reduced locomotor time , distance traveled and average speed ( P < 0 . 05 ) .
Diseases:"
3540	Pretreatment with RAMH ( 5 microg i . c . v . ) could partially reverse such effects of THP ( 3 . 75 mg / kg i . p . ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pretreatment with RAMH ( 5 microg i . c . v . ) could partially reverse such effects of THP ( 3 . 75 mg / kg i . p . ) .
Diseases: "	"Sentence: Pretreatment with RAMH ( 5 microg i . c . v . ) could partially reverse such effects of THP ( 3 . 75 mg / kg i . p . ) .
Diseases:"
3541	Climbing behavior induced by apomorphine was reduced in animals treated with THP .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Climbing behavior induced by apomorphine was reduced in animals treated with THP .
Diseases: "	"Sentence: Climbing behavior induced by apomorphine was reduced in animals treated with THP .
Diseases:"
3542	Such an effect was , however , reversed in presence of RAMH .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Such an effect was , however , reversed in presence of RAMH .
Diseases: "	"Sentence: Such an effect was , however , reversed in presence of RAMH .
Diseases:"
3543	THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced catalepsy , reducing amphetamine - induced hyperactivity and reducing apomorphine - induced climbing in mice .	O O O O O O O O O O O O B O O O O O B O O O O O O O O O	['catalepsy', 'hyperactivity']	2	7	"Sentence: THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced catalepsy , reducing amphetamine - induced hyperactivity and reducing apomorphine - induced climbing in mice .
Diseases: catalepsy, hyperactivity"	"Sentence: THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced catalepsy , reducing amphetamine - induced hyperactivity and reducing apomorphine - induced climbing in mice .
Diseases:"
3544	Such effects of THP were reversed by RAMH indicating the involvement of histamine H ( 3 ) - receptors .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Such effects of THP were reversed by RAMH indicating the involvement of histamine H ( 3 ) - receptors .
Diseases: "	"Sentence: Such effects of THP were reversed by RAMH indicating the involvement of histamine H ( 3 ) - receptors .
Diseases:"
3545	Findings suggest a potential for H ( 3 ) - receptor antagonists in improving the refractory cases of schizophrenia .	O O O O O O O O O O O O O O O O O O B O	['schizophrenia']	1	3	"Sentence: Findings suggest a potential for H ( 3 ) - receptor antagonists in improving the refractory cases of schizophrenia .
Diseases: schizophrenia"	"Sentence: Findings suggest a potential for H ( 3 ) - receptor antagonists in improving the refractory cases of schizophrenia .
Diseases:"
3546	Transient platypnea - orthodeoxia - like syndrome induced by propafenone overdose in a young woman with Ebstein 's anomaly .	O B I I I I I O O O B O O O O O B I I O	"['platypnea - orthodeoxia - like syndrome', 'overdose', ""ebstein 's anomaly""]"	3	20	"Sentence: Transient platypnea - orthodeoxia - like syndrome induced by propafenone overdose in a young woman with Ebstein 's anomaly .
Diseases: platypnea - orthodeoxia - like syndrome, overdose, ebstein 's anomaly"	"Sentence: Transient platypnea - orthodeoxia - like syndrome induced by propafenone overdose in a young woman with Ebstein 's anomaly .
Diseases:"
3547	In this report we describe the case of a 37 - year - old white woman with Ebstein 's anomaly , who developed a rare syndrome called platypnea - orthodeoxia , characterized by massive right - to - left interatrial shunting with transient profound hypoxia and cyanosis .	O O O O O O O O O O O O O O O O O B I I O O O O O O O B I I O O O O O O O O O O O O O O B O B O	"['hypoxia', 'cyanosis', ""ebstein 's anomaly"", 'platypnea - orthodeoxia']"	4	22	"Sentence: In this report we describe the case of a 37 - year - old white woman with Ebstein 's anomaly , who developed a rare syndrome called platypnea - orthodeoxia , characterized by massive right - to - left interatrial shunting with transient profound hypoxia and cyanosis .
Diseases: hypoxia, cyanosis, ebstein 's anomaly, platypnea - orthodeoxia"	"Sentence: In this report we describe the case of a 37 - year - old white woman with Ebstein 's anomaly , who developed a rare syndrome called platypnea - orthodeoxia , characterized by massive right - to - left interatrial shunting with transient profound hypoxia and cyanosis .
Diseases:"
3548	This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure , and was probably precipitated by a propafenone overdose .	O O O O O O B I I O O O O O O O O O O O O O O O O O O B O	['overdose', 'patent foramen ovale']	2	8	"Sentence: This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure , and was probably precipitated by a propafenone overdose .
Diseases: overdose, patent foramen ovale"	"Sentence: This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure , and was probably precipitated by a propafenone overdose .
Diseases:"
3549	This drug caused biventricular dysfunction , due to its negative inotropic effect , and hypotension , due to its peripheral vasodilatory effect .	O O O B I O O O O O O O O O B O O O O O O O O	['hypotension', 'biventricular dysfunction']	2	9	"Sentence: This drug caused biventricular dysfunction , due to its negative inotropic effect , and hypotension , due to its peripheral vasodilatory effect .
Diseases: hypotension, biventricular dysfunction"	"Sentence: This drug caused biventricular dysfunction , due to its negative inotropic effect , and hypotension , due to its peripheral vasodilatory effect .
Diseases:"
3550	These effects gave rise to an increase in the right atrial pressure and a decrease in the left one with a consequent stretching of the foramen ovale and the creation of massive right - to - left shunting .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These effects gave rise to an increase in the right atrial pressure and a decrease in the left one with a consequent stretching of the foramen ovale and the creation of massive right - to - left shunting .
Diseases: "	"Sentence: These effects gave rise to an increase in the right atrial pressure and a decrease in the left one with a consequent stretching of the foramen ovale and the creation of massive right - to - left shunting .
Diseases:"
3551	In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography .
Diseases: "	"Sentence: In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography .
Diseases:"
3552	A Phase II trial of cisplatin plus WR - 2721 ( amifostine ) for metastatic breast carcinoma : an Eastern Cooperative Oncology Group Study ( E8188 ) .	O O O O O O O O O O O O O O O B I O O O O O O O O O O O	['breast carcinoma']	1	4	"Sentence: A Phase II trial of cisplatin plus WR - 2721 ( amifostine ) for metastatic breast carcinoma : an Eastern Cooperative Oncology Group Study ( E8188 ) .
Diseases: breast carcinoma"	"Sentence: A Phase II trial of cisplatin plus WR - 2721 ( amifostine ) for metastatic breast carcinoma : an Eastern Cooperative Oncology Group Study ( E8188 ) .
Diseases:"
3553	Cisplatin has minimal antitumor activity when used as second - or third - line treatment of metastatic breast carcinoma .	O O O O O O O O O O O O O O O O O B I O	['breast carcinoma']	1	4	"Sentence: Cisplatin has minimal antitumor activity when used as second - or third - line treatment of metastatic breast carcinoma .
Diseases: breast carcinoma"	"Sentence: Cisplatin has minimal antitumor activity when used as second - or third - line treatment of metastatic breast carcinoma .
Diseases:"
3554	Older reports suggest an objective response rate of 8 % when 60 - 120 mg / m2 of cisplatin is administered every 3 - 4 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Older reports suggest an objective response rate of 8 % when 60 - 120 mg / m2 of cisplatin is administered every 3 - 4 weeks .
Diseases: "	"Sentence: Older reports suggest an objective response rate of 8 % when 60 - 120 mg / m2 of cisplatin is administered every 3 - 4 weeks .
Diseases:"
3555	Although a dose - response effect has been observed with cisplatin , the dose - limiting toxicities associated with cisplatin ( e . g . , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .	O O O O O O O O O O O O O O O O B O O O O O O O O O B O B O O B O O O O O O O O O B I O	['neurotoxicity', 'nephrotoxicity', 'toxicities', 'ototoxicity', 'breast carcinoma']	5	20	"Sentence: Although a dose - response effect has been observed with cisplatin , the dose - limiting toxicities associated with cisplatin ( e . g . , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
Diseases: neurotoxicity, nephrotoxicity, toxicities, ototoxicity, breast carcinoma"	"Sentence: Although a dose - response effect has been observed with cisplatin , the dose - limiting toxicities associated with cisplatin ( e . g . , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .
Diseases:"
3556	WR - 2721 or amifostine initially was developed to protect military personnel in the event of nuclear war .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: WR - 2721 or amifostine initially was developed to protect military personnel in the event of nuclear war .
Diseases: "	"Sentence: WR - 2721 or amifostine initially was developed to protect military personnel in the event of nuclear war .
Diseases:"
3557	Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy .
Diseases: "	"Sentence: Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy .
Diseases:"
3558	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin - induced nephrotoxicity , ototoxicity , and neuropathy were reduced .	O O O O O O O O O O O O O O O O O B O B O O B O O O	['nephrotoxicity', 'ototoxicity', 'neuropathy']	3	11	"Sentence: Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin - induced nephrotoxicity , ototoxicity , and neuropathy were reduced .
Diseases: nephrotoxicity, ototoxicity, neuropathy"	"Sentence: Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin - induced nephrotoxicity , ototoxicity , and neuropathy were reduced .
Diseases:"
3559	METHODS : A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one , but not more than one , chemotherapy regimen for metastatic disease .	O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O	['breast carcinoma']	1	4	"Sentence: METHODS : A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one , but not more than one , chemotherapy regimen for metastatic disease .
Diseases: breast carcinoma"	"Sentence: METHODS : A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one , but not more than one , chemotherapy regimen for metastatic disease .
Diseases:"
3560	Patients received amifostine , 910 mg / m2 intravenously over 15 minutes .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients received amifostine , 910 mg / m2 intravenously over 15 minutes .
Diseases: "	"Sentence: Patients received amifostine , 910 mg / m2 intravenously over 15 minutes .
Diseases:"
3561	After completion of the amifostine infusion , cisplatin 120 mg / m2 was administered over 30 minutes .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After completion of the amifostine infusion , cisplatin 120 mg / m2 was administered over 30 minutes .
Diseases: "	"Sentence: After completion of the amifostine infusion , cisplatin 120 mg / m2 was administered over 30 minutes .
Diseases:"
3562	Intravenous hydration and mannitol was administered before and after cisplatin .	O O O O O O O O O O O	[]	0	0	"Sentence: Intravenous hydration and mannitol was administered before and after cisplatin .
Diseases: "	"Sentence: Intravenous hydration and mannitol was administered before and after cisplatin .
Diseases:"
3563	Treatment was administered every 3 weeks until disease progression .	O O O O O O O O O O	[]	0	0	"Sentence: Treatment was administered every 3 weeks until disease progression .
Diseases: "	"Sentence: Treatment was administered every 3 weeks until disease progression .
Diseases:"
3564	Forty - four patients were enrolled in the study of which 7 ( 16 % ) were ineligible .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Forty - four patients were enrolled in the study of which 7 ( 16 % ) were ineligible .
Diseases: "	"Sentence: Forty - four patients were enrolled in the study of which 7 ( 16 % ) were ineligible .
Diseases:"
3565	A median of 2 cycles of therapy was administered to the 37 eligible patients .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A median of 2 cycles of therapy was administered to the 37 eligible patients .
Diseases: "	"Sentence: A median of 2 cycles of therapy was administered to the 37 eligible patients .
Diseases:"
3566	Six partial responses were observed for an overall response rate of 16 % .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Six partial responses were observed for an overall response rate of 16 % .
Diseases: "	"Sentence: Six partial responses were observed for an overall response rate of 16 % .
Diseases:"
3567	Most patients ( 57 % ) stopped treatment because of disease progression .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Most patients ( 57 % ) stopped treatment because of disease progression .
Diseases: "	"Sentence: Most patients ( 57 % ) stopped treatment because of disease progression .
Diseases:"
3568	Neurologic toxicity was reported in 52 % of patients .	B I O O O O O O O O	['neurologic toxicity']	1	5	"Sentence: Neurologic toxicity was reported in 52 % of patients .
Diseases: neurologic toxicity"	"Sentence: Neurologic toxicity was reported in 52 % of patients .
Diseases:"
3569	Seven different life - threatening toxicities were observed in patients while receiving treatment .	O O O O O B O O O O O O O O	['toxicities']	1	3	"Sentence: Seven different life - threatening toxicities were observed in patients while receiving treatment .
Diseases: toxicities"	"Sentence: Seven different life - threatening toxicities were observed in patients while receiving treatment .
Diseases:"
3570	The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16 % .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16 % .
Diseases: "	"Sentence: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16 % .
Diseases:"
3571	Neither a tumor - protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial .	O O B O O O O O B O O O O O O O O O O O O O O O O	['tumor', 'toxicity']	2	5	"Sentence: Neither a tumor - protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial .
Diseases: tumor, toxicity"	"Sentence: Neither a tumor - protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial .
Diseases:"
3572	Warfarin - induced iliopsoas hemorrhage with subsequent femoral nerve palsy .	O O O O B O O B I I O	['femoral nerve palsy', 'hemorrhage']	2	9	"Sentence: Warfarin - induced iliopsoas hemorrhage with subsequent femoral nerve palsy .
Diseases: femoral nerve palsy, hemorrhage"	"Sentence: Warfarin - induced iliopsoas hemorrhage with subsequent femoral nerve palsy .
Diseases:"
3573	We present the case of a 28 - year - old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip .	O O O O O O O O O O O O O O O O O O O O B I O O O B O O O B O O O O O	['pain', 'contracture', 'muscle tear']	3	7	"Sentence: We present the case of a 28 - year - old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip .
Diseases: pain, contracture, muscle tear"	"Sentence: We present the case of a 28 - year - old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip .
Diseases:"
3574	Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment , resulting in a femoral nerve palsy and partial loss of quadriceps functions .	O O O O O B O O B I O O O O B I I O B I I I I O	['nerve entrapment', 'partial loss of quadriceps functions', 'hematoma', 'femoral nerve palsy']	4	23	"Sentence: Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment , resulting in a femoral nerve palsy and partial loss of quadriceps functions .
Diseases: nerve entrapment, partial loss of quadriceps functions, hematoma, femoral nerve palsy"	"Sentence: Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment , resulting in a femoral nerve palsy and partial loss of quadriceps functions .
Diseases:"
3575	Anticoagulant - induced femoral nerve palsy represents the most common form of warfarin - induced peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .	O O O B I I O O O O O O O O O B I O O O O O O B O O O O O O O O B I I I O O O B O O O O O	['pain', 'peripheral neuropathy', 'motor and sensory impairment', 'femoral nerve palsy', 'contracture']	5	19	"Sentence: Anticoagulant - induced femoral nerve palsy represents the most common form of warfarin - induced peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .
Diseases: pain, peripheral neuropathy, motor and sensory impairment, femoral nerve palsy, contracture"	"Sentence: Anticoagulant - induced femoral nerve palsy represents the most common form of warfarin - induced peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .
Diseases:"
3576	Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis .	B I O O O O O O O B I O	['rheumatoid arthritis', 'myasthenia gravis']	2	12	"Sentence: Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis .
Diseases: rheumatoid arthritis, myasthenia gravis"	"Sentence: Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis .
Diseases:"
3577	We have described a unique patient who had reversible and dose - related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis .	O O O O O O O O O O O O O B I O O O O O O B I O	['rheumatoid arthritis', 'myasthenia gravis']	2	12	"Sentence: We have described a unique patient who had reversible and dose - related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis .
Diseases: rheumatoid arthritis, myasthenia gravis"	"Sentence: We have described a unique patient who had reversible and dose - related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis .
Diseases:"
3578	Although acetylcholine receptor antibodies were not detectable , the time course was consistent with an autoimmune process .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although acetylcholine receptor antibodies were not detectable , the time course was consistent with an autoimmune process .
Diseases: "	"Sentence: Although acetylcholine receptor antibodies were not detectable , the time course was consistent with an autoimmune process .
Diseases:"
3579	Nephrotoxicity of combined cephalothin - gentamicin regimen .	B O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Nephrotoxicity of combined cephalothin - gentamicin regimen .
Diseases: nephrotoxicity"	"Sentence: Nephrotoxicity of combined cephalothin - gentamicin regimen .
Diseases:"
3580	Two patients developed acute tubular necrosis , characterized clinically by acute oliguric renal failure , while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy .	O O O B I I O O O O O B I I O O O O O O O O O O O O O O O	['oliguric renal failure', 'acute tubular necrosis']	2	12	"Sentence: Two patients developed acute tubular necrosis , characterized clinically by acute oliguric renal failure , while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy .
Diseases: oliguric renal failure, acute tubular necrosis"	"Sentence: Two patients developed acute tubular necrosis , characterized clinically by acute oliguric renal failure , while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy .
Diseases:"
3581	Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity .	O O O O O O O O O O O O O O O O B O	['nephrotoxicity']	1	4	"Sentence: Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity .
Diseases: nephrotoxicity"	"Sentence: Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity .
Diseases:"
3582	High doses of this antibiotic combination should be avoided especially in elderly patients .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: High doses of this antibiotic combination should be avoided especially in elderly patients .
Diseases: "	"Sentence: High doses of this antibiotic combination should be avoided especially in elderly patients .
Diseases:"
3583	Patients with renal insufficiency should not be given this regimen .	O O B I O O O O O O O	['renal insufficiency']	1	5	"Sentence: Patients with renal insufficiency should not be given this regimen .
Diseases: renal insufficiency"	"Sentence: Patients with renal insufficiency should not be given this regimen .
Diseases:"
3584	Components of lemon essential oil attenuate dementia induced by scopolamine .	O O O O O O B O O O O	['dementia']	1	3	"Sentence: Components of lemon essential oil attenuate dementia induced by scopolamine .
Diseases: dementia"	"Sentence: Components of lemon essential oil attenuate dementia induced by scopolamine .
Diseases:"
3585	The anti - dementia effects of s - limonene and s - perillyl alcohol were observed using the passive avoidance test ( PA ) and the open field habituation test ( OFH ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dementia']	1	3	"Sentence: The anti - dementia effects of s - limonene and s - perillyl alcohol were observed using the passive avoidance test ( PA ) and the open field habituation test ( OFH ) .
Diseases: dementia"	"Sentence: The anti - dementia effects of s - limonene and s - perillyl alcohol were observed using the passive avoidance test ( PA ) and the open field habituation test ( OFH ) .
Diseases:"
3586	These lemon essential oils showed strong ability to improve memory impaired by scopolamine ; however , s - perillyl alcohol relieved the deficit of associative memory in PA only , and did not improve non - associative memory significantly in OFH .	O O O O O O O O O B I O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O	['deficit of associative memory', 'memory impaired']	2	9	"Sentence: These lemon essential oils showed strong ability to improve memory impaired by scopolamine ; however , s - perillyl alcohol relieved the deficit of associative memory in PA only , and did not improve non - associative memory significantly in OFH .
Diseases: deficit of associative memory, memory impaired"	"Sentence: These lemon essential oils showed strong ability to improve memory impaired by scopolamine ; however , s - perillyl alcohol relieved the deficit of associative memory in PA only , and did not improve non - associative memory significantly in OFH .
Diseases:"
3587	Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle / scopolamine group was significantly lower than that of the vehicle / vehicle group , but this phenomenon was reversed when s - limonene or s - perillyl alcohol were administered before the injection of scopolamine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle / scopolamine group was significantly lower than that of the vehicle / vehicle group , but this phenomenon was reversed when s - limonene or s - perillyl alcohol were administered before the injection of scopolamine .
Diseases: "	"Sentence: Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle / scopolamine group was significantly lower than that of the vehicle / vehicle group , but this phenomenon was reversed when s - limonene or s - perillyl alcohol were administered before the injection of scopolamine .
Diseases:"
3588	Simultaneously , we found that these two lemon essential oil components could inhibit acetylcholinesterase activity in vitro using the Ellman method .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Simultaneously , we found that these two lemon essential oil components could inhibit acetylcholinesterase activity in vitro using the Ellman method .
Diseases: "	"Sentence: Simultaneously , we found that these two lemon essential oil components could inhibit acetylcholinesterase activity in vitro using the Ellman method .
Diseases:"
3589	The selective 5 - HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat .	O O O O O O O O O O O O O O O O O B I O O O O	['memory deficiency']	1	2	"Sentence: The selective 5 - HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat .
Diseases: memory deficiency"	"Sentence: The selective 5 - HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat .
Diseases:"
3590	Antagonists at serotonin type 6 ( 5 - HT ( 6 ) ) receptors show activity in models of learning and memory .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Antagonists at serotonin type 6 ( 5 - HT ( 6 ) ) receptors show activity in models of learning and memory .
Diseases: "	"Sentence: Antagonists at serotonin type 6 ( 5 - HT ( 6 ) ) receptors show activity in models of learning and memory .
Diseases:"
3591	Although the underlying mechanism ( s ) are not well understood , these effects may involve an increase in acetylcholine ( ACh ) levels .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although the underlying mechanism ( s ) are not well understood , these effects may involve an increase in acetylcholine ( ACh ) levels .
Diseases: "	"Sentence: Although the underlying mechanism ( s ) are not well understood , these effects may involve an increase in acetylcholine ( ACh ) levels .
Diseases:"
3592	The present study sought to characterize the cognitive - enhancing effects of the 5 - HT ( 6 ) antagonist Ro4368554 ( 3 - benzenesulfonyl - 7 - ( 4 - methyl - piperazin - 1 - yl ) 1H - indole ) in a rat object recognition task employing a cholinergic ( scopolamine pretreatment ) and a serotonergic - ( tryptophan ( TRP ) depletion ) deficient model , and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The present study sought to characterize the cognitive - enhancing effects of the 5 - HT ( 6 ) antagonist Ro4368554 ( 3 - benzenesulfonyl - 7 - ( 4 - methyl - piperazin - 1 - yl ) 1H - indole ) in a rat object recognition task employing a cholinergic ( scopolamine pretreatment ) and a serotonergic - ( tryptophan ( TRP ) depletion ) deficient model , and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate .
Diseases: "	"Sentence: The present study sought to characterize the cognitive - enhancing effects of the 5 - HT ( 6 ) antagonist Ro4368554 ( 3 - benzenesulfonyl - 7 - ( 4 - methyl - piperazin - 1 - yl ) 1H - indole ) in a rat object recognition task employing a cholinergic ( scopolamine pretreatment ) and a serotonergic - ( tryptophan ( TRP ) depletion ) deficient model , and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate .
Diseases:"
3593	Initial testing in a time - dependent forgetting task employing a 24 - h delay between training and testing showed that metrifonate improved object recognition ( at 10 and 30 mg / kg , p . o . ) , whereas Ro4368554 was inactive .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Initial testing in a time - dependent forgetting task employing a 24 - h delay between training and testing showed that metrifonate improved object recognition ( at 10 and 30 mg / kg , p . o . ) , whereas Ro4368554 was inactive .
Diseases: "	"Sentence: Initial testing in a time - dependent forgetting task employing a 24 - h delay between training and testing showed that metrifonate improved object recognition ( at 10 and 30 mg / kg , p . o . ) , whereas Ro4368554 was inactive .
Diseases:"
3594	Both , Ro4368554 ( 3 and 10 mg / kg , intraperitoneally ( i . p . ) ) and metrifonate ( 10 mg / kg , p . o . , respectively ) reversed memory deficits induced by scopolamine and TRP depletion ( 10 mg / kg , i . p . , and 3 mg / kg , p . o . , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['memory deficits']	1	2	"Sentence: Both , Ro4368554 ( 3 and 10 mg / kg , intraperitoneally ( i . p . ) ) and metrifonate ( 10 mg / kg , p . o . , respectively ) reversed memory deficits induced by scopolamine and TRP depletion ( 10 mg / kg , i . p . , and 3 mg / kg , p . o . , respectively ) .
Diseases: memory deficits"	"Sentence: Both , Ro4368554 ( 3 and 10 mg / kg , intraperitoneally ( i . p . ) ) and metrifonate ( 10 mg / kg , p . o . , respectively ) reversed memory deficits induced by scopolamine and TRP depletion ( 10 mg / kg , i . p . , and 3 mg / kg , p . o . , respectively ) .
Diseases:"
3595	In conclusion , although Ro4368554 did not improve a time - related retention deficit , it reversed a cholinergic and a serotonergic memory deficit , suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and , possibly , other 5 - HT ( 6 ) receptor antagonists .	O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['memory deficit']	1	2	"Sentence: In conclusion , although Ro4368554 did not improve a time - related retention deficit , it reversed a cholinergic and a serotonergic memory deficit , suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and , possibly , other 5 - HT ( 6 ) receptor antagonists .
Diseases: memory deficit"	"Sentence: In conclusion , although Ro4368554 did not improve a time - related retention deficit , it reversed a cholinergic and a serotonergic memory deficit , suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and , possibly , other 5 - HT ( 6 ) receptor antagonists .
Diseases:"
3596	Lone atrial fibrillation associated with creatine monohydrate supplementation .	O B I O O O O O O	['atrial fibrillation']	1	5	"Sentence: Lone atrial fibrillation associated with creatine monohydrate supplementation .
Diseases: atrial fibrillation"	"Sentence: Lone atrial fibrillation associated with creatine monohydrate supplementation .
Diseases:"
3597	Atrial fibrillation in young patients without structural heart disease is rare .	B I O O O O O B I O O O	['heart disease', 'atrial fibrillation']	2	8	"Sentence: Atrial fibrillation in young patients without structural heart disease is rare .
Diseases: heart disease, atrial fibrillation"	"Sentence: Atrial fibrillation in young patients without structural heart disease is rare .
Diseases:"
3598	Therefore , when the arrhythmia is present in this population , reversible causes must be identified and resolved .	O O O O B O O O O O O O O O O O O O O	['arrhythmia']	1	4	"Sentence: Therefore , when the arrhythmia is present in this population , reversible causes must be identified and resolved .
Diseases: arrhythmia"	"Sentence: Therefore , when the arrhythmia is present in this population , reversible causes must be identified and resolved .
Diseases:"
3599	Thyroid disorders , illicit drug or stimulant use , and acute alcohol intoxication are among these causes .	B I O O O O O O O O B I I O O O O O	['acute alcohol intoxication', 'thyroid disorders']	2	7	"Sentence: Thyroid disorders , illicit drug or stimulant use , and acute alcohol intoxication are among these causes .
Diseases: acute alcohol intoxication, thyroid disorders"	"Sentence: Thyroid disorders , illicit drug or stimulant use , and acute alcohol intoxication are among these causes .
Diseases:"
3600	We report the case of a 30 - year - old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response .	O O O O O O O O O O O O O O O O O O O O B I O O O O O	['atrial fibrillation']	1	5	"Sentence: We report the case of a 30 - year - old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response .
Diseases: atrial fibrillation"	"Sentence: We report the case of a 30 - year - old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response .
Diseases:"
3601	His medical history was unremarkable , except for minor fractures of the fingers and foot .	O O O O O O O O O B O O O O O O	['fractures']	1	3	"Sentence: His medical history was unremarkable , except for minor fractures of the fingers and foot .
Diseases: fractures"	"Sentence: His medical history was unremarkable , except for minor fractures of the fingers and foot .
Diseases:"
3602	Thyroid - stimulating hormone , magnesium , and potassium levels were within normal limits , urine drug screen was negative , and alcohol use was denied .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thyroid - stimulating hormone , magnesium , and potassium levels were within normal limits , urine drug screen was negative , and alcohol use was denied .
Diseases: "	"Sentence: Thyroid - stimulating hormone , magnesium , and potassium levels were within normal limits , urine drug screen was negative , and alcohol use was denied .
Diseases:"
3603	However , when the patient was questioned about use of herbal products and supplements , the use of creatine monohydrate was revealed .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , when the patient was questioned about use of herbal products and supplements , the use of creatine monohydrate was revealed .
Diseases: "	"Sentence: However , when the patient was questioned about use of herbal products and supplements , the use of creatine monohydrate was revealed .
Diseases:"
3604	The patient was admitted to the hospital , anticoagulated with unfractionated heparin , and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The patient was admitted to the hospital , anticoagulated with unfractionated heparin , and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control .
Diseases: "	"Sentence: The patient was admitted to the hospital , anticoagulated with unfractionated heparin , and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control .
Diseases:"
3605	When discharged less than 24 hours later , he was receiving metoprolol and aspirin , with follow - up plans for echocardiography and nuclear imaging to assess perfusion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When discharged less than 24 hours later , he was receiving metoprolol and aspirin , with follow - up plans for echocardiography and nuclear imaging to assess perfusion .
Diseases: "	"Sentence: When discharged less than 24 hours later , he was receiving metoprolol and aspirin , with follow - up plans for echocardiography and nuclear imaging to assess perfusion .
Diseases:"
3606	Exogenous creatine is used by athletes to theoretically improve exercise performance .	O O O O O O O O O O O O	[]	0	0	"Sentence: Exogenous creatine is used by athletes to theoretically improve exercise performance .
Diseases: "	"Sentence: Exogenous creatine is used by athletes to theoretically improve exercise performance .
Diseases:"
3607	Vegetarians may also take creatine to replace what they are not consuming from meat , fish , and other animal products .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Vegetarians may also take creatine to replace what they are not consuming from meat , fish , and other animal products .
Diseases: "	"Sentence: Vegetarians may also take creatine to replace what they are not consuming from meat , fish , and other animal products .
Diseases:"
3608	Previous anecdotal reports have linked creatine to the development of arrhythmia .	O O O O O O O O O O B O	['arrhythmia']	1	4	"Sentence: Previous anecdotal reports have linked creatine to the development of arrhythmia .
Diseases: arrhythmia"	"Sentence: Previous anecdotal reports have linked creatine to the development of arrhythmia .
Diseases:"
3609	Clinicians must be diligent when interviewing patients about their drug therapy histories and include questions about their use of herbal products and dietary supplements .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinicians must be diligent when interviewing patients about their drug therapy histories and include questions about their use of herbal products and dietary supplements .
Diseases: "	"Sentence: Clinicians must be diligent when interviewing patients about their drug therapy histories and include questions about their use of herbal products and dietary supplements .
Diseases:"
3610	In addition , it is important to report adverse effects associated with frequently consumed supplements and herbal products to the Food and Drug Administration and in the literature .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , it is important to report adverse effects associated with frequently consumed supplements and herbal products to the Food and Drug Administration and in the literature .
Diseases: "	"Sentence: In addition , it is important to report adverse effects associated with frequently consumed supplements and herbal products to the Food and Drug Administration and in the literature .
Diseases:"
3611	Comparison of developmental toxicity of selective and non - selective cyclooxygenase - 2 inhibitors in CRL : ( WI ) WUBR Wistar rats - - DFU and piroxicam study .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Comparison of developmental toxicity of selective and non - selective cyclooxygenase - 2 inhibitors in CRL : ( WI ) WUBR Wistar rats - - DFU and piroxicam study .
Diseases: toxicity"	"Sentence: Comparison of developmental toxicity of selective and non - selective cyclooxygenase - 2 inhibitors in CRL : ( WI ) WUBR Wistar rats - - DFU and piroxicam study .
Diseases:"
3612	Cyclooxygenase ( COX ) inhibitors are one of the most often ingested drugs during pregnancy .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cyclooxygenase ( COX ) inhibitors are one of the most often ingested drugs during pregnancy .
Diseases: "	"Sentence: Cyclooxygenase ( COX ) inhibitors are one of the most often ingested drugs during pregnancy .
Diseases:"
3613	Unlike general toxicity data , their prenatal toxic effects were not extensively studied before .	O O B O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Unlike general toxicity data , their prenatal toxic effects were not extensively studied before .
Diseases: toxicity"	"Sentence: Unlike general toxicity data , their prenatal toxic effects were not extensively studied before .
Diseases:"
3614	The aim of the experiment was to evaluate the developmental toxicity of the non - selective ( piroxicam ) and selective ( DFU ; 5 , 5 - dimethyl - 3 - ( 3 - fluorophenyl ) - 4 - ( 4 - methylsulphonyl ) phenyl - 2 ( 5H ) - furanon ) COX - 2 inhibitors .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: The aim of the experiment was to evaluate the developmental toxicity of the non - selective ( piroxicam ) and selective ( DFU ; 5 , 5 - dimethyl - 3 - ( 3 - fluorophenyl ) - 4 - ( 4 - methylsulphonyl ) phenyl - 2 ( 5H ) - furanon ) COX - 2 inhibitors .
Diseases: toxicity"	"Sentence: The aim of the experiment was to evaluate the developmental toxicity of the non - selective ( piroxicam ) and selective ( DFU ; 5 , 5 - dimethyl - 3 - ( 3 - fluorophenyl ) - 4 - ( 4 - methylsulphonyl ) phenyl - 2 ( 5H ) - furanon ) COX - 2 inhibitors .
Diseases:"
3615	METHODS : Drugs were separately , orally once daily dosed to pregnant rats from day 8 to 21 ( GD1 = plug day ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Drugs were separately , orally once daily dosed to pregnant rats from day 8 to 21 ( GD1 = plug day ) .
Diseases: "	"Sentence: METHODS : Drugs were separately , orally once daily dosed to pregnant rats from day 8 to 21 ( GD1 = plug day ) .
Diseases:"
3616	Doses were set at 0 . 3 , 3 . 0 and 30 . 0mg / kg for piroxicam and 0 . 2 , 2 . 0 and 20 . 0mg / kg for DFU .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Doses were set at 0 . 3 , 3 . 0 and 30 . 0mg / kg for piroxicam and 0 . 2 , 2 . 0 and 20 . 0mg / kg for DFU .
Diseases: "	"Sentence: Doses were set at 0 . 3 , 3 . 0 and 30 . 0mg / kg for piroxicam and 0 . 2 , 2 . 0 and 20 . 0mg / kg for DFU .
Diseases:"
3617	Fetuses were delivered on GD 21 and routinely examined .	O O O O O O O O O O	[]	0	0	"Sentence: Fetuses were delivered on GD 21 and routinely examined .
Diseases: "	"Sentence: Fetuses were delivered on GD 21 and routinely examined .
Diseases:"
3618	Comprehensive clinical and developmental measurements were done .	O O O O O O O O	[]	0	0	"Sentence: Comprehensive clinical and developmental measurements were done .
Diseases: "	"Sentence: Comprehensive clinical and developmental measurements were done .
Diseases:"
3619	The pooled statistical analysis for ventricular septal ( VSD ) and midline ( MD ) defects was performed for rat fetuses exposed to piroxicam , selective and non - selective COX - 2 inhibitor based on present and historic data .	O O O O O B I I I I I I I I I I O O O O O O O O O O O O O O O O O O O O O O O O O	['ventricular septal ( vsd ) and midline ( md ) defects']	1	16	"Sentence: The pooled statistical analysis for ventricular septal ( VSD ) and midline ( MD ) defects was performed for rat fetuses exposed to piroxicam , selective and non - selective COX - 2 inhibitor based on present and historic data .
Diseases: ventricular septal ( vsd ) and midline ( md ) defects"	"Sentence: The pooled statistical analysis for ventricular septal ( VSD ) and midline ( MD ) defects was performed for rat fetuses exposed to piroxicam , selective and non - selective COX - 2 inhibitor based on present and historic data .
Diseases:"
3620	Maternal toxicity , intrauterine growth retardation , and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam .	O B O B I I O O B I I I I I O O O O O O O O O O O O	['intrauterine growth retardation', 'increase of external and skeletal variations', 'toxicity']	3	16	"Sentence: Maternal toxicity , intrauterine growth retardation , and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam .
Diseases: intrauterine growth retardation, increase of external and skeletal variations, toxicity"	"Sentence: Maternal toxicity , intrauterine growth retardation , and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam .
Diseases:"
3621	Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose .	O O O O O O O O O O O O B O O O O O O O O O O	['toxicity']	1	2	"Sentence: Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose .
Diseases: toxicity"	"Sentence: Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose .
Diseases:"
3622	Lack of teratogenicity was found in piroxicam and DFU - exposed groups .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Lack of teratogenicity was found in piroxicam and DFU - exposed groups .
Diseases: "	"Sentence: Lack of teratogenicity was found in piroxicam and DFU - exposed groups .
Diseases:"
3623	Prenatal exposure to non - selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX - 2 inhibitors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Prenatal exposure to non - selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX - 2 inhibitors .
Diseases: "	"Sentence: Prenatal exposure to non - selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX - 2 inhibitors .
Diseases:"
3624	CONCLUSION : Both selective and non - selective COX - 2 inhibitors were toxic for rats fetuses when administered in the highest dose .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSION : Both selective and non - selective COX - 2 inhibitors were toxic for rats fetuses when administered in the highest dose .
Diseases: "	"Sentence: CONCLUSION : Both selective and non - selective COX - 2 inhibitors were toxic for rats fetuses when administered in the highest dose .
Diseases:"
3625	Unlike DFU , piroxicam was also highly toxic to the dams .	O O O O O O O O O O O O	[]	0	0	"Sentence: Unlike DFU , piroxicam was also highly toxic to the dams .
Diseases: "	"Sentence: Unlike DFU , piroxicam was also highly toxic to the dams .
Diseases:"
3626	Prenatal exposure to selective COX - 2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non - selective drugs and historic control .	O O O O O O O O O O O O O O B I I I I O O O O O O O O O O O O O	['ventricular septal and midline defects']	1	9	"Sentence: Prenatal exposure to selective COX - 2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non - selective drugs and historic control .
Diseases: ventricular septal and midline defects"	"Sentence: Prenatal exposure to selective COX - 2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non - selective drugs and historic control .
Diseases:"
3627	Protective efficacy of neuroactive steroids against cocaine kindled - seizures in mice .	O O O O O O O O O B O O O	['seizures']	1	3	"Sentence: Protective efficacy of neuroactive steroids against cocaine kindled - seizures in mice .
Diseases: seizures"	"Sentence: Protective efficacy of neuroactive steroids against cocaine kindled - seizures in mice .
Diseases:"
3628	Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders .	O O O O O O O O O O O O B I I I O	['neurological and psychiatric disorders']	1	7	"Sentence: Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders .
Diseases: neurological and psychiatric disorders"	"Sentence: Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders .
Diseases:"
3629	They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments .	O O O O B O O O O O O O O O O O O B I O O O O	['drug dependence', 'seizures']	2	4	"Sentence: They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments .
Diseases: drug dependence, seizures"	"Sentence: They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments .
Diseases:"
3630	The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma - aminobutyric acid ( GABA ( A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( seizure kindling ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	['seizure']	1	3	"Sentence: The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma - aminobutyric acid ( GABA ( A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( seizure kindling ) .
Diseases: seizure"	"Sentence: The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma - aminobutyric acid ( GABA ( A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( seizure kindling ) .
Diseases:"
3631	Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled seizures in male , Swiss - Webster mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['seizures']	1	3	"Sentence: Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled seizures in male , Swiss - Webster mice .
Diseases: seizures"	"Sentence: Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled seizures in male , Swiss - Webster mice .
Diseases:"
3632	Kindled seizures were induced by daily administration of 60 mg / kg cocaine for 5 days .	O B O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: Kindled seizures were induced by daily administration of 60 mg / kg cocaine for 5 days .
Diseases: seizures"	"Sentence: Kindled seizures were induced by daily administration of 60 mg / kg cocaine for 5 days .
Diseases:"
3633	All of these positive GABA ( A ) modulators suppressed the expression of kindled seizures , whereas only allopregnanolone and ganaxolone inhibited the development of kindling .	O O O O O O O O O O O O O O B O O O O O O O O O O O O	['seizures']	1	3	"Sentence: All of these positive GABA ( A ) modulators suppressed the expression of kindled seizures , whereas only allopregnanolone and ganaxolone inhibited the development of kindling .
Diseases: seizures"	"Sentence: All of these positive GABA ( A ) modulators suppressed the expression of kindled seizures , whereas only allopregnanolone and ganaxolone inhibited the development of kindling .
Diseases:"
3634	Allopregnanolone and pregnanolone , but not ganaxolone , also reduced cumulative lethality associated with kindling .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Allopregnanolone and pregnanolone , but not ganaxolone , also reduced cumulative lethality associated with kindling .
Diseases: "	"Sentence: Allopregnanolone and pregnanolone , but not ganaxolone , also reduced cumulative lethality associated with kindling .
Diseases:"
3635	These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse .
Diseases: "	"Sentence: These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse .
Diseases:"
3636	Kidney function and morphology after short - term combination therapy with cyclosporine A , tacrolimus and sirolimus in the rat .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Kidney function and morphology after short - term combination therapy with cyclosporine A , tacrolimus and sirolimus in the rat .
Diseases: "	"Sentence: Kidney function and morphology after short - term combination therapy with cyclosporine A , tacrolimus and sirolimus in the rat .
Diseases:"
3637	BACKGROUND : Sirolimus ( SRL ) may supplement calcineurin inhibitors in clinical organ transplantation .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: BACKGROUND : Sirolimus ( SRL ) may supplement calcineurin inhibitors in clinical organ transplantation .
Diseases: "	"Sentence: BACKGROUND : Sirolimus ( SRL ) may supplement calcineurin inhibitors in clinical organ transplantation .
Diseases:"
3638	These are nephrotoxic , but SRL seems to act differently displaying only minor nephrotoxic effects , although this question is still open .	O O B O O O O O O O O O O B O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: These are nephrotoxic , but SRL seems to act differently displaying only minor nephrotoxic effects , although this question is still open .
Diseases: nephrotoxic"	"Sentence: These are nephrotoxic , but SRL seems to act differently displaying only minor nephrotoxic effects , although this question is still open .
Diseases:"
3639	In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described .	O O O O O O O O O O O O O O O O O O B O O O O	['nephrotoxic']	1	4	"Sentence: In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described .
Diseases: nephrotoxic"	"Sentence: In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described .
Diseases:"
3640	The aim of this study was to examine further the renal function , including morphological analysis of the kidneys of male Sprague - Dawley rats treated with either cyclosporine A ( CsA ) , tacrolimus ( FK506 ) or SRL as monotherapies or in different combinations .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The aim of this study was to examine further the renal function , including morphological analysis of the kidneys of male Sprague - Dawley rats treated with either cyclosporine A ( CsA ) , tacrolimus ( FK506 ) or SRL as monotherapies or in different combinations .
Diseases: "	"Sentence: The aim of this study was to examine further the renal function , including morphological analysis of the kidneys of male Sprague - Dawley rats treated with either cyclosporine A ( CsA ) , tacrolimus ( FK506 ) or SRL as monotherapies or in different combinations .
Diseases:"
3641	For a period of 2 weeks , CsA 15 mg / kg / day ( given orally ) , FK506 3 . 0 mg / kg / day ( given orally ) or SRL 0 . 4 mg / kg / day ( given intraperitoneally ) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague - Dawley rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For a period of 2 weeks , CsA 15 mg / kg / day ( given orally ) , FK506 3 . 0 mg / kg / day ( given orally ) or SRL 0 . 4 mg / kg / day ( given intraperitoneally ) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague - Dawley rats .
Diseases: "	"Sentence: For a period of 2 weeks , CsA 15 mg / kg / day ( given orally ) , FK506 3 . 0 mg / kg / day ( given orally ) or SRL 0 . 4 mg / kg / day ( given intraperitoneally ) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague - Dawley rats .
Diseases:"
3642	In the ' conscious catheterized rat ' model , the glomerular filtration rate ( GFR ) was measured as the clearance of Cr ( EDTA ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the ' conscious catheterized rat ' model , the glomerular filtration rate ( GFR ) was measured as the clearance of Cr ( EDTA ) .
Diseases: "	"Sentence: In the ' conscious catheterized rat ' model , the glomerular filtration rate ( GFR ) was measured as the clearance of Cr ( EDTA ) .
Diseases:"
3643	The morphological analysis of the kidneys included a semi - quantitative scoring system analysing the degree of striped fibrosis , subcapsular fibrosis and the number of basophilic tubules , plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red .	O O O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O O B O O O O O O O O	['fibrosis']	1	3	"Sentence: The morphological analysis of the kidneys included a semi - quantitative scoring system analysing the degree of striped fibrosis , subcapsular fibrosis and the number of basophilic tubules , plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red .
Diseases: fibrosis"	"Sentence: The morphological analysis of the kidneys included a semi - quantitative scoring system analysing the degree of striped fibrosis , subcapsular fibrosis and the number of basophilic tubules , plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red .
Diseases:"
3644	RESULTS : CsA , FK506 and SRL all significantly decreased the GFR .	O O O O O O O O O O O O O	[]	0	0	"Sentence: RESULTS : CsA , FK506 and SRL all significantly decreased the GFR .
Diseases: "	"Sentence: RESULTS : CsA , FK506 and SRL all significantly decreased the GFR .
Diseases:"
3645	A further deterioration was seen when CsA was combined with either FK506 or SRL , whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A further deterioration was seen when CsA was combined with either FK506 or SRL , whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances .
Diseases: "	"Sentence: A further deterioration was seen when CsA was combined with either FK506 or SRL , whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances .
Diseases:"
3646	The morphological changes presented a similar pattern .	O O O O O O O O	[]	0	0	"Sentence: The morphological changes presented a similar pattern .
Diseases: "	"Sentence: The morphological changes presented a similar pattern .
Diseases:"
3647	The semi - quantitative scoring was significantly worst in the group treated with CsA plus SRL ( P < 0 . 001 compared with controls ) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls ( P < 0 . 02 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['fibrosis']	1	3	"Sentence: The semi - quantitative scoring was significantly worst in the group treated with CsA plus SRL ( P < 0 . 001 compared with controls ) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls ( P < 0 . 02 ) .
Diseases: fibrosis"	"Sentence: The semi - quantitative scoring was significantly worst in the group treated with CsA plus SRL ( P < 0 . 001 compared with controls ) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls ( P < 0 . 02 ) .
Diseases:"
3648	The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls ( P = 0 . 05 ) .	O O O O O O O O O O O O B O O O O O O O O O O O O	['fibrosis']	1	3	"Sentence: The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls ( P = 0 . 05 ) .
Diseases: fibrosis"	"Sentence: The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls ( P = 0 . 05 ) .
Diseases:"
3649	This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL , whereas FK506 plus SRL was better tolerated .	O O O O O O B O O O O O O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL , whereas FK506 plus SRL was better tolerated .
Diseases: nephrotoxic"	"Sentence: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL , whereas FK506 plus SRL was better tolerated .
Diseases:"
3650	Effect of fucoidan treatment on collagenase - induced intracerebral hemorrhage in rats .	O O O O O O O O B I O O O	['intracerebral hemorrhage']	1	6	"Sentence: Effect of fucoidan treatment on collagenase - induced intracerebral hemorrhage in rats .
Diseases: intracerebral hemorrhage"	"Sentence: Effect of fucoidan treatment on collagenase - induced intracerebral hemorrhage in rats .
Diseases:"
3651	Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke .	O O O O O O O O O B I O B I O	['ischemic stroke', 'brain damage']	2	7	"Sentence: Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke .
Diseases: ischemic stroke, brain damage"	"Sentence: Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke .
Diseases:"
3652	Intracerebral hemorrhage is associated with more inflammation than ischemic stroke .	B I O O O O B O B I O	['inflammation', 'ischemic stroke', 'intracerebral hemorrhage']	3	14	"Sentence: Intracerebral hemorrhage is associated with more inflammation than ischemic stroke .
Diseases: inflammation, ischemic stroke, intracerebral hemorrhage"	"Sentence: Intracerebral hemorrhage is associated with more inflammation than ischemic stroke .
Diseases:"
3653	We tested the sulfated polysaccharide fucoidan , which has been reported to reduce inflammatory brain damage , in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus .	O O O O O O O O O O O O O O B I O O O O O O B I O O O O O O O O O O O	['intracerebral hemorrhage', 'brain damage']	2	9	"Sentence: We tested the sulfated polysaccharide fucoidan , which has been reported to reduce inflammatory brain damage , in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus .
Diseases: intracerebral hemorrhage, brain damage"	"Sentence: We tested the sulfated polysaccharide fucoidan , which has been reported to reduce inflammatory brain damage , in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus .
Diseases:"
3654	Rats were treated with seven day intravenous infusion of fucoidan ( 30 micrograms h - 1 ) or vehicle .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Rats were treated with seven day intravenous infusion of fucoidan ( 30 micrograms h - 1 ) or vehicle .
Diseases: "	"Sentence: Rats were treated with seven day intravenous infusion of fucoidan ( 30 micrograms h - 1 ) or vehicle .
Diseases:"
3655	The hematoma was assessed in vivo by magnetic resonance imaging .	O B O O O O O O O O O	['hematoma']	1	2	"Sentence: The hematoma was assessed in vivo by magnetic resonance imaging .
Diseases: hematoma"	"Sentence: The hematoma was assessed in vivo by magnetic resonance imaging .
Diseases:"
3656	Motor behavior , passive avoidance , and skilled forelimb function were tested repeatedly for six weeks .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Motor behavior , passive avoidance , and skilled forelimb function were tested repeatedly for six weeks .
Diseases: "	"Sentence: Motor behavior , passive avoidance , and skilled forelimb function were tested repeatedly for six weeks .
Diseases:"
3657	Fucoidan - treated rats exhibited evidence of impaired blood clotting and hemodilution , had larger hematomas , and tended to have less inflammation in the vicinity of the hematoma after three days .	O O O O O O O B I I O B O O O B O O O O O O B O O O O O B O O O O	['impaired blood clotting', 'inflammation', 'hematoma', 'hematomas', 'hemodilution']	5	21	"Sentence: Fucoidan - treated rats exhibited evidence of impaired blood clotting and hemodilution , had larger hematomas , and tended to have less inflammation in the vicinity of the hematoma after three days .
Diseases: impaired blood clotting, inflammation, hematoma, hematomas, hemodilution"	"Sentence: Fucoidan - treated rats exhibited evidence of impaired blood clotting and hemodilution , had larger hematomas , and tended to have less inflammation in the vicinity of the hematoma after three days .
Diseases:"
3658	They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test .	O O O O O O O O O O O O O O B O O O O O O O O O O	['hemorrhage']	1	4	"Sentence: They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test .
Diseases: hemorrhage"	"Sentence: They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test .
Diseases:"
3659	Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups .	O B I I O O B I O O O O O O B O O O O O O O O	['hematoma', 'white matter edema', 'neuronal loss']	3	10	"Sentence: Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups .
Diseases: hematoma, white matter edema, neuronal loss"	"Sentence: Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups .
Diseases:"
3660	Investigation of more specific anti - inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage .	O O O O O O O O O O O O O O B I O	['intracerebral hemorrhage']	1	6	"Sentence: Investigation of more specific anti - inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage .
Diseases: intracerebral hemorrhage"	"Sentence: Investigation of more specific anti - inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage .
Diseases:"
3661	Paracetamol - associated coma , metabolic acidosis , renal and hepatic failure .	O O O B O B I O B I I I O	['renal and hepatic failure', 'metabolic acidosis', 'coma']	3	12	"Sentence: Paracetamol - associated coma , metabolic acidosis , renal and hepatic failure .
Diseases: renal and hepatic failure, metabolic acidosis, coma"	"Sentence: Paracetamol - associated coma , metabolic acidosis , renal and hepatic failure .
Diseases:"
3662	A case of metabolic acidosis , acute renal failure and hepatic failure following paracetamol ingestion is presented .	O O O B I O B I I I I I O O O O O O	['acute renal failure and hepatic failure', 'metabolic acidosis']	2	12	"Sentence: A case of metabolic acidosis , acute renal failure and hepatic failure following paracetamol ingestion is presented .
Diseases: acute renal failure and hepatic failure, metabolic acidosis"	"Sentence: A case of metabolic acidosis , acute renal failure and hepatic failure following paracetamol ingestion is presented .
Diseases:"
3663	The diagnostic difficulty at presentation is highlighted .	O O O O O O O O	[]	0	0	"Sentence: The diagnostic difficulty at presentation is highlighted .
Diseases: "	"Sentence: The diagnostic difficulty at presentation is highlighted .
Diseases:"
3664	Continuous arteriovenous haemofiltration proved a valuable means of maintaining fluid and electrolyte balance .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Continuous arteriovenous haemofiltration proved a valuable means of maintaining fluid and electrolyte balance .
Diseases: "	"Sentence: Continuous arteriovenous haemofiltration proved a valuable means of maintaining fluid and electrolyte balance .
Diseases:"
3665	The patient recovered .	O O O O	[]	0	0	"Sentence: The patient recovered .
Diseases: "	"Sentence: The patient recovered .
Diseases:"
3666	Hepatic reactions associated with ketoconazole in the United Kingdom .	O O O O O O O O O O	[]	0	0	"Sentence: Hepatic reactions associated with ketoconazole in the United Kingdom .
Diseases: "	"Sentence: Hepatic reactions associated with ketoconazole in the United Kingdom .
Diseases:"
3667	Ketoconazole was introduced in the United Kingdom in 1981 .	O O O O O O O O O O	[]	0	0	"Sentence: Ketoconazole was introduced in the United Kingdom in 1981 .
Diseases: "	"Sentence: Ketoconazole was introduced in the United Kingdom in 1981 .
Diseases:"
3668	By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug , including five deaths .	O O O O O O O O O O O O O O O B O O O O O O O B O	['hepatotoxicity', 'deaths']	2	6	"Sentence: By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug , including five deaths .
Diseases: hepatotoxicity, deaths"	"Sentence: By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug , including five deaths .
Diseases:"
3669	An analysis of the 75 cases that had been adequately followed up suggested that 16 , including three deaths , were probably related to treatment with the drug .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['deaths']	1	2	"Sentence: An analysis of the 75 cases that had been adequately followed up suggested that 16 , including three deaths , were probably related to treatment with the drug .
Diseases: deaths"	"Sentence: An analysis of the 75 cases that had been adequately followed up suggested that 16 , including three deaths , were probably related to treatment with the drug .
Diseases:"
3670	Of the remainder , 48 were possibly related to treatment , five were unlikely to be so , and six were unclassifiable .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the remainder , 48 were possibly related to treatment , five were unlikely to be so , and six were unclassifiable .
Diseases: "	"Sentence: Of the remainder , 48 were possibly related to treatment , five were unlikely to be so , and six were unclassifiable .
Diseases:"
3671	The mean age of patients in the 16 probable cases was 57 . 9 , with hepatotoxicity being more common in women .	O O O O O O O O O O O O O O O O B O O O O O O	['hepatotoxicity']	1	4	"Sentence: The mean age of patients in the 16 probable cases was 57 . 9 , with hepatotoxicity being more common in women .
Diseases: hepatotoxicity"	"Sentence: The mean age of patients in the 16 probable cases was 57 . 9 , with hepatotoxicity being more common in women .
Diseases:"
3672	The average duration of treatment before the onset of jaundice was 61 days .	O O O O O O O O O B O O O O	['jaundice']	1	3	"Sentence: The average duration of treatment before the onset of jaundice was 61 days .
Diseases: jaundice"	"Sentence: The average duration of treatment before the onset of jaundice was 61 days .
Diseases:"
3673	None of these well validated cases occurred within the first 10 days after treatment .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: None of these well validated cases occurred within the first 10 days after treatment .
Diseases: "	"Sentence: None of these well validated cases occurred within the first 10 days after treatment .
Diseases:"
3674	The results of serum liver function tests suggested hepatocellular injury in 10 ( 63 % ) ; the rest showed a mixed pattern .	O O O O O O O O B I O O O O O O O O O O O O O O	['hepatocellular injury']	1	6	"Sentence: The results of serum liver function tests suggested hepatocellular injury in 10 ( 63 % ) ; the rest showed a mixed pattern .
Diseases: hepatocellular injury"	"Sentence: The results of serum liver function tests suggested hepatocellular injury in 10 ( 63 % ) ; the rest showed a mixed pattern .
Diseases:"
3675	In contrast , the results of histological examination of the liver often showed evidence of cholestasis .	O O O O O O O O O O O O O O O B O	['cholestasis']	1	4	"Sentence: In contrast , the results of histological examination of the liver often showed evidence of cholestasis .
Diseases: cholestasis"	"Sentence: In contrast , the results of histological examination of the liver often showed evidence of cholestasis .
Diseases:"
3676	The characteristics of the 48 patients in the possible cases were similar .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The characteristics of the 48 patients in the possible cases were similar .
Diseases: "	"Sentence: The characteristics of the 48 patients in the possible cases were similar .
Diseases:"
3677	Allergic manifestations such as rash and eosinophilia were rare .	O O O O B O B O O O	['eosinophilia', 'rash']	2	7	"Sentence: Allergic manifestations such as rash and eosinophilia were rare .
Diseases: eosinophilia, rash"	"Sentence: Allergic manifestations such as rash and eosinophilia were rare .
Diseases:"
3678	Hepatitis was usually reversible when treatment was stopped , with the results of liver function tests returning to normal after an average of 3 . 1 months .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hepatitis']	1	3	"Sentence: Hepatitis was usually reversible when treatment was stopped , with the results of liver function tests returning to normal after an average of 3 . 1 months .
Diseases: hepatitis"	"Sentence: Hepatitis was usually reversible when treatment was stopped , with the results of liver function tests returning to normal after an average of 3 . 1 months .
Diseases:"
3679	In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis .	O O O O O B O O O O O O O O O O O O O O B O O O O B O	['deaths', 'jaundice', 'hepatitis']	3	8	"Sentence: In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis .
Diseases: deaths, jaundice, hepatitis"	"Sentence: In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis .
Diseases:"
3680	Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury .	O O O O O O O O O O B O O O O O O O O O O O O B I O	['hepatic injury', 'hepatitis']	2	6	"Sentence: Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury .
Diseases: hepatic injury, hepatitis"	"Sentence: Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury .
Diseases:"
3681	Combined effects of prolonged prostaglandin E1 - induced hypotension and haemodilution on human hepatic function .	O O O O O O O O B O B O O O O O	['haemodilution', 'hypotension']	2	8	"Sentence: Combined effects of prolonged prostaglandin E1 - induced hypotension and haemodilution on human hepatic function .
Diseases: haemodilution, hypotension"	"Sentence: Combined effects of prolonged prostaglandin E1 - induced hypotension and haemodilution on human hepatic function .
Diseases:"
3682	Combined effects of prolonged prostaglandin E1 ( PGE1 ) - induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery .	O O O O O O O O O O O B O B O O O O O O O O O O O O	['haemodilution', 'hypotension']	2	8	"Sentence: Combined effects of prolonged prostaglandin E1 ( PGE1 ) - induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery .
Diseases: haemodilution, hypotension"	"Sentence: Combined effects of prolonged prostaglandin E1 ( PGE1 ) - induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery .
Diseases:"
3683	The patients were randomly allocated to one of three groups ; those in group A ( n = 10 ) were subjected to controlled hypotension alone , those in group B ( n = 10 ) to haemodilution alone and those in group C ( n = 10 ) to both controlled hypotension and haemodilution .	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O B O B O	['haemodilution', 'hypotension']	2	8	"Sentence: The patients were randomly allocated to one of three groups ; those in group A ( n = 10 ) were subjected to controlled hypotension alone , those in group B ( n = 10 ) to haemodilution alone and those in group C ( n = 10 ) to both controlled hypotension and haemodilution .
Diseases: haemodilution, hypotension"	"Sentence: The patients were randomly allocated to one of three groups ; those in group A ( n = 10 ) were subjected to controlled hypotension alone , those in group B ( n = 10 ) to haemodilution alone and those in group C ( n = 10 ) to both controlled hypotension and haemodilution .
Diseases:"
3684	Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution , and final haematocrit values were 21 or 22 % .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['haemodilution']	1	5	"Sentence: Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution , and final haematocrit values were 21 or 22 % .
Diseases: haemodilution"	"Sentence: Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution , and final haematocrit values were 21 or 22 % .
Diseases:"
3685	Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min .	O B O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min .
Diseases: hypotension"	"Sentence: Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min .
Diseases:"
3686	Measurements included arterial ketone body ratio ( AKBR , aceto - acetate / 3 - hydroxybutyrate ) and clinical hepatic function parameters .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Measurements included arterial ketone body ratio ( AKBR , aceto - acetate / 3 - hydroxybutyrate ) and clinical hepatic function parameters .
Diseases: "	"Sentence: Measurements included arterial ketone body ratio ( AKBR , aceto - acetate / 3 - hydroxybutyrate ) and clinical hepatic function parameters .
Diseases:"
3687	AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B .
Diseases: "	"Sentence: AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B .
Diseases:"
3688	In group C , AKBR showed a significant decrease at 120 min ( - 40 % ) and at 180 min ( - 49 % ) after the start of hypotension and at 60 min ( - 32 % ) after recovery of normotension , and SGOT , SGPT , LDH and total bilirubin showed significant increases after operation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: In group C , AKBR showed a significant decrease at 120 min ( - 40 % ) and at 180 min ( - 49 % ) after the start of hypotension and at 60 min ( - 32 % ) after recovery of normotension , and SGOT , SGPT , LDH and total bilirubin showed significant increases after operation .
Diseases: hypotension"	"Sentence: In group C , AKBR showed a significant decrease at 120 min ( - 40 % ) and at 180 min ( - 49 % ) after the start of hypotension and at 60 min ( - 32 % ) after recovery of normotension , and SGOT , SGPT , LDH and total bilirubin showed significant increases after operation .
Diseases:"
3689	The results suggest that a prolonged combination of more than 120 min of PGE1 - induced hypotension and moderate haemodilution would cause impairment of hepatic function .	O O O O O O O O O O O O O O O O B O O B O O B I I I O	['haemodilution', 'hypotension', 'impairment of hepatic function']	3	14	"Sentence: The results suggest that a prolonged combination of more than 120 min of PGE1 - induced hypotension and moderate haemodilution would cause impairment of hepatic function .
Diseases: haemodilution, hypotension, impairment of hepatic function"	"Sentence: The results suggest that a prolonged combination of more than 120 min of PGE1 - induced hypotension and moderate haemodilution would cause impairment of hepatic function .
Diseases:"
3690	Levodopa - induced dyskinesias in patients with Parkinson 's disease : filling the bench - to - bedside gap .	O O O B O O O B I I O O O O O O O O O O	"['dyskinesias', ""parkinson 's disease""]"	2	11	"Sentence: Levodopa - induced dyskinesias in patients with Parkinson 's disease : filling the bench - to - bedside gap .
Diseases: dyskinesias, parkinson 's disease"	"Sentence: Levodopa - induced dyskinesias in patients with Parkinson 's disease : filling the bench - to - bedside gap .
Diseases:"
3691	Levodopa is the most effective drug for the treatment of Parkinson 's disease .	O O O O O O O O O O B I I O	"[""parkinson 's disease""]"	1	5	"Sentence: Levodopa is the most effective drug for the treatment of Parkinson 's disease .
Diseases: parkinson 's disease"	"Sentence: Levodopa is the most effective drug for the treatment of Parkinson 's disease .
Diseases:"
3692	However , the long - term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias .	O O O O O O O O O O O O O O O O O O B O	['dyskinesias']	1	5	"Sentence: However , the long - term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias .
Diseases: dyskinesias"	"Sentence: However , the long - term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias .
Diseases:"
3693	Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa - induced dyskinesias , their pathogenesis is still unclear .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['dyskinesias']	1	5	"Sentence: Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa - induced dyskinesias , their pathogenesis is still unclear .
Diseases: dyskinesias"	"Sentence: Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa - induced dyskinesias , their pathogenesis is still unclear .
Diseases:"
3694	In recent years , evidence from animal models of Parkinson 's disease has provided important information to understand the effect of specific receptor and post - receptor molecular mechanisms underlying the development of dyskinetic movements .	O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O B I O	"['dyskinetic movements', ""parkinson 's disease""]"	2	11	"Sentence: In recent years , evidence from animal models of Parkinson 's disease has provided important information to understand the effect of specific receptor and post - receptor molecular mechanisms underlying the development of dyskinetic movements .
Diseases: dyskinetic movements, parkinson 's disease"	"Sentence: In recent years , evidence from animal models of Parkinson 's disease has provided important information to understand the effect of specific receptor and post - receptor molecular mechanisms underlying the development of dyskinetic movements .
Diseases:"
3695	Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , dopamine receptor subtypes , ionotropic and metabotropic glutamate receptors , and non - dopaminergic neurotransmitter systems in the pathophysiology of levodopa - induced dyskinesias .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['dyskinesias']	1	5	"Sentence: Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , dopamine receptor subtypes , ionotropic and metabotropic glutamate receptors , and non - dopaminergic neurotransmitter systems in the pathophysiology of levodopa - induced dyskinesias .
Diseases: dyskinesias"	"Sentence: Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , dopamine receptor subtypes , ionotropic and metabotropic glutamate receptors , and non - dopaminergic neurotransmitter systems in the pathophysiology of levodopa - induced dyskinesias .
Diseases:"
3696	Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy .	O O B O O O O O O O O O O O O O O O O O B O	['seizures', 'epilepsy']	2	5	"Sentence: Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy .
Diseases: seizures, epilepsy"	"Sentence: Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy .
Diseases:"
3697	In this study , we investigated the therapeutic potential of bone marrow mononuclear cells ( BMCs ) in a model of epilepsy induced by pilocarpine in rats .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['epilepsy']	1	3	"Sentence: In this study , we investigated the therapeutic potential of bone marrow mononuclear cells ( BMCs ) in a model of epilepsy induced by pilocarpine in rats .
Diseases: epilepsy"	"Sentence: In this study , we investigated the therapeutic potential of bone marrow mononuclear cells ( BMCs ) in a model of epilepsy induced by pilocarpine in rats .
Diseases:"
3698	BMCs obtained from green fluorescent protein ( GFP ) transgenic mice or rats were transplanted intravenously after induction of status epilepticus ( SE ) .	O O O O O O O O O O O O O O O O O O O B I O B O O	['se', 'status epilepticus']	2	6	"Sentence: BMCs obtained from green fluorescent protein ( GFP ) transgenic mice or rats were transplanted intravenously after induction of status epilepticus ( SE ) .
Diseases: se, status epilepticus"	"Sentence: BMCs obtained from green fluorescent protein ( GFP ) transgenic mice or rats were transplanted intravenously after induction of status epilepticus ( SE ) .
Diseases:"
3699	Spontaneous recurrent seizures ( SRS ) were monitored using Racine 's seizure severity scale .	B I I O B O O O O O O B O O O	['spontaneous recurrent seizures', 'seizure', 'srs']	3	10	"Sentence: Spontaneous recurrent seizures ( SRS ) were monitored using Racine 's seizure severity scale .
Diseases: spontaneous recurrent seizures, seizure, srs"	"Sentence: Spontaneous recurrent seizures ( SRS ) were monitored using Racine 's seizure severity scale .
Diseases:"
3700	All of the rats in the saline - treated epileptic control group developed SRS , whereas none of the BMC - treated epileptic animals had seizures in the short term ( 15 days after transplantation ) , regardless of the BMC source .	O O O O O O O O O B O O O B O O O O O O O O B O O B O O O O O O O O O O O O O O O O O	['epileptic', 'seizures', 'srs']	3	8	"Sentence: All of the rats in the saline - treated epileptic control group developed SRS , whereas none of the BMC - treated epileptic animals had seizures in the short term ( 15 days after transplantation ) , regardless of the BMC source .
Diseases: epileptic, seizures, srs"	"Sentence: All of the rats in the saline - treated epileptic control group developed SRS , whereas none of the BMC - treated epileptic animals had seizures in the short term ( 15 days after transplantation ) , regardless of the BMC source .
Diseases:"
3701	Over the long - term chronic phase ( 120 days after transplantation ) , only 25 % of BMC - treated epileptic animals had seizures , but with a lower frequency and duration compared to the epileptic control group .	O O O O O O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O O B O O O	['epileptic', 'seizures']	2	5	"Sentence: Over the long - term chronic phase ( 120 days after transplantation ) , only 25 % of BMC - treated epileptic animals had seizures , but with a lower frequency and duration compared to the epileptic control group .
Diseases: epileptic, seizures"	"Sentence: Over the long - term chronic phase ( 120 days after transplantation ) , only 25 % of BMC - treated epileptic animals had seizures , but with a lower frequency and duration compared to the epileptic control group .
Diseases:"
3702	The density of hippocampal neurons in the brains of animals treated with BMCs was markedly preserved .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The density of hippocampal neurons in the brains of animals treated with BMCs was markedly preserved .
Diseases: "	"Sentence: The density of hippocampal neurons in the brains of animals treated with BMCs was markedly preserved .
Diseases:"
3703	At hippocampal Schaeffer collateral - CA1 synapses , long - term potentiation was preserved in BMC - transplanted rats compared to epileptic controls .	O O O O O O O O O O O O O O O O O O O O O B O O	['epileptic']	1	3	"Sentence: At hippocampal Schaeffer collateral - CA1 synapses , long - term potentiation was preserved in BMC - transplanted rats compared to epileptic controls .
Diseases: epileptic"	"Sentence: At hippocampal Schaeffer collateral - CA1 synapses , long - term potentiation was preserved in BMC - transplanted rats compared to epileptic controls .
Diseases:"
3704	The donor - derived GFP ( + ) cells were rarely found in the brains of transplanted epileptic rats .	O O O O O O O O O O O O O O O O O B O O	['epileptic']	1	3	"Sentence: The donor - derived GFP ( + ) cells were rarely found in the brains of transplanted epileptic rats .
Diseases: epileptic"	"Sentence: The donor - derived GFP ( + ) cells were rarely found in the brains of transplanted epileptic rats .
Diseases:"
3705	In conclusion , treatment with BMCs can prevent the development of chronic seizures , reduce neuronal loss , and influence the reorganization of the hippocampal neuronal network .	O O O O O O O O O O O O B O O B I O O O O O O O O O O O	['seizures', 'neuronal loss']	2	6	"Sentence: In conclusion , treatment with BMCs can prevent the development of chronic seizures , reduce neuronal loss , and influence the reorganization of the hippocampal neuronal network .
Diseases: seizures, neuronal loss"	"Sentence: In conclusion , treatment with BMCs can prevent the development of chronic seizures , reduce neuronal loss , and influence the reorganization of the hippocampal neuronal network .
Diseases:"
3706	Cardioprotective effect of salvianolic acid	O O O O O	[]	0	0	"Sentence: Cardioprotective effect of salvianolic acid
Diseases: "	"Sentence: Cardioprotective effect of salvianolic acid
Diseases:"
3707	A on isoproterenol - induced myocardial infarction in rats .	O O O O O B I O O O	['myocardial infarction']	1	6	"Sentence: A on isoproterenol - induced myocardial infarction in rats .
Diseases: myocardial infarction"	"Sentence: A on isoproterenol - induced myocardial infarction in rats .
Diseases:"
3708	The present study was designed to evaluate the cardioprotective potential of salvianolic acid	O O O O O O O O O O O O O	[]	0	0	"Sentence: The present study was designed to evaluate the cardioprotective potential of salvianolic acid
Diseases: "	"Sentence: The present study was designed to evaluate the cardioprotective potential of salvianolic acid
Diseases:"
3709	Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously .	O O O O O O O O O O O O	[]	0	0	"Sentence: Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously .
Diseases: "	"Sentence: Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously .
Diseases:"
3710	Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured .
Diseases: "	"Sentence: Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured .
Diseases:"
3711	Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed .
Diseases: "	"Sentence: Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed .
Diseases:"
3712	Isoproterenol - treated rats showed significant increases in the levels of lactate dehydrogenase , aspartate transaminase , creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase , catalase and glutathione peroxidase in serum and heart .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Isoproterenol - treated rats showed significant increases in the levels of lactate dehydrogenase , aspartate transaminase , creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase , catalase and glutathione peroxidase in serum and heart .
Diseases: "	"Sentence: Isoproterenol - treated rats showed significant increases in the levels of lactate dehydrogenase , aspartate transaminase , creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase , catalase and glutathione peroxidase in serum and heart .
Diseases:"
3713	These rats also showed declines in left ventricular systolic pressure , maximum and minimum rate of developed left ventricular pressure , and elevation of left ventricular end - diastolic pressure and ST - segment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These rats also showed declines in left ventricular systolic pressure , maximum and minimum rate of developed left ventricular pressure , and elevation of left ventricular end - diastolic pressure and ST - segment .
Diseases: "	"Sentence: These rats also showed declines in left ventricular systolic pressure , maximum and minimum rate of developed left ventricular pressure , and elevation of left ventricular end - diastolic pressure and ST - segment .
Diseases:"
3714	In addition , mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP / O was observed in isoproterenol - treated rats .	O O O O B I O O O O O O O O O O O O O O O O O O	['respiratory dysfunction']	1	4	"Sentence: In addition , mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP / O was observed in isoproterenol - treated rats .
Diseases: respiratory dysfunction"	"Sentence: In addition , mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP / O was observed in isoproterenol - treated rats .
Diseases:"
3715	Administration of salvianolic acid	O O O O	[]	0	0	"Sentence: Administration of salvianolic acid
Diseases: "	"Sentence: Administration of salvianolic acid
Diseases:"
3716	A for a period of 8 days significantly attenuated isoproterenol - induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function .	O O O O O O O O O O O O B I O B I O O O O O O	['cardiac dysfunction', 'myocardial injury']	2	8	"Sentence: A for a period of 8 days significantly attenuated isoproterenol - induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function .
Diseases: cardiac dysfunction, myocardial injury"	"Sentence: A for a period of 8 days significantly attenuated isoproterenol - induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function .
Diseases:"
3717	The protective role of salvianolic acid	O O O O O O	[]	0	0	"Sentence: The protective role of salvianolic acid
Diseases: "	"Sentence: The protective role of salvianolic acid
Diseases:"
3718	A against isoproterenol - induced myocardial damage was further confirmed by histopathological examination .	O O O O O B I O O O O O O O	['myocardial damage']	1	4	"Sentence: A against isoproterenol - induced myocardial damage was further confirmed by histopathological examination .
Diseases: myocardial damage"	"Sentence: A against isoproterenol - induced myocardial damage was further confirmed by histopathological examination .
Diseases:"
3719	The results of our study suggest that salvianolic acid	O O O O O O O O O	[]	0	0	"Sentence: The results of our study suggest that salvianolic acid
Diseases: "	"Sentence: The results of our study suggest that salvianolic acid
Diseases:"
3720	A possessing antioxidant activity has a significant protective effect against isoproterenol - induced myocardial infarction .	O O O O O O O O O O O O O B I O	['myocardial infarction']	1	6	"Sentence: A possessing antioxidant activity has a significant protective effect against isoproterenol - induced myocardial infarction .
Diseases: myocardial infarction"	"Sentence: A possessing antioxidant activity has a significant protective effect against isoproterenol - induced myocardial infarction .
Diseases:"
3721	Acute effects of N - ( 2 - propylpentanoyl ) urea on hippocampal amino acid neurotransmitters in pilocarpine - induced seizure in rats .	O O O O O O O O O O O O O O O O O O O O B O O O	['seizure']	1	3	"Sentence: Acute effects of N - ( 2 - propylpentanoyl ) urea on hippocampal amino acid neurotransmitters in pilocarpine - induced seizure in rats .
Diseases: seizure"	"Sentence: Acute effects of N - ( 2 - propylpentanoyl ) urea on hippocampal amino acid neurotransmitters in pilocarpine - induced seizure in rats .
Diseases:"
3722	The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( glutamate , aspartate , glycine and GABA ) of N - ( 2 - propylpentanoyl ) urea ( VPU ) in comparison to its parent compound , valproic acid ( VPA ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( glutamate , aspartate , glycine and GABA ) of N - ( 2 - propylpentanoyl ) urea ( VPU ) in comparison to its parent compound , valproic acid ( VPA ) .
Diseases: "	"Sentence: The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( glutamate , aspartate , glycine and GABA ) of N - ( 2 - propylpentanoyl ) urea ( VPU ) in comparison to its parent compound , valproic acid ( VPA ) .
Diseases:"
3723	VPU was more potent than VPA , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against pilocarpine - induced seizure whereas the corresponding value for VPA was 322 mg / kg .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['seizure']	1	3	"Sentence: VPU was more potent than VPA , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against pilocarpine - induced seizure whereas the corresponding value for VPA was 322 mg / kg .
Diseases: seizure"	"Sentence: VPU was more potent than VPA , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against pilocarpine - induced seizure whereas the corresponding value for VPA was 322 mg / kg .
Diseases:"
3724	In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA .
Diseases: "	"Sentence: In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA .
Diseases:"
3725	Pretreatment with either VPU ( 50 and 100 mg / kg ) or VPA ( 300 and 600 mg / kg ) completely abolished pilocarpine - evoked increases in extracellular glutamate and aspartate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pretreatment with either VPU ( 50 and 100 mg / kg ) or VPA ( 300 and 600 mg / kg ) completely abolished pilocarpine - evoked increases in extracellular glutamate and aspartate .
Diseases: "	"Sentence: Pretreatment with either VPU ( 50 and 100 mg / kg ) or VPA ( 300 and 600 mg / kg ) completely abolished pilocarpine - evoked increases in extracellular glutamate and aspartate .
Diseases:"
3726	In addition , a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level .
Diseases: "	"Sentence: In addition , a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level .
Diseases:"
3727	Based on the finding that VPU and VPA could protect the animals against pilocarpine - induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: Based on the finding that VPU and VPA could protect the animals against pilocarpine - induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
Diseases: seizure"	"Sentence: Based on the finding that VPU and VPA could protect the animals against pilocarpine - induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .
Diseases:"
3728	Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced seizure in experimental animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['seizure']	1	3	"Sentence: Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced seizure in experimental animals .
Diseases: seizure"	"Sentence: Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced seizure in experimental animals .
Diseases:"
3729	Some other mechanism than those being reported herein should be further investigated .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Some other mechanism than those being reported herein should be further investigated .
Diseases: "	"Sentence: Some other mechanism than those being reported herein should be further investigated .
Diseases:"
3730	Acute hepatitis attack after exposure to telithromycin .	O B O O O O O O	['hepatitis']	1	3	"Sentence: Acute hepatitis attack after exposure to telithromycin .
Diseases: hepatitis"	"Sentence: Acute hepatitis attack after exposure to telithromycin .
Diseases:"
3731	Antibiotic - associated hepatotoxicity is rare .	O O O B O O O	['hepatotoxicity']	1	4	"Sentence: Antibiotic - associated hepatotoxicity is rare .
Diseases: hepatotoxicity"	"Sentence: Antibiotic - associated hepatotoxicity is rare .
Diseases:"
3732	With widespread use of antimicrobial agents , however , hepatic injury occurs frequently , and among adverse drug reactions , idiosyncratic reactions are the most serious .	O O O O O O O O O B I O O O O O B I I O O O O O O O O	['hepatic injury', 'adverse drug reactions']	2	8	"Sentence: With widespread use of antimicrobial agents , however , hepatic injury occurs frequently , and among adverse drug reactions , idiosyncratic reactions are the most serious .
Diseases: hepatic injury, adverse drug reactions"	"Sentence: With widespread use of antimicrobial agents , however , hepatic injury occurs frequently , and among adverse drug reactions , idiosyncratic reactions are the most serious .
Diseases:"
3733	A 25 - year - old male patient , with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department , Istanbul , Turkey , with 5 days ' history of jaundice , malaise , nausea , and vomiting .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O B O O B O	['nausea', 'vomiting', 'jaundice']	3	9	"Sentence: A 25 - year - old male patient , with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department , Istanbul , Turkey , with 5 days ' history of jaundice , malaise , nausea , and vomiting .
Diseases: nausea, vomiting, jaundice"	"Sentence: A 25 - year - old male patient , with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department , Istanbul , Turkey , with 5 days ' history of jaundice , malaise , nausea , and vomiting .
Diseases:"
3734	He had been prescribed telithromycin 400 mg / d PO to treat an upper respiratory tract infection 7 days prior .	O O O O O O O O O O O O O B I I I O O O O	['upper respiratory tract infection']	1	4	"Sentence: He had been prescribed telithromycin 400 mg / d PO to treat an upper respiratory tract infection 7 days prior .
Diseases: upper respiratory tract infection"	"Sentence: He had been prescribed telithromycin 400 mg / d PO to treat an upper respiratory tract infection 7 days prior .
Diseases:"
3735	Admission laboratory tests were as follows : alanine aminotransferase , 67 U / L ( reference range , 10 - 37 U / L ) ; aspartate aminotransferase ,	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Admission laboratory tests were as follows : alanine aminotransferase , 67 U / L ( reference range , 10 - 37 U / L ) ; aspartate aminotransferase ,
Diseases: "	"Sentence: Admission laboratory tests were as follows : alanine aminotransferase , 67 U / L ( reference range , 10 - 37 U / L ) ; aspartate aminotransferase ,
Diseases:"
3736	98 U / L ( 10 - 40 U / L ) ; alkaline phosphatase , 513 U / L ( 0 - 270 U / L ) ; gamma - glutamyltransferase , 32 U / L ( 7 - 49 U / L ) ; amylase , 46 U / L ( 0 - 220 U / L ) ; total bilirubin , 20 . 1 mg / dL ( 0 . 2 - 1 . 0 mg / dL ) ; direct bilirubin , 14 . 8 mg / dL ( 0 - 0 . 3 mg / dL ) ; and albumin , 4 . 7 mg / dL	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 98 U / L ( 10 - 40 U / L ) ; alkaline phosphatase , 513 U / L ( 0 - 270 U / L ) ; gamma - glutamyltransferase , 32 U / L ( 7 - 49 U / L ) ; amylase , 46 U / L ( 0 - 220 U / L ) ; total bilirubin , 20 . 1 mg / dL ( 0 . 2 - 1 . 0 mg / dL ) ; direct bilirubin , 14 . 8 mg / dL ( 0 - 0 . 3 mg / dL ) ; and albumin , 4 . 7 mg / dL
Diseases: "	"Sentence: 98 U / L ( 10 - 40 U / L ) ; alkaline phosphatase , 513 U / L ( 0 - 270 U / L ) ; gamma - glutamyltransferase , 32 U / L ( 7 - 49 U / L ) ; amylase , 46 U / L ( 0 - 220 U / L ) ; total bilirubin , 20 . 1 mg / dL ( 0 . 2 - 1 . 0 mg / dL ) ; direct bilirubin , 14 . 8 mg / dL ( 0 - 0 . 3 mg / dL ) ; and albumin , 4 . 7 mg / dL
Diseases:"
3737	( 3 . 5 - 5 . 4 mg / dL ) .	O O O O O O O O O O O O O	[]	0	0	"Sentence: ( 3 . 5 - 5 . 4 mg / dL ) .
Diseases: "	"Sentence: ( 3 . 5 - 5 . 4 mg / dL ) .
Diseases:"
3738	No toxin , alcohol , or other drugs were reported .	O O O O O O O O O O O	[]	0	0	"Sentence: No toxin , alcohol , or other drugs were reported .
Diseases: "	"Sentence: No toxin , alcohol , or other drugs were reported .
Diseases:"
3739	"The patient had suffered a previous episode of "" acute hepatitis of unknown origin , "" that occurred after telithromycin usage ."	O O O O O O O O O O B O O O O O O O O O O O	['hepatitis']	1	3	"Sentence: The patient had suffered a previous episode of "" acute hepatitis of unknown origin , "" that occurred after telithromycin usage .
Diseases: hepatitis"	"Sentence: The patient had suffered a previous episode of "" acute hepatitis of unknown origin , "" that occurred after telithromycin usage .
Diseases:"
3740	Both incidents occurred within a year .	O O O O O O O	[]	0	0	"Sentence: Both incidents occurred within a year .
Diseases: "	"Sentence: Both incidents occurred within a year .
Diseases:"
3741	Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use .
Diseases: "	"Sentence: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use .
Diseases:"
3742	It has been associated with infrequent and usually reversible severe hepatic dysfunction .	O O O O O O O O O O B I O	['hepatic dysfunction']	1	4	"Sentence: It has been associated with infrequent and usually reversible severe hepatic dysfunction .
Diseases: hepatic dysfunction"	"Sentence: It has been associated with infrequent and usually reversible severe hepatic dysfunction .
Diseases:"
3743	Based on a score of 8 on the Naranjo adverse drug reaction probability scale , telithromycin was the probable cause of acute hepatitis in this patient , and pathological findings suggested drug - induced toxic hepatitis .	O O O O O O O O O B I I O O O O O O O O O O B O O O O O O O O O O O B I O	['toxic hepatitis', 'hepatitis', 'adverse drug reaction']	3	9	"Sentence: Based on a score of 8 on the Naranjo adverse drug reaction probability scale , telithromycin was the probable cause of acute hepatitis in this patient , and pathological findings suggested drug - induced toxic hepatitis .
Diseases: toxic hepatitis, hepatitis, adverse drug reaction"	"Sentence: Based on a score of 8 on the Naranjo adverse drug reaction probability scale , telithromycin was the probable cause of acute hepatitis in this patient , and pathological findings suggested drug - induced toxic hepatitis .
Diseases:"
3744	Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time .	O O B O O O O O O O O O O O O O O O O O O O O O O O	['hepatitis']	1	3	"Sentence: Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time .
Diseases: hepatitis"	"Sentence: Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time .
Diseases:"
3745	Here we report a case of acute hepatitis probably associated with the administration of telithromycin .	O O O O O O O B O O O O O O O O	['hepatitis']	1	3	"Sentence: Here we report a case of acute hepatitis probably associated with the administration of telithromycin .
Diseases: hepatitis"	"Sentence: Here we report a case of acute hepatitis probably associated with the administration of telithromycin .
Diseases:"
3746	Spironolactone - induced renal insufficiency and hyperkalemia in patients with heart failure .	O O O B I O B O O O B I O	['renal insufficiency', 'hyperkalemia', 'heart failure']	3	13	"Sentence: Spironolactone - induced renal insufficiency and hyperkalemia in patients with heart failure .
Diseases: renal insufficiency, hyperkalemia, heart failure"	"Sentence: Spironolactone - induced renal insufficiency and hyperkalemia in patients with heart failure .
Diseases:"
3747	A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia ( 2 % ) and renal insufficiency ( 0 % ) .	O O O O O O O O O O O B I O O O O O O B O O O O O B I O O O O O	['renal insufficiency', 'heart failure', 'hyperkalemia']	3	13	"Sentence: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia ( 2 % ) and renal insufficiency ( 0 % ) .
Diseases: renal insufficiency, heart failure, hyperkalemia"	"Sentence: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia ( 2 % ) and renal insufficiency ( 0 % ) .
Diseases:"
3748	Because treatments for heart failure have changed since the benefits of spironolactone were reported , the prevalence of these complications may differ in current clinical practice .	O O O B I O O O O O O O O O O O O O O O O O O O O O O	['heart failure']	1	2	"Sentence: Because treatments for heart failure have changed since the benefits of spironolactone were reported , the prevalence of these complications may differ in current clinical practice .
Diseases: heart failure"	"Sentence: Because treatments for heart failure have changed since the benefits of spironolactone were reported , the prevalence of these complications may differ in current clinical practice .
Diseases:"
3749	We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone .	O O O O O O O O O O O B O B I O B I O O O O O	['renal insufficiency', 'hyperkalemia', 'heart failure']	3	13	"Sentence: We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone .
Diseases: renal insufficiency, hyperkalemia, heart failure"	"Sentence: We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone .
Diseases:"
3750	METHODS : We performed a case control study of heart failure patients treated with spironolactone in our clinical practice .	O O O O O O O O O B I O O O O O O O O O	['heart failure']	1	2	"Sentence: METHODS : We performed a case control study of heart failure patients treated with spironolactone in our clinical practice .
Diseases: heart failure"	"Sentence: METHODS : We performed a case control study of heart failure patients treated with spironolactone in our clinical practice .
Diseases:"
3751	Cases were patients who developed hyperkalemia ( K ( + ) > 5 . 0 mEq / L ) or renal insufficiency ( Cr > or = 2 . 5 mg / dL ) , and they were compared to 2 randomly selected controls per case .	O O O O O B O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O	['renal insufficiency', 'hyperkalemia']	2	10	"Sentence: Cases were patients who developed hyperkalemia ( K ( + ) > 5 . 0 mEq / L ) or renal insufficiency ( Cr > or = 2 . 5 mg / dL ) , and they were compared to 2 randomly selected controls per case .
Diseases: renal insufficiency, hyperkalemia"	"Sentence: Cases were patients who developed hyperkalemia ( K ( + ) > 5 . 0 mEq / L ) or renal insufficiency ( Cr > or = 2 . 5 mg / dL ) , and they were compared to 2 randomly selected controls per case .
Diseases:"
3752	Clinical characteristics , medications , and serum chemistries at baseline and follow - up time periods were compared .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical characteristics , medications , and serum chemistries at baseline and follow - up time periods were compared .
Diseases: "	"Sentence: Clinical characteristics , medications , and serum chemistries at baseline and follow - up time periods were compared .
Diseases:"
3753	Sixty - seven of 926 patients ( 7 . 2 % ) required discontinuation of spironolactone due to hyperkalemia ( n = 33 ) or renal failure ( n = 34 ) .	O O O O O O O O O O O O O O O O O O B O O O O O O B I O O O O O O	['hyperkalemia', 'renal failure']	2	7	"Sentence: Sixty - seven of 926 patients ( 7 . 2 % ) required discontinuation of spironolactone due to hyperkalemia ( n = 33 ) or renal failure ( n = 34 ) .
Diseases: hyperkalemia, renal failure"	"Sentence: Sixty - seven of 926 patients ( 7 . 2 % ) required discontinuation of spironolactone due to hyperkalemia ( n = 33 ) or renal failure ( n = 34 ) .
Diseases:"
3754	Patients who developed hyperkalemia were older and more likely to have diabetes , had higher baseline serum potassium levels and lower baseline potassium supplement doses , and were more likely to be treated with beta - blockers than controls ( n = 134 ) .	O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperkalemia', 'diabetes']	2	6	"Sentence: Patients who developed hyperkalemia were older and more likely to have diabetes , had higher baseline serum potassium levels and lower baseline potassium supplement doses , and were more likely to be treated with beta - blockers than controls ( n = 134 ) .
Diseases: hyperkalemia, diabetes"	"Sentence: Patients who developed hyperkalemia were older and more likely to have diabetes , had higher baseline serum potassium levels and lower baseline potassium supplement doses , and were more likely to be treated with beta - blockers than controls ( n = 134 ) .
Diseases:"
3755	Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine , required higher doses of loop diuretics , and were more likely to be treated with thiazide diuretics than controls .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal insufficiency']	1	5	"Sentence: Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine , required higher doses of loop diuretics , and were more likely to be treated with thiazide diuretics than controls .
Diseases: renal insufficiency"	"Sentence: Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine , required higher doses of loop diuretics , and were more likely to be treated with thiazide diuretics than controls .
Diseases:"
3756	CONCLUSIONS : Spironolactone - induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously .	O O O O O B O B I O O O O O O O O O O O	['renal insufficiency', 'hyperkalemia']	2	10	"Sentence: CONCLUSIONS : Spironolactone - induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously .
Diseases: renal insufficiency, hyperkalemia"	"Sentence: CONCLUSIONS : Spironolactone - induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously .
Diseases:"
3757	This difference is explained by patient comorbidities and more frequent use of beta - blockers .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This difference is explained by patient comorbidities and more frequent use of beta - blockers .
Diseases: "	"Sentence: This difference is explained by patient comorbidities and more frequent use of beta - blockers .
Diseases:"
3758	End - stage renal disease ( ESRD ) after orthotopic liver transplantation ( OLTX ) using calcineurin - based immunotherapy : risk of development and treatment .	B I I I I O B O O O O O O O O O O O O O O O O O O O O	['esrd', 'end - stage renal disease']	2	8	"Sentence: End - stage renal disease ( ESRD ) after orthotopic liver transplantation ( OLTX ) using calcineurin - based immunotherapy : risk of development and treatment .
Diseases: esrd, end - stage renal disease"	"Sentence: End - stage renal disease ( ESRD ) after orthotopic liver transplantation ( OLTX ) using calcineurin - based immunotherapy : risk of development and treatment .
Diseases:"
3759	The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic .	O O O O O O O O O O O B O	['nephrotoxic']	1	4	"Sentence: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic .
Diseases: nephrotoxic"	"Sentence: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic .
Diseases:"
3760	Their use in orthotopic liver transplantation ( OLTX ) has dramatically improved success rates .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Their use in orthotopic liver transplantation ( OLTX ) has dramatically improved success rates .
Diseases: "	"Sentence: Their use in orthotopic liver transplantation ( OLTX ) has dramatically improved success rates .
Diseases:"
3761	Recently , however , we have had an increase of patients who are presenting after OLTX with end - stage renal disease ( ESRD ) .	O O O O O O O O O O O O O O O O O B I I I I O B O O	['esrd', 'end - stage renal disease']	2	8	"Sentence: Recently , however , we have had an increase of patients who are presenting after OLTX with end - stage renal disease ( ESRD ) .
Diseases: esrd, end - stage renal disease"	"Sentence: Recently , however , we have had an increase of patients who are presenting after OLTX with end - stage renal disease ( ESRD ) .
Diseases:"
3762	This retrospective study examines the incidence and treatment of ESRD and chronic renal failure ( CRF ) in OLTX patients .	O O O O O O O O O B O B I I O B O O O O O	['crf', 'esrd', 'chronic renal failure']	3	9	"Sentence: This retrospective study examines the incidence and treatment of ESRD and chronic renal failure ( CRF ) in OLTX patients .
Diseases: crf, esrd, chronic renal failure"	"Sentence: This retrospective study examines the incidence and treatment of ESRD and chronic renal failure ( CRF ) in OLTX patients .
Diseases:"
3763	Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied ( n = 834 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied ( n = 834 ) .
Diseases: "	"Sentence: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied ( n = 834 ) .
Diseases:"
3764	Our prospectively collected database was the source of information .	O O O O O O O O O O	[]	0	0	"Sentence: Our prospectively collected database was the source of information .
Diseases: "	"Sentence: Our prospectively collected database was the source of information .
Diseases:"
3765	Patients were divided into three groups : Controls , no CRF or ESRD , n = 748 ; CRF , sustained serum creatinine > 2 . 5 mg / dl , n = 41 ; and ESRD , n = 45 .	O O O O O O O O O O B O B O O O O O B O O O O O O O O O O O O O O O O O B O O O O O	['esrd', 'crf']	2	5	"Sentence: Patients were divided into three groups : Controls , no CRF or ESRD , n = 748 ; CRF , sustained serum creatinine > 2 . 5 mg / dl , n = 41 ; and ESRD , n = 45 .
Diseases: esrd, crf"	"Sentence: Patients were divided into three groups : Controls , no CRF or ESRD , n = 748 ; CRF , sustained serum creatinine > 2 . 5 mg / dl , n = 41 ; and ESRD , n = 45 .
Diseases:"
3766	Groups were compared for preoperative laboratory variables , diagnosis , postoperative variables , survival , type of ESRD therapy , and survival from onset of ESRD .	O O O O O O O O O O O O O O O O O B O O O O O O O B O	['esrd']	1	2	"Sentence: Groups were compared for preoperative laboratory variables , diagnosis , postoperative variables , survival , type of ESRD therapy , and survival from onset of ESRD .
Diseases: esrd"	"Sentence: Groups were compared for preoperative laboratory variables , diagnosis , postoperative variables , survival , type of ESRD therapy , and survival from onset of ESRD .
Diseases:"
3767	At 13 years after OLTX , the incidence of severe renal dysfunction was 18 . 1 % ( CRF 8 . 6 % and ESRD 9 . 5 % ) .	O O O O O O O O O O B I O O O O O O B O O O O O B O O O O O O	['esrd', 'crf', 'renal dysfunction']	3	8	"Sentence: At 13 years after OLTX , the incidence of severe renal dysfunction was 18 . 1 % ( CRF 8 . 6 % and ESRD 9 . 5 % ) .
Diseases: esrd, crf, renal dysfunction"	"Sentence: At 13 years after OLTX , the incidence of severe renal dysfunction was 18 . 1 % ( CRF 8 . 6 % and ESRD 9 . 5 % ) .
Diseases:"
3768	Compared with control patients , CRF and ESRD patients had higher preoperative serum creatinine levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum creatinine .	O O O O O B O B O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	['esrd', 'crf', 'hepatorenal syndrome']	3	10	"Sentence: Compared with control patients , CRF and ESRD patients had higher preoperative serum creatinine levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum creatinine .
Diseases: esrd, crf, hepatorenal syndrome"	"Sentence: Compared with control patients , CRF and ESRD patients had higher preoperative serum creatinine levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum creatinine .
Diseases:"
3769	Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year , 3 months , and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2 . 6 , 2 . 2 , and 1 . 6 , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O	['esrd', 'crf']	2	5	"Sentence: Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year , 3 months , and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2 . 6 , 2 . 2 , and 1 . 6 , respectively .
Diseases: esrd, crf"	"Sentence: Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year , 3 months , and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2 . 6 , 2 . 2 , and 1 . 6 , respectively .
Diseases:"
3770	Overall survival from the time of OLTX was not significantly different among groups , but by year 13 , the survival of the patients who had ESRD was only 28 . 2 % compared with 54 . 6 % in the control group .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['esrd']	1	2	"Sentence: Overall survival from the time of OLTX was not significantly different among groups , but by year 13 , the survival of the patients who had ESRD was only 28 . 2 % compared with 54 . 6 % in the control group .
Diseases: esrd"	"Sentence: Overall survival from the time of OLTX was not significantly different among groups , but by year 13 , the survival of the patients who had ESRD was only 28 . 2 % compared with 54 . 6 % in the control group .
Diseases:"
3771	Patients developing ESRD had a 6 - year survival after onset of ESRD of 27 % for the patients receiving hemodialysis versus 71 . 4 % for the patients developing ESRD who subsequently received kidney transplants .	O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O	['esrd']	1	2	"Sentence: Patients developing ESRD had a 6 - year survival after onset of ESRD of 27 % for the patients receiving hemodialysis versus 71 . 4 % for the patients developing ESRD who subsequently received kidney transplants .
Diseases: esrd"	"Sentence: Patients developing ESRD had a 6 - year survival after onset of ESRD of 27 % for the patients receiving hemodialysis versus 71 . 4 % for the patients developing ESRD who subsequently received kidney transplants .
Diseases:"
3772	Patients who are more than 10 years post - OLTX have CRF and ESRD at a high rate .	O O O O O O O O O O O B O B O O O O O	['esrd', 'crf']	2	5	"Sentence: Patients who are more than 10 years post - OLTX have CRF and ESRD at a high rate .
Diseases: esrd, crf"	"Sentence: Patients who are more than 10 years post - OLTX have CRF and ESRD at a high rate .
Diseases:"
3773	The development of ESRD decreases survival , particularly in those patients treated with dialysis only .	O O O B O O O O O O O O O O O O	['esrd']	1	2	"Sentence: The development of ESRD decreases survival , particularly in those patients treated with dialysis only .
Diseases: esrd"	"Sentence: The development of ESRD decreases survival , particularly in those patients treated with dialysis only .
Diseases:"
3774	Patients who develop ESRD have a higher preoperative and 1 - year serum creatinine and are more likely to have hepatorenal syndrome .	O O O B O O O O O O O O O O O O O O O O B I O	['esrd', 'hepatorenal syndrome']	2	7	"Sentence: Patients who develop ESRD have a higher preoperative and 1 - year serum creatinine and are more likely to have hepatorenal syndrome .
Diseases: esrd, hepatorenal syndrome"	"Sentence: Patients who develop ESRD have a higher preoperative and 1 - year serum creatinine and are more likely to have hepatorenal syndrome .
Diseases:"
3775	However , an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD .	O O O O O O O O O O O O O O O O O O B O B O	['esrd', 'crf']	2	5	"Sentence: However , an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD .
Diseases: esrd, crf"	"Sentence: However , an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD .
Diseases:"
3776	New strategies for long - term immunosuppression may be needed to decrease this complication .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: New strategies for long - term immunosuppression may be needed to decrease this complication .
Diseases: "	"Sentence: New strategies for long - term immunosuppression may be needed to decrease this complication .
Diseases:"
3777	Effect of intravenous nimodipine on blood pressure and outcome after acute stroke .	O O O O O O O O O O B I O	['acute stroke']	1	3	"Sentence: Effect of intravenous nimodipine on blood pressure and outcome after acute stroke .
Diseases: acute stroke"	"Sentence: Effect of intravenous nimodipine on blood pressure and outcome after acute stroke .
Diseases:"
3778	BACKGROUND AND PURPOSE :	O O O O	[]	0	0	"Sentence: BACKGROUND AND PURPOSE :
Diseases: "	"Sentence: BACKGROUND AND PURPOSE :
Diseases:"
3779	The Intravenous Nimodipine West European Stroke Trial ( INWEST ) found a correlation between nimodipine - induced reduction in blood pressure ( BP ) and an unfavorable outcome in acute stroke .	O O O O O B O O O O O O O O O O O B I I I O O O O O O O O B I O	['stroke', 'reduction in blood pressure', 'acute stroke']	3	9	"Sentence: The Intravenous Nimodipine West European Stroke Trial ( INWEST ) found a correlation between nimodipine - induced reduction in blood pressure ( BP ) and an unfavorable outcome in acute stroke .
Diseases: stroke, reduction in blood pressure, acute stroke"	"Sentence: The Intravenous Nimodipine West European Stroke Trial ( INWEST ) found a correlation between nimodipine - induced reduction in blood pressure ( BP ) and an unfavorable outcome in acute stroke .
Diseases:"
3780	We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction .	O O O O O O O O O O O O O O O O O O O O O O O B I O	['bp reduction']	1	2	"Sentence: We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction .
Diseases: bp reduction"	"Sentence: We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction .
Diseases:"
3781	Patients with a clinical diagnosis of ischemic stroke ( within 24 hours ) were consecutively allocated to receive placebo ( n = 100 ) , 1 mg / h ( low - dose ) nimodipine ( n = 101 ) , or 2 mg / h ( high - dose ) nimodipine ( n = 94 ) .	O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ischemic stroke']	1	4	"Sentence: Patients with a clinical diagnosis of ischemic stroke ( within 24 hours ) were consecutively allocated to receive placebo ( n = 100 ) , 1 mg / h ( low - dose ) nimodipine ( n = 101 ) , or 2 mg / h ( high - dose ) nimodipine ( n = 94 ) .
Diseases: ischemic stroke"	"Sentence: Patients with a clinical diagnosis of ischemic stroke ( within 24 hours ) were consecutively allocated to receive placebo ( n = 100 ) , 1 mg / h ( low - dose ) nimodipine ( n = 101 ) , or 2 mg / h ( high - dose ) nimodipine ( n = 94 ) .
Diseases:"
3782	The correlation between average BP change during the first 2 days and the outcome at day 21 was analyzed .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The correlation between average BP change during the first 2 days and the outcome at day 21 was analyzed .
Diseases: "	"Sentence: The correlation between average BP change during the first 2 days and the outcome at day 21 was analyzed .
Diseases:"
3783	Two hundred sixty - five patients were included in this analysis ( n = 92 , 93 , and 80 for placebo , low dose , and high dose , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two hundred sixty - five patients were included in this analysis ( n = 92 , 93 , and 80 for placebo , low dose , and high dose , respectively ) .
Diseases: "	"Sentence: Two hundred sixty - five patients were included in this analysis ( n = 92 , 93 , and 80 for placebo , low dose , and high dose , respectively ) .
Diseases:"
3784	Nimodipine treatment resulted in a statistically significant reduction in systolic BP ( SBP ) and diastolic BP ( DBP ) from baseline compared with placebo during the first few days .	O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O	['reduction in systolic bp']	1	8	"Sentence: Nimodipine treatment resulted in a statistically significant reduction in systolic BP ( SBP ) and diastolic BP ( DBP ) from baseline compared with placebo during the first few days .
Diseases: reduction in systolic bp"	"Sentence: Nimodipine treatment resulted in a statistically significant reduction in systolic BP ( SBP ) and diastolic BP ( DBP ) from baseline compared with placebo during the first few days .
Diseases:"
3785	In multivariate analysis , a significant correlation between DBP reduction and worsening of the neurological score was found for the high - dose group ( beta = 0 . 49 , P = 0 . 048 ) .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dbp reduction']	1	3	"Sentence: In multivariate analysis , a significant correlation between DBP reduction and worsening of the neurological score was found for the high - dose group ( beta = 0 . 49 , P = 0 . 048 ) .
Diseases: dbp reduction"	"Sentence: In multivariate analysis , a significant correlation between DBP reduction and worsening of the neurological score was found for the high - dose group ( beta = 0 . 49 , P = 0 . 048 ) .
Diseases:"
3786	Patients with a DBP reduction of > or = 20 % in the high - dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency ( Barthel Index < 60 ) ( n / N = 25 / 26 , OR 10 .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['dbp reduction', 'death']	2	5	"Sentence: Patients with a DBP reduction of > or = 20 % in the high - dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency ( Barthel Index < 60 ) ( n / N = 25 / 26 , OR 10 .
Diseases: dbp reduction, death"	"Sentence: Patients with a DBP reduction of > or = 20 % in the high - dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency ( Barthel Index < 60 ) ( n / N = 25 / 26 , OR 10 .
Diseases:"
3787	16 , 95 % CI 1 . 02 to 101 . 74 ) and death alone ( n / N = 9 / 26 , OR 4 . 336 , 95 % CI 1 . 131 16 . 619 ) compared with all placebo patients ( n / N = 62 / 92 and 14 / 92 , respectively ) .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['death']	1	1	"Sentence: 16 , 95 % CI 1 . 02 to 101 . 74 ) and death alone ( n / N = 9 / 26 , OR 4 . 336 , 95 % CI 1 . 131 16 . 619 ) compared with all placebo patients ( n / N = 62 / 92 and 14 / 92 , respectively ) .
Diseases: death"	"Sentence: 16 , 95 % CI 1 . 02 to 101 . 74 ) and death alone ( n / N = 9 / 26 , OR 4 . 336 , 95 % CI 1 . 131 16 . 619 ) compared with all placebo patients ( n / N = 62 / 92 and 14 / 92 , respectively ) .
Diseases:"
3788	There was no correlation between SBP change and outcome .	O O O O O O O O O O	[]	0	0	"Sentence: There was no correlation between SBP change and outcome .
Diseases: "	"Sentence: There was no correlation between SBP change and outcome .
Diseases:"
3789	CONCLUSIONS : DBP , but not SBP , reduction was associated with neurological worsening after the intravenous administration of high - dose nimodipine after acute stroke .	O O O O O O O O O O O O O O O O O O O O O O O O B I O	['acute stroke']	1	3	"Sentence: CONCLUSIONS : DBP , but not SBP , reduction was associated with neurological worsening after the intravenous administration of high - dose nimodipine after acute stroke .
Diseases: acute stroke"	"Sentence: CONCLUSIONS : DBP , but not SBP , reduction was associated with neurological worsening after the intravenous administration of high - dose nimodipine after acute stroke .
Diseases:"
3790	For low - dose nimodipine , the results were not conclusive .	O O O O O O O O O O O O	[]	0	0	"Sentence: For low - dose nimodipine , the results were not conclusive .
Diseases: "	"Sentence: For low - dose nimodipine , the results were not conclusive .
Diseases:"
3791	These results do not confirm or exclude a neuroprotective property of nimodipine .	O O O O O O O O O O O O O	[]	0	0	"Sentence: These results do not confirm or exclude a neuroprotective property of nimodipine .
Diseases: "	"Sentence: These results do not confirm or exclude a neuroprotective property of nimodipine .
Diseases:"
3792	Transient neurologic symptoms after spinal anesthesia : a lower incidence with prilocaine and bupivacaine than with lidocaine .	B I I O O O O O O O O O O O O O O O	['transient neurologic symptoms']	1	5	"Sentence: Transient neurologic symptoms after spinal anesthesia : a lower incidence with prilocaine and bupivacaine than with lidocaine .
Diseases: transient neurologic symptoms"	"Sentence: Transient neurologic symptoms after spinal anesthesia : a lower incidence with prilocaine and bupivacaine than with lidocaine .
Diseases:"
3793	Recent evidence suggests that transient neurologic symptoms ( TNSs ) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine .	O O O O B I I O B O O O O O O O O O O O O	['tnss', 'transient neurologic symptoms']	2	7	"Sentence: Recent evidence suggests that transient neurologic symptoms ( TNSs ) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine .
Diseases: tnss, transient neurologic symptoms"	"Sentence: Recent evidence suggests that transient neurologic symptoms ( TNSs ) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine .
Diseases:"
3794	However , identification of a short - acting local anesthetic to substitute for lidocaine for brief surgical procedures remains an important goal .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , identification of a short - acting local anesthetic to substitute for lidocaine for brief surgical procedures remains an important goal .
Diseases: "	"Sentence: However , identification of a short - acting local anesthetic to substitute for lidocaine for brief surgical procedures remains an important goal .
Diseases:"
3795	Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine .
Diseases: "	"Sentence: Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine .
Diseases:"
3796	Accordingly , the present , prospective double - blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['tnss']	1	2	"Sentence: Accordingly , the present , prospective double - blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs .
Diseases: tnss"	"Sentence: Accordingly , the present , prospective double - blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs .
Diseases:"
3797	METHODS : Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2 . 5 ml 2 % lidocaine in 7 . 5 % glucose , 2 % prilocaine in 7 . 5 % glucose , or 0 . 5 % bupivacaine in 7 . 5 % glucose .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2 . 5 ml 2 % lidocaine in 7 . 5 % glucose , 2 % prilocaine in 7 . 5 % glucose , or 0 . 5 % bupivacaine in 7 . 5 % glucose .
Diseases: "	"Sentence: METHODS : Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2 . 5 ml 2 % lidocaine in 7 . 5 % glucose , 2 % prilocaine in 7 . 5 % glucose , or 0 . 5 % bupivacaine in 7 . 5 % glucose .
Diseases:"
3798	All solutions were provided in blinded vials by the hospital pharmacy .	O O O O O O O O O O O O	[]	0	0	"Sentence: All solutions were provided in blinded vials by the hospital pharmacy .
Diseases: "	"Sentence: All solutions were provided in blinded vials by the hospital pharmacy .
Diseases:"
3799	Details of spinal puncture , extension and regression of spinal block , and the times to reach discharge criteria were noted .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Details of spinal puncture , extension and regression of spinal block , and the times to reach discharge criteria were noted .
Diseases: "	"Sentence: Details of spinal puncture , extension and regression of spinal block , and the times to reach discharge criteria were noted .
Diseases:"
3800	In the evening of postoperative day 1 , patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['tnss']	1	2	"Sentence: In the evening of postoperative day 1 , patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure .
Diseases: tnss"	"Sentence: In the evening of postoperative day 1 , patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure .
Diseases:"
3801	Nine of 30 patients receiving lidocaine experienced TNSs , 1 of 30 patients receiving prilocaine ( P = 0 . 03 ) had them , and none of 30 patients receiving bupivacaine had TNSs .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B O	['tnss']	1	2	"Sentence: Nine of 30 patients receiving lidocaine experienced TNSs , 1 of 30 patients receiving prilocaine ( P = 0 . 03 ) had them , and none of 30 patients receiving bupivacaine had TNSs .
Diseases: tnss"	"Sentence: Nine of 30 patients receiving lidocaine experienced TNSs , 1 of 30 patients receiving prilocaine ( P = 0 . 03 ) had them , and none of 30 patients receiving bupivacaine had TNSs .
Diseases:"
3802	Times to ambulate and to void were similar after lidocaine and prilocaine ( 150 vs . 165 min and 238 vs . 253 min , respectively ) but prolonged after bupivacaine ( 200 and 299 min , respectively ; P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Times to ambulate and to void were similar after lidocaine and prilocaine ( 150 vs . 165 min and 238 vs . 253 min , respectively ) but prolonged after bupivacaine ( 200 and 299 min , respectively ; P < 0 . 05 ) .
Diseases: "	"Sentence: Times to ambulate and to void were similar after lidocaine and prilocaine ( 150 vs . 165 min and 238 vs . 253 min , respectively ) but prolonged after bupivacaine ( 200 and 299 min , respectively ; P < 0 . 05 ) .
Diseases:"
3803	CONCLUSIONS : Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs .	O O O O O O O O O O O O O O O O O O O O O O O O O B O	['tnss']	1	2	"Sentence: CONCLUSIONS : Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs .
Diseases: tnss"	"Sentence: CONCLUSIONS : Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs .
Diseases:"
3804	The role of nicotine in smoking - related cardiovascular disease .	O O O O O O O O B I O	['cardiovascular disease']	1	3	"Sentence: The role of nicotine in smoking - related cardiovascular disease .
Diseases: cardiovascular disease"	"Sentence: The role of nicotine in smoking - related cardiovascular disease .
Diseases:"
3805	Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease .	O O O O O O O O O O O O O B I O	['cardiovascular disease']	1	3	"Sentence: Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease .
Diseases: cardiovascular disease"	"Sentence: Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease .
Diseases:"
3806	Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis , but evidence among humans is too inadequate to be definitive about such an effect .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['atherosclerosis']	1	3	"Sentence: Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis , but evidence among humans is too inadequate to be definitive about such an effect .
Diseases: atherosclerosis"	"Sentence: Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis , but evidence among humans is too inadequate to be definitive about such an effect .
Diseases:"
3807	Almost certainly , nicotine via its hemodynamic effects contributes to acute cardiovascular events , although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Almost certainly , nicotine via its hemodynamic effects contributes to acute cardiovascular events , although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide .
Diseases: "	"Sentence: Almost certainly , nicotine via its hemodynamic effects contributes to acute cardiovascular events , although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide .
Diseases:"
3808	Nicotine does not appear to enhance thrombosis among humans .	O O O O O O B O O O	['thrombosis']	1	4	"Sentence: Nicotine does not appear to enhance thrombosis among humans .
Diseases: thrombosis"	"Sentence: Nicotine does not appear to enhance thrombosis among humans .
Diseases:"
3809	Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events .
Diseases: "	"Sentence: Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events .
Diseases:"
3810	Finally , the dose response for cardiovascular events of nicotine appears to be flat , suggesting that if nicotine is involved , adverse effects might be seen with relatively low - level cigarette exposures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Finally , the dose response for cardiovascular events of nicotine appears to be flat , suggesting that if nicotine is involved , adverse effects might be seen with relatively low - level cigarette exposures .
Diseases: "	"Sentence: Finally , the dose response for cardiovascular events of nicotine appears to be flat , suggesting that if nicotine is involved , adverse effects might be seen with relatively low - level cigarette exposures .
Diseases:"
3811	Seizure resulting from a venlafaxine overdose .	B O O O O B O	['overdose', 'seizure']	2	4	"Sentence: Seizure resulting from a venlafaxine overdose .
Diseases: overdose, seizure"	"Sentence: Seizure resulting from a venlafaxine overdose .
Diseases:"
3812	To report a case of venlafaxine overdose .	O O O O O O B O	['overdose']	1	2	"Sentence: To report a case of venlafaxine overdose .
Diseases: overdose"	"Sentence: To report a case of venlafaxine overdose .
Diseases:"
3813	A 40 - year - old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt .	O O O O O O O O B I O O B O O O O O O O O	['major depression', 'overdose']	2	4	"Sentence: A 40 - year - old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt .
Diseases: major depression, overdose"	"Sentence: A 40 - year - old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt .
Diseases:"
3814	After the ingestion of 26 venlafaxine 50 - mg tablets , the patient experienced a witnessed generalized seizure .	O O O O O O O O O O O O O O O O O B O	['seizure']	1	3	"Sentence: After the ingestion of 26 venlafaxine 50 - mg tablets , the patient experienced a witnessed generalized seizure .
Diseases: seizure"	"Sentence: After the ingestion of 26 venlafaxine 50 - mg tablets , the patient experienced a witnessed generalized seizure .
Diseases:"
3815	She was admitted to the medical intensive care unit , venlafaxine was discontinued , and no further sequelae were seen .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: She was admitted to the medical intensive care unit , venlafaxine was discontinued , and no further sequelae were seen .
Diseases: "	"Sentence: She was admitted to the medical intensive care unit , venlafaxine was discontinued , and no further sequelae were seen .
Diseases:"
3816	To our knowledge , this is the first reported case of venlafaxine overdose that resulted in a generalized seizure .	O O O O O O O O O O O O B O O O O O B O	['overdose', 'seizure']	2	4	"Sentence: To our knowledge , this is the first reported case of venlafaxine overdose that resulted in a generalized seizure .
Diseases: overdose, seizure"	"Sentence: To our knowledge , this is the first reported case of venlafaxine overdose that resulted in a generalized seizure .
Diseases:"
3817	Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions , no emergent therapy was instituted .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions , no emergent therapy was instituted .
Diseases: "	"Sentence: Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions , no emergent therapy was instituted .
Diseases:"
3818	The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae .	O O B O O O O O O O O O O B O O O O O O	['overdose', 'seizure']	2	4	"Sentence: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae .
Diseases: overdose, seizure"	"Sentence: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae .
Diseases:"
3819	Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus .
Diseases: "	"Sentence: Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus .
Diseases:"
3820	The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996 .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996 .
Diseases: "	"Sentence: The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996 .
Diseases:"
3821	Two groups of patients receiving tacrolimus were compared over a period of 1 year , one group comprising hypertensive patients who were receiving nifedipine , and the other comprising nonhypertensive patients not receiving nifedipine .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: Two groups of patients receiving tacrolimus were compared over a period of 1 year , one group comprising hypertensive patients who were receiving nifedipine , and the other comprising nonhypertensive patients not receiving nifedipine .
Diseases: hypertensive"	"Sentence: Two groups of patients receiving tacrolimus were compared over a period of 1 year , one group comprising hypertensive patients who were receiving nifedipine , and the other comprising nonhypertensive patients not receiving nifedipine .
Diseases:"
3822	The time from transplant to baseline was similar in all patients .	O O O O O O O O O O O O	[]	0	0	"Sentence: The time from transplant to baseline was similar in all patients .
Diseases: "	"Sentence: The time from transplant to baseline was similar in all patients .
Diseases:"
3823	Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months .
Diseases: "	"Sentence: Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months .
Diseases:"
3824	The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O	['nephrotoxicity', 'hypertension']	2	6	"Sentence: The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population .
Diseases: nephrotoxicity, hypertension"	"Sentence: The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population .
Diseases:"
3825	Sinus arrest associated with continuous - infusion cimetidine .	B I O O O O O O O	['sinus arrest']	1	3	"Sentence: Sinus arrest associated with continuous - infusion cimetidine .
Diseases: sinus arrest"	"Sentence: Sinus arrest associated with continuous - infusion cimetidine .
Diseases:"
3826	The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias .	O O O O O O O O O O O O O O O B O	['bradyarrhythmias']	1	6	"Sentence: The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias .
Diseases: bradyarrhythmias"	"Sentence: The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias .
Diseases:"
3827	A 40 - year - old man with leukemia and no history of cardiac disease developed recurrent , brief episodes of apparent sinus arrest while receiving continuous - infusion cimetidine 50 mg / hour .	O O O O O O O O B O O O O B I O O O O O O O B I O O O O O O O O O O O	['cardiac disease', 'leukemia', 'sinus arrest']	3	9	"Sentence: A 40 - year - old man with leukemia and no history of cardiac disease developed recurrent , brief episodes of apparent sinus arrest while receiving continuous - infusion cimetidine 50 mg / hour .
Diseases: cardiac disease, leukemia, sinus arrest"	"Sentence: A 40 - year - old man with leukemia and no history of cardiac disease developed recurrent , brief episodes of apparent sinus arrest while receiving continuous - infusion cimetidine 50 mg / hour .
Diseases:"
3828	The arrhythmias were temporally related to cimetidine administration , disappeared after dechallenge , and did not recur during ranitidine treatment .	O B O O O O O O O O O O O O O O O O O O O	['arrhythmias']	1	4	"Sentence: The arrhythmias were temporally related to cimetidine administration , disappeared after dechallenge , and did not recur during ranitidine treatment .
Diseases: arrhythmias"	"Sentence: The arrhythmias were temporally related to cimetidine administration , disappeared after dechallenge , and did not recur during ranitidine treatment .
Diseases:"
3829	This is the first reported case of sinus arrest associated with continuous - infusion cimetidine .	O O O O O O O B I O O O O O O O	['sinus arrest']	1	3	"Sentence: This is the first reported case of sinus arrest associated with continuous - infusion cimetidine .
Diseases: sinus arrest"	"Sentence: This is the first reported case of sinus arrest associated with continuous - infusion cimetidine .
Diseases:"
3830	Composition of gall bladder stones associated with octreotide : response to oral ursodeoxycholic acid .	O O B I I O O O O O O O O O O	['gall bladder stones']	1	3	"Sentence: Composition of gall bladder stones associated with octreotide : response to oral ursodeoxycholic acid .
Diseases: gall bladder stones"	"Sentence: Composition of gall bladder stones associated with octreotide : response to oral ursodeoxycholic acid .
Diseases:"
3831	Octreotide , an effective treatment for acromegaly , induces gall bladder stones in 13 - 60 % of patients .	O O O O O O B O O B I I O O O O O O O O	['gall bladder stones', 'acromegaly']	2	8	"Sentence: Octreotide , an effective treatment for acromegaly , induces gall bladder stones in 13 - 60 % of patients .
Diseases: gall bladder stones, acromegaly"	"Sentence: Octreotide , an effective treatment for acromegaly , induces gall bladder stones in 13 - 60 % of patients .
Diseases:"
3832	Because knowledge of stone composition is essential for studies of their pathogenesis , treatment , and prevention , this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B I O	['acromegalic', 'gall stones']	2	7	"Sentence: Because knowledge of stone composition is essential for studies of their pathogenesis , treatment , and prevention , this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones .
Diseases: acromegalic, gall stones"	"Sentence: Because knowledge of stone composition is essential for studies of their pathogenesis , treatment , and prevention , this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones .
Diseases:"
3833	Chemical analysis of gall stones retrieved at cholecystectomy from two patients , showed that they contained 71 % and 87 % cholesterol by weight .	O O O B I O O O O O O O O O O O O O O O O O O O O	['gall stones']	1	2	"Sentence: Chemical analysis of gall stones retrieved at cholecystectomy from two patients , showed that they contained 71 % and 87 % cholesterol by weight .
Diseases: gall stones"	"Sentence: Chemical analysis of gall stones retrieved at cholecystectomy from two patients , showed that they contained 71 % and 87 % cholesterol by weight .
Diseases:"
3834	In the remaining 12 patients , localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units ( values of < 100 HU predict cholesterol rich , dissolvable stones ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the remaining 12 patients , localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units ( values of < 100 HU predict cholesterol rich , dissolvable stones ) .
Diseases: "	"Sentence: In the remaining 12 patients , localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units ( values of < 100 HU predict cholesterol rich , dissolvable stones ) .
Diseases:"
3835	Gall bladder bile was obtained by ultrasound guided , fine needle puncture from six patients .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Gall bladder bile was obtained by ultrasound guided , fine needle puncture from six patients .
Diseases: "	"Sentence: Gall bladder bile was obtained by ultrasound guided , fine needle puncture from six patients .
Diseases:"
3836	All six patients had supersaturated bile ( mean ( SEM ) cholesterol saturation index of 1 . 19 ( 0 . 08 ) ( range 1 . 01 - 1 . 53 ) ) and all had abnormally rapid cholesterol microcrystal nucleation times ( < 4 days ( range 1 - 4 ) ) , whilst in four , the bile contained cholesterol microcrystals immediately after sampling .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All six patients had supersaturated bile ( mean ( SEM ) cholesterol saturation index of 1 . 19 ( 0 . 08 ) ( range 1 . 01 - 1 . 53 ) ) and all had abnormally rapid cholesterol microcrystal nucleation times ( < 4 days ( range 1 - 4 ) ) , whilst in four , the bile contained cholesterol microcrystals immediately after sampling .
Diseases: "	"Sentence: All six patients had supersaturated bile ( mean ( SEM ) cholesterol saturation index of 1 . 19 ( 0 . 08 ) ( range 1 . 01 - 1 . 53 ) ) and all had abnormally rapid cholesterol microcrystal nucleation times ( < 4 days ( range 1 - 4 ) ) , whilst in four , the bile contained cholesterol microcrystals immediately after sampling .
Diseases:"
3837	Of the 12 patients considered for oral ursodeoxycholic acid ( UDCA ) treatment , two had a blocked cystic duct and were not started on UDCA while one was lost to follow up .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the 12 patients considered for oral ursodeoxycholic acid ( UDCA ) treatment , two had a blocked cystic duct and were not started on UDCA while one was lost to follow up .
Diseases: "	"Sentence: Of the 12 patients considered for oral ursodeoxycholic acid ( UDCA ) treatment , two had a blocked cystic duct and were not started on UDCA while one was lost to follow up .
Diseases:"
3838	After one year of treatment , five of the remaining nine patients showed either partial ( n = 3 ) or complete ( n = 2 ) gall stone dissolution , suggesting that their stones were cholesterol rich .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O	['gall stone']	1	2	"Sentence: After one year of treatment , five of the remaining nine patients showed either partial ( n = 3 ) or complete ( n = 2 ) gall stone dissolution , suggesting that their stones were cholesterol rich .
Diseases: gall stone"	"Sentence: After one year of treatment , five of the remaining nine patients showed either partial ( n = 3 ) or complete ( n = 2 ) gall stone dissolution , suggesting that their stones were cholesterol rich .
Diseases:"
3839	This corresponds , by actuarial ( life table ) analysis , to a combined gall stone dissolution rate of 58 . 3 ( 15 . 9 % ) .	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	['gall stone']	1	2	"Sentence: This corresponds , by actuarial ( life table ) analysis , to a combined gall stone dissolution rate of 58 . 3 ( 15 . 9 % ) .
Diseases: gall stone"	"Sentence: This corresponds , by actuarial ( life table ) analysis , to a combined gall stone dissolution rate of 58 . 3 ( 15 . 9 % ) .
Diseases:"
3840	In conclusion , octreotide induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .	O O O O O B I O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O B I O O O	['gall stone disease', 'gall stones']	2	6	"Sentence: In conclusion , octreotide induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
Diseases: gall stone disease, gall stones"	"Sentence: In conclusion , octreotide induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .
Diseases:"
3841	Cardiovascular complications associated with terbutaline treatment for preterm labor .	B I O O O O O B I O	['preterm labor', 'cardiovascular complications']	2	6	"Sentence: Cardiovascular complications associated with terbutaline treatment for preterm labor .
Diseases: preterm labor, cardiovascular complications"	"Sentence: Cardiovascular complications associated with terbutaline treatment for preterm labor .
Diseases:"
3842	Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor .	O B I O O O O O O O O O O B I O	['preterm labor', 'cardiovascular complications']	2	6	"Sentence: Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor .
Diseases: preterm labor, cardiovascular complications"	"Sentence: Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor .
Diseases:"
3843	Associated corticosteroid therapy and twin gestations appear to be predisposing factors .	O O O O O O O O O O O O	[]	0	0	"Sentence: Associated corticosteroid therapy and twin gestations appear to be predisposing factors .
Diseases: "	"Sentence: Associated corticosteroid therapy and twin gestations appear to be predisposing factors .
Diseases:"
3844	Potential mechanisms of the pathophysiology are briefly discussed .	O O O O O O O O O	[]	0	0	"Sentence: Potential mechanisms of the pathophysiology are briefly discussed .
Diseases: "	"Sentence: Potential mechanisms of the pathophysiology are briefly discussed .
Diseases:"
3845	Neurologic effects of subarachnoid administration of 2 - chloroprocaine - CE , bupivacaine , and low pH normal saline in dogs .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Neurologic effects of subarachnoid administration of 2 - chloroprocaine - CE , bupivacaine , and low pH normal saline in dogs .
Diseases: "	"Sentence: Neurologic effects of subarachnoid administration of 2 - chloroprocaine - CE , bupivacaine , and low pH normal saline in dogs .
Diseases:"
3846	The purpose of this study was to evaluate the neurologic consequences of deliberate subarachnoid injection of large volumes of 2 - chloroprocaine - CE in experimental animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The purpose of this study was to evaluate the neurologic consequences of deliberate subarachnoid injection of large volumes of 2 - chloroprocaine - CE in experimental animals .
Diseases: "	"Sentence: The purpose of this study was to evaluate the neurologic consequences of deliberate subarachnoid injection of large volumes of 2 - chloroprocaine - CE in experimental animals .
Diseases:"
3847	The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated .	O O O O O O O O O O O O O O O O B O O O	['neurotoxicity']	1	4	"Sentence: The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated .
Diseases: neurotoxicity"	"Sentence: The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated .
Diseases:"
3848	The 65 dogs in the study received injections in the subarachnoid space as follows : 6 to 8 ml of bupivacaine ( N = 15 ) , 2 - chloroprocaine - CE ( N = 20 ) , low pH normal saline ( pH 3 . 0 ) ( N = 20 ) , or normal saline ( N = 10 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The 65 dogs in the study received injections in the subarachnoid space as follows : 6 to 8 ml of bupivacaine ( N = 15 ) , 2 - chloroprocaine - CE ( N = 20 ) , low pH normal saline ( pH 3 . 0 ) ( N = 20 ) , or normal saline ( N = 10 ) .
Diseases: "	"Sentence: The 65 dogs in the study received injections in the subarachnoid space as follows : 6 to 8 ml of bupivacaine ( N = 15 ) , 2 - chloroprocaine - CE ( N = 20 ) , low pH normal saline ( pH 3 . 0 ) ( N = 20 ) , or normal saline ( N = 10 ) .
Diseases:"
3849	Of the 20 animals that received subarachnoid injection of 2 - chloroprocaine - CE seven ( 35 % ) developed hind - limb paralysis .	O O O O O O O O O O O O O O O O O O O O O O O B O	['paralysis']	1	2	"Sentence: Of the 20 animals that received subarachnoid injection of 2 - chloroprocaine - CE seven ( 35 % ) developed hind - limb paralysis .
Diseases: paralysis"	"Sentence: Of the 20 animals that received subarachnoid injection of 2 - chloroprocaine - CE seven ( 35 % ) developed hind - limb paralysis .
Diseases:"
3850	None of the animals that received bupivacaine , normal saline , or normal saline titrated to a pH 3 . 0 developed hind - limb paralysis .	O O O O O O O O O O O O O O O O O O O O O O O O O B O	['paralysis']	1	2	"Sentence: None of the animals that received bupivacaine , normal saline , or normal saline titrated to a pH 3 . 0 developed hind - limb paralysis .
Diseases: paralysis"	"Sentence: None of the animals that received bupivacaine , normal saline , or normal saline titrated to a pH 3 . 0 developed hind - limb paralysis .
Diseases:"
3851	Of the 15 spinal cords of the animals that received 2 - chloroprocaine - CE , 13 showed subpial necrosis ; the nerve roots and subarachnoid vessels were normal .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O	['subpial necrosis']	1	5	"Sentence: Of the 15 spinal cords of the animals that received 2 - chloroprocaine - CE , 13 showed subpial necrosis ; the nerve roots and subarachnoid vessels were normal .
Diseases: subpial necrosis"	"Sentence: Of the 15 spinal cords of the animals that received 2 - chloroprocaine - CE , 13 showed subpial necrosis ; the nerve roots and subarachnoid vessels were normal .
Diseases:"
3852	The spinal cords of the animals that received bupivacaine , low pH normal saline ( pH 3 . 0 ) , or normal saline did not show abnormal findings .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The spinal cords of the animals that received bupivacaine , low pH normal saline ( pH 3 . 0 ) , or normal saline did not show abnormal findings .
Diseases: "	"Sentence: The spinal cords of the animals that received bupivacaine , low pH normal saline ( pH 3 . 0 ) , or normal saline did not show abnormal findings .
Diseases:"
3853	Early adjuvant adriamycin in superficial bladder carcinoma .	O O O O O B I O	['bladder carcinoma']	1	4	"Sentence: Early adjuvant adriamycin in superficial bladder carcinoma .
Diseases: bladder carcinoma"	"Sentence: Early adjuvant adriamycin in superficial bladder carcinoma .
Diseases:"
3854	A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder .	O O O O O O O O O O O O B I I I O	['carcinoma of the bladder']	1	7	"Sentence: A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder .
Diseases: carcinoma of the bladder"	"Sentence: A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder .
Diseases:"
3855	Adriamycin ( 50 mg / 50 ml ) was administered intravesically within 24 h after transurethral resection of TA - T1 ( O - A ) bladder tumors .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['bladder tumors']	1	3	"Sentence: Adriamycin ( 50 mg / 50 ml ) was administered intravesically within 24 h after transurethral resection of TA - T1 ( O - A ) bladder tumors .
Diseases: bladder tumors"	"Sentence: Adriamycin ( 50 mg / 50 ml ) was administered intravesically within 24 h after transurethral resection of TA - T1 ( O - A ) bladder tumors .
Diseases:"
3856	Instillation was repeated twice during the first week , then weekly during the first month and afterwards monthly for 1 year .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Instillation was repeated twice during the first week , then weekly during the first month and afterwards monthly for 1 year .
Diseases: "	"Sentence: Instillation was repeated twice during the first week , then weekly during the first month and afterwards monthly for 1 year .
Diseases:"
3857	The tolerance was evaluated in these 110 patients , and 29 patients presented with local side - effects .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The tolerance was evaluated in these 110 patients , and 29 patients presented with local side - effects .
Diseases: "	"Sentence: The tolerance was evaluated in these 110 patients , and 29 patients presented with local side - effects .
Diseases:"
3858	In 24 of these patients chemical cystitis was severe enough for them to drop out of the study .	O O O O O O B O O O O O O O O O O O O	['cystitis']	1	3	"Sentence: In 24 of these patients chemical cystitis was severe enough for them to drop out of the study .
Diseases: cystitis"	"Sentence: In 24 of these patients chemical cystitis was severe enough for them to drop out of the study .
Diseases:"
3859	No systemic side - effects were observed .	O O O O O O O O	[]	0	0	"Sentence: No systemic side - effects were observed .
Diseases: "	"Sentence: No systemic side - effects were observed .
Diseases:"
3860	Recurrence was studied in 82 evaluable patients after 1 year of follow - up and in 72 patients followed for 2 - 3 years ( mean 32 months ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Recurrence was studied in 82 evaluable patients after 1 year of follow - up and in 72 patients followed for 2 - 3 years ( mean 32 months ) .
Diseases: "	"Sentence: Recurrence was studied in 82 evaluable patients after 1 year of follow - up and in 72 patients followed for 2 - 3 years ( mean 32 months ) .
Diseases:"
3861	Of the 82 patients studied after 1 year , 23 had primary and 59 recurrent disease .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the 82 patients studied after 1 year , 23 had primary and 59 recurrent disease .
Diseases: "	"Sentence: Of the 82 patients studied after 1 year , 23 had primary and 59 recurrent disease .
Diseases:"
3862	Of the 82 evaluable patients , 50 did not show any recurrence after 1 year ( 61 % ) , while 32 presented with one or more recurrences ( 39 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the 82 evaluable patients , 50 did not show any recurrence after 1 year ( 61 % ) , while 32 presented with one or more recurrences ( 39 % ) .
Diseases: "	"Sentence: Of the 82 evaluable patients , 50 did not show any recurrence after 1 year ( 61 % ) , while 32 presented with one or more recurrences ( 39 % ) .
Diseases:"
3863	Of these recurrences , 27 were T1 tumors while five progressed to more highly invasive lesions .	O O O O O O O B O O O O O O O O O	['tumors']	1	3	"Sentence: Of these recurrences , 27 were T1 tumors while five progressed to more highly invasive lesions .
Diseases: tumors"	"Sentence: Of these recurrences , 27 were T1 tumors while five progressed to more highly invasive lesions .
Diseases:"
3864	In patients that were free of recurrence during the first year , 80 % remained tumor - free during the 2 - to 3 - year follow - up period .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['tumor']	1	3	"Sentence: In patients that were free of recurrence during the first year , 80 % remained tumor - free during the 2 - to 3 - year follow - up period .
Diseases: tumor"	"Sentence: In patients that were free of recurrence during the first year , 80 % remained tumor - free during the 2 - to 3 - year follow - up period .
Diseases:"
3865	Of the patients developing one or more recurrences during the first year , only 50 % presented with further recurrence once the instillations were stopped .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the patients developing one or more recurrences during the first year , only 50 % presented with further recurrence once the instillations were stopped .
Diseases: "	"Sentence: Of the patients developing one or more recurrences during the first year , only 50 % presented with further recurrence once the instillations were stopped .
Diseases:"
3866	The beneficial effect of Adriamycin appears obvious and might be related to the drug itself , the early and repeated instillations after TUR , or both .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The beneficial effect of Adriamycin appears obvious and might be related to the drug itself , the early and repeated instillations after TUR , or both .
Diseases: "	"Sentence: The beneficial effect of Adriamycin appears obvious and might be related to the drug itself , the early and repeated instillations after TUR , or both .
Diseases:"
3867	Hyperkalemia associated with sulindac therapy .	B O O O O O	['hyperkalemia']	1	4	"Sentence: Hyperkalemia associated with sulindac therapy .
Diseases: hyperkalemia"	"Sentence: Hyperkalemia associated with sulindac therapy .
Diseases:"
3868	Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents ( NSAID ) such as indomethacin .	B O O O O O O O O O O O O O O O O O O	['hyperkalemia']	1	4	"Sentence: Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents ( NSAID ) such as indomethacin .
Diseases: hyperkalemia"	"Sentence: Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents ( NSAID ) such as indomethacin .
Diseases:"
3869	Several recent studies have stressed the renal sparing features of sulindac , owing to its lack of interference with renal prostacyclin synthesis .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Several recent studies have stressed the renal sparing features of sulindac , owing to its lack of interference with renal prostacyclin synthesis .
Diseases: "	"Sentence: Several recent studies have stressed the renal sparing features of sulindac , owing to its lack of interference with renal prostacyclin synthesis .
Diseases:"
3870	We describe 4 patients in whom hyperkalemia ranging from 6 . 1 to 6 . 9 mEq / l developed within 3 to 8 days of sulindac administration .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['hyperkalemia']	1	4	"Sentence: We describe 4 patients in whom hyperkalemia ranging from 6 . 1 to 6 . 9 mEq / l developed within 3 to 8 days of sulindac administration .
Diseases: hyperkalemia"	"Sentence: We describe 4 patients in whom hyperkalemia ranging from 6 . 1 to 6 . 9 mEq / l developed within 3 to 8 days of sulindac administration .
Diseases:"
3871	In all of them normal serum potassium levels reached within 2 to 4 days of stopping sulindac .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In all of them normal serum potassium levels reached within 2 to 4 days of stopping sulindac .
Diseases: "	"Sentence: In all of them normal serum potassium levels reached within 2 to 4 days of stopping sulindac .
Diseases:"
3872	As no other medications known to effect serum potassium had been given concomitantly , this course of events is suggestive of a cause - and - effect relationship between sulindac and hyperkalemia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['hyperkalemia']	1	4	"Sentence: As no other medications known to effect serum potassium had been given concomitantly , this course of events is suggestive of a cause - and - effect relationship between sulindac and hyperkalemia .
Diseases: hyperkalemia"	"Sentence: As no other medications known to effect serum potassium had been given concomitantly , this course of events is suggestive of a cause - and - effect relationship between sulindac and hyperkalemia .
Diseases:"
3873	These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified .
Diseases: "	"Sentence: These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified .
Diseases:"
3874	Ventricular tachyarrhythmias during cesarean section after ritodrine therapy : interaction with anesthetics .	B I O O O O O O O O O O O	['ventricular tachyarrhythmias']	1	8	"Sentence: Ventricular tachyarrhythmias during cesarean section after ritodrine therapy : interaction with anesthetics .
Diseases: ventricular tachyarrhythmias"	"Sentence: Ventricular tachyarrhythmias during cesarean section after ritodrine therapy : interaction with anesthetics .
Diseases:"
3875	This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O	['preterm labor']	1	3	"Sentence: This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section .
Diseases: preterm labor"	"Sentence: This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section .
Diseases:"
3876	Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine .	O O O O O O B I O O O O O O O O O	['cardiovascular complications']	1	3	"Sentence: Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine .
Diseases: cardiovascular complications"	"Sentence: Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine .
Diseases:"
3877	Preoperative assessment should focus on cardiovascular status and serum potassium level .	O O O O O O O O O O O O	[]	0	0	"Sentence: Preoperative assessment should focus on cardiovascular status and serum potassium level .
Diseases: "	"Sentence: Preoperative assessment should focus on cardiovascular status and serum potassium level .
Diseases:"
3878	Delaying induction of anesthesia should be considered whenever possible .	O O O O O O O O O O	[]	0	0	"Sentence: Delaying induction of anesthesia should be considered whenever possible .
Diseases: "	"Sentence: Delaying induction of anesthesia should be considered whenever possible .
Diseases:"
3879	Careful fluid administration and cautious use of titrated doses of ephedrine are advised .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Careful fluid administration and cautious use of titrated doses of ephedrine are advised .
Diseases: "	"Sentence: Careful fluid administration and cautious use of titrated doses of ephedrine are advised .
Diseases:"
3880	After delivery of the infant , there should be no contraindication to the use of an alpha - adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O B O	['tachycardia', 'hypotensive']	2	7	"Sentence: After delivery of the infant , there should be no contraindication to the use of an alpha - adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia .
Diseases: tachycardia, hypotensive"	"Sentence: After delivery of the infant , there should be no contraindication to the use of an alpha - adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia .
Diseases:"
3881	Immunohistochemical , electron microscopic and morphometric studies of estrogen - induced rat prolactinomas after bromocriptine treatment .	O O O O O O O O O O O O B O O O O	['prolactinomas']	1	5	"Sentence: Immunohistochemical , electron microscopic and morphometric studies of estrogen - induced rat prolactinomas after bromocriptine treatment .
Diseases: prolactinomas"	"Sentence: Immunohistochemical , electron microscopic and morphometric studies of estrogen - induced rat prolactinomas after bromocriptine treatment .
Diseases:"
3882	To clarify the effects of bromocriptine on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen - induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine ( 3 mg / kg of body weight ) .	O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['prolactinoma']	1	5	"Sentence: To clarify the effects of bromocriptine on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen - induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine ( 3 mg / kg of body weight ) .
Diseases: prolactinoma"	"Sentence: To clarify the effects of bromocriptine on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen - induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine ( 3 mg / kg of body weight ) .
Diseases:"
3883	One h after treatment , serum prolactin levels decreased markedly .	O O O O O O O O O O O	[]	0	0	"Sentence: One h after treatment , serum prolactin levels decreased markedly .
Diseases: "	"Sentence: One h after treatment , serum prolactin levels decreased markedly .
Diseases:"
3884	Electron microscopy disclosed many secretory granules , slightly distorted rough endoplasmic reticulum , and partially dilated Golgi cisternae in the prolactinoma cells .	O O O O O O O O O O O O O O O O O O O O B O O	['prolactinoma']	1	5	"Sentence: Electron microscopy disclosed many secretory granules , slightly distorted rough endoplasmic reticulum , and partially dilated Golgi cisternae in the prolactinoma cells .
Diseases: prolactinoma"	"Sentence: Electron microscopy disclosed many secretory granules , slightly distorted rough endoplasmic reticulum , and partially dilated Golgi cisternae in the prolactinoma cells .
Diseases:"
3885	Morphometric analysis revealed that the volume density of secretory granules increased , while the volume density of cytoplasmic microtubules decreased .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Morphometric analysis revealed that the volume density of secretory granules increased , while the volume density of cytoplasmic microtubules decreased .
Diseases: "	"Sentence: Morphometric analysis revealed that the volume density of secretory granules increased , while the volume density of cytoplasmic microtubules decreased .
Diseases:"
3886	These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules .
Diseases: "	"Sentence: These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules .
Diseases:"
3887	At 6 h after injection , serum prolactin levels were still considerably lower than in controls .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At 6 h after injection , serum prolactin levels were still considerably lower than in controls .
Diseases: "	"Sentence: At 6 h after injection , serum prolactin levels were still considerably lower than in controls .
Diseases:"
3888	The prolactinoma cells at this time were well granulated , with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae .	O B O O O O O O O O O O O O O O O O O O O	['prolactinoma']	1	5	"Sentence: The prolactinoma cells at this time were well granulated , with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae .
Diseases: prolactinoma"	"Sentence: The prolactinoma cells at this time were well granulated , with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae .
Diseases:"
3889	Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules , Golgi cisternae , and endoplasmic reticulum of the untreated rat prolactinoma cells .	O O O O O O O O O O O O O O O O O O O O O O O B O O	['prolactinoma']	1	5	"Sentence: Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules , Golgi cisternae , and endoplasmic reticulum of the untreated rat prolactinoma cells .
Diseases: prolactinoma"	"Sentence: Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules , Golgi cisternae , and endoplasmic reticulum of the untreated rat prolactinoma cells .
Diseases:"
3890	However , only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells .	O O O O O O O O O O O O O O O O O O O B O O	['adenoma']	1	2	"Sentence: However , only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells .
Diseases: adenoma"	"Sentence: However , only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells .
Diseases:"
3891	An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis , suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis , suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion .
Diseases: "	"Sentence: An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis , suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion .
Diseases:"
3892	On two paradoxical side - effects of prednisolone in rats , ribosomal RNA biosyntheses , and a mechanism of action .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On two paradoxical side - effects of prednisolone in rats , ribosomal RNA biosyntheses , and a mechanism of action .
Diseases: "	"Sentence: On two paradoxical side - effects of prednisolone in rats , ribosomal RNA biosyntheses , and a mechanism of action .
Diseases:"
3893	Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone .	B I O B I O O O O O O O O O O O	['liver enlargement', 'muscle wastage']	2	8	"Sentence: Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone .
Diseases: liver enlargement, muscle wastage"	"Sentence: Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone .
Diseases:"
3894	In the liver both the content of RNA and the biosynthesis of ribosomal RNA increased while both the RNA content and ribosomal RNA biosynthesis were reduced in the gastrocnemius muscle .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the liver both the content of RNA and the biosynthesis of ribosomal RNA increased while both the RNA content and ribosomal RNA biosynthesis were reduced in the gastrocnemius muscle .
Diseases: "	"Sentence: In the liver both the content of RNA and the biosynthesis of ribosomal RNA increased while both the RNA content and ribosomal RNA biosynthesis were reduced in the gastrocnemius muscle .
Diseases:"
3895	It is suggested that the drug acted in a selective and tissue - specific manner to enhance ribosomal RNA synthesis in the liver and depress such synthesis in the muscle .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is suggested that the drug acted in a selective and tissue - specific manner to enhance ribosomal RNA synthesis in the liver and depress such synthesis in the muscle .
Diseases: "	"Sentence: It is suggested that the drug acted in a selective and tissue - specific manner to enhance ribosomal RNA synthesis in the liver and depress such synthesis in the muscle .
Diseases:"
3896	This view supports the contention that the liver and muscle are independent sites of prednisolone action .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This view supports the contention that the liver and muscle are independent sites of prednisolone action .
Diseases: "	"Sentence: This view supports the contention that the liver and muscle are independent sites of prednisolone action .
Diseases:"
3897	Possible intramuscular midazolam - associated cardiorespiratory arrest and death .	O O O O O B I O B O	['death', 'cardiorespiratory arrest']	2	8	"Sentence: Possible intramuscular midazolam - associated cardiorespiratory arrest and death .
Diseases: death, cardiorespiratory arrest"	"Sentence: Possible intramuscular midazolam - associated cardiorespiratory arrest and death .
Diseases:"
3898	Midazolam hydrochloride is commonly used for dental or endoscopic procedures .	O O O O O O O O O O O	[]	0	0	"Sentence: Midazolam hydrochloride is commonly used for dental or endoscopic procedures .
Diseases: "	"Sentence: Midazolam hydrochloride is commonly used for dental or endoscopic procedures .
Diseases:"
3899	Although generally consisted safe when given intramuscularly , intravenous administration is known to cause respiratory and cardiovascular depression .	O O O O O O O O O O O O O O B I I I O	['respiratory and cardiovascular depression']	1	6	"Sentence: Although generally consisted safe when given intramuscularly , intravenous administration is known to cause respiratory and cardiovascular depression .
Diseases: respiratory and cardiovascular depression"	"Sentence: Although generally consisted safe when given intramuscularly , intravenous administration is known to cause respiratory and cardiovascular depression .
Diseases:"
3900	This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam .	O O O O O O O O B I O B O O O O O O O	['death', 'cardiorespiratory arrest']	2	8	"Sentence: This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam .
Diseases: death, cardiorespiratory arrest"	"Sentence: This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam .
Diseases:"
3901	Information regarding midazolam use is reviewed to provide recommendation for safe administration .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Information regarding midazolam use is reviewed to provide recommendation for safe administration .
Diseases: "	"Sentence: Information regarding midazolam use is reviewed to provide recommendation for safe administration .
Diseases:"
3902	Serial epilepsy caused by levodopa / carbidopa administration in two patients on hemodialysis .	O B O O O O O O O O O O O O	['epilepsy']	1	3	"Sentence: Serial epilepsy caused by levodopa / carbidopa administration in two patients on hemodialysis .
Diseases: epilepsy"	"Sentence: Serial epilepsy caused by levodopa / carbidopa administration in two patients on hemodialysis .
Diseases:"
3903	Two patients with similar clinical features are presented : both patients had chronic renal failure , on hemodialysis for many years but recently begun on a high - flux dialyzer ; both had been receiving a carbidopa / levodopa preparation ; and both had the onset of hallucinosis and recurrent seizures , which were refractory to anticonvulsants .	O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B O O O O O O O	['hallucinosis', 'chronic renal failure', 'seizures']	3	10	"Sentence: Two patients with similar clinical features are presented : both patients had chronic renal failure , on hemodialysis for many years but recently begun on a high - flux dialyzer ; both had been receiving a carbidopa / levodopa preparation ; and both had the onset of hallucinosis and recurrent seizures , which were refractory to anticonvulsants .
Diseases: hallucinosis, chronic renal failure, seizures"	"Sentence: Two patients with similar clinical features are presented : both patients had chronic renal failure , on hemodialysis for many years but recently begun on a high - flux dialyzer ; both had been receiving a carbidopa / levodopa preparation ; and both had the onset of hallucinosis and recurrent seizures , which were refractory to anticonvulsants .
Diseases:"
3904	The first patient died without a diagnosis ; the second patient had a dramatic recovery following the administration of vitamin B6 .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The first patient died without a diagnosis ; the second patient had a dramatic recovery following the administration of vitamin B6 .
Diseases: "	"Sentence: The first patient died without a diagnosis ; the second patient had a dramatic recovery following the administration of vitamin B6 .
Diseases:"
3905	Neither patient was considered to have a renal state sufficiently severe enough to explain their presentation .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Neither patient was considered to have a renal state sufficiently severe enough to explain their presentation .
Diseases: "	"Sentence: Neither patient was considered to have a renal state sufficiently severe enough to explain their presentation .
Diseases:"
3906	Effect of L - alpha - glyceryl - phosphorylcholine on amnesia caused by scopolamine .	O O O O O O O O O O B O O O O	['amnesia']	1	2	"Sentence: Effect of L - alpha - glyceryl - phosphorylcholine on amnesia caused by scopolamine .
Diseases: amnesia"	"Sentence: Effect of L - alpha - glyceryl - phosphorylcholine on amnesia caused by scopolamine .
Diseases:"
3907	The present study was carried out to test the effects of L - alpha - glycerylphosphorylcholine ( L - alpha - GFC ) on memory impairment induced by scopolamine in man .	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	['memory impairment']	1	2	"Sentence: The present study was carried out to test the effects of L - alpha - glycerylphosphorylcholine ( L - alpha - GFC ) on memory impairment induced by scopolamine in man .
Diseases: memory impairment"	"Sentence: The present study was carried out to test the effects of L - alpha - glycerylphosphorylcholine ( L - alpha - GFC ) on memory impairment induced by scopolamine in man .
Diseases:"
3908	Thirty - two healthy young volunteers were randomly allocated to four different groups .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty - two healthy young volunteers were randomly allocated to four different groups .
Diseases: "	"Sentence: Thirty - two healthy young volunteers were randomly allocated to four different groups .
Diseases:"
3909	They were given a ten day pretreatment with either L - alpha - GFC or placebo , p . o . , and on the eleventh day either scopolamine or placebo , i . m .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: They were given a ten day pretreatment with either L - alpha - GFC or placebo , p . o . , and on the eleventh day either scopolamine or placebo , i . m .
Diseases: "	"Sentence: They were given a ten day pretreatment with either L - alpha - GFC or placebo , p . o . , and on the eleventh day either scopolamine or placebo , i . m .
Diseases:"
3910	Before and 0 . 5 , 1 , 2 , 3 , and 6 h after injection the subjects were given attention and mnemonic tests .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Before and 0 . 5 , 1 , 2 , 3 , and 6 h after injection the subjects were given attention and mnemonic tests .
Diseases: "	"Sentence: Before and 0 . 5 , 1 , 2 , 3 , and 6 h after injection the subjects were given attention and mnemonic tests .
Diseases:"
3911	The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine .	O O O O O O O O O O O O O B I I I I O O O O	['impairment of attention and memory']	1	7	"Sentence: The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine .
Diseases: impairment of attention and memory"	"Sentence: The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine .
Diseases:"
3912	Seizures induced by the cocaine metabolite benzoylecgonine in rats .	B O O O O O O O O O	['seizures']	1	3	"Sentence: Seizures induced by the cocaine metabolite benzoylecgonine in rats .
Diseases: seizures"	"Sentence: Seizures induced by the cocaine metabolite benzoylecgonine in rats .
Diseases:"
3913	The half - life ( t1 / 2 ) of cocaine is relatively short , but some of the consequences of its use , such as seizures and strokes , can occur hours after exposure .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O	['seizures', 'strokes']	2	5	"Sentence: The half - life ( t1 / 2 ) of cocaine is relatively short , but some of the consequences of its use , such as seizures and strokes , can occur hours after exposure .
Diseases: seizures, strokes"	"Sentence: The half - life ( t1 / 2 ) of cocaine is relatively short , but some of the consequences of its use , such as seizures and strokes , can occur hours after exposure .
Diseases:"
3914	This led us to hypothesize that a metabolite of cocaine may be responsible for some of those delayed sequelae .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This led us to hypothesize that a metabolite of cocaine may be responsible for some of those delayed sequelae .
Diseases: "	"Sentence: This led us to hypothesize that a metabolite of cocaine may be responsible for some of those delayed sequelae .
Diseases:"
3915	We evaluated the potential of the major metabolite of cocaine , benzoylecgonine ( BE ) , to cause seizures .	O O O O O O O O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: We evaluated the potential of the major metabolite of cocaine , benzoylecgonine ( BE ) , to cause seizures .
Diseases: seizures"	"Sentence: We evaluated the potential of the major metabolite of cocaine , benzoylecgonine ( BE ) , to cause seizures .
Diseases:"
3916	Two separate equimolar doses ( 0 . 2 and 0 . 4 mumol ) of either cocaine or BE were injected ventricularly in unanesthetized juvenile rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two separate equimolar doses ( 0 . 2 and 0 . 4 mumol ) of either cocaine or BE were injected ventricularly in unanesthetized juvenile rats .
Diseases: "	"Sentence: Two separate equimolar doses ( 0 . 2 and 0 . 4 mumol ) of either cocaine or BE were injected ventricularly in unanesthetized juvenile rats .
Diseases:"
3917	Treated rats were then evaluated for incidence , latency , and seizure pattern or for locomotor activity in animals without seizures .	O O O O O O O O O O O B O O O O O O O O B O	['seizures', 'seizure']	2	5	"Sentence: Treated rats were then evaluated for incidence , latency , and seizure pattern or for locomotor activity in animals without seizures .
Diseases: seizures, seizure"	"Sentence: Treated rats were then evaluated for incidence , latency , and seizure pattern or for locomotor activity in animals without seizures .
Diseases:"
3918	BE - Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine .	O O O B O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: BE - Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine .
Diseases: seizures"	"Sentence: BE - Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine .
Diseases:"
3919	Whereas cocaine - induced seizures were best characterized as brief , generalized , and tonic and resulted in death , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in death .	O O O O B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O B O	['death', 'seizures']	2	3	"Sentence: Whereas cocaine - induced seizures were best characterized as brief , generalized , and tonic and resulted in death , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in death .
Diseases: death, seizures"	"Sentence: Whereas cocaine - induced seizures were best characterized as brief , generalized , and tonic and resulted in death , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in death .
Diseases:"
3920	Electrical recordings from the hippocampus showed a rhythmic progression in EEG frequency and voltage with clinical seizure expression .	O O O O O O O O O O O O O O O O B O O	['seizure']	1	3	"Sentence: Electrical recordings from the hippocampus showed a rhythmic progression in EEG frequency and voltage with clinical seizure expression .
Diseases: seizure"	"Sentence: Electrical recordings from the hippocampus showed a rhythmic progression in EEG frequency and voltage with clinical seizure expression .
Diseases:"
3921	BE - Injected rats that did not have seizures had significantly more locomotor activity than cocaine - injected animals without seizures .	O O O O O O O O B O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: BE - Injected rats that did not have seizures had significantly more locomotor activity than cocaine - injected animals without seizures .
Diseases: seizures"	"Sentence: BE - Injected rats that did not have seizures had significantly more locomotor activity than cocaine - injected animals without seizures .
Diseases:"
3922	The finding that cocaine - and BE - induced seizures differ in several respects suggests more than one mechanism for cocaine - induced seizures and emphasizes the importance of a cocaine metabolite , BE .	O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O O O O O	['seizures']	1	3	"Sentence: The finding that cocaine - and BE - induced seizures differ in several respects suggests more than one mechanism for cocaine - induced seizures and emphasizes the importance of a cocaine metabolite , BE .
Diseases: seizures"	"Sentence: The finding that cocaine - and BE - induced seizures differ in several respects suggests more than one mechanism for cocaine - induced seizures and emphasizes the importance of a cocaine metabolite , BE .
Diseases:"
3923	Protection against amphetamine - induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614 , an excitatory amino acid antagonist .	O O O O O B O O O O O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: Protection against amphetamine - induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614 , an excitatory amino acid antagonist .
Diseases: neurotoxicity"	"Sentence: Protection against amphetamine - induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614 , an excitatory amino acid antagonist .
Diseases:"
3924	LY274614 , 3SR , 4aRS , 6SR , 8aRS - 6 - [ phosphonomethyl ] decahydr oisoquinoline - 3 - carboxylic acid , has been described as a potent antagonist of the N - methyl - D - aspartate ( NMDA ) subtype of glutamate receptor .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: LY274614 , 3SR , 4aRS , 6SR , 8aRS - 6 - [ phosphonomethyl ] decahydr oisoquinoline - 3 - carboxylic acid , has been described as a potent antagonist of the N - methyl - D - aspartate ( NMDA ) subtype of glutamate receptor .
Diseases: "	"Sentence: LY274614 , 3SR , 4aRS , 6SR , 8aRS - 6 - [ phosphonomethyl ] decahydr oisoquinoline - 3 - carboxylic acid , has been described as a potent antagonist of the N - methyl - D - aspartate ( NMDA ) subtype of glutamate receptor .
Diseases:"
3925	Here its ability to antagonize the prolonged depletion of dopamine in the striatum by amphetamine in iprindole - treated rats is reported .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Here its ability to antagonize the prolonged depletion of dopamine in the striatum by amphetamine in iprindole - treated rats is reported .
Diseases: "	"Sentence: Here its ability to antagonize the prolonged depletion of dopamine in the striatum by amphetamine in iprindole - treated rats is reported .
Diseases:"
3926	A single 18 . 4 mg / kg ( i . p . )	O O O O O O O O O O O O O O	[]	0	0	"Sentence: A single 18 . 4 mg / kg ( i . p . )
Diseases: "	"Sentence: A single 18 . 4 mg / kg ( i . p . )
Diseases:"
3927	dose of ( + / - ) - amphetamine hemisulfate , given to rats pretreated with iprindole , resulted in persistent depletion of dopamine in the striatum 1 week later .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: dose of ( + / - ) - amphetamine hemisulfate , given to rats pretreated with iprindole , resulted in persistent depletion of dopamine in the striatum 1 week later .
Diseases: "	"Sentence: dose of ( + / - ) - amphetamine hemisulfate , given to rats pretreated with iprindole , resulted in persistent depletion of dopamine in the striatum 1 week later .
Diseases:"
3928	This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine ( MK - 801 , a non - competitive antagonist of NMDA receptors ) or by LY274614 ( a competitive antagonist of NMDA receptors ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine ( MK - 801 , a non - competitive antagonist of NMDA receptors ) or by LY274614 ( a competitive antagonist of NMDA receptors ) .
Diseases: "	"Sentence: This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine ( MK - 801 , a non - competitive antagonist of NMDA receptors ) or by LY274614 ( a competitive antagonist of NMDA receptors ) .
Diseases:"
3929	The protective effect of LY274614 was dose - dependent , being maximum at 10 - 40 mgkg ( i . p . ) .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The protective effect of LY274614 was dose - dependent , being maximum at 10 - 40 mgkg ( i . p . ) .
Diseases: "	"Sentence: The protective effect of LY274614 was dose - dependent , being maximum at 10 - 40 mgkg ( i . p . ) .
Diseases:"
3930	A 10 mg / kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum , when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A 10 mg / kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum , when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine .
Diseases: "	"Sentence: A 10 mg / kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum , when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine .
Diseases:"
3931	Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine ; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine ; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine .
Diseases: "	"Sentence: Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine ; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine .
Diseases:"
3932	The prolonged depletion of dopamine in the striatum in mice , given multiple injections of methamphetamine , was also antagonized dose - dependently and completely by LY274614 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The prolonged depletion of dopamine in the striatum in mice , given multiple injections of methamphetamine , was also antagonized dose - dependently and completely by LY274614 .
Diseases: "	"Sentence: The prolonged depletion of dopamine in the striatum in mice , given multiple injections of methamphetamine , was also antagonized dose - dependently and completely by LY274614 .
Diseases:"
3933	The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long - lasting in vivo effects in rats .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['neurotoxic']	1	4	"Sentence: The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long - lasting in vivo effects in rats .
Diseases: neurotoxic"	"Sentence: The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long - lasting in vivo effects in rats .
Diseases:"
3934	Neonatal pyridoxine responsive convulsions due to isoniazid therapy .	O O O B O O O O O	['convulsions']	1	3	"Sentence: Neonatal pyridoxine responsive convulsions due to isoniazid therapy .
Diseases: convulsions"	"Sentence: Neonatal pyridoxine responsive convulsions due to isoniazid therapy .
Diseases:"
3935	A 17 - day - old infant on isoniazid therapy 13 mg / kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits .	O O O O O O O O O O O O O O O O O O O O B O O O O O O B I O	['tuberculosis', 'clonic fits']	2	7	"Sentence: A 17 - day - old infant on isoniazid therapy 13 mg / kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits .
Diseases: tuberculosis, clonic fits"	"Sentence: A 17 - day - old infant on isoniazid therapy 13 mg / kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits .
Diseases:"
3936	No underlying infective or biochemical cause could be found .	O O O O O O O O O O	[]	0	0	"Sentence: No underlying infective or biochemical cause could be found .
Diseases: "	"Sentence: No underlying infective or biochemical cause could be found .
Diseases:"
3937	The fits ceased within 4 hours of administering intramuscular pyridoxine , suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication .	O B O O O O O O O O O O O O O O O O O O O O	['fits']	1	1	"Sentence: The fits ceased within 4 hours of administering intramuscular pyridoxine , suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication .
Diseases: fits"	"Sentence: The fits ceased within 4 hours of administering intramuscular pyridoxine , suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication .
Diseases:"
3938	Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction .	O O O O O O O O O O O O O B I I O	['acute myocardial infarction']	1	8	"Sentence: Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction .
Diseases: acute myocardial infarction"	"Sentence: Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction .
Diseases:"
3939	Nitroglycerin has been shown to reduce ST - segment elevation during acute myocardial infarction , an effect potentiated in the dog by agents that reverse nitroglycerin - induced hypotension .	O O O O O O O O O O O B I I O O O O O O O O O O O O O O B O	['hypotension', 'acute myocardial infarction']	2	11	"Sentence: Nitroglycerin has been shown to reduce ST - segment elevation during acute myocardial infarction , an effect potentiated in the dog by agents that reverse nitroglycerin - induced hypotension .
Diseases: hypotension, acute myocardial infarction"	"Sentence: Nitroglycerin has been shown to reduce ST - segment elevation during acute myocardial infarction , an effect potentiated in the dog by agents that reverse nitroglycerin - induced hypotension .
Diseases:"
3940	Our study was designed to determine the effects of combined nitroglycerin and phenylephrine therapy .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Our study was designed to determine the effects of combined nitroglycerin and phenylephrine therapy .
Diseases: "	"Sentence: Our study was designed to determine the effects of combined nitroglycerin and phenylephrine therapy .
Diseases:"
3941	Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin , sufficient to reduce mean arterial pressure from 107 + / - 6 to 85 + / -	O O O O O B I O O O O O O O O O O O O O O O O O O O O O	['myocardial infarctions']	1	6	"Sentence: Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin , sufficient to reduce mean arterial pressure from 107 + / - 6 to 85 + / -
Diseases: myocardial infarctions"	"Sentence: Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin , sufficient to reduce mean arterial pressure from 107 + / - 6 to 85 + / -
Diseases:"
3942	6 mm	O O	[]	0	0	"Sentence: 6 mm
Diseases: "	"Sentence: 6 mm
Diseases:"
3943	Hg ( P less than 0 . 001 ) , for 60 minutes .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hg ( P less than 0 . 001 ) , for 60 minutes .
Diseases: "	"Sentence: Hg ( P less than 0 . 001 ) , for 60 minutes .
Diseases:"
3944	Left ventricular filling pressure decreased from 19 + / - 2 to 11 + / -	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Left ventricular filling pressure decreased from 19 + / - 2 to 11 + / -
Diseases: "	"Sentence: Left ventricular filling pressure decreased from 19 + / - 2 to 11 + / -
Diseases:"
3945	Hg ( P less than 0 . 001 ) .	O O O O O O O O O O	[]	0	0	"Sentence: Hg ( P less than 0 . 001 ) .
Diseases: "	"Sentence: Hg ( P less than 0 . 001 ) .
Diseases:"
3946	SigmaST , the sum of ST - segment elevations in 16 precordial leads , decreased ( P less than 0 . 02 ) with intravenous nitroglycerin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: SigmaST , the sum of ST - segment elevations in 16 precordial leads , decreased ( P less than 0 . 02 ) with intravenous nitroglycerin .
Diseases: "	"Sentence: SigmaST , the sum of ST - segment elevations in 16 precordial leads , decreased ( P less than 0 . 02 ) with intravenous nitroglycerin .
Diseases:"
3947	Subsequent addition of phenylephrine infusion , sufficient to re - elevate mean arterial pressure to 106 + / - 4 mm	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Subsequent addition of phenylephrine infusion , sufficient to re - elevate mean arterial pressure to 106 + / - 4 mm
Diseases: "	"Sentence: Subsequent addition of phenylephrine infusion , sufficient to re - elevate mean arterial pressure to 106 + / - 4 mm
Diseases:"
3948	Hg ( P less than 0 . 001 ) for 30 minutes , increased left ventricular filling pressure to 17 + / -	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hg ( P less than 0 . 001 ) for 30 minutes , increased left ventricular filling pressure to 17 + / -
Diseases: "	"Sentence: Hg ( P less than 0 . 001 ) for 30 minutes , increased left ventricular filling pressure to 17 + / -
Diseases:"
3949	Hg ( P less than 0 . 05 ) and also significantly increased sigmaST ( P less than 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hg ( P less than 0 . 05 ) and also significantly increased sigmaST ( P less than 0 . 05 ) .
Diseases: "	"Sentence: Hg ( P less than 0 . 05 ) and also significantly increased sigmaST ( P less than 0 . 05 ) .
Diseases:"
3950	Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction .	O O O O O O O O O O O O O O O O O O B I I O	['acute myocardial infarction']	1	8	"Sentence: Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction .
Diseases: acute myocardial infarction"	"Sentence: Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction .
Diseases:"
3951	Elevation of ADAM10 , ADAM17 , MMP - 2 and MMP - 9 expression with media degeneration features CaCl2 - induced thoracic aortic aneurysm in a rat model .	O O O O O O O O O O O O O O O O O O O O O B I I O O O O O	['thoracic aortic aneurysm']	1	11	"Sentence: Elevation of ADAM10 , ADAM17 , MMP - 2 and MMP - 9 expression with media degeneration features CaCl2 - induced thoracic aortic aneurysm in a rat model .
Diseases: thoracic aortic aneurysm"	"Sentence: Elevation of ADAM10 , ADAM17 , MMP - 2 and MMP - 9 expression with media degeneration features CaCl2 - induced thoracic aortic aneurysm in a rat model .
Diseases:"
3952	This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( CaCl ( 2 ) ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .	O O O O O O O O O O B I I O B O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['taa', 'thoracic aortic aneurysm', 'arterial injury']	3	17	"Sentence: This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( CaCl ( 2 ) ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
Diseases: taa, thoracic aortic aneurysm, arterial injury"	"Sentence: This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( CaCl ( 2 ) ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .
Diseases:"
3953	METHODS : Thoracic aorta of male Sprague - Dawley rats was exposed to 0 . 5 M CaCl ( 2 ) or normal saline ( NaCl ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Thoracic aorta of male Sprague - Dawley rats was exposed to 0 . 5 M CaCl ( 2 ) or normal saline ( NaCl ) .
Diseases: "	"Sentence: METHODS : Thoracic aorta of male Sprague - Dawley rats was exposed to 0 . 5 M CaCl ( 2 ) or normal saline ( NaCl ) .
Diseases:"
3954	After 12weeks , animals were euthanized , and CaCl ( 2 ) - treated , CaCl ( 2 ) - untreated ( n = 12 ) and NaCl - treated aortic segments ( n = 12 ) were collected for histological and molecular assessments .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 12weeks , animals were euthanized , and CaCl ( 2 ) - treated , CaCl ( 2 ) - untreated ( n = 12 ) and NaCl - treated aortic segments ( n = 12 ) were collected for histological and molecular assessments .
Diseases: "	"Sentence: After 12weeks , animals were euthanized , and CaCl ( 2 ) - treated , CaCl ( 2 ) - untreated ( n = 12 ) and NaCl - treated aortic segments ( n = 12 ) were collected for histological and molecular assessments .
Diseases:"
3955	MMP - TIMP and ADAM mRNAs were semi - quantitatively analyzed and protein expressions were determined by immunohistochemistry .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: MMP - TIMP and ADAM mRNAs were semi - quantitatively analyzed and protein expressions were determined by immunohistochemistry .
Diseases: "	"Sentence: MMP - TIMP and ADAM mRNAs were semi - quantitatively analyzed and protein expressions were determined by immunohistochemistry .
Diseases:"
3956	Despite similar external diameters among CaCl ( 2 ) - treated , non - CaCl ( 2 ) - treated and NaCl - treated segments , aneurymal alteration ( n = 6 , 50 % ) , media degeneration with regional disruption , fragmentation of elastic fiber , and increased collagen deposition ( n = 12 , 100 % ) were demonstrated in CaCl ( 2 ) - treated segments .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Despite similar external diameters among CaCl ( 2 ) - treated , non - CaCl ( 2 ) - treated and NaCl - treated segments , aneurymal alteration ( n = 6 , 50 % ) , media degeneration with regional disruption , fragmentation of elastic fiber , and increased collagen deposition ( n = 12 , 100 % ) were demonstrated in CaCl ( 2 ) - treated segments .
Diseases: "	"Sentence: Despite similar external diameters among CaCl ( 2 ) - treated , non - CaCl ( 2 ) - treated and NaCl - treated segments , aneurymal alteration ( n = 6 , 50 % ) , media degeneration with regional disruption , fragmentation of elastic fiber , and increased collagen deposition ( n = 12 , 100 % ) were demonstrated in CaCl ( 2 ) - treated segments .
Diseases:"
3957	MMP - 2 , MMP - 9 , ADAM - 10 and ADAM - 17 mRNA levels were increased in CaCl ( 2 ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in CaCl ( 2 ) - untreated segments , as compared with NaCl - treated segments .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: MMP - 2 , MMP - 9 , ADAM - 10 and ADAM - 17 mRNA levels were increased in CaCl ( 2 ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in CaCl ( 2 ) - untreated segments , as compared with NaCl - treated segments .
Diseases: "	"Sentence: MMP - 2 , MMP - 9 , ADAM - 10 and ADAM - 17 mRNA levels were increased in CaCl ( 2 ) - treated segments ( all p < 0 . 01 ) , with trends of elevation in CaCl ( 2 ) - untreated segments , as compared with NaCl - treated segments .
Diseases:"
3958	Immunohistochemistry displayed significantly increased expressions of MMP - 2 , MMP - 9 , ADAM - 10 and ADAM - 17 ( all p < 0 . 01 ) in intima and media for CaCl ( 2 ) - treated segments .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunohistochemistry displayed significantly increased expressions of MMP - 2 , MMP - 9 , ADAM - 10 and ADAM - 17 ( all p < 0 . 01 ) in intima and media for CaCl ( 2 ) - treated segments .
Diseases: "	"Sentence: Immunohistochemistry displayed significantly increased expressions of MMP - 2 , MMP - 9 , ADAM - 10 and ADAM - 17 ( all p < 0 . 01 ) in intima and media for CaCl ( 2 ) - treated segments .
Diseases:"
3959	TIMP mRNA and tissue levels did not differ obviously among the three aortic segments .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: TIMP mRNA and tissue levels did not differ obviously among the three aortic segments .
Diseases: "	"Sentence: TIMP mRNA and tissue levels did not differ obviously among the three aortic segments .
Diseases:"
3960	This study establishes a TAA model by periarterial CaCl ( 2 ) exposure in rats , and demonstrates a significant elevation of expression of MMP - 2 , MMP - 9 , ADAM10 and ADAM17 in the pathogenesis of vascular remodeling .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['taa']	1	2	"Sentence: This study establishes a TAA model by periarterial CaCl ( 2 ) exposure in rats , and demonstrates a significant elevation of expression of MMP - 2 , MMP - 9 , ADAM10 and ADAM17 in the pathogenesis of vascular remodeling .
Diseases: taa"	"Sentence: This study establishes a TAA model by periarterial CaCl ( 2 ) exposure in rats , and demonstrates a significant elevation of expression of MMP - 2 , MMP - 9 , ADAM10 and ADAM17 in the pathogenesis of vascular remodeling .
Diseases:"
3961	When drugs disappear from the patient : elimination of intravenous medication by hemodiafiltration .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: When drugs disappear from the patient : elimination of intravenous medication by hemodiafiltration .
Diseases: "	"Sentence: When drugs disappear from the patient : elimination of intravenous medication by hemodiafiltration .
Diseases:"
3962	Twenty - three hours after heart transplantation , life - threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration ( CVVHDF ) .	O O O O O O O O O O O O B I I O O O O O O O O O O O O O	['right heart failure']	1	3	"Sentence: Twenty - three hours after heart transplantation , life - threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration ( CVVHDF ) .
Diseases: right heart failure"	"Sentence: Twenty - three hours after heart transplantation , life - threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration ( CVVHDF ) .
Diseases:"
3963	Increasing doses of catecholamines , sedatives , and muscle relaxants administered through a central venous catheter were ineffective .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Increasing doses of catecholamines , sedatives , and muscle relaxants administered through a central venous catheter were ineffective .
Diseases: "	"Sentence: Increasing doses of catecholamines , sedatives , and muscle relaxants administered through a central venous catheter were ineffective .
Diseases:"
3964	However , a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis .	O O O O O O O O O O O O O B O O	['hypertensive']	1	3	"Sentence: However , a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis .
Diseases: hypertensive"	"Sentence: However , a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis .
Diseases:"
3965	Thus , interference with the central venous infusion by the dialysis catheter was suspected .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thus , interference with the central venous infusion by the dialysis catheter was suspected .
Diseases: "	"Sentence: Thus , interference with the central venous infusion by the dialysis catheter was suspected .
Diseases:"
3966	The catheters were changed , and hemodynamics stabilized at lower catecholamine doses .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The catheters were changed , and hemodynamics stabilized at lower catecholamine doses .
Diseases: "	"Sentence: The catheters were changed , and hemodynamics stabilized at lower catecholamine doses .
Diseases:"
3967	When the effects of IV drugs are inadequate in patients receiving CVVHDF , interference with adjacent catheters resulting in elimination of the drug by CVVHDF should be suspected .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When the effects of IV drugs are inadequate in patients receiving CVVHDF , interference with adjacent catheters resulting in elimination of the drug by CVVHDF should be suspected .
Diseases: "	"Sentence: When the effects of IV drugs are inadequate in patients receiving CVVHDF , interference with adjacent catheters resulting in elimination of the drug by CVVHDF should be suspected .
Diseases:"
3968	Long - term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel .	O O O O O O O O O B I O O O	['peripheral neurotoxicity']	1	5	"Sentence: Long - term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel .
Diseases: peripheral neurotoxicity"	"Sentence: Long - term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel .
Diseases:"
3969	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .	O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['peripheral neuropathy', 'neurotoxicity']	2	8	"Sentence: Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .
Diseases: peripheral neuropathy, neurotoxicity"	"Sentence: Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .
Diseases:"
3970	This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC - induced peripheral neuropathy in a randomized , placebo - controlled , double - blinded clinical and electro - diagnostic study .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['peripheral neuropathy']	1	5	"Sentence: This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC - induced peripheral neuropathy in a randomized , placebo - controlled , double - blinded clinical and electro - diagnostic study .
Diseases: peripheral neuropathy"	"Sentence: This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC - induced peripheral neuropathy in a randomized , placebo - controlled , double - blinded clinical and electro - diagnostic study .
Diseases:"
3971	Forty - three ovarian cancer patients were available for analysis following six cycles of the same PAC - containing regimen : 23 had been supplemented by glutamate all along the treatment period , at a daily dose of three times 500 mg ( group G ) , and 20 had received a placebo ( group P ) .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ovarian cancer']	1	3	"Sentence: Forty - three ovarian cancer patients were available for analysis following six cycles of the same PAC - containing regimen : 23 had been supplemented by glutamate all along the treatment period , at a daily dose of three times 500 mg ( group G ) , and 20 had received a placebo ( group P ) .
Diseases: ovarian cancer"	"Sentence: Forty - three ovarian cancer patients were available for analysis following six cycles of the same PAC - containing regimen : 23 had been supplemented by glutamate all along the treatment period , at a daily dose of three times 500 mg ( group G ) , and 20 had received a placebo ( group P ) .
Diseases:"
3972	Patients were evaluated by neurological examinations , questionnaires and sensory - motor nerve conduction studies .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients were evaluated by neurological examinations , questionnaires and sensory - motor nerve conduction studies .
Diseases: "	"Sentence: Patients were evaluated by neurological examinations , questionnaires and sensory - motor nerve conduction studies .
Diseases:"
3973	There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G .
Diseases: neurotoxicity"	"Sentence: There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G .
Diseases:"
3974	However , this difference reached statistical significance only with regard to reported pain sensation ( P = 0 . 011 ) .	O O O O O O O O O O O O B O O O O O O O O O	['pain']	1	1	"Sentence: However , this difference reached statistical significance only with regard to reported pain sensation ( P = 0 . 011 ) .
Diseases: pain"	"Sentence: However , this difference reached statistical significance only with regard to reported pain sensation ( P = 0 . 011 ) .
Diseases:"
3975	Also the frequency of abnormal electro - diagnostic findings showed similarity between the two groups ( G : 7 / 23 = 30 . 4 % ; P : 6 / 20 = 30 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Also the frequency of abnormal electro - diagnostic findings showed similarity between the two groups ( G : 7 / 23 = 30 . 4 % ; P : 6 / 20 = 30 % ) .
Diseases: "	"Sentence: Also the frequency of abnormal electro - diagnostic findings showed similarity between the two groups ( G : 7 / 23 = 30 . 4 % ; P : 6 / 20 = 30 % ) .
Diseases:"
3976	This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC .	O O O O O O O O O O O O O O O O O O B I O O O	['peripheral neurotoxicity']	1	5	"Sentence: This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC .
Diseases: peripheral neurotoxicity"	"Sentence: This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC .
Diseases:"
3977	Attentional modulation of perceived pain intensity in capsaicin - induced secondary hyperalgesia .	O O O O B O O O O O O B O	['pain', 'hyperalgesia']	2	6	"Sentence: Attentional modulation of perceived pain intensity in capsaicin - induced secondary hyperalgesia .
Diseases: pain, hyperalgesia"	"Sentence: Attentional modulation of perceived pain intensity in capsaicin - induced secondary hyperalgesia .
Diseases:"
3978	Perceived pain intensity is modulated by attention .	O B O O O O O O	['pain']	1	1	"Sentence: Perceived pain intensity is modulated by attention .
Diseases: pain"	"Sentence: Perceived pain intensity is modulated by attention .
Diseases:"
3979	However , it is not known that how pain intensity ratings are affected by attention in capsaicin - induced secondary hyperalgesia .	O O O O O O O O B O O O O O O O O O O O B O	['pain', 'hyperalgesia']	2	6	"Sentence: However , it is not known that how pain intensity ratings are affected by attention in capsaicin - induced secondary hyperalgesia .
Diseases: pain, hyperalgesia"	"Sentence: However , it is not known that how pain intensity ratings are affected by attention in capsaicin - induced secondary hyperalgesia .
Diseases:"
3980	Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task .	O O O O O B O O O B O O O O O O O O O O O O O O O O O	['pain', 'hyperalgesia']	2	6	"Sentence: Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task .
Diseases: pain, hyperalgesia"	"Sentence: Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task .
Diseases:"
3981	Furthermore , it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin - untreated , control condition .	O O O O O O O O O O O O O B O O O O O O O O O O O O O	['hyperalgesia']	1	4	"Sentence: Furthermore , it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin - untreated , control condition .
Diseases: hyperalgesia"	"Sentence: Furthermore , it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin - untreated , control condition .
Diseases:"
3982	Our findings , showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms .	O O O O O O O O O O O O O O O O O O B O O O O O B O O O O	['pain', 'hyperalgesia']	2	6	"Sentence: Our findings , showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms .
Diseases: pain, hyperalgesia"	"Sentence: Our findings , showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms .
Diseases:"
3983	Testosterone - dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt - sensitive rats .	O O O B O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: Testosterone - dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt - sensitive rats .
Diseases: hypertension"	"Sentence: Testosterone - dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt - sensitive rats .
Diseases:"
3984	Blood pressure ( BP ) is more salt sensitive in men than in premenopausal women .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Blood pressure ( BP ) is more salt sensitive in men than in premenopausal women .
Diseases: "	"Sentence: Blood pressure ( BP ) is more salt sensitive in men than in premenopausal women .
Diseases:"
3985	In Dahl salt - sensitive rats ( DS ) , high - salt ( HS ) diet increases BP more in males than females .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In Dahl salt - sensitive rats ( DS ) , high - salt ( HS ) diet increases BP more in males than females .
Diseases: "	"Sentence: In Dahl salt - sensitive rats ( DS ) , high - salt ( HS ) diet increases BP more in males than females .
Diseases:"
3986	In contrast to the systemic renin - angiotensin system , which is suppressed in response to HS in male DS , intrarenal angiotensinogen expression is increased , and intrarenal levels of ANG II are not suppressed .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast to the systemic renin - angiotensin system , which is suppressed in response to HS in male DS , intrarenal angiotensinogen expression is increased , and intrarenal levels of ANG II are not suppressed .
Diseases: "	"Sentence: In contrast to the systemic renin - angiotensin system , which is suppressed in response to HS in male DS , intrarenal angiotensinogen expression is increased , and intrarenal levels of ANG II are not suppressed .
Diseases:"
3987	In this study , the hypothesis was tested that there is a sexual dimorphism in HS - induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['renal injury']	1	3	"Sentence: In this study , the hypothesis was tested that there is a sexual dimorphism in HS - induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury .
Diseases: renal injury"	"Sentence: In this study , the hypothesis was tested that there is a sexual dimorphism in HS - induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury .
Diseases:"
3988	On a low - salt ( LS ) diet , male DS had higher levels of intrarenal angiotensinogen mRNA than females .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On a low - salt ( LS ) diet , male DS had higher levels of intrarenal angiotensinogen mRNA than females .
Diseases: "	"Sentence: On a low - salt ( LS ) diet , male DS had higher levels of intrarenal angiotensinogen mRNA than females .
Diseases:"
3989	HS diet for 4 wk increased renal cortical angiotensinogen mRNA and protein only in male DS , which was prevented by castration .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: HS diet for 4 wk increased renal cortical angiotensinogen mRNA and protein only in male DS , which was prevented by castration .
Diseases: "	"Sentence: HS diet for 4 wk increased renal cortical angiotensinogen mRNA and protein only in male DS , which was prevented by castration .
Diseases:"
3990	Ovariectomy of female DS had no effect on intrarenal angiotensinogen expression on either diet .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ovariectomy of female DS had no effect on intrarenal angiotensinogen expression on either diet .
Diseases: "	"Sentence: Ovariectomy of female DS had no effect on intrarenal angiotensinogen expression on either diet .
Diseases:"
3991	Radiotelemetric BP was similar between males and castrated rats on LS diet .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Radiotelemetric BP was similar between males and castrated rats on LS diet .
Diseases: "	"Sentence: Radiotelemetric BP was similar between males and castrated rats on LS diet .
Diseases:"
3992	HS diet for 4 wk caused a progressive increase in BP , protein and albumin excretion , and glomerular sclerosis in male DS rats , which were attenuated by castration .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	['glomerular sclerosis']	1	3	"Sentence: HS diet for 4 wk caused a progressive increase in BP , protein and albumin excretion , and glomerular sclerosis in male DS rats , which were attenuated by castration .
Diseases: glomerular sclerosis"	"Sentence: HS diet for 4 wk caused a progressive increase in BP , protein and albumin excretion , and glomerular sclerosis in male DS rats , which were attenuated by castration .
Diseases:"
3993	Testosterone replacement in castrated DS rats increased BP , renal injury , and upregulation of renal angiotensinogen associated with HS diet .	O O O O O O O O O B I O O O O O O O O O O O	['renal injury']	1	3	"Sentence: Testosterone replacement in castrated DS rats increased BP , renal injury , and upregulation of renal angiotensinogen associated with HS diet .
Diseases: renal injury"	"Sentence: Testosterone replacement in castrated DS rats increased BP , renal injury , and upregulation of renal angiotensinogen associated with HS diet .
Diseases:"
3994	Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin - angiotensin system .	O O O O O O B O B I O O O O O O O O O O O O O O O O O O	['renal injury', 'hypertension']	2	5	"Sentence: Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin - angiotensin system .
Diseases: renal injury, hypertension"	"Sentence: Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin - angiotensin system .
Diseases:"
3995	Prenatal protein deprivation alters dopamine - mediated behaviors and dopaminergic and glutamatergic receptor binding .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Prenatal protein deprivation alters dopamine - mediated behaviors and dopaminergic and glutamatergic receptor binding .
Diseases: "	"Sentence: Prenatal protein deprivation alters dopamine - mediated behaviors and dopaminergic and glutamatergic receptor binding .
Diseases:"
3996	Epidemiological evidence indicates that prenatal nutritional deprivation may increase the risk of schizophrenia .	O O O O O O O O O O O O B O	['schizophrenia']	1	3	"Sentence: Epidemiological evidence indicates that prenatal nutritional deprivation may increase the risk of schizophrenia .
Diseases: schizophrenia"	"Sentence: Epidemiological evidence indicates that prenatal nutritional deprivation may increase the risk of schizophrenia .
Diseases:"
3997	The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['schizophrenia']	1	3	"Sentence: The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia .
Diseases: schizophrenia"	"Sentence: The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia .
Diseases:"
3998	We report that prenatally protein deprived ( PD ) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We report that prenatally protein deprived ( PD ) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood .
Diseases: "	"Sentence: We report that prenatally protein deprived ( PD ) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood .
Diseases:"
3999	These differences were not observed during puberty .	O O O O O O O O	[]	0	0	"Sentence: These differences were not observed during puberty .
Diseases: "	"Sentence: These differences were not observed during puberty .
Diseases:"
4000	No changes in haloperidol - induced catalepsy or MK - 801 - induced locomotion were seen following PD .	O O O O O O B O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: No changes in haloperidol - induced catalepsy or MK - 801 - induced locomotion were seen following PD .
Diseases: catalepsy"	"Sentence: No changes in haloperidol - induced catalepsy or MK - 801 - induced locomotion were seen following PD .
Diseases:"
4001	In addition , PD female rats showed increased ( 3 ) H - MK - 801 binding in the striatum and hippocampus , but not in the cortex .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , PD female rats showed increased ( 3 ) H - MK - 801 binding in the striatum and hippocampus , but not in the cortex .
Diseases: "	"Sentence: In addition , PD female rats showed increased ( 3 ) H - MK - 801 binding in the striatum and hippocampus , but not in the cortex .
Diseases:"
4002	PD female rats also showed increased ( 3 ) H - haloperidol binding and decreased dopamine transporter binding in striatum .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PD female rats also showed increased ( 3 ) H - haloperidol binding and decreased dopamine transporter binding in striatum .
Diseases: "	"Sentence: PD female rats also showed increased ( 3 ) H - haloperidol binding and decreased dopamine transporter binding in striatum .
Diseases:"
4003	No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased ( 3 ) H - MK - 801 binding in cortex .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased ( 3 ) H - MK - 801 binding in cortex .
Diseases: "	"Sentence: No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased ( 3 ) H - MK - 801 binding in cortex .
Diseases:"
4004	This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse .	O O O O O O O O O O O O O B I O O O B O O O O O O O O O O O O O O O O O O O	['schizophrenia', 'nutritional deficiency']	2	6	"Sentence: This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse .
Diseases: schizophrenia, nutritional deficiency"	"Sentence: This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse .
Diseases:"
4005	mToR inhibitors - induced proteinuria : mechanisms , significance , and management .	O O O O B O O O O O O O O	['proteinuria']	1	2	"Sentence: mToR inhibitors - induced proteinuria : mechanisms , significance , and management .
Diseases: proteinuria"	"Sentence: mToR inhibitors - induced proteinuria : mechanisms , significance , and management .
Diseases:"
4006	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin ( mToR ) inhibitors , especially sirolimus , in renal transplant recipients with chronic allograft nephropathy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	['chronic allograft nephropathy']	1	9	"Sentence: Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin ( mToR ) inhibitors , especially sirolimus , in renal transplant recipients with chronic allograft nephropathy .
Diseases: chronic allograft nephropathy"	"Sentence: Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin ( mToR ) inhibitors , especially sirolimus , in renal transplant recipients with chronic allograft nephropathy .
Diseases:"
4007	Because proteinuria is a major predictive factor of poor transplantation outcome , many studies focused on this adverse event during the past years .	O B O O O O O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Because proteinuria is a major predictive factor of poor transplantation outcome , many studies focused on this adverse event during the past years .
Diseases: proteinuria"	"Sentence: Because proteinuria is a major predictive factor of poor transplantation outcome , many studies focused on this adverse event during the past years .
Diseases:"
4008	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo .	O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo .
Diseases: proteinuria"	"Sentence: Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo .
Diseases:"
4009	Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients , but the pathways underlying these lesions remain hypothetic .	O O O O O B O O O O O O O O O O O O O O O O O O O	['glomerulosclerosis']	1	4	"Sentence: Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients , but the pathways underlying these lesions remain hypothetic .
Diseases: glomerulosclerosis"	"Sentence: Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients , but the pathways underlying these lesions remain hypothetic .
Diseases:"
4010	We discuss herein the possible mechanisms and the significance of mToR blockade - induced proteinuria .	O O O O O O O O O O O O O O B O	['proteinuria']	1	2	"Sentence: We discuss herein the possible mechanisms and the significance of mToR blockade - induced proteinuria .
Diseases: proteinuria"	"Sentence: We discuss herein the possible mechanisms and the significance of mToR blockade - induced proteinuria .
Diseases:"
4011	Hypothalamic prolactin receptor messenger ribonucleic acid levels , prolactin signaling , and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol .	O O O O O O O O O O O O B O O O O O O O O O O O	['hyperprolactinemic']	1	6	"Sentence: Hypothalamic prolactin receptor messenger ribonucleic acid levels , prolactin signaling , and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol .
Diseases: hyperprolactinemic"	"Sentence: Hypothalamic prolactin receptor messenger ribonucleic acid levels , prolactin signaling , and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol .
Diseases:"
4012	Hyperprolactinemia can reduce fertility and libido .	B O O O O O O	['hyperprolactinemia']	1	6	"Sentence: Hyperprolactinemia can reduce fertility and libido .
Diseases: hyperprolactinemia"	"Sentence: Hyperprolactinemia can reduce fertility and libido .
Diseases:"
4013	Although central prolactin actions are thought to contribute to this , the mechanisms are poorly understood .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although central prolactin actions are thought to contribute to this , the mechanisms are poorly understood .
Diseases: "	"Sentence: Although central prolactin actions are thought to contribute to this , the mechanisms are poorly understood .
Diseases:"
4014	We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility : pulsatile LH secretion and the estrogen - induced LH surge .	O O O O O B O O O O O O O O O O O O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility : pulsatile LH secretion and the estrogen - induced LH surge .
Diseases: hyperprolactinemia"	"Sentence: We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility : pulsatile LH secretion and the estrogen - induced LH surge .
Diseases:"
4015	Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .
Diseases: hyperprolactinemia"	"Sentence: Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .
Diseases:"
4016	Sulpiride did not affect the magnitude of a steroid - induced LH surge or the percentage of GnRH neurons activated during the surge .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sulpiride did not affect the magnitude of a steroid - induced LH surge or the percentage of GnRH neurons activated during the surge .
Diseases: "	"Sentence: Sulpiride did not affect the magnitude of a steroid - induced LH surge or the percentage of GnRH neurons activated during the surge .
Diseases:"
4017	Estradiol is known to influence expression of the long form of prolactin receptors ( PRL - R ) and components of prolactin 's signaling pathway .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Estradiol is known to influence expression of the long form of prolactin receptors ( PRL - R ) and components of prolactin 's signaling pathway .
Diseases: "	"Sentence: Estradiol is known to influence expression of the long form of prolactin receptors ( PRL - R ) and components of prolactin 's signaling pathway .
Diseases:"
4018	To test the hypothesis that estrogen increases PRL - R expression and sensitivity to prolactin , we next demonstrated that estradiol greatly augments prolactin - induced STAT5 activation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To test the hypothesis that estrogen increases PRL - R expression and sensitivity to prolactin , we next demonstrated that estradiol greatly augments prolactin - induced STAT5 activation .
Diseases: "	"Sentence: To test the hypothesis that estrogen increases PRL - R expression and sensitivity to prolactin , we next demonstrated that estradiol greatly augments prolactin - induced STAT5 activation .
Diseases:"
4019	Lastly , we measured PRL - R and suppressor of cytokine signaling ( SOCS - 1 and - 3 and CIS , which reflect the level of prolactin signaling ) mRNAs in response to sulpiride and estradiol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Lastly , we measured PRL - R and suppressor of cytokine signaling ( SOCS - 1 and - 3 and CIS , which reflect the level of prolactin signaling ) mRNAs in response to sulpiride and estradiol .
Diseases: "	"Sentence: Lastly , we measured PRL - R and suppressor of cytokine signaling ( SOCS - 1 and - 3 and CIS , which reflect the level of prolactin signaling ) mRNAs in response to sulpiride and estradiol .
Diseases:"
4020	Sulpiride induced only SOCS - 1 in the medial preoptic area , where GnRH neurons are regulated , but in the arcuate nucleus and choroid plexus , PRL - R , SOCS - 3 , and CIS mRNA levels were also induced .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sulpiride induced only SOCS - 1 in the medial preoptic area , where GnRH neurons are regulated , but in the arcuate nucleus and choroid plexus , PRL - R , SOCS - 3 , and CIS mRNA levels were also induced .
Diseases: "	"Sentence: Sulpiride induced only SOCS - 1 in the medial preoptic area , where GnRH neurons are regulated , but in the arcuate nucleus and choroid plexus , PRL - R , SOCS - 3 , and CIS mRNA levels were also induced .
Diseases:"
4021	Estradiol enhanced these effects on SOCS - 3 and CIS .	O O O O O O O O O O O	[]	0	0	"Sentence: Estradiol enhanced these effects on SOCS - 3 and CIS .
Diseases: "	"Sentence: Estradiol enhanced these effects on SOCS - 3 and CIS .
Diseases:"
4022	Interestingly , estradiol also induced PRL - R , SOCS - 3 , and CIS mRNA levels independently .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Interestingly , estradiol also induced PRL - R , SOCS - 3 , and CIS mRNA levels independently .
Diseases: "	"Sentence: Interestingly , estradiol also induced PRL - R , SOCS - 3 , and CIS mRNA levels independently .
Diseases:"
4023	These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid - dependent manner .	O O O O O O O O O O O B O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid - dependent manner .
Diseases: hyperprolactinemia"	"Sentence: These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid - dependent manner .
Diseases:"
4024	They also provide evidence for estradiol - dependent and brain region - specific regulation of PRL - R expression and signaling responses by prolactin .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: They also provide evidence for estradiol - dependent and brain region - specific regulation of PRL - R expression and signaling responses by prolactin .
Diseases: "	"Sentence: They also provide evidence for estradiol - dependent and brain region - specific regulation of PRL - R expression and signaling responses by prolactin .
Diseases:"
4025	Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir .
Diseases: "	"Sentence: Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir .
Diseases:"
4026	Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir .
Diseases: "	"Sentence: Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir .
Diseases:"
4027	Many patients , however , develop negative long - term side effects such as premature atherosclerosis .	O O O O O O O O O O O O O O B I O	['premature atherosclerosis']	1	5	"Sentence: Many patients , however , develop negative long - term side effects such as premature atherosclerosis .
Diseases: premature atherosclerosis"	"Sentence: Many patients , however , develop negative long - term side effects such as premature atherosclerosis .
Diseases:"
4028	We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice .	O O O O O O O O B I O O O O O O O O O O O O O	['atherosclerotic lesion']	1	6	"Sentence: We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice .
Diseases: atherosclerotic lesion"	"Sentence: We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice .
Diseases:"
4029	Furthermore , peripheral blood monocytes isolated from ritonavir - treated females had less cholesteryl ester accumulation .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Furthermore , peripheral blood monocytes isolated from ritonavir - treated females had less cholesteryl ester accumulation .
Diseases: "	"Sentence: Furthermore , peripheral blood monocytes isolated from ritonavir - treated females had less cholesteryl ester accumulation .
Diseases:"
4030	In the present study , we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the present study , we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir .
Diseases: "	"Sentence: In the present study , we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir .
Diseases:"
4031	We have utilized the human monocyte cell line , THP - 1 as a model to address this question .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We have utilized the human monocyte cell line , THP - 1 as a model to address this question .
Diseases: "	"Sentence: We have utilized the human monocyte cell line , THP - 1 as a model to address this question .
Diseases:"
4032	Briefly , cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage - like phenotype in the presence or absence of 1 nM 17beta - estradiol ( E2 ) , 100 nM progesterone or vehicle ( 0 . 01 % ethanol ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Briefly , cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage - like phenotype in the presence or absence of 1 nM 17beta - estradiol ( E2 ) , 100 nM progesterone or vehicle ( 0 . 01 % ethanol ) .
Diseases: "	"Sentence: Briefly , cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage - like phenotype in the presence or absence of 1 nM 17beta - estradiol ( E2 ) , 100 nM progesterone or vehicle ( 0 . 01 % ethanol ) .
Diseases:"
4033	Cells were then treated with 30 ng / ml ritonavir or vehicle in the presence of aggregated LDL for 24 h . Cell extracts were harvested , and lipid or total RNA was isolated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cells were then treated with 30 ng / ml ritonavir or vehicle in the presence of aggregated LDL for 24 h . Cell extracts were harvested , and lipid or total RNA was isolated .
Diseases: "	"Sentence: Cells were then treated with 30 ng / ml ritonavir or vehicle in the presence of aggregated LDL for 24 h . Cell extracts were harvested , and lipid or total RNA was isolated .
Diseases:"
4034	E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment .	O O O O O O O O O O O O O	[]	0	0	"Sentence: E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment .
Diseases: "	"Sentence: E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment .
Diseases:"
4035	Ritonavir increased the expression of the scavenger receptor , CD36 mRNA , responsible for the uptake of LDL .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ritonavir increased the expression of the scavenger receptor , CD36 mRNA , responsible for the uptake of LDL .
Diseases: "	"Sentence: Ritonavir increased the expression of the scavenger receptor , CD36 mRNA , responsible for the uptake of LDL .
Diseases:"
4036	Additionally , ritonavir treatment selectively increased the relative levels of PPARgamma mRNA , a transcription factor responsible for the regulation of CD36 mRNA expression .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Additionally , ritonavir treatment selectively increased the relative levels of PPARgamma mRNA , a transcription factor responsible for the regulation of CD36 mRNA expression .
Diseases: "	"Sentence: Additionally , ritonavir treatment selectively increased the relative levels of PPARgamma mRNA , a transcription factor responsible for the regulation of CD36 mRNA expression .
Diseases:"
4037	Treatment with E2 , however , failed to prevent these increases at the mRNA level .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Treatment with E2 , however , failed to prevent these increases at the mRNA level .
Diseases: "	"Sentence: Treatment with E2 , however , failed to prevent these increases at the mRNA level .
Diseases:"
4038	E2 did , however , significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: E2 did , however , significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry .
Diseases: "	"Sentence: E2 did , however , significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry .
Diseases:"
4039	This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte - derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte - derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment .
Diseases: "	"Sentence: This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte - derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment .
Diseases:"
4040	Upregulation of brain expression of P - glycoprotein in MRP2 - deficient TR ( - ) rats resembles seizure - induced up - regulation of this drug efflux transporter in normal rats .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: Upregulation of brain expression of P - glycoprotein in MRP2 - deficient TR ( - ) rats resembles seizure - induced up - regulation of this drug efflux transporter in normal rats .
Diseases: seizure"	"Sentence: Upregulation of brain expression of P - glycoprotein in MRP2 - deficient TR ( - ) rats resembles seizure - induced up - regulation of this drug efflux transporter in normal rats .
Diseases:"
4041	The multidrug resistance protein 2 ( MRP2 ) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood - brain barrier ( BBB ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The multidrug resistance protein 2 ( MRP2 ) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood - brain barrier ( BBB ) .
Diseases: "	"Sentence: The multidrug resistance protein 2 ( MRP2 ) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood - brain barrier ( BBB ) .
Diseases:"
4042	MRP2 is absent in the transport - deficient ( TR ( - ) )	O O O O O O O O O O O O O O	[]	0	0	"Sentence: MRP2 is absent in the transport - deficient ( TR ( - ) )
Diseases: "	"Sentence: MRP2 is absent in the transport - deficient ( TR ( - ) )
Diseases:"
4043	Wistar rat mutant , so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2 - deficient rats with those in transport - competent Wistar rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Wistar rat mutant , so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2 - deficient rats with those in transport - competent Wistar rats .
Diseases: "	"Sentence: Wistar rat mutant , so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2 - deficient rats with those in transport - competent Wistar rats .
Diseases:"
4044	By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs ( AEDs ) , we recently reported that phenytoin is a substrate for MRP2 in the BBB .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs ( AEDs ) , we recently reported that phenytoin is a substrate for MRP2 in the BBB .
Diseases: "	"Sentence: By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs ( AEDs ) , we recently reported that phenytoin is a substrate for MRP2 in the BBB .
Diseases:"
4045	However , one drawback of such studies in genetically deficient rats is the fact that compensatory changes with upregulation of other transporters can occur .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , one drawback of such studies in genetically deficient rats is the fact that compensatory changes with upregulation of other transporters can occur .
Diseases: "	"Sentence: However , one drawback of such studies in genetically deficient rats is the fact that compensatory changes with upregulation of other transporters can occur .
Diseases:"
4046	This prompted us to study the brain expression of P - glycoprotein ( Pgp ) , a major drug efflux transporter in many tissues , including the BBB , in TR ( - ) rats compared with nonmutant ( wild - type ) Wistar rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This prompted us to study the brain expression of P - glycoprotein ( Pgp ) , a major drug efflux transporter in many tissues , including the BBB , in TR ( - ) rats compared with nonmutant ( wild - type ) Wistar rats .
Diseases: "	"Sentence: This prompted us to study the brain expression of P - glycoprotein ( Pgp ) , a major drug efflux transporter in many tissues , including the BBB , in TR ( - ) rats compared with nonmutant ( wild - type ) Wistar rats .
Diseases:"
4047	The expression of MRP2 and Pgp in brain and liver sections of TR ( - ) rats and normal Wistar rats was determined with immunohistochemistry , by using a novel , highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219 , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The expression of MRP2 and Pgp in brain and liver sections of TR ( - ) rats and normal Wistar rats was determined with immunohistochemistry , by using a novel , highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219 , respectively .
Diseases: "	"Sentence: The expression of MRP2 and Pgp in brain and liver sections of TR ( - ) rats and normal Wistar rats was determined with immunohistochemistry , by using a novel , highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219 , respectively .
Diseases:"
4048	Immunofluorescence staining with the MRP2 antibody was found to label a high number of microvessels throughout the brain in normal Wistar rats , whereas such labeling was absent in TR ( - ) rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunofluorescence staining with the MRP2 antibody was found to label a high number of microvessels throughout the brain in normal Wistar rats , whereas such labeling was absent in TR ( - ) rats .
Diseases: "	"Sentence: Immunofluorescence staining with the MRP2 antibody was found to label a high number of microvessels throughout the brain in normal Wistar rats , whereas such labeling was absent in TR ( - ) rats .
Diseases:"
4049	TR ( - ) rats exhibited a significant up - regulation of Pgp in brain capillary endothelial cells compared with wild - type controls .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: TR ( - ) rats exhibited a significant up - regulation of Pgp in brain capillary endothelial cells compared with wild - type controls .
Diseases: "	"Sentence: TR ( - ) rats exhibited a significant up - regulation of Pgp in brain capillary endothelial cells compared with wild - type controls .
Diseases:"
4050	No such obvious upregulation of Pgp was observed in liver sections .	O O O O O O O O O O O O	[]	0	0	"Sentence: No such obvious upregulation of Pgp was observed in liver sections .
Diseases: "	"Sentence: No such obvious upregulation of Pgp was observed in liver sections .
Diseases:"
4051	A comparable overexpression of Pgp in the BBB was obtained after pilocarpine - induced seizures in wild - type Wistar rats .	O O O O O O O O O O O O O O B O O O O O O O	['seizures']	1	3	"Sentence: A comparable overexpression of Pgp in the BBB was obtained after pilocarpine - induced seizures in wild - type Wistar rats .
Diseases: seizures"	"Sentence: A comparable overexpression of Pgp in the BBB was obtained after pilocarpine - induced seizures in wild - type Wistar rats .
Diseases:"
4052	Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR ( - ) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR ( - ) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB .
Diseases: "	"Sentence: Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR ( - ) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB .
Diseases:"
4053	CONCLUSIONS : The data on TR ( - ) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : The data on TR ( - ) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB .
Diseases: "	"Sentence: CONCLUSIONS : The data on TR ( - ) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB .
Diseases:"
4054	Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds , the present data substantiate the concept that MRP2 performs a protective role in the BBB .	O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O	['injury to the brain']	1	5	"Sentence: Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds , the present data substantiate the concept that MRP2 performs a protective role in the BBB .
Diseases: injury to the brain"	"Sentence: Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds , the present data substantiate the concept that MRP2 performs a protective role in the BBB .
Diseases:"
4055	Furthermore , our data suggest that TR ( - ) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain , without the need of inducing seizures or other Pgp - enhancing events for this purpose .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['seizures']	1	3	"Sentence: Furthermore , our data suggest that TR ( - ) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain , without the need of inducing seizures or other Pgp - enhancing events for this purpose .
Diseases: seizures"	"Sentence: Furthermore , our data suggest that TR ( - ) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain , without the need of inducing seizures or other Pgp - enhancing events for this purpose .
Diseases:"
4056	Use of chromosome substitution strains to identify seizure susceptibility loci in mice .	O O O O O O O B O O O O O	['seizure']	1	3	"Sentence: Use of chromosome substitution strains to identify seizure susceptibility loci in mice .
Diseases: seizure"	"Sentence: Use of chromosome substitution strains to identify seizure susceptibility loci in mice .
Diseases:"
4057	Seizure susceptibility varies among inbred mouse strains .	B O O O O O O O	['seizure']	1	3	"Sentence: Seizure susceptibility varies among inbred mouse strains .
Diseases: seizure"	"Sentence: Seizure susceptibility varies among inbred mouse strains .
Diseases:"
4058	Chromosome substitution strains ( CSS ) , in which a single chromosome from one inbred strain ( donor ) has been transferred onto a second strain ( host ) by repeated backcrossing , may be used to identify quantitative trait loci ( QTLs ) that contribute to seizure susceptibility .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['seizure']	1	3	"Sentence: Chromosome substitution strains ( CSS ) , in which a single chromosome from one inbred strain ( donor ) has been transferred onto a second strain ( host ) by repeated backcrossing , may be used to identify quantitative trait loci ( QTLs ) that contribute to seizure susceptibility .
Diseases: seizure"	"Sentence: Chromosome substitution strains ( CSS ) , in which a single chromosome from one inbred strain ( donor ) has been transferred onto a second strain ( host ) by repeated backcrossing , may be used to identify quantitative trait loci ( QTLs ) that contribute to seizure susceptibility .
Diseases:"
4059	QTLs for susceptibility to pilocarpine - induced seizures , a model of temporal lobe epilepsy , have not been reported , and CSS have not previously been used to localize seizure susceptibility genes .	O O O O O O O B O O O O B I I O O O O O O O O O O O O O O O B O O O	['temporal lobe epilepsy', 'seizures', 'seizure']	3	8	"Sentence: QTLs for susceptibility to pilocarpine - induced seizures , a model of temporal lobe epilepsy , have not been reported , and CSS have not previously been used to localize seizure susceptibility genes .
Diseases: temporal lobe epilepsy, seizures, seizure"	"Sentence: QTLs for susceptibility to pilocarpine - induced seizures , a model of temporal lobe epilepsy , have not been reported , and CSS have not previously been used to localize seizure susceptibility genes .
Diseases:"
4060	We report QTLs identified using a B6 ( host ) x A / J ( donor ) CSS panel to localize genes involved in susceptibility to pilocarpine - induced seizures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: We report QTLs identified using a B6 ( host ) x A / J ( donor ) CSS panel to localize genes involved in susceptibility to pilocarpine - induced seizures .
Diseases: seizures"	"Sentence: We report QTLs identified using a B6 ( host ) x A / J ( donor ) CSS panel to localize genes involved in susceptibility to pilocarpine - induced seizures .
Diseases:"
4061	Three hundred fifty - five adult male CSS mice , 58 B6 , and 39 A / J were tested for susceptibility to pilocarpine - induced seizures .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: Three hundred fifty - five adult male CSS mice , 58 B6 , and 39 A / J were tested for susceptibility to pilocarpine - induced seizures .
Diseases: seizures"	"Sentence: Three hundred fifty - five adult male CSS mice , 58 B6 , and 39 A / J were tested for susceptibility to pilocarpine - induced seizures .
Diseases:"
4062	Highest stage reached and latency to each stage were recorded for all mice .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Highest stage reached and latency to each stage were recorded for all mice .
Diseases: "	"Sentence: Highest stage reached and latency to each stage were recorded for all mice .
Diseases:"
4063	B6 mice were resistant to seizures and slower to reach stages compared to A / J mice .	O O O O O B O O O O O O O O O O O O	['seizures']	1	3	"Sentence: B6 mice were resistant to seizures and slower to reach stages compared to A / J mice .
Diseases: seizures"	"Sentence: B6 mice were resistant to seizures and slower to reach stages compared to A / J mice .
Diseases:"
4064	The CSS for Chromosomes 10 and 18 progressed to the most severe stages , diverging dramatically from the B6 phenotype .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The CSS for Chromosomes 10 and 18 progressed to the most severe stages , diverging dramatically from the B6 phenotype .
Diseases: "	"Sentence: The CSS for Chromosomes 10 and 18 progressed to the most severe stages , diverging dramatically from the B6 phenotype .
Diseases:"
4065	Latencies to stages were also significantly shorter for CSS10 and CSS18 mice .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Latencies to stages were also significantly shorter for CSS10 and CSS18 mice .
Diseases: "	"Sentence: Latencies to stages were also significantly shorter for CSS10 and CSS18 mice .
Diseases:"
4066	CSS mapping suggests seizure susceptibility loci on mouse Chromosomes 10 and 18 .	O O O B O O O O O O O O O	['seizure']	1	3	"Sentence: CSS mapping suggests seizure susceptibility loci on mouse Chromosomes 10 and 18 .
Diseases: seizure"	"Sentence: CSS mapping suggests seizure susceptibility loci on mouse Chromosomes 10 and 18 .
Diseases:"
4067	This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy .	O O O O O O O O O O O O O O B I I O	['temporal lobe epilepsy']	1	4	"Sentence: This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy .
Diseases: temporal lobe epilepsy"	"Sentence: This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy .
Diseases:"
4068	Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine .	O O O O O O O O O B O O O O	['epilepsy']	1	3	"Sentence: Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine .
Diseases: epilepsy"	"Sentence: Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine .
Diseases:"
4069	Mitochondrial abnormalities have been associated with several aspects of epileptogenesis , such as energy generation , control of cell death , neurotransmitter synthesis , and free radical ( FR ) production .	B I O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['mitochondrial abnormalities', 'death']	2	6	"Sentence: Mitochondrial abnormalities have been associated with several aspects of epileptogenesis , such as energy generation , control of cell death , neurotransmitter synthesis , and free radical ( FR ) production .
Diseases: mitochondrial abnormalities, death"	"Sentence: Mitochondrial abnormalities have been associated with several aspects of epileptogenesis , such as energy generation , control of cell death , neurotransmitter synthesis , and free radical ( FR ) production .
Diseases:"
4070	Increased production of FRs may cause mtDNA damage leading to decreased activities of oxidative phosphorylation complexes containing mtDNA - encoded subunits .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Increased production of FRs may cause mtDNA damage leading to decreased activities of oxidative phosphorylation complexes containing mtDNA - encoded subunits .
Diseases: "	"Sentence: Increased production of FRs may cause mtDNA damage leading to decreased activities of oxidative phosphorylation complexes containing mtDNA - encoded subunits .
Diseases:"
4071	In this study , we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome	O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O	['status epilepticus']	1	4	"Sentence: In this study , we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome
Diseases: status epilepticus"	"Sentence: In this study , we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome
Diseases:"
4072	c oxidase ( CCO ) , complex IV of the respiratory chain , in the chronic phase of the pilocarpine model of temporal lobe epilepsy .	O O O O O O O O O O O O O O O O O O O O O O B I I O	['temporal lobe epilepsy']	1	4	"Sentence: c oxidase ( CCO ) , complex IV of the respiratory chain , in the chronic phase of the pilocarpine model of temporal lobe epilepsy .
Diseases: temporal lobe epilepsy"	"Sentence: c oxidase ( CCO ) , complex IV of the respiratory chain , in the chronic phase of the pilocarpine model of temporal lobe epilepsy .
Diseases:"
4073	DNA analysis revealed low amounts of a 4 . 8 kb mtDNA deletion but with no differences in frequency or quantity in the control and experimental groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: DNA analysis revealed low amounts of a 4 . 8 kb mtDNA deletion but with no differences in frequency or quantity in the control and experimental groups .
Diseases: "	"Sentence: DNA analysis revealed low amounts of a 4 . 8 kb mtDNA deletion but with no differences in frequency or quantity in the control and experimental groups .
Diseases:"
4074	We did not find abnormalities in the expression and distribution of an mtDNA - encoded subunit of CCO ( CCO - I ) or a relative decrease in CCO - I when compared with nuclear - encoded subunits ( CCO - IV and SDH - fp ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We did not find abnormalities in the expression and distribution of an mtDNA - encoded subunit of CCO ( CCO - I ) or a relative decrease in CCO - I when compared with nuclear - encoded subunits ( CCO - IV and SDH - fp ) .
Diseases: "	"Sentence: We did not find abnormalities in the expression and distribution of an mtDNA - encoded subunit of CCO ( CCO - I ) or a relative decrease in CCO - I when compared with nuclear - encoded subunits ( CCO - IV and SDH - fp ) .
Diseases:"
4075	No abnormality in CCO activity was observed through histochemistry .	O O O O O O O O O O	[]	0	0	"Sentence: No abnormality in CCO activity was observed through histochemistry .
Diseases: "	"Sentence: No abnormality in CCO activity was observed through histochemistry .
Diseases:"
4076	Although evidences of mitochondrial abnormalities were found in previously published studies , our results do not suggest that the FRs , generated during the acute phase , determined important abnormalities in mtDNA , in expression of CCO - I , and in CCO activity .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['mitochondrial abnormalities']	1	4	"Sentence: Although evidences of mitochondrial abnormalities were found in previously published studies , our results do not suggest that the FRs , generated during the acute phase , determined important abnormalities in mtDNA , in expression of CCO - I , and in CCO activity .
Diseases: mitochondrial abnormalities"	"Sentence: Although evidences of mitochondrial abnormalities were found in previously published studies , our results do not suggest that the FRs , generated during the acute phase , determined important abnormalities in mtDNA , in expression of CCO - I , and in CCO activity .
Diseases:"
4077	Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation .	O O O B I O O O O O O	['thrombotic microangiopathy']	1	8	"Sentence: Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation .
Diseases: thrombotic microangiopathy"	"Sentence: Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation .
Diseases:"
4078	Thrombotic microangiopathy is a well - known problem in patients following renal transplantation .	B I O O O O O O O O O O O O	['thrombotic microangiopathy']	1	8	"Sentence: Thrombotic microangiopathy is a well - known problem in patients following renal transplantation .
Diseases: thrombotic microangiopathy"	"Sentence: Thrombotic microangiopathy is a well - known problem in patients following renal transplantation .
Diseases:"
4079	In postrenal transplantation , thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome .	O O O O B I O O O O O B I I O	['hemolytic uremic syndrome', 'thrombotic microangiopathy']	2	16	"Sentence: In postrenal transplantation , thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome .
Diseases: hemolytic uremic syndrome, thrombotic microangiopathy"	"Sentence: In postrenal transplantation , thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome .
Diseases:"
4080	We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature .	O O O O O O O B I O O O O O O O O O O O O	['thrombotic microangiopathy']	1	8	"Sentence: We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature .
Diseases: thrombotic microangiopathy"	"Sentence: We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature .
Diseases:"
4081	MATERIALS AND METHODS : We investigated the causes of thrombotic microangiopathy during a 1 - year period , from June 2003 to June 2004 , at the King Fahad National Guard Hospital in Riyadh , Saudi Arabia , by reviewing the slides of all transplant biopsies ( n = 25 ) performed during this interval .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['thrombotic microangiopathy']	1	8	"Sentence: MATERIALS AND METHODS : We investigated the causes of thrombotic microangiopathy during a 1 - year period , from June 2003 to June 2004 , at the King Fahad National Guard Hospital in Riyadh , Saudi Arabia , by reviewing the slides of all transplant biopsies ( n = 25 ) performed during this interval .
Diseases: thrombotic microangiopathy"	"Sentence: MATERIALS AND METHODS : We investigated the causes of thrombotic microangiopathy during a 1 - year period , from June 2003 to June 2004 , at the King Fahad National Guard Hospital in Riyadh , Saudi Arabia , by reviewing the slides of all transplant biopsies ( n = 25 ) performed during this interval .
Diseases:"
4082	Pre - and posttransplant crossmatching was done when possible .	O O O O O O O O O O	[]	0	0	"Sentence: Pre - and posttransplant crossmatching was done when possible .
Diseases: "	"Sentence: Pre - and posttransplant crossmatching was done when possible .
Diseases:"
4083	Five cases of thrombotic microangiopathy were found .	O O O B I O O O	['thrombotic microangiopathy']	1	8	"Sentence: Five cases of thrombotic microangiopathy were found .
Diseases: thrombotic microangiopathy"	"Sentence: Five cases of thrombotic microangiopathy were found .
Diseases:"
4084	Three of these cases were from the 25 transplantations performed at King Fahad National Guard Hospital , while the other 2 transplantations had been performed abroad and were referred to us for follow - up .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Three of these cases were from the 25 transplantations performed at King Fahad National Guard Hospital , while the other 2 transplantations had been performed abroad and were referred to us for follow - up .
Diseases: "	"Sentence: Three of these cases were from the 25 transplantations performed at King Fahad National Guard Hospital , while the other 2 transplantations had been performed abroad and were referred to us for follow - up .
Diseases:"
4085	Three cases were related to cyclosporine , and 1 case was secondary to both cyclosporine and tacrolimus .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Three cases were related to cyclosporine , and 1 case was secondary to both cyclosporine and tacrolimus .
Diseases: "	"Sentence: Three cases were related to cyclosporine , and 1 case was secondary to both cyclosporine and tacrolimus .
Diseases:"
4086	The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus .	O O O O O O B I O O O B I O O O O B I I O	['antiphospholipid syndrome', 'systemic lupus erythematosus', 'thrombotic microangiopathy']	3	27	"Sentence: The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus .
Diseases: antiphospholipid syndrome, systemic lupus erythematosus, thrombotic microangiopathy"	"Sentence: The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus .
Diseases:"
4087	In the literature , the most - frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome .	O O O O O O O O O O B I I O O O O O O O O O B I I O	['hemolytic uremic syndrome']	1	7	"Sentence: In the literature , the most - frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome .
Diseases: hemolytic uremic syndrome"	"Sentence: In the literature , the most - frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome .
Diseases:"
4088	Other causes include drug - related ( cyclosporine , tacrolimus ) toxicity , procoagulant status , and antibody - mediated rejection .	O O O O O O O O O O O B O O O O O O O O O O	['toxicity']	1	2	"Sentence: Other causes include drug - related ( cyclosporine , tacrolimus ) toxicity , procoagulant status , and antibody - mediated rejection .
Diseases: toxicity"	"Sentence: Other causes include drug - related ( cyclosporine , tacrolimus ) toxicity , procoagulant status , and antibody - mediated rejection .
Diseases:"
4089	We found that the most - frequent cause of thrombotic microangiopathy was drug related , secondary mainly to cyclosporine .	O O O O O O O O O B I O O O O O O O O O	['thrombotic microangiopathy']	1	8	"Sentence: We found that the most - frequent cause of thrombotic microangiopathy was drug related , secondary mainly to cyclosporine .
Diseases: thrombotic microangiopathy"	"Sentence: We found that the most - frequent cause of thrombotic microangiopathy was drug related , secondary mainly to cyclosporine .
Diseases:"
4090	In the current study , the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature ( 20 % ) .	O O O O O O O O B I O O O O O O O O O O O O O O	['thrombotic microangiopathy']	1	8	"Sentence: In the current study , the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature ( 20 % ) .
Diseases: thrombotic microangiopathy"	"Sentence: In the current study , the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature ( 20 % ) .
Diseases:"
4091	Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose .	O O B I I I I I O O O O O B O	['left ventricular systolic and diastolic dysfunction', 'overdose']	2	13	"Sentence: Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose .
Diseases: left ventricular systolic and diastolic dysfunction, overdose"	"Sentence: Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose .
Diseases:"
4092	Catecholamine - induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon .	O O O B O O O O O O O O O O O O O O O O O	['cardiomyopathy']	1	4	"Sentence: Catecholamine - induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon .
Diseases: cardiomyopathy"	"Sentence: Catecholamine - induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon .
Diseases:"
4093	In contrast , reports of myocardial dysfunction due to acute iatrogenic overdose are rare .	O O O O O B I O O O O B O O O	['myocardial dysfunction', 'overdose']	2	6	"Sentence: In contrast , reports of myocardial dysfunction due to acute iatrogenic overdose are rare .
Diseases: myocardial dysfunction, overdose"	"Sentence: In contrast , reports of myocardial dysfunction due to acute iatrogenic overdose are rare .
Diseases:"
4094	A 35 - year - old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise , profound , albeit transient , left ventricular systolic and diastolic dysfunction , and only modestly elevated biochemical markers of myocardial necrosis .	O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O B I I I I I O O O O O O O O B I O	['left ventricular systolic and diastolic dysfunction', 'myocardial stunning', 'myocardial necrosis']	3	22	"Sentence: A 35 - year - old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise , profound , albeit transient , left ventricular systolic and diastolic dysfunction , and only modestly elevated biochemical markers of myocardial necrosis .
Diseases: left ventricular systolic and diastolic dysfunction, myocardial stunning, myocardial necrosis"	"Sentence: A 35 - year - old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise , profound , albeit transient , left ventricular systolic and diastolic dysfunction , and only modestly elevated biochemical markers of myocardial necrosis .
Diseases:"
4095	Our case illustrates the serious consequences of medical errors that can be avoided through improved medication labeling and staff supervision .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Our case illustrates the serious consequences of medical errors that can be avoided through improved medication labeling and staff supervision .
Diseases: "	"Sentence: Our case illustrates the serious consequences of medical errors that can be avoided through improved medication labeling and staff supervision .
Diseases:"
4096	Urinary bladder cancer in Wegener 's granulomatosis : risks and relation to cyclophosphamide .	B I I O B I I O O O O O O O	"[""wegener 's granulomatosis"", 'urinary bladder cancer']"	2	14	"Sentence: Urinary bladder cancer in Wegener 's granulomatosis : risks and relation to cyclophosphamide .
Diseases: wegener 's granulomatosis, urinary bladder cancer"	"Sentence: Urinary bladder cancer in Wegener 's granulomatosis : risks and relation to cyclophosphamide .
Diseases:"
4097	To assess and characterise the risk of bladder cancer , and its relation to cyclophosphamide , in patients with Wegener 's granulomatosis .	O O O O O O O B I O O O O O O O O O O B I I O	"['bladder cancer', ""wegener 's granulomatosis""]"	2	13	"Sentence: To assess and characterise the risk of bladder cancer , and its relation to cyclophosphamide , in patients with Wegener 's granulomatosis .
Diseases: bladder cancer, wegener 's granulomatosis"	"Sentence: To assess and characterise the risk of bladder cancer , and its relation to cyclophosphamide , in patients with Wegener 's granulomatosis .
Diseases:"
4098	In the population based , nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener 's granulomatosis , 1969 - 95 , was identified .	O O O O O O O O O O O O O O O B I I O O O O O O O O	"[""wegener 's granulomatosis""]"	1	9	"Sentence: In the population based , nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener 's granulomatosis , 1969 - 95 , was identified .
Diseases: wegener 's granulomatosis"	"Sentence: In the population based , nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener 's granulomatosis , 1969 - 95 , was identified .
Diseases:"
4099	Through linkage with the Swedish Cancer Register , all subjects in this cohort diagnosed with bladder cancer were identified .	O O O O O B O O O O O O O O O B I O O O	['bladder cancer', 'cancer']	2	5	"Sentence: Through linkage with the Swedish Cancer Register , all subjects in this cohort diagnosed with bladder cancer were identified .
Diseases: bladder cancer, cancer"	"Sentence: Through linkage with the Swedish Cancer Register , all subjects in this cohort diagnosed with bladder cancer were identified .
Diseases:"
4100	Nested within the cohort , a matched case - control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios ( ORs ) as relative risk .	O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O	['bladder cancer']	1	3	"Sentence: Nested within the cohort , a matched case - control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios ( ORs ) as relative risk .
Diseases: bladder cancer"	"Sentence: Nested within the cohort , a matched case - control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios ( ORs ) as relative risk .
Diseases:"
4101	In the cohort the cumulative risk of bladder cancer after Wegener 's granulomatosis , and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener 's granulomatosis , were also estimated .	O O O O O O O B I O B I I O O O O O O O O O B I O O O O O O B I I O O O O O	"['bladder cancer', ""wegener 's granulomatosis""]"	2	13	"Sentence: In the cohort the cumulative risk of bladder cancer after Wegener 's granulomatosis , and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener 's granulomatosis , were also estimated .
Diseases: bladder cancer, wegener 's granulomatosis"	"Sentence: In the cohort the cumulative risk of bladder cancer after Wegener 's granulomatosis , and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener 's granulomatosis , were also estimated .
Diseases:"
4102	The median cumulative doses of cyclophosphamide among cases ( n = 11 ) and controls ( n = 25 ) were 113 g and 25 g , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The median cumulative doses of cyclophosphamide among cases ( n = 11 ) and controls ( n = 25 ) were 113 g and 25 g , respectively .
Diseases: "	"Sentence: The median cumulative doses of cyclophosphamide among cases ( n = 11 ) and controls ( n = 25 ) were 113 g and 25 g , respectively .
Diseases:"
4103	The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide ( OR = 2 . 0 , 95 % confidence interval ( CI ) 0 . 8 to 4 . 9 ) .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bladder cancer']	1	3	"Sentence: The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide ( OR = 2 . 0 , 95 % confidence interval ( CI ) 0 . 8 to 4 . 9 ) .
Diseases: bladder cancer"	"Sentence: The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide ( OR = 2 . 0 , 95 % confidence interval ( CI ) 0 . 8 to 4 . 9 ) .
Diseases:"
4104	Treatment duration longer than 1 year was associated with an eightfold increased risk ( OR = 7 . 7 , 95 % CI 0 . 9 to 69 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Treatment duration longer than 1 year was associated with an eightfold increased risk ( OR = 7 . 7 , 95 % CI 0 . 9 to 69 ) .
Diseases: "	"Sentence: Treatment duration longer than 1 year was associated with an eightfold increased risk ( OR = 7 . 7 , 95 % CI 0 . 9 to 69 ) .
Diseases:"
4105	The absolute risk for bladder cancer in the cohort reached 10 % 16 years after diagnosis of Wegener 's granulomatosis , and a history of bladder cancer was ( non - significantly ) twice as common as expected at the time of diagnosis of Wegener 's granulomatosis .	O O O O B I O O O O O O O O O O O B I I O O O O O B I O O O O O O O O O O O O O O O O O B I I O	"['bladder cancer', ""wegener 's granulomatosis""]"	2	13	"Sentence: The absolute risk for bladder cancer in the cohort reached 10 % 16 years after diagnosis of Wegener 's granulomatosis , and a history of bladder cancer was ( non - significantly ) twice as common as expected at the time of diagnosis of Wegener 's granulomatosis .
Diseases: bladder cancer, wegener 's granulomatosis"	"Sentence: The absolute risk for bladder cancer in the cohort reached 10 % 16 years after diagnosis of Wegener 's granulomatosis , and a history of bladder cancer was ( non - significantly ) twice as common as expected at the time of diagnosis of Wegener 's granulomatosis .
Diseases:"
4106	The results indicate a dose - response relationship between cyclophosphamide and the risk of bladder cancer , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before Wegener 's granulomatosis .	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O B I I O	"['bladder cancer', ""wegener 's granulomatosis""]"	2	13	"Sentence: The results indicate a dose - response relationship between cyclophosphamide and the risk of bladder cancer , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before Wegener 's granulomatosis .
Diseases: bladder cancer, wegener 's granulomatosis"	"Sentence: The results indicate a dose - response relationship between cyclophosphamide and the risk of bladder cancer , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before Wegener 's granulomatosis .
Diseases:"
4107	L - arginine transport in humans with cortisol - induced hypertension .	O O O O O O O O O O B O	['hypertension']	1	3	"Sentence: L - arginine transport in humans with cortisol - induced hypertension .
Diseases: hypertension"	"Sentence: L - arginine transport in humans with cortisol - induced hypertension .
Diseases:"
4108	A deficient L - arginine - nitric oxide system is implicated in cortisol - induced hypertension .	O O O O O O O O O O O O O O O B O	['hypertension']	1	3	"Sentence: A deficient L - arginine - nitric oxide system is implicated in cortisol - induced hypertension .
Diseases: hypertension"	"Sentence: A deficient L - arginine - nitric oxide system is implicated in cortisol - induced hypertension .
Diseases:"
4109	We investigate whether abnormalities in L - arginine uptake contribute to this deficiency .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: We investigate whether abnormalities in L - arginine uptake contribute to this deficiency .
Diseases: "	"Sentence: We investigate whether abnormalities in L - arginine uptake contribute to this deficiency .
Diseases:"
4110	Eight healthy men were recruited .	O O O O O O	[]	0	0	"Sentence: Eight healthy men were recruited .
Diseases: "	"Sentence: Eight healthy men were recruited .
Diseases:"
4111	Hydrocortisone acetate ( 50 mg ) was given orally every 6 hours for 24 hours after a 5 - day fixed - salt diet ( 150 mmol / d ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hydrocortisone acetate ( 50 mg ) was given orally every 6 hours for 24 hours after a 5 - day fixed - salt diet ( 150 mmol / d ) .
Diseases: "	"Sentence: Hydrocortisone acetate ( 50 mg ) was given orally every 6 hours for 24 hours after a 5 - day fixed - salt diet ( 150 mmol / d ) .
Diseases:"
4112	Crossover studies were performed 2 weeks apart .	O O O O O O O O	[]	0	0	"Sentence: Crossover studies were performed 2 weeks apart .
Diseases: "	"Sentence: Crossover studies were performed 2 weeks apart .
Diseases:"
4113	Thirty milliliters of blood was obtained for isolation of peripheral blood mononuclear cells after each treatment period .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty milliliters of blood was obtained for isolation of peripheral blood mononuclear cells after each treatment period .
Diseases: "	"Sentence: Thirty milliliters of blood was obtained for isolation of peripheral blood mononuclear cells after each treatment period .
Diseases:"
4114	L - arginine uptake was assessed in mononuclear cells incubated with L - arginine ( 1 to 300 micromol / L ) , incorporating 100 nmol / L	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: L - arginine uptake was assessed in mononuclear cells incubated with L - arginine ( 1 to 300 micromol / L ) , incorporating 100 nmol / L
Diseases: "	"Sentence: L - arginine uptake was assessed in mononuclear cells incubated with L - arginine ( 1 to 300 micromol / L ) , incorporating 100 nmol / L
Diseases:"
4115	[ 3H ] - l - arginine for a period of 5 minutes at 37 degrees C . Forearm [ 3H ] - L - arginine extraction was calculated after infusion of [ 3H ] - L - arginine into the brachial artery at a rate of 100 nCi / min for 80 minutes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: [ 3H ] - l - arginine for a period of 5 minutes at 37 degrees C . Forearm [ 3H ] - L - arginine extraction was calculated after infusion of [ 3H ] - L - arginine into the brachial artery at a rate of 100 nCi / min for 80 minutes .
Diseases: "	"Sentence: [ 3H ] - l - arginine for a period of 5 minutes at 37 degrees C . Forearm [ 3H ] - L - arginine extraction was calculated after infusion of [ 3H ] - L - arginine into the brachial artery at a rate of 100 nCi / min for 80 minutes .
Diseases:"
4116	Deep forearm venous samples were collected for determination of L - arginine extraction .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Deep forearm venous samples were collected for determination of L - arginine extraction .
Diseases: "	"Sentence: Deep forearm venous samples were collected for determination of L - arginine extraction .
Diseases:"
4117	Plasma cortisol concentrations were significantly raised during the active phase ( 323 + / - 43 to 1082 + / - 245 mmol / L , P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma cortisol concentrations were significantly raised during the active phase ( 323 + / - 43 to 1082 + / - 245 mmol / L , P < 0 . 05 ) .
Diseases: "	"Sentence: Plasma cortisol concentrations were significantly raised during the active phase ( 323 + / - 43 to 1082 + / - 245 mmol / L , P < 0 . 05 ) .
Diseases:"
4118	Systolic blood pressure was elevated by an average of 7 mm Hg .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Systolic blood pressure was elevated by an average of 7 mm Hg .
Diseases: "	"Sentence: Systolic blood pressure was elevated by an average of 7 mm Hg .
Diseases:"
4119	Neither L - arginine transport into mononuclear cells ( placebo vs active , 26 . 3 + / - 3 . 6 vs 29 . 0 + / - 2 . 1 pmol / 10 000 cells per 5 minutes , respectively , at an l - arginine concentration of 300 micromol / L ) nor L - arginine extraction in the forearm ( at 80 minutes , placebo vs active , 1 868 904 + / - 434 962 vs 2 013 910 + / - 770	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Neither L - arginine transport into mononuclear cells ( placebo vs active , 26 . 3 + / - 3 . 6 vs 29 . 0 + / - 2 . 1 pmol / 10 000 cells per 5 minutes , respectively , at an l - arginine concentration of 300 micromol / L ) nor L - arginine extraction in the forearm ( at 80 minutes , placebo vs active , 1 868 904 + / - 434 962 vs 2 013 910 + / - 770
Diseases: "	"Sentence: Neither L - arginine transport into mononuclear cells ( placebo vs active , 26 . 3 + / - 3 . 6 vs 29 . 0 + / - 2 . 1 pmol / 10 000 cells per 5 minutes , respectively , at an l - arginine concentration of 300 micromol / L ) nor L - arginine extraction in the forearm ( at 80 minutes , placebo vs active , 1 868 904 + / - 434 962 vs 2 013 910 + / - 770
Diseases:"
4120	619 disintegrations per minute ) was affected by cortisol treatment ; ie , that L - arginine uptake is not affected by short - term cortisol treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 619 disintegrations per minute ) was affected by cortisol treatment ; ie , that L - arginine uptake is not affected by short - term cortisol treatment .
Diseases: "	"Sentence: 619 disintegrations per minute ) was affected by cortisol treatment ; ie , that L - arginine uptake is not affected by short - term cortisol treatment .
Diseases:"
4121	We conclude that cortisol - induced increases in blood pressure are not associated with abnormalities in the l - arginine transport system .	O O O O O O B I I I O O O O O O O O O O O O O	['increases in blood pressure']	1	5	"Sentence: We conclude that cortisol - induced increases in blood pressure are not associated with abnormalities in the l - arginine transport system .
Diseases: increases in blood pressure"	"Sentence: We conclude that cortisol - induced increases in blood pressure are not associated with abnormalities in the l - arginine transport system .
Diseases:"
4122	MR imaging with quantitative diffusion mapping of tacrolimus - induced neurotoxicity in organ transplant patients .	O O O O O O O O O O B O O O O O	['neurotoxicity']	1	4	"Sentence: MR imaging with quantitative diffusion mapping of tacrolimus - induced neurotoxicity in organ transplant patients .
Diseases: neurotoxicity"	"Sentence: MR imaging with quantitative diffusion mapping of tacrolimus - induced neurotoxicity in organ transplant patients .
Diseases:"
4123	Our objective was to investigate brain MR imaging findings and the utility of diffusion - weighted ( DW ) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Our objective was to investigate brain MR imaging findings and the utility of diffusion - weighted ( DW ) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy .
Diseases: "	"Sentence: Our objective was to investigate brain MR imaging findings and the utility of diffusion - weighted ( DW ) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy .
Diseases:"
4124	Brain MR studies , including DW imaging , were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications .	O O O O O O O O O O O O O O O O O O O O B I O	['neurologic complications']	1	5	"Sentence: Brain MR studies , including DW imaging , were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications .
Diseases: neurologic complications"	"Sentence: Brain MR studies , including DW imaging , were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications .
Diseases:"
4125	In each patient who had abnormalities on the initial MR study , a follow - up MR study was performed 1 month later .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In each patient who had abnormalities on the initial MR study , a follow - up MR study was performed 1 month later .
Diseases: "	"Sentence: In each patient who had abnormalities on the initial MR study , a follow - up MR study was performed 1 month later .
Diseases:"
4126	Apparent diffusion coefficient ( ADC ) values on the initial MR study were correlated with reversibility of the lesions .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Apparent diffusion coefficient ( ADC ) values on the initial MR study were correlated with reversibility of the lesions .
Diseases: "	"Sentence: Apparent diffusion coefficient ( ADC ) values on the initial MR study were correlated with reversibility of the lesions .
Diseases:"
4127	Of the 14 patients , 5 ( 35 . 7 % ) had white matter abnormalities , 1 ( 7 . 1 % ) had putaminal hemorrhage , and 8 ( 57 . 1 % ) had normal findings on initial MR images .	O O O O O O O O O O O O O B I I O O O O O O O O O B I O O O O O O O O O O O O O O O O O	['white matter abnormalities', 'putaminal hemorrhage']	2	9	"Sentence: Of the 14 patients , 5 ( 35 . 7 % ) had white matter abnormalities , 1 ( 7 . 1 % ) had putaminal hemorrhage , and 8 ( 57 . 1 % ) had normal findings on initial MR images .
Diseases: white matter abnormalities, putaminal hemorrhage"	"Sentence: Of the 14 patients , 5 ( 35 . 7 % ) had white matter abnormalities , 1 ( 7 . 1 % ) had putaminal hemorrhage , and 8 ( 57 . 1 % ) had normal findings on initial MR images .
Diseases:"
4128	Among the 5 patients with white matter abnormalities , 4 patients ( 80 . 0 % ) showed higher than normal ADC values on initial MR images , and all showed complete resolution on follow - up images .	O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['white matter abnormalities']	1	3	"Sentence: Among the 5 patients with white matter abnormalities , 4 patients ( 80 . 0 % ) showed higher than normal ADC values on initial MR images , and all showed complete resolution on follow - up images .
Diseases: white matter abnormalities"	"Sentence: Among the 5 patients with white matter abnormalities , 4 patients ( 80 . 0 % ) showed higher than normal ADC values on initial MR images , and all showed complete resolution on follow - up images .
Diseases:"
4129	The remaining 1 patient ( 20 . 0 % ) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis .	O O O O O O O O O O O O O O O O O O O O O B I I O	['cortical laminar necrosis']	1	8	"Sentence: The remaining 1 patient ( 20 . 0 % ) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis .
Diseases: cortical laminar necrosis"	"Sentence: The remaining 1 patient ( 20 . 0 % ) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis .
Diseases:"
4130	Diffusion - weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus - induced neurotoxicity .	O O O O O O O O O O O O O O O O O O B O	['neurotoxicity']	1	4	"Sentence: Diffusion - weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus - induced neurotoxicity .
Diseases: neurotoxicity"	"Sentence: Diffusion - weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus - induced neurotoxicity .
Diseases:"
4131	Octreotide - induced hypoxemia and pulmonary hypertension in premature neonates .	O O O B O B I O O O O	['pulmonary hypertension', 'hypoxemia']	2	6	"Sentence: Octreotide - induced hypoxemia and pulmonary hypertension in premature neonates .
Diseases: pulmonary hypertension, hypoxemia"	"Sentence: Octreotide - induced hypoxemia and pulmonary hypertension in premature neonates .
Diseases:"
4132	The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis .	O O O O O O O O O O O B O B I O	['necrotizing enterocolitis', 'fistula']	2	9	"Sentence: The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis .
Diseases: necrotizing enterocolitis, fistula"	"Sentence: The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis .
Diseases:"
4133	Pulmonary hypertension developed after administration of a somatostatin analogue , octreotide , to enhance resolution of the fistula .	B I O O O O O O O O O O O O O O O B O	['pulmonary hypertension', 'fistula']	2	7	"Sentence: Pulmonary hypertension developed after administration of a somatostatin analogue , octreotide , to enhance resolution of the fistula .
Diseases: pulmonary hypertension, fistula"	"Sentence: Pulmonary hypertension developed after administration of a somatostatin analogue , octreotide , to enhance resolution of the fistula .
Diseases:"
4134	The authors discuss the mechanism of the occurrence of this complication and recommend caution of its use in high - risk premature neonates .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The authors discuss the mechanism of the occurrence of this complication and recommend caution of its use in high - risk premature neonates .
Diseases: "	"Sentence: The authors discuss the mechanism of the occurrence of this complication and recommend caution of its use in high - risk premature neonates .
Diseases:"
4135	Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system : analysis of the mechanism of transformation from exencephaly to anencephaly .	O O O B O O O O O O O O O O O O O O O O O O B O B O	['anencephaly', 'exencephaly']	2	9	"Sentence: Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system : analysis of the mechanism of transformation from exencephaly to anencephaly .
Diseases: anencephaly, exencephaly"	"Sentence: Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system : analysis of the mechanism of transformation from exencephaly to anencephaly .
Diseases:"
4136	Anencephaly has been suggested to develop from exencephaly ; however , there is little direct experimental evidence to support this , and the mechanism of transformation remains unclear .	B O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['exencephaly', 'anencephaly']	2	9	"Sentence: Anencephaly has been suggested to develop from exencephaly ; however , there is little direct experimental evidence to support this , and the mechanism of transformation remains unclear .
Diseases: exencephaly, anencephaly"	"Sentence: Anencephaly has been suggested to develop from exencephaly ; however , there is little direct experimental evidence to support this , and the mechanism of transformation remains unclear .
Diseases:"
4137	We examined this theory using the exo utero development system that allows direct and sequential observations of mid - to late - gestation mouse embryos .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We examined this theory using the exo utero development system that allows direct and sequential observations of mid - to late - gestation mouse embryos .
Diseases: "	"Sentence: We examined this theory using the exo utero development system that allows direct and sequential observations of mid - to late - gestation mouse embryos .
Diseases:"
4138	We observed the exencephaly induced by 5 - azacytidine at embryonic day 13 . 5 ( E13 . 5 ) , let the embryos develop exo utero until E18 . 5 , and re - observed the same embryos at E18 . 5 .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['exencephaly']	1	4	"Sentence: We observed the exencephaly induced by 5 - azacytidine at embryonic day 13 . 5 ( E13 . 5 ) , let the embryos develop exo utero until E18 . 5 , and re - observed the same embryos at E18 . 5 .
Diseases: exencephaly"	"Sentence: We observed the exencephaly induced by 5 - azacytidine at embryonic day 13 . 5 ( E13 . 5 ) , let the embryos develop exo utero until E18 . 5 , and re - observed the same embryos at E18 . 5 .
Diseases:"
4139	We confirmed several cases of transformation from exencephaly to anencephaly .	O O O O O O O B O B O	['anencephaly', 'exencephaly']	2	9	"Sentence: We confirmed several cases of transformation from exencephaly to anencephaly .
Diseases: anencephaly, exencephaly"	"Sentence: We confirmed several cases of transformation from exencephaly to anencephaly .
Diseases:"
4140	However , in many cases , the exencephalic brain tissue was preserved with more or less reduction during this period .	O O O O O O O B O O O O O O O O O O O O O	['exencephalic']	1	4	"Sentence: However , in many cases , the exencephalic brain tissue was preserved with more or less reduction during this period .
Diseases: exencephalic"	"Sentence: However , in many cases , the exencephalic brain tissue was preserved with more or less reduction during this period .
Diseases:"
4141	To analyze the transformation patterns , we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13 . 5 and E18 . 5 .	O O O O O O O O O B O O O O O O B O O O O O O O O O O O O O	['exencephalic', 'exencephaly']	2	9	"Sentence: To analyze the transformation patterns , we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13 . 5 and E18 . 5 .
Diseases: exencephalic, exencephaly"	"Sentence: To analyze the transformation patterns , we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13 . 5 and E18 . 5 .
Diseases:"
4142	It was found that the transformation of exencephalic tissue was not simply size - dependent , and all cases of anencephaly at E18 . 5 resulted from embryos with a large amount of exencephalic tissue at E13 . 5 .	O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O	['anencephaly', 'exencephalic']	2	9	"Sentence: It was found that the transformation of exencephalic tissue was not simply size - dependent , and all cases of anencephaly at E18 . 5 resulted from embryos with a large amount of exencephalic tissue at E13 . 5 .
Diseases: anencephaly, exencephalic"	"Sentence: It was found that the transformation of exencephalic tissue was not simply size - dependent , and all cases of anencephaly at E18 . 5 resulted from embryos with a large amount of exencephalic tissue at E13 . 5 .
Diseases:"
4143	Microscopic observation showed the configuration of exencephaly at E13 . 5 , frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15 . 5 , and multiple modes of reduction in the exencephalic tissue at E18 . 5 .	O O O O O O B O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O	['exencephalic', 'hemorrhaging', 'exencephaly']	3	12	"Sentence: Microscopic observation showed the configuration of exencephaly at E13 . 5 , frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15 . 5 , and multiple modes of reduction in the exencephalic tissue at E18 . 5 .
Diseases: exencephalic, hemorrhaging, exencephaly"	"Sentence: Microscopic observation showed the configuration of exencephaly at E13 . 5 , frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15 . 5 , and multiple modes of reduction in the exencephalic tissue at E18 . 5 .
Diseases:"
4144	From observations of the vasculature , altered distribution patterns of vessels were identified in the exencephalic head .	O O O O O O O O O O O O O O O B O O	['exencephalic']	1	4	"Sentence: From observations of the vasculature , altered distribution patterns of vessels were identified in the exencephalic head .
Diseases: exencephalic"	"Sentence: From observations of the vasculature , altered distribution patterns of vessels were identified in the exencephalic head .
Diseases:"
4145	These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels , subsequent peripheral circulatory failure and / or hemorrhaging in various parts of the exencephalic head , leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly .	O O O O O O O B O O O O O O O O O O O O B I O O O B O O O O O B O O O O O O O O O O O O O B O B O	['hemorrhaging', 'exencephalic', 'exencephaly', 'circulatory failure', 'anencephaly']	5	23	"Sentence: These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels , subsequent peripheral circulatory failure and / or hemorrhaging in various parts of the exencephalic head , leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly .
Diseases: hemorrhaging, exencephalic, exencephaly, circulatory failure, anencephaly"	"Sentence: These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels , subsequent peripheral circulatory failure and / or hemorrhaging in various parts of the exencephalic head , leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly .
Diseases:"
4146	Acute cocaine - induced seizures : differential sensitivity of six inbred mouse strains .	O O O O B O O O O O O O O O	['seizures']	1	3	"Sentence: Acute cocaine - induced seizures : differential sensitivity of six inbred mouse strains .
Diseases: seizures"	"Sentence: Acute cocaine - induced seizures : differential sensitivity of six inbred mouse strains .
Diseases:"
4147	Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine .	O O O O O O O O O O O O O O O B O O O O O O O O	['seizures']	1	3	"Sentence: Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine .
Diseases: seizures"	"Sentence: Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine .
Diseases:"
4148	Cocaine was injected ip over a range of doses ( 50 - 100 mg / kg ) and behavior was monitored for 20 minutes .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cocaine was injected ip over a range of doses ( 50 - 100 mg / kg ) and behavior was monitored for 20 minutes .
Diseases: "	"Sentence: Cocaine was injected ip over a range of doses ( 50 - 100 mg / kg ) and behavior was monitored for 20 minutes .
Diseases:"
4149	Seizure end points included latency to forelimb or hindlimb clonus , latency to clonic running seizure and latency to jumping bouncing seizure .	B O O O O O O O O O O O O O O B O O O O O B O	['seizure']	1	3	"Sentence: Seizure end points included latency to forelimb or hindlimb clonus , latency to clonic running seizure and latency to jumping bouncing seizure .
Diseases: seizure"	"Sentence: Seizure end points included latency to forelimb or hindlimb clonus , latency to clonic running seizure and latency to jumping bouncing seizure .
Diseases:"
4150	A range of strain specific sensitivities was documented with A / J and SJL mice being most sensitive and C57BL / 6J most resistant .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A range of strain specific sensitivities was documented with A / J and SJL mice being most sensitive and C57BL / 6J most resistant .
Diseases: "	"Sentence: A range of strain specific sensitivities was documented with A / J and SJL mice being most sensitive and C57BL / 6J most resistant .
Diseases:"
4151	DBA / 2J , BALB / cByJ and NZW / LacJ strains exhibited intermediate sensitivity .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: DBA / 2J , BALB / cByJ and NZW / LacJ strains exhibited intermediate sensitivity .
Diseases: "	"Sentence: DBA / 2J , BALB / cByJ and NZW / LacJ strains exhibited intermediate sensitivity .
Diseases:"
4152	EEG recordings were made in SJL , A / J and C57BL / 6J mice revealing a close correspondence between electrical activity and behavior .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: EEG recordings were made in SJL , A / J and C57BL / 6J mice revealing a close correspondence between electrical activity and behavior .
Diseases: "	"Sentence: EEG recordings were made in SJL , A / J and C57BL / 6J mice revealing a close correspondence between electrical activity and behavior .
Diseases:"
4153	Additionally , levels of cocaine determined in hippocampus and cortex were not different between sensitive and resistant strains .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Additionally , levels of cocaine determined in hippocampus and cortex were not different between sensitive and resistant strains .
Diseases: "	"Sentence: Additionally , levels of cocaine determined in hippocampus and cortex were not different between sensitive and resistant strains .
Diseases:"
4154	Additional studies of these murine strains may be useful for investigating genetic influences on cocaine - induced seizures .	O O O O O O O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: Additional studies of these murine strains may be useful for investigating genetic influences on cocaine - induced seizures .
Diseases: seizures"	"Sentence: Additional studies of these murine strains may be useful for investigating genetic influences on cocaine - induced seizures .
Diseases:"
4155	Microangiopathic hemolytic anemia complicating FK506 ( tacrolimus ) therapy .	B I I O O O O O O O	['microangiopathic hemolytic anemia']	1	10	"Sentence: Microangiopathic hemolytic anemia complicating FK506 ( tacrolimus ) therapy .
Diseases: microangiopathic hemolytic anemia"	"Sentence: Microangiopathic hemolytic anemia complicating FK506 ( tacrolimus ) therapy .
Diseases:"
4156	We describe 3 episodes of microangiopathic hemolytic anemia ( MAHA ) in 2 solid organ recipients under FK506 ( tacrolimus ) therapy .	O O O O O B I I O B O O O O O O O O O O O O O	['microangiopathic hemolytic anemia', 'maha']	2	13	"Sentence: We describe 3 episodes of microangiopathic hemolytic anemia ( MAHA ) in 2 solid organ recipients under FK506 ( tacrolimus ) therapy .
Diseases: microangiopathic hemolytic anemia, maha"	"Sentence: We describe 3 episodes of microangiopathic hemolytic anemia ( MAHA ) in 2 solid organ recipients under FK506 ( tacrolimus ) therapy .
Diseases:"
4157	In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , aspirin , and dipyridamole led to resolution of MAHA .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['maha']	1	2	"Sentence: In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , aspirin , and dipyridamole led to resolution of MAHA .
Diseases: maha"	"Sentence: In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , aspirin , and dipyridamole led to resolution of MAHA .
Diseases:"
4158	In one patient , reintroduction of FK506 led to rapid recurrence of MAHA .	O O O O O O O O O O O O B O	['maha']	1	2	"Sentence: In one patient , reintroduction of FK506 led to rapid recurrence of MAHA .
Diseases: maha"	"Sentence: In one patient , reintroduction of FK506 led to rapid recurrence of MAHA .
Diseases:"
4159	FK506 - associated MAHA is probably rare but physicians must be aware of this severe complication .	O O O B O O O O O O O O O O O O O	['maha']	1	2	"Sentence: FK506 - associated MAHA is probably rare but physicians must be aware of this severe complication .
Diseases: maha"	"Sentence: FK506 - associated MAHA is probably rare but physicians must be aware of this severe complication .
Diseases:"
4160	In our experience and according to the literature , FK506 does not seem to cross - react with cyclosporin A ( CyA ) , an immuno - suppressive drug already known to induce MAHA .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['maha']	1	2	"Sentence: In our experience and according to the literature , FK506 does not seem to cross - react with cyclosporin A ( CyA ) , an immuno - suppressive drug already known to induce MAHA .
Diseases: maha"	"Sentence: In our experience and according to the literature , FK506 does not seem to cross - react with cyclosporin A ( CyA ) , an immuno - suppressive drug already known to induce MAHA .
Diseases:"
4161	Variant ventricular tachycardia in desipramine toxicity .	O B I O O B O	['ventricular tachycardia', 'toxicity']	2	8	"Sentence: Variant ventricular tachycardia in desipramine toxicity .
Diseases: ventricular tachycardia, toxicity"	"Sentence: Variant ventricular tachycardia in desipramine toxicity .
Diseases:"
4162	We report a case of variant ventricular tachycardia induced by desipramine toxicity .	O O O O O O B I O O O B O	['ventricular tachycardia', 'toxicity']	2	8	"Sentence: We report a case of variant ventricular tachycardia induced by desipramine toxicity .
Diseases: ventricular tachycardia, toxicity"	"Sentence: We report a case of variant ventricular tachycardia induced by desipramine toxicity .
Diseases:"
4163	Unusual features of the arrhythmia are repetitive group beating , progressive shortening of the R - R interval , progressive widening of the QRS complex with eventual failure of intraventricular conduction , and changes in direction of the QRS axis .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['arrhythmia']	1	4	"Sentence: Unusual features of the arrhythmia are repetitive group beating , progressive shortening of the R - R interval , progressive widening of the QRS complex with eventual failure of intraventricular conduction , and changes in direction of the QRS axis .
Diseases: arrhythmia"	"Sentence: Unusual features of the arrhythmia are repetitive group beating , progressive shortening of the R - R interval , progressive widening of the QRS complex with eventual failure of intraventricular conduction , and changes in direction of the QRS axis .
Diseases:"
4164	Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia .	O O O B I O O O O O O O O O B I O	['ventricular tachycardia']	1	6	"Sentence: Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia .
Diseases: ventricular tachycardia"	"Sentence: Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia .
Diseases:"
4165	"Desipramine - induced delirium at "" subtherapeutic "" concentrations : a case report ."	O O O B O O O O O O O O O O	['delirium']	1	3	"Sentence: Desipramine - induced delirium at "" subtherapeutic "" concentrations : a case report .
Diseases: delirium"	"Sentence: Desipramine - induced delirium at "" subtherapeutic "" concentrations : a case report .
Diseases:"
4166	"An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the "" subtherapeutic "" range ."	O O O O O O O O O O B O O O O O O O O O O O O	['delirium']	1	3	"Sentence: An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the "" subtherapeutic "" range .
Diseases: delirium"	"Sentence: An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the "" subtherapeutic "" range .
Diseases:"
4167	Delirium , which may be induced by tricyclic drug therapy in the elderly , can be caused by tricyclics with low anticholinergic potency .	B O O O O O O O O O O O O O O O O O O O O O O O	['delirium']	1	3	"Sentence: Delirium , which may be induced by tricyclic drug therapy in the elderly , can be caused by tricyclics with low anticholinergic potency .
Diseases: delirium"	"Sentence: Delirium , which may be induced by tricyclic drug therapy in the elderly , can be caused by tricyclics with low anticholinergic potency .
Diseases:"
4168	Therapeutic ranges for antidepressants that have been derived from general adult population studies may not be appropriate for the elderly .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Therapeutic ranges for antidepressants that have been derived from general adult population studies may not be appropriate for the elderly .
Diseases: "	"Sentence: Therapeutic ranges for antidepressants that have been derived from general adult population studies may not be appropriate for the elderly .
Diseases:"
4169	Further studies of specifically elderly patients are now required to establish safer and more appropriate guidelines for drug therapy .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Further studies of specifically elderly patients are now required to establish safer and more appropriate guidelines for drug therapy .
Diseases: "	"Sentence: Further studies of specifically elderly patients are now required to establish safer and more appropriate guidelines for drug therapy .
Diseases:"
4170	Mouse strain - dependent effect of amantadine on motility and brain biogenic amines .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mouse strain - dependent effect of amantadine on motility and brain biogenic amines .
Diseases: "	"Sentence: Mouse strain - dependent effect of amantadine on motility and brain biogenic amines .
Diseases:"
4171	The effect of amantadine hydrochloride , injected i . p .	O O O O O O O O O O O	[]	0	0	"Sentence: The effect of amantadine hydrochloride , injected i . p .
Diseases: "	"Sentence: The effect of amantadine hydrochloride , injected i . p .
Diseases:"
4172	in 6 increments of 100 mg / kg each over 30 hr , on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: in 6 increments of 100 mg / kg each over 30 hr , on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice .
Diseases: "	"Sentence: in 6 increments of 100 mg / kg each over 30 hr , on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice .
Diseases:"
4173	These were the albino Sprague - Dawley ICR and BALB / C , the black C57BL / 6 and the brown CDF - I mouse strains .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These were the albino Sprague - Dawley ICR and BALB / C , the black C57BL / 6 and the brown CDF - I mouse strains .
Diseases: "	"Sentence: These were the albino Sprague - Dawley ICR and BALB / C , the black C57BL / 6 and the brown CDF - I mouse strains .
Diseases:"
4174	Amantadine treatment produced a biphasic effect on mouse motility .	O O O O O O O O O O	[]	0	0	"Sentence: Amantadine treatment produced a biphasic effect on mouse motility .
Diseases: "	"Sentence: Amantadine treatment produced a biphasic effect on mouse motility .
Diseases:"
4175	The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB / C mice being the most sensitive .	O O O O O B O O O O O O O O O O O O O O O O O O	['depressed']	1	2	"Sentence: The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB / C mice being the most sensitive .
Diseases: depressed"	"Sentence: The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB / C mice being the most sensitive .
Diseases:"
4176	Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB / C mice being the least sensitive .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB / C mice being the least sensitive .
Diseases: "	"Sentence: Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB / C mice being the least sensitive .
Diseases:"
4177	The locomotor activity was decreased from corresponding controls in all strains studied , except for the ICR mice , during an overnight drug - free period following the fourth amantadine treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The locomotor activity was decreased from corresponding controls in all strains studied , except for the ICR mice , during an overnight drug - free period following the fourth amantadine treatment .
Diseases: "	"Sentence: The locomotor activity was decreased from corresponding controls in all strains studied , except for the ICR mice , during an overnight drug - free period following the fourth amantadine treatment .
Diseases:"
4178	Readministration of amantadine , after a drug - free overnight period , increased motility from respective saline control in all strains with exception of the BALB / C mice where suppression of motility occurred .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O	['suppression of motility']	1	5	"Sentence: Readministration of amantadine , after a drug - free overnight period , increased motility from respective saline control in all strains with exception of the BALB / C mice where suppression of motility occurred .
Diseases: suppression of motility"	"Sentence: Readministration of amantadine , after a drug - free overnight period , increased motility from respective saline control in all strains with exception of the BALB / C mice where suppression of motility occurred .
Diseases:"
4179	Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3 , 4 - dihydroxyphenylacetic acid in the BALB / C mice compared to saline control .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3 , 4 - dihydroxyphenylacetic acid in the BALB / C mice compared to saline control .
Diseases: "	"Sentence: Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3 , 4 - dihydroxyphenylacetic acid in the BALB / C mice compared to saline control .
Diseases:"
4180	Conversely , brain normetanephrine concentration was increased from saline control by amantadine in the BALB / C mice .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Conversely , brain normetanephrine concentration was increased from saline control by amantadine in the BALB / C mice .
Diseases: "	"Sentence: Conversely , brain normetanephrine concentration was increased from saline control by amantadine in the BALB / C mice .
Diseases:"
4181	The results suggest a strain - dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results suggest a strain - dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used .
Diseases: "	"Sentence: The results suggest a strain - dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used .
Diseases:"
4182	The BALB / C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The BALB / C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine .
Diseases: "	"Sentence: The BALB / C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine .
Diseases:"
4183	The biochemical results of brain biogenic amines of BALB / C mouse strain suggest a probable decrease of catecholamine turnover rate and / or metabolism by monoamine oxidase and a resulting increase in O - methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB / C mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O	['behavioral depression']	1	3	"Sentence: The biochemical results of brain biogenic amines of BALB / C mouse strain suggest a probable decrease of catecholamine turnover rate and / or metabolism by monoamine oxidase and a resulting increase in O - methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB / C mice .
Diseases: behavioral depression"	"Sentence: The biochemical results of brain biogenic amines of BALB / C mouse strain suggest a probable decrease of catecholamine turnover rate and / or metabolism by monoamine oxidase and a resulting increase in O - methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB / C mice .
Diseases:"
4184	No enhancement by phenobarbital of the hepatocarcinogenicity of a choline - devoid diet in the rat .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: No enhancement by phenobarbital of the hepatocarcinogenicity of a choline - devoid diet in the rat .
Diseases: "	"Sentence: No enhancement by phenobarbital of the hepatocarcinogenicity of a choline - devoid diet in the rat .
Diseases:"
4185	An experiment was performed to test whether inclusion of phenobarbital in a choline - devoid diet would increase the hepatocarcinogenicity of the diet .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An experiment was performed to test whether inclusion of phenobarbital in a choline - devoid diet would increase the hepatocarcinogenicity of the diet .
Diseases: "	"Sentence: An experiment was performed to test whether inclusion of phenobarbital in a choline - devoid diet would increase the hepatocarcinogenicity of the diet .
Diseases:"
4186	Groups of 5 - week old male Fischer - 344 rats were fed for 7 - 25 months semipurified choline - devoid or choline - supplemented diets , containing or not 0 . 06 % phenobarbital .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Groups of 5 - week old male Fischer - 344 rats were fed for 7 - 25 months semipurified choline - devoid or choline - supplemented diets , containing or not 0 . 06 % phenobarbital .
Diseases: "	"Sentence: Groups of 5 - week old male Fischer - 344 rats were fed for 7 - 25 months semipurified choline - devoid or choline - supplemented diets , containing or not 0 . 06 % phenobarbital .
Diseases:"
4187	No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline - supplemented diet , while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital .	O O O O O B I O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	['hepatocellular carcinomas', 'hepatocellular carcinoma']	2	14	"Sentence: No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline - supplemented diet , while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital .
Diseases: hepatocellular carcinomas, hepatocellular carcinoma"	"Sentence: No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline - supplemented diet , while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital .
Diseases:"
4188	The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10 % and 37 % , respectively , in rats fed the plain choline - devoid diet , and 17 % and 30 % , in rats fed the phenobarbital - containing choline - devoid diet .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hepatocellular carcinomas']	1	7	"Sentence: The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10 % and 37 % , respectively , in rats fed the plain choline - devoid diet , and 17 % and 30 % , in rats fed the phenobarbital - containing choline - devoid diet .
Diseases: hepatocellular carcinomas"	"Sentence: The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10 % and 37 % , respectively , in rats fed the plain choline - devoid diet , and 17 % and 30 % , in rats fed the phenobarbital - containing choline - devoid diet .
Diseases:"
4189	The results evinced no enhancement of the hepatocarcinogenicity of the choline - devoid diet by phenobarbital .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results evinced no enhancement of the hepatocarcinogenicity of the choline - devoid diet by phenobarbital .
Diseases: "	"Sentence: The results evinced no enhancement of the hepatocarcinogenicity of the choline - devoid diet by phenobarbital .
Diseases:"
4190	Sporadic neoplastic lesions were observed in organs other than the liver of some of the animals , irrespective of the diet fed .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sporadic neoplastic lesions were observed in organs other than the liver of some of the animals , irrespective of the diet fed .
Diseases: "	"Sentence: Sporadic neoplastic lesions were observed in organs other than the liver of some of the animals , irrespective of the diet fed .
Diseases:"
4191	Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina .	O O O O O O O O O O O O B I O	['variant angina']	1	4	"Sentence: Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina .
Diseases: variant angina"	"Sentence: Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina .
Diseases:"
4192	The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris ( control group ) .	O O O O O O O O O O O O O B I O O O O O B I O O O O B I O O O O O	['variant angina', 'chest pain', 'angina pectoris']	3	13	"Sentence: The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris ( control group ) .
Diseases: variant angina, chest pain, angina pectoris"	"Sentence: The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris ( control group ) .
Diseases:"
4193	Methylergonovine was administered continuously at a rate of 10 micrograms / min up to 50 micrograms .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Methylergonovine was administered continuously at a rate of 10 micrograms / min up to 50 micrograms .
Diseases: "	"Sentence: Methylergonovine was administered continuously at a rate of 10 micrograms / min up to 50 micrograms .
Diseases:"
4194	In all patients with variant angina , coronary spasm was provoked at a mean dose of 28 + / - 13 micrograms ( mean + / - SD ) .	O O O O B I O B I O O O O O O O O O O O O O O O O O O O O O	['coronary spasm', 'variant angina']	2	9	"Sentence: In all patients with variant angina , coronary spasm was provoked at a mean dose of 28 + / - 13 micrograms ( mean + / - SD ) .
Diseases: coronary spasm, variant angina"	"Sentence: In all patients with variant angina , coronary spasm was provoked at a mean dose of 28 + / - 13 micrograms ( mean + / - SD ) .
Diseases:"
4195	In the control group neither ischemic ST change nor localized spasm occurred .	O O O O O O O O O O B O O	['spasm']	1	2	"Sentence: In the control group neither ischemic ST change nor localized spasm occurred .
Diseases: spasm"	"Sentence: In the control group neither ischemic ST change nor localized spasm occurred .
Diseases:"
4196	The basal tone of the right coronary artery was significantly lower than that of the left coronary artery .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The basal tone of the right coronary artery was significantly lower than that of the left coronary artery .
Diseases: "	"Sentence: The basal tone of the right coronary artery was significantly lower than that of the left coronary artery .
Diseases:"
4197	The percentage of vasoconstriction of the right coronary artery was significantly higher than that of the left coronary artery .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The percentage of vasoconstriction of the right coronary artery was significantly higher than that of the left coronary artery .
Diseases: "	"Sentence: The percentage of vasoconstriction of the right coronary artery was significantly higher than that of the left coronary artery .
Diseases:"
4198	These results suggest that spasm provocation tests , which use an intracoronary injection of a relatively low dose of methylergonovine , have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries .	O O O O B O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O	['variant angina', 'spasm']	2	7	"Sentence: These results suggest that spasm provocation tests , which use an intracoronary injection of a relatively low dose of methylergonovine , have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries .
Diseases: variant angina, spasm"	"Sentence: These results suggest that spasm provocation tests , which use an intracoronary injection of a relatively low dose of methylergonovine , have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries .
Diseases:"
4199	Dobutamine stress echocardiography : a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin - treated long - term survivors of childhood cancer .	O O O O O O O O O O O O O O O O O O O O O O B O	['cancer']	1	1	"Sentence: Dobutamine stress echocardiography : a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin - treated long - term survivors of childhood cancer .
Diseases: cancer"	"Sentence: Dobutamine stress echocardiography : a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin - treated long - term survivors of childhood cancer .
Diseases:"
4200	Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy .	O O O O O O O O O O O O O B O	['cardiomyopathy']	1	4	"Sentence: Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy .
Diseases: cardiomyopathy"	"Sentence: Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy .
Diseases:"
4201	To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long - term survivors of childhood cancer treated with doxorubicin from healthy control subjects .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['cardiac damage', 'cancer']	2	5	"Sentence: To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long - term survivors of childhood cancer treated with doxorubicin from healthy control subjects .
Diseases: cardiac damage, cancer"	"Sentence: To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long - term survivors of childhood cancer treated with doxorubicin from healthy control subjects .
Diseases:"
4202	Echocardiographic data from the experimental group of 21 patients ( mean age 16 + / - 5 years ) treated from 1 . 6 to 14 . 3 years ( median 5 . 3 ) before this study with 27 to 532 mg / m2 of doxorubicin ( mean 196 ) were compared with echocardiographic data from 12 normal age - matched control subjects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Echocardiographic data from the experimental group of 21 patients ( mean age 16 + / - 5 years ) treated from 1 . 6 to 14 . 3 years ( median 5 . 3 ) before this study with 27 to 532 mg / m2 of doxorubicin ( mean 196 ) were compared with echocardiographic data from 12 normal age - matched control subjects .
Diseases: "	"Sentence: Echocardiographic data from the experimental group of 21 patients ( mean age 16 + / - 5 years ) treated from 1 . 6 to 14 . 3 years ( median 5 . 3 ) before this study with 27 to 532 mg / m2 of doxorubicin ( mean 196 ) were compared with echocardiographic data from 12 normal age - matched control subjects .
Diseases:"
4203	Graded dobutamine infusions of 0 . 5 , 2 . 5 , 5 and 10 micrograms / kg per min were administered .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Graded dobutamine infusions of 0 . 5 , 2 . 5 , 5 and 10 micrograms / kg per min were administered .
Diseases: "	"Sentence: Graded dobutamine infusions of 0 . 5 , 2 . 5 , 5 and 10 micrograms / kg per min were administered .
Diseases:"
4204	Echocardiographic Doppler studies were performed before infusion and after 15 min of infusion at each rate .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Echocardiographic Doppler studies were performed before infusion and after 15 min of infusion at each rate .
Diseases: "	"Sentence: Echocardiographic Doppler studies were performed before infusion and after 15 min of infusion at each rate .
Diseases:"
4205	Dobutamine infusion at 10 micrograms / kg per min was discontinued after six studies secondary to a 50 % incidence rate of adverse symptoms .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dobutamine infusion at 10 micrograms / kg per min was discontinued after six studies secondary to a 50 % incidence rate of adverse symptoms .
Diseases: "	"Sentence: Dobutamine infusion at 10 micrograms / kg per min was discontinued after six studies secondary to a 50 % incidence rate of adverse symptoms .
Diseases:"
4206	The most important findings were that compared with values in control subjects , end - systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin - treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The most important findings were that compared with values in control subjects , end - systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin - treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation .
Diseases: "	"Sentence: The most important findings were that compared with values in control subjects , end - systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin - treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation .
Diseases:"
4207	End - systolic left ventricular posterior wall dimension at baseline for the doxorubicin - treated group was 11 + / - 1 . 9 mm versus 13 . 1 + / - 1 . 5 mm for control subjects ( p less than 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: End - systolic left ventricular posterior wall dimension at baseline for the doxorubicin - treated group was 11 + / - 1 . 9 mm versus 13 . 1 + / - 1 . 5 mm for control subjects ( p less than 0 . 01 ) .
Diseases: "	"Sentence: End - systolic left ventricular posterior wall dimension at baseline for the doxorubicin - treated group was 11 + / - 1 . 9 mm versus 13 . 1 + / - 1 . 5 mm for control subjects ( p less than 0 . 01 ) .
Diseases:"
4208	End - systolic left ventricular posterior wall dimension at the 5 - micrograms / kg per min dobutamine infusion for the doxorubicin - treated group was 14 . 1 + / - 2 . 4 mm versus 19 . 3 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: End - systolic left ventricular posterior wall dimension at the 5 - micrograms / kg per min dobutamine infusion for the doxorubicin - treated group was 14 . 1 + / - 2 . 4 mm versus 19 . 3 + / -
Diseases: "	"Sentence: End - systolic left ventricular posterior wall dimension at the 5 - micrograms / kg per min dobutamine infusion for the doxorubicin - treated group was 14 . 1 + / - 2 . 4 mm versus 19 . 3 + / -
Diseases:"
4209	2 . 6 mm for control subjects ( p less than 0 . 01 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 2 . 6 mm for control subjects ( p less than 0 . 01 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: "	"Sentence: 2 . 6 mm for control subjects ( p less than 0 . 01 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
4210	Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure .	O O O O O O O O B I O B I O	['ventricular fibrillation', 'respiratory failure']	2	8	"Sentence: Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure .
Diseases: ventricular fibrillation, respiratory failure"	"Sentence: Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure .
Diseases:"
4211	Cardiac arrhythmias have frequently been reported in association with respiratory failure .	B I O O O O O O O B I O	['cardiac arrhythmias', 'respiratory failure']	2	9	"Sentence: Cardiac arrhythmias have frequently been reported in association with respiratory failure .
Diseases: cardiac arrhythmias, respiratory failure"	"Sentence: Cardiac arrhythmias have frequently been reported in association with respiratory failure .
Diseases:"
4212	The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized .	O O O O O O O O O B I O O O B I O O O O O O	['cardiac disturbances', 'respiratory failure']	2	6	"Sentence: The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized .
Diseases: cardiac disturbances, respiratory failure"	"Sentence: The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized .
Diseases:"
4213	The effects of aminophylline on the ventricular fibrillation threshold during normal acid - base conditions and during respiratory failure were studied in anesthetized open chest dogs .	O O O O O O B I O O O O O O O O O B I O O O O O O O O	['ventricular fibrillation', 'respiratory failure']	2	8	"Sentence: The effects of aminophylline on the ventricular fibrillation threshold during normal acid - base conditions and during respiratory failure were studied in anesthetized open chest dogs .
Diseases: ventricular fibrillation, respiratory failure"	"Sentence: The effects of aminophylline on the ventricular fibrillation threshold during normal acid - base conditions and during respiratory failure were studied in anesthetized open chest dogs .
Diseases:"
4214	The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle .	O B I O O O O O O O O O O O O O O O O O O O O O O O O O O	['ventricular fibrillation']	1	5	"Sentence: The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle .
Diseases: ventricular fibrillation"	"Sentence: The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle .
Diseases:"
4215	During the infusion of aminophylline , the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and carbon dioxide ( CO2 ) were kept within normal limits .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ventricular fibrillation']	1	5	"Sentence: During the infusion of aminophylline , the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and carbon dioxide ( CO2 ) were kept within normal limits .
Diseases: ventricular fibrillation"	"Sentence: During the infusion of aminophylline , the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and carbon dioxide ( CO2 ) were kept within normal limits .
Diseases:"
4216	When respiratory failure was produced by hypoventilation ( pH 7 . 05 to 7 . 25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level .	O B I O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O	['hypoventilation', 'ventricular fibrillation', 'respiratory failure']	3	13	"Sentence: When respiratory failure was produced by hypoventilation ( pH 7 . 05 to 7 . 25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level .
Diseases: hypoventilation, ventricular fibrillation, respiratory failure"	"Sentence: When respiratory failure was produced by hypoventilation ( pH 7 . 05 to 7 . 25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level .
Diseases:"
4217	These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure , pharmacologic agents , particularly aminophylline , may play a significant role .	O O O O O O O O O O O O O O B I O B I O O O O O O O O O O O O O	['ventricular arrhythmias', 'respiratory failure']	2	9	"Sentence: These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure , pharmacologic agents , particularly aminophylline , may play a significant role .
Diseases: ventricular arrhythmias, respiratory failure"	"Sentence: These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure , pharmacologic agents , particularly aminophylline , may play a significant role .
Diseases:"
4218	Case report : acute unintentional carbachol intoxication .	O O O O O O O O	[]	0	0	"Sentence: Case report : acute unintentional carbachol intoxication .
Diseases: "	"Sentence: Case report : acute unintentional carbachol intoxication .
Diseases:"
4219	Intoxications with carbachol , a muscarinic cholinergic receptor agonist are rare .	O O O O O O O O O O O O	[]	0	0	"Sentence: Intoxications with carbachol , a muscarinic cholinergic receptor agonist are rare .
Diseases: "	"Sentence: Intoxications with carbachol , a muscarinic cholinergic receptor agonist are rare .
Diseases:"
4220	We report an interesting case investigating a ( near ) fatal poisoning .	O O O O O O O O O O O B O	['poisoning']	1	3	"Sentence: We report an interesting case investigating a ( near ) fatal poisoning .
Diseases: poisoning"	"Sentence: We report an interesting case investigating a ( near ) fatal poisoning .
Diseases:"
4221	The son of an 84 - year - old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer 's disease .	O O O O O O O O O O O O O O O O O O O O O B I I O	"[""alzheimer 's disease""]"	1	6	"Sentence: The son of an 84 - year - old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer 's disease .
Diseases: alzheimer 's disease"	"Sentence: The son of an 84 - year - old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer 's disease .
Diseases:"
4222	The mode of action was said to be comparable to that of the synthetic compound ' carbamylcholin ' ; that is , carbachol .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mode of action was said to be comparable to that of the synthetic compound ' carbamylcholin ' ; that is , carbachol .
Diseases: "	"Sentence: The mode of action was said to be comparable to that of the synthetic compound ' carbamylcholin ' ; that is , carbachol .
Diseases:"
4223	He bought 25 g of carbachol as pure substance in a pharmacy , and the father was administered 400 to 500 mg .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: He bought 25 g of carbachol as pure substance in a pharmacy , and the father was administered 400 to 500 mg .
Diseases: "	"Sentence: He bought 25 g of carbachol as pure substance in a pharmacy , and the father was administered 400 to 500 mg .
Diseases:"
4224	Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC - mass spectrometry .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC - mass spectrometry .
Diseases: "	"Sentence: Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC - mass spectrometry .
Diseases:"
4225	Minutes after oral administration , the patient developed nausea , sweating and hypotension , and finally collapsed .	O O O O O O O O B O O O B O O O O O	['nausea', 'hypotension']	2	6	"Sentence: Minutes after oral administration , the patient developed nausea , sweating and hypotension , and finally collapsed .
Diseases: nausea, hypotension"	"Sentence: Minutes after oral administration , the patient developed nausea , sweating and hypotension , and finally collapsed .
Diseases:"
4226	Bradycardia , cholinergic symptoms and asystole occurred .	B O O O O B O O	['bradycardia', 'asystole']	2	9	"Sentence: Bradycardia , cholinergic symptoms and asystole occurred .
Diseases: bradycardia, asystole"	"Sentence: Bradycardia , cholinergic symptoms and asystole occurred .
Diseases:"
4227	Initial cardiopulmonary resuscitation and immediate treatment with adrenaline ( epinephrine ) , atropine and furosemide was successful .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Initial cardiopulmonary resuscitation and immediate treatment with adrenaline ( epinephrine ) , atropine and furosemide was successful .
Diseases: "	"Sentence: Initial cardiopulmonary resuscitation and immediate treatment with adrenaline ( epinephrine ) , atropine and furosemide was successful .
Diseases:"
4228	On hospital admission , blood pressure of the intubated , bradyarrhythmic patient was 100 / 65 mmHg .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On hospital admission , blood pressure of the intubated , bradyarrhythmic patient was 100 / 65 mmHg .
Diseases: "	"Sentence: On hospital admission , blood pressure of the intubated , bradyarrhythmic patient was 100 / 65 mmHg .
Diseases:"
4229	Further signs were hyperhidrosis , hypersalivation , bronchorrhoea , and severe miosis ; the electrocardiographic finding was atrio - ventricular dissociation .	O O O B O B O B O O O B O O O O O B I I I O	['hypersalivation', 'bronchorrhoea', 'miosis', 'hyperhidrosis', 'atrio - ventricular dissociation']	5	26	"Sentence: Further signs were hyperhidrosis , hypersalivation , bronchorrhoea , and severe miosis ; the electrocardiographic finding was atrio - ventricular dissociation .
Diseases: hypersalivation, bronchorrhoea, miosis, hyperhidrosis, atrio - ventricular dissociation"	"Sentence: Further signs were hyperhidrosis , hypersalivation , bronchorrhoea , and severe miosis ; the electrocardiographic finding was atrio - ventricular dissociation .
Diseases:"
4230	High doses of atropine ( up to 50 mg per 24 hours ) , adrenaline and dopamine were necessary .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: High doses of atropine ( up to 50 mg per 24 hours ) , adrenaline and dopamine were necessary .
Diseases: "	"Sentence: High doses of atropine ( up to 50 mg per 24 hours ) , adrenaline and dopamine were necessary .
Diseases:"
4231	The patient was extubated 1 week later .	O O O O O O O O	[]	0	0	"Sentence: The patient was extubated 1 week later .
Diseases: "	"Sentence: The patient was extubated 1 week later .
Diseases:"
4232	However , increased dyspnoea and bronchospasm necessitated reintubation .	O O O B O B O O O	['dyspnoea', 'bronchospasm']	2	10	"Sentence: However , increased dyspnoea and bronchospasm necessitated reintubation .
Diseases: dyspnoea, bronchospasm"	"Sentence: However , increased dyspnoea and bronchospasm necessitated reintubation .
Diseases:"
4233	Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction .	B I O O O O B I I O O O O	['proteus mirabilis infection', 'respiratory insufficiency']	2	12	"Sentence: Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction .
Diseases: proteus mirabilis infection, respiratory insufficiency"	"Sentence: Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction .
Diseases:"
4234	One week later , the patient was again extubated and 3 days later was transferred to a peripheral ward .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: One week later , the patient was again extubated and 3 days later was transferred to a peripheral ward .
Diseases: "	"Sentence: One week later , the patient was again extubated and 3 days later was transferred to a peripheral ward .
Diseases:"
4235	On the next day he died , probably as a result of heart failure .	O O O O O O O O O O O O B I O	['heart failure']	1	2	"Sentence: On the next day he died , probably as a result of heart failure .
Diseases: heart failure"	"Sentence: On the next day he died , probably as a result of heart failure .
Diseases:"
4236	Serum samples from the first and second days contained 3 . 6 and 1 . 9 mg / l carbachol , respectively .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serum samples from the first and second days contained 3 . 6 and 1 . 9 mg / l carbachol , respectively .
Diseases: "	"Sentence: Serum samples from the first and second days contained 3 . 6 and 1 . 9 mg / l carbachol , respectively .
Diseases:"
4237	The corresponding urine concentrations amounted to 374 and 554 mg / l . CONCLUSION :	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The corresponding urine concentrations amounted to 374 and 554 mg / l . CONCLUSION :
Diseases: "	"Sentence: The corresponding urine concentrations amounted to 374 and 554 mg / l . CONCLUSION :
Diseases:"
4238	This case started with a media report in a popular newspaper , initiated by published , peer - reviewed research on herbals , and involved human failure in a case history , medical examination and clinical treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This case started with a media report in a popular newspaper , initiated by published , peer - reviewed research on herbals , and involved human failure in a case history , medical examination and clinical treatment .
Diseases: "	"Sentence: This case started with a media report in a popular newspaper , initiated by published , peer - reviewed research on herbals , and involved human failure in a case history , medical examination and clinical treatment .
Diseases:"
4239	For the first time , an analytical method for the determination of carbachol in plasma and urine has been developed .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For the first time , an analytical method for the determination of carbachol in plasma and urine has been developed .
Diseases: "	"Sentence: For the first time , an analytical method for the determination of carbachol in plasma and urine has been developed .
Diseases:"
4240	The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260 .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260 .
Diseases: "	"Sentence: The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260 .
Diseases:"
4241	Especially in old patients , intensivists should consider intoxications ( with cholinergics ) as a cause of acute cardiovascular failure .	O O O O O O O O O O O O O O O O O B I I O	['acute cardiovascular failure']	1	4	"Sentence: Especially in old patients , intensivists should consider intoxications ( with cholinergics ) as a cause of acute cardiovascular failure .
Diseases: acute cardiovascular failure"	"Sentence: Especially in old patients , intensivists should consider intoxications ( with cholinergics ) as a cause of acute cardiovascular failure .
Diseases:"
4242	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine / caffeine in migraine .	O O O O O O O O O O O O O O O B O	['migraine']	1	3	"Sentence: Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine / caffeine in migraine .
Diseases: migraine"	"Sentence: Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine / caffeine in migraine .
Diseases:"
4243	Rizatriptan is a selective 5 - HT ( 1B / 1D ) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['migraine']	1	3	"Sentence: Rizatriptan is a selective 5 - HT ( 1B / 1D ) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine .
Diseases: migraine"	"Sentence: Rizatriptan is a selective 5 - HT ( 1B / 1D ) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine .
Diseases:"
4244	This randomized double - blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg / caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['migraine']	1	3	"Sentence: This randomized double - blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg / caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy .
Diseases: migraine"	"Sentence: This randomized double - blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg / caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy .
Diseases:"
4245	Of patients expressing a preference ( 89 . 1 % ) , more than twice as many preferred rizatriptan to ergotamine / caffeine ( 69 . 9 vs . 30 . 1 % , p < or = 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of patients expressing a preference ( 89 . 1 % ) , more than twice as many preferred rizatriptan to ergotamine / caffeine ( 69 . 9 vs . 30 . 1 % , p < or = 0 . 001 ) .
Diseases: "	"Sentence: Of patients expressing a preference ( 89 . 1 % ) , more than twice as many preferred rizatriptan to ergotamine / caffeine ( 69 . 9 vs . 30 . 1 % , p < or = 0 . 001 ) .
Diseases:"
4246	Faster relief of headache was the most important reason for preference , cited by 67 . 3 % of patients preferring rizatriptan and 54 . 2 % of patients who preferred ergotamine / caffeine .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['headache']	1	2	"Sentence: Faster relief of headache was the most important reason for preference , cited by 67 . 3 % of patients preferring rizatriptan and 54 . 2 % of patients who preferred ergotamine / caffeine .
Diseases: headache"	"Sentence: Faster relief of headache was the most important reason for preference , cited by 67 . 3 % of patients preferring rizatriptan and 54 . 2 % of patients who preferred ergotamine / caffeine .
Diseases:"
4247	The co - primary endpoint of being pain free at 2 h was also in favor of rizatriptan .	O O O O O O O B O O O O O O O O O O O	['pain']	1	1	"Sentence: The co - primary endpoint of being pain free at 2 h was also in favor of rizatriptan .
Diseases: pain"	"Sentence: The co - primary endpoint of being pain free at 2 h was also in favor of rizatriptan .
Diseases:"
4248	Forty - nine percent of patients were pain free 2 h after rizatriptan , compared with 24 . 3 % treated with ergotamine / caffeine ( p < or = 0 . 001 ) , rizatriptan being superior within 1 h of treatment .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Forty - nine percent of patients were pain free 2 h after rizatriptan , compared with 24 . 3 % treated with ergotamine / caffeine ( p < or = 0 . 001 ) , rizatriptan being superior within 1 h of treatment .
Diseases: pain"	"Sentence: Forty - nine percent of patients were pain free 2 h after rizatriptan , compared with 24 . 3 % treated with ergotamine / caffeine ( p < or = 0 . 001 ) , rizatriptan being superior within 1 h of treatment .
Diseases:"
4249	Headache relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for ergotamine / caffeine ( p < or = 0 . 001 ) , with rizatriptan being superior to ergotamine / caffeine within 30 min of dosing .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['headache']	1	2	"Sentence: Headache relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for ergotamine / caffeine ( p < or = 0 . 001 ) , with rizatriptan being superior to ergotamine / caffeine within 30 min of dosing .
Diseases: headache"	"Sentence: Headache relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for ergotamine / caffeine ( p < or = 0 . 001 ) , with rizatriptan being superior to ergotamine / caffeine within 30 min of dosing .
Diseases:"
4250	Almost 36 % of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on ergotamine / caffeine ( p < or = 0 . 001 ) .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Almost 36 % of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on ergotamine / caffeine ( p < or = 0 . 001 ) .
Diseases: pain"	"Sentence: Almost 36 % of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on ergotamine / caffeine ( p < or = 0 . 001 ) .
Diseases:"
4251	Rizatriptan was also superior to ergotamine / caffeine in the proportions of patients with no nausea , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .	O O O O O O O O O O O O O O O B O B O B O B O O O O O O O O O O O O O O O O O O O O O	['nausea', 'vomiting', 'photophobia', 'phonophobia']	4	11	"Sentence: Rizatriptan was also superior to ergotamine / caffeine in the proportions of patients with no nausea , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
Diseases: nausea, vomiting, photophobia, phonophobia"	"Sentence: Rizatriptan was also superior to ergotamine / caffeine in the proportions of patients with no nausea , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .
Diseases:"
4252	More patients were ( completely , very or somewhat ) satisfied 2 h after treatment with rizatriptan ( 69 . 8 % ) than at 2 h after treatment with ergotamine / caffeine ( 38 . 6 % , p < or = 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: More patients were ( completely , very or somewhat ) satisfied 2 h after treatment with rizatriptan ( 69 . 8 % ) than at 2 h after treatment with ergotamine / caffeine ( 38 . 6 % , p < or = 0 . 001 ) .
Diseases: "	"Sentence: More patients were ( completely , very or somewhat ) satisfied 2 h after treatment with rizatriptan ( 69 . 8 % ) than at 2 h after treatment with ergotamine / caffeine ( 38 . 6 % , p < or = 0 . 001 ) .
Diseases:"
4253	Recurrence rates were 31 . 4 % with rizatriptan and 15 . 3 % with ergotamine / caffeine .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Recurrence rates were 31 . 4 % with rizatriptan and 15 . 3 % with ergotamine / caffeine .
Diseases: "	"Sentence: Recurrence rates were 31 . 4 % with rizatriptan and 15 . 3 % with ergotamine / caffeine .
Diseases:"
4254	Both active treatments were well tolerated .	O O O O O O O	[]	0	0	"Sentence: Both active treatments were well tolerated .
Diseases: "	"Sentence: Both active treatments were well tolerated .
Diseases:"
4255	The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and ergotamine / caffeine , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O	['nausea', 'somnolence', 'dizziness']	3	11	"Sentence: The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and ergotamine / caffeine , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .
Diseases: nausea, somnolence, dizziness"	"Sentence: The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and ergotamine / caffeine , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .
Diseases:"
4256	Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy .	B I O B I O O O O O	['thrombotic microangiopathy', 'renal failure']	2	11	"Sentence: Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy .
Diseases: thrombotic microangiopathy, renal failure"	"Sentence: Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy .
Diseases:"
4257	Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a vinca alkaloid .	O O O B O B I O O O B I O B I I O O O B O O O O O O O O O O O O O	['thrombotic microangiopathy', 'renal insufficiency', 'microangiopathic hemolytic anemia', 'carcinoma', 'thrombocytopenia']	5	35	"Sentence: Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a vinca alkaloid .
Diseases: thrombotic microangiopathy, renal insufficiency, microangiopathic hemolytic anemia, carcinoma, thrombocytopenia"	"Sentence: Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a vinca alkaloid .
Diseases:"
4258	One patient had thrombotic thrombocytopenic purpura , three the hemolytic - uremic syndrome , and one an apparent forme fruste of one of these disorders .	O O O B I I O O O B I I I O O O O O O O O O O O O O	['hemolytic - uremic syndrome', 'thrombotic thrombocytopenic purpura']	2	22	"Sentence: One patient had thrombotic thrombocytopenic purpura , three the hemolytic - uremic syndrome , and one an apparent forme fruste of one of these disorders .
Diseases: hemolytic - uremic syndrome, thrombotic thrombocytopenic purpura"	"Sentence: One patient had thrombotic thrombocytopenic purpura , three the hemolytic - uremic syndrome , and one an apparent forme fruste of one of these disorders .
Diseases:"
4259	Histologic examination of the renal tissue showed evidence of intravascular coagulation , primarily affecting the small arteries , arterioles , and glomeruli .	O O O O O O O O O B I O O O O O O O O O O O O	['intravascular coagulation']	1	6	"Sentence: Histologic examination of the renal tissue showed evidence of intravascular coagulation , primarily affecting the small arteries , arterioles , and glomeruli .
Diseases: intravascular coagulation"	"Sentence: Histologic examination of the renal tissue showed evidence of intravascular coagulation , primarily affecting the small arteries , arterioles , and glomeruli .
Diseases:"
4260	Because each patient was tumor - free or had only a small tumor at the onset of this syndrome , the thrombotic microangiopathy may have been induced by chemotherapy .	O O O O B O O O O O O O B O O O O O O O O B I O O O O O O O	['tumor', 'thrombotic microangiopathy']	2	12	"Sentence: Because each patient was tumor - free or had only a small tumor at the onset of this syndrome , the thrombotic microangiopathy may have been induced by chemotherapy .
Diseases: tumor, thrombotic microangiopathy"	"Sentence: Because each patient was tumor - free or had only a small tumor at the onset of this syndrome , the thrombotic microangiopathy may have been induced by chemotherapy .
Diseases:"
4261	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug - induced bone marrow suppression .	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O B O O B O B O O O O B I I O	['anemia', 'nephrotoxicity', 'bone marrow suppression', 'thrombocytopenia', 'renal failure']	5	22	"Sentence: Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug - induced bone marrow suppression .
Diseases: anemia, nephrotoxicity, bone marrow suppression, thrombocytopenia, renal failure"	"Sentence: Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug - induced bone marrow suppression .
Diseases:"
4262	Salvage therapy with nelarabine , etoposide , and cyclophosphamide in relapsed / refractory paediatric T - cell lymphoblastic leukaemia and lymphoma .	O O O O O O O O O O O O O O B I I I I I I O	['t - cell lymphoblastic leukaemia and lymphoma']	1	12	"Sentence: Salvage therapy with nelarabine , etoposide , and cyclophosphamide in relapsed / refractory paediatric T - cell lymphoblastic leukaemia and lymphoma .
Diseases: t - cell lymphoblastic leukaemia and lymphoma"	"Sentence: Salvage therapy with nelarabine , etoposide , and cyclophosphamide in relapsed / refractory paediatric T - cell lymphoblastic leukaemia and lymphoma .
Diseases:"
4263	A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T - cell leukaemia or lymphoma .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I O	['t - cell leukaemia or lymphoma']	1	9	"Sentence: A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T - cell leukaemia or lymphoma .
Diseases: t - cell leukaemia or lymphoma"	"Sentence: A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T - cell leukaemia or lymphoma .
Diseases:"
4264	The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain .	O O O O O O O O O O O O O O O O O B O B I O	['neuropathy', 'musculoskeletal pain']	2	10	"Sentence: The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain .
Diseases: neuropathy, musculoskeletal pain"	"Sentence: The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain .
Diseases:"
4265	Haematological toxicity was greater for the combination than AraG alone , although median time to neutrophil and platelet recovery was consistent with other salvage therapies .	B I O O O O O O O O O O O O O O O O O O O O O O O O	['haematological toxicity']	1	5	"Sentence: Haematological toxicity was greater for the combination than AraG alone , although median time to neutrophil and platelet recovery was consistent with other salvage therapies .
Diseases: haematological toxicity"	"Sentence: Haematological toxicity was greater for the combination than AraG alone , although median time to neutrophil and platelet recovery was consistent with other salvage therapies .
Diseases:"
4266	All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG / VP / CPM .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG / VP / CPM .
Diseases: "	"Sentence: All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG / VP / CPM .
Diseases:"
4267	Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide , although neurological toxicity must be closely monitored .	O O O O O O O O O O O O O O O O O O O B I O O O O O	['neurological toxicity']	1	5	"Sentence: Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide , although neurological toxicity must be closely monitored .
Diseases: neurological toxicity"	"Sentence: Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide , although neurological toxicity must be closely monitored .
Diseases:"
4268	The 3 - week sulphasalazine syndrome strikes again .	O O O O O O O O O	[]	0	0	"Sentence: The 3 - week sulphasalazine syndrome strikes again .
Diseases: "	"Sentence: The 3 - week sulphasalazine syndrome strikes again .
Diseases:"
4269	A 34 - year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral sulphasalazine for sero - negative rheumatoid arthritis .	O O O O O O O O O O O B O B O B O B O O O O O O O O O O O O O O O O B I O	['hepatitis', 'fever', 'dermatitis', 'rheumatoid arthritis', 'lymphadenopathy']	5	18	"Sentence: A 34 - year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral sulphasalazine for sero - negative rheumatoid arthritis .
Diseases: hepatitis, fever, dermatitis, rheumatoid arthritis, lymphadenopathy"	"Sentence: A 34 - year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral sulphasalazine for sero - negative rheumatoid arthritis .
Diseases:"
4270	Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis , associated with erythrophagocytosis and prominent eosinophilic infiltrates , without viral inclusion bodies , suggestive of an adverse drug reaction .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B I I O	['lymphadenitis', 'adverse drug reaction']	2	8	"Sentence: Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis , associated with erythrophagocytosis and prominent eosinophilic infiltrates , without viral inclusion bodies , suggestive of an adverse drug reaction .
Diseases: lymphadenitis, adverse drug reaction"	"Sentence: Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis , associated with erythrophagocytosis and prominent eosinophilic infiltrates , without viral inclusion bodies , suggestive of an adverse drug reaction .
Diseases:"
4271	A week later , fulminant drug - induced hepatitis , associated with the presence of anti - nuclear autoantibodies ( but not with other markers of autoimmunity ) , and accompanied by multi - organ failure and sepsis , supervened .	O O O O O B I I I O O O O O O O O O O O O O O O O O B O O O O O B I I I O B O O O	['multi - organ failure', 'drug - induced hepatitis', 'sepsis', 'autoimmunity']	4	18	"Sentence: A week later , fulminant drug - induced hepatitis , associated with the presence of anti - nuclear autoantibodies ( but not with other markers of autoimmunity ) , and accompanied by multi - organ failure and sepsis , supervened .
Diseases: multi - organ failure, drug - induced hepatitis, sepsis, autoimmunity"	"Sentence: A week later , fulminant drug - induced hepatitis , associated with the presence of anti - nuclear autoantibodies ( but not with other markers of autoimmunity ) , and accompanied by multi - organ failure and sepsis , supervened .
Diseases:"
4272	She subsequently died some 5 weeks after the commencement of her drug therapy .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: She subsequently died some 5 weeks after the commencement of her drug therapy .
Diseases: "	"Sentence: She subsequently died some 5 weeks after the commencement of her drug therapy .
Diseases:"
4273	Post - mortem examination showed evidence of massive hepatocellular necrosis , acute hypersensitivity myocarditis , focal acute tubulo - interstitial nephritis and extensive bone marrow necrosis , with no evidence of malignancy .	O O O O O O O B I I O O O B O O O O O O B O O B I I O O O O O B O	['nephritis', 'malignancy', 'bone marrow necrosis', 'massive hepatocellular necrosis', 'myocarditis']	5	24	"Sentence: Post - mortem examination showed evidence of massive hepatocellular necrosis , acute hypersensitivity myocarditis , focal acute tubulo - interstitial nephritis and extensive bone marrow necrosis , with no evidence of malignancy .
Diseases: nephritis, malignancy, bone marrow necrosis, massive hepatocellular necrosis, myocarditis"	"Sentence: Post - mortem examination showed evidence of massive hepatocellular necrosis , acute hypersensitivity myocarditis , focal acute tubulo - interstitial nephritis and extensive bone marrow necrosis , with no evidence of malignancy .
Diseases:"
4274	"It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called "" 3 - week sulphasalazine syndrome "" , a rare , but often fatal , immunoallergic reaction to sulphasalazine ."	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called "" 3 - week sulphasalazine syndrome "" , a rare , but often fatal , immunoallergic reaction to sulphasalazine .
Diseases: "	"Sentence: It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called "" 3 - week sulphasalazine syndrome "" , a rare , but often fatal , immunoallergic reaction to sulphasalazine .
Diseases:"
4275	Bupropion ( Zyban ) toxicity .	O O O O B O	['toxicity']	1	2	"Sentence: Bupropion ( Zyban ) toxicity .
Diseases: toxicity"	"Sentence: Bupropion ( Zyban ) toxicity .
Diseases:"
4276	Bupropion is a monocyclic antidepressant structurally related to amphetamine .	O O O O O O O O O O	[]	0	0	"Sentence: Bupropion is a monocyclic antidepressant structurally related to amphetamine .
Diseases: "	"Sentence: Bupropion is a monocyclic antidepressant structurally related to amphetamine .
Diseases:"
4277	Zyban , a sustained - release formulation of bupropion hydrochloride , was recently released in Ireland , as a smoking cessation aid .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Zyban , a sustained - release formulation of bupropion hydrochloride , was recently released in Ireland , as a smoking cessation aid .
Diseases: "	"Sentence: Zyban , a sustained - release formulation of bupropion hydrochloride , was recently released in Ireland , as a smoking cessation aid .
Diseases:"
4278	In the initial 6 months since it 's introduction , 12 overdose cases have been reported to The National Poisons Information Centre .	O O O O O O O O O O O B O O O O O O O O O O O	['overdose']	1	2	"Sentence: In the initial 6 months since it 's introduction , 12 overdose cases have been reported to The National Poisons Information Centre .
Diseases: overdose"	"Sentence: In the initial 6 months since it 's introduction , 12 overdose cases have been reported to The National Poisons Information Centre .
Diseases:"
4279	8 patients developed symptoms of toxicity .	O O O O O B O	['toxicity']	1	2	"Sentence: 8 patients developed symptoms of toxicity .
Diseases: toxicity"	"Sentence: 8 patients developed symptoms of toxicity .
Diseases:"
4280	Common features included tachycardia , drowsiness , hallucinations and convulsions .	O O O B O O O B O B O	['hallucinations', 'tachycardia', 'convulsions']	3	12	"Sentence: Common features included tachycardia , drowsiness , hallucinations and convulsions .
Diseases: hallucinations, tachycardia, convulsions"	"Sentence: Common features included tachycardia , drowsiness , hallucinations and convulsions .
Diseases:"
4281	Two patients developed severe cardiac arrhythmias , including one patient who was resuscitated following a cardiac arrest .	O O O O B I O O O O O O O O O B I O	['cardiac arrhythmias', 'cardiac arrest']	2	9	"Sentence: Two patients developed severe cardiac arrhythmias , including one patient who was resuscitated following a cardiac arrest .
Diseases: cardiac arrhythmias, cardiac arrest"	"Sentence: Two patients developed severe cardiac arrhythmias , including one patient who was resuscitated following a cardiac arrest .
Diseases:"
4282	All patients recovered without sequelae .	O O O O O O	[]	0	0	"Sentence: All patients recovered without sequelae .
Diseases: "	"Sentence: All patients recovered without sequelae .
Diseases:"
4283	We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy , following ingestion of 13 . 5 g bupropion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy , following ingestion of 13 . 5 g bupropion .
Diseases: "	"Sentence: We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy , following ingestion of 13 . 5 g bupropion .
Diseases:"
4284	Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine .	O B O O O O O O O B O O O O O O	['tachycardia', 'seizures']	2	6	"Sentence: Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine .
Diseases: tachycardia, seizures"	"Sentence: Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine .
Diseases:"
4285	Zyban caused significant neurological and cardiovascular toxicity in overdose .	O O O B I I I O B O	['overdose', 'neurological and cardiovascular toxicity']	2	9	"Sentence: Zyban caused significant neurological and cardiovascular toxicity in overdose .
Diseases: overdose, neurological and cardiovascular toxicity"	"Sentence: Zyban caused significant neurological and cardiovascular toxicity in overdose .
Diseases:"
4286	The potential toxic effects should be considered when prescribing it as a smoking cessation aid .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The potential toxic effects should be considered when prescribing it as a smoking cessation aid .
Diseases: "	"Sentence: The potential toxic effects should be considered when prescribing it as a smoking cessation aid .
Diseases:"
4287	Survey of complications of indocyanine green angiography in Japan .	O O O O O O O O O O	[]	0	0	"Sentence: Survey of complications of indocyanine green angiography in Japan .
Diseases: "	"Sentence: Survey of complications of indocyanine green angiography in Japan .
Diseases:"
4288	We evaluated the safety of indocyanine green for use in fundus angiography .	O O O O O O O O O O O O O	[]	0	0	"Sentence: We evaluated the safety of indocyanine green for use in fundus angiography .
Diseases: "	"Sentence: We evaluated the safety of indocyanine green for use in fundus angiography .
Diseases:"
4289	METHODS : We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan , which were selected on the basis of the client list from the Topcon Company , which manufactures the indocyanine green fundus camera .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan , which were selected on the basis of the client list from the Topcon Company , which manufactures the indocyanine green fundus camera .
Diseases: "	"Sentence: METHODS : We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan , which were selected on the basis of the client list from the Topcon Company , which manufactures the indocyanine green fundus camera .
Diseases:"
4290	Ophthalmologists at 15 institutions responded , reporting a total of 3 , 774 indocyanine green angiograms performed on 2 , 820 patients between June 1984 and September 1992 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ophthalmologists at 15 institutions responded , reporting a total of 3 , 774 indocyanine green angiograms performed on 2 , 820 patients between June 1984 and September 1992 .
Diseases: "	"Sentence: Ophthalmologists at 15 institutions responded , reporting a total of 3 , 774 indocyanine green angiograms performed on 2 , 820 patients between June 1984 and September 1992 .
Diseases:"
4291	Before angiography , intradermal or intravenous indocyanine green testing , or both was performed at 13 of 15 institutions .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Before angiography , intradermal or intravenous indocyanine green testing , or both was performed at 13 of 15 institutions .
Diseases: "	"Sentence: Before angiography , intradermal or intravenous indocyanine green testing , or both was performed at 13 of 15 institutions .
Diseases:"
4292	For three patients , the decision was made not to proceed with angiography after positive preangiographic testing .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For three patients , the decision was made not to proceed with angiography after positive preangiographic testing .
Diseases: "	"Sentence: For three patients , the decision was made not to proceed with angiography after positive preangiographic testing .
Diseases:"
4293	The dosage of indocyanine green used for angiography varied from 25 to 75 mg , depending upon the institution .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The dosage of indocyanine green used for angiography varied from 25 to 75 mg , depending upon the institution .
Diseases: "	"Sentence: The dosage of indocyanine green used for angiography varied from 25 to 75 mg , depending upon the institution .
Diseases:"
4294	There were 13 cases of adverse reactions ( 0 . 34 % ) , ten of which were mild reactions such as nausea , exanthema , urtication , itchiness , and urgency to defecate , and did not require treatment .	O O O O O O O O O O O O O O O O O O O O O O B O B O B O B O O O O O O O O O O O O	['nausea', 'urtication', 'itchiness', 'exanthema']	4	15	"Sentence: There were 13 cases of adverse reactions ( 0 . 34 % ) , ten of which were mild reactions such as nausea , exanthema , urtication , itchiness , and urgency to defecate , and did not require treatment .
Diseases: nausea, urtication, itchiness, exanthema"	"Sentence: There were 13 cases of adverse reactions ( 0 . 34 % ) , ten of which were mild reactions such as nausea , exanthema , urtication , itchiness , and urgency to defecate , and did not require treatment .
Diseases:"
4295	Also recorded were one case of pain of the vein , which required treatment , and two cases of hypotension .	O O O O O O B O O O O O O O O O O O O B O	['pain', 'hypotension']	2	4	"Sentence: Also recorded were one case of pain of the vein , which required treatment , and two cases of hypotension .
Diseases: pain, hypotension"	"Sentence: Also recorded were one case of pain of the vein , which required treatment , and two cases of hypotension .
Diseases:"
4296	The two hypotensive patients required treatment for shock .	O O B O O O O B O	['shock', 'hypotensive']	2	4	"Sentence: The two hypotensive patients required treatment for shock .
Diseases: shock, hypotensive"	"Sentence: The two hypotensive patients required treatment for shock .
Diseases:"
4297	CONCLUSIONS : A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography .
Diseases: "	"Sentence: CONCLUSIONS : A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography .
Diseases:"
4298	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model .	O O O O O O O O O O O O O B O O O B I O O O	['diabetic neuropathy', 'hyperalgesia']	2	9	"Sentence: Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model .
Diseases: diabetic neuropathy, hyperalgesia"	"Sentence: Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model .
Diseases:"
4299	The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy was investigated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I I I I I I I I I O O O	['diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy']	1	24	"Sentence: The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy was investigated .
Diseases: diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy"	"Sentence: The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy was investigated .
Diseases:"
4300	The changes in pain thresholds were determined using mechanical stimuli - - the modification of the classic paw withdrawal test described by Randall - Selitto .	O O O B O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: The changes in pain thresholds were determined using mechanical stimuli - - the modification of the classic paw withdrawal test described by Randall - Selitto .
Diseases: pain"	"Sentence: The changes in pain thresholds were determined using mechanical stimuli - - the modification of the classic paw withdrawal test described by Randall - Selitto .
Diseases:"
4301	The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia .	O O O O O O O O O O O O O O O O O O O O O O B I O	['diabetic hyperalgesia']	1	6	"Sentence: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia .
Diseases: diabetic hyperalgesia"	"Sentence: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia .
Diseases:"
4302	Pretreatment with L - NOArg and L - NIL but not 7 - NI , significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pretreatment with L - NOArg and L - NIL but not 7 - NI , significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140 .
Diseases: "	"Sentence: Pretreatment with L - NOArg and L - NIL but not 7 - NI , significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140 .
Diseases:"
4303	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['hyperalgesia']	1	4	"Sentence: It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine .
Diseases: hyperalgesia"	"Sentence: It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine .
Diseases:"
4304	Moreover , L - NOArg and 7 - NI but not L - NIL intensify antihyperalgesic activity of HOE 140 or des - Arg10HOE 140 in toxic neuropathy .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['toxic neuropathy']	1	4	"Sentence: Moreover , L - NOArg and 7 - NI but not L - NIL intensify antihyperalgesic activity of HOE 140 or des - Arg10HOE 140 in toxic neuropathy .
Diseases: toxic neuropathy"	"Sentence: Moreover , L - NOArg and 7 - NI but not L - NIL intensify antihyperalgesic activity of HOE 140 or des - Arg10HOE 140 in toxic neuropathy .
Diseases:"
4305	CONCLUSIONS : Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy .	O O O O O O O O O O O O O O O O O O O O O B I I I O	['diabetic and toxic neuropathy']	1	6	"Sentence: CONCLUSIONS : Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy .
Diseases: diabetic and toxic neuropathy"	"Sentence: CONCLUSIONS : Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy .
Diseases:"
4306	In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .	O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O O	['hyperalgesia']	1	4	"Sentence: In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
Diseases: hyperalgesia"	"Sentence: In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .
Diseases:"
4307	Therefore , concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain , even in hospital care .	O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	['neuropathic pain']	1	4	"Sentence: Therefore , concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain , even in hospital care .
Diseases: neuropathic pain"	"Sentence: Therefore , concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain , even in hospital care .
Diseases:"
4308	Cardiac toxicity observed in association with high - dose cyclophosphamide - based chemotherapy for metastatic breast cancer .	B I O O O O O O O O O O O O O B I O	['cardiac toxicity', 'breast cancer']	2	6	"Sentence: Cardiac toxicity observed in association with high - dose cyclophosphamide - based chemotherapy for metastatic breast cancer .
Diseases: cardiac toxicity, breast cancer"	"Sentence: Cardiac toxicity observed in association with high - dose cyclophosphamide - based chemotherapy for metastatic breast cancer .
Diseases:"
4309	Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens .
Diseases: "	"Sentence: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens .
Diseases:"
4310	In high doses , its nonhematological dose - limiting toxicity is cardiomyopathy .	O O O O O O O O O B O B O	['cardiomyopathy', 'toxicity']	2	6	"Sentence: In high doses , its nonhematological dose - limiting toxicity is cardiomyopathy .
Diseases: cardiomyopathy, toxicity"	"Sentence: In high doses , its nonhematological dose - limiting toxicity is cardiomyopathy .
Diseases:"
4311	STUDY DESIGN : We combined paclitaxel , melphalan and high - dose cyclophosphamide , thiotepa , and carboplatin in a triple sequential high - dose regimen for patients with metastatic breast cancer .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['breast cancer']	1	3	"Sentence: STUDY DESIGN : We combined paclitaxel , melphalan and high - dose cyclophosphamide , thiotepa , and carboplatin in a triple sequential high - dose regimen for patients with metastatic breast cancer .
Diseases: breast cancer"	"Sentence: STUDY DESIGN : We combined paclitaxel , melphalan and high - dose cyclophosphamide , thiotepa , and carboplatin in a triple sequential high - dose regimen for patients with metastatic breast cancer .
Diseases:"
4312	Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left - sided chest irradiation .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O B I I O B O O O O O O O O O O O O O O O O O B O O O O O O O B I O O O O O O O O O O O O O	['diabetes mellitus', 'congestive heart failure', 'breast cancer', 'hypertension', 'chf']	5	17	"Sentence: Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left - sided chest irradiation .
Diseases: diabetes mellitus, congestive heart failure, breast cancer, hypertension, chf"	"Sentence: Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left - sided chest irradiation .
Diseases:"
4313	Six of 61 women ( 10 % ) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31 % .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['chf']	1	2	"Sentence: Six of 61 women ( 10 % ) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31 % .
Diseases: chf"	"Sentence: Six of 61 women ( 10 % ) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31 % .
Diseases:"
4314	Incidence of transient cyclophosphamide - related cardiac toxicity ( 10 % ) is comparable to previous recorded literature .	O O O O O O B I O O O O O O O O O O O	['cardiac toxicity']	1	3	"Sentence: Incidence of transient cyclophosphamide - related cardiac toxicity ( 10 % ) is comparable to previous recorded literature .
Diseases: cardiac toxicity"	"Sentence: Incidence of transient cyclophosphamide - related cardiac toxicity ( 10 % ) is comparable to previous recorded literature .
Diseases:"
4315	Older age was significantly correlated with the CHF development ; with median ages for the entire group and for patients developing CHF of 45 and 59 , respectively .	O O O O O O O B O O O O O O O O O O O O O B O O O O O O O	['chf']	1	2	"Sentence: Older age was significantly correlated with the CHF development ; with median ages for the entire group and for patients developing CHF of 45 and 59 , respectively .
Diseases: chf"	"Sentence: Older age was significantly correlated with the CHF development ; with median ages for the entire group and for patients developing CHF of 45 and 59 , respectively .
Diseases:"
4316	No association was found with other pretreatment characteristics .	O O O O O O O O O	[]	0	0	"Sentence: No association was found with other pretreatment characteristics .
Diseases: "	"Sentence: No association was found with other pretreatment characteristics .
Diseases:"
4317	CONCLUSIONS : As a result of these findings , oncologists should carefully monitor fluid balance in older patients .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : As a result of these findings , oncologists should carefully monitor fluid balance in older patients .
Diseases: "	"Sentence: CONCLUSIONS : As a result of these findings , oncologists should carefully monitor fluid balance in older patients .
Diseases:"
4318	Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development .	O O O O O O O O O B O O	['chf']	1	2	"Sentence: Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development .
Diseases: chf"	"Sentence: Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development .
Diseases:"
4319	Inappropriate use of carbamazepine and vigabatrin in typical absence seizures .	O O O O O O O O B I O	['absence seizures']	1	3	"Sentence: Inappropriate use of carbamazepine and vigabatrin in typical absence seizures .
Diseases: absence seizures"	"Sentence: Inappropriate use of carbamazepine and vigabatrin in typical absence seizures .
Diseases:"
4320	Carbamazepine and vigabatrin are contraindicated in typical absence seizures .	O O O O O O O B I O	['absence seizures']	1	3	"Sentence: Carbamazepine and vigabatrin are contraindicated in typical absence seizures .
Diseases: absence seizures"	"Sentence: Carbamazepine and vigabatrin are contraindicated in typical absence seizures .
Diseases:"
4321	Of 18 consecutive referrals of children with resistant typical absences only , eight were erroneously treated with carbamazepine either as monotherapy or as an add - on .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of 18 consecutive referrals of children with resistant typical absences only , eight were erroneously treated with carbamazepine either as monotherapy or as an add - on .
Diseases: "	"Sentence: Of 18 consecutive referrals of children with resistant typical absences only , eight were erroneously treated with carbamazepine either as monotherapy or as an add - on .
Diseases:"
4322	Vigabatrin was also used in the treatment of two children .	O O O O O O O O O O O	[]	0	0	"Sentence: Vigabatrin was also used in the treatment of two children .
Diseases: "	"Sentence: Vigabatrin was also used in the treatment of two children .
Diseases:"
4323	Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks , which resolved on withdrawal of carbamazepine .	O O O O O O O O O O O O O O O B I O O O O O O O O	['myoclonic jerks']	1	5	"Sentence: Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks , which resolved on withdrawal of carbamazepine .
Diseases: myoclonic jerks"	"Sentence: Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks , which resolved on withdrawal of carbamazepine .
Diseases:"
4324	Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment .
Diseases: "	"Sentence: Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment .
Diseases:"
4325	Optimal control of the absences was achieved with sodium valproate , lamotrigine , or ethosuximide alone or in combination .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Optimal control of the absences was achieved with sodium valproate , lamotrigine , or ethosuximide alone or in combination .
Diseases: "	"Sentence: Optimal control of the absences was achieved with sodium valproate , lamotrigine , or ethosuximide alone or in combination .
Diseases:"
4326	Hemolytic anemia associated with the use of omeprazole .	B I O O O O O O O	['hemolytic anemia']	1	5	"Sentence: Hemolytic anemia associated with the use of omeprazole .
Diseases: hemolytic anemia"	"Sentence: Hemolytic anemia associated with the use of omeprazole .
Diseases:"
4327	Omeprazole is the first drug designed to block the final step in the acid secretory process within the parietal cell .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Omeprazole is the first drug designed to block the final step in the acid secretory process within the parietal cell .
Diseases: "	"Sentence: Omeprazole is the first drug designed to block the final step in the acid secretory process within the parietal cell .
Diseases:"
4328	It has been shown to be extremely effective in the treatment of peptic ulcer disease , reflux esophagitis , and the Zollinger - Ellison syndrome .	O O O O O O O O O O O O B I I O B I O O O B I I I O	['peptic ulcer disease', 'reflux esophagitis', 'zollinger - ellison syndrome']	3	20	"Sentence: It has been shown to be extremely effective in the treatment of peptic ulcer disease , reflux esophagitis , and the Zollinger - Ellison syndrome .
Diseases: peptic ulcer disease, reflux esophagitis, zollinger - ellison syndrome"	"Sentence: It has been shown to be extremely effective in the treatment of peptic ulcer disease , reflux esophagitis , and the Zollinger - Ellison syndrome .
Diseases:"
4329	Although clinical experience with omeprazole is still limited , many controlled studies have established the short - term safety of this drug .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although clinical experience with omeprazole is still limited , many controlled studies have established the short - term safety of this drug .
Diseases: "	"Sentence: Although clinical experience with omeprazole is still limited , many controlled studies have established the short - term safety of this drug .
Diseases:"
4330	We report the first case of a serious short - term adverse reaction with the use of omeprazole : hemolytic anemia .	O O O O O O O O O O O O O O O O O O O B I O	['hemolytic anemia']	1	5	"Sentence: We report the first case of a serious short - term adverse reaction with the use of omeprazole : hemolytic anemia .
Diseases: hemolytic anemia"	"Sentence: We report the first case of a serious short - term adverse reaction with the use of omeprazole : hemolytic anemia .
Diseases:"
4331	The patient developed weakness , lethargy , and shortness of breath 2 days after starting therapy with omeprazole .	O O O O O B O O B I I O O O O O O O O	['lethargy', 'shortness of breath']	2	9	"Sentence: The patient developed weakness , lethargy , and shortness of breath 2 days after starting therapy with omeprazole .
Diseases: lethargy, shortness of breath"	"Sentence: The patient developed weakness , lethargy , and shortness of breath 2 days after starting therapy with omeprazole .
Diseases:"
4332	Two weeks after the initiation of therapy , her hematocrit had decreased from 44 . 1 % to 20 . 4 % , and she had a positive direct Coombs antiglobulin test and an elevated indirect bilirubin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two weeks after the initiation of therapy , her hematocrit had decreased from 44 . 1 % to 20 . 4 % , and she had a positive direct Coombs antiglobulin test and an elevated indirect bilirubin .
Diseases: "	"Sentence: Two weeks after the initiation of therapy , her hematocrit had decreased from 44 . 1 % to 20 . 4 % , and she had a positive direct Coombs antiglobulin test and an elevated indirect bilirubin .
Diseases:"
4333	After she discontinued the omeprazole , her hemoglobin and hematocrit gradually returned to normal .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After she discontinued the omeprazole , her hemoglobin and hematocrit gradually returned to normal .
Diseases: "	"Sentence: After she discontinued the omeprazole , her hemoglobin and hematocrit gradually returned to normal .
Diseases:"
4334	The mechanism by which omeprazole caused the patient 's hemolytic anemia is uncertain , but physicians should be alerted to this possible adverse effect .	O O O O O O O O O B I O O O O O O O O O O O O O O	['hemolytic anemia']	1	5	"Sentence: The mechanism by which omeprazole caused the patient 's hemolytic anemia is uncertain , but physicians should be alerted to this possible adverse effect .
Diseases: hemolytic anemia"	"Sentence: The mechanism by which omeprazole caused the patient 's hemolytic anemia is uncertain , but physicians should be alerted to this possible adverse effect .
Diseases:"
4335	The use and toxicity of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT )	O O O B O O O O O O B I I I O O O O O O O	['hiv antibody - positive', 'toxicity']	2	7	"Sentence: The use and toxicity of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT )
Diseases: hiv antibody - positive, toxicity"	"Sentence: The use and toxicity of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT )
Diseases:"
4336	One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
Diseases: "	"Sentence: One hundred and fifty - one patients intolerant to zidovudine ( AZT ) received didanosine ( ddI ) to a maximum dose of 12 . 5 mg / kg / day .
Diseases:"
4337	Patient response was assessed using changes in CD4 + lymphocyte subset count , HIV p24 antigen , weight , and quality of life .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patient response was assessed using changes in CD4 + lymphocyte subset count , HIV p24 antigen , weight , and quality of life .
Diseases: "	"Sentence: Patient response was assessed using changes in CD4 + lymphocyte subset count , HIV p24 antigen , weight , and quality of life .
Diseases:"
4338	Seventy patients developed major opportunistic infections whilst on therapy ; this was the first AIDS diagnosis in 17 .	O O O O B I O O O O O O O O B O O O O	['opportunistic infections', 'aids']	2	6	"Sentence: Seventy patients developed major opportunistic infections whilst on therapy ; this was the first AIDS diagnosis in 17 .
Diseases: opportunistic infections, aids"	"Sentence: Seventy patients developed major opportunistic infections whilst on therapy ; this was the first AIDS diagnosis in 17 .
Diseases:"
4339	Only minor changes in CD4 + lymphocyte subset count were observed in AIDS patients , although a more significant rise occurred in those with earlier stages of disease .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['aids']	1	2	"Sentence: Only minor changes in CD4 + lymphocyte subset count were observed in AIDS patients , although a more significant rise occurred in those with earlier stages of disease .
Diseases: aids"	"Sentence: Only minor changes in CD4 + lymphocyte subset count were observed in AIDS patients , although a more significant rise occurred in those with earlier stages of disease .
Diseases:"
4340	Of those positive for p24 antigen at the commencement of the study 67 % showed a positive response , and this was most likely in those with CD4 + lymphocyte subset counts above 100 mm3 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of those positive for p24 antigen at the commencement of the study 67 % showed a positive response , and this was most likely in those with CD4 + lymphocyte subset counts above 100 mm3 .
Diseases: "	"Sentence: Of those positive for p24 antigen at the commencement of the study 67 % showed a positive response , and this was most likely in those with CD4 + lymphocyte subset counts above 100 mm3 .
Diseases:"
4341	A positive weight response was seen in 16 % of patients .	O O O O O O O O O O O O	[]	0	0	"Sentence: A positive weight response was seen in 16 % of patients .
Diseases: "	"Sentence: A positive weight response was seen in 16 % of patients .
Diseases:"
4342	Most patients showed improvement in individual parameters and global score of quality of life .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Most patients showed improvement in individual parameters and global score of quality of life .
Diseases: "	"Sentence: Most patients showed improvement in individual parameters and global score of quality of life .
Diseases:"
4343	Adverse reactions possibly attributable to didanosine were common .	O O O O O O O O O	[]	0	0	"Sentence: Adverse reactions possibly attributable to didanosine were common .
Diseases: "	"Sentence: Adverse reactions possibly attributable to didanosine were common .
Diseases:"
4344	The most common side - effect was diarrhoea , which resulted in cessation of therapy in 19 individuals .	O O O O O O O B O O O O O O O O O O O	['diarrhoea']	1	4	"Sentence: The most common side - effect was diarrhoea , which resulted in cessation of therapy in 19 individuals .
Diseases: diarrhoea"	"Sentence: The most common side - effect was diarrhoea , which resulted in cessation of therapy in 19 individuals .
Diseases:"
4345	Peripheral neuropathy occurred in 12 patients and pancreatitis in six .	B I O O O O O B O O O	['peripheral neuropathy', 'pancreatitis']	2	8	"Sentence: Peripheral neuropathy occurred in 12 patients and pancreatitis in six .
Diseases: peripheral neuropathy, pancreatitis"	"Sentence: Peripheral neuropathy occurred in 12 patients and pancreatitis in six .
Diseases:"
4346	Thirteen patients developed a raised serum amylase without abdominal pain .	O O O O O O O O B I O	['abdominal pain']	1	4	"Sentence: Thirteen patients developed a raised serum amylase without abdominal pain .
Diseases: abdominal pain"	"Sentence: Thirteen patients developed a raised serum amylase without abdominal pain .
Diseases:"
4347	Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild , did not require treatment and returned to normal on ceasing didanosine .	O O O B I I O O B O O O O O O O O O O O O O O O O O	['diabetes', 'glucose tolerance curves']	2	6	"Sentence: Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild , did not require treatment and returned to normal on ceasing didanosine .
Diseases: diabetes, glucose tolerance curves"	"Sentence: Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild , did not require treatment and returned to normal on ceasing didanosine .
Diseases:"
4348	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia ?	O O O O O O O O O O B I O	['hemolytic anemia']	1	5	"Sentence: Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia ?
Diseases: hemolytic anemia"	"Sentence: Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia ?
Diseases:"
4349	Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis .	O O O O O O O O O O O O O O O O O O O O O O O O O B O	['hemolysis']	1	3	"Sentence: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis .
Diseases: hemolysis"	"Sentence: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis .
Diseases:"
4350	We aimed to investigate whether there is a relation between hemoglobin , haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['anemia']	1	2	"Sentence: We aimed to investigate whether there is a relation between hemoglobin , haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia .
Diseases: anemia"	"Sentence: We aimed to investigate whether there is a relation between hemoglobin , haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia .
Diseases:"
4351	Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin .	O O B I I I I I O O O O O O O O O O	['chronically infected with hepatitis c virus']	1	7	"Sentence: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin .
Diseases: chronically infected with hepatitis c virus"	"Sentence: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin .
Diseases:"
4352	Serum hemoglobin , haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin - 2 were investigated before and after therapy .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serum hemoglobin , haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin - 2 were investigated before and after therapy .
Diseases: "	"Sentence: Serum hemoglobin , haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin - 2 were investigated before and after therapy .
Diseases:"
4353	We observed a significant decrease in haptoglobin levels at the end of the treatment period .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We observed a significant decrease in haptoglobin levels at the end of the treatment period .
Diseases: "	"Sentence: We observed a significant decrease in haptoglobin levels at the end of the treatment period .
Diseases:"
4354	Hemoglobin levels also decreased but insignificantly by treatment .	O O O O O O O O O	[]	0	0	"Sentence: Hemoglobin levels also decreased but insignificantly by treatment .
Diseases: "	"Sentence: Hemoglobin levels also decreased but insignificantly by treatment .
Diseases:"
4355	In contrast with the literature , serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast with the literature , serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy .
Diseases: "	"Sentence: In contrast with the literature , serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy .
Diseases:"
4356	We found no correlation of angiogenesis soluble markers with either hemoglobin or haptoglobin .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: We found no correlation of angiogenesis soluble markers with either hemoglobin or haptoglobin .
Diseases: "	"Sentence: We found no correlation of angiogenesis soluble markers with either hemoglobin or haptoglobin .
Diseases:"
4357	This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation .	O O O O O O O O O O O O O O O O O O B O O O B I O O O O O O O O	['anemia', 'hepatitis c']	2	5	"Sentence: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation .
Diseases: anemia, hepatitis c"	"Sentence: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation .
Diseases:"
4358	Future research with larger number of patients is needed to find out modifiable factors that will improve the safety of ribavirin therapy .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Future research with larger number of patients is needed to find out modifiable factors that will improve the safety of ribavirin therapy .
Diseases: "	"Sentence: Future research with larger number of patients is needed to find out modifiable factors that will improve the safety of ribavirin therapy .
Diseases:"
4359	Cocaine causes memory and learning impairments in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by topiramate .	O O B I I I O O O O O O O O O O O O O O O O O O	['memory and learning impairments']	1	5	"Sentence: Cocaine causes memory and learning impairments in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by topiramate .
Diseases: memory and learning impairments"	"Sentence: Cocaine causes memory and learning impairments in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by topiramate .
Diseases:"
4360	Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced - behaviour is poorly understood .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced - behaviour is poorly understood .
Diseases: toxicity"	"Sentence: Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced - behaviour is poorly understood .
Diseases:"
4361	Nuclear factor kappa B ( NFkappaB ) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms .	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['toxicity']	1	2	"Sentence: Nuclear factor kappa B ( NFkappaB ) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms .
Diseases: toxicity"	"Sentence: Nuclear factor kappa B ( NFkappaB ) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms .
Diseases:"
4362	Therefore NFkappaB activity , oxidative stress , neuronal nitric oxide synthase ( nNOS ) activity , spatial learning and memory as well as the effect of topiramate , a previously proposed therapy for cocaine addiction , were evaluated in an experimental model of cocaine administration in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	['cocaine addiction']	1	4	"Sentence: Therefore NFkappaB activity , oxidative stress , neuronal nitric oxide synthase ( nNOS ) activity , spatial learning and memory as well as the effect of topiramate , a previously proposed therapy for cocaine addiction , were evaluated in an experimental model of cocaine administration in rats .
Diseases: cocaine addiction"	"Sentence: Therefore NFkappaB activity , oxidative stress , neuronal nitric oxide synthase ( nNOS ) activity , spatial learning and memory as well as the effect of topiramate , a previously proposed therapy for cocaine addiction , were evaluated in an experimental model of cocaine administration in rats .
Diseases:"
4363	NFkappaB activity was decreased in the frontal cortex of cocaine treated rats , as well as GSH concentration and glutathione peroxidase activity in the hippocampus , whereas nNOS activity in the hippocampus was increased .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NFkappaB activity was decreased in the frontal cortex of cocaine treated rats , as well as GSH concentration and glutathione peroxidase activity in the hippocampus , whereas nNOS activity in the hippocampus was increased .
Diseases: "	"Sentence: NFkappaB activity was decreased in the frontal cortex of cocaine treated rats , as well as GSH concentration and glutathione peroxidase activity in the hippocampus , whereas nNOS activity in the hippocampus was increased .
Diseases:"
4364	Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex .
Diseases: "	"Sentence: Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex .
Diseases:"
4365	In contrast , learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase .
Diseases: "	"Sentence: In contrast , learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase .
Diseases:"
4366	These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine .
Diseases: "	"Sentence: These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine .
Diseases:"
4367	Topiramate prevented all the alterations observed , showing novel neuroprotective properties .	O O O O O O O O O O O O	[]	0	0	"Sentence: Topiramate prevented all the alterations observed , showing novel neuroprotective properties .
Diseases: "	"Sentence: Topiramate prevented all the alterations observed , showing novel neuroprotective properties .
Diseases:"
4368	Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG - 9 .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG - 9 .
Diseases: "	"Sentence: Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG - 9 .
Diseases:"
4369	The antinociceptive effect of 3 alpha - tropyl 2 - ( p - bromophenyl ) propionate	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The antinociceptive effect of 3 alpha - tropyl 2 - ( p - bromophenyl ) propionate
Diseases: "	"Sentence: The antinociceptive effect of 3 alpha - tropyl 2 - ( p - bromophenyl ) propionate
Diseases:"
4370	[ ( + / - ) - PG - 9 ] ( 10 - 40 mg kg - 1 s . c . ; 30 - 60 mg kg - 1 p . o .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: [ ( + / - ) - PG - 9 ] ( 10 - 40 mg kg - 1 s . c . ; 30 - 60 mg kg - 1 p . o .
Diseases: "	"Sentence: [ ( + / - ) - PG - 9 ] ( 10 - 40 mg kg - 1 s . c . ; 30 - 60 mg kg - 1 p . o .
Diseases:"
4371	; 10 - 30 mg kg - 1 i . v . ; 10 - 30 micrograms / mouse i . c . v . ) was examined in mice , rats and guinea pigs by use of the hot - plate , abdominal - constriction , tail - flick and paw - pressure tests .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ; 10 - 30 mg kg - 1 i . v . ; 10 - 30 micrograms / mouse i . c . v . ) was examined in mice , rats and guinea pigs by use of the hot - plate , abdominal - constriction , tail - flick and paw - pressure tests .
Diseases: "	"Sentence: ; 10 - 30 mg kg - 1 i . v . ; 10 - 30 micrograms / mouse i . c . v . ) was examined in mice , rats and guinea pigs by use of the hot - plate , abdominal - constriction , tail - flick and paw - pressure tests .
Diseases:"
4372	( + / - ) - PG - 9 antinociception peaked 15 min after injection and then slowly diminished .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ( + / - ) - PG - 9 antinociception peaked 15 min after injection and then slowly diminished .
Diseases: "	"Sentence: ( + / - ) - PG - 9 antinociception peaked 15 min after injection and then slowly diminished .
Diseases:"
4373	The antinociception produced by ( + / - ) - PG - 9 was prevented by the unselective muscarinic antagonist atropine , the M1 - selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium - 3 , but not by the opioid antagonist naloxone , the gamma - aminobutyric acidB antagonist 3 - aminopropyl - diethoxy - methyl - phosphinic acid , the H3 agonist R - ( alpha ) - methylhistamine , the D2 antagonist quinpirole , the 5 - hydroxytryptamine4 antagonist 2 - methoxy - 4 - amino - 5 - chlorobenzoic acid 2 - ( diethylamino ) ethyl ester hydrochloride , the 5 - hydroxytryptamin1A antagonist 1 - ( 2 - methoxyphenyl ) - 4 - [ 4 - ( 2 - phthalimido ) butyl ] piperazine hydrobromide and the polyamines depletor reserpine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The antinociception produced by ( + / - ) - PG - 9 was prevented by the unselective muscarinic antagonist atropine , the M1 - selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium - 3 , but not by the opioid antagonist naloxone , the gamma - aminobutyric acidB antagonist 3 - aminopropyl - diethoxy - methyl - phosphinic acid , the H3 agonist R - ( alpha ) - methylhistamine , the D2 antagonist quinpirole , the 5 - hydroxytryptamine4 antagonist 2 - methoxy - 4 - amino - 5 - chlorobenzoic acid 2 - ( diethylamino ) ethyl ester hydrochloride , the 5 - hydroxytryptamin1A antagonist 1 - ( 2 - methoxyphenyl ) - 4 - [ 4 - ( 2 - phthalimido ) butyl ] piperazine hydrobromide and the polyamines depletor reserpine .
Diseases: "	"Sentence: The antinociception produced by ( + / - ) - PG - 9 was prevented by the unselective muscarinic antagonist atropine , the M1 - selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium - 3 , but not by the opioid antagonist naloxone , the gamma - aminobutyric acidB antagonist 3 - aminopropyl - diethoxy - methyl - phosphinic acid , the H3 agonist R - ( alpha ) - methylhistamine , the D2 antagonist quinpirole , the 5 - hydroxytryptamine4 antagonist 2 - methoxy - 4 - amino - 5 - chlorobenzoic acid 2 - ( diethylamino ) ethyl ester hydrochloride , the 5 - hydroxytryptamin1A antagonist 1 - ( 2 - methoxyphenyl ) - 4 - [ 4 - ( 2 - phthalimido ) butyl ] piperazine hydrobromide and the polyamines depletor reserpine .
Diseases:"
4374	Based on these data , it can be postulated that ( + / - ) - PG - 9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Based on these data , it can be postulated that ( + / - ) - PG - 9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission .
Diseases: "	"Sentence: Based on these data , it can be postulated that ( + / - ) - PG - 9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission .
Diseases:"
4375	( + / - ) - PG - 9 ( 10 - 40 mg kg - 1 i . p . ) was able to prevent amnesia induced by scopolamine ( 1 mg kg - 1 i . p . )	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: ( + / - ) - PG - 9 ( 10 - 40 mg kg - 1 i . p . ) was able to prevent amnesia induced by scopolamine ( 1 mg kg - 1 i . p . )
Diseases: amnesia"	"Sentence: ( + / - ) - PG - 9 ( 10 - 40 mg kg - 1 i . p . ) was able to prevent amnesia induced by scopolamine ( 1 mg kg - 1 i . p . )
Diseases:"
4376	and dicyclomine ( 2 mg kg - 1 i . p . )	O O O O O O O O O O O O O	[]	0	0	"Sentence: and dicyclomine ( 2 mg kg - 1 i . p . )
Diseases: "	"Sentence: and dicyclomine ( 2 mg kg - 1 i . p . )
Diseases:"
4377	in the mouse passive - avoidance test .	O O O O O O O O	[]	0	0	"Sentence: in the mouse passive - avoidance test .
Diseases: "	"Sentence: in the mouse passive - avoidance test .
Diseases:"
4378	Affinity profiles of ( + / - ) - PG - 9 for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4 / M1 selectivity ratio of 10 . 2 that might be responsible for the antinociception and the anti - amnesic effect induced by ( + / - ) - PG - 9 through an increase in acetylcholine extracellular levels .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['amnesic']	1	3	"Sentence: Affinity profiles of ( + / - ) - PG - 9 for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4 / M1 selectivity ratio of 10 . 2 that might be responsible for the antinociception and the anti - amnesic effect induced by ( + / - ) - PG - 9 through an increase in acetylcholine extracellular levels .
Diseases: amnesic"	"Sentence: Affinity profiles of ( + / - ) - PG - 9 for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4 / M1 selectivity ratio of 10 . 2 that might be responsible for the antinociception and the anti - amnesic effect induced by ( + / - ) - PG - 9 through an increase in acetylcholine extracellular levels .
Diseases:"
4379	In the antinociceptive and antiamnesic dose range , ( + / - ) - PG - 9 did not impair mouse performance evaluated by the rota - rod test and Animex apparatus .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the antinociceptive and antiamnesic dose range , ( + / - ) - PG - 9 did not impair mouse performance evaluated by the rota - rod test and Animex apparatus .
Diseases: "	"Sentence: In the antinociceptive and antiamnesic dose range , ( + / - ) - PG - 9 did not impair mouse performance evaluated by the rota - rod test and Animex apparatus .
Diseases:"
4380	Hyperbaric oxygen therapy for control of intractable cyclophosphamide - induced hemorrhagic cystitis .	O O O O O O O O O O B I O	['hemorrhagic cystitis']	1	7	"Sentence: Hyperbaric oxygen therapy for control of intractable cyclophosphamide - induced hemorrhagic cystitis .
Diseases: hemorrhagic cystitis"	"Sentence: Hyperbaric oxygen therapy for control of intractable cyclophosphamide - induced hemorrhagic cystitis .
Diseases:"
4381	We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener 's granulomatosis .	O O O O O O B I O O O O O B I I O	"[""wegener 's granulomatosis"", 'hemorrhagic cystitis']"	2	15	"Sentence: We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener 's granulomatosis .
Diseases: wegener 's granulomatosis, hemorrhagic cystitis"	"Sentence: We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener 's granulomatosis .
Diseases:"
4382	Conservative treatment , including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha , failed to totally control hemorrhage .	O O O O O O O O O O O O O O O O O O O O B O	['hemorrhage']	1	4	"Sentence: Conservative treatment , including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha , failed to totally control hemorrhage .
Diseases: hemorrhage"	"Sentence: Conservative treatment , including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha , failed to totally control hemorrhage .
Diseases:"
4383	We then used hyperbaric oxygen at an absolute pressure of 2 atm , 5 days a week for 8 consecutive weeks .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We then used hyperbaric oxygen at an absolute pressure of 2 atm , 5 days a week for 8 consecutive weeks .
Diseases: "	"Sentence: We then used hyperbaric oxygen at an absolute pressure of 2 atm , 5 days a week for 8 consecutive weeks .
Diseases:"
4384	The bleeding ceased completely by the end of treatment and the patient remained free of hematuria thereafter .	O B O O O O O O O O O O O O O B O O	['hematuria', 'bleeding']	2	5	"Sentence: The bleeding ceased completely by the end of treatment and the patient remained free of hematuria thereafter .
Diseases: hematuria, bleeding"	"Sentence: The bleeding ceased completely by the end of treatment and the patient remained free of hematuria thereafter .
Diseases:"
4385	No side effect was noted during the course of therapy .	O O O O O O O O O O O	[]	0	0	"Sentence: No side effect was noted during the course of therapy .
Diseases: "	"Sentence: No side effect was noted during the course of therapy .
Diseases:"
4386	In future , this form of therapy can offer a safe alternative in the treatment of cyclophosphamide - induced hemorrhagic cystitis .	O O O O O O O O O O O O O O O O O O O B I O	['hemorrhagic cystitis']	1	7	"Sentence: In future , this form of therapy can offer a safe alternative in the treatment of cyclophosphamide - induced hemorrhagic cystitis .
Diseases: hemorrhagic cystitis"	"Sentence: In future , this form of therapy can offer a safe alternative in the treatment of cyclophosphamide - induced hemorrhagic cystitis .
Diseases:"
4387	Further studies on effects of irrigation solutions on rat bladders .	O O O O O O O O O O O	[]	0	0	"Sentence: Further studies on effects of irrigation solutions on rat bladders .
Diseases: "	"Sentence: Further studies on effects of irrigation solutions on rat bladders .
Diseases:"
4388	Further studies on the effects of certain irrigating fluids on the rat bladder for 18 hours are reported .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Further studies on the effects of certain irrigating fluids on the rat bladder for 18 hours are reported .
Diseases: "	"Sentence: Further studies on the effects of certain irrigating fluids on the rat bladder for 18 hours are reported .
Diseases:"
4389	The results have shown that the degradation product p - choloroaniline is not a significant factor in chlorhexidine - digluconate associated erosive cystitis .	O O O O O O O O O O O O O O O O O O O O O O B O	['cystitis']	1	3	"Sentence: The results have shown that the degradation product p - choloroaniline is not a significant factor in chlorhexidine - digluconate associated erosive cystitis .
Diseases: cystitis"	"Sentence: The results have shown that the degradation product p - choloroaniline is not a significant factor in chlorhexidine - digluconate associated erosive cystitis .
Diseases:"
4390	A high percentage of kanamycin - colistin and povidone - iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage .	O O O O O O O O O O O O O O O O B O O O O O O O O O	['cystitis']	1	3	"Sentence: A high percentage of kanamycin - colistin and povidone - iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage .
Diseases: cystitis"	"Sentence: A high percentage of kanamycin - colistin and povidone - iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage .
Diseases:"
4391	Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['cystitis']	1	3	"Sentence: Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures .
Diseases: cystitis"	"Sentence: Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures .
Diseases:"
4392	Clinical experiences in an open and a double - blind trial .	O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical experiences in an open and a double - blind trial .
Diseases: "	"Sentence: Clinical experiences in an open and a double - blind trial .
Diseases:"
4393	A total of sixty patients were trated with bromperidol first in open conditions ( 20 patients ) , then on a double blind basis ( 40 patients ) with haloperidol as the reference substance .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A total of sixty patients were trated with bromperidol first in open conditions ( 20 patients ) , then on a double blind basis ( 40 patients ) with haloperidol as the reference substance .
Diseases: "	"Sentence: A total of sixty patients were trated with bromperidol first in open conditions ( 20 patients ) , then on a double blind basis ( 40 patients ) with haloperidol as the reference substance .
Diseases:"
4394	The open study lasted for four weeks ; the drug was administrated in the form of 1 mg tablets .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The open study lasted for four weeks ; the drug was administrated in the form of 1 mg tablets .
Diseases: "	"Sentence: The open study lasted for four weeks ; the drug was administrated in the form of 1 mg tablets .
Diseases:"
4395	The daily dose ( initial dose : 1 mg ; mean dose at the end of the trial : 4 . 47 mg ) was always administered in one single dose .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The daily dose ( initial dose : 1 mg ; mean dose at the end of the trial : 4 . 47 mg ) was always administered in one single dose .
Diseases: "	"Sentence: The daily dose ( initial dose : 1 mg ; mean dose at the end of the trial : 4 . 47 mg ) was always administered in one single dose .
Diseases:"
4396	Nineteen patients finished the trial , and in 18 cases the therapeutic result was considered very good to good .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nineteen patients finished the trial , and in 18 cases the therapeutic result was considered very good to good .
Diseases: "	"Sentence: Nineteen patients finished the trial , and in 18 cases the therapeutic result was considered very good to good .
Diseases:"
4397	These results were confirmed by statistical analysis .	O O O O O O O O	[]	0	0	"Sentence: These results were confirmed by statistical analysis .
Diseases: "	"Sentence: These results were confirmed by statistical analysis .
Diseases:"
4398	Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms ; no other side effects were observed .	O O O O O O B I I O O O O O O O O	['extrapyramidal concomitant symptoms']	1	9	"Sentence: Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms ; no other side effects were observed .
Diseases: extrapyramidal concomitant symptoms"	"Sentence: Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms ; no other side effects were observed .
Diseases:"
4399	The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects .
Diseases: "	"Sentence: The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects .
Diseases:"
4400	In the double blind study with haloperidol , both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group .	O O O O O O O O O O O O O O O O O O O O B I I I I I I I O	['psychotic syndromes belonging predominantly to the schizophrenia group']	1	11	"Sentence: In the double blind study with haloperidol , both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group .
Diseases: psychotic syndromes belonging predominantly to the schizophrenia group"	"Sentence: In the double blind study with haloperidol , both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group .
Diseases:"
4401	Certain clues , including the onset of action , seem to be indicative of the superiority of bromperidol .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Certain clues , including the onset of action , seem to be indicative of the superiority of bromperidol .
Diseases: "	"Sentence: Certain clues , including the onset of action , seem to be indicative of the superiority of bromperidol .
Diseases:"
4402	No differences were observed with respect to side effects and general tolerability .	O O O O O O O O O O O O O	[]	0	0	"Sentence: No differences were observed with respect to side effects and general tolerability .
Diseases: "	"Sentence: No differences were observed with respect to side effects and general tolerability .
Diseases:"
4403	Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats .	O O B I O O O O O O O O O O	['cognitive dysfunction']	1	3	"Sentence: Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats .
Diseases: cognitive dysfunction"	"Sentence: Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats .
Diseases:"
4404	The antiepileptic drugs , phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use .	O O O O O O O O O O O O B I O O O O	['cognitive impairment']	1	3	"Sentence: The antiepileptic drugs , phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use .
Diseases: cognitive impairment"	"Sentence: The antiepileptic drugs , phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use .
Diseases:"
4405	The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs .	O O O O O O O O O O O O O O O O B I O O O O	['cognitive impairment']	1	3	"Sentence: The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs .
Diseases: cognitive impairment"	"Sentence: The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs .
Diseases:"
4406	Curcumin has shown antioxidant , anti - inflammatory and neuro - protective properties .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Curcumin has shown antioxidant , anti - inflammatory and neuro - protective properties .
Diseases: "	"Sentence: Curcumin has shown antioxidant , anti - inflammatory and neuro - protective properties .
Diseases:"
4407	Therefore , the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone - and carbamazepine - induced cognitive impairment and oxidative stress in rats .	O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	['cognitive impairment']	1	3	"Sentence: Therefore , the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone - and carbamazepine - induced cognitive impairment and oxidative stress in rats .
Diseases: cognitive impairment"	"Sentence: Therefore , the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone - and carbamazepine - induced cognitive impairment and oxidative stress in rats .
Diseases:"
4408	Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied .	O O O O O O O O O O O O	[]	0	0	"Sentence: Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied .
Diseases: "	"Sentence: Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied .
Diseases:"
4409	Vehicle / drugs were administered daily for 21days to male Wistar rats .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Vehicle / drugs were administered daily for 21days to male Wistar rats .
Diseases: "	"Sentence: Vehicle / drugs were administered daily for 21days to male Wistar rats .
Diseases:"
4410	Passive avoidance paradigm and elevated plus maze test were used to assess cognitive function .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Passive avoidance paradigm and elevated plus maze test were used to assess cognitive function .
Diseases: "	"Sentence: Passive avoidance paradigm and elevated plus maze test were used to assess cognitive function .
Diseases:"
4411	At the end of study period , serum phenobarbitone and carbamazepine , whole brain malondialdehyde and reduced glutathione levels were estimated .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At the end of study period , serum phenobarbitone and carbamazepine , whole brain malondialdehyde and reduced glutathione levels were estimated .
Diseases: "	"Sentence: At the end of study period , serum phenobarbitone and carbamazepine , whole brain malondialdehyde and reduced glutathione levels were estimated .
Diseases:"
4412	The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress .	O O O O O O O O O O O B I I I I O O O O O O O O	['impairment of learning and memory']	1	7	"Sentence: The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress .
Diseases: impairment of learning and memory"	"Sentence: The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress .
Diseases:"
4413	Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs .	O O O O O B I O O O O O O O O O O O O	['cognitive impairment']	1	3	"Sentence: Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs .
Diseases: cognitive impairment"	"Sentence: Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs .
Diseases:"
4414	Curcumin co - administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Curcumin co - administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine .
Diseases: "	"Sentence: Curcumin co - administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine .
Diseases:"
4415	These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations .	O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O	['deterioration of cognitive functions']	1	7	"Sentence: These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations .
Diseases: deterioration of cognitive functions"	"Sentence: These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations .
Diseases:"
4416	The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs .	O O O O O O O O O O O O O O O O O O O O O O B I O O O O O	['cognitive impairment']	1	3	"Sentence: The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs .
Diseases: cognitive impairment"	"Sentence: The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs .
Diseases:"
4417	Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model .	O O O O O O O O O B I O O	['status epilepticus']	1	4	"Sentence: Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model .
Diseases: status epilepticus"	"Sentence: Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model .
Diseases:"
4418	Pyrrolidine dithiocarbamate ( PDTC ) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa - beta .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pyrrolidine dithiocarbamate ( PDTC ) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa - beta .
Diseases: "	"Sentence: Pyrrolidine dithiocarbamate ( PDTC ) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa - beta .
Diseases:"
4419	Both , production of reactive oxygen species as well as activation of NF - kappaB have been implicated in severe neuronal damage in different sub - regions of the hippocampus as well as in the surrounding cortices .	O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O	['neuronal damage']	1	4	"Sentence: Both , production of reactive oxygen species as well as activation of NF - kappaB have been implicated in severe neuronal damage in different sub - regions of the hippocampus as well as in the surrounding cortices .
Diseases: neuronal damage"	"Sentence: Both , production of reactive oxygen species as well as activation of NF - kappaB have been implicated in severe neuronal damage in different sub - regions of the hippocampus as well as in the surrounding cortices .
Diseases:"
4420	The effect of PDTC on status epilepticus - associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model .	O O O O O B I O O O O O O O O O O O O O O O O O O O	['status epilepticus']	1	4	"Sentence: The effect of PDTC on status epilepticus - associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model .
Diseases: status epilepticus"	"Sentence: The effect of PDTC on status epilepticus - associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model .
Diseases:"
4421	Treatment with 150 mg / kg PDTC before and following status epilepticus significantly increased the mortality rate to 100 % .	O O O O O O O O O O B I O O O O O O O O O	['status epilepticus']	1	4	"Sentence: Treatment with 150 mg / kg PDTC before and following status epilepticus significantly increased the mortality rate to 100 % .
Diseases: status epilepticus"	"Sentence: Treatment with 150 mg / kg PDTC before and following status epilepticus significantly increased the mortality rate to 100 % .
Diseases:"
4422	Administration of 50 mg / kg	O O O O O O	[]	0	0	"Sentence: Administration of 50 mg / kg
Diseases: "	"Sentence: Administration of 50 mg / kg
Diseases:"
4423	PDTC	O	[]	0	0	"Sentence: PDTC
Diseases: "	"Sentence: PDTC
Diseases:"
4424	( low - dose ) did not exert major effects on the development of a status epilepticus or the mortality rate .	O O O O O O O O O O O O O O O B I O O O O O	['status epilepticus']	1	4	"Sentence: ( low - dose ) did not exert major effects on the development of a status epilepticus or the mortality rate .
Diseases: status epilepticus"	"Sentence: ( low - dose ) did not exert major effects on the development of a status epilepticus or the mortality rate .
Diseases:"
4425	In vehicle - treated rats , status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons .	O O O O O O B I O O B I O O O O O O O O O O O	['neuronal damage', 'status epilepticus']	2	9	"Sentence: In vehicle - treated rats , status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons .
Diseases: neuronal damage, status epilepticus"	"Sentence: In vehicle - treated rats , status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons .
Diseases:"
4426	Low - dose PDTC treatment almost completely protected from lesions in the piriform cortex .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Low - dose PDTC treatment almost completely protected from lesions in the piriform cortex .
Diseases: "	"Sentence: Low - dose PDTC treatment almost completely protected from lesions in the piriform cortex .
Diseases:"
4427	A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle - and PDTC - treated rats following status epilepticus .	O O O O O O O O O O O O O O O O O O O O O O B I O	['status epilepticus']	1	4	"Sentence: A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle - and PDTC - treated rats following status epilepticus .
Diseases: status epilepticus"	"Sentence: A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle - and PDTC - treated rats following status epilepticus .
Diseases:"
4428	In conclusion , the NF - kappaB inhibitor and antioxidant PDTC protected the piriform cortex , whereas it did not affect hilar neuronal loss .	O O O O O O O O O O O O O O O O O O O O O O B I O	['neuronal loss']	1	4	"Sentence: In conclusion , the NF - kappaB inhibitor and antioxidant PDTC protected the piriform cortex , whereas it did not affect hilar neuronal loss .
Diseases: neuronal loss"	"Sentence: In conclusion , the NF - kappaB inhibitor and antioxidant PDTC protected the piriform cortex , whereas it did not affect hilar neuronal loss .
Diseases:"
4429	These data might indicate that the generation of reactive oxygen species and activation of NF - kappaB plays a more central role in seizure - associated neuronal damage in the temporal cortex as compared to the hippocampal hilus .	O O O O O O O O O O O O O O O O O O O O O O O B O O B I O O O O O O O O O O O	['neuronal damage', 'seizure']	2	6	"Sentence: These data might indicate that the generation of reactive oxygen species and activation of NF - kappaB plays a more central role in seizure - associated neuronal damage in the temporal cortex as compared to the hippocampal hilus .
Diseases: neuronal damage, seizure"	"Sentence: These data might indicate that the generation of reactive oxygen species and activation of NF - kappaB plays a more central role in seizure - associated neuronal damage in the temporal cortex as compared to the hippocampal hilus .
Diseases:"
4430	However , future investigations are necessary to exactly analyze the biochemical mechanisms by which PDTC exerted its beneficial effects in the piriform cortex .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , future investigations are necessary to exactly analyze the biochemical mechanisms by which PDTC exerted its beneficial effects in the piriform cortex .
Diseases: "	"Sentence: However , future investigations are necessary to exactly analyze the biochemical mechanisms by which PDTC exerted its beneficial effects in the piriform cortex .
Diseases:"
4431	Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions : a 12 - week , randomized , open - label study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions : a 12 - week , randomized , open - label study .
Diseases: "	"Sentence: Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions : a 12 - week , randomized , open - label study .
Diseases:"
4432	Nicotine polacrilex lozenges deliver 25 % to 27 % more nicotine compared with equivalent doses of nicotine polacrilex gum .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nicotine polacrilex lozenges deliver 25 % to 27 % more nicotine compared with equivalent doses of nicotine polacrilex gum .
Diseases: "	"Sentence: Nicotine polacrilex lozenges deliver 25 % to 27 % more nicotine compared with equivalent doses of nicotine polacrilex gum .
Diseases:"
4433	The increased nicotine exposure from the lozenge has raised questions about the relative safety of the lozenge and gum .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The increased nicotine exposure from the lozenge has raised questions about the relative safety of the lozenge and gum .
Diseases: "	"Sentence: The increased nicotine exposure from the lozenge has raised questions about the relative safety of the lozenge and gum .
Diseases:"
4434	The objective of this study was to compare the safety profiles of the 4 - mg nicotine lozenge and 4 - mg nicotine gum in smokers with selected label - restricted diseases .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The objective of this study was to compare the safety profiles of the 4 - mg nicotine lozenge and 4 - mg nicotine gum in smokers with selected label - restricted diseases .
Diseases: "	"Sentence: The objective of this study was to compare the safety profiles of the 4 - mg nicotine lozenge and 4 - mg nicotine gum in smokers with selected label - restricted diseases .
Diseases:"
4435	This was a multicenter , randomized , open - label study in adult smokers with heart disease , hypertension not controlled by medication , and / or diabetes mellitus .	O O O O O O O O O O O O O O O B I O B O O O O O O O O B I O	['heart disease', 'diabetes mellitus', 'hypertension']	3	8	"Sentence: This was a multicenter , randomized , open - label study in adult smokers with heart disease , hypertension not controlled by medication , and / or diabetes mellitus .
Diseases: heart disease, diabetes mellitus, hypertension"	"Sentence: This was a multicenter , randomized , open - label study in adult smokers with heart disease , hypertension not controlled by medication , and / or diabetes mellitus .
Diseases:"
4436	Patients were randomized in a 1 : 1 ratio to receive the 4 - mg nicotine lozenge or 4 - mg nicotine gum .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients were randomized in a 1 : 1 ratio to receive the 4 - mg nicotine lozenge or 4 - mg nicotine gum .
Diseases: "	"Sentence: Patients were randomized in a 1 : 1 ratio to receive the 4 - mg nicotine lozenge or 4 - mg nicotine gum .
Diseases:"
4437	Safety assessments were made at baseline and at 2 , 4 , 6 , and 12 weeks after the start of product use .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Safety assessments were made at baseline and at 2 , 4 , 6 , and 12 weeks after the start of product use .
Diseases: "	"Sentence: Safety assessments were made at baseline and at 2 , 4 , 6 , and 12 weeks after the start of product use .
Diseases:"
4438	Nine hundred one patients were randomized to treatment , 447 who received the lozenge and 454 who received the gum ( safety population ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nine hundred one patients were randomized to treatment , 447 who received the lozenge and 454 who received the gum ( safety population ) .
Diseases: "	"Sentence: Nine hundred one patients were randomized to treatment , 447 who received the lozenge and 454 who received the gum ( safety population ) .
Diseases:"
4439	The majority were women ( 52 . 7 % ) .	O O O O O O O O O O O	[]	0	0	"Sentence: The majority were women ( 52 . 7 % ) .
Diseases: "	"Sentence: The majority were women ( 52 . 7 % ) .
Diseases:"
4440	Patients ' mean age was 53 . 9 years , their mean weight was 193 . 9 pounds , and they smoked a mean of 25 . 2 cigarettes per day at baseline .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients ' mean age was 53 . 9 years , their mean weight was 193 . 9 pounds , and they smoked a mean of 25 . 2 cigarettes per day at baseline .
Diseases: "	"Sentence: Patients ' mean age was 53 . 9 years , their mean weight was 193 . 9 pounds , and they smoked a mean of 25 . 2 cigarettes per day at baseline .
Diseases:"
4441	Five hundred fifty - three patients , 264 taking the lozenge and 289 taking the gum , used the study product for > or = 4 days per week during the first 2 weeks ( evaluable population ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Five hundred fifty - three patients , 264 taking the lozenge and 289 taking the gum , used the study product for > or = 4 days per week during the first 2 weeks ( evaluable population ) .
Diseases: "	"Sentence: Five hundred fifty - three patients , 264 taking the lozenge and 289 taking the gum , used the study product for > or = 4 days per week during the first 2 weeks ( evaluable population ) .
Diseases:"
4442	The nicotine lozenge and nicotine gum were equally well tolerated , despite increased nicotine exposure from the lozenge .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The nicotine lozenge and nicotine gum were equally well tolerated , despite increased nicotine exposure from the lozenge .
Diseases: "	"Sentence: The nicotine lozenge and nicotine gum were equally well tolerated , despite increased nicotine exposure from the lozenge .
Diseases:"
4443	The incidence of adverse events in the 2 groups was similar during the first 2 weeks of product use ( evaluation population : 55 . 3 % lozenge , 54 . 7 % gum ) , as well as during the entire study ( safety population : 63 . 8 % and 58 . 6 % , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The incidence of adverse events in the 2 groups was similar during the first 2 weeks of product use ( evaluation population : 55 . 3 % lozenge , 54 . 7 % gum ) , as well as during the entire study ( safety population : 63 . 8 % and 58 . 6 % , respectively ) .
Diseases: "	"Sentence: The incidence of adverse events in the 2 groups was similar during the first 2 weeks of product use ( evaluation population : 55 . 3 % lozenge , 54 . 7 % gum ) , as well as during the entire study ( safety population : 63 . 8 % and 58 . 6 % , respectively ) .
Diseases:"
4444	Stratification of patients by sex , age , extent of concurrent smoking , extent of product use , and severity of adverse events revealed no clinically significant differences between the lozenge and gum .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Stratification of patients by sex , age , extent of concurrent smoking , extent of product use , and severity of adverse events revealed no clinically significant differences between the lozenge and gum .
Diseases: "	"Sentence: Stratification of patients by sex , age , extent of concurrent smoking , extent of product use , and severity of adverse events revealed no clinically significant differences between the lozenge and gum .
Diseases:"
4445	The most common adverse events were nausea ( 17 . 2 % and 16 . 1 % ; 95 % CI , - 3 . 7 to 6 . 0 ) , hiccups ( 10 . 7 % and 6 . 6 % ; 95 % CI , 0 . 5 to 7 . 8 ) , and headache ( 8 . 7 % and 9 . 9 % ; 95 % Cl , - 5 . 0 to 2 . 6 ) .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['nausea', 'headache', 'hiccups']	3	9	"Sentence: The most common adverse events were nausea ( 17 . 2 % and 16 . 1 % ; 95 % CI , - 3 . 7 to 6 . 0 ) , hiccups ( 10 . 7 % and 6 . 6 % ; 95 % CI , 0 . 5 to 7 . 8 ) , and headache ( 8 . 7 % and 9 . 9 % ; 95 % Cl , - 5 . 0 to 2 . 6 ) .
Diseases: nausea, headache, hiccups"	"Sentence: The most common adverse events were nausea ( 17 . 2 % and 16 . 1 % ; 95 % CI , - 3 . 7 to 6 . 0 ) , hiccups ( 10 . 7 % and 6 . 6 % ; 95 % CI , 0 . 5 to 7 . 8 ) , and headache ( 8 . 7 % and 9 . 9 % ; 95 % Cl , - 5 . 0 to 2 . 6 ) .
Diseases:"
4446	Serious adverse events were reported in 11 and 13 patients in the respective groups .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serious adverse events were reported in 11 and 13 patients in the respective groups .
Diseases: "	"Sentence: Serious adverse events were reported in 11 and 13 patients in the respective groups .
Diseases:"
4447	Fewer than 6 % of patients in either group were considered by the investigator to have a worsening of their overall disease condition during the study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fewer than 6 % of patients in either group were considered by the investigator to have a worsening of their overall disease condition during the study .
Diseases: "	"Sentence: Fewer than 6 % of patients in either group were considered by the investigator to have a worsening of their overall disease condition during the study .
Diseases:"
4448	The majority of patients ( > 60 % ) experienced no change in their disease status from baseline .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The majority of patients ( > 60 % ) experienced no change in their disease status from baseline .
Diseases: "	"Sentence: The majority of patients ( > 60 % ) experienced no change in their disease status from baseline .
Diseases:"
4449	The 4 - mg nicotine lozenge and 4 - mg nicotine gum had comparable safety profiles in these patients with label - restricted medical conditions .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The 4 - mg nicotine lozenge and 4 - mg nicotine gum had comparable safety profiles in these patients with label - restricted medical conditions .
Diseases: "	"Sentence: The 4 - mg nicotine lozenge and 4 - mg nicotine gum had comparable safety profiles in these patients with label - restricted medical conditions .
Diseases:"
4450	Development of levodopa - induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and / or duration of symptoms .	O O O O O B O B O O O O O O O O O O O O O O O	['dyskinesias', 'parkinsonian']	2	9	"Sentence: Development of levodopa - induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and / or duration of symptoms .
Diseases: dyskinesias, parkinsonian"	"Sentence: Development of levodopa - induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and / or duration of symptoms .
Diseases:"
4451	Levodopa - induced dyskinesias ( LIDs ) present a major problem for the long - term management of Parkinson 's disease ( PD ) patients .	O O O B O B O O O O O O O O O O O O B I I O B O O O	"['dyskinesias', 'lids', 'pd', ""parkinson 's disease""]"	4	17	"Sentence: Levodopa - induced dyskinesias ( LIDs ) present a major problem for the long - term management of Parkinson 's disease ( PD ) patients .
Diseases: dyskinesias, lids, pd, parkinson 's disease"	"Sentence: Levodopa - induced dyskinesias ( LIDs ) present a major problem for the long - term management of Parkinson 's disease ( PD ) patients .
Diseases:"
4452	Due to the interdependence of risk factors in clinical populations , it is difficult to independently examine factors that may influence the development of LIDs .	O O O O O O O O O O O O O O O O O O O O O O O O B O	['lids']	1	2	"Sentence: Due to the interdependence of risk factors in clinical populations , it is difficult to independently examine factors that may influence the development of LIDs .
Diseases: lids"	"Sentence: Due to the interdependence of risk factors in clinical populations , it is difficult to independently examine factors that may influence the development of LIDs .
Diseases:"
4453	Using macaque monkeys with different types of MPTP - induced parkinsonism , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of levodopa therapy may be involved in the development of LIDs .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['lids', 'parkinsonism']	2	6	"Sentence: Using macaque monkeys with different types of MPTP - induced parkinsonism , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of levodopa therapy may be involved in the development of LIDs .
Diseases: lids, parkinsonism"	"Sentence: Using macaque monkeys with different types of MPTP - induced parkinsonism , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of levodopa therapy may be involved in the development of LIDs .
Diseases:"
4454	Monkeys with acute ( short - term ) MPTP exposure , rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['dyskinesia']	1	5	"Sentence: Monkeys with acute ( short - term ) MPTP exposure , rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration .
Diseases: dyskinesia"	"Sentence: Monkeys with acute ( short - term ) MPTP exposure , rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration .
Diseases:"
4455	In contrast , monkeys with long - term MPTP exposure , slow symptom progression and / or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs ( e . g . , dyskinesia developed no sooner than 146 days of chronic levodopa administration ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O B O O O O O O O O O O O O	['lids', 'dyskinesia']	2	7	"Sentence: In contrast , monkeys with long - term MPTP exposure , slow symptom progression and / or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs ( e . g . , dyskinesia developed no sooner than 146 days of chronic levodopa administration ) .
Diseases: lids, dyskinesia"	"Sentence: In contrast , monkeys with long - term MPTP exposure , slow symptom progression and / or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs ( e . g . , dyskinesia developed no sooner than 146 days of chronic levodopa administration ) .
Diseases:"
4456	All animals were similarly symptomatic at the start of levodopa treatment and had similar therapeutic responses to the drug .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All animals were similarly symptomatic at the start of levodopa treatment and had similar therapeutic responses to the drug .
Diseases: "	"Sentence: All animals were similarly symptomatic at the start of levodopa treatment and had similar therapeutic responses to the drug .
Diseases:"
4457	These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['lids']	1	2	"Sentence: These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs .
Diseases: lids"	"Sentence: These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs .
Diseases:"
4458	Propylthiouracil - induced perinuclear - staining antineutrophil cytoplasmic autoantibody - positive vasculitis in conjunction with pericarditis .	O O O O O O O O O O O B O O O B O	['pericarditis', 'vasculitis']	2	8	"Sentence: Propylthiouracil - induced perinuclear - staining antineutrophil cytoplasmic autoantibody - positive vasculitis in conjunction with pericarditis .
Diseases: pericarditis, vasculitis"	"Sentence: Propylthiouracil - induced perinuclear - staining antineutrophil cytoplasmic autoantibody - positive vasculitis in conjunction with pericarditis .
Diseases:"
4459	To describe a case of propylthiouracil - induced vasculitis manifesting with pericarditis .	O O O O O O O O B O O B O	['pericarditis', 'vasculitis']	2	8	"Sentence: To describe a case of propylthiouracil - induced vasculitis manifesting with pericarditis .
Diseases: pericarditis, vasculitis"	"Sentence: To describe a case of propylthiouracil - induced vasculitis manifesting with pericarditis .
Diseases:"
4460	METHODS : We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis , fever , and glomerulonephritis developed .	O O O O O O O O O O O O B O O O O O O O O B O B O O B O O	['glomerulonephritis', 'pericarditis', 'fever', 'hyperthyroidism']	4	18	"Sentence: METHODS : We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis , fever , and glomerulonephritis developed .
Diseases: glomerulonephritis, pericarditis, fever, hyperthyroidism"	"Sentence: METHODS : We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis , fever , and glomerulonephritis developed .
Diseases:"
4461	Serologic testing and immunologic studies were done , and a pericardial biopsy was performed .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serologic testing and immunologic studies were done , and a pericardial biopsy was performed .
Diseases: "	"Sentence: Serologic testing and immunologic studies were done , and a pericardial biopsy was performed .
Diseases:"
4462	A 25 - year - old woman with Graves ' disease had a febrile illness and evidence of pericarditis , which was confirmed by biopsy .	O O O O O O O O B I I O O B I O O O B O O O O O O O	"['febrile illness', 'pericarditis', ""graves ' disease""]"	3	14	"Sentence: A 25 - year - old woman with Graves ' disease had a febrile illness and evidence of pericarditis , which was confirmed by biopsy .
Diseases: febrile illness, pericarditis, graves ' disease"	"Sentence: A 25 - year - old woman with Graves ' disease had a febrile illness and evidence of pericarditis , which was confirmed by biopsy .
Diseases:"
4463	Serologic evaluation revealed the presence of perinuclear - staining antineutrophil cytoplasmic autoantibodies ( pANCA ) against myeloperoxidase ( MPO ) .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serologic evaluation revealed the presence of perinuclear - staining antineutrophil cytoplasmic autoantibodies ( pANCA ) against myeloperoxidase ( MPO ) .
Diseases: "	"Sentence: Serologic evaluation revealed the presence of perinuclear - staining antineutrophil cytoplasmic autoantibodies ( pANCA ) against myeloperoxidase ( MPO ) .
Diseases:"
4464	Propylthiouracil therapy was withdrawn , and she was treated with a 1 - month course of prednisone , which alleviated her symptoms .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Propylthiouracil therapy was withdrawn , and she was treated with a 1 - month course of prednisone , which alleviated her symptoms .
Diseases: "	"Sentence: Propylthiouracil therapy was withdrawn , and she was treated with a 1 - month course of prednisone , which alleviated her symptoms .
Diseases:"
4465	A literature review revealed no prior reports of pericarditis in anti - MPO pANCA - positive vasculitis associated with propylthio - uracil therapy .	O O O O O O O O B O O O O O O O B O O O O O O O	['pericarditis', 'vasculitis']	2	8	"Sentence: A literature review revealed no prior reports of pericarditis in anti - MPO pANCA - positive vasculitis associated with propylthio - uracil therapy .
Diseases: pericarditis, vasculitis"	"Sentence: A literature review revealed no prior reports of pericarditis in anti - MPO pANCA - positive vasculitis associated with propylthio - uracil therapy .
Diseases:"
4466	CONCLUSION : Pericarditis may be the initial manifestation of drug - induced vasculitis attributable to propylthio - uracil therapy .	O O B O O O O O O O O O B O O O O O O O	['pericarditis', 'vasculitis']	2	8	"Sentence: CONCLUSION : Pericarditis may be the initial manifestation of drug - induced vasculitis attributable to propylthio - uracil therapy .
Diseases: pericarditis, vasculitis"	"Sentence: CONCLUSION : Pericarditis may be the initial manifestation of drug - induced vasculitis attributable to propylthio - uracil therapy .
Diseases:"
4467	Two mouse lines selected for differential sensitivities to beta - carboline - induced seizures are also differentially sensitive to various pharmacological effects of other GABA ( A ) receptor ligands .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: Two mouse lines selected for differential sensitivities to beta - carboline - induced seizures are also differentially sensitive to various pharmacological effects of other GABA ( A ) receptor ligands .
Diseases: seizures"	"Sentence: Two mouse lines selected for differential sensitivities to beta - carboline - induced seizures are also differentially sensitive to various pharmacological effects of other GABA ( A ) receptor ligands .
Diseases:"
4468	Two mouse lines were selectively bred according to their sensitivity ( BS line ) or resistance ( BR line ) to seizures induced by a single i . p . injection of methyl beta - carboline - 3 - carboxylate ( beta - CCM ) , an inverse agonist of the GABA ( A ) receptor benzodiazepine site .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: Two mouse lines were selectively bred according to their sensitivity ( BS line ) or resistance ( BR line ) to seizures induced by a single i . p . injection of methyl beta - carboline - 3 - carboxylate ( beta - CCM ) , an inverse agonist of the GABA ( A ) receptor benzodiazepine site .
Diseases: seizures"	"Sentence: Two mouse lines were selectively bred according to their sensitivity ( BS line ) or resistance ( BR line ) to seizures induced by a single i . p . injection of methyl beta - carboline - 3 - carboxylate ( beta - CCM ) , an inverse agonist of the GABA ( A ) receptor benzodiazepine site .
Diseases:"
4469	Our aim was to characterize both lines ' sensitivities to various physiological effects of other ligands of the GABA ( A ) receptor .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Our aim was to characterize both lines ' sensitivities to various physiological effects of other ligands of the GABA ( A ) receptor .
Diseases: "	"Sentence: Our aim was to characterize both lines ' sensitivities to various physiological effects of other ligands of the GABA ( A ) receptor .
Diseases:"
4470	We measured diazepam - induced anxiolysis with the elevated plus - maze test , diazepam - induced sedation by recording the vigilance states , and picrotoxin - and pentylenetetrazol - induced seizures after i . p . injections .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['seizures']	1	3	"Sentence: We measured diazepam - induced anxiolysis with the elevated plus - maze test , diazepam - induced sedation by recording the vigilance states , and picrotoxin - and pentylenetetrazol - induced seizures after i . p . injections .
Diseases: seizures"	"Sentence: We measured diazepam - induced anxiolysis with the elevated plus - maze test , diazepam - induced sedation by recording the vigilance states , and picrotoxin - and pentylenetetrazol - induced seizures after i . p . injections .
Diseases:"
4471	Results presented here show that the differential sensitivities of BS and BR lines to beta - CCM can be extended to diazepam , picrotoxin , and pentylenetetrazol , suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA ( A ) receptor .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Results presented here show that the differential sensitivities of BS and BR lines to beta - CCM can be extended to diazepam , picrotoxin , and pentylenetetrazol , suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA ( A ) receptor .
Diseases: "	"Sentence: Results presented here show that the differential sensitivities of BS and BR lines to beta - CCM can be extended to diazepam , picrotoxin , and pentylenetetrazol , suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA ( A ) receptor .
Diseases:"
4472	Analgesic effect of intravenous ketamine in cancer patients on morphine therapy : a randomized , controlled , double - blind , crossover , double - dose study .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['cancer']	1	1	"Sentence: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy : a randomized , controlled , double - blind , crossover , double - dose study .
Diseases: cancer"	"Sentence: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy : a randomized , controlled , double - blind , crossover , double - dose study .
Diseases:"
4473	Pain not responsive to morphine is often problematic .	B O O O O O O O O	['pain']	1	1	"Sentence: Pain not responsive to morphine is often problematic .
Diseases: pain"	"Sentence: Pain not responsive to morphine is often problematic .
Diseases:"
4474	Animal and clinical studies have suggested that N - methyl - D - aspartate ( NMDA ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult pain syndromes , such as neuropathic pain .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O B I O	['neuropathic pain', 'pain']	2	6	"Sentence: Animal and clinical studies have suggested that N - methyl - D - aspartate ( NMDA ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult pain syndromes , such as neuropathic pain .
Diseases: neuropathic pain, pain"	"Sentence: Animal and clinical studies have suggested that N - methyl - D - aspartate ( NMDA ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult pain syndromes , such as neuropathic pain .
Diseases:"
4475	A slow bolus of subhypnotic doses of ketamine ( 0 . 25 mg / kg or 0 . 50 mg / kg ) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized , double - blind , crossover , double - dose study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O	['pain', 'cancer']	2	3	"Sentence: A slow bolus of subhypnotic doses of ketamine ( 0 . 25 mg / kg or 0 . 50 mg / kg ) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized , double - blind , crossover , double - dose study .
Diseases: pain, cancer"	"Sentence: A slow bolus of subhypnotic doses of ketamine ( 0 . 25 mg / kg or 0 . 50 mg / kg ) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized , double - blind , crossover , double - dose study .
Diseases:"
4476	Pain intensity on a 0 to 10 numerical scale ; nausea and vomiting , drowsiness , confusion , and dry mouth , using a scale from 0 to 3 ( not at all , slight , a lot , awful ) ; Mini - Mental State Examination ( MMSE ) ( 0 - 30 ) ; and arterial pressure were recorded before administration of drugs ( T0 ) and after 30 minutes ( T30 ) , 60 minutes ( T60 ) , 120 minutes ( T120 ) , and 180 minutes ( T180 ) .	B O O O O O O O O O B O B O O O B O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['confusion', 'nausea', 'dry mouth', 'vomiting', 'pain']	5	11	"Sentence: Pain intensity on a 0 to 10 numerical scale ; nausea and vomiting , drowsiness , confusion , and dry mouth , using a scale from 0 to 3 ( not at all , slight , a lot , awful ) ; Mini - Mental State Examination ( MMSE ) ( 0 - 30 ) ; and arterial pressure were recorded before administration of drugs ( T0 ) and after 30 minutes ( T30 ) , 60 minutes ( T60 ) , 120 minutes ( T120 ) , and 180 minutes ( T180 ) .
Diseases: confusion, nausea, dry mouth, vomiting, pain"	"Sentence: Pain intensity on a 0 to 10 numerical scale ; nausea and vomiting , drowsiness , confusion , and dry mouth , using a scale from 0 to 3 ( not at all , slight , a lot , awful ) ; Mini - Mental State Examination ( MMSE ) ( 0 - 30 ) ; and arterial pressure were recorded before administration of drugs ( T0 ) and after 30 minutes ( T30 ) , 60 minutes ( T60 ) , 120 minutes ( T120 ) , and 180 minutes ( T180 ) .
Diseases:"
4477	Ketamine , but not saline solution , significantly reduced the pain intensity in almost all the patients at both doses .	O O O O O O O O O O B O O O O O O O O O O	['pain']	1	1	"Sentence: Ketamine , but not saline solution , significantly reduced the pain intensity in almost all the patients at both doses .
Diseases: pain"	"Sentence: Ketamine , but not saline solution , significantly reduced the pain intensity in almost all the patients at both doses .
Diseases:"
4478	This effect was more relevant in patients treated with higher doses .	O O O O O O O O O O O O	[]	0	0	"Sentence: This effect was more relevant in patients treated with higher doses .
Diseases: "	"Sentence: This effect was more relevant in patients treated with higher doses .
Diseases:"
4479	"Hallucinations occurred in 4 patients , and an unpleasant sensation ( "" empty head "" ) was also reported by 2 patients ."	B O O O O O O O O O O O O O O O O O O O O O O	['hallucinations']	1	3	"Sentence: Hallucinations occurred in 4 patients , and an unpleasant sensation ( "" empty head "" ) was also reported by 2 patients .
Diseases: hallucinations"	"Sentence: Hallucinations occurred in 4 patients , and an unpleasant sensation ( "" empty head "" ) was also reported by 2 patients .
Diseases:"
4480	These episodes reversed after the administration of diazepam 1 mg intravenously .	O O O O O O O O O O O O	[]	0	0	"Sentence: These episodes reversed after the administration of diazepam 1 mg intravenously .
Diseases: "	"Sentence: These episodes reversed after the administration of diazepam 1 mg intravenously .
Diseases:"
4481	Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0 . 50 mg / kg .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0 . 50 mg / kg .
Diseases: "	"Sentence: Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0 . 50 mg / kg .
Diseases:"
4482	A significant difference in MMSE was observed at T30 in patients who received 0 . 50 mg / kg of ketamine .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A significant difference in MMSE was observed at T30 in patients who received 0 . 50 mg / kg of ketamine .
Diseases: "	"Sentence: A significant difference in MMSE was observed at T30 in patients who received 0 . 50 mg / kg of ketamine .
Diseases:"
4483	Ketamine can improve morphine analgesia in difficult pain syndromes , such as neuropathic pain .	O O O O O O O B O O O O B I O	['neuropathic pain', 'pain']	2	6	"Sentence: Ketamine can improve morphine analgesia in difficult pain syndromes , such as neuropathic pain .
Diseases: neuropathic pain, pain"	"Sentence: Ketamine can improve morphine analgesia in difficult pain syndromes , such as neuropathic pain .
Diseases:"
4484	However , the occurrence of central adverse effects should be taken into account , especially when using higher doses .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the occurrence of central adverse effects should be taken into account , especially when using higher doses .
Diseases: "	"Sentence: However , the occurrence of central adverse effects should be taken into account , especially when using higher doses .
Diseases:"
4485	This observation should be tested in studies of prolonged ketamine administration .	O O O O O O O O O O O O	[]	0	0	"Sentence: This observation should be tested in studies of prolonged ketamine administration .
Diseases: "	"Sentence: This observation should be tested in studies of prolonged ketamine administration .
Diseases:"
4486	Endocrine screening in 1 , 022 men with erectile dysfunction : clinical significance and cost - effective strategy .	O O O O O O O O B I O O O O O O O O O	['erectile dysfunction']	1	4	"Sentence: Endocrine screening in 1 , 022 men with erectile dysfunction : clinical significance and cost - effective strategy .
Diseases: erectile dysfunction"	"Sentence: Endocrine screening in 1 , 022 men with erectile dysfunction : clinical significance and cost - effective strategy .
Diseases:"
4487	We reviewed the results of serum testosterone and prolactin determination in 1 , 022 patients referred because of erectile dysfunction and compared the data with history , results of physical examination , other etiological investigations and effects of endocrine therapy to refine the rules of cost - effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['erectile dysfunction']	1	4	"Sentence: We reviewed the results of serum testosterone and prolactin determination in 1 , 022 patients referred because of erectile dysfunction and compared the data with history , results of physical examination , other etiological investigations and effects of endocrine therapy to refine the rules of cost - effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities .
Diseases: erectile dysfunction"	"Sentence: We reviewed the results of serum testosterone and prolactin determination in 1 , 022 patients referred because of erectile dysfunction and compared the data with history , results of physical examination , other etiological investigations and effects of endocrine therapy to refine the rules of cost - effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities .
Diseases:"
4488	MATERIALS AND METHODS : Testosterone and prolactin were determined by radioimmunoassay .	O O O O O O O O O O O O	[]	0	0	"Sentence: MATERIALS AND METHODS : Testosterone and prolactin were determined by radioimmunoassay .
Diseases: "	"Sentence: MATERIALS AND METHODS : Testosterone and prolactin were determined by radioimmunoassay .
Diseases:"
4489	Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire , gynecomastia or testosterone less than 4 ng . / ml .	O O O O O O O O O O O O O O O O B I I O B O O O O O O O O O O	['gynecomastia', 'low sexual desire']	2	9	"Sentence: Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire , gynecomastia or testosterone less than 4 ng . / ml .
Diseases: gynecomastia, low sexual desire"	"Sentence: Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire , gynecomastia or testosterone less than 4 ng . / ml .
Diseases:"
4490	Determination was repeated in case of abnormal first results .	O O O O O O O O O O	[]	0	0	"Sentence: Determination was repeated in case of abnormal first results .
Diseases: "	"Sentence: Determination was repeated in case of abnormal first results .
Diseases:"
4491	Prolactin results were compared with those of a previous personal cohort of 1 , 340 patients with erectile dysfunction and systematic prolactin determination .	O O O O O O O O O O O O O O O O O B I O O O O O	['erectile dysfunction']	1	4	"Sentence: Prolactin results were compared with those of a previous personal cohort of 1 , 340 patients with erectile dysfunction and systematic prolactin determination .
Diseases: erectile dysfunction"	"Sentence: Prolactin results were compared with those of a previous personal cohort of 1 , 340 patients with erectile dysfunction and systematic prolactin determination .
Diseases:"
4492	Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire , small testes and gynecomastia .	O O O O O O O O O O B I I O O O O B O	['gynecomastia', 'low sexual desire']	2	9	"Sentence: Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire , small testes and gynecomastia .
Diseases: gynecomastia, low sexual desire"	"Sentence: Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire , small testes and gynecomastia .
Diseases:"
4493	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia .	O O O O O O O O O O O B O O O B O	['hypogonadism', 'hyperprolactinemia']	2	12	"Sentence: Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia .
Diseases: hypogonadism, hyperprolactinemia"	"Sentence: Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia .
Diseases:"
4494	Testosterone was less than 3 ng . / ml .	O O O O O O O O O O	[]	0	0	"Sentence: Testosterone was less than 3 ng . / ml .
Diseases: "	"Sentence: Testosterone was less than 3 ng . / ml .
Diseases:"
4495	in 107 patients but normal in 40 % at repeat determination .	O O O O O O O O O O O O	[]	0	0	"Sentence: in 107 patients but normal in 40 % at repeat determination .
Diseases: "	"Sentence: in 107 patients but normal in 40 % at repeat determination .
Diseases:"
4496	The prevalence of repeatedly low testosterone increased with age ( 4 % before age 50 years and 9 % 50 years or older ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The prevalence of repeatedly low testosterone increased with age ( 4 % before age 50 years and 9 % 50 years or older ) .
Diseases: "	"Sentence: The prevalence of repeatedly low testosterone increased with age ( 4 % before age 50 years and 9 % 50 years or older ) .
Diseases:"
4497	Two pituitary tumors were discovered after testosterone determination .	O B I O O O O O O	['pituitary tumors']	1	4	"Sentence: Two pituitary tumors were discovered after testosterone determination .
Diseases: pituitary tumors"	"Sentence: Two pituitary tumors were discovered after testosterone determination .
Diseases:"
4498	Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction ( definite improvement in only 16 of 44 [ 36 % ] after androgen therapy , normal morning or nocturnal erections in 30 % and definite vasculogenic contributions in 42 % ) .	O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypothalamic dysfunction', 'erectile dysfunction']	2	8	"Sentence: Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction ( definite improvement in only 16 of 44 [ 36 % ] after androgen therapy , normal morning or nocturnal erections in 30 % and definite vasculogenic contributions in 42 % ) .
Diseases: hypothalamic dysfunction, erectile dysfunction"	"Sentence: Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction ( definite improvement in only 16 of 44 [ 36 % ] after androgen therapy , normal morning or nocturnal erections in 30 % and definite vasculogenic contributions in 42 % ) .
Diseases:"
4499	Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40 % of the cases with low testosterone , including 37 % of those subsequently improved by androgen therapy .	O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['low sexual desire']	1	3	"Sentence: Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40 % of the cases with low testosterone , including 37 % of those subsequently improved by androgen therapy .
Diseases: low sexual desire"	"Sentence: Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40 % of the cases with low testosterone , including 37 % of those subsequently improved by androgen therapy .
Diseases:"
4500	Prolactin exceeded 20 ng . / ml .	O O O O O O O O	[]	0	0	"Sentence: Prolactin exceeded 20 ng . / ml .
Diseases: "	"Sentence: Prolactin exceeded 20 ng . / ml .
Diseases:"
4501	in 5 men and was normal in 2 at repeat determination .	O O O O O O O O O O O O	[]	0	0	"Sentence: in 5 men and was normal in 2 at repeat determination .
Diseases: "	"Sentence: in 5 men and was normal in 2 at repeat determination .
Diseases:"
4502	Only 1 prolactinoma was discovered .	O O B O O O	['prolactinoma']	1	5	"Sentence: Only 1 prolactinoma was discovered .
Diseases: prolactinoma"	"Sentence: Only 1 prolactinoma was discovered .
Diseases:"
4503	These data are lower than those we found during the last 2 decades ( overall prolactin greater than 20 ng . / ml .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These data are lower than those we found during the last 2 decades ( overall prolactin greater than 20 ng . / ml .
Diseases: "	"Sentence: These data are lower than those we found during the last 2 decades ( overall prolactin greater than 20 ng . / ml .
Diseases:"
4504	in 1 . 86 % of 1 , 821 patients , prolactinomas in 7 , 0 . 38 % ) .	O O O O O O O O O O O B O O O O O O O O O	['prolactinomas']	1	5	"Sentence: in 1 . 86 % of 1 , 821 patients , prolactinomas in 7 , 0 . 38 % ) .
Diseases: prolactinomas"	"Sentence: in 1 . 86 % of 1 , 821 patients , prolactinomas in 7 , 0 . 38 % ) .
Diseases:"
4505	Bromocriptine was definitely effective in cases with prolactin greater than 35 ng . / ml .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Bromocriptine was definitely effective in cases with prolactin greater than 35 ng . / ml .
Diseases: "	"Sentence: Bromocriptine was definitely effective in cases with prolactin greater than 35 ng . / ml .
Diseases:"
4506	( 8 of 12 compared to only 9 of 22 cases with prolactin between 20 and 35 ng . / ml . ) .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ( 8 of 12 compared to only 9 of 22 cases with prolactin between 20 and 35 ng . / ml . ) .
Diseases: "	"Sentence: ( 8 of 12 compared to only 9 of 22 cases with prolactin between 20 and 35 ng . / ml . ) .
Diseases:"
4507	Testosterone was low in less than 50 % of cases with prolactin greater than 35 ng . / ml .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Testosterone was low in less than 50 % of cases with prolactin greater than 35 ng . / ml .
Diseases: "	"Sentence: Testosterone was low in less than 50 % of cases with prolactin greater than 35 ng . / ml .
Diseases:"
4508	CONCLUSIONS : Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction can not justify their routine determination .	O O O O O O O O O O O O O B I O O O O O O O	['erectile dysfunction']	1	4	"Sentence: CONCLUSIONS : Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction can not justify their routine determination .
Diseases: erectile dysfunction"	"Sentence: CONCLUSIONS : Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction can not justify their routine determination .
Diseases:"
4509	However , cost - effective screening strategies recommended so far missed 40 to 50 % of cases improved with endocrine therapy and the pituitary tumors .	O O O O O O O O O O O O O O O O O O O O O O O B I O	['pituitary tumors']	1	4	"Sentence: However , cost - effective screening strategies recommended so far missed 40 to 50 % of cases improved with endocrine therapy and the pituitary tumors .
Diseases: pituitary tumors"	"Sentence: However , cost - effective screening strategies recommended so far missed 40 to 50 % of cases improved with endocrine therapy and the pituitary tumors .
Diseases:"
4510	We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years .	O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O	['low sexual desire']	1	3	"Sentence: We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years .
Diseases: low sexual desire"	"Sentence: We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years .
Diseases:"
4511	Prolactin should be determined only in cases of low sexual desire , gynecomastia and / or testosterone less than 4 ng . / ml .	O O O O O O O O B I I O B O O O O O O O O O O O O	['gynecomastia', 'low sexual desire']	2	9	"Sentence: Prolactin should be determined only in cases of low sexual desire , gynecomastia and / or testosterone less than 4 ng . / ml .
Diseases: gynecomastia, low sexual desire"	"Sentence: Prolactin should be determined only in cases of low sexual desire , gynecomastia and / or testosterone less than 4 ng . / ml .
Diseases:"
4512	Thiopentone pretreatment for propofol injection pain in ambulatory patients .	O O O O O B O O O O	['pain']	1	1	"Sentence: Thiopentone pretreatment for propofol injection pain in ambulatory patients .
Diseases: pain"	"Sentence: Thiopentone pretreatment for propofol injection pain in ambulatory patients .
Diseases:"
4513	This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia .	O O O O O B O O O O O O	['pain']	1	1	"Sentence: This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia .
Diseases: pain"	"Sentence: This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia .
Diseases:"
4514	In a randomized , double - blind trial , 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In a randomized , double - blind trial , 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol .
Diseases: "	"Sentence: In a randomized , double - blind trial , 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol .
Diseases:"
4515	Patients in Group C received 2 ml normal saline , Group L , 2 ml , lidocaine 2 % ( 40 mg ) and Group T , 2 ml thiopentone 2 . 5 % ( 50 mg ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients in Group C received 2 ml normal saline , Group L , 2 ml , lidocaine 2 % ( 40 mg ) and Group T , 2 ml thiopentone 2 . 5 % ( 50 mg ) .
Diseases: "	"Sentence: Patients in Group C received 2 ml normal saline , Group L , 2 ml , lidocaine 2 % ( 40 mg ) and Group T , 2 ml thiopentone 2 . 5 % ( 50 mg ) .
Diseases:"
4516	Venous discomfort was assessed with a visual analogue scale ( VAS ) 5 - 15 sec after commencing propofol administration using an infusion pump ( rate 1000 micrograms . kg - 1 . min - 1 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Venous discomfort was assessed with a visual analogue scale ( VAS ) 5 - 15 sec after commencing propofol administration using an infusion pump ( rate 1000 micrograms . kg - 1 . min - 1 ) .
Diseases: "	"Sentence: Venous discomfort was assessed with a visual analogue scale ( VAS ) 5 - 15 sec after commencing propofol administration using an infusion pump ( rate 1000 micrograms . kg - 1 . min - 1 ) .
Diseases:"
4517	Loss of consciousness occurred in 60 - 90 sec .	B I I O O O O O O O	['loss of consciousness']	1	3	"Sentence: Loss of consciousness occurred in 60 - 90 sec .
Diseases: loss of consciousness"	"Sentence: Loss of consciousness occurred in 60 - 90 sec .
Diseases:"
4518	Visual analogue scores ( mean + / - SD ) during induction were lower in Groups L ( 3 . 3 + / - 2 . 5 ) and T ( 4 . 1 + / - 2 . 7 ) than in Group C ( 5 . 6 + / - 2 . 3 ) ; P = 0 . 0031 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Visual analogue scores ( mean + / - SD ) during induction were lower in Groups L ( 3 . 3 + / - 2 . 5 ) and T ( 4 . 1 + / - 2 . 7 ) than in Group C ( 5 . 6 + / - 2 . 3 ) ; P = 0 . 0031 .
Diseases: "	"Sentence: Visual analogue scores ( mean + / - SD ) during induction were lower in Groups L ( 3 . 3 + / - 2 . 5 ) and T ( 4 . 1 + / - 2 . 7 ) than in Group C ( 5 . 6 + / - 2 . 3 ) ; P = 0 . 0031 .
Diseases:"
4519	The incidence of venous discomfort was lower in Group L ( 76 . 6 % ; P < 0 . 05 ) than in Group C ( 100 % ) but not different from Group T ( 90 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The incidence of venous discomfort was lower in Group L ( 76 . 6 % ; P < 0 . 05 ) than in Group C ( 100 % ) but not different from Group T ( 90 % ) .
Diseases: "	"Sentence: The incidence of venous discomfort was lower in Group L ( 76 . 6 % ; P < 0 . 05 ) than in Group C ( 100 % ) but not different from Group T ( 90 % ) .
Diseases:"
4520	The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction ( r = 0 . 7045 ; P < 0 . 0001 ) .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction ( r = 0 . 7045 ; P < 0 . 0001 ) .
Diseases: pain"	"Sentence: The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction ( r = 0 . 7045 ; P < 0 . 0001 ) .
Diseases:"
4521	Recovery room discharge times were similar : C ( 75 . 9 + / - 19 . 4 min ) ; L 73 . 6 + / - 21 . 6 min ) ; T ( 77 . 1 + / - 18 . 9 min ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Recovery room discharge times were similar : C ( 75 . 9 + / - 19 . 4 min ) ; L 73 . 6 + / - 21 . 6 min ) ; T ( 77 . 1 + / - 18 . 9 min ) .
Diseases: "	"Sentence: Recovery room discharge times were similar : C ( 75 . 9 + / - 19 . 4 min ) ; L 73 . 6 + / - 21 . 6 min ) ; T ( 77 . 1 + / - 18 . 9 min ) .
Diseases:"
4522	Assessing their overall satisfaction , 89 . 7 % would choose propofol anaesthesia again .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Assessing their overall satisfaction , 89 . 7 % would choose propofol anaesthesia again .
Diseases: "	"Sentence: Assessing their overall satisfaction , 89 . 7 % would choose propofol anaesthesia again .
Diseases:"
4523	We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity .	O O O O O O O O O O O O B O O O O O O O O O O	['pain']	1	1	"Sentence: We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity .
Diseases: pain"	"Sentence: We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity .
Diseases:"
4524	Comparison of i . v . glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children .	O O O O O O O O O O O O O B O B O O O O O O O O	['arrhythmias', 'bradycardia']	2	9	"Sentence: Comparison of i . v . glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children .
Diseases: arrhythmias, bradycardia"	"Sentence: Comparison of i . v . glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children .
Diseases:"
4525	The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg - 1 and atropine 10 and 20 micrograms kg - 1 i . v .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg - 1 and atropine 10 and 20 micrograms kg - 1 i . v .
Diseases: "	"Sentence: The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg - 1 and atropine 10 and 20 micrograms kg - 1 i . v .
Diseases:"
4526	immediately before the induction of anaesthesia , to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children , was studied .	O O O O O O O O O B O B O O O O O O O O O O O	['bradycardia', 'arrhythmia']	2	9	"Sentence: immediately before the induction of anaesthesia , to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children , was studied .
Diseases: bradycardia, arrhythmia"	"Sentence: immediately before the induction of anaesthesia , to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children , was studied .
Diseases:"
4527	A control group was included for comparison with the lower dose range of glycopyrrolate and atropine .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A control group was included for comparison with the lower dose range of glycopyrrolate and atropine .
Diseases: "	"Sentence: A control group was included for comparison with the lower dose range of glycopyrrolate and atropine .
Diseases:"
4528	A frequency of bradycardia of 50 % was noted in the control group , but this was not significantly different from the frequency with the active drugs .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: A frequency of bradycardia of 50 % was noted in the control group , but this was not significantly different from the frequency with the active drugs .
Diseases: bradycardia"	"Sentence: A frequency of bradycardia of 50 % was noted in the control group , but this was not significantly different from the frequency with the active drugs .
Diseases:"
4529	Bradycardia ( defined as a decrease in heart rate to less than 50 beat min - 1 ) was prevented when the larger dose of either active drug was used .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: Bradycardia ( defined as a decrease in heart rate to less than 50 beat min - 1 ) was prevented when the larger dose of either active drug was used .
Diseases: bradycardia"	"Sentence: Bradycardia ( defined as a decrease in heart rate to less than 50 beat min - 1 ) was prevented when the larger dose of either active drug was used .
Diseases:"
4530	It is recommended that either glycopyrrolate 10 micrograms kg - 1 or atropine 20 micrograms kg - 1 i . v .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is recommended that either glycopyrrolate 10 micrograms kg - 1 or atropine 20 micrograms kg - 1 i . v .
Diseases: "	"Sentence: It is recommended that either glycopyrrolate 10 micrograms kg - 1 or atropine 20 micrograms kg - 1 i . v .
Diseases:"
4531	should immediately precede induction of anaesthesia , in children , if the repeated administration of suxamethonium is anticipated .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: should immediately precede induction of anaesthesia , in children , if the repeated administration of suxamethonium is anticipated .
Diseases: "	"Sentence: should immediately precede induction of anaesthesia , in children , if the repeated administration of suxamethonium is anticipated .
Diseases:"
4532	Reduction in caffeine toxicity by acetaminophen .	O O O B O O O	['toxicity']	1	2	"Sentence: Reduction in caffeine toxicity by acetaminophen .
Diseases: toxicity"	"Sentence: Reduction in caffeine toxicity by acetaminophen .
Diseases:"
4533	A patient who allegedly consumed 100 tablets of an over - the - counter analgesic containing sodium acetylsalicylate , caffeine , and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A patient who allegedly consumed 100 tablets of an over - the - counter analgesic containing sodium acetylsalicylate , caffeine , and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum .
Diseases: "	"Sentence: A patient who allegedly consumed 100 tablets of an over - the - counter analgesic containing sodium acetylsalicylate , caffeine , and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum .
Diseases:"
4534	Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS , attention was focused on the possibility that the presence of acetaminophen ( 52 micrograms / mL ) reduced the CNS toxicity of caffeine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	['toxicity']	1	2	"Sentence: Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS , attention was focused on the possibility that the presence of acetaminophen ( 52 micrograms / mL ) reduced the CNS toxicity of caffeine .
Diseases: toxicity"	"Sentence: Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS , attention was focused on the possibility that the presence of acetaminophen ( 52 micrograms / mL ) reduced the CNS toxicity of caffeine .
Diseases:"
4535	Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['seizures', 'convulsions']	2	7	"Sentence: Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .
Diseases: seizures, convulsions"	"Sentence: Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .
Diseases:"
4536	The frequency of sound - induced seizures after 12 . 5 or 25 mg / kg caffeine was reduced from 50 to 5 % by acetaminophen .	O O O O O O B O O O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: The frequency of sound - induced seizures after 12 . 5 or 25 mg / kg caffeine was reduced from 50 to 5 % by acetaminophen .
Diseases: seizures"	"Sentence: The frequency of sound - induced seizures after 12 . 5 or 25 mg / kg caffeine was reduced from 50 to 5 % by acetaminophen .
Diseases:"
4537	In the absence of caffeine , acetaminophen ( up to 300 mg / kg ) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: In the absence of caffeine , acetaminophen ( up to 300 mg / kg ) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .
Diseases: seizures"	"Sentence: In the absence of caffeine , acetaminophen ( up to 300 mg / kg ) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .
Diseases:"
4538	Acetaminophen ( up to 150 micrograms / mL ) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Acetaminophen ( up to 150 micrograms / mL ) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex .
Diseases: "	"Sentence: Acetaminophen ( up to 150 micrograms / mL ) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex .
Diseases:"
4539	Thus the mechanism by which acetaminophen antagonizes the actions of caffeine in the CNS remains unknown .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thus the mechanism by which acetaminophen antagonizes the actions of caffeine in the CNS remains unknown .
Diseases: "	"Sentence: Thus the mechanism by which acetaminophen antagonizes the actions of caffeine in the CNS remains unknown .
Diseases:"
4540	Flestolol : an ultra - short - acting beta - adrenergic blocking agent .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Flestolol : an ultra - short - acting beta - adrenergic blocking agent .
Diseases: "	"Sentence: Flestolol : an ultra - short - acting beta - adrenergic blocking agent .
Diseases:"
4541	Flestolol ( ACC - 9089 ) is a nonselective , competitive , ultra - short - acting beta - adrenergic blocking agent , without any intrinsic sympathomimetic activity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Flestolol ( ACC - 9089 ) is a nonselective , competitive , ultra - short - acting beta - adrenergic blocking agent , without any intrinsic sympathomimetic activity .
Diseases: "	"Sentence: Flestolol ( ACC - 9089 ) is a nonselective , competitive , ultra - short - acting beta - adrenergic blocking agent , without any intrinsic sympathomimetic activity .
Diseases:"
4542	Flestolol is metabolized by plasma esterases and has an elimination half - life of approximately 6 . 5 minutes .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Flestolol is metabolized by plasma esterases and has an elimination half - life of approximately 6 . 5 minutes .
Diseases: "	"Sentence: Flestolol is metabolized by plasma esterases and has an elimination half - life of approximately 6 . 5 minutes .
Diseases:"
4543	This agent was well tolerated in healthy volunteers at doses up to 100 micrograms / kg / min .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This agent was well tolerated in healthy volunteers at doses up to 100 micrograms / kg / min .
Diseases: "	"Sentence: This agent was well tolerated in healthy volunteers at doses up to 100 micrograms / kg / min .
Diseases:"
4544	In long - term infusion studies , flestolol was well tolerated at the effective beta - blocking dose ( 5 micrograms / kg / min ) for up to seven days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In long - term infusion studies , flestolol was well tolerated at the effective beta - blocking dose ( 5 micrograms / kg / min ) for up to seven days .
Diseases: "	"Sentence: In long - term infusion studies , flestolol was well tolerated at the effective beta - blocking dose ( 5 micrograms / kg / min ) for up to seven days .
Diseases:"
4545	Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta - adrenergic blockade .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta - adrenergic blockade .
Diseases: "	"Sentence: Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta - adrenergic blockade .
Diseases:"
4546	Flestolol produced a dose - dependent attenuation of isoproterenol - induced tachycardia .	O O O O O O O O O O O B O	['tachycardia']	1	4	"Sentence: Flestolol produced a dose - dependent attenuation of isoproterenol - induced tachycardia .
Diseases: tachycardia"	"Sentence: Flestolol produced a dose - dependent attenuation of isoproterenol - induced tachycardia .
Diseases:"
4547	Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers .
Diseases: "	"Sentence: Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers .
Diseases:"
4548	In contrast with other beta blockers , flestolol - induced effects reverse rapidly ( within 30 minutes ) following discontinuation because of its short half - life .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast with other beta blockers , flestolol - induced effects reverse rapidly ( within 30 minutes ) following discontinuation because of its short half - life .
Diseases: "	"Sentence: In contrast with other beta blockers , flestolol - induced effects reverse rapidly ( within 30 minutes ) following discontinuation because of its short half - life .
Diseases:"
4549	Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia .	O O O O O O O O B I O	['supraventricular tachyarrhythmia']	1	10	"Sentence: Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia .
Diseases: supraventricular tachyarrhythmia"	"Sentence: Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia .
Diseases:"
4550	In patients with unstable angina , flestolol infusion was found to be safe and effective in controlling chest pain .	O O O B I O O O O O O O O O O O O B I O	['unstable angina', 'chest pain']	2	7	"Sentence: In patients with unstable angina , flestolol infusion was found to be safe and effective in controlling chest pain .
Diseases: unstable angina, chest pain"	"Sentence: In patients with unstable angina , flestolol infusion was found to be safe and effective in controlling chest pain .
Diseases:"
4551	It is concluded that flestolol is a potent , well - tolerated , ultra - short - acting beta - adrenergic blocking agent .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is concluded that flestolol is a potent , well - tolerated , ultra - short - acting beta - adrenergic blocking agent .
Diseases: "	"Sentence: It is concluded that flestolol is a potent , well - tolerated , ultra - short - acting beta - adrenergic blocking agent .
Diseases:"
4552	Use of flestolol in the critical care setting is currently undergoing investigation .	O O O O O O O O O O O O O	[]	0	0	"Sentence: Use of flestolol in the critical care setting is currently undergoing investigation .
Diseases: "	"Sentence: Use of flestolol in the critical care setting is currently undergoing investigation .
Diseases:"
4553	Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension .	O O O O O O O O O B O O O B I O	['renovascular hypertension', 'nephrosclerosis']	2	9	"Sentence: Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension .
Diseases: renovascular hypertension, nephrosclerosis"	"Sentence: Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension .
Diseases:"
4554	The effect of a 6 - week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip renovascular hypertension .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B I O	['renovascular hypertension', 'albuminuria']	2	7	"Sentence: The effect of a 6 - week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip renovascular hypertension .
Diseases: renovascular hypertension, albuminuria"	"Sentence: The effect of a 6 - week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip renovascular hypertension .
Diseases:"
4555	Six weeks after clipping of one renal artery , hypertensive rats ( 178 + / - 4 mm Hg ) were randomly assigned to three groups : untreated hypertensive controls ( n = 8 ) , enalapril - treated ( n = 8 ) , or nitrendipine - treated ( n = 10 ) .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: Six weeks after clipping of one renal artery , hypertensive rats ( 178 + / - 4 mm Hg ) were randomly assigned to three groups : untreated hypertensive controls ( n = 8 ) , enalapril - treated ( n = 8 ) , or nitrendipine - treated ( n = 10 ) .
Diseases: hypertensive"	"Sentence: Six weeks after clipping of one renal artery , hypertensive rats ( 178 + / - 4 mm Hg ) were randomly assigned to three groups : untreated hypertensive controls ( n = 8 ) , enalapril - treated ( n = 8 ) , or nitrendipine - treated ( n = 10 ) .
Diseases:"
4556	Sham - operated rats served as normotensive controls ( 128 + / -	O O O O O O O O O O O O O	[]	0	0	"Sentence: Sham - operated rats served as normotensive controls ( 128 + / -
Diseases: "	"Sentence: Sham - operated rats served as normotensive controls ( 128 + / -
Diseases:"
4557	3 mm Hg , n = 8 ) .	O O O O O O O O O	[]	0	0	"Sentence: 3 mm Hg , n = 8 ) .
Diseases: "	"Sentence: 3 mm Hg , n = 8 ) .
Diseases:"
4558	After 6 weeks of treatment , renal hemodynamics ( glomerular filtration rate and renal plasma flow ) were measured in the anesthetized rats .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 6 weeks of treatment , renal hemodynamics ( glomerular filtration rate and renal plasma flow ) were measured in the anesthetized rats .
Diseases: "	"Sentence: After 6 weeks of treatment , renal hemodynamics ( glomerular filtration rate and renal plasma flow ) were measured in the anesthetized rats .
Diseases:"
4559	Renal tissue was obtained for determination of glomerular size and sclerosis .	O O O O O O O O O O O O	[]	0	0	"Sentence: Renal tissue was obtained for determination of glomerular size and sclerosis .
Diseases: "	"Sentence: Renal tissue was obtained for determination of glomerular size and sclerosis .
Diseases:"
4560	Enalapril but not nitrendipine reduced blood pressure significantly .	O O O O O O O O O	[]	0	0	"Sentence: Enalapril but not nitrendipine reduced blood pressure significantly .
Diseases: "	"Sentence: Enalapril but not nitrendipine reduced blood pressure significantly .
Diseases:"
4561	After 6 weeks of therapy , glomerular filtration rate was not different among the studied groups .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 6 weeks of therapy , glomerular filtration rate was not different among the studied groups .
Diseases: "	"Sentence: After 6 weeks of therapy , glomerular filtration rate was not different among the studied groups .
Diseases:"
4562	Renal plasma flow increased , but albumin excretion and glomerulosclerosis did not change after enalapril treatment .	O O O O O O O O O B O O O O O O O	['glomerulosclerosis']	1	4	"Sentence: Renal plasma flow increased , but albumin excretion and glomerulosclerosis did not change after enalapril treatment .
Diseases: glomerulosclerosis"	"Sentence: Renal plasma flow increased , but albumin excretion and glomerulosclerosis did not change after enalapril treatment .
Diseases:"
4563	In contrast , in the nitrendipine - treated group albuminuria increased from 12 . 8 + / - 2 progressively to 163 + / - 55 compared with 19 . 2 + / -	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['albuminuria']	1	3	"Sentence: In contrast , in the nitrendipine - treated group albuminuria increased from 12 . 8 + / - 2 progressively to 163 + / - 55 compared with 19 . 2 + / -
Diseases: albuminuria"	"Sentence: In contrast , in the nitrendipine - treated group albuminuria increased from 12 . 8 + / - 2 progressively to 163 + / - 55 compared with 19 . 2 + / -
Diseases:"
4564	9 mg / 24 hr in the hypertensive controls .	O O O O O O O B O O	['hypertensive']	1	3	"Sentence: 9 mg / 24 hr in the hypertensive controls .
Diseases: hypertensive"	"Sentence: 9 mg / 24 hr in the hypertensive controls .
Diseases:"
4565	Furthermore , glomerulosclerosis index was significantly increased in the nitrendipine - treated group compared with the hypertensive controls ( 0 . 38 + / - 0 . 1 versus 0 . 13 + / - 0 . 04 ) .	O O B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive', 'glomerulosclerosis']	2	9	"Sentence: Furthermore , glomerulosclerosis index was significantly increased in the nitrendipine - treated group compared with the hypertensive controls ( 0 . 38 + / - 0 . 1 versus 0 . 13 + / - 0 . 04 ) .
Diseases: hypertensive, glomerulosclerosis"	"Sentence: Furthermore , glomerulosclerosis index was significantly increased in the nitrendipine - treated group compared with the hypertensive controls ( 0 . 38 + / - 0 . 1 versus 0 . 13 + / - 0 . 04 ) .
Diseases:"
4566	In addition , glomerular size was higher in the nitrendipine - treated group ( 14 . 9 + / - 0 . 17 10 ( - 3 ) mm2 ) but lower in the enalapril - treated group ( 11 . 5 + / - 0 . 15 10 ( - 3 ) mm2 ) compared with the hypertensive controls ( 12 . 1 + / - 0 . 17 10 ( - 3 ) mm2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: In addition , glomerular size was higher in the nitrendipine - treated group ( 14 . 9 + / - 0 . 17 10 ( - 3 ) mm2 ) but lower in the enalapril - treated group ( 11 . 5 + / - 0 . 15 10 ( - 3 ) mm2 ) compared with the hypertensive controls ( 12 . 1 + / - 0 . 17 10 ( - 3 ) mm2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: hypertensive"	"Sentence: In addition , glomerular size was higher in the nitrendipine - treated group ( 14 . 9 + / - 0 . 17 10 ( - 3 ) mm2 ) but lower in the enalapril - treated group ( 11 . 5 + / - 0 . 15 10 ( - 3 ) mm2 ) compared with the hypertensive controls ( 12 . 1 + / - 0 . 17 10 ( - 3 ) mm2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
4567	Treatment of tinnitus by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through ventilation tubes .	O O B O O O O O O O O O O O O O O O	['tinnitus']	1	3	"Sentence: Treatment of tinnitus by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through ventilation tubes .
Diseases: tinnitus"	"Sentence: Treatment of tinnitus by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through ventilation tubes .
Diseases:"
4568	Idiopathic subjective tinnitus ( IST ) is one of the most obscure otological pathologies .	B I I O B O O O O O O O O O O	['idiopathic subjective tinnitus', 'ist']	2	11	"Sentence: Idiopathic subjective tinnitus ( IST ) is one of the most obscure otological pathologies .
Diseases: idiopathic subjective tinnitus, ist"	"Sentence: Idiopathic subjective tinnitus ( IST ) is one of the most obscure otological pathologies .
Diseases:"
4569	This paper presents the results of treating IST by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through a grommet , for five weekly courses .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['ist']	1	1	"Sentence: This paper presents the results of treating IST by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through a grommet , for five weekly courses .
Diseases: ist"	"Sentence: This paper presents the results of treating IST by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through a grommet , for five weekly courses .
Diseases:"
4570	Fifty - two patients suffering from intractable tinnitus entered this therapeutic trial , but only nine finished all five courses .	O O O O O O O B O O O O O O O O O O O O O	['tinnitus']	1	3	"Sentence: Fifty - two patients suffering from intractable tinnitus entered this therapeutic trial , but only nine finished all five courses .
Diseases: tinnitus"	"Sentence: Fifty - two patients suffering from intractable tinnitus entered this therapeutic trial , but only nine finished all five courses .
Diseases:"
4571	In one patient , the tinnitus was almost completely abolished , but in all the nine patients the decompensated tinnitus changed to a compensated one .	O O O O O B O O O O O O O O O O O O O B O O O O O O	['tinnitus']	1	3	"Sentence: In one patient , the tinnitus was almost completely abolished , but in all the nine patients the decompensated tinnitus changed to a compensated one .
Diseases: tinnitus"	"Sentence: In one patient , the tinnitus was almost completely abolished , but in all the nine patients the decompensated tinnitus changed to a compensated one .
Diseases:"
4572	We suggest this mode of treatment for patients that were previously treated by drugs , acupuncture and biofeedback , with disappointing results .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We suggest this mode of treatment for patients that were previously treated by drugs , acupuncture and biofeedback , with disappointing results .
Diseases: "	"Sentence: We suggest this mode of treatment for patients that were previously treated by drugs , acupuncture and biofeedback , with disappointing results .
Diseases:"
4573	Patients should be warned about the side effects of vertigo and vomiting , which subsides gradually with every new instillation , and that the tinnitus may not disappear but will be alleviated , enabling them to cope more easily with the disease and lead a more normal life .	O O O O O O O O O B O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['tinnitus', 'vomiting', 'vertigo']	3	8	"Sentence: Patients should be warned about the side effects of vertigo and vomiting , which subsides gradually with every new instillation , and that the tinnitus may not disappear but will be alleviated , enabling them to cope more easily with the disease and lead a more normal life .
Diseases: tinnitus, vomiting, vertigo"	"Sentence: Patients should be warned about the side effects of vertigo and vomiting , which subsides gradually with every new instillation , and that the tinnitus may not disappear but will be alleviated , enabling them to cope more easily with the disease and lead a more normal life .
Diseases:"
4574	Perhexiline maleate and peripheral neuropathy .	O O O B I O	['peripheral neuropathy']	1	5	"Sentence: Perhexiline maleate and peripheral neuropathy .
Diseases: peripheral neuropathy"	"Sentence: Perhexiline maleate and peripheral neuropathy .
Diseases:"
4575	Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate , a drug widely used in France ( and in clinical trials in the United States ) for the prophylactic treatment of angina pectoris .	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['peripheral neuropathy', 'angina pectoris']	2	11	"Sentence: Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate , a drug widely used in France ( and in clinical trials in the United States ) for the prophylactic treatment of angina pectoris .
Diseases: peripheral neuropathy, angina pectoris"	"Sentence: Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate , a drug widely used in France ( and in clinical trials in the United States ) for the prophylactic treatment of angina pectoris .
Diseases:"
4576	In 24 patients with this complication , the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder .	O O O O O O O O O O O O O O O O O O O O O O B I O	['demyelinating disorder']	1	5	"Sentence: In 24 patients with this complication , the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder .
Diseases: demyelinating disorder"	"Sentence: In 24 patients with this complication , the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder .
Diseases:"
4577	Improvement was noted with cessation of therapy .	O O O O O O O O	[]	0	0	"Sentence: Improvement was noted with cessation of therapy .
Diseases: "	"Sentence: Improvement was noted with cessation of therapy .
Diseases:"
4578	In a few cases the presence of active denervation signified a poor prognosis , with only slight improvement .	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In a few cases the presence of active denervation signified a poor prognosis , with only slight improvement .
Diseases: "	"Sentence: In a few cases the presence of active denervation signified a poor prognosis , with only slight improvement .
Diseases:"
4579	The underlying mechanism causing the neuropathy is not yet fully known , although some evidence indicates that it may be a lipid storage process .	O O O O O B O O O O O O O O O O O O O O O O O O O	['neuropathy']	1	3	"Sentence: The underlying mechanism causing the neuropathy is not yet fully known , although some evidence indicates that it may be a lipid storage process .
Diseases: neuropathy"	"Sentence: The underlying mechanism causing the neuropathy is not yet fully known , although some evidence indicates that it may be a lipid storage process .
Diseases:"
4580	Effect of humoral modulators of morphine - induced increase in locomotor activity of mice .	O O O O O O O O B I I I O O O	['increase in locomotor activity']	1	6	"Sentence: Effect of humoral modulators of morphine - induced increase in locomotor activity of mice .
Diseases: increase in locomotor activity"	"Sentence: Effect of humoral modulators of morphine - induced increase in locomotor activity of mice .
Diseases:"
4581	The effect of humoral modulators on the morphine - induced increase in locomotor activity of mice was studied .	O O O O O O O O O O B I I I O O O O O	['increase in locomotor activity']	1	6	"Sentence: The effect of humoral modulators on the morphine - induced increase in locomotor activity of mice was studied .
Diseases: increase in locomotor activity"	"Sentence: The effect of humoral modulators on the morphine - induced increase in locomotor activity of mice was studied .
Diseases:"
4582	The subcutaneous administration of 10 mg / kg of morphine - HC1 produced a marked increase in locomotor activity in mice .	O O O O O O O O O O O O O O O B I I I O O O	['increase in locomotor activity']	1	6	"Sentence: The subcutaneous administration of 10 mg / kg of morphine - HC1 produced a marked increase in locomotor activity in mice .
Diseases: increase in locomotor activity"	"Sentence: The subcutaneous administration of 10 mg / kg of morphine - HC1 produced a marked increase in locomotor activity in mice .
Diseases:"
4583	The morphine - induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine .	O O O O B O O O O O O O O O	['hyperactivity']	1	2	"Sentence: The morphine - induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine .
Diseases: hyperactivity"	"Sentence: The morphine - induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine .
Diseases:"
4584	In contrast , both methscopolamine and neostigmine , which do not penetrate the blood - brain barrier , had no effect on the hyperactivity produced by morphine .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['hyperactivity']	1	2	"Sentence: In contrast , both methscopolamine and neostigmine , which do not penetrate the blood - brain barrier , had no effect on the hyperactivity produced by morphine .
Diseases: hyperactivity"	"Sentence: In contrast , both methscopolamine and neostigmine , which do not penetrate the blood - brain barrier , had no effect on the hyperactivity produced by morphine .
Diseases:"
4585	Pretreatment of mice with alpha - methyltyrosine ( 20 mg / kg i . p .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pretreatment of mice with alpha - methyltyrosine ( 20 mg / kg i . p .
Diseases: "	"Sentence: Pretreatment of mice with alpha - methyltyrosine ( 20 mg / kg i . p .
Diseases:"
4586	, one hour ) , an inhibitor of tyrosine hydroxylase , significantly decreased the activity - increasing effects of morphine .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: , one hour ) , an inhibitor of tyrosine hydroxylase , significantly decreased the activity - increasing effects of morphine .
Diseases: "	"Sentence: , one hour ) , an inhibitor of tyrosine hydroxylase , significantly decreased the activity - increasing effects of morphine .
Diseases:"
4587	On the other hand , pretreatment with p - chlorophenylalamine ( 3 X 320 mg / kg i . p .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On the other hand , pretreatment with p - chlorophenylalamine ( 3 X 320 mg / kg i . p .
Diseases: "	"Sentence: On the other hand , pretreatment with p - chlorophenylalamine ( 3 X 320 mg / kg i . p .
Diseases:"
4588	, 24 hr ) , a serotonin depletor , caused no significant change in the hyperactivity .	O O O O O O O O O O O O O O O B O	['hyperactivity']	1	2	"Sentence: , 24 hr ) , a serotonin depletor , caused no significant change in the hyperactivity .
Diseases: hyperactivity"	"Sentence: , 24 hr ) , a serotonin depletor , caused no significant change in the hyperactivity .
Diseases:"
4589	The study suggests that the activity - increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The study suggests that the activity - increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain .
Diseases: "	"Sentence: The study suggests that the activity - increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain .
Diseases:"
4590	And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses .
Diseases: "	"Sentence: And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses .
Diseases:"
4591	It is also suggested from collected evidence that the activity - increasing effects of morphine in mice are mediated by mechanisms different from those which mediate the activity - increasing effects of morphine in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is also suggested from collected evidence that the activity - increasing effects of morphine in mice are mediated by mechanisms different from those which mediate the activity - increasing effects of morphine in rats .
Diseases: "	"Sentence: It is also suggested from collected evidence that the activity - increasing effects of morphine in mice are mediated by mechanisms different from those which mediate the activity - increasing effects of morphine in rats .
Diseases:"
4592	Mechanisms of FK 506 - induced hypertension in the rat .	O O O O O O B O O O O	['hypertension']	1	3	"Sentence: Mechanisms of FK 506 - induced hypertension in the rat .
Diseases: hypertension"	"Sentence: Mechanisms of FK 506 - induced hypertension in the rat .
Diseases:"
4593	- Tacrolimus ( FK 506 ) is a powerful , widely used immunosuppressant .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: - Tacrolimus ( FK 506 ) is a powerful , widely used immunosuppressant .
Diseases: "	"Sentence: - Tacrolimus ( FK 506 ) is a powerful , widely used immunosuppressant .
Diseases:"
4594	The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity .	O O O O O O O O O O B O B O	['nephrotoxicity', 'hypertension']	2	6	"Sentence: The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity .
Diseases: nephrotoxicity, hypertension"	"Sentence: The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity .
Diseases:"
4595	To clarify the mechanisms of FK 506 - induced hypertension , we studied the chronic effects of FK 506 on the synthesis of endothelin - 1 ( ET - 1 ) , the expression of mRNA of ET - 1 and endothelin - converting enzyme - 1 ( ECE - 1 ) , the endothelial nitric oxide synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C - type natriuretic peptide ( CNP ) in rat blood vessels .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: To clarify the mechanisms of FK 506 - induced hypertension , we studied the chronic effects of FK 506 on the synthesis of endothelin - 1 ( ET - 1 ) , the expression of mRNA of ET - 1 and endothelin - converting enzyme - 1 ( ECE - 1 ) , the endothelial nitric oxide synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C - type natriuretic peptide ( CNP ) in rat blood vessels .
Diseases: hypertension"	"Sentence: To clarify the mechanisms of FK 506 - induced hypertension , we studied the chronic effects of FK 506 on the synthesis of endothelin - 1 ( ET - 1 ) , the expression of mRNA of ET - 1 and endothelin - converting enzyme - 1 ( ECE - 1 ) , the endothelial nitric oxide synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C - type natriuretic peptide ( CNP ) in rat blood vessels .
Diseases:"
4596	In addition , the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506 - induced hypertension in rats was studied .	O O O O O O O O O O O O O O O O O O O O B O O O O O	['hypertension']	1	3	"Sentence: In addition , the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506 - induced hypertension in rats was studied .
Diseases: hypertension"	"Sentence: In addition , the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506 - induced hypertension in rats was studied .
Diseases:"
4597	FK 506 , 5 mg .	O O O O O O	[]	0	0	"Sentence: FK 506 , 5 mg .
Diseases: "	"Sentence: FK 506 , 5 mg .
Diseases:"
4598	kg - 1 .	O O O O	[]	0	0	"Sentence: kg - 1 .
Diseases: "	"Sentence: kg - 1 .
Diseases:"
4599	d - 1 given for 4 weeks , elevated blood pressure from 102 + / - 13 to 152 + / - 15 mm Hg and increased the synthesis of ET - 1 and the levels of ET - 1 mRNA in the mesenteric artery ( 240 % and 230 % , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: d - 1 given for 4 weeks , elevated blood pressure from 102 + / - 13 to 152 + / - 15 mm Hg and increased the synthesis of ET - 1 and the levels of ET - 1 mRNA in the mesenteric artery ( 240 % and 230 % , respectively ) .
Diseases: "	"Sentence: d - 1 given for 4 weeks , elevated blood pressure from 102 + / - 13 to 152 + / - 15 mm Hg and increased the synthesis of ET - 1 and the levels of ET - 1 mRNA in the mesenteric artery ( 240 % and 230 % , respectively ) .
Diseases:"
4600	Little change was observed in the expression of ECE - 1 mRNA and CNP mRNA .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Little change was observed in the expression of ECE - 1 mRNA and CNP mRNA .
Diseases: "	"Sentence: Little change was observed in the expression of ECE - 1 mRNA and CNP mRNA .
Diseases:"
4601	FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta ( 48 % and 55 % , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta ( 48 % and 55 % , respectively ) .
Diseases: "	"Sentence: FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta ( 48 % and 55 % , respectively ) .
Diseases:"
4602	The administration of FR 139317 ( 10 mg . kg - 1 .	O O O O O O O O O O O O O	[]	0	0	"Sentence: The administration of FR 139317 ( 10 mg . kg - 1 .
Diseases: "	"Sentence: The administration of FR 139317 ( 10 mg . kg - 1 .
Diseases:"
4603	d - 1 ) prevented FK 506 - induced hypertension in rats .	O O O O O O O O O B O O O	['hypertension']	1	3	"Sentence: d - 1 ) prevented FK 506 - induced hypertension in rats .
Diseases: hypertension"	"Sentence: d - 1 ) prevented FK 506 - induced hypertension in rats .
Diseases:"
4604	These results indicate that FK 506 may increase blood pressure not only by increasing ET - 1 production but also by decreasing NO synthesis in the vasculature .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These results indicate that FK 506 may increase blood pressure not only by increasing ET - 1 production but also by decreasing NO synthesis in the vasculature .
Diseases: "	"Sentence: These results indicate that FK 506 may increase blood pressure not only by increasing ET - 1 production but also by decreasing NO synthesis in the vasculature .
Diseases:"
4605	Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy .	O O O B O O O O O O O	['apnea']	1	2	"Sentence: Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy .
Diseases: apnea"	"Sentence: Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy .
Diseases:"
4606	Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus ( OP ) poisons .	O O O B O O O O O O O O O O O O O O O	['apnea']	1	2	"Sentence: Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus ( OP ) poisons .
Diseases: apnea"	"Sentence: Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus ( OP ) poisons .
Diseases:"
4607	Here , we present a similar incident in a severely depressed patient who received electroconvulsive therapy ( ECT ) .	O O O O O O O O O O B O O O O O O O O O	['depressed']	1	2	"Sentence: Here , we present a similar incident in a severely depressed patient who received electroconvulsive therapy ( ECT ) .
Diseases: depressed"	"Sentence: Here , we present a similar incident in a severely depressed patient who received electroconvulsive therapy ( ECT ) .
Diseases:"
4608	Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team .	O B O O O O O O O O O O O O O O O O O O O O	['apnea']	1	2	"Sentence: Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team .
Diseases: apnea"	"Sentence: Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team .
Diseases:"
4609	The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor : a double - blind placebo - controlled and randomized study .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O	['sexual dysfunction']	1	2	"Sentence: The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor : a double - blind placebo - controlled and randomized study .
Diseases: sexual dysfunction"	"Sentence: The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor : a double - blind placebo - controlled and randomized study .
Diseases:"
4610	To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .	O O O O O O O O O O O O O O O O O B I O B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['sexual dysfunction', 'sd']	2	4	"Sentence: To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
Diseases: sexual dysfunction, sd"	"Sentence: To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .
Diseases:"
4611	PATIENTS AND METHODS : The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PATIENTS AND METHODS : The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI .
Diseases: "	"Sentence: PATIENTS AND METHODS : The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI .
Diseases:"
4612	The men were randomly assigned to bupropion SR ( 150 mg twice daily , 117 ) or placebo ( twice daily , 117 ) for 12 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The men were randomly assigned to bupropion SR ( 150 mg twice daily , 117 ) or placebo ( twice daily , 117 ) for 12 weeks .
Diseases: "	"Sentence: The men were randomly assigned to bupropion SR ( 150 mg twice daily , 117 ) or placebo ( twice daily , 117 ) for 12 weeks .
Diseases:"
4613	Efficacy was evaluated using the Clinical Global Impression - Sexual Function ( CGI - SF ; the primary outcome measure ) , the International Index of Erectile Function ( IIEF ) , Arizona Sexual Experience Scale ( ASEX ) , and Erectile Dysfunction Inventory of Treatment Satisfaction ( EDITS ) ( secondary outcome measures ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	['erectile dysfunction']	1	4	"Sentence: Efficacy was evaluated using the Clinical Global Impression - Sexual Function ( CGI - SF ; the primary outcome measure ) , the International Index of Erectile Function ( IIEF ) , Arizona Sexual Experience Scale ( ASEX ) , and Erectile Dysfunction Inventory of Treatment Satisfaction ( EDITS ) ( secondary outcome measures ) .
Diseases: erectile dysfunction"	"Sentence: Efficacy was evaluated using the Clinical Global Impression - Sexual Function ( CGI - SF ; the primary outcome measure ) , the International Index of Erectile Function ( IIEF ) , Arizona Sexual Experience Scale ( ASEX ) , and Erectile Dysfunction Inventory of Treatment Satisfaction ( EDITS ) ( secondary outcome measures ) .
Diseases:"
4614	Participants were followed biweekly during study period .	O O O O O O O O	[]	0	0	"Sentence: Participants were followed biweekly during study period .
Diseases: "	"Sentence: Participants were followed biweekly during study period .
Diseases:"
4615	After 12 weeks of treatment , the mean ( sd ) scores for CGI - SF were significantly lower , i . e . better , in patients on bupropion SR , at 2 . 4 ( 1 . 2 ) , than in the placebo group , at 3 . 9 ( 1 . 1 ) ( P = 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 12 weeks of treatment , the mean ( sd ) scores for CGI - SF were significantly lower , i . e . better , in patients on bupropion SR , at 2 . 4 ( 1 . 2 ) , than in the placebo group , at 3 . 9 ( 1 . 1 ) ( P = 0 . 01 ) .
Diseases: "	"Sentence: After 12 weeks of treatment , the mean ( sd ) scores for CGI - SF were significantly lower , i . e . better , in patients on bupropion SR , at 2 . 4 ( 1 . 2 ) , than in the placebo group , at 3 . 9 ( 1 . 1 ) ( P = 0 . 01 ) .
Diseases:"
4616	Men who received bupropion had a significant increase in the total IIEF score ( 54 . 4 % vs 1 . 2 % ; P = 0 . 003 ) , and in the five different domains of the IIEF .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Men who received bupropion had a significant increase in the total IIEF score ( 54 . 4 % vs 1 . 2 % ; P = 0 . 003 ) , and in the five different domains of the IIEF .
Diseases: "	"Sentence: Men who received bupropion had a significant increase in the total IIEF score ( 54 . 4 % vs 1 . 2 % ; P = 0 . 003 ) , and in the five different domains of the IIEF .
Diseases:"
4617	Total ASEX scores were significantly lower , i . e . better , among men who received bupropion than placebo , at 15 . 5 ( 4 . 3 ) vs 21 . 5 ( 4 . 7 ) ( P = 0 . 002 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Total ASEX scores were significantly lower , i . e . better , among men who received bupropion than placebo , at 15 . 5 ( 4 . 3 ) vs 21 . 5 ( 4 . 7 ) ( P = 0 . 002 ) .
Diseases: "	"Sentence: Total ASEX scores were significantly lower , i . e . better , among men who received bupropion than placebo , at 15 . 5 ( 4 . 3 ) vs 21 . 5 ( 4 . 7 ) ( P = 0 . 002 ) .
Diseases:"
4618	The EDITS scores were 67 . 4 ( 10 . 2 ) for the bupropion and 36 . 3 ( 11 . 7 ) for the placebo group ( P = 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The EDITS scores were 67 . 4 ( 10 . 2 ) for the bupropion and 36 . 3 ( 11 . 7 ) for the placebo group ( P = 0 . 001 ) .
Diseases: "	"Sentence: The EDITS scores were 67 . 4 ( 10 . 2 ) for the bupropion and 36 . 3 ( 11 . 7 ) for the placebo group ( P = 0 . 001 ) .
Diseases:"
4619	The ASEX score and CGI - SF score were correlated ( P = 0 . 003 ) .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The ASEX score and CGI - SF score were correlated ( P = 0 . 003 ) .
Diseases: "	"Sentence: The ASEX score and CGI - SF score were correlated ( P = 0 . 003 ) .
Diseases:"
4620	In linear regression analyses the CGI - SF score was not affected significantly by the duration of SD , type of SSRI used and age .	O O O O O O O O O O O O O O O O O B O O O O O O O O	['sd']	1	1	"Sentence: In linear regression analyses the CGI - SF score was not affected significantly by the duration of SD , type of SSRI used and age .
Diseases: sd"	"Sentence: In linear regression analyses the CGI - SF score was not affected significantly by the duration of SD , type of SSRI used and age .
Diseases:"
4621	CONCLUSIONS : Bupropion is an effective treatment for male SD induced by SSRIs .	O O O O O O O O O B O O O O	['sd']	1	1	"Sentence: CONCLUSIONS : Bupropion is an effective treatment for male SD induced by SSRIs .
Diseases: sd"	"Sentence: CONCLUSIONS : Bupropion is an effective treatment for male SD induced by SSRIs .
Diseases:"
4622	These results provide empirical support for conducting a further study of bupropion .	O O O O O O O O O O O O O	[]	0	0	"Sentence: These results provide empirical support for conducting a further study of bupropion .
Diseases: "	"Sentence: These results provide empirical support for conducting a further study of bupropion .
Diseases:"
4623	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis - B surface antigen ( HBSAG ) seropositive cancer patients undergoing cytotoxic chemotherapy .	O O O O O B I O O O O O O O O O O O O B O O O O O	['cancer', 'hepatitis b']	2	6	"Sentence: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis - B surface antigen ( HBSAG ) seropositive cancer patients undergoing cytotoxic chemotherapy .
Diseases: cancer, hepatitis b"	"Sentence: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis - B surface antigen ( HBSAG ) seropositive cancer patients undergoing cytotoxic chemotherapy .
Diseases:"
4624	Hepatitis B virus ( HBV ) is one of the major causes of chronic liver disease worldwide .	B I O O O O O O O O O O O O B I O O	['liver disease', 'hepatitis b']	2	6	"Sentence: Hepatitis B virus ( HBV ) is one of the major causes of chronic liver disease worldwide .
Diseases: liver disease, hepatitis b"	"Sentence: Hepatitis B virus ( HBV ) is one of the major causes of chronic liver disease worldwide .
Diseases:"
4625	Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy ( CT ) and this has mainly been attributed to HBV reactivation .	B O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['hepatic complication', 'cancer']	2	6	"Sentence: Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy ( CT ) and this has mainly been attributed to HBV reactivation .
Diseases: hepatic complication, cancer"	"Sentence: Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy ( CT ) and this has mainly been attributed to HBV reactivation .
Diseases:"
4626	In this study , cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine .	O O O O B O O O O O B I O O B I O O O O O O O O O O O O O O O O O O O O	['hematological malignancies', 'hbv infection', 'cancer']	3	12	"Sentence: In this study , cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine .
Diseases: hematological malignancies, hbv infection, cancer"	"Sentence: In this study , cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine .
Diseases:"
4627	The objectives were to assess the efficacy of lamivudine in reducing the incidence of HBV reactivation , and diminishing morbidity and mortality during CT .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The objectives were to assess the efficacy of lamivudine in reducing the incidence of HBV reactivation , and diminishing morbidity and mortality during CT .
Diseases: "	"Sentence: The objectives were to assess the efficacy of lamivudine in reducing the incidence of HBV reactivation , and diminishing morbidity and mortality during CT .
Diseases:"
4628	Two groups were compared in this study .	O O O O O O O O	[]	0	0	"Sentence: Two groups were compared in this study .
Diseases: "	"Sentence: Two groups were compared in this study .
Diseases:"
4629	The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment .
Diseases: "	"Sentence: The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment .
Diseases:"
4630	The historical controls consisted of 50 consecutive patients who underwent CT without prophylactic lamivudine .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The historical controls consisted of 50 consecutive patients who underwent CT without prophylactic lamivudine .
Diseases: "	"Sentence: The historical controls consisted of 50 consecutive patients who underwent CT without prophylactic lamivudine .
Diseases:"
4631	They were followed up during and for 8 weeks after CT .	O O O O O O O O O O O O	[]	0	0	"Sentence: They were followed up during and for 8 weeks after CT .
Diseases: "	"Sentence: They were followed up during and for 8 weeks after CT .
Diseases:"
4632	The outcomes were compared for both groups .	O O O O O O O O	[]	0	0	"Sentence: The outcomes were compared for both groups .
Diseases: "	"Sentence: The outcomes were compared for both groups .
Diseases:"
4633	Of our control group ( n = 50 ) , 21 patients ( 42 % ) were established hepatitis .	O O O O O O O O O O O O O O O O O O B O	['hepatitis']	1	3	"Sentence: Of our control group ( n = 50 ) , 21 patients ( 42 % ) were established hepatitis .
Diseases: hepatitis"	"Sentence: Of our control group ( n = 50 ) , 21 patients ( 42 % ) were established hepatitis .
Diseases:"
4634	Twelve ( 24 % ) of them were evaluated as severe hepatitis .	O O O O O O O O O O O B O	['hepatitis']	1	3	"Sentence: Twelve ( 24 % ) of them were evaluated as severe hepatitis .
Diseases: hepatitis"	"Sentence: Twelve ( 24 % ) of them were evaluated as severe hepatitis .
Diseases:"
4635	In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient ( 2 . 7 % ) of 37 patients ( p < 0 . 006 ) .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['hepatitis']	1	3	"Sentence: In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient ( 2 . 7 % ) of 37 patients ( p < 0 . 006 ) .
Diseases: hepatitis"	"Sentence: In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient ( 2 . 7 % ) of 37 patients ( p < 0 . 006 ) .
Diseases:"
4636	Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase ( ALT )	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase ( ALT )
Diseases: "	"Sentence: Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase ( ALT )
Diseases:"
4637	values in the control group than the prophylactic lamivudine group ; 154 : 64 ( p < 0 . 32 ) .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: values in the control group than the prophylactic lamivudine group ; 154 : 64 ( p < 0 . 32 ) .
Diseases: "	"Sentence: values in the control group than the prophylactic lamivudine group ; 154 : 64 ( p < 0 . 32 ) .
Diseases:"
4638	Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy .	O O O O O O O O O O O O O O O O O B O O O O O O O	['cancer']	1	1	"Sentence: Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy .
Diseases: cancer"	"Sentence: Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy .
Diseases:"
4639	Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT .
Diseases: "	"Sentence: Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT .
Diseases:"
4640	Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats .	O O O O B I I O O O O O O O O	['impairment of learning']	1	5	"Sentence: Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats .
Diseases: impairment of learning"	"Sentence: Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats .
Diseases:"
4641	Rg1 , as a ginsenoside extracted from Panax ginseng , could ameliorate spatial learning impairment .	O O O O O O O O O O O O O B I O	['learning impairment']	1	2	"Sentence: Rg1 , as a ginsenoside extracted from Panax ginseng , could ameliorate spatial learning impairment .
Diseases: learning impairment"	"Sentence: Rg1 , as a ginsenoside extracted from Panax ginseng , could ameliorate spatial learning impairment .
Diseases:"
4642	Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine .
Diseases: "	"Sentence: Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine .
Diseases:"
4643	The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect .	O O O O O O O O O O O O O B I O O O O O O O O O O O O	['learning impairment']	1	2	"Sentence: The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect .
Diseases: learning impairment"	"Sentence: The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect .
Diseases:"
4644	Male rats were subcutaneously injected with morphine ( 10 mg / kg ) twice a day at 12 hour intervals for 10 days , and Rg1 ( 30 mg / kg ) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Male rats were subcutaneously injected with morphine ( 10 mg / kg ) twice a day at 12 hour intervals for 10 days , and Rg1 ( 30 mg / kg ) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days .
Diseases: "	"Sentence: Male rats were subcutaneously injected with morphine ( 10 mg / kg ) twice a day at 12 hour intervals for 10 days , and Rg1 ( 30 mg / kg ) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days .
Diseases:"
4645	Spatial learning capacity was assessed in the Morris water maze .	O O O O O O O O O O O	[]	0	0	"Sentence: Spatial learning capacity was assessed in the Morris water maze .
Diseases: "	"Sentence: Spatial learning capacity was assessed in the Morris water maze .
Diseases:"
4646	The results showed that rats treated with Morphine / Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results showed that rats treated with Morphine / Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency .
Diseases: "	"Sentence: The results showed that rats treated with Morphine / Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency .
Diseases:"
4647	By implantation of electrodes and electrophysiological recording in vivo , the results showed that Rg1 restored the long - term potentiation ( LTP ) impaired by morphine in both freely moving and anaesthetised rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: By implantation of electrodes and electrophysiological recording in vivo , the results showed that Rg1 restored the long - term potentiation ( LTP ) impaired by morphine in both freely moving and anaesthetised rats .
Diseases: "	"Sentence: By implantation of electrodes and electrophysiological recording in vivo , the results showed that Rg1 restored the long - term potentiation ( LTP ) impaired by morphine in both freely moving and anaesthetised rats .
Diseases:"
4648	The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine , but not changed LTP in the slices from normal saline - or morphine / Rg1 - treated rats ; this restoration could be inhibited by N - methyl - D - aspartate ( NMDA ) receptor antagonist MK801 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine , but not changed LTP in the slices from normal saline - or morphine / Rg1 - treated rats ; this restoration could be inhibited by N - methyl - D - aspartate ( NMDA ) receptor antagonist MK801 .
Diseases: "	"Sentence: The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine , but not changed LTP in the slices from normal saline - or morphine / Rg1 - treated rats ; this restoration could be inhibited by N - methyl - D - aspartate ( NMDA ) receptor antagonist MK801 .
Diseases:"
4649	We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine - inhibited LTP .	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine - inhibited LTP .
Diseases: "	"Sentence: We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine - inhibited LTP .
Diseases:"
4650	This effect is NMDA receptor dependent .	O O O O O O O	[]	0	0	"Sentence: This effect is NMDA receptor dependent .
Diseases: "	"Sentence: This effect is NMDA receptor dependent .
Diseases:"
4651	A study on the effect of the duration of subcutaneous heparin injection on bruising and pain .	O O O O O O O O O O O O O B O B O	['bruising', 'pain']	2	5	"Sentence: A study on the effect of the duration of subcutaneous heparin injection on bruising and pain .
Diseases: bruising, pain"	"Sentence: A study on the effect of the duration of subcutaneous heparin injection on bruising and pain .
Diseases:"
4652	AIM : This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin .	O O O O O O O O O O O O O O O B O B O O O O O O O O O O	['bruising', 'pain']	2	5	"Sentence: AIM : This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin .
Diseases: bruising, pain"	"Sentence: AIM : This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin .
Diseases:"
4653	Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described , the effect of injection duration on the occurrence of bruising and pain is little documented .	O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O B O B O O O O	['bruising', 'pain']	2	5	"Sentence: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described , the effect of injection duration on the occurrence of bruising and pain is little documented .
Diseases: bruising, pain"	"Sentence: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described , the effect of injection duration on the occurrence of bruising and pain is little documented .
Diseases:"
4654	DESIGN :	O O	[]	0	0	"Sentence: DESIGN :
Diseases: "	"Sentence: DESIGN :
Diseases:"
4655	This study was designed as within - subject , quasi - experimental research .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: This study was designed as within - subject , quasi - experimental research .
Diseases: "	"Sentence: This study was designed as within - subject , quasi - experimental research .
Diseases:"
4656	The sample for the study consisted of 50 patients to whom subcutaneous heparin was administered .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The sample for the study consisted of 50 patients to whom subcutaneous heparin was administered .
Diseases: "	"Sentence: The sample for the study consisted of 50 patients to whom subcutaneous heparin was administered .
Diseases:"
4657	Heparin was injected over 10 seconds on the right abdominal site and 30 seconds on the left abdominal site .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Heparin was injected over 10 seconds on the right abdominal site and 30 seconds on the left abdominal site .
Diseases: "	"Sentence: Heparin was injected over 10 seconds on the right abdominal site and 30 seconds on the left abdominal site .
Diseases:"
4658	Injections areas were assessed for the presence of bruising at 48 and 72 hours after each injection .	O O O O O O O O B O O O O O O O O O	['bruising']	1	3	"Sentence: Injections areas were assessed for the presence of bruising at 48 and 72 hours after each injection .
Diseases: bruising"	"Sentence: Injections areas were assessed for the presence of bruising at 48 and 72 hours after each injection .
Diseases:"
4659	Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper .	O O O B O O O O O O O O O O O O O	['bruising']	1	3	"Sentence: Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper .
Diseases: bruising"	"Sentence: Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper .
Diseases:"
4660	The visual analog scale ( VAS ) was used to measure pain intensity and a stop - watch was used to time the pain period .	O O O O O O O O O O O B O O O O O O O O O O O B O O	['pain']	1	1	"Sentence: The visual analog scale ( VAS ) was used to measure pain intensity and a stop - watch was used to time the pain period .
Diseases: pain"	"Sentence: The visual analog scale ( VAS ) was used to measure pain intensity and a stop - watch was used to time the pain period .
Diseases:"
4661	Data were analysed using chi - square test , Mann - Whitney U , Wilcoxon signed ranks tests and correlation .	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Data were analysed using chi - square test , Mann - Whitney U , Wilcoxon signed ranks tests and correlation .
Diseases: "	"Sentence: Data were analysed using chi - square test , Mann - Whitney U , Wilcoxon signed ranks tests and correlation .
Diseases:"
4662	The percentage of bruising occurrence was 64 % with the injection of 10 seconds duration and 42 % in the 30 - second injection .	O O O B O O O O O O O O O O O O O O O O O O O O O	['bruising']	1	3	"Sentence: The percentage of bruising occurrence was 64 % with the injection of 10 seconds duration and 42 % in the 30 - second injection .
Diseases: bruising"	"Sentence: The percentage of bruising occurrence was 64 % with the injection of 10 seconds duration and 42 % in the 30 - second injection .
Diseases:"
4663	It was determined that the size of the bruising was smaller in the 30 - second injection .	O O O O O O O O B O O O O O O O O O	['bruising']	1	3	"Sentence: It was determined that the size of the bruising was smaller in the 30 - second injection .
Diseases: bruising"	"Sentence: It was determined that the size of the bruising was smaller in the 30 - second injection .
Diseases:"
4664	Pain intensity and pain period were statistically significantly lower for the 30 - second injection than for the 10 - second injection .	B O O B O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Pain intensity and pain period were statistically significantly lower for the 30 - second injection than for the 10 - second injection .
Diseases: pain"	"Sentence: Pain intensity and pain period were statistically significantly lower for the 30 - second injection than for the 10 - second injection .
Diseases:"
4665	CONCLUSIONS : It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin .	O O O O O O O O O O O O B O B O O O O O O O	['bruising', 'pain']	2	5	"Sentence: CONCLUSIONS : It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin .
Diseases: bruising, pain"	"Sentence: CONCLUSIONS : It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin .
Diseases:"
4666	This study should be repeated on a larger sample .	O O O O O O O O O O	[]	0	0	"Sentence: This study should be repeated on a larger sample .
Diseases: "	"Sentence: This study should be repeated on a larger sample .
Diseases:"
4667	RELEVANCE TO CLINICAL PRACTICE :	O O O O O	[]	0	0	"Sentence: RELEVANCE TO CLINICAL PRACTICE :
Diseases: "	"Sentence: RELEVANCE TO CLINICAL PRACTICE :
Diseases:"
4668	When administering subcutaneous heparin injections , it is important to extend the duration of the injection .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When administering subcutaneous heparin injections , it is important to extend the duration of the injection .
Diseases: "	"Sentence: When administering subcutaneous heparin injections , it is important to extend the duration of the injection .
Diseases:"
4669	Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats .	O O O O O O O O O O O O O B I O O O	['orofacial dyskinesia']	1	7	"Sentence: Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats .
Diseases: orofacial dyskinesia"	"Sentence: Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats .
Diseases:"
4670	Reserpine - and haloperidol - induced orofacial dyskinesia are putative animal models of tardive dyskinesia ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .	O O O O O O B I O O O O O B I O B O O O O O O O O O O O O O O	['tardive dyskinesia', 'orofacial dyskinesia', 'td']	3	18	"Sentence: Reserpine - and haloperidol - induced orofacial dyskinesia are putative animal models of tardive dyskinesia ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
Diseases: tardive dyskinesia, orofacial dyskinesia, td"	"Sentence: Reserpine - and haloperidol - induced orofacial dyskinesia are putative animal models of tardive dyskinesia ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .
Diseases:"
4671	In the present study , the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats .	O O O O O O O O B I O O O O O O O O O O	['orofacial dyskinesia']	1	7	"Sentence: In the present study , the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats .
Diseases: orofacial dyskinesia"	"Sentence: In the present study , the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats .
Diseases:"
4672	Reserpine injection ( one dose of 1 mg / kg s . c . )	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Reserpine injection ( one dose of 1 mg / kg s . c . )
Diseases: "	"Sentence: Reserpine injection ( one dose of 1 mg / kg s . c . )
Diseases:"
4673	every other day for 3 days caused a significant increase in vacuous chewing , tongue protrusion and duration of facial twitching , compared to the control .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: every other day for 3 days caused a significant increase in vacuous chewing , tongue protrusion and duration of facial twitching , compared to the control .
Diseases: "	"Sentence: every other day for 3 days caused a significant increase in vacuous chewing , tongue protrusion and duration of facial twitching , compared to the control .
Diseases:"
4674	Haloperidol administration ( one dose of 12 mg / kg once a week s . c . ) for 4 weeks caused an increase in vacuous chewing , tongue protrusion and duration of facial twitching observed in four weekly evaluations .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Haloperidol administration ( one dose of 12 mg / kg once a week s . c . ) for 4 weeks caused an increase in vacuous chewing , tongue protrusion and duration of facial twitching observed in four weekly evaluations .
Diseases: "	"Sentence: Haloperidol administration ( one dose of 12 mg / kg once a week s . c . ) for 4 weeks caused an increase in vacuous chewing , tongue protrusion and duration of facial twitching observed in four weekly evaluations .
Diseases:"
4675	After the treatments and behavioral observation , glutamate uptake by segments of the brain was analyzed .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After the treatments and behavioral observation , glutamate uptake by segments of the brain was analyzed .
Diseases: "	"Sentence: After the treatments and behavioral observation , glutamate uptake by segments of the brain was analyzed .
Diseases:"
4676	A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol , compared to the control .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol , compared to the control .
Diseases: "	"Sentence: A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol , compared to the control .
Diseases:"
4677	Importantly , a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia .	O O O O O O O O O O O O O O O O B I O	['orofacial diskinesia']	1	6	"Sentence: Importantly , a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia .
Diseases: orofacial diskinesia"	"Sentence: Importantly , a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia .
Diseases:"
4678	These results indicate that early changes in glutamate transport may be related to the development of vacuous chewing movements in rats .	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These results indicate that early changes in glutamate transport may be related to the development of vacuous chewing movements in rats .
Diseases: "	"Sentence: These results indicate that early changes in glutamate transport may be related to the development of vacuous chewing movements in rats .
Diseases:"
4679	Acute psychosis due to treatment with phenytoin in a nonepileptic patient .	B I O O O O O O O O O O	['acute psychosis']	1	3	"Sentence: Acute psychosis due to treatment with phenytoin in a nonepileptic patient .
Diseases: acute psychosis"	"Sentence: Acute psychosis due to treatment with phenytoin in a nonepileptic patient .
Diseases:"
4680	The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs .	O O O B O O O O O O O O O O O O O B O O O O O O O	['psychosis', 'epileptic']	2	5	"Sentence: The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs .
Diseases: psychosis, epileptic"	"Sentence: The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs .
Diseases:"
4681	The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described .	O O O O O O O O B O O O O B I O O O	['psychosis', 'trigeminal neuralgia']	2	9	"Sentence: The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described .
Diseases: psychosis, trigeminal neuralgia"	"Sentence: The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described .
Diseases:"
4682	This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication , unrelated to seizures .	O O O O O B I O O O O O O O B O O O O O O O O O O O B O	['epileptic', 'psychotic symptoms', 'seizures']	3	8	"Sentence: This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication , unrelated to seizures .
Diseases: epileptic, psychotic symptoms, seizures"	"Sentence: This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication , unrelated to seizures .
Diseases:"
4683	The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats : a preliminary study .	O O O O O O O O O B O O O O O O O	['nephrotoxicity']	1	4	"Sentence: The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats : a preliminary study .
Diseases: nephrotoxicity"	"Sentence: The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats : a preliminary study .
Diseases:"
4684	In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin ( GM ) nephrotoxicity .	O O O O O O O O O O O O O O O O B I I O O O O O O B O	['acute renal failure', 'nephrotoxicity']	2	9	"Sentence: In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin ( GM ) nephrotoxicity .
Diseases: acute renal failure, nephrotoxicity"	"Sentence: In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin ( GM ) nephrotoxicity .
Diseases:"
4685	Rats were treated with the vehicle ( 2 mL / kg of distilled water and 5 % w / v cellulose , 10 days ) , gum Arabic ( 2 mL / kg of a 10 % w / v aqueous suspension of gum Arabic powder , orally for 10 days ) , or gum Arabic concomitantly with GM ( 80mg / kg / day intramuscularly , during the last six days of the treatment period ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Rats were treated with the vehicle ( 2 mL / kg of distilled water and 5 % w / v cellulose , 10 days ) , gum Arabic ( 2 mL / kg of a 10 % w / v aqueous suspension of gum Arabic powder , orally for 10 days ) , or gum Arabic concomitantly with GM ( 80mg / kg / day intramuscularly , during the last six days of the treatment period ) .
Diseases: "	"Sentence: Rats were treated with the vehicle ( 2 mL / kg of distilled water and 5 % w / v cellulose , 10 days ) , gum Arabic ( 2 mL / kg of a 10 % w / v aqueous suspension of gum Arabic powder , orally for 10 days ) , or gum Arabic concomitantly with GM ( 80mg / kg / day intramuscularly , during the last six days of the treatment period ) .
Diseases:"
4686	Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .
Diseases: nephrotoxicity"	"Sentence: Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .
Diseases:"
4687	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group )
Diseases: "	"Sentence: The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group )
Diseases:"
4688	The GM - induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	['tubular necrosis']	1	4	"Sentence: The GM - induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
Diseases: tubular necrosis"	"Sentence: The GM - induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .
Diseases:"
4689	It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity .	O O O O O O O O O O O O O O O O O O O O O O O B O	['nephrotoxicity']	1	4	"Sentence: It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity .
Diseases: nephrotoxicity"	"Sentence: It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity .
Diseases:"
4690	Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure , and on the mechanism ( s ) involved .	O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O	['chronic renal failure']	1	4	"Sentence: Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure , and on the mechanism ( s ) involved .
Diseases: chronic renal failure"	"Sentence: Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure , and on the mechanism ( s ) involved .
Diseases:"
4691	Visual hallucinations associated with zonisamide .	B I O O O O	['visual hallucinations']	1	2	"Sentence: Visual hallucinations associated with zonisamide .
Diseases: visual hallucinations"	"Sentence: Visual hallucinations associated with zonisamide .
Diseases:"
4692	Zonisamide is a broad - spectrum antiepileptic drug used to treat various types of seizures .	O O O O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: Zonisamide is a broad - spectrum antiepileptic drug used to treat various types of seizures .
Diseases: seizures"	"Sentence: Zonisamide is a broad - spectrum antiepileptic drug used to treat various types of seizures .
Diseases:"
4693	Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased .	O B I O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O	['visual hallucinations']	1	2	"Sentence: Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased .
Diseases: visual hallucinations"	"Sentence: Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased .
Diseases:"
4694	All three had been diagnosed earlier with epilepsy , and their electroencephalogram ( EEG ) findings were abnormal .	O O O O O O O B O O O O O O O O O O O	['epilepsy']	1	3	"Sentence: All three had been diagnosed earlier with epilepsy , and their electroencephalogram ( EEG ) findings were abnormal .
Diseases: epilepsy"	"Sentence: All three had been diagnosed earlier with epilepsy , and their electroencephalogram ( EEG ) findings were abnormal .
Diseases:"
4695	During monitoring , visual hallucinations did not correlate with EEG readings , nor did video recording capture any of the described events .	O O O B I O O O O O O O O O O O O O O O O O O	['visual hallucinations']	1	2	"Sentence: During monitoring , visual hallucinations did not correlate with EEG readings , nor did video recording capture any of the described events .
Diseases: visual hallucinations"	"Sentence: During monitoring , visual hallucinations did not correlate with EEG readings , nor did video recording capture any of the described events .
Diseases:"
4696	None of the patients had experienced visual hallucinations before this event .	O O O O O O B I O O O O	['visual hallucinations']	1	2	"Sentence: None of the patients had experienced visual hallucinations before this event .
Diseases: visual hallucinations"	"Sentence: None of the patients had experienced visual hallucinations before this event .
Diseases:"
4697	The only recent change in their treatment was the introduction or increased dosage of zonisamide .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The only recent change in their treatment was the introduction or increased dosage of zonisamide .
Diseases: "	"Sentence: The only recent change in their treatment was the introduction or increased dosage of zonisamide .
Diseases:"
4698	With either discontinuation or decreased dosage of the drug the symptoms disappeared and did not recur .	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: With either discontinuation or decreased dosage of the drug the symptoms disappeared and did not recur .
Diseases: "	"Sentence: With either discontinuation or decreased dosage of the drug the symptoms disappeared and did not recur .
Diseases:"
4699	Further observations and reports will help clarify this adverse effect .	O O O O O O O O O O O	[]	0	0	"Sentence: Further observations and reports will help clarify this adverse effect .
Diseases: "	"Sentence: Further observations and reports will help clarify this adverse effect .
Diseases:"
4700	Until then , clinicians need to be aware of this possible complication associated with zonisamide .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Until then , clinicians need to be aware of this possible complication associated with zonisamide .
Diseases: "	"Sentence: Until then , clinicians need to be aware of this possible complication associated with zonisamide .
Diseases:"
4701	GLEPP1 receptor tyrosine phosphatase ( Ptpro ) in rat PAN nephrosis .	O O O O O O O O O O B O	['nephrosis']	1	3	"Sentence: GLEPP1 receptor tyrosine phosphatase ( Ptpro ) in rat PAN nephrosis .
Diseases: nephrosis"	"Sentence: GLEPP1 receptor tyrosine phosphatase ( Ptpro ) in rat PAN nephrosis .
Diseases:"
4702	A marker of acute podocyte injury .	O O O O O O O	[]	0	0	"Sentence: A marker of acute podocyte injury .
Diseases: "	"Sentence: A marker of acute podocyte injury .
Diseases:"
4703	Glomerular epithelial protein 1 ( GLEPP1 ) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Glomerular epithelial protein 1 ( GLEPP1 ) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes .
Diseases: "	"Sentence: Glomerular epithelial protein 1 ( GLEPP1 ) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes .
Diseases:"
4704	This receptor plays a role in regulating the structure and function of podocyte foot process .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This receptor plays a role in regulating the structure and function of podocyte foot process .
Diseases: "	"Sentence: This receptor plays a role in regulating the structure and function of podocyte foot process .
Diseases:"
4705	To better understand the utility of GLEPP1 as a marker of glomerular injury , the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry , Western blot and RNase protection assay in a model of podocyte injury in the rat .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['glomerular injury']	1	3	"Sentence: To better understand the utility of GLEPP1 as a marker of glomerular injury , the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry , Western blot and RNase protection assay in a model of podocyte injury in the rat .
Diseases: glomerular injury"	"Sentence: To better understand the utility of GLEPP1 as a marker of glomerular injury , the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry , Western blot and RNase protection assay in a model of podocyte injury in the rat .
Diseases:"
4706	Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside ( PAN , 20 mg / 100 g BW ) .	O O B O O O O O O O O O O O O O O O O O O O O	['nephrosis']	1	3	"Sentence: Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside ( PAN , 20 mg / 100 g BW ) .
Diseases: nephrosis"	"Sentence: Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside ( PAN , 20 mg / 100 g BW ) .
Diseases:"
4707	Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement ( days 5 - 11 ) and the chronic phase of proteinuria associated with glomerulosclerosis ( days 45 - 126 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O B O O O O O O O	['proteinuria', 'glomerulosclerosis']	2	8	"Sentence: Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement ( days 5 - 11 ) and the chronic phase of proteinuria associated with glomerulosclerosis ( days 45 - 126 ) .
Diseases: proteinuria, glomerulosclerosis"	"Sentence: Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement ( days 5 - 11 ) and the chronic phase of proteinuria associated with glomerulosclerosis ( days 45 - 126 ) .
Diseases:"
4708	At day 5 , GLEPP1 protein and mRNA were reduced from the normal range ( 265 . 2 + / - 79 . 6 x 10 ( 6 ) moles / glomerulus and 100 % ) to 15 % of normal ( 41 . 8 + / - 4 . 8 x 10 ( 6 ) moles / glomerulus , p < 0 . 005 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At day 5 , GLEPP1 protein and mRNA were reduced from the normal range ( 265 . 2 + / - 79 . 6 x 10 ( 6 ) moles / glomerulus and 100 % ) to 15 % of normal ( 41 . 8 + / - 4 . 8 x 10 ( 6 ) moles / glomerulus , p < 0 . 005 ) .
Diseases: "	"Sentence: At day 5 , GLEPP1 protein and mRNA were reduced from the normal range ( 265 . 2 + / - 79 . 6 x 10 ( 6 ) moles / glomerulus and 100 % ) to 15 % of normal ( 41 . 8 + / - 4 . 8 x 10 ( 6 ) moles / glomerulus , p < 0 . 005 ) .
Diseases:"
4709	This occurred in association with an increase in urinary protein content from 1 . 8 + / - 1 to 99 . 0 + / - 61 mg / day ( p < 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This occurred in association with an increase in urinary protein content from 1 . 8 + / - 1 to 99 . 0 + / - 61 mg / day ( p < 0 . 001 ) .
Diseases: "	"Sentence: This occurred in association with an increase in urinary protein content from 1 . 8 + / - 1 to 99 . 0 + / - 61 mg / day ( p < 0 . 001 ) .
Diseases:"
4710	In contrast , podocalyxin did not change significantly at this time .	O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , podocalyxin did not change significantly at this time .
Diseases: "	"Sentence: In contrast , podocalyxin did not change significantly at this time .
Diseases:"
4711	By day 11 , GLEPP1 protein and mRNA had begun to return towards baseline .	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: By day 11 , GLEPP1 protein and mRNA had begun to return towards baseline .
Diseases: "	"Sentence: By day 11 , GLEPP1 protein and mRNA had begun to return towards baseline .
Diseases:"
4712	By day 45 - 126 , at a time when glomerular scarring was present , GLEPP1 was absent from glomerulosclerotic areas although the total glomerular content of GLEPP1 was not different from normal .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: By day 45 - 126 , at a time when glomerular scarring was present , GLEPP1 was absent from glomerulosclerotic areas although the total glomerular content of GLEPP1 was not different from normal .
Diseases: "	"Sentence: By day 45 - 126 , at a time when glomerular scarring was present , GLEPP1 was absent from glomerulosclerotic areas although the total glomerular content of GLEPP1 was not different from normal .
Diseases:"
4713	We conclude that GLEPP1 expression , unlike podocalyxin , reflects podocyte injury induced by PAN .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We conclude that GLEPP1 expression , unlike podocalyxin , reflects podocyte injury induced by PAN .
Diseases: "	"Sentence: We conclude that GLEPP1 expression , unlike podocalyxin , reflects podocyte injury induced by PAN .
Diseases:"
4714	GLEPP1 expression may be a useful marker of podocyte injury .	O O O O O O O O O O O	[]	0	0	"Sentence: GLEPP1 expression may be a useful marker of podocyte injury .
Diseases: "	"Sentence: GLEPP1 expression may be a useful marker of podocyte injury .
Diseases:"
4715	Ticlopidine - induced aplastic anemia : report of three Chinese patients and review of the literature .	O O O B I O O O O O O O O O O O O	['aplastic anemia']	1	5	"Sentence: Ticlopidine - induced aplastic anemia : report of three Chinese patients and review of the literature .
Diseases: aplastic anemia"	"Sentence: Ticlopidine - induced aplastic anemia : report of three Chinese patients and review of the literature .
Diseases:"
4716	In this study , three Chinese patients with ticlopidine - induced aplastic anemia were reported and another 13 patients in the English literature were reviewed .	O O O O O O O O O O O B I O O O O O O O O O O O O O	['aplastic anemia']	1	5	"Sentence: In this study , three Chinese patients with ticlopidine - induced aplastic anemia were reported and another 13 patients in the English literature were reviewed .
Diseases: aplastic anemia"	"Sentence: In this study , three Chinese patients with ticlopidine - induced aplastic anemia were reported and another 13 patients in the English literature were reviewed .
Diseases:"
4717	We attempted to find underlying similarities , evaluate the risk factors , and identify appropriate treatment for this complication .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We attempted to find underlying similarities , evaluate the risk factors , and identify appropriate treatment for this complication .
Diseases: "	"Sentence: We attempted to find underlying similarities , evaluate the risk factors , and identify appropriate treatment for this complication .
Diseases:"
4718	All but one of the patients were over 60 years old , and the 6 who died were all older than 65 .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All but one of the patients were over 60 years old , and the 6 who died were all older than 65 .
Diseases: "	"Sentence: All but one of the patients were over 60 years old , and the 6 who died were all older than 65 .
Diseases:"
4719	Therefore , old age may be a risk factor for developing this complication .	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Therefore , old age may be a risk factor for developing this complication .
Diseases: "	"Sentence: Therefore , old age may be a risk factor for developing this complication .
Diseases:"
4720	Agranulocytosis occurred 3 - 20 weeks after initiation of ticlopidine , so frequent examination of white cell count during treatment is recommended .	B O O O O O O O O O O O O O O O O O O O O O O	['agranulocytosis']	1	6	"Sentence: Agranulocytosis occurred 3 - 20 weeks after initiation of ticlopidine , so frequent examination of white cell count during treatment is recommended .
Diseases: agranulocytosis"	"Sentence: Agranulocytosis occurred 3 - 20 weeks after initiation of ticlopidine , so frequent examination of white cell count during treatment is recommended .
Diseases:"
4721	There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression .	O O O O O O O O O O O O O O O O O B I I O	['bone marrow suppression']	1	3	"Sentence: There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression .
Diseases: bone marrow suppression"	"Sentence: There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression .
Diseases:"
4722	Treatment for ticlopidine - induced aplastic anemia with colony - stimulating factors seemed to have little effect .	O O O O O B I O O O O O O O O O O O	['aplastic anemia']	1	5	"Sentence: Treatment for ticlopidine - induced aplastic anemia with colony - stimulating factors seemed to have little effect .
Diseases: aplastic anemia"	"Sentence: Treatment for ticlopidine - induced aplastic anemia with colony - stimulating factors seemed to have little effect .
Diseases:"
4723	The fact that 5 of the 6 patients who received concurrent calcium channel blockers died , should alert clinicians to be more cautious when using these two drugs simultaneously .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The fact that 5 of the 6 patients who received concurrent calcium channel blockers died , should alert clinicians to be more cautious when using these two drugs simultaneously .
Diseases: "	"Sentence: The fact that 5 of the 6 patients who received concurrent calcium channel blockers died , should alert clinicians to be more cautious when using these two drugs simultaneously .
Diseases:"
4724	Facilitation of memory retrieval by pre - test morphine and its state dependency in the step - through type passive avoidance learning test in mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Facilitation of memory retrieval by pre - test morphine and its state dependency in the step - through type passive avoidance learning test in mice .
Diseases: "	"Sentence: Facilitation of memory retrieval by pre - test morphine and its state dependency in the step - through type passive avoidance learning test in mice .
Diseases:"
4725	Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial ( pre - test ) , and pre - test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial ( pre - test ) , and pre - test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .
Diseases: amnesia"	"Sentence: Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial ( pre - test ) , and pre - test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .
Diseases:"
4726	Similarly , pre - test scopolamine partially reversed the scopolamine - induced amnesia , but not significantly ; and pre - test cycloheximide failed to reverse the cycloheximide - induced amnesia .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O	['amnesia']	1	2	"Sentence: Similarly , pre - test scopolamine partially reversed the scopolamine - induced amnesia , but not significantly ; and pre - test cycloheximide failed to reverse the cycloheximide - induced amnesia .
Diseases: amnesia"	"Sentence: Similarly , pre - test scopolamine partially reversed the scopolamine - induced amnesia , but not significantly ; and pre - test cycloheximide failed to reverse the cycloheximide - induced amnesia .
Diseases:"
4727	These results suggest that the facilitation of memory retrieval by pre - test morphine might be the direct action of morphine rather than a state dependent effect .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These results suggest that the facilitation of memory retrieval by pre - test morphine might be the direct action of morphine rather than a state dependent effect .
Diseases: "	"Sentence: These results suggest that the facilitation of memory retrieval by pre - test morphine might be the direct action of morphine rather than a state dependent effect .
Diseases:"
4728	Test conditions influence the response to a drug challenge in rodents .	O O O O O O O O O O O O	[]	0	0	"Sentence: Test conditions influence the response to a drug challenge in rodents .
Diseases: "	"Sentence: Test conditions influence the response to a drug challenge in rodents .
Diseases:"
4729	These studies were conducted to examine the differential response to a drug challenge under varied experimental test conditions routinely employed to study drug - induced behavioral and neurophysiological responses in rodents .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These studies were conducted to examine the differential response to a drug challenge under varied experimental test conditions routinely employed to study drug - induced behavioral and neurophysiological responses in rodents .
Diseases: "	"Sentence: These studies were conducted to examine the differential response to a drug challenge under varied experimental test conditions routinely employed to study drug - induced behavioral and neurophysiological responses in rodents .
Diseases:"
4730	Apomorphine , a nonselective dopamine agonist , was selected due to its biphasic behavioral effects , its ability to induce hypothermia , and to produce distinct changes to dopamine turnover in the rodent brain .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['hypothermia']	1	3	"Sentence: Apomorphine , a nonselective dopamine agonist , was selected due to its biphasic behavioral effects , its ability to induce hypothermia , and to produce distinct changes to dopamine turnover in the rodent brain .
Diseases: hypothermia"	"Sentence: Apomorphine , a nonselective dopamine agonist , was selected due to its biphasic behavioral effects , its ability to induce hypothermia , and to produce distinct changes to dopamine turnover in the rodent brain .
Diseases:"
4731	From such experiments there is evidence that characterization and detection of apomorphine - induced activity in rodents critically depends upon the test conditions employed .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: From such experiments there is evidence that characterization and detection of apomorphine - induced activity in rodents critically depends upon the test conditions employed .
Diseases: "	"Sentence: From such experiments there is evidence that characterization and detection of apomorphine - induced activity in rodents critically depends upon the test conditions employed .
Diseases:"
4732	In rats , detection of apomorphine - induced hyperactivity was facilitated by a period of acclimatization to the test conditions .	O O O O O O O O B O O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: In rats , detection of apomorphine - induced hyperactivity was facilitated by a period of acclimatization to the test conditions .
Diseases: hyperactivity"	"Sentence: In rats , detection of apomorphine - induced hyperactivity was facilitated by a period of acclimatization to the test conditions .
Diseases:"
4733	Moreover , test conditions can impact upon other physiological responses to apomorphine such as drug - induced hypothermia .	O O O O O O O O O O O O O O O O O B O	['hypothermia']	1	3	"Sentence: Moreover , test conditions can impact upon other physiological responses to apomorphine such as drug - induced hypothermia .
Diseases: hypothermia"	"Sentence: Moreover , test conditions can impact upon other physiological responses to apomorphine such as drug - induced hypothermia .
Diseases:"
4734	In mice , apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage .	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In mice , apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage .
Diseases: "	"Sentence: In mice , apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage .
Diseases:"
4735	Drug - induced gross activity counts were increased in the novel exploratory box only , while measures of stereotypic behavior were similar in both .	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Drug - induced gross activity counts were increased in the novel exploratory box only , while measures of stereotypic behavior were similar in both .
Diseases: "	"Sentence: Drug - induced gross activity counts were increased in the novel exploratory box only , while measures of stereotypic behavior were similar in both .
Diseases:"
4736	By contrast , apomorphine - induced locomotion was more prominent in the novel exploratory box .	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: By contrast , apomorphine - induced locomotion was more prominent in the novel exploratory box .
Diseases: "	"Sentence: By contrast , apomorphine - induced locomotion was more prominent in the novel exploratory box .
Diseases:"
4737	Dopamine turnover ratios ( DOPAC : DA and HVA : DA ) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dopamine turnover ratios ( DOPAC : DA and HVA : DA ) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts .
Diseases: "	"Sentence: Dopamine turnover ratios ( DOPAC : DA and HVA : DA ) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts .
Diseases:"
4738	However , apomorphine - induced reductions in striatal dopamine turnover were detected in both novel and home cage environments .	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , apomorphine - induced reductions in striatal dopamine turnover were detected in both novel and home cage environments .
Diseases: "	"Sentence: However , apomorphine - induced reductions in striatal dopamine turnover were detected in both novel and home cage environments .
Diseases:"
4739	The implications of these findings are discussed with particular emphasis upon conducting psychopharmacological challenge tests in rodents .	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The implications of these findings are discussed with particular emphasis upon conducting psychopharmacological challenge tests in rodents .
Diseases: "	"Sentence: The implications of these findings are discussed with particular emphasis upon conducting psychopharmacological challenge tests in rodents .
Diseases:"
